<SEC-DOCUMENT>0000078003-22-000101.txt : 20221109
<SEC-HEADER>0000078003-22-000101.hdr.sgml : 20221109
<ACCEPTANCE-DATETIME>20221109160515
ACCESSION NUMBER:		0000078003-22-000101
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20221002
FILED AS OF DATE:		20221109
DATE AS OF CHANGE:		20221109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		221372495

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pfe-20221002.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:532d8f3f-927e-412c-bdcb-1806e94574ca,g:7cd44193-98b9-486c-9ee0-61ec890b3036,d:8c2530a91ced4c48b9620128206808f1--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:pfe="http://www.pfizer.com/20221002" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pfe-20221002</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfMy0xLTEtMS00Mjk2NzE_0ffa4759-f8c3-4998-974d-8c839ae8032f">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNC0xLTEtMS00Mjk2NzE_5f7e015c-b945-40cb-b909-1f332d908f16">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNS0xLTEtMS00Mjk2NzE_040efffb-a703-4f39-bdb3-0dc919681ccf">2022</ix:nonNumeric><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNi0xLTEtMS00Mjk2NzE_834ed5c7-ddad-4f2a-ba8f-11c86fe88eb8">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNy0xLTEtMS00Mjk2NzE_c6b8b9a8-2806-45d6-b10b-63ea9a2e6a0e">false</ix:nonNumeric><ix:nonNumeric contextRef="i22e6b4b0386445c2b216f9309b164440_I20221002" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xNTc3L2ZyYWc6NTM5NTI5ZmUyY2UyNDhhNDhlODMyMWFjNjI2OTE5ODUvdGFibGU6YmJmYTg5OTUzMGI2NGI0OWFjNDBiMTc4NmEzMGJiOWQvdGFibGVyYW5nZTpiYmZhODk5NTMwYjY0YjQ5YWM0MGIxNzg2YTMwYmI5ZF8yLTEtMS0xLTQ1NDY5NA_853050f9-cf4b-44b0-be3d-8aa8b4a52dfa">P3M</ix:nonNumeric><ix:nonNumeric contextRef="id8bf1cff4bcf46a8a95e2b2f3561e4d8_I20221002" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xNTc3L2ZyYWc6NTM5NTI5ZmUyY2UyNDhhNDhlODMyMWFjNjI2OTE5ODUvdGFibGU6YmJmYTg5OTUzMGI2NGI0OWFjNDBiMTc4NmEzMGJiOWQvdGFibGVyYW5nZTpiYmZhODk5NTMwYjY0YjQ5YWM0MGIxNzg2YTMwYmI5ZF8zLTEtMS0xLTQ1NDY5NA_7a77205f-e1ad-4b66-a018-d22464406d42">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i26e1cf1555744ef5a90bad26608bf34f_I20221002" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xNTc3L2ZyYWc6NTM5NTI5ZmUyY2UyNDhhNDhlODMyMWFjNjI2OTE5ODUvdGFibGU6YmJmYTg5OTUzMGI2NGI0OWFjNDBiMTc4NmEzMGJiOWQvdGFibGVyYW5nZTpiYmZhODk5NTMwYjY0YjQ5YWM0MGIxNzg2YTMwYmI5ZF80LTEtMS0xLTQ1NDY5NA_8a784c25-870c-4984-89b5-3f6d0c38507c">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pfe-20221002.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieebdaac648754d8f9991d9345808cedb_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0729378a52374c80919b47eeb89d45c8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf59b86323f44bc955f877e15b9942e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98083abf5b10468887a10a5321465a07_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3ad8bd638b94660a81910320140a0ff_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee207eb562eb45749d0e09bd8ae27d99_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd2c296b7794de18cd9165e100b3645_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac935618aa1f4c02973c960cd4d50198_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dfdf4b4d9474432ac2661c4f07bf9ae_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1fa5b9f5af24e07a8d83bc03ff721d2_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291c881a539a4386ace0953f2e533606_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i322ef81511754d73bd045b355aa263b0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a00c9907efc45b58509f370291e703d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1008d0f3e2cb4f1fb4612f491b9815d9_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4007c71e914cfe8b9ecfa0a6b9a28f_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e546bd59bb47fb8d148abae15673a7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4178e1df50642f481342387e7983453_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283349b3ae194291807e57850205a00e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd63e0776794a11af6999e725dd9bf9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38fb06657953481f9327c4d7af5221d3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316fd24dd0da46e5872d02ce9db0a499_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439e2eb2ea67457d989b7d096b2578b6_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i982bd66098e642c180e76a8b23cfce05_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2eff56d6b9143a8a6236c386a684328_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a860a4fb70d417db1e5ece4d14a5929_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106884611a9443b0b91471c3127aab17_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd1ece70cb9426792fd297de161a638_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871492c1af0c4c41901ad429f9c97997_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1d8a56f33e04a88aa94910108df6baf_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc3cdee01052447a8c008a36884f4ece_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if55bdd083c8e4d4bb0f0f79015f34b54_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0830a768fb84418ac3aa1b642de41a4_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aaed31d336142a38895f4e58c290bc0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cfba0bc31044aafb04e8793a359fd30_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fbbfb560fd84535bc70f59962461307_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf00def957b4c1ca037635793efebf2_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i269d8be2dbe14366928f6a655f330c99_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3adb48a9ed804129abc01342e3aa820b_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7eead2d41724d1284b95a8f2c3ba977_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icff95de7b4364937bb8f6fa9332bb480_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e9bcba37374979b4f81bb0e1923a9a_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad49f13a7aaf431ca7ad807765db51a1_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie720b049f06b4803a5325d0052df106f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a4179e99414d2bb29dae8a9ef43064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27da68353c034955b1c275a580f01f68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5305bfba0e7a4d7fbbd4c84a4873871d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef44849268d4847a9fb27d3a90011e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b19de1c61d540f7a92683b6fcef0492_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58476ceafd6b43a0803a9cdb179436a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb8a629a946b4ceca7ca7dd72b1af40b_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b1498a92d54a268ebfb1b8e658f31d_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if663a3d9b11e4c838a4f9123bcff64b2_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342523194f354c36af8db3ac1d92928a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad01e12648344a0bbd128d9c7131aebc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5e26c69446465d846729c653f45303_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46f714a106f496988fe9d996ad5882b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c21ac9482a54fb3991813baf028f817_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ec159b1e1141eb90a039d6e396bcd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1414142218df48a784a0e0af5a6fa08a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f38a2438be4f7bb12b558b25272ce5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c0af948675a4a7f9a78ce4430cb4045_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733fe6690f964b79a59503138cfacb8c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e44f06dea84bef93e7ada7841e6e73_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6c8f9bc04f475da96d6d469914b62b_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="operatingsegment"><xbrli:measure>pfe:operatingSegment</xbrli:measure></xbrli:unit><xbrli:context id="if04c3dccab614a94b2908a489d743aff_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6ba2fc692f44b495f2e7f584a00bef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7508bb16fd44454482e06b74af164e0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0861c1e153d4341b6f1aa2768a8b9e3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b757dbbd6f4f2bad32cff5eca993e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6721d042bce841789b97c61224022594_D20220609-20220609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:ReViralAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-09</xbrli:startDate><xbrli:endDate>2022-06-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02ecae4c145465fbebfc17542366c8c_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01574368db75427a9223807866f28b02_D20220311-20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87882967ea9849de8a349199b28d5e06_D20220311-20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e5aabb88f345f8b7eacf17c16cdd86_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id429ba78c8b54ea280edb5594ad15554_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic44d8c4f02f348958a5ef9d3d3956478_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14aafbc729874cbe90872af65ea59b36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509aed2b3fb94e35abdfcdc538d2275b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc75e310f54444b94ce2100463e4260_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia87a0c62e89e454eb69933abb4c4cf0c_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifc89d78c61c749e883b46dd57f1a3ccf_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fbf4bc1a0894e7788da3e8ed8f24508_I20220718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aeaaa46a5c645458d5ca97b3f043df5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f67e1304894aa8b40ea227ea7a7e3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8fc0f572a7426d9fcc873efb1de4f8_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18bc5b7d65614c15bf509693d653ef09_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002cc11dc66a4c92ab91ce99b0fab752_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id859aeb95872427ca6e14971df36fe79_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i420561cd7e844911961eee63ae39bdd0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b27e6f401f4351a27e511e00a11af2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesUSDDenominatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a94f1c0e3654553b739db0514bb91f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesEURDenominatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ie15724356ec94a19bb862b3f6307566e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesGBPDenominatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i600244a7a17344ab962cbad5adad812f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e0ab0e158f46899e45c2d773856f14_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:A1365ConsumerHealthcareJVLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife71c632282645c6972017eea707a24b_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42142f3d667447f8b004965d67fb5bef_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:A1365ConsumerHealthcareJVLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7af860819f54f01861664b5ad041b8f_D20220104-20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-04</xbrli:startDate><xbrli:endDate>2022-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58af9a3440794bd6aecec41e17eef71e_I20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7381e87f7646fd8e2cbda19e2e2d0f_D20220104-20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:ResearchAndDevelopmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-04</xbrli:startDate><xbrli:endDate>2022-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158261a31a1c413799e169c8d84fe9ba_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i722d6d36e0a3476b89b0cdc056d0f26a_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21b538a5cc974cf8b8cff85d8c511b6c_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CorporateEnablingFunctionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28697c549ce3454c8ce5980750988a6d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:GoToMarketModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27e5b4edce54e8e8a8ad6d6a9acc7e8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa3843da72a42f2b5f23f8d547a2b0c_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd388f3beca428899e121e6042d61eb_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c083a6cc0c4200a8e2f51e5486ed99_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4619b114ec194ad0b6cdf916bfe7a1e4_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743f0eb0d1d04686a3138f343d0a91a4_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35ac29855a1475ca5478fc62e1fd74f_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd5613cc06a4d73a6e8eaa13a7d3b73_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ef4b0d7cca452089dd78603de3cf6c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e35f95c0c3442aaabb2dfc697eddc0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f0a9e3dc01d4e41b2c5e11386542b1f_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf45616770c74e4290c92f85fa0706ef_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id365d50df2a645fa85ed477f05ab1838_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b8da4f7456e442295e4b41cd995dae1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72db9e61e2aa40229247e0d3b02b0e82_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32df0ec003834b6eab05cf61f39fa6e3_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4744ad08ba8409a820a07a834ff061c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd31dba911048de993662a30bd60e24_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5974e3684a5d4959a373f6a880ead072_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba30fd6c8d04ca8bac5eceecaea0094_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0aea8b98cb34108abfe4081d7793e2c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300033c0ba2c4182978046a909b7606b_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f516286c63343f28a4664b266e75256_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9ab2b2fea44955974b44346416d463_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7dbe8638f7401a94c5382e4b054e25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7081406b1b62439ab5fd196c928df604_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8b45d1675445aa8d696f11839ca704_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672675a4e5374596930c5eb56c56fb6e_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b1a60419934acf858ae1b59d2c713d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f37bc9a3284a51bb64a83d09a3d26a_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ffcb4ce1bd422f80c0659256ce5949_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5120c338e7784bc0a405cf860830dc96_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechCerevelTherapeuticsLLCAndArvinasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c3b88c09f446329b1ec1583f33a3b3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c5aec14bf13443d865368553c8fb09f_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e03b80a6e31462388cb8fa87c81fae5_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e604c4a1134172a1157b3846f7e9db_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bcdf5d6697b4dfda841c81ef6f0b444_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fcb9d12f7e8461f800a28613f391b63_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2a3f390d88441aa84493f5b915fa1fa_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28d11de768f4acfa1899aa6f92f42fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe7a5df8a364aef9def98d475a8dd2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedabc8fc306843ffb9c2a5c9a5abf093_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c0c0bfa0bc7435f8a1cb14d125612d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1218785b15a4b428afe5839d3c22095_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a588750f30485cba7eb82683ef423b_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id36f1bf78a2e4329b60d5e5ca4f34e82_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc5b6fe28ec4fc892354bdc356b0801_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4713ca3234b4b16be713694331b20e8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84465afd71b54fbca86dd39dd5eb14e4_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ac6485d813484ab3e2a5f79e9312df_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a51b3abaa324634a216f2ccf13bdd62_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2d2fd4d529d4ffaa9992caf594aea98_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i365aa8bb027248c0a4bd72e05fd31c0c_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ab2d49d10a4441badf49b57db6e345_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf645fee7504d31b036a7ca132adbff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3509896f64d41e5a5a8a7c49b85adbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd50bf1cd5ba47938f5f06d79c2b2891_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i805f99cc930d4f27b83f2f5f22fcfd16_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7edb8146745e45e3b80ad081fff12d94_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89eef82eb7a14b73bef78f769ed99bc2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb21d2ec5e54e368a11d0e46bd687d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff481cae963c450595873c78d321b75f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7fb7cfc61124350803a3395415aa187_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if479661c13be4b20ac5fb45721ae4f0d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2479bf3cc9724ee0ab05e372bdb15b2f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a25515655044cabbf3baefce125c4ee_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia48d8b4d17584751a31563d542bdfdaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d99910901024c4c8acc5114294068dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icab958fb460e4fa0a9e49791a40852e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04206940cb3c4f31828b818000eb0def_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i619ff852ea974bb5b961b5bfe763d05f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49460c8694894c998f43812db50d6a6f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4935735833a74f51b431b13978755e1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i524be4274845416fb3a8a00458bd6bb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i117594e26d1a4ad898c33e699b9f7077_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i914b27e478a94963b2d4b101e6efc8ac_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefaeb8ef2b2844f88d07b978d1f21090_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c6d752d4524b33be36259fef0edbf9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c24fe9c58be452aad86c0e034bcaf6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a8a497745744779127896961eb99b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i226bc50d44474921a2117b15aecd4339_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e0de40ca8c4677bfae29d91ebdde69_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36e3c0460a4e4852a56a67d528410e84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a162167b3964440947ee8fc8433d811_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a069f7f44c44a79a99da7df5e7d726_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1606489f92c4bd28f5d5bb811476ad6_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia35aa9908c74494b8436d59196094589_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa20c368a6845188d5f86675163ec4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752fb6da23f74a17911b22b40176bdc2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb8301baf634a788c90da0b7e186fba_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i458c5f84f016420085b60cd199bcf73a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i979b62479efe4c33bd39145b1249c177_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a58581671444d0fa9352733c8859022_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10e532bbebdc45249c16d40c3dc0a715_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106748186c314412998ca5807842edcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia171432125c34b90be8e8604e663907d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e5471772584760b1d1f8ac3c7d5a73_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf9771697dc4c2187d4f9d4b5006611_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3394bb954a4bb283a0430941d2b0da_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c13c8d6f5e4476488e457cd130177b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7bfbd5763f1476397cb82ac7bae3159_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib536482e78464a5cb14145115c86217a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7009eec6815484bb288be0b6939cfe8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4fdd3aa58c54a848f098867c06f5d18_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e77d36f6bb74d9ea078650432f1a0bd_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d65cc9d472404c97ea4a88ed62138c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9222f579cb5d4c8f968c453d8254f49d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4959ff73f845669686173848f68817_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb79de0c54d447a940125fd8c11fe37_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e06b72b11c542d6afc570e8531710d8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b92fd6f4ac4766a4f58f450bc26d49_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b6382776a542a8abe220fd855457a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867802a8f854403f9965faf6c388210a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51c9c8f46d854bf5b5db351b98fd1a31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a36bebd932477abb647b4c3f1f7229_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1ae606958948a09710f9127386e909_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01adb0c331434d4eb30ff9aa4a978d62_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195a713f2d9b41099053b0da037cb644_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57a34ccba5c84e5783572681c5b10269_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1a042fb56a476cb18d112a8229dba2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f9e24f27f7455ba6e05f483af693eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i208c5cb34c6642f493f12b122be74aab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d030e31054241cbb0485358571b9bde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8472588c67134a13847983bdf694f4dc_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9029b150d0054adc95f1fb9398955ea9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55958062514846a5817b8f0a50f35dd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9722c4887b744055b1904ff63ab244d9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c60017d6ba741f68386b4b24baef910_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic477a3d1dd454d778619d8af4d4a6650_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i827e7ba807c442599109f6cd0c3eb032_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b5aa6d82a8b42f0a39f8d78d409bf1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8da0892f39d46c096dc066b6ec8a83e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3186066be71c42b5a02001d1a9f376b0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144d47acfac140678093066f01a98ba7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c6ddfb9327a4b028b11b10328f2ba51_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2ed77de0ce405e8cf9e819442e6528_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia942bf711c884c0c8389c2c4658f859b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97507b074e0e4f6f92c18c2fd703b228_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1460ce67a1664a4886f261a31538b94c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33dbb0a3d25e4ded9172ca71bd57e611_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8154274534c145acaa81abeaebf413da_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45883a91d50a47eb96c4f3afbd992dee_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3150d83c1054e43ac64649354bfd47a_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e1a99b384254f579445b74f46691315_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i069ae598e0f0477282f60735e915b8af_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bfd27b3218b487a9810f8d0eca2c8eb_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc254f3841504538bd25d1e598f7efcb_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9ed02e04a84fd4a77116dcbcdb1d7a_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50bf294318854802b0ca58dbe517a298_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f316f885ed4d329752000102edb162_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14b13073e4e4613b080addd6621f2f9_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b98292d9c1417a926a79b66406286a_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f6af82b6d024b0eafd8f31e35b20075_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if474000c1ec5464d9c71367ad5ee9f35_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34242284b9494732b030b9e714db61b6_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f47fc0e281c43afac185ec01923d406_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04751deef2cd46b99805e78bd859c289_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667311c49e1242729a0e2cfbeb12d37b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9e5de858194ea3a1564e487b4e84b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8308f5a4b0dc4a5e84bd59beff89e949_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id224ff09ffe74524973bc9034a6a86ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c782fb34650411c8db8781a876e6df3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9991d2e7245d461895c706bb1a8bece9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749f749980d34e25acc4fb7966c17205_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i203cdb0ebc574f27943dd1e51d1b1277_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i912798045f5b4639aa7284fc67e728b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd6baec7c42411ea48eebdb0f2f23db_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b292fac08314732827dde98a31e18b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f31c2acdf14f1cb842ad2f9b51b800_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia27c96bd99bc47d68e917e7d12a78b77_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54cb4a7821fb491f8936f9f3177f14a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa472f98c9c4c3ba6c39332849653eb_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>pfe:patent</xbrli:measure></xbrli:unit><xbrli:context id="i7ec7a704d40b402d8dd76af6c1782133_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad227400e764448bb7ce0ca5ce1db320_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91598b6cfce147ed85f80c515a585148_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ModernaTXPatentInfringementCaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>pfe:defendant</xbrli:measure></xbrli:unit><xbrli:context id="ie3a4c1b86275499193f0bb113f4c657c_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i498fe9705333412a85d84b8175400688_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>pfe:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="i165a698ddb8e4740889d260adc4009bb_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf2ffc020fc4128a1f9ebec292fe188_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260c3e9ac18c409aa7e150f37f31c193_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e893c8b2754cf0b8dd3ad3ebd5f8c9_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d04b7cdf357409082229e55e47bebc1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id294f09255c94f85a1408cb0dd253fd3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i848bc701f6dd422990599b16e3035373_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92dccc52a63e495ab4c634079bac8732_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d607e6b68ed4e24ab93bdeca6299e0b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0dfdeb3dc774794b361ecf3023e31d0_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38bad6387f68492a8b7da8ed99819fa5_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb5f43508edc415e9ccadc3761d6ec7b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2531e34ef9984e79a95c51a52ce63392_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i359c961cd6c843d087dbaa286f62f72c_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20c933385df4b25a75dc3230695c60d_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678fe644ebee4937ad3471779808b530_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c601e0fb53d4bfc88abc7f48831dff4_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8f4ae7d6e40411abaa1ab3cee43b803_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib210c73f222b479aacb31d6c32738d5d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370133c2be5a4be79dd89de09dd1a1b8_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe95faf72a3246748e2a732611bcf248_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30773c6942964c0980876adfe8b4a851_D20220101-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i764cde6156604a799beae35a5e6999f2_D20220101-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a882359d454a71b139c8ee18e1de06_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c21eb451cf4e45b21d701f1947ac11_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6173132078d438bbba880f5dfde1512_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icced37b763334b1db16365dedf95e6d1_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d134762ff946cba4a83f58faf4e361_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:ReViralAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71295b17171746288ec47f20b8ee151f_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:ReViralAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71fb5a9220eb4286ad607375052a2cf9_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ae880bca4843ffa60f855563953d75_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbfd79f30ac46d99ff22eebda466560_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ff7971d70164752ac30c9be1a49a15b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f4fc3e7944444dba03aff7ca27b97f_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2887f09b32694901bc3771fd88f8b571_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i880f15025068413dad240be909e60e93_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d02fa2996741259f33220479bb03a3_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i192d7d95f8b84ad2b81b3eb16434a86a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89cf38054c742fbb7e8b11d2e93a06c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4458f5262e14479a0a31486f5d571a3_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56465e50cdb148659d882d69f8907dce_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9616f23c18c4880ac9e0c371d696ad1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9fab9cc315446eb0e13ffaff8ac454_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f52d12f36247d5a3bc27c6d932e64c_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a747b5aa22c4f1886ff55881482a458_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia080a8aa1141463990cc38aa96fa8e59_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a6341d784a94e3087d8228477c40d27_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2dfe09f313047a18e739d76fbc1485c_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e6cd06a51948a1b9a6198a5b0d7711_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1858be123e4843836e844815b1712b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c033a90c144654982cec00e6120cd9_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63858517ad514373922e2e8b09241570_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc4117e5afe4c0e842be69332f62eae_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9e0a2c8196543638ffe58bb564300d7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafc3f7a9cee4ec19c29b091247d4bdb_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9199195ad7641279516c969753b478c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38648544e7c43219d1df8126f6b9dc6_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607941fb91174f77a6d963a5372b1b3a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida92047028cd4bed94eef70e5400c5bf_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736289ab886a4191b2b2182031ea21a6_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb736aee91454a25a6441df3dd80d5e0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if613572161c346fcac294c7e32c378a8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e054adec2e4bad8ec56ba5798ba8ae_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b47973e6ac40f7962fdc8d0adb611d_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf979907b2914655ac6e0a1a750fc363_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f53b0965de4c1fa8b977d9f6510ac0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eae5a52dc634277ae8d307ccfb995d2_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55da2d7f85e40b58f460bad5984b81c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia10d0e1d609e4e219fef4b97c4939891_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db8e7e6e5bd43f899b2d9e49d1a99f0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if421226bc57541e4a9ce23fe47d542e2_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c319b3ee06435f8203948f53950fa4_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46cead4bca44470bb6e5485ad16d704d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f8c171007c41bbb0447b451c0d89d1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d1e1da5edbd418b9ed52c7482de82cd_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e87bf34d54945c1bb8dffaa5340c8c2_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f9228a4392140c5aadff356ad41e232_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ddb4a7f8df94efd865ffc529de4e9e0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586dad3bf41b4478a6a7bf583b2bf621_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e4b745d89e249d491f381c3aaf895c5_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ef446f60f046bca0e069bd65549c9f_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d914ca9794640ffa3ec5e10b6cee5f5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930a1f7cfa9d456bae7cb9c7c1e3e816_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b8fafd05bb4f5db3a80e0c919d745d_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac2d287a23b4b88b22df7d728b108e5_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b85277d9f04472693fc3c174486102f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffcfc2ea0698426aaf9c9ef575fd797b_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief03ef0a913a488da5d349f44b79df38_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ac32c435d7417a8258ad657ca4d5db_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9e7601d2a949b391ea06de7ce817d2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847b7cc69e5c45d4b6eb6fdfa02ac9fd_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78cb321690f41a9bb94aed3b1906a7a_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4c063dba364bb6ba775ef1b933b60e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1192155b8f54c838c4960883dd5cd12_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i219d3b8b6bdf41049720a23a2998280a_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8900fe5ad7d64b02bae061fd7863a809_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1f67297a35446ffbfeb15e1560ea010_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia94e68a684f34fdeb284ae983ecf8590_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997a8d6896fd403da5f90a6718f7b5c2_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c282565578941d5950ca8e622206e11_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3450d41f6f8c4add8f70e81bad35f8a1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb3e653eb0046c7ac2807a447d5a81d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife21a256301a4c639bb9b4d83799b744_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3564594ecfbb4ce7bddde0cfd454db19_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681fcc33174e41159cf96193a702c0dc_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f4ff79e8e54212839e35689b460762_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f46d7110d242bd9da8d5dc2c2f396b_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dceba1ae2e14264b25308d846b234a3_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fead61708764dc986e38daecc3da97a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc960090f944473b1de0a5c83bdb9a9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a2a488847c40d88bb4f5f52dec7967_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e18531693d04b6a98fe0852c4c5025b_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0452040fe699493da4f37d561f3f548d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b42fa5a6cd411a8ce00a20130d39dc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2892d1f59005440db65ec4752ff8a06f_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09231dfffc444767bb73115a01b1de18_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a48fa456e8e4117a0324151697d5442_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f936ba9ca84017b4b97358942bfc9e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8e83a1b35f4cb0aa9adf9618682ad6_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f393eca9894fb1887c099d45a0457c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73121833f65a48dabeef6c4f70ffc8fe_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e0cee382be47eaab3cef8255b4bbf3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb25ad491f0f4cd4868a150b3df14736_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5874fba6c68e4599a0fc3fb5193f6357_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed5fec2776a43d5b52002377b487e31_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b5bcfbd37054eeb8cf0f03e878adeb1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cad181f9d3a4c559ea98c3fe153c7e0_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabe9fee66024117bd6b35cc88a984d3_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19b5d2be8736491eb3d14bd80d72787c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb8d7d4ec27458b904b759251802162_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i528162cfdd864c2f9cfe732522d830b7_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb1258143354aadafcf0cffc1e8922c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1973fbbf1e499b9274056be29d6f9c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a43c802a36b4c2db68c41cc136daf70_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271e8b9e93e84bcfaa8c788053977b20_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20359a48688484fa197f302f7463767_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4034cba9c5324ca795292cedaf88e6a4_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c5554206f8a46328005d910c6b0e431_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i427f057de3fd4215b2b63624f5c325a0_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee23be5e923547fab2329d5b56c61ed8_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6646c1fa39b14bd4a1f5e9affc1282cd_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab54fbd61cf24874aab5381668df8403_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c3e0cbcbcf4b03a734bd12c5194903_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec65066e53f40bfab7cdd1c00671818_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218a664fe1c4469bae3b80333f3e0cec_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b91d02d234645c793606aa29b0d901d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5d2ac36d9d4be0b0289526710db8fb_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia969cc2c0ebf47d8816380e47bf220ed_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42322074968a4077a5a1b52768045df2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f3be521f224b8fa223498877d51452_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41086f4199fa4adf853900d30d476fc0_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35c1201fcf34260b06f08c7d2dca0d9_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9f1313cc29448587a6446dbf0c3f3a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e86ded88f3c4dc6812eb051724b5fbc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i693bafa1895348fbb803b977431d462f_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91260f6cb4049409f21cbe3937ebc85_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db6bbabd95c45ea956e59e8ea612ed0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e33f7150c6471c938a45f53ef7a709_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice7fb1f835ee48e7963f5d0bb55330f0_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ab61c3fcb34e45a64f5455f6442ef3_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia102ac741b5e451aa63ffe982d59beac_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae5f3828ae041d8bde249471bd9e321_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeace31d957b42c2a7709f9948bc9709_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878d1447a4ca4813b621dc3cc89befa2_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if602f21734f7495d8b816aa6bcd6498c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e66fa2a70a4649a96bfd9b2e39b902_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28dbbb6bb0e41d5a7fee7ddf2c97859_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37857266a0444b1a85059b213ce1320c_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3b9a9454c04c2a91c44f60a9080c13_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id633b0178823447f98f4fb90652a4b43_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib646354746ad4597828f14cf71b869f0_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801deeefe2ab4c79a8fc02da44868706_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia62e7abf3e4d48e080bf9026efbb11a2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i004d3ce3105a4fed95460eec415470e3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11eb45e9cf444c2aaec2c6742022efdb_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b25b150fb1c45e9a0380f915623fdb2_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib80b331462b2491d9db4424b5e8bd924_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6692eee652446979a0b8ecce8cf90bc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da74bd9833e4cd6a768fed715ba4cb1_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id176e11c7c904d469cd2382368b11d61_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0836f20c7ba46df8c7fb318c2836678_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a2ad9788911406e9443bb89ba74f344_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea562808de51468f86c413b0feafe114_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973e5c192f1f459782b9e4ea90048122_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a004a95111a4f2db0d2669d2f610693_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f100f20573b432288b09f6b64c4671e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa66a51bca84785ad4c259d04a22cfd_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d54941efa2941f699fe6aa44f0a4954_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ee738588b245b38e912a7df8a75d04_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76089b0f719c43e08c7f98682f02aa83_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e3fef4910241e5bcb815efea4ec15c_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f57ceefda7c437a8b98c4564c51b6f7_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if69e9f4ce5be4a61997e3ab67969be34_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf753ff3c5554491887de93db1fe560b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdcaea6d26ee46e0bafa9e9f9da6496d_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0acf4ae0c84031a293157923acb753_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b1ca93f57b4e6ba57c282fa30f3976_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357d700ae87d4d468163149932549cc6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c2de171ee654cf8884e29fdc4318a0d_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ceb413b1694f46ae29ffadc6262050_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5bc27120a7c4359a1cd74322bb22c5b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7f810aa79a45b0bb5466e60f929931_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4093973df5c94ed990eeaa9c48d107c5_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56622c1212fe46f68f7c8455f4d2a523_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d1bf41d84d4d41a0c1deb806b16620_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900010cf3afc449c8b72dce7cc16fe0d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71bf78dbc98843239656272f490339bc_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de406d2bea4496db2a3b0790f7858dc_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib61ec39f8eec4e90a85dfdf93b4b8e60_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83462764e3144e25ad4064bdf364bb72_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09ed1dfe1fc44eba41758c7b72b1220_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f066e1ee0b44eba6238a376debfc1d_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b3896ecd1f4b91b83726ec4b21f326_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15ad6f996594166971b1dbb8262b0ea_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b7b3fe6f55498d913853d8a9489481_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69fbc0b4b93c4abe94a8ee2dcd69e98e_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70124bbf39724876b8acf2c4bfeca836_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206d32a63e3f4cfd8f6c8d75168367bd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie87e55493f364c369dc8ad1d40cbd422_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib27f8e680678446f86545701da276329_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fbeed7d4fbf439a9819aa469673b46b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b58aba96014c749e5dd13a48805369_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a3dfcdc4c8a44a08bb30d6681bb333e_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43bf4a89a5f40c9abaea813b2440c31_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eda3444dc5f41b4bba147d8d43c862e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c61ae6ba8c4e6ba44617ed0e6e6331_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809d717936604b26a18012f7b8b9e2cc_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic160791460df43c18efb41f047eb99f2_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e39688a3c748cbb50e3f3fbd49323d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2b596d2f9944daa642c722ddb35c58_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id911b17700454881be23254e2132425f_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c47732986f4e1cb33d655f70e90bda_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e972355f674b2c8872f2e11d8a753f_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8472823d53ca4530ba656db6b08aacbe_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4401e5c37dd1444192245cd5facba3fb_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027f314cb29d4db7820ad2436483ee1d_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iace4e825c4024bd7baccc5a0fc1b6426_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39b763d5ca341f5afd21c2f801ad63d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531e99cb29294ab58cbd26ac7ff982c6_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18af7be85824b4aace60f7124ab2108_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992624b40ab1462a957959426582393d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5155b8e6532848ec99ad1757626c1d0a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i622fdfe2355249ccbc9c305380b6be81_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4503374f47504e53a8a556f65267f8dd_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d0c096b86f4eaba702765dd3329741_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92617f0978cb4c60a86dd7c4cabc5122_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ebe86d55ea4421c89f72c68a2c75f59_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc10872084e8447ab3832bbc01a6c62f_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7feed05291314be8ab413820d9581a34_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34e46c91a314553b59159136459f579_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b801e727bf47de83a1422fd1a40ba7_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb622ed9f6534687aa3bf61cf0d3f889_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a658246e2b34fd6a44cebc005385303_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a9464430b1419fba05017b8bd79cf5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde011cdb7ec481f92dc1a4d3d485ee1_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica70d473e5c64734bc680a816c324426_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7336380d9d6f4a4495fae7cd4004e307_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ef9df7820e54c5ebe5b2bbcfce634fb_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111ea6956a0241f7b44852b8f11b8f68_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f1dfd6335a24eddb48dd65039a27f6d_D20210101-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e6b4b0386445c2b216f9309b164440_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-03</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8bf1cff4bcf46a8a95e2b2f3561e4d8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e1cf1555744ef5a90bad26608bf34f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5156002b7783431eaae2362428a7dad3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia747d02316fd4b71a97be55a1aeac96c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec84b4e39aa4cbfa3468dab7b9c69a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134056e8daf84277a6603491cf1250cf_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f817b3f9c904714845e29d3b0c9c8f6_D20220101-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTEw_9923cd38-7dbe-4b3b-b819-55589f178430" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA0_6ca71259-76f1-49da-935c-89714090a072" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEwLTEtMS00Mjk2NzE_5b3efcd4-f969-46c7-80c1-a92dec07a833 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEyLTEtMS00Mjk2NzE_82f8212f-cbfd-4463-bb16-46a3bf600668 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTItMS0xLTQyOTY3MQ_4963ea75-ee90-4f56-94c3-f8145aae7c59 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTQtMS0xLTQyOTY3MQ_eefa11be-3c33-414f-aa24-e637b9e13a2d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC00LTEtMS00Mjk2NzE_a263b85b-e520-4043-a264-bac7e134fa07 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC0yLTEtMS00Mjk2NzE_7ec794a7-64fc-462c-ba71-8d64150189b3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjIy_3f8ba6ba-a903-4756-95e1-240772a5e732" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNC0xLTEtNDI5Njcx_65a1690b-56f3-43a3-ba0b-a7b1b251e5f2 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNi0xLTEtNDI5Njcx_0a9e4766-78e0-4f4d-a516-d8ff1d77c48e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktOC0xLTEtNDI5Njcx_d3fed0bf-d915-4612-8a1c-f7389bce1827 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktMi0xLTEtNDI5Njcx_4ec007b4-6ac4-497a-8dec-4da658597588" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS02LTEtMS00Mjk2NzE_8544ae2b-5f21-437e-b021-ac522c5a2d24 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS00LTEtMS00Mjk2NzE_29b75c68-773e-4ad8-bbb3-abd94eb1b2cb id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS0yLTEtMS00Mjk2NzE_0f02e791-2a53-4174-8273-fb3671668c74 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS04LTEtMS00Mjk2NzE_94b6c3d5-e3c3-45f7-bb93-09c0ebe86c83" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNi0xLTEtNDI5Njcx_626fee7e-657f-4788-a035-b8cd2f31808f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNC0xLTEtNDI5Njcx_97d270b7-b1ce-45e6-b737-833c464ba639 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItOC0xLTEtNDI5Njcx_00d1ae0d-5416-453b-a4cc-e1d982d37e99 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItMi0xLTEtNDI5Njcx_57e6f583-7137-404d-adb6-5515aacc01aa" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC00LTEtMS00Mjk2NzE_2fa4bb9e-0957-4c96-9091-0393874e4de4 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi00LTEtMS00Mjk2NzE_53845acb-2cf8-4668-b312-61c0ac2a9c31 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS0yLTEtMS00Mjk2NzE_5eb218ae-d9ad-49f3-b2f8-d149de85dbf7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC04LTEtMS00Mjk2NzE_3b2e2844-68e7-410e-8433-e1a05ba0a696 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS00LTEtMS00Mjk2NzE_ed942a2c-7590-489c-aabc-dfef446d4052 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC0yLTEtMS00Mjk2NzE_4f224122-0a35-4e3f-9dd0-11041329633b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi0yLTEtMS00Mjk2NzE_44117283-5b09-4994-af4d-2d8dda2ed9cf id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS04LTEtMS00Mjk2NzE_7624d374-59ee-4834-9165-8897722eb1be id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC02LTEtMS00Mjk2NzE_4e16e5b6-403b-4338-ba8d-a34667b802d1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi04LTEtMS00Mjk2NzE_e873dbff-e914-4e5b-8326-561e7d2cf216 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS02LTEtMS00Mjk2NzE_5f1649a3-e04e-4ee8-a021-870ef2ee4d98 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi02LTEtMS00Mjk2NzE_5437d538-f3b1-46a7-bced-fe9257f5f05a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTgtMS0xLTQyOTY3MQ_f6b12f8a-bcea-47d3-9125-6393606efd3c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTYtMS0xLTQyOTY3MQ_945cea22-a4ed-4fcc-a514-2cd8d824094b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTQtMS0xLTQyOTY3MQ_0c8722b8-2872-4bf9-b21e-e3d503546382 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTEwLTEtMS00Mjk2NzE_1b1bd2f4-3d49-406d-a698-4ea9fc91acac" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMi0xLTEtNDI5Njcx_3ccb185c-d21e-497d-9541-82146f5868b4 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMC0xLTEtNDI5Njcx_493e4ba9-7b8f-408d-ac44-f4a29de69d63 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC00LTEtMS00Mjk2NzE_de3ad6c3-47cb-4953-bb35-35061c8d9092 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0yLTEtMS00Mjk2NzE_4ca766d1-f980-4cf2-8135-ebd81ac499b7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC02LTEtMS00Mjk2NzE_4bd91447-2eeb-4b1d-84e8-75f3886b7b62" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS0yLTEtMS00Mjk2NzE_024cc055-6b5e-4f81-9da0-c6acda341735 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS00LTEtMS00Mjk2NzE_e4668477-5c06-4db4-abbd-1dbe4b47532b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTA5_e27b3df5-fe48-465d-9f76-7923a63796dc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE0LTEtMS00Mjk2NzE_c87a90a1-97f6-4519-9d12-26b54b67d3b6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtOC0xLTEtNDI5Njcx_3970ef26-7ab4-4db5-9b5c-26484f676cc9 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTQtMS0xLTQyOTY3MQ_226e5b3b-54b5-4194-b403-f87f87f87f9c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE2LTEtMS00Mjk2NzE_eee3e1e2-82fe-4633-bb68-b14a0ba0abc1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTQtMS0xLTQyOTY3MQ_074836b2-faee-4d14-b5d9-ab6657e72802 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNi0xLTEtNDI5Njcx_ce73b70f-34ce-448f-807d-04c0483f9a88 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTYtMS0xLTQyOTY3MQ_bab49336-8663-4d3a-b54b-642ee3f94a67 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNi0xLTEtNDI5Njcx_070c8ab3-8d87-4f6e-aab6-87c2cfbc7637 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNi0xLTEtNDI5Njcx_9efc31e5-89bc-4e23-ab26-ff76bde76ab9 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTYtMS0xLTQyOTY3MQ_6962e718-3d63-4e6f-9c5e-93659d844f06 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTgtMS0xLTQyOTY3MQ_bea1bcfd-0ccb-44e5-9196-b6600e3f9f50 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktOC0xLTEtNDI5Njcx_013b7d41-ff1d-4bc4-9652-bab9578b9d88 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTQtMS0xLTQyOTY3MQ_ddcf4ce1-5e2a-490e-b1be-26e2a0de3ab1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTYtMS0xLTQyOTY3MQ_2c73d3fe-554a-48ee-a459-c86ae5e5b0d6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtOC0xLTEtNDI5Njcx_4cdfb2b0-ed3d-4b43-8cda-eab2c971db6e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTYtMS0xLTQyOTY3MQ_1b6cb69e-152f-4b80-b384-2bb98a4369c5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtNC0xLTEtNDI5Njcx_9035346d-b158-4367-9a1d-296132bb041b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtMi0xLTEtNDI5Njcx_982648aa-6469-48be-99c5-f6a8806bdbf1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgw_14ab4f6d-72db-4770-bbaf-3b5b5c0fc91d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNi0xLTEtNDI5Njcx_b59868eb-033a-4a90-b591-19c42eeddd39 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtMi0xLTEtNDI5Njcx_9c51b6f7-67c7-432c-9e63-82529e0ef233 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNC0xLTEtNDI5Njcx_8a45feee-639e-4454-b3fc-f9624de079ab id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtOC0xLTEtNDI5Njcx_553fd7bb-a59b-4591-a381-13146ee4220f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtOC0xLTEtNDI5Njcx_318869ec-9960-4b91-bdb4-182356a4bc99 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNi0xLTEtNDI5Njcx_b6b5bcac-63bf-4b98-85bf-a5df968d5b98 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNC0xLTEtNDI5Njcx_82f5e9db-b6b1-4de1-aa74-6c64330ab4e1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtOC0xLTEtNDI5Njcx_e0cfea43-1a3e-48c2-acee-7ea66cde29d7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtMi0xLTEtNDI5Njcx_60d08d81-6843-466f-90a4-c0b3b770f412 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNi0xLTEtNDI5Njcx_7ac490a0-73b9-452d-bf96-cfa38f3b8865 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNC0xLTEtNDI5Njcx_7dfd910b-3aeb-4666-97de-f5798800d3f7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtMi0xLTEtNDI5Njcx_90ce7781-3290-4ad3-93af-3e5a8675bded" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMC0xLTEtNDI5Njcx_68f6d789-f455-46c8-a3ed-e2cdffa43f1b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMi0xLTEtNDI5Njcx_e4c0ad7d-28f7-4dad-9153-c0c4f47032a1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0yLTEtMS00Mjk2NzE_09ed946a-8297-4206-96f6-5ac122523c37 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMi0xLTEtNDI5Njcx_e6e616e8-ff43-412f-bc24-145f96133e33 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNC0xLTEtNDI5Njcx_4142aa1c-bf9b-4904-9c6e-b7c56de66c64 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTItMS0xLTQyOTY3MQ_47c50bf9-f17a-4da7-b80f-308b9a10ebb6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS00LTEtMS00Mjk2NzE_1f004768-3046-4785-bc33-1afae8b0ea63 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS02LTEtMS00Mjk2NzE_911b960f-8d0b-4b2f-9c38-e805e112bc95 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtOC0xLTEtNDI5Njcx_7cece672-8cf3-429c-83fa-1158c7aa755c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNi0xLTEtNDI5Njcx_0afa9a43-daf4-408b-9916-d5dd42011727 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTAtMS0xLTQyOTY3MQ_68ce4977-b848-4e99-96dd-167dd7408585 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS04LTEtMS00Mjk2NzE_d800e503-a11e-4212-9c70-e64fafc7d253" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtOC0xLTEtNDI5Njcx_e1a657ce-6f92-4b88-a040-01ced8e13634 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtMTAtMS0xLTQyOTY3MQ_861ab00a-20e7-4f30-8db0-607aa59a0e6f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNC0xLTEtNDI5Njcx_f54c2b3d-bcc0-4b2c-8ef0-3b3d36e9523a id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNi0xLTEtNDI5Njcx_29ca35ef-f9cf-434c-8106-d7cfe2617f64" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNC0xLTEtNDI5Njcx_282468d2-ace2-4483-8f10-fd7dd8256097 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtMi0xLTEtNDI5Njcx_cf9e841a-ac3f-456b-b46b-755690a8aad7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNi0xLTEtNDI5Njcx_691a0ba8-5225-48b9-a6f4-1e75e20d734d id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtOC0xLTEtNDI5Njcx_8c5b20ac-1e31-43a7-9a2e-80389b83155b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy02LTEtMS00Mjk2NzE_a1c2893c-c20e-46fd-b88f-599e3e194b3b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy04LTEtMS00Mjk2NzE_86b449de-4569-4595-9b66-d97adb3d390c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy00LTEtMS00Mjk2NzE_824ff5fb-0912-42a1-801a-3a2c58508bc5 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy0yLTEtMS00Mjk2NzE_87621f1f-793f-4e86-9eb5-afa1e0e859ec" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNC0xLTEtNDI5Njcx_6bfa4ccb-a89e-4014-b8a0-4f826bebfb8e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNi0xLTEtNDI5Njcx_0661d1b1-662e-4b85-97d1-02884e9bedf8 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMi0xLTEtNDI5Njcx_842617ea-9719-4eab-b73e-1115756af0c2 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTItMS0xLTQyOTY3MQ_ceabc205-2d62-4e44-a517-a8483c87e5fc id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTQtMS0xLTQyOTY3MQ_0ef21eca-e6b7-48e6-88e1-69577f2efbaf id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTAtMS0xLTQyOTY3MQ_ccb81272-5aac-4f1e-a246-4576be170c8b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMi0xLTEtNDI5Njcx_5af25e10-6100-474a-80a2-768f0c5ece86 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0yLTEtMS00Mjk2NzE_98c53b55-1c37-4942-a131-1e3138a4fac2 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMC0xLTEtNDI5Njcx_321577f7-e593-49a7-a7ac-2b0830e4ef5b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS00LTEtMS00Mjk2NzE_50bb3f84-6761-493d-849a-d1eae1d8d3fc id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS02LTEtMS00Mjk2NzE_99b7ca62-b866-4c59-9bc7-b23b4df8d23e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS04LTEtMS00Mjk2NzE_80861cc7-b44f-4666-ac47-8bdbf158d915" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTItMS0xLTQyOTY3MQ_f3c770c9-7c9d-4ac9-9927-009949ba22bc id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTAtMS0xLTQyOTY3MQ_eafab965-bc26-4ea2-845d-e55fc001d4d0 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNC0xLTEtNDI5Njcx_e9f4df3e-bde7-47ac-80c2-730480077951 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMi0xLTEtNDI5Njcx_e9b9138e-fb58-4795-8f2c-a4d80e522093" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC0yLTEtMS00Mjk2NzE_312e8447-359d-4343-b5cc-758a50fea8f6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC00LTEtMS00Mjk2NzE_45240349-7a57-4b66-8563-1735eb215c7e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC02LTEtMS00Mjk2NzE_bd465f0a-3160-4eee-9aaa-b9f143521049 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC04LTEtMS00Mjk2NzE_89cdec7c-14cd-4eb1-b43e-bd10aaa766ee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy0yLTEtMS00Mjk2NzE_6b841c4b-f673-47a6-b336-32d761d15aeb id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy00LTEtMS00Mjk2NzE_86dd17bd-21d4-44d2-8df2-23e29c42b7bd id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy02LTEtMS00Mjk2NzE_2b68c9b4-d476-4c72-85b2-8e48b07f8779 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy04LTEtMS00Mjk2NzE_2b96c6ba-c542-4577-a709-22e7b00662cd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTEwLTEtMS00Mjk2NzE_79069066-5ead-4735-9ca9-a0c728f6a653 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTQtMS0xLTQyOTY3MQ_fbd1b23a-4de5-4731-90bf-a49e2f6a8698 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTYtMS0xLTQyOTY3MQ_668cc3dd-3341-4358-a350-cbf225cdbb2c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTgtMS0xLTQyOTY3MQ_a17914fb-258b-418b-a9ca-4563cd5cfc48" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtMi0xLTEtNDI5Njcx_ca5fa3ae-21d5-4c48-93b1-a60c41f42be6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtOC0xLTEtNDI5Njcx_a5ab5888-7716-4238-ad86-b88c6ea5907f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNi0xLTEtNDI5Njcx_bff3b0ab-ad48-49ee-979e-f9df13844b8c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNC0xLTEtNDI5Njcx_7c89b3c6-eae2-4569-9415-e7d0b862ac03" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS04LTEtMS00Mjk2NzE_50323117-4703-41a1-9272-feb994edeef3 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS02LTEtMS00Mjk2NzE_b00bcbae-500f-4f0f-9340-0122991a721f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS0yLTEtMS00Mjk2NzE_38c92c39-bf18-49b7-a4a0-e25b66dbb213 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS00LTEtMS00Mjk2NzE_613077e8-5b40-4023-b819-a7c214d9ee06" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy00LTEtMS00Mjk2NzE_bde52b2e-a777-41dc-b155-e237fd719780 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy0yLTEtMS00Mjk2NzE_947423da-75c5-4888-8435-7ecabccea84f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcx_2a1b3533-c56a-4df2-8c6f-c6e181e09ceb" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMi0xMC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtNC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNS0xMC0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtMi0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi00LTEtMS00Mjk2NzE_5b63501f-3025-4448-9dae-f21d2b141cde id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi04LTEtMS00Mjk2NzE_14fa5f10-49f6-42ad-ba5c-7d5ca8c04911 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi0yLTEtMS00Mjk2NzE_df7dc9d1-9615-488a-bbd0-c4f83be85ba2 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi02LTEtMS00Mjk2NzE_59824e27-a17c-4205-aae0-a5a482b9df27" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi04LTEtMS00Mjk2NzE_339c5e19-4e13-4c0a-b6bc-eae3c491dace id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0yLTEtMS00Mjk2NzE_7a699dba-090b-429c-97be-830060b328be id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC04LTEtMS00Mjk2NzE_e29d8cd7-34c4-4497-9fe5-877dba1f1d25 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0yLTEtMS00Mjk2NzE_9a8f71b8-8682-4d0b-8e7c-5991fa04886e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS02LTEtMS00Mjk2NzE_3bb528dd-20b9-49b4-a972-f922d43fbdbe id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS0yLTEtMS00Mjk2NzE_35815b41-cffb-4b5c-9359-d379a907975e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS04LTEtMS00Mjk2NzE_75e41cf7-4116-4583-ad8e-d640a5fc5cc1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS00LTEtMS00Mjk2NzE_6c6b2ad1-9924-43b6-ab58-ece897ccfd1f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItNi0xLTEtNDI5Njcx_a1142993-e425-47ab-a0d1-446a18afad15 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtNi0xLTEtNDI5Njcx_9566c9fd-ec55-4d73-93d7-4a3c4e2174e6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMi0xLTEtNDI5Njcx_0ca3d8fc-7f0e-4e03-aace-8bacdd754f47 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtOC0xLTEtNDI5Njcx_5f924545-7cdf-419a-a41b-dab24a74c232 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMTItMS0xLTQyOTY3MQ_6b832ab6-88f2-4aab-a51a-d9475eb4d0ef id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMi0xLTEtNDI5Njcx_31a4bf64-afc9-420a-8aea-da78984567bc id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMTItMS0xLTQyOTY3MQ_1bfb8b75-ee82-4190-b19d-033448001fcf id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItOC0xLTEtNDI5Njcx_77fa5bda-2010-4cea-bb57-14533aeb9398" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDI5Njcx_8d93185f-f688-4c82-9b63-c777dc394dbb id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQyOTY3MQ_29765147-b42d-4233-b960-9afb141a29f6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDI5Njcx_8e5f7ad6-da14-4ab6-a1fb-eeb35bf1b71d id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDI5Njcx_937c2db7-ab03-49fc-b286-d87052678df6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQyOTY3MQ_ffb545fb-dd46-48ab-b6ea-e15473bc3022 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00Mjk2NzE_d37a0d72-b1c1-4bb5-9324-bd5157a70838 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQyOTY3MQ_ecc725f6-bf13-469b-8990-b9f59b18f062 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQyOTY3MQ_567f37c7-d373-4a0f-8f15-d40650e2874b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy04LTEtMS00Mjk2NzE_9b9133fb-bec2-4fcc-9258-400dd16c8db6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy02LTEtMS00Mjk2NzE_e6d2f62f-dc75-4d22-a788-915b8e020593 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy00LTEtMS00Mjk2NzE_14057630-317a-4fd9-baff-f0c8fddf43b1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy0yLTEtMS00Mjk2NzE_5a0039dd-c615-4609-86b3-a10613f0009a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy0yLTEtMS00Mjk2NzE_0ba4fb7e-a5d2-45f8-ba67-e60282dfe1d5 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy02LTEtMS00Mjk2NzE_de4ae461-5f30-4b05-adde-e986999b00d6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy04LTEtMS00Mjk2NzE_238101c9-15cc-4c5a-9e7b-f64e349a2256 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy00LTEtMS00Mjk2NzE_342264cc-7d35-46b0-a05b-7b425eca7b6f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC0yLTEtMS00Mjk2NzE_7eb1ff7a-3406-4304-b88a-2092e3e02ae7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC04LTEtMS00Mjk2NzE_a02c4c71-59e8-4024-a3bc-f64111e01fcd id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC00LTEtMS00Mjk2NzE_df798dc8-fee2-4fe7-884d-28e38adcae75 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC02LTEtMS00Mjk2NzE_42e675e3-ca94-417e-8df2-65d6b5bc7731" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNC0xLTEtNDI5Njcx_48b764de-0dc5-44cb-9b4e-5f3ce7a6c4ae id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNi0xLTEtNDI5Njcx_7f6beebf-da84-4f02-b2bf-af18544731d0 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItMTAtMS0xLTQyOTY3MQ_321a2ac2-0b2c-4ad4-a271-586a8acff56b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItOC0xLTEtNDI5Njcx_9cd29b34-d049-4128-be6e-e3926374efee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC00LTEtMS00Mjk2NzE_04673e43-36a2-45b3-b7ca-236158b88b87 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtNi0xLTEtNDI5Njcx_133301ad-6e91-4536-9645-63f6f0547007 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNi0xLTEtNDI5Njcx_ce90d9e5-ce46-4ede-9dd4-d3cea269650a id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTAtMS0xLTQyOTY3MQ_90670622-0649-4a76-bd2a-b31e91dfd5a3 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTAtMS0xLTQyOTY3MQ_1b6c0327-f807-478a-a8f0-0ac11991b5cb id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMi0xLTEtNDI5Njcx_96c0b094-7093-4d3c-91b6-849a99bc222f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMi0xLTEtNDI5Njcx_d76f42da-fb4e-446f-9ea5-f98760068047 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtMi0xLTEtNDI5Njcx_f3cec9d4-f77d-4580-b599-484f01f1a5a7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktMi0xLTEtNDI5Njcx_d0a45c0d-3364-46a7-9fd4-57a6b63bf52e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktNC0xLTEtNDI5Njcx_b1341912-72e5-4de9-b371-e3fad6bff794 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS0yLTEtMS00Mjk2NzE_0bf627f4-8dad-4eec-b99a-5aad854ec232 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtOC0xLTEtNDI5Njcx_07a36bed-d910-4d73-a6c6-5fd6bc7522b9 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItMi0xLTEtNDI5Njcx_e6218ca2-efe4-463d-9ce3-af6f1be6bb3d id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNC0xLTEtNDI5Njcx_211174d9-e259-4f54-9f87-7cc752aad16c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtNC0xLTEtNDI5Njcx_3bc803cd-e2a3-4377-b12f-8e60922a30b1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTItMS0xLTQyOTY3MQ_9ae39430-7552-4461-b69f-37394ff1a54e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNC0xLTEtNDI5Njcx_0bed8693-ae85-4b96-8618-be975923ee6b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtOC0xLTEtNDI5Njcx_9c90dcf1-6e88-4be7-b902-e170d48b4afa id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTItMS0xLTQyOTY3MQ_ab926219-d9a7-4b2b-bb7a-cd8b338b1a85 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTItMS0xLTQyOTY3MQ_8fa38e40-5385-4021-9ea5-fd9e6bbd255e id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNi0xLTEtNDI5Njcx_60eac3c4-32fd-43f6-8b03-4e76cadca988 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS00LTEtMS00Mjk2NzE_445e562c-2eb9-43d1-b0fc-b2019b0639a5 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctOC0xLTEtNDI5Njcx_6ed77661-b985-4278-9f00-9b1b503b67b7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTAtMS0xLTQyOTY3MQ_28197c73-6bbb-446f-a947-8e733c8ed5e2 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTItMS0xLTQyOTY3MQ_7434b05a-74c7-4239-a3ea-997576f4353d id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctNi0xLTEtNDI5Njcx_ce613522-b2e6-449d-9bda-6bbc50ef4241 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC0yLTEtMS00Mjk2NzE_a28803af-4e40-48eb-b68f-7954fb1a17f1 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtMi0xLTEtNDI5Njcx_72ec13bf-f3db-48f3-ae79-5c72c3f1d49f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtOC0xLTEtNDI5Njcx_24e61d1d-f7c7-46f8-9779-ec9d74a71fe3 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtNC0xLTEtNDI5Njcx_3303e9d7-5cc1-4910-8497-2ac64d94653a id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItNC0xLTEtNDI5Njcx_d4c83559-1407-444f-99a6-6ba36c9f1d63 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTAtMS0xLTQyOTY3MQ_f4b64b37-90c3-402a-baac-3d920218e6fd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNi0xLTEtNDI5Njcx_42cb499f-f636-4adc-b8ac-a98d69c36b83 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtOC0xLTEtNDI5Njcx_7ba0e3ea-e682-4737-996e-6547c9d8d1f8 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNC0xLTEtNDI5Njcx_03da9fde-fd5e-4bb9-b48b-aefe07d232a3 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNC0xLTEtNDI5Njcx_a4541278-e2cb-4393-a38b-ae8cad9d8c18 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktOC0xLTEtNDI5Njcx_0ac023e0-501c-45e6-8b76-9e5c1d60aa3c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNi0xLTEtNDI5Njcx_ad4f3559-591c-4f22-b2f9-04973e92ea32 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtOC0xLTEtNDI5Njcx_3fbd4518-51fe-483f-89a1-5cf9bf4a4751 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtMi0xLTEtNDI5Njcx_b8d35731-3c3a-44a7-85f7-4d37b26a1ee7 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItMi0xLTEtNDI5Njcx_a86e56c8-94cb-4066-986c-23c2b8d97686 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNC0xLTEtNDI5Njcx_8ece4338-3312-4216-a456-9e7e99d62f1b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNi0xLTEtNDI5Njcx_e1f2d427-f765-49fa-839a-f5c432154997 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNi0xLTEtNDI5Njcx_7fca1ffd-896d-495a-a9d5-7b0cede00795 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItOC0xLTEtNDI5Njcx_6cc8c14f-d7d8-4564-87d8-7758542b84a4 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktMi0xLTEtNDI5Njcx_a31d12ad-733d-454f-aacf-b9a02ebc2ddf id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNC0xLTEtNDI5Njcx_afc4de30-418f-4e3e-b0ca-ef2323eda3f9 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtMi0xLTEtNDI5Njcx_970aaef8-b5d6-42fb-a76a-f958b99c1684" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0xMC0xLTEtNDU1NDg4_e2b9857d-9a48-440e-b892-39f78f609815" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi00LTEtMS00Mjk2NzE_8bfa4640-17ef-44ef-ac97-dc7b2d8e9c11 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi0yLTEtMS00Mjk2NzE_71e44f3a-392e-466e-875b-5da4ad8a675d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTE5_795908f7-063c-467e-8921-7a9634d8d597" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC02LTEtMS00Mjk2NzE_ff34748e-e1cd-45ce-93ab-98ed5e2b47a4 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC04LTEtMS00Mjk2NzE_8c1270d2-bc3a-444c-810e-7d0db83546a0 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC0yLTEtMS00Mjk2NzE_2baaca16-26a8-47d2-a221-754f24fd20cb id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC00LTEtMS00Mjk2NzE_f2ce4cd5-9bc0-46df-98a2-0a1357007693" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTItMS0xLTQyOTY3MQ_a3b2da09-2fff-4dbe-9c94-5f0fbde322fa id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNC0xLTEtNDI5Njcx_7701f7ed-5376-447f-a11e-2b480b14bb8f id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNi0xLTEtNDI5Njcx_34e03b37-a1b3-477f-b8ea-6fc43d6d69b6 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMi0xLTEtNDI5Njcx_2721d866-8f12-475d-b329-5b2c2055214b id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTAtMS0xLTQyOTY3MQ_a4939c53-51b1-4072-8a3d-80ee90e928f2 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTQtMS0xLTQyOTY3MQ_b6b9f342-3cf2-42b3-b1e1-5ae23c7067e7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS00LTEtMS00Mjk2NzE_78979520-f128-45f4-991e-aab26f802b5d id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS04LTEtMS00Mjk2NzE_ff367060-a416-42eb-ac91-4c9ed4241d0c id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS02LTEtMS00Mjk2NzE_64fe25dd-a57e-463f-adf8-62bd1b937c40 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS0yLTEtMS00Mjk2NzE_0e091c4d-563d-4a8d-8711-bd269d2da7a9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC04LTEtMS00Mjk2NzE_ee5555c1-19b6-4724-8563-ebcc82def2cf id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC0yLTEtMS00Mjk2NzE_488adaed-49b4-417c-9242-a756da55a909 id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC00LTEtMS00Mjk2NzE_9fb5c4b0-0fed-4b82-a748-fa1f573f1bdd id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC02LTEtMS00Mjk2NzE_41178dd3-7bc7-461d-b007-624d30582aa9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i8c2530a91ced4c48b9620128206808f1_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl84Mg_ce67eccb-14c5-402d-8b09-8297c5d6b3f8">10-Q</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl84Nw_61ff7ac3-26bf-49e0-815e-173a1e143c53">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMTE_aa8629be-bca5-4b6a-ba5e-0c39116c0c4b">October&#160;2, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMjA_044a5d38-05a5-4dd8-b323-d824b0efe6a8">&#9744;</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  TRANSITION REPORT PURSUANT TO SECTION 13</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the transition period from _______ to _______</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8zOTI_a997713f-5115-4ca4-982e-a70a0ce726f9">1-3619</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">----</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80MDI_d811168c-bbb0-4682-86ac-772e008c44a7">PFIZER INC</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6MGRmYTk0ZWQ2NjY0NDkwNzg4OWExYWI2ODVlODZmM2UvdGFibGVyYW5nZTowZGZhOTRlZDY2NjQ0OTA3ODg5YTFhYjY4NWU4NmYzZV8wLTAtMS0xLTQyOTY3MQ_d6f1377f-2b97-4417-b6e1-2a8e916fba7a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6MGRmYTk0ZWQ2NjY0NDkwNzg4OWExYWI2ODVlODZmM2UvdGFibGVyYW5nZTowZGZhOTRlZDY2NjQ0OTA3ODg5YTFhYjY4NWU4NmYzZV8wLTEtMS0xLTQyOTY3MQ_47425e84-fe17-4f37-a361-0f70c08656d9">13-5315170</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(State of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMTkz_bd5d65e3-ea33-4e50-8aad-c637b12aff9a" continuedAt="ic705b8548e98437787cc6c00d26c5827"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">235 East 42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">nd</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="ic705b8548e98437787cc6c00d26c5827"> Street</ix:continuation>, <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80ODc_fa06f775-df17-4d55-94fa-a7266f1e7f35">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80OTE_65a003f1-2535-4ea9-95a7-cffe29eebc99">New York</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80OTU_d42da7ac-9918-47e0-8619-9717a7f644de">10017</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices)&#160;&#160;(zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl81NTM_800b53ab-63d8-4b28-8762-4cea84470bb4">212</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">) <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl81NTc_ab770b57-0493-45fa-9b10-e62a88b1839f">733-2323</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY18zLTAtMS0xLTQyOTY3MQ_dc4b9a64-0381-4aaa-b29c-ed5f6033cbf2">Common Stock, $.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY18zLTItMS0xLTQyOTY3MQ_caa4fa7b-1e83-4635-b8e7-eb613c3178a7">PFE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY18zLTQtMS0xLTQyOTY3MQ_be0e118a-7653-4df4-b7a6-3dd04b2b0824">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY180LTAtMS0xLTQyOTY3MQ_4db57078-1899-4325-b473-67eb7d037e67">1.000% Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY180LTItMS0xLTQyOTY3MQ_19e736c4-784e-4aef-947b-a0e468c0223e">PFE27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY180LTQtMS0xLTQyOTY3MQ_83c89b24-fb1e-4a98-b97e-499b1e4363bf">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6ZTkwZjc1OGM5NmMzNDI4OWE1OTNkZmQ0NDFkZTQ4YmYvdGFibGVyYW5nZTplOTBmNzU4Yzk2YzM0Mjg5YTU5M2RmZDQ0MWRlNDhiZl8wLTAtMS0xLTQyOTY3MQ_e3511144-f1f9-4477-825c-1683fc331d1c">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6NGRmNDFmYTBkNjRjNDAwNDkzZWY0ZmZiMTlkNmU5ZmEvdGFibGVyYW5nZTo0ZGY0MWZhMGQ2NGM0MDA0OTNlZjRmZmIxOWQ2ZTlmYV8wLTAtMS0xLTQyOTY3MQ_928c18d3-1723-44a5-877d-c1ecf022b1c5">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8xNjA0_21912e89-e889-4b05-928b-6efd7012e5e1">Large Accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8xNzIx_26185feb-6f36-4384-92ad-6aaaa1749eaa">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8xNzQ5_68aeea55-7ddf-4d19-9c28-ec21373802ca">&#9744;</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6NzIxNTkzY2UyNTk3NGZkYjgwNzc1NGQ3OTIwMzBjMTEvdGFibGVyYW5nZTo3MjE1OTNjZTI1OTc0ZmRiODA3NzU0ZDc5MjAzMGMxMV8wLTEtMS0xLTQyOTY3MQ_1de13be9-a9ef-4372-ab80-5df819fca7bd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At November&#160;4, 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieebdaac648754d8f9991d9345808cedb_I20221104" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMTMx_55e2c30a-8a1f-4f44-b7e9-e3641eb5e693">5,613,314,537</ix:nonFraction> shares of the issuer&#8217;s voting common stock were outstanding.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_4"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:92.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_10">PART I.&#160;&#160;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_19">Condensed Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_19">5</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_22">Condensed Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_22">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_25">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_25">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_28">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_28">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_31">9</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_34">10</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management&#8217;<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_112">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_112">38</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_169">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_169">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_169">59</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_172">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_172">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_172">59</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_175">PART II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_178">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_178">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_178">60</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_181">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_181">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_181">60</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_184">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_184">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_184">60</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_196">Item </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_196">6</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_196">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_196">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_196">60</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8c2530a91ced4c48b9620128206808f1_199">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8c2530a91ced4c48b9620128206808f1_199">60</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A = Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_7"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEFINED TERMS </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August&#160;28, 2022 and August&#160;29, 2021, and for U.S. subsidiaries is as of and for the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021. References to &#8220;Notes&#8221; in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2021 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the fiscal year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ACIP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advisory Committee on Immunization Practices</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ALK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">anaplastic lymphoma kinase</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Alliance revenues</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Arena</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arena Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Astellas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. </span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Arvinas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arvinas, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ATTR-CM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transthyretin amyloid cardiomyopathy</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Biohaven</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biohaven Pharmaceutical Holding Company Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BioNTech</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioNTech SE</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Biopharmaceuticals Business</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biologics License Application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BOD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Board of Directors</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CDC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Centers for Disease Control and Prevention</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CGRP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">calcitonin gene-related peptide</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">conditional marketing authorisation</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Comirnaty*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the Comirnaty Original/Omicron BA.1 Vaccine, and Comirnaty Original/Omicron BA.4/BA.5 Vaccine</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cond. J-NDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conditional Japan New Drug Application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK Consumer Healthcare JV</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">novel coronavirus disease of 2019</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Western Europe, Scandinavian countries and Finland</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: U.S., Developed Europe, Japan, Australia, Canada, South Korea and New Zealand</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Japan, Australia, Canada, South Korea and New Zealand</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Commission</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Central Europe, Eastern Europe, the Middle East, Africa and Turkey</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">earnings per share</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Union</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EUA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emergency use authorization</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Exchange Act</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FFDCA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Federal Food, Drug and Cosmetic Act</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This Quarterly Report on Form 10-Q for the quarterly period ended October 2, 2022</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generally Accepted Accounting Principles</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GIST</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">gastrointestinal stromal tumors</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GPD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Product Development organization</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GlaxoSmithKline plc</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Haleon</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Haleon plc</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">HIPAA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Health Insurance Portability and Accountability Act of 1996 </span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hospira</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hospira, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in-process research and development</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Internal Revenue Service</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JAK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janus kinase</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">joint venture</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">King</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">London Interbank Offered Rate</span></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LOE</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">loss of exclusivity</span></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic colorectal cancer</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCSPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-sensitive prostate cancer</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meridian</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Meridian Medical Technologies, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mRNA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">messenger ribonucleic acid</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MSA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Manufacturing Supply Agreement</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mylan N.V.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Myovant</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Myovant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New Drug Application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">nmCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ODT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">oral disintegrating tablet</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OPKO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPKO Health, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">over-the-counter</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Paxlovid*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PC1</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer CentreOne</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PGS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer Global Supply</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pharmacia</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmacia Corporation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PRAC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmacovigilance Risk Assessment Committee</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PsA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">psoriatic arthritis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">QTD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quarter-to-date or three months ended</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RCC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">renal cell carcinoma</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">research and development</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ReViral</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ReViral Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">sNDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">supplemental new drug application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">TSAs</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transition service arrangements</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">UC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ulcerative colitis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Upjohn Business</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer&#8217;s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Viatris</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Viatris Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ViiV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ViiV Healthcare Limited</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">WRDM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide Research, Development and Medical</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">YTD</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Year-to-date or nine months ended</span></div></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:5.25pt">Paxlovid and emergency uses of the Pfizer-BioNTech COVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), have not been approved or licensed by the FDA. Paxlovid has not been approved, but has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of the vaccines have been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and 5 years and older for the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">www.covid19oralrx.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"> www.cvdvaccine-us.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_10"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART I.&#160; FINANCIAL INFORMATION</span></td></tr></table></div><div id="i8c2530a91ced4c48b9620128206808f1_16"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i8c2530a91ced4c48b9620128206808f1_19"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi0yLTEtMS00Mjk2NzE_0d2f32e3-fc44-419b-ac40-ed721b1df0c4">22,638</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi00LTEtMS00Mjk2NzE_53508527-59e5-4b04-b339-aa3c0a96b5ba">24,035</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi02LTEtMS00Mjk2NzE_b77efff8-b498-4a62-badc-66fc8e5683e7">76,040</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi04LTEtMS00Mjk2NzE_796ef32c-d175-43b7-a17d-f11dbc00f7a1">57,450</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC0yLTEtMS00Mjk2NzE_4f224122-0a35-4e3f-9dd0-11041329633b">6,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC00LTEtMS00Mjk2NzE_2fa4bb9e-0957-4c96-9091-0393874e4de4">9,932</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC02LTEtMS00Mjk2NzE_4e16e5b6-403b-4338-ba8d-a34667b802d1">24,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC04LTEtMS00Mjk2NzE_3b2e2844-68e7-410e-8433-e1a05ba0a696">21,085</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS0yLTEtMS00Mjk2NzE_5eb218ae-d9ad-49f3-b2f8-d149de85dbf7">3,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS00LTEtMS00Mjk2NzE_ed942a2c-7590-489c-aabc-dfef446d4052">2,899</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS02LTEtMS00Mjk2NzE_5f1649a3-e04e-4ee8-a021-870ef2ee4d98">9,032</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS04LTEtMS00Mjk2NzE_7624d374-59ee-4834-9165-8897722eb1be">8,599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi0yLTEtMS00Mjk2NzE_44117283-5b09-4994-af4d-2d8dda2ed9cf">2,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi00LTEtMS00Mjk2NzE_53845acb-2cf8-4668-b312-61c0ac2a9c31">2,681</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi02LTEtMS00Mjk2NzE_5437d538-f3b1-46a7-bced-fe9257f5f05a">7,813</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi04LTEtMS00Mjk2NzE_e873dbff-e914-4e5b-8326-561e7d2cf216">6,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy0yLTEtMS00Mjk2NzE_6b841c4b-f673-47a6-b336-32d761d15aeb">524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy00LTEtMS00Mjk2NzE_86dd17bd-21d4-44d2-8df2-23e29c42b7bd">762</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy02LTEtMS00Mjk2NzE_2b68c9b4-d476-4c72-85b2-8e48b07f8779">880</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy04LTEtMS00Mjk2NzE_2b96c6ba-c542-4577-a709-22e7b00662cd">1,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC0yLTEtMS00Mjk2NzE_c6f1a830-a06c-4aee-b411-dbcfdf0db397">822</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC00LTEtMS00Mjk2NzE_12564d12-d1de-4a1d-b19f-e68162b72f4c">968</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC02LTEtMS00Mjk2NzE_24b3c54a-1ed1-4cf0-b08a-310df7b96c86">2,478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC04LTEtMS00Mjk2NzE_4c968175-e21e-46db-a922-4133737c989e">2,743</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS0yLTEtMS00Mjk2NzE_34bcc20a-e5be-429c-b94f-6f138e7cbe27">199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS00LTEtMS00Mjk2NzE_141dd8be-cd50-436f-837b-ef41ccff4cea">646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS02LTEtMS00Mjk2NzE_145386f7-f7d9-4efb-9fea-731199de4d5f">580</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS04LTEtMS00Mjk2NzE_54f66fdc-5dc7-4948-9ac6-470ea2a10152">667</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtMi0xLTEtNDI5Njcx_f1b974a0-f721-495a-8c2b-980eb4a3ce37">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtNC0xLTEtNDI5Njcx_d9cd9e2d-ef0d-49db-a455-b92cb5f2cd3e">1,696</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtNi0xLTEtNDI5Njcx_50f1acec-2b6c-4013-976d-04cd151bc671">1,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtOC0xLTEtNDI5Njcx_c73d25a5-a77c-4dd2-88a4-ed2e393f3f2f">4,043</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItMi0xLTEtNDI5Njcx_b74f2c58-927b-4637-aa3a-c9597d8cf8cf">9,001</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItNC0xLTEtNDI5Njcx_172e3528-8ecc-40f4-af06-c7e17485dfc9">7,843</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItNi0xLTEtNDI5Njcx_4e8fb54b-fcf7-4213-a1ea-c8a2a751111c">29,498</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItOC0xLTEtNDI5Njcx_2e242f61-5239-41a5-98e5-721d370cf9b2">20,484</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtMi0xLTEtNDI5Njcx_4eb2b6a5-1f1a-421b-b817-c1191f7c3d6d">356</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtNC0xLTEtNDI5Njcx_a47edd62-4f20-4aeb-a7ef-50ef3f6f501c">328</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtNi0xLTEtNDI5Njcx_03a980c4-325c-4d90-bff7-b2b2cb451d1e">3,098</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtOC0xLTEtNDI5Njcx_ac1c1dbf-708e-4e89-a981-7f7938fc773e">1,603</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtMi0xLTEtNDI5Njcx_416538c6-e744-49fc-9aa9-3f45248cb579">8,645</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtNC0xLTEtNDI5Njcx_863dddf0-ab18-4813-820b-d11680080ce1">8,171</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtNi0xLTEtNDI5Njcx_34acbfd2-99d7-4235-9ce1-574d0a5c82b1">26,400</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtOC0xLTEtNDI5Njcx_60475f03-882a-4932-bae3-06cddd35fd5b">18,881</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtMi0xLTEtNDI5Njcx_228e252c-df71-46d0-b57f-9c45515485d8">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtNC0xLTEtNDI5Njcx_e0e01aa3-ff0f-4f73-a1a4-f933ae8285cc">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtNi0xLTEtNDI5Njcx_856e4129-e341-4d20-9abc-8dafc7c44156">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtOC0xLTEtNDI5Njcx_a413be57-7984-4da2-8432-8482b7d0d5ea">248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktMi0xLTEtNDI5Njcx_af606b4c-87ec-42de-956b-526ea06907cb">8,623</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktNC0xLTEtNDI5Njcx_77e42dec-780d-4cc2-a113-b4f4303e9058">8,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktNi0xLTEtNDI5Njcx_0da6bb42-f51c-4c21-b95c-6ee74117d514">26,404</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktOC0xLTEtNDI5Njcx_f0e3a417-e3b2-4970-be31-50791f00af2f">18,633</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtMi0xLTEtNDI5Njcx_a0c4ce66-f3fa-4631-a780-30767f7e8c82">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtNC0xLTEtNDI5Njcx_5082c4d4-be7c-44dc-a173-63c37277ff56">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtNi0xLTEtNDI5Njcx_218d2c96-c588-4ddc-a74f-f0b8798ba361">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtOC0xLTEtNDI5Njcx_628167c0-35b4-4574-a786-60249ba4dc66">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtMi0xLTEtNDI5Njcx_290251bb-ed91-4bfc-ac6c-267c2a555383">8,608</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtNC0xLTEtNDI5Njcx_b5b96016-85af-4fd1-a40d-2949271ef80c">8,146</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtNi0xLTEtNDI5Njcx_d8b044ba-010d-4060-b320-b1b1b43e21a5">26,378</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtOC0xLTEtNDI5Njcx_34bb7a0a-5926-41b4-912b-8f94aadbee57">18,586</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtMi0xLTEtNDI5Njcx_c746c8ce-8261-43a8-a7b0-6378a9d90029">1.54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtNC0xLTEtNDI5Njcx_69f55294-c32a-4413-a154-4e70e102f494">1.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtNi0xLTEtNDI5Njcx_3ed71641-a75c-43fd-99e1-dae56520d95f">4.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtOC0xLTEtNDI5Njcx_d68c2377-17ab-48a5-abec-a4b7bdb59f62">3.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtMi0xLTEtNDI5Njcx_4b644c3a-8f1d-4e62-9a88-c4e1dfdf8f5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtNC0xLTEtNDI5Njcx_803452eb-2ea5-4704-83a7-5958ffa2f389">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtNi0xLTEtNDI5Njcx_63db5c22-1a42-4c9d-a2a2-530755d686e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtOC0xLTEtNDI5Njcx_159c7866-e6d0-4f2c-bad4-aece6bbf341d">0.04</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtMi0xLTEtNDI5Njcx_1943d969-9185-4faa-b7bf-098ae3d3a9ec">1.54</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtNC0xLTEtNDI5Njcx_24cac765-9335-4af9-a7fc-57228b907685">1.45</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtNi0xLTEtNDI5Njcx_2d22198c-a112-44b5-bc65-15f66cdc2392">4.71</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtOC0xLTEtNDI5Njcx_6f12f487-86ad-4e2b-b7f7-f6f809f01f3a">3.32</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktMi0xLTEtNDI5Njcx_c58fc77d-f4a2-4d02-98fb-b042079f20cf">1.51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktNC0xLTEtNDI5Njcx_596f751c-e7e8-491e-b9ee-42110386a239">1.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktNi0xLTEtNDI5Njcx_0a08a7d0-f1c7-4006-8e51-24c2c8c2f13b">4.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktOC0xLTEtNDI5Njcx_066c7566-bb69-4363-af47-3837c8ad7592">3.31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtMi0xLTEtNDI5Njcx_21dffebc-39be-4083-983f-bbb38442168a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtNC0xLTEtNDI5Njcx_2944049d-84c7-4eea-b969-3aa9bf4f57b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtNi0xLTEtNDI5Njcx_70f44876-41b4-4f5d-bcae-fd2efbe4069f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtOC0xLTEtNDI5Njcx_ab9d3617-6d6f-4b02-b2df-8a6fab37d1e7">0.04</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtMi0xLTEtNDI5Njcx_e92c5af5-b4da-48d8-9c90-dc36670225fd">1.51</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtNC0xLTEtNDI5Njcx_e836a2c9-303e-49f8-90eb-b0ffab2451da">1.42</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtNi0xLTEtNDI5Njcx_fb64428f-3962-444f-9bd3-a895cfc51ceb">4.60</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtOC0xLTEtNDI5Njcx_e709698c-585d-44f1-ab35-dbdda97f29a1">3.27</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtMi0xLTEtNDI5Njcx_e39187ea-0aba-4412-a3a1-de7fd27cb46d">5,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtNC0xLTEtNDI5Njcx_da641e26-9461-4303-a760-b0c9f2f5063b">5,609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtNi0xLTEtNDI5Njcx_e2f09dbf-7fbd-4e14-85c0-9a960721a8fb">5,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtOC0xLTEtNDI5Njcx_2e4f2604-2b4e-4270-b447-4e9b6373c111">5,597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;diluted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtMi0xLTEtNDI5Njcx_a0eb934e-9638-4dbe-a3cc-9d182105ed32">5,718</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtNC0xLTEtNDI5Njcx_3aeab3f9-33a6-4a93-b31e-a09d575bd5c9">5,725</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtNi0xLTEtNDI5Njcx_10502147-b493-4635-8a7a-59d01b94ecfa">5,729</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtOC0xLTEtNDI5Njcx_6a812a9e-b1b1-44bd-9c15-b7ef80dc5e71">5,688</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d" footnoteRole="http://www.xbrl.org/2003/role/footnote">Exclusive of amortization of intangible assets.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></ix:footnote></div><div style="margin-top:54pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_22"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER&#160;INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi0yLTEtMS00Mjk2NzE_af606b4c-87ec-42de-956b-526ea06907cb">8,623</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi00LTEtMS00Mjk2NzE_77e42dec-780d-4cc2-a113-b4f4303e9058">8,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi02LTEtMS00Mjk2NzE_0da6bb42-f51c-4c21-b95c-6ee74117d514">26,404</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi04LTEtMS00Mjk2NzE_f0e3a417-e3b2-4970-be31-50791f00af2f">18,633</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC0yLTEtMS00Mjk2NzE_2776ae9a-8b10-499e-80a6-15eddb465857">918</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC00LTEtMS00Mjk2NzE_eccd41a6-1c9c-40fc-8dc8-83bfbfbe33c4">866</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC02LTEtMS00Mjk2NzE_e5b09af2-592c-4dd4-928a-6641c991fdb5">2,549</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC04LTEtMS00Mjk2NzE_6bcdabee-e31e-45c2-b809-7f2631f6c487">366</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy0yLTEtMS00Mjk2NzE_818a491e-b825-4383-aef6-199c434bf957">589</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy00LTEtMS00Mjk2NzE_7b1e59b8-d5c9-4c88-be6f-71f5a4efd6ed">213</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy02LTEtMS00Mjk2NzE_9cf5b4ae-ce58-4a3a-b231-d34db7833798">1,443</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy04LTEtMS00Mjk2NzE_2a1105f1-cc66-4f79-b7b7-0f2c79d0c3ae">179</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC0yLTEtMS00Mjk2NzE_7eb1ff7a-3406-4304-b88a-2092e3e02ae7">615</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC00LTEtMS00Mjk2NzE_df798dc8-fee2-4fe7-884d-28e38adcae75">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC02LTEtMS00Mjk2NzE_42e675e3-ca94-417e-8df2-65d6b5bc7731">972</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC04LTEtMS00Mjk2NzE_a02c4c71-59e8-4024-a3bc-f64111e01fcd">286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS0yLTEtMS00Mjk2NzE_c2bb2176-72c6-4344-a356-4ee12070bf74">26</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS00LTEtMS00Mjk2NzE_9b83c0b3-09a4-428f-8e0e-4e8379ac010e">261</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS02LTEtMS00Mjk2NzE_36344dc3-5d45-4408-8122-4ec7c270cad1">471</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS04LTEtMS00Mjk2NzE_37883361-5053-4f85-94a3-a9d044085235">464</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtMi0xLTEtNDI5Njcx_c0141236-bcee-4a39-98b4-3cc498da7bba">777</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtNC0xLTEtNDI5Njcx_6b19560c-54ca-4f18-9e15-3b71b6497486">266</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtNi0xLTEtNDI5Njcx_5d0443a5-fea0-4485-9989-5fb4db4632c6">1,397</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtOC0xLTEtNDI5Njcx_411a1590-a301-4bd1-a61e-41687042695f">128</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtMi0xLTEtNDI5Njcx_cf9e841a-ac3f-456b-b46b-755690a8aad7">606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNC0xLTEtNDI5Njcx_282468d2-ace2-4483-8f10-fd7dd8256097">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNi0xLTEtNDI5Njcx_691a0ba8-5225-48b9-a6f4-1e75e20d734d">1,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtOC0xLTEtNDI5Njcx_8c5b20ac-1e31-43a7-9a2e-80389b83155b">172</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtMi0xLTEtNDI5Njcx_23aa35a5-1cad-4a59-a5b6-d1af741612b1">171</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtNC0xLTEtNDI5Njcx_8bfe948a-a8ef-4c51-a45f-d33161985d2c">257</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtNi0xLTEtNDI5Njcx_62b4451a-997a-45d2-bf5b-0089d10249c9">303</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtOC0xLTEtNDI5Njcx_9ef43871-630e-4ed9-9653-0bcf2bb46ec5">300</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtMi0xLTEtNDI5Njcx_f3a397d0-4555-49b6-b352-3d9672fc39d0">31</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtNC0xLTEtNDI5Njcx_1c121d60-12ba-453a-a42c-f93b42e1da22">39</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtNi0xLTEtNDI5Njcx_897e4f72-8960-4822-bbae-72a88673114a">99</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtOC0xLTEtNDI5Njcx_7b50b7b3-7252-4967-b032-d62da6cf13ba">119</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtMi0xLTEtNDI5Njcx_61a9b43e-c133-4b8c-bd2b-e2031e28a1ce">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtNC0xLTEtNDI5Njcx_f6eb9fc1-c403-43b8-866b-8b47d4309265">58</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtNi0xLTEtNDI5Njcx_b6361547-3579-4827-9c81-b6e45e028064">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtOC0xLTEtNDI5Njcx_e1d7e970-9148-4bc3-8207-498c26f2c7fa">62</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtMi0xLTEtNDI5Njcx_905c5677-7309-43f6-a70e-2d0f206c9e79">29</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtNC0xLTEtNDI5Njcx_42c60f47-1537-4b02-bcf6-69ceeae20a8a">97</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtNi0xLTEtNDI5Njcx_83839270-8eb3-46a4-9278-6ad7ce504dcf">107</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtOC0xLTEtNDI5Njcx_821b61da-fbb6-4001-b932-0fc7b6b88a66">181</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktMi0xLTEtNDI5Njcx_caeb3bbd-be1c-4a95-af44-4e09a5ba60d1">1,144</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktNC0xLTEtNDI5Njcx_043c5449-43bc-47b2-8e55-af4a2d56e37d">959</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktNi0xLTEtNDI5Njcx_efb9bf8d-71fd-472a-b098-0174535b225e">2,488</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktOC0xLTEtNDI5Njcx_759e7a63-b6a8-44f4-bdee-26492a3819cd">382</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtMi0xLTEtNDI5Njcx_2d6d9d61-4f29-41a6-84f9-a425ffad5c65">33</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtNC0xLTEtNDI5Njcx_2e9f1186-ba74-4ed0-97a3-7a4e4b10dca0">65</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtNi0xLTEtNDI5Njcx_8b218b31-6b1e-4194-9d68-45b49ac1e3e5">149</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtOC0xLTEtNDI5Njcx_aca22b7d-887e-4341-9f00-736ec381bc10">44</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtMi0xLTEtNDI5Njcx_5c4612ba-c16f-47ff-b488-e7a5c9cafdea">1,111</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtNC0xLTEtNDI5Njcx_3dd9c36b-a0e3-4994-8069-5391165d7e17">894</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtNi0xLTEtNDI5Njcx_bb5ed637-00b4-4368-8f98-94ec40bca30a">2,339</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtOC0xLTEtNDI5Njcx_feb4c3f4-07b3-4bd8-bfbc-e5bb88122709">338</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtMi0xLTEtNDI5Njcx_23d2d2d9-335a-4d01-b2dc-9b02198824c0">7,512</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtNC0xLTEtNDI5Njcx_527ae35c-ed37-40ce-90d7-7e58597fdd2f">7,265</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtNi0xLTEtNDI5Njcx_1fab5d5f-54f6-428a-be7c-aff0b243df0f">24,065</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtOC0xLTEtNDI5Njcx_3091c783-e039-4f76-a4cb-63494e485a3a">18,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtMi0xLTEtNDI5Njcx_6513a284-a76c-4d8c-bfa3-4ace5459ac7c">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtNC0xLTEtNDI5Njcx_2fbf9b6b-e001-4cda-b60e-acb1847c9c0d">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtNi0xLTEtNDI5Njcx_3086bdd0-f711-490d-a407-aaaba94db787">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtOC0xLTEtNDI5Njcx_0549a699-807a-4754-8b4d-a2046ab38159">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtMi0xLTEtNDI5Njcx_22a81fa4-ccf4-40a5-93a2-8f0cc36053ff">7,503</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtNC0xLTEtNDI5Njcx_a279d7e5-c54f-4c4b-b3fa-63e2e3f42c11">7,256</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtNi0xLTEtNDI5Njcx_aeaecbdf-695e-4476-a562-28ba9aba2499">24,049</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtOC0xLTEtNDI5Njcx_e05da5c7-d868-4519-b1e3-cf5dcaaa8b9b">18,248</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></ix:footnote></div><div style="margin-top:215pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMy0yLTEtMS00Mjk2NzE_cf4e4d65-1486-4746-a33c-5937bbdc7be8">1,298</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMy00LTEtMS00Mjk2NzE_0b90a5b5-3614-4d44-97b9-3ee66588bd2e">1,944</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNC0yLTEtMS00Mjk2NzE_a8967ea8-e7fe-452a-8fff-7cd88bf45d0f">34,825</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNC00LTEtMS00Mjk2NzE_cf53af27-dd9a-4d97-b3fe-4576f22cc1e5">29,125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts: 2022&#8212;$<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjoyMDc0MzNjNzdkZTA0MWEyOGEwMjdhM2Y4OTNlMDY2OF83Mg_9ceaac9d-3e7a-4864-80ab-70179347d3bb">474</ix:nonFraction>; 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjoyMDc0MzNjNzdkZTA0MWEyOGEwMjdhM2Y4OTNlMDY2OF83OQ_2cdbfe81-cf38-485e-9dfd-e467863ea5b6">492</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS0yLTEtMS00Mjk2NzE_8dea0fb4-2870-48e8-8ca2-15a8a52651e2">16,076</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS00LTEtMS00Mjk2NzE_66c48892-7236-4f48-b71f-b5bca7a84db2">11,479</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNi0yLTEtMS00Mjk2NzE_2c2a4ad8-f0d0-418b-8404-7ee7ce05127f">9,513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNi00LTEtMS00Mjk2NzE_7cd7d519-dab4-4911-ad7b-813bcd270500">9,059</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNy0yLTEtMS00Mjk2NzE_b07fc493-22ac-4f7d-be4d-14207965e9f2">2,544</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNy00LTEtMS00Mjk2NzE_c01b7bfa-e6c8-495a-a5a1-905f533d7baa">4,266</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOC0yLTEtMS00Mjk2NzE_4703f480-9a29-47f7-bb70-d742ec7b9863">6,149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOC00LTEtMS00Mjk2NzE_7ba236ab-f41e-4cd8-9743-8a54693ed601">3,820</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOS0yLTEtMS00Mjk2NzE_9cf81448-7737-472c-9634-6d1f650b3f83">70,403</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOS00LTEtMS00Mjk2NzE_db77c06d-7ed7-44b9-bcc6-8c194bf6fad8">59,693</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTAtMi0xLTEtNDI5Njcx_615391bf-0d65-49fb-aec8-ebbeee8be69c">9,826</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTAtNC0xLTEtNDI5Njcx_bb8584d6-d994-457d-b0c2-3f7ed39e21a1">16,472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTEtMi0xLTEtNDI5Njcx_64c52689-61ba-452f-b5ec-fdca113713ce">4,062</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTEtNC0xLTEtNDI5Njcx_836f5d08-9f3d-4db4-b66d-29515e352593">5,054</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, less accumulated depreciation: 2022&#8212;$<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246YWQ4NTlhY2FiYmYwNGMwMDgyMjQ3NmJmOGMyNjRlZjNfNjk_f2cf1c79-45a8-4634-b38a-bfc21c56cfa3">14,931</ix:nonFraction>; 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246YWQ4NTlhY2FiYmYwNGMwMDgyMjQ3NmJmOGMyNjRlZjNfNzY_1a34ad73-a804-4859-8c8c-85f686e538a7">15,074</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItMi0xLTEtNDI5Njcx_203d18b9-c82b-458f-8691-a58cc2b87a9b">15,441</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItNC0xLTEtNDI5Njcx_4e2929f8-8644-4aed-8ed6-85696e7f2576">14,882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTMtMi0xLTEtNDI5Njcx_fdefa490-9fc9-4d97-9a7b-6cf1e99f42f3">28,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTMtNC0xLTEtNDI5Njcx_25595542-c95a-4264-aea2-e3aee71233a1">25,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtMi0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e">49,441</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtNC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633">49,208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTUtMi0xLTEtNDI5Njcx_cf584daa-d9ac-4cb5-8377-eaab4258fc08">7,136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTUtNC0xLTEtNDI5Njcx_5fea5ffc-9fe6-4251-a87f-973921514b65">3,341</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTYtMi0xLTEtNDI5Njcx_2a969fb6-d0dd-48a1-8d8b-48b7df1d5da3">10,890</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTYtNC0xLTEtNDI5Njcx_a4bad6a1-cb13-47fb-94d8-577fce63eec3">7,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTgtMi0xLTEtNDI5Njcx_ee00c873-9492-4649-a43f-090bba2eeb95">195,350</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTgtNC0xLTEtNDI5Njcx_5c1b895a-4a35-46a9-b88d-e52420bb7c14">181,476</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities and Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt: 2022&#8212;$<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtMC0xLTEtNDI5NjcxL3RleHRyZWdpb246ZmVmYTZlZjEyODI3NDFmZmEwNWMyY2JiNDNiYjE1NTNfNzU_48b06320-5225-4ad8-9eff-78e46a287c57">2,566</ix:nonFraction>; 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtMC0xLTEtNDI5NjcxL3RleHRyZWdpb246ZmVmYTZlZjEyODI3NDFmZmEwNWMyY2JiNDNiYjE1NTNfODI_7dfb11a0-9b5c-4d6d-9b31-60cee8ff385d">1,636</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtMi0xLTEtNDI5Njcx_90cfa78e-bcc1-4e48-a15b-0199bd853c3c">4,040</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtNC0xLTEtNDI5Njcx_6d54ba55-d20e-4046-8506-1482ba1fa655">2,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjItMi0xLTEtNDI5Njcx_962d85a0-32ab-4c8b-ab03-adb777bb2592">6,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjItNC0xLTEtNDI5Njcx_60e4d723-b8cb-442c-b450-ae0a0820c5bd">5,578</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjMtMi0xLTEtNDI5Njcx_6fec2267-d1d6-41b4-b526-3e48ef52e69f">2,245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjMtNC0xLTEtNDI5Njcx_bbcdcea3-956c-4b9e-a1f4-01e7a3d2f58a">2,249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjQtMi0xLTEtNDI5Njcx_05a61d95-f3ae-4c6a-8ace-21a91a77c62d">3,071</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjQtNC0xLTEtNDI5Njcx_3e98f885-ef3d-4676-919f-244f35f0711e">1,266</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjUtMi0xLTEtNDI5Njcx_28253c3a-0498-4c4a-bc3d-c187d91cd0d7">2,852</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjUtNC0xLTEtNDI5Njcx_f3261cf7-6f00-4ebc-af62-42147082bbb6">3,332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjYtMi0xLTEtNDI5Njcx_971f3c6d-0b01-41a7-826d-be8f25593f67">6,191</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjYtNC0xLTEtNDI5Njcx_55f2b27f-13ea-46b5-9bb4-8f26c6161763">3,067</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjctMi0xLTEtNDI5Njcx_946a74b5-8c55-4cac-8f08-9e67c5baad21">19,647</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjctNC0xLTEtNDI5Njcx_932d384a-1ea0-48f0-81c6-1da6084b0d15">24,939</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjktMi0xLTEtNDI5Njcx_ed7b7c9b-7a37-4343-8321-b94736bedd6b">44,314</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjktNC0xLTEtNDI5Njcx_a0a51e5f-0eb0-4bd1-aaca-6d7d2dc13d34">42,671</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzEtMi0xLTEtNDI5Njcx_059d7115-7fb1-42af-881a-6c818e311891">32,629</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzEtNC0xLTEtNDI5Njcx_c00dc365-d02e-4820-8049-07ae88cb9825">36,195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzItMi0xLTEtNDI5Njcx_40ad85cf-22ab-4e52-a875-71a9f5d3b9ed">2,738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzItNC0xLTEtNDI5Njcx_5724bd56-864d-42c2-b875-1794b1b1f66d">3,489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzMtMi0xLTEtNDI5Njcx_175c54af-f665-453e-ba31-3f9195e5de9b">222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzMtNC0xLTEtNDI5Njcx_7495f7ab-5733-461e-86b2-070beeeab74e">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzQtMi0xLTEtNDI5Njcx_02421082-5d89-4aa3-9a38-a3f35f86964b">616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzQtNC0xLTEtNDI5Njcx_d4aeb96d-bb3e-4675-bf94-257b6fd0f7c2">349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzUtMi0xLTEtNDI5Njcx_99fd9320-9327-47ef-bc65-ac50130b23f9">9,701</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzUtNC0xLTEtNDI5Njcx_432fe9e2-a73a-470b-9ae5-bb840c6ce9b8">11,331</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzYtMi0xLTEtNDI5Njcx_ab0230ae-339b-4b05-a893-d59621665eca">12,239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzYtNC0xLTEtNDI5Njcx_9bac4a11-5408-40cd-a67e-2deedf772f59">9,743</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzctMi0xLTEtNDI5Njcx_18d4b297-86fc-41ae-9eff-4c69a985375c">102,459</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzctNC0xLTEtNDI5Njcx_79e1877c-a982-49f0-913c-fba1ce033681">104,013</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzktMi0xLTEtNDI5Njcx_79f0791d-482b-4480-914c-c33e39e7c2cc"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzktNC0xLTEtNDI5Njcx_26e3a627-da8b-4cbe-90cd-c1663bbe3bf2"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDItMi0xLTEtNDI5Njcx_1b13b1fd-7263-478b-8776-3cb9a46674fe">476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDItNC0xLTEtNDI5Njcx_0f4a9efe-2eee-4d5a-8b8f-a9c319a3c3e5">473</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDMtMi0xLTEtNDI5Njcx_d83006f6-1133-4821-ae6b-a53bd6f3da74">91,359</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDMtNC0xLTEtNDI5Njcx_95484da9-83c4-44e3-9bb9-27ca25a609e8">90,591</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDUtMi0xLTEtNDI5Njcx_686ac483-63f9-4b7e-854a-d06e7c4b60ba">113,945</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDUtNC0xLTEtNDI5Njcx_9b00a116-a4ba-4a62-88da-9a889ab0d28b">111,361</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDYtMi0xLTEtNDI5Njcx_e1df6b29-c7bb-499c-bac8-301f6303b14a">122,967</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDYtNC0xLTEtNDI5Njcx_c2e51b02-e44f-4e13-96af-9cbac8103b94">103,394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDctMi0xLTEtNDI5Njcx_e41c7e25-5faf-46ca-8450-b0fe4adae7ff">8,225</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDctNC0xLTEtNDI5Njcx_c199a958-9523-489a-8ed2-30d761f3aaef">5,897</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pfizer Inc. shareholders&#8217; equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDgtMi0xLTEtNDI5Njcx_0c656369-448a-4396-89b1-aa8c89a89d64">92,631</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDgtNC0xLTEtNDI5Njcx_36107412-754e-4cd5-9e88-884d2542e6d4">77,201</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDktMi0xLTEtNDI5Njcx_7084633b-65e0-4116-af2a-f0eb21be1256">259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDktNC0xLTEtNDI5Njcx_eecc6e98-fc3c-41d1-a45c-7f7210df4457">262</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTAtMi0xLTEtNDI5Njcx_47eadae7-2f1c-4025-a083-ac8450d4c10b">92,891</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTAtNC0xLTEtNDI5Njcx_20240e05-adf1-4f05-b20f-3131d511c8d0">77,462</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTEtMi0xLTEtNDI5Njcx_abe6c33f-0313-4806-8e76-d7982be446f5">195,350</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTEtNC0xLTEtNDI5Njcx_1d862d13-c6f0-44a3-a325-1d2c4073a528">181,476</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:65pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp. <br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, July&#160;3, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98083abf5b10468887a10a5321465a07_I20220703" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy02LTEtMS00Mjk2NzE_90eba9b9-3725-4f85-99e1-44835fcd9ddb">9,496</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98083abf5b10468887a10a5321465a07_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy04LTEtMS00Mjk2NzE_05ce0ce2-ec36-41b5-962b-50fe6c6ce7af">476</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3ad8bd638b94660a81910320140a0ff_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xMC0xLTEtNDI5Njcx_f2c85268-93c0-46e7-a8c3-e60c189f4d28">91,183</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee207eb562eb45749d0e09bd8ae27d99_I20220703" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xMi0xLTEtNDI5Njcx_9aa6caf3-50f4-493f-9d07-dbf43dfe4b1c">3,903</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee207eb562eb45749d0e09bd8ae27d99_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xNC0xLTEtNDI5Njcx_eb2652fe-ffb0-47a4-a02d-0c7fe129acd0">113,939</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd2c296b7794de18cd9165e100b3645_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xNi0xLTEtNDI5Njcx_922f065c-c55f-48c9-8bdf-5185e77e12b5">116,608</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac935618aa1f4c02973c960cd4d50198_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xOC0xLTEtNDI5Njcx_4ae13d59-8a9f-4167-b458-d15e9b7745e8">7,119</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dfdf4b4d9474432ac2661c4f07bf9ae_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0yMC0xLTEtNDI5Njcx_86428006-a9ef-49cb-a998-e3c92f5f4f93">87,208</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fa5b9f5af24e07a8d83bc03ff721d2_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0yMi0xLTEtNDI5Njcx_40decfed-27f4-47a9-a93a-4480a118e5b8">261</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291c881a539a4386ace0953f2e533606_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0yNC0xLTEtNDI5Njcx_bc187de1-c0eb-43b1-a51e-e502ea92ef85">87,469</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322ef81511754d73bd045b355aa263b0_D20220704-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0xNi0xLTEtNDI5Njcx_e998a6d2-52ba-457e-be00-bd86322e34be">8,608</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0yMC0xLTEtNDI5Njcx_c345f511-3bb6-4116-8f66-4f402f639203">8,608</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0yMi0xLTEtNDI5Njcx_361cbc95-2859-4759-9353-2cc729ea3196">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0yNC0xLTEtNDI5Njcx_1b856178-e053-4ad2-93df-d7fb49256835">8,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a00c9907efc45b58509f370291e703d_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0xOC0xLTEtNDI5Njcx_7979e95d-62e0-489e-a4bb-6282321fb48e">1,106</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0yMC0xLTEtNDI5Njcx_97f6831a-216c-4884-be93-dae8b0190cb9">1,106</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0yMi0xLTEtNDI5Njcx_a5fa4955-928d-4243-9c58-d5e70aa283c2">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0yNC0xLTEtNDI5Njcx_d1c6e1e4-78b8-4de3-b9dd-84f2d803fda3">1,111</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNi0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjpkNWMwZmY4YjMxNDc0MWNlYjk4YTFmOTVjMmNiNTNjZF8zMjk4NTM0ODgzMzcx_513c9d67-314b-4854-b5ce-2a860e7b83e4">0.40</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i322ef81511754d73bd045b355aa263b0_D20220704-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNy0xNi0xLTEtNDI5Njcx_0b1a7b1c-8423-42f2-83dc-d9a95f7d36ae">2,245</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNy0yMC0xLTEtNDI5Njcx_5defb571-840c-4782-8c0b-0427430a1ca3">2,245</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNy0yNC0xLTEtNDI5Njcx_d00da56e-6fce-4ebc-b0c6-291c6aa613c4">2,245</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfOS0yMi0xLTEtNDI5Njcx_a0cf46df-fccd-4d3c-b1f2-bab072967f13">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfOS0yNC0xLTEtNDI5Njcx_2a320a14-534f-47c1-9e09-2a52393c2586">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1008d0f3e2cb4f1fb4612f491b9815d9_D20220704-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtNi0xLTEtNDI5Njcx_9465b756-fcce-4a56-8e10-9a7771ba03b8">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4007c71e914cfe8b9ecfa0a6b9a28f_D20220704-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMTAtMS0xLTQyOTY3MQ_16fb1a44-02ac-4815-b7d4-599e3a123d7c">172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4e546bd59bb47fb8d148abae15673a7_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMTQtMS0xLTQyOTY3MQ_f7f25dd0-7f1e-4fb7-846d-601454d325b9">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i322ef81511754d73bd045b355aa263b0_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMTYtMS0xLTQyOTY3MQ_83da7b14-9bc3-417b-8721-999234e5f289">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMjAtMS0xLTQyOTY3MQ_a857173a-40c3-4489-9f7e-51fc8d8e3e48">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMjQtMS0xLTQyOTY3MQ_197347ff-d51a-41e9-82a0-fb69275c89a3">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTEtMjQtMS0xLTQyOTY3MQ_47c2d308-49f5-42ff-9860-3567dd14c29c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4007c71e914cfe8b9ecfa0a6b9a28f_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMTAtMS0xLTQyOTY3MQ_e7ed9a83-e953-4fca-9827-d8b2870a3a4a">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMjAtMS0xLTQyOTY3MQ_bcabe258-a60e-4a6a-9bd9-be130db3028d">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMjItMS0xLTQyOTY3MQ_34d67c89-9919-4c29-b1d9-64d8cdff5c80">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMjQtMS0xLTQyOTY3MQ_97e14b27-df15-4d83-b636-e40a2872f192">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, October&#160;2, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4178e1df50642f481342387e7983453_I20221002" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtNi0xLTEtNDI5Njcx_5470e14d-5ade-4656-b958-977a9956d106">9,515</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4178e1df50642f481342387e7983453_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtOC0xLTEtNDI5Njcx_afc0877a-0cdd-4226-afce-2ebeb3ee7f00">476</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283349b3ae194291807e57850205a00e_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTAtMS0xLTQyOTY3MQ_ea064329-a0ce-4f67-81a5-ff694645f46a">91,359</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTItMS0xLTQyOTY3MQ_fbcd5659-df73-4b3a-9178-89354de72ffb">3,903</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTQtMS0xLTQyOTY3MQ_fca70616-71ff-4685-a3c5-653c2cec315f">113,945</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fb06657953481f9327c4d7af5221d3_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTYtMS0xLTQyOTY3MQ_1b330152-aa5e-49c1-93f1-2400ba7106de">122,967</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i316fd24dd0da46e5872d02ce9db0a499_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTgtMS0xLTQyOTY3MQ_5df09b9a-395a-4dbf-853b-536a00555d6b">8,225</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439e2eb2ea67457d989b7d096b2578b6_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMjAtMS0xLTQyOTY3MQ_10f7a3f5-1289-43cc-b5ca-879c4c99ebe0">92,631</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982bd66098e642c180e76a8b23cfce05_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMjItMS0xLTQyOTY3MQ_b9d71ce7-f2d0-43a9-a1dc-13dcc97bf884">259</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMjQtMS0xLTQyOTY3MQ_faa9c44b-6c21-4a3c-9940-a00bb64bf862">92,891</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="63" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp. <br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, July&#160;4, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2eff56d6b9143a8a6236c386a684328_I20210704" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktNi0xLTEtNDI5Njcx_e289a723-8279-4cc4-b65b-a4683b03360f">9,450</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2eff56d6b9143a8a6236c386a684328_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktOC0xLTEtNDI5Njcx_5ebb432b-4f80-4de3-b734-e55427394edc">472</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a860a4fb70d417db1e5ece4d14a5929_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTAtMS0xLTQyOTY3MQ_00df457b-4107-489c-8afe-a9ab176065d7">89,336</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i106884611a9443b0b91471c3127aab17_I20210704" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTItMS0xLTQyOTY3MQ_06cb2858-66e1-4f9a-a25a-06fd2ca3a0b3">3,851</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i106884611a9443b0b91471c3127aab17_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTQtMS0xLTQyOTY3MQ_3fe83113-5e9c-4c59-9a6f-a84575270089">111,356</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd1ece70cb9426792fd297de161a638_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTYtMS0xLTQyOTY3MQ_9715e198-9da5-45a4-8956-6af1de8f2208">96,346</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i871492c1af0c4c41901ad429f9c97997_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTgtMS0xLTQyOTY3MQ_d902d639-a46d-4f63-9391-a6a35c322252">4,758</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d8a56f33e04a88aa94910108df6baf_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMjAtMS0xLTQyOTY3MQ_18c0a62a-d7b6-458b-97cb-29cd3d450770">70,042</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cdee01052447a8c008a36884f4ece_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMjItMS0xLTQyOTY3MQ_3f7975e5-6515-428c-a6f3-14cff78ccc20">273</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if55bdd083c8e4d4bb0f0f79015f34b54_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMjQtMS0xLTQyOTY3MQ_7a9040ef-19c7-4699-aa8c-938fd91e3bbf">70,315</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMTYtMS0xLTQyOTY3MQ_966ddda2-4033-44a8-b2d1-76b0db9be0a8">8,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMjAtMS0xLTQyOTY3MQ_c56b6361-a466-4f2b-a6eb-c012227a3c5c">8,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMjItMS0xLTQyOTY3MQ_050761b9-4a0a-4f1f-b2bf-672fb7cac2de">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMjQtMS0xLTQyOTY3MQ_bee6b4fe-6fed-4142-b505-bd8fe21aa79a">8,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other&#160;comprehensive income/(loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0830a768fb84418ac3aa1b642de41a4_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMTgtMS0xLTQyOTY3MQ_1bacabfb-8175-4bd2-bdf2-a1ff24cb9c69">891</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMjAtMS0xLTQyOTY3MQ_a2666239-fb02-4fe4-b0b8-7e990a8c6fc1">891</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMjItMS0xLTQyOTY3MQ_4e304900-47cc-47e9-bc27-eb116ce51cf4">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMjQtMS0xLTQyOTY3MQ_594c4dcb-ff26-40db-88f5-f1f757a38684">894</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246NmVmNTQwOTU3NjEzNGIyNjk4MDIwOTBjYTY0MDI3NDJfMzI5ODUzNDg4MzM3MQ_1d4ce70c-219a-4325-ab92-98f52fac0103">0.39</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjMtMTYtMS0xLTQyOTY3MQ_2a030d1d-78b9-4242-8682-e10429acd469">2,192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjMtMjAtMS0xLTQyOTY3MQ_bfde294b-caa4-450b-9d80-3fb4d446f218">2,192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjMtMjQtMS0xLTQyOTY3MQ_1a7c6ba5-ee95-4ab4-b840-73bfe5e32da8">2,192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjUtMjItMS0xLTQyOTY3MQ_a1c80239-3382-4cdc-a352-9bb83f2cd913">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjUtMjQtMS0xLTQyOTY3MQ_8b80e861-b875-4c1c-ac50-7393fd9978dd">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7aaed31d336142a38895f4e58c290bc0_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtNi0xLTEtNDI5Njcx_27dfe408-0bb1-4a16-9715-a98e0683caa8">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aaed31d336142a38895f4e58c290bc0_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtOC0xLTEtNDI5Njcx_19bcd152-4926-4b88-83d9-ea0e788d9a20">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cfba0bc31044aafb04e8793a359fd30_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMTAtMS0xLTQyOTY3MQ_021d0c7a-8b3e-44a6-b789-55a5446c5e22">637</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fbbfb560fd84535bc70f59962461307_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMTQtMS0xLTQyOTY3MQ_8a7dcbaf-ecf0-4899-8551-965324618583">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMTYtMS0xLTQyOTY3MQ_a4886a78-c568-4294-86d6-9d059353095e">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMjAtMS0xLTQyOTY3MQ_27e3245a-f217-45cf-80b3-7fd6d9488b0b">634</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMjQtMS0xLTQyOTY3MQ_e0d01fc8-db4e-4c20-b8b9-02656d1afa7f">634</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjctMjQtMS0xLTQyOTY3MQ_8d75ad29-33b0-4924-bda3-007467c098a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMTYtMS0xLTQyOTY3MQ_b8376c5c-a4ef-4b3d-8212-e7d2f6a79346">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMjAtMS0xLTQyOTY3MQ_4571bbcc-0c00-4d7e-aba4-96c313e4f6ed">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMjItMS0xLTQyOTY3MQ_e1240ed8-e399-49b9-9882-b5fc30566abb">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMjQtMS0xLTQyOTY3MQ_5cd3ec01-45e3-4d8f-ac9d-ff953fdc3242">46</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, October&#160;3, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtNi0xLTEtNDI5Njcx_0f25f818-b05c-4670-a15c-bd06aa70cc65">9,462</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtOC0xLTEtNDI5Njcx_a0b520c1-01e9-4713-8423-2596794d85b0">473</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269d8be2dbe14366928f6a655f330c99_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTAtMS0xLTQyOTY3MQ_f156eea0-f54a-453c-9b51-38d1fad38f5e">89,973</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTItMS0xLTQyOTY3MQ_3fa74561-518f-4a8a-a386-7eb0940388b6">3,851</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTQtMS0xLTQyOTY3MQ_8b848ebd-17a4-457e-a5dc-ec3d114409c9">111,359</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eead2d41724d1284b95a8f2c3ba977_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTYtMS0xLTQyOTY3MQ_a2d02789-a8ed-4184-81cc-13137eb6a1dc">102,252</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icff95de7b4364937bb8f6fa9332bb480_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTgtMS0xLTQyOTY3MQ_f085e3b2-eb7a-4770-917c-d2d1657f08ef">5,649</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e9bcba37374979b4f81bb0e1923a9a_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMjAtMS0xLTQyOTY3MQ_b8f2144f-886f-4c5b-ae16-b978701745bc">75,691</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad49f13a7aaf431ca7ad807765db51a1_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMjItMS0xLTQyOTY3MQ_fd5e1f9f-fb36-47cf-b02a-5f4c8b2eeea4">275</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMjQtMS0xLTQyOTY3MQ_2c0a92da-9a70-4b28-bbf5-8e9a5c001d6f">75,967</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, January&#160;1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie720b049f06b4803a5325d0052df106f_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy02LTEtMS00Mjk2NzE_8cfbcf07-bebe-4ed9-b0cd-efc03efe7ff6">9,471</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie720b049f06b4803a5325d0052df106f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy04LTEtMS00Mjk2NzE_c1d69d67-ec85-4ac5-af63-b7bf368b6cb6">473</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a4179e99414d2bb29dae8a9ef43064_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xMC0xLTEtNDI5Njcx_263300ab-d611-406a-b4aa-e0c66462d32e">90,591</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i27da68353c034955b1c275a580f01f68_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xMi0xLTEtNDI5Njcx_f280db95-be8b-4de5-a594-82db9b2f4545">3,851</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27da68353c034955b1c275a580f01f68_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xNC0xLTEtNDI5Njcx_b10cca00-ceb6-491c-9af0-96bf4c144d02">111,361</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5305bfba0e7a4d7fbbd4c84a4873871d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xNi0xLTEtNDI5Njcx_752462e7-44df-436d-b190-fec829ff5f66">103,394</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ef44849268d4847a9fb27d3a90011e9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xOC0xLTEtNDI5Njcx_a217b104-7d80-4dd2-9201-6df3186e4c50">5,897</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b19de1c61d540f7a92683b6fcef0492_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0yMC0xLTEtNDI5Njcx_c6b78856-9bc0-407e-b443-cd7bc15c8455">77,201</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58476ceafd6b43a0803a9cdb179436a3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0yMi0xLTEtNDI5Njcx_c64b60fa-f7f4-46ef-ac44-402385a9c5e1">262</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0yNC0xLTEtNDI5Njcx_0bf5fe78-66ea-431b-92bd-0d958b013cc8">77,462</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0xNi0xLTEtNDI5Njcx_170ba43d-4cf2-4b83-b5a8-feb1ac81d6f0">26,378</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0yMC0xLTEtNDI5Njcx_5be67b04-a9fc-4ec6-af72-a72c60b00d0d">26,378</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0yMi0xLTEtNDI5Njcx_499d0d6b-1938-4fc0-8623-1a2ce9b494a2">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0yNC0xLTEtNDI5Njcx_48cb8343-0058-4492-bef4-6d262cd7748e">26,404</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other&#160;comprehensive income/(loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8a629a946b4ceca7ca7dd72b1af40b_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0xOC0xLTEtNDI5Njcx_3e853167-af2b-4420-b2be-17b1e4935e86">2,328</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0yMC0xLTEtNDI5Njcx_52549b66-ab98-4345-a10c-26a898e1a5b8">2,328</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0yMi0xLTEtNDI5Njcx_e5cf3dcf-920a-49f5-ae4c-5d92930211c0">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0yNC0xLTEtNDI5Njcx_8e8b26fa-05db-4700-99e8-d008ee837075">2,339</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNi0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjo0Y2Y3NzAzMWUwNzE0ZDRmOGI3ZTA4M2ZiZGUyYjk5Y18zMjk4NTM0ODgzMzcx_b74cf16c-e547-4455-9891-a78e3832d02d">1.20</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNy0xNi0xLTEtNDI5Njcx_019742ce-2a72-4b79-9467-7aa6ff07c260">6,734</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNy0yMC0xLTEtNDI5Njcx_de2ac956-6515-47d0-9421-a86a02f3d9fd">6,734</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNy0yNC0xLTEtNDI5Njcx_b6fc76d6-2dc7-4827-bb3a-70efaabd08d4">6,734</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfOS0yMi0xLTEtNDI5Njcx_93a154e5-cc2a-483f-8f02-cd9647ebf199">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfOS0yNC0xLTEtNDI5Njcx_bea61b42-37a0-4b96-a396-c074fc10f2cf">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9b1498a92d54a268ebfb1b8e658f31d_D20220101-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtNi0xLTEtNDI5Njcx_14cf6788-312f-4896-9df3-f3feb4c10c9f">45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b1498a92d54a268ebfb1b8e658f31d_D20220101-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtOC0xLTEtNDI5Njcx_b8afd134-1393-48b1-8e10-b05f11f406fd">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if663a3d9b11e4c838a4f9123bcff64b2_D20220101-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTAtMS0xLTQyOTY3MQ_78b977b0-7339-496a-9b39-67c768c3d428">760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTItMS0xLTQyOTY3MQ_057311d5-7ed1-4f71-af5c-86e948710d6d">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTQtMS0xLTQyOTY3MQ_b5a54fd2-9608-4517-8dbb-2b60fecabc6f">584</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTYtMS0xLTQyOTY3MQ_8360e813-1cc9-41f2-9b4d-7de03782e8c8">71</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMjAtMS0xLTQyOTY3MQ_e0054154-7e7b-4d18-891e-22210de03e00">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMjQtMS0xLTQyOTY3MQ_42e438a8-4cac-43f8-b2fe-1898a94f05bc">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMTItMS0xLTQyOTY3MQ_95288d55-ef44-45da-965e-ebcf5847ec31">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMTQtMS0xLTQyOTY3MQ_80f85a3b-516d-45c9-8b49-92c9a4a661e3">2,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMjAtMS0xLTQyOTY3MQ_629aa986-4fda-4848-86d1-bceb59da70c1">2,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMjQtMS0xLTQyOTY3MQ_6c31d06d-cdcd-4d15-8144-646d9d3d50aa">2,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if663a3d9b11e4c838a4f9123bcff64b2_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMTAtMS0xLTQyOTY3MQ_af170df4-7df7-4b53-b689-f259b38395bc">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMTYtMS0xLTQyOTY3MQ_f2377e77-a248-49ac-9ab4-1364ec2a9171">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMjAtMS0xLTQyOTY3MQ_4e767329-c4ca-485f-a0f1-d8ebf3049a21">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMjItMS0xLTQyOTY3MQ_5cde321b-bc09-4d2e-a9ca-fe1f91b30d1c">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMjQtMS0xLTQyOTY3MQ_b5f8b5ce-79f0-49a3-b263-426387ead38b">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, October&#160;2, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4178e1df50642f481342387e7983453_I20221002" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtNi0xLTEtNDI5Njcx_698749c2-a713-4650-9ed7-4fe64cb3931c">9,515</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4178e1df50642f481342387e7983453_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtOC0xLTEtNDI5Njcx_07611401-f714-4915-ad8e-241ddaf72c9a">476</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283349b3ae194291807e57850205a00e_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTAtMS0xLTQyOTY3MQ_64de36fd-ec4e-4097-bae2-9fb7cc829c8c">91,359</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTItMS0xLTQyOTY3MQ_44dd3ffd-caac-490b-8ee5-c90d647f6c6a">3,903</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTQtMS0xLTQyOTY3MQ_7836b565-9fee-463c-9f30-490fdd45bfb9">113,945</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fb06657953481f9327c4d7af5221d3_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTYtMS0xLTQyOTY3MQ_f21a8b46-c5f9-46f5-a4db-06791554ad91">122,967</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i316fd24dd0da46e5872d02ce9db0a499_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTgtMS0xLTQyOTY3MQ_f1167bcc-ec1f-4d78-a9cc-5d5d1c3f67bc">8,225</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439e2eb2ea67457d989b7d096b2578b6_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMjAtMS0xLTQyOTY3MQ_f79e7021-0af5-4778-ae86-2ccb934e6502">92,631</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982bd66098e642c180e76a8b23cfce05_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMjItMS0xLTQyOTY3MQ_e31bf2b8-2250-4303-909c-0c58aa769ee9">259</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMjQtMS0xLTQyOTY3MQ_124eef16-43d4-450f-ba3a-de5a4360591e">92,891</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="63" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, January&#160;1, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i342523194f354c36af8db3ac1d92928a_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktNi0xLTEtNDI5Njcx_6c7e838a-7f1f-48d8-af83-d249758ba403">9,407</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342523194f354c36af8db3ac1d92928a_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktOC0xLTEtNDI5Njcx_f73fbcbf-f7cd-41a1-99ce-8e0bdc12d55b">470</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad01e12648344a0bbd128d9c7131aebc_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTAtMS0xLTQyOTY3MQ_00c5132d-337c-4fd7-85be-9f183b919ed4">88,674</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7a5e26c69446465d846729c653f45303_I20201231" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTItMS0xLTQyOTY3MQ_e49293e3-d232-4181-ab11-10a940ee6e0f">3,840</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a5e26c69446465d846729c653f45303_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTQtMS0xLTQyOTY3MQ_e34af603-78f8-4b76-a3f3-2c512e46b1d8">110,988</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id46f714a106f496988fe9d996ad5882b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTYtMS0xLTQyOTY3MQ_f6c5ba0e-a370-40be-9ebc-2e5e7f119b54">90,392</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c21ac9482a54fb3991813baf028f817_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTgtMS0xLTQyOTY3MQ_22213e64-ab98-49a4-9843-9cb7704afc7e">5,310</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ec159b1e1141eb90a039d6e396bcd0_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMjAtMS0xLTQyOTY3MQ_e3c30edc-4cf6-4d09-baff-c3b5a3f0e219">63,238</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1414142218df48a784a0e0af5a6fa08a_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMjItMS0xLTQyOTY3MQ_c3aca57a-39a9-45db-abb2-886cdf2a0fa5">235</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f38a2438be4f7bb12b558b25272ce5_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMjQtMS0xLTQyOTY3MQ_b9f451a3-cf25-4102-9a2b-c51307df67d2">63,473</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMTYtMS0xLTQyOTY3MQ_3650b008-2ade-415c-879f-7d21113ae8a3">18,586</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMjAtMS0xLTQyOTY3MQ_9ff9b9c7-0e8e-49c5-a8cc-ee7da5fcfb52">18,586</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMjItMS0xLTQyOTY3MQ_1f489583-c9b0-44a2-b97e-26ac18d272f4">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMjQtMS0xLTQyOTY3MQ_48e059ef-d066-43a0-b22a-dc4704d7900f">18,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other&#160;comprehensive income/(loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c0af948675a4a7f9a78ce4430cb4045_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjEtMTgtMS0xLTQyOTY3MQ_ee92c3e8-588a-48df-a564-b9d57ec4dcca">338</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjEtMjAtMS0xLTQyOTY3MQ_d9c16ce9-0159-41b8-a855-ad6a9ac210d9">338</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjEtMjQtMS0xLTQyOTY3MQ_c3f7a0f5-7760-4cee-89c2-c734cc8d5c37">338</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246NDgzYWQ0YzQwNjhjNDA3NGJkMWFjODZjODgzNjE5YmJfMzI5ODUzNDg4MzM3MQ_a517df94-c906-4e49-9b34-62e0f9a7249e">1.17</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjMtMTYtMS0xLTQyOTY3MQ_44d659be-d157-46b4-84dd-ba2c5b068a5a">6,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjMtMjAtMS0xLTQyOTY3MQ_3d600588-074f-4890-9ac3-d29448e3b1b7">6,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjMtMjQtMS0xLTQyOTY3MQ_1f11fc44-444f-4077-aa55-40c073738d1f">6,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjUtMjItMS0xLTQyOTY3MQ_03e8a52a-a4dc-415a-b92c-9e07def0aedd">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjUtMjQtMS0xLTQyOTY3MQ_dcd5278e-0ac5-46dd-8cfd-ae89dbc4402b">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i733fe6690f964b79a59503138cfacb8c_D20210101-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtNi0xLTEtNDI5Njcx_c6594ea3-42c0-4dd2-b420-fa7230e794a4">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733fe6690f964b79a59503138cfacb8c_D20210101-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtOC0xLTEtNDI5Njcx_bd7fa9a4-7e5c-43ca-9655-9f425c7212ea">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e44f06dea84bef93e7ada7841e6e73_D20210101-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTAtMS0xLTQyOTY3MQ_04c4a7f5-ff7f-423e-9069-d64599a4b930">1,300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8c6c8f9bc04f475da96d6d469914b62b_D20210101-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTItMS0xLTQyOTY3MQ_c65cd988-85ea-454a-8401-29ced9530c4a">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c6c8f9bc04f475da96d6d469914b62b_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTQtMS0xLTQyOTY3MQ_e8bed361-5967-49fd-a4bd-b5e342e165e6">371</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTYtMS0xLTQyOTY3MQ_9bf75cb6-c4aa-40ce-9811-74e9829ec180">77</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMjAtMS0xLTQyOTY3MQ_41471c68-3d95-4267-b244-f7ecb1e93e76">855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMjQtMS0xLTQyOTY3MQ_f0dea1a5-28f7-4004-8a5e-57ed70a73fee">855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjctMjQtMS0xLTQyOTY3MQ_8285da36-3317-4cd5-b8b3-f3cee0ae5e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMTYtMS0xLTQyOTY3MQ_3cb41271-34ed-4609-b52f-dbd27fd1b135">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMjAtMS0xLTQyOTY3MQ_9d63774e-3d3d-4bb7-b975-fe7820995a14">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMjItMS0xLTQyOTY3MQ_3e314145-e78b-418b-9144-88c1e764b993">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMjQtMS0xLTQyOTY3MQ_b40d5ade-333a-4234-bf63-91a5f09d6547">79</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, October&#160;3, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtNi0xLTEtNDI5Njcx_eb286a48-6729-4aed-a374-7089c04cea07">9,462</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtOC0xLTEtNDI5Njcx_943f309b-445b-48d6-abc8-bf69a086988b">473</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269d8be2dbe14366928f6a655f330c99_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTAtMS0xLTQyOTY3MQ_3659b244-5e1e-4809-a422-191c5c28129a">89,973</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTItMS0xLTQyOTY3MQ_b63d21f7-ab64-4cf8-b178-df5bf9ee4802">3,851</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTQtMS0xLTQyOTY3MQ_c5c06960-8ce5-4df6-9b0e-df431f9d72cb">111,359</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eead2d41724d1284b95a8f2c3ba977_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTYtMS0xLTQyOTY3MQ_8b69f7f2-1c0f-47f2-bb1b-dde06420a7fd">102,252</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icff95de7b4364937bb8f6fa9332bb480_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTgtMS0xLTQyOTY3MQ_4ddb729c-af9b-4136-968b-cee1ca2734fc">5,649</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e9bcba37374979b4f81bb0e1923a9a_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMjAtMS0xLTQyOTY3MQ_45fa52e5-5af7-4014-9a4a-017e59fbaf75">75,691</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad49f13a7aaf431ca7ad807765db51a1_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMjItMS0xLTQyOTY3MQ_580a31ec-2d96-4b29-81e3-939268f1a0d4">275</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMjQtMS0xLTQyOTY3MQ_fd1a3a5d-f62a-4f40-adfc-b03536e4e5ef">75,967</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMy0yLTEtMS00Mjk2NzE_0da6bb42-f51c-4c21-b95c-6ee74117d514">26,404</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMy00LTEtMS00Mjk2NzE_f0e3a417-e3b2-4970-be31-50791f00af2f">18,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued operations&#8212;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNC0yLTEtMS00Mjk2NzE_d03aff67-1620-41ff-adc5-382fd44f3322">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNC00LTEtMS00Mjk2NzE_26b0da2d-3146-43ec-b587-9bb66de1ddb1">248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income from continuing operations before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNS0yLTEtMS00Mjk2NzE_cbffdd60-ec23-48b9-970b-b38277a18d66">26,400</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNS00LTEtMS00Mjk2NzE_378dde27-c40e-42d1-83bd-7601477a85a1">18,881</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNy0yLTEtMS00Mjk2NzE_5e0eeb22-5479-4903-943e-8d5149eeba59">3,545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNy00LTEtMS00Mjk2NzE_71a04981-229e-40b6-855a-a7fbbe4163fc">3,856</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Asset write-offs and impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfOC0yLTEtMS00Mjk2NzE_a7e309ed-939e-4bd3-a68b-c07f43b2a21b">287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfOC00LTEtMS00Mjk2NzE_f072f1b4-5b45-4b6f-a183-aa07179fbc70">93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTAtMi0xLTEtNDI5Njcx_904a4295-91cb-4da5-a639-1e91ff518d69">3,399</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTAtNC0xLTEtNDI5Njcx_0af669ad-0943-418e-8fbf-5cd981edc53c">3,610</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTItMi0xLTEtNDI5Njcx_9cd7cf38-651b-42cc-9e18-9449567c3038">508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTItNC0xLTEtNDI5Njcx_2c4e2591-0c92-43f5-b73a-b01b76b2f5d9">686</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTMtMi0xLTEtNDI5Njcx_d223a465-131d-4343-bb7e-084b1af76c65">532</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTMtNC0xLTEtNDI5Njcx_66292d13-e7b3-41a2-bb19-457d0443386d">1,933</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTQtMi0xLTEtNDI5Njcx_757fca48-e10d-4c3d-a4a6-55acc45de90d">1,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTQtNC0xLTEtNDI5Njcx_f6b6affe-52e0-472f-83d4-c9f24f346f77">1,848</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other changes in assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTUtMi0xLTEtNDI5Njcx_ea3936ee-0d8a-403a-8b77-2f4a12a7dfc2">7,605</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTUtNC0xLTEtNDI5Njcx_a31bf8ca-1331-44eb-a0aa-18031b9e6eed">10,867</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTYtMi0xLTEtNDI5Njcx_275bc53f-56df-43a1-af16-6f0f16fa483d">20,685</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTYtNC0xLTEtNDI5Njcx_790c1dac-4bf6-443b-a46b-d546d7106a5e">26,993</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTctMi0xLTEtNDI5Njcx_cfa89042-b39e-4acd-bda0-4aeec0b018d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTctNC0xLTEtNDI5Njcx_4b2826ec-bc5e-4727-a129-7cfabedd767b">327</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTgtMi0xLTEtNDI5Njcx_416b864d-7796-4028-98fa-375f7642cfee">20,685</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTgtNC0xLTEtNDI5Njcx_bb071e30-a729-446f-a075-ef205d42e3b9">26,666</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Investing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjEtMi0xLTEtNDI5Njcx_153c6ba5-17ee-4667-acd1-ceb74352349f">2,235</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjEtNC0xLTEtNDI5Njcx_dab0c7df-f1fe-4bec-a628-1bb795d46c57">1,709</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjItMi0xLTEtNDI5Njcx_53db7535-3667-4994-9a38-135f5510f47e">29,701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjItNC0xLTEtNDI5Njcx_79896e91-03fd-43a5-ba73-b09b17bd2ff0">26,280</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjMtMi0xLTEtNDI5Njcx_0bba7621-694f-4c52-96d9-8ba2c386c72c">35,087</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjMtNC0xLTEtNDI5Njcx_5cad9bb9-a195-47f4-84d2-11bc4c394271">15,852</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjQtMi0xLTEtNDI5Njcx_34035c0f-c8b4-494e-98b7-cb16b04c4422">10,877</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjQtNC0xLTEtNDI5Njcx_07cd4c8f-110f-403a-9d64-5647f3f4c9a6">7,152</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjUtMi0xLTEtNDI5Njcx_f3cf3506-89f4-4226-b828-38b2e28b4892">1,627</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjUtNC0xLTEtNDI5Njcx_c5399449-2243-4cca-9711-f0532e9094eb">861</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjYtMi0xLTEtNDI5Njcx_7ec357a5-3b4c-4516-ac04-ac77a3a85ca2">446</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjYtNC0xLTEtNDI5Njcx_61a650ef-f3ca-4bb2-995d-75bb39d4cbe2">569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjctMi0xLTEtNDI5Njcx_602af887-08c0-44f1-9405-3453e46f98da">6,225</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjctNC0xLTEtNDI5Njcx_96408f72-6466-4d4b-94a7-1c1e266a5214">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Dividends received from Haleon/GSK Consumer Healthcare JV (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtMi0xLTEtNDkzOTE5_0e6e5f8e-1797-4a90-92b6-177d6c0c919f">3,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtNC0xLTEtNDkzOTYz_3d1d5be0-7c66-4507-836f-60da4dd67616">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtMi0xLTEtNDI5Njcx_4200200c-22e9-4816-ad17-5ee1ae77d3ca">200</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtNC0xLTEtNDI5Njcx_953a4049-b36f-4825-b2d1-765395c656eb">370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjktMi0xLTEtNDI5Njcx_cdd19ef0-883f-4175-bc8d-b93ad8ac0ede">11,373</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjktNC0xLTEtNDI5Njcx_4fae6192-256c-467e-b963-3e3d05295f77">19,951</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzAtMi0xLTEtNDI5Njcx_36afe603-60bf-402c-9c09-f40516de3aa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzAtNC0xLTEtNDI5Njcx_47ef39cd-a2f0-46d4-bd19-fab15bad2461">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzEtMi0xLTEtNDI5Njcx_7e55d28d-d2c6-4183-8665-6fca3d7fb319">11,373</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzEtNC0xLTEtNDI5Njcx_79347aae-6e1d-4f71-b034-289ade1a1565">19,960</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Financing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzQtMi0xLTEtNDI5Njcx_0ef1a1a3-51d6-4d55-bcce-3d264b4cb9e9">3,887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzQtNC0xLTEtNDI5Njcx_074352e1-a0b6-4928-ac49-57f4f0af47a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Payments on short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzUtMi0xLTEtNDI5Njcx_67ab241a-5f1c-4409-9f0d-31b7edb2d2bc">3,887</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzUtNC0xLTEtNDI5Njcx_43dad0bf-c758-465e-abd6-f4d68a42da27">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzYtMi0xLTEtNDI5Njcx_b7a9e935-d347-417f-9de9-54027d64db3f">870</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzYtNC0xLTEtNDI5Njcx_20a51d5e-338a-4a46-b9a2-64efbd976144">265</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzctMi0xLTEtNDI5Njcx_fac2aaaf-3311-4206-9900-91a5a33eaff6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzctNC0xLTEtNDI5Njcx_8d75810e-12d5-4f8a-9458-0c0a94bde7f0">997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzgtMi0xLTEtNDI5Njcx_1e0c3154-788d-4772-9aca-8479c4f13d29">1,609</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzgtNC0xLTEtNDI5Njcx_e5467d18-e2e8-4ed0-80ae-334481395331">1,001</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzktMi0xLTEtNDI5Njcx_834a5a19-1fe0-4d3a-b29c-567595d99210">2,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzktNC0xLTEtNDI5Njcx_65f519dd-0f97-410a-91ef-9f168d323cdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash dividends paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDAtMi0xLTEtNDI5Njcx_b0ce1ecb-1115-44c7-b152-6db6e6f4a202">6,738</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDAtNC0xLTEtNDI5Njcx_38621988-dd65-43bf-bf8a-97a3c1a2621e">6,540</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDEtMi0xLTEtNDI5Njcx_95b52958-5996-4531-8cee-42cc699617ea">342</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDEtNC0xLTEtNDI5Njcx_265a7ad3-e7bd-46fe-9823-257f68d2137b">185</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDQtMi0xLTEtNDI5Njcx_90ef1cf4-dec0-4a01-b514-33e5bb443376">9,819</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDQtNC0xLTEtNDI5Njcx_546dc1b5-ac77-4b96-8673-4fe6b32a3eef">6,465</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDUtMi0xLTEtNDI5Njcx_9aad791b-1415-45ea-a2c7-d48feb92c75e">139</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDUtNC0xLTEtNDI5Njcx_129e0519-859e-47c0-b06c-4b8c4724f4d5">32</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDYtMi0xLTEtNDI5Njcx_dd2499db-c3b9-4bf9-9ab2-6b47f98317b5">646</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDYtNC0xLTEtNDI5Njcx_406da573-d97a-4955-b454-223804719dc3">209</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDctMi0xLTEtNDI5Njcx_feb46768-d822-4276-8afd-409696cab4fb">1,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f38a2438be4f7bb12b558b25272ce5_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDctNC0xLTEtNDI5Njcx_5b8b190d-c960-4495-91f9-ad6b5c1715c8">1,825</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDgtMi0xLTEtNDI5Njcx_44345a59-8f5a-4c85-94dc-38e99cdd61f9">1,338</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDgtNC0xLTEtNDI5Njcx_797c20a0-5456-4adb-98a6-5673d7dd88b7">2,034</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid/(received) during the period for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTQtMi0xLTEtNDI5Njcx_79d1782a-a692-46e8-b64c-4b73305cc409">4,919</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTQtNC0xLTEtNDI5Njcx_c5464a08-80d2-424b-b45c-b6b4e1297796">2,943</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest paid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTUtMi0xLTEtNDI5Njcx_a8815ddf-7007-4706-944e-a69de649ef1e">1,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTUtNC0xLTEtNDI5Njcx_742e6047-6364-4a01-8461-de19431da57c">1,205</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest rate hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTYtMi0xLTEtNDI5Njcx_6b971251-39ec-4637-a8fa-e79ad27c9578">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTYtNC0xLTEtNDI5Njcx_89c9ac9d-406e-4044-939d-15c82f770ae4">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-cash transaction:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTgtMi0xLTEtNDI5Njcx_d5f04417-9432-4452-b5d1-1ab91d5b24a5">463</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTgtNC0xLTEtNDI5Njcx_a207612c-3412-42ae-a229-2d7f1d351eb3">1,552</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:24pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_34"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div><span><br/></span></div><div id="i8c2530a91ced4c48b9620128206808f1_37"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk4NQ_541ab103-7d48-4866-9615-96ff33c3e821" continuedAt="i3a0ee08c4ed949fd9c712fb37e70fd5c" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3a0ee08c4ed949fd9c712fb37e70fd5c" continuedAt="icf0dbb8266404d46844b3c694cf27dfe"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzkzOQ_b7e20922-3518-4974-a0af-44a5adacd9ad" continuedAt="i7604413bf10b41eb8e1e9de322b863e3" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i7604413bf10b41eb8e1e9de322b863e3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August&#160;28, 2022 and August&#160;29, 2021, and for U.S. subsidiaries is as of and for the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a global structure consisting of <ix:nonFraction unitRef="operatingsegment" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfMTI3Nw_b82b43b2-9eb7-4011-95e0-3abb3831f9df">two</ix:nonFraction> operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Beginning in the third quarter of 2022, we made several additional</span><span style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizational changes to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches. These changes include establishing a new commercial structure within our Biopharma operating segment and realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure. Biopharma is the only reportable segment. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 9B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 13A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities completed in 2021 and 2022 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary and post-closing adjustments for other previously divested businesses. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below.</span></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations, acquired IPR&amp;D expenses and segment reporting.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk1MA_af4f6ad9-59c0-467a-beb6-c0427ac16e8e" continuedAt="icb89edcabf53481ba607f922bc1d97df" escape="true">New Accounting Standard Adopted in 2022</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb89edcabf53481ba607f922bc1d97df">On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.</ix:continuation></span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk1MQ_bdd4152e-5b67-4566-b90e-afcc22b0a281" continuedAt="if73fde0af2914c4b9b9331b90dd1ab64" escape="true">Revenues and Trade Accounts Receivable</ix:nonNumeric></span></div><ix:continuation id="if73fde0af2914c4b9b9331b90dd1ab64" continuedAt="i5c7878319ab44324ba291e01823c83b7"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors&#8217; locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="icf0dbb8266404d46844b3c694cf27dfe"><ix:continuation id="i5c7878319ab44324ba291e01823c83b7"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk3OA_7122d103-1d43-488f-ae35-233722da6737" continuedAt="ia75a7f9eea054fda80595442dc0e554f" escape="true">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</ix:nonNumeric></span></div><div><ix:continuation id="ia75a7f9eea054fda80595442dc0e554f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04c3dccab614a94b2908a489d743aff_I20221002" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMS0yLTEtMS00Mjk2NzE_5217600a-5536-422c-b95f-6f341203fb31">1,133</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6ba2fc692f44b495f2e7f584a00bef_I20211231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMS00LTEtMS00Mjk2NzE_52cd01ad-53c9-418e-8992-f448ff3e02c0">1,077</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002" decimals="-6" name="pfe:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMy0yLTEtMS00Mjk2NzE_f40422c5-2fcb-4ead-bfcc-af0a02af537f">3,991</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508bb16fd44454482e06b74af164e0f_I20211231" decimals="-6" name="pfe:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMy00LTEtMS00Mjk2NzE_fdbcd608-3b3a-44fb-9e07-710e37b27822">3,811</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNC0yLTEtMS00Mjk2NzE_e72e4a30-f174-47a5-9a1d-9e6fb381cea5">418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508bb16fd44454482e06b74af164e0f_I20211231" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNC00LTEtMS00Mjk2NzE_beed9764-19cb-456b-b6ef-999ad983eac0">528</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0861c1e153d4341b6f1aa2768a8b9e3_I20221002" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNS0yLTEtMS00Mjk2NzE_1595640e-9859-4305-99c4-785283e01c39">497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b757dbbd6f4f2bad32cff5eca993e2_I20211231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNS00LTEtMS00Mjk2NzE_9b3ad6fe-7f39-498e-a70d-d3ac3f74b5d1">433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNi0yLTEtMS00Mjk2NzE_a2172298-acc1-4fca-9f95-205c8504cf2e">6,038</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNi00LTEtMS00Mjk2NzE_dceb283f-c344-4001-9de4-2f852e165f78">5,850</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">D. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk0Ng_18021d28-58e1-4b1e-9fab-ad17ac6f11f6" continuedAt="i4543e0f3c6264383ba5b8526a9cbfcd1" escape="true">Acquired In-Process Research and Development Expenses</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i4543e0f3c6264383ba5b8526a9cbfcd1" continuedAt="i09ebfb69b3b344a792472f3bdd80c890"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we began reporting acquired IPR&amp;D expense as a separate line item in our consolidated statements of income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;D. These costs were previously recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed. The fair value of IPR&amp;D acquired in connection with a business combination is recorded on the balance sheet as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Identifiable intangible assets</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i09ebfb69b3b344a792472f3bdd80c890">.</ix:continuation> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Notes 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_40"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfOTA2Mw_3f8302cb-4dc3-4ebf-938d-772be0e17a8f" continuedAt="ida22a54c87694b6cbbe4d789c1c88496" escape="true">Acquisitions, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement</ix:nonNumeric></span></div><ix:continuation id="ida22a54c87694b6cbbe4d789c1c88496" continuedAt="ic3a9cfd91d2a4d769fa6d681f395ec91"><div style="margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisitions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ReViral</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;&#8211;On June 9, 2022, which fell in our international third quarter of 2022, we acquired ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral therapeutics that target respiratory syncytial virus, for a total consideration of up to $<ix:nonFraction unitRef="usd" contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjc0ODc3OTA4Mzk0Ng_34759188-bd14-4cb9-82ff-385efb4f8dbd">536</ix:nonFraction> million, including upfront payments of $<ix:nonFraction unitRef="usd" contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjc0ODc3OTA4Mzk3MQ_bc40f181-c84e-4ee6-8972-7e6743a9d5b1">436</ix:nonFraction> million upon closing (including a base payment of $<ix:nonFraction unitRef="usd" contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609" decimals="-6" name="pfe:PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MDE0MA_688aafaf-53e1-482c-9d6f-6371f3ee2f7f">425</ix:nonFraction> million plus working capital adjustments) and an additional $<ix:nonFraction unitRef="usd" contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjc0ODc3OTA4Mzk5Mg_65a6aabf-01f9-4879-9775-d2ae403beb04">100</ix:nonFraction> million contingent upon future development milestones.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We accounted for the transaction as an asset acquisition since the lead asset, sisunatovir, represented substantially all of the fair value of the gross assets acquired. At the acquisition date, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI3NTUzNg_ccbe57c5-9fa7-4f00-98d3-388072f789b5">426</ix:nonFraction> million charge representing an acquired IPR&amp;D asset with no alternative use in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which is presented as a cash outflow from operating activities. Other assets acquired and liabilities assumed were not significant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic3a9cfd91d2a4d769fa6d681f395ec91" continuedAt="i3d12cb9a676f42bbaf48bef1938dc680"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Arena&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 11, 2022, we acquired Arena, a clinical stage company, for $<ix:nonFraction unitRef="usdPerShare" contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311" decimals="0" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3MjU0_7292aa0c-0900-41ff-a44a-d941c6746f04">100</ix:nonFraction> per share in cash. The total fair value of the consideration transferred was $<ix:nonFraction unitRef="usd" contextRef="i01574368db75427a9223807866f28b02_D20220311-20220311" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3MzM1_521e5329-d594-4ae4-ab78-70e4dab03bae">6.6</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="i01574368db75427a9223807866f28b02_D20220311-20220311" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3MzQw_142bef6b-d1e8-4dd7-8a93-dac8b2b3834b">6.2</ix:nonFraction> billion, net of cash acquired). In addition, $<ix:nonFraction unitRef="usd" contextRef="i87882967ea9849de8a349199b28d5e06_D20220311-20220311" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3Mzgx_d09bc815-890c-4256-b8ea-db9778528c68">138</ix:nonFraction> million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Arena&#8217;s portfolio includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including UC, Crohn&#8217;s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In connection with this acquisition, we provisionally recorded: (i) $<ix:nonFraction unitRef="usd" contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MDY4_6014f0e3-ec20-4c17-b8f6-5c610ede61c0">5.5</ix:nonFraction> billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, consisting of $<ix:nonFraction unitRef="usd" contextRef="id0e5aabb88f345f8b7eacf17c16cdd86_I20220311" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MTIx_599a3f94-b551-4ddb-874f-b9923401ec00">5.0</ix:nonFraction> billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">IPR&amp;D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and $<ix:nonFraction unitRef="usd" contextRef="id429ba78c8b54ea280edb5594ad15554_I20220311" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MTM4_46b8b02a-d9b7-4d38-922b-9b7c47b35ef9">460</ix:nonFraction> million of indefinite-lived </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, (ii) $<ix:nonFraction unitRef="usd" contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MTk5_7ec71a86-7e5c-4dc2-9cab-582abea463ab">1.0</ix:nonFraction> billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and (iii) $<ix:nonFraction unitRef="usd" contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MjI1_72638cab-4dc2-4b8f-8b02-7c7f0f396e94">505</ix:nonFraction> million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Discontinued Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Meridian&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, we completed the sale of our Meridian subsidiary. In the three and nine months ended October&#160;2, 2022, the amounts recorded under the interim TSAs and MSA were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upjohn Separation and Combination with Mylan&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination and to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The amounts recorded under these agreements were not material to our consolidated results of operations in the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021. Net amounts due from Viatris under the agreements were approximately $<ix:nonFraction unitRef="usd" contextRef="ic44d8c4f02f348958a5ef9d3d3956478_I20221002" decimals="-6" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjI2Ng_2810762e-8dbc-4431-b844-0527b3e8b2d6">167</ix:nonFraction> million as of October&#160;2, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i14aafbc729874cbe90872af65ea59b36_I20211231" decimals="-6" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjI4Mg_a50723c1-2b26-4978-912c-03d1fb8facee">53</ix:nonFraction> million as of December 31, 2021. The cash flows associated with the agreements are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $<ix:nonFraction unitRef="usd" contextRef="i509aed2b3fb94e35abdfcdc538d2275b_D20210101-20210404" decimals="-6" name="pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjQ1NQ_239504ff-aff3-4c0b-b7b3-09f27ef6333a">277</ix:nonFraction> million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financing activities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the three and nine months ended October&#160;3, 2021 reflects pre-tax loss from discontinued operations of $<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjcyMQ_efdd289a-a51b-4972-8556-d8049abae7e6">17</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjcyOA_6841573f-6b81-48ea-9a35-062dd87fd0e1">353</ix:nonFraction> million, respectively, and primarily includes pre-disposal operations related to our former Meridian subsidiary including a $<ix:nonFraction unitRef="usd" contextRef="i5fc75e310f54444b94ce2100463e4260_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjg0Nw_1db9f5e9-42c0-4cf3-812f-e6686c71166e">345</ix:nonFraction>&#160;million pre-tax expense in the first nine months of 2021 to resolve a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas (prior to presenting Meridian as discontinued operations, this EpiPen litigation amount was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span><span style="color:#b2b2b2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended October&#160;2, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> reflects pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzI0Nw_8109be1a-1293-49e0-81e2-20fd402485b7">15</ix:nonFraction> million and pre-tax income of $<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzI1NA_3b14452c-5997-4334-a45a-3b854ae4c195">9</ix:nonFraction> million from discontinued operations, respectively, and relates to post-closing adjustments for previously divested businesses primarily for tax and legal matters.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Equity-Method Investment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Haleon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumer Healthcare JV&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operated globally under the GSK Consumer Healthcare name. In exchange for the contribution of our consumer healthcare business to the JV, we received a <ix:nonFraction unitRef="number" contextRef="ia87a0c62e89e454eb69933abb4c4cf0c_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzcxNg_678d0b53-efb5-4e11-ba7f-83c2cee83201">32</ix:nonFraction>% equity stake in the new company and GSK owned the remaining <ix:nonFraction unitRef="number" contextRef="ifc89d78c61c749e883b46dd57f1a3ccf_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzc3OQ_557395b8-4426-4466-884a-35177fe3dae9">68</ix:nonFraction>%. On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint Consumer Healthcare business of GSK and Pfizer following the demerger. We continue to own <ix:nonFraction unitRef="number" contextRef="i2fbf4bc1a0894e7788da3e8ed8f24508_I20220718" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ2MTE3NA_7502d2fd-7dca-47d1-bb24-2310e1e72cf2">32</ix:nonFraction>% of the ordinary shares of Haleon after the demerger. We continue to account for our interest in Haleon as an equity-method investment. The carrying value of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in Haleon as of October&#160;2, 2022 and in the Consumer Healthcare JV as of December 31, 2021 is $<ix:nonFraction unitRef="usd" contextRef="i0aeaaa46a5c645458d5ca97b3f043df5_I20221002" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzk1MA_2a5fec6b-fbaf-4980-a84a-4e690dc90229">9.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i03f67e1304894aa8b40ea227ea7a7e3b_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzk2Ng_8bca30ed-a1ec-46c0-b86b-50bff161a6da">16.3</ix:nonFraction> billion, respectively, and is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of our investment in Haleon as of October&#160;2, 2022, based on quoted market prices of Haleon stock, was $<ix:nonFraction unitRef="usd" contextRef="i0aeaaa46a5c645458d5ca97b3f043df5_I20221002" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MTY0MA_d9db57d5-1b28-46dd-ad20-179d6f4a53d1">9.1</ix:nonFraction> billion. Haleon/the Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2021 is primarily due to dividends totaling approximately $<ix:nonFraction unitRef="usd" contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002" decimals="-8" name="pfe:ProceedsFromEquityMethodInvestmentDistributionTotal" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ1Nzk5Ng_1067390d-e463-4489-ac15-cdeb55791fa0">4.5</ix:nonFraction> billion, of which cash flows of $<ix:nonFraction unitRef="usd" contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002" decimals="-8" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI4MzAxNg_261a62dc-9ccd-4214-b388-d0b6f4c20214">4.0</ix:nonFraction> billion are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities from continuing operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI4MzAzOQ_54064f61-68d5-4bd1-9246-c54c0cf39556">584</ix:nonFraction> million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as $<ix:nonFraction unitRef="usd" contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002" decimals="-8" sign="-" name="pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNDQ0NA_e2a0e0c3-fd34-47a7-b067-4a76683b954b">2.4</ix:nonFraction> billion in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), partially offset by our share of the JV&#8217;s earnings. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our total share of the JV&#8217;s earnings generated in the second quarter of 2022, which we recorded in our operating results in the third quarter of 2022, was $<ix:nonFraction unitRef="usd" contextRef="i2a8fc0f572a7426d9fcc873efb1de4f8_D20220704-20221002" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ1MjUxMg_d618415a-521b-469b-b174-9bf69e827aa7">67</ix:nonFraction> million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2021 and first six months of 2022, which we recorded in our operating results in the first nine months of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i3d12cb9a676f42bbaf48bef1938dc680"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, was $<ix:nonFraction unitRef="usd" contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTA1Ng_414ae620-cfe5-4749-bc16-3d5bfb951519">402</ix:nonFraction> million. Our total share of the JV&#8217;s earnings generated in the second quarter of 2021, which we recorded in our operating results in the third quarter of 2021, was $<ix:nonFraction unitRef="usd" contextRef="i18bc5b7d65614c15bf509693d653ef09_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ1MjUwNQ_ef32eb84-e4ca-40b7-941f-3b1e13890f73">106</ix:nonFraction> million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2020 and first six months of 2021, which we recorded in our operating results in the first nine months of 2021, was $<ix:nonFraction unitRef="usd" contextRef="i002cc11dc66a4c92ab91ce99b0fab752_D20210101-20211003" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTM2OA_04957598-f672-4640-bce6-510076bc1d28">324</ix:nonFraction> million. In the third quarter and first nine months of 2022, our equity-method income included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also includes charges of $<ix:nonFraction unitRef="usd" contextRef="i2a8fc0f572a7426d9fcc873efb1de4f8_D20220704-20221002" decimals="-6" name="pfe:EquityMethodInvestmentAdjustmentOfBasisDifferences" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MDE2NQ_5e390d60-4b09-4262-8343-721cadf49646">118</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002" decimals="-6" name="pfe:EquityMethodInvestmentAdjustmentOfBasisDifferences" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MDE4OQ_22773790-51d9-4d41-9ca3-cfe1323754ea">119</ix:nonFraction> million, respectively, primarily for adjustments to our equity-method basis differences related to the separation of Haleon/the GSK Consumer Healthcare JV from GSK. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV was not material to our results of operations in the third quarter and first nine months of 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-right:9pt"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfOTA2MQ_b0863e55-bd1a-46b1-ba66-cef14ec2ef01" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three and nine months ending June 30, 2022, the most recent period available, and for the three and nine months ending June 30, 2021, is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC0yLTEtMS00Mjk2NzE_21228f7c-2c0b-4cf4-a238-0dd741934eb9">3,218</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC00LTEtMS00Mjk2NzE_435ec536-60a9-4433-9f77-a72f5bae5342">3,152</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC02LTEtMS00Mjk2NzE_87674a98-c5f1-4764-8460-2888d8883cce">10,164</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC04LTEtMS00Mjk2NzE_8b8228ef-4e13-4723-b7b4-94928d35c3e6">9,428</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS0yLTEtMS00Mjk2NzE_748dcab9-04ec-4549-aed3-881dc492a817">1,196</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS00LTEtMS00Mjk2NzE_90364702-e061-47d4-8878-f339eb1b331f">1,180</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS02LTEtMS00Mjk2NzE_5e29f997-537d-4b61-9360-4af8487bfcde">3,830</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS04LTEtMS00Mjk2NzE_e4eb1ac8-9a11-4be4-a7d9-62d56bdb5350">3,536</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi0yLTEtMS00Mjk2NzE_c799b6e7-941b-47ea-9846-00e70c44e64b">2,022</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi00LTEtMS00Mjk2NzE_eff099cf-6cd7-4d0c-91d1-5e2c72d5b2c9">1,972</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi02LTEtMS00Mjk2NzE_caf49688-9e91-49b2-a0f1-db5bfbd81248">6,334</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi04LTEtMS00Mjk2NzE_8919dd51-a9b8-4277-b9c3-313ee211f9ec">5,892</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy0yLTEtMS00Mjk2NzE_cf4bf0ca-178c-48ac-ac87-1fa3f5bb47c5">226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy00LTEtMS00Mjk2NzE_bf36abbf-95ff-4573-af4b-502e4b39d9a8">348</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy02LTEtMS00Mjk2NzE_e6cfdf77-e385-4144-9aac-3162f3627df8">1,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy04LTEtMS00Mjk2NzE_ec8609f0-7b1d-4e7c-b245-36521275e844">1,064</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC0yLTEtMS00Mjk2NzE_24d0a434-d492-4968-8089-b3a119e06abc">226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC00LTEtMS00Mjk2NzE_ac86e8d0-f169-4ad9-ac73-f0b2888d6484">348</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC02LTEtMS00Mjk2NzE_ae8ec31c-39ed-4a9e-acbb-6709af3eb630">1,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC04LTEtMS00Mjk2NzE_14de4467-6429-4215-a68b-75ae6a56d50b">1,064</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS0yLTEtMS00Mjk2NzE_ef6ef1f5-4cdc-48db-9944-a4544b354e13">210</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS00LTEtMS00Mjk2NzE_741136ba-cc16-49d8-9f6a-af5d6025f5a2">330</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS02LTEtMS00Mjk2NzE_21d2d5a0-7b43-4b3a-a1b3-7d54324cca53">1,256</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS04LTEtMS00Mjk2NzE_317c4287-74c3-4430-a955-bc8d21f44767">1,012</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with GSK&#8217;s previously announced planned demerger of at least <ix:nonFraction unitRef="number" contextRef="i420561cd7e844911961eee63ae39bdd0_I20220331" decimals="2" name="pfe:DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTc5MA_61950d51-e194-44c1-89ca-603696c25173">80</ix:nonFraction>% of GSK&#8217;s <ix:nonFraction unitRef="number" contextRef="ifc89d78c61c749e883b46dd57f1a3ccf_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTgwMg_432ded41-a0e1-4b42-9b49-1b7131578c94">68</ix:nonFraction>% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i70b27e6f401f4351a27e511e00a11af2_I20220331" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTk1Nw_2a30e73a-c428-4cea-bf35-a536593c0ad5">8.75</ix:nonFraction> billion in U.S. dollar-denominated senior notes of various maturities, &#8364;<ix:nonFraction unitRef="eur" contextRef="i5a94f1c0e3654553b739db0514bb91f8_I20220331" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjAyMw_61ac1744-58ea-44d9-a793-325455b3640b">2.35</ix:nonFraction> billion in euro-denominated senior notes of various maturities and &#163;<ix:nonFraction unitRef="gbp" contextRef="ie15724356ec94a19bb862b3f6307566e_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjA4NQ_f615d84a-8ac3-4b77-85eb-698fd12c8b96">700</ix:nonFraction> million in U.K. pound-denominated senior notes of various maturities (collectively, the &#8220;notes&#8221;). The notes were guaranteed by GSK generally up to and excluding the date of the demerger (the &#8220;Guarantee Assumption Date&#8221;). We agreed to indemnify GSK for <ix:nonFraction unitRef="number" contextRef="i600244a7a17344ab962cbad5adad812f_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjMzMg_427d56e1-1069-496a-be3c-1b0ccbdb7197">32</ix:nonFraction>% (representing our pro rata equity interest in the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we nor any of our subsidiaries were an issuer or guarantor of any of the notes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of &#163;<ix:nonFraction unitRef="gbp" contextRef="i28e0ab0e158f46899e45c2d773856f14_I20220703" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjg4OA_dd29dd9a-47f8-4ceb-9958-7e9137af17a2">2.9</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i28e0ab0e158f46899e45c2d773856f14_I20220703" decimals="-8" name="us-gaap:OtherShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjg5Mg_778adc0e-5fe0-4d60-98c5-70e8addaa300">3.7</ix:nonFraction> billion as of the end of our second quarter of 2022), at an interest rate of <ix:nonFraction unitRef="number" contextRef="i28e0ab0e158f46899e45c2d773856f14_I20220703" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjk1MA_f3d9abd1-e257-4d64-93d4-fe3ebd86e5f8">1.365</ix:nonFraction>% per annum payable semi-annually in arrears. In conjunction with the demerger, we received &#163;<ix:nonFraction unitRef="gbp" contextRef="ife71c632282645c6972017eea707a24b_D20220701-20220731" decimals="-8" name="pfe:ProceedsFromEquityMethodInvestmentDistributionTotal" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNzMwNw_1afa24f4-7e35-4fb8-8a31-8408bd794c25">3.5</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="ife71c632282645c6972017eea707a24b_D20220701-20220731" decimals="-8" name="pfe:ProceedsFromEquityMethodInvestmentDistributionTotal" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNzMxMQ_27b5f7fa-499d-4a7a-a8fc-aa36e6a714f5">4.2</ix:nonFraction> billion) in dividends from the JV in July 2022, of which $<ix:nonFraction unitRef="usd" contextRef="ife71c632282645c6972017eea707a24b_D20220701-20220731" decimals="-8" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI4NjMyNw_99ab4ac1-bb94-40de-8565-6f512675370f">4.0</ix:nonFraction>&#160;billion related to a one-time pre-separation dividend, which decreased the carrying value of our investment (as discussed above). Simultaneous with the receipt of the dividends, we repaid the &#163;<ix:nonFraction unitRef="gbp" contextRef="i42142f3d667447f8b004965d67fb5bef_I20220731" decimals="-8" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MzI0MQ_47200092-d13b-4f18-85c8-d2c07fd7515f">2.9</ix:nonFraction> billion loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata loan from the JV. In conjunction with these transactions, our indemnification of GSK&#8217;s guarantee discussed above was terminated.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Collaborative Arrangement</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Biohaven&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its subsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Under the terms of the agreement, Biohaven would  lead R&amp;D globally and we would have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January&#160;4, 2022, we paid Biohaven $<ix:nonFraction unitRef="usd" contextRef="id7af860819f54f01861664b5ad041b8f_D20220104-20220104" decimals="-6" name="pfe:PrepaymentsAndPaymentsToCollaboratorsCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODM5OA_13cbce96-ae01-4816-9099-a6e780a3408f">500</ix:nonFraction> million, including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id7af860819f54f01861664b5ad041b8f_D20220104-20220104" decimals="-6" name="pfe:PaymentsToCollaboratorsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODQzNA_5986c44d-be22-4734-9c8f-eaab84a6a403">150</ix:nonFraction> million and an equity investment of $<ix:nonFraction unitRef="usd" contextRef="i58af9a3440794bd6aecec41e17eef71e_I20220104" decimals="-6" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODQ2NQ_0c10f001-45b8-4280-815f-d5c05ad1c364">350</ix:nonFraction> million. We recognized $<ix:nonFraction unitRef="usd" contextRef="ifc7381e87f7646fd8e2cbda19e2e2d0f_D20220104-20220104" decimals="-6" name="pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODQ4Mw_30fd8ff8-1aed-4e49-8beb-a5267650a272">263</ix:nonFraction>&#160;million for the upfront payment and premium paid on our equity investment in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2022, within our fiscal fourth quarter of 2022, we acquired all outstanding common shares of Biohaven not already owned by us for $<ix:nonFraction unitRef="usdPerShare" contextRef="i158261a31a1c413799e169c8d84fe9ba_I20221031" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MTg0Mw_ffc7eeea-021d-46ab-8da5-e3014760bf73">148.50</ix:nonFraction> per share, in cash, for payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i722d6d36e0a3476b89b0cdc056d0f26a_D20221001-20221031" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MTg2NA_cb907b7b-db59-45b6-9646-3291d433efc3">11.5</ix:nonFraction>&#160;billion.</span></div></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_46"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxNA_ed440617-d7a4-47b5-9785-f72b55fdbeb0" continuedAt="ia9b2a03f55014f008da613a104c3bc00" escape="true">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ix:nonNumeric></span></div><ix:continuation id="ia9b2a03f55014f008da613a104c3bc00" continuedAt="i60da94d2242646999635dc3a185ab762"><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We continue our </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i60da94d2242646999635dc3a185ab762" continuedAt="ia87d2f8685194be3a8ff417eb790232e"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts to ensure our cost base and support model align appropriately with our operating structure. While certain direct costs transferred to the Consumer Healthcare JV, and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, of $<ix:nonFraction unitRef="usd" contextRef="i21b538a5cc974cf8b8cff85d8c511b6c_I20221002" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfOTAw_83c52ee2-2a7a-4707-b089-29126f8be9ef">1.8</ix:nonFraction>&#160;billion, to be incurred primarily from 2020 through 2022, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We have also made several organizational changes in the third quarter of 2022 to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). We expect costs of $<ix:nonFraction unitRef="usd" contextRef="i28697c549ce3454c8ce5980750988a6d_I20221002" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMTQzNw_5c50471b-3cf1-4a2b-a1c3-2f6481cc9a70">1.4</ix:nonFraction>&#160;billion to be incurred primarily from 2020 through 2022, with all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $<ix:nonFraction unitRef="usd" contextRef="ie27e5b4edce54e8e8a8ad6d6a9acc7e8_I20221002" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMTg3OQ_8625744f-f490-4a10-ab99-12b75c706391">800</ix:nonFraction>&#160;million to be incurred primarily from 2020 through 2023, with approximately <ix:nonFraction unitRef="number" contextRef="i7fa3843da72a42f2b5f23f8d547a2b0c_D20220101-20221002" decimals="2" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMTkwMg_a1bb07d3-381e-4969-80dd-4eae474d95d6">25</ix:nonFraction>% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program costs discussed above may be rounded and represent approximations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of this program in the fourth quarter of 2019 through October&#160;2, 2022, we incurred costs of $<ix:nonFraction unitRef="usd" contextRef="iadd388f3beca428899e121e6042d61eb_I20221002" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjM0NQ_6ba58113-1eed-4831-96b8-d2f2e7b80989">2.8</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="i76c083a6cc0c4200a8e2f51e5486ed99_I20221002" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjM1OA_19d56aa0-16b9-4442-862c-ad610cce4f1f">1.1</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i76c083a6cc0c4200a8e2f51e5486ed99_I20221002" decimals="-6" name="pfe:RestructuringChargesChargesIncurredToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjM2Mg_43b051cd-1fe6-4c45-9189-ec179495d698">862</ix:nonFraction>&#160;million of restructuring charges) is associated with Biopharma. </span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc3Mw_157090ea-278b-4d2e-8ce4-215083c7d31d" continuedAt="iccd09ded5a0f42c5bcd1800af81c0f02" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC0yLTEtMS00Mjk2NzE_82afe042-bf4c-4fc0-ba7b-e5427e3e1f1a">158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC00LTEtMS00Mjk2NzE_eefe1f99-4870-40f5-ab26-2fe0f8a48d76">630</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC02LTEtMS00Mjk2NzE_31395e3d-1081-4fd4-a809-27db76afb091">293</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC04LTEtMS00Mjk2NzE_d3078836-457e-4711-a5e0-1ddee162aaab">649</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS0yLTEtMS00Mjk2NzE_3b5491b0-7714-4a98-9a38-1d790073f882">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS00LTEtMS00Mjk2NzE_e216659c-047d-44aa-8d2c-274fe4d37d41">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS02LTEtMS00Mjk2NzE_2fac98cf-85d3-494b-bc99-13f63e8814a2">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS04LTEtMS00Mjk2NzE_ca3df2d0-8b6f-471f-8436-78bbbd836778">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi0yLTEtMS00Mjk2NzE_5125732d-cc0d-4925-88fd-cc9397bf9099">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi00LTEtMS00Mjk2NzE_d8aa5cf4-c5c6-49fa-a0dd-c830b434bb0e">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi02LTEtMS00Mjk2NzE_a28d56b7-0790-490e-8189-911c5fa1a885">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi04LTEtMS00Mjk2NzE_60ed7ac6-d4b1-47f6-a97c-ed1deef5d5fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy0yLTEtMS00Mjk2NzE_0ba4fb7e-a5d2-45f8-ba67-e60282dfe1d5">177</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy00LTEtMS00Mjk2NzE_342264cc-7d35-46b0-a05b-7b425eca7b6f">643</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy02LTEtMS00Mjk2NzE_de4ae461-5f30-4b05-adde-e986999b00d6">368</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy04LTEtMS00Mjk2NzE_238101c9-15cc-4c5a-9e7b-f64e349a2256">656</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC0yLTEtMS00Mjk2NzE_488adaed-49b4-417c-9242-a756da55a909">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC00LTEtMS00Mjk2NzE_9fb5c4b0-0fed-4b82-a748-fa1f573f1bdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC02LTEtMS00Mjk2NzE_41178dd3-7bc7-461d-b007-624d30582aa9">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC04LTEtMS00Mjk2NzE_ee5555c1-19b6-4724-8563-ebcc82def2cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS0yLTEtMS00Mjk2NzE_35815b41-cffb-4b5c-9359-d379a907975e">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS00LTEtMS00Mjk2NzE_6c6b2ad1-9924-43b6-ab58-ece897ccfd1f">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS02LTEtMS00Mjk2NzE_3bb528dd-20b9-49b4-a972-f922d43fbdbe">170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS04LTEtMS00Mjk2NzE_75e41cf7-4116-4583-ad8e-d640a5fc5cc1">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtMi0xLTEtNDI5Njcx_34bcc20a-e5be-429c-b94f-6f138e7cbe27">199</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtNC0xLTEtNDI5Njcx_141dd8be-cd50-436f-837b-ef41ccff4cea">646</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtNi0xLTEtNDI5Njcx_145386f7-f7d9-4efb-9fea-731199de4d5f">580</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtOC0xLTEtNDI5Njcx_54f66fdc-5dc7-4948-9ac6-470ea2a10152">667</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4619b114ec194ad0b6cdf916bfe7a1e4_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtMi0xLTEtNDI5Njcx_406beaf7-da06-4c63-82b3-f2ffa4a7f914">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743f0eb0d1d04686a3138f343d0a91a4_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtNC0xLTEtNDI5Njcx_4315ad1d-059c-4ef2-9001-76e1a6fa253b">63</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id35ac29855a1475ca5478fc62e1fd74f_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtNi0xLTEtNDI5Njcx_6dda7f23-631b-4d47-94ff-4b4202490b4f">5</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fd5613cc06a4d73a6e8eaa13a7d3b73_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtOC0xLTEtNDI5Njcx_ce3bfd24-48c9-46d2-b893-3e2ef1ccb704">51</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ef4b0d7cca452089dd78603de3cf6c_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtMi0xLTEtNDI5Njcx_60d08d81-6843-466f-90a4-c0b3b770f412">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e35f95c0c3442aaabb2dfc697eddc0_D20210705-20211003" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNC0xLTEtNDI5Njcx_82f5e9db-b6b1-4de1-aa74-6c64330ab4e1">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0a9e3dc01d4e41b2c5e11386542b1f_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNi0xLTEtNDI5Njcx_b6b5bcac-63bf-4b98-85bf-a5df968d5b98">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf45616770c74e4290c92f85fa0706ef_D20210101-20211003" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtOC0xLTEtNDI5Njcx_553fd7bb-a59b-4591-a381-13146ee4220f">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365d50df2a645fa85ed477f05ab1838_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtMi0xLTEtNDI5Njcx_9c51b6f7-67c7-432c-9e63-82529e0ef233">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNC0xLTEtNDI5Njcx_7dfd910b-3aeb-4666-97de-f5798800d3f7">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNi0xLTEtNDI5Njcx_b59868eb-033a-4a90-b591-19c42eeddd39">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtOC0xLTEtNDI5Njcx_318869ec-9960-4b91-bdb4-182356a4bc99">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtMi0xLTEtNDI5Njcx_90ce7781-3290-4ad3-93af-3e5a8675bded">7</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNC0xLTEtNDI5Njcx_8a45feee-639e-4454-b3fc-f9624de079ab">27</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNi0xLTEtNDI5Njcx_7ac490a0-73b9-452d-bf96-cfa38f3b8865">22</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtOC0xLTEtNDI5Njcx_e0cfea43-1a3e-48c2-acee-7ea66cde29d7">76</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ef4b0d7cca452089dd78603de3cf6c_D20220704-20221002" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtMi0xLTEtNDI5Njcx_b8d35731-3c3a-44a7-85f7-4d37b26a1ee7">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e35f95c0c3442aaabb2dfc697eddc0_D20210705-20211003" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNC0xLTEtNDI5Njcx_03da9fde-fd5e-4bb9-b48b-aefe07d232a3">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0a9e3dc01d4e41b2c5e11386542b1f_D20220101-20221002" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNi0xLTEtNDI5Njcx_ad4f3559-591c-4f22-b2f9-04973e92ea32">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf45616770c74e4290c92f85fa0706ef_D20210101-20211003" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtOC0xLTEtNDI5Njcx_7ba0e3ea-e682-4737-996e-6547c9d8d1f8">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365d50df2a645fa85ed477f05ab1838_D20220704-20221002" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktMi0xLTEtNDI5Njcx_a31d12ad-733d-454f-aacf-b9a02ebc2ddf">136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNC0xLTEtNDI5Njcx_afc4de30-418f-4e3e-b0ca-ef2323eda3f9">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNi0xLTEtNDI5Njcx_42cb499f-f636-4adc-b8ac-a98d69c36b83">344</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktOC0xLTEtNDI5Njcx_0ac023e0-501c-45e6-8b76-9e5c1d60aa3c">287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8da4f7456e442295e4b41cd995dae1_D20220704-20221002" decimals="-6" name="pfe:ImplementationCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtMi0xLTEtNDI5Njcx_970aaef8-b5d6-42fb-a76a-f958b99c1684">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72db9e61e2aa40229247e0d3b02b0e82_D20210705-20211003" decimals="-6" name="pfe:ImplementationCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNC0xLTEtNDI5Njcx_8ece4338-3312-4216-a456-9e7e99d62f1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32df0ec003834b6eab05cf61f39fa6e3_D20220101-20221002" decimals="-6" name="pfe:ImplementationCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNi0xLTEtNDI5Njcx_e1f2d427-f765-49fa-839a-f5c432154997">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4744ad08ba8409a820a07a834ff061c_D20210101-20211003" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtOC0xLTEtNDI5Njcx_3fbd4518-51fe-483f-89a1-5cf9bf4a4751">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItMi0xLTEtNDI5Njcx_a86e56c8-94cb-4066-986c-23c2b8d97686">150</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNC0xLTEtNDI5Njcx_a4541278-e2cb-4393-a38b-ae8cad9d8c18">151</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNi0xLTEtNDI5Njcx_7fca1ffd-896d-495a-a9d5-7b0cede00795">384</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItOC0xLTEtNDI5Njcx_6cc8c14f-d7d8-4564-87d8-7758542b84a4">316</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtMi0xLTEtNDI5Njcx_8521e85a-288e-445a-9208-dbec4fadc927">357</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtNC0xLTEtNDI5Njcx_966cbe8e-024b-41aa-9d88-2fd6c0b5e64e">760</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtNi0xLTEtNDI5Njcx_b81876ef-79da-4d01-a982-8ca175f37323">982</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtOC0xLTEtNDI5Njcx_4fcd624e-5bb8-4fd3-8679-6719a9d06554">1,008</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83" footnoteRole="http://www.xbrl.org/2003/role/footnote">Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $<ix:nonFraction unitRef="usd" contextRef="i1fd31dba911048de993662a30bd60e24_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjU2Mg_b66a3f13-496c-4eaa-a4fd-30661f4c58dd">62</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5974e3684a5d4959a373f6a880ead072_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjU2OQ_0d9ffe8e-9926-414c-9423-3c0533a6e533">108</ix:nonFraction>&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $<ix:nonFraction unitRef="usd" contextRef="i2ba30fd6c8d04ca8bac5eceecaea0094_D20210705-20211003" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjY0MA_3e05b6e5-49dc-43f0-be54-bd71f43b5b84">616</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic0aea8b98cb34108abfe4081d7793e2c_D20210101-20211003" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjY1OA_827e2066-3bae-454d-b112-4827752353b2">617</ix:nonFraction>&#160;million for the three and nine months ended October&#160;3, 2021, respectively.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents external costs for banking, legal, accounting and other similar services.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia87d2f8685194be3a8ff417eb790232e"><ix:continuation id="iccd09ded5a0f42c5bcd1800af81c0f02"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October&#160;2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $<ix:nonFraction unitRef="usd" contextRef="i300033c0ba2c4182978046a909b7606b_D20220101-20220403" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzEzNA_228e7a2a-4f57-4f4d-abd1-cc28375ee5b9">138</ix:nonFraction>&#160;million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></span></div></ix:continuation><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOA_2c2f86a4-55a8-45ac-88f7-60f96b22ee63" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:40.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f516286c63343f28a4664b266e75256_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi0yLTEtMS00Mjk2NzE_df7dc9d1-9615-488a-bbd0-c4f83be85ba2">1,014</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9ab2b2fea44955974b44346416d463_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi00LTEtMS00Mjk2NzE_5b63501f-3025-4448-9dae-f21d2b141cde">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7dbe8638f7401a94c5382e4b054e25_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi02LTEtMS00Mjk2NzE_59824e27-a17c-4205-aae0-a5a482b9df27">57</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi04LTEtMS00Mjk2NzE_14fa5f10-49f6-42ad-ba5c-7d5ca8c04911">1,071</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7081406b1b62439ab5fd196c928df604_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy0yLTEtMS00Mjk2NzE_d640a873-639e-4b9f-92d3-559bb29140c9">293</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8b45d1675445aa8d696f11839ca704_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy00LTEtMS00Mjk2NzE_37cd62e2-ed76-4106-a6c8-60182dcd4f20">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672675a4e5374596930c5eb56c56fb6e_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy02LTEtMS00Mjk2NzE_1ff33ef0-4d62-44a7-b15a-259b0d25adc9">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy04LTEtMS00Mjk2NzE_beacace5-91a9-46ac-8250-9646abefa306">368</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7081406b1b62439ab5fd196c928df604_D20220101-20221002" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC0yLTEtMS00Mjk2NzE_312e8447-359d-4343-b5cc-758a50fea8f6">447</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e8b45d1675445aa8d696f11839ca704_D20220101-20221002" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC00LTEtMS00Mjk2NzE_45240349-7a57-4b66-8563-1735eb215c7e">44</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i672675a4e5374596930c5eb56c56fb6e_D20220101-20221002" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC02LTEtMS00Mjk2NzE_bd465f0a-3160-4eee-9aaa-b9f143521049">80</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC04LTEtMS00Mjk2NzE_89cdec7c-14cd-4eb1-b43e-bd10aaa766ee">572</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, October&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b1a60419934acf858ae1b59d2c713d_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS0yLTEtMS00Mjk2NzE_0f02e791-2a53-4174-8273-fb3671668c74">859</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f37bc9a3284a51bb64a83d09a3d26a_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS00LTEtMS00Mjk2NzE_29b75c68-773e-4ad8-bbb3-abd94eb1b2cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ffcb4ce1bd422f80c0659256ce5949_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS02LTEtMS00Mjk2NzE_8544ae2b-5f21-437e-b021-ac522c5a2d24">8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS04LTEtMS00Mjk2NzE_94b6c3d5-e3c3-45f7-bb93-09c0ebe86c83">867</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i7508bb16fd44454482e06b74af164e0f_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzU3MQ_7b4afb87-3fe2-4a7f-b8fd-8b08a0e41495">816</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i20b757dbbd6f4f2bad32cff5eca993e2_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzYwOQ_ffad3ed9-fc1a-4efe-9805-ae44d8f7fc5a">255</ix:nonFraction> million).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes adjustments for foreign currency translation.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzcwOA_960ea11b-b120-4f04-837c-315b300969d2">758</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="id0861c1e153d4341b6f1aa2768a8b9e3_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc0Ng_eb3ff197-80ae-491a-896c-1157d86a0575">110</ix:nonFraction> million).</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_49"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQ1_10e566f8-73ff-468d-a91f-5139b4d9189b" continuedAt="i9562d95b15e4473b8aa80f43778069bf" escape="true">Other (Income)/Deductions&#8212;Net</ix:nonNumeric></span></div><ix:continuation id="i9562d95b15e4473b8aa80f43778069bf" continuedAt="iee8a47acc5db4f1f918cbb432851cbe2"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI5_ff0e5ec0-feaf-46b7-9f1d-f61ff412ae7b" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy0yLTEtMS00Mjk2NzE_b91964d7-f378-4c70-8e2e-61bf9e5b9c8f">70</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy00LTEtMS00Mjk2NzE_827d9b78-ce19-443a-bbed-33922938d375">10</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy02LTEtMS00Mjk2NzE_a2273a8d-4514-4dbd-a7d2-157b5e1065a6">114</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy04LTEtMS00Mjk2NzE_a7da31e4-2554-4dd4-85f7-b1519881cbad">21</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC0yLTEtMS00Mjk2NzE_7d35f7de-cb2e-4e67-892e-731a52975629">311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC00LTEtMS00Mjk2NzE_60fe0c04-3505-49b3-bcbe-207897bf5fa0">325</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC02LTEtMS00Mjk2NzE_71034e20-790f-4ada-99ab-518bb1368416">925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC04LTEtMS00Mjk2NzE_266bd1d6-7d94-45a2-b2e9-fbe07c00f65e">975</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS0yLTEtMS00Mjk2NzE_39aaa6e6-c55c-4d13-8a12-16be6e47e59f">240</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS00LTEtMS00Mjk2NzE_4041944e-1891-4359-8d77-f7b09f31f2fe">315</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS02LTEtMS00Mjk2NzE_241d38d7-0ff1-449d-a9d8-f08e6d03fd81">811</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS04LTEtMS00Mjk2NzE_b7ce08e1-85f7-4377-b6ad-adffa214e96d">954</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi0yLTEtMS00Mjk2NzE_fe983548-6421-4ab6-abef-25bbfa671ac7">239</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi00LTEtMS00Mjk2NzE_655a64d3-5878-4035-8a39-609f2a228280">261</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi02LTEtMS00Mjk2NzE_289d4a27-d468-44df-875b-6594180de671">628</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi04LTEtMS00Mjk2NzE_5f2684ad-f36f-4da0-a913-b175b3a48a39">649</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy0yLTEtMS00Mjk2NzE_57b1ec53-cd2b-4922-8a9b-a02a894671c6">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy00LTEtMS00Mjk2NzE_f39b7803-322e-4eb9-8639-03cb6816b6e4">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy02LTEtMS00Mjk2NzE_6f3c578d-70ae-4f61-8dbd-823fb2cf1ff4">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy04LTEtMS00Mjk2NzE_7e36110f-439a-48db-9582-4979767cdc04">99</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC0yLTEtMS00Mjk2NzE_2baaca16-26a8-47d2-a221-754f24fd20cb">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC00LTEtMS00Mjk2NzE_f2ce4cd5-9bc0-46df-98a2-0a1357007693">400</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC02LTEtMS00Mjk2NzE_ff34748e-e1cd-45ce-93ab-98ed5e2b47a4">1,353</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC04LTEtMS00Mjk2NzE_8c1270d2-bc3a-444c-810e-7d0db83546a0">1,601</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS0yLTEtMS00Mjk2NzE_0e091c4d-563d-4a8d-8711-bd269d2da7a9">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS00LTEtMS00Mjk2NzE_78979520-f128-45f4-991e-aab26f802b5d">65</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS02LTEtMS00Mjk2NzE_64fe25dd-a57e-463f-adf8-62bd1b937c40">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS04LTEtMS00Mjk2NzE_ff367060-a416-42eb-ac91-4c9ed4241d0c">317</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtMi0xLTEtNDI5Njcx_843f98da-2316-412b-b884-5efb9c0e0d59">306</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtNC0xLTEtNDI5Njcx_f45d2fac-9141-40af-83be-82dab4c8f169">1,132</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtNi0xLTEtNDI5Njcx_975d495b-f1ec-4d5c-8b03-54db93c6ac00">294</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtOC0xLTEtNDI5Njcx_177b72f1-5468-4824-b45e-9f514b8edc26">1,635</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtMi0xLTEtNDI5Njcx_2011f701-2d72-4e23-865d-e2ce5d6b0dbd">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtNC0xLTEtNDI5Njcx_dbc779dc-0284-4d2d-80c6-2f5d2a8bf168">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtNi0xLTEtNDI5Njcx_26548de6-29f3-439e-bcb8-f61b305fe115">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtOC0xLTEtNDI5Njcx_ffc01b36-fe76-4d1a-a916-adb38d167cc0">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain asset impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItMi0xLTEtNDI5Njcx_57e6f583-7137-404d-adb6-5515aacc01aa">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNC0xLTEtNDI5Njcx_97d270b7-b1ce-45e6-b737-833c464ba639">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNi0xLTEtNDI5Njcx_626fee7e-657f-4788-a035-b8cd2f31808f">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItOC0xLTEtNDI5Njcx_00d1ae0d-5416-453b-a4cc-e1d982d37e99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haleon/Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtMi0xLTEtNDI5Njcx_ca5fa3ae-21d5-4c48-93b1-a60c41f42be6">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNC0xLTEtNDI5Njcx_7c89b3c6-eae2-4569-9415-e7d0b862ac03">105</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNi0xLTEtNDI5Njcx_bff3b0ab-ad48-49ee-979e-f9df13844b8c">283</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtOC0xLTEtNDI5Njcx_a5ab5888-7716-4238-ad86-b88c6ea5907f">307</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtMi0xLTEtNDI5Njcx_edc894d3-afbc-40da-b838-7717b52664c1">198</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtNC0xLTEtNDI5Njcx_ddf8be5d-96ea-4f03-9c9f-03cf0d96a2fb">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtNi0xLTEtNDI5Njcx_b89d5766-8a3c-469f-bcbe-b407a9e694ee">260</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtOC0xLTEtNDI5Njcx_c658d3e9-d2db-4a89-981c-eb45407911a1">502</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtMi0xLTEtNDI5Njcx_f1b974a0-f721-495a-8c2b-980eb4a3ce37">59</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtNC0xLTEtNDI5Njcx_d9cd9e2d-ef0d-49db-a455-b92cb5f2cd3e">1,696</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtNi0xLTEtNDI5Njcx_50f1acec-2b6c-4013-976d-04cd151bc671">1,063</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtOC0xLTEtNDI5Njcx_c73d25a5-a77c-4dd2-88a4-ed2e393f3f2f">4,043</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829" footnoteRole="http://www.xbrl.org/2003/role/footnote">The losses in the first nine months of 2022 include, among other things, unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i5120c338e7784bc0a405cf860830dc96_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfMTA5_a3f01062-a6ae-4db8-8698-9d26eb469a39">974</ix:nonFraction>&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i60c3b88c09f446329b1ec1583f33a3b3_D20210705-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfMjk1_4d7cda5e-2421-4d26-ba9a-fa85de00f235">420</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9c5aec14bf13443d865368553c8fb09f_D20210101-20211003" decimals="-8" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfMzAy_c6d69c31-6d23-400e-921e-a3c6520fe9cf">1.5</ix:nonFraction>&#160;billion, respectively, related to investments in BioNTech and Cerevel. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1" footnoteRole="http://www.xbrl.org/2003/role/footnote">The first nine months of 2021 included, among other things, $<ix:nonFraction unitRef="usd" contextRef="i4e03b80a6e31462388cb8fa87c81fae5_D20210101-20211003" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNDEx_7db6f0b8-f108-40bf-9c0a-7b6ba5a1b7dc">188</ix:nonFraction>&#160;million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amount in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.</span></ix:footnote></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></ix:footnote></div></ix:nonNumeric><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OA_8e2a4916-492d-4ddb-a678-c714ce6f7e6c" continuedAt="icf4d34b6eb0a40b39501ad4b7cc48705" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional information about the intangible asset that was impaired during 2022 (impairment recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended October 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset&#8211;&#8211;IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e604c4a1134172a1157b3846f7e9db_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bcdf5d6697b4dfda841c81ef6f0b444_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fcb9d12f7e8461f800a28613f391b63_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a3f390d88441aa84493f5b915fa1fa_D20220101-20221002" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0xMC0xLTEtNDU1NDg4_e2b9857d-9a48-440e-b892-39f78f609815">200</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1F </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="iee8a47acc5db4f1f918cbb432851cbe2"><ix:continuation id="icf4d34b6eb0a40b39501ad4b7cc48705"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" footnoteRole="http://www.xbrl.org/2003/role/footnote">Reflects an intangible asset written down to fair value in 2022. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</ix:footnote></span></ix:continuation></ix:continuation></div><div id="i8c2530a91ced4c48b9620128206808f1_55"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5MQ_97c52c60-4dfe-4165-b8a5-72b5bdccd97d" continuedAt="ieace515fa5684442aeea9507d0c45b21" escape="true">Tax Matters</ix:nonNumeric></span></div><ix:continuation id="ieace515fa5684442aeea9507d0c45b21" continuedAt="id66678a4026348509e4b0b239a53dc2a"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for continuing operations was <ix:nonFraction unitRef="number" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMTE1_82be704d-2dc8-4ab3-9154-c4498d45fe39">4.0</ix:nonFraction>% for the third quarter of 2022, compared to (<ix:nonFraction unitRef="number" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMTU2_43826c41-a945-4d0b-bb83-18dae5218eec">4.2</ix:nonFraction>)% for the third quarter of 2021, and was <ix:nonFraction unitRef="number" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMTkz_1f43cf33-9e9e-4504-8cee-bbf250f56b0b">10.5</ix:nonFraction>% for the first nine months of 2022, compared to <ix:nonFraction unitRef="number" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjE5_411f443b-00df-4e63-8194-b3cbafd58844">7.8</ix:nonFraction>% for the first nine months of 2021. The higher effective tax rates for the third quarter and first nine months of 2022, compared to the third quarter and first nine months of 2021, were mainly due to the non-recurrence of certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK, partially offset by tax benefits in the third quarter of 2022 related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years that included the closing of U.S. IRS audits covering five tax years.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-9" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfNTk4_e1bbba40-e708-423f-ad2c-7553cedfbd21">15</ix:nonFraction> billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fourth annual installment of this liability was paid by its April 18, 2022 due date. The fifth annual installment is due April 18, 2023 and is reported in current </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of October&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. During the third quarter of 2022, Pfizer reached resolution of disputed issues at the IRS Independent Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2011-2015. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2022 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2011.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id66678a4026348509e4b0b239a53dc2a"><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ2NQ_8c228b24-c514-442b-a38a-03fb71ca420d" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:53.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy0yLTEtMS00Mjk2NzE_87621f1f-793f-4e86-9eb5-afa1e0e859ec">20</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy00LTEtMS00Mjk2NzE_824ff5fb-0912-42a1-801a-3a2c58508bc5">32</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy02LTEtMS00Mjk2NzE_a1c2893c-c20e-46fd-b88f-599e3e194b3b">165</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy04LTEtMS00Mjk2NzE_86b449de-4569-4595-9b66-d97adb3d390c">30</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC0yLTEtMS00Mjk2NzE_6bf73934-c0fb-4d7e-a3bc-64295487eb55">47</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC00LTEtMS00Mjk2NzE_fbfc8d99-4059-455d-ad4c-afe52615880b">21</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC02LTEtMS00Mjk2NzE_1158b742-bbb5-4ee9-aaea-043e582ba26c">177</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC04LTEtMS00Mjk2NzE_30400b46-b9e0-4174-a5c3-5fd0f9524afd">28</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS0yLTEtMS00Mjk2NzE_00d45593-4914-4e04-b0b4-29052503d241">72</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS00LTEtMS00Mjk2NzE_ff3c495f-cae0-49d4-a292-45a6367f6857">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS02LTEtMS00Mjk2NzE_153a9a7f-926f-4e6e-8066-2d78061b0904">97</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS04LTEtMS00Mjk2NzE_eb55c515-6c0c-48a5-a8c5-a269845ffd86">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi0yLTEtMS00Mjk2NzE_7c26345b-4541-40ac-a17c-e059f2984015">25</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi00LTEtMS00Mjk2NzE_041b8975-0b23-4f46-af18-be532fe41080">34</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi02LTEtMS00Mjk2NzE_47f47b19-72f3-4643-9c9c-cbc64b1112f9">80</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi04LTEtMS00Mjk2NzE_e27aaf81-b85b-4ea5-aeb8-14d28198b380">76</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy0yLTEtMS00Mjk2NzE_ae756119-033c-4e5e-90f1-3567fd67ce51">97</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy00LTEtMS00Mjk2NzE_195e9bcb-014a-4f81-8cc8-edaeac4f9542">33</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy02LTEtMS00Mjk2NzE_87f52213-2aad-46a8-9299-cb4b4a04d93a">175</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy04LTEtMS00Mjk2NzE_40d7cd60-3e8c-4edb-af50-fadf35f03653">16</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC0yLTEtMS00Mjk2NzE_e830575d-f220-4715-a5a9-61cb74407575">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC00LTEtMS00Mjk2NzE_bdd88251-cfe6-41c1-b734-1e7ed76aa09e">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC02LTEtMS00Mjk2NzE_5d98e1b0-5e6e-4b2b-982c-825efbdeb005">137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC04LTEtMS00Mjk2NzE_14ee1f57-e6b6-49c4-86b4-d0ae7ac5ea81">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS0yLTEtMS00Mjk2NzE_6f421d76-9cc4-4715-b009-0e0008d32ed1">21</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS00LTEtMS00Mjk2NzE_6a0c3e8d-d86b-43e1-9a82-4d9280fdb294">32</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS02LTEtMS00Mjk2NzE_309e2a5e-9888-4ee9-a797-ace256fdcd83">38</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS04LTEtMS00Mjk2NzE_44076e31-e4cf-4992-8a9d-34c77529bbb1">37</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtMi0xLTEtNDI5Njcx_d0b23d8e-872b-4d09-82e3-c89ea65fa625">7</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtNC0xLTEtNDI5Njcx_6ab8e115-0210-41e9-94f2-aa0c64d8341c">22</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtNi0xLTEtNDI5Njcx_14186a6b-7464-42a8-96dd-ca5349b10f4a">23</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtOC0xLTEtNDI5Njcx_e3d10764-0be0-4f37-90b8-262defd1a774">39</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctMi0xLTEtNDI5Njcx_08deea1f-b796-46b4-b16e-311367fc5f91">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctNC0xLTEtNDI5Njcx_6760df7d-adda-4417-9a12-0a77401e14d3">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctNi0xLTEtNDI5Njcx_9eec21e8-e8fb-4685-89a5-789d50e7150e">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctOC0xLTEtNDI5Njcx_801789ae-105b-42b8-874d-7b50259472f0">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktMi0xLTEtNDI5Njcx_bc2f0990-0958-44c6-b3ab-bd3309254174">8</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktNC0xLTEtNDI5Njcx_6f91e897-ce77-422d-97a9-0ee978bcfba9">36</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktNi0xLTEtNDI5Njcx_aed5677f-d41c-4517-8c38-a42dae9055a1">26</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktOC0xLTEtNDI5Njcx_d7a41926-4604-4994-b5e8-4bea685ca2d7">54</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtMi0xLTEtNDI5Njcx_ec19f2c9-f02d-4cfa-8317-463248c6974b">33</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtNC0xLTEtNDI5Njcx_a7327d94-797e-4315-9ede-0b4aebc7be04">65</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtNi0xLTEtNDI5Njcx_be853de4-6ae5-47e4-8c3a-1dda5be8e607">149</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtOC0xLTEtNDI5Njcx_ababaf4f-81ce-414b-9f3f-94735a67545c">44</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4" footnoteRole="http://www.xbrl.org/2003/role/footnote">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_61"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzM4_6811584b-333e-4d41-85f6-71ed3ff6edfe" continuedAt="i0acb6f2b21244226a894555ef360ccf2" escape="true">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ix:nonNumeric></span></div><ix:continuation id="i0acb6f2b21244226a894555ef360ccf2"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzQx_dc031836-122e-4158-b632-9d254a039033" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia28d11de768f4acfa1899aa6f92f42fe_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy0yLTEtMS00Mjk2NzE_197d52ab-5c53-46aa-809a-121dfa72ad0a">6,172</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe7a5df8a364aef9def98d475a8dd2c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy00LTEtMS00Mjk2NzE_7fcb174b-bc68-4c67-989c-62dfe4c31ef7">119</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedabc8fc306843ffb9c2a5c9a5abf093_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy02LTEtMS00Mjk2NzE_efd27229-02ff-46ad-847f-8d1153fc0b11">220</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0c0bfa0bc7435f8a1cb14d125612d0_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy0xMC0xLTEtNDI5Njcx_2483dcb3-f049-4e9d-b2b1-31d652132fd9">377</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ef44849268d4847a9fb27d3a90011e9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy0xMi0xLTEtNDI5Njcx_e8132244-46b9-4fe5-bc07-59a0e60bbb26">5,897</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1218785b15a4b428afe5839d3c22095_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0yLTEtMS00Mjk2NzE_4ca766d1-f980-4cf2-8135-ebd81ac499b7">2,373</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a588750f30485cba7eb82683ef423b_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC00LTEtMS00Mjk2NzE_de3ad6c3-47cb-4953-bb35-35061c8d9092">391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id36f1bf78a2e4329b60d5e5ca4f34e82_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC02LTEtMS00Mjk2NzE_4bd91447-2eeb-4b1d-84e8-75f3886b7b62">265</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cc5b6fe28ec4fc892354bdc356b0801_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMC0xLTEtNDI5Njcx_493e4ba9-7b8f-408d-ac44-f4a29de69d63">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8a629a946b4ceca7ca7dd72b1af40b_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMi0xLTEtNDI5Njcx_3ccb185c-d21e-497d-9541-82146f5868b4">2,328</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, October 2, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4713ca3234b4b16be713694331b20e8_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS0yLTEtMS00Mjk2NzE_15d0adff-39ec-4f70-8310-a0c1959fe2b8">8,545</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84465afd71b54fbca86dd39dd5eb14e4_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS00LTEtMS00Mjk2NzE_725de47b-e946-43b6-9c9c-b24c8e1fc67c">509</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3ac6485d813484ab3e2a5f79e9312df_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS02LTEtMS00Mjk2NzE_98d629f6-d26d-4b54-bce1-d789e8026bfd">485</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a51b3abaa324634a216f2ccf13bdd62_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS0xMC0xLTEtNDI5Njcx_f25f93c6-47bf-433a-bb18-48b94cf2dfaa">296</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i316fd24dd0da46e5872d02ce9db0a499_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS0xMi0xLTEtNDI5Njcx_ef6b9d29-397e-43f1-b9fb-ce2639caf251">8,225</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div style="text-indent:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_64"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQxOA_d5ac8b0a-dc39-4dc7-8605-ae77aa8ad77b" continuedAt="ie00135a3823f4bd6b20ae9ddebdee947" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="ie00135a3823f4bd6b20ae9ddebdee947" continuedAt="i602816b7efeb4bbe8d70d72766a861bf"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMA_3b846a03-4ee5-4ccd-a0c3-5155c630d834" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d2fd4d529d4ffaa9992caf594aea98_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0yLTEtMS00Mjk2NzE_c508d5d1-4bf7-42a8-8bb3-02457f9d69b4">12,154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365aa8bb027248c0a4bd72e05fd31c0c_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS00LTEtMS00Mjk2NzE_6ef0cd95-ec5e-40af-9858-9abb260f3018">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ab2d49d10a4441badf49b57db6e345_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS02LTEtMS00Mjk2NzE_bf7ffdf9-d629-498a-96da-cec023d79b20">12,154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf645fee7504d31b036a7ca132adbff_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0xMC0xLTEtNDI5Njcx_5367d8d6-abf3-4e48-8d22-a4ca4f1498c7">5,365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3509896f64d41e5a5a8a7c49b85adbd_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0xMi0xLTEtNDI5Njcx_af9b08ca-496a-415f-8254-7dd42183c2a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd50bf1cd5ba47938f5f06d79c2b2891_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0xNC0xLTEtNDI5Njcx_2a39fc30-ed34-4d2e-ae5e-06d420fc55c8">5,365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805f99cc930d4f27b83f2f5f22fcfd16_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0yLTEtMS00Mjk2NzE_45d1b6a0-f6f0-4a73-92cb-e27d61fd98c9">15,885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7edb8146745e45e3b80ad081fff12d94_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC00LTEtMS00Mjk2NzE_35e8ae51-2fbb-42ae-aeb4-eabff4035f91">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89eef82eb7a14b73bef78f769ed99bc2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC02LTEtMS00Mjk2NzE_6487a0ae-3be8-4943-ac31-4b870fe3b57e">15,885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb21d2ec5e54e368a11d0e46bd687d8_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0xMC0xLTEtNDI5Njcx_e95fc7f9-a42e-4daf-bf48-042fa337e3e2">17,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff481cae963c450595873c78d321b75f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0xMi0xLTEtNDI5Njcx_86949c1c-4046-4518-b9d0-80d3061ec8c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7fb7cfc61124350803a3395415aa187_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0xNC0xLTEtNDI5Njcx_5898cbdb-ae25-4b02-a949-75cd35b2da0c">17,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if479661c13be4b20ac5fb45721ae4f0d_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0yLTEtMS00Mjk2NzE_f991cd5a-e5a7-45b8-bf0b-c2b10598dd9c">2,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2479bf3cc9724ee0ab05e372bdb15b2f_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS00LTEtMS00Mjk2NzE_b106459d-f815-41a1-a5ca-d5714c3ae9e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a25515655044cabbf3baefce125c4ee_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS02LTEtMS00Mjk2NzE_cdea9ce6-f8b1-4a03-86fa-40d5ec5417d8">2,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48d8b4d17584751a31563d542bdfdaa_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0xMC0xLTEtNDI5Njcx_f50a9e57-0f87-4862-8af5-c59732efbbfe">4,050</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d99910901024c4c8acc5114294068dd_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0xMi0xLTEtNDI5Njcx_5d9db267-15f1-4c4b-a08e-1dbd3ba19ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab958fb460e4fa0a9e49791a40852e2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0xNC0xLTEtNDI5Njcx_fcabf883-5c72-4396-a332-c80b785917ff">4,050</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04206940cb3c4f31828b818000eb0def_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMi0xLTEtNDI5Njcx_b4be98bb-1cfb-4a21-8bba-54e489254af2">1,361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619ff852ea974bb5b961b5bfe763d05f_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtNC0xLTEtNDI5Njcx_3717dce6-beae-4290-83bd-332a371e3f42">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49460c8694894c998f43812db50d6a6f_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtNi0xLTEtNDI5Njcx_400b7f64-93de-4add-8a04-5cd87898c997">1,361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4935735833a74f51b431b13978755e1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMTAtMS0xLTQyOTY3MQ_45d7660f-8bbc-4785-9d67-33f41e3fdeaa">647</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524be4274845416fb3a8a00458bd6bb7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMTItMS0xLTQyOTY3MQ_acad6260-33a6-4cd3-be88-43397c47cc95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117594e26d1a4ad898c33e699b9f7077_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMTQtMS0xLTQyOTY3MQ_c6ef2385-5e8e-4e85-94b1-93e2c7d1b514">647</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914b27e478a94963b2d4b101e6efc8ac_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMi0xLTEtNDI5Njcx_ad5043de-d569-4d17-92ed-74e1796a4dc3">20,176</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefaeb8ef2b2844f88d07b978d1f21090_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtNC0xLTEtNDI5Njcx_f5272774-4428-45a0-8633-ed7e44a89e68">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c6d752d4524b33be36259fef0edbf9_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtNi0xLTEtNDI5Njcx_2e80e03c-f694-4d2a-91f7-e1a6c975eeeb">20,176</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24fe9c58be452aad86c0e034bcaf6b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMTAtMS0xLTQyOTY3MQ_28716ef0-8bf8-4cba-876f-f2124515121f">22,014</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a8a497745744779127896961eb99b3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMTItMS0xLTQyOTY3MQ_3c090dc6-844f-400c-a203-016ceb5d311c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226bc50d44474921a2117b15aecd4339_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMTQtMS0xLTQyOTY3MQ_a9c28ceb-30fd-4875-8630-abf4213483c3">22,014</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914b27e478a94963b2d4b101e6efc8ac_I20221002" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMi0xLTEtNDI5Njcx_c498c695-347a-4913-aae2-ff139442e67e">32,330</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefaeb8ef2b2844f88d07b978d1f21090_I20221002" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItNC0xLTEtNDI5Njcx_b46fb37c-092e-40f2-992f-c484ffae70d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c6d752d4524b33be36259fef0edbf9_I20221002" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItNi0xLTEtNDI5Njcx_6d6cdeb5-773f-40a1-8e5c-9c883ebb968c">32,330</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24fe9c58be452aad86c0e034bcaf6b_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMTAtMS0xLTQyOTY3MQ_adf5dcd6-ca8d-4c56-9ba2-89fde7bd5298">27,379</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a8a497745744779127896961eb99b3_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMTItMS0xLTQyOTY3MQ_aa6926c1-3e5e-448b-9226-26dbc0527fc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226bc50d44474921a2117b15aecd4339_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMTQtMS0xLTQyOTY3MQ_6cbc1d9f-7374-422c-ab67-332e9080832b">27,379</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMi0xLTEtNDI5Njcx_9cd2f757-8cbe-4c9c-b01f-396759476a24">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e0de40ca8c4677bfae29d91ebdde69_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtNC0xLTEtNDI5Njcx_a8cdebd4-6773-4e51-ac12-7ab3521ed95a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtNi0xLTEtNDI5Njcx_c34d995e-eb57-4853-8bdd-ee18bb755093">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMTAtMS0xLTQyOTY3MQ_ea2b1071-7d8e-41a8-8220-3106e3c42b98">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e3c0460a4e4852a56a67d528410e84_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMTItMS0xLTQyOTY3MQ_7f979bb9-b4b5-4595-a564-615852941f21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a162167b3964440947ee8fc8433d811_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMTQtMS0xLTQyOTY3MQ_a19f15f9-9767-4640-8b4a-70b491c45ccb">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMi0xLTEtNDI5Njcx_c89677e9-5bd9-4244-8682-846973875e79">1,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtNC0xLTEtNDI5Njcx_28d03c50-eb46-41c7-bf50-a9565aec7b42">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35aa9908c74494b8436d59196094589_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtNi0xLTEtNDI5Njcx_c5841de4-ac23-4689-a81b-fa0ccd5b1d65">1,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMTAtMS0xLTQyOTY3MQ_9d9938ae-5c17-4b44-b5b7-54fbc70b1ea5">704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMTItMS0xLTQyOTY3MQ_8db8ef72-8265-4adf-a538-b7ef0ddd6a21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMTQtMS0xLTQyOTY3MQ_b51f56e2-72c5-424f-959c-e7a469dc8afa">704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMi0xLTEtNDI5Njcx_d87169ff-1f63-4ed1-93b9-c081cfe59778">1,959</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctNC0xLTEtNDI5Njcx_1e985522-9cfd-47ba-973d-32c0aa552062">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctNi0xLTEtNDI5Njcx_d085be36-2390-472b-88dc-2058cf14a497">1,959</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMTAtMS0xLTQyOTY3MQ_f3d3b2af-e379-4bfb-839e-3c2a0c7804df">709</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMTItMS0xLTQyOTY3MQ_3693c016-e734-4fcc-aaed-11ec85e44d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMTQtMS0xLTQyOTY3MQ_4758cc4e-f384-4661-b6fe-136068fafe4c">709</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMi0xLTEtNDI5Njcx_842617ea-9719-4eab-b73e-1115756af0c2">2,972</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNC0xLTEtNDI5Njcx_6bfa4ccb-a89e-4014-b8a0-4f826bebfb8e">2,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e532bbebdc45249c16d40c3dc0a715_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNi0xLTEtNDI5Njcx_0661d1b1-662e-4b85-97d1-02884e9bedf8">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106748186c314412998ca5807842edcf_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTAtMS0xLTQyOTY3MQ_ccb81272-5aac-4f1e-a246-4576be170c8b">3,876</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia171432125c34b90be8e8604e663907d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTItMS0xLTQyOTY3MQ_ceabc205-2d62-4e44-a517-a8483c87e5fc">3,849</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTQtMS0xLTQyOTY3MQ_0ef21eca-e6b7-48e6-88e1-69577f2efbaf">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e5471772584760b1d1f8ac3c7d5a73_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMi0xLTEtNDI5Njcx_8a18a191-e3da-4f43-bce0-136d229ad6f5">285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf9771697dc4c2187d4f9d4b5006611_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItNC0xLTEtNDI5Njcx_2243178d-427b-4597-aff4-e141aa2c3835">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3394bb954a4bb283a0430941d2b0da_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItNi0xLTEtNDI5Njcx_eba7e30e-cc11-45cd-9130-c53bbef01607">285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c13c8d6f5e4476488e457cd130177b9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMTAtMS0xLTQyOTY3MQ_4eda45c8-8f35-41f9-b6a9-02240fc00336">465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bfbd5763f1476397cb82ac7bae3159_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMTItMS0xLTQyOTY3MQ_aa043d55-287e-49b2-9da4-b0209348199d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib536482e78464a5cb14145115c86217a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMTQtMS0xLTQyOTY3MQ_f89d5a7a-1487-4ff8-9d16-0533e6125e69">465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7009eec6815484bb288be0b6939cfe8_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMi0xLTEtNDI5Njcx_ba27b663-329c-4d62-bdff-69d7f3159aff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fdd3aa58c54a848f098867c06f5d18_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtNC0xLTEtNDI5Njcx_f36cd1fd-93c8-4d69-b881-b6bb4b930a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e77d36f6bb74d9ea078650432f1a0bd_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtNi0xLTEtNDI5Njcx_3423583e-1b6b-4f27-a122-e67b1dcd2d61">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d65cc9d472404c97ea4a88ed62138c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMTAtMS0xLTQyOTY3MQ_30095d9c-b374-4081-bc0c-a09ecc72cc06">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9222f579cb5d4c8f968c453d8254f49d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMTItMS0xLTQyOTY3MQ_a2d87fd8-db90-4450-8e32-42c22f4e41f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4959ff73f845669686173848f68817_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMTQtMS0xLTQyOTY3MQ_5c29b185-480a-4642-9797-341bc01f44e4">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb79de0c54d447a940125fd8c11fe37_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMi0xLTEtNDI5Njcx_b97b44cb-4dfa-448e-b458-415e5f6c6023">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e06b72b11c542d6afc570e8531710d8_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtNC0xLTEtNDI5Njcx_3b15c082-17ec-4053-899d-fb70f1f6a729">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b92fd6f4ac4766a4f58f450bc26d49_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtNi0xLTEtNDI5Njcx_863e44bb-80a0-436c-aef1-2956c047765b">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b6382776a542a8abe220fd855457a0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMTAtMS0xLTQyOTY3MQ_e292e4d4-eb71-49df-be2f-83801da7f093">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867802a8f854403f9965faf6c388210a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMTItMS0xLTQyOTY3MQ_6f563084-40aa-4faa-8a90-28569ffc3475">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c9c8f46d854bf5b5db351b98fd1a31_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMTQtMS0xLTQyOTY3MQ_076a2d98-8e5d-439d-959c-c1a68d1bce5a">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMi0xLTEtNDI5Njcx_244f1c93-15bf-4f29-8d5e-87b138410cb6">358</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtNC0xLTEtNDI5Njcx_7c16aac2-55b8-4df8-8579-09e5e592b4a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e532bbebdc45249c16d40c3dc0a715_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtNi0xLTEtNDI5Njcx_15bf4323-a22c-4989-9878-5dcc83a115b4">358</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106748186c314412998ca5807842edcf_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMTAtMS0xLTQyOTY3MQ_aa0dada3-abe3-4894-9fd5-f924204a75dc">521</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia171432125c34b90be8e8604e663907d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMTItMS0xLTQyOTY3MQ_a7058e1c-d21e-4bda-a6b9-fe3ffcd654cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMTQtMS0xLTQyOTY3MQ_9dcf42c4-e653-49cc-9b01-2375f73d5847">521</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMi0xLTEtNDI5Njcx_05bde3b3-0050-4a06-aea1-d122ee1c2f98">3,330</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtNC0xLTEtNDI5Njcx_00330600-b7ac-4e51-be12-0a14074ad3a9">2,960</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e532bbebdc45249c16d40c3dc0a715_I20221002" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtNi0xLTEtNDI5Njcx_dab4d92a-6fc9-4599-8ffc-fe342fa0e092">370</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106748186c314412998ca5807842edcf_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMTAtMS0xLTQyOTY3MQ_e2d3a6b1-5347-44c8-b54a-439b3391ba36">4,397</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia171432125c34b90be8e8604e663907d_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMTItMS0xLTQyOTY3MQ_54e31ed1-91a2-4b1a-abab-7524f31fe825">3,849</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMTQtMS0xLTQyOTY3MQ_a13f2f32-b00f-47d9-82b2-f80e508775ed">548</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMi0xLTEtNDI5Njcx_53859080-764e-4f57-b4f3-78b5f08c1059">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e0de40ca8c4677bfae29d91ebdde69_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktNC0xLTEtNDI5Njcx_4f341024-3c12-45bd-9300-e0a3d48d3b9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktNi0xLTEtNDI5Njcx_8f6d155a-4519-43ab-93bd-b4b764261ef0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMTAtMS0xLTQyOTY3MQ_a8500e4d-ad0c-4582-8462-1f50b93d1a2c">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e3c0460a4e4852a56a67d528410e84_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMTItMS0xLTQyOTY3MQ_df924dba-c1fa-4085-b19e-01d1c214072a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a162167b3964440947ee8fc8433d811_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMTQtMS0xLTQyOTY3MQ_515b69c6-bce7-47ca-a09a-d06e7f9092a3">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMi0xLTEtNDI5Njcx_306c3bf5-c70e-4b16-8861-fd28f30b85ea">812</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtNC0xLTEtNDI5Njcx_19e8a66a-2f55-4685-b699-4069451d4f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35aa9908c74494b8436d59196094589_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtNi0xLTEtNDI5Njcx_e7dfbbba-fa2c-4cd3-8034-504217ea63b1">812</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMTAtMS0xLTQyOTY3MQ_8e80b3da-d243-40d2-9b40-e52a08e7ce81">242</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMTItMS0xLTQyOTY3MQ_79286274-2050-4532-b6e7-0a5935f07d57">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMTQtMS0xLTQyOTY3MQ_3bd48b17-b64d-474f-bf17-4e24e99ba05a">242</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMi0xLTEtNDI5Njcx_e51491b1-cf91-4036-93c7-9a4ca1a933db">812</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtNC0xLTEtNDI5Njcx_cf672100-f728-4b03-b7f4-a916db93f9c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtNi0xLTEtNDI5Njcx_865a7abd-e653-496e-80ce-f2609dc28380">812</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMTAtMS0xLTQyOTY3MQ_f8478683-7b10-4afd-b0ce-ec1838c49c42">259</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMTItMS0xLTQyOTY3MQ_abc71c04-58dd-4e03-85c4-4c4647041594">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMTQtMS0xLTQyOTY3MQ_ef6154a5-dbae-43a8-bb04-309f4c7d75d1">259</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMi0xLTEtNDI5Njcx_2721d866-8f12-475d-b329-5b2c2055214b">631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNC0xLTEtNDI5Njcx_7701f7ed-5376-447f-a11e-2b480b14bb8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNi0xLTEtNDI5Njcx_34e03b37-a1b3-477f-b8ea-6fc43d6d69b6">631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTAtMS0xLTQyOTY3MQ_a4939c53-51b1-4072-8a3d-80ee90e928f2">808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTItMS0xLTQyOTY3MQ_a3b2da09-2fff-4dbe-9c94-5f0fbde322fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTQtMS0xLTQyOTY3MQ_b6b9f342-3cf2-42b3-b1e1-5ae23c7067e7">808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMi0xLTEtNDI5Njcx_1171fa5d-a990-4dce-b6dd-3887e4dd9487">1,444</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtNC0xLTEtNDI5Njcx_68eb4e11-43bf-43f5-afcd-a5c48228f56f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtNi0xLTEtNDI5Njcx_a6d17163-d941-4744-bde8-fe34f8773911">1,444</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMTAtMS0xLTQyOTY3MQ_399e316f-77f1-4512-b4fd-de2c80676e87">1,067</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMTItMS0xLTQyOTY3MQ_1b7bedf4-4ef3-4bbf-93d8-bc9ee2303813">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMTQtMS0xLTQyOTY3MQ_7bd00b95-4610-410f-b624-5c9ec76268b0">1,067</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMi0xLTEtNDI5Njcx_0567457b-deea-461b-96e0-4ce4428828b3">39,063</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtNC0xLTEtNDI5Njcx_77d3c1b9-9a98-41c5-b6ac-288445b57b19">2,960</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtNi0xLTEtNDI5Njcx_0e15f87e-f1de-4ad3-85a0-6c4f34b3beec">36,103</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMTAtMS0xLTQyOTY3MQ_8a36bf65-2b79-4442-ae9c-20eb2a73efde">33,552</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMTItMS0xLTQyOTY3MQ_aef80481-1807-4dea-b404-833fdaed270b">3,849</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMTQtMS0xLTQyOTY3MQ_9c742870-e104-4e8c-93eb-665fb711eba0">29,703</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMi0xLTEtNDI5Njcx_8e7673b3-4e93-467e-a025-c767aa628327">295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtNC0xLTEtNDI5Njcx_9a2d1c25-1dfc-4fec-b5b7-a1a2ba581e31">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35aa9908c74494b8436d59196094589_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtNi0xLTEtNDI5Njcx_70844d9c-4aab-411c-b711-139d0275b61e">295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMTAtMS0xLTQyOTY3MQ_a43413fe-fcf0-49a7-852c-ee87ac2c62f1">476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMTItMS0xLTQyOTY3MQ_5273e68a-00b4-4596-8f5a-ce3787b27113">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMTQtMS0xLTQyOTY3MQ_bed83355-66eb-40aa-81d0-efce3bdd883f">476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMi0xLTEtNDI5Njcx_9e967f72-61bc-4da1-8ce5-092adad416e7">295</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtNC0xLTEtNDI5Njcx_b4c974d0-5c0d-40f3-9aab-12275139d7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtNi0xLTEtNDI5Njcx_a4924d24-bfe1-4641-b933-6fb6602c6ed7">295</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMTAtMS0xLTQyOTY3MQ_b11cc28a-1655-4977-bdad-093d0b313124">476</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMTItMS0xLTQyOTY3MQ_a87a2ce2-2081-4e68-8e84-db0bbe39226e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMTQtMS0xLTQyOTY3MQ_f5e9133f-4f52-49b3-a4b1-34ed19763686">476</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMi0xLTEtNDI5Njcx_b500e193-c56d-48b5-ab5e-c44c01c2c1f6">330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e0de40ca8c4677bfae29d91ebdde69_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtNC0xLTEtNDI5Njcx_9f1b240e-2243-4d05-84e6-b22ea603b40e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtNi0xLTEtNDI5Njcx_80e4db31-67da-4489-bda3-84cd6b29a8db">330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMTAtMS0xLTQyOTY3MQ_06db1f9b-b673-40d3-8568-d338a67c4329">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e3c0460a4e4852a56a67d528410e84_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMTItMS0xLTQyOTY3MQ_7ace3813-17c4-43f9-b243-d99f1385b87c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a162167b3964440947ee8fc8433d811_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMTQtMS0xLTQyOTY3MQ_37e554be-7d51-4323-bdf5-ccb55ebaf1e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMi0xLTEtNDI5Njcx_3402fe28-2755-47e0-8e3f-542375fa85c0">1,153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtNC0xLTEtNDI5Njcx_2186b06f-7203-48ed-b6b6-ce541196a06c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35aa9908c74494b8436d59196094589_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtNi0xLTEtNDI5Njcx_c047bd2d-8468-4691-b9db-2d98abcbe226">1,153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMTAtMS0xLTQyOTY3MQ_1ee66717-d1e5-472a-9a4c-369558fa0816">405</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMTItMS0xLTQyOTY3MQ_0a2741ae-4525-4ee0-b8d6-a0bec3cfcd9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMTQtMS0xLTQyOTY3MQ_12dc26ef-2ace-4172-9fb8-7608d34ccbe6">405</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMi0xLTEtNDI5Njcx_d30b0c33-26f8-4845-9888-4fa218d7888f">1,482</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtNC0xLTEtNDI5Njcx_11c05dcf-98d7-423c-9a74-a69e4f1cf360">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtNi0xLTEtNDI5Njcx_af06d470-c30f-4cf4-9fc3-a6fde340506c">1,482</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMTAtMS0xLTQyOTY3MQ_7fa43dd8-9114-4462-96c8-a1ab53df9e44">405</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMTItMS0xLTQyOTY3MQ_5e6265fd-3ad0-4278-a6df-5a5891868623">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMTQtMS0xLTQyOTY3MQ_0f7802e3-59c5-43e1-bc43-5acb9e0c41dd">405</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMi0xLTEtNDI5Njcx_1a729372-b6ce-4a45-b2f8-f53384694524">1,777</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctNC0xLTEtNDI5Njcx_24b84c04-2972-4940-aa3a-833d797c016c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctNi0xLTEtNDI5Njcx_1d467308-218d-48d9-91ff-e6444943a729">1,777</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMTAtMS0xLTQyOTY3MQ_578b318c-c085-4030-8b81-c08b7afc8e65">881</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979b62479efe4c33bd39145b1249c177_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMTItMS0xLTQyOTY3MQ_d29d96cc-fd3b-419f-b020-e7df53e70cda">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a58581671444d0fa9352733c8859022_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMTQtMS0xLTQyOTY3MQ_036f8a5a-35ec-46f1-b8c1-d34b27c76c94">881</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6" footnoteRole="http://www.xbrl.org/2003/role/footnote">Long-term equity securities of $<ix:nonFraction unitRef="usd" contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002" decimals="-6" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMjA2_9f5b4689-9ddd-48ed-a868-963dfaa8f939">139</ix:nonFraction> million as of October&#160;2, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231" decimals="-6" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMjIy_99b27d55-7935-437a-8963-d159e1f9b410">194</ix:nonFraction> million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of Long-term debt, excluding the current portion was $<ix:nonFraction unitRef="usd" contextRef="i49a36bebd932477abb647b4c3f1f7229_I20221002" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfNzY3_fd0ae72d-b78b-4e22-b1aa-f9cb05d99e14">33</ix:nonFraction>&#160;billion as of October&#160;2, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i4d1ae606958948a09710f9127386e909_I20211231" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfNzgz_085e4f60-b268-418d-adcc-ccb8e6067894">36</ix:nonFraction>&#160;billion as of December 31, 2021. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $<ix:nonFraction unitRef="usd" contextRef="i01adb0c331434d4eb30ff9aa4a978d62_I20221002" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfODgz_20683e3c-0107-47db-bf0b-996602f8e024">29</ix:nonFraction>&#160;billion as of October&#160;2, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i195a713f2d9b41099053b0da037cb644_I20211231" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfODk5_e2f732b8-0ffe-4051-b8aa-32bb3d80ea93">42</ix:nonFraction>&#160;billion as of December 31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i602816b7efeb4bbe8d70d72766a861bf" continuedAt="i09dee0048fef442eb028263ff351365c">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of October&#160;2, 2022 and December 31, 2021. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</ix:continuation></span></div><div id="i8c2530a91ced4c48b9620128206808f1_67"></div><ix:continuation id="i09dee0048fef442eb028263ff351365c" continuedAt="if6e0641457564ecbbfd63ccf15c0a8d4"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Short-Term, Long-Term and Equity-Method Investments</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzg3_cc6057e5-2d94-410c-b9d4-30c40dd210dc" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy0yLTEtMS00Mjk2NzE_947423da-75c5-4888-8435-7ecabccea84f">12,154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy00LTEtMS00Mjk2NzE_bde52b2e-a777-41dc-b155-e237fd719780">5,365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNC0yLTEtMS00Mjk2NzE_baa21488-6912-4309-a7d9-187ab6de4d96">20,176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNC00LTEtMS00Mjk2NzE_379bc9f9-903d-4316-aa68-8b6a86a1c4f0">22,014</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNS0yLTEtMS00Mjk2NzE_f9cf7e36-be73-490e-8f57-acce56d9db4c">2,495</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNS00LTEtMS00Mjk2NzE_c3c68bcd-449f-4dd3-bd7e-6eed4629f8e5">1,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNi0yLTEtMS00Mjk2NzE_a8967ea8-e7fe-452a-8fff-7cd88bf45d0f">34,825</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNi00LTEtMS00Mjk2NzE_cf53af27-dd9a-4d97-b3fe-4576f22cc1e5">29,125</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfOS0yLTEtMS00Mjk2NzE_b0f87030-77e0-48d0-b266-3dd9d3f2d4f2">2,972</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfOS00LTEtMS00Mjk2NzE_8f3836a0-57c6-4a0c-9287-2a44d2e8b260">3,876</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTEtMi0xLTEtNDI5Njcx_3517e2bb-81fa-402a-b96a-593712b2b5e8">358</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTEtNC0xLTEtNDI5Njcx_fae844c1-0532-473b-b623-3fc8c1af42ee">521</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTItMi0xLTEtNDI5Njcx_87cc9480-6fec-47ef-833d-39be57fea5f1">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTItNC0xLTEtNDI5Njcx_7822f030-1b1c-4810-ac77-84917717138c">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtMi0xLTEtNDI5Njcx_982648aa-6469-48be-99c5-f6a8806bdbf1">696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtNC0xLTEtNDI5Njcx_9035346d-b158-4367-9a1d-296132bb041b">623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTQtMi0xLTEtNDI5Njcx_64c52689-61ba-452f-b5ec-fdca113713ce">4,062</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTQtNC0xLTEtNDI5Njcx_836f5d08-9f3d-4db4-b66d-29515e352593">5,054</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTUtMi0xLTEtNDI5Njcx_615391bf-0d65-49fb-aec8-ebbeee8be69c">9,826</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTUtNC0xLTEtNDI5Njcx_bb8584d6-d994-457d-b0c2-3f7ed39e21a1">16,472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTYtMi0xLTEtNDI5Njcx_ef12678a-c4a9-4282-a8a8-f395114f5870">13,888</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTYtNC0xLTEtNDI5Njcx_d6cb898f-98f0-4926-a2e4-d4591125be23">21,526</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTctMi0xLTEtNDI5Njcx_5b895280-1d15-4b47-adc2-3b43fd0bf4ad">969</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTctNC0xLTEtNDI5Njcx_d6fa3280-0b94-4189-9315-2105b0ba369f">268</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcx_2a1b3533-c56a-4df2-8c6f-c6e181e09ceb" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes money market funds primarily invested in U.S. Treasury and government debt.</ix:footnote> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgw_14ab4f6d-72db-4770-bbaf-3b5b5c0fc91d" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represent investments in the life sciences sector</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-bottom:5pt;margin-top:3pt"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYz_047b7592-a33b-414d-adbb-c903291de5aa" escape="true"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcy_e712f67d-5e81-4793-addc-79ed887c6739" escape="true"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzkz_93c9743d-5d61-48b8-96ff-3a7c105cd188" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0yLTEtMS00Mjk2NzE_2df9f235-ed0c-4da2-ae2d-49920a1452b7">16,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS00LTEtMS00Mjk2NzE_581a4c42-8554-48b1-ac80-d30fefa8dd15">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS02LTEtMS00Mjk2NzE_d64ef7bf-2f8d-4b39-b26c-e643febeeffa">567</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS04LTEtMS00Mjk2NzE_5334c435-3dfe-478a-9dcb-3abb7de504d7">16,169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xMC0xLTEtNDI5Njcx_a7953ec7-5207-4ae1-bc02-23134b5df2cb">15,885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xMi0xLTEtNDI5Njcx_e302ff35-8495-4f81-9f66-9dd23baed1eb">285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xNC0xLTEtNDI5Njcx_0d491650-0c7d-4c24-b12c-68d4774a019b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xNy0xLTEtNDI5Njcx_c1b7baca-efdd-4c21-98f6-9bf88521a50e">18,032</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xOS0xLTEtNDI5Njcx_70d93a48-0e59-4034-b978-6b783b858b85">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0yMS0xLTEtNDI5Njcx_736c1a4d-8ec8-4907-9faf-00689cb8c7d8">263</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0yMy0xLTEtNDI5Njcx_9118e8a2-d86e-4eff-b383-d5801d7cad75">17,783</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0yLTEtMS00Mjk2NzE_615a23ed-1d00-4aac-a661-2f5afcae39f9">2,932</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi00LTEtMS00Mjk2NzE_d82497f5-0fac-403f-95f7-edb1ea0f0f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi02LTEtMS00Mjk2NzE_a4604df2-765b-4d4a-bf24-3cd8f0d71c4f">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi04LTEtMS00Mjk2NzE_dca25b25-868e-4b46-85a7-9cdbbadd4935">2,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xMC0xLTEtNDI5Njcx_d444fd45-e499-45eb-ac51-a373c8070b0b">2,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xMi0xLTEtNDI5Njcx_1405579d-326b-4586-82a4-e64310289a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xNC0xLTEtNDI5Njcx_737e7e96-1ac4-469e-8e19-cbd5266f9a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xNy0xLTEtNDI5Njcx_6bc44a40-ea1b-48c4-a671-5caee0b7dbab">4,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xOS0xLTEtNDI5Njcx_f6912357-e86b-40cb-bd7d-c1d90e5cf5e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0yMS0xLTEtNDI5Njcx_fe9e7b81-df50-4d82-b610-107569c0eec1">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0yMy0xLTEtNDI5Njcx_a246a89a-a53c-42f8-b0bd-92eb6e10a7e7">4,055</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0yLTEtMS00Mjk2NzE_96a3112e-a109-4363-be7b-8f0d49d11ab4">1,446</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy00LTEtMS00Mjk2NzE_9216394a-be08-45c9-bf94-d009f39c95af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy02LTEtMS00Mjk2NzE_e93414bc-d2af-4ade-b702-802de7597ee0">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy04LTEtMS00Mjk2NzE_aa9e19ec-ffa7-4541-ac2e-5698aa353921">1,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xMC0xLTEtNDI5Njcx_fe2e5e9a-d81d-498f-be4f-8ae11f7fd48f">1,361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xMi0xLTEtNDI5Njcx_de921558-aeb9-40b2-b52d-f899a21fbaaa">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xNC0xLTEtNDI5Njcx_bf210220-b72a-4b47-8402-0b2d3fac66b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xNy0xLTEtNDI5Njcx_498cd2e7-b39c-4039-be5e-7af5422ae104">698</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xOS0xLTEtNDI5Njcx_fa3a4a57-f9a8-4563-b5b1-7ebba9cf0f7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0yMS0xLTEtNDI5Njcx_690243f0-9463-4f21-ba6d-454f408543f8">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0yMy0xLTEtNDI5Njcx_b214815a-7c05-4970-aa61-f61abcea9c99">697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0yLTEtMS00Mjk2NzE_a9db0a6c-26e0-414f-babc-12ca64f99fad">1,557</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS00LTEtMS00Mjk2NzE_28fb3a50-650b-427c-9580-295d275c2822">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS02LTEtMS00Mjk2NzE_3a342654-e230-4524-9588-09a7e9e8fe1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS04LTEtMS00Mjk2NzE_6519ce6d-3103-48bc-bfa0-808f162941f5">1,557</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xMC0xLTEtNDI5Njcx_7b5928fe-dfe5-4beb-a17d-0d4b33fb00ca">1,525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xMi0xLTEtNDI5Njcx_83c47711-527d-4f56-8e5b-1b1ebde92a72">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xNC0xLTEtNDI5Njcx_1312e7ac-e195-4183-9f55-cc78302f0b0e">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xNy0xLTEtNDI5Njcx_c736cf33-e477-47cc-b3f7-f3d5085568f0">947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xOS0xLTEtNDI5Njcx_b1a93b64-ee58-4b5d-9ff1-2b45ba4cfedf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0yMS0xLTEtNDI5Njcx_2776711d-5bd9-4822-8926-720052fe488d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0yMy0xLTEtNDI5Njcx_9e643432-7531-4b9b-8a72-caf2e2a2faa8">947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMi0xLTEtNDI5Njcx_f842f040-b8e4-4994-9851-0f020634b0bb">1,943</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtNC0xLTEtNDI5Njcx_30e2be8e-a374-46ed-be20-286e5edb39ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtNi0xLTEtNDI5Njcx_9391f9f4-5fb6-40c3-8790-d4ecfe09b926">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtOC0xLTEtNDI5Njcx_b9bf777f-8177-42dc-bc0c-5a9ebaae87d3">1,943</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTAtMS0xLTQyOTY3MQ_ea5d9566-e63d-4e63-8200-e45efb7a26ab">1,939</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTItMS0xLTQyOTY3MQ_ea05db34-02ba-4a56-9298-f97357d0d9e4">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTQtMS0xLTQyOTY3MQ_67b12052-5d00-432c-a655-a6a7b6d836e9">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTctMS0xLTQyOTY3MQ_a6a75555-7716-4e82-9851-603987a878cd">1,102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTktMS0xLTQyOTY3MQ_5d09aa87-eabc-4364-9d3b-ff0e86653125">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMjEtMS0xLTQyOTY3MQ_ac3552bf-5d74-4a75-95b7-bb4de9b690ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMjMtMS0xLTQyOTY3MQ_a862fcdb-9ee6-4aac-ad74-67670bead7a1">1,102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMi0xLTEtNDI5Njcx_8d133005-2a9d-4393-9d4d-eb1618b5b964">24,589</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtNC0xLTEtNDI5Njcx_159c5ea4-4e07-4694-97d9-fb11c9452dbc">26</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtNi0xLTEtNDI5Njcx_c4d68bb3-6817-4c82-a475-9b342277e5fb">580</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtOC0xLTEtNDI5Njcx_87bf48b5-3ee5-40f0-b173-1ad66aaef225">24,034</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTAtMS0xLTQyOTY3MQ_db1256a1-f8b7-4b1c-8d9c-c8eea82ccb6d">23,641</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTItMS0xLTQyOTY3MQ_50dfcc45-f279-465b-9f7d-590927db043c">381</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTQtMS0xLTQyOTY3MQ_7b42a9e2-9af7-4f5f-b18d-7d6b741ff5f3">13</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:DebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTctMS0xLTQyOTY3MQ_fa1342fd-46e2-4083-bd8c-0c625e920694">24,835</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTktMS0xLTQyOTY3MQ_ee83fd54-bffc-41e1-84d1-ce4918b66085">14</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMjEtMS0xLTQyOTY3MQ_8833cf4b-0bc8-4e60-8f2d-410fa154bf83">265</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMjMtMS0xLTQyOTY3MQ_0194bdea-7609-4055-a9e6-c0267ebfefe5">24,584</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if6e0641457564ecbbfd63ccf15c0a8d4" continuedAt="ia6a022ce01954fdcb942ca4a4afe04d1"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgz_b999d31e-6dc8-4ba0-bffe-6f2190c090ad" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:53.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy0yLTEtMS00Mjk2NzE_5a0039dd-c615-4609-86b3-a10613f0009a">112</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy00LTEtMS00Mjk2NzE_14057630-317a-4fd9-baff-f0c8fddf43b1">400</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy02LTEtMS00Mjk2NzE_e6d2f62f-dc75-4d22-a788-915b8e020593">1,353</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy04LTEtMS00Mjk2NzE_9b9133fb-bec2-4fcc-9258-400dd16c8db6">1,601</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC0yLTEtMS00Mjk2NzE_94f6bbeb-c0bf-4d02-8bbb-bfa0530a8f53">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC00LTEtMS00Mjk2NzE_8d23549f-944b-43ac-876e-4fa961cd7c37">78</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC02LTEtMS00Mjk2NzE_ff9742e8-5920-4257-a24f-84206c1a5ae1">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC04LTEtMS00Mjk2NzE_99d67a21-92b3-41b1-bd0d-1ad83484bf54">83</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS0yLTEtMS00Mjk2NzE_38c92c39-bf18-49b7-a4a0-e25b66dbb213">116</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS00LTEtMS00Mjk2NzE_613077e8-5b40-4023-b819-a7c214d9ee06">322</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS02LTEtMS00Mjk2NzE_b00bcbae-500f-4f0f-9340-0122991a721f">1,436</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS04LTEtMS00Mjk2NzE_50323117-4703-41a1-9272-feb994edeef3">1,518</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2" footnoteRole="http://www.xbrl.org/2003/role/footnote">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNjMz_1fb1b85f-420d-49e9-81f7-3da3b48ec76b">148</ix:nonFraction> million and upward adjustments of $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNjYy_17e6f54e-67a1-4d96-bbdc-803b4fc70d59">201</ix:nonFraction> million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_70"></div><ix:continuation id="ia6a022ce01954fdcb942ca4a4afe04d1" continuedAt="i41801b23f67a477f8a846233abb477af"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjI5_289a3850-3a74-48a7-9a86-505d33cb7fb8" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfMy0yLTEtMS00Mjk2NzE_aef2f8ce-5fb9-4ece-91de-70637ef59019">2,550</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfMy00LTEtMS00Mjk2NzE_148c01ee-5fab-4fec-ad18-20b6751c3b7e">1,636</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:OtherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC0yLTEtMS00Mjk2NzE_7ec794a7-64fc-462c-ba71-8d64150189b3">1,474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC00LTEtMS00Mjk2NzE_a263b85b-e520-4043-a264-bac7e134fa07">605</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:ShorttermDebtGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNS0yLTEtMS00Mjk2NzE_08517b84-1384-4e5d-81bf-08995055d06a">4,024</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:ShorttermDebtGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNS00LTEtMS00Mjk2NzE_5304c55d-8d40-4d25-8cf6-ac2b5216c472">2,241</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNi0yLTEtMS00Mjk2NzE_b9245094-751c-4b63-8fa4-197f633fb4fe">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNi00LTEtMS00Mjk2NzE_ba7d9714-bd61-4b93-bd8c-57da5e9256a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfOC0yLTEtMS00Mjk2NzE_297108d3-84dd-4f20-8cf1-d42de089f14e">4,040</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfOC00LTEtMS00Mjk2NzE_95fdccf8-5606-440f-9ab2-19f93cdbf41c">2,241</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjIy_3f8ba6ba-a903-4756-95e1-240772a5e732" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_73"></div><ix:continuation id="i41801b23f67a477f8a846233abb477af" continuedAt="i46c73311903e4be89119ba63fafb0d92"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RleHRyZWdpb246ZWUzNmNjYjVmNjQ4NDNhMzhiZjU1Njk1NzFlOTNjOGVfMjk_0adf5b63-1e28-4496-99aa-483b13099c73" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:73.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMi0yLTEtMS00Mjk2NzE_d64a34ce-f458-42c7-b440-586664062e1c">31,831</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d030e31054241cbb0485358571b9bde_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMi00LTEtMS00Mjk2NzE_907edb18-0add-4f28-ae66-e09aa4bbc7f1">34,948</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMy0yLTEtMS00Mjk2NzE_87f01870-a516-4773-85c8-c217f4e7574b">976</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d030e31054241cbb0485358571b9bde_I20211231" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMy00LTEtMS00Mjk2NzE_b86404b0-9bd1-456e-b16d-56ceda0764b9">1,438</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNC0yLTEtMS00Mjk2NzE_4cc9bea5-f4aa-4b89-b730-612e17b07e2a">178</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d030e31054241cbb0485358571b9bde_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNC00LTEtMS00Mjk2NzE_199861a0-b1d1-4bc8-a984-f18a98d0db27">195</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002" decimals="-6" name="us-gaap:OtherLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNS0yLTEtMS00Mjk2NzE_735e891e-c5df-4bde-a57e-5310280e2877">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d030e31054241cbb0485358571b9bde_I20211231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNS00LTEtMS00Mjk2NzE_4af72b28-3da9-4ac0-8150-2859ebfc1edf">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNi0yLTEtMS00Mjk2NzE_aff28af7-4525-46bf-a6aa-31fa81cb7d3c">32,629</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d030e31054241cbb0485358571b9bde_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNi00LTEtMS00Mjk2NzE_42dbdab3-264c-4849-97cd-dd17157b44ce">36,195</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_76"></div><ix:continuation id="i46c73311903e4be89119ba63fafb0d92" continuedAt="i77dc21ddb1994fa4af286bd6842b722e"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Risk&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, and Canadian dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to <ix:nonNumeric contextRef="i8472588c67134a13847983bdf694f4dc_D20220101-20221002" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfODQy_8b963a7e-fb09-4681-a8e5-511de3448567">two years</ix:nonNumeric>. We may seek to protect against possible declines in the reported net investments of our foreign business entities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div></ix:continuation><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk4NQ_80e1e2b4-73e2-40b0-a9fa-2f2888a0e569" continuedAt="icf832a6b11ef47a8be9ecff04f31d2cd" escape="true"></ix:nonNumeric><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAxNw_35d0f543-6868-4cba-a687-8df47dae899b" continuedAt="icb1a53bb63a145218ef086b5f520e631" escape="true"></ix:nonNumeric><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAxOQ_c5ae1d25-f231-47e8-ba8d-df5af49c19db" continuedAt="iee2dc581b8674912809f5f52f2e691e4" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i77dc21ddb1994fa4af286bd6842b722e" continuedAt="i0033ab0e2fd343a38d7a172a22e9e164"><ix:continuation id="icf832a6b11ef47a8be9ecff04f31d2cd"><ix:continuation id="icb1a53bb63a145218ef086b5f520e631"><ix:continuation id="iee2dc581b8674912809f5f52f2e691e4"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0yLTEtMS00Mjk2NzE_98c53b55-1c37-4942-a131-1e3138a4fac2">33,274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS00LTEtMS00Mjk2NzE_50bb3f84-6761-493d-849a-d1eae1d8d3fc">2,479</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS02LTEtMS00Mjk2NzE_99b7ca62-b866-4c59-9bc7-b23b4df8d23e">1,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS04LTEtMS00Mjk2NzE_80861cc7-b44f-4666-ac47-8bdbf158d915">29,576</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMC0xLTEtNDI5Njcx_321577f7-e593-49a7-a7ac-2b0830e4ef5b">787</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMi0xLTEtNDI5Njcx_5af25e10-6100-474a-80a2-768f0c5ece86">717</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi0yLTEtMS00Mjk2NzE_6f061895-50fb-430e-b311-1d150d1bf9e1">2,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi00LTEtMS00Mjk2NzE_3987de6a-1f83-4cfd-80aa-6250f03b47ea">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi02LTEtMS00Mjk2NzE_27090c05-9a0b-4672-aa55-f847ab9e7f81">330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55958062514846a5817b8f0a50f35dd6_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi04LTEtMS00Mjk2NzE_60336405-bd7a-4711-b4f8-be2bf3eb43eb">2,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55958062514846a5817b8f0a50f35dd6_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi0xMC0xLTEtNDI5Njcx_796446e0-15f9-4bf9-b076-50f5e3d62f30">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55958062514846a5817b8f0a50f35dd6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi0xMi0xLTEtNDI5Njcx_64487b9a-64d3-4be6-8d35-940757adc233">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9722c4887b744055b1904ff63ab244d9_I20221002" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy00LTEtMS00Mjk2NzE_868c16b2-9c00-4dc0-8bcf-d41e04762125">2,488</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9722c4887b744055b1904ff63ab244d9_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy02LTEtMS00Mjk2NzE_813b0f8b-1641-440a-b7e0-33f4e4a1da0c">1,505</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c60017d6ba741f68386b4b24baef910_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy0xMC0xLTEtNDI5Njcx_8e15927e-5582-464f-bde3-5fe469ec77bc">808</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c60017d6ba741f68386b4b24baef910_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy0xMi0xLTEtNDI5Njcx_e9588cf9-bdc6-4613-8051-aaca2541a4e8">717</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic477a3d1dd454d778619d8af4d4a6650_I20221002" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS0yLTEtMS00Mjk2NzE_0ae18561-e1e8-4cdd-81b2-789c8433e2db">26,426</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic477a3d1dd454d778619d8af4d4a6650_I20221002" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS00LTEtMS00Mjk2NzE_a0193b52-d8b3-4c2e-adf1-9646a44cfd31">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic477a3d1dd454d778619d8af4d4a6650_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS02LTEtMS00Mjk2NzE_247b99c8-784f-440b-850b-a9bdcb9e44d3">273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS04LTEtMS00Mjk2NzE_28856996-490e-4df9-9c6a-01f4185d2f89">21,419</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS0xMC0xLTEtNDI5Njcx_bcc6fc2a-555a-45a4-abbe-604f36a4cbe3">160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS0xMi0xLTEtNDI5Njcx_952744e0-e60f-4154-8e28-d9cbaf07e98e">164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtNC0xLTEtNDI5Njcx_aba714ea-f7e0-4155-8a56-66f5eb305a72">2,771</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtNi0xLTEtNDI5Njcx_ed289bd5-4d5c-47c0-8887-1cf0b138d4cb">1,777</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtMTAtMS0xLTQyOTY3MQ_74083bd1-7ea8-4445-94a2-41f2754a5380">968</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtMTItMS0xLTQyOTY3MQ_3ca45897-9e17-4237-a53d-d5ac43d05748">881</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a" footnoteRole="http://www.xbrl.org/2003/role/footnote">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $<ix:nonFraction unitRef="usd" contextRef="i827e7ba807c442599109f6cd0c3eb032_I20221002" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjM4Mg_2c6a4a55-1cf7-44aa-b6a7-0d132a0bb29a">4.5</ix:nonFraction>&#160;billion as of October&#160;2, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i1b5aa6d82a8b42f0a39f8d78d409bf1e_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjM5Mg_5e5e3f0f-ff41-43cc-95b0-5fffca49337d">4.8</ix:nonFraction>&#160;billion as of December 31, 2021.</ix:footnote></span></div></ix:continuation></ix:continuation></ix:continuation><div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAxNQ_cfc8a7f5-7de0-46d5-81b1-87ef0942bdf9" continuedAt="i30ec50d72c074027826f68aa8ecb8ede" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0">528</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85">204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4">558</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8da0892f39d46c096dc066b6ec8a83e_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC0yLTEtMS00Mjk2NzE_a28803af-4e40-48eb-b68f-7954fb1a17f1">124</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3186066be71c42b5a02001d1a9f376b0_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC00LTEtMS00Mjk2NzE_04673e43-36a2-45b3-b7ca-236158b88b87">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8da0892f39d46c096dc066b6ec8a83e_D20220704-20221002" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS0yLTEtMS00Mjk2NzE_0bf627f4-8dad-4eec-b99a-5aad854ec232">124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3186066be71c42b5a02001d1a9f376b0_D20210705-20211003" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS00LTEtMS00Mjk2NzE_445e562c-2eb9-43d1-b0fc-b2019b0639a5">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtNi0xLTEtNDI5Njcx_133301ad-6e91-4536-9645-63f6f0547007">680</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtOC0xLTEtNDI5Njcx_07a36bed-d910-4d73-a6c6-5fd6bc7522b9">177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTAtMS0xLTQyOTY3MQ_28197c73-6bbb-446f-a947-8e733c8ed5e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTItMS0xLTQyOTY3MQ_8fa38e40-5385-4021-9ea5-fd9e6bbd255e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddfb9327a4b028b11b10328f2ba51_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2ed77de0ce405e8cf9e819442e6528_D20210705-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddfb9327a4b028b11b10328f2ba51_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2ed77de0ce405e8cf9e819442e6528_D20210705-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia942bf711c884c0c8389c2c4658f859b_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97507b074e0e4f6f92c18c2fd703b228_D20210705-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia942bf711c884c0c8389c2c4658f859b_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97507b074e0e4f6f92c18c2fd703b228_D20210705-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1460ce67a1664a4886f261a31538b94c_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktMi0xLTEtNDI5Njcx_d0a45c0d-3364-46a7-9fd4-57a6b63bf52e">420</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33dbb0a3d25e4ded9172ca71bd57e611_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktNC0xLTEtNDI5Njcx_b1341912-72e5-4de9-b371-e3fad6bff794">74</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMi0xLTEtNDI5Njcx_96c0b094-7093-4d3c-91b6-849a99bc222f">420</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNC0xLTEtNDI5Njcx_0bed8693-ae85-4b96-8618-be975923ee6b">74</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNi0xLTEtNDI5Njcx_ce90d9e5-ce46-4ede-9dd4-d3cea269650a">1,396</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtOC0xLTEtNDI5Njcx_24e61d1d-f7c7-46f8-9779-ec9d74a71fe3">453</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTAtMS0xLTQyOTY3MQ_f4b64b37-90c3-402a-baac-3d920218e6fd">647</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTItMS0xLTQyOTY3MQ_ab926219-d9a7-4b2b-bb7a-cd8b338b1a85">21</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="39" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i0033ab0e2fd343a38d7a172a22e9e164" continuedAt="if9d6b19c4db34feaa61af82d92c68b2e"><ix:continuation id="i30ec50d72c074027826f68aa8ecb8ede"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="39" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1">1,339</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78">147</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876">872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f">314</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45883a91d50a47eb96c4f3afbd992dee_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItMi0xLTEtNDI5Njcx_e6218ca2-efe4-463d-9ce3-af6f1be6bb3d">346</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3150d83c1054e43ac64649354bfd47a_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItNC0xLTEtNDI5Njcx_d4c83559-1407-444f-99a6-6ba36c9f1d63">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45883a91d50a47eb96c4f3afbd992dee_D20220101-20221002" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtMi0xLTEtNDI5Njcx_f3cec9d4-f77d-4580-b599-484f01f1a5a7">346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3150d83c1054e43ac64649354bfd47a_D20210101-20211003" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtNC0xLTEtNDI5Njcx_3303e9d7-5cc1-4910-8497-2ac64d94653a">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctNi0xLTEtNDI5Njcx_ce613522-b2e6-449d-9bda-6bbc50ef4241">1,613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctOC0xLTEtNDI5Njcx_6ed77661-b985-4278-9f00-9b1b503b67b7">332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTAtMS0xLTQyOTY3MQ_90670622-0649-4a76-bd2a-b31e91dfd5a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTItMS0xLTQyOTY3MQ_7434b05a-74c7-4239-a3ea-997576f4353d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac">95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069ae598e0f0477282f60735e915b8af_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfd27b3218b487a9810f8d0eca2c8eb_D20210101-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288">52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069ae598e0f0477282f60735e915b8af_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfd27b3218b487a9810f8d0eca2c8eb_D20210101-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc254f3841504538bd25d1e598f7efcb_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b">119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9ed02e04a84fd4a77116dcbcdb1d7a_D20210101-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc254f3841504538bd25d1e598f7efcb_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9ed02e04a84fd4a77116dcbcdb1d7a_D20210101-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50bf294318854802b0ca58dbe517a298_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtMi0xLTEtNDI5Njcx_72ec13bf-f3db-48f3-ae79-5c72c3f1d49f">832</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f316f885ed4d329752000102edb162_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtNC0xLTEtNDI5Njcx_3bc803cd-e2a3-4377-b12f-8e60922a30b1">97</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMi0xLTEtNDI5Njcx_d76f42da-fb4e-446f-9ea5-f98760068047">832</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNC0xLTEtNDI5Njcx_211174d9-e259-4f54-9f87-7cc752aad16c">97</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNi0xLTEtNDI5Njcx_60eac3c4-32fd-43f6-8b03-4e76cadca988">3,264</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtOC0xLTEtNDI5Njcx_9c90dcf1-6e88-4be7-b902-e170d48b4afa">683</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTAtMS0xLTQyOTY3MQ_1b6c0327-f807-478a-a8f0-0ac11991b5cb">1,068</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTItMS0xLTQyOTY3MQ_9ae39430-7552-4461-b69f-37394ff1a54e">204</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span></ix:footnote><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" continuedAt="if0aca0fed87547cc9f65d7e845ea284d" footnoteRole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI into COS were:</ix:footnote></span></div><ix:continuation id="if0aca0fed87547cc9f65d7e845ea284d"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $<ix:nonFraction unitRef="usd" contextRef="ia14b13073e4e4613b080addd6621f2f9_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjA2OA_f026d816-21ba-4298-ae94-80b4409b149b">125</ix:nonFraction> million in the third quarter of 2022; </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $<ix:nonFraction unitRef="usd" contextRef="ib5b98292d9c1417a926a79b66406286a_D20220101-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjEwMQ_232ef55a-df17-4a07-bff5-6d7121fc8917">227</ix:nonFraction> million in the first nine months of 2022;</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $<ix:nonFraction unitRef="usd" contextRef="i3f6af82b6d024b0eafd8f31e35b20075_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjEzMA_00b6f1e3-d892-4989-b02f-826f2e3f30dd">18</ix:nonFraction> million in the third quarter of 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $<ix:nonFraction unitRef="usd" contextRef="if474000c1ec5464d9c71367ad5ee9f35_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjE2Ng_2132382e-cb47-47e2-bf7b-1c05d8812b54">94</ix:nonFraction> million in the first nine months of 2021. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002" decimals="-9" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQ1MA_414d885d-4c33-403f-ac3c-25c36234155b">1</ix:nonFraction> billion within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately <ix:nonNumeric contextRef="i34242284b9494732b030b9e714db61b6_D20220101-20221002" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjUzNw_f550c1cc-d9e0-433c-9b85-97dfba0f5af6">21</ix:nonNumeric> years and relates to foreign currency debt. </span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" footnoteRole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI were reclassified into OID.</ix:footnote></span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" footnoteRole="http://www.xbrl.org/2003/role/footnote">Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related short-term borrowings&#8217; carrying value as of December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i9f47fc0e281c43afac185ec01923d406_I20211231" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQxOQ_9aae5aa1-d785-45c0-9fd8-1b0725c161a1">1.1</ix:nonFraction>&#160;billion. The related long-term debt carrying values as of October&#160;2, 2022 and December 31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i04751deef2cd46b99805e78bd859c289_I20221002" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQwMA_4b6f72c5-9fc4-4062-9f4b-0216f3180deb">726</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i667311c49e1242729a0e2cfbeb12d37b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQxMA_0aa6145a-716e-4cc5-b4c5-871106f0b925">844</ix:nonFraction> million, respectively.</ix:footnote></span></div></ix:continuation><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwMg_fd8f897f-a20a-4993-8ed1-d46b7514c2aa" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our debt in fair value hedges:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0yLTEtMS00Mjk2NzE_7a699dba-090b-429c-97be-830060b328be">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi00LTEtMS00Mjk2NzE_8b7797cb-5d29-4e51-bc9a-fe4061f65802">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi02LTEtMS00Mjk2NzE_b214a9d8-54c0-47b4-925d-f554954019da">16</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi04LTEtMS00Mjk2NzE_339c5e19-4e13-4c0a-b6bc-eae3c491dace">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0xMC0xLTEtNDI5Njcx_ad1cfe24-ace5-4632-a12d-ed52b4cfc59e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0xMi0xLTEtNDI5Njcx_871d629a-ede7-4190-8234-9e0a9387447c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0yLTEtMS00Mjk2NzE_9a8f71b8-8682-4d0b-8e7c-5991fa04886e">2,235</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC00LTEtMS00Mjk2NzE_c8b00395-4104-4122-8c5d-e836e1b09905">330</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC02LTEtMS00Mjk2NzE_2dbcf426-809e-4b78-b3a1-2de9881a98d4">1,061</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9e5de858194ea3a1564e487b4e84b0_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC04LTEtMS00Mjk2NzE_e29d8cd7-34c4-4497-9fe5-877dba1f1d25">2,233</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9e5de858194ea3a1564e487b4e84b0_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0xMC0xLTEtNDI5Njcx_9a4b0453-32ad-4cf0-82f6-e020fe0c7ec1">16</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9e5de858194ea3a1564e487b4e84b0_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0xMi0xLTEtNDI5Njcx_fc65ce9b-3231-438f-9f13-4d6a8fbcffbd">1,154</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad" footnoteRole="http://www.xbrl.org/2003/role/footnote">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_82"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if9d6b19c4db34feaa61af82d92c68b2e" continuedAt="i21c7086c7fcd459881feb64c64414578"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;2, 2022, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by Germany, the U.S., the Netherlands, Japan, the U.K., France, and Canada, as well as money market funds primarily invested in U.S. Treasury and government debt.</span></div></ix:continuation><div><ix:continuation id="i21c7086c7fcd459881feb64c64414578"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of October&#160;2, 2022, the aggregate fair value of these derivative financial instruments that are in a net payable position was $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMzI5ODUzNDg4NDg5OA_00648238-4936-4188-87db-e9e8d880ec0a">595</ix:nonFraction>&#160;million, for which we have posted collateral of $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMTE1NQ_00fd5298-3b81-4d4c-9a2c-bf4219484fca">612</ix:nonFraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of October&#160;2, 2022, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-8" name="pfe:DerivativeNetReceivablePositionAggregateFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMTMzOQ_829855f5-86e5-4b8f-8998-83449a9689ea">1.5</ix:nonFraction>&#160;billion, for which we have received collateral of $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-8" name="us-gaap:SecuritiesReceivedAsCollateral" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMTM4NA_4c92a381-860e-4783-8803-99812d0b113c">1.5</ix:nonFraction>&#160;billion with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i8c2530a91ced4c48b9620128206808f1_85"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTI2_101e5d54-2a68-4542-89fd-1f986a87b1b8" continuedAt="ic60e7e0b6e564e499beb8af9b0655e2c" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="ic60e7e0b6e564e499beb8af9b0655e2c" continuedAt="ic5526e056ccd4c70bc354c4b4bcad352"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"> Inventories</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTIz_9f8ee3ea-a157-4651-85ed-5781b4c7f2c1" escape="true"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTI0_40f21c77-fedf-4e1b-a616-5de678747bee" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMi0yLTEtMS00Mjk2NzE_2cf9048e-f55d-4f1b-9ed5-4f4d88fd2af4">3,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMi00LTEtMS00Mjk2NzE_1e6c9702-f723-4df1-980e-1a79a58d21ed">3,641</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMy0yLTEtMS00Mjk2NzE_58afb1ba-5d01-4d2d-aec2-9ed872d216a3">4,540</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMy00LTEtMS00Mjk2NzE_2a378865-93ff-4238-bdcc-849371003c6a">4,424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNC0yLTEtMS00Mjk2NzE_bf764082-35c5-4f34-8b8b-297ae81dc986">1,813</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNC00LTEtMS00Mjk2NzE_65d04817-85c6-42b6-ba56-e3e987025aab">994</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS0yLTEtMS00Mjk2NzE_024cc055-6b5e-4f81-9da0-c6acda341735">9,513</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS00LTEtMS00Mjk2NzE_e4668477-5c06-4db4-abbd-1dbe4b47532b">9,059</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi0yLTEtMS00Mjk2NzE_71e44f3a-392e-466e-875b-5da4ad8a675d">3,327</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi00LTEtMS00Mjk2NzE_8bfa4640-17ef-44ef-ac97-dc7b2d8e9c11">939</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTA5_e27b3df5-fe48-465d-9f76-7923a63796dc" footnoteRole="http://www.xbrl.org/2003/role/footnote">The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTE5_795908f7-063c-467e-8921-7a9634d8d597" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.</span></ix:footnote></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ic5526e056ccd4c70bc354c4b4bcad352" continuedAt="i6e0351eb6c6841528b2bd07f9379f19f">Other current liabilities</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e0351eb6c6841528b2bd07f9379f19f"> includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $<ix:nonFraction unitRef="usd" contextRef="i8308f5a4b0dc4a5e84bd59beff89e949_I20221002" decimals="-8" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNDcz_f127770a-a27d-4e65-917f-4f67410669ad">4.5</ix:nonFraction>&#160;billion as of October&#160;2, 2022 and $<ix:nonFraction unitRef="usd" contextRef="id224ff09ffe74524973bc9034a6a86ee_I20211231" decimals="-8" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNDg5_5c561567-78c9-47c5-adb2-8e5054e02c53">9.7</ix:nonFraction>&#160;billion as of December 31, 2021.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_88"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDkz_df1593e9-f5c9-4896-8f9b-7bc2e47b5aac" continuedAt="iccd46b981bed4f41a5a422a35d1a0141" escape="true">Identifiable Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="iccd46b981bed4f41a5a422a35d1a0141"><div style="margin-top:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Identifiable Intangible Assets</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc4_9f6cd26f-2f43-41df-be6b-124970d420fc" escape="true"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTEy_0d8eddb9-6091-4834-ade4-d0aa8d58a3a9" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:28.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c782fb34650411c8db8781a876e6df3_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC0yLTEtMS00Mjk2NzE_8f7936a4-ab5b-4073-83d5-5c6473590da8">72,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c782fb34650411c8db8781a876e6df3_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC00LTEtMS00Mjk2NzE_c792f2a0-2d7f-4a21-bdc3-e14c516a3232">55,309</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c782fb34650411c8db8781a876e6df3_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC02LTEtMS00Mjk2NzE_f67c1116-a810-4268-8ac8-f725d87845fd">17,509</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9991d2e7245d461895c706bb1a8bece9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC04LTEtMS00Mjk2NzE_82fbfc77-5764-409b-a76e-3305d0021e03">73,346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9991d2e7245d461895c706bb1a8bece9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC0xMC0xLTEtNDI5Njcx_3fdb39fe-ad3d-4a69-87cc-cd4e141ebee5">53,732</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9991d2e7245d461895c706bb1a8bece9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC0xMi0xLTEtNDI5Njcx_ca6db337-e5e4-43f1-8a6a-3d5d4bdd38fd">19,614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS0yLTEtMS00Mjk2NzE_97209eab-4c08-4b19-a94a-d0caee99221a">922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS00LTEtMS00Mjk2NzE_7c5f2868-3d5f-42c6-8625-327be518316d">832</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS02LTEtMS00Mjk2NzE_7a9f0ecb-cc84-4bf3-b25b-37af59cfc7da">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749f749980d34e25acc4fb7966c17205_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS04LTEtMS00Mjk2NzE_a7e76a47-e498-4f90-ab37-bf1f8143ee08">922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i749f749980d34e25acc4fb7966c17205_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS0xMC0xLTEtNDI5Njcx_74c9297c-2d46-429c-95fb-b3e228d5c8d2">807</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749f749980d34e25acc4fb7966c17205_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS0xMi0xLTEtNDI5Njcx_eed4af36-fb87-4f34-b627-d9d9f35cb6ce">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203cdb0ebc574f27943dd1e51d1b1277_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi0yLTEtMS00Mjk2NzE_82c7c046-e869-49e3-8227-e50de6739bd8">2,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i203cdb0ebc574f27943dd1e51d1b1277_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi00LTEtMS00Mjk2NzE_9d6c4387-41d9-4f9e-8eb9-66bd11fd77b9">1,373</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203cdb0ebc574f27943dd1e51d1b1277_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi02LTEtMS00Mjk2NzE_a71f4544-c91c-4eeb-adad-28872325d673">923</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912798045f5b4639aa7284fc67e728b2_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi04LTEtMS00Mjk2NzE_40a59631-48f0-4187-bea7-e6dfda63e9f1">2,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i912798045f5b4639aa7284fc67e728b2_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi0xMC0xLTEtNDI5Njcx_0f6d8b58-780b-4498-bd12-ecae47beab69">1,299</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912798045f5b4639aa7284fc67e728b2_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi0xMi0xLTEtNDI5Njcx_0bf5fb89-a826-4bcd-a2d2-6bed800f97cb">985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC0yLTEtMS00Mjk2NzE_356e27c7-d227-420c-97b7-07ec8ccd4ac4">76,036</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC00LTEtMS00Mjk2NzE_3bce7369-d347-43b7-9ff4-61e7fa9a5dd1">57,514</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC02LTEtMS00Mjk2NzE_39392511-b500-415f-9d7f-bdade00807a3">18,522</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC04LTEtMS00Mjk2NzE_37c0c989-4859-4451-8118-bdd52baefc66">76,552</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC0xMC0xLTEtNDI5Njcx_006ae5f7-440f-49f4-81b3-eb3ddc31265e">55,838</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC0xMi0xLTEtNDI5Njcx_b367ab98-51a1-4b3c-9f2c-2af57ce3456a">20,714</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd6baec7c42411ea48eebdb0f2f23db_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtMi0xLTEtNDI5Njcx_437b2898-a95d-468e-b1f8-2a76cef73115">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd6baec7c42411ea48eebdb0f2f23db_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtNi0xLTEtNDI5Njcx_ff24a3b1-97aa-4a75-b9c7-eaf60e31d9bd">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b292fac08314732827dde98a31e18b0_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtOC0xLTEtNDI5Njcx_2fc241b4-a5cf-4786-8c80-cd0524542233">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b292fac08314732827dde98a31e18b0_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtMTItMS0xLTQyOTY3MQ_f905d8a8-20a5-4efa-ae38-a9d2ce4f3547">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMi0xLTEtNDI5Njcx_0ca3d8fc-7f0e-4e03-aace-8bacdd754f47">7,829</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtNi0xLTEtNDI5Njcx_9566c9fd-ec55-4d73-93d7-4a3c4e2174e6">7,829</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f31c2acdf14f1cb842ad2f9b51b800_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtOC0xLTEtNDI5Njcx_5f924545-7cdf-419a-a41b-dab24a74c232">3,092</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f31c2acdf14f1cb842ad2f9b51b800_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMTItMS0xLTQyOTY3MQ_6b832ab6-88f2-4aab-a51a-d9475eb4d0ef">3,092</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27c96bd99bc47d68e917e7d12a78b77_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMi0xLTEtNDI5Njcx_31a4bf64-afc9-420a-8aea-da78984567bc">972</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27c96bd99bc47d68e917e7d12a78b77_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItNi0xLTEtNDI5Njcx_a1142993-e425-47ab-a0d1-446a18afad15">972</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54cb4a7821fb491f8936f9f3177f14a4_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItOC0xLTEtNDI5Njcx_77fa5bda-2010-4cea-bb57-14533aeb9398">513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54cb4a7821fb491f8936f9f3177f14a4_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMTItMS0xLTQyOTY3MQ_1bfb8b75-ee82-4190-b19d-033448001fcf">513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtMi0xLTEtNDI5Njcx_bcf68a16-0674-417e-8e07-3e235d416181">9,629</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtNi0xLTEtNDI5Njcx_eead4c77-d39a-44be-986c-76ec9ac478ed">9,629</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtOC0xLTEtNDI5Njcx_b4648c42-d5ad-44fb-99d4-d48bde024a1e">4,432</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtMTItMS0xLTQyOTY3MQ_6c98f02b-5bcc-48e6-bafc-3d576cda52e6">4,432</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16">85,665</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40">57,514</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d">28,151</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c">80,984</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099">55,838</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470">25,146</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for IPR&amp;D, is partially offset by an impairment (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" footnoteRole="http://www.xbrl.org/2003/role/footnote">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</ix:footnote></span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Goodwill</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA5_1295e007-97f0-4488-b456-fb7016bba7d7" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:84.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMi0xMC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633">49,208</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957">1,029</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959">797</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, October&#160;2, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNS0xMC0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e">49,441</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTEw_9923cd38-7dbe-4b3b-b819-55589f178430" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Additions relate to our acquisition of Arena. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA0_6ca71259-76f1-49da-935c-89714090a072" footnoteRole="http://www.xbrl.org/2003/role/footnote">Other represents the impact of foreign exchange.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_91"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTgz_166228f8-33e7-49af-b3b6-ec1107830c58" continuedAt="i17baf9f24f2540d18a98da3689ac3373" escape="true">Pension and Postretirement Benefit Plans</ix:nonNumeric></span></div><div style="margin-top:3pt"><ix:continuation id="i17baf9f24f2540d18a98da3689ac3373" continuedAt="ie0a978dc392d4e10bea8d2e06cbe6735"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTgy_c48b21bb-498c-4d53-bceb-02e33ce5ce53" continuedAt="icda1b07f473d47f1b92be5d704a48220" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS0yLTEtMS00Mjk2NzE_7818a47b-c3eb-4e61-9ed2-1081514c2a11">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS00LTEtMS00Mjk2NzE_6d4b3d89-bee1-416d-951d-3d1810b853a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS02LTEtMS00Mjk2NzE_20778a52-520e-46f5-9cf0-a66c36659e2b">29</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS04LTEtMS00Mjk2NzE_b84db1b8-7fde-405d-aa40-5ca078f48f15">32</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS0xMC0xLTEtNDI5Njcx_3f4cb024-6429-4440-b6f6-d1446cca8bd6">7</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS0xMi0xLTEtNDI5Njcx_9e22f48a-5754-457d-a7b5-408cb3a78779">9</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi0yLTEtMS00Mjk2NzE_94516207-227c-45c6-8adc-7a6c9f31609a">151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi00LTEtMS00Mjk2NzE_63166281-094d-4849-8701-6a31a7352be1">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi02LTEtMS00Mjk2NzE_07b0b843-ce58-4d84-a04a-db3aedaababa">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi04LTEtMS00Mjk2NzE_7d29da5e-0144-485f-a76d-02bf1022bd44">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi0xMC0xLTEtNDI5Njcx_e52bde81-0b49-4d5b-8c48-baa3a630fedd">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi0xMi0xLTEtNDI5Njcx_5348ab7e-522a-4f21-a937-0b69429a127c">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy0yLTEtMS00Mjk2NzE_d58bc246-47f5-41aa-a635-b06a25150b88">195</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy00LTEtMS00Mjk2NzE_db7958f1-d6a4-49d0-adff-293d341ac4e5">261</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy02LTEtMS00Mjk2NzE_05ee9e29-20b3-4d66-b7a8-1fc3e488f1de">72</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy04LTEtMS00Mjk2NzE_5a526747-d9dd-4a1f-b158-5b41bf28529b">83</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy0xMC0xLTEtNDI5Njcx_a43adeb6-3c95-4aa4-acff-9240fc44bdd9">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy0xMi0xLTEtNDI5Njcx_dba435de-3e0c-4cfd-bc30-cd59b7ef264f">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC0yLTEtMS00Mjk2NzE_138acbaa-c129-4bce-892d-e9579bf2887f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC00LTEtMS00Mjk2NzE_d635144e-bbef-4700-889f-8c5fe31daae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC02LTEtMS00Mjk2NzE_ea4b6a40-a749-4bda-a10b-856e2fc2a12d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC04LTEtMS00Mjk2NzE_e41cc862-600d-4914-8fe2-91ad030bc840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC0xMC0xLTEtNDI5Njcx_18a6f04f-601c-4f7f-aa73-44789f726d62">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC0xMi0xLTEtNDI5Njcx_70fa235c-c75d-4dc0-90d5-f41fee2571f2">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0yLTEtMS00Mjk2NzE_09ed946a-8297-4206-96f6-5ac122523c37">193</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS00LTEtMS00Mjk2NzE_1f004768-3046-4785-bc33-1afae8b0ea63">836</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS02LTEtMS00Mjk2NzE_911b960f-8d0b-4b2f-9c38-e805e112bc95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS04LTEtMS00Mjk2NzE_d800e503-a11e-4212-9c70-e64fafc7d253">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMC0xLTEtNDI5Njcx_68f6d789-f455-46c8-a3ed-e2cdffa43f1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMi0xLTEtNDI5Njcx_e6e616e8-ff43-412f-bc24-145f96133e33">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtMi0xLTEtNDI5Njcx_d5a51b2b-db2b-4103-b4b4-b9efaeff5649">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtNC0xLTEtNDI5Njcx_03307c74-680a-4137-a0f5-bf94b26c7a21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtNi0xLTEtNDI5Njcx_2776a96f-98fb-46e7-b487-e2d2737bc725">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtOC0xLTEtNDI5Njcx_e5159c4b-e573-4384-995b-5df7b5c627da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtMTAtMS0xLTQyOTY3MQ_10b1ed69-1324-4f0e-b8b0-19705b81af4e">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtMTItMS0xLTQyOTY3MQ_577d14f7-f731-44bc-ac3e-42d7b49b4bec">64</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtMi0xLTEtNDI5Njcx_5534810e-1d4b-4267-8fc9-f3fa09393afc">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtNC0xLTEtNDI5Njcx_e4f97bc4-572c-4c05-be61-185aeea3db0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtNi0xLTEtNDI5Njcx_9a6c99ba-45e7-4ac4-a043-ebdc371a6a25">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtOC0xLTEtNDI5Njcx_3f5cc810-19cb-4b6c-bf30-ffcb29270b19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtMTAtMS0xLTQyOTY3MQ_0c576024-a217-4a9a-8dc7-199c7686a2a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtMTItMS0xLTQyOTY3MQ_b7660f12-d303-483e-ad64-23626d4dc913">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItMi0xLTEtNDI5Njcx_61d3b7aa-2c52-44f5-a5e5-7dccbef23931">235</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItNC0xLTEtNDI5Njcx_fa100044-1325-46ca-b2a6-8ddd16a7432a">983</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItNi0xLTEtNDI5Njcx_b0955dcd-ddff-4cdc-9ea8-9105cb2d8f79">6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItOC0xLTEtNDI5Njcx_d3181781-d62d-4c29-bef7-840d02175bf7">14</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItMTAtMS0xLTQyOTY3MQ_912fc87d-97aa-4582-80f4-490320f23f92">30</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItMTItMS0xLTQyOTY3MQ_a1fe4f3f-ebdf-45d7-bfbf-42a8f50b8839">96</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="39" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ie0a978dc392d4e10bea8d2e06cbe6735"><div style="margin-top:3pt"><ix:continuation id="icda1b07f473d47f1b92be5d704a48220" continuedAt="ibbafd0ef3e8347eb8e6e5f066c32a9e3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktMi0xLTEtNDI5Njcx_61c08df5-b01f-4e5d-9d15-0aaf97b46a06">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktNC0xLTEtNDI5Njcx_f492c8a4-fea1-4fb7-bca6-2f89fbdb4f39">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktNi0xLTEtNDI5Njcx_73ddf4b6-f16b-4c3d-a451-3a906da6e7b8">89</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktOC0xLTEtNDI5Njcx_2d205667-5012-42eb-a405-d6cc116a845b">98</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktMTAtMS0xLTQyOTY3MQ_e6c364fc-3298-49b2-b438-bd4863f9384f">22</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktMTItMS0xLTQyOTY3MQ_acd0818c-c14c-4f9d-880c-c9b964e9c68a">27</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtMi0xLTEtNDI5Njcx_cbb93d32-1d87-4fb4-b887-bb5b823aa7b3">387</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtNC0xLTEtNDI5Njcx_ec244754-155b-4873-82cc-9baec267583c">341</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtNi0xLTEtNDI5Njcx_d69307ea-b771-4d0a-8ecb-12e2357a0ac8">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtOC0xLTEtNDI5Njcx_5f291a99-f338-4956-b77e-a00cdb799336">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtMTAtMS0xLTQyOTY3MQ_1c2b8eea-c8f1-45bd-a6fa-3872b37e2c85">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtMTItMS0xLTQyOTY3MQ_b1df60ee-22a4-4fb8-9df4-60cdac8c402c">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtMi0xLTEtNDI5Njcx_e2f48177-f370-4641-8a2e-e11b6d1e8047">685</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtNC0xLTEtNDI5Njcx_fcf73a8d-14e3-4917-9e5a-becc1f62f91f">782</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtNi0xLTEtNDI5Njcx_149ff35a-5a19-4f52-ba29-76825fee84a4">229</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtOC0xLTEtNDI5Njcx_aa77c4fd-f678-4c36-908a-11ed05aeb487">246</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtMTAtMS0xLTQyOTY3MQ_1cfd3c00-f58a-4581-83aa-13e5d22fba73">35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtMTItMS0xLTQyOTY3MQ_f66e996a-b9db-43cc-b6df-7bf7d308eb3f">29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItMi0xLTEtNDI5Njcx_2e59fd02-9d7c-4c00-a6c7-d6aacaa9353c">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItNC0xLTEtNDI5Njcx_b3985f68-c6e2-4ca5-8e37-8fa17d175d18">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItNi0xLTEtNDI5Njcx_f8170cdc-f8cc-4f6c-9e48-31234a18d141">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItOC0xLTEtNDI5Njcx_5a7fcab5-54d5-4cfb-a0be-326b2915427b">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItMTAtMS0xLTQyOTY3MQ_a459c139-76a1-4dc8-9e7e-b9a9341a3086">99</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItMTItMS0xLTQyOTY3MQ_89f13b55-3512-4a01-b5cb-dc138793f79e">116</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMi0xLTEtNDI5Njcx_e4c0ad7d-28f7-4dad-9153-c0c4f47032a1">231</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNC0xLTEtNDI5Njcx_4142aa1c-bf9b-4904-9c6e-b7c56de66c64">881</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNi0xLTEtNDI5Njcx_0afa9a43-daf4-408b-9916-d5dd42011727">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtOC0xLTEtNDI5Njcx_7cece672-8cf3-429c-83fa-1158c7aa755c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTAtMS0xLTQyOTY3MQ_68ce4977-b848-4e99-96dd-167dd7408585">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTItMS0xLTQyOTY3MQ_47c50bf9-f17a-4da7-b80f-308b9a10ebb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtMi0xLTEtNDI5Njcx_d90eff6b-0aaa-4cbd-88c4-f0345ec1d25f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtNC0xLTEtNDI5Njcx_a5f90752-1970-422e-ac2b-6d8e630796ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtNi0xLTEtNDI5Njcx_238278ba-4cd2-4271-a465-88adefa1d6ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtOC0xLTEtNDI5Njcx_b3196231-565a-4331-91bd-7f9d1545bc20">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtMTAtMS0xLTQyOTY3MQ_a233a22e-8ad0-4e97-bd1c-77c1fa9b6256">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtMTItMS0xLTQyOTY3MQ_85f9382d-4982-474f-aa96-72460dd5b52a">64</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtMi0xLTEtNDI5Njcx_ba516686-b11b-4962-b69a-61ce4ed80c90">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtNC0xLTEtNDI5Njcx_8d52520b-8a62-4a00-a3be-6f0bbb30f9c0">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtNi0xLTEtNDI5Njcx_546f5958-c439-48fa-b7fd-3ff6813e0aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtOC0xLTEtNDI5Njcx_5e88a948-d76a-4424-b87d-5ae8b343fb49">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtMTAtMS0xLTQyOTY3MQ_2f936037-afd3-446c-8821-e34733411bcd">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtMTItMS0xLTQyOTY3MQ_35fc8ddc-3cb9-49dd-9d9f-f55cf4908849">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtMi0xLTEtNDI5Njcx_10896ca5-c82b-4cbf-9d6b-5e4589d3f3cc">57</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtNC0xLTEtNDI5Njcx_59af847b-a40f-4a94-8b3c-be3fba79a164">1,312</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtNi0xLTEtNDI5Njcx_a4ca2f98-479d-4982-9c37-cefc6e097e8b">20</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtOC0xLTEtNDI5Njcx_84535253-0186-44d9-bf23-138c26f581db">40</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtMTAtMS0xLTQyOTY3MQ_64ae2cf3-775d-447c-92ce-2da7a26f864d">106</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtMTItMS0xLTQyOTY3MQ_c0ea89fe-c0eb-4677-ae9d-dda44f0d7eb2">160</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ibbafd0ef3e8347eb8e6e5f066c32a9e3" continuedAt="i1ce0ec93a86442eaac9a45e2c446bc90">(a)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635" footnoteRole="http://www.xbrl.org/2003/role/footnote"><ix:continuation id="i1ce0ec93a86442eaac9a45e2c446bc90">The third quarter of 2022 mainly reflects interim actuarial remeasurement gains, primarily driven by an increase in the discount rate, partially offset by unfavorable plan asset performance. The first nine months of 2022 mainly reflects interim actuarial remeasurement losses, primarily driven by unfavorable plan asset performance, partially offset by gains due to an increase in the discount rate. In the third quarter and first nine months of 2021, mainly reflects interim actuarial remeasurement gains, primarily due to favorable plan asset performance and an increase in the discount rate.</ix:continuation> </ix:footnote></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended October 2, 2022, we contributed $<ix:nonFraction unitRef="usd" contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfMzkx_ac6158fd-83f2-49bf-bd74-d403dce28b7e">207</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfMzk1_f95da6f9-7c7a-4e21-b9c5-67ae683a05f2">127</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNDAz_5af98571-4225-42cf-be93-3baf55502381">16</ix:nonFraction> million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.</span></div></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_94"></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjM1_3bff5b0b-b17c-4c22-8830-2a253e8939ab" continuedAt="i42c00b906382428da3fb8430de3893a2" escape="true">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ix:nonNumeric></span></div><ix:continuation id="i42c00b906382428da3fb8430de3893a2"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ4_b3767ddc-14e9-41a1-a1d5-6dfd0601712d" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi0yLTEtMS00Mjk2NzE_d9bdf607-b2c7-4efb-bf89-2274cf52925d">8,630</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi00LTEtMS00Mjk2NzE_731c258f-20a9-4be3-a466-6909c636ae72">8,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi02LTEtMS00Mjk2NzE_1aa0bf38-02c5-41e3-9542-cb74e9e5864b">26,373</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi04LTEtMS00Mjk2NzE_eadabe85-c46a-423f-b69f-03f7343c07e0">18,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy0yLTEtMS00Mjk2NzE_b26de5cd-0752-44b3-bcf9-c31fe4fe5bea">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy00LTEtMS00Mjk2NzE_f6aa8860-e07d-40e5-8bf6-13a1c8c4372d">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy02LTEtMS00Mjk2NzE_856e4129-e341-4d20-9abc-8dafc7c44156">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy04LTEtMS00Mjk2NzE_a413be57-7984-4da2-8432-8482b7d0d5ea">248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtMi0xLTEtNDI5Njcx_f80d8650-5ff9-48dc-aa78-00175849dead">8,608</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtNC0xLTEtNDI5Njcx_039bd9e3-8eeb-447b-90d1-ec505977c39a">8,146</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtNi0xLTEtNDI5Njcx_a6e6a6bb-4ca6-4523-8d12-6d3145e1220c">26,378</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtOC0xLTEtNDI5Njcx_ff7bc784-321a-4cde-bbba-74f8be89181d">18,586</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItMi0xLTEtNDI5Njcx_1f595bad-c25d-44d0-901d-c74a79bd0a11">8,630</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItNC0xLTEtNDI5Njcx_07f5add2-dbed-4b54-ad45-135516acaafe">8,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItNi0xLTEtNDI5Njcx_135f927d-6812-49a1-a318-ea69bd4e606f">26,373</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItOC0xLTEtNDI5Njcx_f5cc8df5-d2ea-43d6-ba7b-219cacfa9080">18,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtMi0xLTEtNDI5Njcx_d08284ef-c87c-439d-9051-e1f5101df548">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtNC0xLTEtNDI5Njcx_6d5de488-db7b-44ce-971c-6d7338daeb32">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtNi0xLTEtNDI5Njcx_2331daca-4921-4f4a-8994-2e6f375a1391">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtOC0xLTEtNDI5Njcx_f4407f1c-7dfd-44ba-870f-a5ef94a232ca">248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtMi0xLTEtNDI5Njcx_18600809-8d5c-4442-9031-cfccba0225f8">8,608</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtNC0xLTEtNDI5Njcx_c59f80fd-6bb0-4ea5-ab81-6ec578a29048">8,146</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtNi0xLTEtNDI5Njcx_64dbf22f-b866-4242-a617-b9514c8187d3">26,378</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtOC0xLTEtNDI5Njcx_f9aabd2e-d233-453c-818b-70dbbadc1578">18,586</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtMi0xLTEtNDI5Njcx_e39187ea-0aba-4412-a3a1-de7fd27cb46d">5,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtNC0xLTEtNDI5Njcx_da641e26-9461-4303-a760-b0c9f2f5063b">5,609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtNi0xLTEtNDI5Njcx_e2f09dbf-7fbd-4e14-85c0-9a960721a8fb">5,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtOC0xLTEtNDI5Njcx_6488a65f-0189-4e14-adb2-191d8c4a0047">5,597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options and stock issuable under employee compensation plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctMi0xLTEtNDI5Njcx_19aa2c28-dcf4-4550-b2d7-0387b06dcbb0">111</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctNC0xLTEtNDI5Njcx_fb09938e-91c2-4935-ad04-ac7b07cf1595">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctNi0xLTEtNDI5Njcx_e568f270-dcbe-4887-97b0-f03e1536430c">124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctOC0xLTEtNDI5Njcx_ca341c81-468b-4e7d-9613-43e41ef5794e">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtMi0xLTEtNDI5Njcx_a0eb934e-9638-4dbe-a3cc-9d182105ed32">5,718</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtNC0xLTEtNDI5Njcx_3aeab3f9-33a6-4a93-b31e-a09d575bd5c9">5,725</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtNi0xLTEtNDI5Njcx_10502147-b493-4635-8a7a-59d01b94ecfa">5,729</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtOC0xLTEtNDI5Njcx_6a812a9e-b1b1-44bd-9c15-b7ef80dc5e71">5,688</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktMi0xLTEtNDI5Njcx_4ec007b4-6ac4-497a-8dec-4da658597588">3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNC0xLTEtNDI5Njcx_65a1690b-56f3-43a3-ba0b-a7b1b251e5f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNi0xLTEtNDI5Njcx_0a9e4766-78e0-4f4d-a516-d8ff1d77c48e">1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktOC0xLTEtNDI5Njcx_d3fed0bf-d915-4612-8a1c-f7389bce1827">3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535" footnoteRole="http://www.xbrl.org/2003/role/footnote">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_97"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfNDM0MjM_8202cf90-9c0c-418b-82e5-ade76e1921c6" continuedAt="idf74ac7e1d4f48a49f6047168b0ce3e0" escape="true">Contingencies and Certain Commitments</ix:nonNumeric></span></div><ix:continuation id="idf74ac7e1d4f48a49f6047168b0ce3e0" continuedAt="id166b9bd8880423d9fbc999155bca75b"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-6" name="pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMzI0OQ_8070eb51-b2e5-47dc-ab9f-efcf9af8ff36">1</ix:nonFraction> million in potential or actual governmental monetary sanctions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id166b9bd8880423d9fbc999155bca75b" continuedAt="iadd2e31d78dc47dfb59594d65bdaa65b"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In November 2022, BMS received permission to appeal the High Court&#8217;s decision. Additional challenges remain pending in other jurisdictions. Also, for example, in July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty infringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or BioNTech in other jurisdictions in the future. In addition, in October 2022, Accord Healthcare Ltd. brought suit in the U.K. against the Regents of the University of California challenging the validity of the U.K. patent covering the active ingredient in Xtandi, which expires in 2028. Adverse decisions in these matters could have a material adverse effect on our results of operations.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office. In addition, another patent was challenged in federal court in Delaware; and that case was settled in September 2021 on terms not material to the company. Other challenges to pneumococcal vaccine patents remain pending at the Patent Trial and Appeal Board and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor&#8217;s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we brought a separate patent infringement action against MSN Laboratories Private Ltd. (MSN) asserting the infringement and validity of our compound patent covering the active agreement that was challenged by MSN in its ANDAs seeking approval to market generic versions of tofacitinib immediate release tablets (5 mg, 10 mg) and oral solution 1 mg/mL. In August 2022, we settled our action against MSN on terms not material to us.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iadd2e31d78dc47dfb59594d65bdaa65b" continuedAt="ic959be7cca134143b27013c405a85426"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various U.S. federal courts, asserting the validity and infringement of the patents challenged by the generic companies. We have settled with one of these generic companies on terms not material to us, and we dismissed the patent infringement actions relating to the crystalline form of patent, the composition of matter patent expiring in 2023, the method of use patent, and the tablet formulation patent against the generic companies that had challenged these patents. The composition of matter patent expiring in 2027 remains in suit. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eucrisa</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Braftovi (encorafenib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, a generic company notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Braftovi. The company asserts the invalidity and non-infringement of, among others, a method of use patent expiring in 2033. In September 2022, we brought a patent infringement action against the generic company in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the method of use patent expiring in 2033.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mektovi (binimetinib)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in August 2022, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies assert the invalidity and non-infringement of <ix:nonFraction unitRef="patent" contextRef="ibfa472f98c9c4c3ba6c39332849653eb_D20220801-20220831" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDQ4NA_a7388ef5-1101-4a87-a6ea-05998584f851">two</ix:nonFraction> method of use patents expiring in 2030, a method of use patent expiring in 2031, <ix:nonFraction unitRef="patent" contextRef="i7ec7a704d40b402d8dd76af6c1782133_D20220801-20220831" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDQ5NQ_31a1db9a-d0d4-44ec-8fc0-c982ae2f35eb">two</ix:nonFraction> method of use patents expiring in 2033, and a product by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of all <ix:nonFraction unitRef="patent" contextRef="iad227400e764448bb7ce0ca5ce1db320_D20220801-20220831" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDUwNQ_b808bf61-5527-45c8-b305-8c6d25268c8b">six</ix:nonFraction> patents.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions in Which We are the Defendant</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comirnaty</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia &amp; Upjohn Co. LLC, our wholly owned subsidiary, alleging that Comirnaty infringes U.S. Patent No. 11,246,933, which was issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a second complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia &amp; Upjohn Co. LLC, BioNTech and BioNTech Manufacturing GmbH, alleging that Comirnaty infringes U.S. Patent No. 11,382,979, which was issued in July 2022, and seeking unspecified monetary damages.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring only after March 7, 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes two European patents. In September 2022, ModernaTX filed patent infringement actions in the U.K and in the Netherlands against Pfizer Inc. and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, on the same <ix:nonFraction unitRef="patent" contextRef="i91598b6cfce147ed85f80c515a585148_D20220901-20220930" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDUxMw_e8da88cd-0f81-4c5e-aeaa-840f076365dd">two</ix:nonFraction> patents. In its complaints, Moderna stated that it is seeking damages for alleged infringement occurring only after March 7, 2022. In the U.K., Pfizer and BioNTech have brought an action against ModernaTX seeking to revoke these European patents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paxlovid</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Enanta Pharmaceuticals, Inc. filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes U.S.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patent No. 11,358,953, which was issued in June 2022, and seeking unspecified monetary damages.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic959be7cca134143b27013c405a85426" continuedAt="if9cc151cee2e4c088cdaa00f4298ed32"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters Involving Pfizer and its Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eliquis</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, <ix:nonFraction unitRef="defendant" contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231" decimals="INF" name="pfe:GainContingencyNumberofDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTQ3OTk_241978bf-105f-4033-aa5a-d684975e1395">twenty-five</ix:nonFraction> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the <ix:nonFraction unitRef="patent" contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTUwMTc_52cdca37-36b1-40ec-8805-eb72a2f74b68">three</ix:nonFraction> patents listed in the Orange Book for Eliquis. <ix:nonFraction unitRef="patent" contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231" decimals="INF" name="pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTUwNjc_eb146fda-ba3d-4521-88d4-9dcf9614e23c">One</ix:nonFraction> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all <ix:nonFraction unitRef="patent" contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTU3MzU_e9a0f57f-e1dd-458b-a133-571bc6de3431">three</ix:nonFraction> patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comirnaty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts seeking a judgment of non-infringement for the following <ix:nonFraction unitRef="patent" contextRef="ie3a4c1b86275499193f0bb113f4c657c_D20220701-20220731" decimals="INF" name="us-gaap:LossContingencyPatentsFoundNotInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTY2MDU_c4b4dfe9-94c8-49df-aeb7-deed35bab3fe">three</ix:nonFraction> patents relating to Comirnaty: U.S. Patent Nos. 11,135,312, 11,149,278, and 11,241,493. Outside of the U.S., in the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if9cc151cee2e4c088cdaa00f4298ed32" continuedAt="i2ab8115f3ca24964a9a3e306aa57289e"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lipitor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen (Direct Purchaser)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its current and former affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants&#8217; motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint. In August 2022, the District Court granted Pfizer&#8217;s motion to dismiss the complaint.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Personal Injury Actions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2ab8115f3ca24964a9a3e306aa57289e" continuedAt="ic376ecb9da5a473b83dfb4ed6f0ccc74"><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and <ix:nonFraction unitRef="manufacturer" contextRef="i498fe9705333412a85d84b8175400688_D20180101-20181231" decimals="INF" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMjU4Mjg_9274601f-1917-4bb8-afae-8400188a5100">eight</ix:nonFraction> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson &amp; Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson &amp; Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, asserting a consolidated consumer class action alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chantix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer&#8217;s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic376ecb9da5a473b83dfb4ed6f0ccc74" continuedAt="i2074a13e1bcc486bb97366cbf92a49b3"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as, Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency and/or New Jersey Department of Environmental Protection to perform remedial design, removal and remedial actions, and related environmental remediation activities at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. In January 2022, the Court of Appeals reversed the District Court&#8217;s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals&#8217; decision.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Viatris Securities Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company&#8217;s current and former officers, directors and employees are named as defendants. The complaint alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">State Attorneys General and Multi-District Generics Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2074a13e1bcc486bb97366cbf92a49b3" continuedAt="if374c2b13c9f484ba99faaea20b19057"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020. The Multi-District Litigation also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subpoena &amp; Civil Investigative Demand relating to Tris Pharma/Quillivant XR</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We responded to that subpoena in full and have had no communication with the SDNY in connection with the subpoena since June 2019. Additionally, in September 2020,&#8239;we received a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil Investigative Demand (CID)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the Texas Attorney General&#8217;s office&#8239;seeking records of a similar nature to those requested by the SDNY. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are producing records in response to this request.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received a CID from the U.S. Attorney&#8217;s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the  U.S. Department of Justice&#8217;s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac&#8211;&#8211;State of New Mexico and Mayor and City Council of Baltimore Civil Actions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Biohaven</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, the U.S. Department of Justice's Commercial Litigation Branch and the U.S. Attorney&#8217;s Office for the Western District of New York issued a CID relating to Biohaven. The CID seeks records and information related to, among other things, engagements with health care professionals and co-pay coupons cards. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We are producing records in response to these requests.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if374c2b13c9f484ba99faaea20b19057"><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of October&#160;2, 2022, the estimated fair value of these indemnification obligations is not material to Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the March 2022 indemnity provided by Pfizer to GSK in connection with the issuance of notes by the Consumer Healthcare JV. In conjunction with the completion of GSK&#8217;s demerger transactions in July 2022, GSK&#8217;s guarantee and our related indemnification of GSK&#8217;s guarantee were terminated. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, each of Viatris and Pfizer has agreed to assume, and to indemnify the other for, liabilities arising out of certain matters. Also, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection, includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div></ix:continuation><div id="i8c2530a91ced4c48b9620128206808f1_100"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTA_55d8793a-f6e0-4a22-aae7-64a35a0d25c2" continuedAt="icdb8e369833b498298fe4b316a0dd364" escape="true">Segment, Geographic and Other Revenue Information</ix:nonNumeric></span></div><ix:continuation id="icdb8e369833b498298fe4b316a0dd364" continuedAt="i66f7f312094b4adda15a76288bdbbb02"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Segment Information</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our commercial operations through <ix:nonFraction unitRef="operatingsegment" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzEzMQ_c1430d91-54d3-4214-8891-93db908fec61">two</ix:nonFraction> operating segments, Biopharma and PC1, which are each led by a single manager. Biopharma is the only reportable segment. Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;D services from WRDM and GPD. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the organizational changes in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the new commercial structure within Biopharma is designed to better support and optimize performance across three broad therapeutic areas: </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Primary Care consists of the former Internal Medicine and Vaccines product portfolios, as well as COVID-19 products and potential future mRNA products. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Specialty Care consists of the former Inflammation &amp; Immunology, Rare Disease and Hospital (excluding Paxlovid) product portfolios.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Oncology consists of the former Oncology product portfolio.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Business Activities&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pre-tax costs are not allocated to our operating segment results, such as costs included in Other business activities that are associated with: (i) R&amp;D and medical expenses managed by our WRDM and GPD organizations; (ii) corporate enabling functions and other corporate costs; (iii) overhead costs primarily associated with our manufacturing operations; and (iv) our share of earnings from Haleon/the Consumer Healthcare JV. Additionally, all amortization of intangible assets, acquisition-related items, and certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, are not allocated to our operating segment results. Beginning in the first quarter of 2022, acquisition-related items may now include purchase accounting impacts that previously were included as part of a reconciling item entitled &#8220;Purchase accounting adjustments&#8221; that we no longer separately present, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. The operating results of PC1 are included in Other business activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Assets&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i66f7f312094b4adda15a76288bdbbb02" continuedAt="id815b21b66e840dfa213eb03a6f062f2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment and, accordingly, we do not report asset information by operating segment. Total assets were $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-9" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzMyNjY_57c5b264-b0eb-4891-a195-8651e38c93eb">195</ix:nonFraction> billion as of October&#160;2, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231" decimals="-9" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzMyODI_ed0e743a-8a16-4815-bd20-83fabcee700a">181</ix:nonFraction> billion as of December 31, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Income Statement Information</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjk_9c1260d8-36c0-40ac-a654-69202812b198" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165a698ddb8e4740889d260adc4009bb_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMi0xLTEtNDI5Njcx_eecbcdef-e4f8-49d4-8bd4-656ea5cce5ba">22,319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf2ffc020fc4128a1f9ebec292fe188_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNC0xLTEtNDI5Njcx_0a0d672f-ec7a-4b6e-8e6f-5ab3458cc1b3">23,513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165a698ddb8e4740889d260adc4009bb_D20220704-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNi0xLTEtNDI5Njcx_070c8ab3-8d87-4f6e-aab6-87c2cfbc7637">14,665</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf2ffc020fc4128a1f9ebec292fe188_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtOC0xLTEtNDI5Njcx_3970ef26-7ab4-4db5-9b5c-26484f676cc9">11,848</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260c3e9ac18c409aa7e150f37f31c193_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTAtMS0xLTQyOTY3MQ_d1bed5a4-020e-464f-a27b-5f1ae12de9f4">75,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e893c8b2754cf0b8dd3ad3ebd5f8c9_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTItMS0xLTQyOTY3MQ_bdd64eab-c98f-444f-ac78-4f5d9bdf51a2">56,101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260c3e9ac18c409aa7e150f37f31c193_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTQtMS0xLTQyOTY3MQ_074836b2-faee-4d14-b5d9-ab6657e72802">45,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e893c8b2754cf0b8dd3ad3ebd5f8c9_D20210101-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTYtMS0xLTQyOTY3MQ_1b6cb69e-152f-4b80-b384-2bb98a4369c5">29,952</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d04b7cdf357409082229e55e47bebc1_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMi0xLTEtNDI5Njcx_e9b9138e-fb58-4795-8f2c-a4d80e522093">319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id294f09255c94f85a1408cb0dd253fd3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNC0xLTEtNDI5Njcx_e9f4df3e-bde7-47ac-80c2-730480077951">521</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d04b7cdf357409082229e55e47bebc1_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1">4,007</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id294f09255c94f85a1408cb0dd253fd3_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0">3,303</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTAtMS0xLTQyOTY3MQ_eafab965-bc26-4ea2-845d-e55fc001d4d0">974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848bc701f6dd422990599b16e3035373_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTItMS0xLTQyOTY3MQ_f3c770c9-7c9d-4ac9-9927-009949ba22bc">1,348</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f">9,820</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i848bc701f6dd422990599b16e3035373_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631">7,778</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92dccc52a63e495ab4c634079bac8732_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMi0xLTEtNDI5Njcx_ff43a6a5-6a4b-4385-9ff3-003aa23cf18f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d607e6b68ed4e24ab93bdeca6299e0b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNC0xLTEtNDI5Njcx_ba0766d4-fae0-4e39-b1fd-c9cb6e3a30de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92dccc52a63e495ab4c634079bac8732_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNi0xLTEtNDI5Njcx_ce73b70f-34ce-448f-807d-04c0483f9a88">822</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d607e6b68ed4e24ab93bdeca6299e0b_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtOC0xLTEtNDI5Njcx_4cdfb2b0-ed3d-4b43-8cda-eab2c971db6e">980</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0dfdeb3dc774794b361ecf3023e31d0_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTAtMS0xLTQyOTY3MQ_1de0a812-608b-415d-b04f-edfe7d4c7574">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38bad6387f68492a8b7da8ed99819fa5_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTItMS0xLTQyOTY3MQ_8998c13c-e5d2-434c-9fa8-c8eff9bc4a49">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0dfdeb3dc774794b361ecf3023e31d0_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTQtMS0xLTQyOTY3MQ_226e5b3b-54b5-4194-b403-f87f87f87f9c">2,478</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38bad6387f68492a8b7da8ed99819fa5_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTYtMS0xLTQyOTY3MQ_bab49336-8663-4d3a-b54b-642ee3f94a67">2,778</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5f43508edc415e9ccadc3761d6ec7b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMi0xLTEtNDI5Njcx_b74dcb7a-a748-4301-ad55-bcd16b4b2dec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2531e34ef9984e79a95c51a52ce63392_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNC0xLTEtNDI5Njcx_774bb727-8b6e-456a-8588-15934dc4b735">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb5f43508edc415e9ccadc3761d6ec7b_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNi0xLTEtNDI5Njcx_9efc31e5-89bc-4e23-ab26-ff76bde76ab9">62</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2531e34ef9984e79a95c51a52ce63392_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktOC0xLTEtNDI5Njcx_013b7d41-ff1d-4bc4-9652-bab9578b9d88">41</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i359c961cd6c843d087dbaa286f62f72c_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTAtMS0xLTQyOTY3MQ_ba49b86f-3d4c-47c1-ac24-e55bcbda7c8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20c933385df4b25a75dc3230695c60d_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTItMS0xLTQyOTY3MQ_e00cf9db-c1bc-4239-b073-672ed26e3ba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i359c961cd6c843d087dbaa286f62f72c_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTQtMS0xLTQyOTY3MQ_ddcf4ce1-5e2a-490e-b1be-26e2a0de3ab1">331</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id20c933385df4b25a75dc3230695c60d_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTYtMS0xLTQyOTY3MQ_6962e718-3d63-4e6f-9c5e-93659d844f06">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678fe644ebee4937ad3471779808b530_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTItMS0xLTQyOTY3MQ_4963ea75-ee90-4f56-94c3-f8145aae7c59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c601e0fb53d4bfc88abc7f48831dff4_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTQtMS0xLTQyOTY3MQ_eefa11be-3c33-414f-aa24-e637b9e13a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i678fe644ebee4937ad3471779808b530_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b">773</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c601e0fb53d4bfc88abc7f48831dff4_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead">318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEwLTEtMS00Mjk2NzE_5b3efcd4-f969-46c7-80c1-a92dec07a833">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEyLTEtMS00Mjk2NzE_82f8212f-cbfd-4463-bb16-46a3bf600668">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc">3,095</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3">1,102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTItMS0xLTQyOTY3MQ_b98b7a9b-f80f-4434-b7a4-a5179c63515e">22,638</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTQtMS0xLTQyOTY3MQ_6e3adf5e-9370-4c4d-913b-fc2ac7ad2212">24,035</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTYtMS0xLTQyOTY3MQ_2c73d3fe-554a-48ee-a459-c86ae5e5b0d6">9,001</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTgtMS0xLTQyOTY3MQ_bea1bcfd-0ccb-44e5-9196-b6600e3f9f50">7,843</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTEwLTEtMS00Mjk2NzE_af54e4a2-3db9-4dc9-8559-661087a40fde">76,040</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTEyLTEtMS00Mjk2NzE_b62df8f1-d9a2-4745-9136-0fed3444bfd4">57,450</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE0LTEtMS00Mjk2NzE_c87a90a1-97f6-4519-9d12-26b54b67d3b6">29,498</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE2LTEtMS00Mjk2NzE_eee3e1e2-82fe-4633-bb68-b14a0ba0abc1">20,484</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $<ix:nonFraction unitRef="usd" contextRef="ia8f4ae7d6e40411abaa1ab3cee43b803_D20220704-20221002" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM0OTQ_e4943c92-fe69-43a3-b702-0b0bad8f1f26">112</ix:nonFraction> million in the third quarter of 2022 and $<ix:nonFraction unitRef="usd" contextRef="ib210c73f222b479aacb31d6c32738d5d_D20210705-20211003" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM1MTc_d4702ff5-59f8-4112-b3bc-0be8913635e1">38</ix:nonFraction> million in the third quarter of 2021, and $<ix:nonFraction unitRef="usd" contextRef="i370133c2be5a4be79dd89de09dd1a1b8_D20220101-20221002" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM1NDE_95128768-9c76-4044-8e0c-d36a8890ea61">237</ix:nonFraction> million in the first nine months of 2022 and $<ix:nonFraction unitRef="usd" contextRef="ibe95faf72a3246748e2a732611bcf248_D20210101-20211003" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM1NTc_7f5aeb45-7b17-453a-b807-f4250b1d681c">127</ix:nonFraction> million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $<ix:nonFraction unitRef="usd" contextRef="i30773c6942964c0980876adfe8b4a851_D20220101-20220703" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU0OTc1NTgxNzIxNjU_56723a99-56fa-4c81-836b-5bc3bd461bb6"><ix:nonFraction unitRef="usd" contextRef="i764cde6156604a799beae35a5e6999f2_D20220101-20220703" decimals="-6" sign="-" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU0OTc1NTgxNzIxNjU_fc79ec29-943f-4dad-ac99-55ed7561480c">105</ix:nonFraction></ix:nonFraction> million of costs for the first six months of 2022, $<ix:nonFraction unitRef="usd" contextRef="i68a882359d454a71b139c8ee18e1de06_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTc_3cca34b4-4d3c-4cdf-b2b9-4d0a4671250e"><ix:nonFraction unitRef="usd" contextRef="ie6c21eb451cf4e45b21d701f1947ac11_D20210705-20211003" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTc_9ec41b96-d173-46a9-bea8-87f124b3ae30">57</ix:nonFraction></ix:nonFraction> million of costs in the third quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="if6173132078d438bbba880f5dfde1512_D20210101-20211003" decimals="-6" sign="-" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTA_7058c442-d4c4-42b5-9603-0279b71e1614"><ix:nonFraction unitRef="usd" contextRef="icced37b763334b1db16365dedf95e6d1_D20210101-20211003" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTA_c45cd6e1-1af4-4343-90e2-723fb4de1a71">153</ix:nonFraction></ix:nonFraction> million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $<ix:nonFraction unitRef="usd" contextRef="ia7d134762ff946cba4a83f58faf4e361_D20220704-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjY3MzU_54dfa4c5-a85e-417e-b66e-e9cf69398edb"><ix:nonFraction unitRef="usd" contextRef="i71295b17171746288ec47f20b8ee151f_D20220101-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjY3MzU_69f29904-60c9-4887-afd4-3f0728396f84">426</ix:nonFraction></ix:nonFraction> million of acquired IPR&amp;D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of approximately $<ix:nonFraction unitRef="usd" contextRef="i71fb5a9220eb4286ad607375052a2cf9_D20220704-20221002" decimals="-6" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxMDE3MDU_84ccd85e-90d0-403c-9b1a-3ccdba01fb2f"><ix:nonFraction unitRef="usd" contextRef="i34ae880bca4843ffa60f855563953d75_D20220101-20221002" decimals="-6" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxMDE3MDU_f993d880-a2a1-4fd9-a0c7-c911e98b2c1b">400</ix:nonFraction></ix:nonFraction> million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $<ix:nonFraction unitRef="usd" contextRef="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc0NTc3MDg_5d3b77e4-8ff9-47fa-be5e-b49996425736">516</ix:nonFraction> million. In the third quarter and first nine months of 2021, earnings include $<ix:nonFraction unitRef="usd" contextRef="i4cbfd79f30ac46d99ff22eebda466560_D20210101-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNTQzMTY_3268fda9-3892-4e48-8ffb-bf3646c5daf3"><ix:nonFraction unitRef="usd" contextRef="i1ff7971d70164752ac30c9be1a49a15b_D20210705-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNTQzMTY_b43c41da-725d-4a71-8f2b-50a997cc73f6">706</ix:nonFraction></ix:nonFraction> million of acquired IPR&amp;D expenses associated with our collaboration with Arvinas.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $<ix:nonFraction unitRef="usd" contextRef="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002" decimals="-8" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxMzgzNjY_a26d9c94-7458-4966-b269-da1f207eaae0">1.3</ix:nonFraction> billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $<ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ5OTA_fae94abc-29ad-43ba-8006-aeac94c19cc0">701</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDUwMDk_f126b16d-8445-403d-b31b-936a8bb96795">344</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the remaining amounts primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $<ix:nonFraction unitRef="usd" contextRef="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003" decimals="-8" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDM2MzU_87d68ca6-e0ec-4171-a0bd-88b31648e056">1.6</ix:nonFraction> billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) actuarial valuation and other pension and postretirement plan gains of $<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ1Mjc_add0ae0b-7b49-41ec-8657-c30a2e3532c6">932</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $<ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-8" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ4MDE_739cd3f1-e006-4257-96b8-9d811f6b8cf3">1.1</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ4MzI_e0e1f654-82f8-4300-89e9-d9d371e1eab9">310</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjMxMDE_d1f6b48c-e2a9-40c2-a6f2-aa6d1ce4e4c6">899</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $<ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjMyODI_0bd803bb-d983-44e0-921f-531151bb5190">823</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjMyODc_a04e92ef-889e-4f5f-8f8b-22eaba276733">150</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Geographic Information</span></div><div style="margin-bottom:3pt"><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTI_6a5fdc1b-ae4b-439f-9ca8-6ed3a7735bb5" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f4fc3e7944444dba03aff7ca27b97f_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtMi0xLTEtNDI5Njcx_11a302a9-39c3-4d1f-bc5d-87cffde874cb">13,851</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2887f09b32694901bc3771fd88f8b571_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtNC0xLTEtNDI5Njcx_a8bf398b-5cd3-4ab7-a23f-2cd8772cda8c">7,020</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6f4fc3e7944444dba03aff7ca27b97f_D20220704-20221002" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtNi0xLTEtNDI5Njcx_1f590a65-e0ed-4eeb-9575-2b3e55543df7">97</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880f15025068413dad240be909e60e93_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtOC0xLTEtNDI5Njcx_619fc205-0487-48e3-985d-55aacd085eb5">33,991</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d02fa2996741259f33220479bb03a3_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtMTAtMS0xLTQyOTY3MQ_5ad2132c-4a56-4450-b0f6-ac18b81bb17c">22,066</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i880f15025068413dad240be909e60e93_D20220101-20221002" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtMTItMS0xLTQyOTY3MQ_010ae379-bc04-49a8-80b4-630330135ba5">54</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192d7d95f8b84ad2b81b3eb16434a86a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtMi0xLTEtNDI5Njcx_b9efbd2e-a01b-4ecf-8674-aa56b6b91a32">3,136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89cf38054c742fbb7e8b11d2e93a06c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtNC0xLTEtNDI5Njcx_d7e29c64-6c55-4b80-bef8-3deb8e9328d6">6,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i192d7d95f8b84ad2b81b3eb16434a86a_D20220704-20221002" decimals="2" sign="-" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtNi0xLTEtNDI5Njcx_44a9cfff-0831-4d38-9668-5fa7dbc072cc">50</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4458f5262e14479a0a31486f5d571a3_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtOC0xLTEtNDI5Njcx_9ca325b9-cf79-43ae-99e6-090ad49c989c">14,705</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56465e50cdb148659d882d69f8907dce_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtMTAtMS0xLTQyOTY3MQ_bbf13210-c84a-4f1c-bf08-9af219ac3f50">13,836</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4458f5262e14479a0a31486f5d571a3_D20220101-20221002" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtMTItMS0xLTQyOTY3MQ_9a0839a3-87aa-404b-9c7f-2fd27392d5cc">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9616f23c18c4880ac9e0c371d696ad1_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtMi0xLTEtNDI5Njcx_5925fdbb-c80e-45d6-83eb-8b16bd2e863c">2,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9fab9cc315446eb0e13ffaff8ac454_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtNC0xLTEtNDI5Njcx_c004e755-c331-4f36-ad97-84a321a846ba">4,498</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic9616f23c18c4880ac9e0c371d696ad1_D20220704-20221002" decimals="2" sign="-" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtNi0xLTEtNDI5Njcx_00e013be-dfad-4d72-92cf-acb5013f5afc">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f52d12f36247d5a3bc27c6d932e64c_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtOC0xLTEtNDI5Njcx_51989639-fa1e-4198-a89b-733a45bf9d23">10,671</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a747b5aa22c4f1886ff55881482a458_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtMTAtMS0xLTQyOTY3MQ_e60772c0-2436-4e1c-89c1-515035eda12d">8,617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58f52d12f36247d5a3bc27c6d932e64c_D20220101-20221002" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtMTItMS0xLTQyOTY3MQ_644bb70c-33b9-4f7f-acd9-a6a05e239a5e">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia080a8aa1141463990cc38aa96fa8e59_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtMi0xLTEtNDI5Njcx_85f9a868-4086-4640-a200-89bfb8056f18">3,300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a6341d784a94e3087d8228477c40d27_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtNC0xLTEtNDI5Njcx_6c9d54cc-9c7f-4ca3-95c6-aabcc134d67f">6,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia080a8aa1141463990cc38aa96fa8e59_D20220704-20221002" decimals="2" sign="-" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtNi0xLTEtNDI5Njcx_6f75b97d-f8f5-45ef-9f8e-717cc2ef949b">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2dfe09f313047a18e739d76fbc1485c_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtOC0xLTEtNDI5Njcx_e8c9732a-99b0-475b-bf21-7058578bfc15">16,673</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e6cd06a51948a1b9a6198a5b0d7711_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtMTAtMS0xLTQyOTY3MQ_37819d53-83ab-484c-8a14-7a2f094d9651">12,930</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2dfe09f313047a18e739d76fbc1485c_D20220101-20221002" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtMTItMS0xLTQyOTY3MQ_20531d09-2236-4bd9-aa6a-448f3e53c020">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctMi0xLTEtNDI5Njcx_0d2f32e3-fc44-419b-ac40-ed721b1df0c4">22,638</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctNC0xLTEtNDI5Njcx_53508527-59e5-4b04-b339-aa3c0a96b5ba">24,035</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="2" sign="-" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctNi0xLTEtNDI5Njcx_969bd27f-bd2b-4682-8491-0c72c9da699f">6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctOC0xLTEtNDI5Njcx_b77efff8-b498-4a62-badc-66fc8e5683e7">76,040</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctMTAtMS0xLTQyOTY3MQ_796ef32c-d175-43b7-a17d-f11dbc00f7a1">57,450</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctMTItMS0xLTQyOTY3MQ_94fa9a49-377f-4c61-92e3-9db822439054">32</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Other Revenue Information</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant wholesale customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K. Additionally, revenues from the U.S. government represented <ix:nonFraction unitRef="number" contextRef="i4e1858be123e4843836e844815b1712b_D20220704-20221002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzQ2MTA_d4b07dd8-1d17-4a96-ab53-2673a13564a9">38</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i54c033a90c144654982cec00e6120cd9_D20220101-20221002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzQ2MTc_a50f4b5c-6dbd-4597-a580-4c83bc373674">27</ix:nonFraction>% of total revenues for the three and nine months ended October&#160;2, 2022, respectively, and primarily represent sales of Paxlovid and Comirnaty. Accounts receivable from the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id815b21b66e840dfa213eb03a6f062f2" continuedAt="i670e14ffbcaf4175bc8a4ea45e8fe543"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government represented <ix:nonFraction unitRef="number" contextRef="i63858517ad514373922e2e8b09241570_D20220101-20221002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzQ3ODc_b413c1b4-649a-49c1-a9c8-1ce06267269e">44</ix:nonFraction>% of total trade accounts receivable as of October&#160;2, 2022, and primarily relate to sales of Paxlovid and Comirnaty.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><ix:nonNumeric contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODg_ca1ac006-c960-4885-9ddd-5b6f51688611" continuedAt="ib7bed5f7064e4ef3b6c5c449b4f4e160" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:27.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNC0xLTEtNDI5Njcx_48b764de-0dc5-44cb-9b4e-5f3ce7a6c4ae">22,638</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNi0xLTEtNDI5Njcx_7f6beebf-da84-4f02-b2bf-af18544731d0">24,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItOC0xLTEtNDI5Njcx_9cd29b34-d049-4128-be6e-e3926374efee">76,040</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItMTAtMS0xLTQyOTY3MQ_321a2ac2-0b2c-4ad4-a271-586a8acff56b">57,450</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd31dba911048de993662a30bd60e24_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa">22,319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba30fd6c8d04ca8bac5eceecaea0094_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d">23,513</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5974e3684a5d4959a373f6a880ead072_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708">75,066</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0aea8b98cb34108abfe4081d7793e2c_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7">56,101</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Primary Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefc4117e5afe4c0e842be69332f62eae_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtNC0xLTEtNDI5Njcx_37f02a43-6a49-470d-9091-290837891639">15,846</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e0a2c8196543638ffe58bb564300d7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtNi0xLTEtNDI5Njcx_b547755c-3987-4b5c-8413-89596118215c">16,680</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc3f7a9cee4ec19c29b091247d4bdb_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtOC0xLTEtNDI5Njcx_b141b5ab-79d8-469f-841b-6c7cd726fa7b">55,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9199195ad7641279516c969753b478c_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtMTAtMS0xLTQyOTY3MQ_3e553b05-a1ba-4c3c-ad41-f456e981fdb9">35,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Comirnaty direct sales and alliance revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38648544e7c43219d1df8126f6b9dc6_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNC0xLTEtNDI5Njcx_f54c2b3d-bcc0-4b2c-8ef0-3b3d36e9523a">4,402</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607941fb91174f77a6d963a5372b1b3a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNi0xLTEtNDI5Njcx_29ca35ef-f9cf-434c-8106-d7cfe2617f64">12,977</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida92047028cd4bed94eef70e5400c5bf_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtOC0xLTEtNDI5Njcx_e1a657ce-6f92-4b88-a040-01ced8e13634">26,477</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736289ab886a4191b2b2182031ea21a6_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtMTAtMS0xLTQyOTY3MQ_861ab00a-20e7-4f30-8db0-607aa59a0e6f">24,277</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Paxlovid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">COVID-19 infection (high risk population)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb736aee91454a25a6441df3dd80d5e0_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDUyOTM0_bc68f16b-7483-4b5a-aaf6-70503e707987">7,514</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if613572161c346fcac294c7e32c378a8_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDUyOTM0_9f655cca-4221-418e-ab2b-c370ae5a6721">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e054adec2e4bad8ec56ba5798ba8ae_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDUyOTM0_c7f3acf1-a29a-43bd-bef5-175427ec721e">17,099</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b47973e6ac40f7962fdc8d0adb611d_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQ1MjkzNA_3807a951-b83a-4092-8ebf-d3227b359a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf979907b2914655ac6e0a1a750fc363_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctNC0xLTEtNDUyOTQ4_ccdf22c7-8d25-4b70-a54c-e3769b69148a">1,464</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f53b0965de4c1fa8b977d9f6510ac0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctNi0xLTEtNDUyOTQ4_6fd2a6d8-36a3-452f-aaf5-ef9da17ef0fe">1,346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eae5a52dc634277ae8d307ccfb995d2_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctOC0xLTEtNDUyOTQ4_4f90e3ae-0051-45d0-a257-3466ac832162">5,001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55da2d7f85e40b58f460bad5984b81c_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctMTAtMS0xLTQ1Mjk0OA_5afb1774-e577-43b3-bac4-d6480d524841">4,470</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar family</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10d0e1d609e4e219fef4b97c4939891_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDI5Njcx_8e5f7ad6-da14-4ab6-a1fb-eeb35bf1b71d">1,607</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db8e7e6e5bd43f899b2d9e49d1a99f0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDI5Njcx_937c2db7-ab03-49fc-b286-d87052678df6">1,447</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421226bc57541e4a9ce23fe47d542e2_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDI5Njcx_8d93185f-f688-4c82-9b63-c777dc394dbb">4,601</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c319b3ee06435f8203948f53950fa4_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQyOTY3MQ_29765147-b42d-4233-b960-9afb141a29f6">3,971</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46cead4bca44470bb6e5485ad16d704d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktNC0xLTEtNDUyOTUy_20e8b3f9-b32a-40be-ae96-e2502910eafc">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i18f8c171007c41bbb0447b451c0d89d1_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktNi0xLTEtNDUyOTUy_d97d4fa0-c5df-4ee2-9da8-3780f7754542">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1e1da5edbd418b9ed52c7482de82cd_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktOC0xLTEtNDUyOTUy_ef8c09cc-a25b-4822-bade-2abcbf34f055">327</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e87bf34d54945c1bb8dffaa5340c8c2_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktMTAtMS0xLTQ1Mjk1Mg_fce296ac-8e06-4b06-8134-85340bc21347">420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9228a4392140c5aadff356ad41e232_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTQtMS0xLTQ2MDI4Nw_796fad55-461d-4153-ac8c-af13559f2b29">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ddb4a7f8df94efd865ffc529de4e9e0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTYtMS0xLTQ2MDI4Nw_53142ea6-217f-45df-8b0b-1dc777db64b1">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586dad3bf41b4478a6a7bf583b2bf621_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTgtMS0xLTQ2MDI4Nw_0736cd83-c375-4f16-aeea-0856dba30798">221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e4b745d89e249d491f381c3aaf895c5_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTEwLTEtMS00NjAyODc_4eb0be82-12f8-4186-858a-5927d521676a">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BMP2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef446f60f046bca0e069bd65549c9f_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTQtMS0xLTQ1Mjk1Mg_009e3072-65df-455e-a3b1-dbba10be92f6">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d914ca9794640ffa3ec5e10b6cee5f5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTYtMS0xLTQ1Mjk1Mg_a01e00ff-bfb9-4652-bb3d-e170e6420713">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i930a1f7cfa9d456bae7cb9c7c1e3e816_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTgtMS0xLTQ1Mjk1Mg_4087b9af-bbde-46da-8cc4-2cc42c559d55">201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2b8fafd05bb4f5db3a80e0c919d745d_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTEwLTEtMS00NTI5NTI_3b23170d-ea5b-4e4f-96cc-da8692e81032">186</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac2d287a23b4b88b22df7d728b108e5_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtNC0xLTEtNDI5Njcx_d8e6bd4f-bdcb-4692-a499-be6a425d6627">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b85277d9f04472693fc3c174486102f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtNi0xLTEtNDI5Njcx_500e6b87-550c-4c4d-8919-47e56f43512a">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffcfc2ea0698426aaf9c9ef575fd797b_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtOC0xLTEtNDI5Njcx_b312ff50-8fe7-4ade-9838-853d5e85652d">177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief03ef0a913a488da5d349f44b79df38_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtMTAtMS0xLTQyOTY3MQ_55a13553-5e71-40d8-b86f-0285795865d2">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ac32c435d7417a8258ad657ca4d5db_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQ1MjcxMA_c4e44753-2ab4-4cd8-bc83-5cf0dca74afc">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9e7601d2a949b391ea06de7ce817d2_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQ1MjcxMA_46dd39f4-1e8d-41b2-aa89-9047e3648f76">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847b7cc69e5c45d4b6eb6fdfa02ac9fd_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQ1MjcxMA_f1f12fd2-410b-4504-ae21-fb87a6ba1254">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78cb321690f41a9bb94aed3b1906a7a_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00NTI3MTA_92976070-81f6-49bd-a2a8-df3e2951418e">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trumenba</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal B disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4c063dba364bb6ba775ef1b933b60e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTQtMS0xLTQ2MDMwMw_d0506ac1-9a4e-423f-a34a-8a8dc7a4db36">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1192155b8f54c838c4960883dd5cd12_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTYtMS0xLTQ2MDMxMA_3719999d-99d9-4e13-9778-fac75ab4cbe5">52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219d3b8b6bdf41049720a23a2998280a_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTgtMS0xLTQ2MDM0Ng_71552dbb-ab8d-42a2-a252-80bac3d3ab0a">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8900fe5ad7d64b02bae061fd7863a809_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTEwLTEtMS00NjAzNDk_14f2a2ac-e72b-4f65-9e5f-b52cc7062b2c">102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f67297a35446ffbfeb15e1560ea010_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTQtMS0xLTQ1MjcxMA_a687475a-afcc-4c4a-a4c4-623be71726a1">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94e68a684f34fdeb284ae983ecf8590_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTYtMS0xLTQ1MjcxMA_5be11555-52c6-4684-9df2-5ae45e6dcd54">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997a8d6896fd403da5f90a6718f7b5c2_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTgtMS0xLTQ1MjcxMA_49b592ca-ee70-47fa-8939-dc05fda3f6f1">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c282565578941d5950ca8e622206e11_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTEwLTEtMS00NTI3MTA_aa119ad0-3214-419a-a76f-ef2bb5747d25">409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Primary Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3450d41f6f8c4add8f70e81bad35f8a1_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTQtMS0xLTQ1MzAxNg_119251be-738d-4657-bf99-fb76a7eb079b">451</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibeb3e653eb0046c7ac2807a447d5a81d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTYtMS0xLTQ1MzAxOQ_e5a5212f-43f0-4aec-957c-ab052d30dcc6">479</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife21a256301a4c639bb9b4d83799b744_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTgtMS0xLTQ1Mzk1Mw_67724121-cfe7-4b74-a9a7-4816200d51d8">1,326</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3564594ecfbb4ce7bddde0cfd454db19_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTEwLTEtMS00NTM5NTY_2dd0304d-e3a1-49b3-9ae7-67ae2c7d9869">1,490</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Specialty Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681fcc33174e41159cf96193a702c0dc_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTQtMS0xLTQ1MzQ3NA_f8d28d43-d231-47a0-a2b7-6f4fd4b4bb6d">3,404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f4ff79e8e54212839e35689b460762_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTYtMS0xLTQ1MzQ2Nw_1fc0d80a-6777-474d-8226-00c7f6c54362">3,749</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f46d7110d242bd9da8d5dc2c2f396b_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTgtMS0xLTQ1MjkyMg_0667af40-798e-4433-9439-d0dcc2414d67">10,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dceba1ae2e14264b25308d846b234a3_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTEwLTEtMS00NTI5MjI_76a2da2c-037a-4d0a-8825-37f0d47b6c73">11,205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-CM and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fead61708764dc986e38daecc3da97a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTQtMS0xLTQ2MDMyMQ_f297af21-497b-4ad1-b350-eeae8e649649">602</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cc960090f944473b1de0a5c83bdb9a9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTYtMS0xLTQ2MDMyMQ_3c04c606-9562-432a-8cf5-c336ab159942">501</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a2a488847c40d88bb4f5f52dec7967_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTgtMS0xLTQ2MDMyMQ_000c2567-80f4-420e-bb42-fdef61181f82">1,766</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e18531693d04b6a98fe0852c4c5025b_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTEwLTEtMS00NjAzMjE_5289035a-b162-4633-a983-5c67da881ac8">1,454</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0452040fe699493da4f37d561f3f548d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTQtMS0xLTQ1MjkyMg_1e474bfd-9568-4c6e-9f3c-7309a4f36826">502</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b42fa5a6cd411a8ce00a20130d39dc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTYtMS0xLTQ1MjkyMg_9e34fc9e-b86c-4ec7-835c-bc2775c5145d">610</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2892d1f59005440db65ec4752ff8a06f_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTgtMS0xLTQ1MjkyMg_130051b5-f738-439a-8369-4bbccce16585">1,304</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09231dfffc444767bb73115a01b1de18_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTEwLTEtMS00NTI5MjI_640cac5b-e5f1-40b9-9b96-c35f1c373c2b">1,734</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48fa456e8e4117a0324151697d5442_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTQtMS0xLTQ1MjkyMg_e701d70a-2223-4008-a3e1-d7e021f6a7c0">230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f936ba9ca84017b4b97358942bfc9e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTYtMS0xLTQ1MjkyMg_531d813c-7198-4952-9e22-23fa6a665671">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8e83a1b35f4cb0aa9adf9618682ad6_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTgtMS0xLTQ1MjkyMg_bb50b406-8beb-4cd2-bc18-331ee45a646e">767</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f393eca9894fb1887c099d45a0457c_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTEwLTEtMS00NTI5MjI_700517b0-3d00-47ec-92dd-34cf05320d70">888</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73121833f65a48dabeef6c4f70ffc8fe_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTQtMS0xLTQyOTY3MQ_cf96836c-b2f7-4990-aa82-dba488553522">178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e0cee382be47eaab3cef8255b4bbf3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTYtMS0xLTQyOTY3MQ_ae57bb9c-5f9b-4de2-921f-61d246736872">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb25ad491f0f4cd4868a150b3df14736_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTgtMS0xLTQyOTY3MQ_7e26ad38-fb1b-41c2-a748-c7f7c4434f9b">598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5874fba6c68e4599a0fc3fb5193f6357_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTEwLTEtMS00Mjk2NzE_2b0fd078-60bf-4a81-ae39-ece2eb8b1ca7">515</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed5fec2776a43d5b52002377b487e31_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTQtMS0xLTQ1MjkyMg_855e1b37-98ba-4d04-bec7-389b621fd106">131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5bcfbd37054eeb8cf0f03e878adeb1_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTYtMS0xLTQ1MjkyMg_a66eae42-7945-4cf9-b42b-92fc8879c80f">172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cad181f9d3a4c559ea98c3fe153c7e0_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTgtMS0xLTQ1MjkyMg_0152f499-7343-4b39-8e40-8e2d96c65a9e">403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabe9fee66024117bd6b35cc88a984d3_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTEwLTEtMS00NTI5MjI_56ea440e-6fcb-4a95-a863-a2b5baa789f7">485</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ig Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b5d2be8736491eb3d14bd80d72787c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQyOTY3MQ_ecc725f6-bf13-469b-8990-b9f59b18f062">124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb8d7d4ec27458b904b759251802162_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQyOTY3MQ_ffb545fb-dd46-48ab-b6ea-e15473bc3022">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528162cfdd864c2f9cfe732522d830b7_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQyOTY3MQ_567f37c7-d373-4a0f-8f15-d40650e2874b">356</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb1258143354aadafcf0cffc1e8922c_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00Mjk2NzE_d37a0d72-b1c1-4bb5-9324-bd5157a70838">311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb1973fbbf1e499b9274056be29d6f9c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTQtMS0xLTQ1MjkyMg_00633f91-22ef-47d2-8d4d-65f60f96c128">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a43c802a36b4c2db68c41cc136daf70_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTYtMS0xLTQ1MjkyMg_9b22f501-ffc7-4d29-9cb7-5e6885330260">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271e8b9e93e84bcfaa8c788053977b20_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTgtMS0xLTQ1MjkyMg_ac27d6de-b315-499e-afc4-c8a3f2945a8e">325</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20359a48688484fa197f302f7463767_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTEwLTEtMS00NTI5MjI_6203be47-e14f-4bbf-957c-91020bd88526">328</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4034cba9c5324ca795292cedaf88e6a4_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTQtMS0xLTQyOTY3MQ_f0af5a0d-c316-48eb-9654-ccd0acd461f7">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5554206f8a46328005d910c6b0e431_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTYtMS0xLTQyOTY3MQ_2322761f-ac29-418c-943f-ce44270b4b8e">107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427f057de3fd4215b2b63624f5c325a0_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTgtMS0xLTQyOTY3MQ_8e00abb8-de1e-49c9-9395-cdc113045a5a">302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee23be5e923547fab2329d5b56c61ed8_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTEwLTEtMS00Mjk2NzE_634fd517-b9c0-4148-b3f4-20d68d7d7c5c">306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6646c1fa39b14bd4a1f5e9affc1282cd_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTQtMS0xLTQ1MjkyMg_7d5f94fe-18f6-4bba-afe3-0e49383c8fb0">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab54fbd61cf24874aab5381668df8403_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTYtMS0xLTQ1MjkyMg_df799439-a880-4e6f-acb8-f35266a03c9a">95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c3e0cbcbcf4b03a734bd12c5194903_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTgtMS0xLTQ1MjkyMg_e09697ca-67e2-4f24-afbe-e7aee7da244b">261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec65066e53f40bfab7cdd1c00671818_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTEwLTEtMS00NTI5MjI_cf5f4043-a380-42f4-9d09-4b22cc0c8fb2">284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218a664fe1c4469bae3b80333f3e0cec_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTQtMS0xLTQyOTY3MQ_ac87910f-324d-4d6a-864b-ff4bb18ac46c">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b91d02d234645c793606aa29b0d901d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTYtMS0xLTQyOTY3MQ_ed5bb512-cb71-44f0-83e7-d8fb267700b4">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5d2ac36d9d4be0b0289526710db8fb_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTgtMS0xLTQyOTY3MQ_b745e02b-320a-434b-aa10-8ea22720197c">250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia969cc2c0ebf47d8816380e47bf220ed_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTEwLTEtMS00Mjk2NzE_71dd62aa-b432-4122-a521-0b95dbbdc0da">198</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42322074968a4077a5a1b52768045df2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTQtMS0xLTQyOTY3MQ_b667b300-2ed0-489f-a86e-71c0ea7ccb39">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f3be521f224b8fa223498877d51452_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTYtMS0xLTQyOTY3MQ_467f1f78-75bf-4922-b49b-c0abcccdd9cc">109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41086f4199fa4adf853900d30d476fc0_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTgtMS0xLTQyOTY3MQ_859c3496-0a33-4b9e-b37f-ba708955c2ef">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35c1201fcf34260b06f08c7d2dca0d9_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTEwLTEtMS00Mjk2NzE_38eb6e81-1daf-49ab-b36d-32fa37820857">320</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9f1313cc29448587a6446dbf0c3f3a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTQtMS0xLTQyOTY3MQ_d6b65384-b2ab-4c4f-83bd-5e71c8762b73">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e86ded88f3c4dc6812eb051724b5fbc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTYtMS0xLTQyOTY3MQ_35acb5a0-591c-4a41-859e-ded5896df6eb">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693bafa1895348fbb803b977431d462f_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTgtMS0xLTQyOTY3MQ_6a6fa30e-f48b-4076-99b2-9fa3cd37bd35">202</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91260f6cb4049409f21cbe3937ebc85_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTEwLTEtMS00Mjk2NzE_a3071e61-376f-4d6f-9b53-61a447cc989a">223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db6bbabd95c45ea956e59e8ea612ed0_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTQtMS0xLTQ1MjkyMg_3704713c-7f03-4b22-9b10-6f0fb688e1ff">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e33f7150c6471c938a45f53ef7a709_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTYtMS0xLTQ1MjkyMg_7e63ed46-04f6-46e1-bb0d-defabfd0ec17">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7fb1f835ee48e7963f5d0bb55330f0_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTgtMS0xLTQ1MjkyMg_3710cc97-4b50-434b-9df7-533c14d9d271">202</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ab61c3fcb34e45a64f5455f6442ef3_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTEwLTEtMS00NTI5MjI_598a0f8e-3f35-4db2-9658-87a96c131b28">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia102ac741b5e451aa63ffe982d59beac_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTQtMS0xLTQ1MjkyMg_836b9b01-016e-4586-850a-be50a906390b">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae5f3828ae041d8bde249471bd9e321_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTYtMS0xLTQ1MjkyMg_11bd627d-cb87-4497-a92f-22682623b1e4">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeace31d957b42c2a7709f9948bc9709_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTgtMS0xLTQ1MjkyMg_6d492ff3-42e1-40e0-970a-65a516337814">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878d1447a4ca4813b621dc3cc89befa2_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTEwLTEtMS00NTI5MjI_6400ce09-e210-40e5-8ff0-865c1d18bd7c">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if602f21734f7495d8b816aa6bcd6498c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTQtMS0xLTQyOTY3MQ_86f16393-ee14-4edb-a2fd-4040d61ecce1">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e66fa2a70a4649a96bfd9b2e39b902_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTYtMS0xLTQyOTY3MQ_feca20da-8207-4601-882c-47ccaff9089d">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28dbbb6bb0e41d5a7fee7ddf2c97859_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTgtMS0xLTQyOTY3MQ_a7fd504b-79d5-49ad-ab86-a078c622a264">171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37857266a0444b1a85059b213ce1320c_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTEwLTEtMS00Mjk2NzE_6af55cf0-27b4-495d-9ab9-aa95299e2e88">204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3b9a9454c04c2a91c44f60a9080c13_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTQtMS0xLTQyOTY3MQ_809419bd-66a9-4340-a5a8-4139d856d78c">374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id633b0178823447f98f4fb90652a4b43_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTYtMS0xLTQyOTY3MQ_d00fda7b-3738-463c-b317-5e2250a9c103">455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib646354746ad4597828f14cf71b869f0_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTgtMS0xLTQyOTY3MQ_ee36e43b-eb84-4c67-aeb6-0429a2405317">1,123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i801deeefe2ab4c79a8fc02da44868706_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTEwLTEtMS00Mjk2NzE_e480ddd4-2567-4129-9015-e21bbeb34e0c">1,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Specialty Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62e7abf3e4d48e080bf9026efbb11a2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTQtMS0xLTQyOTY3MQ_75250629-0f6c-43da-afe2-578128b8a945">586</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i004d3ce3105a4fed95460eec415470e3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTYtMS0xLTQyOTY3MQ_f99aa18b-996b-483e-a742-9cd4821d80a3">702</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11eb45e9cf444c2aaec2c6742022efdb_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTgtMS0xLTQyOTY3MQ_97b1c19e-8f6f-42b9-9949-871a8391b689">1,816</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b25b150fb1c45e9a0380f915623fdb2_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTEwLTEtMS00Mjk2NzE_5648a6a2-96fc-492a-88a7-8aed239adfea">2,134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80b331462b2491d9db4424b5e8bd924_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTQtMS0xLTQyOTY3MQ_5dac27cf-d2c3-4e5f-bbd8-aff8a577e35b">3,070</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6692eee652446979a0b8ecce8cf90bc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTYtMS0xLTQyOTY3MQ_1c5f8348-0b6e-4a4c-9e7c-ba23876dc35d">3,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da74bd9833e4cd6a768fed715ba4cb1_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTgtMS0xLTQyOTY3MQ_2a996689-f73d-4f76-a31c-2600334929f3">9,124</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id176e11c7c904d469cd2382368b11d61_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTEwLTEtMS00Mjk2NzE_da245fa7-a139-4197-afb3-a036392d63ee">9,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0836f20c7ba46df8c7fb318c2836678_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTQtMS0xLTQyOTY3MQ_de3d066f-34fb-497b-9090-f739bfa460c6">1,283</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a2ad9788911406e9443bb89ba74f344_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTYtMS0xLTQyOTY3MQ_726199c9-852b-4a94-9ec2-a896940d8d3a">1,381</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea562808de51468f86c413b0feafe114_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTgtMS0xLTQyOTY3MQ_c22289e5-29e3-451c-ad2b-a88ee376bf16">3,841</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e5c192f1f459782b9e4ea90048122_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTEwLTEtMS00Mjk2NzE_e8d7e6e9-6982-4abf-b74e-a207d08b1da4">4,039</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a004a95111a4f2db0d2669d2f610693_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTQtMS0xLTQyOTY3MQ_01cc96bb-2b8d-44bd-8d6e-cdd8c5245e91">320</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f100f20573b432288b09f6b64c4671e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTYtMS0xLTQyOTY3MQ_8016b052-15c7-4fdb-9daa-f54d5f9081d9">309</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa66a51bca84785ad4c259d04a22cfd_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTgtMS0xLTQyOTY3MQ_1c422d6f-bbb8-432a-bac5-7d3c5eec3206">878</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d54941efa2941f699fe6aa44f0a4954_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTEwLTEtMS00Mjk2NzE_ea3b1167-6aef-4f18-bf79-2b0a0cfc4e3d">879</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ee738588b245b38e912a7df8a75d04_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTQtMS0xLTQyOTY3MQ_58277efe-6f64-495c-b3bc-4a0413dc70ea">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76089b0f719c43e08c7f98682f02aa83_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTYtMS0xLTQyOTY3MQ_9cb42d98-bb65-4b8f-9761-04ebd00ddd97">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e3fef4910241e5bcb815efea4ec15c_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTgtMS0xLTQyOTY3MQ_b0321bca-d661-412d-9f5b-64afe5c2939f">760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f57ceefda7c437a8b98c4564c51b6f7_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTEwLTEtMS00Mjk2NzE_c1d66aef-d476-436a-91e2-c3e75f759495">742</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69e9f4ce5be4a61997e3ab67969be34_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTQtMS0xLTQyOTY3MQ_b56b484b-d8a6-49ea-ae18-af0fd9f6f66b">146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf753ff3c5554491887de93db1fe560b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTYtMS0xLTQyOTY3MQ_64ae03a9-213c-4d19-9702-8d7518b2845e">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdcaea6d26ee46e0bafa9e9f9da6496d_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTgtMS0xLTQyOTY3MQ_9e3df96b-8f75-442e-8ce8-f472192bff4e">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0acf4ae0c84031a293157923acb753_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTEwLTEtMS00Mjk2NzE_4a4f69ae-e862-4bf5-8dcb-bb35578da842">311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b1ca93f57b4e6ba57c282fa30f3976_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTQtMS0xLTQyOTY3MQ_2edbfe61-6863-4266-94ee-2bb0b16321f4">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357d700ae87d4d468163149932549cc6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTYtMS0xLTQyOTY3MQ_f9c2fceb-8209-426c-aacc-a48586492301">136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2de171ee654cf8884e29fdc4318a0d_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTgtMS0xLTQyOTY3MQ_e3e0519f-971d-4517-808e-9e2df9332033">425</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ceb413b1694f46ae29ffadc6262050_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTEwLTEtMS00Mjk2NzE_33df66f7-f21b-457f-8f13-8e8fff682ca8">395</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bc27120a7c4359a1cd74322bb22c5b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTQtMS0xLTQyOTY3MQ_4babf345-26dc-4e1c-9491-4e7b12526201">118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7f810aa79a45b0bb5466e60f929931_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTYtMS0xLTQyOTY3MQ_b716445a-f00b-4d6c-b493-f86b9c554250">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4093973df5c94ed990eeaa9c48d107c5_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTgtMS0xLTQyOTY3MQ_3b600387-b514-471e-b379-20b31de0170f">362</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56622c1212fe46f68f7c8455f4d2a523_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTEwLTEtMS00Mjk2NzE_e4382516-eaf0-43ab-b099-38e3c1ad1287">371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d1bf41d84d4d41a0c1deb806b16620_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTQtMS0xLTQyOTY3MQ_41bc263a-5dbf-4745-808a-d5946349d112">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900010cf3afc449c8b72dce7cc16fe0d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTYtMS0xLTQyOTY3MQ_f9849a5d-a670-459c-805a-c54f0ec480c7">124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71bf78dbc98843239656272f490339bc_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTgtMS0xLTQyOTY3MQ_f85f3218-5961-486f-9c4d-d3cb367a1cd4">357</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de406d2bea4496db2a3b0790f7858dc_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTEwLTEtMS00Mjk2NzE_ba83cd7b-c224-4ec9-ab3f-8cde534ae9db">343</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i670e14ffbcaf4175bc8a4ea45e8fe543"><ix:continuation id="ib7bed5f7064e4ef3b6c5c449b4f4e160"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:27.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61ec39f8eec4e90a85dfdf93b4b8e60_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTQtMS0xLTQyOTY3MQ_ab863e52-8501-499a-9e0f-faccd460c32a">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83462764e3144e25ad4064bdf364bb72_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTYtMS0xLTQyOTY3MQ_a813dec7-cdc8-4830-96c8-0bcb55433c7c">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09ed1dfe1fc44eba41758c7b72b1220_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTgtMS0xLTQyOTY3MQ_96d2174e-ca28-486e-933f-6a77ae624827">308</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f066e1ee0b44eba6238a376debfc1d_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTEwLTEtMS00Mjk2NzE_7f99140d-86a2-4833-a49e-43a51fdbe79f">322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b3896ecd1f4b91b83726ec4b21f326_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTQtMS0xLTQyOTY3MQ_b33e0605-97ea-4944-a764-1874082e03c2">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15ad6f996594166971b1dbb8262b0ea_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTYtMS0xLTQyOTY3MQ_124c0ad5-969a-42f1-b173-8a15a691a5a8">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b7b3fe6f55498d913853d8a9489481_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTgtMS0xLTQyOTY3MQ_94e63db4-d47d-4f71-be23-9003289660f7">287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69fbc0b4b93c4abe94a8ee2dcd69e98e_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTEwLTEtMS00Mjk2NzE_2f6f8fa3-46bd-4a5b-bc1c-a5aec6e3a4b0">537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70124bbf39724876b8acf2c4bfeca836_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTQtMS0xLTQyOTY3MQ_32bff46a-3394-43f0-b632-d7e231087d70">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206d32a63e3f4cfd8f6c8d75168367bd_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTYtMS0xLTQyOTY3MQ_bc7e95d1-6042-48d3-bff6-7eabf3ecdd80">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87e55493f364c369dc8ad1d40cbd422_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTgtMS0xLTQyOTY3MQ_043a7cef-17b8-4226-8def-9946650053dc">247</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27f8e680678446f86545701da276329_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTEwLTEtMS00Mjk2NzE_94a5930a-48dc-4256-8834-6a0c9cc6996b">193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbeed7d4fbf439a9819aa469673b46b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTQtMS0xLTQyOTY3MQ_96fd6808-eedb-4e15-98fa-e22e737f9861">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b58aba96014c749e5dd13a48805369_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTYtMS0xLTQyOTY3MQ_482b969b-aa00-4b96-b5ce-c2f07f3deda6">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3dfcdc4c8a44a08bb30d6681bb333e_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTgtMS0xLTQyOTY3MQ_d080a82d-20f7-4398-ae2a-7cbd4e40d1c1">198</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43bf4a89a5f40c9abaea813b2440c31_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTEwLTEtMS00Mjk2NzE_3bd9b08d-dd71-4545-be9e-557c2ca97d3a">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eda3444dc5f41b4bba147d8d43c862e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTQtMS0xLTQyOTY3MQ_41a881fc-89e0-450a-a43f-f29560856e93">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c61ae6ba8c4e6ba44617ed0e6e6331_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTYtMS0xLTQyOTY3MQ_d646105c-ee46-4a4a-b986-9afd51a396b4">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809d717936604b26a18012f7b8b9e2cc_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTgtMS0xLTQyOTY3MQ_152dddc1-3cc7-47e5-9bf8-5612a509affb">187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic160791460df43c18efb41f047eb99f2_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTEwLTEtMS00Mjk2NzE_b35bb675-42f4-4723-b5fa-58cc60d62517">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e39688a3c748cbb50e3f3fbd49323d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTQtMS0xLTQyOTY3MQ_6f96ab9c-e45d-4624-997a-db62c02d4a6a">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2b596d2f9944daa642c722ddb35c58_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTYtMS0xLTQyOTY3MQ_16f60dd8-e347-4b43-a27a-4c492c7d7656">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id911b17700454881be23254e2132425f_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTgtMS0xLTQyOTY3MQ_07ca6d6d-64e9-4c9f-8d2d-0342d4a557ca">164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c47732986f4e1cb33d655f70e90bda_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTEwLTEtMS00Mjk2NzE_fbe10f47-a51d-4a04-b176-198f2dba0e70">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">, for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> -mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e972355f674b2c8872f2e11d8a753f_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTQtMS0xLTQyOTY3MQ_0c8722b8-2872-4bf9-b21e-e3d503546382">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472823d53ca4530ba656db6b08aacbe_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTYtMS0xLTQyOTY3MQ_945cea22-a4ed-4fcc-a514-2cd8d824094b">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4401e5c37dd1444192245cd5facba3fb_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTgtMS0xLTQyOTY3MQ_f6b12f8a-bcea-47d3-9125-6393606efd3c">156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027f314cb29d4db7820ad2436483ee1d_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTEwLTEtMS00Mjk2NzE_1b1bd2f4-3d49-406d-a698-4ea9fc91acac">136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trazimera</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HER-positive breast cancer and metastatic stomach cancers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace4e825c4024bd7baccc5a0fc1b6426_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTQtMS0xLTQyOTY3MQ_b0fec7eb-584a-411a-9d3d-91d234e49282">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39b763d5ca341f5afd21c2f801ad63d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTYtMS0xLTQyOTY3MQ_28dcc386-72b0-48f4-bc41-3d42f0d9f0a2">45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531e99cb29294ab58cbd26ac7ff982c6_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTgtMS0xLTQyOTY3MQ_3e3975ed-0207-48bd-8faa-2b8487d349ad">149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18af7be85824b4aace60f7124ab2108_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTEwLTEtMS00Mjk2NzE_fc5a7693-47a4-43fe-8379-7f5212c09a40">131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992624b40ab1462a957959426582393d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTQtMS0xLTQyOTY3MQ_a6c4c5c1-09ba-4592-bc80-acee0aabd3a2">45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5155b8e6532848ec99ad1757626c1d0a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTYtMS0xLTQyOTY3MQ_a283efad-7a13-4c8b-b9cd-0f806c4c374a">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i622fdfe2355249ccbc9c305380b6be81_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTgtMS0xLTQyOTY3MQ_f991b78e-2644-46f8-b9f1-516800e6c84b">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4503374f47504e53a8a556f65267f8dd_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTEwLTEtMS00Mjk2NzE_f929b528-7dea-43a9-b226-26a2d374a3d2">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d0c096b86f4eaba702765dd3329741_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTQtMS0xLTQyOTY3MQ_5ed430f0-e0b1-4076-ac6b-07766f8c941e">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i92617f0978cb4c60a86dd7c4cabc5122_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTYtMS0xLTQyOTY3MQ_da6270a0-9816-4820-a6e3-1274826ae1f3">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ebe86d55ea4421c89f72c68a2c75f59_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTgtMS0xLTQyOTY3MQ_aebf3a87-4f6b-47b8-b0c9-3211279fdb87">243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc10872084e8447ab3832bbc01a6c62f_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTEwLTEtMS00Mjk2NzE_229bd941-93db-4b46-9915-f14f30211086">155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7feed05291314be8ab413820d9581a34_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTQtMS0xLTQyOTY3MQ_fbd1b23a-4de5-4731-90bf-a49e2f6a8698">319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34e46c91a314553b59159136459f579_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTYtMS0xLTQyOTY3MQ_668cc3dd-3341-4358-a350-cbf225cdbb2c">521</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b801e727bf47de83a1422fd1a40ba7_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTgtMS0xLTQyOTY3MQ_a17914fb-258b-418b-a9ca-4563cd5cfc48">974</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb622ed9f6534687aa3bf61cf0d3f889_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTEwLTEtMS00Mjk2NzE_79069066-5ead-4735-9ca9-a0c728f6a653">1,348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Alliance revenues included above</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a658246e2b34fd6a44cebc005385303_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTQtMS0xLTQyOTY3MQ_aa74b27b-e029-43be-91c4-6fb72d18cea4">1,689</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a9464430b1419fba05017b8bd79cf5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTYtMS0xLTQyOTY3MQ_fc2bc24b-83b8-432b-b22f-3642aadca53b">2,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde011cdb7ec481f92dc1a4d3d485ee1_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTgtMS0xLTQyOTY3MQ_6f4867db-9cd0-4a81-b155-dce5f254dc89">6,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica70d473e5c64734bc680a816c324426_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTEwLTEtMS00Mjk2NzE_5635311a-555b-422b-8098-c661e7c6770e">5,718</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($<ix:nonFraction unitRef="usd" contextRef="i7336380d9d6f4a4495fae7cd4004e307_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU1Njc_f2b0c3ef-8a69-4aed-bb0c-4790df02f01e">7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4ef9df7820e54c5ebe5b2bbcfce634fb_D20220101-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU1NzQ_9179279d-daba-436f-a071-8611cfcdeb00">108</ix:nonFraction>&#160;million for the third quarter and the first nine months of 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i111ea6956a0241f7b44852b8f11b8f68_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc0NTEzOTQ_f61e56ef-771a-4b71-ac7d-a6324f8d92dc">187</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2f1dfd6335a24eddb48dd65039a27f6d_D20210101-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU2MTc_1d99a33d-b25a-4941-8958-b2ae498b727e">274</ix:nonFraction>&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed" footnoteRole="http://www.xbrl.org/2003/role/footnote">Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc" footnoteRole="http://www.xbrl.org/2003/role/footnote">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult). </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Immunoglobulin (Ig) portfolio includes the revenues from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Panzyga, Octagam and Cutaquig.</span></ix:footnote></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC.</span></ix:footnote></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzY5Mjc_ab3fb277-1d9b-427f-ad70-63b76588b547">22</ix:nonFraction>&#160;billion as of October&#160;2, 2022, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of this amount, we expect to recognize revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i22e6b4b0386445c2b216f9309b164440_I20221002" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzcxNjc_e6f95e6d-34a9-405a-ba05-04173b206f79">9</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="id8bf1cff4bcf46a8a95e2b2f3561e4d8_I20221002" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzcxNzk_88733067-7c93-4016-b36a-61bd8b7c5e58">13</ix:nonFraction> billion in 2023 and $<ix:nonFraction unitRef="usd" contextRef="i26e1cf1555744ef5a90bad26608bf34f_I20221002" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzcxOTQ_6b1c4730-beac-4cb6-a44e-131c8fa4c054">200</ix:nonFraction> million in 2024. Remaining performance obligations are based on foreign exchange rates as of the end of the third quarter of 2022 and exclude arrangements with an original expected contract duration of less than one year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers in international markets for supply of Comirnaty and Paxlovid. The deferred revenues related to Comirnaty and Paxlovid total $<ix:nonFraction unitRef="usd" contextRef="i5156002b7783431eaae2362428a7dad3_I20221002" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2MTI_6a998a2c-408d-4e74-8870-95ac221abf77">6.2</ix:nonFraction> billion as of October&#160;2, 2022, with $<ix:nonFraction unitRef="usd" contextRef="i5156002b7783431eaae2362428a7dad3_I20221002" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2MzA_4dd003b3-1878-4e38-ad20-f9bc55e6d5c1">6.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i5156002b7783431eaae2362428a7dad3_I20221002" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2Mzc_36f2b42e-829e-4fd5-a10a-5cb2810614eb">126</ix:nonFraction> million recorded in current and noncurrent liabilities, respectively. The deferred revenues related to Comirnaty total $<ix:nonFraction unitRef="usd" contextRef="ia747d02316fd4b71a97be55a1aeac96c_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc3NTE_bad2e8c8-fc71-4257-af02-be06d4a29795">3.3</ix:nonFraction> billion as of December 31, 2021, with $<ix:nonFraction unitRef="usd" contextRef="ia747d02316fd4b71a97be55a1aeac96c_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc3ODQ_c56e9b60-3b10-469a-8fe7-7ec086fc4f41">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia747d02316fd4b71a97be55a1aeac96c_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc3OTE_d22feb7f-dd14-49a3-a7d1-280eb5676aa4">249</ix:nonFraction> million recorded in current liabilities and noncurrent liabilities, respectively. There were <ix:nonFraction unitRef="usd" contextRef="i2ec84b4e39aa4cbfa3468dab7b9c69a5_I20211231" decimals="INF" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc4Nzk_0443e8a0-2424-47c0-93e8-09dbf7afb399">no</ix:nonFraction> deferred revenues associated with Paxlovid as of December 31, 2021. The increase in Comirnaty and Paxlovid deferred revenues during the first nine months of 2022 was primarily the result of additional advance payments received as we entered into new or amended contracts, including new advance payments received for Paxlovid contracts, less amounts recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as we delivered the products to our customers and the impact of foreign exchange. During the third quarter and first nine months of 2022, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i134056e8daf84277a6603491cf1250cf_D20220704-20221002" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc0NTEyMjE_d74cbde5-6a71-492b-b3a0-df0e013e761e">68</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0f817b3f9c904714845e29d3b0c9c8f6_D20220101-20221002" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzgzNTQ_10e60b03-493b-4545-ad83-98d506981fcd">2.5</ix:nonFraction> billion, respectively, that was included in the balance of Comirnaty deferred revenues as of December 31, 2021. The Comirnaty and Paxlovid deferred revenues as of October&#160;2, 2022 will be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proportionately as we transfer control of the products to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the last three months of 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of October&#160;2, 2022 or December 31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF<br/> OPERATIONS</span></div><div id="i8c2530a91ced4c48b9620128206808f1_115"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and since they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business and Strategy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Beginning in the fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a global structure consisting of two operating segments: Biopharma and PC1. Beginning in the third quarter of 2022, we made several additional</span><span style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizational changes to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches. Biopharma is the only reportable segment. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 85% has been incurred since inception and through the third quarter of 2022. These charges include costs and expenses related to separation of legal entities and transaction costs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our business, strategy and operating environment, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2021 Form 10-K.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Development Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. Our significant recent business development activities include the transactions discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the following:</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Global Blood Therapeutics, Inc. (GBT)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, for $68.50 per share, in cash, for payments of approximately $5.3 billion, net of cash acquired, plus repayment of third-party debt of $331 million.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Biohaven</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT (rimegepant), an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. The transaction includes the acquisition of Biohaven&#8217;s CGRP programs, including rimegepant, zavegepant and a portfolio of five pre-clinical CGRP assets. Under the terms of the agreement, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5 billion, plus repayment of third-party debt of $863 million and redemption of Biohaven&#8217;s redeemable preferred stock for $495 million. Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.&#8217;s shares to Biohaven shareholders. Biohaven Ltd. is a new publicly traded company that retained Biohaven&#8217;s non-CGRP development stage pipeline compounds. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.&#8217;s shares in the distribution and currently owns approximately 1.5% of Biohaven Ltd.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This acquisition follows on the November 2021 collaboration for the commercialization of rimegepant and zavegepant outside the U.S., in connection with which Pfizer acquired 2.6% of Biohaven&#8217;s common stock (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Biohaven Ltd. will also have the right to receive tiered royalties from Pfizer on any annual net sales of rimegepant and zavegepant in the U.S. in excess of $5.25 billion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the more significant recent transactions through February&#160;24, 2022, the filing date of our 2021 Form 10-K, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Third Quarter 2022 and First Nine Months of 2022 Performance</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased $1.4 billion, or 6%, in the third quarter of 2022 to $22.6 billion from $24.0 billion in the third quarter of 2021, reflecting an operational decrease of $441 million, or 2%, as well as an unfavorable impact of foreign exchange of $957 million, or 4%. The operational decrease was primarily driven by a decline in Comirnaty, partially offset by growth from Paxlovid. Revenues increased $18.6 billion, or 32%, in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the first nine months of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 to $76.0 billion from $57.4 billion in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the first nine months of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021, reflecting an operational increase of $21.6 billion, or 38%, as well as an unfavorable impact of foreign exchange of $3.0 billion, or 5%. The operational increase was primarily driven by growth from Paxlovid and Comirnaty. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of Paxlovid and Comirnaty, revenues increased 2% operationally in both the third quarter and first nine months of 2022, reflecting strong growth in Eliquis, the Prevnar family and Vyndaqel/Vyndamax, partially offset by declines in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xeljanz, Sutent and certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. Revenues in the first nine months of 2022 were also negatively impacted by declines in Chantix/Champix.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geography</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections for more information, including a discussion of key drivers of our revenue performance. For information regarding the primary indications or class of certain products, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13C.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $1.2&#160;billion in the third quarter of 2022, compared to the same period in 2021, was primarily attributable to decreases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by: (i) lower revenues; (ii) lower net periodic benefit credits associated with pension and other postretirement plans; (iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net losses on equity securities in the third quarter of 2022 versus net gains on equity securities in the third quarter of 2021 and (iv) an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $9.0 billion in the first nine months of 2022, compared to the same period in 2021, was primarily attributable to higher revenues, partially offset by: (i) an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net losses on equity securities in the first nine months of 2022 versus net gains on equity securities in the first nine months of 2021; (iii) lower net periodic benefit credits associated with pension and other postretirement plans and (iv) increases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our tax provision and effective tax rate, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision/(Benefit) for Taxes on Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Operating Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below, as well as in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Government Regulation and Price Constraints </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Operating Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our 2021 Form 10-K.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights and Collaboration/Licensing Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from 2022 through 2025. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on patent rights we consider most significant in relation to our business as a whole, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K. For a discussion of recent developments with respect to patent litigation, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A1.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment/Pricing and Access&#8211;&#8211;Government and Other Payer Group Pressures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Governments globally, as well as private third-party payers in the U.S., may use a variety of measures to control costs, including, among others, proposing pricing reform or legislation, employing formularies to control costs, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement. We anticipate that these and similar initiatives will continue to increase pricing and access pressures globally. In the U.S., in August 2022, President Biden signed into law the IRA, which includes significant drug pricing provisions, including (i) inflation rebates, where drug manufacturers must pay a rebate to the government if the prices of their covered single-source drugs and biologics rise faster than the rate of inflation; (ii) Medicare Part D redesign whereby beneficiaries&#8217; out-of-pocket costs are capped, payment obligation for initial coverage is redistributed with drug manufacturers paying 10% on all drugs and the coverage gap is eliminated, as well as requiring Part D plans to pay a larger portion of the catastrophic phase with drug manufacturers covering 20% of the costs; and (iii) Medicare negotiation, which requires the Secretary of the U.S. Department of Health and Human Services (HHS) to negotiate prices for certain drugs covered by Medicare Part B and Part D through a Drug Price Negotiation Program. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. In addition, in October 2022, President Biden signed an executive order that instructs the Secretary of HHS to consider whether to select for testing new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs. Also in the U.S., we implemented a policy in 2022 that will help improve contract pharmacy integrity. HHS has sent letters to numerous manufacturers that have also implemented contract pharmacy integrity initiatives expressing the view that their programs are in violation of the 340B statute, and referring those programs for potential enforcement action. We believe that our program is consistent with the statute. Additional legal or legislative developments with respect to the 340B program may have an adverse impact on our integrity initiative, and we may face enforcement action or penalties, depending upon such developments. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Pressures and Managed Care Organizations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and &#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8211;&#8211;Pricing and Reimbursement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections in our 2021 Form 10-K and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Operating Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the MD&amp;A in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Supply</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;We periodically encounter supply delays, disruptions and shortages, including due to voluntary product recalls. In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential presence or formation of nitrosamines. This has led to recalls, including our voluntary recall of Chantix in 2021 and additional voluntary recalls initiated for other products in 2022 due to the presence of nitrosamines above the applicable acceptable intake limit, and may lead to additional recalls or other market actions for Pfizer products. For information on our Chantix recall in 2021 and risks related to product manufacturing, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8211;&#8211;Product Manufacturing, Sales and Marketing Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Global Economic Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to economic cycles. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2021 Form 10-K.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Russia/Ukraine Conflict</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Our global operations may be impacted by certain factors in the global economic environment including impacts of political or civil unrest or military action, including the armed conflict between Russia and Ukraine. Consistent with our commitment to putting patients first, we are maintaining the supply of medicines to Russia, including the provision of needed medicines to patients already enrolled in clinical trials. Effective March 14, 2022, Pfizer is donating the equivalent of profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine, in addition to our ongoing efforts to support the humanitarian response in the region. To date, we have donated $20 million to 10 global and local non-governmental organizations to support humanitarian relief and response efforts. We will continue to support Ukrainian relief efforts through this method until peace is achieved. Additionally, we are not initiating new clinical trials in Russia, have stopped recruiting new patients in our ongoing clinical trials in the country, and halted all new investments with local suppliers intended to build manufacturing capacity in Russia. For both the nine months ended October 2, 2022 and the fiscal year ended December 31, 2021, the business of our Russia and Ukraine subsidiaries represented less than 1% of our consolidated revenues and assets, and while we are monitoring the effects of the armed conflict between Russia and Ukraine, the situation continues to evolve and the long-term implications, including the broader economic consequences of the conflict, are difficult to predict at this time. While as of now, we do not anticipate any significant negative impacts on our business from this conflict, continued regional instability, geopolitical shifts, potential additional sanctions and other restrictive measures against Russia, neighboring countries or allies of Russia, any retaliatory measures taken by Russia, neighboring countries or allies of Russia, and actions by our customers or suppliers in response to such measures could adversely affect the global macroeconomic environment, our operations, currency exchange rates and financial markets, which could in turn adversely impact our business and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;The COVID-19 pandemic has impacted our business, operations and financial condition and results. </span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Response to COVID-19</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is continuing to help lead the global effort to confront the COVID-19 pandemic by advancing a vision for industry-wide collaboration while continuing to make significant investments in breakthrough science and global manufacturing.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Comirnaty</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">We have collaborated with BioNTech to jointly develop Comirnaty, a mRNA-based coronavirus vaccine to help prevent COVID-19. For additional information, including information regarding EUAs for a booster dose of an Omicron-adapted bivalent vaccine for individuals ages 5 years and older, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Developments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A. We continue to evaluate our vaccine and the short- and long-term safety and efficacy of Comirnaty. We are also studying monovalent, bivalent and variant-adapted vaccine candidates to potentially help prevent COVID-19 caused by variants of concern, as well as a next-generation mRNA vaccine candidate.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">The companies have entered into agreements to supply pre-specified doses of Comirnaty in 2022 with multiple developed and emerging countries around the world and are continuing to deliver doses of Comirnaty to governments under such agreements. We also signed agreements with multiple countries to supply Comirnaty doses in 2023 and are currently negotiating similar potential agreements with multiple countries as well. Additionally, we will continue our efforts to help </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ensure equitable access to Comirnaty and anticipate delivering at least two billion doses to low- and middle-income countries&#8212;one billion of which were delivered in 2021 and approximately 600 million of which were delivered in the first nine months of 2022. Certain of the aforementioned doses to low- and middle-income countries are being supplied to the U.S. government at a not-for-profit price to be donated to the world&#8217;s poorest nations.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">While to date sales of Comirnaty in the U.S. have been to the government, we expect in 2023, sales of Comirnaty in the U.S. will transition to commercial market sales only as we anticipate the expiration of current contracts and depletion of the vaccines purchased through them. Internationally, we expect sales of Comirnaty in international developed markets to generally be under government contracts in 2023, and in emerging markets, under a combination of private channels and government contracts; in both cases, we expect to generally transition to commercial markets in 2024.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.59pt">As of November 1, 2022, we forecasted approximately $34&#160;billion of revenues for Comirnaty in 2022, with gross profit to be split evenly with BioNTech, which includes doses expected to be delivered in fiscal 2022, primarily under contracts signed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of mid-October 2022.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Paxlovid</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">In December 2021, the FDA authorized the emergency use of Paxlovid, a novel oral COVID-19 treatment, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid has been granted an authorization or approval in many other countries. In June 2022, we submitted an NDA to the FDA for approval of Paxlovid for the treatment of COVID-19 in both vaccinated and unvaccinated individuals who are at high risk for progression to severe illness from COVID-19 consistent with the current EUA. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Developments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">We continue to evaluate Paxlovid in other populations, including in non-hospitalized, symptomatic, pediatric patients with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease (Phase 2/3 study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients)) and those who are immunocompromised, hospitalized with severe COVID-19 and at increased risk for poor outcomes due to the disease (Phase 2, EPIC-Hos (Evaluation of Protease Inhibition for COVID-19 in Hospitalized Patients)). We are also studying Paxlovid in those who are pregnant.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">We have entered into agreements to supply pre-specified courses of Paxlovid to multiple countries, such as the U.S. and U.K., as well as agreements with UNICEF and the Global Fund to supply low- and middle-income countries. Through the nine months of 2022, we have shipped 31 million treatment courses globally, and we have capacity to meet the demand for Paxlovid in a flexible manner going forward.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.46pt">As of November 1, 2022, we forecasted approximately $22&#160;billion of revenues for Paxlovid in 2022, which includes treatment courses expected to be delivered in fiscal 2022, primarily relating to supply contracts signed or committed as of mid-October 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of COVID-19 on Our Business and Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our on-going monitoring and assessment, we have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration, severity and the global macroeconomic impact of the pandemic, as well as COVID-19 vaccine and oral COVID-19 treatment revenues, supply and contracts, which remain dynamic. Despite careful tracking and planning, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. We are focused on all aspects of our business and are implementing measures aimed at mitigating issues where possible, including by using digital technology to assist in operations for our commercial, manufacturing, R&amp;D and corporate enabling functions globally.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in our 2021 Form 10-K, in addition to our introduction of Comirnaty and Paxlovid, our business and operations were impacted by the pandemic in various ways; certain of those impacts have continued in 2022. For additional detail and discussion on the impact of the COVID-19 pandemic on certain of our products, sales and marketing, supply chain and clinical trials, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income&#8212;Revenues by Geography </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenues&#8212;Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections within MD&amp;A and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;COVID-19 Pandemic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections of the MD&amp;A of our 2021 Form 10-K. </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to pursue efforts to maintain the continuity of our operations while monitoring for new developments related to the pandemic. Future developments could result in additional favorable or unfavorable impacts on our business, operations or financial condition and results. If we experience significant disruption in our manufacturing or supply chains or significant disruptions in clinical trials or other operations, if demand for our products is significantly reduced as a result of the COVID-19 pandemic, or if demand for our COVID-19 vaccine or oral COVID-19 treatment is reduced or no longer exists, we could experience a material adverse impact on our business, operations and financial condition and results. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors&#8212;COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2021 Form 10-K.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_121"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Fair Value (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Revenues (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Asset Impairments (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Tax Assets and Liabilities and Income Tax Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Pension and Postretirement Benefit Plans (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and Legal and Environmental Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2021 Form 10-K. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K for a discussion about the risks associated with estimates and assumptions.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of a recently adopted accounting standard, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a discussion of presentation changes for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_124"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div id="i8c2530a91ced4c48b9620128206808f1_127"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Geography</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents worldwide revenues by geography:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">World-wide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-national</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change in Revenues</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating segments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer CentreOne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,638&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,035&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,851&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,020&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,786&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,014&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="57" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">World-wide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-national</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change in Revenues</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating segments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer CentreOne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,040&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,450&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,991&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,066&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,049&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,384&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Third Quarter of 2022 vs. Third Quarter of 2021</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following provides an analysis of the change in worldwide revenues by geographic areas in the third quarter of 2022:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended October 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide declines from Comirnaty, Xeljanz and Ibrance, partially offset by worldwide growth from Paxlovid, Eliquis, Prevnar family, Vyndaqel/Vyndamax, Xtandi and Inlyta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Decline from PC1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lower revenues for Sutent, primarily reflecting lower volume demand in Europe following its loss of exclusivity in January 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operational growth/(decline), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,831&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,272)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unfavorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(957)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(957)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,397)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,831&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,228)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.24pt">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A for additional analysis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging markets revenues decreased $3.0 billion, or 48%, in the third quarter of 2022 to $3.3 billion from $6.3 billion in the third quarter of 2021, reflecting an operational decrease of $2.8 billion, or 45%, and an unfavorable impact from foreign exchange of approximately 3%. The operational decrease in emerging markets was primarily driven by declines from Comirnaty and certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, partially offset by growth from Paxlovid.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">First Nine Months of 2022 vs. First Nine Months of 2021</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:65.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following provides an analysis of the worldwide change in revenues by geographic areas in the first nine months of 2022:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended October 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide growth from Paxlovid, Comirnaty, Eliquis, Prevnar family, Vyndaqel/Vyndamax and Inlyta, partially offset by worldwide declines from Xeljanz and Ibrance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decline from PC1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(332)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lower revenues for Chantix/Champix and Sutent: </span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">The decrease in Chantix/Champix was driven by the ongoing global pause in shipments of Chantix due to the presence of N-nitroso-varenicline above an acceptable level of intake set by various global regulators, the ultimate timing for resolution of which may vary by country</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">The decrease for Sutent primarily reflects lower volume demand in Europe and the U.S. following its loss of exclusivity in January 2022 and August 2021, respectively</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(632)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(386)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operational growth/(decline), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,585&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,925&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,659&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unfavorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,995)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,995)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,590&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,925&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,665&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.24pt">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A for additional analysis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging markets revenues increased $3.7 billion, or 29%, in the first nine months of 2022 to $16.7 billion from $12.9 billion in the first nine months of 2021, reflecting an operational increase of $4.4 billion, or 34%, and an unfavorable impact from foreign exchange of approximately 5%. The operational increase in emerging markets was primarily driven by growth from Comirnaty, Paxlovid and Nimenrix, partially offset by declines in certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, as well as the Prevnar family.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents information about revenue deductions:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid and related state program rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based contract rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns and cash discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,019&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,737&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our accruals for revenue deductions, including the balance sheet classification of these accruals, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues&#8211;&#8211;Selected Product Discussion</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Biopharma</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:83pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="42" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="33" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$4,402</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 65%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" rowspan="33" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,908&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">QTD declines largely driven by a previously announced amendment to the supply agreement with the EC whereby all doses scheduled for delivery in June through August 2022 would instead be delivered in the fourth quarter of 2022 and similar shifts in scheduled deliveries to other developed countries, as well as slower demand in emerging markets. Declines were partially offset by growth in the U.S., driven primarily by deliveries of the Omicron BA.4/BA.5-adapted bivalent booster, following its EUA in late-August 2022, as well as the granting of an EUA in June 2022 for a primary vaccination series for children 6 months to less than 5 years of age.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">YTD performance was largely driven by operational growth in international markets, led by increased sales of doses to serve emerging markets and increased deliveries to certain international developed markets in the first six months of 2022, as well as the granting of an EUA in the U.S. in October 2021 for a primary vaccination series for children 5 to 11 years of age and QTD U.S. growth drivers noted above, partially offset by QTD declines noted above.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,402&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$26,477</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 14% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,303&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,657&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,619&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,477&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,277&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paxlovid</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$7,514</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">&#160;* </span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,044&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Driven by the U.S. launch under EUA in December 2021 and international launches in late 2021 and early 2022 following regulatory approvals or EUAs.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$17,099</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">*</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,514&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,099&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliquis</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,464</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 15%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth driven primarily by continued oral anti-coagulant adoption and market share gains in non-valvular atrial fibrillation in the U.S., as well as favorable changes in channel mix in the U.S., partially offset by declines in certain emerging markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In addition, YTD performance was impacted by growth in oral anti-coagulant adoption and market share gains in certain markets in Europe, partially offset by the non-recurrence of an $80 million favorable adjustment related to the Medicare &#8220;coverage gap&#8221; provision recorded in the first quarter of 2021 in the U.S.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$5,001</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 16%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,979&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,440&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,001&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,470&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prevnar family</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,607</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 14% </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily driven by the adult indications in the U.S. due to strong patient demand following the launch of Prevnar 20 for the eligible adult population, partially offset by unfavorable timing of government and private purchasing of Prevnar 13 for the pediatric indication globally and adult indication internationally.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">YTD growth was partially offset by competitive pressures in China for the pediatric indication.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$4,601</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 18%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,130&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,601&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ibrance</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,283</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 3%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:95%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Global declines primarily driven by prior-year clinical trial purchases internationally, planned price decreases that recently went into effect in international developed markets, and continued increase in the proportion of patients accessing Ibrance through the U.S. Patient Assistance Program.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">YTD declines were partially offset by higher volumes in emerging markets.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$3,841</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 2%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,493&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,039&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vyndaqel/ <br/>Vyndamax</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$602</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 29%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth largely driven by continued strong uptake of the ATTR-CM indication, primarily in developed Europe and the U.S., partially offset by a planned price decrease that went into effect in Japan in the second quarter of 2022.</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,766</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 28%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xeljanz</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="6" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$502</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 14% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines driven primarily by decreased prescription volumes globally resulting from ongoing shifts in prescribing patterns related to JAK class label changes. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In addition, YTD was impacted by declines in net price due to unfavorable changes in channel mix and unfavorable wholesaler inventory buying patterns in the U.S.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,304</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 22% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" rowspan="6" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$320</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 3%  </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance largely due to steady demand growth across the mCRPC, nmCRPC, and mCSPC indications.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">YTD demand growth was offset largely by unfavorable changes in channel mix and fluctuating enrollment rates in the Xtandi Patient Assistance Program.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$878</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Flat</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inlyta</span></td><td colspan="3" rowspan="6" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$252</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 3% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily reflects continued adoption in emerging markets of combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">YTD growth also driven by continued adoption in developed Europe.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$760</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 6%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pfizer CentreOne</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Segment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PC1</span></td><td colspan="3" rowspan="6" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QTD</span></td><td colspan="3" rowspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$319</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 35% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines primarily driven by lower COVID-19 manufacturing activities performed on behalf of customers, including Comirnaty supply to BioNTech, and lower manufacturing of divested products under manufacturing and supply agreements.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YTD</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$974</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 25%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Comirnaty includes direct sales and alliance revenues related to sales of the Pfizer-BioNTech COVID-19 vaccine, which are recorded within our Primary Care therapeutic area. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in PC1. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 13C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Indicates calculation not meaningful.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K for information regarding the expiration of various patent rights, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the primary indications or class of the selected products discussed.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_136"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:38.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>&#160;Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,063&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,932&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,696&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,085&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Percentage of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8212;net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(59)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,696)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(97)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,043)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="39" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*  Indicates calculation not meaningful. </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Cost of Sales</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased $3.9 billion in the third quarter of 2022, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a reduction of $4.1&#160;billion due to lower sales of Comirnaty (see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A); and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $600&#160;million favorable impact of foreign exchange and hedging activity,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase of $800&#160;million for Paxlovid, including a charge of $400&#160;million related to excess raw materials.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $3.6&#160;billion in the first nine months of 2022, mainly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an unfavorable impact of $3.4&#160;billion due to increased sales of Comirnaty, which includes a charge for the 50% gross profit split with BioNTech and applicable royalty expenses; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase of $1.8&#160;billion for Paxlovid, which includes the charge of $400&#160;million discussed above; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $450&#160;million write off of inventory related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, which was recorded in the second quarter of 2022,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $2.0&#160;billion favorable impact of foreign exchange and hedging activity.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as a percentage of revenues in the third quarter of 2022 was primarily driven by favorable changes in sales mix, including significant sales of Paxlovid, and lower sales of Comirnaty, as well as the favorable impacts of foreign exchange and hedging activity, partially offset by the charge of $400&#160;million related to Paxlovid discussed above.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percentage of revenues in the first nine months of 2022 was primarily due to the favorable impacts of Paxlovid, foreign exchange and hedging activity, partially offset by the unfavorable impact of Comirnaty, as well as the $450&#160;million inventory write-off related to COVID-19 products and the charge of $400&#160;million related to Paxlovid discussed above.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Selling, Informational and Administrative (SI&amp;A) Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI&amp;A expenses increased $492 million in the third quarter of 2022, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase of $290&#160;million for Paxlovid and Comirnaty marketing and promotional expenses and a higher provision for U.S. healthcare reform fees based on sales of Paxlovid and Comirnaty; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase of $125&#160;million for marketing and promotional expenses for recently launched products,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $112&#160;million favorable impact of foreign exchange.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI&amp;A expenses increased $433 million in the first nine months of 2022, mainly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase of $720&#160;million for Paxlovid and Comirnaty marketing and promotional expenses and a higher provision for U.S. healthcare reform fees based on sales of Paxlovid and Comirnaty; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase of $300&#160;million for marketing and promotional expenses for recently launched products,</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a decrease of $270&#160;million in our liability to be paid to participants of our supplemental savings plan; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $244&#160;million favorable impact of foreign exchange. </span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Research and Development (R&amp;D) Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased $15 million in the third quarter, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">increased costs of $290&#160;million to develop recently acquired assets, as well as investments for certain oncology and non-COVID-19 vaccines programs, </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower spending of $270&#160;million on programs to prevent and treat COVID-19 and various late-stage clinical programs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased $898 million in the first nine months of 2022,</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily driven by increased costs of $800&#160;million to develop recently acquired assets, as well as investments across multiple late-stage clinical programs, including development costs and at-risk manufacturing related to programs to prevent and treat COVID-19.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Acquired In-Process Research and Development (IPR&amp;D) Expenses</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses decreased $237 million in the third quarter of 2022, primarily reflecting an upfront payment to Arvinas and a premium paid on our equity investment in Arvinas totaling $706 million in the third quarter of 2021, partially offset by an upfront payment of $426 million related to the closing of the acquisition of ReViral in the third quarter of 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses decreased $120 million in the first nine months of 2022, largely due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the payments to Arvinas in the third quarter of 2021; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the acquisition of Amplyx Pharmaceuticals, Inc. in the second quarter of 2021,</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the upfront payment related to the closing of the acquisition of ReViral in the third quarter of 2022;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.15pt">an upfront payment to Biohaven and a premium paid on our equity investment in Biohaven totaling $263&#160;million in the first quarter of 2022; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $76&#160;million premium paid on our equity investment in BioNTech to develop a potential mRNA vaccine against shingles in the first quarter of 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 2D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets decreased $146 million in the third quarter and $265 million in the first nine months of 2022, primarily as a result of lower amortization of Comirnaty sales milestones to BioNTech.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transforming to a More Focused Company Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;For a description of our program, as well as the anticipated and actual costs, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program savings discussed below may be rounded and represent approximations. In connection with restructuring our corporate enabling functions, we expect gross cost savings of $1.0&#160;billion, or net cost savings, excluding merit and inflation growth and certain real estate cost increases, of $700 million, to be achieved primarily from 2021 through 2022. In connection with transforming our marketing strategy, we expect net cost savings of $1.4&#160;billion, to be achieved primarily from 2022 through 2024. In connection with manufacturing network optimization, we expect net cost savings of $550 million to be achieved primarily from 2020 through 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain qualifying costs for this program were recorded in the first three quarters of 2022 and 2021 and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to this program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Other (Income)/Deductions&#8212;Net</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period-over-period changes were primarily driven by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">net losses on equity securities in 2022 versus net gains recognized in 2021; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower net periodic benefit credits associated with pension and postretirement plans incurred in 2022 compared to 2021; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an intangible asset impairment charge recorded in the third quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_142"></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision/(Benefit) for Taxes on Income</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(328)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate on continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="39" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">* Indicates calculation not meaningful.</span></div></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_145"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our discontinued operations, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_133"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comprehensive update of Pfizer&#8217;s development pipeline was published as of November&#160;1, 2022 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information as of the date of this filing about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below include filing and approval milestones for products that have occurred in the last twelve months and generally do not include approvals that may have occurred prior to that time. The tables include filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Vaccine Products</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">PATIENT POPULATION AND DATE OF APPROVAL/FILING</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">COVID-19 VACCINE PRODUCT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">PRIMARY SERIES<br/>OR BOOSTER</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">16 Years of age and older</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">12-15 Years of age</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">5-11 Years of age</span></td><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">6 Months through 4 Years of age</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">JAPAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">JAPAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">JAPAN</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">JAPAN</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="4" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Comirnaty</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">30-&#181;g 2-dose primary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">10-&#181;g 2-dose primary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="9" style="border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">3-&#181;g 3-dose primary</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Primary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%"> Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">May 2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">May 2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Oct. 2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Nov. 2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">June 2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">30-&#181;g booster dose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">10-&#181;g booster dose</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Booster</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Oct. 2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Jan.  2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Feb. 2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%"> Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">May 2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Sep. 2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%"> June</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Comirnaty Original/Omicron BA.4/BA.5 Vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Booster</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">30-&#181;g booster dose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">10-&#181;g booster dose</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sep. 2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Aug. 2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sep. 2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Oct. 2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sep. 2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Comirnaty Original/Omicron BA.1 Vaccine</span></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Booster</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">30-&#181;g  booster dose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:95%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">Sep. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:95%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.6pt">All COVID-19 vaccine p</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">roducts listed in this table are being developed in collaboration with BioNTech.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">FDA has authorized a third 30-&#181;g primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">FDA has authorized a third 10-&#181;g primary series dose to individuals 5-11 years of age with certain kinds of immunocompromise.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">FDA has authorized a second booster dose in adults ages 50 years and older who have previously received a first booster of any authorized COVID-19 vaccine. The FDA also has authorized a second booster dose for individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise and who have received a first booster dose of any authorized COVID-19 vaccine.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Comirnaty wild-type booster in these populations has been replaced by the booster of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5).</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.14pt">Refers to the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) and Comirnaty Original/Omicron BA.4/BA.5 Vaccine.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Products</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.796%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT</span></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DISEASE AREA</span></td><td colspan="9" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">APPROVED/FILED*</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">JAPAN</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Cibinqo<br/>(abrocitinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Atopic dermatitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Xeljanz <br/>(tofacitinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Ankylosing spondylitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Myfembree</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">(relugolix fixed dose combination)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Uterine fibroids (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Endometriosis (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Lorbrena/Lorviqua </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">(lorlatinib)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">First-line ALK-positive NSCLC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mar. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Ngenla</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">(somatrogon)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Pediatric growth hormone deficiency</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Prevnar 20/Apexxnar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">(Vaccine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Immunization to prevent invasive and non-invasive pneumococcal infections (adults)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">TicoVac<br/>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Immunization to prevent tick-borne encephalitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aug. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:107%">Paxlovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:107%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:107%">(nirmatrelvir [PF-07321332]; ritonavir)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">COVID-19 infection (high risk population)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EUA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CMA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:107%">Nurtec ODT/Vydura</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:107%">(rimegepant)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Acute migraine</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Apr. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Migraine prevention</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Apr. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:107%">ritlecitinib (PF-06651600)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Alopecia areata</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:107%">zavegepant<br/>(intranasal)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Acute migraine</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:5.25pt">For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with Myovant. In June 2022, the FDA accepted for review a sNDA for Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) proposing updates to Myfembree&#8217;s U.S. Prescribing Information based on safety and efficacy data from the Phase 3 LIBERTY randomized withdrawal study in premenopausal women with heavy menstrual bleeding associated with uterine fibroids for up to two years. The Prescription Drug User Fee Act goal date for this sNDA is January 29, 2023.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with OPKO. In January 2022, Pfizer and OPKO received a Complete Response Letter (CRL) from the FDA for the BLA for somatrogon. Discussions are ongoing with the FDA regarding the CRL and how to best address their concerns.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">In October 2021, the CDC&#8217;s ACIP voted to recommend Prevnar 20 for routine use in adults. Specifically, the ACIP voted to recommend the following: (i) adults 65 years of age or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either pneumococcal 20-valent conjugate vaccine (PCV20) or pneumococcal 15-valent conjugate vaccine (PCV15)). If PCV15 is used, this should be followed by a dose of pneumococcal polysaccharide vaccine (PPSV23); and (ii) adults aged 19 years of age or older with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23. The recommendations were published in the Morbidity and Mortality Weekly Report on January 28, 2022. The publication also notes &#8220;for adults who have received pneumococcal conjugate vaccine (PCV13) but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of Prevnar 20 may be used if PPSV23 is not available.&#8221; In October 2022, the CDC&#8217;s ACIP voted to recommend a single dose of Prevnar 20 to help protect adults previously vaccinated with Prevnar 13 or both Prevnar 13 and PPSV23 against invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae serotypes in Prevnar 20.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">In January 2022, the EMA approved the CMA of Paxlovid for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. In June 2022, we announced the submission of an NDA to the FDA for approval of Paxlovid for the treatment of COVID-19 in both vaccinated and unvaccinated individuals who are at high risk for progression to severe illness from COVID-19.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, in light of the results from the completed required postmarketing safety study of Xeljanz, ORAL Surveillance (A3921133), the U.S. label for Xeljanz was revised. In addition, in October 2022, the PRAC of the EMA concluded their assessment of JAK inhibitors authorized for inflammatory diseases in the EU, including Xeljanz and Cibinqo, and recommended that risk minimization measures, including special warnings and precautions for use, should be revised for such JAK inhibitors. The resulting label changes are expected to be finalized in January 2023. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Post-Authorization/Approval Data </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Product Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections of our 2021 Form 10-K.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the following products received regulatory approvals in the last twelve months: Cresemba for fungal infection and Besponsa for second line acute lymphoblastic leukemia, both in December 2021; Paxlovid for COVID-19 infection in February 2022; Cibinqo for atopic dermatitis in April 2022; Lorbrena for non-small cell lung cancer (first line and second line therapy) in April 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about additional indications and new drug candidates in late-stage development:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.983%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="11" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;text-indent:7.2pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT/CANDIDATE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PROPOSED DISEASE AREA</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ibrance (palbociclib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">ER+/HER2+ metastatic breast cancer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Xtandi (enzalutamide)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-metastatic high-risk castration sensitive prostate cancer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for first-line mCRPC</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for DNA Damage Repair (DDR)-deficient mCSPC</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06482077 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunization to prevent invasive and non-invasive pneumococcal infections (pediatric)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">somatrogon (PF-06836922)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Adult growth hormone deficiency</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">First-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">-mutant mCRC</span></div></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Mektovi (binimetinib) and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> (pembrolizumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">-mutant metastatic or unresectable locally advanced melanoma</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Paxlovid (nirmatrelvir [PF-07321332]; ritonavir)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">COVID-19 infection (</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">pediatric)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">zavegepant (oral)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Migraine prevention</span></td></tr><tr style="height:21pt"><td colspan="3" rowspan="18" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;text-indent:5.65pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">aztreonam-avibactam<br/>(PF-06947387)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Treatment of infections caused by Gram-negative bacteria with limited or no treatment options</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">fidanacogene elaparvovec (PF-06838435)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Hemophilia B</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">giroctocogene fitelparvovec </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(PF-07055480)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Hemophilia A</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06425090 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent primary clostridioides difficile infection</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06886992 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent serogroups meningococcal infection (adolescent and young adults)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PF-06928316 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent respiratory syncytial virus infection (maternal)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Immunization to prevent respiratory syncytial virus infection (older adults)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">sasanlimab (PF-06801591)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">fordadistrogene movaparvovec (PF-06939926)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Duchenne muscular dystrophy (ambulatory)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">marstacimab (PF-06741086)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Hemophilia</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">elranatamab (PF-06863135)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Multiple myeloma triple-class refractory</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Multiple myeloma double-class exposed</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Newly diagnosed multiple myeloma </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Omicron-based mRNA vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Immunization to prevent COVID-19 (adults)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">etrasimod (PF-07915503)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Ulcerative colitis (moderately to severely active)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">VLA15 (PF-07307405) vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(j)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Immunization to prevent Lyme Disease</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">PF-07252220 (quadrivalent mRNA-based vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Immunization to prevent influenza</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">inclacumab (PF-07940370)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Sickle Cell Disease</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with The Alliance Foundation Trials, LLC.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with OPKO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme Corp. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.14pt">Being developed in collaboration with Spark Therapeutics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with Sangamo Therapeutics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Multiple myeloma triple-class refractory is currently in a Phase 2 registration-enabling study.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.41pt">Being developed in collaboration with BioNTech.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.41pt">Being developed in collaboration with Valneva SE.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myfembree combination with estradiol and norethindrone acetate for contraceptive efficacy is currently enrolling in a Phase 3 study as of November 2022 as a potential label update rather than a distinct registration, and has been removed from the table above.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our R&amp;D organization, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_148"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP reported performance measures. As such, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted diluted EPS to present the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide&#8211;&#8211;prior to considering certain income statement elements as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measure</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Definition</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relevance of Metrics to Our Business Performance</span></td></tr><tr style="height:99pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors useful information to:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">assist in modeling expected future performance on a normalized basis</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:65pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses and Adjusted other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, each before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted diluted EPS</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Most directly comparable GAAP measure.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part versus three budgeted metrics, one of which is Adjusted diluted EPS (as defined for annual incentive compensation purposes), which is derived from Adjusted income and accounts for 40% of the bonus pool funding tied to financial performance. Additionally, the payout for performance share awards is determined in part by Adjusted net income, which is derived from Adjusted income. Beginning in the first quarter of 2022, we no longer exclude any expenses for acquired IPR&amp;D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for annual incentive compensation purposes. The bonus pool funding, which is largely based on financial performance, is adjusted by our R&amp;D pipeline performance, as measured by four metrics, and performance against certain of our environmental, social and governance (ESG) metrics, and may be further modified by our Compensation Committee&#8217;s assessment of other factors.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their most directly comparable GAAP measures of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8212;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first quarter of 2022, our reconciliation of certain GAAP reported to non-GAAP adjusted information is updated to reflect the following, and prior-period information has been revised to conform to the current period presentation:</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjusted Income and Adjusted Diluted EPS</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Non-GAAP Adjusted financial measures include expenses for all acquired IPR&amp;D costs incurred in connection with upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities, as well as asset acquisitions of acquired IPR&amp;D. Previously, certain of these items were excluded from our non-GAAP adjusted results. Acquired IPR&amp;D expenses that previously would have been excluded from non-GAAP Adjusted income but are now included in both GAAP Reported income and non-GAAP Adjusted income were approximately: (i) $426 million pre-tax ($389 million, net of tax), or $0.07 per share, in the third quarter of 2022; (ii) $765&#160;million pre-tax ($665&#160;million, net of tax), or $0.12 per share, in the first nine months of 2022; (iii) $706&#160;million pre-tax ($540&#160;million, net of tax), or $0.09 per share, in the third quarter of 2021 and (iv) $892&#160;million pre-tax ($726&#160;million, net of tax), or $0.13 per share, in the first nine months of 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We began excluding all amortization of intangibles from non-GAAP Adjusted income, compared to excluding only amortization of intangibles related to large mergers or acquisitions under the prior methodology, and presenting it as a separate reconciling line. Previously, the adjustment under the prior methodology was included as part of a reconciling line entitled &#8220;Purchase accounting adjustments&#8221; that we no longer separately present. The impact of this policy change resulted in benefits of $0.01 and $0.04 on Adjusted diluted EPS in the third quarter and first nine months of 2022, respectively, and $0.02 and $0.07 in the third quarter and first nine months of 2021, respectively.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition-Related Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adjusted income continues to exclude certain acquisition-related items, which are comprised of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies. Beginning in the first quarter of 2022, acquisition-related items may now include purchase accounting impacts that previously would have been included as part of a reconciling line entitled &#8220;Purchase accounting adjustments&#8221; that we no longer separately present, such as: (i) the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value; (ii) depreciation related to the increase/decrease in fair value of acquired fixed assets; (iii) amortization related to the increase in fair value of acquired debt and (iv) the fair value changes for contingent consideration. </span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adjusted income continues to exclude the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our therapeutic areas and product lines for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Certain Significant Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adjusted income continues to exclude certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to LOE or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Gains and losses on equity securities, and pension and postretirement actuarial remeasurement gains and losses have a very high degree of inherent market volatility, which we do not control and cannot predict with any level of certainty and because we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of GAAP Reported to Non-GAAP Adjusted information&#8212;Certain Line Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a non-inclusive list of certain significant items and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A of our 2021 Form 10-K for additional information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Three Months Ended October 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(59)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(193)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(325)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">349&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(109)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,038&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,239&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(515)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,172&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.78&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nine Months Ended October 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">24,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">26,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(344)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">701&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,348)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(225)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(536)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">621&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;Non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,621&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,635&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,298)</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,165&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.44&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Three Months Ended October 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,899</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,696)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(899)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,587)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,899&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,719&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(570)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,279&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.27&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nine Months Ended October 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">21,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,043)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3.27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(310)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,597)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(932)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;Non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,976)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,975&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,140&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,747)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,653&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.28&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Items that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP reported income from continuing operations were: 4.0% and 10.5% in the three and nine months ended October 2, 2022, respectively, and (4.2)% and 7.8% in the three and nine months ended October 3, 2021, respectively. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Our effective tax rates on non-GAAP adjusted income were: 4.4% and 11.9% in the three and nine months ended October 2, 2022, respectively, and 14.7% and 15.7% in the three and nine months ended October 3, 2021, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Acquisition-related items in the three and nine months ended October 2, 2022 primarily represent integration and other costs for the acquisition of Arena in March 2022. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Relates to the previously divested Meridian subsidiary and post-closing adjustments for other previously divested businesses. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">For the third quarter of 2022, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">adjustment of $325&#160;million primarily includes charges of $212&#160;million mostly representing our equity-method accounting pro rata share of costs of preparing for separation from GSK recorded by Haleon/the GSK Consumer Healthcare JV, and adjustments to our equity-method basis differences which are also related to the separation of Haleon/the GSK Consumer Healthcare JV from GSK, and charges of $77&#160;million for certain legal matters. For the first nine months of 2022, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> adjustment of $536 million primarily includes charges of $273&#160;million mostly representing our equity-method accounting pro rata share of restructuring charges and costs of preparing for separation from GSK recorded by Haleon/the GSK Consumer Healthcare JV, and adjustments to our equity-method basis differences which are also related to the separation of Haleon/the GSK Consumer Healthcare JV from GSK, and charges of $175 million for certain legal matters. For the third quarter of 2021, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">adjustment of $126&#160;million primarily includes charges of $64&#160;million for certain legal matters and charges of $55&#160;million mostly representing our equity-method accounting pro rata share of restructuring charges and costs of preparing for separation from GSK recorded by the GSK Consumer Healthcare JV. For the first nine months of 2021, amounts in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of $119&#160;million primarily include costs for consulting, legal, tax and advisory services associated with a non-recurring internal reorganization of legal entities. For the first nine months of 2021, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">adjustment of $200&#160;million primarily includes charges of $136&#160;million mostly representing our equity-method accounting pro rata share of restructuring charges and costs of preparing for separation from GSK recorded by the GSK Consumer Healthcare JV, and charges of $92&#160;million for certain legal matters. The third quarter and first nine months of 2022 and 2021 include insignificant reconciling amounts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Continuing Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:49.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drivers of change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by/(used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,993&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The change was driven primarily by (i) a decrease in the change in amounts due to BioNTech for the gross profit split for Comirnaty (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as well as (ii) the impact of timing of receipts and payments in the ordinary course of business, partially offset by (iii) higher net income adjusted for non-cash items, including an increase from non-cash unrealized losses on equity securities recognized in 2022, compared to unrealized gains recognized in 2021.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,373)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,951)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change was driven mainly by a $19.2&#160;billion increase in redemptions of short-term investments with original maturities of greater than three months and $4.0 billion of dividends received from our Haleon/GSK Consumer Healthcare JV investment that were allocated to investing activities, partially offset by $6.2 billion cash paid for the acquisition of Arena, net of cash acquired, a $3.7&#160;billion increase in net purchases of short-term investments with original maturities of three months or less, and a $3.4&#160;billion increase in purchases of short-term investments with original maturities of greater than three months.</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities from continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,819)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,465)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change was driven mostly by $2.0 billion purchases of the Company&#8217;s common stock in 2022 and a $997&#160;million decrease in proceeds from the issuance of long-term debt.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Cash flows from discontinued operations relate to previously divested businesses (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div id="i8c2530a91ced4c48b9620128206808f1_160"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our significant operating cash flows, which is a key strength of our liquidity and capital resources and our primary funding source, as well as our financial assets, access to capital markets, revolving credit agreements, and available lines of credit, we believe that we have, and will maintain, the ability to meet our liquidity needs to support ongoing operations, our capital allocation objectives, and our contractual and other obligations for the foreseeable future. For additional information, including information about off-balance sheet arrangements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2021 Form 10-K. For information about the sources and uses of our funds, as well as our operating cash flows, see our condensed consolidated statements of cash flows, condensed consolidated balance sheets, condensed consolidated statements of equity, and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A. For information on our money market funds, available-for sale-debt securities and long-term debt, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Capacity&#8211;&#8211;Lines of Credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;As of October&#160;2, 2022, we had access to a $7 billion committed U.S. revolving credit facility expiring in 2026, which may be used for general corporate purposes including to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have provided us an additional $332 million in lines of credit, of which $302 million expire within one year. Essentially all lines of credit were unused as of October&#160;2, 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Allocation Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Our capital allocation framework is primarily devised to facilitate (i) the achievement of medical breakthroughs through R&amp;D investments and business development activities and (ii) returning capital to shareholders through dividends and share repurchases. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within this MD&amp;A and within the MD&amp;A of our 2021 Form 10-K.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, our BOD declared a dividend of $0.40 per share, payable on December 5, 2022, to shareholders of record at the close of business on November 4, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we purchased 39&#160;million shares of our common stock at a cost of $2.0 billion under our publicly announced share purchase plan. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 2 for more information. At October&#160;2, 2022, our remaining share-purchase authorization was approximately $3.3 billion.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In keeping with Pfizer&#8217;s transformation into a more focused, global leader in science-based innovative medicines and vaccines, we intend to exit our 32% ownership interest in Haleon in a disciplined manner, with the objective of maximizing value for our shareholders. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;For information about off-balance sheet arrangements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2021 Form 10-K. For more information on guarantees and indemnifications, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, in connection with GSK&#8217;s previously announced planned demerger, the Consumer Healthcare JV issued notes of $8.75 billion, &#8364;2.35 billion and &#163;700 million with various maturities. GSK guaranteed the notes and we agreed to indemnify GSK for 32% of any amount payable by GSK. In conjunction with the completion of GSK&#8217;s demerger transactions in July 2022, GSK&#8217;s guarantee and our related indemnification of GSK&#8217;s guarantee were terminated. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Economic Conditions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Beginning in our second quarter of 2022, our operations in Turkey function in a hyperinflationary economy. The impact to Pfizer is not considered material. For more information about global economic conditions, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;The Global Economic Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our diverse sources of funds, global economic conditions, and information about credit ratings, market risk and LIBOR, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within MD&amp;A in our 2021 Form 10-K.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_163"></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Standards, Not Adopted as of October&#160;2, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Standard/Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Effect on the <br/>Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Reference rate reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provides temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The new guidance provides the following optional expedients: </span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:2.63pt">Simplify accounting analyses under current U.S. GAAP for contract modifications.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:2.63pt">Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:2.63pt">Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Elections can be adopted prospectively at any time through December 31, 2022.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are assessing the impact, but currently do not expect this new guidance to have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2022, the FASB issued </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">final guidance to clarify that a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> contractual restriction on the sale of an equity security</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value. Recognizing a contractual sale restriction as a separate unit of account is not permitted.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 1, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">with early adoption permitted.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are assessing the impact, but currently do not expect this new guidance to have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September 2022, the FASB issued final guidance to enhance transparency about an entity&#8217;s use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">supplier finance programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Under the final guidance, the buyer in a supplier finance program is required to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented.</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">January 1, 2023, except for the amendment on rollforward information, which is effective January 1, 2024. Early adoption is permitted.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are assessing the impact, but currently we expect this new guidance to result in increased disclosure in the notes to financial statements.</span></td></tr></table></div><div id="i8c2530a91ced4c48b9620128206808f1_166"></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;potential,&#8221; &#8220;hope&#8221; and other words and terms of similar meaning or by using future dates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include forward-looking information in our discussion of the following, among other topics:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution, growth, performance, timing of exclusivity and potential benefits;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">strategic reviews, capital allocation objectives, dividends and share repurchases;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for impact of or changes to existing or new government regulations or laws;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing and product supply. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, forward-looking information in this Form 10-Q includes statements relating to specific future actions and effects, including, among others, the expected benefits of the organizational changes to further transform our operations, our efforts to respond to COVID-19, including our plans and expectations regarding Comirnaty and Paxlovid, and any potential future vaccines or treatments; the forecasted revenue, demand, manufacturing and supply of Comirnaty and Paxlovid, including expectations of the commercial market for Comirnaty; our expectations regarding the impact of COVID-19 on our business; the expected impact of patent expiries and competition from generic manufacturers; the expected pricing pressures on our products and the anticipated impact to our business; the availability of raw materials for 2022; the expected charges and/or costs in connection with the spin-off of the Upjohn Business and its combination with Mylan; the benefits expected from our business development transactions; our anticipated liquidity position; the anticipated costs and savings from certain of our initiatives, including our Transforming to a More Focused Company program; and our planned capital spending.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section and in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2021 Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form  10-Q. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2021 Form 10-K and within MD&amp;A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below, in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2021 Form 10-K or within MD&amp;A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business, Industry and Operations, and Business Development</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the outcome of R&amp;D activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and/or further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; and whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; the impact of, or uncertainties </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regarding the ability to obtain, recommendations by technical or advisory committees; and the timing of pricing approvals and product launches;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or actions by regulatory authorities based on analysis of ORAL Surveillance or other data, including on other JAK inhibitors in our portfolio;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired products; significant transaction costs; and unknown liabilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully market both new and existing products, including biosimilars;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic), including the impact of vaccine mandates where applicable, on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&amp;D and clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to our efforts to develop and commercialize a vaccine to help prevent COVID-19 and an oral COVID-19 treatment, as well as challenges related to their manufacturing, supply and distribution;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks related to our ability to achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments, including, among other things, whether and when additional supply or purchase agreements will be reached, the risk that demand for any products may be reduced or no longer exist and the possibility that COVID-19 will diminish in severity or prevalence or disappear entirely, which may lead to reduced revenues or excess inventory;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the increased presence of counterfeit medicines or vaccines in the pharmaceutical supply chain;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties; and any significant issues related to our JVs and other third-party business arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation, and recent and possible future changes in global financial markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, civil unrest or military action;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, including our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trade buying patterns;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Legal Proceedings</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any U.S. healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs, including the IRA, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legislation or regulatory action in markets outside of the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as the impact of political unrest or civil unrest or military action, including the ongoing conflict between Russia and Ukraine and the continued economic consequences, unstable governments and legal systems and inter-governmental disputes;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legal defense costs, insurance expenses, settlement costs and contingencies, including those related to actual or alleged environmental contamination;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of an adverse decision or settlement and the adequacy of reserves related to legal proceedings;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of tax related litigation;</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">governmental laws and regulations affecting our operations, including, without limitation, the recently enacted IRA, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., the potential adoption of global minimum taxation requirements and potential changes to existing tax law by the current U.S. Presidential administration and Congress;</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property, Technology and Security</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any business disruption, theft of confidential or proprietary information, extortion or integrity compromise resulting from a cyber-attack or other malfeasance by third parties, including, but not limited to, nation states, employees, business partners or others;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to protect our patents and other intellectual property, such as against claims of invalidity that could result in LOE; claims of patent infringement, including asserted and/or unasserted intellectual property claims; challenges faced by our collaboration or licensing partners to the validity of their patent rights; and in response to any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products, including Comirnaty and Paxlovid.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_169"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item is incorporated by reference from the discussion in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2021 Form 10-K.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_172"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i8c2530a91ced4c48b9620128206808f1_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART II.&#160; OTHER INFORMATION</span></td></tr></table></div><div><span><br/></span></div><div id="i8c2530a91ced4c48b9620128206808f1_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_181"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;Our Operating Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Information and Factors That May Affect Future Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the MD&amp;A of this Form 10-Q and of our 2021 Form 10-K and to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2021 Form 10-K.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes purchases of our common stock during the third quarter of 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Average Price</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Paid per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Approximate Value of Shares That May Yet Be Purchased Under the Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">July 4 through July 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">29,527&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">52.06&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,292,882,444&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">August 1 through August 28, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">18,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">50.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,292,882,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">August 29 through October&#160;2, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">85,565&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">45.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,292,882,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">133,860&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">47.59&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents (i) 131,564 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 2,296 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk&#8212;Capital Allocation Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within the MD&amp;A of this Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div><div id="i8c2530a91ced4c48b9620128206808f1_196"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh311x1002202210q.htm">Exhibit 31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh312x1002202210q.htm">Exhibit 31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh321x1002202210q.htm">Exhibit 32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh322x1002202210q.htm">Exhibit 32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EX-101.SCH<br/>EX-101.CAL<br/>EX-101.LAB<br/>EX-101.PRE<br/>EX-101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema<br/>Inline XBRL Taxonomy Extension Calculation Linkbase<br/>Inline XBRL Taxonomy Extension Label Linkbase<br/>Inline XBRL Taxonomy Extension Presentation Linkbase<br/>Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div id="i8c2530a91ced4c48b9620128206808f1_199"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer B. Damico</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer B. Damico<br/>Senior Vice President and Controller<br/>(Principal Accounting Officer and<br/>Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>pfe-exh311x1002202210q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i86e4ec23a1c0428dbc608677337e71a4_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Executive Officer Pursuant to </font></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Albert Bourla, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;November&#160;9, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALBERT BOURLA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Albert Bourla</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>pfe-exh312x1002202210q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icb60ef26849c41fe93a4cbb62ae2ae53_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Financial Officer Pursuant to </font></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David M. Denton, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;November&#160;9, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; DAVID M. DENTON</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David M. Denton</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer, Executive Vice President</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>pfe-exh321x1002202210q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i79cb7e13af66466a81616365c21218a3_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended October&#160;2, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALBERT BOURLA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Albert Bourla</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>pfe-exh322x1002202210q.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i04f0258b19534c96954716cb1b70b76a_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to 18 U.S.C. Section 1350, I, David M. Denton, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended October&#160;2, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; DAVID M. DENTON</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David M. Denton</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer, Executive Vice President <br></font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pfe-20221002.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:532d8f3f-927e-412c-bdcb-1806e94574ca,g:7cd44193-98b9-486c-9ee0-61ec890b3036-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20221002" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20221002">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20221002_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20221002_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20221002_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20221002_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement" roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement">
        <link:definition>0000010 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives">
        <link:definition>0000011 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNet" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet">
        <link:definition>0000012 - Disclosure - Other (Income)/Deductions - Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMatters" roleURI="http://www.pfizer.com/role/TaxMatters">
        <link:definition>0000013 - Disclosure - Tax Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests">
        <link:definition>0000014 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pfizer.com/role/FinancialInstruments">
        <link:definition>0000015 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.pfizer.com/role/OtherFinancialInformation">
        <link:definition>0000016 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssets" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssets">
        <link:definition>0000017 - Disclosure - Identifiable Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlans" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans">
        <link:definition>0000018 - Disclosure - Pension and Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders">
        <link:definition>0000019 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitments" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments">
        <link:definition>0000020 - Disclosure - Contingencies and Certain Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformation" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation">
        <link:definition>0000021 - Disclosure - Segment, Geographic and Other Revenue Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>0000022 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTables" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables">
        <link:definition>0000023 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables" roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables">
        <link:definition>0000024 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables">
        <link:definition>0000025 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetTables" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables">
        <link:definition>0000026 - Disclosure - Other (Income)/Deductions - Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTables" roleURI="http://www.pfizer.com/role/TaxMattersTables">
        <link:definition>0000027 - Disclosure - Tax Matters (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables">
        <link:definition>0000028 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables">
        <link:definition>0000029 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables">
        <link:definition>0000030 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsTables" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables">
        <link:definition>0000031 - Disclosure - Identifiable Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansTables" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables">
        <link:definition>0000032 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables">
        <link:definition>0000033 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationTables" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables">
        <link:definition>0000034 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000035 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails">
        <link:definition>0000036 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails" roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails">
        <link:definition>0000037 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails" roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails">
        <link:definition>0000038 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Discontinued Operations Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails" roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails">
        <link:definition>0000039 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Equity Method Investment Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails" roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails">
        <link:definition>0000040 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Schedule of Equity-Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail" roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail">
        <link:definition>0000041 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Collaborative Arrangements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails">
        <link:definition>0000042 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail">
        <link:definition>0000043 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail">
        <link:definition>0000044 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail">
        <link:definition>0000045 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail">
        <link:definition>0000046 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails">
        <link:definition>0000047 - Disclosure - Other (Income)/Deductions - Net - Schedule of Impaired Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersNarrativeDetail" roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail">
        <link:definition>0000048 - Disclosure - Tax Matters - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" roleURI="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail">
        <link:definition>0000049 - Disclosure - Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail">
        <link:definition>0000050 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail">
        <link:definition>0000051 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000052 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsbyClassificationTypeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails">
        <link:definition>0000053 - Disclosure - Financial Instruments - Investments by Classification Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails">
        <link:definition>0000054 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1">
        <link:definition>0000054 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails">
        <link:definition>0000055 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails">
        <link:definition>0000056 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsShorttermBorrowingsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails">
        <link:definition>0000057 - Disclosure - Financial Instruments - Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails">
        <link:definition>0000058 - Disclosure - Financial Instruments - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails">
        <link:definition>0000059 - Disclosure - Financial Instruments - Derivative Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails">
        <link:definition>0000060 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails">
        <link:definition>0000061 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails">
        <link:definition>0000062 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails">
        <link:definition>0000063 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCreditRiskDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails">
        <link:definition>0000064 - Disclosure - Financial Instruments - Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationInventoriesDetails" roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails">
        <link:definition>0000065 - Disclosure - Other Financial Information - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationOtherCurrentLiabilitiesDetails" roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails">
        <link:definition>0000066 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail">
        <link:definition>0000067 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1">
        <link:definition>0000067 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsGoodwillDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail">
        <link:definition>0000068 - Disclosure - Identifiable Intangible Assets - Goodwill (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail">
        <link:definition>0000069 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansNarrativeDetail" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail">
        <link:definition>0000070 - Disclosure - Pension and Postretirement Benefit Plans - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails">
        <link:definition>0000071 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitmentsPatentLitigationDetails" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails">
        <link:definition>0000072 - Disclosure - Contingencies and Certain Commitments - Patent Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails">
        <link:definition>0000073 - Disclosure - Contingencies and Certain Commitments - Product Litigation, Commercial and Other Matters, Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationNarrativeDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail">
        <link:definition>0000074 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1">
        <link:definition>0000074 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>0000075 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail">
        <link:definition>0000076 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail">
        <link:definition>0000077 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails">
        <link:definition>0000078 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" abstract="false" name="ShorttermInvestmentsExcludingHeldToMaturitySecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" abstract="false" name="ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_ZirabevMember" abstract="true" name="ZirabevMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BioNTechAndCerevelTherapeuticsLLCMember" abstract="true" name="BioNTechAndCerevelTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ForeignCurrencyShortTermBorrowingsMember" abstract="true" name="ForeignCurrencyShortTermBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SpecialtyCareMember" abstract="true" name="SpecialtyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PrevnarPrevenarFamilyMember" abstract="true" name="PrevnarPrevenarFamilyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PrivateEquityInvestments" abstract="false" name="PrivateEquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_Expiring2033Member" abstract="true" name="Expiring2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RetacritMember" abstract="true" name="RetacritMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SomavertMember" abstract="true" name="SomavertMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IgPortfolioProductsMember" abstract="true" name="IgPortfolioProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ShorttermDebtGross" abstract="false" name="ShorttermDebtGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" abstract="false" name="DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_MeridianMember" abstract="true" name="MeridianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PfizerAndVersusSeveralGenericManufacturersMember" abstract="true" name="PfizerAndVersusSeveralGenericManufacturersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" abstract="false" name="DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EliquisMember" abstract="true" name="EliquisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RestructuringandRelatedCostNoncashChargesPercentage" abstract="false" name="RestructuringandRelatedCostNoncashChargesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_RebatesAndDiscountsAccrual" abstract="false" name="RebatesAndDiscountsAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_XeljanzMember" abstract="true" name="XeljanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ArenaMember" abstract="true" name="ArenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SulperazonMember" abstract="true" name="SulperazonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ReViralAssetAcquisitionMember" abstract="true" name="ReViralAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EquitySecuritiesFVNIRestrictedNoncurrent" abstract="false" name="EquitySecuritiesFVNIRestrictedNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" abstract="false" name="RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_MedrolMember" abstract="true" name="MedrolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences" abstract="false" name="EquityMethodInvestmentAdjustmentOfBasisDifferences" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" abstract="true" name="PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_NotesDue20271.000Member" abstract="true" name="NotesDue20271.000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PrimaryCareMember" abstract="true" name="PrimaryCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember" abstract="true" name="BioNTechCerevelTherapeuticsLLCAndArvinasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ZaviceftaMember" abstract="true" name="ZaviceftaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherSpecialtyCareMember" abstract="true" name="OtherSpecialtyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DevelopedRestOfWorldMember" abstract="true" name="DevelopedRestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" abstract="false" name="DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherOncologyProductsMember" abstract="true" name="OtherOncologyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GenotropinMember" abstract="true" name="GenotropinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" abstract="false" name="PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" abstract="true" name="ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ExpirationPeriodDomain" abstract="true" name="ExpirationPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ConsumerHealthcareJVHaleonMember" abstract="true" name="ConsumerHealthcareJVHaleonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BraftoviMember" abstract="true" name="BraftoviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" abstract="true" name="RestructuringChargesAndAcquisitionRelatedCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" abstract="false" name="EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_HedgedItemAxis" abstract="true" name="HedgedItemAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" abstract="true" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_PrepaymentsAndPaymentsToCollaboratorsCash" abstract="false" name="PrepaymentsAndPaymentsToCollaboratorsCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_XtandiAllianceRevenuesMember" abstract="true" name="XtandiAllianceRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" abstract="false" name="GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" abstract="false" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ReconcilingItemsOtherMember" abstract="true" name="ReconcilingItemsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_EnbrelMember" abstract="true" name="EnbrelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RestructuringChargesChargesIncurredToDate" abstract="false" name="RestructuringChargesChargesIncurredToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" abstract="true" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_Expiring2030Member" abstract="true" name="Expiring2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ViivHealthcareLimitedMember" abstract="true" name="ViivHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PremarinFamilyMember" abstract="true" name="PremarinFamilyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PatentInfringementMember" abstract="true" name="PatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_InlytaMember" abstract="true" name="InlytaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherNonoperatingIncomeExpenseNet" abstract="false" name="OtherNonoperatingIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CorporateEnablingFunctionsMember" abstract="true" name="CorporateEnablingFunctionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ModernaTXPatentInfringementCaseMember" abstract="true" name="ModernaTXPatentInfringementCaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LongtermInvestmentsMember" abstract="true" name="LongtermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherPrimaryCareProductsMember" abstract="true" name="OtherPrimaryCareProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" abstract="false" name="PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ExpirationPeriodAxis" abstract="true" name="ExpirationPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" abstract="false" name="RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" abstract="false" name="DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ImplementationCosts" abstract="false" name="ImplementationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AssetWriteOffsAndAssetImpairmentCharges" abstract="false" name="AssetWriteOffsAndAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScheduleOfAccruedLiabilitiesLineItems" abstract="true" name="ScheduleOfAccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_FocusedCompanyPlanMember" abstract="true" name="FocusedCompanyPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" abstract="false" name="DebtSecuritiesAccumulatedGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DerivativeNetReceivablePositionAggregateFairValue" abstract="false" name="DerivativeNetReceivablePositionAggregateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RestructuringAssetImpairmentCharges" abstract="false" name="RestructuringAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" abstract="false" name="DebtSecuritiesAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_HeldToMaturityCashEquivalents" abstract="false" name="HeldToMaturityCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_A1365ConsumerHealthcareJVLoanMember" abstract="true" name="A1365ConsumerHealthcareJVLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IbranceMember" abstract="true" name="IbranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" abstract="false" name="AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PaxlovidMember" abstract="true" name="PaxlovidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" abstract="true" name="PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BesponsaMember" abstract="true" name="BesponsaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" abstract="false" name="IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EmergingMarketsMember" abstract="true" name="EmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ScheduleOfAccruedLiabilitiesTable" abstract="true" name="ScheduleOfAccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_BavencioAllianceRevenuesMember" abstract="true" name="BavencioAllianceRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" abstract="false" name="DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EpiPenMember" abstract="true" name="EpiPenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PfizerCentreOneSegmentMember" abstract="true" name="PfizerCentreOneSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" abstract="false" name="SiteContingencyRegulatoryProceedingsDisclosureThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_VyndaqelMember" abstract="true" name="VyndaqelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ForeignCurrencyDebtMember" abstract="true" name="ForeignCurrencyDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ReFactoAfXynthaMember" abstract="true" name="ReFactoAfXynthaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BioNTechMember" abstract="true" name="BioNTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_VfendMember" abstract="true" name="VfendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_XalkoriMember" abstract="true" name="XalkoriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ComirnatyAndPaxlovidMember" abstract="true" name="ComirnatyAndPaxlovidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_GainContingencyNumberofDefendants" abstract="false" name="GainContingencyNumberofDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_SutentMember" abstract="true" name="SutentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ArvinasIncMember" abstract="true" name="ArvinasIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember" abstract="true" name="ReconcilingItemsAmortizationOfIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherTaxAssetsCurrent" abstract="false" name="OtherTaxAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_GSKMember" abstract="true" name="GSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BiohavenMember" abstract="true" name="BiohavenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AssetImpairmentsMember" abstract="true" name="AssetImpairmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ReconcilingItemsAcquisitionRelatedCostsMember" abstract="true" name="ReconcilingItemsAcquisitionRelatedCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" abstract="false" name="DebtSecuritiesMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ProceedsFromEquityMethodInvestmentDistributionTotal" abstract="false" name="ProceedsFromEquityMethodInvestmentDistributionTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" abstract="false" name="LossContingencyNumberOfDefendantsOtherThanMainDefendant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" abstract="false" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" abstract="false" name="DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_GoToMarketModelMember" abstract="true" name="GoToMarketModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" abstract="true" name="PfizerandBMSVersusSeveralGenericManufacturersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" abstract="true" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_BiopharmaSegmentMember" abstract="true" name="BiopharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" abstract="false" name="PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherAntiinfectivesMember" abstract="true" name="OtherAntiinfectivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GovernmentAndGovernmentSponsoredMember" abstract="true" name="GovernmentAndGovernmentSponsoredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" abstract="false" name="LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_TotalAllianceBiopharmaceuticalsMember" abstract="true" name="TotalAllianceBiopharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ToviazMember" abstract="true" name="ToviazMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" abstract="false" name="HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DevelopedEuropeMember" abstract="true" name="DevelopedEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_NimenrixMember" abstract="true" name="NimenrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ZithromaxZmaxMember" abstract="true" name="ZithromaxZmaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" abstract="false" name="BusinessCombinationAcquisitionRelatedCostsTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" abstract="false" name="CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" abstract="false" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AromasinMember" abstract="true" name="AromasinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ViatrisMember" abstract="true" name="ViatrisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" abstract="false" name="PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ResearchAndDevelopmentInProcessMember" abstract="true" name="ResearchAndDevelopmentInProcessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BosulifMember" abstract="true" name="BosulifMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TrumenbaMember" abstract="true" name="TrumenbaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" abstract="false" name="LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AccruedRebates" abstract="false" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherAccruals" abstract="false" name="OtherAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_TrazimeraMember" abstract="true" name="TrazimeraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RestructuringChargesAndAcquisitionRelatedCosts" abstract="false" name="RestructuringChargesAndAcquisitionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_InterestPaidReceivedInterestRateHedges" abstract="false" name="InterestPaidReceivedInterestRateHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_MektoviMember" abstract="true" name="MektoviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_FSMEIMMUNTicoVacMember" abstract="true" name="FSMEIMMUNTicoVacMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ManufacturingOptimizationMember" abstract="true" name="ManufacturingOptimizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" abstract="false" name="AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_LicensingAgreementsAndOtherMember" abstract="true" name="LicensingAgreementsAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentsToCollaboratorsUpfrontPayment" abstract="false" name="PaymentsToCollaboratorsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BeneFIXMember" abstract="true" name="BeneFIXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" abstract="true" name="BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" abstract="false" name="PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BMP2Member" abstract="true" name="BMP2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" abstract="false" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember" abstract="true" name="ConsumerHealthcareJVSeniorNotesEURDenominatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RuxienceMember" abstract="true" name="RuxienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DocetaxelMember" abstract="true" name="DocetaxelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_HedgedItemDomain" abstract="true" name="HedgedItemDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LorbrenaMember" abstract="true" name="LorbrenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" abstract="true" name="ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ComirnatyMember" abstract="true" name="ComirnatyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesAmortizedCostBasis" abstract="false" name="DebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ChantixChampixMember" abstract="true" name="ChantixChampixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PercentageChangeInRevenue" abstract="false" name="PercentageChangeInRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_FragminMember" abstract="true" name="FragminMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" abstract="false" name="PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" abstract="false" name="ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_InflectraMember" abstract="true" name="InflectraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pfe-20221002_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:532d8f3f-927e-412c-bdcb-1806e94574ca,g:7cd44193-98b9-486c-9ee0-61ec890b3036-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4310b8f-0714-4269-8608-848d90b71cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_a3483d74-545a-4045-b6d8-6c672a9ad7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_c4310b8f-0714-4269-8608-848d90b71cda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_a3483d74-545a-4045-b6d8-6c672a9ad7f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_38c6e2f3-c566-4dcf-a4c7-d60bf468b572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_c4310b8f-0714-4269-8608-848d90b71cda" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_38c6e2f3-c566-4dcf-a4c7-d60bf468b572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ca782b4b-f7b4-4f28-8f1e-0f563d2df333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9146a941-bcc4-4b2a-abbf-b8df440f1369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ca782b4b-f7b4-4f28-8f1e-0f563d2df333" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9146a941-bcc4-4b2a-abbf-b8df440f1369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1833ec57-f688-40db-ae05-d853de469d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ca782b4b-f7b4-4f28-8f1e-0f563d2df333" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1833ec57-f688-40db-ae05-d853de469d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b70a848-5d9c-4e1b-966c-4a63a1da435d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b70a848-5d9c-4e1b-966c-4a63a1da435d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_378d0797-c5f8-43ad-8274-e7cbbdd20670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_378d0797-c5f8-43ad-8274-e7cbbdd20670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_285b623b-130a-4a22-90e1-257ab6be59cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_285b623b-130a-4a22-90e1-257ab6be59cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_347bb328-f817-4377-8b4c-347567164175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_347bb328-f817-4377-8b4c-347567164175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_ac9b1c98-4a36-48bc-ad22-c71c46464237" xlink:href="pfe-20221002.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_ac9b1c98-4a36-48bc-ad22-c71c46464237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_f461a46a-d4ef-4d62-9302-7180f8f6e45a" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_f461a46a-d4ef-4d62-9302-7180f8f6e45a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dacfc0d5-0a73-4acf-a878-93c4bd0e45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dacfc0d5-0a73-4acf-a878-93c4bd0e45f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a3fc5fcf-68a6-4282-aada-4d93a94f597c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_520878f1-dc1c-453d-a969-e0275102d203" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a3fc5fcf-68a6-4282-aada-4d93a94f597c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_14c25e2a-cb39-43a8-adc7-63d3eacef786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6a89c360-6a3b-45f3-bcec-a2edd640e525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_14c25e2a-cb39-43a8-adc7-63d3eacef786" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6a89c360-6a3b-45f3-bcec-a2edd640e525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3f1666c3-ca84-4a66-95bc-3292a540db07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_14c25e2a-cb39-43a8-adc7-63d3eacef786" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3f1666c3-ca84-4a66-95bc-3292a540db07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6960ed0-6c43-4ef1-83d4-5a0226d7f6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_57412c65-3af0-4f36-b52a-cd7502ffd5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6960ed0-6c43-4ef1-83d4-5a0226d7f6a0" xlink:to="loc_us-gaap_ProfitLoss_57412c65-3af0-4f36-b52a-cd7502ffd5e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bc91f6e8-1d72-4d62-bf19-537794d02e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6960ed0-6c43-4ef1-83d4-5a0226d7f6a0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bc91f6e8-1d72-4d62-bf19-537794d02e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f3d4cb47-b87b-4c6c-b639-c7425062ee46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_451b6d4e-43c2-42b6-aa5a-ccb2d97b60fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_f3d4cb47-b87b-4c6c-b639-c7425062ee46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_451b6d4e-43c2-42b6-aa5a-ccb2d97b60fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_85020305-0111-4675-b489-81cc15726a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_f3d4cb47-b87b-4c6c-b639-c7425062ee46" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_85020305-0111-4675-b489-81cc15726a7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_4ea4428e-0ad6-41b3-9f7e-ea83d04487bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f18aa04b-6abf-4376-aab0-0771d3de2ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_4ea4428e-0ad6-41b3-9f7e-ea83d04487bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f18aa04b-6abf-4376-aab0-0771d3de2ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ac482246-c228-40d1-8501-192e4850bc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_4ea4428e-0ad6-41b3-9f7e-ea83d04487bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ac482246-c228-40d1-8501-192e4850bc9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_53717b3a-5af7-431f-b3b2-b2d4c6d2cadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2c5b33e-e681-4333-970c-c1263ba2918a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_53717b3a-5af7-431f-b3b2-b2d4c6d2cadf" xlink:to="loc_us-gaap_ProfitLoss_f2c5b33e-e681-4333-970c-c1263ba2918a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7dbfef93-9dc5-45e8-8b3a-046b5fac3225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_53717b3a-5af7-431f-b3b2-b2d4c6d2cadf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7dbfef93-9dc5-45e8-8b3a-046b5fac3225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4546b691-cf04-45c0-847d-516f28242306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_bb795cfb-db38-4946-ad8c-ef98456d686c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4546b691-cf04-45c0-847d-516f28242306" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_bb795cfb-db38-4946-ad8c-ef98456d686c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_6d451eac-236f-4539-b5d2-42e546a2d16d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4546b691-cf04-45c0-847d-516f28242306" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_6d451eac-236f-4539-b5d2-42e546a2d16d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_7dc9efea-a2d3-4da5-bb4c-7f47886e7228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_f726cc33-efd4-4c76-95b2-fece04e152b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_7dc9efea-a2d3-4da5-bb4c-7f47886e7228" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_f726cc33-efd4-4c76-95b2-fece04e152b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_a1aac59e-5f0b-49fa-8839-7df3a49d94bc" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_7dc9efea-a2d3-4da5-bb4c-7f47886e7228" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_a1aac59e-5f0b-49fa-8839-7df3a49d94bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2e4214e4-c616-4a06-9f5c-7e0df6effa0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_259dd607-e91f-4180-bd18-548a9e06b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2e4214e4-c616-4a06-9f5c-7e0df6effa0e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_259dd607-e91f-4180-bd18-548a9e06b3c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d0b503a4-3dac-40a7-8a8a-c35331a1e885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2e4214e4-c616-4a06-9f5c-7e0df6effa0e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d0b503a4-3dac-40a7-8a8a-c35331a1e885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_476dd43e-1a30-4c7b-8da6-f0aa8ed511ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f1fc2a46-4166-4e07-aabb-f31fb0f4ff4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_476dd43e-1a30-4c7b-8da6-f0aa8ed511ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f1fc2a46-4166-4e07-aabb-f31fb0f4ff4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_1626cb2c-4357-4cb6-95ef-f6ad193bca68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_476dd43e-1a30-4c7b-8da6-f0aa8ed511ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_1626cb2c-4357-4cb6-95ef-f6ad193bca68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_33a1be85-ceae-46da-bca0-eeff716d6ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_f2c5ee83-c3f1-4c7a-afa5-864d479a412e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_33a1be85-ceae-46da-bca0-eeff716d6ea6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_f2c5ee83-c3f1-4c7a-afa5-864d479a412e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_7cd7577e-4de2-4f15-a401-0ae15cb681df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_33a1be85-ceae-46da-bca0-eeff716d6ea6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_7cd7577e-4de2-4f15-a401-0ae15cb681df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_28f6a065-b606-4398-a868-6f29c0f4b5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_33a1be85-ceae-46da-bca0-eeff716d6ea6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_28f6a065-b606-4398-a868-6f29c0f4b5e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_f59481ed-eb6f-4d41-bc03-1c8e07f2d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_33a1be85-ceae-46da-bca0-eeff716d6ea6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_f59481ed-eb6f-4d41-bc03-1c8e07f2d65c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5383a37b-da0d-4e05-9259-47a9b63651be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5a0a5f5-511c-4c03-b3eb-d3264c4d5380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5383a37b-da0d-4e05-9259-47a9b63651be" xlink:to="loc_us-gaap_StockholdersEquity_f5a0a5f5-511c-4c03-b3eb-d3264c4d5380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_39d6ba6f-8d0c-4fda-8d99-9540166c4a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5383a37b-da0d-4e05-9259-47a9b63651be" xlink:to="loc_us-gaap_MinorityInterest_39d6ba6f-8d0c-4fda-8d99-9540166c4a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b86dd9f6-2140-48c6-8546-29b107896c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_098c1194-58be-4315-9600-87034366f757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b86dd9f6-2140-48c6-8546-29b107896c41" xlink:to="loc_us-gaap_CommonStockValue_098c1194-58be-4315-9600-87034366f757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_123e4b3e-44ef-403f-abea-02b23bfdc8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b86dd9f6-2140-48c6-8546-29b107896c41" xlink:to="loc_us-gaap_AdditionalPaidInCapital_123e4b3e-44ef-403f-abea-02b23bfdc8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_276c04d8-0a6c-4aaa-93f3-3ece185d18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b86dd9f6-2140-48c6-8546-29b107896c41" xlink:to="loc_us-gaap_TreasuryStockValue_276c04d8-0a6c-4aaa-93f3-3ece185d18b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56772ea5-85fc-40af-8193-66979266827c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b86dd9f6-2140-48c6-8546-29b107896c41" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56772ea5-85fc-40af-8193-66979266827c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c6a6cb6-98ca-47a1-9068-6e04d2ff0def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b86dd9f6-2140-48c6-8546-29b107896c41" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c6a6cb6-98ca-47a1-9068-6e04d2ff0def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_eba9844c-61cd-4847-bdeb-2abaa574e639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:to="loc_us-gaap_DebtCurrent_eba9844c-61cd-4847-bdeb-2abaa574e639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1d1b5606-acf8-462f-aed8-eac2c5ea3984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:to="loc_us-gaap_AccountsPayableCurrent_1d1b5606-acf8-462f-aed8-eac2c5ea3984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_edf9e7d9-3245-4fe7-8a3a-ad84de2952be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:to="loc_us-gaap_DividendsPayableCurrent_edf9e7d9-3245-4fe7-8a3a-ad84de2952be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_ddfd3d57-49d8-446a-9a07-9a6bb00fab9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:to="loc_us-gaap_TaxesPayableCurrent_ddfd3d57-49d8-446a-9a07-9a6bb00fab9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_549e9a57-f370-4d9d-9c79-81d45637d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_549e9a57-f370-4d9d-9c79-81d45637d51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0e9c8ce7-a3bb-487a-8aad-eeec9ba1667b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0e9c8ce7-a3bb-487a-8aad-eeec9ba1667b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8eea741f-c680-4042-ac1c-867c84cf1d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_69f63a79-353c-4f7c-a496-cb4e59ec7905" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8eea741f-c680-4042-ac1c-867c84cf1d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4b9f773-6f43-48e2-9ebb-5d945432939a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4b9f773-6f43-48e2-9ebb-5d945432939a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f46041d7-fc32-4b93-bac7-d2d2a7c183c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f46041d7-fc32-4b93-bac7-d2d2a7c183c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_620c3675-1e79-41ff-ac97-2700e8e811ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_620c3675-1e79-41ff-ac97-2700e8e811ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_9f1fd220-7de4-4dfb-88c9-48aa090748de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_9f1fd220-7de4-4dfb-88c9-48aa090748de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_02d9bc79-e8c0-4b91-bb55-f5e734bbe2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_02d9bc79-e8c0-4b91-bb55-f5e734bbe2f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_181354e7-9269-4417-afb4-fd1260e9e318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_181354e7-9269-4417-afb4-fd1260e9e318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_ee89caad-62a0-491d-8722-4fb5e3cda220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5738f125-ae49-479f-b45f-0b61139f07e5" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_ee89caad-62a0-491d-8722-4fb5e3cda220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4663202c-798b-4615-aea7-941607bdbeac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9a69d339-c13a-46e1-a118-56a7bc223846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4663202c-798b-4615-aea7-941607bdbeac" xlink:to="loc_us-gaap_Liabilities_9a69d339-c13a-46e1-a118-56a7bc223846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f313a645-aa9f-4aff-8fab-f6d8d9c5fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4663202c-798b-4615-aea7-941607bdbeac" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f313a645-aa9f-4aff-8fab-f6d8d9c5fb16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc466680-c00e-487f-a46c-6253ebdbcd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4663202c-798b-4615-aea7-941607bdbeac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc466680-c00e-487f-a46c-6253ebdbcd50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7c36c1e0-8e2d-42d9-9a1b-556567a20d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b144dcda-b95b-414e-b7f1-7f8b459ba6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7c36c1e0-8e2d-42d9-9a1b-556567a20d23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b144dcda-b95b-414e-b7f1-7f8b459ba6f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_acdb4be9-5026-4f8d-b7ba-18a06b9f845b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7c36c1e0-8e2d-42d9-9a1b-556567a20d23" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_acdb4be9-5026-4f8d-b7ba-18a06b9f845b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_97f9282a-cfed-4273-b541-a3042cb26f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7c36c1e0-8e2d-42d9-9a1b-556567a20d23" xlink:to="loc_us-gaap_InventoryNet_97f9282a-cfed-4273-b541-a3042cb26f7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_68c3411d-32f0-4e28-8cd8-379de3624b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7c36c1e0-8e2d-42d9-9a1b-556567a20d23" xlink:to="loc_us-gaap_OtherAssetsCurrent_68c3411d-32f0-4e28-8cd8-379de3624b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_0bed1807-7de6-4400-8d4c-ee05cb417c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7c36c1e0-8e2d-42d9-9a1b-556567a20d23" xlink:to="loc_us-gaap_OtherShortTermInvestments_0bed1807-7de6-4400-8d4c-ee05cb417c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent_1fd04e04-666d-4b77-98da-d210be0340d8" xlink:href="pfe-20221002.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7c36c1e0-8e2d-42d9-9a1b-556567a20d23" xlink:to="loc_pfe_OtherTaxAssetsCurrent_1fd04e04-666d-4b77-98da-d210be0340d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_28c79a52-55e7-4e4e-9edc-818a7819a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_us-gaap_AssetsCurrent_28c79a52-55e7-4e4e-9edc-818a7819a16b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_27a562d0-727c-46f1-8f8e-091a4e420ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_us-gaap_OtherLongTermInvestments_27a562d0-727c-46f1-8f8e-091a4e420ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_81ba40f5-a242-4afc-b95f-693317940c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_81ba40f5-a242-4afc-b95f-693317940c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_151076fb-6bb5-473b-80a1-63c2fc3a72d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_151076fb-6bb5-473b-80a1-63c2fc3a72d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_410cd590-d164-422e-b305-c8e477c3cb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_us-gaap_Goodwill_410cd590-d164-422e-b305-c8e477c3cb88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_4628fc0e-2fb0-4269-a189-ed3460b32b1c" xlink:href="pfe-20221002.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_4628fc0e-2fb0-4269-a189-ed3460b32b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d550f44f-1d54-4a41-9201-39380e331fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d550f44f-1d54-4a41-9201-39380e331fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3ada5440-abca-40db-ae79-806161b7cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c7fbffdb-6c90-412d-b743-3ea322344ba2" xlink:to="loc_us-gaap_EquityMethodInvestments_3ada5440-abca-40db-ae79-806161b7cc8c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_040a2142-fc9f-414d-a7f6-1aede944162c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_040a2142-fc9f-414d-a7f6-1aede944162c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_348c8ab9-9111-4adc-a87c-6e1344fc4797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_348c8ab9-9111-4adc-a87c-6e1344fc4797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_e3a4c0a8-78b7-4482-b298-f7bf91485c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_e3a4c0a8-78b7-4482-b298-f7bf91485c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_e8973cfb-c39f-4736-9ae9-1d5735cb3a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_e8973cfb-c39f-4736-9ae9-1d5735cb3a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07155980-a308-4773-a72e-60e290a90d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07155980-a308-4773-a72e-60e290a90d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_7418d6ce-7ed4-47f2-ae8f-295c4b51b71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_7418d6ce-7ed4-47f2-ae8f-295c4b51b71b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b194d15f-9cf4-4300-a27c-ae5f23833681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b194d15f-9cf4-4300-a27c-ae5f23833681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0794592e-ae66-4d92-9ba2-ba4c284aa9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4b18e7d-7628-40e9-8155-0b3e3c58a838" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0794592e-ae66-4d92-9ba2-ba4c284aa9b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7329fa5-588c-462a-b4d6-33c8ce557198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fdcfc2c1-9566-4180-93d1-211830fbf5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7329fa5-588c-462a-b4d6-33c8ce557198" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fdcfc2c1-9566-4180-93d1-211830fbf5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d9f82daa-28e2-475d-83d1-07d113868bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7329fa5-588c-462a-b4d6-33c8ce557198" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d9f82daa-28e2-475d-83d1-07d113868bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_909fde2c-0e7b-4587-a9ad-97a316b30760" xlink:href="pfe-20221002.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_909fde2c-0e7b-4587-a9ad-97a316b30760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_658bc4ad-b819-4eec-8c2b-1e442d3d7187" xlink:href="pfe-20221002.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_658bc4ad-b819-4eec-8c2b-1e442d3d7187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2fe8e7a8-db89-471e-953a-1e7c5bd8551c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_us-gaap_ShareBasedCompensation_2fe8e7a8-db89-471e-953a-1e7c5bd8551c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3517e153-9de2-4d4d-a3f6-ecd9d8aca876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3517e153-9de2-4d4d-a3f6-ecd9d8aca876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_a8ca7cbf-0846-4c0a-956a-103ff964b675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_a8ca7cbf-0846-4c0a-956a-103ff964b675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_233e0eb9-175c-4fd2-a533-558e046fd1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_233e0eb9-175c-4fd2-a533-558e046fd1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_167828bc-d2ab-4703-85a7-cd6c6345558e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_167828bc-d2ab-4703-85a7-cd6c6345558e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_4d8410a9-e26e-4af0-b464-91464327fa8b" xlink:href="pfe-20221002.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_ac9e8101-e62c-4954-95ce-1a3f3b533c0e" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_4d8410a9-e26e-4af0-b464-91464327fa8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_6e4bef27-e825-4a18-ace5-7411019a7fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_6e4bef27-e825-4a18-ace5-7411019a7fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_959f772a-0df1-4189-9b15-d912ff102852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_959f772a-0df1-4189-9b15-d912ff102852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_31180309-c39f-4f35-874f-b3def065e381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_31180309-c39f-4f35-874f-b3def065e381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4db9a2a5-a1c9-4a5b-a82d-37b12f938cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4db9a2a5-a1c9-4a5b-a82d-37b12f938cc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0b5cf60d-2794-4550-9896-41981b274834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0b5cf60d-2794-4550-9896-41981b274834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_795b2f59-14e7-46e7-b008-57a43a024117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_795b2f59-14e7-46e7-b008-57a43a024117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_139b5ce8-15e4-4450-84f1-684eab50a78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_139b5ce8-15e4-4450-84f1-684eab50a78e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_6831dcaf-fdbf-458e-8e8f-184441d71b2d" xlink:href="pfe-20221002.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_6831dcaf-fdbf-458e-8e8f-184441d71b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_271f40f7-2453-4a60-bad5-00ab89eb54fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f3cd5542-37b7-4ab7-b3c9-0d460bc17309" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_271f40f7-2453-4a60-bad5-00ab89eb54fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74e143b0-0634-454b-af76-5870dc784c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed18fb67-fb62-4112-8a0b-ed2d18f05418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74e143b0-0634-454b-af76-5870dc784c72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed18fb67-fb62-4112-8a0b-ed2d18f05418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e317ce0-3c09-4171-9bc5-7fa99225ccae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74e143b0-0634-454b-af76-5870dc784c72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e317ce0-3c09-4171-9bc5-7fa99225ccae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0d2efc2-9590-4ee6-825f-20a3f3213594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74e143b0-0634-454b-af76-5870dc784c72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0d2efc2-9590-4ee6-825f-20a3f3213594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18d8c461-e002-4cfe-b37b-e113363107b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74e143b0-0634-454b-af76-5870dc784c72" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18d8c461-e002-4cfe-b37b-e113363107b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d19a2373-458f-491b-a6d5-7a84d6f86da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_02096eae-3210-41cc-9241-a87228c5e70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d19a2373-458f-491b-a6d5-7a84d6f86da2" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_02096eae-3210-41cc-9241-a87228c5e70c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0e03f86a-600c-4063-9ef8-0f9ebeeb5415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d19a2373-458f-491b-a6d5-7a84d6f86da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0e03f86a-600c-4063-9ef8-0f9ebeeb5415" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ad31d433-45fc-462d-9988-63f5e441c616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_f5088c37-2231-402b-84d7-e00997d16f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_ad31d433-45fc-462d-9988-63f5e441c616" xlink:to="loc_us-gaap_CostOfRevenue_f5088c37-2231-402b-84d7-e00997d16f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc63bcaa-1747-4ead-b9e7-8ae79e8ff3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_ad31d433-45fc-462d-9988-63f5e441c616" xlink:to="loc_us-gaap_Revenues_bc63bcaa-1747-4ead-b9e7-8ae79e8ff3c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_06bad217-b6e5-42cb-b975-bc84303e5f7a" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_214fdf23-ac81-4adf-8344-6b62242afd11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_06bad217-b6e5-42cb-b975-bc84303e5f7a" xlink:to="loc_us-gaap_RestructuringCharges_214fdf23-ac81-4adf-8344-6b62242afd11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_0e0d12a5-b7bb-4311-9f43-29fffe4ba6c2" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_06bad217-b6e5-42cb-b975-bc84303e5f7a" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_0e0d12a5-b7bb-4311-9f43-29fffe4ba6c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_7aefc67b-249c-4cee-b09b-9380a8c10288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_06bad217-b6e5-42cb-b975-bc84303e5f7a" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_7aefc67b-249c-4cee-b09b-9380a8c10288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_c1f4e823-1800-4fa2-83cb-c7f000e922f2" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_79a92328-2f0e-4f74-a842-57653bf28fc6" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_c1f4e823-1800-4fa2-83cb-c7f000e922f2" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_79a92328-2f0e-4f74-a842-57653bf28fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_48205c8a-38de-4829-9979-0930142e0691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_c1f4e823-1800-4fa2-83cb-c7f000e922f2" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_48205c8a-38de-4829-9979-0930142e0691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a9aba8ec-b183-4b7e-80ca-b39dcce885c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_c1f4e823-1800-4fa2-83cb-c7f000e922f2" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a9aba8ec-b183-4b7e-80ca-b39dcce885c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_bbe2a160-08d4-4dc4-bd1d-30e88faf96f1" xlink:href="pfe-20221002.xsd#pfe_ImplementationCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_c1f4e823-1800-4fa2-83cb-c7f000e922f2" xlink:to="loc_pfe_ImplementationCosts_bbe2a160-08d4-4dc4-bd1d-30e88faf96f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_23edb8bd-78f7-4310-acde-3d0f656106d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_272df96c-7052-49d1-b7b6-ba8c011e78d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_23edb8bd-78f7-4310-acde-3d0f656106d3" xlink:to="loc_us-gaap_SeveranceCosts1_272df96c-7052-49d1-b7b6-ba8c011e78d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_4a12b78c-6e09-440d-ac05-c423a0684525" xlink:href="pfe-20221002.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_23edb8bd-78f7-4310-acde-3d0f656106d3" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_4a12b78c-6e09-440d-ac05-c423a0684525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_4b02c4b3-dd04-425b-a03c-076bf945a451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_23edb8bd-78f7-4310-acde-3d0f656106d3" xlink:to="loc_us-gaap_BusinessExitCosts1_4b02c4b3-dd04-425b-a03c-076bf945a451" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_71da2a33-39b8-478a-a05a-2c3e5ee6ee7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_33773d45-ac41-44f2-aae6-4e765367650e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_71da2a33-39b8-478a-a05a-2c3e5ee6ee7a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_33773d45-ac41-44f2-aae6-4e765367650e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f2859ebb-4d2a-47b7-8d91-70dce88ab8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_71da2a33-39b8-478a-a05a-2c3e5ee6ee7a" xlink:to="loc_us-gaap_InterestExpense_f2859ebb-4d2a-47b7-8d91-70dce88ab8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_976b6f06-e878-4c3a-aeec-0325acce8e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_976b6f06-e878-4c3a-aeec-0325acce8e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_2153ef17-6c87-4aa4-8b0f-017f648fcb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_2153ef17-6c87-4aa4-8b0f-017f648fcb28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a18f594a-713a-4894-b603-43706ace7186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a18f594a-713a-4894-b603-43706ace7186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e6277e31-d4ed-4d00-b144-2baefec6a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e6277e31-d4ed-4d00-b144-2baefec6a45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_ffc0d701-dd37-4f74-8841-5224a8c8b7b9" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_ffc0d701-dd37-4f74-8841-5224a8c8b7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_1fd0898f-d4b6-46fd-928f-36b2a882d347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_1fd0898f-d4b6-46fd-928f-36b2a882d347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_055d084c-8b8f-48b7-a5fa-aa7ec2233e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_055d084c-8b8f-48b7-a5fa-aa7ec2233e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_2df80f47-66f1-487f-abf8-28b126042cc1" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_2df80f47-66f1-487f-abf8-28b126042cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_1f513015-6bdd-4952-bec1-9118a9db322f" xlink:href="pfe-20221002.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_1f513015-6bdd-4952-bec1-9118a9db322f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d09d2516-e890-4dc4-a220-83945756da23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_14602ef5-358e-4dc7-b5f2-09aaf7b26890" xlink:to="loc_us-gaap_AssetImpairmentCharges_d09d2516-e890-4dc4-a220-83945756da23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_8d071dd6-17aa-4ed2-9f53-90059f21cec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_2ce0150a-f0c9-41bf-9308-1c9de9d3f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_8d071dd6-17aa-4ed2-9f53-90059f21cec3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_2ce0150a-f0c9-41bf-9308-1c9de9d3f94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_44782f82-5b02-4a60-8b3e-4ef162b181d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_8d071dd6-17aa-4ed2-9f53-90059f21cec3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_44782f82-5b02-4a60-8b3e-4ef162b181d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2f53c48c-b463-4725-a014-f8d937144ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a18abf4b-e36e-4793-a84b-280d6787fb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2f53c48c-b463-4725-a014-f8d937144ff3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a18abf4b-e36e-4793-a84b-280d6787fb8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4dacd643-c748-43c6-90bc-5a9883aca911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2f53c48c-b463-4725-a014-f8d937144ff3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4dacd643-c748-43c6-90bc-5a9883aca911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_dea168e1-16d2-488a-a996-a934e0d62b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_0487a2a3-5230-48d0-ab0b-9b416ee50546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_dea168e1-16d2-488a-a996-a934e0d62b7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_0487a2a3-5230-48d0-ab0b-9b416ee50546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_cfe26ba0-7282-456c-905a-564512ac60b6" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_dea168e1-16d2-488a-a996-a934e0d62b7a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_cfe26ba0-7282-456c-905a-564512ac60b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_36cc482f-4373-4178-9a84-eb822e7fa809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4b15d4c0-2dd4-493d-8906-0ec22c52e50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_36cc482f-4373-4178-9a84-eb822e7fa809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4b15d4c0-2dd4-493d-8906-0ec22c52e50e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_8b115852-da0b-4951-a932-25fff3022d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_36cc482f-4373-4178-9a84-eb822e7fa809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_8b115852-da0b-4951-a932-25fff3022d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1429ce56-987c-416c-9302-04ef813254b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_36cc482f-4373-4178-9a84-eb822e7fa809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1429ce56-987c-416c-9302-04ef813254b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_7a5def2a-107d-4a3c-b36f-6e1e069a724e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_36cc482f-4373-4178-9a84-eb822e7fa809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_7a5def2a-107d-4a3c-b36f-6e1e069a724e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_858ba167-1d16-4230-a3a0-10cada1f719e" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_53bc2c57-234b-4d20-9419-0596493838e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_858ba167-1d16-4230-a3a0-10cada1f719e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_53bc2c57-234b-4d20-9419-0596493838e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b0364af2-7358-4f3a-a4ad-b508fedc2900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_858ba167-1d16-4230-a3a0-10cada1f719e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b0364af2-7358-4f3a-a4ad-b508fedc2900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_8b6abeba-a613-4b15-962b-30b809c3eee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_858ba167-1d16-4230-a3a0-10cada1f719e" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_8b6abeba-a613-4b15-962b-30b809c3eee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_bf26904c-e1e0-4ca9-b926-8b95caca0545" xlink:href="pfe-20221002.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0534721a-8a68-4763-a513-a18242e5f2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_bf26904c-e1e0-4ca9-b926-8b95caca0545" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0534721a-8a68-4763-a513-a18242e5f2ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ef6db87-4f02-4c33-b8c8-d1f5d8db5974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_bf26904c-e1e0-4ca9-b926-8b95caca0545" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ef6db87-4f02-4c33-b8c8-d1f5d8db5974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_549c1bdf-7c4c-47ec-bbcb-3eeebf328cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_62173c0c-9ad4-4f74-b221-55460826d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_549c1bdf-7c4c-47ec-bbcb-3eeebf328cb6" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_62173c0c-9ad4-4f74-b221-55460826d5b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_7080ed11-0626-4353-b25e-79f8924f663c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_549c1bdf-7c4c-47ec-bbcb-3eeebf328cb6" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_7080ed11-0626-4353-b25e-79f8924f663c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0465d179-087e-400a-a35b-0673ddba5b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_bfd01cf1-9beb-4bd8-80a4-c73c47939965" xlink:href="pfe-20221002.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0465d179-087e-400a-a35b-0673ddba5b7a" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_bfd01cf1-9beb-4bd8-80a4-c73c47939965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_62e799dd-328c-4c45-a437-e69cc4a0eb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0465d179-087e-400a-a35b-0673ddba5b7a" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_62e799dd-328c-4c45-a437-e69cc4a0eb62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_ae24048d-d317-45a5-95cc-3dc105f9b20e" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0465d179-087e-400a-a35b-0673ddba5b7a" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_ae24048d-d317-45a5-95cc-3dc105f9b20e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1f9290f3-615f-4711-a47a-a89314b144e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0465d179-087e-400a-a35b-0673ddba5b7a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1f9290f3-615f-4711-a47a-a89314b144e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4db49964-b91f-43d7-a9a5-8c089dcb1e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_cf6d7a6a-5c69-42d4-8175-5b5b23932b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_4db49964-b91f-43d7-a9a5-8c089dcb1e66" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_cf6d7a6a-5c69-42d4-8175-5b5b23932b9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_506de67f-e2c7-4d4a-a693-bc4867809fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_4db49964-b91f-43d7-a9a5-8c089dcb1e66" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_506de67f-e2c7-4d4a-a693-bc4867809fa4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsInvestmentsbyClassificationTypeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_4b688d46-69a1-4ab0-8317-f8b017a6a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_85b050db-8db3-4a71-b8c5-a918048166a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_4b688d46-69a1-4ab0-8317-f8b017a6a2ab" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_85b050db-8db3-4a71-b8c5-a918048166a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_186927f0-92b1-4775-8306-8dcce49706f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_4b688d46-69a1-4ab0-8317-f8b017a6a2ab" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_186927f0-92b1-4775-8306-8dcce49706f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_825ce895-09cb-4547-8a59-fe33a1c54481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_4b688d46-69a1-4ab0-8317-f8b017a6a2ab" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_825ce895-09cb-4547-8a59-fe33a1c54481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments_c2b5d487-4b74-4bb4-ac34-fec19f5f7d2b" xlink:href="pfe-20221002.xsd#pfe_PrivateEquityInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_4b688d46-69a1-4ab0-8317-f8b017a6a2ab" xlink:to="loc_pfe_PrivateEquityInvestments_c2b5d487-4b74-4bb4-ac34-fec19f5f7d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_becbddd1-5849-4b9d-94fc-2423726c21c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_1792fce2-b2a5-4fdb-9d6b-787d33a4ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_becbddd1-5849-4b9d-94fc-2423726c21c0" xlink:to="loc_us-gaap_OtherLongTermInvestments_1792fce2-b2a5-4fdb-9d6b-787d33a4ec95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_bdd1208d-7b35-4303-979a-5b8a96805c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_becbddd1-5849-4b9d-94fc-2423726c21c0" xlink:to="loc_us-gaap_EquityMethodInvestments_bdd1208d-7b35-4303-979a-5b8a96805c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_d91f377a-0598-417d-899f-1280c6950642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7ad696c4-d807-45d6-969b-ecab57ee5025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherShortTermInvestments_d91f377a-0598-417d-899f-1280c6950642" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7ad696c4-d807-45d6-969b-ecab57ee5025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_074141be-a4cb-4ca8-b075-12c1fa4e0d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherShortTermInvestments_d91f377a-0598-417d-899f-1280c6950642" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_074141be-a4cb-4ca8-b075-12c1fa4e0d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_cbd8f6c8-cfe2-4c76-9e79-1b575c022ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherShortTermInvestments_d91f377a-0598-417d-899f-1280c6950642" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_cbd8f6c8-cfe2-4c76-9e79-1b575c022ba7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_f4694144-b0cd-4d14-86c1-9054907cefac" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f97463b2-b2d2-4b7a-a095-bb3f950d185f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_f4694144-b0cd-4d14-86c1-9054907cefac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f97463b2-b2d2-4b7a-a095-bb3f950d185f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_130b1fbe-65c0-463e-ae3b-c72fd6e9a95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_f4694144-b0cd-4d14-86c1-9054907cefac" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_130b1fbe-65c0-463e-ae3b-c72fd6e9a95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_04daa0c8-71d8-434c-acef-cec459495259" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4b5fea11-8991-4762-b875-6c38148cf3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_04daa0c8-71d8-434c-acef-cec459495259" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4b5fea11-8991-4762-b875-6c38148cf3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1fb6440d-964b-42be-aeb6-20940e27d87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_04daa0c8-71d8-434c-acef-cec459495259" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1fb6440d-964b-42be-aeb6-20940e27d87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_7aa3bf10-ed29-4c38-9133-d1d44899bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cc2c64b1-b74b-467e-840e-c4a5fd2e8d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_7aa3bf10-ed29-4c38-9133-d1d44899bfc9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cc2c64b1-b74b-467e-840e-c4a5fd2e8d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_2a3b17e4-12b0-4617-ae45-0eb3a16628f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_7aa3bf10-ed29-4c38-9133-d1d44899bfc9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_2a3b17e4-12b0-4617-ae45-0eb3a16628f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_515fe73b-f9bc-42d1-adc3-d8237eecc7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_7aa3bf10-ed29-4c38-9133-d1d44899bfc9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_515fe73b-f9bc-42d1-adc3-d8237eecc7d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_4a9a1aa7-45b5-4739-99d5-39efe19e121a" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3978e5d6-884f-4c72-904e-eec82752f872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_4a9a1aa7-45b5-4739-99d5-39efe19e121a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3978e5d6-884f-4c72-904e-eec82752f872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_59e8a60b-4615-40b5-889c-7adbe050100e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_4a9a1aa7-45b5-4739-99d5-39efe19e121a" xlink:to="loc_us-gaap_HeldToMaturitySecurities_59e8a60b-4615-40b5-889c-7adbe050100e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5f4403b4-c925-4565-a59b-fe049927b87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5d3e6fdc-7fda-449b-833c-e2dbe0835bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5f4403b4-c925-4565-a59b-fe049927b87d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5d3e6fdc-7fda-449b-833c-e2dbe0835bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6306e577-9b08-4a31-a525-326acdaba62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5f4403b4-c925-4565-a59b-fe049927b87d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6306e577-9b08-4a31-a525-326acdaba62d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_2915e1fe-30bd-423d-adbd-435240b888eb" xlink:href="pfe-20221002.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5f4403b4-c925-4565-a59b-fe049927b87d" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_2915e1fe-30bd-423d-adbd-435240b888eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e5a1a6f-e394-4a68-a6fb-f0ede62927bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e383f658-c988-44e6-91a2-4ee2b4801e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e5a1a6f-e394-4a68-a6fb-f0ede62927bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e383f658-c988-44e6-91a2-4ee2b4801e67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_acd19718-d69d-48c3-aedb-a32f2909715f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e5a1a6f-e394-4a68-a6fb-f0ede62927bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_acd19718-d69d-48c3-aedb-a32f2909715f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2af55e8-e092-401c-a40d-4887c614ce6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e5a1a6f-e394-4a68-a6fb-f0ede62927bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2af55e8-e092-401c-a40d-4887c614ce6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_21b8a6a6-c70a-40e9-a1ac-64ce415e170c" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_13a0b0f6-1765-488c-a750-72d18d34f84c" xlink:href="pfe-20221002.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_21b8a6a6-c70a-40e9-a1ac-64ce415e170c" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_13a0b0f6-1765-488c-a750-72d18d34f84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_8d8317f0-cb0b-4de2-ba1c-3211739f959c" xlink:href="pfe-20221002.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_21b8a6a6-c70a-40e9-a1ac-64ce415e170c" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_8d8317f0-cb0b-4de2-ba1c-3211739f959c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_db2ade37-cdeb-4fb3-850a-3e207e08220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7d59abc-9c48-4102-ae2c-76c34cc44de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_db2ade37-cdeb-4fb3-850a-3e207e08220c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7d59abc-9c48-4102-ae2c-76c34cc44de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bc3acecc-fd16-450a-aead-aaa1ca17194f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_db2ade37-cdeb-4fb3-850a-3e207e08220c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bc3acecc-fd16-450a-aead-aaa1ca17194f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_72da2947-b71f-47a6-8bc2-26d5ce08df4e" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3d06a49a-7bd4-45a3-b0fd-4080bc407ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_72da2947-b71f-47a6-8bc2-26d5ce08df4e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3d06a49a-7bd4-45a3-b0fd-4080bc407ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_91263365-38f9-4e95-ab21-72fef47decb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_72da2947-b71f-47a6-8bc2-26d5ce08df4e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_91263365-38f9-4e95-ab21-72fef47decb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_b2ad9ca1-5672-4320-af27-1ec3b6635b52" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f2f49161-9c67-4c58-b992-cbd7e35d5fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_b2ad9ca1-5672-4320-af27-1ec3b6635b52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f2f49161-9c67-4c58-b992-cbd7e35d5fcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_a7bd98c4-308c-4f01-a139-8ec42a9ee1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_b2ad9ca1-5672-4320-af27-1ec3b6635b52" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_a7bd98c4-308c-4f01-a139-8ec42a9ee1b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_aec02323-1f82-4268-b7c2-3c4a9bf9edb1" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_dbf35b77-b30e-4382-a8aa-1947af06ea41" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_aec02323-1f82-4268-b7c2-3c4a9bf9edb1" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_dbf35b77-b30e-4382-a8aa-1947af06ea41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_ba767ae1-2584-4bbf-bfc5-561acc50dc00" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_aec02323-1f82-4268-b7c2-3c4a9bf9edb1" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_ba767ae1-2584-4bbf-bfc5-561acc50dc00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_3c764608-c922-4248-aa01-9ac38dd040eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_aec02323-1f82-4268-b7c2-3c4a9bf9edb1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_3c764608-c922-4248-aa01-9ac38dd040eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e5f2bde2-dd34-4e55-bf90-0cb5898427d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3ba22d1c-7b7f-48ef-8aff-6ce7c7ca769e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e5f2bde2-dd34-4e55-bf90-0cb5898427d8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3ba22d1c-7b7f-48ef-8aff-6ce7c7ca769e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4fe7a60-c358-49d1-a81a-955730e41f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e5f2bde2-dd34-4e55-bf90-0cb5898427d8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4fe7a60-c358-49d1-a81a-955730e41f39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsShorttermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c8d769b5-9ea1-49a3-847c-53b64decae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_6268ee89-ef97-447e-8202-493f4aec38cd" xlink:href="pfe-20221002.xsd#pfe_ShorttermDebtGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_c8d769b5-9ea1-49a3-847c-53b64decae4a" xlink:to="loc_pfe_ShorttermDebtGross_6268ee89-ef97-447e-8202-493f4aec38cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_5f483ea1-5efe-478c-8ad6-d03005ed4d57" xlink:href="pfe-20221002.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_c8d769b5-9ea1-49a3-847c-53b64decae4a" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_5f483ea1-5efe-478c-8ad6-d03005ed4d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_7248e330-7e58-4b92-917f-4560723e3db4" xlink:href="pfe-20221002.xsd#pfe_ShorttermDebtGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_4ba2aa14-5cd9-4d9a-a6e5-b01d6215dd66" xlink:href="pfe-20221002.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_7248e330-7e58-4b92-917f-4560723e3db4" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_4ba2aa14-5cd9-4d9a-a6e5-b01d6215dd66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_b9494b4e-f27b-43de-a440-27679bc6313f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_7248e330-7e58-4b92-917f-4560723e3db4" xlink:to="loc_us-gaap_OtherShortTermBorrowings_b9494b4e-f27b-43de-a440-27679bc6313f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1d409570-303a-4da2-9515-ec290457a155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ec37aa57-0ffe-490c-a272-de130f52c4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1d409570-303a-4da2-9515-ec290457a155" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ec37aa57-0ffe-490c-a272-de130f52c4db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_35b7f572-a57f-468b-959e-ac51e05efee0" xlink:href="pfe-20221002.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1d409570-303a-4da2-9515-ec290457a155" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_35b7f572-a57f-468b-959e-ac51e05efee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4010a62d-1bf2-43f1-8839-e8c3c9cbfd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1d409570-303a-4da2-9515-ec290457a155" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4010a62d-1bf2-43f1-8839-e8c3c9cbfd58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_3b77d84a-c9e1-4b1e-a4e0-22bbec3922aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1d409570-303a-4da2-9515-ec290457a155" xlink:to="loc_us-gaap_OtherLongTermDebt_3b77d84a-c9e1-4b1e-a4e0-22bbec3922aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6419e7df-2e58-4be4-bb62-b52dc5c460a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a126bfbd-c622-4288-ad15-02b5fab3db0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6419e7df-2e58-4be4-bb62-b52dc5c460a1" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a126bfbd-c622-4288-ad15-02b5fab3db0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_661f3436-fcec-4acb-a3fa-c3bdf4221c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6419e7df-2e58-4be4-bb62-b52dc5c460a1" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_661f3436-fcec-4acb-a3fa-c3bdf4221c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_0ec5fa85-fb03-462d-b659-391f857cd05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6419e7df-2e58-4be4-bb62-b52dc5c460a1" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_0ec5fa85-fb03-462d-b659-391f857cd05a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1282303-27ab-4f36-a9bc-bb486148b165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_505b2b08-b55b-46bc-bda2-9312c30f10b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1282303-27ab-4f36-a9bc-bb486148b165" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_505b2b08-b55b-46bc-bda2-9312c30f10b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2ef893fa-38a7-47ba-9b80-f3f6390c8734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1282303-27ab-4f36-a9bc-bb486148b165" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2ef893fa-38a7-47ba-9b80-f3f6390c8734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b36862ae-f3bd-483d-8d74-3ef674c0b028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3e53282a-0bc4-4f9d-a0ab-13712e3ecacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b36862ae-f3bd-483d-8d74-3ef674c0b028" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3e53282a-0bc4-4f9d-a0ab-13712e3ecacd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_75d79aa3-b298-482f-a300-622050a115fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b36862ae-f3bd-483d-8d74-3ef674c0b028" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_75d79aa3-b298-482f-a300-622050a115fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_79d8ceb8-9da7-4f31-890a-dd0c189dcf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_70670cda-1968-4f27-804a-0b3f4caf35dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_79d8ceb8-9da7-4f31-890a-dd0c189dcf6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_70670cda-1968-4f27-804a-0b3f4caf35dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_500e7fbf-fa92-4336-9acf-6ab0a8bde8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_79d8ceb8-9da7-4f31-890a-dd0c189dcf6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_500e7fbf-fa92-4336-9acf-6ab0a8bde8e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fcaae7ab-9a82-46b1-b0ad-10f5d169777a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2522dce0-9fc4-4142-aaea-997002c5ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fcaae7ab-9a82-46b1-b0ad-10f5d169777a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2522dce0-9fc4-4142-aaea-997002c5ae1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3e15c8b7-ee2b-4076-819a-b24f00ef3d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fcaae7ab-9a82-46b1-b0ad-10f5d169777a" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3e15c8b7-ee2b-4076-819a-b24f00ef3d38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3d9573ad-aab1-4649-93f8-989893c827f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3d9573ad-aab1-4649-93f8-989893c827f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_3302bebe-2bab-41a0-946e-1b2da80ed421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_3302bebe-2bab-41a0-946e-1b2da80ed421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6ec6ee82-3f36-4124-89ba-4641edb7b863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6ec6ee82-3f36-4124-89ba-4641edb7b863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_dba62a17-cdf8-4e72-9121-8e8c86ff94e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_dba62a17-cdf8-4e72-9121-8e8c86ff94e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_fac30f8c-8800-4e58-b2ab-ffadce18d2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_fac30f8c-8800-4e58-b2ab-ffadce18d2ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_76ab2d0e-95a7-4881-a97c-365150fce512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_76ab2d0e-95a7-4881-a97c-365150fce512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_092e27db-fc59-41eb-b2f1-c20a23bd8d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8d5054-b734-47f7-b0d7-5a7871d7f7ab" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_092e27db-fc59-41eb-b2f1-c20a23bd8d68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d609689f-f0d7-4b6e-8616-104da6bfde41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_50986806-0c0d-4502-b686-4af9ec2d23bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d609689f-f0d7-4b6e-8616-104da6bfde41" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_50986806-0c0d-4502-b686-4af9ec2d23bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6c3092ef-e392-4476-8e1a-1ead623fe6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d609689f-f0d7-4b6e-8616-104da6bfde41" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6c3092ef-e392-4476-8e1a-1ead623fe6e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_77644b93-43eb-4e26-bbb9-6fc688ba24d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_3e5041c4-fc60-405f-a15f-bf1c296f30e9" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_77644b93-43eb-4e26-bbb9-6fc688ba24d0" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_3e5041c4-fc60-405f-a15f-bf1c296f30e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15218a4f-e92b-4465-96bf-8d29ac802802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_77644b93-43eb-4e26-bbb9-6fc688ba24d0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15218a4f-e92b-4465-96bf-8d29ac802802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b8576bcb-5507-462a-9227-50c50d1c1694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_e7aeeaad-415f-4a4b-993b-cebf08a9093b" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b8576bcb-5507-462a-9227-50c50d1c1694" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_e7aeeaad-415f-4a4b-993b-cebf08a9093b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d4d29ad4-6319-458f-a1ce-0fa89614d121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b8576bcb-5507-462a-9227-50c50d1c1694" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d4d29ad4-6319-458f-a1ce-0fa89614d121" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pfe-20221002_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:532d8f3f-927e-412c-bdcb-1806e94574ca,g:7cd44193-98b9-486c-9ee0-61ec890b3036-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20221002.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended" id="i768c83c360dd46bfa06082537288ce46_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_23aac756-74a9-46c2-9ad0-50067f65a830" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentType_23aac756-74a9-46c2-9ad0-50067f65a830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ab177670-17c6-4895-a0e0-9f7c1de1f250" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentQuarterlyReport_ab177670-17c6-4895-a0e0-9f7c1de1f250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_549045de-6d61-477b-96bc-e853177248cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentPeriodEndDate_549045de-6d61-477b-96bc-e853177248cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_78c03f43-7cce-4daf-a3f3-f7e4f6428c3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentTransitionReport_78c03f43-7cce-4daf-a3f3-f7e4f6428c3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a6b9def2-854b-457d-9b76-87b5f79a1ba9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityFileNumber_a6b9def2-854b-457d-9b76-87b5f79a1ba9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a021864f-97e4-4e08-a57b-0859415171c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityRegistrantName_a021864f-97e4-4e08-a57b-0859415171c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ded6364d-379d-4aad-9366-9fcc2bc176af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ded6364d-379d-4aad-9366-9fcc2bc176af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e12b8bd6-c67f-4094-95cf-a0014c819700" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityTaxIdentificationNumber_e12b8bd6-c67f-4094-95cf-a0014c819700" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_82c2d51e-cd29-4520-a22e-3f7c18810dae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressAddressLine1_82c2d51e-cd29-4520-a22e-3f7c18810dae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_24399b7e-9947-434c-ba9b-934c1415ab3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressCityOrTown_24399b7e-9947-434c-ba9b-934c1415ab3e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1a9103e9-cf1b-44e0-b381-c6a0566231d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressStateOrProvince_1a9103e9-cf1b-44e0-b381-c6a0566231d1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dedbab9b-130b-4b2b-995e-2f2e0853b9a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressPostalZipCode_dedbab9b-130b-4b2b-995e-2f2e0853b9a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3a761265-32a7-445f-b345-4aa97e83205c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_CityAreaCode_3a761265-32a7-445f-b345-4aa97e83205c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_321c1021-8be1-479d-8c5b-a7cad479559b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_LocalPhoneNumber_321c1021-8be1-479d-8c5b-a7cad479559b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f6b761f7-c373-495b-abb2-3fc2ef8bd52b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_Security12bTitle_f6b761f7-c373-495b-abb2-3fc2ef8bd52b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c18afd5f-2979-4f39-9b08-2fd866ee61b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_TradingSymbol_c18afd5f-2979-4f39-9b08-2fd866ee61b2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_75e8ee4c-35b8-4391-a58b-4e37e16e9f25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_SecurityExchangeName_75e8ee4c-35b8-4391-a58b-4e37e16e9f25" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_73f8a5ce-f206-4b25-8b00-b2398eeaf8e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityCurrentReportingStatus_73f8a5ce-f206-4b25-8b00-b2398eeaf8e1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_80deaac6-5ed5-4ef4-a08a-dd20d4eb5ea6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityInteractiveDataCurrent_80deaac6-5ed5-4ef4-a08a-dd20d4eb5ea6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c3aaba2d-8396-4c75-bb93-33c8319fe03d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityFilerCategory_c3aaba2d-8396-4c75-bb93-33c8319fe03d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f5949d49-a65e-4775-b331-1898db76d1d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntitySmallBusiness_f5949d49-a65e-4775-b331-1898db76d1d9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3b85c47f-da41-42a4-84a5-d3e4c33acab7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityEmergingGrowthCompany_3b85c47f-da41-42a4-84a5-d3e4c33acab7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5c521e63-454f-475f-9f2f-b1b1a91cb62f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityShellCompany_5c521e63-454f-475f-9f2f-b1b1a91cb62f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d8607d7f-9fce-429e-a08c-fd5e159c01f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d8607d7f-9fce-429e-a08c-fd5e159c01f1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7ae8bc76-a54c-4552-b06a-3cca7fd04aa0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityCentralIndexKey_7ae8bc76-a54c-4552-b06a-3cca7fd04aa0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0777b050-1394-4802-873d-568800a1c87a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_CurrentFiscalYearEndDate_0777b050-1394-4802-873d-568800a1c87a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f1a7aff0-3637-4dcd-822a-d3a75f73c7ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentFiscalYearFocus_f1a7aff0-3637-4dcd-822a-d3a75f73c7ed" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_103b2417-9261-4acd-beef-9e979e9e7eba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentFiscalPeriodFocus_103b2417-9261-4acd-beef-9e979e9e7eba" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_763e3750-40d8-4a68-b660-22fb504e8153" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_AmendmentFlag_763e3750-40d8-4a68-b660-22fb504e8153" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_73b64b00-3cc6-4388-bd2c-1a7e22c80118" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntitiesTable_73b64b00-3cc6-4388-bd2c-1a7e22c80118" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4798faac-ead0-4698-b469-85771fa1c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_73b64b00-3cc6-4388-bd2c-1a7e22c80118" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4798faac-ead0-4698-b469-85771fa1c228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4798faac-ead0-4698-b469-85771fa1c228_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4798faac-ead0-4698-b469-85771fa1c228" xlink:to="loc_us-gaap_ClassOfStockDomain_4798faac-ead0-4698-b469-85771fa1c228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4798faac-ead0-4698-b469-85771fa1c228" xlink:to="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_094f268f-2129-4e1d-abc7-a0e6da3587cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:to="loc_us-gaap_CommonStockMember_094f268f-2129-4e1d-abc7-a0e6da3587cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_e0dcc8c6-046e-4572-930c-b12f2ad0add2" xlink:href="pfe-20221002.xsd#pfe_NotesDue20271.000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:to="loc_pfe_NotesDue20271.000Member_e0dcc8c6-046e-4572-930c-b12f2ad0add2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="extended" id="i38298112ebb94502bd17474ddd3eb91c_CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_693ffff1-6d6e-4773-a8c1-ce9a89a027f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_693ffff1-6d6e-4773-a8c1-ce9a89a027f5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_602a492e-bcce-40ad-8cc5-e95b00a8d441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_CommonStockSharesIssued_602a492e-bcce-40ad-8cc5-e95b00a8d441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f8f3c82-c126-466d-9051-bbf49ef326e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f8f3c82-c126-466d-9051-bbf49ef326e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_e17fcc14-c063-45de-b973-35734982caf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_TreasuryStockShares_e17fcc14-c063-45de-b973-35734982caf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8e6b0fcb-8310-4a90-b054-a0eacace4af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_ProfitLoss_8e6b0fcb-8310-4a90-b054-a0eacace4af1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4778b5cd-61ab-435d-8a53-8441a0377cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4778b5cd-61ab-435d-8a53-8441a0377cc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCashAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_562883f4-606c-48f9-9d68-e71875e7f405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:to="loc_us-gaap_DividendsCommonStockCash_562883f4-606c-48f9-9d68-e71875e7f405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b7e5911f-8e80-4fee-b0eb-0a0442fd0e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b7e5911f-8e80-4fee-b0eb-0a0442fd0e47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6fa82925-47f7-4429-8fc6-80dcf4fab991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6fa82925-47f7-4429-8fc6-80dcf4fab991" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5384596-731c-46a1-bb72-305c95cf5912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5384596-731c-46a1-bb72-305c95cf5912" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d692e5d6-5c55-493c-8af1-a66ab1fb3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d692e5d6-5c55-493c-8af1-a66ab1fb3df3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_86b7ec7b-774d-4b98-b5a7-33fc914a9187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_86b7ec7b-774d-4b98-b5a7-33fc914a9187" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_83505ea0-51d9-4a89-b734-2026db80a350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockholdersEquityOther_83505ea0-51d9-4a89-b734-2026db80a350" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_947d8923-cc99-41f8-9317-13f5731fb860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5e58603-47a6-457d-93b8-b366471dee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_313faf6c-4fd7-434b-b4ad-7c98624660c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5b63b7c-2e1b-4d90-872b-5b5c378baea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_693ffff1-6d6e-4773-a8c1-ce9a89a027f5" xlink:to="loc_us-gaap_StatementTable_f5b63b7c-2e1b-4d90-872b-5b5c378baea5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e845621-cb7e-4a26-9c27-7f9c12276ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f5b63b7c-2e1b-4d90-872b-5b5c378baea5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e845621-cb7e-4a26-9c27-7f9c12276ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e845621-cb7e-4a26-9c27-7f9c12276ae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e845621-cb7e-4a26-9c27-7f9c12276ae7" xlink:to="loc_us-gaap_EquityComponentDomain_1e845621-cb7e-4a26-9c27-7f9c12276ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e845621-cb7e-4a26-9c27-7f9c12276ae7" xlink:to="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:to="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_de640dd3-a648-4447-90ae-75f474c2425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_CommonStockMember_de640dd3-a648-4447-90ae-75f474c2425a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_152a611a-3eb2-41fd-b5b0-abdf395520c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_152a611a-3eb2-41fd-b5b0-abdf395520c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_526a9328-9714-4be6-a857-1073bcce25ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_TreasuryStockMember_526a9328-9714-4be6-a857-1073bcce25ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_915eed4d-1a91-442d-ad0a-1a548af605a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_RetainedEarningsMember_915eed4d-1a91-442d-ad0a-1a548af605a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6bc57cb-910a-4d35-80a4-47ced12552fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6bc57cb-910a-4d35-80a4-47ced12552fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c24aaacd-6860-4188-992e-456c1b79a1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c24aaacd-6860-4188-992e-456c1b79a1cf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="extended" id="id10542f0a6b44353ad8bdcd6766680eb_BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_58027d1e-7fc2-4023-91cc-737f4bf8979c" xlink:href="pfe-20221002.xsd#pfe_RebatesAndDiscountsAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_58027d1e-7fc2-4023-91cc-737f4bf8979c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates_a57e75c9-bd84-4789-8b9b-980d4a25805b" xlink:href="pfe-20221002.xsd#pfe_AccruedRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:to="loc_pfe_AccruedRebates_a57e75c9-bd84-4789-8b9b-980d4a25805b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals_c7895ce7-caff-4991-8d4b-df3258a5fb35" xlink:href="pfe-20221002.xsd#pfe_OtherAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:to="loc_pfe_OtherAccruals_c7895ce7-caff-4991-8d4b-df3258a5fb35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_00436c80-044c-4aac-8dc1-0b9a870ad964" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_00436c80-044c-4aac-8dc1-0b9a870ad964" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_060ba8e7-b659-4c66-8491-f9f48a178549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_00436c80-044c-4aac-8dc1-0b9a870ad964" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_060ba8e7-b659-4c66-8491-f9f48a178549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_060ba8e7-b659-4c66-8491-f9f48a178549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_060ba8e7-b659-4c66-8491-f9f48a178549" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_060ba8e7-b659-4c66-8491-f9f48a178549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_060ba8e7-b659-4c66-8491-f9f48a178549" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_878ac76b-e5fc-49af-98dc-1c534d05bda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:to="loc_us-gaap_AccountsReceivableMember_878ac76b-e5fc-49af-98dc-1c534d05bda3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_071c7f7b-a5d5-401c-b2b5-c502440ee741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_071c7f7b-a5d5-401c-b2b5-c502440ee741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06fc5b84-db5a-4e41-a704-9da2ac11d5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06fc5b84-db5a-4e41-a704-9da2ac11d5f5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails" xlink:type="extended" id="i343cfc9943f64eb89eae9486e23551a0_AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bd33a6e6-7dbc-4be8-a0c8-b10f1cc282be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bd33a6e6-7dbc-4be8-a0c8-b10f1cc282be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_78fa3068-b755-4056-8787-1f1de35501dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_78fa3068-b755-4056-8787-1f1de35501dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments_3fe46141-814f-45a0-801c-10136d69c7e7" xlink:href="pfe-20221002.xsd#pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments_3fe46141-814f-45a0-801c-10136d69c7e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_7cc6c5e0-ae7a-4c5c-a077-a2886d6475ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_7cc6c5e0-ae7a-4c5c-a077-a2886d6475ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_807ee97d-df88-4ac6-b3a4-3fd10454def4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_807ee97d-df88-4ac6-b3a4-3fd10454def4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4b26960a-5035-4fff-8a4f-62a43aaeb888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4b26960a-5035-4fff-8a4f-62a43aaeb888" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1a59cb02-e071-4b42-bf6a-e0d4c53d1b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1a59cb02-e071-4b42-bf6a-e0d4c53d1b61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_10464551-a017-4ee8-900b-d90d60ce104e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_10464551-a017-4ee8-900b-d90d60ce104e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_ab63a08c-2563-4a6e-80f1-e7c686fabbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_ab63a08c-2563-4a6e-80f1-e7c686fabbf7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b446d22a-6291-448b-9228-41f91358e060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b446d22a-6291-448b-9228-41f91358e060" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a3faf595-4902-48ad-8858-8fcc7b2a159c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_Goodwill_a3faf595-4902-48ad-8858-8fcc7b2a159c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b4d04ae4-3527-4178-8148-c9fca1c84de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b4d04ae4-3527-4178-8148-c9fca1c84de0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_200c4def-1376-4a66-b1c2-96886e2bf1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_AssetAcquisitionAxis_200c4def-1376-4a66-b1c2-96886e2bf1a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_200c4def-1376-4a66-b1c2-96886e2bf1a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_200c4def-1376-4a66-b1c2-96886e2bf1a7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_200c4def-1376-4a66-b1c2-96886e2bf1a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8848ff1b-e498-49be-987d-03c236ad7c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_200c4def-1376-4a66-b1c2-96886e2bf1a7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8848ff1b-e498-49be-987d-03c236ad7c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReViralAssetAcquisitionMember_4bb556be-118a-4297-a179-f43b6a83c5d9" xlink:href="pfe-20221002.xsd#pfe_ReViralAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_8848ff1b-e498-49be-987d-03c236ad7c75" xlink:to="loc_pfe_ReViralAssetAcquisitionMember_4bb556be-118a-4297-a179-f43b6a83c5d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4e846520-62dd-435d-be26-ee150ca87760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4e846520-62dd-435d-be26-ee150ca87760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e846520-62dd-435d-be26-ee150ca87760_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e846520-62dd-435d-be26-ee150ca87760" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e846520-62dd-435d-be26-ee150ca87760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ca0269-0033-4441-ab48-747b5035cde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e846520-62dd-435d-be26-ee150ca87760" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ca0269-0033-4441-ab48-747b5035cde1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArenaMember_302776d6-df0f-4495-b08b-2e419232e3bc" xlink:href="pfe-20221002.xsd#pfe_ArenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ca0269-0033-4441-ab48-747b5035cde1" xlink:to="loc_pfe_ArenaMember_302776d6-df0f-4495-b08b-2e419232e3bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_884eafbe-9d10-4e72-b022-5d6419b91fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_884eafbe-9d10-4e72-b022-5d6419b91fe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_884eafbe-9d10-4e72-b022-5d6419b91fe6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_884eafbe-9d10-4e72-b022-5d6419b91fe6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_884eafbe-9d10-4e72-b022-5d6419b91fe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_884eafbe-9d10-4e72-b022-5d6419b91fe6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ee67c0e-8b77-43d8-9136-1294a94090fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ee67c0e-8b77-43d8-9136-1294a94090fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_fdf4d767-5d0f-4942-b9f7-34987b25790c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:to="loc_us-gaap_LicensingAgreementsMember_fdf4d767-5d0f-4942-b9f7-34987b25790c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_20364ebf-050d-4934-abff-f7bc977dd136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_20364ebf-050d-4934-abff-f7bc977dd136" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20364ebf-050d-4934-abff-f7bc977dd136_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20364ebf-050d-4934-abff-f7bc977dd136" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20364ebf-050d-4934-abff-f7bc977dd136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_de571e68-b96a-4cba-80aa-473a8d8c5e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20364ebf-050d-4934-abff-f7bc977dd136" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_de571e68-b96a-4cba-80aa-473a8d8c5e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_39ed922c-cebc-4f77-b744-8f42741d140f" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_de571e68-b96a-4cba-80aa-473a8d8c5e44" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_39ed922c-cebc-4f77-b744-8f42741d140f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails" xlink:type="extended" id="i8485e02bad9d41568c720043cda92054_AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_314dba6a-a450-40fd-b60a-539de3261dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_314dba6a-a450-40fd-b60a-539de3261dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_eedd67eb-b71e-47f3-a78f-7e1b029ba674" xlink:href="pfe-20221002.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_eedd67eb-b71e-47f3-a78f-7e1b029ba674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_add87bc7-2843-4236-bc02-2354926b3f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_add87bc7-2843-4236-bc02-2354926b3f6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_45aed36d-cf53-40ea-8486-e60efcefae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_45aed36d-cf53-40ea-8486-e60efcefae5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_02aa8335-c950-4143-8bc2-d79feb8061a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_srt_CounterpartyNameAxis_02aa8335-c950-4143-8bc2-d79feb8061a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02aa8335-c950-4143-8bc2-d79feb8061a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_02aa8335-c950-4143-8bc2-d79feb8061a4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02aa8335-c950-4143-8bc2-d79feb8061a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63e74972-7b84-4a8b-b84a-510c9c9ebf90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_02aa8335-c950-4143-8bc2-d79feb8061a4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63e74972-7b84-4a8b-b84a-510c9c9ebf90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_84321a6f-d067-456f-9a40-0995485a6270" xlink:href="pfe-20221002.xsd#pfe_ViatrisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63e74972-7b84-4a8b-b84a-510c9c9ebf90" xlink:to="loc_pfe_ViatrisMember_84321a6f-d067-456f-9a40-0995485a6270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea773889-68d2-4c7e-90d3-4848b99cc663" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_srt_ProductOrServiceAxis_ea773889-68d2-4c7e-90d3-4848b99cc663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea773889-68d2-4c7e-90d3-4848b99cc663_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ea773889-68d2-4c7e-90d3-4848b99cc663" xlink:to="loc_srt_ProductsAndServicesDomain_ea773889-68d2-4c7e-90d3-4848b99cc663_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0d9d1d0-69ac-4c37-adcb-237177347fea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ea773889-68d2-4c7e-90d3-4848b99cc663" xlink:to="loc_srt_ProductsAndServicesDomain_e0d9d1d0-69ac-4c37-adcb-237177347fea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_1a3bcf69-4a76-458d-9f77-126e540eb258" xlink:href="pfe-20221002.xsd#pfe_EpiPenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e0d9d1d0-69ac-4c37-adcb-237177347fea" xlink:to="loc_pfe_EpiPenMember_1a3bcf69-4a76-458d-9f77-126e540eb258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_eea3c541-69a6-4452-a3b0-71b7edaf288b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_eea3c541-69a6-4452-a3b0-71b7edaf288b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_eea3c541-69a6-4452-a3b0-71b7edaf288b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_eea3c541-69a6-4452-a3b0-71b7edaf288b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_eea3c541-69a6-4452-a3b0-71b7edaf288b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fc80069a-bec7-4935-8b47-98e7a6bd49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_eea3c541-69a6-4452-a3b0-71b7edaf288b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fc80069a-bec7-4935-8b47-98e7a6bd49ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5459cd18-9dcc-4d3c-ae3d-4e3d1e9d0b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_fc80069a-bec7-4935-8b47-98e7a6bd49ce" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5459cd18-9dcc-4d3c-ae3d-4e3d1e9d0b04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5140caf2-68ab-49b5-8531-3c065d76c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5140caf2-68ab-49b5-8531-3c065d76c68f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5140caf2-68ab-49b5-8531-3c065d76c68f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5140caf2-68ab-49b5-8531-3c065d76c68f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5140caf2-68ab-49b5-8531-3c065d76c68f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_edb83efa-0f61-4616-af29-355d99700021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5140caf2-68ab-49b5-8531-3c065d76c68f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_edb83efa-0f61-4616-af29-355d99700021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_2b0fdad6-e94c-4c49-bb39-b76417af3347" xlink:href="pfe-20221002.xsd#pfe_MeridianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_edb83efa-0f61-4616-af29-355d99700021" xlink:to="loc_pfe_MeridianMember_2b0fdad6-e94c-4c49-bb39-b76417af3347" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails" xlink:type="extended" id="iccad9932536a4195b4f82e1e2cac9b8a_AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dd8df06b-acd4-491b-aa85-2ce9879a9d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dd8df06b-acd4-491b-aa85-2ce9879a9d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_77fecdaf-c0a5-4f75-8fb4-ebb935b5b78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestments_77fecdaf-c0a5-4f75-8fb4-ebb935b5b78b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_814b2bfc-c7a8-4f3e-ad8b-11f025c26923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_814b2bfc-c7a8-4f3e-ad8b-11f025c26923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal_6db9a3c3-443e-414e-bd9b-922ec64b7d65" xlink:href="pfe-20221002.xsd#pfe_ProceedsFromEquityMethodInvestmentDistributionTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal_6db9a3c3-443e-414e-bd9b-922ec64b7d65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d91312ce-d560-4ec7-b38c-b60f699f561f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d91312ce-d560-4ec7-b38c-b60f699f561f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b7bf2c4d-eb55-4eac-9d3f-2d35a85ade1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b7bf2c4d-eb55-4eac-9d3f-2d35a85ade1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_ef92cbfb-481b-4604-bd3a-69368dadf6d6" xlink:href="pfe-20221002.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_ef92cbfb-481b-4604-bd3a-69368dadf6d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6fbbcdb-cec5-4fbf-b866-bc1d03260705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6fbbcdb-cec5-4fbf-b866-bc1d03260705" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences_3f77744f-101b-43bb-b9ca-2e3db85a155c" xlink:href="pfe-20221002.xsd#pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences_3f77744f-101b-43bb-b9ca-2e3db85a155c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal_ed489ac8-263a-42f0-adf6-38d200527e65" xlink:href="pfe-20221002.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal_ed489ac8-263a-42f0-adf6-38d200527e65" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5b18d8fd-8980-4c6a-967b-b62a8d8895d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5b18d8fd-8980-4c6a-967b-b62a8d8895d5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_f25013da-2fda-4787-b936-adc65dfc9dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_OtherShortTermBorrowings_f25013da-2fda-4787-b936-adc65dfc9dfb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0f7662b0-258f-498a-8804-0b86b7505213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0f7662b0-258f-498a-8804-0b86b7505213" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_88f49e3b-dd8e-4fe8-86cf-5c707f0bac39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_88f49e3b-dd8e-4fe8-86cf-5c707f0bac39" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9e2afaa2-3698-430f-9740-037ceeac5a3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_dei_LegalEntityAxis_9e2afaa2-3698-430f-9740-037ceeac5a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9e2afaa2-3698-430f-9740-037ceeac5a3c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9e2afaa2-3698-430f-9740-037ceeac5a3c" xlink:to="loc_dei_EntityDomain_9e2afaa2-3698-430f-9740-037ceeac5a3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9e2afaa2-3698-430f-9740-037ceeac5a3c" xlink:to="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember_294248ca-0b52-43e0-85ed-73a86acfcdad" xlink:href="pfe-20221002.xsd#pfe_GSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:to="loc_pfe_GSKMember_294248ca-0b52-43e0-85ed-73a86acfcdad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_418bf7e7-1f9f-40b8-bb89-e5760969b1d2" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_418bf7e7-1f9f-40b8-bb89-e5760969b1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_695040d0-ea1c-4356-b48f-ab2000255e07" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_695040d0-ea1c-4356-b48f-ab2000255e07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_695040d0-ea1c-4356-b48f-ab2000255e07_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_695040d0-ea1c-4356-b48f-ab2000255e07" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_695040d0-ea1c-4356-b48f-ab2000255e07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c3edc5cf-dd89-49ac-89fa-3c46d9c9f80e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_695040d0-ea1c-4356-b48f-ab2000255e07" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c3edc5cf-dd89-49ac-89fa-3c46d9c9f80e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_f1f433e3-24ca-40cd-921b-a7d2b4ba05dd" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c3edc5cf-dd89-49ac-89fa-3c46d9c9f80e" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_f1f433e3-24ca-40cd-921b-a7d2b4ba05dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7f00816-d961-41cd-809a-df79219f47f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7f00816-d961-41cd-809a-df79219f47f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f00816-d961-41cd-809a-df79219f47f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7f00816-d961-41cd-809a-df79219f47f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f00816-d961-41cd-809a-df79219f47f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6badde5-7e59-47ad-8cec-a14999decbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7f00816-d961-41cd-809a-df79219f47f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6badde5-7e59-47ad-8cec-a14999decbeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_f362785c-dd80-4383-8b62-ec6340d1fc49" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6badde5-7e59-47ad-8cec-a14999decbeb" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_f362785c-dd80-4383-8b62-ec6340d1fc49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6bef51ac-50c6-4c16-a128-36af2392d8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6bef51ac-50c6-4c16-a128-36af2392d8d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6bef51ac-50c6-4c16-a128-36af2392d8d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6bef51ac-50c6-4c16-a128-36af2392d8d7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6bef51ac-50c6-4c16-a128-36af2392d8d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cb292f09-56c1-4058-99be-a49eb70ce5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6bef51ac-50c6-4c16-a128-36af2392d8d7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cb292f09-56c1-4058-99be-a49eb70ce5a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a3af4b8d-833c-402f-b17b-d939e0f8c460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cb292f09-56c1-4058-99be-a49eb70ce5a3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a3af4b8d-833c-402f-b17b-d939e0f8c460" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_262d366d-8f43-4140-93bd-597ccaec2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_262d366d-8f43-4140-93bd-597ccaec2d11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_262d366d-8f43-4140-93bd-597ccaec2d11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_262d366d-8f43-4140-93bd-597ccaec2d11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_262d366d-8f43-4140-93bd-597ccaec2d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb6fda90-3f10-4676-986c-fbcf8798be6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_262d366d-8f43-4140-93bd-597ccaec2d11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb6fda90-3f10-4676-986c-fbcf8798be6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5e89ada2-6397-4ed7-81a6-fed824261128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb6fda90-3f10-4676-986c-fbcf8798be6b" xlink:to="loc_us-gaap_SeniorNotesMember_5e89ada2-6397-4ed7-81a6-fed824261128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1be3a022-452d-495d-b4b9-44ac5acc56af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_DebtInstrumentAxis_1be3a022-452d-495d-b4b9-44ac5acc56af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1be3a022-452d-495d-b4b9-44ac5acc56af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1be3a022-452d-495d-b4b9-44ac5acc56af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1be3a022-452d-495d-b4b9-44ac5acc56af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1be3a022-452d-495d-b4b9-44ac5acc56af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember_27e14f12-dc9e-4cd3-83aa-99a2d2d528c7" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember_27e14f12-dc9e-4cd3-83aa-99a2d2d528c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember_2ee7ed63-5a3b-44c0-84b3-21718880a788" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember_2ee7ed63-5a3b-44c0-84b3-21718880a788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember_ffbc5125-b58a-4d92-ac8a-58f200ea32b6" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember_ffbc5125-b58a-4d92-ac8a-58f200ea32b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_A1365ConsumerHealthcareJVLoanMember_4e34f232-60cc-41fb-8382-94a3ce1dafff" xlink:href="pfe-20221002.xsd#pfe_A1365ConsumerHealthcareJVLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_A1365ConsumerHealthcareJVLoanMember_4e34f232-60cc-41fb-8382-94a3ce1dafff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7e7aec31-3d27-452e-9af8-311058237a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7e7aec31-3d27-452e-9af8-311058237a07" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7e7aec31-3d27-452e-9af8-311058237a07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7e7aec31-3d27-452e-9af8-311058237a07" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7e7aec31-3d27-452e-9af8-311058237a07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6dee9d9e-493d-4ea2-94b3-95bcde4d80c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7e7aec31-3d27-452e-9af8-311058237a07" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6dee9d9e-493d-4ea2-94b3-95bcde4d80c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_f330427d-ec6d-402c-b563-05b86194316a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6dee9d9e-493d-4ea2-94b3-95bcde4d80c8" xlink:to="loc_us-gaap_LoansPayableMember_f330427d-ec6d-402c-b563-05b86194316a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails" xlink:type="extended" id="i4bff0e9d5086466db1c3fa61470ffe38_AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0a023a70-668c-41b8-b587-4ca8344190da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_Revenues_0a023a70-668c-41b8-b587-4ca8344190da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ad50e997-fd51-49d8-83f4-50babf2e9938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_CostOfRevenue_ad50e997-fd51-49d8-83f4-50babf2e9938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_991cf688-3929-41ac-b1d1-4d9705552b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_GrossProfit_991cf688-3929-41ac-b1d1-4d9705552b5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f70407e3-c4e7-4dba-bebe-a492e43c714d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f70407e3-c4e7-4dba-bebe-a492e43c714d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_20310ffa-e69b-4f99-b14b-2cb530536149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_ProfitLoss_20310ffa-e69b-4f99-b14b-2cb530536149" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4bf2e37-0541-4e5a-853d-e5359fdbf771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_NetIncomeLoss_a4bf2e37-0541-4e5a-853d-e5359fdbf771" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3ec99057-60fc-4144-91f6-b3fcd87b6677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3ec99057-60fc-4144-91f6-b3fcd87b6677" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_83112088-2cf2-4841-b558-c537a4b9f7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3ec99057-60fc-4144-91f6-b3fcd87b6677" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_83112088-2cf2-4841-b558-c537a4b9f7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_83112088-2cf2-4841-b558-c537a4b9f7f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_83112088-2cf2-4841-b558-c537a4b9f7f1" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_83112088-2cf2-4841-b558-c537a4b9f7f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c1b624b7-31ed-439d-9198-bef6bc8897a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_83112088-2cf2-4841-b558-c537a4b9f7f1" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c1b624b7-31ed-439d-9198-bef6bc8897a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_de13f023-1701-48fd-b124-858d2f686c46" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c1b624b7-31ed-439d-9198-bef6bc8897a8" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_de13f023-1701-48fd-b124-858d2f686c46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail" xlink:type="extended" id="ief365b3a3c3440febf12c566547b5bbf_AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_c783d35f-c341-49e1-8cd7-cf42873410ee" xlink:href="pfe-20221002.xsd#pfe_PrepaymentsAndPaymentsToCollaboratorsCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_c783d35f-c341-49e1-8cd7-cf42873410ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPayment_d9e541d3-06e0-4c99-806a-a1c9e2c65226" xlink:href="pfe-20221002.xsd#pfe_PaymentsToCollaboratorsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_PaymentsToCollaboratorsUpfrontPayment_d9e541d3-06e0-4c99-806a-a1c9e2c65226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_967106f2-0601-4a08-b007-371bfd215196" xlink:href="pfe-20221002.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_967106f2-0601-4a08-b007-371bfd215196" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_49425f4c-761c-4ccb-83ac-d15b89b43b09" xlink:href="pfe-20221002.xsd#pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_49425f4c-761c-4ccb-83ac-d15b89b43b09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_09384cab-1eb2-48c9-81b7-2c302f3d8e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_09384cab-1eb2-48c9-81b7-2c302f3d8e06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5336da59-1b67-4e42-b103-29cca89e65d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5336da59-1b67-4e42-b103-29cca89e65d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_TypeOfArrangementAxis_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de15600-6fb6-4000-bd67-d2dd8ad24a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de15600-6fb6-4000-bd67-d2dd8ad24a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_97d9ea4c-7687-472c-8e1a-a6487c1e8783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de15600-6fb6-4000-bd67-d2dd8ad24a8a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_97d9ea4c-7687-472c-8e1a-a6487c1e8783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9175efe2-0d2f-4e7c-b393-396e25370ecd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_srt_CounterpartyNameAxis_9175efe2-0d2f-4e7c-b393-396e25370ecd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9175efe2-0d2f-4e7c-b393-396e25370ecd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9175efe2-0d2f-4e7c-b393-396e25370ecd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9175efe2-0d2f-4e7c-b393-396e25370ecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_399af7ca-ab3a-4df2-bb16-ceffb2f59a4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9175efe2-0d2f-4e7c-b393-396e25370ecd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_399af7ca-ab3a-4df2-bb16-ceffb2f59a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiohavenMember_f8a4c7b4-e2db-48f0-8943-86653fd38f5d" xlink:href="pfe-20221002.xsd#pfe_BiohavenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_399af7ca-ab3a-4df2-bb16-ceffb2f59a4e" xlink:to="loc_pfe_BiohavenMember_f8a4c7b4-e2db-48f0-8943-86653fd38f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5c8ebecb-f304-45f1-a0f4-5b56bef83476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5c8ebecb-f304-45f1-a0f4-5b56bef83476" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c8ebecb-f304-45f1-a0f4-5b56bef83476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c8ebecb-f304-45f1-a0f4-5b56bef83476" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c8ebecb-f304-45f1-a0f4-5b56bef83476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345a7309-256a-4f9d-830d-fadc1ac35dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c8ebecb-f304-45f1-a0f4-5b56bef83476" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345a7309-256a-4f9d-830d-fadc1ac35dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentInProcessMember_f4df8fc9-f2b1-4c4d-abe9-64cc0a28bb28" xlink:href="pfe-20221002.xsd#pfe_ResearchAndDevelopmentInProcessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345a7309-256a-4f9d-830d-fadc1ac35dac" xlink:to="loc_pfe_ResearchAndDevelopmentInProcessMember_f4df8fc9-f2b1-4c4d-abe9-64cc0a28bb28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c025d6d4-0783-4f9b-9b8d-c50d2ed6f3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c025d6d4-0783-4f9b-9b8d-c50d2ed6f3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiohavenMember_3dd9c931-da03-40c3-8ce6-33fab826d51b" xlink:href="pfe-20221002.xsd#pfe_BiohavenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c025d6d4-0783-4f9b-9b8d-c50d2ed6f3fc" xlink:to="loc_pfe_BiohavenMember_3dd9c931-da03-40c3-8ce6-33fab826d51b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_054b80a1-00f7-4835-9b91-701149b9c334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_054b80a1-00f7-4835-9b91-701149b9c334" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_054b80a1-00f7-4835-9b91-701149b9c334_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_054b80a1-00f7-4835-9b91-701149b9c334" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_054b80a1-00f7-4835-9b91-701149b9c334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2058f860-8f17-4304-9cea-b680c4803746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_054b80a1-00f7-4835-9b91-701149b9c334" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2058f860-8f17-4304-9cea-b680c4803746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_33e2256d-5099-4e15-95d5-5c22beb83539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2058f860-8f17-4304-9cea-b680c4803746" xlink:to="loc_us-gaap_SubsequentEventMember_33e2256d-5099-4e15-95d5-5c22beb83539" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended" id="iaa5f65d59b224b14aad47eeffc6f69d0_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bdecb242-75f7-4364-977a-f934bd63b93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bdecb242-75f7-4364-977a-f934bd63b93b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_cfc60307-79dc-4569-bf66-a282723fad28" xlink:href="pfe-20221002.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_cfc60307-79dc-4569-bf66-a282723fad28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_722f3a73-5cf5-4f96-b470-2b5bcce59cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_722f3a73-5cf5-4f96-b470-2b5bcce59cd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesChargesIncurredToDate_c2486440-7e56-4a0a-8144-399c57a90464" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesChargesIncurredToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_pfe_RestructuringChargesChargesIncurredToDate_c2486440-7e56-4a0a-8144-399c57a90464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f202fe77-d004-4680-8e08-34e591fbe54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f202fe77-d004-4680-8e08-34e591fbe54a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f202fe77-d004-4680-8e08-34e591fbe54a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f202fe77-d004-4680-8e08-34e591fbe54a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f202fe77-d004-4680-8e08-34e591fbe54a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f202fe77-d004-4680-8e08-34e591fbe54a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CorporateEnablingFunctionsMember_59db640d-3690-4684-b432-d8992ccd7582" xlink:href="pfe-20221002.xsd#pfe_CorporateEnablingFunctionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:to="loc_pfe_CorporateEnablingFunctionsMember_59db640d-3690-4684-b432-d8992ccd7582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GoToMarketModelMember_c9f942f7-fa16-4645-b197-5b3cae2ab7b9" xlink:href="pfe-20221002.xsd#pfe_GoToMarketModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:to="loc_pfe_GoToMarketModelMember_c9f942f7-fa16-4645-b197-5b3cae2ab7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember_4b9e974b-abd7-4da2-88ae-d8f355510824" xlink:href="pfe-20221002.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:to="loc_pfe_ManufacturingOptimizationMember_4b9e974b-abd7-4da2-88ae-d8f355510824" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:to="loc_us-gaap_RestructuringPlanAxis_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7" xlink:to="loc_us-gaap_RestructuringPlanDomain_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9898d33a-d9ef-4758-9eaa-807d3871a541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7" xlink:to="loc_us-gaap_RestructuringPlanDomain_9898d33a-d9ef-4758-9eaa-807d3871a541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember_e2461564-ccff-42c6-8183-3bdf7badafd7" xlink:href="pfe-20221002.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_9898d33a-d9ef-4758-9eaa-807d3871a541" xlink:to="loc_pfe_FocusedCompanyPlanMember_e2461564-ccff-42c6-8183-3bdf7badafd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_32c732b0-9a26-4480-8305-3f735ce3d773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_32c732b0-9a26-4480-8305-3f735ce3d773" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_32c732b0-9a26-4480-8305-3f735ce3d773_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32c732b0-9a26-4480-8305-3f735ce3d773" xlink:to="loc_us-gaap_SegmentDomain_32c732b0-9a26-4480-8305-3f735ce3d773_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8f1d4bea-cb81-45a3-97c5-0b56e6de4002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32c732b0-9a26-4480-8305-3f735ce3d773" xlink:to="loc_us-gaap_SegmentDomain_8f1d4bea-cb81-45a3-97c5-0b56e6de4002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_2f42d360-f0a9-4d87-985f-c3c58c3d51bb" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8f1d4bea-cb81-45a3-97c5-0b56e6de4002" xlink:to="loc_pfe_BiopharmaSegmentMember_2f42d360-f0a9-4d87-985f-c3c58c3d51bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="extended" id="i10c5095e6bab41ae8a61b0341f625f27_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_5dded54c-ebfd-4e6d-9923-da941c4a2142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_us-gaap_SeveranceCosts1_5dded54c-ebfd-4e6d-9923-da941c4a2142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_ee030d25-4dba-4385-9a01-f8051e27ccee" xlink:href="pfe-20221002.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_ee030d25-4dba-4385-9a01-f8051e27ccee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_ee175b01-819e-4b44-b54e-c07f5d7ba79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_us-gaap_BusinessExitCosts1_ee175b01-819e-4b44-b54e-c07f5d7ba79d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1662339b-cf08-4502-8399-187fa26a31a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_us-gaap_RestructuringCharges_1662339b-cf08-4502-8399-187fa26a31a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_c04b1167-ad0f-4f70-8d69-bd826ef22484" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_c04b1167-ad0f-4f70-8d69-bd826ef22484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_86ff3187-d736-4aea-94be-1ff808b1332b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_86ff3187-d736-4aea-94be-1ff808b1332b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_f6358a75-455b-4bd4-ac74-9a71c86fb896" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_f6358a75-455b-4bd4-ac74-9a71c86fb896" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_761d62fc-6d4d-420e-a292-a3821446d274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_761d62fc-6d4d-420e-a292-a3821446d274" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_86576b06-7221-4dd2-8787-0287af40788e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_86576b06-7221-4dd2-8787-0287af40788e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_e7a1c085-b29f-4d5b-bbfd-ea9f2c66c7a4" xlink:href="pfe-20221002.xsd#pfe_ImplementationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_ImplementationCosts_e7a1c085-b29f-4d5b-bbfd-ea9f2c66c7a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e5f12d0d-0b69-4faf-b3fa-ef2677d81ddf" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e5f12d0d-0b69-4faf-b3fa-ef2677d81ddf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a7fc8cc2-c884-4903-8dbd-41e97821a9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a7fc8cc2-c884-4903-8dbd-41e97821a9a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6bfec93d-d468-4178-a7f1-c7646858ce59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6bfec93d-d468-4178-a7f1-c7646858ce59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6bfec93d-d468-4178-a7f1-c7646858ce59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6bfec93d-d468-4178-a7f1-c7646858ce59" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6bfec93d-d468-4178-a7f1-c7646858ce59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6bfec93d-d468-4178-a7f1-c7646858ce59" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_60f8035f-2bc0-4e25-a7a8-629739e4a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_60f8035f-2bc0-4e25-a7a8-629739e4a0cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_16b30362-d8ac-49b5-9371-8d063aaa5152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_CostOfSalesMember_16b30362-d8ac-49b5-9371-8d063aaa5152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4fecb4c-2df8-46b9-93ea-71124a41fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4fecb4c-2df8-46b9-93ea-71124a41fe60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fbd840c-0db3-4438-bb54-616347961b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fbd840c-0db3-4438-bb54-616347961b95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_a0f92fe5-8feb-4c25-b349-ed670842c2e7" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_a0f92fe5-8feb-4c25-b349-ed670842c2e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dde9d232-f624-4408-87af-2d20510d52c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dde9d232-f624-4408-87af-2d20510d52c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArenaMember_d73bdad0-0cb6-4c7c-953c-54d1751772eb" xlink:href="pfe-20221002.xsd#pfe_ArenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dde9d232-f624-4408-87af-2d20510d52c3" xlink:to="loc_pfe_ArenaMember_d73bdad0-0cb6-4c7c-953c-54d1751772eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16" xlink:to="loc_us-gaap_SegmentDomain_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_81a745bd-73a2-4a1d-ae09-f4915dba6b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16" xlink:to="loc_us-gaap_SegmentDomain_81a745bd-73a2-4a1d-ae09-f4915dba6b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_fb20ab4b-2625-4ce3-af71-300ee2db68ab" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_81a745bd-73a2-4a1d-ae09-f4915dba6b66" xlink:to="loc_pfe_BiopharmaSegmentMember_fb20ab4b-2625-4ce3-af71-300ee2db68ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="extended" id="i93d1ba65d02543ea8d35f3b315aa890c_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8f5a4a10-63c3-4889-9b44-cea926418dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f5a4a10-63c3-4889-9b44-cea926418dd5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b2171229-cd49-4542-886a-fe6296cdd59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:to="loc_us-gaap_RestructuringReserve_b2171229-cd49-4542-886a-fe6296cdd59a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bb2528a5-e90c-4cab-9ba9-cc71b646b37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:to="loc_us-gaap_RestructuringCharges_bb2528a5-e90c-4cab-9ba9-cc71b646b37c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_3b5d0144-f03e-45c6-85d0-f7ad6edd9a70" xlink:href="pfe-20221002.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_3b5d0144-f03e-45c6-85d0-f7ad6edd9a70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_215af3d4-dc5b-4f66-aa22-08f42f9f708d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f5a4a10-63c3-4889-9b44-cea926418dd5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_52973531-7cca-4050-a343-7840516642a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_52973531-7cca-4050-a343-7840516642a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_52973531-7cca-4050-a343-7840516642a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_52973531-7cca-4050-a343-7840516642a3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_52973531-7cca-4050-a343-7840516642a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_52973531-7cca-4050-a343-7840516642a3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_85a24395-03a4-48e3-bd85-508df55db26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:to="loc_us-gaap_EmployeeSeveranceMember_85a24395-03a4-48e3-bd85-508df55db26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember_5be01bf5-c41b-4109-874b-d15956eda6fc" xlink:href="pfe-20221002.xsd#pfe_AssetImpairmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:to="loc_pfe_AssetImpairmentsMember_5be01bf5-c41b-4109-874b-d15956eda6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_088ca55f-a154-44c0-98e2-0d7b54bcd6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:to="loc_us-gaap_OtherRestructuringMember_088ca55f-a154-44c0-98e2-0d7b54bcd6ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_a189060e-9f12-4f20-954a-f347a4bb53de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_a189060e-9f12-4f20-954a-f347a4bb53de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_79b0a3f7-6c2f-41cb-a44e-5d2ab3aaf8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_79b0a3f7-6c2f-41cb-a44e-5d2ab3aaf8e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNetFootnotesDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended" id="i56788b7a080f4924967eb6fa82e22d07_OtherIncomeDeductionsNetFootnotesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5edf68bf-298b-4c77-85f0-31bc543101de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5edf68bf-298b-4c77-85f0-31bc543101de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_83a52641-ffab-4589-8067-82d1d53b633e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:to="loc_us-gaap_ProceedsFromCollaborators_83a52641-ffab-4589-8067-82d1d53b633e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:to="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_58043382-a653-4768-a80b-8f77ae7364a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_srt_CounterpartyNameAxis_58043382-a653-4768-a80b-8f77ae7364a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58043382-a653-4768-a80b-8f77ae7364a8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_58043382-a653-4768-a80b-8f77ae7364a8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58043382-a653-4768-a80b-8f77ae7364a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b10239ea-4f04-48d8-9aeb-8fdb7afc9c85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_58043382-a653-4768-a80b-8f77ae7364a8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b10239ea-4f04-48d8-9aeb-8fdb7afc9c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_5171b0ec-8b11-44e0-ad5e-f1890de4a0e3" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b10239ea-4f04-48d8-9aeb-8fdb7afc9c85" xlink:to="loc_pfe_BioNTechMember_5171b0ec-8b11-44e0-ad5e-f1890de4a0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c31aa3c1-4285-4520-b738-492607c335f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c31aa3c1-4285-4520-b738-492607c335f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c31aa3c1-4285-4520-b738-492607c335f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c31aa3c1-4285-4520-b738-492607c335f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c31aa3c1-4285-4520-b738-492607c335f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0b98ad1-81e3-43a9-a63d-fae3f057ea79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c31aa3c1-4285-4520-b738-492607c335f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0b98ad1-81e3-43a9-a63d-fae3f057ea79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3dcde481-4df4-42f5-967e-2b8fa8b230a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0b98ad1-81e3-43a9-a63d-fae3f057ea79" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3dcde481-4df4-42f5-967e-2b8fa8b230a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d999f69b-a970-4033-a261-8d84d91f694f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d999f69b-a970-4033-a261-8d84d91f694f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d999f69b-a970-4033-a261-8d84d91f694f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d999f69b-a970-4033-a261-8d84d91f694f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d999f69b-a970-4033-a261-8d84d91f694f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8a600918-661a-4312-a12f-06464646c932" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d999f69b-a970-4033-a261-8d84d91f694f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8a600918-661a-4312-a12f-06464646c932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_7369b66f-9aea-4860-8598-930840ce22a7" xlink:href="pfe-20221002.xsd#pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8a600918-661a-4312-a12f-06464646c932" xlink:to="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_7369b66f-9aea-4860-8598-930840ce22a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_7a0d7c89-9c34-48eb-bc4b-adf3d9164909" xlink:href="pfe-20221002.xsd#pfe_BioNTechAndCerevelTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_7369b66f-9aea-4860-8598-930840ce22a7" xlink:to="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_7a0d7c89-9c34-48eb-bc4b-adf3d9164909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5ff7956-513c-41f8-a8d0-5505d91bc8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5ff7956-513c-41f8-a8d0-5505d91bc8ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c5ff7956-513c-41f8-a8d0-5505d91bc8ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5ff7956-513c-41f8-a8d0-5505d91bc8ed" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c5ff7956-513c-41f8-a8d0-5505d91bc8ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_572b1fca-bda2-4543-be87-c42f8f389bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5ff7956-513c-41f8-a8d0-5505d91bc8ed" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_572b1fca-bda2-4543-be87-c42f8f389bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_66edc932-75ca-4f60-ab0b-9573772c705c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_572b1fca-bda2-4543-be87-c42f8f389bc8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_66edc932-75ca-4f60-ab0b-9573772c705c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8908ebf5-d0e5-4838-8615-c8e71729f144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8908ebf5-d0e5-4838-8615-c8e71729f144" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8908ebf5-d0e5-4838-8615-c8e71729f144_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8908ebf5-d0e5-4838-8615-c8e71729f144" xlink:to="loc_us-gaap_SegmentDomain_8908ebf5-d0e5-4838-8615-c8e71729f144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b183b6b5-2240-4602-b47f-2c5b23612d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8908ebf5-d0e5-4838-8615-c8e71729f144" xlink:to="loc_us-gaap_SegmentDomain_b183b6b5-2240-4602-b47f-2c5b23612d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_105e127b-e3c3-4bf1-a739-405e37e46296" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b183b6b5-2240-4602-b47f-2c5b23612d28" xlink:to="loc_pfe_BiopharmaSegmentMember_105e127b-e3c3-4bf1-a739-405e37e46296" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails" xlink:type="extended" id="i859cc33f2557451b9e55832480265950_OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_7c9df42a-0887-4806-a6d1-8d7ef2e2ad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_7c9df42a-0887-4806-a6d1-8d7ef2e2ad2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7e400f4c-e388-4394-9e0c-93aab1ea4cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7e400f4c-e388-4394-9e0c-93aab1ea4cb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76bf6a2b-69c9-465e-acaa-a34afe1c67c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76bf6a2b-69c9-465e-acaa-a34afe1c67c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_684edf24-b530-4da3-82dc-d04180a4c981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76bf6a2b-69c9-465e-acaa-a34afe1c67c1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_684edf24-b530-4da3-82dc-d04180a4c981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e853746-8c04-436d-a557-cf12fcf2ee7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e853746-8c04-436d-a557-cf12fcf2ee7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e853746-8c04-436d-a557-cf12fcf2ee7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e853746-8c04-436d-a557-cf12fcf2ee7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e853746-8c04-436d-a557-cf12fcf2ee7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e853746-8c04-436d-a557-cf12fcf2ee7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_423b77fe-e0a6-47cd-bb7e-1fe6b78063b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_423b77fe-e0a6-47cd-bb7e-1fe6b78063b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0edd7425-71f7-4121-b079-20949ef3c426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0edd7425-71f7-4121-b079-20949ef3c426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6c54022d-55f6-49a1-a938-ac44094220be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6c54022d-55f6-49a1-a938-ac44094220be" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended" id="i0b3d07e224364df3a8b84994f712dce0_AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f7869e56-37e1-4659-ba34-00fcde463d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f7869e56-37e1-4659-ba34-00fcde463d89" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0c81823-cb0e-439d-87fe-c3b2bcb82be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0c81823-cb0e-439d-87fe-c3b2bcb82be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a3bdfa95-f562-4469-ab3c-5965f1ef77c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a3bdfa95-f562-4469-ab3c-5965f1ef77c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e8ad1b5-9e71-49c4-9e18-48db7640953f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ad57d7f9-9a86-471d-ba13-af092c216548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f7869e56-37e1-4659-ba34-00fcde463d89" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ad57d7f9-9a86-471d-ba13-af092c216548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e822e4d2-f20d-4b98-b225-5838b94fe478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ad57d7f9-9a86-471d-ba13-af092c216548" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e822e4d2-f20d-4b98-b225-5838b94fe478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e822e4d2-f20d-4b98-b225-5838b94fe478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e822e4d2-f20d-4b98-b225-5838b94fe478" xlink:to="loc_us-gaap_EquityComponentDomain_e822e4d2-f20d-4b98-b225-5838b94fe478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_19f6823b-4ecf-4e05-8048-ff22eee07901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e822e4d2-f20d-4b98-b225-5838b94fe478" xlink:to="loc_us-gaap_EquityComponentDomain_19f6823b-4ecf-4e05-8048-ff22eee07901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_19f6823b-4ecf-4e05-8048-ff22eee07901" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3268d5fb-10c7-490f-8af9-b8782ee16bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3268d5fb-10c7-490f-8af9-b8782ee16bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2b05c98f-d808-4abe-a4ac-a82ad66b036a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2b05c98f-d808-4abe-a4ac-a82ad66b036a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f2736ded-c755-4973-8dbe-df1af08dabe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f2736ded-c755-4973-8dbe-df1af08dabe1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_72b2d912-8a06-46f4-a239-7f70587d4836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_72b2d912-8a06-46f4-a239-7f70587d4836" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="extended" id="i52d476ca66c24120aabd42e3e2152f05_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d083c2df-f0fc-4994-9b2f-87dde62eb4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d083c2df-f0fc-4994-9b2f-87dde62eb4af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_480a7b9b-de6c-42cc-8e42-e566eb975ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_480a7b9b-de6c-42cc-8e42-e566eb975ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_2902889e-2531-4ace-b94c-ed2cfe50b9b9" xlink:href="pfe-20221002.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_2902889e-2531-4ace-b94c-ed2cfe50b9b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_6c6521f2-9b86-4b29-be03-78c74277b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_6c6521f2-9b86-4b29-be03-78c74277b09a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_84b2bf95-f25b-4919-98f5-e09957b79ad2" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_84b2bf95-f25b-4919-98f5-e09957b79ad2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_e2d676c2-d20f-42fe-94de-e4b07e04cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_e2d676c2-d20f-42fe-94de-e4b07e04cc49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_b1cefd22-437e-4e5a-a679-9abb6782e106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_b1cefd22-437e-4e5a-a679-9abb6782e106" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6e55ae1f-fccd-49d2-813c-b7f9a14f3aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6e55ae1f-fccd-49d2-813c-b7f9a14f3aae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_99627433-18e0-4ccc-a447-face7d7a67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_Assets_99627433-18e0-4ccc-a447-face7d7a67a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_e1f3cf4f-4909-479a-9ea1-6f90bd1bad16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_e1f3cf4f-4909-479a-9ea1-6f90bd1bad16" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7918e33c-776c-412c-90c7-18fd238443bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7918e33c-776c-412c-90c7-18fd238443bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1d8eb720-b87e-4c11-b628-d118141cde79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeLiabilities_1d8eb720-b87e-4c11-b628-d118141cde79" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ef5199c3-fed6-44f4-bf17-436343168cc2" xlink:href="pfe-20221002.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ef5199c3-fed6-44f4-bf17-436343168cc2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1527e7a2-cd6b-4137-949e-a555ed840ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1527e7a2-cd6b-4137-949e-a555ed840ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ba2eb530-cb80-40e2-b451-0d44690d58f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ba2eb530-cb80-40e2-b451-0d44690d58f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c9284909-f362-4759-94ec-bf141055e505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c9284909-f362-4759-94ec-bf141055e505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b1f24fa7-da87-41c8-aba5-7e239f4260f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b1f24fa7-da87-41c8-aba5-7e239f4260f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fa02d89-65d3-4b34-881b-161a5b79b09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fa02d89-65d3-4b34-881b-161a5b79b09e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fa02d89-65d3-4b34-881b-161a5b79b09e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fa02d89-65d3-4b34-881b-161a5b79b09e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fa02d89-65d3-4b34-881b-161a5b79b09e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fa02d89-65d3-4b34-881b-161a5b79b09e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c032a0e2-6ce3-40d6-b119-727541e38f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c032a0e2-6ce3-40d6-b119-727541e38f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e0ff4382-45b4-4fce-8220-6dce5c62aa23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e0ff4382-45b4-4fce-8220-6dce5c62aa23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b3dfbb60-a947-45fc-8426-03c7b1f90e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b3dfbb60-a947-45fc-8426-03c7b1f90e42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b3dfbb60-a947-45fc-8426-03c7b1f90e42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b3dfbb60-a947-45fc-8426-03c7b1f90e42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b3dfbb60-a947-45fc-8426-03c7b1f90e42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b3dfbb60-a947-45fc-8426-03c7b1f90e42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_bec06e57-6991-4340-8736-6a76bb914694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_bec06e57-6991-4340-8736-6a76bb914694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_06726571-4775-4d25-83aa-ab565e59f6cb" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:to="loc_pfe_LongtermInvestmentsMember_06726571-4775-4d25-83aa-ab565e59f6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e899d9c-c086-45b1-8d13-5200d64c620c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e899d9c-c086-45b1-8d13-5200d64c620c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2e899d9c-c086-45b1-8d13-5200d64c620c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e899d9c-c086-45b1-8d13-5200d64c620c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2e899d9c-c086-45b1-8d13-5200d64c620c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_931c394b-aaba-4339-8b29-315a5158c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e899d9c-c086-45b1-8d13-5200d64c620c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_931c394b-aaba-4339-8b29-315a5158c3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_79166231-1a08-49db-9d24-68d72a1ec5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_931c394b-aaba-4339-8b29-315a5158c3a7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_79166231-1a08-49db-9d24-68d72a1ec5ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_73f36402-216b-4beb-a7e2-807e92a9c72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:to="loc_us-gaap_InterestRateContractMember_73f36402-216b-4beb-a7e2-807e92a9c72e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6cda2415-a191-438e-90ac-5ce38e059bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6cda2415-a191-438e-90ac-5ce38e059bff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i805585f863be42a191e32cd44f26b5f4_FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88fc348f-79b3-44c1-83dd-6debfccfde47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_cd932c54-01b9-446d-baea-0a7c00bcd424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88fc348f-79b3-44c1-83dd-6debfccfde47" xlink:to="loc_us-gaap_LongTermDebtFairValue_cd932c54-01b9-446d-baea-0a7c00bcd424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88fc348f-79b3-44c1-83dd-6debfccfde47" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a0a86c8e-4691-4747-b42b-4441b6a9e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a0a86c8e-4691-4747-b42b-4441b6a9e13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a0a86c8e-4691-4747-b42b-4441b6a9e13c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a0a86c8e-4691-4747-b42b-4441b6a9e13c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a0a86c8e-4691-4747-b42b-4441b6a9e13c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_01c3b2fc-9501-425e-b706-a91686440de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a0a86c8e-4691-4747-b42b-4441b6a9e13c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_01c3b2fc-9501-425e-b706-a91686440de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_01c3b2fc-9501-425e-b706-a91686440de1" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0fdf28d6-f8e4-4439-8b63-cfba64177b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0fdf28d6-f8e4-4439-8b63-cfba64177b56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1b2d2e23-cc3e-4db9-a214-58d0cb1ddce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1b2d2e23-cc3e-4db9-a214-58d0cb1ddce4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_16f00967-01c9-48f7-9145-02ceecd535d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_16f00967-01c9-48f7-9145-02ceecd535d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16f00967-01c9-48f7-9145-02ceecd535d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_16f00967-01c9-48f7-9145-02ceecd535d0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16f00967-01c9-48f7-9145-02ceecd535d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71dfb173-fc79-4d95-acaf-455f1056bbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_16f00967-01c9-48f7-9145-02ceecd535d0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71dfb173-fc79-4d95-acaf-455f1056bbd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7aa35bff-a7be-4c25-9882-75c6327e0bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71dfb173-fc79-4d95-acaf-455f1056bbd6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7aa35bff-a7be-4c25-9882-75c6327e0bd3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="extended" id="i40fadd7cd70b4f9f8ab6f5a0f72739bb_FinancialInstrumentsScheduleofInvestmentSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b49af2-ed93-42de-99c0-df01a91cdf33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b49af2-ed93-42de-99c0-df01a91cdf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_769e3db2-9313-48cb-847b-70303f878ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_769e3db2-9313-48cb-847b-70303f878ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34b21b3e-1ee9-4f72-a0dd-db0a265cb04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34b21b3e-1ee9-4f72-a0dd-db0a265cb04f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0059c88-3516-40b7-8324-0d3bf672ebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0059c88-3516-40b7-8324-0d3bf672ebdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_41b8dd70-6b2f-4b38-96f5-561ea6c18eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_41b8dd70-6b2f-4b38-96f5-561ea6c18eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2c5c20f2-a363-4f5b-a9c3-b70553f2fa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2c5c20f2-a363-4f5b-a9c3-b70553f2fa07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_768fa056-884c-490d-9f8a-d7dc7d8a3241" xlink:href="pfe-20221002.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_768fa056-884c-490d-9f8a-d7dc7d8a3241" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb3f28f0-6f81-43c3-9b28-7e26162d04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_45d13347-eff5-43a1-bf5c-49d554006e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecurities_45d13347-eff5-43a1-bf5c-49d554006e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7ea473ff-d918-438d-8e0a-8404ed4e796b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7ea473ff-d918-438d-8e0a-8404ed4e796b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0f5647b6-b08b-4c44-bfdb-b9a14649ea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0f5647b6-b08b-4c44-bfdb-b9a14649ea97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fa55a1eb-f65f-4ea7-a5dc-fd057551abdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fa55a1eb-f65f-4ea7-a5dc-fd057551abdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_9e4e6545-dceb-4abf-87a9-47b012a99565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_9e4e6545-dceb-4abf-87a9-47b012a99565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e2100bae-f53c-41c1-b6b7-19d4f246c8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e2100bae-f53c-41c1-b6b7-19d4f246c8a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_9f4b7ac3-337d-4f64-ad81-35cd8e34cb11" xlink:href="pfe-20221002.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_9f4b7ac3-337d-4f64-ad81-35cd8e34cb11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_d2f13a79-6cd7-4b02-8434-ec3fbe929c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_b1a61352-3af8-43c7-a12f-67510c55a81a" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_b1a61352-3af8-43c7-a12f-67510c55a81a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_1bb08260-ed00-4c75-bd8b-30548769c526" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_1bb08260-ed00-4c75-bd8b-30548769c526" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_4c234cdc-3321-4c55-bf98-fb8ee3fe6d02" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_4c234cdc-3321-4c55-bf98-fb8ee3fe6d02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_2c154b2d-6e95-42c6-9799-ecba5d70d552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_2c154b2d-6e95-42c6-9799-ecba5d70d552" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_995ddfeb-cead-4fd7-a590-6af725c93f10" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_995ddfeb-cead-4fd7-a590-6af725c93f10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_fc11fece-ee14-4453-8e54-7967973653ee" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_fc11fece-ee14-4453-8e54-7967973653ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_d5f56f14-1725-460f-8677-adbd4d06db98" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_d5f56f14-1725-460f-8677-adbd4d06db98" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_20588b2a-3455-4e13-aeeb-2f3d9721a112" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_20588b2a-3455-4e13-aeeb-2f3d9721a112" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fc3e73fb-3508-41c8-84e0-14b3b62e4713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_20588b2a-3455-4e13-aeeb-2f3d9721a112" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fc3e73fb-3508-41c8-84e0-14b3b62e4713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc3e73fb-3508-41c8-84e0-14b3b62e4713_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc3e73fb-3508-41c8-84e0-14b3b62e4713" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc3e73fb-3508-41c8-84e0-14b3b62e4713_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc3e73fb-3508-41c8-84e0-14b3b62e4713" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_4b5f05bf-ab47-4d22-8809-f1a966101cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_BankTimeDepositsMember_4b5f05bf-ab47-4d22-8809-f1a966101cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4ad44b6b-57cc-4784-8e53-0e5b93d9f707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4ad44b6b-57cc-4784-8e53-0e5b93d9f707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7e8c611-14aa-43df-8621-d0e988982f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7e8c611-14aa-43df-8621-d0e988982f70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3af7ad14-70f6-4be3-8e90-08b4f03ff0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3af7ad14-70f6-4be3-8e90-08b4f03ff0f0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended" id="i044ffc9f785d46a58da1056eda4321b5_FinancialInstrumentsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_17c10bb7-0b43-46e8-9dbb-7d137904f0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_17c10bb7-0b43-46e8-9dbb-7d137904f0e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_431897c0-8bc2-490b-8341-6d048bc1930f" xlink:href="pfe-20221002.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_431897c0-8bc2-490b-8341-6d048bc1930f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_da06737b-00cd-451e-bd59-46b97e493070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_da06737b-00cd-451e-bd59-46b97e493070" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_6f628ed5-24f0-40bc-b144-6f0dd18935b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_OtherLongTermDebt_6f628ed5-24f0-40bc-b144-6f0dd18935b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_63d9a68a-7326-43f0-bf59-0c16dbd68d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_63d9a68a-7326-43f0-bf59-0c16dbd68d0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b9f1a319-b7a9-4064-90b8-b680bcf5c851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_DebtInstrumentTable_b9f1a319-b7a9-4064-90b8-b680bcf5c851" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dc395dc8-3502-4a31-8a15-e1d8d6c1e231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b9f1a319-b7a9-4064-90b8-b680bcf5c851" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dc395dc8-3502-4a31-8a15-e1d8d6c1e231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc395dc8-3502-4a31-8a15-e1d8d6c1e231_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dc395dc8-3502-4a31-8a15-e1d8d6c1e231" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc395dc8-3502-4a31-8a15-e1d8d6c1e231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8afd16bf-a8ed-4d4c-be08-914af1e5e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dc395dc8-3502-4a31-8a15-e1d8d6c1e231" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8afd16bf-a8ed-4d4c-be08-914af1e5e8cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_41d9af8f-7c58-4f11-8162-c80b99354596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8afd16bf-a8ed-4d4c-be08-914af1e5e8cd" xlink:to="loc_us-gaap_UnsecuredDebtMember_41d9af8f-7c58-4f11-8162-c80b99354596" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsDerivativeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended" id="ia7348cecc28843bc8c27e40316e8e3dd_FinancialInstrumentsDerivativeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_57c08793-2afa-47c5-ab87-dde8cd3d2717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_ffe6f745-e0c5-4e7e-8cd9-b1d2b77f5cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_57c08793-2afa-47c5-ab87-dde8cd3d2717" xlink:to="loc_us-gaap_DerivativeTermOfContract_ffe6f745-e0c5-4e7e-8cd9-b1d2b77f5cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f99b172f-9266-413b-83b4-a21c1a82527c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_57c08793-2afa-47c5-ab87-dde8cd3d2717" xlink:to="loc_us-gaap_DerivativeTable_f99b172f-9266-413b-83b4-a21c1a82527c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ea032b07-69c9-427e-b06b-08e0911c4ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f99b172f-9266-413b-83b4-a21c1a82527c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ea032b07-69c9-427e-b06b-08e0911c4ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ea032b07-69c9-427e-b06b-08e0911c4ad6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea032b07-69c9-427e-b06b-08e0911c4ad6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ea032b07-69c9-427e-b06b-08e0911c4ad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f52d0e25-5aca-4917-9ec1-5892fa90f080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea032b07-69c9-427e-b06b-08e0911c4ad6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f52d0e25-5aca-4917-9ec1-5892fa90f080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1216085d-7a96-409e-9c46-23745e428e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f52d0e25-5aca-4917-9ec1-5892fa90f080" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1216085d-7a96-409e-9c46-23745e428e16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="extended" id="i87c0f00b98cf4996b863360069daaef9_FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_af7a8edf-23b9-43c2-b1da-1c2293b38363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_af7a8edf-23b9-43c2-b1da-1c2293b38363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_08e12a06-c614-4cba-b82c-af7e1066da06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:to="loc_us-gaap_DerivativeAssets_08e12a06-c614-4cba-b82c-af7e1066da06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c4776ec8-60e4-4412-b312-e44920761a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:to="loc_us-gaap_DerivativeLiabilities_c4776ec8-60e4-4412-b312-e44920761a67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:to="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis_db810cb5-77ba-42bf-bf02-252b8dc18d19" xlink:href="pfe-20221002.xsd#pfe_HedgedItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:to="loc_pfe_HedgedItemAxis_db810cb5-77ba-42bf-bf02-252b8dc18d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_db810cb5-77ba-42bf-bf02-252b8dc18d19_default" xlink:href="pfe-20221002.xsd#pfe_HedgedItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_HedgedItemAxis_db810cb5-77ba-42bf-bf02-252b8dc18d19" xlink:to="loc_pfe_HedgedItemDomain_db810cb5-77ba-42bf-bf02-252b8dc18d19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_1a93cbdb-ff26-4a84-a9ed-0feed5ce8e10" xlink:href="pfe-20221002.xsd#pfe_HedgedItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_HedgedItemAxis_db810cb5-77ba-42bf-bf02-252b8dc18d19" xlink:to="loc_pfe_HedgedItemDomain_1a93cbdb-ff26-4a84-a9ed-0feed5ce8e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_0daf868e-c109-45bb-8b64-b157ee9e70b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_HedgedItemDomain_1a93cbdb-ff26-4a84-a9ed-0feed5ce8e10" xlink:to="loc_us-gaap_SalesMember_0daf868e-c109-45bb-8b64-b157ee9e70b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_dfa46191-9a9b-4159-acff-499b1f2f461c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:to="loc_us-gaap_HedgingDesignationAxis_dfa46191-9a9b-4159-acff-499b1f2f461c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_dfa46191-9a9b-4159-acff-499b1f2f461c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_dfa46191-9a9b-4159-acff-499b1f2f461c" xlink:to="loc_us-gaap_HedgingDesignationDomain_dfa46191-9a9b-4159-acff-499b1f2f461c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_dfa46191-9a9b-4159-acff-499b1f2f461c" xlink:to="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_44e312cc-1a44-47d1-9f50-b3e8927e398a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_44e312cc-1a44-47d1-9f50-b3e8927e398a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_71d1a43b-16d6-42b7-af20-2f4744174c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:to="loc_us-gaap_NondesignatedMember_71d1a43b-16d6-42b7-af20-2f4744174c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1039615c-e127-4926-b1c1-f73ebc388dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1039615c-e127-4926-b1c1-f73ebc388dc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1039615c-e127-4926-b1c1-f73ebc388dc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1039615c-e127-4926-b1c1-f73ebc388dc7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1039615c-e127-4926-b1c1-f73ebc388dc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1039615c-e127-4926-b1c1-f73ebc388dc7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d4522576-9dcf-4daf-a7d3-3c94d0c2ac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d4522576-9dcf-4daf-a7d3-3c94d0c2ac0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_fcc8d5d7-e5bc-4356-838c-1b4450c1b933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:to="loc_us-gaap_InterestRateContractMember_fcc8d5d7-e5bc-4356-838c-1b4450c1b933" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="extended" id="ibf99c5319d99465d84ee066a0a18d38b_FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c5714b39-726a-41c8-b0b6-191d854d84b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c5714b39-726a-41c8-b0b6-191d854d84b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_94d1a151-3657-42b8-a852-f679103929b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_94d1a151-3657-42b8-a852-f679103929b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_32aeb2c6-2836-4a99-92eb-3fdb6456f0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_32aeb2c6-2836-4a99-92eb-3fdb6456f0e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0af97d6f-95fe-49ec-a3ff-aedf23924f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0af97d6f-95fe-49ec-a3ff-aedf23924f42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_feb896ab-a41e-44be-b983-136ce18c17b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_feb896ab-a41e-44be-b983-136ce18c17b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_53763dc6-ec92-43fe-b623-c91273f84223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_53763dc6-ec92-43fe-b623-c91273f84223" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1db06676-6fd0-440e-b488-957529ae152f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1db06676-6fd0-440e-b488-957529ae152f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_1449a599-371c-47a5-bfd1-b9907b39c3a0" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_1449a599-371c-47a5-bfd1-b9907b39c3a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_66a0ddcc-ed7a-416d-8815-120a99428753" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_66a0ddcc-ed7a-416d-8815-120a99428753" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_009c1de3-8860-4821-a69c-7f9bed70b477" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_009c1de3-8860-4821-a69c-7f9bed70b477" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ff9fb99-7582-4117-aa83-0670bb81516c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ff9fb99-7582-4117-aa83-0670bb81516c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_77bbbe6c-625b-4853-94a3-be98122d993e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_77bbbe6c-625b-4853-94a3-be98122d993e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_466ab040-9d34-4e09-9218-a7999b9d0e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_466ab040-9d34-4e09-9218-a7999b9d0e2f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_a0a80b89-d08f-4965-a5da-6aded8640e46" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_a0a80b89-d08f-4965-a5da-6aded8640e46" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_0d631493-ec7b-43d7-bd96-2ff30aadd4a4" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_0d631493-ec7b-43d7-bd96-2ff30aadd4a4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_77ca5236-c3d8-41a1-9ae3-4c65f8b38fce" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_77ca5236-c3d8-41a1-9ae3-4c65f8b38fce" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9e806258-dac6-43c3-9f2f-deeb5d60635f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:to="loc_us-gaap_CashFlowHedgingMember_9e806258-dac6-43c3-9f2f-deeb5d60635f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_3e492ccf-b62b-4f53-990e-5f41e08160e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:to="loc_us-gaap_FairValueHedgingMember_3e492ccf-b62b-4f53-990e-5f41e08160e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_91700837-afa3-47f4-9aea-eb4602ece8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_91700837-afa3-47f4-9aea-eb4602ece8b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3e78bd48-fa93-4c56-bbe7-df95b7545192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_HedgingDesignationAxis_3e78bd48-fa93-4c56-bbe7-df95b7545192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3e78bd48-fa93-4c56-bbe7-df95b7545192_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_3e78bd48-fa93-4c56-bbe7-df95b7545192" xlink:to="loc_us-gaap_HedgingDesignationDomain_3e78bd48-fa93-4c56-bbe7-df95b7545192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_3e78bd48-fa93-4c56-bbe7-df95b7545192" xlink:to="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_59db1ea3-f09f-418d-b254-c91717f9c6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_59db1ea3-f09f-418d-b254-c91717f9c6ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_37d3be3c-49a8-4a83-baec-fba482c7fdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:to="loc_us-gaap_NondesignatedMember_37d3be3c-49a8-4a83-baec-fba482c7fdd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f3d95915-65fd-4981-ae12-0a94a3ef08a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f3d95915-65fd-4981-ae12-0a94a3ef08a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_8dcfc126-8a1b-4e59-acae-0ef1f3aab651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:to="loc_us-gaap_InterestRateContractMember_8dcfc126-8a1b-4e59-acae-0ef1f3aab651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4b4a5c39-8199-4353-a2dd-61b4d612da37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4b4a5c39-8199-4353-a2dd-61b4d612da37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b4a5c39-8199-4353-a2dd-61b4d612da37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b4a5c39-8199-4353-a2dd-61b4d612da37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b4a5c39-8199-4353-a2dd-61b4d612da37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b4a5c39-8199-4353-a2dd-61b4d612da37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a00c4076-af15-4df3-a8e7-3fd056824747" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a00c4076-af15-4df3-a8e7-3fd056824747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_e599123a-2d09-4903-99b9-91bc177b8e09" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:to="loc_pfe_ForeignCurrencyDebtMember_e599123a-2d09-4903-99b9-91bc177b8e09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="extended" id="i1c7290fefbb247128fb414ab0ca82ea2_FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa58d57c-f376-4c05-8d45-2fdd0bc21247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa58d57c-f376-4c05-8d45-2fdd0bc21247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_c93b7a7b-d901-4a82-ac52-98b059353f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_c93b7a7b-d901-4a82-ac52-98b059353f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_9a601fe1-ac0a-4386-9c52-8312c1429746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_9a601fe1-ac0a-4386-9c52-8312c1429746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_40a65ee2-1fe7-4541-8fb3-6dcd01b69352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_DebtCurrent_40a65ee2-1fe7-4541-8fb3-6dcd01b69352" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3249ba92-eb65-49b7-aad3-d3372bcb5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_LongTermDebt_3249ba92-eb65-49b7-aad3-d3372bcb5b43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_660825cb-0865-4b1b-bf93-21b936d37a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:to="loc_us-gaap_HedgingDesignationAxis_660825cb-0865-4b1b-bf93-21b936d37a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_660825cb-0865-4b1b-bf93-21b936d37a6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_660825cb-0865-4b1b-bf93-21b936d37a6f" xlink:to="loc_us-gaap_HedgingDesignationDomain_660825cb-0865-4b1b-bf93-21b936d37a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7ecef292-c0ef-4443-a408-d8c89c4c84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_660825cb-0865-4b1b-bf93-21b936d37a6f" xlink:to="loc_us-gaap_HedgingDesignationDomain_7ecef292-c0ef-4443-a408-d8c89c4c84d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_57dfc767-daea-4d30-899c-f45194cc1c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7ecef292-c0ef-4443-a408-d8c89c4c84d2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_57dfc767-daea-4d30-899c-f45194cc1c33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9adccb48-be86-42f5-81b9-d106835dc22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9adccb48-be86-42f5-81b9-d106835dc22e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9adccb48-be86-42f5-81b9-d106835dc22e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9adccb48-be86-42f5-81b9-d106835dc22e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9adccb48-be86-42f5-81b9-d106835dc22e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d73c8f9e-d05e-4a99-9d49-41dba9a960ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9adccb48-be86-42f5-81b9-d106835dc22e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d73c8f9e-d05e-4a99-9d49-41dba9a960ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ee990678-ea84-4be6-8075-0f97ffbe7986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d73c8f9e-d05e-4a99-9d49-41dba9a960ff" xlink:to="loc_us-gaap_CostOfSalesMember_ee990678-ea84-4be6-8075-0f97ffbe7986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_91a6cfb9-7aa7-43ab-9109-f5450dfc8903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_91a6cfb9-7aa7-43ab-9109-f5450dfc8903" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_91a6cfb9-7aa7-43ab-9109-f5450dfc8903_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_91a6cfb9-7aa7-43ab-9109-f5450dfc8903" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_91a6cfb9-7aa7-43ab-9109-f5450dfc8903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_91a6cfb9-7aa7-43ab-9109-f5450dfc8903" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_77b4a91b-e234-4aec-8110-6c32882213e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_77b4a91b-e234-4aec-8110-6c32882213e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a3dfafa2-92a0-43d5-90d6-7c4ae0143080" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a3dfafa2-92a0-43d5-90d6-7c4ae0143080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_ac9c63a9-9508-4d9e-b70d-627eebecf2fa" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:to="loc_pfe_ForeignCurrencyDebtMember_ac9c63a9-9508-4d9e-b70d-627eebecf2fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="extended" id="i3893a8f9d869495e8acf6eb4b0275bc7_FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_d599429d-0302-4c7b-a50b-3d805c24ca28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_d599429d-0302-4c7b-a50b-3d805c24ca28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_92cd44dd-117a-458a-957c-32878db3dc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_92cd44dd-117a-458a-957c-32878db3dc80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_07ec07a3-c39d-4aa9-acc2-7bce91aad8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_07ec07a3-c39d-4aa9-acc2-7bce91aad8cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0f3bc0dd-cff5-4896-9206-9b166c27165f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:to="loc_us-gaap_DerivativeTable_0f3bc0dd-cff5-4896-9206-9b166c27165f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a5bbf3e-1277-4c7a-8172-19503422cf67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0f3bc0dd-cff5-4896-9206-9b166c27165f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a5bbf3e-1277-4c7a-8172-19503422cf67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7a5bbf3e-1277-4c7a-8172-19503422cf67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a5bbf3e-1277-4c7a-8172-19503422cf67" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7a5bbf3e-1277-4c7a-8172-19503422cf67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a5bbf3e-1277-4c7a-8172-19503422cf67" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtMember_4cb56cdc-9190-455a-b121-abb7d40f4877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:to="loc_us-gaap_ShortTermDebtMember_4cb56cdc-9190-455a-b121-abb7d40f4877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_94bcf997-41d4-4a39-856c-dbc8722053c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:to="loc_us-gaap_LongTermDebtMember_94bcf997-41d4-4a39-856c-dbc8722053c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended" id="iaee2b489832844e8b90ca94ee43fa865_OtherFinancialInformationOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37fbe5f8-1835-4a81-9e55-36c4adcb1433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3ccc8bf7-3765-4d94-8aba-23f73327c054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37fbe5f8-1835-4a81-9e55-36c4adcb1433" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3ccc8bf7-3765-4d94-8aba-23f73327c054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37fbe5f8-1835-4a81-9e55-36c4adcb1433" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:to="loc_srt_CounterpartyNameAxis_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_016fb548-4629-48f4-bcf7-d954c61d98a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_016fb548-4629-48f4-bcf7-d954c61d98a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_cced6bf3-ba80-48e6-ad9e-565655913df7" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_016fb548-4629-48f4-bcf7-d954c61d98a1" xlink:to="loc_pfe_BioNTechMember_cced6bf3-ba80-48e6-ad9e-565655913df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a02cfeca-54f5-4301-8175-97f40cb4a682" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:to="loc_srt_ProductOrServiceAxis_a02cfeca-54f5-4301-8175-97f40cb4a682" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a02cfeca-54f5-4301-8175-97f40cb4a682_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a02cfeca-54f5-4301-8175-97f40cb4a682" xlink:to="loc_srt_ProductsAndServicesDomain_a02cfeca-54f5-4301-8175-97f40cb4a682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_835fe26b-ecbe-4c4c-b413-1f441623f0e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a02cfeca-54f5-4301-8175-97f40cb4a682" xlink:to="loc_srt_ProductsAndServicesDomain_835fe26b-ecbe-4c4c-b413-1f441623f0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_c59cc252-70c0-4372-91c6-b51e1faed006" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_835fe26b-ecbe-4c4c-b413-1f441623f0e6" xlink:to="loc_pfe_ComirnatyMember_c59cc252-70c0-4372-91c6-b51e1faed006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_80f645fd-d109-4aba-b7f3-d3ebc3d38cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:to="loc_us-gaap_TypeOfArrangementAxis_80f645fd-d109-4aba-b7f3-d3ebc3d38cad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80f645fd-d109-4aba-b7f3-d3ebc3d38cad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80f645fd-d109-4aba-b7f3-d3ebc3d38cad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80f645fd-d109-4aba-b7f3-d3ebc3d38cad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e611ec8-3682-41a8-b44b-01ca6ea8549a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80f645fd-d109-4aba-b7f3-d3ebc3d38cad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e611ec8-3682-41a8-b44b-01ca6ea8549a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_783817f6-3ec6-4082-a886-31986632c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e611ec8-3682-41a8-b44b-01ca6ea8549a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_783817f6-3ec6-4082-a886-31986632c54d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="extended" id="i1ee842e0b11c46f1b4f2847967476d87_IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7e2858de-fe41-442a-9128-9df1ebc37b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7e2858de-fe41-442a-9128-9df1ebc37b3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_40fa7575-495d-4229-8076-29e7bd1e917d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_40fa7575-495d-4229-8076-29e7bd1e917d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fae5a544-be5a-4501-b784-cece4df74343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fae5a544-be5a-4501-b784-cece4df74343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2cbf156e-474c-48e9-a7d9-4018a40faebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2cbf156e-474c-48e9-a7d9-4018a40faebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7852d51b-3741-4833-b473-9b0b4c6fb2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:to="loc_us-gaap_TradeNamesMember_7852d51b-3741-4833-b473-9b0b4c6fb2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_be835353-ce19-42c5-a674-eca44ef5330c" xlink:href="pfe-20221002.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_be835353-ce19-42c5-a674-eca44ef5330c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a925a810-3687-4aa8-a7ce-b8e1fe8aac92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:to="loc_srt_CounterpartyNameAxis_a925a810-3687-4aa8-a7ce-b8e1fe8aac92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a925a810-3687-4aa8-a7ce-b8e1fe8aac92_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a925a810-3687-4aa8-a7ce-b8e1fe8aac92" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a925a810-3687-4aa8-a7ce-b8e1fe8aac92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c7feb77-b97a-4813-9c35-e655fc5487ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a925a810-3687-4aa8-a7ce-b8e1fe8aac92" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c7feb77-b97a-4813-9c35-e655fc5487ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_ca253661-d6f7-40af-b4ff-8527b5608b84" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c7feb77-b97a-4813-9c35-e655fc5487ca" xlink:to="loc_pfe_BioNTechMember_ca253661-d6f7-40af-b4ff-8527b5608b84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9604a66c-90f4-4f14-9fe2-7dd516573017" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:to="loc_srt_ProductOrServiceAxis_9604a66c-90f4-4f14-9fe2-7dd516573017" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9604a66c-90f4-4f14-9fe2-7dd516573017_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9604a66c-90f4-4f14-9fe2-7dd516573017" xlink:to="loc_srt_ProductsAndServicesDomain_9604a66c-90f4-4f14-9fe2-7dd516573017_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4203d788-d627-4474-a01d-84249207d695" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9604a66c-90f4-4f14-9fe2-7dd516573017" xlink:to="loc_srt_ProductsAndServicesDomain_4203d788-d627-4474-a01d-84249207d695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_b1515c5c-4c69-4497-8b37-2fe693502294" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4203d788-d627-4474-a01d-84249207d695" xlink:to="loc_pfe_ComirnatyMember_b1515c5c-4c69-4497-8b37-2fe693502294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_850027aa-3dc5-4994-8338-5de031018d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49c684cb-020b-4bd7-a3b5-5d5f26fb976f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_850027aa-3dc5-4994-8338-5de031018d82" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49c684cb-020b-4bd7-a3b5-5d5f26fb976f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_850027aa-3dc5-4994-8338-5de031018d82" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_56d62423-b6da-49a3-a072-03412a277554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_56d62423-b6da-49a3-a072-03412a277554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_56d62423-b6da-49a3-a072-03412a277554_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_56d62423-b6da-49a3-a072-03412a277554" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_56d62423-b6da-49a3-a072-03412a277554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_56d62423-b6da-49a3-a072-03412a277554" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_79842307-c7f8-43f1-b182-5cb2b18ad153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:to="loc_us-gaap_TradeNamesMember_79842307-c7f8-43f1-b182-5cb2b18ad153" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e7200949-730e-490d-af0f-bdeb1c414e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e7200949-730e-490d-af0f-bdeb1c414e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_0f53c6bb-b0d3-4499-a9e8-4124f8e17660" xlink:href="pfe-20221002.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_0f53c6bb-b0d3-4499-a9e8-4124f8e17660" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e97aab70-c892-4565-9295-3576d5ecfd40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e97aab70-c892-4565-9295-3576d5ecfd40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e97aab70-c892-4565-9295-3576d5ecfd40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e97aab70-c892-4565-9295-3576d5ecfd40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e97aab70-c892-4565-9295-3576d5ecfd40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3824f521-e3e1-4ae4-83bf-27e54098ceec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e97aab70-c892-4565-9295-3576d5ecfd40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3824f521-e3e1-4ae4-83bf-27e54098ceec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArenaMember_85160075-bb12-4f79-9276-fb9b6a3342ab" xlink:href="pfe-20221002.xsd#pfe_ArenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3824f521-e3e1-4ae4-83bf-27e54098ceec" xlink:to="loc_pfe_ArenaMember_85160075-bb12-4f79-9276-fb9b6a3342ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended" id="i64617f6af5df404b95396b71ec930be9_PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_902f2672-4809-4f6b-a3bf-5ad259dac462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_902f2672-4809-4f6b-a3bf-5ad259dac462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_150397e3-d689-48fc-a3f8-05bc83b0c3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_150397e3-d689-48fc-a3f8-05bc83b0c3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000194c9-df50-426f-a476-b18e57037434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000194c9-df50-426f-a476-b18e57037434" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0cc42a7b-e70f-40e8-8cdb-b0f475344068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0cc42a7b-e70f-40e8-8cdb-b0f475344068" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cc66f91f-f408-449b-b7bd-b3d759094108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cc66f91f-f408-449b-b7bd-b3d759094108" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_1e43d95e-3cf6-46d1-8c9f-f29a7315c89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_1e43d95e-3cf6-46d1-8c9f-f29a7315c89f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_5dc088e1-c06d-4e85-ad58-51fb63bf6511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_5dc088e1-c06d-4e85-ad58-51fb63bf6511" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ccbde864-fb5b-4d3a-8a9b-dcf07aecec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ccbde864-fb5b-4d3a-8a9b-dcf07aecec0e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ec84657d-b396-45df-9d02-4162cb6cea84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ec84657d-b396-45df-9d02-4162cb6cea84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ec84657d-b396-45df-9d02-4162cb6cea84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ec84657d-b396-45df-9d02-4162cb6cea84" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ec84657d-b396-45df-9d02-4162cb6cea84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ec84657d-b396-45df-9d02-4162cb6cea84" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_845265f7-8697-4a5d-b19b-c9d5c29b977e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_845265f7-8697-4a5d-b19b-c9d5c29b977e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6bd584c2-58ab-4dee-b9cd-5306831e631e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6bd584c2-58ab-4dee-b9cd-5306831e631e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_32df4b22-c75d-44a8-a52a-522f2f690119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_32df4b22-c75d-44a8-a52a-522f2f690119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_32df4b22-c75d-44a8-a52a-522f2f690119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_32df4b22-c75d-44a8-a52a-522f2f690119" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_32df4b22-c75d-44a8-a52a-522f2f690119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_32df4b22-c75d-44a8-a52a-522f2f690119" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_7eee58bc-799e-4e1f-a372-1daed6219da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:to="loc_us-gaap_DomesticPlanMember_7eee58bc-799e-4e1f-a372-1daed6219da6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70920f7a-73e2-418a-852e-4540f8662222" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_7eee58bc-799e-4e1f-a372-1daed6219da6" xlink:to="loc_country_US_70920f7a-73e2-418a-852e-4540f8662222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_015b5cd8-8b20-499f-9eeb-6548bbce0b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:to="loc_us-gaap_ForeignPlanMember_015b5cd8-8b20-499f-9eeb-6548bbce0b53" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#PensionandPostretirementBenefitPlansNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="extended" id="i77d6b66c7f3446b490daaa81d84b1186_PensionandPostretirementBenefitPlansNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbd6e6fe-a70a-4848-9d40-e46d46d74639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5674a21b-265d-4cbb-8745-489f5e5d7296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbd6e6fe-a70a-4848-9d40-e46d46d74639" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5674a21b-265d-4cbb-8745-489f5e5d7296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbd6e6fe-a70a-4848-9d40-e46d46d74639" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_359e589b-aa20-4fc4-b81e-081c94cece04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_359e589b-aa20-4fc4-b81e-081c94cece04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e29597c-98b7-4012-a6ac-f30a1267781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e29597c-98b7-4012-a6ac-f30a1267781a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_2811b493-7d69-4e62-97f0-6a2282af07a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_2811b493-7d69-4e62-97f0-6a2282af07a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2811b493-7d69-4e62-97f0-6a2282af07a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2811b493-7d69-4e62-97f0-6a2282af07a4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2811b493-7d69-4e62-97f0-6a2282af07a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2811b493-7d69-4e62-97f0-6a2282af07a4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_8dc4fa9c-bf39-4504-846b-e13980821b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:to="loc_us-gaap_DomesticPlanMember_8dc4fa9c-bf39-4504-846b-e13980821b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ae7e2cb5-3b80-46a3-aeac-55d77d572d33" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_8dc4fa9c-bf39-4504-846b-e13980821b57" xlink:to="loc_country_US_ae7e2cb5-3b80-46a3-aeac-55d77d572d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ba51b883-3048-499b-8c18-d5c39d4bd5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:to="loc_us-gaap_ForeignPlanMember_ba51b883-3048-499b-8c18-d5c39d4bd5c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#ContingenciesandCertainCommitmentsPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="extended" id="iad1d0da8992d4fca928d4f028c2ff9b6_ContingenciesandCertainCommitmentsPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_2889e6ae-3011-4431-98c8-acad6202dea0" xlink:href="pfe-20221002.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_2889e6ae-3011-4431-98c8-acad6202dea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_c377787e-0574-417b-8507-e429cfd8b10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_c377787e-0574-417b-8507-e429cfd8b10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_d6786904-bb9e-43d2-9f4c-ca066d07f9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_d6786904-bb9e-43d2-9f4c-ca066d07f9f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants_39f299eb-9bfa-467a-9b47-18cce091a380" xlink:href="pfe-20221002.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_pfe_GainContingencyNumberofDefendants_39f299eb-9bfa-467a-9b47-18cce091a380" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_c2c2d5f0-a0f0-4baf-96d4-621b9c8c792c" xlink:href="pfe-20221002.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_c2c2d5f0-a0f0-4baf-96d4-621b9c8c792c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsFoundNotInfringedNumber_e335a9dc-0935-478e-9688-5a8bd59018b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsFoundNotInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_us-gaap_LossContingencyPatentsFoundNotInfringedNumber_e335a9dc-0935-478e-9688-5a8bd59018b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b0add50d-b0ca-412e-9857-4c172f4dea9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_srt_ProductOrServiceAxis_b0add50d-b0ca-412e-9857-4c172f4dea9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b0add50d-b0ca-412e-9857-4c172f4dea9f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b0add50d-b0ca-412e-9857-4c172f4dea9f" xlink:to="loc_srt_ProductsAndServicesDomain_b0add50d-b0ca-412e-9857-4c172f4dea9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b0add50d-b0ca-412e-9857-4c172f4dea9f" xlink:to="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_a2dc1104-80a8-4867-94e0-40a5463a537c" xlink:href="pfe-20221002.xsd#pfe_MektoviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:to="loc_pfe_MektoviMember_a2dc1104-80a8-4867-94e0-40a5463a537c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_214e72cf-e7f9-47fe-b10b-0dc95ce8b042" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:to="loc_pfe_ComirnatyMember_214e72cf-e7f9-47fe-b10b-0dc95ce8b042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_a92161e2-d42b-4042-9c79-232c5dd87efe" xlink:href="pfe-20221002.xsd#pfe_EliquisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:to="loc_pfe_EliquisMember_a92161e2-d42b-4042-9c79-232c5dd87efe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a2b94344-6154-4f8d-af5c-560ca167cb7a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_srt_LitigationCaseAxis_a2b94344-6154-4f8d-af5c-560ca167cb7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a2b94344-6154-4f8d-af5c-560ca167cb7a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a2b94344-6154-4f8d-af5c-560ca167cb7a" xlink:to="loc_srt_LitigationCaseTypeDomain_a2b94344-6154-4f8d-af5c-560ca167cb7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a2b94344-6154-4f8d-af5c-560ca167cb7a" xlink:to="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndVersusSeveralGenericManufacturersMember_c4c9f6fd-9a09-4946-9c95-a46112739db4" xlink:href="pfe-20221002.xsd#pfe_PfizerAndVersusSeveralGenericManufacturersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_PfizerAndVersusSeveralGenericManufacturersMember_c4c9f6fd-9a09-4946-9c95-a46112739db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ModernaTXPatentInfringementCaseMember_f863396f-4266-4d01-9008-86c91592e322" xlink:href="pfe-20221002.xsd#pfe_ModernaTXPatentInfringementCaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_ModernaTXPatentInfringementCaseMember_f863396f-4266-4d01-9008-86c91592e322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_7865b7d6-6dbe-421f-b816-34f56323f25a" xlink:href="pfe-20221002.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_7865b7d6-6dbe-421f-b816-34f56323f25a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember_45a0bb12-9173-4e04-ae46-af25aa01a93c" xlink:href="pfe-20221002.xsd#pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember_45a0bb12-9173-4e04-ae46-af25aa01a93c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f" xlink:to="loc_us-gaap_GainContingencyNatureDomain_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_99b791d6-6350-4a93-a4a2-e915b4aff9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f" xlink:to="loc_us-gaap_GainContingencyNatureDomain_99b791d6-6350-4a93-a4a2-e915b4aff9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_b9bc5850-4172-48e9-b574-459ee7dbee5e" xlink:href="pfe-20221002.xsd#pfe_PatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_99b791d6-6350-4a93-a4a2-e915b4aff9a3" xlink:to="loc_pfe_PatentInfringementMember_b9bc5850-4172-48e9-b574-459ee7dbee5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_26a106c9-9e12-4149-9904-d20850dce951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_us-gaap_LitigationStatusAxis_26a106c9-9e12-4149-9904-d20850dce951" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_26a106c9-9e12-4149-9904-d20850dce951_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_26a106c9-9e12-4149-9904-d20850dce951" xlink:to="loc_us-gaap_LitigationStatusDomain_26a106c9-9e12-4149-9904-d20850dce951_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3a8b8b3c-10d2-4004-a794-8dadcea9f974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_26a106c9-9e12-4149-9904-d20850dce951" xlink:to="loc_us-gaap_LitigationStatusDomain_3a8b8b3c-10d2-4004-a794-8dadcea9f974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f1774f4a-1d40-40d4-b91e-d5e735e9da3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3a8b8b3c-10d2-4004-a794-8dadcea9f974" xlink:to="loc_us-gaap_PendingLitigationMember_f1774f4a-1d40-40d4-b91e-d5e735e9da3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ExpirationPeriodAxis_a3a843cb-b233-4078-80a0-b141fc6f544b" xlink:href="pfe-20221002.xsd#pfe_ExpirationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_pfe_ExpirationPeriodAxis_a3a843cb-b233-4078-80a0-b141fc6f544b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ExpirationPeriodDomain_a3a843cb-b233-4078-80a0-b141fc6f544b_default" xlink:href="pfe-20221002.xsd#pfe_ExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_ExpirationPeriodAxis_a3a843cb-b233-4078-80a0-b141fc6f544b" xlink:to="loc_pfe_ExpirationPeriodDomain_a3a843cb-b233-4078-80a0-b141fc6f544b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:href="pfe-20221002.xsd#pfe_ExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_ExpirationPeriodAxis_a3a843cb-b233-4078-80a0-b141fc6f544b" xlink:to="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_Expiring2030Member_baa7dd42-7502-4b0c-86ce-cd271dd24a63" xlink:href="pfe-20221002.xsd#pfe_Expiring2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:to="loc_pfe_Expiring2030Member_baa7dd42-7502-4b0c-86ce-cd271dd24a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_Expiring2033Member_1d428e82-0c77-48e1-86b0-71696dbc38a3" xlink:href="pfe-20221002.xsd#pfe_Expiring2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:to="loc_pfe_Expiring2033Member_1d428e82-0c77-48e1-86b0-71696dbc38a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails" xlink:type="extended" id="ia219713224794d8eb3ce4523d8b8d3cd_ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e876bf7d-2f03-439b-985a-fcfdbba5ca3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_dd430df0-2c24-4656-8a53-72f51f659085" xlink:href="pfe-20221002.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e876bf7d-2f03-439b-985a-fcfdbba5ca3a" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_dd430df0-2c24-4656-8a53-72f51f659085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e876bf7d-2f03-439b-985a-fcfdbba5ca3a" xlink:to="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:to="loc_srt_LitigationCaseAxis_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5" xlink:to="loc_srt_LitigationCaseTypeDomain_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f67f8dc2-d67b-4ef6-ae6b-e05306675214" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5" xlink:to="loc_srt_LitigationCaseTypeDomain_f67f8dc2-d67b-4ef6-ae6b-e05306675214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_55734cb2-6682-45a7-8616-98723a70634b" xlink:href="pfe-20221002.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f67f8dc2-d67b-4ef6-ae6b-e05306675214" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_55734cb2-6682-45a7-8616-98723a70634b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3fe7b80-cc11-49ac-884b-d3b171e258b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:to="loc_srt_ProductOrServiceAxis_a3fe7b80-cc11-49ac-884b-d3b171e258b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3fe7b80-cc11-49ac-884b-d3b171e258b2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a3fe7b80-cc11-49ac-884b-d3b171e258b2" xlink:to="loc_srt_ProductsAndServicesDomain_a3fe7b80-cc11-49ac-884b-d3b171e258b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd291e67-e8f3-4525-b1fe-b4efa50422e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a3fe7b80-cc11-49ac-884b-d3b171e258b2" xlink:to="loc_srt_ProductsAndServicesDomain_dd291e67-e8f3-4525-b1fe-b4efa50422e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember_6e810d6f-a00a-43d3-adf5-e139fc978eec" xlink:href="pfe-20221002.xsd#pfe_DocetaxelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dd291e67-e8f3-4525-b1fe-b4efa50422e7" xlink:to="loc_pfe_DocetaxelMember_6e810d6f-a00a-43d3-adf5-e139fc978eec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e709d891-34e3-4726-b311-00271444eaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:to="loc_us-gaap_LitigationStatusAxis_e709d891-34e3-4726-b311-00271444eaf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_e709d891-34e3-4726-b311-00271444eaf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_e709d891-34e3-4726-b311-00271444eaf5" xlink:to="loc_us-gaap_LitigationStatusDomain_e709d891-34e3-4726-b311-00271444eaf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_aad39a6a-a7a3-4958-aed1-8584e83805ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_e709d891-34e3-4726-b311-00271444eaf5" xlink:to="loc_us-gaap_LitigationStatusDomain_aad39a6a-a7a3-4958-aed1-8584e83805ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_08a758e8-f921-4213-bff4-0dd8aef51d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_aad39a6a-a7a3-4958-aed1-8584e83805ac" xlink:to="loc_us-gaap_PendingLitigationMember_08a758e8-f921-4213-bff4-0dd8aef51d43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="extended" id="ie0603f53ef314bfab8e1b0027b954cda_SegmentGeographicandOtherRevenueInformationNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cdf47fb5-a02a-4096-9dd4-745c375b4ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cdf47fb5-a02a-4096-9dd4-745c375b4ac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_810ceaef-f5f2-4809-b40c-2556a2ad65ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_Assets_810ceaef-f5f2-4809-b40c-2556a2ad65ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9518f4b5-2e71-4e39-9501-a126dc2c967f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9518f4b5-2e71-4e39-9501-a126dc2c967f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ecb8a309-f161-4e67-b03d-b0bead9c19fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ecb8a309-f161-4e67-b03d-b0bead9c19fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c9c82b0-7431-4dd2-9a9c-ab3f0fa2cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c9c82b0-7431-4dd2-9a9c-ab3f0fa2cfbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7903dbc2-74fe-4c63-9173-89d47b63a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7903dbc2-74fe-4c63-9173-89d47b63a9e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d75432e-7e7c-47b5-929f-3650a86aa634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d75432e-7e7c-47b5-929f-3650a86aa634" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78bfd9b6-a72d-4e47-9e28-dfe8104377b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78bfd9b6-a72d-4e47-9e28-dfe8104377b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fbb6f7f9-cae1-4595-8281-2a66599908d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fbb6f7f9-cae1-4595-8281-2a66599908d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_ef0f81ef-50b4-4727-9835-1826ca9c5e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_ef0f81ef-50b4-4727-9835-1826ca9c5e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e7e46595-58fa-403c-9a8b-f1a80adac20f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e7e46595-58fa-403c-9a8b-f1a80adac20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e345e990-5833-43ac-8ebf-9aaf45be18c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e345e990-5833-43ac-8ebf-9aaf45be18c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_2782a8ab-5f18-4f1d-8336-4b1aa9130135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_2782a8ab-5f18-4f1d-8336-4b1aa9130135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8db1110f-0751-448a-a3b8-1476fcbddd03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8db1110f-0751-448a-a3b8-1476fcbddd03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a1f43332-d9b2-4788-925a-c0f76a5ba46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:to="loc_us-gaap_SalesRevenueNetMember_a1f43332-d9b2-4788-925a-c0f76a5ba46f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_681549c6-12d4-4c8a-8aac-109c21af1c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:to="loc_us-gaap_AccountsReceivableMember_681549c6-12d4-4c8a-8aac-109c21af1c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e2f72bc8-3e0b-4450-9983-90c669418da6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:to="loc_srt_NameOfMajorCustomerDomain_e2f72bc8-3e0b-4450-9983-90c669418da6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:to="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_699d35b6-35ac-4448-9d3e-376c0f32723c" xlink:href="pfe-20221002.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_699d35b6-35ac-4448-9d3e-376c0f32723c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:to="loc_srt_ProductsAndServicesDomain_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:to="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:href="pfe-20221002.xsd#pfe_ComirnatyAndPaxlovidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:to="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_e755b9f1-815b-45fe-9e8e-de6d10f6ef28" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:to="loc_pfe_ComirnatyMember_e755b9f1-815b-45fe-9e8e-de6d10f6ef28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_fd8d836c-4bd0-4934-839f-31bdbf105a62" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:to="loc_pfe_PaxlovidMember_fd8d836c-4bd0-4934-839f-31bdbf105a62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c567d667-6c31-4397-a711-e9b2aa53d87d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:to="loc_us-gaap_SegmentDomain_c567d667-6c31-4397-a711-e9b2aa53d87d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:to="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_ad076227-b385-453c-aaeb-20562b6676d4" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:to="loc_pfe_BiopharmaSegmentMember_ad076227-b385-453c-aaeb-20562b6676d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail_1"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="extended" id="iaa9a2638dfe2436ea1f9f6b482c74191_SegmentGeographicandOtherRevenueInformationNarrativeDetail_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cdf47fb5-a02a-4096-9dd4-745c375b4ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cdf47fb5-a02a-4096-9dd4-745c375b4ac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_810ceaef-f5f2-4809-b40c-2556a2ad65ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_Assets_810ceaef-f5f2-4809-b40c-2556a2ad65ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9518f4b5-2e71-4e39-9501-a126dc2c967f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9518f4b5-2e71-4e39-9501-a126dc2c967f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ecb8a309-f161-4e67-b03d-b0bead9c19fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ecb8a309-f161-4e67-b03d-b0bead9c19fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c9c82b0-7431-4dd2-9a9c-ab3f0fa2cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c9c82b0-7431-4dd2-9a9c-ab3f0fa2cfbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7903dbc2-74fe-4c63-9173-89d47b63a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7903dbc2-74fe-4c63-9173-89d47b63a9e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d75432e-7e7c-47b5-929f-3650a86aa634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d75432e-7e7c-47b5-929f-3650a86aa634" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78bfd9b6-a72d-4e47-9e28-dfe8104377b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78bfd9b6-a72d-4e47-9e28-dfe8104377b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fbb6f7f9-cae1-4595-8281-2a66599908d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fbb6f7f9-cae1-4595-8281-2a66599908d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e7e46595-58fa-403c-9a8b-f1a80adac20f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e7e46595-58fa-403c-9a8b-f1a80adac20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e345e990-5833-43ac-8ebf-9aaf45be18c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e345e990-5833-43ac-8ebf-9aaf45be18c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_2782a8ab-5f18-4f1d-8336-4b1aa9130135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_2782a8ab-5f18-4f1d-8336-4b1aa9130135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8db1110f-0751-448a-a3b8-1476fcbddd03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8db1110f-0751-448a-a3b8-1476fcbddd03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a1f43332-d9b2-4788-925a-c0f76a5ba46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:to="loc_us-gaap_SalesRevenueNetMember_a1f43332-d9b2-4788-925a-c0f76a5ba46f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_681549c6-12d4-4c8a-8aac-109c21af1c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:to="loc_us-gaap_AccountsReceivableMember_681549c6-12d4-4c8a-8aac-109c21af1c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e2f72bc8-3e0b-4450-9983-90c669418da6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:to="loc_srt_NameOfMajorCustomerDomain_e2f72bc8-3e0b-4450-9983-90c669418da6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:to="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_699d35b6-35ac-4448-9d3e-376c0f32723c" xlink:href="pfe-20221002.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_699d35b6-35ac-4448-9d3e-376c0f32723c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:to="loc_srt_ProductsAndServicesDomain_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:to="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:href="pfe-20221002.xsd#pfe_ComirnatyAndPaxlovidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:to="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_e755b9f1-815b-45fe-9e8e-de6d10f6ef28" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:to="loc_pfe_ComirnatyMember_e755b9f1-815b-45fe-9e8e-de6d10f6ef28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_fd8d836c-4bd0-4934-839f-31bdbf105a62" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:to="loc_pfe_PaxlovidMember_fd8d836c-4bd0-4934-839f-31bdbf105a62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c567d667-6c31-4397-a711-e9b2aa53d87d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:to="loc_us-gaap_SegmentDomain_c567d667-6c31-4397-a711-e9b2aa53d87d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:to="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_ad076227-b385-453c-aaeb-20562b6676d4" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:to="loc_pfe_BiopharmaSegmentMember_ad076227-b385-453c-aaeb-20562b6676d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended" id="ia2da24c54e0844bd8c891703b447332f_SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07606409-68cb-4e15-b7a8-53e5071289ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07606409-68cb-4e15-b7a8-53e5071289ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8825a0b0-8f9f-47f4-a3d9-a00be2fd806c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8825a0b0-8f9f-47f4-a3d9-a00be2fd806c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_bcfb4e34-d44c-40a4-9226-ffb6ffdb894e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_InvestmentIncomeDividend_bcfb4e34-d44c-40a4-9226-ffb6ffdb894e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_91d4d6fa-2218-4776-b907-5cad0ed54b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_OperatingExpenses_91d4d6fa-2218-4776-b907-5cad0ed54b07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5053eef0-60c8-4b44-b3a5-e879537ae5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5053eef0-60c8-4b44-b3a5-e879537ae5bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_bda62945-169d-40b0-b5a1-4fd5c42174f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostDirectMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_CostDirectMaterial_bda62945-169d-40b0-b5a1-4fd5c42174f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d1887f7c-31e9-4621-8ed8-feb93145c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_InventoryWriteDown_d1887f7c-31e9-4621-8ed8-feb93145c43b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_980c426a-9b26-4c06-a0ef-cfeec81ec46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_980c426a-9b26-4c06-a0ef-cfeec81ec46d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_43bf5982-7f6f-4ade-9fb6-4f49854e00bd" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_43bf5982-7f6f-4ade-9fb6-4f49854e00bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_8a9ee8c3-5d83-49da-bf72-0ef71cdea3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_8a9ee8c3-5d83-49da-bf72-0ef71cdea3d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f9f38a60-5b6a-419f-9702-4b97c701ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f9f38a60-5b6a-419f-9702-4b97c701ab0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f9f38a60-5b6a-419f-9702-4b97c701ab0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9f38a60-5b6a-419f-9702-4b97c701ab0c" xlink:to="loc_us-gaap_SegmentDomain_f9f38a60-5b6a-419f-9702-4b97c701ab0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17105ec8-09e1-4bd9-90f4-7a1e8c9d2854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9f38a60-5b6a-419f-9702-4b97c701ab0c" xlink:to="loc_us-gaap_SegmentDomain_17105ec8-09e1-4bd9-90f4-7a1e8c9d2854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_f426f571-9c53-4031-b169-bd17b7ebec52" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_17105ec8-09e1-4bd9-90f4-7a1e8c9d2854" xlink:to="loc_pfe_BiopharmaSegmentMember_f426f571-9c53-4031-b169-bd17b7ebec52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2d1117ca-e8f6-4aba-ba85-da09552896ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_ConsolidationItemsAxis_2d1117ca-e8f6-4aba-ba85-da09552896ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2d1117ca-e8f6-4aba-ba85-da09552896ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2d1117ca-e8f6-4aba-ba85-da09552896ba" xlink:to="loc_srt_ConsolidationItemsDomain_2d1117ca-e8f6-4aba-ba85-da09552896ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2d1117ca-e8f6-4aba-ba85-da09552896ba" xlink:to="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_38487693-61d4-49e2-a1ec-798a3930fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:to="loc_us-gaap_OperatingSegmentsMember_38487693-61d4-49e2-a1ec-798a3930fe83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_997461f7-058d-4199-9612-b7db89c7cb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:to="loc_us-gaap_CorporateNonSegmentMember_997461f7-058d-4199-9612-b7db89c7cb2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_e0fcbc8e-fb97-4aab-be71-6e892372caac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_e0fcbc8e-fb97-4aab-be71-6e892372caac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_663ed30e-6553-4c84-8053-479c388bc526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_663ed30e-6553-4c84-8053-479c388bc526" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_663ed30e-6553-4c84-8053-479c388bc526_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_663ed30e-6553-4c84-8053-479c388bc526" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_663ed30e-6553-4c84-8053-479c388bc526_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_663ed30e-6553-4c84-8053-479c388bc526" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember_f6455fd5-e951-4afb-8438-f391e5401a2d" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:to="loc_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember_f6455fd5-e951-4afb-8438-f391e5401a2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_2a1c236e-ef7e-401d-9a39-422a3545d068" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsAcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:to="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_2a1c236e-ef7e-401d-9a39-422a3545d068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsOtherMember_c5df15cf-9cf1-4e3c-85e6-9ebed3703dd7" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:to="loc_pfe_ReconcilingItemsOtherMember_c5df15cf-9cf1-4e3c-85e6-9ebed3703dd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c91a31a5-b869-48f4-90b0-c4b1f3cc5542" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c91a31a5-b869-48f4-90b0-c4b1f3cc5542" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c91a31a5-b869-48f4-90b0-c4b1f3cc5542_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c91a31a5-b869-48f4-90b0-c4b1f3cc5542" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c91a31a5-b869-48f4-90b0-c4b1f3cc5542_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4d0d54fb-3631-439e-88ab-8e5f1dfe2c28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c91a31a5-b869-48f4-90b0-c4b1f3cc5542" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4d0d54fb-3631-439e-88ab-8e5f1dfe2c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_a6d67cea-d286-408b-ae64-ad6936032aca" xlink:href="pfe-20221002.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4d0d54fb-3631-439e-88ab-8e5f1dfe2c28" xlink:to="loc_pfe_ViivHealthcareLimitedMember_a6d67cea-d286-408b-ae64-ad6936032aca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_b22c354b-7e5e-4f61-a783-6a2d4c1a50df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_RestatementAxis_b22c354b-7e5e-4f61-a783-6a2d4c1a50df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b22c354b-7e5e-4f61-a783-6a2d4c1a50df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_b22c354b-7e5e-4f61-a783-6a2d4c1a50df" xlink:to="loc_srt_RestatementDomain_b22c354b-7e5e-4f61-a783-6a2d4c1a50df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_0ad715c4-1881-42a1-ab16-43b2279bb7e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_b22c354b-7e5e-4f61-a783-6a2d4c1a50df" xlink:to="loc_srt_RestatementDomain_0ad715c4-1881-42a1-ab16-43b2279bb7e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_ddfba69e-4e18-468f-a8da-3da85fa9de45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_0ad715c4-1881-42a1-ab16-43b2279bb7e3" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_ddfba69e-4e18-468f-a8da-3da85fa9de45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_16e5de45-b970-45f5-8101-555ab46c8ee7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_ProductOrServiceAxis_16e5de45-b970-45f5-8101-555ab46c8ee7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16e5de45-b970-45f5-8101-555ab46c8ee7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_16e5de45-b970-45f5-8101-555ab46c8ee7" xlink:to="loc_srt_ProductsAndServicesDomain_16e5de45-b970-45f5-8101-555ab46c8ee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ee2beb65-36f0-4688-8ff3-530239cdc7d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_16e5de45-b970-45f5-8101-555ab46c8ee7" xlink:to="loc_srt_ProductsAndServicesDomain_ee2beb65-36f0-4688-8ff3-530239cdc7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_4af21de5-48ad-4e6e-9185-9f92b49c5a4d" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ee2beb65-36f0-4688-8ff3-530239cdc7d8" xlink:to="loc_pfe_PaxlovidMember_4af21de5-48ad-4e6e-9185-9f92b49c5a4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_50f7caf5-ac1d-412e-bb1b-bf467b70b53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_50f7caf5-ac1d-412e-bb1b-bf467b70b53e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_50f7caf5-ac1d-412e-bb1b-bf467b70b53e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_50f7caf5-ac1d-412e-bb1b-bf467b70b53e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_50f7caf5-ac1d-412e-bb1b-bf467b70b53e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3fa3dc28-20a6-4979-99c8-6affd4069308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_50f7caf5-ac1d-412e-bb1b-bf467b70b53e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3fa3dc28-20a6-4979-99c8-6affd4069308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cc5cfe80-98f7-4516-be79-e713651da5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3fa3dc28-20a6-4979-99c8-6affd4069308" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cc5cfe80-98f7-4516-be79-e713651da5b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_731865ad-3fc1-40e1-a2f3-5870d3357aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_731865ad-3fc1-40e1-a2f3-5870d3357aaa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_731865ad-3fc1-40e1-a2f3-5870d3357aaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_731865ad-3fc1-40e1-a2f3-5870d3357aaa" xlink:to="loc_us-gaap_AssetAcquisitionDomain_731865ad-3fc1-40e1-a2f3-5870d3357aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_01a44274-1d44-4b3c-bc12-e619944eb6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_731865ad-3fc1-40e1-a2f3-5870d3357aaa" xlink:to="loc_us-gaap_AssetAcquisitionDomain_01a44274-1d44-4b3c-bc12-e619944eb6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReViralAssetAcquisitionMember_37ced281-21ba-45ea-ba51-32740839efc5" xlink:href="pfe-20221002.xsd#pfe_ReViralAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_01a44274-1d44-4b3c-bc12-e619944eb6d1" xlink:to="loc_pfe_ReViralAssetAcquisitionMember_37ced281-21ba-45ea-ba51-32740839efc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1158e14f-90cf-47a7-8e8b-306dbed0d3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1158e14f-90cf-47a7-8e8b-306dbed0d3bc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1158e14f-90cf-47a7-8e8b-306dbed0d3bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1158e14f-90cf-47a7-8e8b-306dbed0d3bc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1158e14f-90cf-47a7-8e8b-306dbed0d3bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb496004-222e-408f-92af-82753e8ca2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1158e14f-90cf-47a7-8e8b-306dbed0d3bc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb496004-222e-408f-92af-82753e8ca2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6d03a2e3-b0bd-42c1-954d-57a3a004dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb496004-222e-408f-92af-82753e8ca2a9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6d03a2e3-b0bd-42c1-954d-57a3a004dacf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d0724328-5c5e-4408-899a-64aed63f3910" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_CounterpartyNameAxis_d0724328-5c5e-4408-899a-64aed63f3910" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0724328-5c5e-4408-899a-64aed63f3910_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d0724328-5c5e-4408-899a-64aed63f3910" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0724328-5c5e-4408-899a-64aed63f3910_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87e71424-6ba3-49e2-84a7-68a1a9c72a6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d0724328-5c5e-4408-899a-64aed63f3910" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87e71424-6ba3-49e2-84a7-68a1a9c72a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember_3d1bed11-cc37-421c-b250-f8d7a5c506db" xlink:href="pfe-20221002.xsd#pfe_ArvinasIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87e71424-6ba3-49e2-84a7-68a1a9c72a6d" xlink:to="loc_pfe_ArvinasIncMember_3d1bed11-cc37-421c-b250-f8d7a5c506db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended" id="i0066726eb7a24025bf70c3926c8dc89a_SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a63d9b1-9ff2-4632-ad49-23a4b248be89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a63d9b1-9ff2-4632-ad49-23a4b248be89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PercentageChangeInRevenue_758221cb-5916-4379-8134-2feab2317458" xlink:href="pfe-20221002.xsd#pfe_PercentageChangeInRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:to="loc_pfe_PercentageChangeInRevenue_758221cb-5916-4379-8134-2feab2317458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f77d7f4b-04ae-478f-a8b7-ae5bf2b1d169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f77d7f4b-04ae-478f-a8b7-ae5bf2b1d169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5fdc859d-8ae7-4caa-9daa-4259543215f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f77d7f4b-04ae-478f-a8b7-ae5bf2b1d169" xlink:to="loc_srt_StatementGeographicalAxis_5fdc859d-8ae7-4caa-9daa-4259543215f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5fdc859d-8ae7-4caa-9daa-4259543215f2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5fdc859d-8ae7-4caa-9daa-4259543215f2" xlink:to="loc_srt_SegmentGeographicalDomain_5fdc859d-8ae7-4caa-9daa-4259543215f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5fdc859d-8ae7-4caa-9daa-4259543215f2" xlink:to="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9c8a0c29-e167-4de2-8a64-73be6d04c4a4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_country_US_9c8a0c29-e167-4de2-8a64-73be6d04c4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_23fd8f35-4810-4914-814d-219d8216f712" xlink:href="pfe-20221002.xsd#pfe_DevelopedEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_pfe_DevelopedEuropeMember_23fd8f35-4810-4914-814d-219d8216f712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_a9d0e124-70ff-4b02-b561-67417737dbee" xlink:href="pfe-20221002.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_pfe_DevelopedRestOfWorldMember_a9d0e124-70ff-4b02-b561-67417737dbee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_7e795422-1ed4-485b-b97e-5e8942873d97" xlink:href="pfe-20221002.xsd#pfe_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_pfe_EmergingMarketsMember_7e795422-1ed4-485b-b97e-5e8942873d97" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended" id="ie1987714e5404578985549b9e13dcb1d_SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_eaa5feb4-901d-4f6f-9cbf-f858b4a4162f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24c32b3a-f169-49f8-814b-d98d35534ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_eaa5feb4-901d-4f6f-9cbf-f858b4a4162f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24c32b3a-f169-49f8-814b-d98d35534ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_eaa5feb4-901d-4f6f-9cbf-f858b4a4162f" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2944a1bc-7735-47da-8eba-68b935b5bb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:to="loc_us-gaap_ReportingUnitAxis_2944a1bc-7735-47da-8eba-68b935b5bb27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_2944a1bc-7735-47da-8eba-68b935b5bb27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2944a1bc-7735-47da-8eba-68b935b5bb27" xlink:to="loc_us-gaap_ReportingUnitDomain_2944a1bc-7735-47da-8eba-68b935b5bb27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2944a1bc-7735-47da-8eba-68b935b5bb27" xlink:to="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrimaryCareMember_f4a4a142-8b70-4f12-a901-e973bbc9174a" xlink:href="pfe-20221002.xsd#pfe_PrimaryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:to="loc_pfe_PrimaryCareMember_f4a4a142-8b70-4f12-a901-e973bbc9174a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SpecialtyCareMember_3d5d8c52-1107-47f0-a3fd-2d5818df15ba" xlink:href="pfe-20221002.xsd#pfe_SpecialtyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:to="loc_pfe_SpecialtyCareMember_3d5d8c52-1107-47f0-a3fd-2d5818df15ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember_f0cc7365-62a6-490f-a5d8-b0f571508721" xlink:href="pfe-20221002.xsd#pfe_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:to="loc_pfe_OncologyMember_f0cc7365-62a6-490f-a5d8-b0f571508721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b046126c-23cd-480f-b0a1-e772728c2150" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:to="loc_srt_ProductOrServiceAxis_b046126c-23cd-480f-b0a1-e772728c2150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b046126c-23cd-480f-b0a1-e772728c2150_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b046126c-23cd-480f-b0a1-e772728c2150" xlink:to="loc_srt_ProductsAndServicesDomain_b046126c-23cd-480f-b0a1-e772728c2150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b046126c-23cd-480f-b0a1-e772728c2150" xlink:to="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_ef8b983c-7935-4119-a56f-24bcba3760f4" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ComirnatyMember_ef8b983c-7935-4119-a56f-24bcba3760f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_eb51945f-2b57-4018-ac09-8564edddbdd4" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_PaxlovidMember_eb51945f-2b57-4018-ac09-8564edddbdd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_a13feda1-a1bb-45fa-83d6-09ff2ef62b12" xlink:href="pfe-20221002.xsd#pfe_EliquisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_EliquisMember_a13feda1-a1bb-45fa-83d6-09ff2ef62b12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_45045ddb-97f6-4b2d-8c2a-722174cf870c" xlink:href="pfe-20221002.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_45045ddb-97f6-4b2d-8c2a-722174cf870c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember_66bb7527-b3b7-4acd-b86d-8201786adcb5" xlink:href="pfe-20221002.xsd#pfe_PremarinFamilyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_PremarinFamilyMember_66bb7527-b3b7-4acd-b86d-8201786adcb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember_595711ec-21d9-40f2-af17-378779853443" xlink:href="pfe-20221002.xsd#pfe_NimenrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_NimenrixMember_595711ec-21d9-40f2-af17-378779853443" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BMP2Member_73656fd2-cc95-4c28-99ce-57d24b960fd5" xlink:href="pfe-20221002.xsd#pfe_BMP2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BMP2Member_73656fd2-cc95-4c28-99ce-57d24b960fd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_130c85b3-01e6-43ec-8451-417961aaa1af" xlink:href="pfe-20221002.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_130c85b3-01e6-43ec-8451-417961aaa1af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember_3d4ffcd5-dcd7-4682-aad6-490e753647ee" xlink:href="pfe-20221002.xsd#pfe_ToviazMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ToviazMember_3d4ffcd5-dcd7-4682-aad6-490e753647ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrumenbaMember_9df8a79b-2b91-43dc-9b16-6e3c60ef4778" xlink:href="pfe-20221002.xsd#pfe_TrumenbaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_TrumenbaMember_9df8a79b-2b91-43dc-9b16-6e3c60ef4778" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember_406706f6-b725-4996-8c76-b6cee0ebaaa4" xlink:href="pfe-20221002.xsd#pfe_ChantixChampixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ChantixChampixMember_406706f6-b725-4996-8c76-b6cee0ebaaa4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPrimaryCareProductsMember_ceb6ec21-bce6-4ba5-b217-6be9afb9b62e" xlink:href="pfe-20221002.xsd#pfe_OtherPrimaryCareProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherPrimaryCareProductsMember_ceb6ec21-bce6-4ba5-b217-6be9afb9b62e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember_829f5d52-37ac-4756-a2fd-21ad7f1d726e" xlink:href="pfe-20221002.xsd#pfe_VyndaqelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_VyndaqelMember_829f5d52-37ac-4756-a2fd-21ad7f1d726e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_4eba3998-85ff-431b-a1c9-85d6109227f9" xlink:href="pfe-20221002.xsd#pfe_XeljanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_XeljanzMember_4eba3998-85ff-431b-a1c9-85d6109227f9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember_8323772e-0c7c-4d60-88ae-f5d4acab114e" xlink:href="pfe-20221002.xsd#pfe_EnbrelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_EnbrelMember_8323772e-0c7c-4d60-88ae-f5d4acab114e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember_1e2a268b-86a4-47d1-bd3d-3de6d1ad28e6" xlink:href="pfe-20221002.xsd#pfe_SulperazonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_SulperazonMember_1e2a268b-86a4-47d1-bd3d-3de6d1ad28e6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraMember_1f93b248-9ac3-421a-a9fd-c99666b9000a" xlink:href="pfe-20221002.xsd#pfe_InflectraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_InflectraMember_1f93b248-9ac3-421a-a9fd-c99666b9000a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IgPortfolioProductsMember_47cddb08-4f4d-4a40-8257-c874c6262af1" xlink:href="pfe-20221002.xsd#pfe_IgPortfolioProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_IgPortfolioProductsMember_47cddb08-4f4d-4a40-8257-c874c6262af1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember_fa551ba9-25ac-49dc-93da-031e55816db7" xlink:href="pfe-20221002.xsd#pfe_BeneFIXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BeneFIXMember_fa551ba9-25ac-49dc-93da-031e55816db7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember_7599f1db-9d9d-48b3-adfe-52be401a5827" xlink:href="pfe-20221002.xsd#pfe_ZaviceftaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ZaviceftaMember_7599f1db-9d9d-48b3-adfe-52be401a5827" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember_a6562d80-73c6-4bfa-9292-7cd961035bf9" xlink:href="pfe-20221002.xsd#pfe_GenotropinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_GenotropinMember_a6562d80-73c6-4bfa-9292-7cd961035bf9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember_c5982290-b005-47ad-94a5-432b3d59bd28" xlink:href="pfe-20221002.xsd#pfe_ZithromaxZmaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ZithromaxZmaxMember_c5982290-b005-47ad-94a5-432b3d59bd28" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember_eea2a7d9-e38f-4405-9ab9-39b94aa9e322" xlink:href="pfe-20221002.xsd#pfe_MedrolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_MedrolMember_eea2a7d9-e38f-4405-9ab9-39b94aa9e322" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember_96f78452-2eb0-418b-afa8-34908bab5e03" xlink:href="pfe-20221002.xsd#pfe_FragminMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_FragminMember_96f78452-2eb0-418b-afa8-34908bab5e03" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember_f3ed3b9e-f415-400b-860d-f0d15cfefc96" xlink:href="pfe-20221002.xsd#pfe_SomavertMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_SomavertMember_f3ed3b9e-f415-400b-860d-f0d15cfefc96" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember_a71953e2-e028-488f-a43f-686cb640dcaa" xlink:href="pfe-20221002.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ReFactoAfXynthaMember_a71953e2-e028-488f-a43f-686cb640dcaa" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember_e0bf9cdb-636d-426f-8836-e05b42d40f6d" xlink:href="pfe-20221002.xsd#pfe_VfendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_VfendMember_e0bf9cdb-636d-426f-8836-e05b42d40f6d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember_83dfead3-1091-47cf-a7dd-2efd28b559ce" xlink:href="pfe-20221002.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherAntiinfectivesMember_83dfead3-1091-47cf-a7dd-2efd28b559ce" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherSpecialtyCareMember_faef3ad4-981b-4ea3-9ad8-bcc9d6c626d1" xlink:href="pfe-20221002.xsd#pfe_OtherSpecialtyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherSpecialtyCareMember_faef3ad4-981b-4ea3-9ad8-bcc9d6c626d1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember_1f1f34f9-9d44-4142-8280-a79589b5a682" xlink:href="pfe-20221002.xsd#pfe_IbranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_IbranceMember_1f1f34f9-9d44-4142-8280-a79589b5a682" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_5745e7af-7f25-422a-930f-ba9a72e1baeb" xlink:href="pfe-20221002.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_5745e7af-7f25-422a-930f-ba9a72e1baeb" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember_fa249bf1-e79b-49f0-aa57-99d4c859072d" xlink:href="pfe-20221002.xsd#pfe_InlytaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_InlytaMember_fa249bf1-e79b-49f0-aa57-99d4c859072d" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember_4f0bff6f-53bd-4e8c-a64e-f1694b49d096" xlink:href="pfe-20221002.xsd#pfe_ZirabevMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ZirabevMember_4f0bff6f-53bd-4e8c-a64e-f1694b49d096" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember_5045427d-674d-49ae-92bd-ab2431f91060" xlink:href="pfe-20221002.xsd#pfe_BosulifMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BosulifMember_5045427d-674d-49ae-92bd-ab2431f91060" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember_69b9ded8-f63c-43b8-a666-50d9ab5e52be" xlink:href="pfe-20221002.xsd#pfe_XalkoriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_XalkoriMember_69b9ded8-f63c-43b8-a666-50d9ab5e52be" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember_50a75f6d-63c5-4ff3-b3ec-6e4258b38281" xlink:href="pfe-20221002.xsd#pfe_RuxienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_RuxienceMember_50a75f6d-63c5-4ff3-b3ec-6e4258b38281" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember_72ddebdd-fd11-4edf-a6c9-852db5f8a581" xlink:href="pfe-20221002.xsd#pfe_RetacritMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_RetacritMember_72ddebdd-fd11-4edf-a6c9-852db5f8a581" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember_48d0127e-908c-4c71-939e-682743ecb0f2" xlink:href="pfe-20221002.xsd#pfe_SutentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_SutentMember_48d0127e-908c-4c71-939e-682743ecb0f2" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember_88307c18-ab0c-4e2d-a91a-160bd257ec1b" xlink:href="pfe-20221002.xsd#pfe_LorbrenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_LorbrenaMember_88307c18-ab0c-4e2d-a91a-160bd257ec1b" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BavencioAllianceRevenuesMember_64aaa9e1-4948-4171-8c6d-7be219680257" xlink:href="pfe-20221002.xsd#pfe_BavencioAllianceRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BavencioAllianceRevenuesMember_64aaa9e1-4948-4171-8c6d-7be219680257" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember_b3f19de4-d321-41f4-bddf-2374deb0fbc4" xlink:href="pfe-20221002.xsd#pfe_AromasinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_AromasinMember_b3f19de4-d321-41f4-bddf-2374deb0fbc4" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember_5a0f92ae-21cc-442f-9f3d-ece0876f83c2" xlink:href="pfe-20221002.xsd#pfe_BesponsaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BesponsaMember_5a0f92ae-21cc-442f-9f3d-ece0876f83c2" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember_a95ba273-e375-46cf-9ec2-53578caa7688" xlink:href="pfe-20221002.xsd#pfe_BraftoviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BraftoviMember_a95ba273-e375-46cf-9ec2-53578caa7688" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrazimeraMember_892e51f9-322d-4170-a1b2-147ee69a2e10" xlink:href="pfe-20221002.xsd#pfe_TrazimeraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_TrazimeraMember_892e51f9-322d-4170-a1b2-147ee69a2e10" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_e925b583-856a-4fab-88a9-cbf2a4d6957e" xlink:href="pfe-20221002.xsd#pfe_MektoviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_MektoviMember_e925b583-856a-4fab-88a9-cbf2a4d6957e" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember_a6427e89-f271-46b9-b48f-ee0ff9dcdf3c" xlink:href="pfe-20221002.xsd#pfe_OtherOncologyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherOncologyProductsMember_a6427e89-f271-46b9-b48f-ee0ff9dcdf3c" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_a1d4eb0e-6bf8-4093-95b3-79b252354074" xlink:href="pfe-20221002.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_a1d4eb0e-6bf8-4093-95b3-79b252354074" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30" xlink:to="loc_us-gaap_SegmentDomain_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30" xlink:to="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_21be3957-32a3-411d-ab59-083cc968c3d7" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:to="loc_pfe_BiopharmaSegmentMember_21be3957-32a3-411d-ab59-083cc968c3d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneSegmentMember_295e256d-b8ce-48d3-8a30-967a0dbdda94" xlink:href="pfe-20221002.xsd#pfe_PfizerCentreOneSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:to="loc_pfe_PfizerCentreOneSegmentMember_295e256d-b8ce-48d3-8a30-967a0dbdda94" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails" xlink:type="extended" id="i67766f308a7c412cbce24520d018da12_SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3ff777f7-8332-40f3-a8ba-6332cadffb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_605a0d55-03d2-429f-9d83-4b27c75afed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3ff777f7-8332-40f3-a8ba-6332cadffb00" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_605a0d55-03d2-429f-9d83-4b27c75afed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3ff777f7-8332-40f3-a8ba-6332cadffb00" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:to="loc_srt_CounterpartyNameAxis_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_893b0881-0827-41b1-8f9b-7abaf42446a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_893b0881-0827-41b1-8f9b-7abaf42446a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_b4a2e392-7f46-4abe-995e-40e99342ea6b" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_893b0881-0827-41b1-8f9b-7abaf42446a2" xlink:to="loc_pfe_BioNTechMember_b4a2e392-7f46-4abe-995e-40e99342ea6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_df51db9c-336f-4aa2-a390-3cc17ffb0f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_df51db9c-336f-4aa2-a390-3cc17ffb0f42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_df51db9c-336f-4aa2-a390-3cc17ffb0f42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_df51db9c-336f-4aa2-a390-3cc17ffb0f42" xlink:to="loc_us-gaap_SegmentDomain_df51db9c-336f-4aa2-a390-3cc17ffb0f42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fc53cea8-fb8b-4df7-9ac6-a4cec565726b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_df51db9c-336f-4aa2-a390-3cc17ffb0f42" xlink:to="loc_us-gaap_SegmentDomain_fc53cea8-fb8b-4df7-9ac6-a4cec565726b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneSegmentMember_1e235473-4f30-4754-bb58-e3cdd6d55940" xlink:href="pfe-20221002.xsd#pfe_PfizerCentreOneSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fc53cea8-fb8b-4df7-9ac6-a4cec565726b" xlink:to="loc_pfe_PfizerCentreOneSegmentMember_1e235473-4f30-4754-bb58-e3cdd6d55940" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pfe-20221002_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:532d8f3f-927e-412c-bdcb-1806e94574ca,g:7cd44193-98b9-486c-9ee0-61ec890b3036-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2a74fb23-11f9-4fca-abeb-7292ebc83f14_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_55a92ee1-ed05-4c55-8657-a6ce4ef4e679_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SomavertMember_a187a169-6aa6-43d2-8fab-c523d4e11263_terseLabel_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_label_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_documentation_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember" xlink:href="pfe-20221002.xsd#pfe_SomavertMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SomavertMember" xlink:to="lab_pfe_SomavertMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_5b4bc216-13c6-4e3b-9cf7-0d4a1cedb8ce_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_1fa5e7ff-2a1e-451e-ba2a-cdda03856bd0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term borrowings, principal amount</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81bd1d1d-f57d-4794-bec6-bf97a2a43ec5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f65f5962-4903-4fa7-869c-7cc4fb08e2a8_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e90b3554-f85d-4f88-8c3e-ac1b7a717e94_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b4c1dd27-7ae3-4316-bbdb-04034d5b0f9b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5ac829cd-3223-432d-be54-4a4ac0583c4f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4341f78c-dd65-4e90-880e-ab6f94b7bbaf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_14caef90-2ede-4a12-b497-2961520a1008_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_dc578655-dd1a-48f1-8e8a-766d33d505b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit costs/(credits)</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f45f166f-0c93-450e-9e8e-2aea8b255ca6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_7c32a295-3fd4-45e3-aa0c-60d808a09571_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_9df005db-c696-4286-9f6d-f7f771a35467_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet" xlink:href="pfe-20221002.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeExpenseNet" xlink:to="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_4a46ab6f-bd45-4cde-9d82-96320aedbc92_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) on interest rate contract Recognized in OID</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_1e097bcf-30a2-43ff-8daa-ec213b3e00d9_terseLabel_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_label_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_documentation_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember" xlink:href="pfe-20221002.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAntiinfectivesMember" xlink:to="lab_pfe_OtherAntiinfectivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_22917cf4-ee97-48b5-844c-b9e128c2d763_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TrazimeraMember_6cde56de-c3c3-4bb6-bd4b-c61d579eb39a_terseLabel_en-US" xlink:label="lab_pfe_TrazimeraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trazimera [Member]</link:label>
    <link:label id="lab_pfe_TrazimeraMember_label_en-US" xlink:label="lab_pfe_TrazimeraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trazimera [Member]</link:label>
    <link:label id="lab_pfe_TrazimeraMember_documentation_en-US" xlink:label="lab_pfe_TrazimeraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trazimera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrazimeraMember" xlink:href="pfe-20221002.xsd#pfe_TrazimeraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TrazimeraMember" xlink:to="lab_pfe_TrazimeraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_01282307-3a9e-4a07-9d9f-bee02f9b5915_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_8b4ed672-0ea0-4a09-9861-bcdededfd0b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ToviazMember_3b06d229-b8a3-4336-ab8b-074920d6142d_terseLabel_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_label_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_documentation_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember" xlink:href="pfe-20221002.xsd#pfe_ToviazMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ToviazMember" xlink:to="lab_pfe_ToviazMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_9d78c0b8-eed7-4603-b8b8-b63eece96d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_cd8409b4-8541-4ebd-89b8-3e6aacb78d5c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_c8ce088b-14ed-4ebf-9548-35a1f0801c41_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a63289a9-f58c-4f45-b59a-15c89bfa43a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_6edec3be-5d16-4c9b-b910-6c5d9a897749_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9a71d946-c064-41e1-a1f0-66068297bb5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_e4a6eaa1-ec8a-4a27-8270-2a3a2a8db166_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2071df00-7fe6-4b62-acd5-ff3439d7a4f3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_d01a74b4-37f4-4839-89e0-c047414a38bf_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_84d3cd59-fb50-4ce2-9514-9ec129796fc6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f6331f69-0062-47f0-9a3c-90646e236ac9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_3c2d5da0-4383-419f-8f9e-913e25cb77fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EnbrelMember_69177041-7322-4438-a658-d48c6b5c3206_terseLabel_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel (Outside the U.S. and Canada) [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_label_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_documentation_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember" xlink:href="pfe-20221002.xsd#pfe_EnbrelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnbrelMember" xlink:to="lab_pfe_EnbrelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_d6d82b76-91dc-4388-8a2e-452e13e9eef6_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gains and Losses on Investment Securities</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_label_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:to="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_6828dfad-a237-46e2-b87b-0495abab144c_terseLabel_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_label_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_documentation_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:href="pfe-20221002.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:to="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_fa00825f-7f79-4763-911b-bc9290bb6ede_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReconcilingItemsOtherMember_617786ca-5b92-4103-9fb0-158f28bfe97a_terseLabel_en-US" xlink:label="lab_pfe_ReconcilingItemsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Significant Items [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsOtherMember_label_en-US" xlink:label="lab_pfe_ReconcilingItemsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Other [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsOtherMember_documentation_en-US" xlink:label="lab_pfe_ReconcilingItemsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsOtherMember" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReconcilingItemsOtherMember" xlink:to="lab_pfe_ReconcilingItemsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6ed14caa-81e3-49d2-837a-dbd322342fc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AromasinMember_195a302f-f8b5-4bb1-be80-73063e96c5a5_terseLabel_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin [Member]</link:label>
    <link:label id="lab_pfe_AromasinMember_label_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin [Member]</link:label>
    <link:label id="lab_pfe_AromasinMember_documentation_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember" xlink:href="pfe-20221002.xsd#pfe_AromasinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AromasinMember" xlink:to="lab_pfe_AromasinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7865f027-4be6-48f6-9a6d-84f2b59fafa7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MedrolMember_90a360c8-f43b-414c-9ce2-2115bd4a399d_terseLabel_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_label_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_documentation_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember" xlink:href="pfe-20221002.xsd#pfe_MedrolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedrolMember" xlink:to="lab_pfe_MedrolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_ef42187b-b6c4-4721-a2d0-15984a80ae17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bdc3fcf4-2d25-44e5-a116-9c46abf8792e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit costs/(credits) recorded in Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9f6e251f-b318-4195-850f-858ea0258975_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost/(credit) reported in income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e1e698e5-5af6-4669-b0f2-d7b2dfc11e3a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_8f69114a-8af1-445f-9314-64124fc2ce9b_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_c1be9b2f-d022-4954-a263-d682205f8e71_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_label_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_documentation_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants" xlink:href="pfe-20221002.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyNumberofDefendants" xlink:to="lab_pfe_GainContingencyNumberofDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_d29e0483-fedd-4f7a-a25b-73ac9b3a924e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8aba7b3b-bd40-4921-85db-a763fa91ce23_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3ab0a70e-0e9a-4c57-b914-865d5fffa2d5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income attributable to shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_5a2a8d68-a633-423a-9744-a7c20ad72f78_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_147a3beb-c7fb-430d-814e-d80074f26ed5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive common stock equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_292d6eee-c430-412a-9c98-46d25fee5a38_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_964b3576-33f5-4b50-8e9d-8fe11d52b4b8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_65bd521f-7414-42b3-9c90-976ce918220a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_92d0ace1-245b-4354-99f5-4737950e996f_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) operating activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_00c9a053-8e84-4108-9a87-843bca54fd0a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ebc32e50-0b73-4835-be8d-e9941454a63c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_89f308a5-1135-41da-8af4-126adaaa36a9_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency short-term borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_label_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Short Term Borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency short - term borrowings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:to="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_7bd48774-4948-4843-bd24-12c37cf0d1b5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_cfef7dd2-0a69-4942-8c1e-2a40eb2e551b_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_c20da609-3e8f-4c3d-89f2-8979241a483c_terseLabel_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_label_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_documentation_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:href="pfe-20221002.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:to="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShorttermDebtGross_bdb8873d-ff71-4a61-b1fa-944e95fe4f14_totalLabel_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term borrowings, principal amount</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_label_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_documentation_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross" xlink:href="pfe-20221002.xsd#pfe_ShorttermDebtGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermDebtGross" xlink:to="lab_pfe_ShorttermDebtGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_d2e1d74d-b1c5-4047-953c-8772533ad7b6_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Numerator&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcf32502-ab71-4c11-9187-acd1fee33f41_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_afbd203b-7e7f-4968-b173-5e54fd084de9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_9324bd85-3ae6-4d91-974b-bfb788778cca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, per share in cash (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_e2271f13-aae3-42d9-a057-065d8ba1ab09_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0cc19f81-3fd6-44c2-b990-ecb37f874ebb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid/(received) during the period for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6c13812e-74ae-4606-a45a-07b8bb7274e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_bad5d35b-2d5a-421a-a294-428c6bc96c77_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f4f943a7-1062-4313-a4cc-eee1733da0d7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_d40f3af7-256d-4185-92b0-acb22c2c3541_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment [Member]</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_3a319918-6644-4a7d-b95a-f083cbe8811d_negatedTerseLabel_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan contributions in excess of expense/income</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_label_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_documentation_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:href="pfe-20221002.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:to="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f3b01536-7bbd-4a90-85df-44d5ae5288b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_21ee6d3c-22d0-4aec-9c3a-e3d478493741_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6e19c928-77a0-4fe3-977c-319bdbe5a439_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_5c665c2c-2f41-431e-a552-8933ff0b6aa1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post closing compensation expense</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_4638ba11-376d-45f5-a1db-a42110abf89e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1dff3728-ac3c-4709-ac6b-1cc28ca167a7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d36d4196-9bff-4f28-a804-11f920cd1c5a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_06d87b2e-10cd-48f5-9a87-42a685e629f9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_30a21de8-e8aa-467d-9db3-9ca24ab6a6b4_terseLabel_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government [Member]</link:label>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_label_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored [Member]</link:label>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_documentation_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember" xlink:href="pfe-20221002.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GovernmentAndGovernmentSponsoredMember" xlink:to="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_b7ec34ae-8c0b-4523-a313-ef0a8b524507_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements and Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_label_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember" xlink:href="pfe-20221002.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsAndOtherMember" xlink:to="lab_pfe_LicensingAgreementsAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_56ff4499-c404-48ae-9045-2bddbb2616b8_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_7c5ba4cf-f8cd-4bbe-a24d-4026b7b4de19_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_08e49993-5d33-4b16-8111-43a1762fe72e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_85c265c0-1bf1-4e87-942b-cf75f70e9f76_verboseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit costs/(credits) other than service costs</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_28f287a3-13b0-4512-a062-2c2e2a24cb42_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected restructuring cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_76ced9cc-f596-4a89-af29-6915f61ce40c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_ce12f340-36ca-4b3e-9ebd-ed3157724237_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_a144db18-898f-49ad-a67d-f6c9b0d0e16e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_555e519b-c73c-4a03-b9f2-f22860a526d0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e7eef6b5-60f9-4324-a0ad-6536bb2f66ff_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5bda5833-7695-4883-94ae-14c0db7a8e8a_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_b0dbb9b6-63c4-4004-a0ba-f3397cbeba36_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax assets</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_label_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_documentation_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent" xlink:href="pfe-20221002.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxAssetsCurrent" xlink:to="lab_pfe_OtherTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FragminMember_1cff7d74-3453-41b6-848d-611fda66d82f_terseLabel_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_label_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_documentation_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember" xlink:href="pfe-20221002.xsd#pfe_FragminMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FragminMember" xlink:to="lab_pfe_FragminMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b137c930-4813-4e53-83f4-8a990c34727b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_d96647ce-9b96-4fa3-ace2-05c0a2d4b896_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits and other [Member]</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e76c5e2a-aabf-4c58-85f3-593e2ab9595e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_5772d05b-24d8-428f-8817-90a43a41d684_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_234aa226-3197-49d7-a97a-b5d540d275d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrivateEquityInvestments_adfb145d-7ddd-4ac2-8121-2976e5463bec_terseLabel_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private equity securities at cost</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_label_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Investments</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_documentation_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments" xlink:href="pfe-20221002.xsd#pfe_PrivateEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrivateEquityInvestments" xlink:to="lab_pfe_PrivateEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetImpairmentsMember_50ed233f-aa6d-47d8-986b-1a06e229d9bd_terseLabel_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_label_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairments [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_documentation_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember" xlink:href="pfe-20221002.xsd#pfe_AssetImpairmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetImpairmentsMember" xlink:to="lab_pfe_AssetImpairmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39fa7416-c034-481f-bf02-d6a0c71e72cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_37d79b79-b600-4c68-a0ae-23a798f5d814_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_07b74c6e-e0e4-4f00-a875-d4a6b178c491_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35d53649-0797-4f9c-850e-a25502de5320_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember_6823ae0f-57a2-42e9-a0d8-5311d1691fc9_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, USD Denominated [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV Senior Notes, USD Denominated [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV Senior Notes, USD Denominated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" xlink:to="lab_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f02ec5ae-fa1c-41ee-bc52-dfc513bdde51_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_93303db4-f3bb-468c-9b6e-30e5e5d27cb5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SpecialtyCareMember_210a6777-fa88-4a69-b679-77b4af2c1057_terseLabel_en-US" xlink:label="lab_pfe_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Care [Member]</link:label>
    <link:label id="lab_pfe_SpecialtyCareMember_label_en-US" xlink:label="lab_pfe_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Care [Member]</link:label>
    <link:label id="lab_pfe_SpecialtyCareMember_documentation_en-US" xlink:label="lab_pfe_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SpecialtyCareMember" xlink:href="pfe-20221002.xsd#pfe_SpecialtyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SpecialtyCareMember" xlink:to="lab_pfe_SpecialtyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f39740fb-bb8b-4d39-ad61-660a24aab512_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_6cb3d50d-6b39-4cf0-a8e9-983f92819fca_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet" xlink:to="lab_us-gaap_InterestRevenueExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fed0887f-68fe-400b-8a03-500108908763_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_4d990fdb-8cdd-4221-9e7c-457d28fe494e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining period of hedging exposure</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_407fde10-a1e3-48ee-adef-a75b54af93f3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_a3d26601-eb75-49ae-8e85-f2e78bbcdb69_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_1eca0581-7b06-4e66-834c-a361ac250693_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3af7898a-b301-43b9-9f09-294de501ee91_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af2eba67-f503-4185-8df7-4bf9c4f6f087_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_2c27f4dd-4b6d-4c29-afac-1fb41762b049_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_46491733-6745-4924-b7e3-9a318b504c35_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee terminations</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BiopharmaSegmentMember_6bce007e-3a98-4061-a5eb-3a30826faa60_terseLabel_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_label_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_documentation_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiopharmaSegmentMember" xlink:to="lab_pfe_BiopharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_b69f3131-1549-4279-b5af-a09309a98a8c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received from Haleon/GSK Consumer Healthcare JV (Note 2C)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_398a9b05-6b70-4b5e-9328-f1fdd8867b77_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received, return of capital</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0ba97bfa-7c08-416d-8365-5bd7a34cee16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_8289b149-adf5-4755-b5eb-761c14951d50_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_697da8bc-97af-44e6-aaac-16a1df5f6c1d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f5ce0a11-9ce3-41e0-a47a-f22c4a03a241_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c0cddcbd-46ef-4c69-8272-abd2940d56ea_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes from continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember_3b7c45cd-320a-4c90-8396-6aada736de9a_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, GBP Denominated [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV Senior Notes, GBP Denominated [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV Senior Notes, GBP Denominated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" xlink:to="lab_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_cb54cf68-3637-4190-8fa1-13cfd68f9edb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-method investment, quoted market value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_afe31b59-ef25-44b6-bd1b-b9c024a9a5fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_e16495f1-2202-4012-8eea-034a80d3a7ea_terseLabel_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_label_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_documentation_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember" xlink:href="pfe-20221002.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FSMEIMMUNTicoVacMember" xlink:to="lab_pfe_FSMEIMMUNTicoVacMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_8a4784b0-7812-4790-ba12-0e5986232849_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ef46faeb-9fd9-431b-b9fd-f8e6e28fa49c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_293d7f8c-73ba-45f5-af16-231bec1d2456_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ca3dac5c-1840-420f-b4d1-3e9062768c1a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5c39b0a5-4630-4020-9bd2-66d9cd197d88_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_90841239-8bf0-497d-87e0-276939f31be3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_82b4ca69-705a-44e7-bf45-c28a289afff2_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to curtailments of prior service costs and other, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_968f1055-d7ee-4a3f-9748-49101cb54576_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_a6e92df3-f1e8-4a5b-9af8-1d84447b2060_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term equity securities held in trust</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:href="pfe-20221002.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:to="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_ee1f3e02-20eb-4b05-b146-9bfd0aa63a8f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_185fff5e-1b1c-4b26-828e-fbb34715b3f1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6a37e67f-c300-4261-a83a-01d90f5bacf8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4f2aa94a-b948-4425-906d-b46e8250b3b1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_72a053c2-6b4b-46fe-8221-5a378fcd8b35_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gain expected to be reclassified within the next 12 months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal_6e924829-a478-409a-9ba1-a6482e017fd4_terseLabel_en-US" xlink:label="lab_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received, total</link:label>
    <link:label id="lab_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal_label_en-US" xlink:label="lab_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Total</link:label>
    <link:label id="lab_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal_documentation_en-US" xlink:label="lab_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal" xlink:href="pfe-20221002.xsd#pfe_ProceedsFromEquityMethodInvestmentDistributionTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal" xlink:to="lab_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a985e61f-8f2b-4c47-acdf-f6d887e24efe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b1c75f8f-9d18-4010-bbc0-eafb3f302a6d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_2586c681-12f5-45fe-8c4e-27acb31f1387_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_4dd022a8-14ec-49bb-b044-a2ac7a26dd67_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PremarinFamilyMember_c5874060-903b-4b91-b2ac-7f3567c14896_terseLabel_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_label_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_documentation_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember" xlink:href="pfe-20221002.xsd#pfe_PremarinFamilyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PremarinFamilyMember" xlink:to="lab_pfe_PremarinFamilyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ComirnatyAndPaxlovidMember_bb939911-930e-4637-ad1b-32e17ef01ef3_terseLabel_en-US" xlink:label="lab_pfe_ComirnatyAndPaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paxlovid and Comirnaty [Member]</link:label>
    <link:label id="lab_pfe_ComirnatyAndPaxlovidMember_label_en-US" xlink:label="lab_pfe_ComirnatyAndPaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty and Paxlovid [Member]</link:label>
    <link:label id="lab_pfe_ComirnatyAndPaxlovidMember_documentation_en-US" xlink:label="lab_pfe_ComirnatyAndPaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty and Paxlovid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyAndPaxlovidMember" xlink:href="pfe-20221002.xsd#pfe_ComirnatyAndPaxlovidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ComirnatyAndPaxlovidMember" xlink:to="lab_pfe_ComirnatyAndPaxlovidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_39e1a768-d13d-48c5-b4cb-03af503a95d5_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ea36d937-7129-40ba-9b97-dddbe33b6422_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZaviceftaMember_329cda46-9a23-46e1-91fa-c18683e35df1_terseLabel_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta [Member]</link:label>
    <link:label id="lab_pfe_ZaviceftaMember_label_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta [Member]</link:label>
    <link:label id="lab_pfe_ZaviceftaMember_documentation_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember" xlink:href="pfe-20221002.xsd#pfe_ZaviceftaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZaviceftaMember" xlink:to="lab_pfe_ZaviceftaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7219cc5a-f85b-426c-90d3-3ce4974a33db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_f29cecf8-3aec-46c1-9779-76b0ffa39894_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_58119623-50b4-45e2-8a2a-1e606812a1e1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by employer</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_706addfd-262c-4cec-99cb-0b066e138918_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_7ad6a9ad-ce1c-410c-9a59-8f87cbbdd6c4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_8427db7a-37ea-42cb-b311-0cd569bb3440_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemptions/sales of long-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_61e78b92-a61e-4381-9ea8-8784f6613d42_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_0d935dfc-af4c-4bb3-8ce6-963578c56c5d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc0f0990-31d8-49f7-b403-f9a47af9d57e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9a39896f-79b8-4c56-b856-6eceb7063873_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd18ad9f-0ef2-4287-8e2c-72c6cdd2bd18_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HedgedItemDomain_fc2bc052-101f-4348-b78b-e56ed562aae4_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_label_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_documentation_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Hedged Item [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain" xlink:href="pfe-20221002.xsd#pfe_HedgedItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemDomain" xlink:to="lab_pfe_HedgedItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_465ea5dd-a6de-4d9b-9ad0-e1dfbdffb0ec_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term investments and equity-method investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_fb7b7b53-8da4-440b-8903-e0995a6d4c1c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9e02d09b-c30e-401d-bbf1-68b899a02e8d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related items</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e749466-3105-4279-a8d9-f9c62cdcb730_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d51e6c64-e90a-4acc-b51d-7e607d488343_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_0eaee955-c0c5-4844-b98d-d170e6af27f8_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_23133355-38df-4566-85fe-21aebb2d9718_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_58702a1a-7a5d-473f-b0f6-becfdc3c3e3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZithromaxZmaxMember_242eb59c-1d6c-425f-91d0-d8aec608aeb9_terseLabel_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_label_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_documentation_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax / Zmax [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember" xlink:href="pfe-20221002.xsd#pfe_ZithromaxZmaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZithromaxZmaxMember" xlink:to="lab_pfe_ZithromaxZmaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EpiPenMember_e6138fe9-889f-4ef8-9832-97c92f6242a6_terseLabel_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_label_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_documentation_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember" xlink:href="pfe-20221002.xsd#pfe_EpiPenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EpiPenMember" xlink:to="lab_pfe_EpiPenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9f44968b-0a08-4535-9fa3-c59e6d976c70_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2cd471fd-0c4c-4b22-afbe-7eb101b4e87a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_8145b49b-194e-4308-8a8b-a733e3831ef4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_b7c7fda0-0a04-49fb-854d-7a8ef5b24cfe_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_143158b2-d647-45cf-b000-b8e57f8bc01e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_7628270f-ce6a-45cb-985f-60072dbeb6fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8a9d017b-78bc-45c2-9dcc-3414db21a547_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_1cc45ce9-067d-422a-994d-eb81e0c7589c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_43359470-d807-4ca2-9138-436673735314_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income/(loss) before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_346708a1-b332-4964-bc38-ba3b806ce8d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_b9d9fd01-2c65-4540-b823-dafc615e4523_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VfendMember_f7a23a6d-51d4-40e5-9f13-419fcb2ae08f_terseLabel_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_label_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_documentation_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember" xlink:href="pfe-20221002.xsd#pfe_VfendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VfendMember" xlink:to="lab_pfe_VfendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_526370cd-08a8-49e8-8c6d-835f8b91b9ec_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in a net payable position</link:label>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Liability Position, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:to="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_992b2f5a-2baf-4975-962a-99af0571a1e3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_02ddd1de-ca19-499f-84e2-1fc8fa2f372c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_df17db1e-d80a-4b97-ba37-394fcd3fa390_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_86d67c0e-a890-4b65-ac36-a3a44f250055_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_label_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:href="pfe-20221002.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:to="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_fa6dd8db-343c-49a7-8e3a-b93d06257327_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses, gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_27eb1223-e3df-4f4b-b53b-7d27ee38acdd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisition, cash portion</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherPrimaryCareProductsMember_0c4f189c-6e86-4cf4-a6ae-882ab8b93ca0_terseLabel_en-US" xlink:label="lab_pfe_OtherPrimaryCareProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Primary Care [Member]</link:label>
    <link:label id="lab_pfe_OtherPrimaryCareProductsMember_label_en-US" xlink:label="lab_pfe_OtherPrimaryCareProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Primary Care Products [Member]</link:label>
    <link:label id="lab_pfe_OtherPrimaryCareProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherPrimaryCareProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Primary Care Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPrimaryCareProductsMember" xlink:href="pfe-20221002.xsd#pfe_OtherPrimaryCareProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherPrimaryCareProductsMember" xlink:to="lab_pfe_OtherPrimaryCareProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_174cc5f6-b87e-435c-904e-f16d6aedc775_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_159df9d7-a05c-46e2-9f0a-bc7570a130c2_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_623db79b-00b3-4a97-8d00-5b7a97b66158_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_02e430b9-45ed-47de-84e2-a8f3d6b754af_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_b4251418-e823-4ffe-bfed-482f329accb9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Classification Type</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_373109d4-affd-432e-891e-87506f39eae2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_9e9de9da-6bf8-4aa8-ad7f-dd28638dc524_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to curtailments of prior service costs and other, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPayment_60e60af8-d42e-49e6-b356-f69b78e3d7f4_terseLabel_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment to collaborators</link:label>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPayment_label_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Collaborators, Upfront Payment</link:label>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPayment_documentation_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Collaborators, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPayment" xlink:href="pfe-20221002.xsd#pfe_PaymentsToCollaboratorsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsToCollaboratorsUpfrontPayment" xlink:to="lab_pfe_PaymentsToCollaboratorsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_13700e7d-c8d9-4505-b44b-f4bbefec2040_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_6733cda1-90ec-47b5-af9a-0499bdeb73ba_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_766929ba-9797-4a00-bc3c-9e64715e7121_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_f6a99852-9daf-44d4-b69e-c329635f3b54_verboseLabel_en-US" xlink:label="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to collaborators</link:label>
    <link:label id="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_label_en-US" xlink:label="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments and Payments to Collaborators, Cash</link:label>
    <link:label id="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_documentation_en-US" xlink:label="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments and Payments to Collaborators, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:href="pfe-20221002.xsd#pfe_PrepaymentsAndPaymentsToCollaboratorsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:to="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8dcbd4cc-eace-4d0a-a1c6-27e5eab1caae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerAndVersusSeveralGenericManufacturersMember_7c280f94-77c6-4f9b-8484-d7ddeb9c913b_terseLabel_en-US" xlink:label="lab_pfe_PfizerAndVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndVersusSeveralGenericManufacturersMember_label_en-US" xlink:label="lab_pfe_PfizerAndVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndVersusSeveralGenericManufacturersMember_documentation_en-US" xlink:label="lab_pfe_PfizerAndVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and Versus Several Generic Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndVersusSeveralGenericManufacturersMember" xlink:href="pfe-20221002.xsd#pfe_PfizerAndVersusSeveralGenericManufacturersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerAndVersusSeveralGenericManufacturersMember" xlink:to="lab_pfe_PfizerAndVersusSeveralGenericManufacturersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a2760de4-dfd1-4d45-8bd1-ee0cd35b24ca_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_4afaee3d-8db2-4d47-8cf0-ab3ccafbd644_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ArenaMember_6ed4a79f-bc2e-4537-8fd5-6fdf9c2e143e_terseLabel_en-US" xlink:label="lab_pfe_ArenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arena [Member]</link:label>
    <link:label id="lab_pfe_ArenaMember_label_en-US" xlink:label="lab_pfe_ArenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arena [Member]</link:label>
    <link:label id="lab_pfe_ArenaMember_documentation_en-US" xlink:label="lab_pfe_ArenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArenaMember" xlink:href="pfe-20221002.xsd#pfe_ArenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ArenaMember" xlink:to="lab_pfe_ArenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e327176-362c-46c0-aeec-2a98dc768f76_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b4cc09b1-3dbe-4298-8277-cac4951f6011_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41fa9819-dd8c-4204-9f4a-0211336519f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IbranceMember_3fce49a5-0ebf-4a22-a10d-d403080a4afe_terseLabel_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_label_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_documentation_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember" xlink:href="pfe-20221002.xsd#pfe_IbranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IbranceMember" xlink:to="lab_pfe_IbranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_2320984c-256f-427d-a95d-52333380c831_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ce618f54-6761-4615-b5ac-8ff034d2e439_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_85ee9b1c-cf10-429b-85ee-cc3d27bc1ca6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_6402d0cd-a830-4163-b874-3962220db0c9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-off</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GSKMember_8695c239-2102-4cd0-ad4e-dac54249b26e_terseLabel_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_label_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_documentation_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember" xlink:href="pfe-20221002.xsd#pfe_GSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKMember" xlink:to="lab_pfe_GSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6cb77219-995c-43d4-9301-9e6172e630ea_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_a3789fcb-6d04-4db3-be2f-511e5a67024c_terseLabel_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_label_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Intangible Assets Not Associated With Single Function</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_documentation_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:href="pfe-20221002.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:to="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1686ba2-23d6-4d88-8c50-0a9475bbabe7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_93c75bea-a22f-4540-945d-882e520b17d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_4e06cd65-304b-4c3a-8cb8-d494a80e1ecf_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_559ad291-ff1a-41fc-8f2e-d2446bc79d70_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_483d1298-d38c-402b-890a-2b8f301dbefa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f3927e10-4a74-4a15-9e6a-d30ce2157e4e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_9e0b56bd-5c1a-4afd-a356-4c8bee0ec6cc_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_646ed63b-ac8b-44c4-9fd5-e3c3672da8e0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_302b5e4f-840b-4f8e-977d-cf255d099b23_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReViralAssetAcquisitionMember_0cdd1b5e-5196-4c83-a698-ec8ef1d704b0_terseLabel_en-US" xlink:label="lab_pfe_ReViralAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ReViral [Member]</link:label>
    <link:label id="lab_pfe_ReViralAssetAcquisitionMember_label_en-US" xlink:label="lab_pfe_ReViralAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ReViral Asset Acquisition [Member]</link:label>
    <link:label id="lab_pfe_ReViralAssetAcquisitionMember_documentation_en-US" xlink:label="lab_pfe_ReViralAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ReViral Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReViralAssetAcquisitionMember" xlink:href="pfe-20221002.xsd#pfe_ReViralAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReViralAssetAcquisitionMember" xlink:to="lab_pfe_ReViralAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9b7846a8-9914-41f3-80e4-1384df82f553_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_2399dbe9-b4ad-44f6-80b8-96aed8f14834_terseLabel_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment pursuant to terms of the separation agreement</link:label>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_label_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Pursuant to Terms of Separation Agreement, Financing Activities</link:label>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_documentation_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Pursuant to Terms of Separation Agreement, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:href="pfe-20221002.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:to="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f0180a28-b82c-4550-ad4a-3aab5d9bb31e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income/(loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_8172c6a4-9d64-4c6f-93cc-1082fdd64b53_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional depreciation&#8211;&#8211;asset restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_56c22c27-3a10-4352-b0e6-609735a8b41d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_b8907449-129a-4726-a927-c0baa216ea51_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_fe13c69c-2041-4f9b-9891-b3856b6f1fb0_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_90efa4bd-fe1e-4f05-8fc4-cec6d201d149_terseLabel_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract" xlink:href="pfe-20221002.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FinancialInstrumentsAbstract" xlink:to="lab_pfe_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8d6171d3-f78c-474c-a39a-340787c418f0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate for income from continuing operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_cd6e383e-0429-4ac4-ad00-6b118a8e2a3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_caf0fb9d-8d1d-452f-ad59-38f849b8d2be_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SulperazonMember_4f279921-98ec-49aa-b5a5-0b68f2442e93_terseLabel_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_label_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_documentation_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember" xlink:href="pfe-20221002.xsd#pfe_SulperazonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SulperazonMember" xlink:to="lab_pfe_SulperazonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_86d6ce51-ef87-47c3-baa0-e17744021634_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherAccruals_ce8549bd-0dae-462d-9a2a-c1a9032319a6_terseLabel_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_label_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_documentation_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals" xlink:href="pfe-20221002.xsd#pfe_OtherAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAccruals" xlink:to="lab_pfe_OtherAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BraftoviMember_48cfbb46-bbf5-4d9b-9c74-4e5b4327d39a_terseLabel_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_label_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_documentation_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember" xlink:href="pfe-20221002.xsd#pfe_BraftoviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BraftoviMember" xlink:to="lab_pfe_BraftoviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_65db93e6-82d7-4dd5-a8ab-d45f459553a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_c9e50a7f-1913-4407-b3ac-cb9bc0684fdd_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_efdb2e3b-b35a-402a-a640-86bd86434ecc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefit obligations</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrimaryCareMember_4b6d7aeb-1efb-451a-8aa1-149a17cc42b3_terseLabel_en-US" xlink:label="lab_pfe_PrimaryCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Care [Member]</link:label>
    <link:label id="lab_pfe_PrimaryCareMember_label_en-US" xlink:label="lab_pfe_PrimaryCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Care [Member]</link:label>
    <link:label id="lab_pfe_PrimaryCareMember_documentation_en-US" xlink:label="lab_pfe_PrimaryCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrimaryCareMember" xlink:href="pfe-20221002.xsd#pfe_PrimaryCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrimaryCareMember" xlink:to="lab_pfe_PrimaryCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TrumenbaMember_d81476dc-b5f3-4bea-957d-39a5686847a0_terseLabel_en-US" xlink:label="lab_pfe_TrumenbaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trumenba [Member]</link:label>
    <link:label id="lab_pfe_TrumenbaMember_label_en-US" xlink:label="lab_pfe_TrumenbaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trumenba [Member]</link:label>
    <link:label id="lab_pfe_TrumenbaMember_documentation_en-US" xlink:label="lab_pfe_TrumenbaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trumenba</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrumenbaMember" xlink:href="pfe-20221002.xsd#pfe_TrumenbaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TrumenbaMember" xlink:to="lab_pfe_TrumenbaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_fe4d432c-215f-45cd-b8d7-b4de0b139db9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring cost incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a396fec2-fb20-4503-88c9-abf6689257a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_d0bd0e65-2486-4be1-bcaa-c773326d6aba_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_28e5069f-f3d9-4d65-a7d3-efff9813b32d_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fcd378b0-8acc-40b9-89c6-3dd50d50bb85_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_ce99da69-229c-4076-b7de-73dc93221124_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GoToMarketModelMember_96ce435d-50ed-435e-b21c-53c3887fa9bf_terseLabel_en-US" xlink:label="lab_pfe_GoToMarketModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go-to Market Model [Member]</link:label>
    <link:label id="lab_pfe_GoToMarketModelMember_label_en-US" xlink:label="lab_pfe_GoToMarketModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go-to Market Model [Member]</link:label>
    <link:label id="lab_pfe_GoToMarketModelMember_documentation_en-US" xlink:label="lab_pfe_GoToMarketModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go-to Market Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GoToMarketModelMember" xlink:href="pfe-20221002.xsd#pfe_GoToMarketModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GoToMarketModelMember" xlink:to="lab_pfe_GoToMarketModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DevelopedEuropeMember_01206036-9bad-4609-bfb2-034599e04fc2_terseLabel_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_label_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_documentation_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember" xlink:href="pfe-20221002.xsd#pfe_DevelopedEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedEuropeMember" xlink:to="lab_pfe_DevelopedEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_6a26d9b7-918a-4767-bc98-e31b04bbdbbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_fb9c49a3-049e-4da0-b8b8-252b5b0849b1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_452e7b24-36d4-4505-b985-1ee2db51202a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_f5877b5f-3c7d-4197-8a50-f5f733742a30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_05f55679-40d4-4ae2-a779-06ae261ae568_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_3e60448d-53f1-46e7-be37-36b01e5e127b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_c03910dd-0acb-4cae-9b35-25a291ae3d52_negatedTotalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86fdc7d1-8e0c-44c8-926e-4a61aa786b7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7bc4f6d9-e358-40d7-b887-2949ec879dc8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InflectraMember_94bf0f9f-ff41-40cc-8fa9-50a975568d22_terseLabel_en-US" xlink:label="lab_pfe_InflectraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:label id="lab_pfe_InflectraMember_label_en-US" xlink:label="lab_pfe_InflectraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:label id="lab_pfe_InflectraMember_documentation_en-US" xlink:label="lab_pfe_InflectraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraMember" xlink:href="pfe-20221002.xsd#pfe_InflectraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraMember" xlink:to="lab_pfe_InflectraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_f11a46c0-97fb-484f-8360-f3c4a65c1737_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Business Activities [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_7c0457e6-e44e-4114-8be7-597860195cde_negatedTerseLabel_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utilization and other</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_label_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_documentation_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:href="pfe-20221002.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:to="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_200045ad-6f8e-4796-ba6e-3a5b360121e6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_5b732589-64e0-4960-ac06-ee72b845d2b2_terseLabel_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of expected costs to be non-cash</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_label_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_documentation_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:href="pfe-20221002.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:to="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_f0462ee5-982d-4c9a-9713-5dfa53fe31ef_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ca6c5599-8911-4440-93be-7cd035e5f594_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_177eb73c-71b1-441c-a1ec-a1c32ecfcb80_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_f7ca631a-64fa-4e63-9de1-f224b04d83ae_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c66116ec-3650-41d7-ba5d-3fc2e0d4868f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_44beac3c-77d6-4091-9252-f598cf044df9_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c0a658ad-33d1-4285-8618-fea03742878b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Pfizer Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_A1365ConsumerHealthcareJVLoanMember_72833d22-c3b3-402a-8f1b-6648522fc055_terseLabel_en-US" xlink:label="lab_pfe_A1365ConsumerHealthcareJVLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.365% Consumer Healthcare JV Loan [Member]</link:label>
    <link:label id="lab_pfe_A1365ConsumerHealthcareJVLoanMember_label_en-US" xlink:label="lab_pfe_A1365ConsumerHealthcareJVLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.365% Consumer Healthcare JV Loan [Member]</link:label>
    <link:label id="lab_pfe_A1365ConsumerHealthcareJVLoanMember_documentation_en-US" xlink:label="lab_pfe_A1365ConsumerHealthcareJVLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.365% Consumer Healthcare JV Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_A1365ConsumerHealthcareJVLoanMember" xlink:href="pfe-20221002.xsd#pfe_A1365ConsumerHealthcareJVLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_A1365ConsumerHealthcareJVLoanMember" xlink:to="lab_pfe_A1365ConsumerHealthcareJVLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_b762d175-34b2-4bcf-b11c-a26919dbf67f_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain" xlink:to="lab_us-gaap_GainContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_795a6650-8f09-430c-9920-422536a5b8c7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1df2efbf-fa2b-40ef-a26a-1f07b394f5ff_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb66d31c-49fd-4bc2-aaa9-3737b89e8051_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PatentInfringementMember_080b2940-65ca-4172-8208-8098539e7ac5_terseLabel_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_label_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_documentation_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember" xlink:href="pfe-20221002.xsd#pfe_PatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentInfringementMember" xlink:to="lab_pfe_PatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_9e2d94cc-9921-4a62-8691-9fc83699a24a_terseLabel_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_label_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_documentation_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:href="pfe-20221002.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:to="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_80336a6c-e6ad-4f83-b916-7dba14bbda41_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_b0a0a448-8394-4532-a53a-97e42394a759_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ExpirationPeriodDomain_5ee8340f-c9c9-42f2-bfc9-4f826428c8f1_terseLabel_en-US" xlink:label="lab_pfe_ExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Period [Domain]</link:label>
    <link:label id="lab_pfe_ExpirationPeriodDomain_label_en-US" xlink:label="lab_pfe_ExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Period [Domain]</link:label>
    <link:label id="lab_pfe_ExpirationPeriodDomain_documentation_en-US" xlink:label="lab_pfe_ExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ExpirationPeriodDomain" xlink:href="pfe-20221002.xsd#pfe_ExpirationPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ExpirationPeriodDomain" xlink:to="lab_pfe_ExpirationPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_a549e7d6-1e0f-476e-941d-e9b5d7711f15_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_49b594e4-e657-4938-9782-130f3044f9cc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_da9ea7a9-510e-4653-a4a2-05591b1f7268_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_00b348c5-3671-46d2-8382-bc31a23ddc01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_eebdef05-329a-4e73-9c82-0571e60976d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_25d836af-6a2f-4c58-9220-d665e3f57f48_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_3d966e6f-548a-4bff-8ca0-34341caa96cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain legal matters, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_ba0f9aca-296d-4937-8939-5ebf800e0475_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_51fdad13-7f36-479c-afa6-f8aeeca0f749_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $.05 par value [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_61f0eab8-6277-4c00-af8d-a60588312da6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ArvinasIncMember_af5f4ebc-eb21-480a-ac0d-4dbd7cc21e1c_terseLabel_en-US" xlink:label="lab_pfe_ArvinasIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arvinas Inc [Member]</link:label>
    <link:label id="lab_pfe_ArvinasIncMember_label_en-US" xlink:label="lab_pfe_ArvinasIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arvinas Inc [Member]</link:label>
    <link:label id="lab_pfe_ArvinasIncMember_documentation_en-US" xlink:label="lab_pfe_ArvinasIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arvinas Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember" xlink:href="pfe-20221002.xsd#pfe_ArvinasIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ArvinasIncMember" xlink:to="lab_pfe_ArvinasIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_be971592-9a33-4fa6-b9af-f6abcb570568_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment transactions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_6f2d6517-c18a-4f63-bc07-d0d88173c8b5_terseLabel_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for disclosure of proceedings under environmental laws</link:label>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_label_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency, Regulatory Proceedings, Disclosure Threshold</link:label>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_documentation_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency, Regulatory Proceedings, Disclosure Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:href="pfe-20221002.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:to="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6dfa89b1-db87-4a62-96a5-3ccae8ff3f7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_a31b5dd9-e4d7-4361-9168-ae352feae8bc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_dcafc5ea-fc11-4ae5-8d56-981a24904c66_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_36f7f479-9584-456e-bb6a-f0ae1ed10a93_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HedgedItemAxis_5c1a3d26-c832-48c3-a523-b53e629d2b5d_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_label_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_documentation_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis" xlink:href="pfe-20221002.xsd#pfe_HedgedItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemAxis" xlink:to="lab_pfe_HedgedItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_fdd2681b-68fc-48ac-b5d3-685acaecca34_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e94381b9-3ce2-4012-9582-7ee6f090cb80_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_f013c188-3801-4efd-9c04-8db16a013d17_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:to="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_23a13f79-f40a-45c0-8193-2bcc0cb2e0d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_453acb4c-e2ba-4690-aeb4-89122386ce92_terseLabel_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontrade receivables</link:label>
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontrade Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="lab_us-gaap_NontradeReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_daec58a3-15a1-4194-832b-bb8dfe24dff8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_9935eb37-6cc9-439a-ae82-4aadad3ba63a_terseLabel_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20221002.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_42be3f4d-3e26-44bc-a4fb-0092207807e6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_45357584-212c-4949-935c-f88f0f18b62a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ef3e09b0-9b38-400a-a798-6b400aac9f57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_319d5e8d-8e7d-4be3-9fb1-a864cedca940_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_ed3c2895-e3e0-422c-ae51-7d5698795acb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss), before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f82e5891-4aca-4a2d-9c8a-d61a71de29f1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_d6859a2d-3cc1-4b68-9acb-d07b6162178f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_556c80f1-4ab3-46a6-82c6-65d5bca41551_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7c51cb40-b3c2-4cff-be5c-2bb66c7d96f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_42e2e855-a010-4de0-9a8a-33b2ac610aa1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts: 2022&#8212;$474; 2021&#8212;$492</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_852d6ae2-962a-44aa-8dbf-325927c56f23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_035e6239-4f4d-4756-9b86-7dd5bee32443_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8d1c63d6-1566-4977-b74b-8ea78df41a54_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BesponsaMember_35a7d0dc-b8b8-49a3-8c10-e805cfeab0ec_terseLabel_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_label_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_documentation_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember" xlink:href="pfe-20221002.xsd#pfe_BesponsaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BesponsaMember" xlink:to="lab_pfe_BesponsaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_46b5f79b-b586-44f8-b075-a2e46cc877df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_d9d68438-0cd1-4ef3-98ae-60ee90348ab8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_e78d468a-9f30-4fc8-98d0-ba9cef4348a9_terseLabel_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_label_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_documentation_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember" xlink:href="pfe-20221002.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FocusedCompanyPlanMember" xlink:to="lab_pfe_FocusedCompanyPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_05d5c76f-ba9e-4fb7-b87e-b908f3576380_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_12874094-7ce4-472a-8e59-50ad92dfc5bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2c2dc881-071b-4124-abf4-6bbad42f8bcd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_1e17d6c3-946e-4f79-adf2-41f1009a39d9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0f3fd5cd-6476-4c68-854d-e1258d90164e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_cd747daa-5bbc-4d7d-ab89-93e325b73d0e_terseLabel_en-US" xlink:label="lab_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech, Cerevel Therapeutics, LLC and Arvinas [Member]</link:label>
    <link:label id="lab_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_label_en-US" xlink:label="lab_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech, Cerevel Therapeutics, LLC and Arvinas [Member]</link:label>
    <link:label id="lab_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_documentation_en-US" xlink:label="lab_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech, Cerevel Therapeutics, LLC and Arvinas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember" xlink:href="pfe-20221002.xsd#pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember" xlink:to="lab_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7612a661-5e6c-4977-acea-a72dc23ff7da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_800b378f-6b7a-4ca0-9db8-8ce71fce57ac_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_cb7f7ebc-3272-46d2-9a26-43cb78b05ce3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_0b5242b3-8aa6-4e65-8e5b-d68434dc9edb_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4c47ebda-9ccc-41b1-8a7f-b528edbb5f60_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_eeaa49f8-eee8-45b7-a37e-1aaefde675d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05f807f8-2a08-4a73-8172-89d7415d94aa_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_985a2ace-1986-46f5-86ba-b9678b535450_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b8df9eae-6199-427b-878c-e794561d85db_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6fa2af64-f01d-428b-b5ca-b65b369f17db_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0d4c24b-c518-4663-ae31-87ddd634b2b6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accum. Other Comp. Loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dc205737-833c-4c25-b42e-5cbf25d67a37_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_f64598c3-0bd4-4c95-a7c6-5b20346ff035_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_f6b1ce63-cb1f-490d-adf3-b00a2b57c191_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_78e3db78-ddc7-4d5e-910c-f6d010c02043_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon, expired December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:href="pfe-20221002.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_37597675-7f5e-4622-b51c-d624ef2dd1d1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_14f8334c-cd5f-4178-8049-4f567495943f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e538375f-b127-4b4d-9d6a-a97fb90fc35d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0db2a7aa-a5f4-46a2-aa2d-62323e2f2ebc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3ce7d17d-c970-4565-937a-0504b29b2193_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_74921e5f-0973-4cd6-90f8-f5f78190eed6_terseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders diluted</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_81b0fd40-80fe-4c96-a99a-da3c7075ea31_terseLabel_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, principal amount</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_label_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_documentation_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:href="pfe-20221002.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:to="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d670cfd3-94f0-4b7f-9602-cc03ebd3ab38_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standard Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_96a8c73a-b3b7-4332-b221-799c56f470e0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LorbrenaMember_3184c923-1738-43de-95ff-dabdeeaf53cf_terseLabel_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena [Member]</link:label>
    <link:label id="lab_pfe_LorbrenaMember_label_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena [Member]</link:label>
    <link:label id="lab_pfe_LorbrenaMember_documentation_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember" xlink:href="pfe-20221002.xsd#pfe_LorbrenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LorbrenaMember" xlink:to="lab_pfe_LorbrenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5840aca1-f6ba-458a-a412-9fa9f53d141f_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_9191de98-d4ad-48dc-ac8f-2ed7328933b4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_890b385f-52ae-4c49-a479-da7ac0d94002_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_372a69cc-d65f-4cf7-a3b5-d24d7534c5b1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_fbd37141-68ce-4a8e-a5f4-49fd1f5caf09_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_Goodwill_95361e06-22a1-4115-81f8-e44f8bd7d13d_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_0f73eb52-c8aa-411d-b8e5-b25c766ee7c5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_6d00d0c5-647d-4fac-9356-a53a6ccc1821_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_615e6fb2-7016-4b41-b3e9-7c23cc5437bc_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_54804281-52c0-477a-b66a-24941b4c7dfb_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_f18bc5fd-a27d-4411-bc1f-affa244b24ff_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral received</link:label>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_label_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Received as Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesReceivedAsCollateral" xlink:to="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_cdd304c7-c161-4bcd-b202-bb63f1c5e4b5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e3581673-3108-4eb5-8215-304bd8bce144_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_927129a1-2f4f-459d-a6eb-6704eb738074_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c84bd7a4-9341-4426-8fb9-e66e5b587ace_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_be7aad49-1a6b-479e-b36f-ae09f1a01a31_netLabel_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_label_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_documentation_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges" xlink:href="pfe-20221002.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringAssetImpairmentCharges" xlink:to="lab_pfe_RestructuringAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsFoundNotInfringedNumber_cd6c2a93-fd59-4780-9194-fdfadb4e1a92_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsFoundNotInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of patents found not infringed</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsFoundNotInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsFoundNotInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Found Not Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsFoundNotInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsFoundNotInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsFoundNotInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsFoundNotInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_7080be0a-ed94-49c7-9e20-6b4ca33b7339_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Service (Costs)/Credits and Other [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_298c144a-21b9-410f-bbb0-07b28b0335ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_59f9d5b7-7b85-43df-a614-567a0358773f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerCentreOneSegmentMember_71ef0259-5836-4d8b-9976-7498b0b1f557_terseLabel_en-US" xlink:label="lab_pfe_PfizerCentreOneSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PC1 [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneSegmentMember_label_en-US" xlink:label="lab_pfe_PfizerCentreOneSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne Segment [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneSegmentMember_documentation_en-US" xlink:label="lab_pfe_PfizerCentreOneSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneSegmentMember" xlink:href="pfe-20221002.xsd#pfe_PfizerCentreOneSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerCentreOneSegmentMember" xlink:to="lab_pfe_PfizerCentreOneSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_a2004ab1-dab3-45b8-bc4f-94e791d91f68_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative impairment losses and downward price adjustments on equity securities</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:href="pfe-20221002.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_d74f6552-db30-4e47-9f8a-3ebd5cf372ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_67dc44e0-4438-4830-8842-9783e058712d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cc2d13ac-7bba-4eac-b1c2-c81efc4fe6a8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0c438c3e-98c1-44df-abff-b6a68d0c2ad2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add'l Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_d43e5f6d-1eaa-4fc4-b544-29057ccc03d7_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements and Other [Member]</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_aceeb576-95f9-4883-88d1-0556da2713f1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_87a18f5a-1ce3-4e13-a2d7-3463e2a844d7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4de2855e-6396-43ab-a4f5-bd733cd39708_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share&#8211;&#8211;basic:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4ea3a563-77c8-4aca-b870-54fc4b63b0f1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Numerator&#8211;&#8211;Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a07cf388-960f-4fc9-ac20-aa1e7b6e78c0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VyndaqelMember_1ba53afc-ee65-4ec9-a32b-4e722e9ecf2c_terseLabel_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel/Vyndamax [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_label_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_documentation_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember" xlink:href="pfe-20221002.xsd#pfe_VyndaqelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VyndaqelMember" xlink:to="lab_pfe_VyndaqelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_19d9d4c3-23cc-4c56-a8d3-a8248ee887a9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3421068b-6f4b-4d08-9313-63a3caeaea2e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares&#8211;&#8211;diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_064d547b-096a-409c-9413-a5e8fa9ed343_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_29250d11-a697-4cd9-bbc6-ed8feb6ca0d2_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_d8fcd973-74b4-414f-8fd0-dadea8c027b4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f60c5431-9b8c-407e-84dd-b3150b871924_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_c0d6defa-8cf2-4da7-a9db-61132fce687d_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from collaborations, out-licensing arrangements and sales of compound/product rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_label_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:to="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_556aee62-593a-4643-9d87-0816dedd6385_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_b1e3421f-6ab9-4759-802a-b1208e78cc9c_terseLabel_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment and premium paid in equity investment</link:label>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_label_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment</link:label>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_documentation_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:href="pfe-20221002.xsd#pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:to="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a72010c3-910e-434f-91a0-c7c8b5c28690_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4f46896b-1c65-4323-b782-dcebf1b0a780_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NimenrixMember_bdf0ef3a-f9b1-4218-9106-add977a487ce_terseLabel_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_label_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_documentation_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember" xlink:href="pfe-20221002.xsd#pfe_NimenrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NimenrixMember" xlink:to="lab_pfe_NimenrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EmergingMarketsMember_cd633c73-90c7-49dd-b32c-c8a1bb178a0d_terseLabel_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_label_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_documentation_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember" xlink:href="pfe-20221002.xsd#pfe_EmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EmergingMarketsMember" xlink:to="lab_pfe_EmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_15c9b0ce-c799-440d-ac59-5e7b933b1c93_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b05f52c6-28f5-49d3-9c91-e7c6f0d3f0d5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_3feb37fa-bd4b-4c9a-b22f-fca9049e12d4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_61970439-5d20-48cb-b128-2e7bbf7f0d57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaxlovidMember_60b00633-69d9-484b-95ab-b950a1715b7e_terseLabel_en-US" xlink:label="lab_pfe_PaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paxlovid [Member]</link:label>
    <link:label id="lab_pfe_PaxlovidMember_label_en-US" xlink:label="lab_pfe_PaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paxlovid [Member]</link:label>
    <link:label id="lab_pfe_PaxlovidMember_documentation_en-US" xlink:label="lab_pfe_PaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paxlovid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaxlovidMember" xlink:to="lab_pfe_PaxlovidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_50cf41e9-7734-4bed-b203-3d34c5161c97_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ada63f81-c4bd-4b76-8a98-ec0eac49a5f5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_1f64e02a-92c8-4959-a640-e48ad0d4212c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit, actuarial valuation and other pension and postretirement plan gains</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_03ef13e9-2c6b-4815-bb21-8bc48928f211_terseLabel_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity cash equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_label_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_documentation_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldToMaturityCashEquivalents" xlink:href="pfe-20221002.xsd#pfe_HeldToMaturityCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldToMaturityCashEquivalents" xlink:to="lab_pfe_HeldToMaturityCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_72b7260d-ce2e-4743-8b3a-283463895cbb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dbec25ce-9167-44c2-a1d1-e6056e25c1bc_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value [Member]</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_15324d78-a6d7-458d-9343-c5ab54c0de5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6d565976-4457-46c8-b9da-dd57d8c19db7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_72edb1a7-1476-4e13-a0a8-40aafe922cca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_dcc2d066-7321-439d-a542-81a2effce1a6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration costs and other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_641badd1-889a-4516-afc2-70eccd12cf2d_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs associated with acquisitions and cost-reduction/productivity initiatives</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_label_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:to="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_a969e1fc-32f5-43d4-b56a-2d5d42a3f8b2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_57e71621-10e7-4a16-ab4b-d5e93d3142af_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e5105382-5b87-40ba-9d1d-8bc4745036ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_669cc594-e6fd-4964-a937-bc2ce6c20d3c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other taxes payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_7cd7e5b5-fc05-4931-813a-5a889648e34b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_Expiring2030Member_246d0d28-7c80-4abb-a2f9-e4432cf75ce2_terseLabel_en-US" xlink:label="lab_pfe_Expiring2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring 2030 [Member]</link:label>
    <link:label id="lab_pfe_Expiring2030Member_label_en-US" xlink:label="lab_pfe_Expiring2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring 2030 [Member]</link:label>
    <link:label id="lab_pfe_Expiring2030Member_documentation_en-US" xlink:label="lab_pfe_Expiring2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_Expiring2030Member" xlink:href="pfe-20221002.xsd#pfe_Expiring2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_Expiring2030Member" xlink:to="lab_pfe_Expiring2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments_b6632126-6308-44ce-9593-8283e2e5bff3_terseLabel_en-US" xlink:label="lab_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for asset acquisition, base payment</link:label>
    <link:label id="lab_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments_label_en-US" xlink:label="lab_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions, Before Working Capital Adjustments</link:label>
    <link:label id="lab_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments_documentation_en-US" xlink:label="lab_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions, Before Working Capital Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" xlink:href="pfe-20221002.xsd#pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" xlink:to="lab_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_29af305b-d7e0-4f88-a5b1-a2bd664aae0b_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Derivative, Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_506e99ef-09b8-4167-b723-a973d0422a7a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ace9945-e4f2-40d4-a08e-017c8f05aae3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_575e545d-11e7-4764-b8c7-275e7845b892_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_11ea6a22-0834-499e-9147-b68e5680c728_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d40b3346-f467-4efa-b4ed-c8ea6507543e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Certain Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5af6b80f-6cf5-4b1c-96f5-722b69c230be_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b2426d30-46df-45b3-9483-e4d7d71fd4de_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_474a7b45-dc1c-4710-b361-63434c94ffc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_c02964ea-7c3a-49a6-8c53-1a52971fea08_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_aeb18838-0df0-406d-953e-4ccb9dd09db7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a66fdd8e-ac37-4121-bb92-a42536ad9de4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_54b5416e-3252-48ca-9c6e-7f4cf9c71569_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Haleon/Consumer Healthcare JV equity method (income)/loss</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_label_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:to="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_1fcffad0-361c-4fcb-a3db-4914d536511b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_449ee7ae-a05e-48d2-8e82-6e34eea8f92d_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_documentation_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:href="pfe-20221002.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1f76ec10-e790-476e-91a6-aa2d164111e2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8902f21c-b4a6-4954-ab30-96dcbc2eb945_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ea6c7e95-1dca-46dd-b672-2d21f0f54906_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives qualifying as hedges, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_171dcdca-ca8b-4b1d-a949-9870947884da_terseLabel_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_label_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_documentation_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember" xlink:href="pfe-20221002.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedRestOfWorldMember" xlink:to="lab_pfe_DevelopedRestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_e4f1fda1-c242-4a7f-9254-5af5a3f9e789_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_f24432bf-a93f-4b96-8000-67841e163fe8_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_bc227339-009d-45fa-8936-c246c2567002_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity [Member]</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_11ec408f-a758-4184-89bd-73bc2c8e162d_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OncologyMember_2ba0f27c-3ea5-449a-b6bf-1c5ae60f116c_terseLabel_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_label_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_documentation_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember" xlink:href="pfe-20221002.xsd#pfe_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OncologyMember" xlink:to="lab_pfe_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_28540697-b21c-4bd9-b77a-cb0cba902285_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_b01368d3-ec1a-4a04-b97f-7686e8d83e6b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ab5c004-9ded-44cd-b14a-ac44294f306a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesChargesIncurredToDate_f651083e-72e6-427d-9c95-3c1dea850b1a_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesChargesIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges incurred to date</link:label>
    <link:label id="lab_pfe_RestructuringChargesChargesIncurredToDate_label_en-US" xlink:label="lab_pfe_RestructuringChargesChargesIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Charges Incurred to Date</link:label>
    <link:label id="lab_pfe_RestructuringChargesChargesIncurredToDate_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesChargesIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Charges Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesChargesIncurredToDate" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesChargesIncurredToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesChargesIncurredToDate" xlink:to="lab_pfe_RestructuringChargesChargesIncurredToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_babc6b32-bbd4-4ed0-bdac-ff27cef1b4c1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_74a8419f-ffe8-4aa7-a6fe-e03cefb36157_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_ea0788ce-2cc1-4d3a-8a94-116c496c3d10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_73fcab58-957c-4998-91cf-da2a6366604c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b81bb90d-ce3f-4e6b-b6bf-317fd36ffb67_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss) before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8d601dbc-0c0e-435f-ac1f-b5f14b444472_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_46fb5c6a-5492-41a4-b30f-1c85dfa14f68_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f540b9d1-7c37-43b4-818a-6a09241fcc0f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income/(loss) attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_9466655f-d96e-45d2-b72d-a6c5d495d309_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_8b4891d1-b350-4a27-afce-accb60a86d3e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_76f782b4-e70a-488b-8dcb-78ea896bfafd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_4655f806-4bfc-4b44-aa6e-1d6478eeb4a9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7ec4b54a-e98f-441a-825b-1876a7c97f07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7934837a-cae3-4dcc-88a7-1add9c0ede08_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9fc34f65-9ab3-4df8-b697-784574cee111_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9865671-ef7a-4853-b4d1-d28a85edb42f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c142c096-2bbe-40ce-8b84-786d7c16e3e2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7aa334ec-5f52-4c31-b940-bddadf9b6176_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3498791d-c12e-4855-bcb3-b48c779757db_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9439c6f2-010c-4a9d-a662-64b2100fb258_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_aaa70c0f-d570-4a53-809d-7ace8b58cf0c_terseLabel_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_label_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Settlement Contracts, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:to="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_ccf8d498-919c-44d5-af95-8335003f6b53_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_90ec6767-a625-4c3d-88aa-a7ecdea28d54_terseLabel_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ReFacto AF/Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_label_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_documentation_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember" xlink:href="pfe-20221002.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReFactoAfXynthaMember" xlink:to="lab_pfe_ReFactoAfXynthaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherSpecialtyCareMember_0ae879c0-2117-4e52-a636-23f40b29d528_terseLabel_en-US" xlink:label="lab_pfe_OtherSpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Specialty Care [Member]</link:label>
    <link:label id="lab_pfe_OtherSpecialtyCareMember_label_en-US" xlink:label="lab_pfe_OtherSpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Specialty Care [Member]</link:label>
    <link:label id="lab_pfe_OtherSpecialtyCareMember_documentation_en-US" xlink:label="lab_pfe_OtherSpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Specialty Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherSpecialtyCareMember" xlink:href="pfe-20221002.xsd#pfe_OtherSpecialtyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSpecialtyCareMember" xlink:to="lab_pfe_OtherSpecialtyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_7cd567bd-2812-425f-8136-989131f7e7a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RuxienceMember_d3df4f7d-e0fa-419e-90d5-229d3f3bb000_terseLabel_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience [Member]</link:label>
    <link:label id="lab_pfe_RuxienceMember_label_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience [Member]</link:label>
    <link:label id="lab_pfe_RuxienceMember_documentation_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember" xlink:href="pfe-20221002.xsd#pfe_RuxienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RuxienceMember" xlink:to="lab_pfe_RuxienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_6c86c382-7946-4b26-9c04-6d4a3863dfb1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Termination Costs [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MeridianMember_4842a6a8-e876-425d-9586-6a4405b0735e_terseLabel_en-US" xlink:label="lab_pfe_MeridianMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meridian [Member]</link:label>
    <link:label id="lab_pfe_MeridianMember_label_en-US" xlink:label="lab_pfe_MeridianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meridian [Member]</link:label>
    <link:label id="lab_pfe_MeridianMember_documentation_en-US" xlink:label="lab_pfe_MeridianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meridian</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember" xlink:href="pfe-20221002.xsd#pfe_MeridianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MeridianMember" xlink:to="lab_pfe_MeridianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8ab01842-64b1-44c6-9b51-c54d94b22561_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_14965042-312b-4811-b555-a12c5cd941a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty-related income</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9afa3722-8fe8-4ff5-9041-72a5f2a288a5_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_10aa35bd-bcd2-48ea-b80e-f9a0b8c2fcac_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9e844a96-7f8d-4129-ac55-eaf375afe745_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f6412646-c220-4a7e-bdf6-7c16022d0b0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember_02b59468-cf66-4ed5-93b8-e35c9bbb3950_terseLabel_en-US" xlink:label="lab_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member]</link:label>
    <link:label id="lab_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember_label_en-US" xlink:label="lab_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member]</link:label>
    <link:label id="lab_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember_documentation_en-US" xlink:label="lab_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" xlink:href="pfe-20221002.xsd#pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" xlink:to="lab_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember_b83ed7d1-f9c6-46ef-8e3b-2d226e60e4fb_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, EUR Denominated [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV Senior Notes, EUR Denominated [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV Senior Notes, EUR Denominated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember" xlink:to="lab_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_35301b0c-de07-4a99-a3c1-588fb194869d_terseLabel_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in a net receivable position</link:label>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_label_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Receivable Position, Aggregate Fair Value</link:label>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_documentation_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Receivable Position, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:href="pfe-20221002.xsd#pfe_DerivativeNetReceivablePositionAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:to="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IgPortfolioProductsMember_5fb73862-9289-4f88-a004-e04bac7de6ba_terseLabel_en-US" xlink:label="lab_pfe_IgPortfolioProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ig Portfolio Products [Member]</link:label>
    <link:label id="lab_pfe_IgPortfolioProductsMember_label_en-US" xlink:label="lab_pfe_IgPortfolioProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ig Portfolio Products [Member]</link:label>
    <link:label id="lab_pfe_IgPortfolioProductsMember_documentation_en-US" xlink:label="lab_pfe_IgPortfolioProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ig Portfolio Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IgPortfolioProductsMember" xlink:href="pfe-20221002.xsd#pfe_IgPortfolioProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IgPortfolioProductsMember" xlink:to="lab_pfe_IgPortfolioProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_420a6e2e-b4c9-4f03-95a9-2227a8353865_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_530180be-c47a-4dc9-b896-eaf429832d0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a41c99c-4414-422f-8664-058cd092663b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0f3019f5-64ec-441a-badf-c124f029832e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c8b3390-aed4-46cc-9165-b1e47c15565c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ffe855f7-de30-43b9-945e-74a45be9e9f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, less accumulated depreciation: 2022&#8212;$14,931; 2021&#8212;$15,074</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_f6b5d76c-2ced-4a2d-b32f-e0bfa496d765_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_6773e834-bd79-4254-9007-707f76a1378f_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_pfe_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_pfe_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_pfe_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract" xlink:href="pfe-20221002.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherFinancialInformationAbstract" xlink:to="lab_pfe_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_ff91c307-2066-4f57-9f27-995101d1f19b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_aff7d490-cd3a-4e0a-ace9-ba43ef91dd0d_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_c7a31d2d-f420-464c-ae19-617a0af7f00b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets-IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_db1f1979-d4a6-4cac-a1fb-a774bc593021_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_3da4e4f5-dc17-4fbf-b986-b1087ba74565_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_58a66fb6-ecee-452b-94c3-be705b7d5dfc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_2505c145-d414-4e8e-8acc-d0d02dcca62a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_542c93b2-a3b7-4aff-8c5b-187bcde30051_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_47dd3de0-3a44-4257-b378-38a1958c5c3f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_d1dce244-caa1-4ff8-8d9e-aff31fd81a71_negatedTerseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease due to foreign currency translation</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:href="pfe-20221002.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:to="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_08108cba-d603-4818-97ea-33d52b160514_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_12321c99-a77c-4c15-85fb-86a40a716043_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_3f5a1937-900f-4c7c-9eb0-da3334a6e088_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bc027a27-99fa-4e50-85a1-97673d2a18f9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ComirnatyMember_abc0f8b2-d168-4177-b61a-2f14a09a8e75_terseLabel_en-US" xlink:label="lab_pfe_ComirnatyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty direct sales and alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_ComirnatyMember_b49f7f30-22ba-4636-9598-a7b83ee17c5a_verboseLabel_en-US" xlink:label="lab_pfe_ComirnatyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty [Member]</link:label>
    <link:label id="lab_pfe_ComirnatyMember_label_en-US" xlink:label="lab_pfe_ComirnatyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty [Member]</link:label>
    <link:label id="lab_pfe_ComirnatyMember_documentation_en-US" xlink:label="lab_pfe_ComirnatyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ComirnatyMember" xlink:to="lab_pfe_ComirnatyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_81c4e6f1-7bed-4721-8962-f3825f5dd3bf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c23661ba-39a7-4557-9c73-e86ab7830f27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_eb5a276d-0983-48ac-ae33-3bf03ed9bbf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BiohavenMember_950590a2-8dfd-4f51-9b36-5f6998494893_terseLabel_en-US" xlink:label="lab_pfe_BiohavenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biohaven [Member]</link:label>
    <link:label id="lab_pfe_BiohavenMember_label_en-US" xlink:label="lab_pfe_BiohavenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biohaven [Member]</link:label>
    <link:label id="lab_pfe_BiohavenMember_documentation_en-US" xlink:label="lab_pfe_BiohavenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biohaven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiohavenMember" xlink:href="pfe-20221002.xsd#pfe_BiohavenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiohavenMember" xlink:to="lab_pfe_BiohavenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_2917cd31-7bdf-4fd8-9645-0e7ba013fea7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8859d3e3-9b33-4616-945d-2db33c007d75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6bd80443-4c7c-4cb4-b4eb-d3d34d5f62a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6aec6e27-5adf-419e-b57f-271a2a09c9df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d4ca8d5f-1681-4f66-b313-15b102e91038_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_ba817540-8d05-4a8c-8fc3-37d909ac564d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_8b24c265-df4e-4264-8c82-ede6eb1a8053_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_790dde49-30fc-4b87-8d78-c59b620fc978_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains/(losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b4b0b68e-16c4-4433-87e6-54cb2f9e44fe_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_df0c2436-a9c5-4645-a715-14f64db999e5_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d4e2363e-db16-4cc3-b24d-400ec99252b8_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_c51b7a7f-d92b-4327-81b8-10cd89268e19_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_ebc1115e-36ef-4816-89f6-d1569b89c961_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_a135ed33-f48e-4227-9785-f9209a4077bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_273afd72-ece5-41e8-9cae-70b9039302a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_77528145-50d2-4c83-a1cd-c6f66d5e359e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_3546dd8a-3402-4881-abae-7774899adcad_terseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders Basic</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_04a25400-8dcc-4fe1-9f78-05652b0e5443_terseLabel_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20221002.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_81cffc12-a3e4-42a3-94e4-a2a4dbeedda8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c8dd446f-a4f5-4caa-bd21-8d43370cdb52_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_f17cca51-a7c2-4bba-850c-1954eb45b49a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_7ffeb22f-0015-4472-bfab-bbd2c04f402e_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants other than main defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:href="pfe-20221002.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:to="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d7ae4723-97c0-4280-80c6-36afbde838f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_a6033453-f4a9-4a9b-a4ff-671c27794de5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_dac359af-a819-428f-a2d9-a8c695ab09d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_59ffda31-142a-42e5-ace1-06f2e30ab4f3_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e9827c11-9969-4ffa-99e6-9c61a707d474_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3c00adc4-c967-4caa-be9e-a9717b35fa95_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8cec4d49-ee19-49d5-b28b-1a520f87b932_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BMP2Member_beacdd0b-7e27-4cb0-9990-3069b704f374_terseLabel_en-US" xlink:label="lab_pfe_BMP2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_label_en-US" xlink:label="lab_pfe_BMP2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_documentation_en-US" xlink:label="lab_pfe_BMP2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BMP2Member" xlink:href="pfe-20221002.xsd#pfe_BMP2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BMP2Member" xlink:to="lab_pfe_BMP2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_494a3298-fe88-4efc-b713-0d7585527ca8_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_label_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_documentation_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember" xlink:href="pfe-20221002.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingOptimizationMember" xlink:to="lab_pfe_ManufacturingOptimizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c65bb0da-133e-4d59-84b4-3e710be772ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5b4a13d7-57cf-4fc3-9aed-5dfad9d205d5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, period of recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_cf732eb3-2071-497d-a753-d329ec4e66a7_totalLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:to="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20271.000Member_06c889b1-fa47-4750-bf97-d5bac3a98957_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2027 [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member" xlink:href="pfe-20221002.xsd#pfe_NotesDue20271.000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member" xlink:to="lab_pfe_NotesDue20271.000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_38921dea-20d4-46a7-be5a-f6665f7415a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_cac49017-8d10-47d7-92d4-17dce4729ddb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_6dfc0d46-0332-463a-8930-6a60bd2b1021_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, pre-tax income (loss)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_ee1d576a-ef12-43f6-b896-6f67ad5de783_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_c1e4fea7-bb52-46a6-83e5-61ce21a1d48f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges/(credits):</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BosulifMember_e2a50b75-982c-4e7c-bcda-382ef08d2e51_terseLabel_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_label_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_documentation_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember" xlink:href="pfe-20221002.xsd#pfe_BosulifMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BosulifMember" xlink:to="lab_pfe_BosulifMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_19374335-2b48-4b23-8d85-d6f2bb00c4cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_83fc749c-53ca-47f3-b155-4bc5e16f5a22_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_16ee4ebd-fec6-42f9-b62c-b56f94f65de3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_bee65238-96b7-491e-8eeb-da3b0c3eecb7_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_f0671d23-64e7-4260-90af-210b01a852a3_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring</link:label>
    <link:label id="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_label_en-US" xlink:label="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring</link:label>
    <link:label id="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:to="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MektoviMember_72e14157-7d1b-42af-aa42-31031fc27e34_terseLabel_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_label_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_documentation_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember" xlink:href="pfe-20221002.xsd#pfe_MektoviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MektoviMember" xlink:to="lab_pfe_MektoviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_920f7321-515a-4913-9c9c-89f84b0ef1b2_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_5aa6ef85-3b85-4744-96ee-3019f4da1471_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_3de918be-6888-4827-bc6d-13050ed9a5f4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend received, distribution</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_2e03d774-8893-405a-8f80-f577b6f08e97_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_49606193-eaa1-4b23-bb5c-6badea9eaf94_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_6bd76686-5dae-4ac8-8cd8-5cd106a181a5_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_215e7d7d-1efe-42b8-ba24-c369644df50a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_379dda74-f646-4d06-985f-b68001bbd473_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d3eaad6a-1dd8-411d-a795-3b2f5174963f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment transactions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e9830410-8556-4920-a343-430af78e193b_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency - U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_b2de32da-ac5b-4213-b8c5-c6f6d4ed0be1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographic and Other Revenue Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cb8899d8-9c07-4789-ae33-7c5f0f6ed594_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_25e9fd42-1a8d-40e2-b223-8901879606fd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_2c1132ab-bb68-45db-a927-87fc35d0497a_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed investment from collaborator</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Investment From Collaborator, Amount</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Investment From Collaborator, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:href="pfe-20221002.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:to="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_c834415e-0b22-49dd-9e43-48a60e414d26_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a5fc2f7-414c-4478-b7f3-cccb8f940aa4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bee5720b-fac4-4883-bfea-3102cf92b369_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value [Member]</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c86c9e5-4c48-43b8-aeab-d4ad0a6fe820_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bbeef5a4-f4fb-4088-a4c0-5144cb98485e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BeneFIXMember_1958994e-4246-4802-afa7-456d15ccfa26_terseLabel_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeneFIX [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_label_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_documentation_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember" xlink:href="pfe-20221002.xsd#pfe_BeneFIXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BeneFIXMember" xlink:to="lab_pfe_BeneFIXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_4d829e44-14d7-416b-b0f3-c091d5c1e34b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upward price adjustments on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c32f162a-efaa-4a41-ac29-1748f8e570b6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_3c19cfd1-df78-471d-9966-0a2ebafe0bfd_terseLabel_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_label_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_documentation_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember" xlink:href="pfe-20221002.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XtandiAllianceRevenuesMember" xlink:to="lab_pfe_XtandiAllianceRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4f607a2b-fe8a-4f4f-9db3-6151a3fb7007_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_849affb8-2720-491b-86c8-02ceb5fa9fcd_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0c12cd4f-191c-4e6f-af8a-210ee3058eeb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_877e4552-d651-4ca1-a2fb-ea105e16bc47_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges/(credits)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_b4cdceee-0f36-4914-b5e5-c885c047f1f5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XeljanzMember_08599da6-b68f-41f5-8783-6cd31e415468_terseLabel_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_label_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_documentation_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember" xlink:href="pfe-20221002.xsd#pfe_XeljanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XeljanzMember" xlink:to="lab_pfe_XeljanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_310b24af-8404-4b59-89b6-3d65d329c080_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_Expiring2033Member_a7d195c8-c7e9-4908-9783-1cdfb74aeb43_terseLabel_en-US" xlink:label="lab_pfe_Expiring2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring 2033 [Member]</link:label>
    <link:label id="lab_pfe_Expiring2033Member_label_en-US" xlink:label="lab_pfe_Expiring2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring 2033 [Member]</link:label>
    <link:label id="lab_pfe_Expiring2033Member_documentation_en-US" xlink:label="lab_pfe_Expiring2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiring 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_Expiring2033Member" xlink:href="pfe-20221002.xsd#pfe_Expiring2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_Expiring2033Member" xlink:to="lab_pfe_Expiring2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_312e0f6b-3e95-4626-8de9-8f679071be20_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a8855367-facc-41b5-9984-48153428a6d4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InlytaMember_e58499c2-880d-4f5b-81b0-fbe1b97c16c0_terseLabel_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_label_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_documentation_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember" xlink:href="pfe-20221002.xsd#pfe_InlytaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InlytaMember" xlink:to="lab_pfe_InlytaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_143fdcac-3486-498e-afe3-0810a6790dd1_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_7ff87d50-7d3b-49c0-98fa-f77c1697f411_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis" xlink:to="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_33f558e6-548f-4b96-8372-ff53a6e66f62_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_52d50a31-4e2b-4e19-8e05-e1b941abac69_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_174cedc3-e01f-4360-8414-a66cc65b05a4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares&#8211;&#8211;basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b16c1e4-98ab-47f5-8233-a2a8f3b1d998_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_1ec39b27-3e7a-41d6-9016-1c57d530d0d1_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5b82346e-34e4-43f0-b284-20c9c584e56d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_8ea28307-c7d6-4c39-816d-c11dd990e8e1_verboseLabel_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-offs and impairments</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_documentation_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:href="pfe-20221002.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:to="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_ea21a756-d237-4c03-b3c5-7123356a5abb_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other net, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_70b180cb-21db-45d8-aac3-5c6b543853ae_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_80e0f2c9-dcda-47eb-a95e-0da8eb0a5599_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, consideration transferred (up to)</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6dc2ce76-581d-4b23-bc22-0d5b467c7805_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash transaction:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_beb5ac1a-be1c-49d6-9c75-b8dd8b1b592d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCashAbstract_676d24e4-78d9-4347-affc-d044602bacc3_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared, per share</link:label>
    <link:label id="lab_us-gaap_DividendsCashAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCashAbstract" xlink:to="lab_us-gaap_DividendsCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2663c2fd-0eee-447c-975c-ecaeb4389487_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_a66af894-291e-4775-8559-f735ab3fb209_terseLabel_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar Family [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_label_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar Prevenar Family [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_documentation_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar/Prevenar Family 13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember" xlink:href="pfe-20221002.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrevnarPrevenarFamilyMember" xlink:to="lab_pfe_PrevnarPrevenarFamilyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_6d99adb5-0d64-4845-8ceb-ee4c3f605adc_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses on asset disposals</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_42bef522-f0da-449c-8796-23f1c7bcaa1f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_730b421f-f14b-4d93-993c-a91df77f2117_negatedLabel_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_label_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_documentation_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:href="pfe-20221002.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:to="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_13d1f3dc-19d2-4085-9e8c-e088b418519e_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items [Member]</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_4f3bf0d5-625e-49b4-b500-38d2e5234c7d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RetacritMember_4946dbdd-be79-49ff-a4a3-dcc37545e23d_terseLabel_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_label_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_documentation_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember" xlink:href="pfe-20221002.xsd#pfe_RetacritMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RetacritMember" xlink:to="lab_pfe_RetacritMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_9b0e794d-4ddb-4e31-991f-c58a33f061e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_119343e4-13c6-4d28-8092-3897800973a7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ResearchAndDevelopmentInProcessMember_eaa28446-5603-4561-81d9-cbf023ffda79_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentInProcessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development Expense [Member]</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentInProcessMember_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentInProcessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process [Member]</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentInProcessMember_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentInProcessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentInProcessMember" xlink:href="pfe-20221002.xsd#pfe_ResearchAndDevelopmentInProcessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentInProcessMember" xlink:to="lab_pfe_ResearchAndDevelopmentInProcessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ChantixChampixMember_27a83edb-145d-478d-97d4-d3f4c36fa69c_terseLabel_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_label_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_documentation_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember" xlink:href="pfe-20221002.xsd#pfe_ChantixChampixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ChantixChampixMember" xlink:to="lab_pfe_ChantixChampixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_4a7e6928-7f6c-4ea9-9d30-fc14f7b3e1ca_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_8d70f9f5-ef7a-4a16-9de4-52836012c4f5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings, including current portion of long-term debt: 2022&#8212;$2,566; 2021&#8212;$1,636</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_83383c83-1f82-43f4-a30b-237bbfa2221a_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_1d8e38e6-d347-4f48-8bee-2cbb40f4a02e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_21420534-15c2-452b-886e-328ba14a3a35_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_64595538-1488-4721-a1a5-4119ea8a4bdf_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1090bac9-ebc6-49ae-91fa-93769839cd13_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0f44fd27-cbad-4261-b91c-95f59d04fafb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6a63ee2c-1518-4360-a585-a6e6dfd121e3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_fd901f96-488c-46bb-a759-dd2264222751_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10dd4eb0-8c65-4428-a99f-7126474ba66a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_4e6e9780-39d6-491f-9d74-111bc69f3016_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_da9f6327-14a5-48fe-b2e5-7ac36d5b62b4_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_87628da0-ea8f-4219-a5a4-0df833f850fe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PercentageChangeInRevenue_da639fef-9220-4e2c-8b57-b2248989ec3f_terseLabel_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_label_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_documentation_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage change in revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PercentageChangeInRevenue" xlink:href="pfe-20221002.xsd#pfe_PercentageChangeInRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PercentageChangeInRevenue" xlink:to="lab_pfe_PercentageChangeInRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_cd813e67-1f35-47f9-8fef-c8f335acd5af_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77d5b199-d2e6-4fc3-8540-74cdadf69a54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CorporateEnablingFunctionsMember_88961929-a1b2-4f14-bb7e-b040fe32a4b8_terseLabel_en-US" xlink:label="lab_pfe_CorporateEnablingFunctionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Enabling Functions [Member]</link:label>
    <link:label id="lab_pfe_CorporateEnablingFunctionsMember_label_en-US" xlink:label="lab_pfe_CorporateEnablingFunctionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Enabling Functions [Member]</link:label>
    <link:label id="lab_pfe_CorporateEnablingFunctionsMember_documentation_en-US" xlink:label="lab_pfe_CorporateEnablingFunctionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Enabling Functions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CorporateEnablingFunctionsMember" xlink:href="pfe-20221002.xsd#pfe_CorporateEnablingFunctionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CorporateEnablingFunctionsMember" xlink:to="lab_pfe_CorporateEnablingFunctionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9b5cd59d-bec6-468c-8253-77fceb0c51be_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_693f33e6-8c31-4a32-bb25-d1273ab432ed_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ExpirationPeriodAxis_3de2342b-0ecb-4f0a-b0df-043367a7f75c_terseLabel_en-US" xlink:label="lab_pfe_ExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Period [Axis]</link:label>
    <link:label id="lab_pfe_ExpirationPeriodAxis_label_en-US" xlink:label="lab_pfe_ExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Period [Axis]</link:label>
    <link:label id="lab_pfe_ExpirationPeriodAxis_documentation_en-US" xlink:label="lab_pfe_ExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ExpirationPeriodAxis" xlink:href="pfe-20221002.xsd#pfe_ExpirationPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ExpirationPeriodAxis" xlink:to="lab_pfe_ExpirationPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_f5175e24-c320-4a09-8fdb-d025599afcc5_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostDirectMaterial_b72776fc-f79c-4e17-99b3-07e1c3e1561b_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, excess raw materials</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostDirectMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial" xlink:to="lab_us-gaap_CostDirectMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_93057df5-575e-4f93-9676-4c888ae40d5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains)/losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fe14d9b1-675c-472e-a0ba-43d1e329a27f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b92e7e65-8ee9-4a41-8c74-37be16531c43_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_512a828f-a743-412a-85f3-55ee26697834_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences_bf31f911-fe77-4966-bbd7-796dac2382f6_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, adjustment of basis differences</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Adjustment of Basis Differences</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Adjustment of Basis Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences" xlink:href="pfe-20221002.xsd#pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences" xlink:to="lab_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_adce8fab-ba87-4815-9941-d4e85de89745_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_c6ce6ff3-285d-4453-b80d-60e7960052a5_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) on hedged item Recognized in OID</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_73b31838-7bcd-4a50-91af-446296803ea5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DocetaxelMember_c71d44dd-0f40-4b3b-8c56-6d8f3e06cb47_terseLabel_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_label_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_documentation_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember" xlink:href="pfe-20221002.xsd#pfe_DocetaxelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DocetaxelMember" xlink:to="lab_pfe_DocetaxelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_cb1a6159-3eaa-4022-8fb7-e882345459e4_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, within 1 year, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_190a608f-8019-4a1a-94bd-3d6c6c88ba08_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend" xlink:to="lab_us-gaap_InvestmentIncomeDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ViatrisMember_6fcbdbd7-980d-4732-b379-45589f0ad929_terseLabel_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris [Member]</link:label>
    <link:label id="lab_pfe_ViatrisMember_label_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris [Member]</link:label>
    <link:label id="lab_pfe_ViatrisMember_documentation_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember" xlink:href="pfe-20221002.xsd#pfe_ViatrisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViatrisMember" xlink:to="lab_pfe_ViatrisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_3a9f5192-50d6-4e08-9f12-31894d1c831c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share&#8211;&#8211;diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_f1f5be3f-9c3f-4fab-8c76-e4f6486e07a1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory sales [Member]</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc47a515-6968-4e52-baa8-c742455f2dc7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_8c36331e-dc38-4bb8-9dae-8eae5731fb3a_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_f68c890c-78f1-4a53-8bd6-a8c8996c3f62_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Not Designated as Hedges [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f19eb5e8-eb16-4d52-a69e-9869783e8184_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_2b4a3ffb-0862-47c3-9a25-958898f7f0e4_totalLabel_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term investments</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_label_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_documentation_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:href="pfe-20221002.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:to="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_7923f0e7-d7b4-4286-8e74-770bdca1b92d_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f5947b6a-cac4-4a4b-88a6-8577efca936c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_db0c8857-4c51-4096-8472-f87e73f2dd37_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_e0006791-aacf-42c0-8eac-0e19b54789cd_terseLabel_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_label_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_documentation_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:href="pfe-20221002.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:to="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d7f05f0c-a123-4dc4-aa33-4b8564dffe92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_a639f732-5288-4974-97ce-e35320cddb2d_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5f7c52da-a8a6-427b-84f2-e21264ac8a69_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_77bd2c66-e6e7-494a-851a-c4faf1e8d034_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_abdaf244-1099-4376-a0fc-3bafa346b7f0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember_a081e0a9-89ed-48fd-9029-f1ecc3251ce9_terseLabel_en-US" xlink:label="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and Cerevel [Member]</link:label>
    <link:label id="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember_label_en-US" xlink:label="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and Cerevel Therapeutics, LLC [Member]</link:label>
    <link:label id="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember_documentation_en-US" xlink:label="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and Cerevel Therapeutics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:href="pfe-20221002.xsd#pfe_BioNTechAndCerevelTherapeuticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:to="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6e2520c0-4343-40f1-a50c-e00998c8793c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3c178c27-7de2-4dbc-ad44-8651c607bb49_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets, less Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_84de0115-2f90-45fe-8f51-912c3c418304_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_6df4c97e-c3c4-499c-b2f7-9f3f45298b5c_terseLabel_en-US" xlink:label="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-Related Items [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_label_en-US" xlink:label="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Acquisition Related Costs [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_documentation_en-US" xlink:label="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsAcquisitionRelatedCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:to="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c77f70ff-6147-495f-b819-eefe61ec4d9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_a7b7f963-bc12-452d-b911-57ea63a4434f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b525ae7b-65b3-4c28-b812-e7473e3df638_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8d807423-2e8b-453b-9f3b-262b1ae35b20_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_4b9bba7b-3f1e-477d-bfde-d4c7e7b12a49_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_90c75e35-2c61-43dc-9ba2-f70837cb0783_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_5f1b62e2-31bd-4aec-98da-cdda6460ac8e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_da3bbeab-4edf-4362-9e0f-99dd22a6db23_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AccruedRebates_51c328d8-7983-4d01-aa21-550124b46dc4_terseLabel_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_label_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_documentation_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates" xlink:href="pfe-20221002.xsd#pfe_AccruedRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AccruedRebates" xlink:to="lab_pfe_AccruedRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_6cf4a05c-b642-4b04-93c4-72d52b7ccddc_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember_57e482ca-51f1-4bfb-8cb6-8a6eeed01ade_terseLabel_en-US" xlink:label="lab_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember_label_en-US" xlink:label="lab_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Amortization of Intangible Assets [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember_documentation_en-US" xlink:label="lab_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember" xlink:to="lab_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_47638906-b1fe-4578-a8d4-7160fbd9682f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefit plans, net prior service cost (credit), tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_ea1e72a2-51e5-4246-be0c-84f19737dc7d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_5637ecd0-5e8d-45cd-928f-9a589123a13f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_6c9d4a4e-d68e-4374-b109-99de6fdf57c7_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency long-term debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_label_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency long - term debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyDebtMember" xlink:to="lab_pfe_ForeignCurrencyDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_2753f0e2-063d-445f-8178-b2de30640949_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_673e9f14-1366-4ff0-93f8-39becc671e6d_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and other [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BioNTechMember_40f4316d-2995-40d2-a2b0-c64f30aa04c5_terseLabel_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech [Member]</link:label>
    <link:label id="lab_pfe_BioNTechMember_label_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech [Member]</link:label>
    <link:label id="lab_pfe_BioNTechMember_documentation_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BionTech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechMember" xlink:to="lab_pfe_BioNTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_fdb0479e-5f3b-4f9b-abbc-e9fbb5fb4978_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Assets at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_bec79c1b-d4d9-4373-9ad2-2385528e0702_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1709c6be-191c-4da9-bb61-1a1533334291_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_43128bbe-698c-4300-b37d-0f336f80b2f2_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_aee72475-71a2-40d5-a929-d12e9fae55b3_terseLabel_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued rebates and other sales-related accruals</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_label_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates And Discounts Accrual</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_documentation_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndDiscountsAccrual" xlink:href="pfe-20221002.xsd#pfe_RebatesAndDiscountsAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RebatesAndDiscountsAccrual" xlink:to="lab_pfe_RebatesAndDiscountsAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4a090ad7-1e34-4dee-a31c-a2964bd7b1a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_bd48e5df-0c2b-4781-aaec-ca16b5e60f64_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_abd1f3dc-04a7-48eb-b2e5-924f8b189139_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency - non U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_89644e60-07f3-4a6f-8c88-de139f53d9e4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemptions/sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9917b342-eb0a-4e20-b8f3-d177cf3d723d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SutentMember_25b16cc3-9995-494b-9e6a-60ace565f496_terseLabel_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_label_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_documentation_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember" xlink:href="pfe-20221002.xsd#pfe_SutentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SutentMember" xlink:to="lab_pfe_SutentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_e0ff95a3-2027-41b8-895e-255430c1fb13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_9f9a5f13-e975-4574-9d54-86d8fe29ca2d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_93adb86c-2fe4-41f9-947e-43d85f0eb80b_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral posted</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_d9d9760a-54f0-4f90-8077-3385d0cd3019_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5b2ea3b3-b9bf-418a-9348-4dd437157feb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d0f9e518-05eb-4fdc-a80d-ceee0d60a2bb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c727deef-4be8-4cec-a3f1-617302a3aa27_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtMember_93aacb8b-530c-4207-867d-0b212a2359f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtMember_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtMember" xlink:to="lab_us-gaap_ShortTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_a2ea7ad2-9713-4b4a-bf33-8e241258c741_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e9bc46da-daa8-484a-bd1a-4ca4f862039d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_8bc273ed-cec8-4db5-9d3b-985aa4756d0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EliquisMember_8491644e-3fa7-436c-b5e5-87410821a018_terseLabel_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis alliance revenues and direct sales [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_label_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_documentation_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember" xlink:href="pfe-20221002.xsd#pfe_EliquisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliquisMember" xlink:to="lab_pfe_EliquisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a16e37c3-5b9e-4050-a187-a2c39b503edd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_955aea77-12d0-4cef-9453-62589b0aedcb_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brands [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherOncologyProductsMember_6170be52-af76-48df-bd23-df5285ec5779_terseLabel_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Oncology [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_label_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember" xlink:href="pfe-20221002.xsd#pfe_OtherOncologyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherOncologyProductsMember" xlink:to="lab_pfe_OtherOncologyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_571f4ed5-8ab7-4fc5-825b-367ce45674dd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_4f1b26b3-59d5-4420-88aa-f690fdd58cc1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent inventories not included above</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_89ddb573-8c28-472f-8bb6-45d9493b5485_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_92b90f43-3581-4177-9a3a-c36102d8c8b8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsumerHealthcareJVHaleonMember_ed27ca03-f5c0-447a-92ce-f55d68adc38b_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVHaleonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV / Haleon [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVHaleonMember_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVHaleonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV / Haleon [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVHaleonMember_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVHaleonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV / Haleon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareJVHaleonMember" xlink:to="lab_pfe_ConsumerHealthcareJVHaleonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_a221522b-3c03-4c85-834a-5ef4745eec9f_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Classification of Accruals</link:label>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_label_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_documentation_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:to="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_29ea0972-8c0b-4df0-b04d-47fc65287a01_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_0cf4b073-3b51-402f-b4e9-9a146fcb7a31_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Actively Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ImplementationCosts_5ad13fbb-290e-43a8-bd1f-0c2d4d9de6dd_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_label_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation Costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_documentation_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts" xlink:href="pfe-20221002.xsd#pfe_ImplementationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCosts" xlink:to="lab_pfe_ImplementationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9c2fa6f6-6020-487a-8052-3cff73afcecb_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_4a3d7b8c-467c-44c4-9dce-1a6330d5c0e9_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0d7ba630-5687-4ff5-b1d6-b2131f27481c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_c5e735d6-0192-458e-9001-f9cee8b5f88b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components and Changes in Restructuring Accruals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_db9f0422-2d82-4e01-97ed-05ea64957dd5_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_100c277b-d58a-4056-9a96-e2b3a83aa864_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition Related Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XalkoriMember_734d1c5c-9a0f-4339-b4f0-816ee5c55d5a_terseLabel_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_label_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_documentation_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember" xlink:href="pfe-20221002.xsd#pfe_XalkoriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalkoriMember" xlink:to="lab_pfe_XalkoriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8ff7621d-7500-4ad7-a7b3-1c1148ba369a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common-share equivalents: stock options and stock issuable under employee compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1565c951-4b57-4b81-952f-1bff7903ab78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_e2f9e4bf-8ae6-4936-937c-af2c0c8374ec_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a75da9a3-e784-4284-ad8e-d39f115b2830_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BavencioAllianceRevenuesMember_a07b3932-486f-47ab-bbd2-f4a68f03e33c_terseLabel_en-US" xlink:label="lab_pfe_BavencioAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bavencio Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_BavencioAllianceRevenuesMember_label_en-US" xlink:label="lab_pfe_BavencioAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bavencio Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_BavencioAllianceRevenuesMember_documentation_en-US" xlink:label="lab_pfe_BavencioAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bavencio Alliance Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BavencioAllianceRevenuesMember" xlink:href="pfe-20221002.xsd#pfe_BavencioAllianceRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BavencioAllianceRevenuesMember" xlink:to="lab_pfe_BavencioAllianceRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_f081429b-67cb-4b53-81a2-1f70a68dea1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_124d3cfc-0710-406c-9d2f-cf9d1e5138c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GenotropinMember_0834176b-a1be-43c2-9420-108feb725f27_terseLabel_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_label_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_documentation_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember" xlink:href="pfe-20221002.xsd#pfe_GenotropinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenotropinMember" xlink:to="lab_pfe_GenotropinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_93d36bef-64d1-42c6-8e8b-3a225a81dcbb_terseLabel_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_label_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_documentation_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember" xlink:href="pfe-20221002.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViivHealthcareLimitedMember" xlink:to="lab_pfe_ViivHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_90ce9319-4f38-4d75-9659-ce157250d3c3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_85b4a806-e3c5-4ae1-9723-9f2454418d1f_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax assets and other noncurrent tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:href="pfe-20221002.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:to="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_939a79cf-4077-4dd9-b34b-a7b4161c3d21_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_f21bd01c-fdc1-4625-97dc-d3bef4c44a53_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_label_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs, Transaction Costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:to="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZirabevMember_2dafee0f-c44f-4ceb-9e55-4ab82653457c_terseLabel_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev [Member]</link:label>
    <link:label id="lab_pfe_ZirabevMember_label_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev [Member]</link:label>
    <link:label id="lab_pfe_ZirabevMember_documentation_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember" xlink:href="pfe-20221002.xsd#pfe_ZirabevMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZirabevMember" xlink:to="lab_pfe_ZirabevMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_be50fb33-7a30-48af-be64-d6a9b5c40661_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e2660178-fa76-4860-bab1-21e8b0f67201_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0ad956c9-c0e1-4ac6-b4cb-ac5c640a6502_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_a37f6a8d-0bde-47c3-8ee1-62c318bc2083_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other net, Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_55f46e63-bf7a-43c4-bbca-7899d4a7ac7e_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b4473212-f6ef-4017-9b19-4df23269f345_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6371127c-eeae-4e91-8966-ea20a0f5b4b5_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_65cdfe24-eecb-4206-a298-a423b0e57d37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_0051e8f2-3e94-4d99-a89a-2489173fe805_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c0cc110d-4c75-4743-aeee-2f3f2c62d777_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermInvestmentsMember_64557a52-ade7-48b5-a1d1-c713be71d443_terseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember" xlink:to="lab_pfe_LongtermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_d911134a-8b34-48fe-8fcc-e7328f263809_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_676129e8-d11f-40ad-9ba0-ceaa9b7594f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_ddf86784-36c5-4997-971f-2a64d310ef65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal_e984f176-b0ef-44a4-9f77-7d7fb814fb2f_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed percent of ownership disposal</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" xlink:href="pfe-20221002.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f6c9d58e-84c1-43b6-964d-f9317ad81eeb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_dd801b44-dbc0-47ab-a01d-1231675f9913_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1725aedc-08e6-4a42-986c-74defc0de58e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_442e74fa-382d-4bab-8c04-ceca80e245c4_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ModernaTXPatentInfringementCaseMember_cbf83889-39e2-421a-8bcf-be1e62fb1c3f_terseLabel_en-US" xlink:label="lab_pfe_ModernaTXPatentInfringementCaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ModernaTX Patent Infringement Case [Member]</link:label>
    <link:label id="lab_pfe_ModernaTXPatentInfringementCaseMember_label_en-US" xlink:label="lab_pfe_ModernaTXPatentInfringementCaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ModernaTX Patent Infringement Case [Member]</link:label>
    <link:label id="lab_pfe_ModernaTXPatentInfringementCaseMember_documentation_en-US" xlink:label="lab_pfe_ModernaTXPatentInfringementCaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ModernaTX Patent Infringement Case</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ModernaTXPatentInfringementCaseMember" xlink:href="pfe-20221002.xsd#pfe_ModernaTXPatentInfringementCaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ModernaTXPatentInfringementCaseMember" xlink:to="lab_pfe_ModernaTXPatentInfringementCaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_af23a421-d36a-40fc-a8eb-8912c1ef9513_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_f0709216-1873-4e2d-8edf-92306d560f2a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c2d7bf91-9bf8-4de8-b372-1f45e7176dee_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_b9ca891b-b856-4b98-817f-ace544ad96fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_85518340-4744-4c1a-829e-f9d603dec830_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_2444ea62-ddd9-4b29-b4b5-aa233eab4277_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1cf566fb-8e3f-43ae-aa17-2aa598061370_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1b5a3664-3cf1-423f-a892-193bd3225158_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bead9171-4d8e-4ad9-963e-d978b6bdffc4_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_97fdb6d9-fa28-4da3-95b8-3349ad673b67_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_93872644-75b8-4857-bc28-45b444b3ef09_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c127add-2593-4e5f-8acc-e50e9ddff3ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Plans [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InterestPaidReceivedInterestRateHedges_f9737e5e-2a99-436e-9f59-394d95ac4bd2_terseLabel_en-US" xlink:label="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate hedges</link:label>
    <link:label id="lab_pfe_InterestPaidReceivedInterestRateHedges_label_en-US" xlink:label="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid (Received), Interest Rate Hedges</link:label>
    <link:label id="lab_pfe_InterestPaidReceivedInterestRateHedges_documentation_en-US" xlink:label="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid (Received), Interest Rate Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InterestPaidReceivedInterestRateHedges" xlink:href="pfe-20221002.xsd#pfe_InterestPaidReceivedInterestRateHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InterestPaidReceivedInterestRateHedges" xlink:to="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_61d681fe-35f8-489f-9736-e96fdd898dee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pfe-20221002_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:532d8f3f-927e-412c-bdcb-1806e94574ca,g:7cd44193-98b9-486c-9ee0-61ec890b3036-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20221002.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cbf2c001-1e4d-47aa-bb57-753a3cdfebf2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_73b64b00-3cc6-4388-bd2c-1a7e22c80118" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cbf2c001-1e4d-47aa-bb57-753a3cdfebf2" xlink:to="loc_dei_EntitiesTable_73b64b00-3cc6-4388-bd2c-1a7e22c80118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4798faac-ead0-4698-b469-85771fa1c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_73b64b00-3cc6-4388-bd2c-1a7e22c80118" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4798faac-ead0-4698-b469-85771fa1c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4798faac-ead0-4698-b469-85771fa1c228" xlink:to="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_094f268f-2129-4e1d-abc7-a0e6da3587cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:to="loc_us-gaap_CommonStockMember_094f268f-2129-4e1d-abc7-a0e6da3587cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_e0dcc8c6-046e-4572-930c-b12f2ad0add2" xlink:href="pfe-20221002.xsd#pfe_NotesDue20271.000Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_476d51c7-faf3-4103-a261-0c849b4bc10c" xlink:to="loc_pfe_NotesDue20271.000Member_e0dcc8c6-046e-4572-930c-b12f2ad0add2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_73b64b00-3cc6-4388-bd2c-1a7e22c80118" xlink:to="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_23aac756-74a9-46c2-9ad0-50067f65a830" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentType_23aac756-74a9-46c2-9ad0-50067f65a830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ab177670-17c6-4895-a0e0-9f7c1de1f250" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentQuarterlyReport_ab177670-17c6-4895-a0e0-9f7c1de1f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_549045de-6d61-477b-96bc-e853177248cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentPeriodEndDate_549045de-6d61-477b-96bc-e853177248cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_78c03f43-7cce-4daf-a3f3-f7e4f6428c3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentTransitionReport_78c03f43-7cce-4daf-a3f3-f7e4f6428c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a6b9def2-854b-457d-9b76-87b5f79a1ba9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityFileNumber_a6b9def2-854b-457d-9b76-87b5f79a1ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a021864f-97e4-4e08-a57b-0859415171c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityRegistrantName_a021864f-97e4-4e08-a57b-0859415171c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ded6364d-379d-4aad-9366-9fcc2bc176af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ded6364d-379d-4aad-9366-9fcc2bc176af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e12b8bd6-c67f-4094-95cf-a0014c819700" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityTaxIdentificationNumber_e12b8bd6-c67f-4094-95cf-a0014c819700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_82c2d51e-cd29-4520-a22e-3f7c18810dae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressAddressLine1_82c2d51e-cd29-4520-a22e-3f7c18810dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_24399b7e-9947-434c-ba9b-934c1415ab3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressCityOrTown_24399b7e-9947-434c-ba9b-934c1415ab3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1a9103e9-cf1b-44e0-b381-c6a0566231d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressStateOrProvince_1a9103e9-cf1b-44e0-b381-c6a0566231d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dedbab9b-130b-4b2b-995e-2f2e0853b9a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityAddressPostalZipCode_dedbab9b-130b-4b2b-995e-2f2e0853b9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3a761265-32a7-445f-b345-4aa97e83205c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_CityAreaCode_3a761265-32a7-445f-b345-4aa97e83205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_321c1021-8be1-479d-8c5b-a7cad479559b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_LocalPhoneNumber_321c1021-8be1-479d-8c5b-a7cad479559b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f6b761f7-c373-495b-abb2-3fc2ef8bd52b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_Security12bTitle_f6b761f7-c373-495b-abb2-3fc2ef8bd52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c18afd5f-2979-4f39-9b08-2fd866ee61b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_TradingSymbol_c18afd5f-2979-4f39-9b08-2fd866ee61b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_75e8ee4c-35b8-4391-a58b-4e37e16e9f25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_SecurityExchangeName_75e8ee4c-35b8-4391-a58b-4e37e16e9f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_73f8a5ce-f206-4b25-8b00-b2398eeaf8e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityCurrentReportingStatus_73f8a5ce-f206-4b25-8b00-b2398eeaf8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_80deaac6-5ed5-4ef4-a08a-dd20d4eb5ea6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityInteractiveDataCurrent_80deaac6-5ed5-4ef4-a08a-dd20d4eb5ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c3aaba2d-8396-4c75-bb93-33c8319fe03d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityFilerCategory_c3aaba2d-8396-4c75-bb93-33c8319fe03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f5949d49-a65e-4775-b331-1898db76d1d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntitySmallBusiness_f5949d49-a65e-4775-b331-1898db76d1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3b85c47f-da41-42a4-84a5-d3e4c33acab7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityEmergingGrowthCompany_3b85c47f-da41-42a4-84a5-d3e4c33acab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5c521e63-454f-475f-9f2f-b1b1a91cb62f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityShellCompany_5c521e63-454f-475f-9f2f-b1b1a91cb62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d8607d7f-9fce-429e-a08c-fd5e159c01f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d8607d7f-9fce-429e-a08c-fd5e159c01f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7ae8bc76-a54c-4552-b06a-3cca7fd04aa0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_EntityCentralIndexKey_7ae8bc76-a54c-4552-b06a-3cca7fd04aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0777b050-1394-4802-873d-568800a1c87a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_CurrentFiscalYearEndDate_0777b050-1394-4802-873d-568800a1c87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f1a7aff0-3637-4dcd-822a-d3a75f73c7ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentFiscalYearFocus_f1a7aff0-3637-4dcd-822a-d3a75f73c7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_103b2417-9261-4acd-beef-9e979e9e7eba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_DocumentFiscalPeriodFocus_103b2417-9261-4acd-beef-9e979e9e7eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_763e3750-40d8-4a68-b660-22fb504e8153" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ebe7d2f-9f89-4f0f-bc08-ca0332a4e2be" xlink:to="loc_dei_AmendmentFlag_763e3750-40d8-4a68-b660-22fb504e8153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da8ee060-04db-4219-8ad2-a63d1ddb5394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da8ee060-04db-4219-8ad2-a63d1ddb5394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fbec3efc-49dc-4419-8c9e-dc1303b975c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fbec3efc-49dc-4419-8c9e-dc1303b975c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4a387e4-fde7-40c7-9cc4-2ecf9f2a0c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4a387e4-fde7-40c7-9cc4-2ecf9f2a0c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5830f59a-b200-43dd-960b-7bad67ae580c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5830f59a-b200-43dd-960b-7bad67ae580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_040e83ae-41fc-401d-b745-09d4c4431da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_040e83ae-41fc-401d-b745-09d4c4431da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_f3f08894-e88a-45be-8748-bdd6cba0d4fc" xlink:href="pfe-20221002.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_f3f08894-e88a-45be-8748-bdd6cba0d4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_c40f40c8-d793-4e84-a9c9-dc502b60fcf0" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_c40f40c8-d793-4e84-a9c9-dc502b60fcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_732922f0-2c70-4eb5-99fb-2066d8f81411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a736b57e-6753-43de-a4e4-ff643e3108b2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_732922f0-2c70-4eb5-99fb-2066d8f81411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86db9390-84bd-403c-846e-85fbdb436471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86db9390-84bd-403c-846e-85fbdb436471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cb6be821-0c10-444d-aadb-ce84d8b706db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cb6be821-0c10-444d-aadb-ce84d8b706db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f7d09678-b63d-4e95-968d-8fd13e4f9064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f7d09678-b63d-4e95-968d-8fd13e4f9064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_41163c0b-0630-4526-9c3f-fc038b5b84ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_41163c0b-0630-4526-9c3f-fc038b5b84ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_32e389ed-1315-4b3d-9359-60636fafbac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_ProfitLoss_32e389ed-1315-4b3d-9359-60636fafbac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4a281897-4506-4b9e-b30b-eb1c8ffa1c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4a281897-4506-4b9e-b30b-eb1c8ffa1c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_97031360-6fef-4e02-a376-21bc5285b6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_NetIncomeLoss_97031360-6fef-4e02-a376-21bc5285b6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_5fb5da99-4152-4e66-bb03-7df683493b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_5fb5da99-4152-4e66-bb03-7df683493b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6f4d06a3-4e75-4d15-a9ba-c9b256dc0df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_5fb5da99-4152-4e66-bb03-7df683493b29" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6f4d06a3-4e75-4d15-a9ba-c9b256dc0df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f82423c2-aff1-40d9-ac16-855d4095f678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_5fb5da99-4152-4e66-bb03-7df683493b29" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f82423c2-aff1-40d9-ac16-855d4095f678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f1668708-f067-47fc-b3b0-21f3bd3d4357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_5fb5da99-4152-4e66-bb03-7df683493b29" xlink:to="loc_us-gaap_EarningsPerShareBasic_f1668708-f067-47fc-b3b0-21f3bd3d4357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_2d971668-9646-4a8f-9941-0a0c05cd865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_2d971668-9646-4a8f-9941-0a0c05cd865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8219bcf9-f1f7-494e-b92b-706747a356ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2d971668-9646-4a8f-9941-0a0c05cd865c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8219bcf9-f1f7-494e-b92b-706747a356ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_dfa88d7d-edee-478e-b62d-18999ce2b7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2d971668-9646-4a8f-9941-0a0c05cd865c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_dfa88d7d-edee-478e-b62d-18999ce2b7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1731f664-b486-492e-beec-8f28f6be2f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2d971668-9646-4a8f-9941-0a0c05cd865c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1731f664-b486-492e-beec-8f28f6be2f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cea8a856-70cf-4df8-ab44-2ec9f9e76059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cea8a856-70cf-4df8-ab44-2ec9f9e76059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2fdd7183-6b2f-4321-b062-9581c6020bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c67fe142-8936-46ca-9369-bac126111ac6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2fdd7183-6b2f-4321-b062-9581c6020bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a5141a01-0dd0-4d3d-9e8a-e0ca15229c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_ProfitLoss_a5141a01-0dd0-4d3d-9e8a-e0ca15229c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_d4ed8847-56a4-4e44-adbd-4660ca16f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_d4ed8847-56a4-4e44-adbd-4660ca16f1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_1ab7ab07-459a-4c79-ba5f-e161563f3327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_1ab7ab07-459a-4c79-ba5f-e161563f3327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d25cec63-b50a-46f2-8d36-91eb239ed47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d25cec63-b50a-46f2-8d36-91eb239ed47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_aea8d553-303d-4dfe-a182-467d1db069d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_aea8d553-303d-4dfe-a182-467d1db069d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_53c79ea6-ec53-48ea-88fa-487acbff2665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_53c79ea6-ec53-48ea-88fa-487acbff2665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_cf8b00ef-5404-4eda-ac65-a93e3df17133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_cf8b00ef-5404-4eda-ac65-a93e3df17133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_6e401ddf-bfe3-4759-af47-eef9503aed90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_6e401ddf-bfe3-4759-af47-eef9503aed90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6232c190-dd7c-48bc-acbd-7f8c1684fc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6232c190-dd7c-48bc-acbd-7f8c1684fc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_0c77c42b-c632-45be-a480-1c595967e1b9" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_0c77c42b-c632-45be-a480-1c595967e1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_49214759-b50b-4c80-a0ff-39c920f3dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_49214759-b50b-4c80-a0ff-39c920f3dec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_81ed70e2-6b6d-42e1-8139-48e91e3f84c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_81ed70e2-6b6d-42e1-8139-48e91e3f84c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_81ed8e91-2a60-44cd-ac4a-55f7f644e1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_81ed8e91-2a60-44cd-ac4a-55f7f644e1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cc0e40d1-beff-41b1-884c-cee5acf845d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cc0e40d1-beff-41b1-884c-cee5acf845d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0fab9c79-67b6-47ed-8cbc-1a44e2dc8738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0fab9c79-67b6-47ed-8cbc-1a44e2dc8738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1bccedab-b0ef-414f-929b-f074d9827ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1bccedab-b0ef-414f-929b-f074d9827ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cd72b3fc-a440-45af-b809-14167a8cf9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fbcf8a2b-ab42-4512-9ffe-f909c81f1c2c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cd72b3fc-a440-45af-b809-14167a8cf9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d7b3fcd0-31a9-4632-a3d4-b5efe029d1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d7b3fcd0-31a9-4632-a3d4-b5efe029d1b4" xlink:to="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_185f327c-9df8-490e-be71-4169e7011ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_185f327c-9df8-490e-be71-4169e7011ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_1e9ae330-0d9d-44a0-aeb0-b1492ddfc2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_OtherShortTermInvestments_1e9ae330-0d9d-44a0-aeb0-b1492ddfc2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_703983dd-0b37-46b5-95c9-eac550f8c4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_703983dd-0b37-46b5-95c9-eac550f8c4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_76876992-874c-4c7a-9b39-05c60f885de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_InventoryNet_76876992-874c-4c7a-9b39-05c60f885de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent_bdc37e6e-b51c-42bc-afd9-ef1cfffa070c" xlink:href="pfe-20221002.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_pfe_OtherTaxAssetsCurrent_bdc37e6e-b51c-42bc-afd9-ef1cfffa070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f63788ad-50ae-44bc-83a2-6252457ea3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_OtherAssetsCurrent_f63788ad-50ae-44bc-83a2-6252457ea3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a9263302-f8cb-48ce-83c2-361e5cc19adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_AssetsCurrent_a9263302-f8cb-48ce-83c2-361e5cc19adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e0b6c4fe-6463-47ea-8975-7814c1cc4b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_EquityMethodInvestments_e0b6c4fe-6463-47ea-8975-7814c1cc4b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_671a7315-7557-4967-9abb-bc9ed93d095a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_OtherLongTermInvestments_671a7315-7557-4967-9abb-bc9ed93d095a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e4042056-4d7e-4ff1-8ed6-869262e0d054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e4042056-4d7e-4ff1-8ed6-869262e0d054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_48e6ee55-0c42-4d6d-aeea-4c0f5ab29f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_48e6ee55-0c42-4d6d-aeea-4c0f5ab29f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7f62e69a-e36c-4507-80a6-038d36e186c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_Goodwill_7f62e69a-e36c-4507-80a6-038d36e186c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_241e7d3b-c37c-430a-adc7-202e6e9361a9" xlink:href="pfe-20221002.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_241e7d3b-c37c-430a-adc7-202e6e9361a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7d089c8e-c479-4b41-abe1-7c21e9add751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7d089c8e-c479-4b41-abe1-7c21e9add751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ff4e04e8-9458-43ef-956c-a6b9fbcef319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_003bfb31-d615-4409-b6a7-21031b6a06a8" xlink:to="loc_us-gaap_Assets_ff4e04e8-9458-43ef-956c-a6b9fbcef319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d7b3fcd0-31a9-4632-a3d4-b5efe029d1b4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_f7b04a5a-bb15-419d-a835-0066df682c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_DebtCurrent_f7b04a5a-bb15-419d-a835-0066df682c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_65f98e6d-a72d-4362-ac3b-12e8d2dd796e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_AccountsPayableCurrent_65f98e6d-a72d-4362-ac3b-12e8d2dd796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_8343f1d1-ced4-48b3-bdea-406c96b03085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_DividendsPayableCurrent_8343f1d1-ced4-48b3-bdea-406c96b03085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_f07a2327-4eed-4e4a-bb20-6f64648dbdae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_TaxesPayableCurrent_f07a2327-4eed-4e4a-bb20-6f64648dbdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_29db3839-dbd6-45a5-97c4-8fb31ded67af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_29db3839-dbd6-45a5-97c4-8fb31ded67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eeddd8cb-60cd-4a04-8ba4-4bc43d25f1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eeddd8cb-60cd-4a04-8ba4-4bc43d25f1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dcd07c18-f2ea-4f79-9373-85472d9a7490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dcd07c18-f2ea-4f79-9373-85472d9a7490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4c314225-b343-432c-a6e2-7a929a5d8e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_LiabilitiesCurrent_4c314225-b343-432c-a6e2-7a929a5d8e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_27f36248-46ea-438f-b49a-f2b51f521527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_27f36248-46ea-438f-b49a-f2b51f521527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_6fe54534-6e1f-4c3b-bf12-b0b9ac87794a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_6fe54534-6e1f-4c3b-bf12-b0b9ac87794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_58290608-8e87-4278-8469-2d9644b10916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_58290608-8e87-4278-8469-2d9644b10916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6ee4161c-3d4a-4096-a4c0-41bcaa64427e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6ee4161c-3d4a-4096-a4c0-41bcaa64427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_f9e28797-c680-4725-b056-9a087c853fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_f9e28797-c680-4725-b056-9a087c853fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_58c299e3-ed91-401e-9919-ef23a8c761a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_58c299e3-ed91-401e-9919-ef23a8c761a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_50a0242a-1d69-49d3-8e5b-93c91404ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_Liabilities_50a0242a-1d69-49d3-8e5b-93c91404ddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_31a3d10d-b033-44cd-aebb-34c0c54d2e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_31a3d10d-b033-44cd-aebb-34c0c54d2e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_18020c3b-fdec-4153-b902-9fe34c647a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_CommonStockValue_18020c3b-fdec-4153-b902-9fe34c647a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_20b48eae-019f-432c-a709-6e5388f6324d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_20b48eae-019f-432c-a709-6e5388f6324d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_08086898-f83b-4000-b53f-d33c912c5a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_TreasuryStockValue_08086898-f83b-4000-b53f-d33c912c5a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5284a277-8852-49c8-b63c-71fb384c9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5284a277-8852-49c8-b63c-71fb384c9abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fd04c290-48a6-4a38-8e67-e07d8220a9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fd04c290-48a6-4a38-8e67-e07d8220a9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_79083fcb-07ee-4f98-bc9c-704cd0cf2a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_StockholdersEquity_79083fcb-07ee-4f98-bc9c-704cd0cf2a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_49973ce1-d3ce-433c-96d2-ec94f23e97ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_MinorityInterest_49973ce1-d3ce-433c-96d2-ec94f23e97ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7073eb18-a2d2-428b-8e4a-3fbe2d6f0379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7073eb18-a2d2-428b-8e4a-3fbe2d6f0379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f5e3104-7b1a-45f0-9efd-76b0e4990a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0c47dd6-f1d9-41df-9efe-4c27e2d2f4fd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f5e3104-7b1a-45f0-9efd-76b0e4990a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6b371492-2cde-4bb5-b602-b45f33d4425d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_41797d10-4bff-47b2-bf24-1ff05eb69df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6b371492-2cde-4bb5-b602-b45f33d4425d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_41797d10-4bff-47b2-bf24-1ff05eb69df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_44a398a9-665f-4332-bf0f-422f3052e949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6b371492-2cde-4bb5-b602-b45f33d4425d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_44a398a9-665f-4332-bf0f-422f3052e949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_89c8912e-f435-41f5-9650-dfd1f3c67425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6b371492-2cde-4bb5-b602-b45f33d4425d" xlink:to="loc_us-gaap_LongTermDebtCurrent_89c8912e-f435-41f5-9650-dfd1f3c67425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2cc0912e-4b7a-458b-9d0d-73abfe36eba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5b63b7c-2e1b-4d90-872b-5b5c378baea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2cc0912e-4b7a-458b-9d0d-73abfe36eba0" xlink:to="loc_us-gaap_StatementTable_f5b63b7c-2e1b-4d90-872b-5b5c378baea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e845621-cb7e-4a26-9c27-7f9c12276ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5b63b7c-2e1b-4d90-872b-5b5c378baea5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e845621-cb7e-4a26-9c27-7f9c12276ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e845621-cb7e-4a26-9c27-7f9c12276ae7" xlink:to="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:to="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_de640dd3-a648-4447-90ae-75f474c2425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_CommonStockMember_de640dd3-a648-4447-90ae-75f474c2425a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_152a611a-3eb2-41fd-b5b0-abdf395520c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_152a611a-3eb2-41fd-b5b0-abdf395520c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_526a9328-9714-4be6-a857-1073bcce25ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_TreasuryStockMember_526a9328-9714-4be6-a857-1073bcce25ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_915eed4d-1a91-442d-ad0a-1a548af605a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_RetainedEarningsMember_915eed4d-1a91-442d-ad0a-1a548af605a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6bc57cb-910a-4d35-80a4-47ced12552fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_b37386cf-dd59-40bf-bb63-2af086242406" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6bc57cb-910a-4d35-80a4-47ced12552fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c24aaacd-6860-4188-992e-456c1b79a1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f907a9b-f778-4f88-ade6-f935a6393b70" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c24aaacd-6860-4188-992e-456c1b79a1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_693ffff1-6d6e-4773-a8c1-ce9a89a027f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5b63b7c-2e1b-4d90-872b-5b5c378baea5" xlink:to="loc_us-gaap_StatementLineItems_693ffff1-6d6e-4773-a8c1-ce9a89a027f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_693ffff1-6d6e-4773-a8c1-ce9a89a027f5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_602a492e-bcce-40ad-8cc5-e95b00a8d441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_CommonStockSharesIssued_602a492e-bcce-40ad-8cc5-e95b00a8d441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f8f3c82-c126-466d-9051-bbf49ef326e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f8f3c82-c126-466d-9051-bbf49ef326e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_e17fcc14-c063-45de-b973-35734982caf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_TreasuryStockShares_e17fcc14-c063-45de-b973-35734982caf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8e6b0fcb-8310-4a90-b054-a0eacace4af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_ProfitLoss_8e6b0fcb-8310-4a90-b054-a0eacace4af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4778b5cd-61ab-435d-8a53-8441a0377cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4778b5cd-61ab-435d-8a53-8441a0377cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCashAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_562883f4-606c-48f9-9d68-e71875e7f405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:to="loc_us-gaap_DividendsCommonStockCash_562883f4-606c-48f9-9d68-e71875e7f405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b7e5911f-8e80-4fee-b0eb-0a0442fd0e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_a6d702a4-ea79-4e35-928e-335403aa435e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b7e5911f-8e80-4fee-b0eb-0a0442fd0e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6fa82925-47f7-4429-8fc6-80dcf4fab991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6fa82925-47f7-4429-8fc6-80dcf4fab991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5384596-731c-46a1-bb72-305c95cf5912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5384596-731c-46a1-bb72-305c95cf5912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d692e5d6-5c55-493c-8af1-a66ab1fb3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d692e5d6-5c55-493c-8af1-a66ab1fb3df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_86b7ec7b-774d-4b98-b5a7-33fc914a9187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_86b7ec7b-774d-4b98-b5a7-33fc914a9187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_83505ea0-51d9-4a89-b734-2026db80a350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockholdersEquityOther_83505ea0-51d9-4a89-b734-2026db80a350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_947d8923-cc99-41f8-9317-13f5731fb860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_CommonStockSharesIssued_947d8923-cc99-41f8-9317-13f5731fb860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5e58603-47a6-457d-93b8-b366471dee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5e58603-47a6-457d-93b8-b366471dee3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_313faf6c-4fd7-434b-b4ad-7c98624660c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9784283-7d5a-456e-8a10-ee85e893ebb2" xlink:to="loc_us-gaap_TreasuryStockShares_313faf6c-4fd7-434b-b4ad-7c98624660c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e25d500b-3b12-43ad-b8a1-77d1a829b134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_b88c4f58-bc9e-4478-95cb-1c8c74f204e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e25d500b-3b12-43ad-b8a1-77d1a829b134" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_b88c4f58-bc9e-4478-95cb-1c8c74f204e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="pfe-20221002.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_109e9885-7683-4383-95b3-9029ea4cfd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:to="loc_us-gaap_ProfitLoss_109e9885-7683-4383-95b3-9029ea4cfd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0d346ba6-6046-43c0-8bc5-afcba54d9e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0d346ba6-6046-43c0-8bc5-afcba54d9e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b3e73eb8-bd8d-43c4-889a-910a54d5ffed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b3e73eb8-bd8d-43c4-889a-910a54d5ffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2f5e72e0-30c0-42b1-ad36-822bd5fd720a" xlink:href="pfe-20221002.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_2f5e72e0-30c0-42b1-ad36-822bd5fd720a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_3ef505f2-8a17-45bb-9d49-3b60cb6c1e70" xlink:href="pfe-20221002.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_3ef505f2-8a17-45bb-9d49-3b60cb6c1e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_26f4e96b-975a-4aac-80ce-13ace4c273dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_26f4e96b-975a-4aac-80ce-13ace4c273dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_298b8a62-b15a-4f2a-9c2d-e150f057806e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:to="loc_us-gaap_ShareBasedCompensation_298b8a62-b15a-4f2a-9c2d-e150f057806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_6cd9a2d8-f214-4624-b9e8-ee4531960d29" xlink:href="pfe-20221002.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_6cd9a2d8-f214-4624-b9e8-ee4531960d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_def78657-6076-4b3f-8cff-ed76bb8674e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_def78657-6076-4b3f-8cff-ed76bb8674e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_65e75361-f790-4b2d-a105-4dcadfcc3aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0ed12e-5813-4bb6-8f70-cb8d1bfba58c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_65e75361-f790-4b2d-a105-4dcadfcc3aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d9472b86-9099-4056-a699-9d2a20958d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d9472b86-9099-4056-a699-9d2a20958d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c6c57564-750c-497d-a6ea-23cf5e273642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c6c57564-750c-497d-a6ea-23cf5e273642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6b6826f-936c-4251-88da-65a761fefefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf47542-77f4-4ae6-ae66-da54c9ba3477" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6b6826f-936c-4251-88da-65a761fefefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9b17e764-3a78-4063-a7f2-9c649b501d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9b17e764-3a78-4063-a7f2-9c649b501d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_da449258-6931-48e2-8b23-5196f78a3863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_da449258-6931-48e2-8b23-5196f78a3863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_bd90a5d2-f520-4ce7-a43c-d145e99df0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_bd90a5d2-f520-4ce7-a43c-d145e99df0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_89bf6a44-0389-46d0-9f6d-86130db32a12" xlink:href="pfe-20221002.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_89bf6a44-0389-46d0-9f6d-86130db32a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9381ebd4-32cd-4e71-aced-b6b2aa0ff46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9381ebd4-32cd-4e71-aced-b6b2aa0ff46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_ad411351-5a78-432b-802a-1b69872612cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_ad411351-5a78-432b-802a-1b69872612cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_615958d5-d2e4-4f92-a011-2f0f06424e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_615958d5-d2e4-4f92-a011-2f0f06424e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_cc1f0106-8be7-47de-8940-fff3a9eb535b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_cc1f0106-8be7-47de-8940-fff3a9eb535b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5cc8c092-f882-4885-9899-b225ba930feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5cc8c092-f882-4885-9899-b225ba930feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_3de83990-6fd4-4083-b42f-b5e18e9035da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_3de83990-6fd4-4083-b42f-b5e18e9035da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_ac320dc4-afce-4485-b396-29a4e78f48ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_ac320dc4-afce-4485-b396-29a4e78f48ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5869bff8-8656-4858-a37b-fcd93091e79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9ed535c-adc0-4d9c-b94d-13049b58b7a7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5869bff8-8656-4858-a37b-fcd93091e79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_933c8eec-bba8-4b53-9cd2-5a15dc8da08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_933c8eec-bba8-4b53-9cd2-5a15dc8da08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_2df9c072-3b8d-4a98-b0ad-4cd7a9064e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_2df9c072-3b8d-4a98-b0ad-4cd7a9064e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_5f045f9e-0147-40b3-a353-e0f2c8b50415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_5f045f9e-0147-40b3-a353-e0f2c8b50415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_046dbac2-2d42-4c4b-bb3a-387849db5b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_046dbac2-2d42-4c4b-bb3a-387849db5b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ec0c0a20-577c-473a-a3f9-ffdad9bf60bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ec0c0a20-577c-473a-a3f9-ffdad9bf60bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_761937cf-6840-497a-96af-75aa7ba2b2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_761937cf-6840-497a-96af-75aa7ba2b2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_faac8c63-8c4f-4b77-b659-4ca5feaaf94e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_faac8c63-8c4f-4b77-b659-4ca5feaaf94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_263dbf8d-3081-4970-974c-d2afdd03b7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_263dbf8d-3081-4970-974c-d2afdd03b7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c56ccde8-44d6-415b-8ad1-ae4599880f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e807aeb3-d977-436c-80df-6a040009b080" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c56ccde8-44d6-415b-8ad1-ae4599880f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bb54ee3-b5e4-4e31-8bf5-dd674e34c694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bb54ee3-b5e4-4e31-8bf5-dd674e34c694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4808ddb4-b224-4dc5-9590-31b54ff0d301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4808ddb4-b224-4dc5-9590-31b54ff0d301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e09a81d1-c68d-413c-92ae-5d125111233b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e09a81d1-c68d-413c-92ae-5d125111233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2843276f-26e3-4642-8316-7ebcc6280e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2843276f-26e3-4642-8316-7ebcc6280e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5e9fe4f2-445b-484b-aac8-2392b8e029ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafaaa84-091e-455b-90c2-7c2bbc867d0a" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5e9fe4f2-445b-484b-aac8-2392b8e029ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ae46c4e-6185-4dde-b22c-6139b720540d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5e9fe4f2-445b-484b-aac8-2392b8e029ea" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ae46c4e-6185-4dde-b22c-6139b720540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_b852450e-0888-417c-b0f6-a75054dcaf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ae46c4e-6185-4dde-b22c-6139b720540d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_b852450e-0888-417c-b0f6-a75054dcaf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ff50e260-3182-4e4a-9ab8-c6b587304fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ae46c4e-6185-4dde-b22c-6139b720540d" xlink:to="loc_us-gaap_InterestPaidNet_ff50e260-3182-4e4a-9ab8-c6b587304fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InterestPaidReceivedInterestRateHedges_0284f3bf-ca94-421f-a4e4-9cd6a3b0586e" xlink:href="pfe-20221002.xsd#pfe_InterestPaidReceivedInterestRateHedges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5ae46c4e-6185-4dde-b22c-6139b720540d" xlink:to="loc_pfe_InterestPaidReceivedInterestRateHedges_0284f3bf-ca94-421f-a4e4-9cd6a3b0586e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_455c4ea6-10a5-435f-8bac-bdca4d772e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5e9fe4f2-445b-484b-aac8-2392b8e029ea" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_455c4ea6-10a5-435f-8bac-bdca4d772e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4ff48b12-3021-4b8e-8f69-6dcf3efd0e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_455c4ea6-10a5-435f-8bac-bdca4d772e1a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4ff48b12-3021-4b8e-8f69-6dcf3efd0e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="pfe-20221002.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d24128e6-783d-4dff-b3f8-6c29039d193c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_25475297-ab66-4196-ab25-0b6515724405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d24128e6-783d-4dff-b3f8-6c29039d193c" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_25475297-ab66-4196-ab25-0b6515724405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_6f89809b-8fde-4792-8bf0-bcd36e6d736a" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_532f3a60-6261-423c-9f42-c6bd9abfefd0" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_6f89809b-8fde-4792-8bf0-bcd36e6d736a" xlink:to="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_532f3a60-6261-423c-9f42-c6bd9abfefd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cded79fb-72b9-4626-9c05-5f8d7774cd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d8d4e7ac-80fc-4040-800b-67ba2066cf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cded79fb-72b9-4626-9c05-5f8d7774cd35" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d8d4e7ac-80fc-4040-800b-67ba2066cf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNet"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_f69a7240-7078-40de-9a82-5ad863537dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_63b2b333-9f08-4f92-bf96-b5242e1e1bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f69a7240-7078-40de-9a82-5ad863537dc6" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_63b2b333-9f08-4f92-bf96-b5242e1e1bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:type="simple" xlink:href="pfe-20221002.xsd#TaxMatters"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0b8664da-4d43-4334-91c3-1835de22cd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_fdd05419-9af5-4e2b-9b9d-73f66c78a033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0b8664da-4d43-4334-91c3-1835de22cd88" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_fdd05419-9af5-4e2b-9b9d-73f66c78a033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" xlink:href="pfe-20221002.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f8d59bb6-41ce-4e8f-8f8c-32ae504ce057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_8f5184c6-a34a-4003-9742-a70b3b81d947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f8d59bb6-41ce-4e8f-8f8c-32ae504ce057" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_8f5184c6-a34a-4003-9742-a70b3b81d947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_87d0f49c-52db-4df8-892b-5711ff277e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_baf41ab8-9fba-479b-84e0-8c958de7be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87d0f49c-52db-4df8-892b-5711ff277e8f" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_baf41ab8-9fba-479b-84e0-8c958de7be7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_20f340b4-bdaf-45f0-b5a3-adc3a303a343" xlink:href="pfe-20221002.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_31968284-2fa3-4585-9c42-2feba037ec12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_20f340b4-bdaf-45f0-b5a3-adc3a303a343" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_31968284-2fa3-4585-9c42-2feba037ec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_698fc8a6-b43f-4167-b1b7-be667bdafee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b8be3cfc-091d-41bc-b123-81ce6cf8a56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_698fc8a6-b43f-4167-b1b7-be667bdafee6" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b8be3cfc-091d-41bc-b123-81ce6cf8a56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="simple" xlink:href="pfe-20221002.xsd#PensionandPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a55e0537-0345-49a2-90bc-e6bfe61cf130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_eb3a5cca-6a7c-4c06-b209-e1007237ca91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a55e0537-0345-49a2-90bc-e6bfe61cf130" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_eb3a5cca-6a7c-4c06-b209-e1007237ca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="simple" xlink:href="pfe-20221002.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd2cac33-ba94-4e15-a140-16539a245c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_84b702a9-f01c-449c-b7b8-8a30b0e71d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd2cac33-ba94-4e15-a140-16539a245c83" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_84b702a9-f01c-449c-b7b8-8a30b0e71d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="simple" xlink:href="pfe-20221002.xsd#ContingenciesandCertainCommitments"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1dcbf2f-578e-4f9d-9479-3ff6dedce8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_887c3637-d21a-4ed1-a8bc-794ede00cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c1dcbf2f-578e-4f9d-9479-3ff6dedce8b4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_887c3637-d21a-4ed1-a8bc-794ede00cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformation"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c9949f89-726b-405e-9da7-76adaa8154a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_8cee8a81-3f64-4cd8-9afe-a66833e63bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c9949f89-726b-405e-9da7-76adaa8154a1" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_8cee8a81-3f64-4cd8-9afe-a66833e63bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pfe-20221002.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_598fbd8b-b56c-4fbd-a010-442eb8102a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_97ba08c4-57bb-4d05-bd32-9be16e728b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_598fbd8b-b56c-4fbd-a010-442eb8102a03" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_97ba08c4-57bb-4d05-bd32-9be16e728b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aeb40eee-2a52-4814-bde7-01aa92d7de62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_598fbd8b-b56c-4fbd-a010-442eb8102a03" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aeb40eee-2a52-4814-bde7-01aa92d7de62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4912b5fc-fba5-405e-9f10-abc42dde486c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_598fbd8b-b56c-4fbd-a010-442eb8102a03" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4912b5fc-fba5-405e-9f10-abc42dde486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_137a263e-0b86-46dc-87e3-93d1cd71b436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_598fbd8b-b56c-4fbd-a010-442eb8102a03" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_137a263e-0b86-46dc-87e3-93d1cd71b436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_549e4a17-8a51-4e71-9d54-76f5cff74d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_eac05d71-ea03-4762-be39-272a1ae90ed5" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_549e4a17-8a51-4e71-9d54-76f5cff74d45" xlink:to="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_eac05d71-ea03-4762-be39-272a1ae90ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_4302e125-e26f-429d-bca1-c9f056f1bf8e" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_6614ca5b-73ca-4267-82d3-98fab450d244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_4302e125-e26f-429d-bca1-c9f056f1bf8e" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_6614ca5b-73ca-4267-82d3-98fab450d244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fe94cd4e-3353-4123-b696-bca7a3fe6d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_cfa737ee-1845-429d-acf4-d54ee66ed158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fe94cd4e-3353-4123-b696-bca7a3fe6d7e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_cfa737ee-1845-429d-acf4-d54ee66ed158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_a41be43b-56cc-44b5-84be-34624e58c032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fe94cd4e-3353-4123-b696-bca7a3fe6d7e" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_a41be43b-56cc-44b5-84be-34624e58c032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNetTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_2866d74a-93b3-42d5-9d8f-818990173bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_70dde0e2-3f6d-4e1e-9565-c2050ac55343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2866d74a-93b3-42d5-9d8f-818990173bf2" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_70dde0e2-3f6d-4e1e-9565-c2050ac55343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_ef44d6f6-e5a4-4e20-ad29-3a196e3a3df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2866d74a-93b3-42d5-9d8f-818990173bf2" xlink:to="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_ef44d6f6-e5a4-4e20-ad29-3a196e3a3df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#TaxMattersTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0e22526e-2ef1-440e-976c-fd2403b5d4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_ff4d1c03-68df-4c3c-b8fa-b0fd92139120" xlink:href="pfe-20221002.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0e22526e-2ef1-440e-976c-fd2403b5d4d0" xlink:to="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_ff4d1c03-68df-4c3c-b8fa-b0fd92139120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_38b419f1-c123-4334-a965-51c113818cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2c0626b5-9407-4e10-b0af-094db2230675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_38b419f1-c123-4334-a965-51c113818cd0" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2c0626b5-9407-4e10-b0af-094db2230675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d2b185c8-6cc8-4efd-b53c-4eebeadd34fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d2b185c8-6cc8-4efd-b53c-4eebeadd34fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_3b30ea83-7548-429e-b734-63e8d5e49479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_3b30ea83-7548-429e-b734-63e8d5e49479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_8c89ebfb-8d1a-4bfc-880e-7eeed6c69d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_8c89ebfb-8d1a-4bfc-880e-7eeed6c69d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_38fbbdcd-894f-4199-a6b8-6fe6b3db5f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_38fbbdcd-894f-4199-a6b8-6fe6b3db5f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_71f0e579-1a27-4998-a5c4-9bae3faac0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_71f0e579-1a27-4998-a5c4-9bae3faac0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_23aec722-8c57-4700-8692-b341489deb81" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_23aec722-8c57-4700-8692-b341489deb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_d97fe433-ec10-4eb4-b7d5-9ff515b760d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_d97fe433-ec10-4eb4-b7d5-9ff515b760d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_10991a65-6488-472b-85ff-f1dae8e62c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_10991a65-6488-472b-85ff-f1dae8e62c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_45443931-574c-44cd-b05b-dd9aa5b27ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_45443931-574c-44cd-b05b-dd9aa5b27ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_3c63cb12-6649-49ee-91e7-b81e6d0581b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_3c63cb12-6649-49ee-91e7-b81e6d0581b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_2d3e302a-4a5d-45df-ae7f-227433b72772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_2d3e302a-4a5d-45df-ae7f-227433b72772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1951374d-245b-49ee-827f-47a948a758ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1951374d-245b-49ee-827f-47a948a758ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c2f28bd3-d12e-4fa7-b9e3-1b8084f91e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_924813f7-5b2b-464c-b96d-79fe915d00cc" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c2f28bd3-d12e-4fa7-b9e3-1b8084f91e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_1d79c732-a42a-456c-a8ac-55a343814916" xlink:href="pfe-20221002.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bc4d3178-7677-4e7e-83eb-298b3c23c181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_1d79c732-a42a-456c-a8ac-55a343814916" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bc4d3178-7677-4e7e-83eb-298b3c23c181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_506c80ef-017e-409e-88b3-31c33558c35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_1d79c732-a42a-456c-a8ac-55a343814916" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_506c80ef-017e-409e-88b3-31c33558c35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81168385-656e-4cde-aac2-37340a7ea9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1e74fb0a-2095-4af8-a4bf-187e26a01137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81168385-656e-4cde-aac2-37340a7ea9bb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1e74fb0a-2095-4af8-a4bf-187e26a01137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_c1e8838f-1074-44ab-87f0-f289b06058be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81168385-656e-4cde-aac2-37340a7ea9bb" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_c1e8838f-1074-44ab-87f0-f289b06058be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e21dffe4-fdda-4ffc-9dac-4789a8c7a284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81168385-656e-4cde-aac2-37340a7ea9bb" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e21dffe4-fdda-4ffc-9dac-4789a8c7a284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#PensionandPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4260e7db-d77a-4cbb-a7a0-75c9c007d444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3a4138c5-064b-45cd-b897-bdee2766140c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4260e7db-d77a-4cbb-a7a0-75c9c007d444" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3a4138c5-064b-45cd-b897-bdee2766140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d1c803aa-12ea-475d-a767-da7a7e81346e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a0ebfa78-91f0-4453-92c2-0ebedbb68d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d1c803aa-12ea-475d-a767-da7a7e81346e" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a0ebfa78-91f0-4453-92c2-0ebedbb68d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6597faa0-0e77-478f-96ec-82ecdce3d6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a9279f6b-ce28-4fe2-8836-e8c3dd656e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6597faa0-0e77-478f-96ec-82ecdce3d6c5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a9279f6b-ce28-4fe2-8836-e8c3dd656e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_e944a91f-f7f4-4158-86a7-7a1fd41238c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6597faa0-0e77-478f-96ec-82ecdce3d6c5" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_e944a91f-f7f4-4158-86a7-7a1fd41238c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_5d684b9d-e058-48ca-87ef-421081b00212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6597faa0-0e77-478f-96ec-82ecdce3d6c5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_5d684b9d-e058-48ca-87ef-421081b00212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7b15e1a-8d7f-4b23-be96-669556b9095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_153700a4-f925-4599-a245-c2ca258cda9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7b15e1a-8d7f-4b23-be96-669556b9095f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_153700a4-f925-4599-a245-c2ca258cda9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf56afba-c1fc-41dc-bdb1-5a8fb82fe2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_00436c80-044c-4aac-8dc1-0b9a870ad964" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf56afba-c1fc-41dc-bdb1-5a8fb82fe2d3" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_00436c80-044c-4aac-8dc1-0b9a870ad964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_060ba8e7-b659-4c66-8491-f9f48a178549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_00436c80-044c-4aac-8dc1-0b9a870ad964" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_060ba8e7-b659-4c66-8491-f9f48a178549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_060ba8e7-b659-4c66-8491-f9f48a178549" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_878ac76b-e5fc-49af-98dc-1c534d05bda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:to="loc_us-gaap_AccountsReceivableMember_878ac76b-e5fc-49af-98dc-1c534d05bda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_071c7f7b-a5d5-401c-b2b5-c502440ee741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_071c7f7b-a5d5-401c-b2b5-c502440ee741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06fc5b84-db5a-4e41-a704-9da2ac11d5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63f33ce4-344a-4877-b21c-3daa8b44c31f" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06fc5b84-db5a-4e41-a704-9da2ac11d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_00436c80-044c-4aac-8dc1-0b9a870ad964" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_58027d1e-7fc2-4023-91cc-737f4bf8979c" xlink:href="pfe-20221002.xsd#pfe_RebatesAndDiscountsAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_58027d1e-7fc2-4023-91cc-737f4bf8979c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates_a57e75c9-bd84-4789-8b9b-980d4a25805b" xlink:href="pfe-20221002.xsd#pfe_AccruedRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:to="loc_pfe_AccruedRebates_a57e75c9-bd84-4789-8b9b-980d4a25805b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals_c7895ce7-caff-4991-8d4b-df3258a5fb35" xlink:href="pfe-20221002.xsd#pfe_OtherAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_926f4e9d-d8cf-4d04-a73f-d5873a72543e" xlink:to="loc_pfe_OtherAccruals_c7895ce7-caff-4991-8d4b-df3258a5fb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_fde8e0de-423d-43bf-aace-a025bed0ee18" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_fde8e0de-423d-43bf-aace-a025bed0ee18" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_200c4def-1376-4a66-b1c2-96886e2bf1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_AssetAcquisitionAxis_200c4def-1376-4a66-b1c2-96886e2bf1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8848ff1b-e498-49be-987d-03c236ad7c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_200c4def-1376-4a66-b1c2-96886e2bf1a7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8848ff1b-e498-49be-987d-03c236ad7c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReViralAssetAcquisitionMember_4bb556be-118a-4297-a179-f43b6a83c5d9" xlink:href="pfe-20221002.xsd#pfe_ReViralAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_8848ff1b-e498-49be-987d-03c236ad7c75" xlink:to="loc_pfe_ReViralAssetAcquisitionMember_4bb556be-118a-4297-a179-f43b6a83c5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4e846520-62dd-435d-be26-ee150ca87760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4e846520-62dd-435d-be26-ee150ca87760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ca0269-0033-4441-ab48-747b5035cde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e846520-62dd-435d-be26-ee150ca87760" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ca0269-0033-4441-ab48-747b5035cde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArenaMember_302776d6-df0f-4495-b08b-2e419232e3bc" xlink:href="pfe-20221002.xsd#pfe_ArenaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ca0269-0033-4441-ab48-747b5035cde1" xlink:to="loc_pfe_ArenaMember_302776d6-df0f-4495-b08b-2e419232e3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_884eafbe-9d10-4e72-b022-5d6419b91fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_884eafbe-9d10-4e72-b022-5d6419b91fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_884eafbe-9d10-4e72-b022-5d6419b91fe6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ee67c0e-8b77-43d8-9136-1294a94090fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ee67c0e-8b77-43d8-9136-1294a94090fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_fdf4d767-5d0f-4942-b9f7-34987b25790c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9b8bc615-f9a4-420b-8d40-2408f72ecfeb" xlink:to="loc_us-gaap_LicensingAgreementsMember_fdf4d767-5d0f-4942-b9f7-34987b25790c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_20364ebf-050d-4934-abff-f7bc977dd136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_20364ebf-050d-4934-abff-f7bc977dd136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_de571e68-b96a-4cba-80aa-473a8d8c5e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20364ebf-050d-4934-abff-f7bc977dd136" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_de571e68-b96a-4cba-80aa-473a8d8c5e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_39ed922c-cebc-4f77-b744-8f42741d140f" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_de571e68-b96a-4cba-80aa-473a8d8c5e44" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_39ed922c-cebc-4f77-b744-8f42741d140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b55e3d7-a66d-44e8-b43f-6821e09d3495" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bd33a6e6-7dbc-4be8-a0c8-b10f1cc282be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bd33a6e6-7dbc-4be8-a0c8-b10f1cc282be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_78fa3068-b755-4056-8787-1f1de35501dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_78fa3068-b755-4056-8787-1f1de35501dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments_3fe46141-814f-45a0-801c-10136d69c7e7" xlink:href="pfe-20221002.xsd#pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments_3fe46141-814f-45a0-801c-10136d69c7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_7cc6c5e0-ae7a-4c5c-a077-a2886d6475ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_7cc6c5e0-ae7a-4c5c-a077-a2886d6475ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_807ee97d-df88-4ac6-b3a4-3fd10454def4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_807ee97d-df88-4ac6-b3a4-3fd10454def4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4b26960a-5035-4fff-8a4f-62a43aaeb888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4b26960a-5035-4fff-8a4f-62a43aaeb888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1a59cb02-e071-4b42-bf6a-e0d4c53d1b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1a59cb02-e071-4b42-bf6a-e0d4c53d1b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_10464551-a017-4ee8-900b-d90d60ce104e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_10464551-a017-4ee8-900b-d90d60ce104e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_ab63a08c-2563-4a6e-80f1-e7c686fabbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_ab63a08c-2563-4a6e-80f1-e7c686fabbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b446d22a-6291-448b-9228-41f91358e060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b446d22a-6291-448b-9228-41f91358e060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a3faf595-4902-48ad-8858-8fcc7b2a159c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_Goodwill_a3faf595-4902-48ad-8858-8fcc7b2a159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b4d04ae4-3527-4178-8148-c9fca1c84de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e103f5e0-baa5-40b2-9897-bc625fbbc33d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b4d04ae4-3527-4178-8148-c9fca1c84de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_d1f7ee9c-f69c-4877-a910-0ecd707a9527" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_d1f7ee9c-f69c-4877-a910-0ecd707a9527" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_02aa8335-c950-4143-8bc2-d79feb8061a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_srt_CounterpartyNameAxis_02aa8335-c950-4143-8bc2-d79feb8061a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63e74972-7b84-4a8b-b84a-510c9c9ebf90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_02aa8335-c950-4143-8bc2-d79feb8061a4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63e74972-7b84-4a8b-b84a-510c9c9ebf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_84321a6f-d067-456f-9a40-0995485a6270" xlink:href="pfe-20221002.xsd#pfe_ViatrisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63e74972-7b84-4a8b-b84a-510c9c9ebf90" xlink:to="loc_pfe_ViatrisMember_84321a6f-d067-456f-9a40-0995485a6270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea773889-68d2-4c7e-90d3-4848b99cc663" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_srt_ProductOrServiceAxis_ea773889-68d2-4c7e-90d3-4848b99cc663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0d9d1d0-69ac-4c37-adcb-237177347fea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ea773889-68d2-4c7e-90d3-4848b99cc663" xlink:to="loc_srt_ProductsAndServicesDomain_e0d9d1d0-69ac-4c37-adcb-237177347fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_1a3bcf69-4a76-458d-9f77-126e540eb258" xlink:href="pfe-20221002.xsd#pfe_EpiPenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e0d9d1d0-69ac-4c37-adcb-237177347fea" xlink:to="loc_pfe_EpiPenMember_1a3bcf69-4a76-458d-9f77-126e540eb258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_eea3c541-69a6-4452-a3b0-71b7edaf288b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_eea3c541-69a6-4452-a3b0-71b7edaf288b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fc80069a-bec7-4935-8b47-98e7a6bd49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_eea3c541-69a6-4452-a3b0-71b7edaf288b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fc80069a-bec7-4935-8b47-98e7a6bd49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5459cd18-9dcc-4d3c-ae3d-4e3d1e9d0b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_fc80069a-bec7-4935-8b47-98e7a6bd49ce" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5459cd18-9dcc-4d3c-ae3d-4e3d1e9d0b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5140caf2-68ab-49b5-8531-3c065d76c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5140caf2-68ab-49b5-8531-3c065d76c68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_edb83efa-0f61-4616-af29-355d99700021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5140caf2-68ab-49b5-8531-3c065d76c68f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_edb83efa-0f61-4616-af29-355d99700021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_2b0fdad6-e94c-4c49-bb39-b76417af3347" xlink:href="pfe-20221002.xsd#pfe_MeridianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_edb83efa-0f61-4616-af29-355d99700021" xlink:to="loc_pfe_MeridianMember_2b0fdad6-e94c-4c49-bb39-b76417af3347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_09d4c17b-818b-44b2-b848-f579d9336219" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_314dba6a-a450-40fd-b60a-539de3261dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_314dba6a-a450-40fd-b60a-539de3261dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_eedd67eb-b71e-47f3-a78f-7e1b029ba674" xlink:href="pfe-20221002.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_eedd67eb-b71e-47f3-a78f-7e1b029ba674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_add87bc7-2843-4236-bc02-2354926b3f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_add87bc7-2843-4236-bc02-2354926b3f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_45aed36d-cf53-40ea-8486-e60efcefae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_629d5c04-ff2a-4bcc-8817-c6aaa27236f4" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_45aed36d-cf53-40ea-8486-e60efcefae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_df4d9261-1d3e-47f6-b3ab-03c7fbd2c74e" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_df4d9261-1d3e-47f6-b3ab-03c7fbd2c74e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9e2afaa2-3698-430f-9740-037ceeac5a3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_dei_LegalEntityAxis_9e2afaa2-3698-430f-9740-037ceeac5a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9e2afaa2-3698-430f-9740-037ceeac5a3c" xlink:to="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember_294248ca-0b52-43e0-85ed-73a86acfcdad" xlink:href="pfe-20221002.xsd#pfe_GSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:to="loc_pfe_GSKMember_294248ca-0b52-43e0-85ed-73a86acfcdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_418bf7e7-1f9f-40b8-bb89-e5760969b1d2" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_464a80c5-8697-4df2-82f6-2848cb34faf9" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_418bf7e7-1f9f-40b8-bb89-e5760969b1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_695040d0-ea1c-4356-b48f-ab2000255e07" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_695040d0-ea1c-4356-b48f-ab2000255e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c3edc5cf-dd89-49ac-89fa-3c46d9c9f80e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_695040d0-ea1c-4356-b48f-ab2000255e07" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c3edc5cf-dd89-49ac-89fa-3c46d9c9f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_f1f433e3-24ca-40cd-921b-a7d2b4ba05dd" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c3edc5cf-dd89-49ac-89fa-3c46d9c9f80e" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_f1f433e3-24ca-40cd-921b-a7d2b4ba05dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7f00816-d961-41cd-809a-df79219f47f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7f00816-d961-41cd-809a-df79219f47f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6badde5-7e59-47ad-8cec-a14999decbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7f00816-d961-41cd-809a-df79219f47f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6badde5-7e59-47ad-8cec-a14999decbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_f362785c-dd80-4383-8b62-ec6340d1fc49" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d6badde5-7e59-47ad-8cec-a14999decbeb" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_f362785c-dd80-4383-8b62-ec6340d1fc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6bef51ac-50c6-4c16-a128-36af2392d8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6bef51ac-50c6-4c16-a128-36af2392d8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cb292f09-56c1-4058-99be-a49eb70ce5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6bef51ac-50c6-4c16-a128-36af2392d8d7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cb292f09-56c1-4058-99be-a49eb70ce5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a3af4b8d-833c-402f-b17b-d939e0f8c460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cb292f09-56c1-4058-99be-a49eb70ce5a3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a3af4b8d-833c-402f-b17b-d939e0f8c460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_262d366d-8f43-4140-93bd-597ccaec2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_262d366d-8f43-4140-93bd-597ccaec2d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb6fda90-3f10-4676-986c-fbcf8798be6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_262d366d-8f43-4140-93bd-597ccaec2d11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb6fda90-3f10-4676-986c-fbcf8798be6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5e89ada2-6397-4ed7-81a6-fed824261128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb6fda90-3f10-4676-986c-fbcf8798be6b" xlink:to="loc_us-gaap_SeniorNotesMember_5e89ada2-6397-4ed7-81a6-fed824261128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1be3a022-452d-495d-b4b9-44ac5acc56af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_DebtInstrumentAxis_1be3a022-452d-495d-b4b9-44ac5acc56af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1be3a022-452d-495d-b4b9-44ac5acc56af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember_27e14f12-dc9e-4cd3-83aa-99a2d2d528c7" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember_27e14f12-dc9e-4cd3-83aa-99a2d2d528c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember_2ee7ed63-5a3b-44c0-84b3-21718880a788" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember_2ee7ed63-5a3b-44c0-84b3-21718880a788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember_ffbc5125-b58a-4d92-ac8a-58f200ea32b6" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember_ffbc5125-b58a-4d92-ac8a-58f200ea32b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_A1365ConsumerHealthcareJVLoanMember_4e34f232-60cc-41fb-8382-94a3ce1dafff" xlink:href="pfe-20221002.xsd#pfe_A1365ConsumerHealthcareJVLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac128406-6e7e-4c22-80f3-a31601026a6b" xlink:to="loc_pfe_A1365ConsumerHealthcareJVLoanMember_4e34f232-60cc-41fb-8382-94a3ce1dafff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7e7aec31-3d27-452e-9af8-311058237a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7e7aec31-3d27-452e-9af8-311058237a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6dee9d9e-493d-4ea2-94b3-95bcde4d80c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7e7aec31-3d27-452e-9af8-311058237a07" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6dee9d9e-493d-4ea2-94b3-95bcde4d80c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_f330427d-ec6d-402c-b563-05b86194316a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6dee9d9e-493d-4ea2-94b3-95bcde4d80c8" xlink:to="loc_us-gaap_LoansPayableMember_f330427d-ec6d-402c-b563-05b86194316a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cec63ab-da5c-4336-aba1-4738f3e4dc27" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dd8df06b-acd4-491b-aa85-2ce9879a9d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dd8df06b-acd4-491b-aa85-2ce9879a9d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_77fecdaf-c0a5-4f75-8fb4-ebb935b5b78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestments_77fecdaf-c0a5-4f75-8fb4-ebb935b5b78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_814b2bfc-c7a8-4f3e-ad8b-11f025c26923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_814b2bfc-c7a8-4f3e-ad8b-11f025c26923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal_6db9a3c3-443e-414e-bd9b-922ec64b7d65" xlink:href="pfe-20221002.xsd#pfe_ProceedsFromEquityMethodInvestmentDistributionTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal_6db9a3c3-443e-414e-bd9b-922ec64b7d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d91312ce-d560-4ec7-b38c-b60f699f561f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d91312ce-d560-4ec7-b38c-b60f699f561f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b7bf2c4d-eb55-4eac-9d3f-2d35a85ade1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b7bf2c4d-eb55-4eac-9d3f-2d35a85ade1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_ef92cbfb-481b-4604-bd3a-69368dadf6d6" xlink:href="pfe-20221002.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_ef92cbfb-481b-4604-bd3a-69368dadf6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6fbbcdb-cec5-4fbf-b866-bc1d03260705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6fbbcdb-cec5-4fbf-b866-bc1d03260705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences_3f77744f-101b-43bb-b9ca-2e3db85a155c" xlink:href="pfe-20221002.xsd#pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences_3f77744f-101b-43bb-b9ca-2e3db85a155c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal_ed489ac8-263a-42f0-adf6-38d200527e65" xlink:href="pfe-20221002.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal_ed489ac8-263a-42f0-adf6-38d200527e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5b18d8fd-8980-4c6a-967b-b62a8d8895d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5b18d8fd-8980-4c6a-967b-b62a8d8895d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_f25013da-2fda-4787-b936-adc65dfc9dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_OtherShortTermBorrowings_f25013da-2fda-4787-b936-adc65dfc9dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0f7662b0-258f-498a-8804-0b86b7505213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0f7662b0-258f-498a-8804-0b86b7505213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_88f49e3b-dd8e-4fe8-86cf-5c707f0bac39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_264d1d67-5a68-4eb8-940e-dca2ef878e29" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_88f49e3b-dd8e-4fe8-86cf-5c707f0bac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_1d086497-9717-451b-be47-d0e06472086f" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3ec99057-60fc-4144-91f6-b3fcd87b6677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_1d086497-9717-451b-be47-d0e06472086f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3ec99057-60fc-4144-91f6-b3fcd87b6677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_83112088-2cf2-4841-b558-c537a4b9f7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3ec99057-60fc-4144-91f6-b3fcd87b6677" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_83112088-2cf2-4841-b558-c537a4b9f7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c1b624b7-31ed-439d-9198-bef6bc8897a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_83112088-2cf2-4841-b558-c537a4b9f7f1" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c1b624b7-31ed-439d-9198-bef6bc8897a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVHaleonMember_de13f023-1701-48fd-b124-858d2f686c46" xlink:href="pfe-20221002.xsd#pfe_ConsumerHealthcareJVHaleonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c1b624b7-31ed-439d-9198-bef6bc8897a8" xlink:to="loc_pfe_ConsumerHealthcareJVHaleonMember_de13f023-1701-48fd-b124-858d2f686c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3ec99057-60fc-4144-91f6-b3fcd87b6677" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0a023a70-668c-41b8-b587-4ca8344190da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_Revenues_0a023a70-668c-41b8-b587-4ca8344190da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ad50e997-fd51-49d8-83f4-50babf2e9938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_CostOfRevenue_ad50e997-fd51-49d8-83f4-50babf2e9938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_991cf688-3929-41ac-b1d1-4d9705552b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_GrossProfit_991cf688-3929-41ac-b1d1-4d9705552b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f70407e3-c4e7-4dba-bebe-a492e43c714d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f70407e3-c4e7-4dba-bebe-a492e43c714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_20310ffa-e69b-4f99-b14b-2cb530536149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_ProfitLoss_20310ffa-e69b-4f99-b14b-2cb530536149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4bf2e37-0541-4e5a-853d-e5359fdbf771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7815a0c6-7d25-4565-bf54-a97ba5bd030a" xlink:to="loc_us-gaap_NetIncomeLoss_a4bf2e37-0541-4e5a-853d-e5359fdbf771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_d2701e28-bd9d-420b-a190-3f84998c5d7c" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_d2701e28-bd9d-420b-a190-3f84998c5d7c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_TypeOfArrangementAxis_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de15600-6fb6-4000-bd67-d2dd8ad24a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_96185a1f-31d7-4715-aa8d-8dbb2a92fdcc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de15600-6fb6-4000-bd67-d2dd8ad24a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_97d9ea4c-7687-472c-8e1a-a6487c1e8783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de15600-6fb6-4000-bd67-d2dd8ad24a8a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_97d9ea4c-7687-472c-8e1a-a6487c1e8783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9175efe2-0d2f-4e7c-b393-396e25370ecd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_srt_CounterpartyNameAxis_9175efe2-0d2f-4e7c-b393-396e25370ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_399af7ca-ab3a-4df2-bb16-ceffb2f59a4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9175efe2-0d2f-4e7c-b393-396e25370ecd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_399af7ca-ab3a-4df2-bb16-ceffb2f59a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiohavenMember_f8a4c7b4-e2db-48f0-8943-86653fd38f5d" xlink:href="pfe-20221002.xsd#pfe_BiohavenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_399af7ca-ab3a-4df2-bb16-ceffb2f59a4e" xlink:to="loc_pfe_BiohavenMember_f8a4c7b4-e2db-48f0-8943-86653fd38f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5c8ebecb-f304-45f1-a0f4-5b56bef83476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5c8ebecb-f304-45f1-a0f4-5b56bef83476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345a7309-256a-4f9d-830d-fadc1ac35dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c8ebecb-f304-45f1-a0f4-5b56bef83476" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345a7309-256a-4f9d-830d-fadc1ac35dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentInProcessMember_f4df8fc9-f2b1-4c4d-abe9-64cc0a28bb28" xlink:href="pfe-20221002.xsd#pfe_ResearchAndDevelopmentInProcessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345a7309-256a-4f9d-830d-fadc1ac35dac" xlink:to="loc_pfe_ResearchAndDevelopmentInProcessMember_f4df8fc9-f2b1-4c4d-abe9-64cc0a28bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c025d6d4-0783-4f9b-9b8d-c50d2ed6f3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4bfc9b35-7902-4e1a-a7ef-d4163bd205fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c025d6d4-0783-4f9b-9b8d-c50d2ed6f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiohavenMember_3dd9c931-da03-40c3-8ce6-33fab826d51b" xlink:href="pfe-20221002.xsd#pfe_BiohavenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c025d6d4-0783-4f9b-9b8d-c50d2ed6f3fc" xlink:to="loc_pfe_BiohavenMember_3dd9c931-da03-40c3-8ce6-33fab826d51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_054b80a1-00f7-4835-9b91-701149b9c334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_054b80a1-00f7-4835-9b91-701149b9c334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2058f860-8f17-4304-9cea-b680c4803746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_054b80a1-00f7-4835-9b91-701149b9c334" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2058f860-8f17-4304-9cea-b680c4803746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_33e2256d-5099-4e15-95d5-5c22beb83539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2058f860-8f17-4304-9cea-b680c4803746" xlink:to="loc_us-gaap_SubsequentEventMember_33e2256d-5099-4e15-95d5-5c22beb83539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fd67087-4b2c-469c-aad0-2c27b58e4957" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_c783d35f-c341-49e1-8cd7-cf42873410ee" xlink:href="pfe-20221002.xsd#pfe_PrepaymentsAndPaymentsToCollaboratorsCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_c783d35f-c341-49e1-8cd7-cf42873410ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPayment_d9e541d3-06e0-4c99-806a-a1c9e2c65226" xlink:href="pfe-20221002.xsd#pfe_PaymentsToCollaboratorsUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_PaymentsToCollaboratorsUpfrontPayment_d9e541d3-06e0-4c99-806a-a1c9e2c65226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_967106f2-0601-4a08-b007-371bfd215196" xlink:href="pfe-20221002.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_967106f2-0601-4a08-b007-371bfd215196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_49425f4c-761c-4ccb-83ac-d15b89b43b09" xlink:href="pfe-20221002.xsd#pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_49425f4c-761c-4ccb-83ac-d15b89b43b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_09384cab-1eb2-48c9-81b7-2c302f3d8e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_09384cab-1eb2-48c9-81b7-2c302f3d8e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5336da59-1b67-4e42-b103-29cca89e65d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c9c7866-73cf-427d-991d-b53bfe17c120" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5336da59-1b67-4e42-b103-29cca89e65d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2f1ed719-ecf6-45f6-883e-f4ac146f6f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2f1ed719-ecf6-45f6-883e-f4ac146f6f51" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f202fe77-d004-4680-8e08-34e591fbe54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f202fe77-d004-4680-8e08-34e591fbe54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f202fe77-d004-4680-8e08-34e591fbe54a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CorporateEnablingFunctionsMember_59db640d-3690-4684-b432-d8992ccd7582" xlink:href="pfe-20221002.xsd#pfe_CorporateEnablingFunctionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:to="loc_pfe_CorporateEnablingFunctionsMember_59db640d-3690-4684-b432-d8992ccd7582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GoToMarketModelMember_c9f942f7-fa16-4645-b197-5b3cae2ab7b9" xlink:href="pfe-20221002.xsd#pfe_GoToMarketModelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:to="loc_pfe_GoToMarketModelMember_c9f942f7-fa16-4645-b197-5b3cae2ab7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember_4b9e974b-abd7-4da2-88ae-d8f355510824" xlink:href="pfe-20221002.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab399492-48f5-497a-b02e-611d5665bfd3" xlink:to="loc_pfe_ManufacturingOptimizationMember_4b9e974b-abd7-4da2-88ae-d8f355510824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:to="loc_us-gaap_RestructuringPlanAxis_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9898d33a-d9ef-4758-9eaa-807d3871a541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_c3fa9e3d-c6f0-4714-86bf-054b5aa179c7" xlink:to="loc_us-gaap_RestructuringPlanDomain_9898d33a-d9ef-4758-9eaa-807d3871a541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember_e2461564-ccff-42c6-8183-3bdf7badafd7" xlink:href="pfe-20221002.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_9898d33a-d9ef-4758-9eaa-807d3871a541" xlink:to="loc_pfe_FocusedCompanyPlanMember_e2461564-ccff-42c6-8183-3bdf7badafd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_32c732b0-9a26-4480-8305-3f735ce3d773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_32c732b0-9a26-4480-8305-3f735ce3d773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8f1d4bea-cb81-45a3-97c5-0b56e6de4002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32c732b0-9a26-4480-8305-3f735ce3d773" xlink:to="loc_us-gaap_SegmentDomain_8f1d4bea-cb81-45a3-97c5-0b56e6de4002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_2f42d360-f0a9-4d87-985f-c3c58c3d51bb" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8f1d4bea-cb81-45a3-97c5-0b56e6de4002" xlink:to="loc_pfe_BiopharmaSegmentMember_2f42d360-f0a9-4d87-985f-c3c58c3d51bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_db391473-d69b-4a09-8cef-da0316dcfc71" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bdecb242-75f7-4364-977a-f934bd63b93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bdecb242-75f7-4364-977a-f934bd63b93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_cfc60307-79dc-4569-bf66-a282723fad28" xlink:href="pfe-20221002.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_cfc60307-79dc-4569-bf66-a282723fad28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_722f3a73-5cf5-4f96-b470-2b5bcce59cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_722f3a73-5cf5-4f96-b470-2b5bcce59cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesChargesIncurredToDate_c2486440-7e56-4a0a-8144-399c57a90464" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesChargesIncurredToDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_71b70bf7-22d3-4509-9179-19d7c366c764" xlink:to="loc_pfe_RestructuringChargesChargesIncurredToDate_c2486440-7e56-4a0a-8144-399c57a90464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e122ecae-2279-4a98-9012-4b2687bb1bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e122ecae-2279-4a98-9012-4b2687bb1bce" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6bfec93d-d468-4178-a7f1-c7646858ce59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6bfec93d-d468-4178-a7f1-c7646858ce59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6bfec93d-d468-4178-a7f1-c7646858ce59" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_60f8035f-2bc0-4e25-a7a8-629739e4a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_60f8035f-2bc0-4e25-a7a8-629739e4a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_16b30362-d8ac-49b5-9371-8d063aaa5152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_CostOfSalesMember_16b30362-d8ac-49b5-9371-8d063aaa5152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4fecb4c-2df8-46b9-93ea-71124a41fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d4fecb4c-2df8-46b9-93ea-71124a41fe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fbd840c-0db3-4438-bb54-616347961b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fbd840c-0db3-4438-bb54-616347961b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_a0f92fe5-8feb-4c25-b349-ed670842c2e7" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0e5d406-67c9-46f3-b93c-f1927fbb5976" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_a0f92fe5-8feb-4c25-b349-ed670842c2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dde9d232-f624-4408-87af-2d20510d52c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eaf5afdf-8d4f-44dc-b04d-75e4b6d6cce1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dde9d232-f624-4408-87af-2d20510d52c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArenaMember_d73bdad0-0cb6-4c7c-953c-54d1751772eb" xlink:href="pfe-20221002.xsd#pfe_ArenaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dde9d232-f624-4408-87af-2d20510d52c3" xlink:to="loc_pfe_ArenaMember_d73bdad0-0cb6-4c7c-953c-54d1751772eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_81a745bd-73a2-4a1d-ae09-f4915dba6b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_56a4eb70-7404-4e34-8ca2-5b9fd43d6e16" xlink:to="loc_us-gaap_SegmentDomain_81a745bd-73a2-4a1d-ae09-f4915dba6b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_fb20ab4b-2625-4ce3-af71-300ee2db68ab" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_81a745bd-73a2-4a1d-ae09-f4915dba6b66" xlink:to="loc_pfe_BiopharmaSegmentMember_fb20ab4b-2625-4ce3-af71-300ee2db68ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_616a04fe-1b70-4183-8031-f7cbe190f5cc" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_5dded54c-ebfd-4e6d-9923-da941c4a2142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_us-gaap_SeveranceCosts1_5dded54c-ebfd-4e6d-9923-da941c4a2142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_ee030d25-4dba-4385-9a01-f8051e27ccee" xlink:href="pfe-20221002.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_ee030d25-4dba-4385-9a01-f8051e27ccee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_ee175b01-819e-4b44-b54e-c07f5d7ba79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_us-gaap_BusinessExitCosts1_ee175b01-819e-4b44-b54e-c07f5d7ba79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1662339b-cf08-4502-8399-187fa26a31a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_18e87871-744a-4d11-b3b5-327a9d4296a8" xlink:to="loc_us-gaap_RestructuringCharges_1662339b-cf08-4502-8399-187fa26a31a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_c04b1167-ad0f-4f70-8d69-bd826ef22484" xlink:href="pfe-20221002.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_c04b1167-ad0f-4f70-8d69-bd826ef22484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_86ff3187-d736-4aea-94be-1ff808b1332b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_86ff3187-d736-4aea-94be-1ff808b1332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_f6358a75-455b-4bd4-ac74-9a71c86fb896" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_f6358a75-455b-4bd4-ac74-9a71c86fb896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_761d62fc-6d4d-420e-a292-a3821446d274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_761d62fc-6d4d-420e-a292-a3821446d274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_86576b06-7221-4dd2-8787-0287af40788e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_86576b06-7221-4dd2-8787-0287af40788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_e7a1c085-b29f-4d5b-bbfd-ea9f2c66c7a4" xlink:href="pfe-20221002.xsd#pfe_ImplementationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_ImplementationCosts_e7a1c085-b29f-4d5b-bbfd-ea9f2c66c7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e5f12d0d-0b69-4faf-b3fa-ef2677d81ddf" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e5f12d0d-0b69-4faf-b3fa-ef2677d81ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a7fc8cc2-c884-4903-8dbd-41e97821a9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_76d75c7f-e89c-4a8f-a528-81b41d6a30cb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a7fc8cc2-c884-4903-8dbd-41e97821a9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bc60582b-cc42-49ae-9141-94952945a178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bc60582b-cc42-49ae-9141-94952945a178" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_52973531-7cca-4050-a343-7840516642a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_52973531-7cca-4050-a343-7840516642a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_52973531-7cca-4050-a343-7840516642a3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_85a24395-03a4-48e3-bd85-508df55db26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:to="loc_us-gaap_EmployeeSeveranceMember_85a24395-03a4-48e3-bd85-508df55db26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember_5be01bf5-c41b-4109-874b-d15956eda6fc" xlink:href="pfe-20221002.xsd#pfe_AssetImpairmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:to="loc_pfe_AssetImpairmentsMember_5be01bf5-c41b-4109-874b-d15956eda6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_088ca55f-a154-44c0-98e2-0d7b54bcd6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e4f6ab0f-15b7-4199-b281-f92555b40191" xlink:to="loc_us-gaap_OtherRestructuringMember_088ca55f-a154-44c0-98e2-0d7b54bcd6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_028a5b94-ea13-40bd-a1a6-dbd0a82f4d60" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_a189060e-9f12-4f20-954a-f347a4bb53de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_a189060e-9f12-4f20-954a-f347a4bb53de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_79b0a3f7-6c2f-41cb-a44e-5d2ab3aaf8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07ca99ae-e0f8-40c8-92f5-8e08297f2fbd" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_79b0a3f7-6c2f-41cb-a44e-5d2ab3aaf8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8f5a4a10-63c3-4889-9b44-cea926418dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5505322-ef69-477f-9df9-a801f63f9b96" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8f5a4a10-63c3-4889-9b44-cea926418dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f5a4a10-63c3-4889-9b44-cea926418dd5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b2171229-cd49-4542-886a-fe6296cdd59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:to="loc_us-gaap_RestructuringReserve_b2171229-cd49-4542-886a-fe6296cdd59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bb2528a5-e90c-4cab-9ba9-cc71b646b37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:to="loc_us-gaap_RestructuringCharges_bb2528a5-e90c-4cab-9ba9-cc71b646b37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_3b5d0144-f03e-45c6-85d0-f7ad6edd9a70" xlink:href="pfe-20221002.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_3b5d0144-f03e-45c6-85d0-f7ad6edd9a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_215af3d4-dc5b-4f66-aa22-08f42f9f708d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c039a6df-05e8-4a55-91c8-e37932834a86" xlink:to="loc_us-gaap_RestructuringReserve_215af3d4-dc5b-4f66-aa22-08f42f9f708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e9ae075c-095d-483b-bd8c-eb413722be92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e9ae075c-095d-483b-bd8c-eb413722be92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fa0a73c6-af8c-4d4e-98bd-5ca7d835e909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_InterestExpense_fa0a73c6-af8c-4d4e-98bd-5ca7d835e909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_8aeab7e3-64e1-436f-998c-006af1719458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_8aeab7e3-64e1-436f-998c-006af1719458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_2b000b35-952c-4ff7-95ec-5842686769b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_2b000b35-952c-4ff7-95ec-5842686769b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_16c83005-daf1-453f-ba37-2d779859a78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_16c83005-daf1-453f-ba37-2d779859a78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_209aa617-04a4-4e10-806c-f58aace6b2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_209aa617-04a4-4e10-806c-f58aace6b2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_af0e8f01-c279-4093-8ab3-52cb561cf614" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_af0e8f01-c279-4093-8ab3-52cb561cf614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_2e711483-52f7-4af5-9976-5e4032b6c5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_2e711483-52f7-4af5-9976-5e4032b6c5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c4de353d-ca0e-4400-82d4-c97e9844c94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c4de353d-ca0e-4400-82d4-c97e9844c94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_de03b6b3-bce2-443f-8ce2-920b3004064f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_AssetImpairmentCharges_de03b6b3-bce2-443f-8ce2-920b3004064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_822fd193-3426-42d7-90eb-1e1abef78513" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_822fd193-3426-42d7-90eb-1e1abef78513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_923a83ef-e2d1-4a66-9d20-8e94035dd78e" xlink:href="pfe-20221002.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_923a83ef-e2d1-4a66-9d20-8e94035dd78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c6487fbe-45c5-42d8-af84-43b93ed81b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41a20893-f7bd-4c34-8e57-141d16418a30" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c6487fbe-45c5-42d8-af84-43b93ed81b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNetFootnotesDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_b6257891-0bdf-494c-9e23-9daef9e44274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b6257891-0bdf-494c-9e23-9daef9e44274" xlink:to="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_58043382-a653-4768-a80b-8f77ae7364a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_srt_CounterpartyNameAxis_58043382-a653-4768-a80b-8f77ae7364a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b10239ea-4f04-48d8-9aeb-8fdb7afc9c85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_58043382-a653-4768-a80b-8f77ae7364a8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b10239ea-4f04-48d8-9aeb-8fdb7afc9c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_5171b0ec-8b11-44e0-ad5e-f1890de4a0e3" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b10239ea-4f04-48d8-9aeb-8fdb7afc9c85" xlink:to="loc_pfe_BioNTechMember_5171b0ec-8b11-44e0-ad5e-f1890de4a0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c31aa3c1-4285-4520-b738-492607c335f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c31aa3c1-4285-4520-b738-492607c335f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0b98ad1-81e3-43a9-a63d-fae3f057ea79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c31aa3c1-4285-4520-b738-492607c335f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0b98ad1-81e3-43a9-a63d-fae3f057ea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3dcde481-4df4-42f5-967e-2b8fa8b230a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0b98ad1-81e3-43a9-a63d-fae3f057ea79" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3dcde481-4df4-42f5-967e-2b8fa8b230a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d999f69b-a970-4033-a261-8d84d91f694f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d999f69b-a970-4033-a261-8d84d91f694f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8a600918-661a-4312-a12f-06464646c932" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d999f69b-a970-4033-a261-8d84d91f694f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8a600918-661a-4312-a12f-06464646c932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_7369b66f-9aea-4860-8598-930840ce22a7" xlink:href="pfe-20221002.xsd#pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8a600918-661a-4312-a12f-06464646c932" xlink:to="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_7369b66f-9aea-4860-8598-930840ce22a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_7a0d7c89-9c34-48eb-bc4b-adf3d9164909" xlink:href="pfe-20221002.xsd#pfe_BioNTechAndCerevelTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember_7369b66f-9aea-4860-8598-930840ce22a7" xlink:to="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_7a0d7c89-9c34-48eb-bc4b-adf3d9164909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5ff7956-513c-41f8-a8d0-5505d91bc8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5ff7956-513c-41f8-a8d0-5505d91bc8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_572b1fca-bda2-4543-be87-c42f8f389bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5ff7956-513c-41f8-a8d0-5505d91bc8ed" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_572b1fca-bda2-4543-be87-c42f8f389bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_66edc932-75ca-4f60-ab0b-9573772c705c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_572b1fca-bda2-4543-be87-c42f8f389bc8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_66edc932-75ca-4f60-ab0b-9573772c705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8908ebf5-d0e5-4838-8615-c8e71729f144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8908ebf5-d0e5-4838-8615-c8e71729f144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b183b6b5-2240-4602-b47f-2c5b23612d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8908ebf5-d0e5-4838-8615-c8e71729f144" xlink:to="loc_us-gaap_SegmentDomain_b183b6b5-2240-4602-b47f-2c5b23612d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_105e127b-e3c3-4bf1-a739-405e37e46296" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b183b6b5-2240-4602-b47f-2c5b23612d28" xlink:to="loc_pfe_BiopharmaSegmentMember_105e127b-e3c3-4bf1-a739-405e37e46296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_197e3466-f505-4d91-82f4-b9b74962dccd" xlink:to="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5edf68bf-298b-4c77-85f0-31bc543101de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5edf68bf-298b-4c77-85f0-31bc543101de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_83a52641-ffab-4589-8067-82d1d53b633e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f9592a22-8bc4-4249-90e2-e8cc9508d5af" xlink:to="loc_us-gaap_ProceedsFromCollaborators_83a52641-ffab-4589-8067-82d1d53b633e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_a0299df0-9809-4792-a3f6-c3312ce25633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_a0299df0-9809-4792-a3f6-c3312ce25633" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76bf6a2b-69c9-465e-acaa-a34afe1c67c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fc3f10e8-fa9e-477b-8dc2-c1947dd46a17" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76bf6a2b-69c9-465e-acaa-a34afe1c67c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_684edf24-b530-4da3-82dc-d04180a4c981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76bf6a2b-69c9-465e-acaa-a34afe1c67c1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_684edf24-b530-4da3-82dc-d04180a4c981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e853746-8c04-436d-a557-cf12fcf2ee7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e853746-8c04-436d-a557-cf12fcf2ee7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e853746-8c04-436d-a557-cf12fcf2ee7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_423b77fe-e0a6-47cd-bb7e-1fe6b78063b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_423b77fe-e0a6-47cd-bb7e-1fe6b78063b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0edd7425-71f7-4121-b079-20949ef3c426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0edd7425-71f7-4121-b079-20949ef3c426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6c54022d-55f6-49a1-a938-ac44094220be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9853c031-07df-41b4-a276-2b5350c37798" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6c54022d-55f6-49a1-a938-ac44094220be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e836bb0-9d28-488b-bfaa-7253d795bad8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_7c9df42a-0887-4806-a6d1-8d7ef2e2ad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_7c9df42a-0887-4806-a6d1-8d7ef2e2ad2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7e400f4c-e388-4394-9e0c-93aab1ea4cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5ef947f2-d5d3-467c-a5a2-4c319b681ea9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7e400f4c-e388-4394-9e0c-93aab1ea4cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#TaxMattersNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6c0b467d-4f68-47e1-9f55-bf4047bf1847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_05930403-2502-40ee-823c-74d193c21254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c0b467d-4f68-47e1-9f55-bf4047bf1847" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_05930403-2502-40ee-823c-74d193c21254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_568d42cb-a99d-48e3-b697-0f6984d058f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c0b467d-4f68-47e1-9f55-bf4047bf1847" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_568d42cb-a99d-48e3-b697-0f6984d058f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0228d517-c7bf-43ac-a234-58807ac3549d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0228d517-c7bf-43ac-a234-58807ac3549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_c2f7b810-73e6-4094-9b09-c3a53684fb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_c2f7b810-73e6-4094-9b09-c3a53684fb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_bb361e09-197f-4211-9134-739499e92dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_bb361e09-197f-4211-9134-739499e92dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6ec02d66-5eb4-4a2f-97e0-3db988669d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_6ec02d66-5eb4-4a2f-97e0-3db988669d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96f66fea-bdfc-475d-898f-c147f71e1da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96f66fea-bdfc-475d-898f-c147f71e1da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_dfd8b454-43f6-4ec7-b7b9-45a51c373f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_dfd8b454-43f6-4ec7-b7b9-45a51c373f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_60fd08c1-e249-4497-8305-eadc75bc592e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_60fd08c1-e249-4497-8305-eadc75bc592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_10840a9e-0cf6-4d2e-be2b-a32764761edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_10840a9e-0cf6-4d2e-be2b-a32764761edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_4940515b-468d-4322-8528-66871843300a" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_4940515b-468d-4322-8528-66871843300a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_dc686cf3-84ec-4475-88c2-c8337c60b281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_dc686cf3-84ec-4475-88c2-c8337c60b281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_c8815a9d-a8f9-4e06-99bc-1f95107daad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce167920-074a-4e57-a15e-649ca6a3744e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_c8815a9d-a8f9-4e06-99bc-1f95107daad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b01e3730-d098-4cb8-ae26-05a910f52b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ad57d7f9-9a86-471d-ba13-af092c216548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b01e3730-d098-4cb8-ae26-05a910f52b97" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ad57d7f9-9a86-471d-ba13-af092c216548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e822e4d2-f20d-4b98-b225-5838b94fe478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ad57d7f9-9a86-471d-ba13-af092c216548" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e822e4d2-f20d-4b98-b225-5838b94fe478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_19f6823b-4ecf-4e05-8048-ff22eee07901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e822e4d2-f20d-4b98-b225-5838b94fe478" xlink:to="loc_us-gaap_EquityComponentDomain_19f6823b-4ecf-4e05-8048-ff22eee07901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_19f6823b-4ecf-4e05-8048-ff22eee07901" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3268d5fb-10c7-490f-8af9-b8782ee16bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_3268d5fb-10c7-490f-8af9-b8782ee16bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2b05c98f-d808-4abe-a4ac-a82ad66b036a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_2b05c98f-d808-4abe-a4ac-a82ad66b036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f2736ded-c755-4973-8dbe-df1af08dabe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f2736ded-c755-4973-8dbe-df1af08dabe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_72b2d912-8a06-46f4-a239-7f70587d4836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2de11d3d-3620-4116-9b62-365f83f6830b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_72b2d912-8a06-46f4-a239-7f70587d4836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f7869e56-37e1-4659-ba34-00fcde463d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ad57d7f9-9a86-471d-ba13-af092c216548" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f7869e56-37e1-4659-ba34-00fcde463d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f7869e56-37e1-4659-ba34-00fcde463d89" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0c81823-cb0e-439d-87fe-c3b2bcb82be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0c81823-cb0e-439d-87fe-c3b2bcb82be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a3bdfa95-f562-4469-ab3c-5965f1ef77c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a3bdfa95-f562-4469-ab3c-5965f1ef77c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e8ad1b5-9e71-49c4-9e18-48db7640953f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b92c3019-77e8-43dc-a6be-6c7b44061baf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e8ad1b5-9e71-49c4-9e18-48db7640953f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a963e1ab-1ce1-4065-aa43-6366bf6e465b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a963e1ab-1ce1-4065-aa43-6366bf6e465b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_19bbc9fc-f5d5-493e-9b45-cccdffc93fb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1527e7a2-cd6b-4137-949e-a555ed840ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1527e7a2-cd6b-4137-949e-a555ed840ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ba2eb530-cb80-40e2-b451-0d44690d58f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ba2eb530-cb80-40e2-b451-0d44690d58f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c9284909-f362-4759-94ec-bf141055e505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c9284909-f362-4759-94ec-bf141055e505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b1f24fa7-da87-41c8-aba5-7e239f4260f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c66fa1-64d6-4cf6-a1df-86a6f8219ea3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b1f24fa7-da87-41c8-aba5-7e239f4260f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fa02d89-65d3-4b34-881b-161a5b79b09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fa02d89-65d3-4b34-881b-161a5b79b09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fa02d89-65d3-4b34-881b-161a5b79b09e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c032a0e2-6ce3-40d6-b119-727541e38f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c032a0e2-6ce3-40d6-b119-727541e38f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e0ff4382-45b4-4fce-8220-6dce5c62aa23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0dd03c97-f801-4c83-bde2-57c3e48cb5c0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e0ff4382-45b4-4fce-8220-6dce5c62aa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b3dfbb60-a947-45fc-8426-03c7b1f90e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b3dfbb60-a947-45fc-8426-03c7b1f90e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b3dfbb60-a947-45fc-8426-03c7b1f90e42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_bec06e57-6991-4340-8736-6a76bb914694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_bec06e57-6991-4340-8736-6a76bb914694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_06726571-4775-4d25-83aa-ab565e59f6cb" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ed358fcc-5310-45c5-92a8-85eaaa242c71" xlink:to="loc_pfe_LongtermInvestmentsMember_06726571-4775-4d25-83aa-ab565e59f6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e899d9c-c086-45b1-8d13-5200d64c620c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e899d9c-c086-45b1-8d13-5200d64c620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_931c394b-aaba-4339-8b29-315a5158c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e899d9c-c086-45b1-8d13-5200d64c620c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_931c394b-aaba-4339-8b29-315a5158c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_79166231-1a08-49db-9d24-68d72a1ec5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_931c394b-aaba-4339-8b29-315a5158c3a7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_79166231-1a08-49db-9d24-68d72a1ec5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6c7b932b-1b6e-45ab-bd2d-d6d4a252c01d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_73f36402-216b-4beb-a7e2-807e92a9c72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:to="loc_us-gaap_InterestRateContractMember_73f36402-216b-4beb-a7e2-807e92a9c72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6cda2415-a191-438e-90ac-5ce38e059bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d2575174-270e-4a75-8921-0fdfe12fe245" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6cda2415-a191-438e-90ac-5ce38e059bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2516304-3b8d-40d3-9ace-8410972303d3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d083c2df-f0fc-4994-9b2f-87dde62eb4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d083c2df-f0fc-4994-9b2f-87dde62eb4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_480a7b9b-de6c-42cc-8e42-e566eb975ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_480a7b9b-de6c-42cc-8e42-e566eb975ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_2902889e-2531-4ace-b94c-ed2cfe50b9b9" xlink:href="pfe-20221002.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_2902889e-2531-4ace-b94c-ed2cfe50b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_6c6521f2-9b86-4b29-be03-78c74277b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_6c6521f2-9b86-4b29-be03-78c74277b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_84b2bf95-f25b-4919-98f5-e09957b79ad2" xlink:href="pfe-20221002.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_84b2bf95-f25b-4919-98f5-e09957b79ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_e2d676c2-d20f-42fe-94de-e4b07e04cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_e2d676c2-d20f-42fe-94de-e4b07e04cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_b1cefd22-437e-4e5a-a679-9abb6782e106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_b1cefd22-437e-4e5a-a679-9abb6782e106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6e55ae1f-fccd-49d2-813c-b7f9a14f3aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6e55ae1f-fccd-49d2-813c-b7f9a14f3aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_99627433-18e0-4ccc-a447-face7d7a67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_Assets_99627433-18e0-4ccc-a447-face7d7a67a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_e1f3cf4f-4909-479a-9ea1-6f90bd1bad16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_e1f3cf4f-4909-479a-9ea1-6f90bd1bad16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7918e33c-776c-412c-90c7-18fd238443bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7918e33c-776c-412c-90c7-18fd238443bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1d8eb720-b87e-4c11-b628-d118141cde79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_us-gaap_DerivativeLiabilities_1d8eb720-b87e-4c11-b628-d118141cde79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ef5199c3-fed6-44f4-bf17-436343168cc2" xlink:href="pfe-20221002.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a82ca0f3-d987-4679-9c23-d1c15eac8ce1" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ef5199c3-fed6-44f4-bf17-436343168cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_14027fea-ff11-40c5-9099-8c270c704e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14027fea-ff11-40c5-9099-8c270c704e7d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a0a86c8e-4691-4747-b42b-4441b6a9e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a0a86c8e-4691-4747-b42b-4441b6a9e13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_01c3b2fc-9501-425e-b706-a91686440de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a0a86c8e-4691-4747-b42b-4441b6a9e13c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_01c3b2fc-9501-425e-b706-a91686440de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_01c3b2fc-9501-425e-b706-a91686440de1" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0fdf28d6-f8e4-4439-8b63-cfba64177b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0fdf28d6-f8e4-4439-8b63-cfba64177b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1b2d2e23-cc3e-4db9-a214-58d0cb1ddce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e405cd89-589c-4349-aa48-520bfe51d8a5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1b2d2e23-cc3e-4db9-a214-58d0cb1ddce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_16f00967-01c9-48f7-9145-02ceecd535d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_16f00967-01c9-48f7-9145-02ceecd535d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71dfb173-fc79-4d95-acaf-455f1056bbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_16f00967-01c9-48f7-9145-02ceecd535d0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71dfb173-fc79-4d95-acaf-455f1056bbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7aa35bff-a7be-4c25-9882-75c6327e0bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71dfb173-fc79-4d95-acaf-455f1056bbd6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7aa35bff-a7be-4c25-9882-75c6327e0bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88fc348f-79b3-44c1-83dd-6debfccfde47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84bfa02e-2aec-4fc6-a647-56ee4372d11a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88fc348f-79b3-44c1-83dd-6debfccfde47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_cd932c54-01b9-446d-baea-0a7c00bcd424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88fc348f-79b3-44c1-83dd-6debfccfde47" xlink:to="loc_us-gaap_LongTermDebtFairValue_cd932c54-01b9-446d-baea-0a7c00bcd424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsInvestmentsbyClassificationTypeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e7ab93ae-eeca-493f-a7b5-912d78fca467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_da4736f6-a3ce-48b0-b0c1-51625da65654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e7ab93ae-eeca-493f-a7b5-912d78fca467" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_da4736f6-a3ce-48b0-b0c1-51625da65654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_79a366d8-f6d7-4cc2-a6a5-69605db593d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_da4736f6-a3ce-48b0-b0c1-51625da65654" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_79a366d8-f6d7-4cc2-a6a5-69605db593d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5861e506-844c-4d3e-ad40-d4d64287a58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_da4736f6-a3ce-48b0-b0c1-51625da65654" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5861e506-844c-4d3e-ad40-d4d64287a58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_7c0fe6b2-5f9b-4b4c-b01b-d02599aabd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_da4736f6-a3ce-48b0-b0c1-51625da65654" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_7c0fe6b2-5f9b-4b4c-b01b-d02599aabd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_41aa8ed1-bfca-4a39-a4ca-1cd25429a8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_da4736f6-a3ce-48b0-b0c1-51625da65654" xlink:to="loc_us-gaap_OtherShortTermInvestments_41aa8ed1-bfca-4a39-a4ca-1cd25429a8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_6326e935-1488-43a5-bd0d-0bcc910a394b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e7ab93ae-eeca-493f-a7b5-912d78fca467" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_6326e935-1488-43a5-bd0d-0bcc910a394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_da9313fc-5720-432e-9927-d55f5bb2ef42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_6326e935-1488-43a5-bd0d-0bcc910a394b" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_da9313fc-5720-432e-9927-d55f5bb2ef42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3b813f5b-fd2b-4ef5-9883-4895940e1ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_6326e935-1488-43a5-bd0d-0bcc910a394b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3b813f5b-fd2b-4ef5-9883-4895940e1ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_36f7784b-c3e2-4211-a486-7921deca8bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_6326e935-1488-43a5-bd0d-0bcc910a394b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_36f7784b-c3e2-4211-a486-7921deca8bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments_8071b908-5f02-4933-a39a-c80c682d08aa" xlink:href="pfe-20221002.xsd#pfe_PrivateEquityInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_6326e935-1488-43a5-bd0d-0bcc910a394b" xlink:to="loc_pfe_PrivateEquityInvestments_8071b908-5f02-4933-a39a-c80c682d08aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_867d6577-23a6-4130-bc70-d8570df34190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_6326e935-1488-43a5-bd0d-0bcc910a394b" xlink:to="loc_us-gaap_OtherLongTermInvestments_867d6577-23a6-4130-bc70-d8570df34190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_df9d95fa-9af2-4f6b-8f70-68436939d20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e7ab93ae-eeca-493f-a7b5-912d78fca467" xlink:to="loc_us-gaap_EquityMethodInvestments_df9d95fa-9af2-4f6b-8f70-68436939d20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_4d9d8d06-1794-43dd-a538-194c3148150e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e7ab93ae-eeca-493f-a7b5-912d78fca467" xlink:to="loc_us-gaap_LongTermInvestments_4d9d8d06-1794-43dd-a538-194c3148150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldToMaturityCashEquivalents_379e6c27-c839-4c93-bf50-a5e6301dca14" xlink:href="pfe-20221002.xsd#pfe_HeldToMaturityCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e7ab93ae-eeca-493f-a7b5-912d78fca467" xlink:to="loc_pfe_HeldToMaturityCashEquivalents_379e6c27-c839-4c93-bf50-a5e6301dca14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b4029244-a144-4cca-a3f0-d093dbb95c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_20588b2a-3455-4e13-aeeb-2f3d9721a112" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b4029244-a144-4cca-a3f0-d093dbb95c31" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_20588b2a-3455-4e13-aeeb-2f3d9721a112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fc3e73fb-3508-41c8-84e0-14b3b62e4713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_20588b2a-3455-4e13-aeeb-2f3d9721a112" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fc3e73fb-3508-41c8-84e0-14b3b62e4713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc3e73fb-3508-41c8-84e0-14b3b62e4713" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_4b5f05bf-ab47-4d22-8809-f1a966101cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_BankTimeDepositsMember_4b5f05bf-ab47-4d22-8809-f1a966101cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4ad44b6b-57cc-4784-8e53-0e5b93d9f707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4ad44b6b-57cc-4784-8e53-0e5b93d9f707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7e8c611-14aa-43df-8621-d0e988982f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c7e8c611-14aa-43df-8621-d0e988982f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3af7ad14-70f6-4be3-8e90-08b4f03ff0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_baf44a78-0f62-451a-822d-325d21562897" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3af7ad14-70f6-4be3-8e90-08b4f03ff0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:href="pfe-20221002.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_20588b2a-3455-4e13-aeeb-2f3d9721a112" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b49af2-ed93-42de-99c0-df01a91cdf33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b49af2-ed93-42de-99c0-df01a91cdf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_769e3db2-9313-48cb-847b-70303f878ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_769e3db2-9313-48cb-847b-70303f878ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34b21b3e-1ee9-4f72-a0dd-db0a265cb04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34b21b3e-1ee9-4f72-a0dd-db0a265cb04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0059c88-3516-40b7-8324-0d3bf672ebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_04c5fe2e-0093-4878-811c-bdfd250d1c14" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0059c88-3516-40b7-8324-0d3bf672ebdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_41b8dd70-6b2f-4b38-96f5-561ea6c18eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_41b8dd70-6b2f-4b38-96f5-561ea6c18eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2c5c20f2-a363-4f5b-a9c3-b70553f2fa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2c5c20f2-a363-4f5b-a9c3-b70553f2fa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_768fa056-884c-490d-9f8a-d7dc7d8a3241" xlink:href="pfe-20221002.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_768fa056-884c-490d-9f8a-d7dc7d8a3241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb3f28f0-6f81-43c3-9b28-7e26162d04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_97a0e526-e172-41c3-95a6-7810a67d1069" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb3f28f0-6f81-43c3-9b28-7e26162d04ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_45d13347-eff5-43a1-bf5c-49d554006e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecurities_45d13347-eff5-43a1-bf5c-49d554006e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7ea473ff-d918-438d-8e0a-8404ed4e796b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7ea473ff-d918-438d-8e0a-8404ed4e796b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0f5647b6-b08b-4c44-bfdb-b9a14649ea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0f5647b6-b08b-4c44-bfdb-b9a14649ea97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fa55a1eb-f65f-4ea7-a5dc-fd057551abdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_f7a27169-2688-4d54-b1af-e56fec35a895" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fa55a1eb-f65f-4ea7-a5dc-fd057551abdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_9e4e6545-dceb-4abf-87a9-47b012a99565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_9e4e6545-dceb-4abf-87a9-47b012a99565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e2100bae-f53c-41c1-b6b7-19d4f246c8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e2100bae-f53c-41c1-b6b7-19d4f246c8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_9f4b7ac3-337d-4f64-ad81-35cd8e34cb11" xlink:href="pfe-20221002.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_9f4b7ac3-337d-4f64-ad81-35cd8e34cb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_d2f13a79-6cd7-4b02-8434-ec3fbe929c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4960da42-6b82-477d-bd50-92ea87cc7b5a" xlink:to="loc_us-gaap_HeldToMaturitySecurities_d2f13a79-6cd7-4b02-8434-ec3fbe929c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_b1a61352-3af8-43c7-a12f-67510c55a81a" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_b1a61352-3af8-43c7-a12f-67510c55a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_1bb08260-ed00-4c75-bd8b-30548769c526" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_1bb08260-ed00-4c75-bd8b-30548769c526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_4c234cdc-3321-4c55-bf98-fb8ee3fe6d02" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_4c234cdc-3321-4c55-bf98-fb8ee3fe6d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_2c154b2d-6e95-42c6-9799-ecba5d70d552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_2c154b2d-6e95-42c6-9799-ecba5d70d552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_995ddfeb-cead-4fd7-a590-6af725c93f10" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_995ddfeb-cead-4fd7-a590-6af725c93f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_fc11fece-ee14-4453-8e54-7967973653ee" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_fc11fece-ee14-4453-8e54-7967973653ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_d5f56f14-1725-460f-8677-adbd4d06db98" xlink:href="pfe-20221002.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c61b993b-652b-41c8-a6ca-e8b8998a3d99" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_d5f56f14-1725-460f-8677-adbd4d06db98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b1dd07dd-c255-4ff7-b3df-79342dca03c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_caf012ab-3dab-4ccc-ae95-c1425d60b410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1dd07dd-c255-4ff7-b3df-79342dca03c5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_caf012ab-3dab-4ccc-ae95-c1425d60b410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_37c385fc-6131-4ad5-a1f7-4b1f3bb43c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1dd07dd-c255-4ff7-b3df-79342dca03c5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_37c385fc-6131-4ad5-a1f7-4b1f3bb43c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_847274a5-5407-4262-bbdb-9f80e783df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1dd07dd-c255-4ff7-b3df-79342dca03c5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_847274a5-5407-4262-bbdb-9f80e783df8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5e164d41-bb58-41af-a4f5-20f8b523b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_37a525a5-54fa-4f1b-b491-9af3f4a31cd8" xlink:href="pfe-20221002.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e164d41-bb58-41af-a4f5-20f8b523b24e" xlink:to="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_37a525a5-54fa-4f1b-b491-9af3f4a31cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_b2f77815-ea6b-45ef-883e-dbc48d7e7397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e164d41-bb58-41af-a4f5-20f8b523b24e" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_b2f77815-ea6b-45ef-883e-dbc48d7e7397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5b049f9f-4797-4428-975d-cb915d43f449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0d291157-5b8b-455e-9ae1-914bcbdb66c9" xlink:href="pfe-20221002.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5b049f9f-4797-4428-975d-cb915d43f449" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0d291157-5b8b-455e-9ae1-914bcbdb66c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_58e9393c-0847-4491-85c9-dd0b39436495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5b049f9f-4797-4428-975d-cb915d43f449" xlink:to="loc_us-gaap_OtherShortTermBorrowings_58e9393c-0847-4491-85c9-dd0b39436495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_a5cc24a6-153f-40d8-86d2-369543c7561a" xlink:href="pfe-20221002.xsd#pfe_ShorttermDebtGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5b049f9f-4797-4428-975d-cb915d43f449" xlink:to="loc_pfe_ShorttermDebtGross_a5cc24a6-153f-40d8-86d2-369543c7561a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_f2ab88a1-7a6d-45a4-a0de-7ab220d450d9" xlink:href="pfe-20221002.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5b049f9f-4797-4428-975d-cb915d43f449" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_f2ab88a1-7a6d-45a4-a0de-7ab220d450d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_72c5ad42-12d7-437d-8e20-4db24dfb0cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5b049f9f-4797-4428-975d-cb915d43f449" xlink:to="loc_us-gaap_DebtCurrent_72c5ad42-12d7-437d-8e20-4db24dfb0cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38495b52-713f-4b30-9036-944bfad06870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b9f1a319-b7a9-4064-90b8-b680bcf5c851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38495b52-713f-4b30-9036-944bfad06870" xlink:to="loc_us-gaap_DebtInstrumentTable_b9f1a319-b7a9-4064-90b8-b680bcf5c851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dc395dc8-3502-4a31-8a15-e1d8d6c1e231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b9f1a319-b7a9-4064-90b8-b680bcf5c851" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dc395dc8-3502-4a31-8a15-e1d8d6c1e231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8afd16bf-a8ed-4d4c-be08-914af1e5e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dc395dc8-3502-4a31-8a15-e1d8d6c1e231" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8afd16bf-a8ed-4d4c-be08-914af1e5e8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_41d9af8f-7c58-4f11-8162-c80b99354596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8afd16bf-a8ed-4d4c-be08-914af1e5e8cd" xlink:to="loc_us-gaap_UnsecuredDebtMember_41d9af8f-7c58-4f11-8162-c80b99354596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b9f1a319-b7a9-4064-90b8-b680bcf5c851" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_17c10bb7-0b43-46e8-9dbb-7d137904f0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_17c10bb7-0b43-46e8-9dbb-7d137904f0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_431897c0-8bc2-490b-8341-6d048bc1930f" xlink:href="pfe-20221002.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_431897c0-8bc2-490b-8341-6d048bc1930f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_da06737b-00cd-451e-bd59-46b97e493070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_da06737b-00cd-451e-bd59-46b97e493070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_6f628ed5-24f0-40bc-b144-6f0dd18935b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_OtherLongTermDebt_6f628ed5-24f0-40bc-b144-6f0dd18935b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_63d9a68a-7326-43f0-bf59-0c16dbd68d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9654f0f5-9058-4079-92f8-76f074f7a540" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_63d9a68a-7326-43f0-bf59-0c16dbd68d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsDerivativeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_844e9e9b-b8f8-44ae-9169-431cc3770e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f99b172f-9266-413b-83b4-a21c1a82527c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_844e9e9b-b8f8-44ae-9169-431cc3770e18" xlink:to="loc_us-gaap_DerivativeTable_f99b172f-9266-413b-83b4-a21c1a82527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ea032b07-69c9-427e-b06b-08e0911c4ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f99b172f-9266-413b-83b4-a21c1a82527c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ea032b07-69c9-427e-b06b-08e0911c4ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f52d0e25-5aca-4917-9ec1-5892fa90f080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea032b07-69c9-427e-b06b-08e0911c4ad6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f52d0e25-5aca-4917-9ec1-5892fa90f080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1216085d-7a96-409e-9c46-23745e428e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f52d0e25-5aca-4917-9ec1-5892fa90f080" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1216085d-7a96-409e-9c46-23745e428e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_57c08793-2afa-47c5-ab87-dde8cd3d2717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f99b172f-9266-413b-83b4-a21c1a82527c" xlink:to="loc_us-gaap_DerivativeLineItems_57c08793-2afa-47c5-ab87-dde8cd3d2717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_ffe6f745-e0c5-4e7e-8cd9-b1d2b77f5cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_57c08793-2afa-47c5-ab87-dde8cd3d2717" xlink:to="loc_us-gaap_DerivativeTermOfContract_ffe6f745-e0c5-4e7e-8cd9-b1d2b77f5cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_829bfe2e-c9ec-40c2-999f-1d4d0009a85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_829bfe2e-c9ec-40c2-999f-1d4d0009a85f" xlink:to="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis_db810cb5-77ba-42bf-bf02-252b8dc18d19" xlink:href="pfe-20221002.xsd#pfe_HedgedItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:to="loc_pfe_HedgedItemAxis_db810cb5-77ba-42bf-bf02-252b8dc18d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_1a93cbdb-ff26-4a84-a9ed-0feed5ce8e10" xlink:href="pfe-20221002.xsd#pfe_HedgedItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemAxis_db810cb5-77ba-42bf-bf02-252b8dc18d19" xlink:to="loc_pfe_HedgedItemDomain_1a93cbdb-ff26-4a84-a9ed-0feed5ce8e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_0daf868e-c109-45bb-8b64-b157ee9e70b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemDomain_1a93cbdb-ff26-4a84-a9ed-0feed5ce8e10" xlink:to="loc_us-gaap_SalesMember_0daf868e-c109-45bb-8b64-b157ee9e70b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_dfa46191-9a9b-4159-acff-499b1f2f461c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:to="loc_us-gaap_HedgingDesignationAxis_dfa46191-9a9b-4159-acff-499b1f2f461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_dfa46191-9a9b-4159-acff-499b1f2f461c" xlink:to="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_44e312cc-1a44-47d1-9f50-b3e8927e398a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_44e312cc-1a44-47d1-9f50-b3e8927e398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_71d1a43b-16d6-42b7-af20-2f4744174c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_fbf7d5d7-956c-4d3b-a29e-325bb5a8a17c" xlink:to="loc_us-gaap_NondesignatedMember_71d1a43b-16d6-42b7-af20-2f4744174c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1039615c-e127-4926-b1c1-f73ebc388dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1039615c-e127-4926-b1c1-f73ebc388dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1039615c-e127-4926-b1c1-f73ebc388dc7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d4522576-9dcf-4daf-a7d3-3c94d0c2ac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d4522576-9dcf-4daf-a7d3-3c94d0c2ac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_fcc8d5d7-e5bc-4356-838c-1b4450c1b933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_254a9804-4efe-4aff-83f2-918b6115814e" xlink:to="loc_us-gaap_InterestRateContractMember_fcc8d5d7-e5bc-4356-838c-1b4450c1b933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3ab4fae9-8e75-4d9a-b650-f4587e690e62" xlink:to="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_af7a8edf-23b9-43c2-b1da-1c2293b38363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_af7a8edf-23b9-43c2-b1da-1c2293b38363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_08e12a06-c614-4cba-b82c-af7e1066da06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:to="loc_us-gaap_DerivativeAssets_08e12a06-c614-4cba-b82c-af7e1066da06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c4776ec8-60e4-4412-b312-e44920761a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_57a039a6-d3d3-49ab-ac86-2173924030a0" xlink:to="loc_us-gaap_DerivativeLiabilities_c4776ec8-60e4-4412-b312-e44920761a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83384784-0295-402b-bab0-ba3b00bf7704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83384784-0295-402b-bab0-ba3b00bf7704" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c0cfe0ba-6ce5-4bdc-88a9-165daea296c5" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9e806258-dac6-43c3-9f2f-deeb5d60635f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:to="loc_us-gaap_CashFlowHedgingMember_9e806258-dac6-43c3-9f2f-deeb5d60635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_3e492ccf-b62b-4f53-990e-5f41e08160e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:to="loc_us-gaap_FairValueHedgingMember_3e492ccf-b62b-4f53-990e-5f41e08160e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_91700837-afa3-47f4-9aea-eb4602ece8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8344fe20-11b2-42fe-9571-49a8450f2c95" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_91700837-afa3-47f4-9aea-eb4602ece8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3e78bd48-fa93-4c56-bbe7-df95b7545192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_HedgingDesignationAxis_3e78bd48-fa93-4c56-bbe7-df95b7545192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_3e78bd48-fa93-4c56-bbe7-df95b7545192" xlink:to="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_59db1ea3-f09f-418d-b254-c91717f9c6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_59db1ea3-f09f-418d-b254-c91717f9c6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_37d3be3c-49a8-4a83-baec-fba482c7fdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_172b55c5-9037-4ed4-a694-ad8a7ad36fba" xlink:to="loc_us-gaap_NondesignatedMember_37d3be3c-49a8-4a83-baec-fba482c7fdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a5e395f-0d52-4a56-ab0d-d49cbe1eec77" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f3d95915-65fd-4981-ae12-0a94a3ef08a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f3d95915-65fd-4981-ae12-0a94a3ef08a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_8dcfc126-8a1b-4e59-acae-0ef1f3aab651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ba35a247-e9c0-4c32-a765-ef66873c8488" xlink:to="loc_us-gaap_InterestRateContractMember_8dcfc126-8a1b-4e59-acae-0ef1f3aab651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4b4a5c39-8199-4353-a2dd-61b4d612da37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4b4a5c39-8199-4353-a2dd-61b4d612da37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b4a5c39-8199-4353-a2dd-61b4d612da37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a00c4076-af15-4df3-a8e7-3fd056824747" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a00c4076-af15-4df3-a8e7-3fd056824747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_e599123a-2d09-4903-99b9-91bc177b8e09" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_419fea6b-a628-46ab-8c8f-44308d454de8" xlink:to="loc_pfe_ForeignCurrencyDebtMember_e599123a-2d09-4903-99b9-91bc177b8e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_edb4130c-f355-49bf-aab5-fdb4de43f691" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c5714b39-726a-41c8-b0b6-191d854d84b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c5714b39-726a-41c8-b0b6-191d854d84b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_94d1a151-3657-42b8-a852-f679103929b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_94d1a151-3657-42b8-a852-f679103929b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_32aeb2c6-2836-4a99-92eb-3fdb6456f0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_32aeb2c6-2836-4a99-92eb-3fdb6456f0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0af97d6f-95fe-49ec-a3ff-aedf23924f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0af97d6f-95fe-49ec-a3ff-aedf23924f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_feb896ab-a41e-44be-b983-136ce18c17b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_feb896ab-a41e-44be-b983-136ce18c17b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_53763dc6-ec92-43fe-b623-c91273f84223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_53763dc6-ec92-43fe-b623-c91273f84223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1db06676-6fd0-440e-b488-957529ae152f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1db06676-6fd0-440e-b488-957529ae152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_1449a599-371c-47a5-bfd1-b9907b39c3a0" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_1449a599-371c-47a5-bfd1-b9907b39c3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_66a0ddcc-ed7a-416d-8815-120a99428753" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_66a0ddcc-ed7a-416d-8815-120a99428753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_009c1de3-8860-4821-a69c-7f9bed70b477" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_009c1de3-8860-4821-a69c-7f9bed70b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ff9fb99-7582-4117-aa83-0670bb81516c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ff9fb99-7582-4117-aa83-0670bb81516c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_77bbbe6c-625b-4853-94a3-be98122d993e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_77bbbe6c-625b-4853-94a3-be98122d993e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_466ab040-9d34-4e09-9218-a7999b9d0e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_466ab040-9d34-4e09-9218-a7999b9d0e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_a0a80b89-d08f-4965-a5da-6aded8640e46" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_a0a80b89-d08f-4965-a5da-6aded8640e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_0d631493-ec7b-43d7-bd96-2ff30aadd4a4" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_0d631493-ec7b-43d7-bd96-2ff30aadd4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_77ca5236-c3d8-41a1-9ae3-4c65f8b38fce" xlink:href="pfe-20221002.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1e6e709a-e252-4c6d-87c3-bbc22322d139" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_77ca5236-c3d8-41a1-9ae3-4c65f8b38fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9bb09bd6-5e50-4a93-8721-76f7be800bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9bb09bd6-5e50-4a93-8721-76f7be800bda" xlink:to="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_660825cb-0865-4b1b-bf93-21b936d37a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:to="loc_us-gaap_HedgingDesignationAxis_660825cb-0865-4b1b-bf93-21b936d37a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7ecef292-c0ef-4443-a408-d8c89c4c84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_660825cb-0865-4b1b-bf93-21b936d37a6f" xlink:to="loc_us-gaap_HedgingDesignationDomain_7ecef292-c0ef-4443-a408-d8c89c4c84d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_57dfc767-daea-4d30-899c-f45194cc1c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7ecef292-c0ef-4443-a408-d8c89c4c84d2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_57dfc767-daea-4d30-899c-f45194cc1c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9adccb48-be86-42f5-81b9-d106835dc22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9adccb48-be86-42f5-81b9-d106835dc22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d73c8f9e-d05e-4a99-9d49-41dba9a960ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9adccb48-be86-42f5-81b9-d106835dc22e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d73c8f9e-d05e-4a99-9d49-41dba9a960ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ee990678-ea84-4be6-8075-0f97ffbe7986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d73c8f9e-d05e-4a99-9d49-41dba9a960ff" xlink:to="loc_us-gaap_CostOfSalesMember_ee990678-ea84-4be6-8075-0f97ffbe7986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_91a6cfb9-7aa7-43ab-9109-f5450dfc8903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_91a6cfb9-7aa7-43ab-9109-f5450dfc8903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_91a6cfb9-7aa7-43ab-9109-f5450dfc8903" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_77b4a91b-e234-4aec-8110-6c32882213e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_77b4a91b-e234-4aec-8110-6c32882213e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a3dfafa2-92a0-43d5-90d6-7c4ae0143080" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_a3dfafa2-92a0-43d5-90d6-7c4ae0143080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_ac9c63a9-9508-4d9e-b70d-627eebecf2fa" xlink:href="pfe-20221002.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_08ef3e5a-a049-4866-82f2-5ea53a29c23b" xlink:to="loc_pfe_ForeignCurrencyDebtMember_ac9c63a9-9508-4d9e-b70d-627eebecf2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f2a66016-2261-4a18-b108-3ed4c954a16b" xlink:to="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa58d57c-f376-4c05-8d45-2fdd0bc21247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa58d57c-f376-4c05-8d45-2fdd0bc21247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_c93b7a7b-d901-4a82-ac52-98b059353f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_c93b7a7b-d901-4a82-ac52-98b059353f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_9a601fe1-ac0a-4386-9c52-8312c1429746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_9a601fe1-ac0a-4386-9c52-8312c1429746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_40a65ee2-1fe7-4541-8fb3-6dcd01b69352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_DebtCurrent_40a65ee2-1fe7-4541-8fb3-6dcd01b69352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3249ba92-eb65-49b7-aad3-d3372bcb5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_821d6d15-f6e7-4b70-a0c7-b1eab8c5def7" xlink:to="loc_us-gaap_LongTermDebt_3249ba92-eb65-49b7-aad3-d3372bcb5b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0ca19d16-c9f8-43c0-8215-0ec2cf71ff0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0f3bc0dd-cff5-4896-9206-9b166c27165f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0ca19d16-c9f8-43c0-8215-0ec2cf71ff0a" xlink:to="loc_us-gaap_DerivativeTable_0f3bc0dd-cff5-4896-9206-9b166c27165f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a5bbf3e-1277-4c7a-8172-19503422cf67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0f3bc0dd-cff5-4896-9206-9b166c27165f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a5bbf3e-1277-4c7a-8172-19503422cf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a5bbf3e-1277-4c7a-8172-19503422cf67" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtMember_4cb56cdc-9190-455a-b121-abb7d40f4877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:to="loc_us-gaap_ShortTermDebtMember_4cb56cdc-9190-455a-b121-abb7d40f4877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_94bcf997-41d4-4a39-856c-dbc8722053c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75cb8df3-ba91-40a9-9983-8c89ec3a018a" xlink:to="loc_us-gaap_LongTermDebtMember_94bcf997-41d4-4a39-856c-dbc8722053c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0f3bc0dd-cff5-4896-9206-9b166c27165f" xlink:to="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_d599429d-0302-4c7b-a50b-3d805c24ca28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_d599429d-0302-4c7b-a50b-3d805c24ca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_92cd44dd-117a-458a-957c-32878db3dc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_92cd44dd-117a-458a-957c-32878db3dc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_07ec07a3-c39d-4aa9-acc2-7bce91aad8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0f7ac581-e2e5-4e3d-9812-064606ad1260" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_07ec07a3-c39d-4aa9-acc2-7bce91aad8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#FinancialInstrumentsCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_8c51669e-972e-4bb6-af8a-37835fca8a99" xlink:href="pfe-20221002.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_fd159194-badc-471f-b49c-9d9db7616ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8c51669e-972e-4bb6-af8a-37835fca8a99" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_fd159194-badc-471f-b49c-9d9db7616ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_581b6acf-39fe-4d9b-8ecc-93c2ff786f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8c51669e-972e-4bb6-af8a-37835fca8a99" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_581b6acf-39fe-4d9b-8ecc-93c2ff786f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue_8a2e36d1-a59d-4af7-8585-ae001eab63c1" xlink:href="pfe-20221002.xsd#pfe_DerivativeNetReceivablePositionAggregateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8c51669e-972e-4bb6-af8a-37835fca8a99" xlink:to="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue_8a2e36d1-a59d-4af7-8585-ae001eab63c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_b85e2ca6-8e35-4a44-be81-534f778cf77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8c51669e-972e-4bb6-af8a-37835fca8a99" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_b85e2ca6-8e35-4a44-be81-534f778cf77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_f7f45691-2f23-48c6-8b28-dce8af5afb21" xlink:href="pfe-20221002.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9f0f0faf-a20e-42eb-bbe2-ca1335fbca62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_f7f45691-2f23-48c6-8b28-dce8af5afb21" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9f0f0faf-a20e-42eb-bbe2-ca1335fbca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a46ddd8c-134e-4277-ba6c-857284528692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_f7f45691-2f23-48c6-8b28-dce8af5afb21" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a46ddd8c-134e-4277-ba6c-857284528692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c9d82b7c-30be-4a94-a0ae-0b161f1bf3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_f7f45691-2f23-48c6-8b28-dce8af5afb21" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c9d82b7c-30be-4a94-a0ae-0b161f1bf3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c072f396-0278-4a65-90f4-1c681b9b951b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_f7f45691-2f23-48c6-8b28-dce8af5afb21" xlink:to="loc_us-gaap_InventoryNet_c072f396-0278-4a65-90f4-1c681b9b951b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_90ff9d1a-4c1b-4d8e-9cc7-34d859a16dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_f7f45691-2f23-48c6-8b28-dce8af5afb21" xlink:to="loc_us-gaap_InventoryNoncurrent_90ff9d1a-4c1b-4d8e-9cc7-34d859a16dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_3d62d583-989e-4969-8113-db8f9a48f123" xlink:href="pfe-20221002.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_3d62d583-989e-4969-8113-db8f9a48f123" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:to="loc_srt_CounterpartyNameAxis_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_016fb548-4629-48f4-bcf7-d954c61d98a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ac9c661f-6e59-4e5b-b876-fe50f5c4a1c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_016fb548-4629-48f4-bcf7-d954c61d98a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_cced6bf3-ba80-48e6-ad9e-565655913df7" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_016fb548-4629-48f4-bcf7-d954c61d98a1" xlink:to="loc_pfe_BioNTechMember_cced6bf3-ba80-48e6-ad9e-565655913df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a02cfeca-54f5-4301-8175-97f40cb4a682" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:to="loc_srt_ProductOrServiceAxis_a02cfeca-54f5-4301-8175-97f40cb4a682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_835fe26b-ecbe-4c4c-b413-1f441623f0e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a02cfeca-54f5-4301-8175-97f40cb4a682" xlink:to="loc_srt_ProductsAndServicesDomain_835fe26b-ecbe-4c4c-b413-1f441623f0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_c59cc252-70c0-4372-91c6-b51e1faed006" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_835fe26b-ecbe-4c4c-b413-1f441623f0e6" xlink:to="loc_pfe_ComirnatyMember_c59cc252-70c0-4372-91c6-b51e1faed006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_80f645fd-d109-4aba-b7f3-d3ebc3d38cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:to="loc_us-gaap_TypeOfArrangementAxis_80f645fd-d109-4aba-b7f3-d3ebc3d38cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e611ec8-3682-41a8-b44b-01ca6ea8549a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80f645fd-d109-4aba-b7f3-d3ebc3d38cad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e611ec8-3682-41a8-b44b-01ca6ea8549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_783817f6-3ec6-4082-a886-31986632c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e611ec8-3682-41a8-b44b-01ca6ea8549a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_783817f6-3ec6-4082-a886-31986632c54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37fbe5f8-1835-4a81-9e55-36c4adcb1433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86168ccd-c990-42bc-89e5-10d7be55b490" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37fbe5f8-1835-4a81-9e55-36c4adcb1433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3ccc8bf7-3765-4d94-8aba-23f73327c054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37fbe5f8-1835-4a81-9e55-36c4adcb1433" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3ccc8bf7-3765-4d94-8aba-23f73327c054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fae15348-0361-4b4e-ae4b-74b7f8f8bebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fae15348-0361-4b4e-ae4b-74b7f8f8bebe" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524e1dc2-042c-4021-9d8e-d71f7f7cdc9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2cbf156e-474c-48e9-a7d9-4018a40faebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2cbf156e-474c-48e9-a7d9-4018a40faebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7852d51b-3741-4833-b473-9b0b4c6fb2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:to="loc_us-gaap_TradeNamesMember_7852d51b-3741-4833-b473-9b0b4c6fb2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_be835353-ce19-42c5-a674-eca44ef5330c" xlink:href="pfe-20221002.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_90c447e2-bade-46e0-ae37-e611d15b2a4e" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_be835353-ce19-42c5-a674-eca44ef5330c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a925a810-3687-4aa8-a7ce-b8e1fe8aac92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:to="loc_srt_CounterpartyNameAxis_a925a810-3687-4aa8-a7ce-b8e1fe8aac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c7feb77-b97a-4813-9c35-e655fc5487ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a925a810-3687-4aa8-a7ce-b8e1fe8aac92" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c7feb77-b97a-4813-9c35-e655fc5487ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_ca253661-d6f7-40af-b4ff-8527b5608b84" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c7feb77-b97a-4813-9c35-e655fc5487ca" xlink:to="loc_pfe_BioNTechMember_ca253661-d6f7-40af-b4ff-8527b5608b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9604a66c-90f4-4f14-9fe2-7dd516573017" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:to="loc_srt_ProductOrServiceAxis_9604a66c-90f4-4f14-9fe2-7dd516573017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4203d788-d627-4474-a01d-84249207d695" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9604a66c-90f4-4f14-9fe2-7dd516573017" xlink:to="loc_srt_ProductsAndServicesDomain_4203d788-d627-4474-a01d-84249207d695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_b1515c5c-4c69-4497-8b37-2fe693502294" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4203d788-d627-4474-a01d-84249207d695" xlink:to="loc_pfe_ComirnatyMember_b1515c5c-4c69-4497-8b37-2fe693502294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27ff488b-2145-4ee6-adb7-a29a2751a8f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7e2858de-fe41-442a-9128-9df1ebc37b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7e2858de-fe41-442a-9128-9df1ebc37b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_40fa7575-495d-4229-8076-29e7bd1e917d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_40fa7575-495d-4229-8076-29e7bd1e917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fae5a544-be5a-4501-b784-cece4df74343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_232cdd75-5233-4777-88c2-068da6cbee5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fae5a544-be5a-4501-b784-cece4df74343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fae15348-0361-4b4e-ae4b-74b7f8f8bebe" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_56d62423-b6da-49a3-a072-03412a277554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_56d62423-b6da-49a3-a072-03412a277554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_56d62423-b6da-49a3-a072-03412a277554" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_79842307-c7f8-43f1-b182-5cb2b18ad153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:to="loc_us-gaap_TradeNamesMember_79842307-c7f8-43f1-b182-5cb2b18ad153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e7200949-730e-490d-af0f-bdeb1c414e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e7200949-730e-490d-af0f-bdeb1c414e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_0f53c6bb-b0d3-4499-a9e8-4124f8e17660" xlink:href="pfe-20221002.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_229a179e-c903-4d9a-9f62-37ffceca0f33" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_0f53c6bb-b0d3-4499-a9e8-4124f8e17660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e97aab70-c892-4565-9295-3576d5ecfd40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e97aab70-c892-4565-9295-3576d5ecfd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3824f521-e3e1-4ae4-83bf-27e54098ceec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e97aab70-c892-4565-9295-3576d5ecfd40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3824f521-e3e1-4ae4-83bf-27e54098ceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArenaMember_85160075-bb12-4f79-9276-fb9b6a3342ab" xlink:href="pfe-20221002.xsd#pfe_ArenaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3824f521-e3e1-4ae4-83bf-27e54098ceec" xlink:to="loc_pfe_ArenaMember_85160075-bb12-4f79-9276-fb9b6a3342ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_850027aa-3dc5-4994-8338-5de031018d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e0bde656-0f2f-451d-8838-b81fe509c586" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_850027aa-3dc5-4994-8338-5de031018d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49c684cb-020b-4bd7-a3b5-5d5f26fb976f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_850027aa-3dc5-4994-8338-5de031018d82" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49c684cb-020b-4bd7-a3b5-5d5f26fb976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_310eaaef-1703-4b91-9ac9-1e43e824c5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fae15348-0361-4b4e-ae4b-74b7f8f8bebe" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_310eaaef-1703-4b91-9ac9-1e43e824c5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9deb77f9-c0bd-4880-b032-55ada71ca182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fae15348-0361-4b4e-ae4b-74b7f8f8bebe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9deb77f9-c0bd-4880-b032-55ada71ca182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1651c2e3-9544-4a9d-9aed-dbe7acd8ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fae15348-0361-4b4e-ae4b-74b7f8f8bebe" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1651c2e3-9544-4a9d-9aed-dbe7acd8ed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#IdentifiableIntangibleAssetsGoodwillDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69bbc036-c146-40e2-8309-7388e94b38c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b0a23670-f16c-45c9-a6a7-cb9dc5c99848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69bbc036-c146-40e2-8309-7388e94b38c5" xlink:to="loc_us-gaap_GoodwillRollForward_b0a23670-f16c-45c9-a6a7-cb9dc5c99848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9bcde7fe-2cd0-4eb7-a892-b5f73ec049bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b0a23670-f16c-45c9-a6a7-cb9dc5c99848" xlink:to="loc_us-gaap_Goodwill_9bcde7fe-2cd0-4eb7-a892-b5f73ec049bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8e529232-5e5b-4255-b774-9fd617cba7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b0a23670-f16c-45c9-a6a7-cb9dc5c99848" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8e529232-5e5b-4255-b774-9fd617cba7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5eaf3253-6a00-4291-bc24-bf780f7a3ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b0a23670-f16c-45c9-a6a7-cb9dc5c99848" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5eaf3253-6a00-4291-bc24-bf780f7a3ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c8e1a336-d3e5-4164-ad02-18f512761180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b0a23670-f16c-45c9-a6a7-cb9dc5c99848" xlink:to="loc_us-gaap_Goodwill_c8e1a336-d3e5-4164-ad02-18f512761180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_de1c86b1-2ba5-428b-a76c-50d95513ef86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_de1c86b1-2ba5-428b-a76c-50d95513ef86" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ec84657d-b396-45df-9d02-4162cb6cea84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ec84657d-b396-45df-9d02-4162cb6cea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ec84657d-b396-45df-9d02-4162cb6cea84" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_845265f7-8697-4a5d-b19b-c9d5c29b977e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_845265f7-8697-4a5d-b19b-c9d5c29b977e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6bd584c2-58ab-4dee-b9cd-5306831e631e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_48a47981-1957-4b4c-984c-6e2a21ce6743" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6bd584c2-58ab-4dee-b9cd-5306831e631e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_32df4b22-c75d-44a8-a52a-522f2f690119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_32df4b22-c75d-44a8-a52a-522f2f690119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_32df4b22-c75d-44a8-a52a-522f2f690119" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_7eee58bc-799e-4e1f-a372-1daed6219da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:to="loc_us-gaap_DomesticPlanMember_7eee58bc-799e-4e1f-a372-1daed6219da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70920f7a-73e2-418a-852e-4540f8662222" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_7eee58bc-799e-4e1f-a372-1daed6219da6" xlink:to="loc_country_US_70920f7a-73e2-418a-852e-4540f8662222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_015b5cd8-8b20-499f-9eeb-6548bbce0b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_62b357c6-badd-4104-9842-15346572f37c" xlink:to="loc_us-gaap_ForeignPlanMember_015b5cd8-8b20-499f-9eeb-6548bbce0b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b929e1ab-f0f1-4aa7-b0f7-a7c7bdd450f2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_902f2672-4809-4f6b-a3bf-5ad259dac462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_902f2672-4809-4f6b-a3bf-5ad259dac462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_150397e3-d689-48fc-a3f8-05bc83b0c3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_150397e3-d689-48fc-a3f8-05bc83b0c3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000194c9-df50-426f-a476-b18e57037434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000194c9-df50-426f-a476-b18e57037434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0cc42a7b-e70f-40e8-8cdb-b0f475344068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0cc42a7b-e70f-40e8-8cdb-b0f475344068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cc66f91f-f408-449b-b7bd-b3d759094108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cc66f91f-f408-449b-b7bd-b3d759094108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_1e43d95e-3cf6-46d1-8c9f-f29a7315c89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_1e43d95e-3cf6-46d1-8c9f-f29a7315c89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_5dc088e1-c06d-4e85-ad58-51fb63bf6511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_5dc088e1-c06d-4e85-ad58-51fb63bf6511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ccbde864-fb5b-4d3a-8a9b-dcf07aecec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9793d755-4909-45e8-bd68-d4ee27db569a" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ccbde864-fb5b-4d3a-8a9b-dcf07aecec0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#PensionandPostretirementBenefitPlansNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_766d79ac-31c0-4288-8278-d4a65cf3f641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_766d79ac-31c0-4288-8278-d4a65cf3f641" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bdea3971-a2b1-43d7-92c8-6cd9b92aac3e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_359e589b-aa20-4fc4-b81e-081c94cece04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_359e589b-aa20-4fc4-b81e-081c94cece04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e29597c-98b7-4012-a6ac-f30a1267781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_08414842-8efb-47b6-bee4-6703d088d19e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e29597c-98b7-4012-a6ac-f30a1267781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_2811b493-7d69-4e62-97f0-6a2282af07a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_2811b493-7d69-4e62-97f0-6a2282af07a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2811b493-7d69-4e62-97f0-6a2282af07a4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_8dc4fa9c-bf39-4504-846b-e13980821b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:to="loc_us-gaap_DomesticPlanMember_8dc4fa9c-bf39-4504-846b-e13980821b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ae7e2cb5-3b80-46a3-aeac-55d77d572d33" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_8dc4fa9c-bf39-4504-846b-e13980821b57" xlink:to="loc_country_US_ae7e2cb5-3b80-46a3-aeac-55d77d572d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ba51b883-3048-499b-8c18-d5c39d4bd5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_97ca3944-969f-4661-b073-c4f30bc79063" xlink:to="loc_us-gaap_ForeignPlanMember_ba51b883-3048-499b-8c18-d5c39d4bd5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbd6e6fe-a70a-4848-9d40-e46d46d74639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa1037b-44bc-41c7-8f92-30aed8ceaaa5" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbd6e6fe-a70a-4848-9d40-e46d46d74639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5674a21b-265d-4cbb-8745-489f5e5d7296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbd6e6fe-a70a-4848-9d40-e46d46d74639" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5674a21b-265d-4cbb-8745-489f5e5d7296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4f6b55f9-08a2-4756-a426-72ec0efda61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_c9679feb-5e08-42dc-8f66-b708e54251e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f6b55f9-08a2-4756-a426-72ec0efda61b" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_c9679feb-5e08-42dc-8f66-b708e54251e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_bc66d649-1084-4a3f-b93b-1a910686c440" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c9679feb-5e08-42dc-8f66-b708e54251e9" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_bc66d649-1084-4a3f-b93b-1a910686c440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ed84ee3b-aa01-49d5-95d5-7f72152debca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c9679feb-5e08-42dc-8f66-b708e54251e9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ed84ee3b-aa01-49d5-95d5-7f72152debca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_34338b90-93b7-408e-82c7-ffd1cf99e8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c9679feb-5e08-42dc-8f66-b708e54251e9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_34338b90-93b7-408e-82c7-ffd1cf99e8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_edbb7197-5c12-4d8b-8693-6d80dfa4db34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f6b55f9-08a2-4756-a426-72ec0efda61b" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_edbb7197-5c12-4d8b-8693-6d80dfa4db34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_d6ef0305-ad14-46fc-99d9-93bb3f541b06" xlink:href="pfe-20221002.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_edbb7197-5c12-4d8b-8693-6d80dfa4db34" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_d6ef0305-ad14-46fc-99d9-93bb3f541b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0de97ff6-87dd-499f-b50d-13e2637cbb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_edbb7197-5c12-4d8b-8693-6d80dfa4db34" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0de97ff6-87dd-499f-b50d-13e2637cbb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_01d1f265-44f5-4fde-9141-1b470b6d28ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_edbb7197-5c12-4d8b-8693-6d80dfa4db34" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_01d1f265-44f5-4fde-9141-1b470b6d28ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cfefd841-0a5b-460e-9bce-d8f41eef26f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f6b55f9-08a2-4756-a426-72ec0efda61b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cfefd841-0a5b-460e-9bce-d8f41eef26f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b01b1dd0-a794-45d0-87d0-df99ee52c658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cfefd841-0a5b-460e-9bce-d8f41eef26f8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b01b1dd0-a794-45d0-87d0-df99ee52c658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_88890be7-079e-4b46-80bd-444f0a8580b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cfefd841-0a5b-460e-9bce-d8f41eef26f8" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_88890be7-079e-4b46-80bd-444f0a8580b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d98896cc-ba3e-4d8f-8a9e-48804bf8abce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cfefd841-0a5b-460e-9bce-d8f41eef26f8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d98896cc-ba3e-4d8f-8a9e-48804bf8abce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d81c2a25-f644-458c-a7e3-8d46ac155854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cfefd841-0a5b-460e-9bce-d8f41eef26f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d81c2a25-f644-458c-a7e3-8d46ac155854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#ContingenciesandCertainCommitmentsPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ee64a4a4-682f-4786-9726-1d8f54dd6a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ee64a4a4-682f-4786-9726-1d8f54dd6a1b" xlink:to="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b0add50d-b0ca-412e-9857-4c172f4dea9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_srt_ProductOrServiceAxis_b0add50d-b0ca-412e-9857-4c172f4dea9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b0add50d-b0ca-412e-9857-4c172f4dea9f" xlink:to="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_a2dc1104-80a8-4867-94e0-40a5463a537c" xlink:href="pfe-20221002.xsd#pfe_MektoviMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:to="loc_pfe_MektoviMember_a2dc1104-80a8-4867-94e0-40a5463a537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_214e72cf-e7f9-47fe-b10b-0dc95ce8b042" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:to="loc_pfe_ComirnatyMember_214e72cf-e7f9-47fe-b10b-0dc95ce8b042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_a92161e2-d42b-4042-9c79-232c5dd87efe" xlink:href="pfe-20221002.xsd#pfe_EliquisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9c73b61b-46ff-46aa-8fb9-ca6b106b3940" xlink:to="loc_pfe_EliquisMember_a92161e2-d42b-4042-9c79-232c5dd87efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a2b94344-6154-4f8d-af5c-560ca167cb7a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_srt_LitigationCaseAxis_a2b94344-6154-4f8d-af5c-560ca167cb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a2b94344-6154-4f8d-af5c-560ca167cb7a" xlink:to="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndVersusSeveralGenericManufacturersMember_c4c9f6fd-9a09-4946-9c95-a46112739db4" xlink:href="pfe-20221002.xsd#pfe_PfizerAndVersusSeveralGenericManufacturersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_PfizerAndVersusSeveralGenericManufacturersMember_c4c9f6fd-9a09-4946-9c95-a46112739db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ModernaTXPatentInfringementCaseMember_f863396f-4266-4d01-9008-86c91592e322" xlink:href="pfe-20221002.xsd#pfe_ModernaTXPatentInfringementCaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_ModernaTXPatentInfringementCaseMember_f863396f-4266-4d01-9008-86c91592e322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_7865b7d6-6dbe-421f-b816-34f56323f25a" xlink:href="pfe-20221002.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_7865b7d6-6dbe-421f-b816-34f56323f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember_45a0bb12-9173-4e04-ae46-af25aa01a93c" xlink:href="pfe-20221002.xsd#pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8d58045a-f3bb-4ef0-8195-b5845090ce9f" xlink:to="loc_pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember_45a0bb12-9173-4e04-ae46-af25aa01a93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_99b791d6-6350-4a93-a4a2-e915b4aff9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_3614eb7f-d6d7-4eee-bc66-ef50dbaeb33f" xlink:to="loc_us-gaap_GainContingencyNatureDomain_99b791d6-6350-4a93-a4a2-e915b4aff9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_b9bc5850-4172-48e9-b574-459ee7dbee5e" xlink:href="pfe-20221002.xsd#pfe_PatentInfringementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_99b791d6-6350-4a93-a4a2-e915b4aff9a3" xlink:to="loc_pfe_PatentInfringementMember_b9bc5850-4172-48e9-b574-459ee7dbee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_26a106c9-9e12-4149-9904-d20850dce951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_us-gaap_LitigationStatusAxis_26a106c9-9e12-4149-9904-d20850dce951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3a8b8b3c-10d2-4004-a794-8dadcea9f974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_26a106c9-9e12-4149-9904-d20850dce951" xlink:to="loc_us-gaap_LitigationStatusDomain_3a8b8b3c-10d2-4004-a794-8dadcea9f974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f1774f4a-1d40-40d4-b91e-d5e735e9da3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3a8b8b3c-10d2-4004-a794-8dadcea9f974" xlink:to="loc_us-gaap_PendingLitigationMember_f1774f4a-1d40-40d4-b91e-d5e735e9da3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ExpirationPeriodAxis_a3a843cb-b233-4078-80a0-b141fc6f544b" xlink:href="pfe-20221002.xsd#pfe_ExpirationPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_pfe_ExpirationPeriodAxis_a3a843cb-b233-4078-80a0-b141fc6f544b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:href="pfe-20221002.xsd#pfe_ExpirationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ExpirationPeriodAxis_a3a843cb-b233-4078-80a0-b141fc6f544b" xlink:to="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_Expiring2030Member_baa7dd42-7502-4b0c-86ce-cd271dd24a63" xlink:href="pfe-20221002.xsd#pfe_Expiring2030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:to="loc_pfe_Expiring2030Member_baa7dd42-7502-4b0c-86ce-cd271dd24a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_Expiring2033Member_1d428e82-0c77-48e1-86b0-71696dbc38a3" xlink:href="pfe-20221002.xsd#pfe_Expiring2033Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ExpirationPeriodDomain_8694e2d4-7f23-41d8-bec2-3817f24e7bb1" xlink:to="loc_pfe_Expiring2033Member_1d428e82-0c77-48e1-86b0-71696dbc38a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d384e3ce-eb3a-4489-8973-14311ca462d5" xlink:to="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_2889e6ae-3011-4431-98c8-acad6202dea0" xlink:href="pfe-20221002.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_2889e6ae-3011-4431-98c8-acad6202dea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_c377787e-0574-417b-8507-e429cfd8b10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_c377787e-0574-417b-8507-e429cfd8b10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_d6786904-bb9e-43d2-9f4c-ca066d07f9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_d6786904-bb9e-43d2-9f4c-ca066d07f9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants_39f299eb-9bfa-467a-9b47-18cce091a380" xlink:href="pfe-20221002.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_pfe_GainContingencyNumberofDefendants_39f299eb-9bfa-467a-9b47-18cce091a380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_c2c2d5f0-a0f0-4baf-96d4-621b9c8c792c" xlink:href="pfe-20221002.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_c2c2d5f0-a0f0-4baf-96d4-621b9c8c792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsFoundNotInfringedNumber_e335a9dc-0935-478e-9688-5a8bd59018b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsFoundNotInfringedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_408b4189-787f-471c-a2f1-7be61ed284a5" xlink:to="loc_us-gaap_LossContingencyPatentsFoundNotInfringedNumber_e335a9dc-0935-478e-9688-5a8bd59018b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a034511-b154-43b9-b74a-3725b125cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a034511-b154-43b9-b74a-3725b125cb3c" xlink:to="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:to="loc_srt_LitigationCaseAxis_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f67f8dc2-d67b-4ef6-ae6b-e05306675214" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a5433ca9-cab4-4c3e-aebd-bc5d2f711aa5" xlink:to="loc_srt_LitigationCaseTypeDomain_f67f8dc2-d67b-4ef6-ae6b-e05306675214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_55734cb2-6682-45a7-8616-98723a70634b" xlink:href="pfe-20221002.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f67f8dc2-d67b-4ef6-ae6b-e05306675214" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_55734cb2-6682-45a7-8616-98723a70634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3fe7b80-cc11-49ac-884b-d3b171e258b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:to="loc_srt_ProductOrServiceAxis_a3fe7b80-cc11-49ac-884b-d3b171e258b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd291e67-e8f3-4525-b1fe-b4efa50422e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a3fe7b80-cc11-49ac-884b-d3b171e258b2" xlink:to="loc_srt_ProductsAndServicesDomain_dd291e67-e8f3-4525-b1fe-b4efa50422e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember_6e810d6f-a00a-43d3-adf5-e139fc978eec" xlink:href="pfe-20221002.xsd#pfe_DocetaxelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dd291e67-e8f3-4525-b1fe-b4efa50422e7" xlink:to="loc_pfe_DocetaxelMember_6e810d6f-a00a-43d3-adf5-e139fc978eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e709d891-34e3-4726-b311-00271444eaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:to="loc_us-gaap_LitigationStatusAxis_e709d891-34e3-4726-b311-00271444eaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_aad39a6a-a7a3-4958-aed1-8584e83805ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_e709d891-34e3-4726-b311-00271444eaf5" xlink:to="loc_us-gaap_LitigationStatusDomain_aad39a6a-a7a3-4958-aed1-8584e83805ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_08a758e8-f921-4213-bff4-0dd8aef51d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_aad39a6a-a7a3-4958-aed1-8584e83805ac" xlink:to="loc_us-gaap_PendingLitigationMember_08a758e8-f921-4213-bff4-0dd8aef51d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e876bf7d-2f03-439b-985a-fcfdbba5ca3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_67fffae6-0760-4653-b102-afcfb93a1be6" xlink:to="loc_us-gaap_LossContingenciesLineItems_e876bf7d-2f03-439b-985a-fcfdbba5ca3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_dd430df0-2c24-4656-8a53-72f51f659085" xlink:href="pfe-20221002.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e876bf7d-2f03-439b-985a-fcfdbba5ca3a" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_dd430df0-2c24-4656-8a53-72f51f659085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_920a24b5-d2a5-48f1-bfba-8a903c823d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_920a24b5-d2a5-48f1-bfba-8a903c823d8d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_ef0f81ef-50b4-4727-9835-1826ca9c5e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_ef0f81ef-50b4-4727-9835-1826ca9c5e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7e46595-58fa-403c-9a8b-f1a80adac20f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e345e990-5833-43ac-8ebf-9aaf45be18c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e345e990-5833-43ac-8ebf-9aaf45be18c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_2782a8ab-5f18-4f1d-8336-4b1aa9130135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3348f8f0-3748-4a82-b6ce-6178e6915e01" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_2782a8ab-5f18-4f1d-8336-4b1aa9130135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8db1110f-0751-448a-a3b8-1476fcbddd03" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a1f43332-d9b2-4788-925a-c0f76a5ba46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:to="loc_us-gaap_SalesRevenueNetMember_a1f43332-d9b2-4788-925a-c0f76a5ba46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_681549c6-12d4-4c8a-8aac-109c21af1c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ea3c0f6-61c6-4479-9b96-e219e34c78b6" xlink:to="loc_us-gaap_AccountsReceivableMember_681549c6-12d4-4c8a-8aac-109c21af1c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e2f72bc8-3e0b-4450-9983-90c669418da6" xlink:to="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_699d35b6-35ac-4448-9d3e-376c0f32723c" xlink:href="pfe-20221002.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d347ebbe-279b-4ef2-83ff-38a37c2055e3" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_699d35b6-35ac-4448-9d3e-376c0f32723c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c7d8fa2-5425-4a7b-8f90-a23401f85fc5" xlink:to="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:href="pfe-20221002.xsd#pfe_ComirnatyAndPaxlovidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af89ce2b-9ecb-4aa0-96ef-6ab0b04becff" xlink:to="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_e755b9f1-815b-45fe-9e8e-de6d10f6ef28" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:to="loc_pfe_ComirnatyMember_e755b9f1-815b-45fe-9e8e-de6d10f6ef28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_fd8d836c-4bd0-4934-839f-31bdbf105a62" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ComirnatyAndPaxlovidMember_bc8e1c61-9826-4e09-b789-86c088281de5" xlink:to="loc_pfe_PaxlovidMember_fd8d836c-4bd0-4934-839f-31bdbf105a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c567d667-6c31-4397-a711-e9b2aa53d87d" xlink:to="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_ad076227-b385-453c-aaeb-20562b6676d4" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d8945fb7-8dd0-4565-9d94-093d1c420a93" xlink:to="loc_pfe_BiopharmaSegmentMember_ad076227-b385-453c-aaeb-20562b6676d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cd9314d2-62f3-4b03-bfbc-02f5eaaef72a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cdf47fb5-a02a-4096-9dd4-745c375b4ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cdf47fb5-a02a-4096-9dd4-745c375b4ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_810ceaef-f5f2-4809-b40c-2556a2ad65ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_Assets_810ceaef-f5f2-4809-b40c-2556a2ad65ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9518f4b5-2e71-4e39-9501-a126dc2c967f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9518f4b5-2e71-4e39-9501-a126dc2c967f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ecb8a309-f161-4e67-b03d-b0bead9c19fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ecb8a309-f161-4e67-b03d-b0bead9c19fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c9c82b0-7431-4dd2-9a9c-ab3f0fa2cfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c9c82b0-7431-4dd2-9a9c-ab3f0fa2cfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7903dbc2-74fe-4c63-9173-89d47b63a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7903dbc2-74fe-4c63-9173-89d47b63a9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d75432e-7e7c-47b5-929f-3650a86aa634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d75432e-7e7c-47b5-929f-3650a86aa634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78bfd9b6-a72d-4e47-9e28-dfe8104377b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78bfd9b6-a72d-4e47-9e28-dfe8104377b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fbb6f7f9-cae1-4595-8281-2a66599908d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_57d06961-5bee-4f76-abb1-4b9eb371de97" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fbb6f7f9-cae1-4595-8281-2a66599908d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail_1"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1b030988-3567-436c-a438-031e4b832472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1b030988-3567-436c-a438-031e4b832472" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f9f38a60-5b6a-419f-9702-4b97c701ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f9f38a60-5b6a-419f-9702-4b97c701ab0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17105ec8-09e1-4bd9-90f4-7a1e8c9d2854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9f38a60-5b6a-419f-9702-4b97c701ab0c" xlink:to="loc_us-gaap_SegmentDomain_17105ec8-09e1-4bd9-90f4-7a1e8c9d2854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_f426f571-9c53-4031-b169-bd17b7ebec52" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_17105ec8-09e1-4bd9-90f4-7a1e8c9d2854" xlink:to="loc_pfe_BiopharmaSegmentMember_f426f571-9c53-4031-b169-bd17b7ebec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2d1117ca-e8f6-4aba-ba85-da09552896ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_ConsolidationItemsAxis_2d1117ca-e8f6-4aba-ba85-da09552896ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2d1117ca-e8f6-4aba-ba85-da09552896ba" xlink:to="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_38487693-61d4-49e2-a1ec-798a3930fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:to="loc_us-gaap_OperatingSegmentsMember_38487693-61d4-49e2-a1ec-798a3930fe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_997461f7-058d-4199-9612-b7db89c7cb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:to="loc_us-gaap_CorporateNonSegmentMember_997461f7-058d-4199-9612-b7db89c7cb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_e0fcbc8e-fb97-4aab-be71-6e892372caac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c8a0cf20-712f-411a-a820-fd03fdab51df" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_e0fcbc8e-fb97-4aab-be71-6e892372caac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_663ed30e-6553-4c84-8053-479c388bc526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_663ed30e-6553-4c84-8053-479c388bc526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_663ed30e-6553-4c84-8053-479c388bc526" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember_f6455fd5-e951-4afb-8438-f391e5401a2d" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:to="loc_pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember_f6455fd5-e951-4afb-8438-f391e5401a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_2a1c236e-ef7e-401d-9a39-422a3545d068" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsAcquisitionRelatedCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:to="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_2a1c236e-ef7e-401d-9a39-422a3545d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsOtherMember_c5df15cf-9cf1-4e3c-85e6-9ebed3703dd7" xlink:href="pfe-20221002.xsd#pfe_ReconcilingItemsOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_69f0b713-57b0-4336-8efc-262cab848f29" xlink:to="loc_pfe_ReconcilingItemsOtherMember_c5df15cf-9cf1-4e3c-85e6-9ebed3703dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c91a31a5-b869-48f4-90b0-c4b1f3cc5542" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c91a31a5-b869-48f4-90b0-c4b1f3cc5542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4d0d54fb-3631-439e-88ab-8e5f1dfe2c28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c91a31a5-b869-48f4-90b0-c4b1f3cc5542" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4d0d54fb-3631-439e-88ab-8e5f1dfe2c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_a6d67cea-d286-408b-ae64-ad6936032aca" xlink:href="pfe-20221002.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4d0d54fb-3631-439e-88ab-8e5f1dfe2c28" xlink:to="loc_pfe_ViivHealthcareLimitedMember_a6d67cea-d286-408b-ae64-ad6936032aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_b22c354b-7e5e-4f61-a783-6a2d4c1a50df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_RestatementAxis_b22c354b-7e5e-4f61-a783-6a2d4c1a50df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_0ad715c4-1881-42a1-ab16-43b2279bb7e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_b22c354b-7e5e-4f61-a783-6a2d4c1a50df" xlink:to="loc_srt_RestatementDomain_0ad715c4-1881-42a1-ab16-43b2279bb7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_ddfba69e-4e18-468f-a8da-3da85fa9de45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_0ad715c4-1881-42a1-ab16-43b2279bb7e3" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_ddfba69e-4e18-468f-a8da-3da85fa9de45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_16e5de45-b970-45f5-8101-555ab46c8ee7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_ProductOrServiceAxis_16e5de45-b970-45f5-8101-555ab46c8ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ee2beb65-36f0-4688-8ff3-530239cdc7d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_16e5de45-b970-45f5-8101-555ab46c8ee7" xlink:to="loc_srt_ProductsAndServicesDomain_ee2beb65-36f0-4688-8ff3-530239cdc7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_4af21de5-48ad-4e6e-9185-9f92b49c5a4d" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ee2beb65-36f0-4688-8ff3-530239cdc7d8" xlink:to="loc_pfe_PaxlovidMember_4af21de5-48ad-4e6e-9185-9f92b49c5a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_50f7caf5-ac1d-412e-bb1b-bf467b70b53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_50f7caf5-ac1d-412e-bb1b-bf467b70b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3fa3dc28-20a6-4979-99c8-6affd4069308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_50f7caf5-ac1d-412e-bb1b-bf467b70b53e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3fa3dc28-20a6-4979-99c8-6affd4069308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cc5cfe80-98f7-4516-be79-e713651da5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3fa3dc28-20a6-4979-99c8-6affd4069308" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cc5cfe80-98f7-4516-be79-e713651da5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_731865ad-3fc1-40e1-a2f3-5870d3357aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_731865ad-3fc1-40e1-a2f3-5870d3357aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_01a44274-1d44-4b3c-bc12-e619944eb6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_731865ad-3fc1-40e1-a2f3-5870d3357aaa" xlink:to="loc_us-gaap_AssetAcquisitionDomain_01a44274-1d44-4b3c-bc12-e619944eb6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReViralAssetAcquisitionMember_37ced281-21ba-45ea-ba51-32740839efc5" xlink:href="pfe-20221002.xsd#pfe_ReViralAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_01a44274-1d44-4b3c-bc12-e619944eb6d1" xlink:to="loc_pfe_ReViralAssetAcquisitionMember_37ced281-21ba-45ea-ba51-32740839efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1158e14f-90cf-47a7-8e8b-306dbed0d3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1158e14f-90cf-47a7-8e8b-306dbed0d3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb496004-222e-408f-92af-82753e8ca2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1158e14f-90cf-47a7-8e8b-306dbed0d3bc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb496004-222e-408f-92af-82753e8ca2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6d03a2e3-b0bd-42c1-954d-57a3a004dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb496004-222e-408f-92af-82753e8ca2a9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6d03a2e3-b0bd-42c1-954d-57a3a004dacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d0724328-5c5e-4408-899a-64aed63f3910" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_srt_CounterpartyNameAxis_d0724328-5c5e-4408-899a-64aed63f3910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87e71424-6ba3-49e2-84a7-68a1a9c72a6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d0724328-5c5e-4408-899a-64aed63f3910" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87e71424-6ba3-49e2-84a7-68a1a9c72a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember_3d1bed11-cc37-421c-b250-f8d7a5c506db" xlink:href="pfe-20221002.xsd#pfe_ArvinasIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87e71424-6ba3-49e2-84a7-68a1a9c72a6d" xlink:to="loc_pfe_ArvinasIncMember_3d1bed11-cc37-421c-b250-f8d7a5c506db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_04f4aa73-cd82-4f41-afc8-2b64d5fc15b8" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07606409-68cb-4e15-b7a8-53e5071289ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07606409-68cb-4e15-b7a8-53e5071289ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8825a0b0-8f9f-47f4-a3d9-a00be2fd806c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8825a0b0-8f9f-47f4-a3d9-a00be2fd806c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_bcfb4e34-d44c-40a4-9226-ffb6ffdb894e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_InvestmentIncomeDividend_bcfb4e34-d44c-40a4-9226-ffb6ffdb894e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_91d4d6fa-2218-4776-b907-5cad0ed54b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_OperatingExpenses_91d4d6fa-2218-4776-b907-5cad0ed54b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5053eef0-60c8-4b44-b3a5-e879537ae5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5053eef0-60c8-4b44-b3a5-e879537ae5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_bda62945-169d-40b0-b5a1-4fd5c42174f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostDirectMaterial"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_CostDirectMaterial_bda62945-169d-40b0-b5a1-4fd5c42174f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d1887f7c-31e9-4621-8ed8-feb93145c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_InventoryWriteDown_d1887f7c-31e9-4621-8ed8-feb93145c43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_980c426a-9b26-4c06-a0ef-cfeec81ec46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_980c426a-9b26-4c06-a0ef-cfeec81ec46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_43bf5982-7f6f-4ade-9fb6-4f49854e00bd" xlink:href="pfe-20221002.xsd#pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_43bf5982-7f6f-4ade-9fb6-4f49854e00bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_8a9ee8c3-5d83-49da-bf72-0ef71cdea3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_72146260-d36d-403e-ab30-e996a5127b7d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_8a9ee8c3-5d83-49da-bf72-0ef71cdea3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_412220c2-7bcd-4b0a-9421-716aa5ab1ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f77d7f4b-04ae-478f-a8b7-ae5bf2b1d169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_412220c2-7bcd-4b0a-9421-716aa5ab1ed3" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f77d7f4b-04ae-478f-a8b7-ae5bf2b1d169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5fdc859d-8ae7-4caa-9daa-4259543215f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f77d7f4b-04ae-478f-a8b7-ae5bf2b1d169" xlink:to="loc_srt_StatementGeographicalAxis_5fdc859d-8ae7-4caa-9daa-4259543215f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5fdc859d-8ae7-4caa-9daa-4259543215f2" xlink:to="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9c8a0c29-e167-4de2-8a64-73be6d04c4a4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_country_US_9c8a0c29-e167-4de2-8a64-73be6d04c4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_23fd8f35-4810-4914-814d-219d8216f712" xlink:href="pfe-20221002.xsd#pfe_DevelopedEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_pfe_DevelopedEuropeMember_23fd8f35-4810-4914-814d-219d8216f712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_a9d0e124-70ff-4b02-b561-67417737dbee" xlink:href="pfe-20221002.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_pfe_DevelopedRestOfWorldMember_a9d0e124-70ff-4b02-b561-67417737dbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_7e795422-1ed4-485b-b97e-5e8942873d97" xlink:href="pfe-20221002.xsd#pfe_EmergingMarketsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6f673a2a-914c-40f1-8ede-dea74a9d5b52" xlink:to="loc_pfe_EmergingMarketsMember_7e795422-1ed4-485b-b97e-5e8942873d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f77d7f4b-04ae-478f-a8b7-ae5bf2b1d169" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a63d9b1-9ff2-4632-ad49-23a4b248be89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a63d9b1-9ff2-4632-ad49-23a4b248be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PercentageChangeInRevenue_758221cb-5916-4379-8134-2feab2317458" xlink:href="pfe-20221002.xsd#pfe_PercentageChangeInRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a361497b-4522-407c-b6ab-4c2cbf4ec60e" xlink:to="loc_pfe_PercentageChangeInRevenue_758221cb-5916-4379-8134-2feab2317458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_71d68dd9-449f-402e-b010-7b6a573302ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_71d68dd9-449f-402e-b010-7b6a573302ae" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2944a1bc-7735-47da-8eba-68b935b5bb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:to="loc_us-gaap_ReportingUnitAxis_2944a1bc-7735-47da-8eba-68b935b5bb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2944a1bc-7735-47da-8eba-68b935b5bb27" xlink:to="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrimaryCareMember_f4a4a142-8b70-4f12-a901-e973bbc9174a" xlink:href="pfe-20221002.xsd#pfe_PrimaryCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:to="loc_pfe_PrimaryCareMember_f4a4a142-8b70-4f12-a901-e973bbc9174a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SpecialtyCareMember_3d5d8c52-1107-47f0-a3fd-2d5818df15ba" xlink:href="pfe-20221002.xsd#pfe_SpecialtyCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:to="loc_pfe_SpecialtyCareMember_3d5d8c52-1107-47f0-a3fd-2d5818df15ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember_f0cc7365-62a6-490f-a5d8-b0f571508721" xlink:href="pfe-20221002.xsd#pfe_OncologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_0b72bc51-7757-4b33-b836-7060cc05c1a5" xlink:to="loc_pfe_OncologyMember_f0cc7365-62a6-490f-a5d8-b0f571508721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b046126c-23cd-480f-b0a1-e772728c2150" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:to="loc_srt_ProductOrServiceAxis_b046126c-23cd-480f-b0a1-e772728c2150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b046126c-23cd-480f-b0a1-e772728c2150" xlink:to="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_ef8b983c-7935-4119-a56f-24bcba3760f4" xlink:href="pfe-20221002.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ComirnatyMember_ef8b983c-7935-4119-a56f-24bcba3760f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_eb51945f-2b57-4018-ac09-8564edddbdd4" xlink:href="pfe-20221002.xsd#pfe_PaxlovidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_PaxlovidMember_eb51945f-2b57-4018-ac09-8564edddbdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_a13feda1-a1bb-45fa-83d6-09ff2ef62b12" xlink:href="pfe-20221002.xsd#pfe_EliquisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_EliquisMember_a13feda1-a1bb-45fa-83d6-09ff2ef62b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_45045ddb-97f6-4b2d-8c2a-722174cf870c" xlink:href="pfe-20221002.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_45045ddb-97f6-4b2d-8c2a-722174cf870c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember_66bb7527-b3b7-4acd-b86d-8201786adcb5" xlink:href="pfe-20221002.xsd#pfe_PremarinFamilyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_PremarinFamilyMember_66bb7527-b3b7-4acd-b86d-8201786adcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember_595711ec-21d9-40f2-af17-378779853443" xlink:href="pfe-20221002.xsd#pfe_NimenrixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_NimenrixMember_595711ec-21d9-40f2-af17-378779853443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BMP2Member_73656fd2-cc95-4c28-99ce-57d24b960fd5" xlink:href="pfe-20221002.xsd#pfe_BMP2Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BMP2Member_73656fd2-cc95-4c28-99ce-57d24b960fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_130c85b3-01e6-43ec-8451-417961aaa1af" xlink:href="pfe-20221002.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_130c85b3-01e6-43ec-8451-417961aaa1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember_3d4ffcd5-dcd7-4682-aad6-490e753647ee" xlink:href="pfe-20221002.xsd#pfe_ToviazMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ToviazMember_3d4ffcd5-dcd7-4682-aad6-490e753647ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrumenbaMember_9df8a79b-2b91-43dc-9b16-6e3c60ef4778" xlink:href="pfe-20221002.xsd#pfe_TrumenbaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_TrumenbaMember_9df8a79b-2b91-43dc-9b16-6e3c60ef4778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember_406706f6-b725-4996-8c76-b6cee0ebaaa4" xlink:href="pfe-20221002.xsd#pfe_ChantixChampixMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ChantixChampixMember_406706f6-b725-4996-8c76-b6cee0ebaaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPrimaryCareProductsMember_ceb6ec21-bce6-4ba5-b217-6be9afb9b62e" xlink:href="pfe-20221002.xsd#pfe_OtherPrimaryCareProductsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherPrimaryCareProductsMember_ceb6ec21-bce6-4ba5-b217-6be9afb9b62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember_829f5d52-37ac-4756-a2fd-21ad7f1d726e" xlink:href="pfe-20221002.xsd#pfe_VyndaqelMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_VyndaqelMember_829f5d52-37ac-4756-a2fd-21ad7f1d726e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_4eba3998-85ff-431b-a1c9-85d6109227f9" xlink:href="pfe-20221002.xsd#pfe_XeljanzMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_XeljanzMember_4eba3998-85ff-431b-a1c9-85d6109227f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember_8323772e-0c7c-4d60-88ae-f5d4acab114e" xlink:href="pfe-20221002.xsd#pfe_EnbrelMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_EnbrelMember_8323772e-0c7c-4d60-88ae-f5d4acab114e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember_1e2a268b-86a4-47d1-bd3d-3de6d1ad28e6" xlink:href="pfe-20221002.xsd#pfe_SulperazonMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_SulperazonMember_1e2a268b-86a4-47d1-bd3d-3de6d1ad28e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraMember_1f93b248-9ac3-421a-a9fd-c99666b9000a" xlink:href="pfe-20221002.xsd#pfe_InflectraMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_InflectraMember_1f93b248-9ac3-421a-a9fd-c99666b9000a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IgPortfolioProductsMember_47cddb08-4f4d-4a40-8257-c874c6262af1" xlink:href="pfe-20221002.xsd#pfe_IgPortfolioProductsMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_IgPortfolioProductsMember_47cddb08-4f4d-4a40-8257-c874c6262af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember_fa551ba9-25ac-49dc-93da-031e55816db7" xlink:href="pfe-20221002.xsd#pfe_BeneFIXMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BeneFIXMember_fa551ba9-25ac-49dc-93da-031e55816db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember_7599f1db-9d9d-48b3-adfe-52be401a5827" xlink:href="pfe-20221002.xsd#pfe_ZaviceftaMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ZaviceftaMember_7599f1db-9d9d-48b3-adfe-52be401a5827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember_a6562d80-73c6-4bfa-9292-7cd961035bf9" xlink:href="pfe-20221002.xsd#pfe_GenotropinMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_GenotropinMember_a6562d80-73c6-4bfa-9292-7cd961035bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember_c5982290-b005-47ad-94a5-432b3d59bd28" xlink:href="pfe-20221002.xsd#pfe_ZithromaxZmaxMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ZithromaxZmaxMember_c5982290-b005-47ad-94a5-432b3d59bd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember_eea2a7d9-e38f-4405-9ab9-39b94aa9e322" xlink:href="pfe-20221002.xsd#pfe_MedrolMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_MedrolMember_eea2a7d9-e38f-4405-9ab9-39b94aa9e322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember_96f78452-2eb0-418b-afa8-34908bab5e03" xlink:href="pfe-20221002.xsd#pfe_FragminMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_FragminMember_96f78452-2eb0-418b-afa8-34908bab5e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember_f3ed3b9e-f415-400b-860d-f0d15cfefc96" xlink:href="pfe-20221002.xsd#pfe_SomavertMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_SomavertMember_f3ed3b9e-f415-400b-860d-f0d15cfefc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember_a71953e2-e028-488f-a43f-686cb640dcaa" xlink:href="pfe-20221002.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ReFactoAfXynthaMember_a71953e2-e028-488f-a43f-686cb640dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember_e0bf9cdb-636d-426f-8836-e05b42d40f6d" xlink:href="pfe-20221002.xsd#pfe_VfendMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_VfendMember_e0bf9cdb-636d-426f-8836-e05b42d40f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember_83dfead3-1091-47cf-a7dd-2efd28b559ce" xlink:href="pfe-20221002.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherAntiinfectivesMember_83dfead3-1091-47cf-a7dd-2efd28b559ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherSpecialtyCareMember_faef3ad4-981b-4ea3-9ad8-bcc9d6c626d1" xlink:href="pfe-20221002.xsd#pfe_OtherSpecialtyCareMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherSpecialtyCareMember_faef3ad4-981b-4ea3-9ad8-bcc9d6c626d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember_1f1f34f9-9d44-4142-8280-a79589b5a682" xlink:href="pfe-20221002.xsd#pfe_IbranceMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_IbranceMember_1f1f34f9-9d44-4142-8280-a79589b5a682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_5745e7af-7f25-422a-930f-ba9a72e1baeb" xlink:href="pfe-20221002.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_5745e7af-7f25-422a-930f-ba9a72e1baeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember_fa249bf1-e79b-49f0-aa57-99d4c859072d" xlink:href="pfe-20221002.xsd#pfe_InlytaMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_InlytaMember_fa249bf1-e79b-49f0-aa57-99d4c859072d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember_4f0bff6f-53bd-4e8c-a64e-f1694b49d096" xlink:href="pfe-20221002.xsd#pfe_ZirabevMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_ZirabevMember_4f0bff6f-53bd-4e8c-a64e-f1694b49d096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember_5045427d-674d-49ae-92bd-ab2431f91060" xlink:href="pfe-20221002.xsd#pfe_BosulifMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BosulifMember_5045427d-674d-49ae-92bd-ab2431f91060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember_69b9ded8-f63c-43b8-a666-50d9ab5e52be" xlink:href="pfe-20221002.xsd#pfe_XalkoriMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_XalkoriMember_69b9ded8-f63c-43b8-a666-50d9ab5e52be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember_50a75f6d-63c5-4ff3-b3ec-6e4258b38281" xlink:href="pfe-20221002.xsd#pfe_RuxienceMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_RuxienceMember_50a75f6d-63c5-4ff3-b3ec-6e4258b38281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember_72ddebdd-fd11-4edf-a6c9-852db5f8a581" xlink:href="pfe-20221002.xsd#pfe_RetacritMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_RetacritMember_72ddebdd-fd11-4edf-a6c9-852db5f8a581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember_48d0127e-908c-4c71-939e-682743ecb0f2" xlink:href="pfe-20221002.xsd#pfe_SutentMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_SutentMember_48d0127e-908c-4c71-939e-682743ecb0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember_88307c18-ab0c-4e2d-a91a-160bd257ec1b" xlink:href="pfe-20221002.xsd#pfe_LorbrenaMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_LorbrenaMember_88307c18-ab0c-4e2d-a91a-160bd257ec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BavencioAllianceRevenuesMember_64aaa9e1-4948-4171-8c6d-7be219680257" xlink:href="pfe-20221002.xsd#pfe_BavencioAllianceRevenuesMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BavencioAllianceRevenuesMember_64aaa9e1-4948-4171-8c6d-7be219680257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember_b3f19de4-d321-41f4-bddf-2374deb0fbc4" xlink:href="pfe-20221002.xsd#pfe_AromasinMember"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_AromasinMember_b3f19de4-d321-41f4-bddf-2374deb0fbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember_5a0f92ae-21cc-442f-9f3d-ece0876f83c2" xlink:href="pfe-20221002.xsd#pfe_BesponsaMember"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BesponsaMember_5a0f92ae-21cc-442f-9f3d-ece0876f83c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember_a95ba273-e375-46cf-9ec2-53578caa7688" xlink:href="pfe-20221002.xsd#pfe_BraftoviMember"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_BraftoviMember_a95ba273-e375-46cf-9ec2-53578caa7688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrazimeraMember_892e51f9-322d-4170-a1b2-147ee69a2e10" xlink:href="pfe-20221002.xsd#pfe_TrazimeraMember"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_TrazimeraMember_892e51f9-322d-4170-a1b2-147ee69a2e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_e925b583-856a-4fab-88a9-cbf2a4d6957e" xlink:href="pfe-20221002.xsd#pfe_MektoviMember"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_MektoviMember_e925b583-856a-4fab-88a9-cbf2a4d6957e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember_a6427e89-f271-46b9-b48f-ee0ff9dcdf3c" xlink:href="pfe-20221002.xsd#pfe_OtherOncologyProductsMember"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_OtherOncologyProductsMember_a6427e89-f271-46b9-b48f-ee0ff9dcdf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_a1d4eb0e-6bf8-4093-95b3-79b252354074" xlink:href="pfe-20221002.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddfbf214-8f9a-4993-b26a-3aca2aba49be" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_a1d4eb0e-6bf8-4093-95b3-79b252354074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_891b2d7e-9fe6-4d7e-b63f-f87dbfd95a30" xlink:to="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_21be3957-32a3-411d-ab59-083cc968c3d7" xlink:href="pfe-20221002.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:to="loc_pfe_BiopharmaSegmentMember_21be3957-32a3-411d-ab59-083cc968c3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneSegmentMember_295e256d-b8ce-48d3-8a30-967a0dbdda94" xlink:href="pfe-20221002.xsd#pfe_PfizerCentreOneSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_84295457-8c33-41f6-8721-84ad46d80a69" xlink:to="loc_pfe_PfizerCentreOneSegmentMember_295e256d-b8ce-48d3-8a30-967a0dbdda94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_eaa5feb4-901d-4f6f-9cbf-f858b4a4162f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ea53766-9769-47de-8084-e0cb45acc0ec" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_eaa5feb4-901d-4f6f-9cbf-f858b4a4162f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24c32b3a-f169-49f8-814b-d98d35534ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_eaa5feb4-901d-4f6f-9cbf-f858b4a4162f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24c32b3a-f169-49f8-814b-d98d35534ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails" xlink:type="simple" xlink:href="pfe-20221002.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ec2abb8a-6a43-43e1-b0ff-ff63c5b19d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ec2abb8a-6a43-43e1-b0ff-ff63c5b19d00" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:to="loc_srt_CounterpartyNameAxis_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_893b0881-0827-41b1-8f9b-7abaf42446a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2b835ed7-f9a1-4c5a-ad69-ef7a4d0e2dec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_893b0881-0827-41b1-8f9b-7abaf42446a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_b4a2e392-7f46-4abe-995e-40e99342ea6b" xlink:href="pfe-20221002.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_893b0881-0827-41b1-8f9b-7abaf42446a2" xlink:to="loc_pfe_BioNTechMember_b4a2e392-7f46-4abe-995e-40e99342ea6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_df51db9c-336f-4aa2-a390-3cc17ffb0f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_df51db9c-336f-4aa2-a390-3cc17ffb0f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fc53cea8-fb8b-4df7-9ac6-a4cec565726b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_df51db9c-336f-4aa2-a390-3cc17ffb0f42" xlink:to="loc_us-gaap_SegmentDomain_fc53cea8-fb8b-4df7-9ac6-a4cec565726b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneSegmentMember_1e235473-4f30-4754-bb58-e3cdd6d55940" xlink:href="pfe-20221002.xsd#pfe_PfizerCentreOneSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fc53cea8-fb8b-4df7-9ac6-a4cec565726b" xlink:to="loc_pfe_PfizerCentreOneSegmentMember_1e235473-4f30-4754-bb58-e3cdd6d55940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3ff777f7-8332-40f3-a8ba-6332cadffb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b85fd354-c9b3-4760-8cb7-aa6976b1ced0" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3ff777f7-8332-40f3-a8ba-6332cadffb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_605a0d55-03d2-429f-9d83-4b27c75afed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3ff777f7-8332-40f3-a8ba-6332cadffb00" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_605a0d55-03d2-429f-9d83-4b27c75afed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075755312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  02,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">235 East 42nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,613,314,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, $.05 par value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">1.000% Notes due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160076999808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 22,638<span></span>
</td>
<td class="nump">$ 24,035<span></span>
</td>
<td class="nump">$ 76,040<span></span>
</td>
<td class="nump">$ 57,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6,063<span></span>
</td>
<td class="nump">9,932<span></span>
</td>
<td class="nump">24,696<span></span>
</td>
<td class="nump">21,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,391<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
<td class="nump">9,032<span></span>
</td>
<td class="nump">8,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">7,813<span></span>
</td>
<td class="nump">6,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">524<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">822<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(1,696)<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="num">(4,043)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">9,001<span></span>
</td>
<td class="nump">7,843<span></span>
</td>
<td class="nump">29,498<span></span>
</td>
<td class="nump">20,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">356<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">1,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,645<span></span>
</td>
<td class="nump">8,171<span></span>
</td>
<td class="nump">26,400<span></span>
</td>
<td class="nump">18,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,623<span></span>
</td>
<td class="nump">8,159<span></span>
</td>
<td class="nump">26,404<span></span>
</td>
<td class="nump">18,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,608<span></span>
</td>
<td class="nump">$ 8,146<span></span>
</td>
<td class="nump">$ 26,378<span></span>
</td>
<td class="nump">$ 18,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.54<span></span>
</td>
<td class="nump">1.45<span></span>
</td>
<td class="nump">4.71<span></span>
</td>
<td class="nump">3.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.51<span></span>
</td>
<td class="nump">1.43<span></span>
</td>
<td class="nump">4.60<span></span>
</td>
<td class="nump">3.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares&#8211;&#8211;basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">5,609<span></span>
</td>
<td class="nump">5,606<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares&#8211;&#8211;diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,718<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">5,729<span></span>
</td>
<td class="nump">5,688<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Exclusive of amortization of intangible assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075667488">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,623<span></span>
</td>
<td class="nump">$ 8,159<span></span>
</td>
<td class="nump">$ 26,404<span></span>
</td>
<td class="nump">$ 18,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(918)<span></span>
</td>
<td class="num">(866)<span></span>
</td>
<td class="num">(2,549)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">589<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(615)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(972)<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(777)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="num">(1,397)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">606<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Other comprehensive income (loss), available-for-sale securities, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax', window );">Reclassification adjustments related to curtailments of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income/(loss), before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,144)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
<td class="num">(2,488)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss) before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,111)<span></span>
</td>
<td class="num">(894)<span></span>
</td>
<td class="num">(2,339)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income/(loss) before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,512<span></span>
</td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">24,065<span></span>
</td>
<td class="nump">18,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income/(loss) attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income/(loss) attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,503<span></span>
</td>
<td class="nump">$ 7,256<span></span>
</td>
<td class="nump">$ 24,049<span></span>
</td>
<td class="nump">$ 18,248<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160077233776">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="nump">$ 1,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,825<span></span>
</td>
<td class="nump">29,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts: 2022&#8212;$474; 2021&#8212;$492</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,076<span></span>
</td>
<td class="nump">11,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,513<span></span>
</td>
<td class="nump">9,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherTaxAssetsCurrent', window );">Current tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">4,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,149<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,403<span></span>
</td>
<td class="nump">59,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,826<span></span>
</td>
<td class="nump">16,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, less accumulated depreciation: 2022&#8212;$14,931; 2021&#8212;$15,074</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,441<span></span>
</td>
<td class="nump">14,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">28,151<span></span>
</td>
<td class="nump">25,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">49,441<span></span>
</td>
<td class="nump">49,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,136<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,890<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195,350<span></span>
</td>
<td class="nump">181,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings, including current portion of long-term debt: 2022&#8212;$2,566; 2021&#8212;$1,636</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,267<span></span>
</td>
<td class="nump">5,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,191<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,647<span></span>
</td>
<td class="nump">24,939<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,314<span></span>
</td>
<td class="nump">42,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,629<span></span>
</td>
<td class="nump">36,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,738<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent', window );">Postretirement benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Noncurrent deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">616<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Other taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,701<span></span>
</td>
<td class="nump">11,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,239<span></span>
</td>
<td class="nump">9,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102,459<span></span>
</td>
<td class="nump">104,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">476<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,359<span></span>
</td>
<td class="nump">90,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(113,945)<span></span>
</td>
<td class="num">(111,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122,967<span></span>
</td>
<td class="nump">103,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,225)<span></span>
</td>
<td class="num">(5,897)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Pfizer Inc. shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,631<span></span>
</td>
<td class="nump">77,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">259<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,891<span></span>
</td>
<td class="nump">77,462<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 195,350<span></span>
</td>
<td class="nump">$ 181,476<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for IPR&amp;D, is partially offset by an impairment (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Tax Assets, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079958656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property, plant and equipment, accumulated depreciation</a></td>
<td class="nump">14,931<span></span>
</td>
<td class="nump">15,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">$ 2,566<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160071387600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Shareholders' Equity [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Add'l Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th" colspan="2"><div>Accum. Other Comp. Loss [Member]</div></th>
<th class="th"><div>Noncontrolling Interests [Member]</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 63,473<span></span>
</td>
<td class="nump">$ 63,238<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">$ 88,674<span></span>
</td>
<td class="num">$ (110,988)<span></span>
</td>
<td class="nump">$ 90,392<span></span>
</td>
<td class="num">$ (5,310)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">18,633<span></span>
</td>
<td class="nump">18,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared, per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(6,569)<span></span>
</td>
<td class="num">(6,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="num">$ (371)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Oct. 03, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Oct. 03, 2021</a></td>
<td class="nump">75,967<span></span>
</td>
<td class="nump">75,691<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">89,973<span></span>
</td>
<td class="num">$ (111,359)<span></span>
</td>
<td class="nump">102,252<span></span>
</td>
<td class="num">(5,649)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Ending balance (in shares) at Oct. 03, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jul. 04, 2021</a></td>
<td class="nump">70,315<span></span>
</td>
<td class="nump">70,042<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
<td class="nump">89,336<span></span>
</td>
<td class="num">$ (111,356)<span></span>
</td>
<td class="nump">96,346<span></span>
</td>
<td class="num">(4,758)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Beginning balance (in shares) at Jul. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">8,159<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="num">(894)<span></span>
</td>
<td class="num">(891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(891)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared, per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(2,192)<span></span>
</td>
<td class="num">(2,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Oct. 03, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Oct. 03, 2021</a></td>
<td class="nump">75,967<span></span>
</td>
<td class="nump">75,691<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">89,973<span></span>
</td>
<td class="num">$ (111,359)<span></span>
</td>
<td class="nump">102,252<span></span>
</td>
<td class="num">(5,649)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Ending balance (in shares) at Oct. 03, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">77,462<span></span>
</td>
<td class="nump">77,201<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">90,591<span></span>
</td>
<td class="num">$ (111,361)<span></span>
</td>
<td class="nump">103,394<span></span>
</td>
<td class="num">(5,897)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">26,404<span></span>
</td>
<td class="nump">26,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="num">(2,339)<span></span>
</td>
<td class="num">(2,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,328)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared, per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(6,734)<span></span>
</td>
<td class="num">(6,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="num">$ (584)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Oct. 02, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Oct. 02, 2022</a></td>
<td class="nump">92,891<span></span>
</td>
<td class="nump">92,631<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">91,359<span></span>
</td>
<td class="num">$ (113,945)<span></span>
</td>
<td class="nump">122,967<span></span>
</td>
<td class="num">(8,225)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Ending balance (in shares) at Oct. 02, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jul. 03, 2022</a></td>
<td class="nump">87,469<span></span>
</td>
<td class="nump">87,208<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">91,183<span></span>
</td>
<td class="num">$ (113,939)<span></span>
</td>
<td class="nump">116,608<span></span>
</td>
<td class="num">(7,119)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Beginning balance (in shares) at Jul. 03, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">8,623<span></span>
</td>
<td class="nump">8,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="num">(1,111)<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared, per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(2,245)<span></span>
</td>
<td class="num">(2,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Oct. 02, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Oct. 02, 2022</a></td>
<td class="nump">$ 92,891<span></span>
</td>
<td class="nump">$ 92,631<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 91,359<span></span>
</td>
<td class="num">$ (113,945)<span></span>
</td>
<td class="nump">$ 122,967<span></span>
</td>
<td class="num">$ (8,225)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Ending balance (in shares) at Oct. 02, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079888912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160077249248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">$ 26,404<span></span>
</td>
<td class="nump">$ 18,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations before allocation to noncontrolling interests</a></td>
<td class="nump">26,400<span></span>
</td>
<td class="nump">18,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,545<span></span>
</td>
<td class="nump">3,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_AssetWriteOffsAndAssetImpairmentCharges', window );">Asset write-offs and impairments</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="num">(3,399)<span></span>
</td>
<td class="num">(3,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="num">(532)<span></span>
</td>
<td class="num">(1,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other adjustments, net</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="num">(1,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Other changes in assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="num">(7,605)<span></span>
</td>
<td class="nump">10,867<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities from continuing operations</a></td>
<td class="nump">20,685<span></span>
</td>
<td class="nump">26,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) operating activities from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">20,685<span></span>
</td>
<td class="nump">26,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(2,235)<span></span>
</td>
<td class="num">(1,709)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(29,701)<span></span>
</td>
<td class="num">(26,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from redemptions/sales of short-term investments</a></td>
<td class="nump">35,087<span></span>
</td>
<td class="nump">15,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess', window );">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</a></td>
<td class="num">(10,877)<span></span>
</td>
<td class="num">(7,152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of long-term investments</a></td>
<td class="num">(1,627)<span></span>
</td>
<td class="num">(861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments', window );">Proceeds from redemptions/sales of long-term investments</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="num">(6,225)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Dividends received from Haleon/GSK Consumer Healthcare JV (Note 2C)</a></td>
<td class="nump">3,960<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by/(used in) investing activities from continuing operations</a></td>
<td class="num">(11,373)<span></span>
</td>
<td class="num">(19,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) investing activities from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="num">(11,373)<span></span>
</td>
<td class="num">(19,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="nump">3,887<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments on short-term borrowings</a></td>
<td class="num">(3,887)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="num">(1,609)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Cash dividends paid</a></td>
<td class="num">(6,738)<span></span>
</td>
<td class="num">(6,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(342)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="num">(9,819)<span></span>
</td>
<td class="num">(6,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="num">(646)<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid/(received) during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">4,919<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_InterestPaidReceivedInterestRateHedges', window );">Interest rate hedges</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash transaction:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 1,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetWriteOffsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Write-Offs And Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetWriteOffsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InterestPaidReceivedInterestRateHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Paid (Received), Interest Rate Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InterestPaidReceivedInterestRateHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074788608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August&#160;28, 2022 and August&#160;29, 2021, and for U.S. subsidiaries is as of and for the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Beginning in the third quarter of 2022, we made several additional</span><span style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizational changes to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches. These changes include establishing a new commercial structure within our Biopharma operating segment and realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure. Biopharma is the only reportable segment. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 9B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 13A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities completed in 2021 and 2022 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary and post-closing adjustments for other previously divested businesses. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below.</span></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations, acquired IPR&amp;D expenses and segment reporting.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. New Accounting Standard Adopted in 2022</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Revenues and Trade Accounts Receivable</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors&#8217; locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">D. Acquired In-Process Research and Development Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we began reporting acquired IPR&amp;D expense as a separate line item in our consolidated statements of income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;D. These costs were previously recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed. The fair value of IPR&amp;D acquired in connection with a business combination is recorded on the balance sheet as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Notes 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160080816688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract', window );"><strong>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock', window );">Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement</a></td>
<td class="text">Acquisitions, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement<div style="margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisitions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ReViral</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;&#8211;On June 9, 2022, which fell in our international third quarter of 2022, we acquired ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral therapeutics that target respiratory syncytial virus, for a total consideration of up to $536 million, including upfront payments of $436 million upon closing (including a base payment of $425 million plus working capital adjustments) and an additional $100 million contingent upon future development milestones.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We accounted for the transaction as an asset acquisition since the lead asset, sisunatovir, represented substantially all of the fair value of the gross assets acquired. At the acquisition date, we recorded a $426 million charge representing an acquired IPR&amp;D asset with no alternative use in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which is presented as a cash outflow from operating activities. Other assets acquired and liabilities assumed were not significant.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Arena&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 11, 2022, we acquired Arena, a clinical stage company, for $100 per share in cash. The total fair value of the consideration transferred was $6.6&#160;billion ($6.2 billion, net of cash acquired). In addition, $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Arena&#8217;s portfolio includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including UC, Crohn&#8217;s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In connection with this acquisition, we provisionally recorded: (i) $5.5 billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, consisting of $5.0 billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">IPR&amp;D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and $460 million of indefinite-lived </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, (ii) $1.0 billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and (iii) $505 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Discontinued Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Meridian&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, we completed the sale of our Meridian subsidiary. In the three and nine months ended October&#160;2, 2022, the amounts recorded under the interim TSAs and MSA were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upjohn Separation and Combination with Mylan&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination and to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The amounts recorded under these agreements were not material to our consolidated results of operations in the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021. Net amounts due from Viatris under the agreements were approximately $167 million as of October&#160;2, 2022 and $53 million as of December 31, 2021. The cash flows associated with the agreements are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financing activities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the three and nine months ended October&#160;3, 2021 reflects pre-tax loss from discontinued operations of $17 million and $353 million, respectively, and primarily includes pre-disposal operations related to our former Meridian subsidiary including a $345&#160;million pre-tax expense in the first nine months of 2021 to resolve a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas (prior to presenting Meridian as discontinued operations, this EpiPen litigation amount was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span><span style="color:#b2b2b2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended October&#160;2, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> reflects pre-tax loss of $15 million and pre-tax income of $9 million from discontinued operations, respectively, and relates to post-closing adjustments for previously divested businesses primarily for tax and legal matters.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Equity-Method Investment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Haleon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumer Healthcare JV&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operated globally under the GSK Consumer Healthcare name. In exchange for the contribution of our consumer healthcare business to the JV, we received a 32% equity stake in the new company and GSK owned the remaining 68%. On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint Consumer Healthcare business of GSK and Pfizer following the demerger. We continue to own 32% of the ordinary shares of Haleon after the demerger. We continue to account for our interest in Haleon as an equity-method investment. The carrying value of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in Haleon as of October&#160;2, 2022 and in the Consumer Healthcare JV as of December 31, 2021 is $9.6 billion and $16.3 billion, respectively, and is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of our investment in Haleon as of October&#160;2, 2022, based on quoted market prices of Haleon stock, was $9.1 billion. Haleon/the Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2021 is primarily due to dividends totaling approximately $4.5 billion, of which cash flows of $4.0 billion are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities from continuing operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $584 million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as $2.4 billion in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), partially offset by our share of the JV&#8217;s earnings. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our total share of the JV&#8217;s earnings generated in the second quarter of 2022, which we recorded in our operating results in the third quarter of 2022, was $67 million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2021 and first six months of 2022, which we recorded in our operating results in the first nine months of </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, was $402 million. Our total share of the JV&#8217;s earnings generated in the second quarter of 2021, which we recorded in our operating results in the third quarter of 2021, was $106 million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2020 and first six months of 2021, which we recorded in our operating results in the first nine months of 2021, was $324 million. In the third quarter and first nine months of 2022, our equity-method income included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also includes charges of $118 million and $119 million, respectively, primarily for adjustments to our equity-method basis differences related to the separation of Haleon/the GSK Consumer Healthcare JV from GSK. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV was not material to our results of operations in the third quarter and first nine months of 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:45.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three and nine months ending June 30, 2022, the most recent period available, and for the three and nine months ending June 30, 2021, is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,218&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,164&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,428&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,536)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,892&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with GSK&#8217;s previously announced planned demerger of at least 80% of GSK&#8217;s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, &#8364;2.35 billion in euro-denominated senior notes of various maturities and &#163;700 million in U.K. pound-denominated senior notes of various maturities (collectively, the &#8220;notes&#8221;). The notes were guaranteed by GSK generally up to and excluding the date of the demerger (the &#8220;Guarantee Assumption Date&#8221;). We agreed to indemnify GSK for 32% (representing our pro rata equity interest in the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we nor any of our subsidiaries were an issuer or guarantor of any of the notes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of &#163;2.9 billion ($3.7 billion as of the end of our second quarter of 2022), at an interest rate of 1.365% per annum payable semi-annually in arrears. In conjunction with the demerger, we received &#163;3.5 billion ($4.2 billion) in dividends from the JV in July 2022, of which $4.0&#160;billion related to a one-time pre-separation dividend, which decreased the carrying value of our investment (as discussed above). Simultaneous with the receipt of the dividends, we repaid the &#163;2.9 billion loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata loan from the JV. In conjunction with these transactions, our indemnification of GSK&#8217;s guarantee discussed above was terminated.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Collaborative Arrangement</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Biohaven&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its subsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Under the terms of the agreement, Biohaven would  lead R&amp;D globally and we would have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January&#160;4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263&#160;million for the upfront payment and premium paid on our equity investment in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2022, within our fiscal fourth quarter of 2022, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5&#160;billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160161266880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We continue our </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts to ensure our cost base and support model align appropriately with our operating structure. While certain direct costs transferred to the Consumer Healthcare JV, and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, of $1.8&#160;billion, to be incurred primarily from 2020 through 2022, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We have also made several organizational changes in the third quarter of 2022 to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). We expect costs of $1.4&#160;billion to be incurred primarily from 2020 through 2022, with all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $800&#160;million to be incurred primarily from 2020 through 2023, with approximately 25% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program costs discussed above may be rounded and represent approximations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of this program in the fourth quarter of 2019 through October&#160;2, 2022, we incurred costs of $2.8&#160;billion, of which $1.1 billion ($862&#160;million of restructuring charges) is associated with Biopharma. </span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(63)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(51)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62&#160;million and $108&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $616&#160;million and $617&#160;million for the three and nine months ended October&#160;3, 2021, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October&#160;2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138&#160;million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:40.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.096%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(447)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(572)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, October&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($816 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($255 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes adjustments for foreign currency translation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($758 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($110 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160078617840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income)/Deductions - Net</a></td>
<td class="text">Other (Income)/Deductions&#8212;Net<div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(628)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,601)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,635)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain asset impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haleon/Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,696)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,043)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The first nine months of 2021 included, among other things, $188&#160;million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amount in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.551%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional information about the intangible asset that was impaired during 2022 (impairment recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended October 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset&#8211;&#8211;IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1F </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reflects an intangible asset written down to fair value in 2022. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075614240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Tax Matters</a></td>
<td class="text">Tax Matters<div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for continuing operations was 4.0% for the third quarter of 2022, compared to (4.2)% for the third quarter of 2021, and was 10.5% for the first nine months of 2022, compared to 7.8% for the first nine months of 2021. The higher effective tax rates for the third quarter and first nine months of 2022, compared to the third quarter and first nine months of 2021, were mainly due to the non-recurrence of certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK, partially offset by tax benefits in the third quarter of 2022 related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years that included the closing of U.S. IRS audits covering five tax years.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fourth annual installment of this liability was paid by its April 18, 2022 due date. The fifth annual installment is due April 18, 2023 and is reported in current </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of October&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. During the third quarter of 2022, Pfizer reached resolution of disputed issues at the IRS Independent Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2011-2015. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2022 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2011.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:53.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.382%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074643424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</a></td>
<td class="text">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.819%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(220)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,897)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, October 2, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,545)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(485)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,225)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074574768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,014&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,014&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,330&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,330&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,379&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,379&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,397&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,063&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,103&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,552&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,703&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Long-term equity securities of $139 million as of October&#160;2, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of Long-term debt, excluding the current portion was $33&#160;billion as of October&#160;2, 2022 and $36&#160;billion as of December 31, 2021. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $29&#160;billion as of October&#160;2, 2022 and $42&#160;billion as of December 31, 2021.</span></div>The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of October&#160;2, 2022 and December 31, 2021. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.<div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Short-Term, Long-Term and Equity-Method Investments</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.885%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,014&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,825&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,125&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,888&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,526&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes money market funds primarily invested in U.S. Treasury and government debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represent investments in the life sciences sector.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(567)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,055&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(580)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23,641&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,835&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(265)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,584&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements. </span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:53.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,601)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,518)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:73.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.235%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,831&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,948&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,629&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,195&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Risk&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, and Canadian dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(124)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(420)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(420)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="39" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(346)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(832)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(97)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(204)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI into COS were:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $125 million in the third quarter of 2022; </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $227 million in the first nine months of 2022;</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $18 million in the third quarter of 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $94 million in the first nine months of 2021. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $1 billion within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related short-term borrowings&#8217; carrying value as of December 31, 2021 was $1.1&#160;billion. The related long-term debt carrying values as of October&#160;2, 2022 and December 31, 2021 were $726 million and $844 million, respectively.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:27.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.655%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our debt in fair value hedges:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(330)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;2, 2022, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by Germany, the U.S., the Netherlands, Japan, the U.K., France, and Canada, as well as money market funds primarily invested in U.S. Treasury and government debt.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of October&#160;2, 2022, the aggregate fair value of these derivative financial instruments that are in a net payable position was $595&#160;million, for which we have posted collateral of $612 million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of October&#160;2, 2022, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $1.5&#160;billion, for which we have received collateral of $1.5&#160;billion with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079870576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"> Inventories</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,513&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.</span></div><div style="margin-bottom:5pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div>Other current liabilities includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $4.5&#160;billion as of October&#160;2, 2022 and $9.7&#160;billion as of December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074616528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets</a></td>
<td class="text">Identifiable Intangible Assets<div style="margin-top:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Identifiable Intangible Assets</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,309)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,732)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(807)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,299)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,036&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,514)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,522&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,552&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,838)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,714&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,665&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,514)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,151&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,984&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,838)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,146&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for IPR&amp;D, is partially offset by an impairment (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Goodwill</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:84.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,208&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, October&#160;2, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,441&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Additions relate to our acquisition of Arena. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Other represents the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074678768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Postretirement Benefit Plans</a></td>
<td class="text">Pension and Postretirement Benefit Plans<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.569%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(983)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.569%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(685)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The third quarter of 2022 mainly reflects interim actuarial remeasurement gains, primarily driven by an increase in the discount rate, partially offset by unfavorable plan asset performance. The first nine months of 2022 mainly reflects interim actuarial remeasurement losses, primarily driven by unfavorable plan asset performance, partially offset by gains due to an increase in the discount rate. In the third quarter and first nine months of 2021, mainly reflects interim actuarial remeasurement gains, primarily due to favorable plan asset performance and an increase in the discount rate. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended October 2, 2022, we contributed $207 million, $127 million, and $16 million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074817952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</a></td>
<td class="text">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,608&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,146&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,378&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,608&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,146&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,378&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options and stock issuable under employee compensation plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,718&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074586928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Certain Commitments</a></td>
<td class="text">Contingencies and Certain Commitments<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In November 2022, BMS received permission to appeal the High Court&#8217;s decision. Additional challenges remain pending in other jurisdictions. Also, for example, in July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty infringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or BioNTech in other jurisdictions in the future. In addition, in October 2022, Accord Healthcare Ltd. brought suit in the U.K. against the Regents of the University of California challenging the validity of the U.K. patent covering the active ingredient in Xtandi, which expires in 2028. Adverse decisions in these matters could have a material adverse effect on our results of operations.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office. In addition, another patent was challenged in federal court in Delaware; and that case was settled in September 2021 on terms not material to the company. Other challenges to pneumococcal vaccine patents remain pending at the Patent Trial and Appeal Board and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor&#8217;s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we brought a separate patent infringement action against MSN Laboratories Private Ltd. (MSN) asserting the infringement and validity of our compound patent covering the active agreement that was challenged by MSN in its ANDAs seeking approval to market generic versions of tofacitinib immediate release tablets (5 mg, 10 mg) and oral solution 1 mg/mL. In August 2022, we settled our action against MSN on terms not material to us.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various U.S. federal courts, asserting the validity and infringement of the patents challenged by the generic companies. We have settled with one of these generic companies on terms not material to us, and we dismissed the patent infringement actions relating to the crystalline form of patent, the composition of matter patent expiring in 2023, the method of use patent, and the tablet formulation patent against the generic companies that had challenged these patents. The composition of matter patent expiring in 2027 remains in suit. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eucrisa</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Braftovi (encorafenib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, a generic company notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Braftovi. The company asserts the invalidity and non-infringement of, among others, a method of use patent expiring in 2033. In September 2022, we brought a patent infringement action against the generic company in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the method of use patent expiring in 2033.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mektovi (binimetinib)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in August 2022, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies assert the invalidity and non-infringement of two method of use patents expiring in 2030, a method of use patent expiring in 2031, two method of use patents expiring in 2033, and a product by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of all six patents.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions in Which We are the Defendant</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comirnaty</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia &amp; Upjohn Co. LLC, our wholly owned subsidiary, alleging that Comirnaty infringes U.S. Patent No. 11,246,933, which was issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a second complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia &amp; Upjohn Co. LLC, BioNTech and BioNTech Manufacturing GmbH, alleging that Comirnaty infringes U.S. Patent No. 11,382,979, which was issued in July 2022, and seeking unspecified monetary damages.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring only after March 7, 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes two European patents. In September 2022, ModernaTX filed patent infringement actions in the U.K and in the Netherlands against Pfizer Inc. and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, on the same two patents. In its complaints, Moderna stated that it is seeking damages for alleged infringement occurring only after March 7, 2022. In the U.K., Pfizer and BioNTech have brought an action against ModernaTX seeking to revoke these European patents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paxlovid</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Enanta Pharmaceuticals, Inc. filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes U.S.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patent No. 11,358,953, which was issued in June 2022, and seeking unspecified monetary damages.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters Involving Pfizer and its Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eliquis</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comirnaty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts seeking a judgment of non-infringement for the following three patents relating to Comirnaty: U.S. Patent Nos. 11,135,312, 11,149,278, and 11,241,493. Outside of the U.S., in the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lipitor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen (Direct Purchaser)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its current and former affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants&#8217; motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint. In August 2022, the District Court granted Pfizer&#8217;s motion to dismiss the complaint.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Personal Injury Actions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson &amp; Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson &amp; Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, asserting a consolidated consumer class action alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chantix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer&#8217;s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as, Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency and/or New Jersey Department of Environmental Protection to perform remedial design, removal and remedial actions, and related environmental remediation activities at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. In January 2022, the Court of Appeals reversed the District Court&#8217;s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals&#8217; decision.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Viatris Securities Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company&#8217;s current and former officers, directors and employees are named as defendants. The complaint alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">State Attorneys General and Multi-District Generics Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020. The Multi-District Litigation also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subpoena &amp; Civil Investigative Demand relating to Tris Pharma/Quillivant XR</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We responded to that subpoena in full and have had no communication with the SDNY in connection with the subpoena since June 2019. Additionally, in September 2020,&#8239;we received a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil Investigative Demand (CID)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the Texas Attorney General&#8217;s office&#8239;seeking records of a similar nature to those requested by the SDNY. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are producing records in response to this request.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received a CID from the U.S. Attorney&#8217;s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the  U.S. Department of Justice&#8217;s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac&#8211;&#8211;State of New Mexico and Mayor and City Council of Baltimore Civil Actions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Biohaven</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, the U.S. Department of Justice's Commercial Litigation Branch and the U.S. Attorney&#8217;s Office for the Western District of New York issued a CID relating to Biohaven. The CID seeks records and information related to, among other things, engagements with health care professionals and co-pay coupons cards. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We are producing records in response to these requests.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of October&#160;2, 2022, the estimated fair value of these indemnification obligations is not material to Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the March 2022 indemnity provided by Pfizer to GSK in connection with the issuance of notes by the Consumer Healthcare JV. In conjunction with the completion of GSK&#8217;s demerger transactions in July 2022, GSK&#8217;s guarantee and our related indemnification of GSK&#8217;s guarantee were terminated. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, each of Viatris and Pfizer has agreed to assume, and to indemnify the other for, liabilities arising out of certain matters. Also, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection, includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160070869936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, Geographic and Other Revenue Information</a></td>
<td class="text">Segment, Geographic and Other Revenue Information<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Segment Information</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our commercial operations through two operating segments, Biopharma and PC1, which are each led by a single manager. Biopharma is the only reportable segment. Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;D services from WRDM and GPD. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the organizational changes in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the new commercial structure within Biopharma is designed to better support and optimize performance across three broad therapeutic areas: </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Primary Care consists of the former Internal Medicine and Vaccines product portfolios, as well as COVID-19 products and potential future mRNA products. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Specialty Care consists of the former Inflammation &amp; Immunology, Rare Disease and Hospital (excluding Paxlovid) product portfolios.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Oncology consists of the former Oncology product portfolio.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Business Activities&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pre-tax costs are not allocated to our operating segment results, such as costs included in Other business activities that are associated with: (i) R&amp;D and medical expenses managed by our WRDM and GPD organizations; (ii) corporate enabling functions and other corporate costs; (iii) overhead costs primarily associated with our manufacturing operations; and (iv) our share of earnings from Haleon/the Consumer Healthcare JV. Additionally, all amortization of intangible assets, acquisition-related items, and certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, are not allocated to our operating segment results. Beginning in the first quarter of 2022, acquisition-related items may now include purchase accounting impacts that previously were included as part of a reconciling item entitled &#8220;Purchase accounting adjustments&#8221; that we no longer separately present, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. The operating results of PC1 are included in Other business activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Assets&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment and, accordingly, we do not report asset information by operating segment. Total assets were $195 billion as of October&#160;2, 2022 and $181 billion as of December 31, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Income Statement Information</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.155%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,007)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,820)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(822)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(980)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,478)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(773)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,095)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,638&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,035&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,001&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,843&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,450&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,498&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,484&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $426 million of acquired IPR&amp;D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of approximately $400 million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $516 million. In the third quarter and first nine months of 2021, earnings include $706 million of acquired IPR&amp;D expenses associated with our collaboration with Arvinas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $701 million ($344 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the remaining amounts primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) actuarial valuation and other pension and postretirement plan gains of $932 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $1.1 billion ($310 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $899 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $823 million ($150 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Geographic Information</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.364%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,851&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,991&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,066&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,671&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,638&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,035&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,450&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Other Revenue Information</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant wholesale customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K. Additionally, revenues from the U.S. government represented 38% and 27% of total revenues for the three and nine months ended October&#160;2, 2022, respectively, and primarily represent sales of Paxlovid and Comirnaty. Accounts receivable from the </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government represented 44% of total trade accounts receivable as of October&#160;2, 2022, and primarily relate to sales of Paxlovid and Comirnaty.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:27.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">76,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">57,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">23,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">75,066</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">56,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Primary Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">55,676</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Comirnaty direct sales and alliance revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,402&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26,477&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,277&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Paxlovid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">COVID-19 infection (high risk population)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,099&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar family</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BMP2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trumenba</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal B disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Primary Care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Specialty Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">11,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-CM and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ig Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Specialty Care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,039&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:27.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">, for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> -mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trazimera</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HER-positive breast cancer and metastatic stomach cancers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Alliance revenues included above</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult). </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Immunoglobulin (Ig) portfolio includes the revenues from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Panzyga, Octagam and Cutaquig.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totaled approximately $22&#160;billion as of October&#160;2, 2022, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of this amount, we expect to recognize revenue of approximately $9 billion in 2022, $13 billion in 2023 and $200 million in 2024. Remaining performance obligations are based on foreign exchange rates as of the end of the third quarter of 2022 and exclude arrangements with an original expected contract duration of less than one year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers in international markets for supply of Comirnaty and Paxlovid. The deferred revenues related to Comirnaty and Paxlovid total $6.2 billion as of October&#160;2, 2022, with $6.1 billion and $126 million recorded in current and noncurrent liabilities, respectively. The deferred revenues related to Comirnaty total $3.3 billion as of December 31, 2021, with $3.0 billion and $249 million recorded in current liabilities and noncurrent liabilities, respectively. There were no deferred revenues associated with Paxlovid as of December 31, 2021. The increase in Comirnaty and Paxlovid deferred revenues during the first nine months of 2022 was primarily the result of additional advance payments received as we entered into new or amended contracts, including new advance payments received for Paxlovid contracts, less amounts recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as we delivered the products to our customers and the impact of foreign exchange. During the third quarter and first nine months of 2022, we recognized revenue of $68 million and $2.5 billion, respectively, that was included in the balance of Comirnaty deferred revenues as of December 31, 2021. The Comirnaty and Paxlovid deferred revenues as of October&#160;2, 2022 will be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proportionately as we transfer control of the products to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the last three months of 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of October&#160;2, 2022 or December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079769392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August&#160;28, 2022 and August&#160;29, 2021, and for U.S. subsidiaries is as of and for the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Beginning in the third quarter of 2022, we made several additional</span><span style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizational changes to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches. These changes include establishing a new commercial structure within our Biopharma operating segment and realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure. Biopharma is the only reportable segment. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 9B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 13A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities completed in 2021 and 2022 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary and post-closing adjustments for other previously divested businesses. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below.</span></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations, acquired IPR&amp;D expenses and segment reporting.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standard Adopted</a></td>
<td class="text">New Accounting Standard Adopted in 2022On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues and Trade Accounts Receivable</a></td>
<td class="text">Revenues and Trade Accounts Receivable<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors&#8217; locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development Expenses</a></td>
<td class="text">Acquired In-Process Research and Development Expenses<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we began reporting acquired IPR&amp;D expense as a separate line item in our consolidated statements of income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;D. These costs were previously recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed. The fair value of IPR&amp;D acquired in connection with a business combination is recorded on the balance sheet as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Identifiable intangible assets</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074643424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock', window );">Schedule of Balance Sheet Classification of Accruals</a></td>
<td class="text">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079870576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract', window );"><strong>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:45.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three and nine months ending June 30, 2022, the most recent period available, and for the three and nine months ending June 30, 2021, is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,218&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,164&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,428&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,536)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,892&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160071296192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(63)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(51)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62&#160;million and $108&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $616&#160;million and $617&#160;million for the three and nine months ended October&#160;3, 2021, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October&#160;2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138&#160;million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Components and Changes in Restructuring Accruals</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:40.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.096%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(447)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(572)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, October&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($816 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($255 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes adjustments for foreign currency translation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($758 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($110 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074770336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other (Income)/Deductions - Net</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(628)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,601)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,635)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain asset impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haleon/Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,696)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,043)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The first nine months of 2021 included, among other things, $188&#160;million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amount in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of Impaired Intangible Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.551%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional information about the intangible asset that was impaired during 2022 (impairment recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended October 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset&#8211;&#8211;IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1F </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reflects an intangible asset written down to fair value in 2022. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074868752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:53.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.382%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160161264032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.819%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,172)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(220)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,897)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, October 2, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,545)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(485)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,225)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160076728576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,014&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,014&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,330&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,330&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,379&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,379&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,397&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,063&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,960&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,103&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,552&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,703&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Long-term equity securities of $139 million as of October&#160;2, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Investments by Classification Type</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.885%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,014&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,825&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,125&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,888&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,526&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes money market funds primarily invested in U.S. Treasury and government debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represent investments in the life sciences sector.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of Held-to-maturity Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(567)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,055&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(580)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23,641&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,835&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(265)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,584&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(567)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,055&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(580)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23,641&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,835&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(265)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,584&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(567)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,055&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(580)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23,641&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,835&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(265)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,584&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock', window );">Schedule of Gains and Losses on Investment Securities</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:53.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,601)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,518)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Borrowings</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:73.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.235%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,831&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,948&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,629&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,195&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Schedule of Derivative Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(124)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(420)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(420)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="39" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(346)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(832)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(97)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(204)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI into COS were:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $125 million in the third quarter of 2022; </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $227 million in the first nine months of 2022;</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $18 million in the third quarter of 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $94 million in the first nine months of 2021. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $1 billion within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related short-term borrowings&#8217; carrying value as of December 31, 2021 was $1.1&#160;billion. The related long-term debt carrying values as of October&#160;2, 2022 and December 31, 2021 were $726 million and $844 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:27.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.655%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our debt in fair value hedges:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(330)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074634192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories, Current</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,513&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Components of Inventories, Noncurrent</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,513&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160076736240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,309)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,732)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(807)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,299)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,036&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,514)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,522&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,552&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,838)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,714&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,665&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,514)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,151&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,984&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,838)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,146&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for IPR&amp;D, is partially offset by an impairment (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite Lived Intangible Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,309)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,732)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(807)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,299)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,036&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,514)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,522&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,552&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,838)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,714&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,665&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,514)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,151&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,984&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,838)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,146&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for IPR&amp;D, is partially offset by an impairment (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:84.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,208&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, October&#160;2, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,441&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Additions relate to our acquisition of Arena. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Other represents the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079831936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Periodic Benefit Costs</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.569%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(983)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.569%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(685)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>(a)The third quarter of 2022 mainly reflects interim actuarial remeasurement gains, primarily driven by an increase in the discount rate, partially offset by unfavorable plan asset performance. The first nine months of 2022 mainly reflects interim actuarial remeasurement losses, primarily driven by unfavorable plan asset performance, partially offset by gains due to an increase in the discount rate. In the third quarter and first nine months of 2021, mainly reflects interim actuarial remeasurement gains, primarily due to favorable plan asset performance and an increase in the discount rate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074820656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earning Per Share</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,608&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,146&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,378&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,608&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,146&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,378&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,586&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options and stock issuable under employee compensation plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,718&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079816176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information by Segment</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.155%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,007)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,820)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(822)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(980)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,478)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(773)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,095)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,638&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,035&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,001&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,843&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,450&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,498&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,484&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $426 million of acquired IPR&amp;D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of approximately $400 million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $516 million. In the third quarter and first nine months of 2021, earnings include $706 million of acquired IPR&amp;D expenses associated with our collaboration with Arvinas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $701 million ($344 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the remaining amounts primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) actuarial valuation and other pension and postretirement plan gains of $932 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $1.1 billion ($310 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $899 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $823 million ($150 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues by Geographic Region</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.364%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,851&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,991&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,066&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,671&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,638&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,035&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,450&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Significant Product Revenues</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:27.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">76,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">57,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">23,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">75,066</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">56,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Primary Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">55,676</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Comirnaty direct sales and alliance revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,402&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26,477&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,277&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Paxlovid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">COVID-19 infection (high risk population)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,099&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar family</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BMP2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trumenba</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal B disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Primary Care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Specialty Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">11,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-CM and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ig Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Specialty Care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,039&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:27.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 2, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oct. 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">, for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> -mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trazimera</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HER-positive breast cancer and metastatic stomach cancers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Alliance revenues included above</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult). </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Immunoglobulin (Ig) portfolio includes the revenues from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Panzyga, Octagam and Cutaquig.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160074868752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2022 </div>
<div>operatingSegment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075677088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">$ 6,038<span></span>
</td>
<td class="nump">$ 5,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Trade accounts receivable, less allowance for doubtful accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,991<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Accruals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RebatesAndDiscountsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RebatesAndDiscountsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Accrued Liabilities [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072162832">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 09, 2022</div></th>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to acquire businesses, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,225<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember', window );">Arena [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to acquire businesses, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember', window );">Arena [Member] | Restructuring Charges And Acquisition-Related Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Post closing compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember', window );">Arena [Member] | IPR&amp;D [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember', window );">Arena [Member] | Licensing Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=pfe_ReViralAssetAcquisitionMember', window );">ReViral [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred (up to)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments', window );">Payment for asset acquisition, base payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions, Before Working Capital Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pfe_ReViralAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pfe_ReViralAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072566416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Discontinued Operations Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations, pre-tax income (loss)</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss on litigation settlement</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_EpiPenMember', window );">Epi Pen [Member] | Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss on litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ViatrisMember', window );">Viatris [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Nontrade receivables</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities', window );">Payment pursuant to terms of the separation agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Pursuant to Terms of Separation Agreement, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ViatrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ViatrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160068480448">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Equity Method Investment Narrative (Details)<br> &#8364; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 18, 2022</div></th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Dividends received, return of capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,960<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_A1365ConsumerHealthcareJVLoanMember', window );">1.365% Consumer Healthcare JV Loan [Member] | Loans Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.365%<span></span>
</td>
<td class="nump">1.365%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchase amount | &#163;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ConsumerHealthcareJVHaleonMember', window );">Consumer Healthcare JV / Haleon [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity-method investment, quoted market value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal', window );">Dividends received, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">&#163; 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Dividends received, return of capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Dividend received, distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation', window );">Decrease due to foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity method investment earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences', window );">Equity method investment, adjustment of basis differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_GSKMember', window );">GSK [Member] | Consumer Healthcare JV / Haleon [Member] | Disposed of by Sale [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal', window );">Proposed percent of ownership disposal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_GSKMember', window );">GSK [Member] | Consumer Healthcare JV / Haleon [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_ConsumerHealthcareJVHaleonMember', window );">Consumer Healthcare JV / Haleon [Member] | Senior Notes [Member] | Senior Notes, USD Denominated [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_ConsumerHealthcareJVHaleonMember', window );">Consumer Healthcare JV / Haleon [Member] | Senior Notes [Member] | Senior Notes, EUR Denominated [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_ConsumerHealthcareJVHaleonMember', window );">Consumer Healthcare JV / Haleon [Member] | Senior Notes [Member] | Senior Notes, GBP Denominated [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="15"></td></tr>
<tr><td colspan="15"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Adjustment of Basis Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Increase (Decrease), Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ProceedsFromEquityMethodInvestmentDistributionTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Equity Method Investment, Distribution, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ProceedsFromEquityMethodInvestmentDistributionTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_A1365ConsumerHealthcareJVLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_A1365ConsumerHealthcareJVLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ConsumerHealthcareJVHaleonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ConsumerHealthcareJVHaleonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareJVHaleonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareJVHaleonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_ConsumerHealthcareJVHaleonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_ConsumerHealthcareJVHaleonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160070929856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Schedule of Equity-Method Investment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 8,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">8,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="nump">$ 8,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ConsumerHealthcareJVHaleonMember', window );">Consumer Healthcare JV / Haleon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,536)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ConsumerHealthcareJVHaleonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ConsumerHealthcareJVHaleonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160070930912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Collaborative Arrangements (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 04, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_BiohavenMember', window );">Biohaven [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisition, cash portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Biohaven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PrepaymentsAndPaymentsToCollaboratorsCash', window );">Payment to collaborators</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsToCollaboratorsUpfrontPayment', window );">Upfront payment to collaborators</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount', window );">Committed investment from collaborator</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Biohaven [Member] | Acquired In-Process Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment', window );">Upfront payment and premium paid in equity investment</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Investment From Collaborator, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsToCollaboratorsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Collaborators, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsToCollaboratorsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrepaymentsAndPaymentsToCollaboratorsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments and Payments to Collaborators, Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrepaymentsAndPaymentsToCollaboratorsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_BiohavenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_BiohavenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BiohavenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BiohavenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_ResearchAndDevelopmentInProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_ResearchAndDevelopmentInProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160070878096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - Focused Company Plan [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost incurred to date</a></td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Biopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost incurred to date</a></td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringChargesChargesIncurredToDate', window );">Restructuring charges incurred to date</a></td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CorporateEnablingFunctionsMember', window );">Corporate Enabling Functions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_GoToMarketModelMember', window );">Go-to Market Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember', window );">Manufacturing Optimization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage', window );">Percentage of expected costs to be non-cash</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesChargesIncurredToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Charges Incurred to Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesChargesIncurredToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Noncash Charges, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringandRelatedCostNoncashChargesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CorporateEnablingFunctionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_CorporateEnablingFunctionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_GoToMarketModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_GoToMarketModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072473616">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee terminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringAssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit costs/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts', window );">Total costs associated with acquisitions and cost-reduction/productivity initiatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (income)/deductions&#8211;&#8211;net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs/(credits) recorded in Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, informational and administrative expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember', window );">Restructuring Charges And Acquisition-Related Costs [Member] | Arena [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Post closing compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62&#160;million and $108&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $616&#160;million and $617&#160;million for the three and nine months ended October&#160;3, 2021, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents external costs for banking, legal, accounting and other similar services.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October&#160;2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138&#160;million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Acquisition Related Costs and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072475808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember', window );">Asset Impairment Charges [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Exit Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($816 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($255 million).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62&#160;million and $108&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $616&#160;million and $617&#160;million for the three and nine months ended October&#160;3, 2021, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes adjustments for foreign currency translation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($758 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($110 million).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072168480">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (114)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">311<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Net interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">240<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty-related income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(239)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net (gains)/losses on asset disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains)/losses recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">112<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
<td class="num">(1,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights', window );">Income from collaborations, out-licensing arrangements and sales of compound/product rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit costs/(credits) other than service costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
<td class="num">(1,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Certain asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization', window );">Haleon/Consumer Healthcare JV equity method (income)/loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">51<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (1,696)<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
<td class="num">$ (4,043)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The first nine months of 2021 included, among other things, $188&#160;million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amount in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160071997200">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (116)<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="num">$ (1,436)<span></span>
</td>
<td class="nump">$ 1,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember', window );">BioNTech, Cerevel Therapeutics, LLC and Arvinas [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndCerevelTherapeuticsLLCMember', window );">BioNTech and Cerevel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndCerevelTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndCerevelTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072150304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Schedule of Impaired Intangible Assets (Details) - IPR&amp;D [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[2]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets-IPR&amp;D</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets-IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets-IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets-IPR&amp;D</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1F </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2021 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Reflects an intangible asset written down to fair value in 2022. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079992352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Narrative (Detail) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate for income from continuing operations</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="num">(4.20%)<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075666192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 20<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (165)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives qualifying as hedges, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to curtailments of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect', window );">Pension and other postretirement benefit plans, net prior service cost (credit), tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (33)<span></span>
</td>
<td class="num">$ (65)<span></span>
</td>
<td class="num">$ (149)<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072500256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th" colspan="2"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 87,469<span></span>
</td>
<td class="nump">$ 70,315<span></span>
</td>
<td class="nump">$ 77,462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 63,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,111)<span></span>
</td>
<td class="num">(894)<span></span>
</td>
<td class="num">(2,339)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,891<span></span>
</td>
<td class="nump">75,967<span></span>
</td>
<td class="nump">92,891<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">75,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,119)<span></span>
</td>
<td class="num">(4,758)<span></span>
</td>
<td class="num">(5,897)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,106)<span></span>
</td>
<td class="num">(891)<span></span>
</td>
<td class="num">(2,328)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,225)<span></span>
</td>
<td class="num">$ (5,649)<span></span>
</td>
<td class="num">(8,225)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,649)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,373)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,545)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-For-Sale Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(485)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160066795520">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 12,154<span></span>
</td>
<td class="nump">$ 5,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,890<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195,350<span></span>
</td>
<td class="nump">181,476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">812<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">631<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,063<span></span>
</td>
<td class="nump">33,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">295<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent', window );">Long-term equity securities held in trust</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">812<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">295<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,176<span></span>
</td>
<td class="nump">22,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,330<span></span>
</td>
<td class="nump">27,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,972<span></span>
</td>
<td class="nump">3,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">358<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,330<span></span>
</td>
<td class="nump">4,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,960<span></span>
</td>
<td class="nump">3,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,960<span></span>
</td>
<td class="nump">3,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,960<span></span>
</td>
<td class="nump">3,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">812<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">631<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,103<span></span>
</td>
<td class="nump">29,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">295<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">812<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">295<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,176<span></span>
</td>
<td class="nump">22,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,330<span></span>
</td>
<td class="nump">27,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">12<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">358<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">370<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,154<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,154<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,169<span></span>
</td>
<td class="nump">17,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,885<span></span>
</td>
<td class="nump">17,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">285<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,885<span></span>
</td>
<td class="nump">17,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">285<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">4,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">4,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes money market funds primarily invested in U.S. Treasury and government debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Long-term equity securities of $139 million as of October&#160;2, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restricted, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNIRestrictedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term Investments Excluding Held-To-Maturity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of life settlement contracts accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 30<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=73718008&amp;loc=d3e42732-111610<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160066515984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160071114880">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments by Classification Type (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 12,154<span></span>
</td>
<td class="nump">$ 5,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,176<span></span>
</td>
<td class="nump">22,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,825<span></span>
</td>
<td class="nump">29,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,972<span></span>
</td>
<td class="nump">3,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">358<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PrivateEquityInvestments', window );">Private equity securities at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">696<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Total Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,826<span></span>
</td>
<td class="nump">16,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total long-term investments and equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,888<span></span>
</td>
<td class="nump">21,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_HeldToMaturityCashEquivalents', window );">Held-to-maturity cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 969<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes money market funds primarily invested in U.S. Treasury and government debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represent investments in the life sciences sector</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldToMaturityCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held-To-Maturity Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldToMaturityCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160066576608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Investment Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 24,589<span></span>
</td>
<td class="nump">$ 24,835<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss', window );">Debt securities, gross unrealized losses</a></td>
<td class="num">(580)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity', window );">Debt securities, fair value</a></td>
<td class="nump">24,034<span></span>
</td>
<td class="nump">24,584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue', window );">Debt securities maturities, within 1 year, fair value</a></td>
<td class="nump">23,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue', window );">Debt securities maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue', window );">Debt securities maturities, over 5 years, fair value</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">16,711<span></span>
</td>
<td class="nump">18,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="num">(567)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">16,169<span></span>
</td>
<td class="nump">17,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">15,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="nump">16,169<span></span>
</td>
<td class="nump">17,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">1,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">2,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">1,446<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="nump">$ 1,434<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Next Twelve Months, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Year Two Through Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079308272">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains)/losses recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 112<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
<td class="num">$ (1,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 116<span></span>
</td>
<td class="num">$ (322)<span></span>
</td>
<td class="nump">$ 1,436<span></span>
</td>
<td class="num">$ (1,518)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075731520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative impairment losses and downward price adjustments on equity securities</a></td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative upward price adjustments on equity securities</a></td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079122368">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting', window );">Current portion of long-term debt, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_ShorttermDebtGross', window );">Total short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,024<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,040<span></span>
</td>
<td class="nump">$ 2,241<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160071113840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="nump">32,629<span></span>
</td>
<td class="nump">36,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt, principal amount</a></td>
<td class="nump">31,831<span></span>
</td>
<td class="nump">34,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="nump">$ 32,629<span></span>
</td>
<td class="nump">$ 36,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160071060528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160068363536">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,771<span></span>
</td>
<td class="nump">$ 968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,274<span></span>
</td>
<td class="nump">29,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,426<span></span>
</td>
<td class="nump">21,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">283<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">273<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_HedgedItemAxis=us-gaap_SalesMember', window );">Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HedgedItemAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HedgedItemAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160071966352">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (420)<span></span>
</td>
<td class="num">$ (74)<span></span>
</td>
<td class="num">$ (832)<span></span>
</td>
<td class="num">$ (97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Derivative, Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">589<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax', window );">All other net, Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">615<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">972<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax', window );">All other net, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">647<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Non-Derivative, Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Non-Derivative, Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">49<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivative Financial Instruments Not Designated as Hedges [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative, Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(832)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Derivative, Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">528<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">61<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">558<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="nump">872<span></span>
</td>
<td class="num">(314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Derivative, Amount of Gains/(Losses) on interest rate contract Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Derivative, Amount of Gains/(Losses) on hedged item Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">124<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Derivative, Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">680<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The amounts reclassified from OCI were reclassified into OID.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related short-term borrowings&#8217; carrying value as of December 31, 2021 was $1.1&#160;billion. The related long-term debt carrying values as of October&#160;2, 2022 and December 31, 2021 were $726 million and $844 million, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The amounts reclassified from OCI into COS were:<div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $125 million in the third quarter of 2022; </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $227 million in the first nine months of 2022;</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $18 million in the third quarter of 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $94 million in the first nine months of 2021. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $1 billion within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. </span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pfe_ForeignCurrencyDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pfe_ForeignCurrencyDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160068328944">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 615<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="nump">$ 972<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember', window );">Foreign currency short-term borrowings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember', window );">Foreign currency long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Pre-tax gain expected to be reclassified within the next 12 months</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Remaining period of hedging exposure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cost of sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 125<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="num">$ (94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160070942720">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermDebtMember', window );">Short-term Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Actively Hedged Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Actively Hedged Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">2,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(330)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,061<span></span>
</td>
<td class="nump">$ 1,154<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072184688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue', window );">Derivatives in a net payable position</a></td>
<td class="nump">$ 595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral posted</a></td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_DerivativeNetReceivablePositionAggregateFairValue', window );">Derivatives in a net receivable position</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Collateral received</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DerivativeNetReceivablePositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Net Receivable Position, Aggregate Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DerivativeNetReceivablePositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetLiabilityPositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesReceivedAsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesReceivedAsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160077186160">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,159<span></span>
</td>
<td class="nump">$ 3,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,540<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,513<span></span>
</td>
<td class="nump">9,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories not included above</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160168848144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 19,647<span></span>
</td>
<td class="nump">$ 24,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | Comirnaty direct sales and alliance revenues [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075557328">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76,036<span></span>
</td>
<td class="nump">$ 76,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(57,514)<span></span>
</td>
<td class="num">(55,838)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,522<span></span>
</td>
<td class="nump">20,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,629<span></span>
</td>
<td class="nump">4,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">85,665<span></span>
</td>
<td class="nump">80,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(57,514)<span></span>
</td>
<td class="num">(55,838)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">28,151<span></span>
</td>
<td class="nump">25,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">827<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,829<span></span>
</td>
<td class="nump">3,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">972<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,818<span></span>
</td>
<td class="nump">73,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(55,309)<span></span>
</td>
<td class="num">(53,732)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,509<span></span>
</td>
<td class="nump">19,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(55,309)<span></span>
</td>
<td class="num">(53,732)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">922<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(832)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(832)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,373)<span></span>
</td>
<td class="num">(1,299)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">923<span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,373)<span></span>
</td>
<td class="num">$ (1,299)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for IPR&amp;D, is partially offset by an impairment (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160170736736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Goodwill (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, beginning</a></td>
<td class="nump">$ 49,208<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Other</a></td>
<td class="num">(797)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, ending</a></td>
<td class="nump">$ 49,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Additions relate to our acquisition of Arena. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Other represents the impact of foreign exchange.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160066541808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="num">(782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="num">(881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(983)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(1,312)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (30)<span></span>
</td>
<td class="num">$ (96)<span></span>
</td>
<td class="num">$ (106)<span></span>
</td>
<td class="num">$ (160)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The third quarter of 2022 mainly reflects interim actuarial remeasurement gains, primarily driven by an increase in the discount rate, partially offset by unfavorable plan asset performance. The first nine months of 2022 mainly reflects interim actuarial remeasurement losses, primarily driven by unfavorable plan asset performance, partially offset by gains due to an increase in the discount rate. In the third quarter and first nine months of 2021, mainly reflects interim actuarial remeasurement gains, primarily due to favorable plan asset performance and an increase in the discount rate.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075756000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">$ 207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079081744">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Basic</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,630<span></span>
</td>
<td class="nump">$ 8,159<span></span>
</td>
<td class="nump">$ 26,373<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,608<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
<td class="nump">26,378<span></span>
</td>
<td class="nump">18,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,630<span></span>
</td>
<td class="nump">8,159<span></span>
</td>
<td class="nump">26,373<span></span>
</td>
<td class="nump">18,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,608<span></span>
</td>
<td class="nump">$ 8,146<span></span>
</td>
<td class="nump">$ 26,378<span></span>
</td>
<td class="nump">$ 18,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">5,609<span></span>
</td>
<td class="nump">5,606<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common-share equivalents: stock options and stock issuable under employee compensation plans (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,718<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">5,729<span></span>
</td>
<td class="nump">5,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160072129008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments - Patent Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>patent</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>patent</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>patent </div>
<div>defendant</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold', window );">Threshold for disclosure of proceedings under environmental laws | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_MektoviMember', window );">Mektovi [Member] | Pfizer and Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_MektoviMember', window );">Mektovi [Member] | Pfizer and Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] | Expiring 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_MektoviMember', window );">Mektovi [Member] | Pfizer and Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] | Expiring 2033 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember', window );">Comirnaty direct sales and alliance revenues [Member] | ModernaTX Patent Infringement Case [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Loss contingency, number of patents allegedly infringed upon</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember', window );">Comirnaty direct sales and alliance revenues [Member] | Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsFoundNotInfringedNumber', window );">Loss contingency, number of patents found not infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_EliquisMember', window );">Eliquis alliance revenues and direct sales [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019', window );">Number of patents allegedly infringed upon, expired December 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyNumberofDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyNumberofDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Site Contingency, Regulatory Proceedings, Disclosure Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsFoundNotInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity was found not to have infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsFoundNotInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MektoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MektoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerAndVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerAndVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ExpirationPeriodAxis=pfe_Expiring2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ExpirationPeriodAxis=pfe_Expiring2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ExpirationPeriodAxis=pfe_Expiring2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ExpirationPeriodAxis=pfe_Expiring2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_ModernaTXPatentInfringementCaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_ModernaTXPatentInfringementCaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079334864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments - Product Litigation, Commercial and Other Matters, Legal Proceedings (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember', window );">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Docetaxel [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant', window );">Number of defendants other than main defendant</a></td>
<td class="nump">8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Defendants Other Than Main Defendant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_DocetaxelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_DocetaxelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160075496368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Narrative (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($) </div>
<div>operatingSegment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | operatingSegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 195,350,000,000<span></span>
</td>
<td class="nump">$ 195,350,000,000<span></span>
</td>
<td class="nump">$ 181,476,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">22,000,000,000<span></span>
</td>
<td class="nump">22,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current</a></td>
<td class="nump">6,191,000,000<span></span>
</td>
<td class="nump">6,191,000,000<span></span>
</td>
<td class="nump">3,067,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember', window );">U.S. Government [Member] | Paxlovid and Comirnaty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">6,200,000,000<span></span>
</td>
<td class="nump">6,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current</a></td>
<td class="nump">6,100,000,000<span></span>
</td>
<td class="nump">6,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, noncurrent</a></td>
<td class="nump">126,000,000<span></span>
</td>
<td class="nump">126,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember', window );">U.S. Government [Member] | Comirnaty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="nump">$ 68,000,000<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember', window );">U.S. Government [Member] | Paxlovid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | U.S. Government [Member] | Paxlovid and Comirnaty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk [Member] | Trade Accounts Receivable [Member] | U.S. Government [Member] | Paxlovid and Comirnaty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-03', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-03</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 9,000,000,000<span></span>
</td>
<td class="nump">$ 9,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period of recognition</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 13,000,000,000<span></span>
</td>
<td class="nump">$ 13,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period of recognition</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period of recognition</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyAndPaxlovidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyAndPaxlovidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PaxlovidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PaxlovidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-03">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-03</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160073161984">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 09, 2022</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,638<span></span>
</td>
<td class="nump">$ 24,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,040<span></span>
</td>
<td class="nump">$ 57,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,001<span></span>
</td>
<td class="nump">7,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,498<span></span>
</td>
<td class="nump">20,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains/(losses) recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4],[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring', window );">Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Net periodic benefit, actuarial valuation and other pension and postretirement plan gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Arvinas Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=pfe_ReViralAssetAcquisitionMember', window );">ReViral [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 426<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, informational and administrative expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring', window );">Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other Business Activities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,007)<span></span>
</td>
<td class="num">(3,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,820)<span></span>
</td>
<td class="num">(7,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other Business Activities [Member] | Paxlovid [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Cost, excess raw materials</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other Business Activities [Member] | Reclassification Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">$ (105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Items [Member] | Amortization of Intangible Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(822)<span></span>
</td>
<td class="num">(980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,478)<span></span>
</td>
<td class="num">(2,778)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Items [Member] | Acquisition-Related Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(331)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Items [Member] | Certain Significant Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(773)<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,095)<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains/(losses) recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300)<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,319<span></span>
</td>
<td class="nump">23,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,066<span></span>
</td>
<td class="nump">56,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,319<span></span>
</td>
<td class="nump">23,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,066<span></span>
</td>
<td class="nump">56,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,665<span></span>
</td>
<td class="nump">11,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,222<span></span>
</td>
<td class="nump">29,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member] | Reclassification Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $426 million of acquired IPR&amp;D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of approximately $400 million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $516 million. In the third quarter and first nine months of 2021, earnings include $706 million of acquired IPR&amp;D expenses associated with our collaboration with Arvinas.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $701 million ($344 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the remaining amounts primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) actuarial valuation and other pension and postretirement plan gains of $932 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $1.1 billion ($310 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $899 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $823 million ($150 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of 10 percent of greater of fair value of plan assets or benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ArvinasIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ArvinasIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pfe_ReViralAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pfe_ReViralAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PaxlovidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PaxlovidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160076944928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 22,638<span></span>
</td>
<td class="nump">$ 24,035<span></span>
</td>
<td class="nump">$ 76,040<span></span>
</td>
<td class="nump">$ 57,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage change in revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,851<span></span>
</td>
<td class="nump">7,020<span></span>
</td>
<td class="nump">$ 33,991<span></span>
</td>
<td class="nump">22,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage change in revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,136<span></span>
</td>
<td class="nump">6,221<span></span>
</td>
<td class="nump">$ 14,705<span></span>
</td>
<td class="nump">13,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage change in revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,351<span></span>
</td>
<td class="nump">4,498<span></span>
</td>
<td class="nump">$ 10,671<span></span>
</td>
<td class="nump">8,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage change in revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 6,296<span></span>
</td>
<td class="nump">$ 16,673<span></span>
</td>
<td class="nump">$ 12,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage change in revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PercentageChangeInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage change in revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PercentageChangeInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160065664816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 22,638<span></span>
</td>
<td class="nump">$ 24,035<span></span>
</td>
<td class="nump">$ 76,040<span></span>
</td>
<td class="nump">$ 57,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">22,319<span></span>
</td>
<td class="nump">23,513<span></span>
</td>
<td class="nump">75,066<span></span>
</td>
<td class="nump">56,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneSegmentMember', window );">PC1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">319<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember', window );">Total Alliance revenues [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
<td class="nump">6,320<span></span>
</td>
<td class="nump">5,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,846<span></span>
</td>
<td class="nump">16,680<span></span>
</td>
<td class="nump">55,676<span></span>
</td>
<td class="nump">35,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">4,402<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="nump">26,477<span></span>
</td>
<td class="nump">24,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,514<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,099<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Eliquis alliance revenues and direct sales [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">5,001<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">4,601<span></span>
</td>
<td class="nump">3,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Premarin family [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Nimenrix [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | BMP2 [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Toviaz [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Trumenba [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | Chantix / Champix [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember', window );">Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">451<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,404<span></span>
</td>
<td class="nump">3,749<span></span>
</td>
<td class="nump">10,267<span></span>
</td>
<td class="nump">11,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Vyndaqel/Vyndamax [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">602<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">502<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">131<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Ig Portfolio Products [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">124<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Medrol [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Fragmin [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Somavert [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | ReFacto AF/Xyntha [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | Vfend [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | All other Anti-infectives [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">374<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember', window );">Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">586<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,070<span></span>
</td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">9,124<span></span>
</td>
<td class="nump">9,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Ibrance [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Xtandi alliance revenues [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">320<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Inlyta [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">252<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Zirabev [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">146<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Bosulif [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">141<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Xalkori [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Ruxience [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Retacrit [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Sutent [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Lorbrena [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Aromasin [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Besponsa [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Braftovi [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">58<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Trazimera [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Mektovi [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | All other Oncology [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Immunoglobulin (Ig) portfolio includes the revenues from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Panzyga, Octagam and Cutaquig.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PaxlovidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PaxlovidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PremarinFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PremarinFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_NimenrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_NimenrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BMP2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BMP2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ToviazMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ToviazMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TrumenbaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TrumenbaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ChantixChampixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ChantixChampixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherPrimaryCareProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherPrimaryCareProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VyndaqelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VyndaqelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SulperazonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SulperazonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InflectraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InflectraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IgPortfolioProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IgPortfolioProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BeneFIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BeneFIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZaviceftaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZaviceftaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenotropinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenotropinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MedrolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MedrolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FragminMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FragminMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SomavertMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SomavertMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VfendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VfendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherSpecialtyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherSpecialtyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IbranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IbranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InlytaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InlytaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZirabevMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZirabevMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XalkoriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XalkoriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RuxienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RuxienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RetacritMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RetacritMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SutentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SutentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_LorbrenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_LorbrenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BavencioAllianceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BavencioAllianceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AromasinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AromasinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BesponsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BesponsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BraftoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BraftoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TrazimeraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TrazimeraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MektoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MektoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140160079966464">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 22,638<span></span>
</td>
<td class="nump">$ 24,035<span></span>
</td>
<td class="nump">$ 76,040<span></span>
</td>
<td class="nump">$ 57,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneSegmentMember', window );">PC1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">319<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | PC1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>pfe-20221002_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20221002"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pfe-20221002.xsd" xlink:type="simple"/>
    <context id="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ieebdaac648754d8f9991d9345808cedb_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ief168de902d9492590aa5220b5b73f29_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0729378a52374c80919b47eeb89d45c8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iecf59b86323f44bc955f877e15b9942e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98083abf5b10468887a10a5321465a07_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id3ad8bd638b94660a81910320140a0ff_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="iee207eb562eb45749d0e09bd8ae27d99_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i0cd2c296b7794de18cd9165e100b3645_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="iac935618aa1f4c02973c960cd4d50198_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i1dfdf4b4d9474432ac2661c4f07bf9ae_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id1fa5b9f5af24e07a8d83bc03ff721d2_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i291c881a539a4386ace0953f2e533606_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i322ef81511754d73bd045b355aa263b0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3a00c9907efc45b58509f370291e703d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1008d0f3e2cb4f1fb4612f491b9815d9_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9c4007c71e914cfe8b9ecfa0a6b9a28f_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if4e546bd59bb47fb8d148abae15673a7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia4178e1df50642f481342387e7983453_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i283349b3ae194291807e57850205a00e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i9cd63e0776794a11af6999e725dd9bf9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i38fb06657953481f9327c4d7af5221d3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i316fd24dd0da46e5872d02ce9db0a499_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i439e2eb2ea67457d989b7d096b2578b6_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i982bd66098e642c180e76a8b23cfce05_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie2eff56d6b9143a8a6236c386a684328_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i9a860a4fb70d417db1e5ece4d14a5929_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i106884611a9443b0b91471c3127aab17_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i9dd1ece70cb9426792fd297de161a638_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i871492c1af0c4c41901ad429f9c97997_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="ib1d8a56f33e04a88aa94910108df6baf_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="idc3cdee01052447a8c008a36884f4ece_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="if55bdd083c8e4d4bb0f0f79015f34b54_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id0830a768fb84418ac3aa1b642de41a4_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7aaed31d336142a38895f4e58c290bc0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0cfba0bc31044aafb04e8793a359fd30_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7fbbfb560fd84535bc70f59962461307_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0bf00def957b4c1ca037635793efebf2_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i269d8be2dbe14366928f6a655f330c99_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i3adb48a9ed804129abc01342e3aa820b_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="id7eead2d41724d1284b95a8f2c3ba977_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="icff95de7b4364937bb8f6fa9332bb480_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i89e9bcba37374979b4f81bb0e1923a9a_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iad49f13a7aaf431ca7ad807765db51a1_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie720b049f06b4803a5325d0052df106f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93a4179e99414d2bb29dae8a9ef43064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27da68353c034955b1c275a580f01f68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5305bfba0e7a4d7fbbd4c84a4873871d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ef44849268d4847a9fb27d3a90011e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b19de1c61d540f7a92683b6fcef0492_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58476ceafd6b43a0803a9cdb179436a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idb8a629a946b4ceca7ca7dd72b1af40b_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib9b1498a92d54a268ebfb1b8e658f31d_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if663a3d9b11e4c838a4f9123bcff64b2_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i342523194f354c36af8db3ac1d92928a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad01e12648344a0bbd128d9c7131aebc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a5e26c69446465d846729c653f45303_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id46f714a106f496988fe9d996ad5882b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c21ac9482a54fb3991813baf028f817_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7ec159b1e1141eb90a039d6e396bcd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1414142218df48a784a0e0af5a6fa08a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00f38a2438be4f7bb12b558b25272ce5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1c0af948675a4a7f9a78ce4430cb4045_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i733fe6690f964b79a59503138cfacb8c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id6e44f06dea84bef93e7ada7841e6e73_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8c6c8f9bc04f475da96d6d469914b62b_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if04c3dccab614a94b2908a489d743aff_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="icf6ba2fc692f44b495f2e7f584a00bef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7508bb16fd44454482e06b74af164e0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0861c1e153d4341b6f1aa2768a8b9e3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i20b757dbbd6f4f2bad32cff5eca993e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6721d042bce841789b97c61224022594_D20220609-20220609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:ReViralAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-09</endDate>
        </period>
    </context>
    <context id="if02ecae4c145465fbebfc17542366c8c_I20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="i01574368db75427a9223807866f28b02_D20220311-20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="i87882967ea9849de8a349199b28d5e06_D20220311-20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="id0e5aabb88f345f8b7eacf17c16cdd86_I20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="id429ba78c8b54ea280edb5594ad15554_I20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="ic44d8c4f02f348958a5ef9d3d3956478_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i14aafbc729874cbe90872af65ea59b36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i509aed2b3fb94e35abdfcdc538d2275b_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5fc75e310f54444b94ce2100463e4260_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia87a0c62e89e454eb69933abb4c4cf0c_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="ifc89d78c61c749e883b46dd57f1a3ccf_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i2fbf4bc1a0894e7788da3e8ed8f24508_I20220718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="i0aeaaa46a5c645458d5ca97b3f043df5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i03f67e1304894aa8b40ea227ea7a7e3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2a8fc0f572a7426d9fcc873efb1de4f8_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i18bc5b7d65614c15bf509693d653ef09_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i002cc11dc66a4c92ab91ce99b0fab752_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id859aeb95872427ca6e14971df36fe79_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i420561cd7e844911961eee63ae39bdd0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70b27e6f401f4351a27e511e00a11af2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesUSDDenominatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a94f1c0e3654553b739db0514bb91f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesEURDenominatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie15724356ec94a19bb862b3f6307566e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesGBPDenominatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i600244a7a17344ab962cbad5adad812f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i28e0ab0e158f46899e45c2d773856f14_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:A1365ConsumerHealthcareJVLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ife71c632282645c6972017eea707a24b_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i42142f3d667447f8b004965d67fb5bef_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:A1365ConsumerHealthcareJVLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="id7af860819f54f01861664b5ad041b8f_D20220104-20220104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="i58af9a3440794bd6aecec41e17eef71e_I20220104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-04</instant>
        </period>
    </context>
    <context id="ifc7381e87f7646fd8e2cbda19e2e2d0f_D20220104-20220104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:ResearchAndDevelopmentInProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="i158261a31a1c413799e169c8d84fe9ba_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i722d6d36e0a3476b89b0cdc056d0f26a_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i21b538a5cc974cf8b8cff85d8c511b6c_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CorporateEnablingFunctionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i28697c549ce3454c8ce5980750988a6d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:GoToMarketModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie27e5b4edce54e8e8a8ad6d6a9acc7e8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7fa3843da72a42f2b5f23f8d547a2b0c_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iadd388f3beca428899e121e6042d61eb_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i76c083a6cc0c4200a8e2f51e5486ed99_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4619b114ec194ad0b6cdf916bfe7a1e4_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i743f0eb0d1d04686a3138f343d0a91a4_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id35ac29855a1475ca5478fc62e1fd74f_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0fd5613cc06a4d73a6e8eaa13a7d3b73_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i86ef4b0d7cca452089dd78603de3cf6c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i81e35f95c0c3442aaabb2dfc697eddc0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5f0a9e3dc01d4e41b2c5e11386542b1f_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idf45616770c74e4290c92f85fa0706ef_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id365d50df2a645fa85ed477f05ab1838_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8b8da4f7456e442295e4b41cd995dae1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i72db9e61e2aa40229247e0d3b02b0e82_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i32df0ec003834b6eab05cf61f39fa6e3_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib4744ad08ba8409a820a07a834ff061c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1fd31dba911048de993662a30bd60e24_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5974e3684a5d4959a373f6a880ead072_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2ba30fd6c8d04ca8bac5eceecaea0094_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic0aea8b98cb34108abfe4081d7793e2c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i300033c0ba2c4182978046a909b7606b_D20220101-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5f516286c63343f28a4664b266e75256_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e9ab2b2fea44955974b44346416d463_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d7dbe8638f7401a94c5382e4b054e25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7081406b1b62439ab5fd196c928df604_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0e8b45d1675445aa8d696f11839ca704_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i672675a4e5374596930c5eb56c56fb6e_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if2b1a60419934acf858ae1b59d2c713d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie8f37bc9a3284a51bb64a83d09a3d26a_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i07ffcb4ce1bd422f80c0659256ce5949_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i5120c338e7784bc0a405cf860830dc96_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechCerevelTherapeuticsLLCAndArvinasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i60c3b88c09f446329b1ec1583f33a3b3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9c5aec14bf13443d865368553c8fb09f_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4e03b80a6e31462388cb8fa87c81fae5_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia3e604c4a1134172a1157b3846f7e9db_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6bcdf5d6697b4dfda841c81ef6f0b444_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4fcb9d12f7e8461f800a28613f391b63_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic2a3f390d88441aa84493f5b915fa1fa_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia28d11de768f4acfa1899aa6f92f42fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbe7a5df8a364aef9def98d475a8dd2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedabc8fc306843ffb9c2a5c9a5abf093_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c0c0bfa0bc7435f8a1cb14d125612d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1218785b15a4b428afe5839d3c22095_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie8a588750f30485cba7eb82683ef423b_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id36f1bf78a2e4329b60d5e5ca4f34e82_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6cc5b6fe28ec4fc892354bdc356b0801_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if4713ca3234b4b16be713694331b20e8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i84465afd71b54fbca86dd39dd5eb14e4_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie3ac6485d813484ab3e2a5f79e9312df_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0a51b3abaa324634a216f2ccf13bdd62_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib2d2fd4d529d4ffaa9992caf594aea98_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i365aa8bb027248c0a4bd72e05fd31c0c_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i58ab2d49d10a4441badf49b57db6e345_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ifaf645fee7504d31b036a7ca132adbff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3509896f64d41e5a5a8a7c49b85adbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd50bf1cd5ba47938f5f06d79c2b2891_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i805f99cc930d4f27b83f2f5f22fcfd16_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7edb8146745e45e3b80ad081fff12d94_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i89eef82eb7a14b73bef78f769ed99bc2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ifdb21d2ec5e54e368a11d0e46bd687d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff481cae963c450595873c78d321b75f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7fb7cfc61124350803a3395415aa187_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if479661c13be4b20ac5fb45721ae4f0d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2479bf3cc9724ee0ab05e372bdb15b2f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0a25515655044cabbf3baefce125c4ee_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia48d8b4d17584751a31563d542bdfdaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d99910901024c4c8acc5114294068dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icab958fb460e4fa0a9e49791a40852e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04206940cb3c4f31828b818000eb0def_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i619ff852ea974bb5b961b5bfe763d05f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i49460c8694894c998f43812db50d6a6f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4935735833a74f51b431b13978755e1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i524be4274845416fb3a8a00458bd6bb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i117594e26d1a4ad898c33e699b9f7077_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i914b27e478a94963b2d4b101e6efc8ac_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iefaeb8ef2b2844f88d07b978d1f21090_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i63c6d752d4524b33be36259fef0edbf9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6c24fe9c58be452aad86c0e034bcaf6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56a8a497745744779127896961eb99b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i226bc50d44474921a2117b15aecd4339_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i78e0de40ca8c4677bfae29d91ebdde69_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36e3c0460a4e4852a56a67d528410e84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a162167b3964440947ee8fc8433d811_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39a069f7f44c44a79a99da7df5e7d726_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="if1606489f92c4bd28f5d5bb811476ad6_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia35aa9908c74494b8436d59196094589_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2aa20c368a6845188d5f86675163ec4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i752fb6da23f74a17911b22b40176bdc2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8eb8301baf634a788c90da0b7e186fba_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1b6d88ea8a804863b8b4ec12077d9718_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i458c5f84f016420085b60cd199bcf73a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i979b62479efe4c33bd39145b1249c177_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a58581671444d0fa9352733c8859022_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i10e532bbebdc45249c16d40c3dc0a715_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i106748186c314412998ca5807842edcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia171432125c34b90be8e8604e663907d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6e5471772584760b1d1f8ac3c7d5a73_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="idaf9771697dc4c2187d4f9d4b5006611_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2a3394bb954a4bb283a0430941d2b0da_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4c13c8d6f5e4476488e457cd130177b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7bfbd5763f1476397cb82ac7bae3159_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib536482e78464a5cb14145115c86217a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7009eec6815484bb288be0b6939cfe8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia4fdd3aa58c54a848f098867c06f5d18_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2e77d36f6bb74d9ea078650432f1a0bd_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i88d65cc9d472404c97ea4a88ed62138c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9222f579cb5d4c8f968c453d8254f49d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife4959ff73f845669686173848f68817_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fb79de0c54d447a940125fd8c11fe37_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7e06b72b11c542d6afc570e8531710d8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i29b92fd6f4ac4766a4f58f450bc26d49_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i54b6382776a542a8abe220fd855457a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i867802a8f854403f9965faf6c388210a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51c9c8f46d854bf5b5db351b98fd1a31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49a36bebd932477abb647b4c3f1f7229_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4d1ae606958948a09710f9127386e909_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01adb0c331434d4eb30ff9aa4a978d62_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i195a713f2d9b41099053b0da037cb644_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57a34ccba5c84e5783572681c5b10269_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c1a042fb56a476cb18d112a8229dba2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i18f9e24f27f7455ba6e05f483af693eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2885fade3ad4cc5832c4aa996b4feae_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i208c5cb34c6642f493f12b122be74aab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i3d030e31054241cbb0485358571b9bde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8472588c67134a13847983bdf694f4dc_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9029b150d0054adc95f1fb9398955ea9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i55958062514846a5817b8f0a50f35dd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9722c4887b744055b1904ff63ab244d9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8c60017d6ba741f68386b4b24baef910_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic477a3d1dd454d778619d8af4d4a6650_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i827e7ba807c442599109f6cd0c3eb032_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1b5aa6d82a8b42f0a39f8d78d409bf1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic8da0892f39d46c096dc066b6ec8a83e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3186066be71c42b5a02001d1a9f376b0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i144d47acfac140678093066f01a98ba7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4c6ddfb9327a4b028b11b10328f2ba51_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8a2ed77de0ce405e8cf9e819442e6528_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia942bf711c884c0c8389c2c4658f859b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i97507b074e0e4f6f92c18c2fd703b228_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1460ce67a1664a4886f261a31538b94c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i33dbb0a3d25e4ded9172ca71bd57e611_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8154274534c145acaa81abeaebf413da_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i45883a91d50a47eb96c4f3afbd992dee_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie3150d83c1054e43ac64649354bfd47a_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0e1a99b384254f579445b74f46691315_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i069ae598e0f0477282f60735e915b8af_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6bfd27b3218b487a9810f8d0eca2c8eb_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibc254f3841504538bd25d1e598f7efcb_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4a9ed02e04a84fd4a77116dcbcdb1d7a_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i50bf294318854802b0ca58dbe517a298_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie1f316f885ed4d329752000102edb162_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia14b13073e4e4613b080addd6621f2f9_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib5b98292d9c1417a926a79b66406286a_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3f6af82b6d024b0eafd8f31e35b20075_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if474000c1ec5464d9c71367ad5ee9f35_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i34242284b9494732b030b9e714db61b6_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9f47fc0e281c43afac185ec01923d406_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04751deef2cd46b99805e78bd859c289_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i667311c49e1242729a0e2cfbeb12d37b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ibf9e5de858194ea3a1564e487b4e84b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8308f5a4b0dc4a5e84bd59beff89e949_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id224ff09ffe74524973bc9034a6a86ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c782fb34650411c8db8781a876e6df3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i9991d2e7245d461895c706bb1a8bece9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i749f749980d34e25acc4fb7966c17205_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i203cdb0ebc574f27943dd1e51d1b1277_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i912798045f5b4639aa7284fc67e728b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dd6baec7c42411ea48eebdb0f2f23db_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i9b292fac08314732827dde98a31e18b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4f31c2acdf14f1cb842ad2f9b51b800_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia27c96bd99bc47d68e917e7d12a78b77_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i54cb4a7821fb491f8936f9f3177f14a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9ba175125826473eb8da8d591f564f11_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibfa472f98c9c4c3ba6c39332849653eb_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i7ec7a704d40b402d8dd76af6c1782133_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="iad227400e764448bb7ce0ca5ce1db320_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i91598b6cfce147ed85f80c515a585148_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ModernaTXPatentInfringementCaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie3a4c1b86275499193f0bb113f4c657c_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i498fe9705333412a85d84b8175400688_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i165a698ddb8e4740889d260adc4009bb_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3cf2ffc020fc4128a1f9ebec292fe188_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i260c3e9ac18c409aa7e150f37f31c193_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id5e893c8b2754cf0b8dd3ad3ebd5f8c9_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3d04b7cdf357409082229e55e47bebc1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id294f09255c94f85a1408cb0dd253fd3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i848bc701f6dd422990599b16e3035373_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i92dccc52a63e495ab4c634079bac8732_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2d607e6b68ed4e24ab93bdeca6299e0b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia0dfdeb3dc774794b361ecf3023e31d0_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i38bad6387f68492a8b7da8ed99819fa5_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibb5f43508edc415e9ccadc3761d6ec7b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2531e34ef9984e79a95c51a52ce63392_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i359c961cd6c843d087dbaa286f62f72c_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id20c933385df4b25a75dc3230695c60d_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i678fe644ebee4937ad3471779808b530_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2c601e0fb53d4bfc88abc7f48831dff4_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia8f4ae7d6e40411abaa1ab3cee43b803_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib210c73f222b479aacb31d6c32738d5d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i370133c2be5a4be79dd89de09dd1a1b8_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibe95faf72a3246748e2a732611bcf248_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i30773c6942964c0980876adfe8b4a851_D20220101-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i764cde6156604a799beae35a5e6999f2_D20220101-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i68a882359d454a71b139c8ee18e1de06_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie6c21eb451cf4e45b21d701f1947ac11_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if6173132078d438bbba880f5dfde1512_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icced37b763334b1db16365dedf95e6d1_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia7d134762ff946cba4a83f58faf4e361_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:ReViralAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i71295b17171746288ec47f20b8ee151f_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:ReViralAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i71fb5a9220eb4286ad607375052a2cf9_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i34ae880bca4843ffa60f855563953d75_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4cbfd79f30ac46d99ff22eebda466560_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1ff7971d70164752ac30c9be1a49a15b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id6f4fc3e7944444dba03aff7ca27b97f_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2887f09b32694901bc3771fd88f8b571_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i880f15025068413dad240be909e60e93_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if4d02fa2996741259f33220479bb03a3_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i192d7d95f8b84ad2b81b3eb16434a86a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic89cf38054c742fbb7e8b11d2e93a06c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia4458f5262e14479a0a31486f5d571a3_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i56465e50cdb148659d882d69f8907dce_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic9616f23c18c4880ac9e0c371d696ad1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5e9fab9cc315446eb0e13ffaff8ac454_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i58f52d12f36247d5a3bc27c6d932e64c_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4a747b5aa22c4f1886ff55881482a458_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia080a8aa1141463990cc38aa96fa8e59_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7a6341d784a94e3087d8228477c40d27_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia2dfe09f313047a18e739d76fbc1485c_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic7e6cd06a51948a1b9a6198a5b0d7711_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4e1858be123e4843836e844815b1712b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i54c033a90c144654982cec00e6120cd9_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i63858517ad514373922e2e8b09241570_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iefc4117e5afe4c0e842be69332f62eae_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if9e0a2c8196543638ffe58bb564300d7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icafc3f7a9cee4ec19c29b091247d4bdb_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if9199195ad7641279516c969753b478c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie38648544e7c43219d1df8126f6b9dc6_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i607941fb91174f77a6d963a5372b1b3a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ida92047028cd4bed94eef70e5400c5bf_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i736289ab886a4191b2b2182031ea21a6_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idb736aee91454a25a6441df3dd80d5e0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if613572161c346fcac294c7e32c378a8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i70e054adec2e4bad8ec56ba5798ba8ae_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia2b47973e6ac40f7962fdc8d0adb611d_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icf979907b2914655ac6e0a1a750fc363_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia1f53b0965de4c1fa8b977d9f6510ac0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7eae5a52dc634277ae8d307ccfb995d2_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic55da2d7f85e40b58f460bad5984b81c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia10d0e1d609e4e219fef4b97c4939891_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4db8e7e6e5bd43f899b2d9e49d1a99f0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if421226bc57541e4a9ce23fe47d542e2_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie7c319b3ee06435f8203948f53950fa4_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i46cead4bca44470bb6e5485ad16d704d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i18f8c171007c41bbb0447b451c0d89d1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6d1e1da5edbd418b9ed52c7482de82cd_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1e87bf34d54945c1bb8dffaa5340c8c2_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4f9228a4392140c5aadff356ad41e232_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5ddb4a7f8df94efd865ffc529de4e9e0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i586dad3bf41b4478a6a7bf583b2bf621_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4e4b745d89e249d491f381c3aaf895c5_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i18ef446f60f046bca0e069bd65549c9f_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6d914ca9794640ffa3ec5e10b6cee5f5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i930a1f7cfa9d456bae7cb9c7c1e3e816_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic2b8fafd05bb4f5db3a80e0c919d745d_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaac2d287a23b4b88b22df7d728b108e5_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2b85277d9f04472693fc3c174486102f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iffcfc2ea0698426aaf9c9ef575fd797b_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ief03ef0a913a488da5d349f44b79df38_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i71ac32c435d7417a8258ad657ca4d5db_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7d9e7601d2a949b391ea06de7ce817d2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i847b7cc69e5c45d4b6eb6fdfa02ac9fd_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id78cb321690f41a9bb94aed3b1906a7a_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icb4c063dba364bb6ba775ef1b933b60e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic1192155b8f54c838c4960883dd5cd12_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i219d3b8b6bdf41049720a23a2998280a_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8900fe5ad7d64b02bae061fd7863a809_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib1f67297a35446ffbfeb15e1560ea010_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia94e68a684f34fdeb284ae983ecf8590_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i997a8d6896fd403da5f90a6718f7b5c2_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6c282565578941d5950ca8e622206e11_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3450d41f6f8c4add8f70e81bad35f8a1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibeb3e653eb0046c7ac2807a447d5a81d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ife21a256301a4c639bb9b4d83799b744_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3564594ecfbb4ce7bddde0cfd454db19_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i681fcc33174e41159cf96193a702c0dc_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i79f4ff79e8e54212839e35689b460762_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic1f46d7110d242bd9da8d5dc2c2f396b_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0dceba1ae2e14264b25308d846b234a3_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1fead61708764dc986e38daecc3da97a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6cc960090f944473b1de0a5c83bdb9a9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id9a2a488847c40d88bb4f5f52dec7967_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2e18531693d04b6a98fe0852c4c5025b_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0452040fe699493da4f37d561f3f548d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie1b42fa5a6cd411a8ce00a20130d39dc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2892d1f59005440db65ec4752ff8a06f_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i09231dfffc444767bb73115a01b1de18_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1a48fa456e8e4117a0324151697d5442_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if0f936ba9ca84017b4b97358942bfc9e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibc8e83a1b35f4cb0aa9adf9618682ad6_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i70f393eca9894fb1887c099d45a0457c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i73121833f65a48dabeef6c4f70ffc8fe_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i10e0cee382be47eaab3cef8255b4bbf3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icb25ad491f0f4cd4868a150b3df14736_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5874fba6c68e4599a0fc3fb5193f6357_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7ed5fec2776a43d5b52002377b487e31_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8b5bcfbd37054eeb8cf0f03e878adeb1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1cad181f9d3a4c559ea98c3fe153c7e0_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibabe9fee66024117bd6b35cc88a984d3_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i19b5d2be8736491eb3d14bd80d72787c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iecb8d7d4ec27458b904b759251802162_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i528162cfdd864c2f9cfe732522d830b7_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3fb1258143354aadafcf0cffc1e8922c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ieb1973fbbf1e499b9274056be29d6f9c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7a43c802a36b4c2db68c41cc136daf70_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i271e8b9e93e84bcfaa8c788053977b20_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic20359a48688484fa197f302f7463767_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4034cba9c5324ca795292cedaf88e6a4_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7c5554206f8a46328005d910c6b0e431_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i427f057de3fd4215b2b63624f5c325a0_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iee23be5e923547fab2329d5b56c61ed8_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6646c1fa39b14bd4a1f5e9affc1282cd_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iab54fbd61cf24874aab5381668df8403_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia8c3e0cbcbcf4b03a734bd12c5194903_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibec65066e53f40bfab7cdd1c00671818_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i218a664fe1c4469bae3b80333f3e0cec_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0b91d02d234645c793606aa29b0d901d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3a5d2ac36d9d4be0b0289526710db8fb_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia969cc2c0ebf47d8816380e47bf220ed_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i42322074968a4077a5a1b52768045df2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i75f3be521f224b8fa223498877d51452_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i41086f4199fa4adf853900d30d476fc0_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic35c1201fcf34260b06f08c7d2dca0d9_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8a9f1313cc29448587a6446dbf0c3f3a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8e86ded88f3c4dc6812eb051724b5fbc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i693bafa1895348fbb803b977431d462f_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie91260f6cb4049409f21cbe3937ebc85_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2db6bbabd95c45ea956e59e8ea612ed0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic4e33f7150c6471c938a45f53ef7a709_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ice7fb1f835ee48e7963f5d0bb55330f0_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i29ab61c3fcb34e45a64f5455f6442ef3_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia102ac741b5e451aa63ffe982d59beac_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5ae5f3828ae041d8bde249471bd9e321_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaeace31d957b42c2a7709f9948bc9709_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i878d1447a4ca4813b621dc3cc89befa2_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if602f21734f7495d8b816aa6bcd6498c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie8e66fa2a70a4649a96bfd9b2e39b902_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie28dbbb6bb0e41d5a7fee7ddf2c97859_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i37857266a0444b1a85059b213ce1320c_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0e3b9a9454c04c2a91c44f60a9080c13_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id633b0178823447f98f4fb90652a4b43_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib646354746ad4597828f14cf71b869f0_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i801deeefe2ab4c79a8fc02da44868706_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia62e7abf3e4d48e080bf9026efbb11a2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i004d3ce3105a4fed95460eec415470e3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i11eb45e9cf444c2aaec2c6742022efdb_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4b25b150fb1c45e9a0380f915623fdb2_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib80b331462b2491d9db4424b5e8bd924_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id6692eee652446979a0b8ecce8cf90bc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4da74bd9833e4cd6a768fed715ba4cb1_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id176e11c7c904d469cd2382368b11d61_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie0836f20c7ba46df8c7fb318c2836678_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2a2ad9788911406e9443bb89ba74f344_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iea562808de51468f86c413b0feafe114_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i973e5c192f1f459782b9e4ea90048122_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3a004a95111a4f2db0d2669d2f610693_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3f100f20573b432288b09f6b64c4671e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9aa66a51bca84785ad4c259d04a22cfd_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9d54941efa2941f699fe6aa44f0a4954_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i64ee738588b245b38e912a7df8a75d04_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i76089b0f719c43e08c7f98682f02aa83_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie4e3fef4910241e5bcb815efea4ec15c_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7f57ceefda7c437a8b98c4564c51b6f7_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if69e9f4ce5be4a61997e3ab67969be34_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaf753ff3c5554491887de93db1fe560b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifdcaea6d26ee46e0bafa9e9f9da6496d_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ide0acf4ae0c84031a293157923acb753_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i87b1ca93f57b4e6ba57c282fa30f3976_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i357d700ae87d4d468163149932549cc6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5c2de171ee654cf8884e29fdc4318a0d_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie2ceb413b1694f46ae29ffadc6262050_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie5bc27120a7c4359a1cd74322bb22c5b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ieb7f810aa79a45b0bb5466e60f929931_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4093973df5c94ed990eeaa9c48d107c5_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i56622c1212fe46f68f7c8455f4d2a523_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i41d1bf41d84d4d41a0c1deb806b16620_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i900010cf3afc449c8b72dce7cc16fe0d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i71bf78dbc98843239656272f490339bc_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6de406d2bea4496db2a3b0790f7858dc_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib61ec39f8eec4e90a85dfdf93b4b8e60_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i83462764e3144e25ad4064bdf364bb72_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if09ed1dfe1fc44eba41758c7b72b1220_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i75f066e1ee0b44eba6238a376debfc1d_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia2b3896ecd1f4b91b83726ec4b21f326_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id15ad6f996594166971b1dbb8262b0ea_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if1b7b3fe6f55498d913853d8a9489481_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i69fbc0b4b93c4abe94a8ee2dcd69e98e_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i70124bbf39724876b8acf2c4bfeca836_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i206d32a63e3f4cfd8f6c8d75168367bd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie87e55493f364c369dc8ad1d40cbd422_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib27f8e680678446f86545701da276329_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7fbeed7d4fbf439a9819aa469673b46b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i38b58aba96014c749e5dd13a48805369_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7a3dfcdc4c8a44a08bb30d6681bb333e_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie43bf4a89a5f40c9abaea813b2440c31_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9eda3444dc5f41b4bba147d8d43c862e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i90c61ae6ba8c4e6ba44617ed0e6e6331_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i809d717936604b26a18012f7b8b9e2cc_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic160791460df43c18efb41f047eb99f2_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic2e39688a3c748cbb50e3f3fbd49323d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7f2b596d2f9944daa642c722ddb35c58_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id911b17700454881be23254e2132425f_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i36c47732986f4e1cb33d655f70e90bda_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i10e972355f674b2c8872f2e11d8a753f_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8472823d53ca4530ba656db6b08aacbe_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4401e5c37dd1444192245cd5facba3fb_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i027f314cb29d4db7820ad2436483ee1d_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iace4e825c4024bd7baccc5a0fc1b6426_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic39b763d5ca341f5afd21c2f801ad63d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i531e99cb29294ab58cbd26ac7ff982c6_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if18af7be85824b4aace60f7124ab2108_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i992624b40ab1462a957959426582393d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5155b8e6532848ec99ad1757626c1d0a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i622fdfe2355249ccbc9c305380b6be81_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4503374f47504e53a8a556f65267f8dd_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic9d0c096b86f4eaba702765dd3329741_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i92617f0978cb4c60a86dd7c4cabc5122_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9ebe86d55ea4421c89f72c68a2c75f59_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idc10872084e8447ab3832bbc01a6c62f_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7feed05291314be8ab413820d9581a34_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic34e46c91a314553b59159136459f579_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib4b801e727bf47de83a1422fd1a40ba7_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifb622ed9f6534687aa3bf61cf0d3f889_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3a658246e2b34fd6a44cebc005385303_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i53a9464430b1419fba05017b8bd79cf5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifde011cdb7ec481f92dc1a4d3d485ee1_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ica70d473e5c64734bc680a816c324426_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7336380d9d6f4a4495fae7cd4004e307_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4ef9df7820e54c5ebe5b2bbcfce634fb_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i111ea6956a0241f7b44852b8f11b8f68_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2f1dfd6335a24eddb48dd65039a27f6d_D20210101-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i22e6b4b0386445c2b216f9309b164440_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-03</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id8bf1cff4bcf46a8a95e2b2f3561e4d8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i26e1cf1555744ef5a90bad26608bf34f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i5156002b7783431eaae2362428a7dad3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyAndPaxlovidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia747d02316fd4b71a97be55a1aeac96c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ec84b4e39aa4cbfa3468dab7b9c69a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i134056e8daf84277a6603491cf1250cf_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0f817b3f9c904714845e29d3b0c9c8f6_D20220101-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="operatingsegment">
        <measure>pfe:operatingSegment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="patent">
        <measure>pfe:patent</measure>
    </unit>
    <unit id="defendant">
        <measure>pfe:defendant</measure>
    </unit>
    <unit id="manufacturer">
        <measure>pfe:manufacturer</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfMy0xLTEtMS00Mjk2NzE_0ffa4759-f8c3-4998-974d-8c839ae8032f">0000078003</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNC0xLTEtMS00Mjk2NzE_5f7e015c-b945-40cb-b909-1f332d908f16">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNS0xLTEtMS00Mjk2NzE_040efffb-a703-4f39-bdb3-0dc919681ccf">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNi0xLTEtMS00Mjk2NzE_834ed5c7-ddad-4f2a-ba8f-11c86fe88eb8">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMy9mcmFnOmRjMjYxMTQzMzE5YTRlN2NiMjEyMTg5NmQwNTllYjllL3RhYmxlOjg3MzNiNmQ4MTYwYjRmMjk5MzNjYTBiNzM2M2JiMDFiL3RhYmxlcmFuZ2U6ODczM2I2ZDgxNjBiNGYyOTkzM2NhMGI3MzYzYmIwMWJfNy0xLTEtMS00Mjk2NzE_c6b8b9a8-2806-45d6-b10b-63ea9a2e6a0e">false</dei:AmendmentFlag>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i22e6b4b0386445c2b216f9309b164440_I20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xNTc3L2ZyYWc6NTM5NTI5ZmUyY2UyNDhhNDhlODMyMWFjNjI2OTE5ODUvdGFibGU6YmJmYTg5OTUzMGI2NGI0OWFjNDBiMTc4NmEzMGJiOWQvdGFibGVyYW5nZTpiYmZhODk5NTMwYjY0YjQ5YWM0MGIxNzg2YTMwYmI5ZF8yLTEtMS0xLTQ1NDY5NA_853050f9-cf4b-44b0-be3d-8aa8b4a52dfa">P3M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="id8bf1cff4bcf46a8a95e2b2f3561e4d8_I20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xNTc3L2ZyYWc6NTM5NTI5ZmUyY2UyNDhhNDhlODMyMWFjNjI2OTE5ODUvdGFibGU6YmJmYTg5OTUzMGI2NGI0OWFjNDBiMTc4NmEzMGJiOWQvdGFibGVyYW5nZTpiYmZhODk5NTMwYjY0YjQ5YWM0MGIxNzg2YTMwYmI5ZF8zLTEtMS0xLTQ1NDY5NA_7a77205f-e1ad-4b66-a018-d22464406d42">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i26e1cf1555744ef5a90bad26608bf34f_I20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xNTc3L2ZyYWc6NTM5NTI5ZmUyY2UyNDhhNDhlODMyMWFjNjI2OTE5ODUvdGFibGU6YmJmYTg5OTUzMGI2NGI0OWFjNDBiMTc4NmEzMGJiOWQvdGFibGVyYW5nZTpiYmZhODk5NTMwYjY0YjQ5YWM0MGIxNzg2YTMwYmI5ZF80LTEtMS0xLTQ1NDY5NA_8a784c25-870c-4984-89b5-3f6d0c38507c">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl84Mg_ce67eccb-14c5-402d-8b09-8297c5d6b3f8">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl84Nw_61ff7ac3-26bf-49e0-815e-173a1e143c53">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMTE_aa8629be-bca5-4b6a-ba5e-0c39116c0c4b">2022-10-02</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMjA_044a5d38-05a5-4dd8-b323-d824b0efe6a8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8zOTI_a997713f-5115-4ca4-982e-a70a0ce726f9">1-3619</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80MDI_d811168c-bbb0-4682-86ac-772e008c44a7">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6MGRmYTk0ZWQ2NjY0NDkwNzg4OWExYWI2ODVlODZmM2UvdGFibGVyYW5nZTowZGZhOTRlZDY2NjQ0OTA3ODg5YTFhYjY4NWU4NmYzZV8wLTAtMS0xLTQyOTY3MQ_d6f1377f-2b97-4417-b6e1-2a8e916fba7a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6MGRmYTk0ZWQ2NjY0NDkwNzg4OWExYWI2ODVlODZmM2UvdGFibGVyYW5nZTowZGZhOTRlZDY2NjQ0OTA3ODg5YTFhYjY4NWU4NmYzZV8wLTEtMS0xLTQyOTY3MQ_47425e84-fe17-4f37-a361-0f70c08656d9">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMTkz_bd5d65e3-ea33-4e50-8aad-c637b12aff9a">235 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80ODc_fa06f775-df17-4d55-94fa-a7266f1e7f35">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80OTE_65a003f1-2535-4ea9-95a7-cffe29eebc99">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl80OTU_d42da7ac-9918-47e0-8619-9717a7f644de">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl81NTM_800b53ab-63d8-4b28-8762-4cea84470bb4">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl81NTc_ab770b57-0493-45fa-9b10-e62a88b1839f">733-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY18zLTAtMS0xLTQyOTY3MQ_dc4b9a64-0381-4aaa-b29c-ed5f6033cbf2">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY18zLTItMS0xLTQyOTY3MQ_caa4fa7b-1e83-4635-b8e7-eb613c3178a7">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i290dce53f0ab4574a7d5185e231cac4a_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY18zLTQtMS0xLTQyOTY3MQ_be0e118a-7653-4df4-b7a6-3dd04b2b0824">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY180LTAtMS0xLTQyOTY3MQ_4db57078-1899-4325-b473-67eb7d037e67">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY180LTItMS0xLTQyOTY3MQ_19e736c4-784e-4aef-947b-a0e468c0223e">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id9b155b99a004f62b475a6f5579e06f8_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6YmMzNWQzMWJhOTYyNDYzNThjNjgxYTI0MTIzNjQ1ZWMvdGFibGVyYW5nZTpiYzM1ZDMxYmE5NjI0NjM1OGM2ODFhMjQxMjM2NDVlY180LTQtMS0xLTQyOTY3MQ_83c89b24-fb1e-4a98-b97e-499b1e4363bf">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6ZTkwZjc1OGM5NmMzNDI4OWE1OTNkZmQ0NDFkZTQ4YmYvdGFibGVyYW5nZTplOTBmNzU4Yzk2YzM0Mjg5YTU5M2RmZDQ0MWRlNDhiZl8wLTAtMS0xLTQyOTY3MQ_e3511144-f1f9-4477-825c-1683fc331d1c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6NGRmNDFmYTBkNjRjNDAwNDkzZWY0ZmZiMTlkNmU5ZmEvdGFibGVyYW5nZTo0ZGY0MWZhMGQ2NGM0MDA0OTNlZjRmZmIxOWQ2ZTlmYV8wLTAtMS0xLTQyOTY3MQ_928c18d3-1723-44a5-877d-c1ecf022b1c5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8xNjA0_21912e89-e889-4b05-928b-6efd7012e5e1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8xNzIx_26185feb-6f36-4384-92ad-6aaaa1749eaa">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8xNzQ5_68aeea55-7ddf-4d19-9c28-ec21373802ca">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGFibGU6NzIxNTkzY2UyNTk3NGZkYjgwNzc1NGQ3OTIwMzBjMTEvdGFibGVyYW5nZTo3MjE1OTNjZTI1OTc0ZmRiODA3NzU0ZDc5MjAzMGMxMV8wLTEtMS0xLTQyOTY3MQ_1de13be9-a9ef-4372-ab80-5df819fca7bd">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ieebdaac648754d8f9991d9345808cedb_I20221104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xL2ZyYWc6ZDFkY2FhNDdmZmM4NDIwYmEyODlmYTQ1ZWQxY2I0ZTIvdGV4dHJlZ2lvbjpkMWRjYWE0N2ZmYzg0MjBiYTI4OWZhNDVlZDFjYjRlMl8yMTMx_55e2c30a-8a1f-4f44-b7e9-e3641eb5e693"
      unitRef="shares">5613314537</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi0yLTEtMS00Mjk2NzE_0d2f32e3-fc44-419b-ac40-ed721b1df0c4"
      unitRef="usd">22638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi00LTEtMS00Mjk2NzE_53508527-59e5-4b04-b339-aa3c0a96b5ba"
      unitRef="usd">24035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi02LTEtMS00Mjk2NzE_b77efff8-b498-4a62-badc-66fc8e5683e7"
      unitRef="usd">76040000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMi04LTEtMS00Mjk2NzE_796ef32c-d175-43b7-a17d-f11dbc00f7a1"
      unitRef="usd">57450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC0yLTEtMS00Mjk2NzE_4f224122-0a35-4e3f-9dd0-11041329633b"
      unitRef="usd">6063000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC00LTEtMS00Mjk2NzE_2fa4bb9e-0957-4c96-9091-0393874e4de4"
      unitRef="usd">9932000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC02LTEtMS00Mjk2NzE_4e16e5b6-403b-4338-ba8d-a34667b802d1"
      unitRef="usd">24696000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC04LTEtMS00Mjk2NzE_3b2e2844-68e7-410e-8433-e1a05ba0a696"
      unitRef="usd">21085000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS0yLTEtMS00Mjk2NzE_5eb218ae-d9ad-49f3-b2f8-d149de85dbf7"
      unitRef="usd">3391000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS00LTEtMS00Mjk2NzE_ed942a2c-7590-489c-aabc-dfef446d4052"
      unitRef="usd">2899000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS02LTEtMS00Mjk2NzE_5f1649a3-e04e-4ee8-a021-870ef2ee4d98"
      unitRef="usd">9032000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS04LTEtMS00Mjk2NzE_7624d374-59ee-4834-9165-8897722eb1be"
      unitRef="usd">8599000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi0yLTEtMS00Mjk2NzE_44117283-5b09-4994-af4d-2d8dda2ed9cf"
      unitRef="usd">2696000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi00LTEtMS00Mjk2NzE_53845acb-2cf8-4668-b312-61c0ac2a9c31"
      unitRef="usd">2681000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi02LTEtMS00Mjk2NzE_5437d538-f3b1-46a7-bced-fe9257f5f05a"
      unitRef="usd">7813000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi04LTEtMS00Mjk2NzE_e873dbff-e914-4e5b-8326-561e7d2cf216"
      unitRef="usd">6914000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy0yLTEtMS00Mjk2NzE_6b841c4b-f673-47a6-b336-32d761d15aeb"
      unitRef="usd">524000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy00LTEtMS00Mjk2NzE_86dd17bd-21d4-44d2-8df2-23e29c42b7bd"
      unitRef="usd">762000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy02LTEtMS00Mjk2NzE_2b68c9b4-d476-4c72-85b2-8e48b07f8779"
      unitRef="usd">880000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy04LTEtMS00Mjk2NzE_2b96c6ba-c542-4577-a709-22e7b00662cd"
      unitRef="usd">1000000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC0yLTEtMS00Mjk2NzE_c6f1a830-a06c-4aee-b411-dbcfdf0db397"
      unitRef="usd">822000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC00LTEtMS00Mjk2NzE_12564d12-d1de-4a1d-b19f-e68162b72f4c"
      unitRef="usd">968000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC02LTEtMS00Mjk2NzE_24b3c54a-1ed1-4cf0-b08a-310df7b96c86"
      unitRef="usd">2478000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOC04LTEtMS00Mjk2NzE_4c968175-e21e-46db-a922-4133737c989e"
      unitRef="usd">2743000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS0yLTEtMS00Mjk2NzE_34bcc20a-e5be-429c-b94f-6f138e7cbe27"
      unitRef="usd">199000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS00LTEtMS00Mjk2NzE_141dd8be-cd50-436f-837b-ef41ccff4cea"
      unitRef="usd">646000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS02LTEtMS00Mjk2NzE_145386f7-f7d9-4efb-9fea-731199de4d5f"
      unitRef="usd">580000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfOS04LTEtMS00Mjk2NzE_54f66fdc-5dc7-4948-9ac6-470ea2a10152"
      unitRef="usd">667000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtMi0xLTEtNDI5Njcx_f1b974a0-f721-495a-8c2b-980eb4a3ce37"
      unitRef="usd">59000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtNC0xLTEtNDI5Njcx_d9cd9e2d-ef0d-49db-a455-b92cb5f2cd3e"
      unitRef="usd">1696000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtNi0xLTEtNDI5Njcx_50f1acec-2b6c-4013-976d-04cd151bc671"
      unitRef="usd">-1063000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTEtOC0xLTEtNDI5Njcx_c73d25a5-a77c-4dd2-88a4-ed2e393f3f2f"
      unitRef="usd">4043000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItMi0xLTEtNDI5Njcx_b74f2c58-927b-4637-aa3a-c9597d8cf8cf"
      unitRef="usd">9001000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItNC0xLTEtNDI5Njcx_172e3528-8ecc-40f4-af06-c7e17485dfc9"
      unitRef="usd">7843000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItNi0xLTEtNDI5Njcx_4e8fb54b-fcf7-4213-a1ea-c8a2a751111c"
      unitRef="usd">29498000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTItOC0xLTEtNDI5Njcx_2e242f61-5239-41a5-98e5-721d370cf9b2"
      unitRef="usd">20484000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtMi0xLTEtNDI5Njcx_4eb2b6a5-1f1a-421b-b817-c1191f7c3d6d"
      unitRef="usd">356000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtNC0xLTEtNDI5Njcx_a47edd62-4f20-4aeb-a7ef-50ef3f6f501c"
      unitRef="usd">-328000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtNi0xLTEtNDI5Njcx_03a980c4-325c-4d90-bff7-b2b2cb451d1e"
      unitRef="usd">3098000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTMtOC0xLTEtNDI5Njcx_ac1c1dbf-708e-4e89-a981-7f7938fc773e"
      unitRef="usd">1603000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtMi0xLTEtNDI5Njcx_416538c6-e744-49fc-9aa9-3f45248cb579"
      unitRef="usd">8645000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtNC0xLTEtNDI5Njcx_863dddf0-ab18-4813-820b-d11680080ce1"
      unitRef="usd">8171000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtNi0xLTEtNDI5Njcx_34acbfd2-99d7-4235-9ce1-574d0a5c82b1"
      unitRef="usd">26400000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTQtOC0xLTEtNDI5Njcx_60475f03-882a-4932-bae3-06cddd35fd5b"
      unitRef="usd">18881000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtMi0xLTEtNDI5Njcx_228e252c-df71-46d0-b57f-9c45515485d8"
      unitRef="usd">-21000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtNC0xLTEtNDI5Njcx_e0e01aa3-ff0f-4f73-a1a4-f933ae8285cc"
      unitRef="usd">-13000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtNi0xLTEtNDI5Njcx_856e4129-e341-4d20-9abc-8dafc7c44156"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTYtOC0xLTEtNDI5Njcx_a413be57-7984-4da2-8432-8482b7d0d5ea"
      unitRef="usd">-248000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktMi0xLTEtNDI5Njcx_af606b4c-87ec-42de-956b-526ea06907cb"
      unitRef="usd">8623000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktNC0xLTEtNDI5Njcx_77e42dec-780d-4cc2-a113-b4f4303e9058"
      unitRef="usd">8159000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktNi0xLTEtNDI5Njcx_0da6bb42-f51c-4c21-b95c-6ee74117d514"
      unitRef="usd">26404000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMTktOC0xLTEtNDI5Njcx_f0e3a417-e3b2-4970-be31-50791f00af2f"
      unitRef="usd">18633000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtMi0xLTEtNDI5Njcx_a0c4ce66-f3fa-4631-a780-30767f7e8c82"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtNC0xLTEtNDI5Njcx_5082c4d4-be7c-44dc-a173-63c37277ff56"
      unitRef="usd">12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtNi0xLTEtNDI5Njcx_218d2c96-c588-4ddc-a74f-f0b8798ba361"
      unitRef="usd">27000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjAtOC0xLTEtNDI5Njcx_628167c0-35b4-4574-a786-60249ba4dc66"
      unitRef="usd">47000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtMi0xLTEtNDI5Njcx_290251bb-ed91-4bfc-ac6c-267c2a555383"
      unitRef="usd">8608000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtNC0xLTEtNDI5Njcx_b5b96016-85af-4fd1-a40d-2949271ef80c"
      unitRef="usd">8146000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtNi0xLTEtNDI5Njcx_d8b044ba-010d-4060-b320-b1b1b43e21a5"
      unitRef="usd">26378000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjEtOC0xLTEtNDI5Njcx_34bb7a0a-5926-41b4-912b-8f94aadbee57"
      unitRef="usd">18586000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtMi0xLTEtNDI5Njcx_c746c8ce-8261-43a8-a7b0-6378a9d90029"
      unitRef="usdPerShare">1.54</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtNC0xLTEtNDI5Njcx_69f55294-c32a-4413-a154-4e70e102f494"
      unitRef="usdPerShare">1.45</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtNi0xLTEtNDI5Njcx_3ed71641-a75c-43fd-99e1-dae56520d95f"
      unitRef="usdPerShare">4.70</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjQtOC0xLTEtNDI5Njcx_d68c2377-17ab-48a5-abec-a4b7bdb59f62"
      unitRef="usdPerShare">3.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtMi0xLTEtNDI5Njcx_4b644c3a-8f1d-4e62-9a88-c4e1dfdf8f5d"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtNC0xLTEtNDI5Njcx_803452eb-2ea5-4704-83a7-5958ffa2f389"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtNi0xLTEtNDI5Njcx_63db5c22-1a42-4c9d-a2a2-530755d686e5"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjUtOC0xLTEtNDI5Njcx_159c7866-e6d0-4f2c-bad4-aece6bbf341d"
      unitRef="usdPerShare">-0.04</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtMi0xLTEtNDI5Njcx_1943d969-9185-4faa-b7bf-098ae3d3a9ec"
      unitRef="usdPerShare">1.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtNC0xLTEtNDI5Njcx_24cac765-9335-4af9-a7fc-57228b907685"
      unitRef="usdPerShare">1.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtNi0xLTEtNDI5Njcx_2d22198c-a112-44b5-bc65-15f66cdc2392"
      unitRef="usdPerShare">4.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjYtOC0xLTEtNDI5Njcx_6f12f487-86ad-4e2b-b7f7-f6f809f01f3a"
      unitRef="usdPerShare">3.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktMi0xLTEtNDI5Njcx_c58fc77d-f4a2-4d02-98fb-b042079f20cf"
      unitRef="usdPerShare">1.51</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktNC0xLTEtNDI5Njcx_596f751c-e7e8-491e-b9ee-42110386a239"
      unitRef="usdPerShare">1.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktNi0xLTEtNDI5Njcx_0a08a7d0-f1c7-4006-8e51-24c2c8c2f13b"
      unitRef="usdPerShare">4.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMjktOC0xLTEtNDI5Njcx_066c7566-bb69-4363-af47-3837c8ad7592"
      unitRef="usdPerShare">3.31</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtMi0xLTEtNDI5Njcx_21dffebc-39be-4083-983f-bbb38442168a"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtNC0xLTEtNDI5Njcx_2944049d-84c7-4eea-b969-3aa9bf4f57b1"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtNi0xLTEtNDI5Njcx_70f44876-41b4-4f5d-bcae-fd2efbe4069f"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzAtOC0xLTEtNDI5Njcx_ab9d3617-6d6f-4b02-b2df-8a6fab37d1e7"
      unitRef="usdPerShare">-0.04</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtMi0xLTEtNDI5Njcx_e92c5af5-b4da-48d8-9c90-dc36670225fd"
      unitRef="usdPerShare">1.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtNC0xLTEtNDI5Njcx_e836a2c9-303e-49f8-90eb-b0ffab2451da"
      unitRef="usdPerShare">1.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtNi0xLTEtNDI5Njcx_fb64428f-3962-444f-9bd3-a895cfc51ceb"
      unitRef="usdPerShare">4.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzEtOC0xLTEtNDI5Njcx_e709698c-585d-44f1-ab35-dbdda97f29a1"
      unitRef="usdPerShare">3.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtMi0xLTEtNDI5Njcx_e39187ea-0aba-4412-a3a1-de7fd27cb46d"
      unitRef="shares">5607000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtNC0xLTEtNDI5Njcx_da641e26-9461-4303-a760-b0c9f2f5063b"
      unitRef="shares">5609000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtNi0xLTEtNDI5Njcx_e2f09dbf-7fbd-4e14-85c0-9a960721a8fb"
      unitRef="shares">5606000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzMtOC0xLTEtNDI5Njcx_2e4f2604-2b4e-4270-b447-4e9b6373c111"
      unitRef="shares">5597000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtMi0xLTEtNDI5Njcx_a0eb934e-9638-4dbe-a3cc-9d182105ed32"
      unitRef="shares">5718000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtNC0xLTEtNDI5Njcx_3aeab3f9-33a6-4a93-b31e-a09d575bd5c9"
      unitRef="shares">5725000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtNi0xLTEtNDI5Njcx_10502147-b493-4635-8a7a-59d01b94ecfa"
      unitRef="shares">5729000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfMzQtOC0xLTEtNDI5Njcx_6a812a9e-b1b1-44bd-9c15-b7ef80dc5e71"
      unitRef="shares">5688000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi0yLTEtMS00Mjk2NzE_af606b4c-87ec-42de-956b-526ea06907cb"
      unitRef="usd">8623000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi00LTEtMS00Mjk2NzE_77e42dec-780d-4cc2-a113-b4f4303e9058"
      unitRef="usd">8159000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi02LTEtMS00Mjk2NzE_0da6bb42-f51c-4c21-b95c-6ee74117d514"
      unitRef="usd">26404000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMi04LTEtMS00Mjk2NzE_f0e3a417-e3b2-4970-be31-50791f00af2f"
      unitRef="usd">18633000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC0yLTEtMS00Mjk2NzE_2776ae9a-8b10-499e-80a6-15eddb465857"
      unitRef="usd">-918000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC00LTEtMS00Mjk2NzE_eccd41a6-1c9c-40fc-8dc8-83bfbfbe33c4"
      unitRef="usd">-866000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC02LTEtMS00Mjk2NzE_e5b09af2-592c-4dd4-928a-6641c991fdb5"
      unitRef="usd">-2549000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNC04LTEtMS00Mjk2NzE_6bcdabee-e31e-45c2-b809-7f2631f6c487"
      unitRef="usd">-366000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy0yLTEtMS00Mjk2NzE_818a491e-b825-4383-aef6-199c434bf957"
      unitRef="usd">589000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy00LTEtMS00Mjk2NzE_7b1e59b8-d5c9-4c88-be6f-71f5a4efd6ed"
      unitRef="usd">213000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy02LTEtMS00Mjk2NzE_9cf5b4ae-ce58-4a3a-b231-d34db7833798"
      unitRef="usd">1443000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfNy04LTEtMS00Mjk2NzE_2a1105f1-cc66-4f79-b7b7-0f2c79d0c3ae"
      unitRef="usd">179000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC0yLTEtMS00Mjk2NzE_7eb1ff7a-3406-4304-b88a-2092e3e02ae7"
      unitRef="usd">615000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC00LTEtMS00Mjk2NzE_df798dc8-fee2-4fe7-884d-28e38adcae75"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC02LTEtMS00Mjk2NzE_42e675e3-ca94-417e-8df2-65d6b5bc7731"
      unitRef="usd">972000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC04LTEtMS00Mjk2NzE_a02c4c71-59e8-4024-a3bc-f64111e01fcd"
      unitRef="usd">-286000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS0yLTEtMS00Mjk2NzE_c2bb2176-72c6-4344-a356-4ee12070bf74"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS00LTEtMS00Mjk2NzE_9b83c0b3-09a4-428f-8e0e-4e8379ac010e"
      unitRef="usd">261000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS02LTEtMS00Mjk2NzE_36344dc3-5d45-4408-8122-4ec7c270cad1"
      unitRef="usd">471000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOS04LTEtMS00Mjk2NzE_37883361-5053-4f85-94a3-a9d044085235"
      unitRef="usd">464000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtMi0xLTEtNDI5Njcx_c0141236-bcee-4a39-98b4-3cc498da7bba"
      unitRef="usd">-777000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtNC0xLTEtNDI5Njcx_6b19560c-54ca-4f18-9e15-3b71b6497486"
      unitRef="usd">-266000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtNi0xLTEtNDI5Njcx_5d0443a5-fea0-4485-9989-5fb4db4632c6"
      unitRef="usd">-1397000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTAtOC0xLTEtNDI5Njcx_411a1590-a301-4bd1-a61e-41687042695f"
      unitRef="usd">-128000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtMi0xLTEtNDI5Njcx_cf9e841a-ac3f-456b-b46b-755690a8aad7"
      unitRef="usd">-606000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNC0xLTEtNDI5Njcx_282468d2-ace2-4483-8f10-fd7dd8256097"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNi0xLTEtNDI5Njcx_691a0ba8-5225-48b9-a6f4-1e75e20d734d"
      unitRef="usd">-1094000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtOC0xLTEtNDI5Njcx_8c5b20ac-1e31-43a7-9a2e-80389b83155b"
      unitRef="usd">172000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtMi0xLTEtNDI5Njcx_23aa35a5-1cad-4a59-a5b6-d1af741612b1"
      unitRef="usd">-171000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtNC0xLTEtNDI5Njcx_8bfe948a-a8ef-4c51-a45f-d33161985d2c"
      unitRef="usd">-257000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtNi0xLTEtNDI5Njcx_62b4451a-997a-45d2-bf5b-0089d10249c9"
      unitRef="usd">-303000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTMtOC0xLTEtNDI5Njcx_9ef43871-630e-4ed9-9653-0bcf2bb46ec5"
      unitRef="usd">-300000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtMi0xLTEtNDI5Njcx_f3a397d0-4555-49b6-b352-3d9672fc39d0"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtNC0xLTEtNDI5Njcx_1c121d60-12ba-453a-a42c-f93b42e1da22"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtNi0xLTEtNDI5Njcx_897e4f72-8960-4822-bbae-72a88673114a"
      unitRef="usd">-99000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTUtOC0xLTEtNDI5Njcx_7b50b7b3-7252-4967-b032-d62da6cf13ba"
      unitRef="usd">-119000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtMi0xLTEtNDI5Njcx_61a9b43e-c133-4b8c-bd2b-e2031e28a1ce"
      unitRef="usd">2000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtNC0xLTEtNDI5Njcx_f6eb9fc1-c403-43b8-866b-8b47d4309265"
      unitRef="usd">-58000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtNi0xLTEtNDI5Njcx_b6361547-3579-4827-9c81-b6e45e028064"
      unitRef="usd">-8000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTYtOC0xLTEtNDI5Njcx_e1d7e970-9148-4bc3-8207-498c26f2c7fa"
      unitRef="usd">-62000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtMi0xLTEtNDI5Njcx_905c5677-7309-43f6-a70e-2d0f206c9e79"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtNC0xLTEtNDI5Njcx_42c60f47-1537-4b02-bcf6-69ceeae20a8a"
      unitRef="usd">97000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtNi0xLTEtNDI5Njcx_83839270-8eb3-46a4-9278-6ad7ce504dcf"
      unitRef="usd">107000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTgtOC0xLTEtNDI5Njcx_821b61da-fbb6-4001-b932-0fc7b6b88a66"
      unitRef="usd">181000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktMi0xLTEtNDI5Njcx_caeb3bbd-be1c-4a95-af44-4e09a5ba60d1"
      unitRef="usd">-1144000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktNC0xLTEtNDI5Njcx_043c5449-43bc-47b2-8e55-af4a2d56e37d"
      unitRef="usd">-959000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktNi0xLTEtNDI5Njcx_efb9bf8d-71fd-472a-b098-0174535b225e"
      unitRef="usd">-2488000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTktOC0xLTEtNDI5Njcx_759e7a63-b6a8-44f4-bdee-26492a3819cd"
      unitRef="usd">-382000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtMi0xLTEtNDI5Njcx_2d6d9d61-4f29-41a6-84f9-a425ffad5c65"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtNC0xLTEtNDI5Njcx_2e9f1186-ba74-4ed0-97a3-7a4e4b10dca0"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtNi0xLTEtNDI5Njcx_8b218b31-6b1e-4194-9d68-45b49ac1e3e5"
      unitRef="usd">-149000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjAtOC0xLTEtNDI5Njcx_aca22b7d-887e-4341-9f00-736ec381bc10"
      unitRef="usd">-44000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtMi0xLTEtNDI5Njcx_5c4612ba-c16f-47ff-b488-e7a5c9cafdea"
      unitRef="usd">-1111000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtNC0xLTEtNDI5Njcx_3dd9c36b-a0e3-4994-8069-5391165d7e17"
      unitRef="usd">-894000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtNi0xLTEtNDI5Njcx_bb5ed637-00b4-4368-8f98-94ec40bca30a"
      unitRef="usd">-2339000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjEtOC0xLTEtNDI5Njcx_feb4c3f4-07b3-4bd8-bfbc-e5bb88122709"
      unitRef="usd">-338000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtMi0xLTEtNDI5Njcx_23d2d2d9-335a-4d01-b2dc-9b02198824c0"
      unitRef="usd">7512000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtNC0xLTEtNDI5Njcx_527ae35c-ed37-40ce-90d7-7e58597fdd2f"
      unitRef="usd">7265000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtNi0xLTEtNDI5Njcx_1fab5d5f-54f6-428a-be7c-aff0b243df0f"
      unitRef="usd">24065000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjMtOC0xLTEtNDI5Njcx_3091c783-e039-4f76-a4cb-63494e485a3a"
      unitRef="usd">18296000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtMi0xLTEtNDI5Njcx_6513a284-a76c-4d8c-bfa3-4ace5459ac7c"
      unitRef="usd">10000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtNC0xLTEtNDI5Njcx_2fbf9b6b-e001-4cda-b60e-acb1847c9c0d"
      unitRef="usd">9000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtNi0xLTEtNDI5Njcx_3086bdd0-f711-490d-a407-aaaba94db787"
      unitRef="usd">16000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjQtOC0xLTEtNDI5Njcx_0549a699-807a-4754-8b4d-a2046ab38159"
      unitRef="usd">48000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtMi0xLTEtNDI5Njcx_22a81fa4-ccf4-40a5-93a2-8f0cc36053ff"
      unitRef="usd">7503000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtNC0xLTEtNDI5Njcx_a279d7e5-c54f-4c4b-b3fa-63e2e3f42c11"
      unitRef="usd">7256000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtNi0xLTEtNDI5Njcx_aeaecbdf-695e-4476-a562-28ba9aba2499"
      unitRef="usd">24049000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMjUtOC0xLTEtNDI5Njcx_e05da5c7-d868-4519-b1e3-cf5dcaaa8b9b"
      unitRef="usd">18248000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMy0yLTEtMS00Mjk2NzE_cf4e4d65-1486-4746-a33c-5937bbdc7be8"
      unitRef="usd">1298000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMy00LTEtMS00Mjk2NzE_0b90a5b5-3614-4d44-97b9-3ee66588bd2e"
      unitRef="usd">1944000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNC0yLTEtMS00Mjk2NzE_a8967ea8-e7fe-452a-8fff-7cd88bf45d0f"
      unitRef="usd">34825000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNC00LTEtMS00Mjk2NzE_cf53af27-dd9a-4d97-b3fe-4576f22cc1e5"
      unitRef="usd">29125000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjoyMDc0MzNjNzdkZTA0MWEyOGEwMjdhM2Y4OTNlMDY2OF83Mg_9ceaac9d-3e7a-4864-80ab-70179347d3bb"
      unitRef="usd">474000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjoyMDc0MzNjNzdkZTA0MWEyOGEwMjdhM2Y4OTNlMDY2OF83OQ_2cdbfe81-cf38-485e-9dfd-e467863ea5b6"
      unitRef="usd">492000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS0yLTEtMS00Mjk2NzE_8dea0fb4-2870-48e8-8ca2-15a8a52651e2"
      unitRef="usd">16076000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNS00LTEtMS00Mjk2NzE_66c48892-7236-4f48-b71f-b5bca7a84db2"
      unitRef="usd">11479000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNi0yLTEtMS00Mjk2NzE_2c2a4ad8-f0d0-418b-8404-7ee7ce05127f"
      unitRef="usd">9513000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNi00LTEtMS00Mjk2NzE_7cd7d519-dab4-4911-ad7b-813bcd270500"
      unitRef="usd">9059000000</us-gaap:InventoryNet>
    <pfe:OtherTaxAssetsCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNy0yLTEtMS00Mjk2NzE_b07fc493-22ac-4f7d-be4d-14207965e9f2"
      unitRef="usd">2544000000</pfe:OtherTaxAssetsCurrent>
    <pfe:OtherTaxAssetsCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNy00LTEtMS00Mjk2NzE_c01b7bfa-e6c8-495a-a5a1-905f533d7baa"
      unitRef="usd">4266000000</pfe:OtherTaxAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOC0yLTEtMS00Mjk2NzE_4703f480-9a29-47f7-bb70-d742ec7b9863"
      unitRef="usd">6149000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOC00LTEtMS00Mjk2NzE_7ba236ab-f41e-4cd8-9743-8a54693ed601"
      unitRef="usd">3820000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOS0yLTEtMS00Mjk2NzE_9cf81448-7737-472c-9634-6d1f650b3f83"
      unitRef="usd">70403000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfOS00LTEtMS00Mjk2NzE_db77c06d-7ed7-44b9-bcc6-8c194bf6fad8"
      unitRef="usd">59693000000</us-gaap:AssetsCurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTAtMi0xLTEtNDI5Njcx_615391bf-0d65-49fb-aec8-ebbeee8be69c"
      unitRef="usd">9826000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTAtNC0xLTEtNDI5Njcx_bb8584d6-d994-457d-b0c2-3f7ed39e21a1"
      unitRef="usd">16472000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTEtMi0xLTEtNDI5Njcx_64c52689-61ba-452f-b5ec-fdca113713ce"
      unitRef="usd">4062000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTEtNC0xLTEtNDI5Njcx_836f5d08-9f3d-4db4-b66d-29515e352593"
      unitRef="usd">5054000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246YWQ4NTlhY2FiYmYwNGMwMDgyMjQ3NmJmOGMyNjRlZjNfNjk_f2cf1c79-45a8-4634-b38a-bfc21c56cfa3"
      unitRef="usd">14931000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246YWQ4NTlhY2FiYmYwNGMwMDgyMjQ3NmJmOGMyNjRlZjNfNzY_1a34ad73-a804-4859-8c8c-85f686e538a7"
      unitRef="usd">15074000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItMi0xLTEtNDI5Njcx_203d18b9-c82b-458f-8691-a58cc2b87a9b"
      unitRef="usd">15441000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTItNC0xLTEtNDI5Njcx_4e2929f8-8644-4aed-8ed6-85696e7f2576"
      unitRef="usd">14882000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTMtMi0xLTEtNDI5Njcx_fdefa490-9fc9-4d97-9a7b-6cf1e99f42f3"
      unitRef="usd">28151000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTMtNC0xLTEtNDI5Njcx_25595542-c95a-4264-aea2-e3aee71233a1"
      unitRef="usd">25146000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtMi0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
      unitRef="usd">49441000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtNC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
      unitRef="usd">49208000000</us-gaap:Goodwill>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTUtMi0xLTEtNDI5Njcx_cf584daa-d9ac-4cb5-8377-eaab4258fc08"
      unitRef="usd">7136000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTUtNC0xLTEtNDI5Njcx_5fea5ffc-9fe6-4251-a87f-973921514b65"
      unitRef="usd">3341000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTYtMi0xLTEtNDI5Njcx_2a969fb6-d0dd-48a1-8d8b-48b7df1d5da3"
      unitRef="usd">10890000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTYtNC0xLTEtNDI5Njcx_a4bad6a1-cb13-47fb-94d8-577fce63eec3"
      unitRef="usd">7679000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTgtMi0xLTEtNDI5Njcx_ee00c873-9492-4649-a43f-090bba2eeb95"
      unitRef="usd">195350000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTgtNC0xLTEtNDI5Njcx_5c1b895a-4a35-46a9-b88d-e52420bb7c14"
      unitRef="usd">181476000000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtMC0xLTEtNDI5NjcxL3RleHRyZWdpb246ZmVmYTZlZjEyODI3NDFmZmEwNWMyY2JiNDNiYjE1NTNfNzU_48b06320-5225-4ad8-9eff-78e46a287c57"
      unitRef="usd">2566000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtMC0xLTEtNDI5NjcxL3RleHRyZWdpb246ZmVmYTZlZjEyODI3NDFmZmEwNWMyY2JiNDNiYjE1NTNfODI_7dfb11a0-9b5c-4d6d-9b31-60cee8ff385d"
      unitRef="usd">1636000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtMi0xLTEtNDI5Njcx_90cfa78e-bcc1-4e48-a15b-0199bd853c3c"
      unitRef="usd">4040000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjEtNC0xLTEtNDI5Njcx_6d54ba55-d20e-4046-8506-1482ba1fa655"
      unitRef="usd">2241000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjItMi0xLTEtNDI5Njcx_962d85a0-32ab-4c8b-ab03-adb777bb2592"
      unitRef="usd">6267000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjItNC0xLTEtNDI5Njcx_60e4d723-b8cb-442c-b450-ae0a0820c5bd"
      unitRef="usd">5578000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjMtMi0xLTEtNDI5Njcx_6fec2267-d1d6-41b4-b526-3e48ef52e69f"
      unitRef="usd">2245000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjMtNC0xLTEtNDI5Njcx_bbcdcea3-956c-4b9e-a1f4-01e7a3d2f58a"
      unitRef="usd">2249000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjQtMi0xLTEtNDI5Njcx_05a61d95-f3ae-4c6a-8ace-21a91a77c62d"
      unitRef="usd">3071000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjQtNC0xLTEtNDI5Njcx_3e98f885-ef3d-4676-919f-244f35f0711e"
      unitRef="usd">1266000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjUtMi0xLTEtNDI5Njcx_28253c3a-0498-4c4a-bc3d-c187d91cd0d7"
      unitRef="usd">2852000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjUtNC0xLTEtNDI5Njcx_f3261cf7-6f00-4ebc-af62-42147082bbb6"
      unitRef="usd">3332000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjYtMi0xLTEtNDI5Njcx_971f3c6d-0b01-41a7-826d-be8f25593f67"
      unitRef="usd">6191000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjYtNC0xLTEtNDI5Njcx_55f2b27f-13ea-46b5-9bb4-8f26c6161763"
      unitRef="usd">3067000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjctMi0xLTEtNDI5Njcx_946a74b5-8c55-4cac-8f08-9e67c5baad21"
      unitRef="usd">19647000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjctNC0xLTEtNDI5Njcx_932d384a-1ea0-48f0-81c6-1da6084b0d15"
      unitRef="usd">24939000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjktMi0xLTEtNDI5Njcx_ed7b7c9b-7a37-4343-8321-b94736bedd6b"
      unitRef="usd">44314000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMjktNC0xLTEtNDI5Njcx_a0a51e5f-0eb0-4bd1-aaca-6d7d2dc13d34"
      unitRef="usd">42671000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzEtMi0xLTEtNDI5Njcx_059d7115-7fb1-42af-881a-6c818e311891"
      unitRef="usd">32629000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzEtNC0xLTEtNDI5Njcx_c00dc365-d02e-4820-8049-07ae88cb9825"
      unitRef="usd">36195000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzItMi0xLTEtNDI5Njcx_40ad85cf-22ab-4e52-a875-71a9f5d3b9ed"
      unitRef="usd">2738000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzItNC0xLTEtNDI5Njcx_5724bd56-864d-42c2-b875-1794b1b1f66d"
      unitRef="usd">3489000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzMtMi0xLTEtNDI5Njcx_175c54af-f665-453e-ba31-3f9195e5de9b"
      unitRef="usd">222000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzMtNC0xLTEtNDI5Njcx_7495f7ab-5733-461e-86b2-070beeeab74e"
      unitRef="usd">235000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzQtMi0xLTEtNDI5Njcx_02421082-5d89-4aa3-9a38-a3f35f86964b"
      unitRef="usd">616000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzQtNC0xLTEtNDI5Njcx_d4aeb96d-bb3e-4675-bf94-257b6fd0f7c2"
      unitRef="usd">349000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzUtMi0xLTEtNDI5Njcx_99fd9320-9327-47ef-bc65-ac50130b23f9"
      unitRef="usd">9701000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzUtNC0xLTEtNDI5Njcx_432fe9e2-a73a-470b-9ae5-bb840c6ce9b8"
      unitRef="usd">11331000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzYtMi0xLTEtNDI5Njcx_ab0230ae-339b-4b05-a893-d59621665eca"
      unitRef="usd">12239000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzYtNC0xLTEtNDI5Njcx_9bac4a11-5408-40cd-a67e-2deedf772f59"
      unitRef="usd">9743000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzctMi0xLTEtNDI5Njcx_18d4b297-86fc-41ae-9eff-4c69a985375c"
      unitRef="usd">102459000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzctNC0xLTEtNDI5Njcx_79e1877c-a982-49f0-913c-fba1ce033681"
      unitRef="usd">104013000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzktMi0xLTEtNDI5Njcx_79f0791d-482b-4480-914c-c33e39e7c2cc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMzktNC0xLTEtNDI5Njcx_26e3a627-da8b-4cbe-90cd-c1663bbe3bf2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDItMi0xLTEtNDI5Njcx_1b13b1fd-7263-478b-8776-3cb9a46674fe"
      unitRef="usd">476000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDItNC0xLTEtNDI5Njcx_0f4a9efe-2eee-4d5a-8b8f-a9c319a3c3e5"
      unitRef="usd">473000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDMtMi0xLTEtNDI5Njcx_d83006f6-1133-4821-ae6b-a53bd6f3da74"
      unitRef="usd">91359000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDMtNC0xLTEtNDI5Njcx_95484da9-83c4-44e3-9bb9-27ca25a609e8"
      unitRef="usd">90591000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDUtMi0xLTEtNDI5Njcx_686ac483-63f9-4b7e-854a-d06e7c4b60ba"
      unitRef="usd">113945000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDUtNC0xLTEtNDI5Njcx_9b00a116-a4ba-4a62-88da-9a889ab0d28b"
      unitRef="usd">111361000000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDYtMi0xLTEtNDI5Njcx_e1df6b29-c7bb-499c-bac8-301f6303b14a"
      unitRef="usd">122967000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDYtNC0xLTEtNDI5Njcx_c2e51b02-e44f-4e13-96af-9cbac8103b94"
      unitRef="usd">103394000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDctMi0xLTEtNDI5Njcx_e41c7e25-5faf-46ca-8450-b0fe4adae7ff"
      unitRef="usd">-8225000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDctNC0xLTEtNDI5Njcx_c199a958-9523-489a-8ed2-30d761f3aaef"
      unitRef="usd">-5897000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDgtMi0xLTEtNDI5Njcx_0c656369-448a-4396-89b1-aa8c89a89d64"
      unitRef="usd">92631000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDgtNC0xLTEtNDI5Njcx_36107412-754e-4cd5-9e88-884d2542e6d4"
      unitRef="usd">77201000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDktMi0xLTEtNDI5Njcx_7084633b-65e0-4116-af2a-f0eb21be1256"
      unitRef="usd">259000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNDktNC0xLTEtNDI5Njcx_eecc6e98-fc3c-41d1-a45c-7f7210df4457"
      unitRef="usd">262000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTAtMi0xLTEtNDI5Njcx_47eadae7-2f1c-4025-a083-ac8450d4c10b"
      unitRef="usd">92891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTAtNC0xLTEtNDI5Njcx_20240e05-adf1-4f05-b20f-3131d511c8d0"
      unitRef="usd">77462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTEtMi0xLTEtNDI5Njcx_abe6c33f-0313-4806-8e76-d7982be446f5"
      unitRef="usd">195350000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfNTEtNC0xLTEtNDI5Njcx_1d862d13-c6f0-44a3-a325-1d2c4073a528"
      unitRef="usd">181476000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i98083abf5b10468887a10a5321465a07_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy02LTEtMS00Mjk2NzE_90eba9b9-3725-4f85-99e1-44835fcd9ddb"
      unitRef="shares">9496000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98083abf5b10468887a10a5321465a07_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy04LTEtMS00Mjk2NzE_05ce0ce2-ec36-41b5-962b-50fe6c6ce7af"
      unitRef="usd">476000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3ad8bd638b94660a81910320140a0ff_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xMC0xLTEtNDI5Njcx_f2c85268-93c0-46e7-a8c3-e60c189f4d28"
      unitRef="usd">91183000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="iee207eb562eb45749d0e09bd8ae27d99_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xMi0xLTEtNDI5Njcx_9aa6caf3-50f4-493f-9d07-dbf43dfe4b1c"
      unitRef="shares">3903000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee207eb562eb45749d0e09bd8ae27d99_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xNC0xLTEtNDI5Njcx_eb2652fe-ffb0-47a4-a02d-0c7fe129acd0"
      unitRef="usd">-113939000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cd2c296b7794de18cd9165e100b3645_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xNi0xLTEtNDI5Njcx_922f065c-c55f-48c9-8bdf-5185e77e12b5"
      unitRef="usd">116608000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac935618aa1f4c02973c960cd4d50198_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0xOC0xLTEtNDI5Njcx_4ae13d59-8a9f-4167-b458-d15e9b7745e8"
      unitRef="usd">-7119000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1dfdf4b4d9474432ac2661c4f07bf9ae_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0yMC0xLTEtNDI5Njcx_86428006-a9ef-49cb-a998-e3c92f5f4f93"
      unitRef="usd">87208000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1fa5b9f5af24e07a8d83bc03ff721d2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0yMi0xLTEtNDI5Njcx_40decfed-27f4-47a9-a93a-4480a118e5b8"
      unitRef="usd">261000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i291c881a539a4386ace0953f2e533606_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMy0yNC0xLTEtNDI5Njcx_bc187de1-c0eb-43b1-a51e-e502ea92ef85"
      unitRef="usd">87469000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i322ef81511754d73bd045b355aa263b0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0xNi0xLTEtNDI5Njcx_e998a6d2-52ba-457e-be00-bd86322e34be"
      unitRef="usd">8608000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0yMC0xLTEtNDI5Njcx_c345f511-3bb6-4116-8f66-4f402f639203"
      unitRef="usd">8608000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0yMi0xLTEtNDI5Njcx_361cbc95-2859-4759-9353-2cc729ea3196"
      unitRef="usd">15000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNC0yNC0xLTEtNDI5Njcx_1b856178-e053-4ad2-93df-d7fb49256835"
      unitRef="usd">8623000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a00c9907efc45b58509f370291e703d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0xOC0xLTEtNDI5Njcx_7979e95d-62e0-489e-a4bb-6282321fb48e"
      unitRef="usd">-1106000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0yMC0xLTEtNDI5Njcx_97f6831a-216c-4884-be93-dae8b0190cb9"
      unitRef="usd">-1106000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0yMi0xLTEtNDI5Njcx_a5fa4955-928d-4243-9c58-d5e70aa283c2"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNS0yNC0xLTEtNDI5Njcx_d1c6e1e4-78b8-4de3-b9dd-84f2d803fda3"
      unitRef="usd">-1111000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNi0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjpkNWMwZmY4YjMxNDc0MWNlYjk4YTFmOTVjMmNiNTNjZF8zMjk4NTM0ODgzMzcx_513c9d67-314b-4854-b5ce-2a860e7b83e4"
      unitRef="usdPerShare">0.40</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i322ef81511754d73bd045b355aa263b0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNy0xNi0xLTEtNDI5Njcx_0b1a7b1c-8423-42f2-83dc-d9a95f7d36ae"
      unitRef="usd">2245000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNy0yMC0xLTEtNDI5Njcx_5defb571-840c-4782-8c0b-0427430a1ca3"
      unitRef="usd">2245000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfNy0yNC0xLTEtNDI5Njcx_d00da56e-6fce-4ebc-b0c6-291c6aa613c4"
      unitRef="usd">2245000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfOS0yMi0xLTEtNDI5Njcx_a0cf46df-fccd-4d3c-b1f2-bab072967f13"
      unitRef="usd">7000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfOS0yNC0xLTEtNDI5Njcx_2a320a14-534f-47c1-9e09-2a52393c2586"
      unitRef="usd">7000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1008d0f3e2cb4f1fb4612f491b9815d9_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtNi0xLTEtNDI5Njcx_9465b756-fcce-4a56-8e10-9a7771ba03b8"
      unitRef="shares">20000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9c4007c71e914cfe8b9ecfa0a6b9a28f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMTAtMS0xLTQyOTY3MQ_16fb1a44-02ac-4815-b7d4-599e3a123d7c"
      unitRef="usd">172000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if4e546bd59bb47fb8d148abae15673a7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMTQtMS0xLTQyOTY3MQ_f7f25dd0-7f1e-4fb7-846d-601454d325b9"
      unitRef="usd">-6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i322ef81511754d73bd045b355aa263b0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMTYtMS0xLTQyOTY3MQ_83da7b14-9bc3-417b-8721-999234e5f289"
      unitRef="usd">-5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMjAtMS0xLTQyOTY3MQ_a857173a-40c3-4489-9f7e-51fc8d8e3e48"
      unitRef="usd">161000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTAtMjQtMS0xLTQyOTY3MQ_197347ff-d51a-41e9-82a0-fb69275c89a3"
      unitRef="usd">161000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTEtMjQtMS0xLTQyOTY3MQ_47c2d308-49f5-42ff-9860-3567dd14c29c"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i9c4007c71e914cfe8b9ecfa0a6b9a28f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMTAtMS0xLTQyOTY3MQ_e7ed9a83-e953-4fca-9827-d8b2870a3a4a"
      unitRef="usd">-4000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0c7dc9d45d664131bb481f5f7d1c526f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMjAtMS0xLTQyOTY3MQ_bcabe258-a60e-4a6a-9bd9-be130db3028d"
      unitRef="usd">-4000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i039d2f50ce934867b9e5e3077d19ce80_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMjItMS0xLTQyOTY3MQ_34d67c89-9919-4c29-b1d9-64d8cdff5c80"
      unitRef="usd">4000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTMtMjQtMS0xLTQyOTY3MQ_97e14b27-df15-4d83-b636-e40a2872f192"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia4178e1df50642f481342387e7983453_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtNi0xLTEtNDI5Njcx_5470e14d-5ade-4656-b958-977a9956d106"
      unitRef="shares">9515000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4178e1df50642f481342387e7983453_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtOC0xLTEtNDI5Njcx_afc0877a-0cdd-4226-afce-2ebeb3ee7f00"
      unitRef="usd">476000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i283349b3ae194291807e57850205a00e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTAtMS0xLTQyOTY3MQ_ea064329-a0ce-4f67-81a5-ff694645f46a"
      unitRef="usd">91359000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTItMS0xLTQyOTY3MQ_fbcd5659-df73-4b3a-9178-89354de72ffb"
      unitRef="shares">3903000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTQtMS0xLTQyOTY3MQ_fca70616-71ff-4685-a3c5-653c2cec315f"
      unitRef="usd">-113945000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38fb06657953481f9327c4d7af5221d3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTYtMS0xLTQyOTY3MQ_1b330152-aa5e-49c1-93f1-2400ba7106de"
      unitRef="usd">122967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i316fd24dd0da46e5872d02ce9db0a499_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMTgtMS0xLTQyOTY3MQ_5df09b9a-395a-4dbf-853b-536a00555d6b"
      unitRef="usd">-8225000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i439e2eb2ea67457d989b7d096b2578b6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMjAtMS0xLTQyOTY3MQ_10f7a3f5-1289-43cc-b5ca-879c4c99ebe0"
      unitRef="usd">92631000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i982bd66098e642c180e76a8b23cfce05_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMjItMS0xLTQyOTY3MQ_b9d71ce7-f2d0-43a9-a1dc-13dcc97bf884"
      unitRef="usd">259000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTQtMjQtMS0xLTQyOTY3MQ_faa9c44b-6c21-4a3c-9940-a00bb64bf862"
      unitRef="usd">92891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie2eff56d6b9143a8a6236c386a684328_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktNi0xLTEtNDI5Njcx_e289a723-8279-4cc4-b65b-a4683b03360f"
      unitRef="shares">9450000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2eff56d6b9143a8a6236c386a684328_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktOC0xLTEtNDI5Njcx_5ebb432b-4f80-4de3-b734-e55427394edc"
      unitRef="usd">472000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a860a4fb70d417db1e5ece4d14a5929_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTAtMS0xLTQyOTY3MQ_00df457b-4107-489c-8afe-a9ab176065d7"
      unitRef="usd">89336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i106884611a9443b0b91471c3127aab17_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTItMS0xLTQyOTY3MQ_06cb2858-66e1-4f9a-a25a-06fd2ca3a0b3"
      unitRef="shares">3851000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i106884611a9443b0b91471c3127aab17_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTQtMS0xLTQyOTY3MQ_3fe83113-5e9c-4c59-9a6f-a84575270089"
      unitRef="usd">-111356000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dd1ece70cb9426792fd297de161a638_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTYtMS0xLTQyOTY3MQ_9715e198-9da5-45a4-8956-6af1de8f2208"
      unitRef="usd">96346000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i871492c1af0c4c41901ad429f9c97997_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMTgtMS0xLTQyOTY3MQ_d902d639-a46d-4f63-9391-a6a35c322252"
      unitRef="usd">-4758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1d8a56f33e04a88aa94910108df6baf_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMjAtMS0xLTQyOTY3MQ_18c0a62a-d7b6-458b-97cb-29cd3d450770"
      unitRef="usd">70042000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc3cdee01052447a8c008a36884f4ece_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMjItMS0xLTQyOTY3MQ_3f7975e5-6515-428c-a6f3-14cff78ccc20"
      unitRef="usd">273000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if55bdd083c8e4d4bb0f0f79015f34b54_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMTktMjQtMS0xLTQyOTY3MQ_7a9040ef-19c7-4699-aa8c-938fd91e3bbf"
      unitRef="usd">70315000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMTYtMS0xLTQyOTY3MQ_966ddda2-4033-44a8-b2d1-76b0db9be0a8"
      unitRef="usd">8146000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMjAtMS0xLTQyOTY3MQ_c56b6361-a466-4f2b-a6eb-c012227a3c5c"
      unitRef="usd">8146000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMjItMS0xLTQyOTY3MQ_050761b9-4a0a-4f1f-b2bf-672fb7cac2de"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjAtMjQtMS0xLTQyOTY3MQ_bee6b4fe-6fed-4142-b505-bd8fe21aa79a"
      unitRef="usd">8159000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id0830a768fb84418ac3aa1b642de41a4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMTgtMS0xLTQyOTY3MQ_1bacabfb-8175-4bd2-bdf2-a1ff24cb9c69"
      unitRef="usd">-891000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMjAtMS0xLTQyOTY3MQ_a2666239-fb02-4fe4-b0b8-7e990a8c6fc1"
      unitRef="usd">-891000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMjItMS0xLTQyOTY3MQ_4e304900-47cc-47e9-bc27-eb116ce51cf4"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjEtMjQtMS0xLTQyOTY3MQ_594c4dcb-ff26-40db-88f5-f1f757a38684"
      unitRef="usd">-894000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246NmVmNTQwOTU3NjEzNGIyNjk4MDIwOTBjYTY0MDI3NDJfMzI5ODUzNDg4MzM3MQ_1d4ce70c-219a-4325-ab92-98f52fac0103"
      unitRef="usdPerShare">0.39</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjMtMTYtMS0xLTQyOTY3MQ_2a030d1d-78b9-4242-8682-e10429acd469"
      unitRef="usd">2192000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjMtMjAtMS0xLTQyOTY3MQ_bfde294b-caa4-450b-9d80-3fb4d446f218"
      unitRef="usd">2192000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjMtMjQtMS0xLTQyOTY3MQ_1a7c6ba5-ee95-4ab4-b840-73bfe5e32da8"
      unitRef="usd">2192000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjUtMjItMS0xLTQyOTY3MQ_a1c80239-3382-4cdc-a352-9bb83f2cd913"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjUtMjQtMS0xLTQyOTY3MQ_8b80e861-b875-4c1c-ac50-7393fd9978dd"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7aaed31d336142a38895f4e58c290bc0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtNi0xLTEtNDI5Njcx_27dfe408-0bb1-4a16-9715-a98e0683caa8"
      unitRef="shares">13000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7aaed31d336142a38895f4e58c290bc0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtOC0xLTEtNDI5Njcx_19bcd152-4926-4b88-83d9-ea0e788d9a20"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0cfba0bc31044aafb04e8793a359fd30_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMTAtMS0xLTQyOTY3MQ_021d0c7a-8b3e-44a6-b789-55a5446c5e22"
      unitRef="usd">637000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7fbbfb560fd84535bc70f59962461307_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMTQtMS0xLTQyOTY3MQ_8a7dcbaf-ecf0-4899-8551-965324618583"
      unitRef="usd">-3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMTYtMS0xLTQyOTY3MQ_a4886a78-c568-4294-86d6-9d059353095e"
      unitRef="usd">-1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMjAtMS0xLTQyOTY3MQ_27e3245a-f217-45cf-80b3-7fd6d9488b0b"
      unitRef="usd">634000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjYtMjQtMS0xLTQyOTY3MQ_e0d01fc8-db4e-4c20-b8b9-02656d1afa7f"
      unitRef="usd">634000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjctMjQtMS0xLTQyOTY3MQ_8d75ad29-33b0-4924-bda3-007467c098a8"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i0490f96cf25345b8936ec9623f9bbebc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMTYtMS0xLTQyOTY3MQ_b8376c5c-a4ef-4b3d-8212-e7d2f6a79346"
      unitRef="usd">47000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9f665afb93d3487e95f57be17ec66b24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMjAtMS0xLTQyOTY3MQ_4571bbcc-0c00-4d7e-aba4-96c313e4f6ed"
      unitRef="usd">47000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i195d757ae5984324a93c8f8aad744de9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMjItMS0xLTQyOTY3MQ_e1240ed8-e399-49b9-9882-b5fc30566abb"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMjktMjQtMS0xLTQyOTY3MQ_5cd3ec01-45e3-4d8f-ac9d-ff953fdc3242"
      unitRef="usd">46000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtNi0xLTEtNDI5Njcx_0f25f818-b05c-4670-a15c-bd06aa70cc65"
      unitRef="shares">9462000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtOC0xLTEtNDI5Njcx_a0b520c1-01e9-4713-8423-2596794d85b0"
      unitRef="usd">473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i269d8be2dbe14366928f6a655f330c99_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTAtMS0xLTQyOTY3MQ_f156eea0-f54a-453c-9b51-38d1fad38f5e"
      unitRef="usd">89973000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTItMS0xLTQyOTY3MQ_3fa74561-518f-4a8a-a386-7eb0940388b6"
      unitRef="shares">3851000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTQtMS0xLTQyOTY3MQ_8b848ebd-17a4-457e-a5dc-ec3d114409c9"
      unitRef="usd">-111359000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7eead2d41724d1284b95a8f2c3ba977_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTYtMS0xLTQyOTY3MQ_a2d02789-a8ed-4184-81cc-13137eb6a1dc"
      unitRef="usd">102252000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icff95de7b4364937bb8f6fa9332bb480_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMTgtMS0xLTQyOTY3MQ_f085e3b2-eb7a-4770-917c-d2d1657f08ef"
      unitRef="usd">-5649000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89e9bcba37374979b4f81bb0e1923a9a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMjAtMS0xLTQyOTY3MQ_b8f2144f-886f-4c5b-ae16-b978701745bc"
      unitRef="usd">75691000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad49f13a7aaf431ca7ad807765db51a1_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMjItMS0xLTQyOTY3MQ_fd5e1f9f-fb36-47cf-b02a-5f4c8b2eeea4"
      unitRef="usd">275000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYzYjNiY2Y0MzI1ODRlYjE4YTcxZGE2Mjc1NzQwZTU2L3RhYmxlcmFuZ2U6NjNiM2JjZjQzMjU4NGViMThhNzFkYTYyNzU3NDBlNTZfMzAtMjQtMS0xLTQyOTY3MQ_2c0a92da-9a70-4b28-bbf5-8e9a5c001d6f"
      unitRef="usd">75967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie720b049f06b4803a5325d0052df106f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy02LTEtMS00Mjk2NzE_8cfbcf07-bebe-4ed9-b0cd-efc03efe7ff6"
      unitRef="shares">9471000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie720b049f06b4803a5325d0052df106f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy04LTEtMS00Mjk2NzE_c1d69d67-ec85-4ac5-af63-b7bf368b6cb6"
      unitRef="usd">473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93a4179e99414d2bb29dae8a9ef43064_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xMC0xLTEtNDI5Njcx_263300ab-d611-406a-b4aa-e0c66462d32e"
      unitRef="usd">90591000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i27da68353c034955b1c275a580f01f68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xMi0xLTEtNDI5Njcx_f280db95-be8b-4de5-a594-82db9b2f4545"
      unitRef="shares">3851000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27da68353c034955b1c275a580f01f68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xNC0xLTEtNDI5Njcx_b10cca00-ceb6-491c-9af0-96bf4c144d02"
      unitRef="usd">-111361000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5305bfba0e7a4d7fbbd4c84a4873871d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xNi0xLTEtNDI5Njcx_752462e7-44df-436d-b190-fec829ff5f66"
      unitRef="usd">103394000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ef44849268d4847a9fb27d3a90011e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0xOC0xLTEtNDI5Njcx_a217b104-7d80-4dd2-9201-6df3186e4c50"
      unitRef="usd">-5897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b19de1c61d540f7a92683b6fcef0492_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0yMC0xLTEtNDI5Njcx_c6b78856-9bc0-407e-b443-cd7bc15c8455"
      unitRef="usd">77201000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58476ceafd6b43a0803a9cdb179436a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0yMi0xLTEtNDI5Njcx_c64b60fa-f7f4-46ef-ac44-402385a9c5e1"
      unitRef="usd">262000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMy0yNC0xLTEtNDI5Njcx_0bf5fe78-66ea-431b-92bd-0d958b013cc8"
      unitRef="usd">77462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0xNi0xLTEtNDI5Njcx_170ba43d-4cf2-4b83-b5a8-feb1ac81d6f0"
      unitRef="usd">26378000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0yMC0xLTEtNDI5Njcx_5be67b04-a9fc-4ec6-af72-a72c60b00d0d"
      unitRef="usd">26378000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0yMi0xLTEtNDI5Njcx_499d0d6b-1938-4fc0-8623-1a2ce9b494a2"
      unitRef="usd">27000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNC0yNC0xLTEtNDI5Njcx_48cb8343-0058-4492-bef4-6d262cd7748e"
      unitRef="usd">26404000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idb8a629a946b4ceca7ca7dd72b1af40b_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0xOC0xLTEtNDI5Njcx_3e853167-af2b-4420-b2be-17b1e4935e86"
      unitRef="usd">-2328000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0yMC0xLTEtNDI5Njcx_52549b66-ab98-4345-a10c-26a898e1a5b8"
      unitRef="usd">-2328000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0yMi0xLTEtNDI5Njcx_e5cf3dcf-920a-49f5-ae4c-5d92930211c0"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNS0yNC0xLTEtNDI5Njcx_8e8b26fa-05db-4700-99e8-d008ee837075"
      unitRef="usd">-2339000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNi0wLTEtMS00Mjk2NzEvdGV4dHJlZ2lvbjo0Y2Y3NzAzMWUwNzE0ZDRmOGI3ZTA4M2ZiZGUyYjk5Y18zMjk4NTM0ODgzMzcx_b74cf16c-e547-4455-9891-a78e3832d02d"
      unitRef="usdPerShare">1.20</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNy0xNi0xLTEtNDI5Njcx_019742ce-2a72-4b79-9467-7aa6ff07c260"
      unitRef="usd">6734000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNy0yMC0xLTEtNDI5Njcx_de2ac956-6515-47d0-9421-a86a02f3d9fd"
      unitRef="usd">6734000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfNy0yNC0xLTEtNDI5Njcx_b6fc76d6-2dc7-4827-bb3a-70efaabd08d4"
      unitRef="usd">6734000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfOS0yMi0xLTEtNDI5Njcx_93a154e5-cc2a-483f-8f02-cd9647ebf199"
      unitRef="usd">7000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfOS0yNC0xLTEtNDI5Njcx_bea61b42-37a0-4b96-a396-c074fc10f2cf"
      unitRef="usd">7000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib9b1498a92d54a268ebfb1b8e658f31d_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtNi0xLTEtNDI5Njcx_14cf6788-312f-4896-9df3-f3feb4c10c9f"
      unitRef="shares">45000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib9b1498a92d54a268ebfb1b8e658f31d_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtOC0xLTEtNDI5Njcx_b8afd134-1393-48b1-8e10-b05f11f406fd"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if663a3d9b11e4c838a4f9123bcff64b2_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTAtMS0xLTQyOTY3MQ_78b977b0-7339-496a-9b39-67c768c3d428"
      unitRef="usd">760000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTItMS0xLTQyOTY3MQ_057311d5-7ed1-4f71-af5c-86e948710d6d"
      unitRef="shares">12000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTQtMS0xLTQyOTY3MQ_b5a54fd2-9608-4517-8dbb-2b60fecabc6f"
      unitRef="usd">-584000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMTYtMS0xLTQyOTY3MQ_8360e813-1cc9-41f2-9b4d-7de03782e8c8"
      unitRef="usd">-71000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMjAtMS0xLTQyOTY3MQ_e0054154-7e7b-4d18-891e-22210de03e00"
      unitRef="usd">108000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTAtMjQtMS0xLTQyOTY3MQ_42e438a8-4cac-43f8-b2fe-1898a94f05bc"
      unitRef="usd">108000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMTItMS0xLTQyOTY3MQ_95288d55-ef44-45da-965e-ebcf5847ec31"
      unitRef="shares">39000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ied5f228cf0dc4f189877c80fd1cae9c6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMTQtMS0xLTQyOTY3MQ_80f85a3b-516d-45c9-8b49-92c9a4a661e3"
      unitRef="usd">2000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMjAtMS0xLTQyOTY3MQ_629aa986-4fda-4848-86d1-bceb59da70c1"
      unitRef="usd">2000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTEtMjQtMS0xLTQyOTY3MQ_6c31d06d-cdcd-4d15-8144-646d9d3d50aa"
      unitRef="usd">2000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="if663a3d9b11e4c838a4f9123bcff64b2_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMTAtMS0xLTQyOTY3MQ_af170df4-7df7-4b53-b689-f259b38395bc"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6745d4beec8e45058e8bff34cb487658_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMTYtMS0xLTQyOTY3MQ_f2377e77-a248-49ac-9ab4-1364ec2a9171"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i26469a9a86664f05b1e8df86ff0d9272_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMjAtMS0xLTQyOTY3MQ_4e767329-c4ca-485f-a0f1-d8ebf3049a21"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6d4029e2ef7347e3b04e56aec2703adb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMjItMS0xLTQyOTY3MQ_5cde321b-bc09-4d2e-a9ca-fe1f91b30d1c"
      unitRef="usd">11000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTMtMjQtMS0xLTQyOTY3MQ_b5f8b5ce-79f0-49a3-b263-426387ead38b"
      unitRef="usd">4000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia4178e1df50642f481342387e7983453_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtNi0xLTEtNDI5Njcx_698749c2-a713-4650-9ed7-4fe64cb3931c"
      unitRef="shares">9515000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4178e1df50642f481342387e7983453_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtOC0xLTEtNDI5Njcx_07611401-f714-4915-ad8e-241ddaf72c9a"
      unitRef="usd">476000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i283349b3ae194291807e57850205a00e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTAtMS0xLTQyOTY3MQ_64de36fd-ec4e-4097-bae2-9fb7cc829c8c"
      unitRef="usd">91359000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTItMS0xLTQyOTY3MQ_44dd3ffd-caac-490b-8ee5-c90d647f6c6a"
      unitRef="shares">3903000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cd63e0776794a11af6999e725dd9bf9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTQtMS0xLTQyOTY3MQ_7836b565-9fee-463c-9f30-490fdd45bfb9"
      unitRef="usd">-113945000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38fb06657953481f9327c4d7af5221d3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTYtMS0xLTQyOTY3MQ_f21a8b46-c5f9-46f5-a4db-06791554ad91"
      unitRef="usd">122967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i316fd24dd0da46e5872d02ce9db0a499_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMTgtMS0xLTQyOTY3MQ_f1167bcc-ec1f-4d78-a9cc-5d5d1c3f67bc"
      unitRef="usd">-8225000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i439e2eb2ea67457d989b7d096b2578b6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMjAtMS0xLTQyOTY3MQ_f79e7021-0af5-4778-ae86-2ccb934e6502"
      unitRef="usd">92631000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i982bd66098e642c180e76a8b23cfce05_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMjItMS0xLTQyOTY3MQ_e31bf2b8-2250-4303-909c-0c58aa769ee9"
      unitRef="usd">259000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTQtMjQtMS0xLTQyOTY3MQ_124eef16-43d4-450f-ba3a-de5a4360591e"
      unitRef="usd">92891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i342523194f354c36af8db3ac1d92928a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktNi0xLTEtNDI5Njcx_6c7e838a-7f1f-48d8-af83-d249758ba403"
      unitRef="shares">9407000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i342523194f354c36af8db3ac1d92928a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktOC0xLTEtNDI5Njcx_f73fbcbf-f7cd-41a1-99ce-8e0bdc12d55b"
      unitRef="usd">470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad01e12648344a0bbd128d9c7131aebc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTAtMS0xLTQyOTY3MQ_00c5132d-337c-4fd7-85be-9f183b919ed4"
      unitRef="usd">88674000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i7a5e26c69446465d846729c653f45303_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTItMS0xLTQyOTY3MQ_e49293e3-d232-4181-ab11-10a940ee6e0f"
      unitRef="shares">3840000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a5e26c69446465d846729c653f45303_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTQtMS0xLTQyOTY3MQ_e34af603-78f8-4b76-a3f3-2c512e46b1d8"
      unitRef="usd">-110988000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id46f714a106f496988fe9d996ad5882b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTYtMS0xLTQyOTY3MQ_f6c5ba0e-a370-40be-9ebc-2e5e7f119b54"
      unitRef="usd">90392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c21ac9482a54fb3991813baf028f817_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMTgtMS0xLTQyOTY3MQ_22213e64-ab98-49a4-9843-9cb7704afc7e"
      unitRef="usd">-5310000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7ec159b1e1141eb90a039d6e396bcd0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMjAtMS0xLTQyOTY3MQ_e3c30edc-4cf6-4d09-baff-c3b5a3f0e219"
      unitRef="usd">63238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1414142218df48a784a0e0af5a6fa08a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMjItMS0xLTQyOTY3MQ_c3aca57a-39a9-45db-abb2-886cdf2a0fa5"
      unitRef="usd">235000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00f38a2438be4f7bb12b558b25272ce5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMTktMjQtMS0xLTQyOTY3MQ_b9f451a3-cf25-4102-9a2b-c51307df67d2"
      unitRef="usd">63473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMTYtMS0xLTQyOTY3MQ_3650b008-2ade-415c-879f-7d21113ae8a3"
      unitRef="usd">18586000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMjAtMS0xLTQyOTY3MQ_9ff9b9c7-0e8e-49c5-a8cc-ee7da5fcfb52"
      unitRef="usd">18586000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMjItMS0xLTQyOTY3MQ_1f489583-c9b0-44a2-b97e-26ac18d272f4"
      unitRef="usd">47000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjAtMjQtMS0xLTQyOTY3MQ_48e059ef-d066-43a0-b22a-dc4704d7900f"
      unitRef="usd">18633000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1c0af948675a4a7f9a78ce4430cb4045_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjEtMTgtMS0xLTQyOTY3MQ_ee92c3e8-588a-48df-a564-b9d57ec4dcca"
      unitRef="usd">-338000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjEtMjAtMS0xLTQyOTY3MQ_d9c16ce9-0159-41b8-a855-ad6a9ac210d9"
      unitRef="usd">-338000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjEtMjQtMS0xLTQyOTY3MQ_c3f7a0f5-7760-4cee-89c2-c734cc8d5c37"
      unitRef="usd">-338000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjItMC0xLTEtNDI5NjcxL3RleHRyZWdpb246NDgzYWQ0YzQwNjhjNDA3NGJkMWFjODZjODgzNjE5YmJfMzI5ODUzNDg4MzM3MQ_a517df94-c906-4e49-9b34-62e0f9a7249e"
      unitRef="usdPerShare">1.17</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjMtMTYtMS0xLTQyOTY3MQ_44d659be-d157-46b4-84dd-ba2c5b068a5a"
      unitRef="usd">6569000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjMtMjAtMS0xLTQyOTY3MQ_3d600588-074f-4890-9ac3-d29448e3b1b7"
      unitRef="usd">6569000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjMtMjQtMS0xLTQyOTY3MQ_1f11fc44-444f-4077-aa55-40c073738d1f"
      unitRef="usd">6569000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjUtMjItMS0xLTQyOTY3MQ_03e8a52a-a4dc-415a-b92c-9e07def0aedd"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjUtMjQtMS0xLTQyOTY3MQ_dcd5278e-0ac5-46dd-8cfd-ae89dbc4402b"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i733fe6690f964b79a59503138cfacb8c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtNi0xLTEtNDI5Njcx_c6594ea3-42c0-4dd2-b420-fa7230e794a4"
      unitRef="shares">56000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i733fe6690f964b79a59503138cfacb8c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtOC0xLTEtNDI5Njcx_bd7fa9a4-7e5c-43ca-9655-9f425c7212ea"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id6e44f06dea84bef93e7ada7841e6e73_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTAtMS0xLTQyOTY3MQ_04c4a7f5-ff7f-423e-9069-d64599a4b930"
      unitRef="usd">1300000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8c6c8f9bc04f475da96d6d469914b62b_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTItMS0xLTQyOTY3MQ_c65cd988-85ea-454a-8401-29ced9530c4a"
      unitRef="shares">11000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8c6c8f9bc04f475da96d6d469914b62b_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTQtMS0xLTQyOTY3MQ_e8bed361-5967-49fd-a4bd-b5e342e165e6"
      unitRef="usd">-371000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMTYtMS0xLTQyOTY3MQ_9bf75cb6-c4aa-40ce-9811-74e9829ec180"
      unitRef="usd">-77000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMjAtMS0xLTQyOTY3MQ_41471c68-3d95-4267-b244-f7ecb1e93e76"
      unitRef="usd">855000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjYtMjQtMS0xLTQyOTY3MQ_f0dea1a5-28f7-4004-8a5e-57ed70a73fee"
      unitRef="usd">855000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjctMjQtMS0xLTQyOTY3MQ_8285da36-3317-4cd5-b8b3-f3cee0ae5e1c"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="id3b00eb95ab0495daf928ffecbf98179_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMTYtMS0xLTQyOTY3MQ_3cb41271-34ed-4609-b52f-dbd27fd1b135"
      unitRef="usd">81000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0a00c9d1e2654f2a9f2af74ff5e7cf53_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMjAtMS0xLTQyOTY3MQ_9d63774e-3d3d-4bb7-b975-fe7820995a14"
      unitRef="usd">81000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i814bce82def7437eb8a8fa1efd436a80_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMjItMS0xLTQyOTY3MQ_3e314145-e78b-418b-9144-88c1e764b993"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMjktMjQtMS0xLTQyOTY3MQ_b40d5ade-333a-4234-bf63-91a5f09d6547"
      unitRef="usd">79000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtNi0xLTEtNDI5Njcx_eb286a48-6729-4aed-a374-7089c04cea07"
      unitRef="shares">9462000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bf00def957b4c1ca037635793efebf2_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtOC0xLTEtNDI5Njcx_943f309b-445b-48d6-abc8-bf69a086988b"
      unitRef="usd">473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i269d8be2dbe14366928f6a655f330c99_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTAtMS0xLTQyOTY3MQ_3659b244-5e1e-4809-a422-191c5c28129a"
      unitRef="usd">89973000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTItMS0xLTQyOTY3MQ_b63d21f7-ab64-4cf8-b178-df5bf9ee4802"
      unitRef="shares">3851000000</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3adb48a9ed804129abc01342e3aa820b_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTQtMS0xLTQyOTY3MQ_c5c06960-8ce5-4df6-9b0e-df431f9d72cb"
      unitRef="usd">-111359000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7eead2d41724d1284b95a8f2c3ba977_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTYtMS0xLTQyOTY3MQ_8b69f7f2-1c0f-47f2-bb1b-dde06420a7fd"
      unitRef="usd">102252000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icff95de7b4364937bb8f6fa9332bb480_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMTgtMS0xLTQyOTY3MQ_4ddb729c-af9b-4136-968b-cee1ca2734fc"
      unitRef="usd">-5649000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89e9bcba37374979b4f81bb0e1923a9a_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMjAtMS0xLTQyOTY3MQ_45fa52e5-5af7-4014-9a4a-017e59fbaf75"
      unitRef="usd">75691000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad49f13a7aaf431ca7ad807765db51a1_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMjItMS0xLTQyOTY3MQ_580a31ec-2d96-4b29-81e3-939268f1a0d4"
      unitRef="usd">275000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yOC9mcmFnOjYwNWQ4OTMzYTE2MzRlZjhiMWJmNzhiZWYzYTlkNTc5L3RhYmxlOjYxYWI0ZDNlMjk5ZDQ4MDQ4YWIzMWQyZTJkZDVmOTg0L3RhYmxlcmFuZ2U6NjFhYjRkM2UyOTlkNDgwNDhhYjMxZDJlMmRkNWY5ODRfMzAtMjQtMS0xLTQyOTY3MQ_fd1a3a5d-f62a-4f40-adfc-b03536e4e5ef"
      unitRef="usd">75967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMy0yLTEtMS00Mjk2NzE_0da6bb42-f51c-4c21-b95c-6ee74117d514"
      unitRef="usd">26404000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMy00LTEtMS00Mjk2NzE_f0e3a417-e3b2-4970-be31-50791f00af2f"
      unitRef="usd">18633000000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNC0yLTEtMS00Mjk2NzE_d03aff67-1620-41ff-adc5-382fd44f3322"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNC00LTEtMS00Mjk2NzE_26b0da2d-3146-43ec-b587-9bb66de1ddb1"
      unitRef="usd">-248000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNS0yLTEtMS00Mjk2NzE_cbffdd60-ec23-48b9-970b-b38277a18d66"
      unitRef="usd">26400000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNS00LTEtMS00Mjk2NzE_378dde27-c40e-42d1-83bd-7601477a85a1"
      unitRef="usd">18881000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNy0yLTEtMS00Mjk2NzE_5e0eeb22-5479-4903-943e-8d5149eeba59"
      unitRef="usd">3545000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNy00LTEtMS00Mjk2NzE_71a04981-229e-40b6-855a-a7fbbe4163fc"
      unitRef="usd">3856000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfOC0yLTEtMS00Mjk2NzE_a7e309ed-939e-4bd3-a68b-c07f43b2a21b"
      unitRef="usd">287000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfOC00LTEtMS00Mjk2NzE_f072f1b4-5b45-4b6f-a183-aa07179fbc70"
      unitRef="usd">93000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTAtMi0xLTEtNDI5Njcx_904a4295-91cb-4da5-a639-1e91ff518d69"
      unitRef="usd">-3399000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTAtNC0xLTEtNDI5Njcx_0af669ad-0943-418e-8fbf-5cd981edc53c"
      unitRef="usd">-3610000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTItMi0xLTEtNDI5Njcx_9cd7cf38-651b-42cc-9e18-9449567c3038"
      unitRef="usd">508000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTItNC0xLTEtNDI5Njcx_2c4e2591-0c92-43f5-b73a-b01b76b2f5d9"
      unitRef="usd">686000000</us-gaap:ShareBasedCompensation>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTMtMi0xLTEtNDI5Njcx_d223a465-131d-4343-bb7e-084b1af76c65"
      unitRef="usd">532000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTMtNC0xLTEtNDI5Njcx_66292d13-e7b3-41a2-bb19-457d0443386d"
      unitRef="usd">1933000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTQtMi0xLTEtNDI5Njcx_757fca48-e10d-4c3d-a4a6-55acc45de90d"
      unitRef="usd">-1481000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTQtNC0xLTEtNDI5Njcx_f6b6affe-52e0-472f-83d4-c9f24f346f77"
      unitRef="usd">1848000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTUtMi0xLTEtNDI5Njcx_ea3936ee-0d8a-403a-8b77-2f4a12a7dfc2"
      unitRef="usd">7605000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTUtNC0xLTEtNDI5Njcx_a31bf8ca-1331-44eb-a0aa-18031b9e6eed"
      unitRef="usd">-10867000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTYtMi0xLTEtNDI5Njcx_275bc53f-56df-43a1-af16-6f0f16fa483d"
      unitRef="usd">20685000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTYtNC0xLTEtNDI5Njcx_790c1dac-4bf6-443b-a46b-d546d7106a5e"
      unitRef="usd">26993000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTctMi0xLTEtNDI5Njcx_cfa89042-b39e-4acd-bda0-4aeec0b018d8"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTctNC0xLTEtNDI5Njcx_4b2826ec-bc5e-4727-a129-7cfabedd767b"
      unitRef="usd">-327000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTgtMi0xLTEtNDI5Njcx_416b864d-7796-4028-98fa-375f7642cfee"
      unitRef="usd">20685000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMTgtNC0xLTEtNDI5Njcx_bb071e30-a729-446f-a075-ef205d42e3b9"
      unitRef="usd">26666000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjEtMi0xLTEtNDI5Njcx_153c6ba5-17ee-4667-acd1-ceb74352349f"
      unitRef="usd">2235000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjEtNC0xLTEtNDI5Njcx_dab0c7df-f1fe-4bec-a628-1bb795d46c57"
      unitRef="usd">1709000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjItMi0xLTEtNDI5Njcx_53db7535-3667-4994-9a38-135f5510f47e"
      unitRef="usd">29701000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjItNC0xLTEtNDI5Njcx_79896e91-03fd-43a5-ba73-b09b17bd2ff0"
      unitRef="usd">26280000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjMtMi0xLTEtNDI5Njcx_0bba7621-694f-4c52-96d9-8ba2c386c72c"
      unitRef="usd">35087000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjMtNC0xLTEtNDI5Njcx_5cad9bb9-a195-47f4-84d2-11bc4c394271"
      unitRef="usd">15852000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjQtMi0xLTEtNDI5Njcx_34035c0f-c8b4-494e-98b7-cb16b04c4422"
      unitRef="usd">10877000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjQtNC0xLTEtNDI5Njcx_07cd4c8f-110f-403a-9d64-5647f3f4c9a6"
      unitRef="usd">7152000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjUtMi0xLTEtNDI5Njcx_f3cf3506-89f4-4226-b828-38b2e28b4892"
      unitRef="usd">1627000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjUtNC0xLTEtNDI5Njcx_c5399449-2243-4cca-9711-f0532e9094eb"
      unitRef="usd">861000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjYtMi0xLTEtNDI5Njcx_7ec357a5-3b4c-4516-ac04-ac77a3a85ca2"
      unitRef="usd">446000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjYtNC0xLTEtNDI5Njcx_61a650ef-f3ca-4bb2-995d-75bb39d4cbe2"
      unitRef="usd">569000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjctMi0xLTEtNDI5Njcx_602af887-08c0-44f1-9405-3453e46f98da"
      unitRef="usd">6225000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjctNC0xLTEtNDI5Njcx_96408f72-6466-4d4b-94a7-1c1e266a5214"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtMi0xLTEtNDkzOTE5_0e6e5f8e-1797-4a90-92b6-177d6c0c919f"
      unitRef="usd">3960000000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtNC0xLTEtNDkzOTYz_3d1d5be0-7c66-4507-836f-60da4dd67616"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtMi0xLTEtNDI5Njcx_4200200c-22e9-4816-ad17-5ee1ae77d3ca"
      unitRef="usd">200000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjgtNC0xLTEtNDI5Njcx_953a4049-b36f-4825-b2d1-765395c656eb"
      unitRef="usd">370000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjktMi0xLTEtNDI5Njcx_cdd19ef0-883f-4175-bc8d-b93ad8ac0ede"
      unitRef="usd">-11373000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMjktNC0xLTEtNDI5Njcx_4fae6192-256c-467e-b963-3e3d05295f77"
      unitRef="usd">-19951000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzAtMi0xLTEtNDI5Njcx_36afe603-60bf-402c-9c09-f40516de3aa6"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzAtNC0xLTEtNDI5Njcx_47ef39cd-a2f0-46d4-bd19-fab15bad2461"
      unitRef="usd">-8000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzEtMi0xLTEtNDI5Njcx_7e55d28d-d2c6-4183-8665-6fca3d7fb319"
      unitRef="usd">-11373000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzEtNC0xLTEtNDI5Njcx_79347aae-6e1d-4f71-b034-289ade1a1565"
      unitRef="usd">-19960000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzQtMi0xLTEtNDI5Njcx_0ef1a1a3-51d6-4d55-bcce-3d264b4cb9e9"
      unitRef="usd">3887000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzQtNC0xLTEtNDI5Njcx_074352e1-a0b6-4928-ac49-57f4f0af47a3"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzUtMi0xLTEtNDI5Njcx_67ab241a-5f1c-4409-9f0d-31b7edb2d2bc"
      unitRef="usd">3887000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzUtNC0xLTEtNDI5Njcx_43dad0bf-c758-465e-abd6-f4d68a42da27"
      unitRef="usd">1000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzYtMi0xLTEtNDI5Njcx_b7a9e935-d347-417f-9de9-54027d64db3f"
      unitRef="usd">870000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzYtNC0xLTEtNDI5Njcx_20a51d5e-338a-4a46-b9a2-64efbd976144"
      unitRef="usd">265000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzctMi0xLTEtNDI5Njcx_fac2aaaf-3311-4206-9900-91a5a33eaff6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzctNC0xLTEtNDI5Njcx_8d75810e-12d5-4f8a-9458-0c0a94bde7f0"
      unitRef="usd">997000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzgtMi0xLTEtNDI5Njcx_1e0c3154-788d-4772-9aca-8479c4f13d29"
      unitRef="usd">1609000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzgtNC0xLTEtNDI5Njcx_e5467d18-e2e8-4ed0-80ae-334481395331"
      unitRef="usd">1001000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzktMi0xLTEtNDI5Njcx_834a5a19-1fe0-4d3a-b29c-567595d99210"
      unitRef="usd">2000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfMzktNC0xLTEtNDI5Njcx_65f519dd-0f97-410a-91ef-9f168d323cdc"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDAtMi0xLTEtNDI5Njcx_b0ce1ecb-1115-44c7-b152-6db6e6f4a202"
      unitRef="usd">6738000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDAtNC0xLTEtNDI5Njcx_38621988-dd65-43bf-bf8a-97a3c1a2621e"
      unitRef="usd">6540000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDEtMi0xLTEtNDI5Njcx_95b52958-5996-4531-8cee-42cc699617ea"
      unitRef="usd">-342000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDEtNC0xLTEtNDI5Njcx_265a7ad3-e7bd-46fe-9823-257f68d2137b"
      unitRef="usd">-185000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDQtMi0xLTEtNDI5Njcx_90ef1cf4-dec0-4a01-b514-33e5bb443376"
      unitRef="usd">-9819000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDQtNC0xLTEtNDI5Njcx_546dc1b5-ac77-4b96-8673-4fe6b32a3eef"
      unitRef="usd">-6465000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDUtMi0xLTEtNDI5Njcx_9aad791b-1415-45ea-a2c7-d48feb92c75e"
      unitRef="usd">-139000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDUtNC0xLTEtNDI5Njcx_129e0519-859e-47c0-b06c-4b8c4724f4d5"
      unitRef="usd">-32000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDYtMi0xLTEtNDI5Njcx_dd2499db-c3b9-4bf9-9ab2-6b47f98317b5"
      unitRef="usd">-646000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDYtNC0xLTEtNDI5Njcx_406da573-d97a-4955-b454-223804719dc3"
      unitRef="usd">209000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDctMi0xLTEtNDI5Njcx_feb46768-d822-4276-8afd-409696cab4fb"
      unitRef="usd">1983000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i00f38a2438be4f7bb12b558b25272ce5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDctNC0xLTEtNDI5Njcx_5b8b190d-c960-4495-91f9-ad6b5c1715c8"
      unitRef="usd">1825000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDgtMi0xLTEtNDI5Njcx_44345a59-8f5a-4c85-94dc-38e99cdd61f9"
      unitRef="usd">1338000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaab03f8962c74a05a5f8c11c98ad0a50_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNDgtNC0xLTEtNDI5Njcx_797c20a0-5456-4adb-98a6-5673d7dd88b7"
      unitRef="usd">2034000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTQtMi0xLTEtNDI5Njcx_79d1782a-a692-46e8-b64c-4b73305cc409"
      unitRef="usd">4919000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTQtNC0xLTEtNDI5Njcx_c5464a08-80d2-424b-b45c-b6b4e1297796"
      unitRef="usd">2943000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTUtMi0xLTEtNDI5Njcx_a8815ddf-7007-4706-944e-a69de649ef1e"
      unitRef="usd">1121000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTUtNC0xLTEtNDI5Njcx_742e6047-6364-4a01-8461-de19431da57c"
      unitRef="usd">1205000000</us-gaap:InterestPaidNet>
    <pfe:InterestPaidReceivedInterestRateHedges
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTYtMi0xLTEtNDI5Njcx_6b971251-39ec-4637-a8fa-e79ad27c9578"
      unitRef="usd">28000000</pfe:InterestPaidReceivedInterestRateHedges>
    <pfe:InterestPaidReceivedInterestRateHedges
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTYtNC0xLTEtNDI5Njcx_89c9ac9d-406e-4044-939d-15c82f770ae4"
      unitRef="usd">-26000000</pfe:InterestPaidReceivedInterestRateHedges>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTgtMi0xLTEtNDI5Njcx_d5f04417-9432-4452-b5d1-1ab91d5b24a5"
      unitRef="usd">463000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zMS9mcmFnOmM5MzQ1YmQ1NjIwNzRhZWFhZDZjYTQ0MjZmZTVjMTQ5L3RhYmxlOjliMDg2OTZiYzU0ZTRjOWQ4MGM2MWY1MjM2ODJjZGQyL3RhYmxlcmFuZ2U6OWIwODY5NmJjNTRlNGM5ZDgwYzYxZjUyMzY4MmNkZDJfNTgtNC0xLTEtNDI5Njcx_a207612c-3412-42ae-a229-2d7f1d351eb3"
      unitRef="usd">1552000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk4NQ_541ab103-7d48-4866-9615-96ff33c3e821">Basis of Presentation and Significant Accounting Policies&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer&#x2019;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August&#160;28, 2022 and August&#160;29, 2021, and for U.S. subsidiaries is as of and for the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Beginning in the third quarter of 2022, we made several additional&lt;/span&gt;&lt;span style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;organizational changes to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches. These changes include establishing a new commercial structure within our Biopharma operating segment and realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure. Biopharma is the only reportable segment. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form 10-K and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 9B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; 13A &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business development activities completed in 2021 and 2022 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary and post-closing adjustments for other previously divested businesses. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form 10-K, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations, acquired IPR&amp;amp;D expenses and segment reporting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. New Accounting Standard Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Revenues and Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors&#x2019; locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customers&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deductions from Revenues&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade Accounts Receivable&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1H&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;D. Acquired In-Process Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the first quarter of 2022, we began reporting acquired IPR&amp;amp;D expense as a separate line item in our consolidated statements of income. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Acquired in-process research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;amp;D. These costs were previously recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed. The fair value of IPR&amp;amp;D acquired in connection with a business combination is recorded on the balance sheet as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Notes 1E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;10 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;in our&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2021 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzkzOQ_b7e20922-3518-4974-a0af-44a5adacd9ad">Basis of Presentation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer&#x2019;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August&#160;28, 2022 and August&#160;29, 2021, and for U.S. subsidiaries is as of and for the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Beginning in the third quarter of 2022, we made several additional&lt;/span&gt;&lt;span style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;organizational changes to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches. These changes include establishing a new commercial structure within our Biopharma operating segment and realigning certain enabling and platform functions across the organization to ensure alignment with this new operating structure. Biopharma is the only reportable segment. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form 10-K and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 9B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; 13A &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business development activities completed in 2021 and 2022 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary and post-closing adjustments for other previously divested businesses. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form 10-K, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations, acquired IPR&amp;amp;D expenses and segment reporting.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfMTI3Nw_b82b43b2-9eb7-4011-95e0-3abb3831f9df"
      unitRef="operatingsegment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk1MA_af4f6ad9-59c0-467a-beb6-c0427ac16e8e">New Accounting Standard Adopted in 2022On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk1MQ_bdd4152e-5b67-4566-b90e-afcc22b0a281">Revenues and Trade Accounts Receivable&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our or our third-party subcontractors&#x2019; locations under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customers&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deductions from Revenues&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade Accounts Receivable&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk3OA_7122d103-1d43-488f-ae35-233722da6737">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="if04c3dccab614a94b2908a489d743aff_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMS0yLTEtMS00Mjk2NzE_5217600a-5536-422c-b95f-6f341203fb31"
      unitRef="usd">1133000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="icf6ba2fc692f44b495f2e7f584a00bef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMS00LTEtMS00Mjk2NzE_52cd01ad-53c9-418e-8992-f448ff3e02c0"
      unitRef="usd">1077000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:AccruedRebates
      contextRef="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMy0yLTEtMS00Mjk2NzE_f40422c5-2fcb-4ead-bfcc-af0a02af537f"
      unitRef="usd">3991000000</pfe:AccruedRebates>
    <pfe:AccruedRebates
      contextRef="i7508bb16fd44454482e06b74af164e0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfMy00LTEtMS00Mjk2NzE_fdbcd608-3b3a-44fb-9e07-710e37b27822"
      unitRef="usd">3811000000</pfe:AccruedRebates>
    <pfe:OtherAccruals
      contextRef="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNC0yLTEtMS00Mjk2NzE_e72e4a30-f174-47a5-9a1d-9e6fb381cea5"
      unitRef="usd">418000000</pfe:OtherAccruals>
    <pfe:OtherAccruals
      contextRef="i7508bb16fd44454482e06b74af164e0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNC00LTEtMS00Mjk2NzE_beed9764-19cb-456b-b6ef-999ad983eac0"
      unitRef="usd">528000000</pfe:OtherAccruals>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="id0861c1e153d4341b6f1aa2768a8b9e3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNS0yLTEtMS00Mjk2NzE_1595640e-9859-4305-99c4-785283e01c39"
      unitRef="usd">497000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="i20b757dbbd6f4f2bad32cff5eca993e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNS00LTEtMS00Mjk2NzE_9b3ad6fe-7f39-498e-a70d-d3ac3f74b5d1"
      unitRef="usd">433000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNi0yLTEtMS00Mjk2NzE_a2172298-acc1-4fca-9f95-205c8504cf2e"
      unitRef="usd">6038000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RhYmxlOjc1YTE2N2QxNWU3NzRiMjQ5MTU5ZWI0OGExZTAzZjFmL3RhYmxlcmFuZ2U6NzVhMTY3ZDE1ZTc3NGIyNDkxNTllYjQ4YTFlMDNmMWZfNi00LTEtMS00Mjk2NzE_dceb283f-c344-4001-9de4-2f852e165f78"
      unitRef="usd">5850000000</pfe:RebatesAndDiscountsAccrual>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8zNy9mcmFnOmEyYTU3NzgzODE5YzRlYTZiOGUyYjU5YmY1MDk5YzAwL3RleHRyZWdpb246YTJhNTc3ODM4MTljNGVhNmI4ZTJiNTliZjUwOTljMDBfNzk0Ng_18021d28-58e1-4b1e-9fab-ad17ac6f11f6">Acquired In-Process Research and Development Expenses&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the first quarter of 2022, we began reporting acquired IPR&amp;amp;D expense as a separate line item in our consolidated statements of income. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Acquired in-process research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&amp;amp;D. These costs were previously recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed. The fair value of IPR&amp;amp;D acquired in connection with a business combination is recorded on the balance sheet as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Identifiable intangible assets&lt;/span&gt;.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfOTA2Mw_3f8302cb-4dc3-4ebf-938d-772be0e17a8f">Acquisitions, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;ReViral&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2013;&#x2013;On June 9, 2022, which fell in our international third quarter of 2022, we acquired ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel antiviral therapeutics that target respiratory syncytial virus, for a total consideration of up to $536 million, including upfront payments of $436 million upon closing (including a base payment of $425 million plus working capital adjustments) and an additional $100 million contingent upon future development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We accounted for the transaction as an asset acquisition since the lead asset, sisunatovir, represented substantially all of the fair value of the gross assets acquired. At the acquisition date, we recorded a $426 million charge representing an acquired IPR&amp;amp;D asset with no alternative use in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Acquired in-process research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which is presented as a cash outflow from operating activities. Other assets acquired and liabilities assumed were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Arena&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 11, 2022, we acquired Arena, a clinical stage company, for $100 per share in cash. The total fair value of the consideration transferred was $6.6&#160;billion ($6.2 billion, net of cash acquired). In addition, $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Restructuring charges and certain acquisition-related costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Arena&#x2019;s portfolio includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including UC, Crohn&#x2019;s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In connection with this acquisition, we provisionally recorded: (i) $5.5 billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, consisting of $5.0 billion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and $460 million of indefinite-lived &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, (ii) $1.0 billion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and (iii) $505 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Meridian&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2021, we completed the sale of our Meridian subsidiary. In the three and nine months ended October&#160;2, 2022, the amounts recorded under the interim TSAs and MSA were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Upjohn Separation and Combination with Mylan&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination and to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The amounts recorded under these agreements were not material to our consolidated results of operations in the three and nine months ended October&#160;2, 2022 and October&#160;3, 2021. Net amounts due from Viatris under the agreements were approximately $167 million as of October&#160;2, 2022 and $53 million as of December 31, 2021. The cash flows associated with the agreements are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net cash provided by operating activities from continuing operations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other financing activities, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; for the three and nine months ended October&#160;3, 2021 reflects pre-tax loss from discontinued operations of $17 million and $353 million, respectively, and primarily includes pre-disposal operations related to our former Meridian subsidiary including a $345&#160;million pre-tax expense in the first nine months of 2021 to resolve a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas (prior to presenting Meridian as discontinued operations, this EpiPen litigation amount was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;).&lt;/span&gt;&lt;span style="color:#b2b2b2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the three and nine months ended October&#160;2, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; reflects pre-tax loss of $15 million and pre-tax income of $9 million from discontinued operations, respectively, and relates to post-closing adjustments for previously divested businesses primarily for tax and legal matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Equity-Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Haleon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consumer Healthcare JV&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operated globally under the GSK Consumer Healthcare name. In exchange for the contribution of our consumer healthcare business to the JV, we received a 32% equity stake in the new company and GSK owned the remaining 68%. On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint Consumer Healthcare business of GSK and Pfizer following the demerger. We continue to own 32% of the ordinary shares of Haleon after the demerger. We continue to account for our interest in Haleon as an equity-method investment. The carrying value of our&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment in Haleon as of October&#160;2, 2022 and in the Consumer Healthcare JV as of December 31, 2021 is $9.6 billion and $16.3 billion, respectively, and is reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity-method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The fair value of our investment in Haleon as of October&#160;2, 2022, based on quoted market prices of Haleon stock, was $9.1 billion. Haleon/the Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2021 is primarily due to dividends totaling approximately $4.5 billion, of which cash flows of $4.0 billion are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net cash used in investing activities from continuing operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $584 million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net cash provided by operating activities from continuing operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as well as $2.4 billion in pre-tax foreign currency translation adjustments (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), partially offset by our share of the JV&#x2019;s earnings. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Our total share of the JV&#x2019;s earnings generated in the second quarter of 2022, which we recorded in our operating results in the third quarter of 2022, was $67 million. Our total share of the JV&#x2019;s earnings generated in the fourth quarter of 2021 and first six months of 2022, which we recorded in our operating results in the first nine months of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, was $402 million. Our total share of the JV&#x2019;s earnings generated in the second quarter of 2021, which we recorded in our operating results in the third quarter of 2021, was $106 million. Our total share of the JV&#x2019;s earnings generated in the fourth quarter of 2020 and first six months of 2021, which we recorded in our operating results in the first nine months of 2021, was $324 million. In the third quarter and first nine months of 2022, our equity-method income included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;also includes charges of $118 million and $119 million, respectively, primarily for adjustments to our equity-method basis differences related to the separation of Haleon/the GSK Consumer Healthcare JV from GSK. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV was not material to our results of operations in the third quarter and first nine months of 2021. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:3pt;padding-right:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three and nine months ending June 30, 2022, the most recent period available, and for the three and nine months ending June 30, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with GSK&#x2019;s previously announced planned demerger of at least 80% of GSK&#x2019;s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, &#x20ac;2.35 billion in euro-denominated senior notes of various maturities and &#xa3;700 million in U.K. pound-denominated senior notes of various maturities (collectively, the &#x201c;notes&#x201d;). The notes were guaranteed by GSK generally up to and excluding the date of the demerger (the &#x201c;Guarantee Assumption Date&#x201d;). We agreed to indemnify GSK for 32% (representing our pro rata equity interest in the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity was provided solely for the benefit of GSK. Neither we nor any of our subsidiaries were an issuer or guarantor of any of the notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following its issuance of the notes in March 2022, which fell in our international second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of &#xa3;2.9 billion ($3.7 billion as of the end of our second quarter of 2022), at an interest rate of 1.365% per annum payable semi-annually in arrears. In conjunction with the demerger, we received &#xa3;3.5 billion ($4.2 billion) in dividends from the JV in July 2022, of which $4.0&#160;billion related to a one-time pre-separation dividend, which decreased the carrying value of our investment (as discussed above). Simultaneous with the receipt of the dividends, we repaid the &#xa3;2.9 billion loan from the JV. GSK similarly received pro rata dividends and simultaneously repaid its pro rata loan from the JV. In conjunction with these transactions, our indemnification of GSK&#x2019;s guarantee discussed above was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Collaborative Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration with Biohaven&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven and certain of its subsidiaries to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Under the terms of the agreement, Biohaven would  lead R&amp;amp;D globally and we would have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January&#160;4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263&#160;million for the upfront payment and premium paid on our equity investment in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired in-process research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In October 2022, within our fiscal fourth quarter of 2022, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share, in cash, for payments of approximately $11.5&#160;billion.&lt;/span&gt;&lt;/div&gt;</pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjc0ODc3OTA4Mzk0Ng_34759188-bd14-4cb9-82ff-385efb4f8dbd"
      unitRef="usd">536000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjc0ODc3OTA4Mzk3MQ_bc40f181-c84e-4ee6-8972-7e6743a9d5b1"
      unitRef="usd">436000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <pfe:PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments
      contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MDE0MA_688aafaf-53e1-482c-9d6f-6371f3ee2f7f"
      unitRef="usd">425000000</pfe:PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjc0ODc3OTA4Mzk5Mg_65a6aabf-01f9-4879-9775-d2ae403beb04"
      unitRef="usd">100000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i6721d042bce841789b97c61224022594_D20220609-20220609"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI3NTUzNg_ccbe57c5-9fa7-4f00-98d3-388072f789b5"
      unitRef="usd">426000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3MjU0_7292aa0c-0900-41ff-a44a-d941c6746f04"
      unitRef="usdPerShare">100</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i01574368db75427a9223807866f28b02_D20220311-20220311"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3MzM1_521e5329-d594-4ae4-ab78-70e4dab03bae"
      unitRef="usd">6600000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i01574368db75427a9223807866f28b02_D20220311-20220311"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3MzQw_142bef6b-d1e8-4dd7-8a93-dac8b2b3834b"
      unitRef="usd">6200000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i87882967ea9849de8a349199b28d5e06_D20220311-20220311"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI3Mzgx_d09bc815-890c-4256-b8ea-db9778528c68"
      unitRef="usd">138000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MDY4_6014f0e3-ec20-4c17-b8f6-5c610ede61c0"
      unitRef="usd">5500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id0e5aabb88f345f8b7eacf17c16cdd86_I20220311"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MTIx_599a3f94-b551-4ddb-874f-b9923401ec00"
      unitRef="usd">5000000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id429ba78c8b54ea280edb5594ad15554_I20220311"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MTM4_46b8b02a-d9b7-4d38-922b-9b7c47b35ef9"
      unitRef="usd">460000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MTk5_7ec71a86-7e5c-4dc2-9cab-582abea463ab"
      unitRef="usd">1000000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="if02ecae4c145465fbebfc17542366c8c_I20220311"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTQ5NzU1ODI4MjI1_72638cab-4dc2-4b8f-8b02-7c7f0f396e94"
      unitRef="usd">505000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="ic44d8c4f02f348958a5ef9d3d3956478_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjI2Ng_2810762e-8dbc-4431-b844-0527b3e8b2d6"
      unitRef="usd">167000000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="i14aafbc729874cbe90872af65ea59b36_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjI4Mg_a50723c1-2b26-4978-912c-03d1fb8facee"
      unitRef="usd">53000000</us-gaap:NontradeReceivablesCurrent>
    <pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities
      contextRef="i509aed2b3fb94e35abdfcdc538d2275b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjQ1NQ_239504ff-aff3-4c0b-b7b3-09f27ef6333a"
      unitRef="usd">277000000</pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjcyMQ_efdd289a-a51b-4972-8556-d8049abae7e6"
      unitRef="usd">-17000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjcyOA_6841573f-6b81-48ea-9a35-062dd87fd0e1"
      unitRef="usd">-353000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i5fc75e310f54444b94ce2100463e4260_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjg0Nw_1db9f5e9-42c0-4cf3-812f-e6686c71166e"
      unitRef="usd">-345000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzI0Nw_8109be1a-1293-49e0-81e2-20fd402485b7"
      unitRef="usd">-15000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzI1NA_3b14452c-5997-4334-a45a-3b854ae4c195"
      unitRef="usd">9000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia87a0c62e89e454eb69933abb4c4cf0c_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzcxNg_678d0b53-efb5-4e11-ba7f-83c2cee83201"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifc89d78c61c749e883b46dd57f1a3ccf_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzc3OQ_557395b8-4426-4466-884a-35177fe3dae9"
      unitRef="number">0.68</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2fbf4bc1a0894e7788da3e8ed8f24508_I20220718"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ2MTE3NA_7502d2fd-7dca-47d1-bb24-2310e1e72cf2"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i0aeaaa46a5c645458d5ca97b3f043df5_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzk1MA_2a5fec6b-fbaf-4980-a84a-4e690dc90229"
      unitRef="usd">9600000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i03f67e1304894aa8b40ea227ea7a7e3b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMzk2Ng_8bca30ed-a1ec-46c0-b86b-50bff161a6da"
      unitRef="usd">16300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i0aeaaa46a5c645458d5ca97b3f043df5_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MTY0MA_d9db57d5-1b28-46dd-ad20-179d6f4a53d1"
      unitRef="usd">9100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <pfe:ProceedsFromEquityMethodInvestmentDistributionTotal
      contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ1Nzk5Ng_1067390d-e463-4489-ac15-cdeb55791fa0"
      unitRef="usd">4500000000</pfe:ProceedsFromEquityMethodInvestmentDistributionTotal>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI4MzAxNg_261a62dc-9ccd-4214-b388-d0b6f4c20214"
      unitRef="usd">4000000000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI4MzAzOQ_54064f61-68d5-4bd1-9246-c54c0cf39556"
      unitRef="usd">584000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation
      contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNDQ0NA_e2a0e0c3-fd34-47a7-b067-4a76683b954b"
      unitRef="usd">-2400000000</pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2a8fc0f572a7426d9fcc873efb1de4f8_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ1MjUxMg_d618415a-521b-469b-b174-9bf69e827aa7"
      unitRef="usd">67000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTA1Ng_414ae620-cfe5-4749-bc16-3d5bfb951519"
      unitRef="usd">402000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i18bc5b7d65614c15bf509693d653ef09_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ1MjUwNQ_ef32eb84-e4ca-40b7-941f-3b1e13890f73"
      unitRef="usd">106000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i002cc11dc66a4c92ab91ce99b0fab752_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTM2OA_04957598-f672-4640-bce6-510076bc1d28"
      unitRef="usd">324000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <pfe:EquityMethodInvestmentAdjustmentOfBasisDifferences
      contextRef="i2a8fc0f572a7426d9fcc873efb1de4f8_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MDE2NQ_5e390d60-4b09-4262-8343-721cadf49646"
      unitRef="usd">118000000</pfe:EquityMethodInvestmentAdjustmentOfBasisDifferences>
    <pfe:EquityMethodInvestmentAdjustmentOfBasisDifferences
      contextRef="id10b67f0f81d4bfda1b751f83b63cdda_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MDE4OQ_22773790-51d9-4d41-9ca3-cfe1323754ea"
      unitRef="usd">119000000</pfe:EquityMethodInvestmentAdjustmentOfBasisDifferences>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfOTA2MQ_b0863e55-bd1a-46b1-ba66-cef14ec2ef01">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three and nine months ending June 30, 2022, the most recent period available, and for the three and nine months ending June 30, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:Revenues
      contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC0yLTEtMS00Mjk2NzE_21228f7c-2c0b-4cf4-a238-0dd741934eb9"
      unitRef="usd">3218000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC00LTEtMS00Mjk2NzE_435ec536-60a9-4433-9f77-a72f5bae5342"
      unitRef="usd">3152000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC02LTEtMS00Mjk2NzE_87674a98-c5f1-4764-8460-2888d8883cce"
      unitRef="usd">10164000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNC04LTEtMS00Mjk2NzE_8b8228ef-4e13-4723-b7b4-94928d35c3e6"
      unitRef="usd">9428000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS0yLTEtMS00Mjk2NzE_748dcab9-04ec-4549-aed3-881dc492a817"
      unitRef="usd">1196000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS00LTEtMS00Mjk2NzE_90364702-e061-47d4-8878-f339eb1b331f"
      unitRef="usd">1180000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS02LTEtMS00Mjk2NzE_5e29f997-537d-4b61-9360-4af8487bfcde"
      unitRef="usd">3830000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNS04LTEtMS00Mjk2NzE_e4eb1ac8-9a11-4be4-a7d9-62d56bdb5350"
      unitRef="usd">3536000000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi0yLTEtMS00Mjk2NzE_c799b6e7-941b-47ea-9846-00e70c44e64b"
      unitRef="usd">2022000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi00LTEtMS00Mjk2NzE_eff099cf-6cd7-4d0c-91d1-5e2c72d5b2c9"
      unitRef="usd">1972000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi02LTEtMS00Mjk2NzE_caf49688-9e91-49b2-a0f1-db5bfbd81248"
      unitRef="usd">6334000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNi04LTEtMS00Mjk2NzE_8919dd51-a9b8-4277-b9c3-313ee211f9ec"
      unitRef="usd">5892000000</us-gaap:GrossProfit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy0yLTEtMS00Mjk2NzE_cf4bf0ca-178c-48ac-ac87-1fa3f5bb47c5"
      unitRef="usd">226000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy00LTEtMS00Mjk2NzE_bf36abbf-95ff-4573-af4b-502e4b39d9a8"
      unitRef="usd">348000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy02LTEtMS00Mjk2NzE_e6cfdf77-e385-4144-9aac-3162f3627df8"
      unitRef="usd">1303000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfNy04LTEtMS00Mjk2NzE_ec8609f0-7b1d-4e7c-b245-36521275e844"
      unitRef="usd">1064000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC0yLTEtMS00Mjk2NzE_24d0a434-d492-4968-8089-b3a119e06abc"
      unitRef="usd">226000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC00LTEtMS00Mjk2NzE_ac86e8d0-f169-4ad9-ac73-f0b2888d6484"
      unitRef="usd">348000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC02LTEtMS00Mjk2NzE_ae8ec31c-39ed-4a9e-acbb-6709af3eb630"
      unitRef="usd">1303000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOC04LTEtMS00Mjk2NzE_14de4467-6429-4215-a68b-75ae6a56d50b"
      unitRef="usd">1064000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id859aeb95872427ca6e14971df36fe79_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS0yLTEtMS00Mjk2NzE_ef6ef1f5-4cdc-48db-9944-a4544b354e13"
      unitRef="usd">210000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff18a44099ca4d3bb496bc3acf969103_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS00LTEtMS00Mjk2NzE_741136ba-cc16-49d8-9f6a-af5d6025f5a2"
      unitRef="usd">330000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f040514ce914ebdb121f9956a10f954_D20211001-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS02LTEtMS00Mjk2NzE_21d2d5a0-7b43-4b3a-a1b3-7d54324cca53"
      unitRef="usd">1256000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie271f110b8974e8ba7f98231a7ffb765_D20201001-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RhYmxlOjcwYWM3MDBjYWJiNzQ5OGVhOTg4YTE0NjAyZTFjYzZiL3RhYmxlcmFuZ2U6NzBhYzcwMGNhYmI3NDk4ZWE5ODhhMTQ2MDJlMWNjNmJfOS04LTEtMS00Mjk2NzE_317c4287-74c3-4430-a955-bc8d21f44767"
      unitRef="usd">1012000000</us-gaap:NetIncomeLoss>
    <pfe:DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal
      contextRef="i420561cd7e844911961eee63ae39bdd0_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTc5MA_61950d51-e194-44c1-89ca-603696c25173"
      unitRef="number">0.80</pfe:DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifc89d78c61c749e883b46dd57f1a3ccf_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTgwMg_432ded41-a0e1-4b42-9b49-1b7131578c94"
      unitRef="number">0.68</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i70b27e6f401f4351a27e511e00a11af2_I20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNTk1Nw_2a30e73a-c428-4cea-bf35-a536593c0ad5"
      unitRef="usd">8750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5a94f1c0e3654553b739db0514bb91f8_I20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjAyMw_61ac1744-58ea-44d9-a793-325455b3640b"
      unitRef="eur">2350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie15724356ec94a19bb862b3f6307566e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjA4NQ_f615d84a-8ac3-4b77-85eb-698fd12c8b96"
      unitRef="gbp">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i600244a7a17344ab962cbad5adad812f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjMzMg_427d56e1-1069-496a-be3c-1b0ccbdb7197"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28e0ab0e158f46899e45c2d773856f14_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjg4OA_dd29dd9a-47f8-4ceb-9958-7e9137af17a2"
      unitRef="gbp">2900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i28e0ab0e158f46899e45c2d773856f14_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjg5Mg_778adc0e-5fe0-4d60-98c5-70e8addaa300"
      unitRef="usd">3700000000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28e0ab0e158f46899e45c2d773856f14_I20220703"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNjk1MA_f3d9abd1-e257-4d64-93d4-fe3ebd86e5f8"
      unitRef="number">0.01365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <pfe:ProceedsFromEquityMethodInvestmentDistributionTotal
      contextRef="ife71c632282645c6972017eea707a24b_D20220701-20220731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNzMwNw_1afa24f4-7e35-4fb8-8a31-8408bd794c25"
      unitRef="gbp">3500000000</pfe:ProceedsFromEquityMethodInvestmentDistributionTotal>
    <pfe:ProceedsFromEquityMethodInvestmentDistributionTotal
      contextRef="ife71c632282645c6972017eea707a24b_D20220701-20220731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfNzMxMQ_27b5f7fa-499d-4a7a-a8fc-aa36e6a714f5"
      unitRef="usd">4200000000</pfe:ProceedsFromEquityMethodInvestmentDistributionTotal>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ife71c632282645c6972017eea707a24b_D20220701-20220731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMjE5OTAyMzI4NjMyNw_99ab4ac1-bb94-40de-8565-6f512675370f"
      unitRef="usd">4000000000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i42142f3d667447f8b004965d67fb5bef_I20220731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MzI0MQ_47200092-d13b-4f18-85c8-d2c07fd7515f"
      unitRef="gbp">2900000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <pfe:PrepaymentsAndPaymentsToCollaboratorsCash
      contextRef="id7af860819f54f01861664b5ad041b8f_D20220104-20220104"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODM5OA_13cbce96-ae01-4816-9099-a6e780a3408f"
      unitRef="usd">500000000</pfe:PrepaymentsAndPaymentsToCollaboratorsCash>
    <pfe:PaymentsToCollaboratorsUpfrontPayment
      contextRef="id7af860819f54f01861664b5ad041b8f_D20220104-20220104"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODQzNA_5986c44d-be22-4734-9c8f-eaab84a6a403"
      unitRef="usd">150000000</pfe:PaymentsToCollaboratorsUpfrontPayment>
    <pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
      contextRef="i58af9a3440794bd6aecec41e17eef71e_I20220104"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODQ2NQ_0c10f001-45b8-4280-815f-d5c05ad1c364"
      unitRef="usd">350000000</pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount>
    <pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment
      contextRef="ifc7381e87f7646fd8e2cbda19e2e2d0f_D20220104-20220104"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfODQ4Mw_30fd8ff8-1aed-4e49-8beb-a5267650a272"
      unitRef="usd">263000000</pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i158261a31a1c413799e169c8d84fe9ba_I20221031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MTg0Mw_ffc7eeea-021d-46ab-8da5-e3014760bf73"
      unitRef="usdPerShare">148.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i722d6d36e0a3476b89b0cdc056d0f26a_D20221001-20221031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80MC9mcmFnOmQ4ZDEwMDA3ODU4ZTQ2N2NiOWViYzc3ZmU3NDNlNTVhL3RleHRyZWdpb246ZDhkMTAwMDc4NThlNDY3Y2I5ZWJjNzdmZTc0M2U1NWFfMTY0OTI2NzQ3MTg2NA_cb907b7b-db59-45b6-9646-3291d433efc3"
      unitRef="usd">11500000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxNA_ed440617-d7a4-47b5-9785-f72b55fdbeb0">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Transforming to a More Focused Company Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We continue our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;efforts to ensure our cost base and support model align appropriately with our operating structure. While certain direct costs transferred to the Consumer Healthcare JV, and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;amp;D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, of $1.8&#160;billion, to be incurred primarily from 2020 through 2022, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We have also made several organizational changes in the third quarter of 2022 to further transform our operations to better leverage our expertise in certain areas and in anticipation of potential future new product launches (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). We expect costs of $1.4&#160;billion to be incurred primarily from 2020 through 2022, with all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $800&#160;million to be incurred primarily from 2020 through 2023, with approximately 25% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The program costs discussed above may be rounded and represent approximations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the start of this program in the fourth quarter of 2019 through October&#160;2, 2022, we incurred costs of $2.8&#160;billion, of which $1.1 billion ($862&#160;million of restructuring charges) is associated with Biopharma. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Key Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee terminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exit costs/(credits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Integration costs and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62&#160;million and $108&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $616&#160;million and $617&#160;million for the three and nine months ended October&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October&#160;2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138&#160;million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in restructuring accruals:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Termination&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset&lt;br/&gt;Impairment&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(447)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, October&#160;2, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($816 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($255 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($758 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($110 million).&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i21b538a5cc974cf8b8cff85d8c511b6c_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfOTAw_83c52ee2-2a7a-4707-b089-29126f8be9ef"
      unitRef="usd">1800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i28697c549ce3454c8ce5980750988a6d_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMTQzNw_5c50471b-3cf1-4a2b-a1c3-2f6481cc9a70"
      unitRef="usd">1400000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ie27e5b4edce54e8e8a8ad6d6a9acc7e8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMTg3OQ_8625744f-f490-4a10-ab99-12b75c706391"
      unitRef="usd">800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <pfe:RestructuringandRelatedCostNoncashChargesPercentage
      contextRef="i7fa3843da72a42f2b5f23f8d547a2b0c_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMTkwMg_a1bb07d3-381e-4969-80dd-4eae474d95d6"
      unitRef="number">0.25</pfe:RestructuringandRelatedCostNoncashChargesPercentage>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="iadd388f3beca428899e121e6042d61eb_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjM0NQ_6ba58113-1eed-4831-96b8-d2f2e7b80989"
      unitRef="usd">2800000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i76c083a6cc0c4200a8e2f51e5486ed99_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjM1OA_19d56aa0-16b9-4442-862c-ad610cce4f1f"
      unitRef="usd">1100000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <pfe:RestructuringChargesChargesIncurredToDate
      contextRef="i76c083a6cc0c4200a8e2f51e5486ed99_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjM2Mg_43b051cd-1fe6-4c45-9189-ec179495d698"
      unitRef="usd">862000000</pfe:RestructuringChargesChargesIncurredToDate>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc3Mw_157090ea-278b-4d2e-8ce4-215083c7d31d">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee terminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exit costs/(credits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Integration costs and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62&#160;million and $108&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $616&#160;million and $617&#160;million for the three and nine months ended October&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October&#160;2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138&#160;million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC0yLTEtMS00Mjk2NzE_82afe042-bf4c-4fc0-ba7b-e5427e3e1f1a"
      unitRef="usd">158000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC00LTEtMS00Mjk2NzE_eefe1f99-4870-40f5-ab26-2fe0f8a48d76"
      unitRef="usd">630000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC02LTEtMS00Mjk2NzE_31395e3d-1081-4fd4-a809-27db76afb091"
      unitRef="usd">293000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNC04LTEtMS00Mjk2NzE_d3078836-457e-4711-a5e0-1ddee162aaab"
      unitRef="usd">649000000</us-gaap:SeveranceCosts1>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS0yLTEtMS00Mjk2NzE_3b5491b0-7714-4a98-9a38-1d790073f882"
      unitRef="usd">17000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS00LTEtMS00Mjk2NzE_e216659c-047d-44aa-8d2c-274fe4d37d41"
      unitRef="usd">10000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS02LTEtMS00Mjk2NzE_2fac98cf-85d3-494b-bc99-13f63e8814a2"
      unitRef="usd">44000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNS04LTEtMS00Mjk2NzE_ca3df2d0-8b6f-471f-8436-78bbbd836778"
      unitRef="usd">7000000</pfe:RestructuringAssetImpairmentCharges>
    <us-gaap:BusinessExitCosts1
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi0yLTEtMS00Mjk2NzE_5125732d-cc0d-4925-88fd-cc9397bf9099"
      unitRef="usd">2000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi00LTEtMS00Mjk2NzE_d8aa5cf4-c5c6-49fa-a0dd-c830b434bb0e"
      unitRef="usd">3000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi02LTEtMS00Mjk2NzE_a28d56b7-0790-490e-8189-911c5fa1a885"
      unitRef="usd">31000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNi04LTEtMS00Mjk2NzE_60ed7ac6-d4b1-47f6-a97c-ed1deef5d5fe"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:RestructuringCharges
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy0yLTEtMS00Mjk2NzE_0ba4fb7e-a5d2-45f8-ba67-e60282dfe1d5"
      unitRef="usd">177000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy00LTEtMS00Mjk2NzE_342264cc-7d35-46b0-a05b-7b425eca7b6f"
      unitRef="usd">643000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy02LTEtMS00Mjk2NzE_de4ae461-5f30-4b05-adde-e986999b00d6"
      unitRef="usd">368000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy04LTEtMS00Mjk2NzE_238101c9-15cc-4c5a-9e7b-f64e349a2256"
      unitRef="usd">656000000</us-gaap:RestructuringCharges>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC0yLTEtMS00Mjk2NzE_488adaed-49b4-417c-9242-a756da55a909"
      unitRef="usd">0</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC00LTEtMS00Mjk2NzE_9fb5c4b0-0fed-4b82-a748-fa1f573f1bdd"
      unitRef="usd">0</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC02LTEtMS00Mjk2NzE_41178dd3-7bc7-461d-b007-624d30582aa9"
      unitRef="usd">42000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC04LTEtMS00Mjk2NzE_ee5555c1-19b6-4724-8563-ebcc82def2cf"
      unitRef="usd">0</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS0yLTEtMS00Mjk2NzE_35815b41-cffb-4b5c-9359-d379a907975e"
      unitRef="usd">22000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS00LTEtMS00Mjk2NzE_6c6b2ad1-9924-43b6-ab58-ece897ccfd1f"
      unitRef="usd">3000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS02LTEtMS00Mjk2NzE_3bb528dd-20b9-49b4-a972-f922d43fbdbe"
      unitRef="usd">170000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS04LTEtMS00Mjk2NzE_75e41cf7-4116-4583-ad8e-d640a5fc5cc1"
      unitRef="usd">11000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtMi0xLTEtNDI5Njcx_34bcc20a-e5be-429c-b94f-6f138e7cbe27"
      unitRef="usd">199000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtNC0xLTEtNDI5Njcx_141dd8be-cd50-436f-837b-ef41ccff4cea"
      unitRef="usd">646000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtNi0xLTEtNDI5Njcx_145386f7-f7d9-4efb-9fea-731199de4d5f"
      unitRef="usd">580000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTAtOC0xLTEtNDI5Njcx_54f66fdc-5dc7-4948-9ac6-470ea2a10152"
      unitRef="usd">667000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4619b114ec194ad0b6cdf916bfe7a1e4_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtMi0xLTEtNDI5Njcx_406beaf7-da06-4c63-82b3-f2ffa4a7f914"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i743f0eb0d1d04686a3138f343d0a91a4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtNC0xLTEtNDI5Njcx_4315ad1d-059c-4ef2-9001-76e1a6fa253b"
      unitRef="usd">-63000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id35ac29855a1475ca5478fc62e1fd74f_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtNi0xLTEtNDI5Njcx_6dda7f23-631b-4d47-94ff-4b4202490b4f"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0fd5613cc06a4d73a6e8eaa13a7d3b73_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTEtOC0xLTEtNDI5Njcx_ce3bfd24-48c9-46d2-b893-3e2ef1ccb704"
      unitRef="usd">-51000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i86ef4b0d7cca452089dd78603de3cf6c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtMi0xLTEtNDI5Njcx_60d08d81-6843-466f-90a4-c0b3b770f412"
      unitRef="usd">7000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i81e35f95c0c3442aaabb2dfc697eddc0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNC0xLTEtNDI5Njcx_82f5e9db-b6b1-4de1-aa74-6c64330ab4e1"
      unitRef="usd">19000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i5f0a9e3dc01d4e41b2c5e11386542b1f_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNi0xLTEtNDI5Njcx_b6b5bcac-63bf-4b98-85bf-a5df968d5b98"
      unitRef="usd">22000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="idf45616770c74e4290c92f85fa0706ef_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtOC0xLTEtNDI5Njcx_553fd7bb-a59b-4591-a381-13146ee4220f"
      unitRef="usd">53000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="id365d50df2a645fa85ed477f05ab1838_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtMi0xLTEtNDI5Njcx_9c51b6f7-67c7-432c-9e63-82529e0ef233"
      unitRef="usd">1000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNC0xLTEtNDI5Njcx_7dfd910b-3aeb-4666-97de-f5798800d3f7"
      unitRef="usd">8000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNi0xLTEtNDI5Njcx_b59868eb-033a-4a90-b591-19c42eeddd39"
      unitRef="usd">1000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtOC0xLTEtNDI5Njcx_318869ec-9960-4b91-bdb4-182356a4bc99"
      unitRef="usd">23000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtMi0xLTEtNDI5Njcx_90ce7781-3290-4ad3-93af-3e5a8675bded"
      unitRef="usd">7000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNC0xLTEtNDI5Njcx_8a45feee-639e-4454-b3fc-f9624de079ab"
      unitRef="usd">27000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNi0xLTEtNDI5Njcx_7ac490a0-73b9-452d-bf96-cfa38f3b8865"
      unitRef="usd">22000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtOC0xLTEtNDI5Njcx_e0cfea43-1a3e-48c2-acee-7ea66cde29d7"
      unitRef="usd">76000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <pfe:ImplementationCosts
      contextRef="i86ef4b0d7cca452089dd78603de3cf6c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtMi0xLTEtNDI5Njcx_b8d35731-3c3a-44a7-85f7-4d37b26a1ee7"
      unitRef="usd">14000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i81e35f95c0c3442aaabb2dfc697eddc0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNC0xLTEtNDI5Njcx_03da9fde-fd5e-4bb9-b48b-aefe07d232a3"
      unitRef="usd">8000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i5f0a9e3dc01d4e41b2c5e11386542b1f_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNi0xLTEtNDI5Njcx_ad4f3559-591c-4f22-b2f9-04973e92ea32"
      unitRef="usd">40000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="idf45616770c74e4290c92f85fa0706ef_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtOC0xLTEtNDI5Njcx_7ba0e3ea-e682-4737-996e-6547c9d8d1f8"
      unitRef="usd">29000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="id365d50df2a645fa85ed477f05ab1838_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktMi0xLTEtNDI5Njcx_a31d12ad-733d-454f-aacf-b9a02ebc2ddf"
      unitRef="usd">136000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNC0xLTEtNDI5Njcx_afc4de30-418f-4e3e-b0ca-ef2323eda3f9"
      unitRef="usd">142000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNi0xLTEtNDI5Njcx_42cb499f-f636-4adc-b8ac-a98d69c36b83"
      unitRef="usd">344000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktOC0xLTEtNDI5Njcx_0ac023e0-501c-45e6-8b76-9e5c1d60aa3c"
      unitRef="usd">287000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i8b8da4f7456e442295e4b41cd995dae1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtMi0xLTEtNDI5Njcx_970aaef8-b5d6-42fb-a76a-f958b99c1684"
      unitRef="usd">0</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i72db9e61e2aa40229247e0d3b02b0e82_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNC0xLTEtNDI5Njcx_8ece4338-3312-4216-a456-9e7e99d62f1b"
      unitRef="usd">0</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i32df0ec003834b6eab05cf61f39fa6e3_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNi0xLTEtNDI5Njcx_e1f2d427-f765-49fa-839a-f5c432154997"
      unitRef="usd">0</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="ib4744ad08ba8409a820a07a834ff061c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtOC0xLTEtNDI5Njcx_3fbd4518-51fe-483f-89a1-5cf9bf4a4751"
      unitRef="usd">1000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItMi0xLTEtNDI5Njcx_a86e56c8-94cb-4066-986c-23c2b8d97686"
      unitRef="usd">150000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNC0xLTEtNDI5Njcx_a4541278-e2cb-4393-a38b-ae8cad9d8c18"
      unitRef="usd">151000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNi0xLTEtNDI5Njcx_7fca1ffd-896d-495a-a9d5-7b0cede00795"
      unitRef="usd">384000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItOC0xLTEtNDI5Njcx_6cc8c14f-d7d8-4564-87d8-7758542b84a4"
      unitRef="usd">316000000</pfe:ImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtMi0xLTEtNDI5Njcx_8521e85a-288e-445a-9208-dbec4fadc927"
      unitRef="usd">357000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtNC0xLTEtNDI5Njcx_966cbe8e-024b-41aa-9d88-2fd6c0b5e64e"
      unitRef="usd">760000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtNi0xLTEtNDI5Njcx_b81876ef-79da-4d01-a982-8ca175f37323"
      unitRef="usd">982000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjMtOC0xLTEtNDI5Njcx_4fcd624e-5bb8-4fd3-8679-6719a9d06554"
      unitRef="usd">1008000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <us-gaap:RestructuringCharges
      contextRef="i1fd31dba911048de993662a30bd60e24_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjU2Mg_b66a3f13-496c-4eaa-a4fd-30661f4c58dd"
      unitRef="usd">62000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i5974e3684a5d4959a373f6a880ead072_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjU2OQ_0d9ffe8e-9926-414c-9423-3c0533a6e533"
      unitRef="usd">108000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2ba30fd6c8d04ca8bac5eceecaea0094_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjY0MA_3e05b6e5-49dc-43f0-be54-bd71f43b5b84"
      unitRef="usd">616000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic0aea8b98cb34108abfe4081d7793e2c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMjY1OA_827e2066-3bae-454d-b112-4827752353b2"
      unitRef="usd">617000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i300033c0ba2c4182978046a909b7606b_D20220101-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzEzNA_228e7a2a-4f57-4f4d-abd1-cc28375ee5b9"
      unitRef="usd">138000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOA_2c2f86a4-55a8-45ac-88f7-60f96b22ee63">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in restructuring accruals:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Termination&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset&lt;br/&gt;Impairment&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(447)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, October&#160;2, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($816 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($255 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($758 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($110 million).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i5f516286c63343f28a4664b266e75256_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi0yLTEtMS00Mjk2NzE_df7dc9d1-9615-488a-bbd0-c4f83be85ba2"
      unitRef="usd">1014000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i4e9ab2b2fea44955974b44346416d463_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi00LTEtMS00Mjk2NzE_5b63501f-3025-4448-9dae-f21d2b141cde"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i1d7dbe8638f7401a94c5382e4b054e25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi02LTEtMS00Mjk2NzE_59824e27-a17c-4205-aae0-a5a482b9df27"
      unitRef="usd">57000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi04LTEtMS00Mjk2NzE_14fa5f10-49f6-42ad-ba5c-7d5ca8c04911"
      unitRef="usd">1071000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i7081406b1b62439ab5fd196c928df604_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy0yLTEtMS00Mjk2NzE_d640a873-639e-4b9f-92d3-559bb29140c9"
      unitRef="usd">293000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0e8b45d1675445aa8d696f11839ca704_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy00LTEtMS00Mjk2NzE_37cd62e2-ed76-4106-a6c8-60182dcd4f20"
      unitRef="usd">44000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i672675a4e5374596930c5eb56c56fb6e_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy02LTEtMS00Mjk2NzE_1ff33ef0-4d62-44a7-b15a-259b0d25adc9"
      unitRef="usd">31000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMy04LTEtMS00Mjk2NzE_beacace5-91a9-46ac-8250-9646abefa306"
      unitRef="usd">368000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i7081406b1b62439ab5fd196c928df604_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC0yLTEtMS00Mjk2NzE_312e8447-359d-4343-b5cc-758a50fea8f6"
      unitRef="usd">447000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i0e8b45d1675445aa8d696f11839ca704_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC00LTEtMS00Mjk2NzE_45240349-7a57-4b66-8563-1735eb215c7e"
      unitRef="usd">44000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i672675a4e5374596930c5eb56c56fb6e_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC02LTEtMS00Mjk2NzE_bd465f0a-3160-4eee-9aaa-b9f143521049"
      unitRef="usd">80000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC04LTEtMS00Mjk2NzE_89cdec7c-14cd-4eb1-b43e-bd10aaa766ee"
      unitRef="usd">572000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="if2b1a60419934acf858ae1b59d2c713d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS0yLTEtMS00Mjk2NzE_0f02e791-2a53-4174-8273-fb3671668c74"
      unitRef="usd">859000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie8f37bc9a3284a51bb64a83d09a3d26a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS00LTEtMS00Mjk2NzE_29b75c68-773e-4ad8-bbb3-abd94eb1b2cb"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i07ffcb4ce1bd422f80c0659256ce5949_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS02LTEtMS00Mjk2NzE_8544ae2b-5f21-437e-b021-ac522c5a2d24"
      unitRef="usd">8000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS04LTEtMS00Mjk2NzE_94b6c3d5-e3c3-45f7-bb93-09c0ebe86c83"
      unitRef="usd">867000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7508bb16fd44454482e06b74af164e0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzU3MQ_7b4afb87-3fe2-4a7f-b8fd-8b08a0e41495"
      unitRef="usd">816000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i20b757dbbd6f4f2bad32cff5eca993e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzYwOQ_ffad3ed9-fc1a-4efe-9805-ae44d8f7fc5a"
      unitRef="usd">255000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="icbac0fcdcbcc4e12bdfda3c7e53e7fb4_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzcwOA_960ea11b-b120-4f04-837c-315b300969d2"
      unitRef="usd">758000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id0861c1e153d4341b6f1aa2768a8b9e3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc0Ng_eb3ff197-80ae-491a-896c-1157d86a0575"
      unitRef="usd">110000000</us-gaap:RestructuringReserve>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQ1_10e566f8-73ff-468d-a91f-5139b4d9189b">Other (Income)/Deductions&#x2014;Net&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty-related income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(628)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(649)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain legal matters, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Haleon/Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The first nine months of 2021 included, among other things, $188&#160;million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The amount in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&amp;amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;See &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional information about the intangible asset that was impaired during 2022 (impairment recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;) follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset&#x2013;&#x2013;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1F &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in our 2021 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Reflects an intangible asset written down to fair value in 2022. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/span&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI5_ff0e5ec0-feaf-46b7-9f1d-f61ff412ae7b">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty-related income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(628)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(649)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain legal matters, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Haleon/Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The first nine months of 2021 included, among other things, $188&#160;million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The amount in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&amp;amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;See &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy0yLTEtMS00Mjk2NzE_b91964d7-f378-4c70-8e2e-61bf9e5b9c8f"
      unitRef="usd">70000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy00LTEtMS00Mjk2NzE_827d9b78-ce19-443a-bbed-33922938d375"
      unitRef="usd">10000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy02LTEtMS00Mjk2NzE_a2273a8d-4514-4dbd-a7d2-157b5e1065a6"
      unitRef="usd">114000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMy04LTEtMS00Mjk2NzE_a7da31e4-2554-4dd4-85f7-b1519881cbad"
      unitRef="usd">21000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC0yLTEtMS00Mjk2NzE_7d35f7de-cb2e-4e67-892e-731a52975629"
      unitRef="usd">311000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC00LTEtMS00Mjk2NzE_60fe0c04-3505-49b3-bcbe-207897bf5fa0"
      unitRef="usd">325000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC02LTEtMS00Mjk2NzE_71034e20-790f-4ada-99ab-518bb1368416"
      unitRef="usd">925000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNC04LTEtMS00Mjk2NzE_266bd1d6-7d94-45a2-b2e9-fbe07c00f65e"
      unitRef="usd">975000000</us-gaap:InterestExpense>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS0yLTEtMS00Mjk2NzE_39aaa6e6-c55c-4d13-8a12-16be6e47e59f"
      unitRef="usd">-240000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS00LTEtMS00Mjk2NzE_4041944e-1891-4359-8d77-f7b09f31f2fe"
      unitRef="usd">-315000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS02LTEtMS00Mjk2NzE_241d38d7-0ff1-449d-a9d8-f08e6d03fd81"
      unitRef="usd">-811000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNS04LTEtMS00Mjk2NzE_b7ce08e1-85f7-4377-b6ad-adffa214e96d"
      unitRef="usd">-954000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi0yLTEtMS00Mjk2NzE_fe983548-6421-4ab6-abef-25bbfa671ac7"
      unitRef="usd">239000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi00LTEtMS00Mjk2NzE_655a64d3-5878-4035-8a39-609f2a228280"
      unitRef="usd">261000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi02LTEtMS00Mjk2NzE_289d4a27-d468-44df-875b-6594180de671"
      unitRef="usd">628000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNi04LTEtMS00Mjk2NzE_5f2684ad-f36f-4da0-a913-b175b3a48a39"
      unitRef="usd">649000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy0yLTEtMS00Mjk2NzE_57b1ec53-cd2b-4922-8a9b-a02a894671c6"
      unitRef="usd">-7000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy00LTEtMS00Mjk2NzE_f39b7803-322e-4eb9-8639-03cb6816b6e4"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy02LTEtMS00Mjk2NzE_6f3c578d-70ae-4f61-8dbd-823fb2cf1ff4"
      unitRef="usd">-6000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfNy04LTEtMS00Mjk2NzE_7e36110f-439a-48db-9582-4979767cdc04"
      unitRef="usd">99000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC0yLTEtMS00Mjk2NzE_2baaca16-26a8-47d2-a221-754f24fd20cb"
      unitRef="usd">-112000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC00LTEtMS00Mjk2NzE_f2ce4cd5-9bc0-46df-98a2-0a1357007693"
      unitRef="usd">400000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC02LTEtMS00Mjk2NzE_ff34748e-e1cd-45ce-93ab-98ed5e2b47a4"
      unitRef="usd">-1353000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC04LTEtMS00Mjk2NzE_8c1270d2-bc3a-444c-810e-7d0db83546a0"
      unitRef="usd">1601000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS0yLTEtMS00Mjk2NzE_0e091c4d-563d-4a8d-8711-bd269d2da7a9"
      unitRef="usd">4000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS00LTEtMS00Mjk2NzE_78979520-f128-45f4-991e-aab26f802b5d"
      unitRef="usd">65000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS02LTEtMS00Mjk2NzE_64fe25dd-a57e-463f-adf8-62bd1b937c40"
      unitRef="usd">17000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS04LTEtMS00Mjk2NzE_ff367060-a416-42eb-ac91-4c9ed4241d0c"
      unitRef="usd">317000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtMi0xLTEtNDI5Njcx_843f98da-2316-412b-b884-5efb9c0e0d59"
      unitRef="usd">-306000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtNC0xLTEtNDI5Njcx_f45d2fac-9141-40af-83be-82dab4c8f169"
      unitRef="usd">-1132000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtNi0xLTEtNDI5Njcx_975d495b-f1ec-4d5c-8b03-54db93c6ac00"
      unitRef="usd">-294000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTAtOC0xLTEtNDI5Njcx_177b72f1-5468-4824-b45e-9f514b8edc26"
      unitRef="usd">-1635000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtMi0xLTEtNDI5Njcx_2011f701-2d72-4e23-865d-e2ce5d6b0dbd"
      unitRef="usd">-77000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtNC0xLTEtNDI5Njcx_dbc779dc-0284-4d2d-80c6-2f5d2a8bf168"
      unitRef="usd">-38000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtNi0xLTEtNDI5Njcx_26548de6-29f3-439e-bcb8-f61b305fe115"
      unitRef="usd">-175000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTEtOC0xLTEtNDI5Njcx_ffc01b36-fe76-4d1a-a916-adb38d167cc0"
      unitRef="usd">-112000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:AssetImpairmentCharges
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItMi0xLTEtNDI5Njcx_57e6f583-7137-404d-adb6-5515aacc01aa"
      unitRef="usd">200000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNC0xLTEtNDI5Njcx_97d270b7-b1ce-45e6-b737-833c464ba639"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNi0xLTEtNDI5Njcx_626fee7e-657f-4788-a035-b8cd2f31808f"
      unitRef="usd">200000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItOC0xLTEtNDI5Njcx_00d1ae0d-5416-453b-a4cc-e1d982d37e99"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtMi0xLTEtNDI5Njcx_ca5fa3ae-21d5-4c48-93b1-a60c41f42be6"
      unitRef="usd">-51000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNC0xLTEtNDI5Njcx_7c89b3c6-eae2-4569-9415-e7d0b862ac03"
      unitRef="usd">105000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNi0xLTEtNDI5Njcx_bff3b0ab-ad48-49ee-979e-f9df13844b8c"
      unitRef="usd">283000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtOC0xLTEtNDI5Njcx_a5ab5888-7716-4238-ad86-b88c6ea5907f"
      unitRef="usd">307000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtMi0xLTEtNDI5Njcx_edc894d3-afbc-40da-b838-7717b52664c1"
      unitRef="usd">198000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtNC0xLTEtNDI5Njcx_ddf8be5d-96ea-4f03-9c9f-03cf0d96a2fb"
      unitRef="usd">84000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtNi0xLTEtNDI5Njcx_b89d5766-8a3c-469f-bcbe-b407a9e694ee"
      unitRef="usd">260000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTQtOC0xLTEtNDI5Njcx_c658d3e9-d2db-4a89-981c-eb45407911a1"
      unitRef="usd">502000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtMi0xLTEtNDI5Njcx_f1b974a0-f721-495a-8c2b-980eb4a3ce37"
      unitRef="usd">59000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtNC0xLTEtNDI5Njcx_d9cd9e2d-ef0d-49db-a455-b92cb5f2cd3e"
      unitRef="usd">1696000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtNi0xLTEtNDI5Njcx_50f1acec-2b6c-4013-976d-04cd151bc671"
      unitRef="usd">-1063000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTUtOC0xLTEtNDI5Njcx_c73d25a5-a77c-4dd2-88a4-ed2e393f3f2f"
      unitRef="usd">4043000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5120c338e7784bc0a405cf860830dc96_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfMTA5_a3f01062-a6ae-4db8-8698-9d26eb469a39"
      unitRef="usd">-974000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i60c3b88c09f446329b1ec1583f33a3b3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfMjk1_4d7cda5e-2421-4d26-ba9a-fa85de00f235"
      unitRef="usd">420000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9c5aec14bf13443d865368553c8fb09f_D20210101-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfMzAy_c6d69c31-6d23-400e-921e-a3c6520fe9cf"
      unitRef="usd">1500000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i4e03b80a6e31462388cb8fa87c81fae5_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNDEx_7db6f0b8-f108-40bf-9c0a-7b6ba5a1b7dc"
      unitRef="usd">188000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OA_8e2a4916-492d-4ddb-a678-c714ce6f7e6c">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional information about the intangible asset that was impaired during 2022 (impairment recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;) follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset&#x2013;&#x2013;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1F &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in our 2021 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Reflects an intangible asset written down to fair value in 2022. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/span&gt;</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="ia3e604c4a1134172a1157b3846f7e9db_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i6bcdf5d6697b4dfda841c81ef6f0b444_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i4fcb9d12f7e8461f800a28613f391b63_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ic2a3f390d88441aa84493f5b915fa1fa_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0xMC0xLTEtNDU1NDg4_e2b9857d-9a48-440e-b892-39f78f609815"
      unitRef="usd">200000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5MQ_97c52c60-4dfe-4165-b8a5-72b5bdccd97d">Tax Matters&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Taxes on Income from Continuing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective tax rate for continuing operations was 4.0% for the third quarter of 2022, compared to (4.2)% for the third quarter of 2021, and was 10.5% for the first nine months of 2022, compared to 7.8% for the first nine months of 2021. The higher effective tax rates for the third quarter and first nine months of 2022, compared to the third quarter and first nine months of 2021, were mainly due to the non-recurrence of certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK, partially offset by tax benefits in the third quarter of 2022 related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years that included the closing of U.S. IRS audits covering five tax years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fourth annual installment of this liability was paid by its April 18, 2022 due date. The fifth annual installment is due April 18, 2023 and is reported in current &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of October&#160;2, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining liability is reported in noncurrent &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. During the third quarter of 2022, Pfizer reached resolution of disputed issues at the IRS Independent Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2011-2015. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2022 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2011.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to curtailments of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMTE1_82be704d-2dc8-4ab3-9154-c4498d45fe39"
      unitRef="number">0.040</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMTU2_43826c41-a945-4d0b-bb83-18dae5218eec"
      unitRef="number">-0.042</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMTkz_1f43cf33-9e9e-4504-8cee-bbf250f56b0b"
      unitRef="number">0.105</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjE5_411f443b-00df-4e63-8194-b3cbafd58844"
      unitRef="number">0.078</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfNTk4_e1bbba40-e708-423f-ad2c-7553cedfbd21"
      unitRef="usd">15000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ2NQ_8c228b24-c514-442b-a38a-03fb71ca420d">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to curtailments of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy0yLTEtMS00Mjk2NzE_87621f1f-793f-4e86-9eb5-afa1e0e859ec"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy00LTEtMS00Mjk2NzE_824ff5fb-0912-42a1-801a-3a2c58508bc5"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy02LTEtMS00Mjk2NzE_a1c2893c-c20e-46fd-b88f-599e3e194b3b"
      unitRef="usd">-165000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy04LTEtMS00Mjk2NzE_86b449de-4569-4595-9b66-d97adb3d390c"
      unitRef="usd">-30000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC0yLTEtMS00Mjk2NzE_6bf73934-c0fb-4d7e-a3bc-64295487eb55"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC00LTEtMS00Mjk2NzE_fbfc8d99-4059-455d-ad4c-afe52615880b"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC02LTEtMS00Mjk2NzE_1158b742-bbb5-4ee9-aaea-043e582ba26c"
      unitRef="usd">177000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNC04LTEtMS00Mjk2NzE_30400b46-b9e0-4174-a5c3-5fd0f9524afd"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS0yLTEtMS00Mjk2NzE_00d45593-4914-4e04-b0b4-29052503d241"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS00LTEtMS00Mjk2NzE_ff3c495f-cae0-49d4-a292-45a6367f6857"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS02LTEtMS00Mjk2NzE_153a9a7f-926f-4e6e-8066-2d78061b0904"
      unitRef="usd">97000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNS04LTEtMS00Mjk2NzE_eb55c515-6c0c-48a5-a8c5-a269845ffd86"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi0yLTEtMS00Mjk2NzE_7c26345b-4541-40ac-a17c-e059f2984015"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi00LTEtMS00Mjk2NzE_041b8975-0b23-4f46-af18-be532fe41080"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi02LTEtMS00Mjk2NzE_47f47b19-72f3-4643-9c9c-cbc64b1112f9"
      unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNi04LTEtMS00Mjk2NzE_e27aaf81-b85b-4ea5-aeb8-14d28198b380"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy0yLTEtMS00Mjk2NzE_ae756119-033c-4e5e-90f1-3567fd67ce51"
      unitRef="usd">-97000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy00LTEtMS00Mjk2NzE_195e9bcb-014a-4f81-8cc8-edaeac4f9542"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy02LTEtMS00Mjk2NzE_87f52213-2aad-46a8-9299-cb4b4a04d93a"
      unitRef="usd">-175000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfNy04LTEtMS00Mjk2NzE_40d7cd60-3e8c-4edb-af50-fadf35f03653"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC0yLTEtMS00Mjk2NzE_e830575d-f220-4715-a5a9-61cb74407575"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC00LTEtMS00Mjk2NzE_bdd88251-cfe6-41c1-b734-1e7ed76aa09e"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC02LTEtMS00Mjk2NzE_5d98e1b0-5e6e-4b2b-982c-825efbdeb005"
      unitRef="usd">-137000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOC04LTEtMS00Mjk2NzE_14ee1f57-e6b6-49c4-86b4-d0ae7ac5ea81"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS0yLTEtMS00Mjk2NzE_6f421d76-9cc4-4715-b009-0e0008d32ed1"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS00LTEtMS00Mjk2NzE_6a0c3e8d-d86b-43e1-9a82-4d9280fdb294"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS02LTEtMS00Mjk2NzE_309e2a5e-9888-4ee9-a797-ace256fdcd83"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfOS04LTEtMS00Mjk2NzE_44076e31-e4cf-4992-8a9d-34c77529bbb1"
      unitRef="usd">-37000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtMi0xLTEtNDI5Njcx_d0b23d8e-872b-4d09-82e3-c89ea65fa625"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtNC0xLTEtNDI5Njcx_6ab8e115-0210-41e9-94f2-aa0c64d8341c"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtNi0xLTEtNDI5Njcx_14186a6b-7464-42a8-96dd-ca5349b10f4a"
      unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTYtOC0xLTEtNDI5Njcx_e3d10764-0be0-4f37-90b8-262defd1a774"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctMi0xLTEtNDI5Njcx_08deea1f-b796-46b4-b16e-311367fc5f91"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctNC0xLTEtNDI5Njcx_6760df7d-adda-4417-9a12-0a77401e14d3"
      unitRef="usd">-14000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctNi0xLTEtNDI5Njcx_9eec21e8-e8fb-4685-89a5-789d50e7150e"
      unitRef="usd">-3000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTctOC0xLTEtNDI5Njcx_801789ae-105b-42b8-874d-7b50259472f0"
      unitRef="usd">-15000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktMi0xLTEtNDI5Njcx_bc2f0990-0958-44c6-b3ab-bd3309254174"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktNC0xLTEtNDI5Njcx_6f91e897-ce77-422d-97a9-0ee978bcfba9"
      unitRef="usd">36000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktNi0xLTEtNDI5Njcx_aed5677f-d41c-4517-8c38-a42dae9055a1"
      unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMTktOC0xLTEtNDI5Njcx_d7a41926-4604-4994-b5e8-4bea685ca2d7"
      unitRef="usd">54000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtMi0xLTEtNDI5Njcx_ec19f2c9-f02d-4cfa-8317-463248c6974b"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtNC0xLTEtNDI5Njcx_a7327d94-797e-4315-9ede-0b4aebc7be04"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtNi0xLTEtNDI5Njcx_be853de4-6ae5-47e4-8c3a-1dda5be8e607"
      unitRef="usd">-149000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMjAtOC0xLTEtNDI5Njcx_ababaf4f-81ce-414b-9f3f-94735a67545c"
      unitRef="usd">-44000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzM4_6811584b-333e-4d41-85f6-71ed3ff6edfe">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes, net of tax, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 2C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and the impact of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzQx_dc031836-122e-4158-b632-9d254a039033">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes, net of tax, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 2C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and the impact of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia28d11de768f4acfa1899aa6f92f42fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy0yLTEtMS00Mjk2NzE_197d52ab-5c53-46aa-809a-121dfa72ad0a"
      unitRef="usd">-6172000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbe7a5df8a364aef9def98d475a8dd2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy00LTEtMS00Mjk2NzE_7fcb174b-bc68-4c67-989c-62dfe4c31ef7"
      unitRef="usd">119000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedabc8fc306843ffb9c2a5c9a5abf093_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy02LTEtMS00Mjk2NzE_efd27229-02ff-46ad-847f-8d1153fc0b11"
      unitRef="usd">-220000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c0c0bfa0bc7435f8a1cb14d125612d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy0xMC0xLTEtNDI5Njcx_2483dcb3-f049-4e9d-b2b1-31d652132fd9"
      unitRef="usd">377000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ef44849268d4847a9fb27d3a90011e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfMy0xMi0xLTEtNDI5Njcx_e8132244-46b9-4fe5-bc07-59a0e60bbb26"
      unitRef="usd">-5897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id1218785b15a4b428afe5839d3c22095_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0yLTEtMS00Mjk2NzE_4ca766d1-f980-4cf2-8135-ebd81ac499b7"
      unitRef="usd">-2373000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie8a588750f30485cba7eb82683ef423b_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC00LTEtMS00Mjk2NzE_de3ad6c3-47cb-4953-bb35-35061c8d9092"
      unitRef="usd">391000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id36f1bf78a2e4329b60d5e5ca4f34e82_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC02LTEtMS00Mjk2NzE_4bd91447-2eeb-4b1d-84e8-75f3886b7b62"
      unitRef="usd">-265000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cc5b6fe28ec4fc892354bdc356b0801_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMC0xLTEtNDI5Njcx_493e4ba9-7b8f-408d-ac44-f4a29de69d63"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idb8a629a946b4ceca7ca7dd72b1af40b_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMi0xLTEtNDI5Njcx_3ccb185c-d21e-497d-9541-82146f5868b4"
      unitRef="usd">-2328000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4713ca3234b4b16be713694331b20e8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS0yLTEtMS00Mjk2NzE_15d0adff-39ec-4f70-8310-a0c1959fe2b8"
      unitRef="usd">-8545000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84465afd71b54fbca86dd39dd5eb14e4_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS00LTEtMS00Mjk2NzE_725de47b-e946-43b6-9c9c-b24c8e1fc67c"
      unitRef="usd">509000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3ac6485d813484ab3e2a5f79e9312df_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS02LTEtMS00Mjk2NzE_98d629f6-d26d-4b54-bce1-d789e8026bfd"
      unitRef="usd">-485000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a51b3abaa324634a216f2ccf13bdd62_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS0xMC0xLTEtNDI5Njcx_f25f93c6-47bf-433a-bb18-48b94cf2dfaa"
      unitRef="usd">296000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i316fd24dd0da46e5872d02ce9db0a499_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNS0xMi0xLTEtNDI5Njcx_ef6b9d29-397e-43f1-b9fb-ce2639caf251"
      unitRef="usd">-8225000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQxOA_d5ac8b0a-dc39-4dc7-8605-ae77aa8ad77b">Financial Instruments&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Long-term equity securities of $139 million as of October&#160;2, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of Long-term debt, excluding the current portion was $33&#160;billion as of October&#160;2, 2022 and $36&#160;billion as of December 31, 2021. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $29&#160;billion as of October&#160;2, 2022 and $42&#160;billion as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of October&#160;2, 2022 and December 31, 2021. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Total Short-Term, Long-Term and Equity-Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes our investments by classification type:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities at cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Includes money market funds primarily invested in U.S. Treasury and government debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represent investments in the life sciences sector.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(580)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any expected credit losses to these portfolios would be immaterial to our financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Primarily includes cash collateral. See&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 7F&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Derivative Financial Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Exchange Risk&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, and Canadian dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Risk&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(420)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(420)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="border-bottom:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net gain of $125 million in the third quarter of 2022; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net gain of $227 million in the first nine months of 2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net loss of $18 million in the third quarter of 2021; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net loss of $94 million in the first nine months of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $1 billion within the next 12 months into income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related short-term borrowings&#x2019; carrying value as of December 31, 2021 was $1.1&#160;billion. The related long-term debt carrying values as of October&#160;2, 2022 and December 31, 2021 were $726 million and $844 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1.35pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes cumulative basis adjustments to our debt in fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;F. Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17C &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2021 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of October&#160;2, 2022, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by Germany, the U.S., the Netherlands, Japan, the U.K., France, and Canada, as well as money market funds primarily invested in U.S. Treasury and government debt.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of October&#160;2, 2022, the aggregate fair value of these derivative financial instruments that are in a net payable position was $595&#160;million, for which we have posted collateral of $612 million with a corresponding amount reported in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of October&#160;2, 2022, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $1.5&#160;billion, for which we have received collateral of $1.5&#160;billion with a corresponding amount reported in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Short-term borrowings, including current portion of long-term debt.&lt;/span&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMA_3b846a03-4ee5-4ccd-a0c3-5155c630d834">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Long-term equity securities of $139 million as of October&#160;2, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib2d2fd4d529d4ffaa9992caf594aea98_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0yLTEtMS00Mjk2NzE_c508d5d1-4bf7-42a8-8bb3-02457f9d69b4"
      unitRef="usd">12154000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i365aa8bb027248c0a4bd72e05fd31c0c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS00LTEtMS00Mjk2NzE_6ef0cd95-ec5e-40af-9858-9abb260f3018"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i58ab2d49d10a4441badf49b57db6e345_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS02LTEtMS00Mjk2NzE_bf7ffdf9-d629-498a-96da-cec023d79b20"
      unitRef="usd">12154000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifaf645fee7504d31b036a7ca132adbff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0xMC0xLTEtNDI5Njcx_5367d8d6-abf3-4e48-8d22-a4ca4f1498c7"
      unitRef="usd">5365000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id3509896f64d41e5a5a8a7c49b85adbd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0xMi0xLTEtNDI5Njcx_af9b08ca-496a-415f-8254-7dd42183c2a9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icd50bf1cd5ba47938f5f06d79c2b2891_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNS0xNC0xLTEtNDI5Njcx_2a39fc30-ed34-4d2e-ae5e-06d420fc55c8"
      unitRef="usd">5365000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i805f99cc930d4f27b83f2f5f22fcfd16_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0yLTEtMS00Mjk2NzE_45d1b6a0-f6f0-4a73-92cb-e27d61fd98c9"
      unitRef="usd">15885000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7edb8146745e45e3b80ad081fff12d94_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC00LTEtMS00Mjk2NzE_35e8ae51-2fbb-42ae-aeb4-eabff4035f91"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89eef82eb7a14b73bef78f769ed99bc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC02LTEtMS00Mjk2NzE_6487a0ae-3be8-4943-ac31-4b870fe3b57e"
      unitRef="usd">15885000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifdb21d2ec5e54e368a11d0e46bd687d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0xMC0xLTEtNDI5Njcx_e95fc7f9-a42e-4daf-bf48-042fa337e3e2"
      unitRef="usd">17318000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff481cae963c450595873c78d321b75f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0xMi0xLTEtNDI5Njcx_86949c1c-4046-4518-b9d0-80d3061ec8c1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7fb7cfc61124350803a3395415aa187_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOC0xNC0xLTEtNDI5Njcx_5898cbdb-ae25-4b02-a949-75cd35b2da0c"
      unitRef="usd">17318000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if479661c13be4b20ac5fb45721ae4f0d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0yLTEtMS00Mjk2NzE_f991cd5a-e5a7-45b8-bf0b-c2b10598dd9c"
      unitRef="usd">2931000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2479bf3cc9724ee0ab05e372bdb15b2f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS00LTEtMS00Mjk2NzE_b106459d-f815-41a1-a5ca-d5714c3ae9e1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a25515655044cabbf3baefce125c4ee_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS02LTEtMS00Mjk2NzE_cdea9ce6-f8b1-4a03-86fa-40d5ec5417d8"
      unitRef="usd">2931000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia48d8b4d17584751a31563d542bdfdaa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0xMC0xLTEtNDI5Njcx_f50a9e57-0f87-4862-8af5-c59732efbbfe"
      unitRef="usd">4050000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d99910901024c4c8acc5114294068dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0xMi0xLTEtNDI5Njcx_5d9db267-15f1-4c4b-a08e-1dbd3ba19ead"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icab958fb460e4fa0a9e49791a40852e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfOS0xNC0xLTEtNDI5Njcx_fcabf883-5c72-4396-a332-c80b785917ff"
      unitRef="usd">4050000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i04206940cb3c4f31828b818000eb0def_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMi0xLTEtNDI5Njcx_b4be98bb-1cfb-4a21-8bba-54e489254af2"
      unitRef="usd">1361000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i619ff852ea974bb5b961b5bfe763d05f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtNC0xLTEtNDI5Njcx_3717dce6-beae-4290-83bd-332a371e3f42"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49460c8694894c998f43812db50d6a6f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtNi0xLTEtNDI5Njcx_400b7f64-93de-4add-8a04-5cd87898c997"
      unitRef="usd">1361000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4935735833a74f51b431b13978755e1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMTAtMS0xLTQyOTY3MQ_45d7660f-8bbc-4785-9d67-33f41e3fdeaa"
      unitRef="usd">647000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i524be4274845416fb3a8a00458bd6bb7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMTItMS0xLTQyOTY3MQ_acad6260-33a6-4cd3-be88-43397c47cc95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i117594e26d1a4ad898c33e699b9f7077_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTAtMTQtMS0xLTQyOTY3MQ_c6ef2385-5e8e-4e85-94b1-93e2c7d1b514"
      unitRef="usd">647000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i914b27e478a94963b2d4b101e6efc8ac_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMi0xLTEtNDI5Njcx_ad5043de-d569-4d17-92ed-74e1796a4dc3"
      unitRef="usd">20176000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iefaeb8ef2b2844f88d07b978d1f21090_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtNC0xLTEtNDI5Njcx_f5272774-4428-45a0-8633-ed7e44a89e68"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63c6d752d4524b33be36259fef0edbf9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtNi0xLTEtNDI5Njcx_2e80e03c-f694-4d2a-91f7-e1a6c975eeeb"
      unitRef="usd">20176000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c24fe9c58be452aad86c0e034bcaf6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMTAtMS0xLTQyOTY3MQ_28716ef0-8bf8-4cba-876f-f2124515121f"
      unitRef="usd">22014000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56a8a497745744779127896961eb99b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMTItMS0xLTQyOTY3MQ_3c090dc6-844f-400c-a203-016ceb5d311c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i226bc50d44474921a2117b15aecd4339_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTEtMTQtMS0xLTQyOTY3MQ_a9c28ceb-30fd-4875-8630-abf4213483c3"
      unitRef="usd">22014000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i914b27e478a94963b2d4b101e6efc8ac_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMi0xLTEtNDI5Njcx_c498c695-347a-4913-aae2-ff139442e67e"
      unitRef="usd">32330000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="iefaeb8ef2b2844f88d07b978d1f21090_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItNC0xLTEtNDI5Njcx_b46fb37c-092e-40f2-992f-c484ffae70d6"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i63c6d752d4524b33be36259fef0edbf9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItNi0xLTEtNDI5Njcx_6d6cdeb5-773f-40a1-8e5c-9c883ebb968c"
      unitRef="usd">32330000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i6c24fe9c58be452aad86c0e034bcaf6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMTAtMS0xLTQyOTY3MQ_adf5dcd6-ca8d-4c56-9ba2-89fde7bd5298"
      unitRef="usd">27379000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i56a8a497745744779127896961eb99b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMTItMS0xLTQyOTY3MQ_aa6926c1-3e5e-448b-9226-26dbc0527fc6"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i226bc50d44474921a2117b15aecd4339_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTItMTQtMS0xLTQyOTY3MQ_6cbc1d9f-7374-422c-ab67-332e9080832b"
      unitRef="usd">27379000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMi0xLTEtNDI5Njcx_9cd2f757-8cbe-4c9c-b01f-396759476a24"
      unitRef="usd">9000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i78e0de40ca8c4677bfae29d91ebdde69_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtNC0xLTEtNDI5Njcx_a8cdebd4-6773-4e51-ac12-7ab3521ed95a"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtNi0xLTEtNDI5Njcx_c34d995e-eb57-4853-8bdd-ee18bb755093"
      unitRef="usd">9000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMTAtMS0xLTQyOTY3MQ_ea2b1071-7d8e-41a8-8220-3106e3c42b98"
      unitRef="usd">4000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i36e3c0460a4e4852a56a67d528410e84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMTItMS0xLTQyOTY3MQ_7f979bb9-b4b5-4595-a564-615852941f21"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1a162167b3964440947ee8fc8433d811_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTUtMTQtMS0xLTQyOTY3MQ_a19f15f9-9767-4640-8b4a-70b491c45ccb"
      unitRef="usd">4000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMi0xLTEtNDI5Njcx_c89677e9-5bd9-4244-8682-846973875e79"
      unitRef="usd">1950000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtNC0xLTEtNDI5Njcx_28d03c50-eb46-41c7-bf50-a9565aec7b42"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia35aa9908c74494b8436d59196094589_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtNi0xLTEtNDI5Njcx_c5841de4-ac23-4689-a81b-fa0ccd5b1d65"
      unitRef="usd">1950000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMTAtMS0xLTQyOTY3MQ_9d9938ae-5c17-4b44-b5b7-54fbc70b1ea5"
      unitRef="usd">704000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMTItMS0xLTQyOTY3MQ_8db8ef72-8265-4adf-a538-b7ef0ddd6a21"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTYtMTQtMS0xLTQyOTY3MQ_b51f56e2-72c5-424f-959c-e7a469dc8afa"
      unitRef="usd">704000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMi0xLTEtNDI5Njcx_d87169ff-1f63-4ed1-93b9-c081cfe59778"
      unitRef="usd">1959000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctNC0xLTEtNDI5Njcx_1e985522-9cfd-47ba-973d-32c0aa552062"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctNi0xLTEtNDI5Njcx_d085be36-2390-472b-88dc-2058cf14a497"
      unitRef="usd">1959000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMTAtMS0xLTQyOTY3MQ_f3d3b2af-e379-4bfb-839e-3c2a0c7804df"
      unitRef="usd">709000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMTItMS0xLTQyOTY3MQ_3693c016-e734-4fcc-aaed-11ec85e44d0d"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTctMTQtMS0xLTQyOTY3MQ_4758cc4e-f384-4661-b6fe-136068fafe4c"
      unitRef="usd">709000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMi0xLTEtNDI5Njcx_842617ea-9719-4eab-b73e-1115756af0c2"
      unitRef="usd">2972000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNC0xLTEtNDI5Njcx_6bfa4ccb-a89e-4014-b8a0-4f826bebfb8e"
      unitRef="usd">2960000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i10e532bbebdc45249c16d40c3dc0a715_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNi0xLTEtNDI5Njcx_0661d1b1-662e-4b85-97d1-02884e9bedf8"
      unitRef="usd">12000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i106748186c314412998ca5807842edcf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTAtMS0xLTQyOTY3MQ_ccb81272-5aac-4f1e-a246-4576be170c8b"
      unitRef="usd">3876000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia171432125c34b90be8e8604e663907d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTItMS0xLTQyOTY3MQ_ceabc205-2d62-4e44-a517-a8483c87e5fc"
      unitRef="usd">3849000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTQtMS0xLTQyOTY3MQ_0ef21eca-e6b7-48e6-88e1-69577f2efbaf"
      unitRef="usd">27000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6e5471772584760b1d1f8ac3c7d5a73_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMi0xLTEtNDI5Njcx_8a18a191-e3da-4f43-bce0-136d229ad6f5"
      unitRef="usd">285000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idaf9771697dc4c2187d4f9d4b5006611_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItNC0xLTEtNDI5Njcx_2243178d-427b-4597-aff4-e141aa2c3835"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a3394bb954a4bb283a0430941d2b0da_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItNi0xLTEtNDI5Njcx_eba7e30e-cc11-45cd-9130-c53bbef01607"
      unitRef="usd">285000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c13c8d6f5e4476488e457cd130177b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMTAtMS0xLTQyOTY3MQ_4eda45c8-8f35-41f9-b6a9-02240fc00336"
      unitRef="usd">465000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7bfbd5763f1476397cb82ac7bae3159_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMTItMS0xLTQyOTY3MQ_aa043d55-287e-49b2-9da4-b0209348199d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib536482e78464a5cb14145115c86217a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjItMTQtMS0xLTQyOTY3MQ_f89d5a7a-1487-4ff8-9d16-0533e6125e69"
      unitRef="usd">465000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7009eec6815484bb288be0b6939cfe8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMi0xLTEtNDI5Njcx_ba27b663-329c-4d62-bdff-69d7f3159aff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4fdd3aa58c54a848f098867c06f5d18_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtNC0xLTEtNDI5Njcx_f36cd1fd-93c8-4d69-b881-b6bb4b930a9f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e77d36f6bb74d9ea078650432f1a0bd_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtNi0xLTEtNDI5Njcx_3423583e-1b6b-4f27-a122-e67b1dcd2d61"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88d65cc9d472404c97ea4a88ed62138c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMTAtMS0xLTQyOTY3MQ_30095d9c-b374-4081-bc0c-a09ecc72cc06"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9222f579cb5d4c8f968c453d8254f49d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMTItMS0xLTQyOTY3MQ_a2d87fd8-db90-4450-8e32-42c22f4e41f9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife4959ff73f845669686173848f68817_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjMtMTQtMS0xLTQyOTY3MQ_5c29b185-480a-4642-9797-341bc01f44e4"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5fb79de0c54d447a940125fd8c11fe37_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMi0xLTEtNDI5Njcx_b97b44cb-4dfa-448e-b458-415e5f6c6023"
      unitRef="usd">73000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e06b72b11c542d6afc570e8531710d8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtNC0xLTEtNDI5Njcx_3b15c082-17ec-4053-899d-fb70f1f6a729"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i29b92fd6f4ac4766a4f58f450bc26d49_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtNi0xLTEtNDI5Njcx_863e44bb-80a0-436c-aef1-2956c047765b"
      unitRef="usd">73000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54b6382776a542a8abe220fd855457a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMTAtMS0xLTQyOTY3MQ_e292e4d4-eb71-49df-be2f-83801da7f093"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i867802a8f854403f9965faf6c388210a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMTItMS0xLTQyOTY3MQ_6f563084-40aa-4faa-8a90-28569ffc3475"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51c9c8f46d854bf5b5db351b98fd1a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjQtMTQtMS0xLTQyOTY3MQ_076a2d98-8e5d-439d-959c-c1a68d1bce5a"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMi0xLTEtNDI5Njcx_244f1c93-15bf-4f29-8d5e-87b138410cb6"
      unitRef="usd">358000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtNC0xLTEtNDI5Njcx_7c16aac2-55b8-4df8-8579-09e5e592b4a5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10e532bbebdc45249c16d40c3dc0a715_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtNi0xLTEtNDI5Njcx_15bf4323-a22c-4989-9878-5dcc83a115b4"
      unitRef="usd">358000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i106748186c314412998ca5807842edcf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMTAtMS0xLTQyOTY3MQ_aa0dada3-abe3-4894-9fd5-f924204a75dc"
      unitRef="usd">521000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia171432125c34b90be8e8604e663907d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMTItMS0xLTQyOTY3MQ_a7058e1c-d21e-4bda-a6b9-fe3ffcd654cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjUtMTQtMS0xLTQyOTY3MQ_9dcf42c4-e653-49cc-9b01-2375f73d5847"
      unitRef="usd">521000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i0ef8f0bc7e6042caaaa928e41f8301b3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMi0xLTEtNDI5Njcx_05bde3b3-0050-4a06-aea1-d122ee1c2f98"
      unitRef="usd">3330000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i758d4cc4bc8e4503b9af0d0f4ba9469e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtNC0xLTEtNDI5Njcx_00330600-b7ac-4e51-be12-0a14074ad3a9"
      unitRef="usd">2960000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i10e532bbebdc45249c16d40c3dc0a715_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtNi0xLTEtNDI5Njcx_dab4d92a-6fc9-4599-8ffc-fe342fa0e092"
      unitRef="usd">370000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i106748186c314412998ca5807842edcf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMTAtMS0xLTQyOTY3MQ_e2d3a6b1-5347-44c8-b54a-439b3391ba36"
      unitRef="usd">4397000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="ia171432125c34b90be8e8604e663907d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMTItMS0xLTQyOTY3MQ_54e31ed1-91a2-4b1a-abab-7524f31fe825"
      unitRef="usd">3849000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i60dcf20e9f3c49fc8852ce5c5544572f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjYtMTQtMS0xLTQyOTY3MQ_a13f2f32-b00f-47d9-82b2-f80e508775ed"
      unitRef="usd">548000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMi0xLTEtNDI5Njcx_53859080-764e-4f57-b4f3-78b5f08c1059"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i78e0de40ca8c4677bfae29d91ebdde69_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktNC0xLTEtNDI5Njcx_4f341024-3c12-45bd-9300-e0a3d48d3b9d"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktNi0xLTEtNDI5Njcx_8f6d155a-4519-43ab-93bd-b4b764261ef0"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMTAtMS0xLTQyOTY3MQ_a8500e4d-ad0c-4582-8462-1f50b93d1a2c"
      unitRef="usd">16000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i36e3c0460a4e4852a56a67d528410e84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMTItMS0xLTQyOTY3MQ_df924dba-c1fa-4085-b19e-01d1c214072a"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1a162167b3964440947ee8fc8433d811_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMjktMTQtMS0xLTQyOTY3MQ_515b69c6-bce7-47ca-a09a-d06e7f9092a3"
      unitRef="usd">16000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMi0xLTEtNDI5Njcx_306c3bf5-c70e-4b16-8861-fd28f30b85ea"
      unitRef="usd">812000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtNC0xLTEtNDI5Njcx_19e8a66a-2f55-4685-b699-4069451d4f05"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia35aa9908c74494b8436d59196094589_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtNi0xLTEtNDI5Njcx_e7dfbbba-fa2c-4cd3-8034-504217ea63b1"
      unitRef="usd">812000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMTAtMS0xLTQyOTY3MQ_8e80b3da-d243-40d2-9b40-e52a08e7ce81"
      unitRef="usd">242000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMTItMS0xLTQyOTY3MQ_79286274-2050-4532-b6e7-0a5935f07d57"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzAtMTQtMS0xLTQyOTY3MQ_3bd48b17-b64d-474f-bf17-4e24e99ba05a"
      unitRef="usd">242000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMi0xLTEtNDI5Njcx_e51491b1-cf91-4036-93c7-9a4ca1a933db"
      unitRef="usd">812000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtNC0xLTEtNDI5Njcx_cf672100-f728-4b03-b7f4-a916db93f9c2"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtNi0xLTEtNDI5Njcx_865a7abd-e653-496e-80ce-f2609dc28380"
      unitRef="usd">812000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMTAtMS0xLTQyOTY3MQ_f8478683-7b10-4afd-b0ce-ec1838c49c42"
      unitRef="usd">259000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMTItMS0xLTQyOTY3MQ_abc71c04-58dd-4e03-85c4-4c4647041594"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzEtMTQtMS0xLTQyOTY3MQ_ef6154a5-dbae-43a8-bb04-309f4c7d75d1"
      unitRef="usd">259000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMi0xLTEtNDI5Njcx_2721d866-8f12-475d-b329-5b2c2055214b"
      unitRef="usd">631000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNC0xLTEtNDI5Njcx_7701f7ed-5376-447f-a11e-2b480b14bb8f"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNi0xLTEtNDI5Njcx_34e03b37-a1b3-477f-b8ea-6fc43d6d69b6"
      unitRef="usd">631000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTAtMS0xLTQyOTY3MQ_a4939c53-51b1-4072-8a3d-80ee90e928f2"
      unitRef="usd">808000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTItMS0xLTQyOTY3MQ_a3b2da09-2fff-4dbe-9c94-5f0fbde322fa"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTQtMS0xLTQyOTY3MQ_b6b9f342-3cf2-42b3-b1e1-5ae23c7067e7"
      unitRef="usd">808000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMi0xLTEtNDI5Njcx_1171fa5d-a990-4dce-b6dd-3887e4dd9487"
      unitRef="usd">1444000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtNC0xLTEtNDI5Njcx_68eb4e11-43bf-43f5-afcd-a5c48228f56f"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtNi0xLTEtNDI5Njcx_a6d17163-d941-4744-bde8-fe34f8773911"
      unitRef="usd">1444000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMTAtMS0xLTQyOTY3MQ_399e316f-77f1-4512-b4fd-de2c80676e87"
      unitRef="usd">1067000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMTItMS0xLTQyOTY3MQ_1b7bedf4-4ef3-4bbf-93d8-bc9ee2303813"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzMtMTQtMS0xLTQyOTY3MQ_7bd00b95-4610-410f-b624-5c9ec76268b0"
      unitRef="usd">1067000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMi0xLTEtNDI5Njcx_0567457b-deea-461b-96e0-4ce4428828b3"
      unitRef="usd">39063000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtNC0xLTEtNDI5Njcx_77d3c1b9-9a98-41c5-b6ac-288445b57b19"
      unitRef="usd">2960000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtNi0xLTEtNDI5Njcx_0e15f87e-f1de-4ad3-85a0-6c4f34b3beec"
      unitRef="usd">36103000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMTAtMS0xLTQyOTY3MQ_8a36bf65-2b79-4442-ae9c-20eb2a73efde"
      unitRef="usd">33552000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMTItMS0xLTQyOTY3MQ_aef80481-1807-4dea-b404-833fdaed270b"
      unitRef="usd">3849000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzQtMTQtMS0xLTQyOTY3MQ_9c742870-e104-4e8c-93eb-665fb711eba0"
      unitRef="usd">29703000000</us-gaap:Assets>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMi0xLTEtNDI5Njcx_8e7673b3-4e93-467e-a025-c767aa628327"
      unitRef="usd">295000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtNC0xLTEtNDI5Njcx_9a2d1c25-1dfc-4fec-b5b7-a1a2ba581e31"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ia35aa9908c74494b8436d59196094589_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtNi0xLTEtNDI5Njcx_70844d9c-4aab-411c-b711-139d0275b61e"
      unitRef="usd">295000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMTAtMS0xLTQyOTY3MQ_a43413fe-fcf0-49a7-852c-ee87ac2c62f1"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMTItMS0xLTQyOTY3MQ_5273e68a-00b4-4596-8f5a-ce3787b27113"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDAtMTQtMS0xLTQyOTY3MQ_bed83355-66eb-40aa-81d0-efce3bdd883f"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMi0xLTEtNDI5Njcx_9e967f72-61bc-4da1-8ce5-092adad416e7"
      unitRef="usd">295000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtNC0xLTEtNDI5Njcx_b4c974d0-5c0d-40f3-9aab-12275139d7cb"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtNi0xLTEtNDI5Njcx_a4924d24-bfe1-4641-b933-6fb6602c6ed7"
      unitRef="usd">295000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMTAtMS0xLTQyOTY3MQ_b11cc28a-1655-4977-bdad-093d0b313124"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMTItMS0xLTQyOTY3MQ_a87a2ce2-2081-4e68-8e84-db0bbe39226e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDEtMTQtMS0xLTQyOTY3MQ_f5e9133f-4f52-49b3-a4b1-34ed19763686"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5a71e3f3b32143f18f26104fc7a4cbb8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMi0xLTEtNDI5Njcx_b500e193-c56d-48b5-ab5e-c44c01c2c1f6"
      unitRef="usd">330000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i78e0de40ca8c4677bfae29d91ebdde69_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtNC0xLTEtNDI5Njcx_9f1b240e-2243-4d05-84e6-b22ea603b40e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i79c8e2220c2948e4a16ddc33f226e8bc_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtNi0xLTEtNDI5Njcx_80e4db31-67da-4489-bda3-84cd6b29a8db"
      unitRef="usd">330000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i96ebc2d96bcc485ebc0701c5dd2460c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMTAtMS0xLTQyOTY3MQ_06db1f9b-b673-40d3-8568-d338a67c4329"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i36e3c0460a4e4852a56a67d528410e84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMTItMS0xLTQyOTY3MQ_7ace3813-17c4-43f9-b243-d99f1385b87c"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1a162167b3964440947ee8fc8433d811_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDQtMTQtMS0xLTQyOTY3MQ_37e554be-7d51-4323-bdf5-ccb55ebaf1e9"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i39a069f7f44c44a79a99da7df5e7d726_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMi0xLTEtNDI5Njcx_3402fe28-2755-47e0-8e3f-542375fa85c0"
      unitRef="usd">1153000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if1606489f92c4bd28f5d5bb811476ad6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtNC0xLTEtNDI5Njcx_2186b06f-7203-48ed-b6b6-ce541196a06c"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia35aa9908c74494b8436d59196094589_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtNi0xLTEtNDI5Njcx_c047bd2d-8468-4691-b9db-2d98abcbe226"
      unitRef="usd">1153000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2aa20c368a6845188d5f86675163ec4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMTAtMS0xLTQyOTY3MQ_1ee66717-d1e5-472a-9a4c-369558fa0816"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3610bf2fddc6485899c21d82bc9bd4fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMTItMS0xLTQyOTY3MQ_0a2741ae-4525-4ee0-b8d6-a0bec3cfcd9e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia8e4ec9e513a4604b79f6609f65f23e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDUtMTQtMS0xLTQyOTY3MQ_12dc26ef-2ace-4172-9fb8-7608d34ccbe6"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMi0xLTEtNDI5Njcx_d30b0c33-26f8-4845-9888-4fa218d7888f"
      unitRef="usd">1482000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtNC0xLTEtNDI5Njcx_11c05dcf-98d7-423c-9a74-a69e4f1cf360"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtNi0xLTEtNDI5Njcx_af06d470-c30f-4cf4-9fc3-a6fde340506c"
      unitRef="usd">1482000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMTAtMS0xLTQyOTY3MQ_7fa43dd8-9114-4462-96c8-a1ab53df9e44"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMTItMS0xLTQyOTY3MQ_5e6265fd-3ad0-4278-a6df-5a5891868623"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDYtMTQtMS0xLTQyOTY3MQ_0f7802e3-59c5-43e1-bc43-5acb9e0c41dd"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMi0xLTEtNDI5Njcx_1a729372-b6ce-4a45-b2f8-f53384694524"
      unitRef="usd">1777000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8eb8301baf634a788c90da0b7e186fba_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctNC0xLTEtNDI5Njcx_24b84c04-2972-4940-aa3a-833d797c016c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1b6d88ea8a804863b8b4ec12077d9718_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctNi0xLTEtNDI5Njcx_1d467308-218d-48d9-91ff-e6444943a729"
      unitRef="usd">1777000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMTAtMS0xLTQyOTY3MQ_578b318c-c085-4030-8b81-c08b7afc8e65"
      unitRef="usd">881000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i979b62479efe4c33bd39145b1249c177_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMTItMS0xLTQyOTY3MQ_d29d96cc-fd3b-419f-b020-e7df53e70cda"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7a58581671444d0fa9352733c8859022_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfNDctMTQtMS0xLTQyOTY3MQ_036f8a5a-35ec-46f1-b8c1-d34b27c76c94"
      unitRef="usd">881000000</us-gaap:DerivativeLiabilities>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="i752fb6da23f74a17911b22b40176bdc2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMjA2_9f5b4689-9ddd-48ed-a868-963dfaa8f939"
      unitRef="usd">139000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="i458c5f84f016420085b60cd199bcf73a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMjIy_99b27d55-7935-437a-8963-d159e1f9b410"
      unitRef="usd">194000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="i49a36bebd932477abb647b4c3f1f7229_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfNzY3_fd0ae72d-b78b-4e22-b1aa-f9cb05d99e14"
      unitRef="usd">33000000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4d1ae606958948a09710f9127386e909_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfNzgz_085e4f60-b268-418d-adcc-ccb8e6067894"
      unitRef="usd">36000000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i01adb0c331434d4eb30ff9aa4a978d62_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfODgz_20683e3c-0107-47db-bf0b-996602f8e024"
      unitRef="usd">29000000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i195a713f2d9b41099053b0da037cb644_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfODk5_e2f732b8-0ffe-4051-b8aa-32bb3d80ea93"
      unitRef="usd">42000000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzg3_cc6057e5-2d94-410c-b9d4-30c40dd210dc">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes our investments by classification type:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities at cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Includes money market funds primarily invested in U.S. Treasury and government debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represent investments in the life sciences sector.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy0yLTEtMS00Mjk2NzE_947423da-75c5-4888-8435-7ecabccea84f"
      unitRef="usd">12154000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy00LTEtMS00Mjk2NzE_bde52b2e-a777-41dc-b155-e237fd719780"
      unitRef="usd">5365000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNC0yLTEtMS00Mjk2NzE_baa21488-6912-4309-a7d9-187ab6de4d96"
      unitRef="usd">20176000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNC00LTEtMS00Mjk2NzE_379bc9f9-903d-4316-aa68-8b6a86a1c4f0"
      unitRef="usd">22014000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNS0yLTEtMS00Mjk2NzE_f9cf7e36-be73-490e-8f57-acce56d9db4c"
      unitRef="usd">2495000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNS00LTEtMS00Mjk2NzE_c3c68bcd-449f-4dd3-bd7e-6eed4629f8e5"
      unitRef="usd">1746000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:OtherShortTermInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNi0yLTEtMS00Mjk2NzE_a8967ea8-e7fe-452a-8fff-7cd88bf45d0f"
      unitRef="usd">34825000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfNi00LTEtMS00Mjk2NzE_cf53af27-dd9a-4d97-b3fe-4576f22cc1e5"
      unitRef="usd">29125000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfOS0yLTEtMS00Mjk2NzE_b0f87030-77e0-48d0-b266-3dd9d3f2d4f2"
      unitRef="usd">2972000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfOS00LTEtMS00Mjk2NzE_8f3836a0-57c6-4a0c-9287-2a44d2e8b260"
      unitRef="usd">3876000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTEtMi0xLTEtNDI5Njcx_3517e2bb-81fa-402a-b96a-593712b2b5e8"
      unitRef="usd">358000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTEtNC0xLTEtNDI5Njcx_fae844c1-0532-473b-b623-3fc8c1af42ee"
      unitRef="usd">521000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTItMi0xLTEtNDI5Njcx_87cc9480-6fec-47ef-833d-39be57fea5f1"
      unitRef="usd">36000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTItNC0xLTEtNDI5Njcx_7822f030-1b1c-4810-ac77-84917717138c"
      unitRef="usd">34000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <pfe:PrivateEquityInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtMi0xLTEtNDI5Njcx_982648aa-6469-48be-99c5-f6a8806bdbf1"
      unitRef="usd">696000000</pfe:PrivateEquityInvestments>
    <pfe:PrivateEquityInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtNC0xLTEtNDI5Njcx_9035346d-b158-4367-9a1d-296132bb041b"
      unitRef="usd">623000000</pfe:PrivateEquityInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTQtMi0xLTEtNDI5Njcx_64c52689-61ba-452f-b5ec-fdca113713ce"
      unitRef="usd">4062000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTQtNC0xLTEtNDI5Njcx_836f5d08-9f3d-4db4-b66d-29515e352593"
      unitRef="usd">5054000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTUtMi0xLTEtNDI5Njcx_615391bf-0d65-49fb-aec8-ebbeee8be69c"
      unitRef="usd">9826000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTUtNC0xLTEtNDI5Njcx_bb8584d6-d994-457d-b0c2-3f7ed39e21a1"
      unitRef="usd">16472000000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTYtMi0xLTEtNDI5Njcx_ef12678a-c4a9-4282-a8a8-f395114f5870"
      unitRef="usd">13888000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTYtNC0xLTEtNDI5Njcx_d6cb898f-98f0-4926-a2e4-d4591125be23"
      unitRef="usd">21526000000</us-gaap:LongTermInvestments>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTctMi0xLTEtNDI5Njcx_5b895280-1d15-4b47-adc2-3b43fd0bf4ad"
      unitRef="usd">969000000</pfe:HeldToMaturityCashEquivalents>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTctNC0xLTEtNDI5Njcx_d6fa3280-0b94-4189-9315-2105b0ba369f"
      unitRef="usd">268000000</pfe:HeldToMaturityCashEquivalents>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYz_047b7592-a33b-414d-adbb-c903291de5aa">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(580)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcy_e712f67d-5e81-4793-addc-79ed887c6739">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(580)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzkz_93c9743d-5d61-48b8-96ff-3a7c105cd188">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At October&#160;2, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;15,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(580)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0yLTEtMS00Mjk2NzE_2df9f235-ed0c-4da2-ae2d-49920a1452b7"
      unitRef="usd">16711000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS00LTEtMS00Mjk2NzE_581a4c42-8554-48b1-ac80-d30fefa8dd15"
      unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS02LTEtMS00Mjk2NzE_d64ef7bf-2f8d-4b39-b26c-e643febeeffa"
      unitRef="usd">567000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS04LTEtMS00Mjk2NzE_5334c435-3dfe-478a-9dcb-3abb7de504d7"
      unitRef="usd">16169000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xMC0xLTEtNDI5Njcx_a7953ec7-5207-4ae1-bc02-23134b5df2cb"
      unitRef="usd">15885000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xMi0xLTEtNDI5Njcx_e302ff35-8495-4f81-9f66-9dd23baed1eb"
      unitRef="usd">285000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xNC0xLTEtNDI5Njcx_0d491650-0c7d-4c24-b12c-68d4774a019b"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xNy0xLTEtNDI5Njcx_c1b7baca-efdd-4c21-98f6-9bf88521a50e"
      unitRef="usd">18032000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0xOS0xLTEtNDI5Njcx_70d93a48-0e59-4034-b978-6b783b858b85"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0yMS0xLTEtNDI5Njcx_736c1a4d-8ec8-4907-9faf-00689cb8c7d8"
      unitRef="usd">263000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNS0yMy0xLTEtNDI5Njcx_9118e8a2-d86e-4eff-b383-d5801d7cad75"
      unitRef="usd">17783000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0yLTEtMS00Mjk2NzE_615a23ed-1d00-4aac-a661-2f5afcae39f9"
      unitRef="usd">2932000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi00LTEtMS00Mjk2NzE_d82497f5-0fac-403f-95f7-edb1ea0f0f57"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi02LTEtMS00Mjk2NzE_a4604df2-765b-4d4a-bf24-3cd8f0d71c4f"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi04LTEtMS00Mjk2NzE_dca25b25-868e-4b46-85a7-9cdbbadd4935"
      unitRef="usd">2931000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xMC0xLTEtNDI5Njcx_d444fd45-e499-45eb-ac51-a373c8070b0b"
      unitRef="usd">2931000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xMi0xLTEtNDI5Njcx_1405579d-326b-4586-82a4-e64310289a1b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="i57a34ccba5c84e5783572681c5b10269_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xNC0xLTEtNDI5Njcx_737e7e96-1ac4-469e-8e19-cbd5266f9a6f"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xNy0xLTEtNDI5Njcx_6bc44a40-ea1b-48c4-a671-5caee0b7dbab"
      unitRef="usd">4056000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0xOS0xLTEtNDI5Njcx_f6912357-e86b-40cb-bd7d-c1d90e5cf5e0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0yMS0xLTEtNDI5Njcx_fe9e7b81-df50-4d82-b610-107569c0eec1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00bfa9c24fed4afdb863e6b3ce8127f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNi0yMy0xLTEtNDI5Njcx_a246a89a-a53c-42f8-b0bd-92eb6e10a7e7"
      unitRef="usd">4055000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0yLTEtMS00Mjk2NzE_96a3112e-a109-4363-be7b-8f0d49d11ab4"
      unitRef="usd">1446000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy00LTEtMS00Mjk2NzE_9216394a-be08-45c9-bf94-d009f39c95af"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy02LTEtMS00Mjk2NzE_e93414bc-d2af-4ade-b702-802de7597ee0"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy04LTEtMS00Mjk2NzE_aa9e19ec-ffa7-4541-ac2e-5698aa353921"
      unitRef="usd">1434000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xMC0xLTEtNDI5Njcx_fe2e5e9a-d81d-498f-be4f-8ae11f7fd48f"
      unitRef="usd">1361000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xMi0xLTEtNDI5Njcx_de921558-aeb9-40b2-b52d-f899a21fbaaa"
      unitRef="usd">73000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="i2c1a042fb56a476cb18d112a8229dba2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xNC0xLTEtNDI5Njcx_bf210220-b72a-4b47-8402-0b2d3fac66b8"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xNy0xLTEtNDI5Njcx_498cd2e7-b39c-4039-be5e-7af5422ae104"
      unitRef="usd">698000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0xOS0xLTEtNDI5Njcx_fa3a4a57-f9a8-4563-b5b1-7ebba9cf0f7b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0yMS0xLTEtNDI5Njcx_690243f0-9463-4f21-ba6d-454f408543f8"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18f9e24f27f7455ba6e05f483af693eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfNy0yMy0xLTEtNDI5Njcx_b214815a-7c05-4970-aa61-f61abcea9c99"
      unitRef="usd">697000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0yLTEtMS00Mjk2NzE_a9db0a6c-26e0-414f-babc-12ca64f99fad"
      unitRef="usd">1557000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS00LTEtMS00Mjk2NzE_28fb3a50-650b-427c-9580-295d275c2822"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS02LTEtMS00Mjk2NzE_3a342654-e230-4524-9588-09a7e9e8fe1c"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS04LTEtMS00Mjk2NzE_6519ce6d-3103-48bc-bfa0-808f162941f5"
      unitRef="usd">1557000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xMC0xLTEtNDI5Njcx_7b5928fe-dfe5-4beb-a17d-0d4b33fb00ca"
      unitRef="usd">1525000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xMi0xLTEtNDI5Njcx_83c47711-527d-4f56-8e5b-1b1ebde92a72"
      unitRef="usd">20000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="ic2885fade3ad4cc5832c4aa996b4feae_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xNC0xLTEtNDI5Njcx_1312e7ac-e195-4183-9f55-cc78302f0b0e"
      unitRef="usd">12000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xNy0xLTEtNDI5Njcx_c736cf33-e477-47cc-b3f7-f3d5085568f0"
      unitRef="usd">947000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0xOS0xLTEtNDI5Njcx_b1a93b64-ee58-4b5d-9ff1-2b45ba4cfedf"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0yMS0xLTEtNDI5Njcx_2776711d-5bd9-4822-8926-720052fe488d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i208c5cb34c6642f493f12b122be74aab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfOS0yMy0xLTEtNDI5Njcx_9e643432-7531-4b9b-8a72-caf2e2a2faa8"
      unitRef="usd">947000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMi0xLTEtNDI5Njcx_f842f040-b8e4-4994-9851-0f020634b0bb"
      unitRef="usd">1943000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtNC0xLTEtNDI5Njcx_30e2be8e-a374-46ed-be20-286e5edb39ce"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtNi0xLTEtNDI5Njcx_9391f9f4-5fb6-40c3-8790-d4ecfe09b926"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtOC0xLTEtNDI5Njcx_b9bf777f-8177-42dc-bc0c-5a9ebaae87d3"
      unitRef="usd">1943000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTAtMS0xLTQyOTY3MQ_ea5d9566-e63d-4e63-8200-e45efb7a26ab"
      unitRef="usd">1939000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTItMS0xLTQyOTY3MQ_ea05db34-02ba-4a56-9298-f97357d0d9e4"
      unitRef="usd">3000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="ib1ea22ef0ff2499a81fecdd3db042baf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTQtMS0xLTQyOTY3MQ_67b12052-5d00-432c-a655-a6a7b6d836e9"
      unitRef="usd">1000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTctMS0xLTQyOTY3MQ_a6a75555-7716-4e82-9851-603987a878cd"
      unitRef="usd">1102000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMTktMS0xLTQyOTY3MQ_5d09aa87-eabc-4364-9d3b-ff0e86653125"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMjEtMS0xLTQyOTY3MQ_ac3552bf-5d74-4a75-95b7-bb4de9b690ae"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="icb43fe7a17194fe681956dfe1e3ca7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTAtMjMtMS0xLTQyOTY3MQ_a862fcdb-9ee6-4aac-ad74-67670bead7a1"
      unitRef="usd">1102000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMi0xLTEtNDI5Njcx_8d133005-2a9d-4393-9d4d-eb1618b5b964"
      unitRef="usd">24589000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtNC0xLTEtNDI5Njcx_159c5ea4-4e07-4694-97d9-fb11c9452dbc"
      unitRef="usd">26000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtNi0xLTEtNDI5Njcx_c4d68bb3-6817-4c82-a475-9b342277e5fb"
      unitRef="usd">580000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtOC0xLTEtNDI5Njcx_87bf48b5-3ee5-40f0-b173-1ad66aaef225"
      unitRef="usd">24034000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTAtMS0xLTQyOTY3MQ_db1256a1-f8b7-4b1c-8d9c-c8eea82ccb6d"
      unitRef="usd">23641000000</pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue>
    <pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTItMS0xLTQyOTY3MQ_50dfcc45-f279-465b-9f7d-590927db043c"
      unitRef="usd">381000000</pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue>
    <pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTQtMS0xLTQyOTY3MQ_7b42a9e2-9af7-4f5f-b18d-7d6b741ff5f3"
      unitRef="usd">13000000</pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTctMS0xLTQyOTY3MQ_fa1342fd-46e2-4083-bd8c-0c625e920694"
      unitRef="usd">24835000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMTktMS0xLTQyOTY3MQ_ee83fd54-bffc-41e1-84d1-ce4918b66085"
      unitRef="usd">14000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMjEtMS0xLTQyOTY3MQ_8833cf4b-0bc8-4e60-8f2d-410fa154bf83"
      unitRef="usd">265000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjk2MDE5ODU0MmZkMTQ4MWZhODFlNGFjMGNjZGJhZTU5L3RhYmxlcmFuZ2U6OTYwMTk4NTQyZmQxNDgxZmE4MWU0YWMwY2NkYmFlNTlfMTEtMjMtMS0xLTQyOTY3MQ_0194bdea-7609-4055-a9e6-c0267ebfefe5"
      unitRef="usd">24584000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgz_b999d31e-6dc8-4ba0-bffe-6f2190c090ad">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy0yLTEtMS00Mjk2NzE_5a0039dd-c615-4609-86b3-a10613f0009a"
      unitRef="usd">-112000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy00LTEtMS00Mjk2NzE_14057630-317a-4fd9-baff-f0c8fddf43b1"
      unitRef="usd">400000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy02LTEtMS00Mjk2NzE_e6d2f62f-dc75-4d22-a788-915b8e020593"
      unitRef="usd">-1353000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy04LTEtMS00Mjk2NzE_9b9133fb-bec2-4fcc-9258-400dd16c8db6"
      unitRef="usd">1601000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC0yLTEtMS00Mjk2NzE_94f6bbeb-c0bf-4d02-8bbb-bfa0530a8f53"
      unitRef="usd">5000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC00LTEtMS00Mjk2NzE_8d23549f-944b-43ac-876e-4fa961cd7c37"
      unitRef="usd">78000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC02LTEtMS00Mjk2NzE_ff9742e8-5920-4257-a24f-84206c1a5ae1"
      unitRef="usd">84000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNC04LTEtMS00Mjk2NzE_99d67a21-92b3-41b1-bd0d-1ad83484bf54"
      unitRef="usd">83000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS0yLTEtMS00Mjk2NzE_38c92c39-bf18-49b7-a4a0-e25b66dbb213"
      unitRef="usd">-116000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS00LTEtMS00Mjk2NzE_613077e8-5b40-4023-b819-a7c214d9ee06"
      unitRef="usd">322000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS02LTEtMS00Mjk2NzE_b00bcbae-500f-4f0f-9340-0122991a721f"
      unitRef="usd">-1436000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS04LTEtMS00Mjk2NzE_50323117-4703-41a1-9272-feb994edeef3"
      unitRef="usd">1518000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNjMz_1fb1b85f-420d-49e9-81f7-3da3b48ec76b"
      unitRef="usd">148000000</pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNjYy_17e6f54e-67a1-4d96-bbdc-803b4fc70d59"
      unitRef="usd">201000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjI5_289a3850-3a74-48a7-9a86-505d33cb7fb8">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Primarily includes cash collateral. See&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 7F&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfMy0yLTEtMS00Mjk2NzE_aef2f8ce-5fb9-4ece-91de-70637ef59019"
      unitRef="usd">2550000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfMy00LTEtMS00Mjk2NzE_148c01ee-5fab-4fec-ad18-20b6751c3b7e"
      unitRef="usd">1636000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC0yLTEtMS00Mjk2NzE_7ec794a7-64fc-462c-ba71-8d64150189b3"
      unitRef="usd">1474000000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC00LTEtMS00Mjk2NzE_a263b85b-e520-4043-a264-bac7e134fa07"
      unitRef="usd">605000000</us-gaap:OtherShortTermBorrowings>
    <pfe:ShorttermDebtGross
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNS0yLTEtMS00Mjk2NzE_08517b84-1384-4e5d-81bf-08995055d06a"
      unitRef="usd">4024000000</pfe:ShorttermDebtGross>
    <pfe:ShorttermDebtGross
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNS00LTEtMS00Mjk2NzE_5304c55d-8d40-4d25-8cf6-ac2b5216c472"
      unitRef="usd">2241000000</pfe:ShorttermDebtGross>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNi0yLTEtMS00Mjk2NzE_b9245094-751c-4b63-8fa4-197f633fb4fe"
      unitRef="usd">16000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNi00LTEtMS00Mjk2NzE_ba7d9714-bd61-4b93-bd8c-57da5e9256a7"
      unitRef="usd">0</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtCurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfOC0yLTEtMS00Mjk2NzE_297108d3-84dd-4f20-8cf1-d42de089f14e"
      unitRef="usd">4040000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfOC00LTEtMS00Mjk2NzE_95fdccf8-5606-440f-9ab2-19f93cdbf41c"
      unitRef="usd">2241000000</us-gaap:DebtCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RleHRyZWdpb246ZWUzNmNjYjVmNjQ4NDNhMzhiZjU1Njk1NzFlOTNjOGVfMjk_0adf5b63-1e28-4496-99aa-483b13099c73">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMi0yLTEtMS00Mjk2NzE_d64a34ce-f458-42c7-b440-586664062e1c"
      unitRef="usd">31831000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3d030e31054241cbb0485358571b9bde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMi00LTEtMS00Mjk2NzE_907edb18-0add-4f28-ae66-e09aa4bbc7f1"
      unitRef="usd">34948000000</us-gaap:DebtInstrumentCarryingAmount>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMy0yLTEtMS00Mjk2NzE_87f01870-a516-4773-85c8-c217f4e7574b"
      unitRef="usd">976000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="i3d030e31054241cbb0485358571b9bde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfMy00LTEtMS00Mjk2NzE_b86404b0-9bd1-456e-b16d-56ceda0764b9"
      unitRef="usd">1438000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNC0yLTEtMS00Mjk2NzE_4cc9bea5-f4aa-4b89-b730-612e17b07e2a"
      unitRef="usd">178000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i3d030e31054241cbb0485358571b9bde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNC00LTEtMS00Mjk2NzE_199861a0-b1d1-4bc8-a984-f18a98d0db27"
      unitRef="usd">195000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:OtherLongTermDebt
      contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNS0yLTEtMS00Mjk2NzE_735e891e-c5df-4bde-a57e-5310280e2877"
      unitRef="usd">0</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="i3d030e31054241cbb0485358571b9bde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNS00LTEtMS00Mjk2NzE_4af72b28-3da9-4ac0-8150-2859ebfc1edf"
      unitRef="usd">4000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8bdb0dbdb3524c57926943b1fac9dcef_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNi0yLTEtMS00Mjk2NzE_aff28af7-4525-46bf-a6aa-31fa81cb7d3c"
      unitRef="usd">32629000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3d030e31054241cbb0485358571b9bde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83My9mcmFnOmVlMzZjY2I1ZjY0ODQzYTM4YmY1NTY5NTcxZTkzYzhlL3RhYmxlOmE0ZGYyZWU5MWJhMTRjZDQ5YTAyNDUzZmY0MzJkYzRkL3RhYmxlcmFuZ2U6YTRkZjJlZTkxYmExNGNkNDlhMDI0NTNmZjQzMmRjNGRfNi00LTEtMS00Mjk2NzE_42dbdab3-264c-4849-97cd-dd17157b44ce"
      unitRef="usd">36195000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeTermOfContract
      contextRef="i8472588c67134a13847983bdf694f4dc_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfODQy_8b963a7e-fb09-4681-a8e5-511de3448567">P2Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk4NQ_80e1e2b4-73e2-40b0-a9fa-2f2888a0e569">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAxNw_35d0f543-6868-4cba-a687-8df47dae899b">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAxOQ_c5ae1d25-f231-47e8-ba8d-df5af49c19db">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0yLTEtMS00Mjk2NzE_98c53b55-1c37-4942-a131-1e3138a4fac2"
      unitRef="usd">33274000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS00LTEtMS00Mjk2NzE_50bb3f84-6761-493d-849a-d1eae1d8d3fc"
      unitRef="usd">2479000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS02LTEtMS00Mjk2NzE_99b7ca62-b866-4c59-9bc7-b23b4df8d23e"
      unitRef="usd">1175000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS04LTEtMS00Mjk2NzE_80861cc7-b44f-4666-ac47-8bdbf158d915"
      unitRef="usd">29576000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMC0xLTEtNDI5Njcx_321577f7-e593-49a7-a7ac-2b0830e4ef5b"
      unitRef="usd">787000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="iafc5f6d59e37488abae6d4bfb45a7efa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMi0xLTEtNDI5Njcx_5af25e10-6100-474a-80a2-768f0c5ece86"
      unitRef="usd">717000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi0yLTEtMS00Mjk2NzE_6f061895-50fb-430e-b311-1d150d1bf9e1"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi00LTEtMS00Mjk2NzE_3987de6a-1f83-4cfd-80aa-6250f03b47ea"
      unitRef="usd">9000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i61cb58dd16bc40d2b3de759df4c21ab5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi02LTEtMS00Mjk2NzE_27090c05-9a0b-4672-aa55-f847ab9e7f81"
      unitRef="usd">330000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i55958062514846a5817b8f0a50f35dd6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi04LTEtMS00Mjk2NzE_60336405-bd7a-4711-b4f8-be2bf3eb43eb"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i55958062514846a5817b8f0a50f35dd6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi0xMC0xLTEtNDI5Njcx_796446e0-15f9-4bf9-b076-50f5e3d62f30"
      unitRef="usd">21000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i55958062514846a5817b8f0a50f35dd6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNi0xMi0xLTEtNDI5Njcx_64487b9a-64d3-4be6-8d35-940757adc233"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i9722c4887b744055b1904ff63ab244d9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy00LTEtMS00Mjk2NzE_868c16b2-9c00-4dc0-8bcf-d41e04762125"
      unitRef="usd">2488000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i9722c4887b744055b1904ff63ab244d9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy02LTEtMS00Mjk2NzE_813b0f8b-1641-440a-b7e0-33f4e4a1da0c"
      unitRef="usd">1505000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i8c60017d6ba741f68386b4b24baef910_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy0xMC0xLTEtNDI5Njcx_8e15927e-5582-464f-bde3-5fe469ec77bc"
      unitRef="usd">808000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i8c60017d6ba741f68386b4b24baef910_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNy0xMi0xLTEtNDI5Njcx_e9588cf9-bdc6-4613-8051-aaca2541a4e8"
      unitRef="usd">717000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic477a3d1dd454d778619d8af4d4a6650_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS0yLTEtMS00Mjk2NzE_0ae18561-e1e8-4cdd-81b2-789c8433e2db"
      unitRef="usd">26426000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ic477a3d1dd454d778619d8af4d4a6650_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS00LTEtMS00Mjk2NzE_a0193b52-d8b3-4c2e-adf1-9646a44cfd31"
      unitRef="usd">283000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ic477a3d1dd454d778619d8af4d4a6650_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS02LTEtMS00Mjk2NzE_247b99c8-784f-440b-850b-a9bdcb9e44d3"
      unitRef="usd">273000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS04LTEtMS00Mjk2NzE_28856996-490e-4df9-9c6a-01f4185d2f89"
      unitRef="usd">21419000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS0xMC0xLTEtNDI5Njcx_bcc6fc2a-555a-45a4-abbe-604f36a4cbe3"
      unitRef="usd">160000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i8bba14d0856d4e3682f054f1ae65a9ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfOS0xMi0xLTEtNDI5Njcx_952744e0-e60f-4154-8e28-d9cbaf07e98e"
      unitRef="usd">164000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtNC0xLTEtNDI5Njcx_aba714ea-f7e0-4155-8a56-66f5eb305a72"
      unitRef="usd">2771000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtNi0xLTEtNDI5Njcx_ed289bd5-4d5c-47c0-8887-1cf0b138d4cb"
      unitRef="usd">1777000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtMTAtMS0xLTQyOTY3MQ_74083bd1-7ea8-4445-94a2-41f2754a5380"
      unitRef="usd">968000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfMTAtMTItMS0xLTQyOTY3MQ_3ca45897-9e17-4237-a53d-d5ac43d05748"
      unitRef="usd">881000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i827e7ba807c442599109f6cd0c3eb032_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjM4Mg_2c6a4a55-1cf7-44aa-b6a7-0d132a0bb29a"
      unitRef="usd">4500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1b5aa6d82a8b42f0a39f8d78d409bf1e_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjM5Mg_5e5e3f0f-ff41-43cc-95b0-5fffca49337d"
      unitRef="usd">4800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAxNQ_cfc8a7f5-7de0-46d5-81b1-87ef0942bdf9">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(420)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(420)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="border-bottom:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reclassified from&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net gain of $125 million in the third quarter of 2022; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net gain of $227 million in the first nine months of 2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net loss of $18 million in the third quarter of 2021; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net loss of $94 million in the first nine months of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $1 billion within the next 12 months into income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related short-term borrowings&#x2019; carrying value as of December 31, 2021 was $1.1&#160;billion. The related long-term debt carrying values as of October&#160;2, 2022 and December 31, 2021 were $726 million and $844 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0"
      unitRef="usd">528000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85"
      unitRef="usd">204000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4"
      unitRef="usd">558000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec"
      unitRef="usd">-59000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f"
      unitRef="usd">61000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="idfcb60d286f54359bc205ce60e7dcb0b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="ie5717b599b1c4477b6beedbcfeba21dc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ic8da0892f39d46c096dc066b6ec8a83e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC0yLTEtMS00Mjk2NzE_a28803af-4e40-48eb-b68f-7954fb1a17f1"
      unitRef="usd">-124000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i3186066be71c42b5a02001d1a9f376b0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC00LTEtMS00Mjk2NzE_04673e43-36a2-45b3-b7ca-236158b88b87"
      unitRef="usd">-5000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ic8da0892f39d46c096dc066b6ec8a83e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS0yLTEtMS00Mjk2NzE_0bf627f4-8dad-4eec-b99a-5aad854ec232"
      unitRef="usd">124000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i3186066be71c42b5a02001d1a9f376b0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS00LTEtMS00Mjk2NzE_445e562c-2eb9-43d1-b0fc-b2019b0639a5"
      unitRef="usd">5000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtNi0xLTEtNDI5Njcx_133301ad-6e91-4536-9645-63f6f0547007"
      unitRef="usd">680000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtOC0xLTEtNDI5Njcx_07a36bed-d910-4d73-a6c6-5fd6bc7522b9"
      unitRef="usd">177000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTAtMS0xLTQyOTY3MQ_28197c73-6bbb-446f-a947-8e733c8ed5e2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTItMS0xLTQyOTY3MQ_8fa38e40-5385-4021-9ea5-fd9e6bbd255e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2"
      unitRef="usd">78000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i144d47acfac140678093066f01a98ba7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee"
      unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i10da9f3fe31a4ae296e74063948663f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552"
      unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i4c6ddfb9327a4b028b11b10328f2ba51_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i8a2ed77de0ce405e8cf9e819442e6528_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e"
      unitRef="usd">25000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i4c6ddfb9327a4b028b11b10328f2ba51_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i8a2ed77de0ce405e8cf9e819442e6528_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="ia942bf711c884c0c8389c2c4658f859b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c"
      unitRef="usd">49000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i97507b074e0e4f6f92c18c2fd703b228_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4"
      unitRef="usd">19000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ia942bf711c884c0c8389c2c4658f859b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i97507b074e0e4f6f92c18c2fd703b228_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i1460ce67a1664a4886f261a31538b94c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktMi0xLTEtNDI5Njcx_d0a45c0d-3364-46a7-9fd4-57a6b63bf52e"
      unitRef="usd">-420000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i33dbb0a3d25e4ded9172ca71bd57e611_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktNC0xLTEtNDI5Njcx_b1341912-72e5-4de9-b371-e3fad6bff794"
      unitRef="usd">-74000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMi0xLTEtNDI5Njcx_96c0b094-7093-4d3c-91b6-849a99bc222f"
      unitRef="usd">-420000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNC0xLTEtNDI5Njcx_0bed8693-ae85-4b96-8618-be975923ee6b"
      unitRef="usd">-74000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNi0xLTEtNDI5Njcx_ce90d9e5-ce46-4ede-9dd4-d3cea269650a"
      unitRef="usd">1396000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtOC0xLTEtNDI5Njcx_24e61d1d-f7c7-46f8-9779-ec9d74a71fe3"
      unitRef="usd">453000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTAtMS0xLTQyOTY3MQ_f4b64b37-90c3-402a-baac-3d920218e6fd"
      unitRef="usd">647000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTItMS0xLTQyOTY3MQ_ab926219-d9a7-4b2b-bb7a-cd8b338b1a85"
      unitRef="usd">-21000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1"
      unitRef="usd">1339000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78"
      unitRef="usd">147000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876"
      unitRef="usd">872000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f"
      unitRef="usd">-314000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122"
      unitRef="usd">105000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b"
      unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i8154274534c145acaa81abeaebf413da_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66"
      unitRef="usd">100000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i4f7bbd963c984db8aa8dce0b7ebf2330_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i45883a91d50a47eb96c4f3afbd992dee_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItMi0xLTEtNDI5Njcx_e6218ca2-efe4-463d-9ce3-af6f1be6bb3d"
      unitRef="usd">-346000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ie3150d83c1054e43ac64649354bfd47a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItNC0xLTEtNDI5Njcx_d4c83559-1407-444f-99a6-6ba36c9f1d63"
      unitRef="usd">-6000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i45883a91d50a47eb96c4f3afbd992dee_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtMi0xLTEtNDI5Njcx_f3cec9d4-f77d-4580-b599-484f01f1a5a7"
      unitRef="usd">346000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ie3150d83c1054e43ac64649354bfd47a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtNC0xLTEtNDI5Njcx_3303e9d7-5cc1-4910-8497-2ac64d94653a"
      unitRef="usd">6000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctNi0xLTEtNDI5Njcx_ce613522-b2e6-449d-9bda-6bbc50ef4241"
      unitRef="usd">1613000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctOC0xLTEtNDI5Njcx_6ed77661-b985-4278-9f00-9b1b503b67b7"
      unitRef="usd">332000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTAtMS0xLTQyOTY3MQ_90670622-0649-4a76-bd2a-b31e91dfd5a3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTItMS0xLTQyOTY3MQ_7434b05a-74c7-4239-a3ea-997576f4353d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84"
      unitRef="usd">54000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i0e1a99b384254f579445b74f46691315_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac"
      unitRef="usd">95000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i8ab06e332e5e44b3a04235fe365d2da2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603"
      unitRef="usd">82000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i069ae598e0f0477282f60735e915b8af_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72"
      unitRef="usd">26000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i6bfd27b3218b487a9810f8d0eca2c8eb_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288"
      unitRef="usd">52000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i069ae598e0f0477282f60735e915b8af_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i6bfd27b3218b487a9810f8d0eca2c8eb_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="ibc254f3841504538bd25d1e598f7efcb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b"
      unitRef="usd">119000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i4a9ed02e04a84fd4a77116dcbcdb1d7a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78"
      unitRef="usd">66000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ibc254f3841504538bd25d1e598f7efcb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i4a9ed02e04a84fd4a77116dcbcdb1d7a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i50bf294318854802b0ca58dbe517a298_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtMi0xLTEtNDI5Njcx_72ec13bf-f3db-48f3-ae79-5c72c3f1d49f"
      unitRef="usd">-832000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ie1f316f885ed4d329752000102edb162_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtNC0xLTEtNDI5Njcx_3bc803cd-e2a3-4377-b12f-8e60922a30b1"
      unitRef="usd">-97000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad"
      unitRef="usd">1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0"
      unitRef="usd">1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMi0xLTEtNDI5Njcx_d76f42da-fb4e-446f-9ea5-f98760068047"
      unitRef="usd">-832000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNC0xLTEtNDI5Njcx_211174d9-e259-4f54-9f87-7cc752aad16c"
      unitRef="usd">-97000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNi0xLTEtNDI5Njcx_60eac3c4-32fd-43f6-8b03-4e76cadca988"
      unitRef="usd">3264000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtOC0xLTEtNDI5Njcx_9c90dcf1-6e88-4be7-b902-e170d48b4afa"
      unitRef="usd">683000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTAtMS0xLTQyOTY3MQ_1b6c0327-f807-478a-a8f0-0ac11991b5cb"
      unitRef="usd">1068000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTItMS0xLTQyOTY3MQ_9ae39430-7552-4461-b69f-37394ff1a54e"
      unitRef="usd">-204000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ia14b13073e4e4613b080addd6621f2f9_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjA2OA_f026d816-21ba-4298-ae94-80b4409b149b"
      unitRef="usd">125000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ib5b98292d9c1417a926a79b66406286a_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjEwMQ_232ef55a-df17-4a07-bff5-6d7121fc8917"
      unitRef="usd">227000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i3f6af82b6d024b0eafd8f31e35b20075_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjEzMA_00b6f1e3-d892-4989-b02f-826f2e3f30dd"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if474000c1ec5464d9c71367ad5ee9f35_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjE2Ng_2132382e-cb47-47e2-bf7b-1c05d8812b54"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i9029b150d0054adc95f1fb9398955ea9_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQ1MA_414d885d-4c33-403f-ac3c-25c36234155b"
      unitRef="usd">1000000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i34242284b9494732b030b9e714db61b6_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjUzNw_f550c1cc-d9e0-433c-9b85-97dfba0f5af6">P21Y</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DebtCurrent
      contextRef="i9f47fc0e281c43afac185ec01923d406_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQxOQ_9aae5aa1-d785-45c0-9fd8-1b0725c161a1"
      unitRef="usd">1100000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="i04751deef2cd46b99805e78bd859c289_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQwMA_4b6f72c5-9fc4-4062-9f4b-0216f3180deb"
      unitRef="usd">726000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i667311c49e1242729a0e2cfbeb12d37b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzI5ODUzNDg4NjQxMA_0aa6145a-716e-4cc5-b4c5-871106f0b925"
      unitRef="usd">844000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwMg_fd8f897f-a20a-4993-8ed1-d46b7514c2aa">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1.35pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes cumulative basis adjustments to our debt in fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0yLTEtMS00Mjk2NzE_7a699dba-090b-429c-97be-830060b328be"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi00LTEtMS00Mjk2NzE_8b7797cb-5d29-4e51-bc9a-fe4061f65802"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi02LTEtMS00Mjk2NzE_b214a9d8-54c0-47b4-925d-f554954019da"
      unitRef="usd">16000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi04LTEtMS00Mjk2NzE_339c5e19-4e13-4c0a-b6bc-eae3c491dace"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0xMC0xLTEtNDI5Njcx_ad1cfe24-ace5-4632-a12d-ed52b4cfc59e"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ie78e377fbf3a400abcae8b6bc76aaee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0xMi0xLTEtNDI5Njcx_871d629a-ede7-4190-8234-9e0a9387447c"
      unitRef="usd">0</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0yLTEtMS00Mjk2NzE_9a8f71b8-8682-4d0b-8e7c-5991fa04886e"
      unitRef="usd">2235000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC00LTEtMS00Mjk2NzE_c8b00395-4104-4122-8c5d-e836e1b09905"
      unitRef="usd">-330000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i2deeb47e16ff4718a05a44e5c5e4f7eb_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC02LTEtMS00Mjk2NzE_2dbcf426-809e-4b78-b3a1-2de9881a98d4"
      unitRef="usd">1061000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ibf9e5de858194ea3a1564e487b4e84b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC04LTEtMS00Mjk2NzE_e29d8cd7-34c4-4497-9fe5-877dba1f1d25"
      unitRef="usd">2233000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ibf9e5de858194ea3a1564e487b4e84b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0xMC0xLTEtNDI5Njcx_9a4b0453-32ad-4cf0-82f6-e020fe0c7ec1"
      unitRef="usd">16000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ibf9e5de858194ea3a1564e487b4e84b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0xMi0xLTEtNDI5Njcx_fc65ce9b-3231-438f-9f13-4d6a8fbcffbd"
      unitRef="usd">1154000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:DerivativeNetLiabilityPositionAggregateFairValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMzI5ODUzNDg4NDg5OA_00648238-4936-4188-87db-e9e8d880ec0a"
      unitRef="usd">595000000</us-gaap:DerivativeNetLiabilityPositionAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMTE1NQ_00fd5298-3b81-4d4c-9a2c-bf4219484fca"
      unitRef="usd">612000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <pfe:DerivativeNetReceivablePositionAggregateFairValue
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMTMzOQ_829855f5-86e5-4b8f-8998-83449a9689ea"
      unitRef="usd">1500000000</pfe:DerivativeNetReceivablePositionAggregateFairValue>
    <us-gaap:SecuritiesReceivedAsCollateral
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84Mi9mcmFnOmIwNWRiNzcyODFkYzQzZDRiMTMwZDEyNGE5ODY5OTFjL3RleHRyZWdpb246YjA1ZGI3NzI4MWRjNDNkNGIxMzBkMTI0YTk4Njk5MWNfMTM4NA_4c92a381-860e-4783-8803-99812d0b113c"
      unitRef="usd">1500000000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTI2_101e5d54-2a68-4542-89fd-1f986a87b1b8">Other Financial Information&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A.&lt;/span&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"&gt; Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Other Current Liabilities&lt;/span&gt;&lt;/div&gt;Other current liabilities includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $4.5&#160;billion as of October&#160;2, 2022 and $9.7&#160;billion as of December 31, 2021.</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTIz_9f8ee3ea-a157-4651-85ed-5781b4c7f2c1">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTI0_40f21c77-fedf-4e1b-a616-5de678747bee">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMi0yLTEtMS00Mjk2NzE_2cf9048e-f55d-4f1b-9ed5-4f4d88fd2af4"
      unitRef="usd">3159000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMi00LTEtMS00Mjk2NzE_1e6c9702-f723-4df1-980e-1a79a58d21ed"
      unitRef="usd">3641000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMy0yLTEtMS00Mjk2NzE_58afb1ba-5d01-4d2d-aec2-9ed872d216a3"
      unitRef="usd">4540000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfMy00LTEtMS00Mjk2NzE_2a378865-93ff-4238-bdcc-849371003c6a"
      unitRef="usd">4424000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNC0yLTEtMS00Mjk2NzE_bf764082-35c5-4f34-8b8b-297ae81dc986"
      unitRef="usd">1813000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNC00LTEtMS00Mjk2NzE_65d04817-85c6-42b6-ba56-e3e987025aab"
      unitRef="usd">994000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS0yLTEtMS00Mjk2NzE_024cc055-6b5e-4f81-9da0-c6acda341735"
      unitRef="usd">9513000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS00LTEtMS00Mjk2NzE_e4668477-5c06-4db4-abbd-1dbe4b47532b"
      unitRef="usd">9059000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi0yLTEtMS00Mjk2NzE_71e44f3a-392e-466e-875b-5da4ad8a675d"
      unitRef="usd">3327000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi00LTEtMS00Mjk2NzE_8bfa4640-17ef-44ef-ac97-dc7b2d8e9c11"
      unitRef="usd">939000000</us-gaap:InventoryNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8308f5a4b0dc4a5e84bd59beff89e949_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNDcz_f127770a-a27d-4e65-917f-4f67410669ad"
      unitRef="usd">4500000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id224ff09ffe74524973bc9034a6a86ee_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNDg5_5c561567-78c9-47c5-adb2-8e5054e02c53"
      unitRef="usd">9700000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDkz_df1593e9-f5c9-4896-8f9b-7bc2e47b5aac">Identifiable Intangible Assets&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and for IPR&amp;amp;D, is partially offset by an impairment (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, October&#160;2, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Additions relate to our acquisition of Arena. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Other represents the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc4_9f6cd26f-2f43-41df-be6b-124970d420fc">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and for IPR&amp;amp;D, is partially offset by an impairment (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTEy_0d8eddb9-6091-4834-ade4-d0aa8d58a3a9">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and for IPR&amp;amp;D, is partially offset by an impairment (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2c782fb34650411c8db8781a876e6df3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC0yLTEtMS00Mjk2NzE_8f7936a4-ab5b-4073-83d5-5c6473590da8"
      unitRef="usd">72818000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2c782fb34650411c8db8781a876e6df3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC00LTEtMS00Mjk2NzE_c792f2a0-2d7f-4a21-bdc3-e14c516a3232"
      unitRef="usd">55309000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2c782fb34650411c8db8781a876e6df3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC02LTEtMS00Mjk2NzE_f67c1116-a810-4268-8ac8-f725d87845fd"
      unitRef="usd">17509000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9991d2e7245d461895c706bb1a8bece9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC04LTEtMS00Mjk2NzE_82fbfc77-5764-409b-a76e-3305d0021e03"
      unitRef="usd">73346000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9991d2e7245d461895c706bb1a8bece9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC0xMC0xLTEtNDI5Njcx_3fdb39fe-ad3d-4a69-87cc-cd4e141ebee5"
      unitRef="usd">53732000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9991d2e7245d461895c706bb1a8bece9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNC0xMi0xLTEtNDI5Njcx_ca6db337-e5e4-43f1-8a6a-3d5d4bdd38fd"
      unitRef="usd">19614000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS0yLTEtMS00Mjk2NzE_97209eab-4c08-4b19-a94a-d0caee99221a"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS00LTEtMS00Mjk2NzE_7c5f2868-3d5f-42c6-8625-327be518316d"
      unitRef="usd">832000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib5a6dadaa6fc42c18c2c61a64b2a1773_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS02LTEtMS00Mjk2NzE_7a9f0ecb-cc84-4bf3-b25b-37af59cfc7da"
      unitRef="usd">90000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i749f749980d34e25acc4fb7966c17205_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS04LTEtMS00Mjk2NzE_a7e76a47-e498-4f90-ab37-bf1f8143ee08"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i749f749980d34e25acc4fb7966c17205_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS0xMC0xLTEtNDI5Njcx_74c9297c-2d46-429c-95fb-b3e228d5c8d2"
      unitRef="usd">807000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i749f749980d34e25acc4fb7966c17205_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNS0xMi0xLTEtNDI5Njcx_eed4af36-fb87-4f34-b627-d9d9f35cb6ce"
      unitRef="usd">115000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i203cdb0ebc574f27943dd1e51d1b1277_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi0yLTEtMS00Mjk2NzE_82c7c046-e869-49e3-8227-e50de6739bd8"
      unitRef="usd">2296000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i203cdb0ebc574f27943dd1e51d1b1277_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi00LTEtMS00Mjk2NzE_9d6c4387-41d9-4f9e-8eb9-66bd11fd77b9"
      unitRef="usd">1373000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i203cdb0ebc574f27943dd1e51d1b1277_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi02LTEtMS00Mjk2NzE_a71f4544-c91c-4eeb-adad-28872325d673"
      unitRef="usd">923000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i912798045f5b4639aa7284fc67e728b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi04LTEtMS00Mjk2NzE_40a59631-48f0-4187-bea7-e6dfda63e9f1"
      unitRef="usd">2284000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i912798045f5b4639aa7284fc67e728b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi0xMC0xLTEtNDI5Njcx_0f6d8b58-780b-4498-bd12-ecae47beab69"
      unitRef="usd">1299000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i912798045f5b4639aa7284fc67e728b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfNi0xMi0xLTEtNDI5Njcx_0bf5fb89-a826-4bcd-a2d2-6bed800f97cb"
      unitRef="usd">985000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC0yLTEtMS00Mjk2NzE_356e27c7-d227-420c-97b7-07ec8ccd4ac4"
      unitRef="usd">76036000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC00LTEtMS00Mjk2NzE_3bce7369-d347-43b7-9ff4-61e7fa9a5dd1"
      unitRef="usd">57514000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC02LTEtMS00Mjk2NzE_39392511-b500-415f-9d7f-bdade00807a3"
      unitRef="usd">18522000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC04LTEtMS00Mjk2NzE_37c0c989-4859-4451-8118-bdd52baefc66"
      unitRef="usd">76552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC0xMC0xLTEtNDI5Njcx_006ae5f7-440f-49f4-81b3-eb3ddc31265e"
      unitRef="usd">55838000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfOC0xMi0xLTEtNDI5Njcx_b367ab98-51a1-4b3c-9f2c-2af57ce3456a"
      unitRef="usd">20714000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8dd6baec7c42411ea48eebdb0f2f23db_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtMi0xLTEtNDI5Njcx_437b2898-a95d-468e-b1f8-2a76cef73115"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8dd6baec7c42411ea48eebdb0f2f23db_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtNi0xLTEtNDI5Njcx_ff24a3b1-97aa-4a75-b9c7-eaf60e31d9bd"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9b292fac08314732827dde98a31e18b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtOC0xLTEtNDI5Njcx_2fc241b4-a5cf-4786-8c80-cd0524542233"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9b292fac08314732827dde98a31e18b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTAtMTItMS0xLTQyOTY3MQ_f905d8a8-20a5-4efa-ae38-a9d2ce4f3547"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMi0xLTEtNDI5Njcx_0ca3d8fc-7f0e-4e03-aace-8bacdd754f47"
      unitRef="usd">7829000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtNi0xLTEtNDI5Njcx_9566c9fd-ec55-4d73-93d7-4a3c4e2174e6"
      unitRef="usd">7829000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if4f31c2acdf14f1cb842ad2f9b51b800_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtOC0xLTEtNDI5Njcx_5f924545-7cdf-419a-a41b-dab24a74c232"
      unitRef="usd">3092000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if4f31c2acdf14f1cb842ad2f9b51b800_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMTItMS0xLTQyOTY3MQ_6b832ab6-88f2-4aab-a51a-d9475eb4d0ef"
      unitRef="usd">3092000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia27c96bd99bc47d68e917e7d12a78b77_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMi0xLTEtNDI5Njcx_31a4bf64-afc9-420a-8aea-da78984567bc"
      unitRef="usd">972000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia27c96bd99bc47d68e917e7d12a78b77_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItNi0xLTEtNDI5Njcx_a1142993-e425-47ab-a0d1-446a18afad15"
      unitRef="usd">972000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i54cb4a7821fb491f8936f9f3177f14a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItOC0xLTEtNDI5Njcx_77fa5bda-2010-4cea-bb57-14533aeb9398"
      unitRef="usd">513000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i54cb4a7821fb491f8936f9f3177f14a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMTItMS0xLTQyOTY3MQ_1bfb8b75-ee82-4190-b19d-033448001fcf"
      unitRef="usd">513000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtMi0xLTEtNDI5Njcx_bcf68a16-0674-417e-8e07-3e235d416181"
      unitRef="usd">9629000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtNi0xLTEtNDI5Njcx_eead4c77-d39a-44be-986c-76ec9ac478ed"
      unitRef="usd">9629000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtOC0xLTEtNDI5Njcx_b4648c42-d5ad-44fb-99d4-d48bde024a1e"
      unitRef="usd">4432000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTMtMTItMS0xLTQyOTY3MQ_6c98f02b-5bcc-48e6-bafc-3d576cda52e6"
      unitRef="usd">4432000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16"
      unitRef="usd">85665000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40"
      unitRef="usd">57514000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d"
      unitRef="usd">28151000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c"
      unitRef="usd">80984000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099"
      unitRef="usd">55838000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470"
      unitRef="usd">25146000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA5_1295e007-97f0-4488-b456-fb7016bba7d7">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, October&#160;2, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Additions relate to our acquisition of Arena. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Other represents the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMi0xMC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
      unitRef="usd">49208000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957"
      unitRef="usd">1029000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959"
      unitRef="usd">-797000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNS0xMC0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
      unitRef="usd">49441000000</us-gaap:Goodwill>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTgz_166228f8-33e7-49af-b3b6-ec1107830c58">Pension and Postretirement Benefit Plans&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of net periodic benefit cost/(credit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(983)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The third quarter of 2022 mainly reflects interim actuarial remeasurement gains, primarily driven by an increase in the discount rate, partially offset by unfavorable plan asset performance. The first nine months of 2022 mainly reflects interim actuarial remeasurement losses, primarily driven by unfavorable plan asset performance, partially offset by gains due to an increase in the discount rate. In the third quarter and first nine months of 2021, mainly reflects interim actuarial remeasurement gains, primarily due to favorable plan asset performance and an increase in the discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost/(credit) other than the service cost component are primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended October 2, 2022, we contributed $207 million, $127 million, and $16 million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTgy_c48b21bb-498c-4d53-bceb-02e33ce5ce53">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of net periodic benefit cost/(credit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(983)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="39" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;(a)The third quarter of 2022 mainly reflects interim actuarial remeasurement gains, primarily driven by an increase in the discount rate, partially offset by unfavorable plan asset performance. The first nine months of 2022 mainly reflects interim actuarial remeasurement losses, primarily driven by unfavorable plan asset performance, partially offset by gains due to an increase in the discount rate. In the third quarter and first nine months of 2021, mainly reflects interim actuarial remeasurement gains, primarily due to favorable plan asset performance and an increase in the discount rate.</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS0yLTEtMS00Mjk2NzE_7818a47b-c3eb-4e61-9ed2-1081514c2a11"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS00LTEtMS00Mjk2NzE_6d4b3d89-bee1-416d-951d-3d1810b853a3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS02LTEtMS00Mjk2NzE_20778a52-520e-46f5-9cf0-a66c36659e2b"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS04LTEtMS00Mjk2NzE_b84db1b8-7fde-405d-aa40-5ca078f48f15"
      unitRef="usd">32000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS0xMC0xLTEtNDI5Njcx_3f4cb024-6429-4440-b6f6-d1446cca8bd6"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNS0xMi0xLTEtNDI5Njcx_9e22f48a-5754-457d-a7b5-408cb3a78779"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi0yLTEtMS00Mjk2NzE_94516207-227c-45c6-8adc-7a6c9f31609a"
      unitRef="usd">151000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi00LTEtMS00Mjk2NzE_63166281-094d-4849-8701-6a31a7352be1"
      unitRef="usd">114000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi02LTEtMS00Mjk2NzE_07b0b843-ce58-4d84-a04a-db3aedaababa"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi04LTEtMS00Mjk2NzE_7d29da5e-0144-485f-a76d-02bf1022bd44"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi0xMC0xLTEtNDI5Njcx_e52bde81-0b49-4d5b-8c48-baa3a630fedd"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNi0xMi0xLTEtNDI5Njcx_5348ab7e-522a-4f21-a937-0b69429a127c"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy0yLTEtMS00Mjk2NzE_d58bc246-47f5-41aa-a635-b06a25150b88"
      unitRef="usd">195000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy00LTEtMS00Mjk2NzE_db7958f1-d6a4-49d0-adff-293d341ac4e5"
      unitRef="usd">261000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy02LTEtMS00Mjk2NzE_05ee9e29-20b3-4d66-b7a8-1fc3e488f1de"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy04LTEtMS00Mjk2NzE_5a526747-d9dd-4a1f-b158-5b41bf28529b"
      unitRef="usd">83000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy0xMC0xLTEtNDI5Njcx_a43adeb6-3c95-4aa4-acff-9240fc44bdd9"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfNy0xMi0xLTEtNDI5Njcx_dba435de-3e0c-4cfd-bc30-cd59b7ef264f"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC0yLTEtMS00Mjk2NzE_138acbaa-c129-4bce-892d-e9579bf2887f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC00LTEtMS00Mjk2NzE_d635144e-bbef-4700-889f-8c5fe31daae5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC02LTEtMS00Mjk2NzE_ea4b6a40-a749-4bda-a10b-856e2fc2a12d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC04LTEtMS00Mjk2NzE_e41cc862-600d-4914-8fe2-91ad030bc840"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC0xMC0xLTEtNDI5Njcx_18a6f04f-601c-4f7f-aa73-44789f726d62"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOC0xMi0xLTEtNDI5Njcx_70fa235c-c75d-4dc0-90d5-f41fee2571f2"
      unitRef="usd">-39000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0yLTEtMS00Mjk2NzE_09ed946a-8297-4206-96f6-5ac122523c37"
      unitRef="usd">193000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS00LTEtMS00Mjk2NzE_1f004768-3046-4785-bc33-1afae8b0ea63"
      unitRef="usd">836000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS02LTEtMS00Mjk2NzE_911b960f-8d0b-4b2f-9c38-e805e112bc95"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS04LTEtMS00Mjk2NzE_d800e503-a11e-4212-9c70-e64fafc7d253"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMC0xLTEtNDI5Njcx_68f6d789-f455-46c8-a3ed-e2cdffa43f1b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMi0xLTEtNDI5Njcx_e6e616e8-ff43-412f-bc24-145f96133e33"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtMi0xLTEtNDI5Njcx_d5a51b2b-db2b-4103-b4b4-b9efaeff5649"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtNC0xLTEtNDI5Njcx_03307c74-680a-4137-a0f5-bf94b26c7a21"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtNi0xLTEtNDI5Njcx_2776a96f-98fb-46e7-b487-e2d2737bc725"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtOC0xLTEtNDI5Njcx_e5159c4b-e573-4384-995b-5df7b5c627da"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtMTAtMS0xLTQyOTY3MQ_10b1ed69-1324-4f0e-b8b0-19705b81af4e"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTAtMTItMS0xLTQyOTY3MQ_577d14f7-f731-44bc-ac3e-42d7b49b4bec"
      unitRef="usd">64000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtMi0xLTEtNDI5Njcx_5534810e-1d4b-4267-8fc9-f3fa09393afc"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtNC0xLTEtNDI5Njcx_e4f97bc4-572c-4c05-be61-185aeea3db0d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtNi0xLTEtNDI5Njcx_9a6c99ba-45e7-4ac4-a043-ebdc371a6a25"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtOC0xLTEtNDI5Njcx_3f5cc810-19cb-4b6c-bf30-ffcb29270b19"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtMTAtMS0xLTQyOTY3MQ_0c576024-a217-4a9a-8dc7-199c7686a2a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTEtMTItMS0xLTQyOTY3MQ_b7660f12-d303-483e-ad64-23626d4dc913"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItMi0xLTEtNDI5Njcx_61d3b7aa-2c52-44f5-a5e5-7dccbef23931"
      unitRef="usd">-235000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9dd77f7cff81496bae6114bdfbd9af24_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItNC0xLTEtNDI5Njcx_fa100044-1325-46ca-b2a6-8ddd16a7432a"
      unitRef="usd">-983000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifd9c2206ab454e6682f81beb64cf8156_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItNi0xLTEtNDI5Njcx_b0955dcd-ddff-4cdc-9ea8-9105cb2d8f79"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie5e1c93a002145d19e6d53fb72b61ec8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItOC0xLTEtNDI5Njcx_d3181781-d62d-4c29-bef7-840d02175bf7"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i99779a56a33a44a792965b1ffbf33990_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItMTAtMS0xLTQyOTY3MQ_912fc87d-97aa-4582-80f4-490320f23f92"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ife6ac2645a9946a49e832861c0188d59_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTItMTItMS0xLTQyOTY3MQ_a1fe4f3f-ebdf-45d7-bfbf-42a8f50b8839"
      unitRef="usd">-96000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktMi0xLTEtNDI5Njcx_61c08df5-b01f-4e5d-9d15-0aaf97b46a06"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktNC0xLTEtNDI5Njcx_f492c8a4-fea1-4fb7-bca6-2f89fbdb4f39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktNi0xLTEtNDI5Njcx_73ddf4b6-f16b-4c3d-a451-3a906da6e7b8"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktOC0xLTEtNDI5Njcx_2d205667-5012-42eb-a405-d6cc116a845b"
      unitRef="usd">98000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktMTAtMS0xLTQyOTY3MQ_e6c364fc-3298-49b2-b438-bd4863f9384f"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMTktMTItMS0xLTQyOTY3MQ_acd0818c-c14c-4f9d-880c-c9b964e9c68a"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtMi0xLTEtNDI5Njcx_cbb93d32-1d87-4fb4-b887-bb5b823aa7b3"
      unitRef="usd">387000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtNC0xLTEtNDI5Njcx_ec244754-155b-4873-82cc-9baec267583c"
      unitRef="usd">341000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtNi0xLTEtNDI5Njcx_d69307ea-b771-4d0a-8ecb-12e2357a0ac8"
      unitRef="usd">121000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtOC0xLTEtNDI5Njcx_5f291a99-f338-4956-b77e-a00cdb799336"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtMTAtMS0xLTQyOTY3MQ_1c2b8eea-c8f1-45bd-a6fa-3872b37e2c85"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjAtMTItMS0xLTQyOTY3MQ_b1df60ee-22a4-4fb8-9df4-60cdac8c402c"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtMi0xLTEtNDI5Njcx_e2f48177-f370-4641-8a2e-e11b6d1e8047"
      unitRef="usd">685000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtNC0xLTEtNDI5Njcx_fcf73a8d-14e3-4917-9e5a-becc1f62f91f"
      unitRef="usd">782000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtNi0xLTEtNDI5Njcx_149ff35a-5a19-4f52-ba29-76825fee84a4"
      unitRef="usd">229000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtOC0xLTEtNDI5Njcx_aa77c4fd-f678-4c36-908a-11ed05aeb487"
      unitRef="usd">246000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtMTAtMS0xLTQyOTY3MQ_1cfd3c00-f58a-4581-83aa-13e5d22fba73"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjEtMTItMS0xLTQyOTY3MQ_f66e996a-b9db-43cc-b6df-7bf7d308eb3f"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItMi0xLTEtNDI5Njcx_2e59fd02-9d7c-4c00-a6c7-d6aacaa9353c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItNC0xLTEtNDI5Njcx_b3985f68-c6e2-4ca5-8e37-8fa17d175d18"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItNi0xLTEtNDI5Njcx_f8170cdc-f8cc-4f6c-9e48-31234a18d141"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItOC0xLTEtNDI5Njcx_5a7fcab5-54d5-4cfb-a0be-326b2915427b"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItMTAtMS0xLTQyOTY3MQ_a459c139-76a1-4dc8-9e7e-b9a9341a3086"
      unitRef="usd">-99000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjItMTItMS0xLTQyOTY3MQ_89f13b55-3512-4a01-b5cb-dc138793f79e"
      unitRef="usd">-116000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMi0xLTEtNDI5Njcx_e4c0ad7d-28f7-4dad-9153-c0c4f47032a1"
      unitRef="usd">-231000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNC0xLTEtNDI5Njcx_4142aa1c-bf9b-4904-9c6e-b7c56de66c64"
      unitRef="usd">881000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNi0xLTEtNDI5Njcx_0afa9a43-daf4-408b-9916-d5dd42011727"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtOC0xLTEtNDI5Njcx_7cece672-8cf3-429c-83fa-1158c7aa755c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTAtMS0xLTQyOTY3MQ_68ce4977-b848-4e99-96dd-167dd7408585"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTItMS0xLTQyOTY3MQ_47c50bf9-f17a-4da7-b80f-308b9a10ebb6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtMi0xLTEtNDI5Njcx_d90eff6b-0aaa-4cbd-88c4-f0345ec1d25f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtNC0xLTEtNDI5Njcx_a5f90752-1970-422e-ac2b-6d8e630796ea"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtNi0xLTEtNDI5Njcx_238278ba-4cd2-4271-a465-88adefa1d6ca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtOC0xLTEtNDI5Njcx_b3196231-565a-4331-91bd-7f9d1545bc20"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtMTAtMS0xLTQyOTY3MQ_a233a22e-8ad0-4e97-bd1c-77c1fa9b6256"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjQtMTItMS0xLTQyOTY3MQ_85f9382d-4982-474f-aa96-72460dd5b52a"
      unitRef="usd">64000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtMi0xLTEtNDI5Njcx_ba516686-b11b-4962-b69a-61ce4ed80c90"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtNC0xLTEtNDI5Njcx_8d52520b-8a62-4a00-a3be-6f0bbb30f9c0"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtNi0xLTEtNDI5Njcx_546f5958-c439-48fa-b7fd-3ff6813e0aad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtOC0xLTEtNDI5Njcx_5e88a948-d76a-4424-b87d-5ae8b343fb49"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtMTAtMS0xLTQyOTY3MQ_2f936037-afd3-446c-8821-e34733411bcd"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjUtMTItMS0xLTQyOTY3MQ_35fc8ddc-3cb9-49dd-9d9f-f55cf4908849"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtMi0xLTEtNDI5Njcx_10896ca5-c82b-4cbf-9d6b-5e4589d3f3cc"
      unitRef="usd">-57000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifca153109e8041f9bc16cad0a7b3967a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtNC0xLTEtNDI5Njcx_59af847b-a40f-4a94-8b3c-be3fba79a164"
      unitRef="usd">-1312000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtNi0xLTEtNDI5Njcx_a4ca2f98-479d-4982-9c37-cefc6e097e8b"
      unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9ba175125826473eb8da8d591f564f11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtOC0xLTEtNDI5Njcx_84535253-0186-44d9-bf23-138c26f581db"
      unitRef="usd">-40000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtMTAtMS0xLTQyOTY3MQ_64ae2cf3-775d-447c-92ce-2da7a26f864d"
      unitRef="usd">-106000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i48571b86b73c4443b1499b37e56fcb86_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjYtMTItMS0xLTQyOTY3MQ_c0ea89fe-c0eb-4677-ae9d-dda44f0d7eb2"
      unitRef="usd">-160000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfMzkx_ac6158fd-83f2-49bf-bd74-d403dce28b7e"
      unitRef="usd">207000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="id61811bca9d04331971de3e3fc7d76e4_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfMzk1_f95da6f9-7c7a-4e21-b9c5-67ae683a05f2"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i0b5611f3e72749f2988832915a5d1ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNDAz_5af98571-4225-42cf-be93-3baf55502381"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjM1_3bff5b0b-b17c-4c22-8830-2a253e8939ab">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the detailed calculation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;EPS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common-share equivalents: stock options and stock issuable under employee compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ4_b3767ddc-14e9-41a1-a1d5-6dfd0601712d">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the detailed calculation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;EPS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common-share equivalents: stock options and stock issuable under employee compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi0yLTEtMS00Mjk2NzE_d9bdf607-b2c7-4efb-bf89-2274cf52925d"
      unitRef="usd">8630000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi00LTEtMS00Mjk2NzE_731c258f-20a9-4be3-a466-6909c636ae72"
      unitRef="usd">8159000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi02LTEtMS00Mjk2NzE_1aa0bf38-02c5-41e3-9542-cb74e9e5864b"
      unitRef="usd">26373000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNi04LTEtMS00Mjk2NzE_eadabe85-c46a-423f-b69f-03f7343c07e0"
      unitRef="usd">18834000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy0yLTEtMS00Mjk2NzE_b26de5cd-0752-44b3-bcf9-c31fe4fe5bea"
      unitRef="usd">-21000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy00LTEtMS00Mjk2NzE_f6aa8860-e07d-40e5-8bf6-13a1c8c4372d"
      unitRef="usd">-13000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy02LTEtMS00Mjk2NzE_856e4129-e341-4d20-9abc-8dafc7c44156"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfNy04LTEtMS00Mjk2NzE_a413be57-7984-4da2-8432-8482b7d0d5ea"
      unitRef="usd">-248000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtMi0xLTEtNDI5Njcx_f80d8650-5ff9-48dc-aa78-00175849dead"
      unitRef="usd">8608000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtNC0xLTEtNDI5Njcx_039bd9e3-8eeb-447b-90d1-ec505977c39a"
      unitRef="usd">8146000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtNi0xLTEtNDI5Njcx_a6e6a6bb-4ca6-4523-8d12-6d3145e1220c"
      unitRef="usd">26378000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTAtOC0xLTEtNDI5Njcx_ff7bc784-321a-4cde-bbba-74f8be89181d"
      unitRef="usd">18586000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItMi0xLTEtNDI5Njcx_1f595bad-c25d-44d0-901d-c74a79bd0a11"
      unitRef="usd">8630000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItNC0xLTEtNDI5Njcx_07f5add2-dbed-4b54-ad45-135516acaafe"
      unitRef="usd">8159000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItNi0xLTEtNDI5Njcx_135f927d-6812-49a1-a318-ea69bd4e606f"
      unitRef="usd">26373000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTItOC0xLTEtNDI5Njcx_f5cc8df5-d2ea-43d6-ba7b-219cacfa9080"
      unitRef="usd">18834000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtMi0xLTEtNDI5Njcx_d08284ef-c87c-439d-9051-e1f5101df548"
      unitRef="usd">-21000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtNC0xLTEtNDI5Njcx_6d5de488-db7b-44ce-971c-6d7338daeb32"
      unitRef="usd">-13000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtNi0xLTEtNDI5Njcx_2331daca-4921-4f4a-8994-2e6f375a1391"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTMtOC0xLTEtNDI5Njcx_f4407f1c-7dfd-44ba-870f-a5ef94a232ca"
      unitRef="usd">-248000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtMi0xLTEtNDI5Njcx_18600809-8d5c-4442-9031-cfccba0225f8"
      unitRef="usd">8608000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtNC0xLTEtNDI5Njcx_c59f80fd-6bb0-4ea5-ab81-6ec578a29048"
      unitRef="usd">8146000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtNi0xLTEtNDI5Njcx_64dbf22f-b866-4242-a617-b9514c8187d3"
      unitRef="usd">26378000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTQtOC0xLTEtNDI5Njcx_f9aabd2e-d233-453c-818b-70dbbadc1578"
      unitRef="usd">18586000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtMi0xLTEtNDI5Njcx_e39187ea-0aba-4412-a3a1-de7fd27cb46d"
      unitRef="shares">5607000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtNC0xLTEtNDI5Njcx_da641e26-9461-4303-a760-b0c9f2f5063b"
      unitRef="shares">5609000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtNi0xLTEtNDI5Njcx_e2f09dbf-7fbd-4e14-85c0-9a960721a8fb"
      unitRef="shares">5606000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTYtOC0xLTEtNDI5Njcx_6488a65f-0189-4e14-adb2-191d8c4a0047"
      unitRef="shares">5597000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctMi0xLTEtNDI5Njcx_19aa2c28-dcf4-4550-b2d7-0387b06dcbb0"
      unitRef="shares">111000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctNC0xLTEtNDI5Njcx_fb09938e-91c2-4935-ad04-ac7b07cf1595"
      unitRef="shares">116000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctNi0xLTEtNDI5Njcx_e568f270-dcbe-4887-97b0-f03e1536430c"
      unitRef="shares">124000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTctOC0xLTEtNDI5Njcx_ca341c81-468b-4e7d-9613-43e41ef5794e"
      unitRef="shares">91000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtMi0xLTEtNDI5Njcx_a0eb934e-9638-4dbe-a3cc-9d182105ed32"
      unitRef="shares">5718000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtNC0xLTEtNDI5Njcx_3aeab3f9-33a6-4a93-b31e-a09d575bd5c9"
      unitRef="shares">5725000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtNi0xLTEtNDI5Njcx_10502147-b493-4635-8a7a-59d01b94ecfa"
      unitRef="shares">5729000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTgtOC0xLTEtNDI5Njcx_6a812a9e-b1b1-44bd-9c15-b7ef80dc5e71"
      unitRef="shares">5688000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktMi0xLTEtNDI5Njcx_4ec007b4-6ac4-497a-8dec-4da658597588"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNC0xLTEtNDI5Njcx_65a1690b-56f3-43a3-ba0b-a7b1b251e5f2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNi0xLTEtNDI5Njcx_0a9e4766-78e0-4f4d-a516-d8ff1d77c48e"
      unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktOC0xLTEtNDI5Njcx_d3fed0bf-d915-4612-8a1c-f7389bce1827"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfNDM0MjM_8202cf90-9c0c-418b-82e5-ade76e1921c6">Contingencies and Certain Commitments&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5B.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our legal contingencies include, but are not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#x2019;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A1. Legal Proceedings&#x2013;&#x2013;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In November 2022, BMS received permission to appeal the High Court&#x2019;s decision. Additional challenges remain pending in other jurisdictions. Also, for example, in July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty infringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or BioNTech in other jurisdictions in the future. In addition, in October 2022, Accord Healthcare Ltd. brought suit in the U.K. against the Regents of the University of California challenging the validity of the U.K. patent covering the active ingredient in Xtandi, which expires in 2028. Adverse decisions in these matters could have a material adverse effect on our results of operations.&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office. In addition, another patent was challenged in federal court in Delaware; and that case was settled in September 2021 on terms not material to the company. Other challenges to pneumococcal vaccine patents remain pending at the Patent Trial and Appeal Board and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor&#x2019;s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actions In Which We Are The Plaintiff&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Xeljanz (tofacitinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we brought a separate patent infringement action against MSN Laboratories Private Ltd. (MSN) asserting the infringement and validity of our compound patent covering the active agreement that was challenged by MSN in its ANDAs seeking approval to market generic versions of tofacitinib immediate release tablets (5 mg, 10 mg) and oral solution 1 mg/mL. In August 2022, we settled our action against MSN on terms not material to us.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inlyta (axitinib)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ibrance (palbociclib)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various U.S. federal courts, asserting the validity and infringement of the patents challenged by the generic companies. We have settled with one of these generic companies on terms not material to us, and we dismissed the patent infringement actions relating to the crystalline form of patent, the composition of matter patent expiring in 2023, the method of use patent, and the tablet formulation patent against the generic companies that had challenged these patents. The composition of matter patent expiring in 2027 remains in suit. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eucrisa&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Braftovi (encorafenib)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, a generic company notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Braftovi. The company asserts the invalidity and non-infringement of, among others, a method of use patent expiring in 2033. In September 2022, we brought a patent infringement action against the generic company in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the method of use patent expiring in 2033.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Mektovi (binimetinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in August 2022, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies assert the invalidity and non-infringement of two method of use patents expiring in 2030, a method of use patent expiring in 2031, two method of use patents expiring in 2033, and a product by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of all six patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actions in Which We are the Defendant&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia &amp;amp; Upjohn Co. LLC, our wholly owned subsidiary, alleging that Comirnaty infringes U.S. Patent No. 11,246,933, which was issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a second complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia &amp;amp; Upjohn Co. LLC, BioNTech and BioNTech Manufacturing GmbH, alleging that Comirnaty infringes U.S. Patent No. 11,382,979, which was issued in July 2022, and seeking unspecified monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes three U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring only after March 7, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes two European patents. In September 2022, ModernaTX filed patent infringement actions in the U.K and in the Netherlands against Pfizer Inc. and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, on the same two patents. In its complaints, Moderna stated that it is seeking damages for alleged infringement occurring only after March 7, 2022. In the U.K., Pfizer and BioNTech have brought an action against ModernaTX seeking to revoke these European patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Paxlovid&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, Enanta Pharmaceuticals, Inc. filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes U.S.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patent No. 11,358,953, which was issued in June 2022, and seeking unspecified monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Matters Involving Pfizer and its Collaboration/Licensing Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#x2019; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#x2019;s decision. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts seeking a judgment of non-infringement for the following three patents relating to Comirnaty: U.S. Patent Nos. 11,135,312, 11,149,278, and 11,241,493. Outside of the U.S., in the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A2. Legal Proceedings&#x2013;&#x2013;Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asbestos&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#x2019; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, the District Court dismissed the direct purchaser plaintiffs&#x2019; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#x2019; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs appealed the District Court&#x2019;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EpiPen (Direct Purchaser)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its current and former affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants&#x2019; motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint. In August 2022, the District Court granted Pfizer&#x2019;s motion to dismiss the complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nexium 24HR and Protonix&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Mississippi Attorney General Government Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Zantac &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson &amp;amp; Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson &amp;amp; Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, asserting a consolidated consumer class action alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#x2019; sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Chantix&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer&#x2019;s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A3. Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Monsanto-Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp;amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#x2019;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#x2019;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#x2019;s indemnification obligations relating to Former Monsanto&#x2019;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#x2019;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#x2019;s and New Monsanto&#x2019;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#x2019;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#x2019;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as, Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency and/or New Jersey Department of Environmental Protection to perform remedial design, removal and remedial actions, and related environmental remediation activities at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#x2019; motions to dismiss and dismissed all of plaintiffs&#x2019; claims. In January 2022, the Court of Appeals reversed the District Court&#x2019;s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals&#x2019; decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allergan Complaint for Indemnity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Viatris Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company&#x2019;s current and former officers, directors and employees are named as defendants. The complaint alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A4. Legal Proceedings&#x2013;&#x2013;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Greenstone Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;U.S. Department of Justice Antitrust Division Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;State Attorneys General and Multi-District Generics Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020. The Multi-District Litigation also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subpoena &amp;amp; Civil Investigative Demand relating to Tris Pharma/Quillivant XR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We responded to that subpoena in full and have had no communication with the SDNY in connection with the subpoena since June 2019. Additionally, in September 2020,&#x202f;we received a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Civil Investigative Demand (CID)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from the Texas Attorney General&#x2019;s office&#x202f;seeking records of a similar nature to those requested by the SDNY. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are producing records in response to this request.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Inquiries relating to Meridian Medical Technologies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we received a CID from the U.S. Attorney&#x2019;s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#x2019;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice/SEC Inquiry relating to Russian Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, we received an informal request from the  U.S. Department of Justice&#x2019;s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#x2019;s FCPA Unit. We have produced records pursuant to these requests. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; above for information regarding a government investigation related to Docetaxel marketing practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice Inquiries relating to India Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#x2019;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice/SEC Inquiry relating to China Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#x2019;s FCPA Unit. We have produced records pursuant to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Zantac&#x2013;&#x2013;State of New Mexico and Mayor and City Council of Baltimore Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&#x2013;&#x2013;Product Litigation&#x2013;&#x2013;Zantac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in those jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Inquiries relating to Biohaven&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2022, the U.S. Department of Justice's Commercial Litigation Branch and the U.S. Attorney&#x2019;s Office for the Western District of New York issued a CID relating to Biohaven. The CID seeks records and information related to, among other things, engagements with health care professionals and co-pay coupons cards. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We are producing records in response to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of October&#160;2, 2022, the estimated fair value of these indemnification obligations is not material to Pfizer. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the March 2022 indemnity provided by Pfizer to GSK in connection with the issuance of notes by the Consumer Healthcare JV. In conjunction with the completion of GSK&#x2019;s demerger transactions in July 2022, GSK&#x2019;s guarantee and our related indemnification of GSK&#x2019;s guarantee were terminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, each of Viatris and Pfizer has agreed to assume, and to indemnify the other for, liabilities arising out of certain matters. Also, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection, includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Contingent Consideration for Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1E &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMzI0OQ_8070eb51-b2e5-47dc-ab9f-efcf9af8ff36"
      unitRef="usd">1000000</pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ibfa472f98c9c4c3ba6c39332849653eb_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDQ4NA_a7388ef5-1101-4a87-a6ea-05998584f851"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i7ec7a704d40b402d8dd76af6c1782133_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDQ5NQ_31a1db9a-d0d4-44ec-8fc0-c982ae2f35eb"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="iad227400e764448bb7ce0ca5ce1db320_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDUwNQ_b808bf61-5527-45c8-b305-8c6d25268c8b"
      unitRef="patent">6</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="i91598b6cfce147ed85f80c515a585148_D20220901-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTA5OTUxMTcwMDUxMw_e8da88cd-0f81-4c5e-aeaa-840f076365dd"
      unitRef="patent">2</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <pfe:GainContingencyNumberofDefendants
      contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTQ3OTk_241978bf-105f-4033-aa5a-d684975e1395"
      unitRef="defendant">25</pfe:GainContingencyNumberofDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTUwMTc_52cdca37-36b1-40ec-8805-eb72a2f74b68"
      unitRef="patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
      contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTUwNjc_eb146fda-ba3d-4521-88d4-9dcf9614e23c"
      unitRef="patent">1</pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i31d8c17a2b054d83a0c97695db49fa2e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTU3MzU_e9a0f57f-e1dd-458b-a133-571bc6de3431"
      unitRef="patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPatentsFoundNotInfringedNumber
      contextRef="ie3a4c1b86275499193f0bb113f4c657c_D20220701-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMTY2MDU_c4b4dfe9-94c8-49df-aeb7-deed35bab3fe"
      unitRef="patent">3</us-gaap:LossContingencyPatentsFoundNotInfringedNumber>
    <pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant
      contextRef="i498fe9705333412a85d84b8175400688_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85Ny9mcmFnOjY1NDcxYjUwYzI5MDRlM2FhNDA3NDA5NzdkYmQwM2ZlL3RleHRyZWdpb246NjU0NzFiNTBjMjkwNGUzYWE0MDc0MDk3N2RiZDAzZmVfMjU4Mjg_9274601f-1917-4bb8-afae-8400188a5100"
      unitRef="manufacturer">8</pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTA_55d8793a-f6e0-4a22-aae7-64a35a0d25c2">Segment, Geographic and Other Revenue Information&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our commercial operations through two operating segments, Biopharma and PC1, which are each led by a single manager. Biopharma is the only reportable segment. Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;amp;D services from WRDM and GPD. These services include IPR&amp;amp;D projects for new investigational products and additional indications for in-line products. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the organizational changes in the third quarter of 2022 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the new commercial structure within Biopharma is designed to better support and optimize performance across three broad therapeutic areas: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Primary Care consists of the former Internal Medicine and Vaccines product portfolios, as well as COVID-19 products and potential future mRNA products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Specialty Care consists of the former Inflammation &amp;amp; Immunology, Rare Disease and Hospital (excluding Paxlovid) product portfolios.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Oncology consists of the former Oncology product portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Costs and Business Activities&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain pre-tax costs are not allocated to our operating segment results, such as costs included in Other business activities that are associated with: (i) R&amp;amp;D and medical expenses managed by our WRDM and GPD organizations; (ii) corporate enabling functions and other corporate costs; (iii) overhead costs primarily associated with our manufacturing operations; and (iv) our share of earnings from Haleon/the Consumer Healthcare JV. Additionally, all amortization of intangible assets, acquisition-related items, and certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, are not allocated to our operating segment results. Beginning in the first quarter of 2022, acquisition-related items may now include purchase accounting impacts that previously were included as part of a reconciling item entitled &#x201c;Purchase accounting adjustments&#x201d; that we no longer separately present, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. The operating results of PC1 are included in Other business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Assets&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;segment and, accordingly, we do not report asset information by operating segment. Total assets were $195 billion as of October&#160;2, 2022 and $181 billion as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Selected Income Statement Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reportable Segment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other business activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reconciling Items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(980)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certain significant items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;ncome from continuing operations before provision/(benefit) for taxes on income.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Biopharma&#x2019;s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $426 million of acquired IPR&amp;amp;D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; of approximately $400 million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $516 million. In the third quarter and first nine months of 2021, earnings include $706 million of acquired IPR&amp;amp;D expenses associated with our collaboration with Arvinas.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $1.3 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $701 million ($344 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and the remaining amounts primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $1.6 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and (ii) actuarial valuation and other pension and postretirement plan gains of $932 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $1.1 billion ($310 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;s and the remaining amount primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $899 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $823 million ($150 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;s and the remaining amount primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes revenues by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Other Revenue Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Customers&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For information on our significant wholesale customers, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form 10-K. Additionally, revenues from the U.S. government represented 38% and 27% of total revenues for the three and nine months ended October&#160;2, 2022, respectively, and primarily represent sales of Paxlovid and Comirnaty. Accounts receivable from the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government represented 44% of total trade accounts receivable as of October&#160;2, 2022, and primarily relate to sales of Paxlovid and Comirnaty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Significant Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;TOTAL REVENUES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;76,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;57,450&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;23,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;75,066&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;56,101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Primary Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;55,676&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;35,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:8pt;padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Comirnaty direct sales and alliance revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Active immunization to prevent COVID-19 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Paxlovid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;COVID-19 infection (high risk population)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Prevnar family&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Pneumococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Premarin family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Symptoms of menopause&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Nimenrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Meningococcal ACWY disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BMP2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;FSME-IMMUN/TicoVac&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Toviaz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Overactive bladder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Trumenba&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Meningococcal B disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chantix/Champix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Primary Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Specialty Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;11,205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ATTR-CM and polyneuropathy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xeljanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sulperazon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inflectra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ig Portfolio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BeneFIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zavicefta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Genotropin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zithromax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Medrol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Fragmin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Somavert&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Acromegaly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vfend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fungal infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Anti-infectives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Specialty Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ibrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;HR-positive/HER2-negative metastatic breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mCRPC, nmCRPC, mCSPC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inlyta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zirabev&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Bosulif&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xalkori&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ruxience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%"&gt;Non-hodgkin&#x2019;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#x2019;s Granulomatosis) and microscopic polyangiitis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Retacrit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sutent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Lorbrena&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive metastatic NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Bavencio alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Aromasin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Post-menopausal early and advanced breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Besponsa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Relapsed or refractory B-cell acute lymphoblastic leukemia &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Braftovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Mektovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; (cetuximab)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;, for the treatment of BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; -mutant mCRC after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Trazimera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;HER-positive breast cancer and metastatic stomach cancers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Mektovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Braftovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PFIZER CENTREONE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total Alliance revenues included above&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,689&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Immunoglobulin (Ig) portfolio includes the revenues from&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Panzyga, Octagam and Cutaquig.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; is a registered trademark of ImClone LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remaining Performance Obligations&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totaled approximately $22&#160;billion as of October&#160;2, 2022, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of this amount, we expect to recognize revenue of approximately $9 billion in 2022, $13 billion in 2023 and $200 million in 2024. Remaining performance obligations are based on foreign exchange rates as of the end of the third quarter of 2022 and exclude arrangements with an original expected contract duration of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Revenues&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers in international markets for supply of Comirnaty and Paxlovid. The deferred revenues related to Comirnaty and Paxlovid total $6.2 billion as of October&#160;2, 2022, with $6.1 billion and $126 million recorded in current and noncurrent liabilities, respectively. The deferred revenues related to Comirnaty total $3.3 billion as of December 31, 2021, with $3.0 billion and $249 million recorded in current liabilities and noncurrent liabilities, respectively. There were no deferred revenues associated with Paxlovid as of December 31, 2021. The increase in Comirnaty and Paxlovid deferred revenues during the first nine months of 2022 was primarily the result of additional advance payments received as we entered into new or amended contracts, including new advance payments received for Paxlovid contracts, less amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as we delivered the products to our customers and the impact of foreign exchange. During the third quarter and first nine months of 2022, we recognized revenue of $68 million and $2.5 billion, respectively, that was included in the balance of Comirnaty deferred revenues as of December 31, 2021. The Comirnaty and Paxlovid deferred revenues as of October&#160;2, 2022 will be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; proportionately as we transfer control of the products to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the last three months of 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of October&#160;2, 2022 or December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzEzMQ_c1430d91-54d3-4214-8891-93db908fec61"
      unitRef="operatingsegment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Assets
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzMyNjY_57c5b264-b0eb-4891-a195-8651e38c93eb"
      unitRef="usd">195000000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iecf59b86323f44bc955f877e15b9942e_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzMyODI_ed0e743a-8a16-4815-bd20-83fabcee700a"
      unitRef="usd">181000000000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjk_9c1260d8-36c0-40ac-a654-69202812b198">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reportable Segment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other business activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reconciling Items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(980)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certain significant items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;ncome from continuing operations before provision/(benefit) for taxes on income.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Biopharma&#x2019;s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $426 million of acquired IPR&amp;amp;D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; of approximately $400 million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $516 million. In the third quarter and first nine months of 2021, earnings include $706 million of acquired IPR&amp;amp;D expenses associated with our collaboration with Arvinas.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $1.3 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $701 million ($344 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and the remaining amounts primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $1.6 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and (ii) actuarial valuation and other pension and postretirement plan gains of $932 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $1.1 billion ($310 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;s and the remaining amount primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $899 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $823 million ($150 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;s and the remaining amount primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i165a698ddb8e4740889d260adc4009bb_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMi0xLTEtNDI5Njcx_eecbcdef-e4f8-49d4-8bd4-656ea5cce5ba"
      unitRef="usd">22319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cf2ffc020fc4128a1f9ebec292fe188_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNC0xLTEtNDI5Njcx_0a0d672f-ec7a-4b6e-8e6f-5ab3458cc1b3"
      unitRef="usd">23513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i165a698ddb8e4740889d260adc4009bb_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNi0xLTEtNDI5Njcx_070c8ab3-8d87-4f6e-aab6-87c2cfbc7637"
      unitRef="usd">14665000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3cf2ffc020fc4128a1f9ebec292fe188_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtOC0xLTEtNDI5Njcx_3970ef26-7ab4-4db5-9b5c-26484f676cc9"
      unitRef="usd">11848000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i260c3e9ac18c409aa7e150f37f31c193_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTAtMS0xLTQyOTY3MQ_d1bed5a4-020e-464f-a27b-5f1ae12de9f4"
      unitRef="usd">75066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5e893c8b2754cf0b8dd3ad3ebd5f8c9_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTItMS0xLTQyOTY3MQ_bdd64eab-c98f-444f-ac78-4f5d9bdf51a2"
      unitRef="usd">56101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i260c3e9ac18c409aa7e150f37f31c193_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTQtMS0xLTQyOTY3MQ_074836b2-faee-4d14-b5d9-ab6657e72802"
      unitRef="usd">45222000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id5e893c8b2754cf0b8dd3ad3ebd5f8c9_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTYtMS0xLTQyOTY3MQ_1b6cb69e-152f-4b80-b384-2bb98a4369c5"
      unitRef="usd">29952000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d04b7cdf357409082229e55e47bebc1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMi0xLTEtNDI5Njcx_e9b9138e-fb58-4795-8f2c-a4d80e522093"
      unitRef="usd">319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id294f09255c94f85a1408cb0dd253fd3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNC0xLTEtNDI5Njcx_e9f4df3e-bde7-47ac-80c2-730480077951"
      unitRef="usd">521000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3d04b7cdf357409082229e55e47bebc1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1"
      unitRef="usd">-4007000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id294f09255c94f85a1408cb0dd253fd3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0"
      unitRef="usd">-3303000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTAtMS0xLTQyOTY3MQ_eafab965-bc26-4ea2-845d-e55fc001d4d0"
      unitRef="usd">974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i848bc701f6dd422990599b16e3035373_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTItMS0xLTQyOTY3MQ_f3c770c9-7c9d-4ac9-9927-009949ba22bc"
      unitRef="usd">1348000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f"
      unitRef="usd">-9820000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i848bc701f6dd422990599b16e3035373_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631"
      unitRef="usd">-7778000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92dccc52a63e495ab4c634079bac8732_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMi0xLTEtNDI5Njcx_ff43a6a5-6a4b-4385-9ff3-003aa23cf18f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d607e6b68ed4e24ab93bdeca6299e0b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNC0xLTEtNDI5Njcx_ba0766d4-fae0-4e39-b1fd-c9cb6e3a30de"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i92dccc52a63e495ab4c634079bac8732_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNi0xLTEtNDI5Njcx_ce73b70f-34ce-448f-807d-04c0483f9a88"
      unitRef="usd">-822000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2d607e6b68ed4e24ab93bdeca6299e0b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtOC0xLTEtNDI5Njcx_4cdfb2b0-ed3d-4b43-8cda-eab2c971db6e"
      unitRef="usd">-980000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0dfdeb3dc774794b361ecf3023e31d0_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTAtMS0xLTQyOTY3MQ_1de0a812-608b-415d-b04f-edfe7d4c7574"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38bad6387f68492a8b7da8ed99819fa5_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTItMS0xLTQyOTY3MQ_8998c13c-e5d2-434c-9fa8-c8eff9bc4a49"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia0dfdeb3dc774794b361ecf3023e31d0_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTQtMS0xLTQyOTY3MQ_226e5b3b-54b5-4194-b403-f87f87f87f9c"
      unitRef="usd">-2478000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i38bad6387f68492a8b7da8ed99819fa5_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTYtMS0xLTQyOTY3MQ_bab49336-8663-4d3a-b54b-642ee3f94a67"
      unitRef="usd">-2778000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb5f43508edc415e9ccadc3761d6ec7b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMi0xLTEtNDI5Njcx_b74dcb7a-a748-4301-ad55-bcd16b4b2dec"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2531e34ef9984e79a95c51a52ce63392_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNC0xLTEtNDI5Njcx_774bb727-8b6e-456a-8588-15934dc4b735"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibb5f43508edc415e9ccadc3761d6ec7b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNi0xLTEtNDI5Njcx_9efc31e5-89bc-4e23-ab26-ff76bde76ab9"
      unitRef="usd">-62000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2531e34ef9984e79a95c51a52ce63392_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktOC0xLTEtNDI5Njcx_013b7d41-ff1d-4bc4-9652-bab9578b9d88"
      unitRef="usd">-41000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i359c961cd6c843d087dbaa286f62f72c_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTAtMS0xLTQyOTY3MQ_ba49b86f-3d4c-47c1-ac24-e55bcbda7c8c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id20c933385df4b25a75dc3230695c60d_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTItMS0xLTQyOTY3MQ_e00cf9db-c1bc-4239-b073-672ed26e3ba3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i359c961cd6c843d087dbaa286f62f72c_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTQtMS0xLTQyOTY3MQ_ddcf4ce1-5e2a-490e-b1be-26e2a0de3ab1"
      unitRef="usd">-331000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id20c933385df4b25a75dc3230695c60d_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTYtMS0xLTQyOTY3MQ_6962e718-3d63-4e6f-9c5e-93659d844f06"
      unitRef="usd">-14000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i678fe644ebee4937ad3471779808b530_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTItMS0xLTQyOTY3MQ_4963ea75-ee90-4f56-94c3-f8145aae7c59"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c601e0fb53d4bfc88abc7f48831dff4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTQtMS0xLTQyOTY3MQ_eefa11be-3c33-414f-aa24-e637b9e13a2d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i678fe644ebee4937ad3471779808b530_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b"
      unitRef="usd">-773000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2c601e0fb53d4bfc88abc7f48831dff4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead"
      unitRef="usd">318000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEwLTEtMS00Mjk2NzE_5b3efcd4-f969-46c7-80c1-a92dec07a833"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEyLTEtMS00Mjk2NzE_82f8212f-cbfd-4463-bb16-46a3bf600668"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc"
      unitRef="usd">-3095000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3"
      unitRef="usd">1102000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTItMS0xLTQyOTY3MQ_b98b7a9b-f80f-4434-b7a4-a5179c63515e"
      unitRef="usd">22638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTQtMS0xLTQyOTY3MQ_6e3adf5e-9370-4c4d-913b-fc2ac7ad2212"
      unitRef="usd">24035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTYtMS0xLTQyOTY3MQ_2c73d3fe-554a-48ee-a459-c86ae5e5b0d6"
      unitRef="usd">9001000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTgtMS0xLTQyOTY3MQ_bea1bcfd-0ccb-44e5-9196-b6600e3f9f50"
      unitRef="usd">7843000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTEwLTEtMS00Mjk2NzE_af54e4a2-3db9-4dc9-8559-661087a40fde"
      unitRef="usd">76040000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTEyLTEtMS00Mjk2NzE_b62df8f1-d9a2-4745-9136-0fed3444bfd4"
      unitRef="usd">57450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE0LTEtMS00Mjk2NzE_c87a90a1-97f6-4519-9d12-26b54b67d3b6"
      unitRef="usd">29498000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE2LTEtMS00Mjk2NzE_eee3e1e2-82fe-4633-bb68-b14a0ba0abc1"
      unitRef="usd">20484000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeDividend
      contextRef="ia8f4ae7d6e40411abaa1ab3cee43b803_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM0OTQ_e4943c92-fe69-43a3-b702-0b0bad8f1f26"
      unitRef="usd">112000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="ib210c73f222b479aacb31d6c32738d5d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM1MTc_d4702ff5-59f8-4112-b3bc-0be8913635e1"
      unitRef="usd">38000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i370133c2be5a4be79dd89de09dd1a1b8_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM1NDE_95128768-9c76-4044-8e0c-d36a8890ea61"
      unitRef="usd">237000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="ibe95faf72a3246748e2a732611bcf248_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzM1NTc_7f5aeb45-7b17-453a-b807-f4250b1d681c"
      unitRef="usd">127000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:OperatingExpenses
      contextRef="i30773c6942964c0980876adfe8b4a851_D20220101-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU0OTc1NTgxNzIxNjU_56723a99-56fa-4c81-836b-5bc3bd461bb6"
      unitRef="usd">105000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i764cde6156604a799beae35a5e6999f2_D20220101-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU0OTc1NTgxNzIxNjU_fc79ec29-943f-4dad-ac99-55ed7561480c"
      unitRef="usd">-105000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i68a882359d454a71b139c8ee18e1de06_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTc_3cca34b4-4d3c-4cdf-b2b9-4d0a4671250e"
      unitRef="usd">-57000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie6c21eb451cf4e45b21d701f1947ac11_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTc_9ec41b96-d173-46a9-bea8-87f124b3ae30"
      unitRef="usd">57000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if6173132078d438bbba880f5dfde1512_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTA_7058c442-d4c4-42b5-9603-0279b71e1614"
      unitRef="usd">-153000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icced37b763334b1db16365dedf95e6d1_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjYwMTA_c45cd6e1-1af4-4343-90e2-723fb4de1a71"
      unitRef="usd">153000000</us-gaap:OperatingExpenses>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ia7d134762ff946cba4a83f58faf4e361_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjY3MzU_54dfa4c5-a85e-417e-b66e-e9cf69398edb"
      unitRef="usd">426000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i71295b17171746288ec47f20b8ee151f_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjY3MzU_69f29904-60c9-4887-afd4-3f0728396f84"
      unitRef="usd">426000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:CostDirectMaterial
      contextRef="i71fb5a9220eb4286ad607375052a2cf9_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxMDE3MDU_84ccd85e-90d0-403c-9b1a-3ccdba01fb2f"
      unitRef="usd">400000000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="i34ae880bca4843ffa60f855563953d75_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxMDE3MDU_f993d880-a2a1-4fd9-a0c7-c911e98b2c1b"
      unitRef="usd">400000000</us-gaap:CostDirectMaterial>
    <us-gaap:InventoryWriteDown
      contextRef="ie85b5eec8b5f4e5faf565b16f2c0eccc_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc0NTc3MDg_5d3b77e4-8ff9-47fa-be5e-b49996425736"
      unitRef="usd">516000000</us-gaap:InventoryWriteDown>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i4cbfd79f30ac46d99ff22eebda466560_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNTQzMTY_3268fda9-3892-4e48-8ffb-bf3646c5daf3"
      unitRef="usd">706000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i1ff7971d70164752ac30c9be1a49a15b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNTQzMTY_b43c41da-725d-4a71-8f2b-50a997cc73f6"
      unitRef="usd">706000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ie9db26bd1b074f05a8d6203a7bd4358e_D20220101-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxMzgzNjY_a26d9c94-7458-4966-b269-da1f207eaae0"
      unitRef="usd">-1300000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ5OTA_fae94abc-29ad-43ba-8006-aeac94c19cc0"
      unitRef="usd">701000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="i66d2565fc3c3485f96ae44dc60d736c9_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDUwMDk_f126b16d-8445-403d-b31b-936a8bb96795"
      unitRef="usd">344000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i721af952f6ed45f5b812e47fb9418819_D20210101-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDM2MzU_87d68ca6-e0ec-4171-a0bd-88b31648e056"
      unitRef="usd">1600000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ1Mjc_add0ae0b-7b49-41ec-8657-c30a2e3532c6"
      unitRef="usd">932000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ4MDE_739cd3f1-e006-4257-96b8-9d811f6b8cf3"
      unitRef="usd">1100000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="i514d1bcbb87040de9740b4f4f41ca0e0_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzI3NDg3NzkxNDQ4MzI_e0e1f654-82f8-4300-89e9-d9d371e1eab9"
      unitRef="usd">310000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjMxMDE_d1f6b48c-e2a9-40c2-a6f2-aa6d1ce4e4c6"
      unitRef="usd">899000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjMyODI_0bd803bb-d983-44e0-921f-531151bb5190"
      unitRef="usd">823000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="i12823212add54b5f994971e4c2cbe2bf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc1MjMyODc_a04e92ef-889e-4f5f-8f8b-22eaba276733"
      unitRef="usd">150000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTI_6a5fdc1b-ae4b-439f-9ca8-6ed3a7735bb5">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes revenues by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6f4fc3e7944444dba03aff7ca27b97f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtMi0xLTEtNDI5Njcx_11a302a9-39c3-4d1f-bc5d-87cffde874cb"
      unitRef="usd">13851000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2887f09b32694901bc3771fd88f8b571_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtNC0xLTEtNDI5Njcx_a8bf398b-5cd3-4ab7-a23f-2cd8772cda8c"
      unitRef="usd">7020000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="id6f4fc3e7944444dba03aff7ca27b97f_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtNi0xLTEtNDI5Njcx_1f590a65-e0ed-4eeb-9575-2b3e55543df7"
      unitRef="number">0.97</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i880f15025068413dad240be909e60e93_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtOC0xLTEtNDI5Njcx_619fc205-0487-48e3-985d-55aacd085eb5"
      unitRef="usd">33991000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4d02fa2996741259f33220479bb03a3_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtMTAtMS0xLTQyOTY3MQ_5ad2132c-4a56-4450-b0f6-ac18b81bb17c"
      unitRef="usd">22066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i880f15025068413dad240be909e60e93_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzMtMTItMS0xLTQyOTY3MQ_010ae379-bc04-49a8-80b4-630330135ba5"
      unitRef="number">0.54</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i192d7d95f8b84ad2b81b3eb16434a86a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtMi0xLTEtNDI5Njcx_b9efbd2e-a01b-4ecf-8674-aa56b6b91a32"
      unitRef="usd">3136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic89cf38054c742fbb7e8b11d2e93a06c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtNC0xLTEtNDI5Njcx_d7e29c64-6c55-4b80-bef8-3deb8e9328d6"
      unitRef="usd">6221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i192d7d95f8b84ad2b81b3eb16434a86a_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtNi0xLTEtNDI5Njcx_44a9cfff-0831-4d38-9668-5fa7dbc072cc"
      unitRef="number">-0.50</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4458f5262e14479a0a31486f5d571a3_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtOC0xLTEtNDI5Njcx_9ca325b9-cf79-43ae-99e6-090ad49c989c"
      unitRef="usd">14705000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56465e50cdb148659d882d69f8907dce_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtMTAtMS0xLTQyOTY3MQ_bbf13210-c84a-4f1c-bf08-9af219ac3f50"
      unitRef="usd">13836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="ia4458f5262e14479a0a31486f5d571a3_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzQtMTItMS0xLTQyOTY3MQ_9a0839a3-87aa-404b-9c7f-2fd27392d5cc"
      unitRef="number">0.06</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9616f23c18c4880ac9e0c371d696ad1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtMi0xLTEtNDI5Njcx_5925fdbb-c80e-45d6-83eb-8b16bd2e863c"
      unitRef="usd">2351000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9fab9cc315446eb0e13ffaff8ac454_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtNC0xLTEtNDI5Njcx_c004e755-c331-4f36-ad97-84a321a846ba"
      unitRef="usd">4498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="ic9616f23c18c4880ac9e0c371d696ad1_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtNi0xLTEtNDI5Njcx_00e013be-dfad-4d72-92cf-acb5013f5afc"
      unitRef="number">-0.48</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58f52d12f36247d5a3bc27c6d932e64c_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtOC0xLTEtNDI5Njcx_51989639-fa1e-4198-a89b-733a45bf9d23"
      unitRef="usd">10671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a747b5aa22c4f1886ff55881482a458_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtMTAtMS0xLTQyOTY3MQ_e60772c0-2436-4e1c-89c1-515035eda12d"
      unitRef="usd">8617000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i58f52d12f36247d5a3bc27c6d932e64c_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzUtMTItMS0xLTQyOTY3MQ_644bb70c-33b9-4f7f-acd9-a6a05e239a5e"
      unitRef="number">0.24</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia080a8aa1141463990cc38aa96fa8e59_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtMi0xLTEtNDI5Njcx_85f9a868-4086-4640-a200-89bfb8056f18"
      unitRef="usd">3300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a6341d784a94e3087d8228477c40d27_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtNC0xLTEtNDI5Njcx_6c9d54cc-9c7f-4ca3-95c6-aabcc134d67f"
      unitRef="usd">6296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="ia080a8aa1141463990cc38aa96fa8e59_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtNi0xLTEtNDI5Njcx_6f75b97d-f8f5-45ef-9f8e-717cc2ef949b"
      unitRef="number">-0.48</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2dfe09f313047a18e739d76fbc1485c_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtOC0xLTEtNDI5Njcx_e8c9732a-99b0-475b-bf21-7058578bfc15"
      unitRef="usd">16673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7e6cd06a51948a1b9a6198a5b0d7711_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtMTAtMS0xLTQyOTY3MQ_37819d53-83ab-484c-8a14-7a2f094d9651"
      unitRef="usd">12930000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="ia2dfe09f313047a18e739d76fbc1485c_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzYtMTItMS0xLTQyOTY3MQ_20531d09-2236-4bd9-aa6a-448f3e53c020"
      unitRef="number">0.29</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctMi0xLTEtNDI5Njcx_0d2f32e3-fc44-419b-ac40-ed721b1df0c4"
      unitRef="usd">22638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctNC0xLTEtNDI5Njcx_53508527-59e5-4b04-b339-aa3c0a96b5ba"
      unitRef="usd">24035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctNi0xLTEtNDI5Njcx_969bd27f-bd2b-4682-8491-0c72c9da699f"
      unitRef="number">-0.06</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctOC0xLTEtNDI5Njcx_b77efff8-b498-4a62-badc-66fc8e5683e7"
      unitRef="usd">76040000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctMTAtMS0xLTQyOTY3MQ_796ef32c-d175-43b7-a17d-f11dbc00f7a1"
      unitRef="usd">57450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTpiMmU3OWYzMDMwZWM0NzVkOTE1NjIzMTEyMzM5MDA2ZS90YWJsZXJhbmdlOmIyZTc5ZjMwMzBlYzQ3NWQ5MTU2MjMxMTIzMzkwMDZlXzctMTItMS0xLTQyOTY3MQ_94fa9a49-377f-4c61-92e3-9db822439054"
      unitRef="number">0.32</pfe:PercentageChangeInRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4e1858be123e4843836e844815b1712b_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzQ2MTA_d4b07dd8-1d17-4a96-ab53-2673a13564a9"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i54c033a90c144654982cec00e6120cd9_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzQ2MTc_a50f4b5c-6dbd-4597-a580-4c83bc373674"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i63858517ad514373922e2e8b09241570_D20220101-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzQ3ODc_b413c1b4-649a-49c1-a9c8-1ce06267269e"
      unitRef="number">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODg_ca1ac006-c960-4885-9ddd-5b6f51688611">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;TOTAL REVENUES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;76,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;57,450&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;23,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;75,066&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;56,101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Primary Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;55,676&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;35,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:8pt;padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Comirnaty direct sales and alliance revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Active immunization to prevent COVID-19 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Paxlovid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;COVID-19 infection (high risk population)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Prevnar family&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Pneumococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Premarin family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Symptoms of menopause&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Nimenrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Meningococcal ACWY disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BMP2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;FSME-IMMUN/TicoVac&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Toviaz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Overactive bladder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Trumenba&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Meningococcal B disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chantix/Champix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Primary Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Specialty Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;11,205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ATTR-CM and polyneuropathy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xeljanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sulperazon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inflectra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ig Portfolio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BeneFIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zavicefta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Genotropin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zithromax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Medrol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Fragmin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Somavert&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Acromegaly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vfend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fungal infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Anti-infectives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Specialty Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;2,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ibrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;HR-positive/HER2-negative metastatic breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mCRPC, nmCRPC, mCSPC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inlyta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zirabev&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Bosulif&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xalkori&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ruxience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%"&gt;Non-hodgkin&#x2019;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#x2019;s Granulomatosis) and microscopic polyangiitis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oct. 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Retacrit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sutent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Lorbrena&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive metastatic NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Bavencio alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Aromasin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Post-menopausal early and advanced breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Besponsa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Relapsed or refractory B-cell acute lymphoblastic leukemia &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Braftovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Mektovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; (cetuximab)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;, for the treatment of BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; -mutant mCRC after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Trazimera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;HER-positive breast cancer and metastatic stomach cancers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Mektovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Braftovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PFIZER CENTREONE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total Alliance revenues included above&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,689&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Immunoglobulin (Ig) portfolio includes the revenues from&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Panzyga, Octagam and Cutaquig.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; is a registered trademark of ImClone LLC.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNC0xLTEtNDI5Njcx_48b764de-0dc5-44cb-9b4e-5f3ce7a6c4ae"
      unitRef="usd">22638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief168de902d9492590aa5220b5b73f29_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNi0xLTEtNDI5Njcx_7f6beebf-da84-4f02-b2bf-af18544731d0"
      unitRef="usd">24035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItOC0xLTEtNDI5Njcx_9cd29b34-d049-4128-be6e-e3926374efee"
      unitRef="usd">76040000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if07b3b45900f4c3da1a47364ed453645_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItMTAtMS0xLTQyOTY3MQ_321a2ac2-0b2c-4ad4-a271-586a8acff56b"
      unitRef="usd">57450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fd31dba911048de993662a30bd60e24_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa"
      unitRef="usd">22319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ba30fd6c8d04ca8bac5eceecaea0094_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d"
      unitRef="usd">23513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5974e3684a5d4959a373f6a880ead072_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708"
      unitRef="usd">75066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0aea8b98cb34108abfe4081d7793e2c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7"
      unitRef="usd">56101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefc4117e5afe4c0e842be69332f62eae_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtNC0xLTEtNDI5Njcx_37f02a43-6a49-470d-9091-290837891639"
      unitRef="usd">15846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9e0a2c8196543638ffe58bb564300d7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtNi0xLTEtNDI5Njcx_b547755c-3987-4b5c-8413-89596118215c"
      unitRef="usd">16680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icafc3f7a9cee4ec19c29b091247d4bdb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtOC0xLTEtNDI5Njcx_b141b5ab-79d8-469f-841b-6c7cd726fa7b"
      unitRef="usd">55676000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9199195ad7641279516c969753b478c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzQtMTAtMS0xLTQyOTY3MQ_3e553b05-a1ba-4c3c-ad41-f456e981fdb9"
      unitRef="usd">35804000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie38648544e7c43219d1df8126f6b9dc6_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNC0xLTEtNDI5Njcx_f54c2b3d-bcc0-4b2c-8ef0-3b3d36e9523a"
      unitRef="usd">4402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i607941fb91174f77a6d963a5372b1b3a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNi0xLTEtNDI5Njcx_29ca35ef-f9cf-434c-8106-d7cfe2617f64"
      unitRef="usd">12977000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida92047028cd4bed94eef70e5400c5bf_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtOC0xLTEtNDI5Njcx_e1a657ce-6f92-4b88-a040-01ced8e13634"
      unitRef="usd">26477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736289ab886a4191b2b2182031ea21a6_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtMTAtMS0xLTQyOTY3MQ_861ab00a-20e7-4f30-8db0-607aa59a0e6f"
      unitRef="usd">24277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb736aee91454a25a6441df3dd80d5e0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDUyOTM0_bc68f16b-7483-4b5a-aaf6-70503e707987"
      unitRef="usd">7514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if613572161c346fcac294c7e32c378a8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDUyOTM0_9f655cca-4221-418e-ab2b-c370ae5a6721"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e054adec2e4bad8ec56ba5798ba8ae_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDUyOTM0_c7f3acf1-a29a-43bd-bef5-175427ec721e"
      unitRef="usd">17099000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b47973e6ac40f7962fdc8d0adb611d_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQ1MjkzNA_3807a951-b83a-4092-8ebf-d3227b359a1c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf979907b2914655ac6e0a1a750fc363_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctNC0xLTEtNDUyOTQ4_ccdf22c7-8d25-4b70-a54c-e3769b69148a"
      unitRef="usd">1464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1f53b0965de4c1fa8b977d9f6510ac0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctNi0xLTEtNDUyOTQ4_6fd2a6d8-36a3-452f-aaf5-ef9da17ef0fe"
      unitRef="usd">1346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7eae5a52dc634277ae8d307ccfb995d2_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctOC0xLTEtNDUyOTQ4_4f90e3ae-0051-45d0-a257-3466ac832162"
      unitRef="usd">5001000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic55da2d7f85e40b58f460bad5984b81c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzctMTAtMS0xLTQ1Mjk0OA_5afb1774-e577-43b3-bac4-d6480d524841"
      unitRef="usd">4470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia10d0e1d609e4e219fef4b97c4939891_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDI5Njcx_8e5f7ad6-da14-4ab6-a1fb-eeb35bf1b71d"
      unitRef="usd">1607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4db8e7e6e5bd43f899b2d9e49d1a99f0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDI5Njcx_937c2db7-ab03-49fc-b286-d87052678df6"
      unitRef="usd">1447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if421226bc57541e4a9ce23fe47d542e2_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDI5Njcx_8d93185f-f688-4c82-9b63-c777dc394dbb"
      unitRef="usd">4601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7c319b3ee06435f8203948f53950fa4_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQyOTY3MQ_29765147-b42d-4233-b960-9afb141a29f6"
      unitRef="usd">3971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46cead4bca44470bb6e5485ad16d704d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktNC0xLTEtNDUyOTUy_20e8b3f9-b32a-40be-ae96-e2502910eafc"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18f8c171007c41bbb0447b451c0d89d1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktNi0xLTEtNDUyOTUy_d97d4fa0-c5df-4ee2-9da8-3780f7754542"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d1e1da5edbd418b9ed52c7482de82cd_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktOC0xLTEtNDUyOTUy_ef8c09cc-a25b-4822-bade-2abcbf34f055"
      unitRef="usd">327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e87bf34d54945c1bb8dffaa5340c8c2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzktMTAtMS0xLTQ1Mjk1Mg_fce296ac-8e06-4b06-8134-85340bc21347"
      unitRef="usd">420000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f9228a4392140c5aadff356ad41e232_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTQtMS0xLTQ2MDI4Nw_796fad55-461d-4153-ac8c-af13559f2b29"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ddb4a7f8df94efd865ffc529de4e9e0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTYtMS0xLTQ2MDI4Nw_53142ea6-217f-45df-8b0b-1dc777db64b1"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i586dad3bf41b4478a6a7bf583b2bf621_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTgtMS0xLTQ2MDI4Nw_0736cd83-c375-4f16-aeea-0856dba30798"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e4b745d89e249d491f381c3aaf895c5_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTEwLTEtMS00NjAyODc_4eb0be82-12f8-4186-858a-5927d521676a"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18ef446f60f046bca0e069bd65549c9f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTQtMS0xLTQ1Mjk1Mg_009e3072-65df-455e-a3b1-dbba10be92f6"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d914ca9794640ffa3ec5e10b6cee5f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTYtMS0xLTQ1Mjk1Mg_a01e00ff-bfb9-4652-bb3d-e170e6420713"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i930a1f7cfa9d456bae7cb9c7c1e3e816_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTgtMS0xLTQ1Mjk1Mg_4087b9af-bbde-46da-8cc4-2cc42c559d55"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2b8fafd05bb4f5db3a80e0c919d745d_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEwLTEwLTEtMS00NTI5NTI_3b23170d-ea5b-4e4f-96cc-da8692e81032"
      unitRef="usd">186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaac2d287a23b4b88b22df7d728b108e5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtNC0xLTEtNDI5Njcx_d8e6bd4f-bdcb-4692-a499-be6a425d6627"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b85277d9f04472693fc3c174486102f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtNi0xLTEtNDI5Njcx_500e6b87-550c-4c4d-8919-47e56f43512a"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffcfc2ea0698426aaf9c9ef575fd797b_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtOC0xLTEtNDI5Njcx_b312ff50-8fe7-4ade-9838-853d5e85652d"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief03ef0a913a488da5d349f44b79df38_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzgtMTAtMS0xLTQyOTY3MQ_55a13553-5e71-40d8-b86f-0285795865d2"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71ac32c435d7417a8258ad657ca4d5db_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQ1MjcxMA_c4e44753-2ab4-4cd8-bc83-5cf0dca74afc"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d9e7601d2a949b391ea06de7ce817d2_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQ1MjcxMA_46dd39f4-1e8d-41b2-aa89-9047e3648f76"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i847b7cc69e5c45d4b6eb6fdfa02ac9fd_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQ1MjcxMA_f1f12fd2-410b-4504-ae21-fb87a6ba1254"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id78cb321690f41a9bb94aed3b1906a7a_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00NTI3MTA_92976070-81f6-49bd-a2a8-df3e2951418e"
      unitRef="usd">174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb4c063dba364bb6ba775ef1b933b60e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTQtMS0xLTQ2MDMwMw_d0506ac1-9a4e-423f-a34a-8a8dc7a4db36"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1192155b8f54c838c4960883dd5cd12_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTYtMS0xLTQ2MDMxMA_3719999d-99d9-4e13-9778-fac75ab4cbe5"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i219d3b8b6bdf41049720a23a2998280a_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTgtMS0xLTQ2MDM0Ng_71552dbb-ab8d-42a2-a252-80bac3d3ab0a"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8900fe5ad7d64b02bae061fd7863a809_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTEwLTEtMS00NjAzNDk_14f2a2ac-e72b-4f65-9e5f-b52cc7062b2c"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1f67297a35446ffbfeb15e1560ea010_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTQtMS0xLTQ1MjcxMA_a687475a-afcc-4c4a-a4c4-623be71726a1"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia94e68a684f34fdeb284ae983ecf8590_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTYtMS0xLTQ1MjcxMA_5be11555-52c6-4684-9df2-5ae45e6dcd54"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i997a8d6896fd403da5f90a6718f7b5c2_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTgtMS0xLTQ1MjcxMA_49b592ca-ee70-47fa-8939-dc05fda3f6f1"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c282565578941d5950ca8e622206e11_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTEwLTEtMS00NTI3MTA_aa119ad0-3214-419a-a76f-ef2bb5747d25"
      unitRef="usd">409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3450d41f6f8c4add8f70e81bad35f8a1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTQtMS0xLTQ1MzAxNg_119251be-738d-4657-bf99-fb76a7eb079b"
      unitRef="usd">451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeb3e653eb0046c7ac2807a447d5a81d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTYtMS0xLTQ1MzAxOQ_e5a5212f-43f0-4aec-957c-ab052d30dcc6"
      unitRef="usd">479000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife21a256301a4c639bb9b4d83799b744_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTgtMS0xLTQ1Mzk1Mw_67724121-cfe7-4b74-a9a7-4816200d51d8"
      unitRef="usd">1326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3564594ecfbb4ce7bddde0cfd454db19_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTEwLTEtMS00NTM5NTY_2dd0304d-e3a1-49b3-9ae7-67ae2c7d9869"
      unitRef="usd">1490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i681fcc33174e41159cf96193a702c0dc_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTQtMS0xLTQ1MzQ3NA_f8d28d43-d231-47a0-a2b7-6f4fd4b4bb6d"
      unitRef="usd">3404000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f4ff79e8e54212839e35689b460762_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTYtMS0xLTQ1MzQ2Nw_1fc0d80a-6777-474d-8226-00c7f6c54362"
      unitRef="usd">3749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1f46d7110d242bd9da8d5dc2c2f396b_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTgtMS0xLTQ1MjkyMg_0667af40-798e-4433-9439-d0dcc2414d67"
      unitRef="usd">10267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dceba1ae2e14264b25308d846b234a3_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTEwLTEtMS00NTI5MjI_76a2da2c-037a-4d0a-8825-37f0d47b6c73"
      unitRef="usd">11205000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fead61708764dc986e38daecc3da97a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTQtMS0xLTQ2MDMyMQ_f297af21-497b-4ad1-b350-eeae8e649649"
      unitRef="usd">602000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cc960090f944473b1de0a5c83bdb9a9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTYtMS0xLTQ2MDMyMQ_3c04c606-9562-432a-8cf5-c336ab159942"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9a2a488847c40d88bb4f5f52dec7967_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTgtMS0xLTQ2MDMyMQ_000c2567-80f4-420e-bb42-fdef61181f82"
      unitRef="usd">1766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e18531693d04b6a98fe0852c4c5025b_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTEwLTEtMS00NjAzMjE_5289035a-b162-4633-a983-5c67da881ac8"
      unitRef="usd">1454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0452040fe699493da4f37d561f3f548d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTQtMS0xLTQ1MjkyMg_1e474bfd-9568-4c6e-9f3c-7309a4f36826"
      unitRef="usd">502000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1b42fa5a6cd411a8ce00a20130d39dc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTYtMS0xLTQ1MjkyMg_9e34fc9e-b86c-4ec7-835c-bc2775c5145d"
      unitRef="usd">610000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2892d1f59005440db65ec4752ff8a06f_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTgtMS0xLTQ1MjkyMg_130051b5-f738-439a-8369-4bbccce16585"
      unitRef="usd">1304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09231dfffc444767bb73115a01b1de18_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTEwLTEtMS00NTI5MjI_640cac5b-e5f1-40b9-9b96-c35f1c373c2b"
      unitRef="usd">1734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a48fa456e8e4117a0324151697d5442_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTQtMS0xLTQ1MjkyMg_e701d70a-2223-4008-a3e1-d7e021f6a7c0"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0f936ba9ca84017b4b97358942bfc9e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTYtMS0xLTQ1MjkyMg_531d813c-7198-4952-9e22-23fa6a665671"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc8e83a1b35f4cb0aa9adf9618682ad6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTgtMS0xLTQ1MjkyMg_bb50b406-8beb-4cd2-bc18-331ee45a646e"
      unitRef="usd">767000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70f393eca9894fb1887c099d45a0457c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTEwLTEtMS00NTI5MjI_700517b0-3d00-47ec-92dd-34cf05320d70"
      unitRef="usd">888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73121833f65a48dabeef6c4f70ffc8fe_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTQtMS0xLTQyOTY3MQ_cf96836c-b2f7-4990-aa82-dba488553522"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10e0cee382be47eaab3cef8255b4bbf3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTYtMS0xLTQyOTY3MQ_ae57bb9c-5f9b-4de2-921f-61d246736872"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb25ad491f0f4cd4868a150b3df14736_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTgtMS0xLTQyOTY3MQ_7e26ad38-fb1b-41c2-a748-c7f7c4434f9b"
      unitRef="usd">598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5874fba6c68e4599a0fc3fb5193f6357_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEyLTEwLTEtMS00Mjk2NzE_2b0fd078-60bf-4a81-ae39-ece2eb8b1ca7"
      unitRef="usd">515000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ed5fec2776a43d5b52002377b487e31_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTQtMS0xLTQ1MjkyMg_855e1b37-98ba-4d04-bec7-389b621fd106"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b5bcfbd37054eeb8cf0f03e878adeb1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTYtMS0xLTQ1MjkyMg_a66eae42-7945-4cf9-b42b-92fc8879c80f"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cad181f9d3a4c559ea98c3fe153c7e0_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTgtMS0xLTQ1MjkyMg_0152f499-7343-4b39-8e40-8e2d96c65a9e"
      unitRef="usd">403000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibabe9fee66024117bd6b35cc88a984d3_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTEwLTEtMS00NTI5MjI_56ea440e-6fcb-4a95-a863-a2b5baa789f7"
      unitRef="usd">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19b5d2be8736491eb3d14bd80d72787c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQyOTY3MQ_ecc725f6-bf13-469b-8990-b9f59b18f062"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecb8d7d4ec27458b904b759251802162_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQyOTY3MQ_ffb545fb-dd46-48ab-b6ea-e15473bc3022"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i528162cfdd864c2f9cfe732522d830b7_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQyOTY3MQ_567f37c7-d373-4a0f-8f15-d40650e2874b"
      unitRef="usd">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fb1258143354aadafcf0cffc1e8922c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00Mjk2NzE_d37a0d72-b1c1-4bb5-9324-bd5157a70838"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb1973fbbf1e499b9274056be29d6f9c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTQtMS0xLTQ1MjkyMg_00633f91-22ef-47d2-8d4d-65f60f96c128"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a43c802a36b4c2db68c41cc136daf70_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTYtMS0xLTQ1MjkyMg_9b22f501-ffc7-4d29-9cb7-5e6885330260"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i271e8b9e93e84bcfaa8c788053977b20_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTgtMS0xLTQ1MjkyMg_ac27d6de-b315-499e-afc4-c8a3f2945a8e"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic20359a48688484fa197f302f7463767_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTEwLTEtMS00NTI5MjI_6203be47-e14f-4bbf-957c-91020bd88526"
      unitRef="usd">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4034cba9c5324ca795292cedaf88e6a4_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTQtMS0xLTQyOTY3MQ_f0af5a0d-c316-48eb-9654-ccd0acd461f7"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c5554206f8a46328005d910c6b0e431_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTYtMS0xLTQyOTY3MQ_2322761f-ac29-418c-943f-ce44270b4b8e"
      unitRef="usd">107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i427f057de3fd4215b2b63624f5c325a0_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTgtMS0xLTQyOTY3MQ_8e00abb8-de1e-49c9-9395-cdc113045a5a"
      unitRef="usd">302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee23be5e923547fab2329d5b56c61ed8_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE0LTEwLTEtMS00Mjk2NzE_634fd517-b9c0-4148-b3f4-20d68d7d7c5c"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6646c1fa39b14bd4a1f5e9affc1282cd_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTQtMS0xLTQ1MjkyMg_7d5f94fe-18f6-4bba-afe3-0e49383c8fb0"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab54fbd61cf24874aab5381668df8403_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTYtMS0xLTQ1MjkyMg_df799439-a880-4e6f-acb8-f35266a03c9a"
      unitRef="usd">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8c3e0cbcbcf4b03a734bd12c5194903_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTgtMS0xLTQ1MjkyMg_e09697ca-67e2-4f24-afbe-e7aee7da244b"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibec65066e53f40bfab7cdd1c00671818_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTEwLTEtMS00NTI5MjI_cf5f4043-a380-42f4-9d09-4b22cc0c8fb2"
      unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i218a664fe1c4469bae3b80333f3e0cec_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTQtMS0xLTQyOTY3MQ_ac87910f-324d-4d6a-864b-ff4bb18ac46c"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b91d02d234645c793606aa29b0d901d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTYtMS0xLTQyOTY3MQ_ed5bb512-cb71-44f0-83e7-d8fb267700b4"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a5d2ac36d9d4be0b0289526710db8fb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTgtMS0xLTQyOTY3MQ_b745e02b-320a-434b-aa10-8ea22720197c"
      unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia969cc2c0ebf47d8816380e47bf220ed_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE1LTEwLTEtMS00Mjk2NzE_71dd62aa-b432-4122-a521-0b95dbbdc0da"
      unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42322074968a4077a5a1b52768045df2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTQtMS0xLTQyOTY3MQ_b667b300-2ed0-489f-a86e-71c0ea7ccb39"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75f3be521f224b8fa223498877d51452_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTYtMS0xLTQyOTY3MQ_467f1f78-75bf-4922-b49b-c0abcccdd9cc"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41086f4199fa4adf853900d30d476fc0_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTgtMS0xLTQyOTY3MQ_859c3496-0a33-4b9e-b37f-ba708955c2ef"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic35c1201fcf34260b06f08c7d2dca0d9_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE2LTEwLTEtMS00Mjk2NzE_38eb6e81-1daf-49ab-b36d-32fa37820857"
      unitRef="usd">320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a9f1313cc29448587a6446dbf0c3f3a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTQtMS0xLTQyOTY3MQ_d6b65384-b2ab-4c4f-83bd-5e71c8762b73"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e86ded88f3c4dc6812eb051724b5fbc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTYtMS0xLTQyOTY3MQ_35acb5a0-591c-4a41-859e-ded5896df6eb"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i693bafa1895348fbb803b977431d462f_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTgtMS0xLTQyOTY3MQ_6a6fa30e-f48b-4076-99b2-9fa3cd37bd35"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie91260f6cb4049409f21cbe3937ebc85_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE3LTEwLTEtMS00Mjk2NzE_a3071e61-376f-4d6f-9b53-61a447cc989a"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2db6bbabd95c45ea956e59e8ea612ed0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTQtMS0xLTQ1MjkyMg_3704713c-7f03-4b22-9b10-6f0fb688e1ff"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4e33f7150c6471c938a45f53ef7a709_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTYtMS0xLTQ1MjkyMg_7e63ed46-04f6-46e1-bb0d-defabfd0ec17"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice7fb1f835ee48e7963f5d0bb55330f0_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTgtMS0xLTQ1MjkyMg_3710cc97-4b50-434b-9df7-533c14d9d271"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29ab61c3fcb34e45a64f5455f6442ef3_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTEwLTEtMS00NTI5MjI_598a0f8e-3f35-4db2-9658-87a96c131b28"
      unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia102ac741b5e451aa63ffe982d59beac_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTQtMS0xLTQ1MjkyMg_836b9b01-016e-4586-850a-be50a906390b"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ae5f3828ae041d8bde249471bd9e321_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTYtMS0xLTQ1MjkyMg_11bd627d-cb87-4497-a92f-22682623b1e4"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeace31d957b42c2a7709f9948bc9709_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTgtMS0xLTQ1MjkyMg_6d492ff3-42e1-40e0-970a-65a516337814"
      unitRef="usd">188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i878d1447a4ca4813b621dc3cc89befa2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTEwLTEtMS00NTI5MjI_6400ce09-e210-40e5-8ff0-865c1d18bd7c"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if602f21734f7495d8b816aa6bcd6498c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTQtMS0xLTQyOTY3MQ_86f16393-ee14-4edb-a2fd-4040d61ecce1"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8e66fa2a70a4649a96bfd9b2e39b902_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTYtMS0xLTQyOTY3MQ_feca20da-8207-4601-882c-47ccaff9089d"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie28dbbb6bb0e41d5a7fee7ddf2c97859_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTgtMS0xLTQyOTY3MQ_a7fd504b-79d5-49ad-ab86-a078c622a264"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37857266a0444b1a85059b213ce1320c_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE4LTEwLTEtMS00Mjk2NzE_6af55cf0-27b4-495d-9ab9-aa95299e2e88"
      unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e3b9a9454c04c2a91c44f60a9080c13_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTQtMS0xLTQyOTY3MQ_809419bd-66a9-4340-a5a8-4139d856d78c"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id633b0178823447f98f4fb90652a4b43_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTYtMS0xLTQyOTY3MQ_d00fda7b-3738-463c-b317-5e2250a9c103"
      unitRef="usd">455000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib646354746ad4597828f14cf71b869f0_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTgtMS0xLTQyOTY3MQ_ee36e43b-eb84-4c67-aeb6-0429a2405317"
      unitRef="usd">1123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i801deeefe2ab4c79a8fc02da44868706_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzE5LTEwLTEtMS00Mjk2NzE_e480ddd4-2567-4129-9015-e21bbeb34e0c"
      unitRef="usd">1384000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia62e7abf3e4d48e080bf9026efbb11a2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTQtMS0xLTQyOTY3MQ_75250629-0f6c-43da-afe2-578128b8a945"
      unitRef="usd">586000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i004d3ce3105a4fed95460eec415470e3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTYtMS0xLTQyOTY3MQ_f99aa18b-996b-483e-a742-9cd4821d80a3"
      unitRef="usd">702000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11eb45e9cf444c2aaec2c6742022efdb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTgtMS0xLTQyOTY3MQ_97b1c19e-8f6f-42b9-9949-871a8391b689"
      unitRef="usd">1816000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b25b150fb1c45e9a0380f915623fdb2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIwLTEwLTEtMS00Mjk2NzE_5648a6a2-96fc-492a-88a7-8aed239adfea"
      unitRef="usd">2134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib80b331462b2491d9db4424b5e8bd924_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTQtMS0xLTQyOTY3MQ_5dac27cf-d2c3-4e5f-bbd8-aff8a577e35b"
      unitRef="usd">3070000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6692eee652446979a0b8ecce8cf90bc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTYtMS0xLTQyOTY3MQ_1c5f8348-0b6e-4a4c-9e7c-ba23876dc35d"
      unitRef="usd">3085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4da74bd9833e4cd6a768fed715ba4cb1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTgtMS0xLTQyOTY3MQ_2a996689-f73d-4f76-a31c-2600334929f3"
      unitRef="usd">9124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id176e11c7c904d469cd2382368b11d61_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIxLTEwLTEtMS00Mjk2NzE_da245fa7-a139-4197-afb3-a036392d63ee"
      unitRef="usd">9091000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0836f20c7ba46df8c7fb318c2836678_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTQtMS0xLTQyOTY3MQ_de3d066f-34fb-497b-9090-f739bfa460c6"
      unitRef="usd">1283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a2ad9788911406e9443bb89ba74f344_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTYtMS0xLTQyOTY3MQ_726199c9-852b-4a94-9ec2-a896940d8d3a"
      unitRef="usd">1381000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea562808de51468f86c413b0feafe114_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTgtMS0xLTQyOTY3MQ_c22289e5-29e3-451c-ad2b-a88ee376bf16"
      unitRef="usd">3841000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i973e5c192f1f459782b9e4ea90048122_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIyLTEwLTEtMS00Mjk2NzE_e8d7e6e9-6982-4abf-b74e-a207d08b1da4"
      unitRef="usd">4039000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a004a95111a4f2db0d2669d2f610693_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTQtMS0xLTQyOTY3MQ_01cc96bb-2b8d-44bd-8d6e-cdd8c5245e91"
      unitRef="usd">320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f100f20573b432288b09f6b64c4671e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTYtMS0xLTQyOTY3MQ_8016b052-15c7-4fdb-9daa-f54d5f9081d9"
      unitRef="usd">309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9aa66a51bca84785ad4c259d04a22cfd_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTgtMS0xLTQyOTY3MQ_1c422d6f-bbb8-432a-bac5-7d3c5eec3206"
      unitRef="usd">878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d54941efa2941f699fe6aa44f0a4954_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzIzLTEwLTEtMS00Mjk2NzE_ea3b1167-6aef-4f18-bf79-2b0a0cfc4e3d"
      unitRef="usd">879000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64ee738588b245b38e912a7df8a75d04_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTQtMS0xLTQyOTY3MQ_58277efe-6f64-495c-b3bc-4a0413dc70ea"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76089b0f719c43e08c7f98682f02aa83_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTYtMS0xLTQyOTY3MQ_9cb42d98-bb65-4b8f-9761-04ebd00ddd97"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4e3fef4910241e5bcb815efea4ec15c_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTgtMS0xLTQyOTY3MQ_b0321bca-d661-412d-9f5b-64afe5c2939f"
      unitRef="usd">760000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f57ceefda7c437a8b98c4564c51b6f7_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI0LTEwLTEtMS00Mjk2NzE_c1d66aef-d476-436a-91e2-c3e75f759495"
      unitRef="usd">742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if69e9f4ce5be4a61997e3ab67969be34_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTQtMS0xLTQyOTY3MQ_b56b484b-d8a6-49ea-ae18-af0fd9f6f66b"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf753ff3c5554491887de93db1fe560b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTYtMS0xLTQyOTY3MQ_64ae03a9-213c-4d19-9702-8d7518b2845e"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdcaea6d26ee46e0bafa9e9f9da6496d_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTgtMS0xLTQyOTY3MQ_9e3df96b-8f75-442e-8ce8-f472192bff4e"
      unitRef="usd">432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide0acf4ae0c84031a293157923acb753_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI1LTEwLTEtMS00Mjk2NzE_4a4f69ae-e862-4bf5-8dcb-bb35578da842"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87b1ca93f57b4e6ba57c282fa30f3976_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTQtMS0xLTQyOTY3MQ_2edbfe61-6863-4266-94ee-2bb0b16321f4"
      unitRef="usd">141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i357d700ae87d4d468163149932549cc6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTYtMS0xLTQyOTY3MQ_f9c2fceb-8209-426c-aacc-a48586492301"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c2de171ee654cf8884e29fdc4318a0d_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTgtMS0xLTQyOTY3MQ_e3e0519f-971d-4517-808e-9e2df9332033"
      unitRef="usd">425000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2ceb413b1694f46ae29ffadc6262050_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI2LTEwLTEtMS00Mjk2NzE_33df66f7-f21b-457f-8f13-8e8fff682ca8"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5bc27120a7c4359a1cd74322bb22c5b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTQtMS0xLTQyOTY3MQ_4babf345-26dc-4e1c-9491-4e7b12526201"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb7f810aa79a45b0bb5466e60f929931_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTYtMS0xLTQyOTY3MQ_b716445a-f00b-4d6c-b493-f86b9c554250"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4093973df5c94ed990eeaa9c48d107c5_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTgtMS0xLTQyOTY3MQ_3b600387-b514-471e-b379-20b31de0170f"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56622c1212fe46f68f7c8455f4d2a523_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI3LTEwLTEtMS00Mjk2NzE_e4382516-eaf0-43ab-b099-38e3c1ad1287"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41d1bf41d84d4d41a0c1deb806b16620_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTQtMS0xLTQyOTY3MQ_41bc263a-5dbf-4745-808a-d5946349d112"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i900010cf3afc449c8b72dce7cc16fe0d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTYtMS0xLTQyOTY3MQ_f9849a5d-a670-459c-805a-c54f0ec480c7"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71bf78dbc98843239656272f490339bc_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTgtMS0xLTQyOTY3MQ_f85f3218-5961-486f-9c4d-d3cb367a1cd4"
      unitRef="usd">357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6de406d2bea4496db2a3b0790f7858dc_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI4LTEwLTEtMS00Mjk2NzE_ba83cd7b-c224-4ec9-ab3f-8cde534ae9db"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib61ec39f8eec4e90a85dfdf93b4b8e60_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTQtMS0xLTQyOTY3MQ_ab863e52-8501-499a-9e0f-faccd460c32a"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83462764e3144e25ad4064bdf364bb72_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTYtMS0xLTQyOTY3MQ_a813dec7-cdc8-4830-96c8-0bcb55433c7c"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if09ed1dfe1fc44eba41758c7b72b1220_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTgtMS0xLTQyOTY3MQ_96d2174e-ca28-486e-933f-6a77ae624827"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75f066e1ee0b44eba6238a376debfc1d_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzI5LTEwLTEtMS00Mjk2NzE_7f99140d-86a2-4833-a49e-43a51fdbe79f"
      unitRef="usd">322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b3896ecd1f4b91b83726ec4b21f326_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTQtMS0xLTQyOTY3MQ_b33e0605-97ea-4944-a764-1874082e03c2"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id15ad6f996594166971b1dbb8262b0ea_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTYtMS0xLTQyOTY3MQ_124c0ad5-969a-42f1-b173-8a15a691a5a8"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1b7b3fe6f55498d913853d8a9489481_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTgtMS0xLTQyOTY3MQ_94e63db4-d47d-4f71-be23-9003289660f7"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69fbc0b4b93c4abe94a8ee2dcd69e98e_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMwLTEwLTEtMS00Mjk2NzE_2f6f8fa3-46bd-4a5b-bc1c-a5aec6e3a4b0"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70124bbf39724876b8acf2c4bfeca836_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTQtMS0xLTQyOTY3MQ_32bff46a-3394-43f0-b632-d7e231087d70"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i206d32a63e3f4cfd8f6c8d75168367bd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTYtMS0xLTQyOTY3MQ_bc7e95d1-6042-48d3-bff6-7eabf3ecdd80"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie87e55493f364c369dc8ad1d40cbd422_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTgtMS0xLTQyOTY3MQ_043a7cef-17b8-4226-8def-9946650053dc"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib27f8e680678446f86545701da276329_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMxLTEwLTEtMS00Mjk2NzE_94a5930a-48dc-4256-8834-6a0c9cc6996b"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fbeed7d4fbf439a9819aa469673b46b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTQtMS0xLTQyOTY3MQ_96fd6808-eedb-4e15-98fa-e22e737f9861"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38b58aba96014c749e5dd13a48805369_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTYtMS0xLTQyOTY3MQ_482b969b-aa00-4b96-b5ce-c2f07f3deda6"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a3dfcdc4c8a44a08bb30d6681bb333e_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTgtMS0xLTQyOTY3MQ_d080a82d-20f7-4398-ae2a-7cbd4e40d1c1"
      unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie43bf4a89a5f40c9abaea813b2440c31_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMyLTEwLTEtMS00Mjk2NzE_3bd9b08d-dd71-4545-be9e-557c2ca97d3a"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eda3444dc5f41b4bba147d8d43c862e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTQtMS0xLTQyOTY3MQ_41a881fc-89e0-450a-a43f-f29560856e93"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90c61ae6ba8c4e6ba44617ed0e6e6331_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTYtMS0xLTQyOTY3MQ_d646105c-ee46-4a4a-b986-9afd51a396b4"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i809d717936604b26a18012f7b8b9e2cc_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTgtMS0xLTQyOTY3MQ_152dddc1-3cc7-47e5-9bf8-5612a509affb"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic160791460df43c18efb41f047eb99f2_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMzLTEwLTEtMS00Mjk2NzE_b35bb675-42f4-4723-b5fa-58cc60d62517"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2e39688a3c748cbb50e3f3fbd49323d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTQtMS0xLTQyOTY3MQ_6f96ab9c-e45d-4624-997a-db62c02d4a6a"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f2b596d2f9944daa642c722ddb35c58_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTYtMS0xLTQyOTY3MQ_16f60dd8-e347-4b43-a27a-4c492c7d7656"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id911b17700454881be23254e2132425f_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTgtMS0xLTQyOTY3MQ_07ca6d6d-64e9-4c9f-8d2d-0342d4a557ca"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36c47732986f4e1cb33d655f70e90bda_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM0LTEwLTEtMS00Mjk2NzE_fbe10f47-a51d-4a04-b176-198f2dba0e70"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10e972355f674b2c8872f2e11d8a753f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTQtMS0xLTQyOTY3MQ_0c8722b8-2872-4bf9-b21e-e3d503546382"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8472823d53ca4530ba656db6b08aacbe_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTYtMS0xLTQyOTY3MQ_945cea22-a4ed-4fcc-a514-2cd8d824094b"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4401e5c37dd1444192245cd5facba3fb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTgtMS0xLTQyOTY3MQ_f6b12f8a-bcea-47d3-9125-6393606efd3c"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i027f314cb29d4db7820ad2436483ee1d_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTEwLTEtMS00Mjk2NzE_1b1bd2f4-3d49-406d-a698-4ea9fc91acac"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iace4e825c4024bd7baccc5a0fc1b6426_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTQtMS0xLTQyOTY3MQ_b0fec7eb-584a-411a-9d3d-91d234e49282"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic39b763d5ca341f5afd21c2f801ad63d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTYtMS0xLTQyOTY3MQ_28dcc386-72b0-48f4-bc41-3d42f0d9f0a2"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i531e99cb29294ab58cbd26ac7ff982c6_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTgtMS0xLTQyOTY3MQ_3e3975ed-0207-48bd-8faa-2b8487d349ad"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if18af7be85824b4aace60f7124ab2108_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM2LTEwLTEtMS00Mjk2NzE_fc5a7693-47a4-43fe-8379-7f5212c09a40"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i992624b40ab1462a957959426582393d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTQtMS0xLTQyOTY3MQ_a6c4c5c1-09ba-4592-bc80-acee0aabd3a2"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5155b8e6532848ec99ad1757626c1d0a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTYtMS0xLTQyOTY3MQ_a283efad-7a13-4c8b-b9cd-0f806c4c374a"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i622fdfe2355249ccbc9c305380b6be81_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTgtMS0xLTQyOTY3MQ_f991b78e-2644-46f8-b9f1-516800e6c84b"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4503374f47504e53a8a556f65267f8dd_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM3LTEwLTEtMS00Mjk2NzE_f929b528-7dea-43a9-b226-26a2d374a3d2"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9d0c096b86f4eaba702765dd3329741_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTQtMS0xLTQyOTY3MQ_5ed430f0-e0b1-4076-ac6b-07766f8c941e"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92617f0978cb4c60a86dd7c4cabc5122_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTYtMS0xLTQyOTY3MQ_da6270a0-9816-4820-a6e3-1274826ae1f3"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ebe86d55ea4421c89f72c68a2c75f59_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTgtMS0xLTQyOTY3MQ_aebf3a87-4f6b-47b8-b0c9-3211279fdb87"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc10872084e8447ab3832bbc01a6c62f_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM4LTEwLTEtMS00Mjk2NzE_229bd941-93db-4b46-9915-f14f30211086"
      unitRef="usd">155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7feed05291314be8ab413820d9581a34_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTQtMS0xLTQyOTY3MQ_fbd1b23a-4de5-4731-90bf-a49e2f6a8698"
      unitRef="usd">319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic34e46c91a314553b59159136459f579_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTYtMS0xLTQyOTY3MQ_668cc3dd-3341-4358-a350-cbf225cdbb2c"
      unitRef="usd">521000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4b801e727bf47de83a1422fd1a40ba7_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTgtMS0xLTQyOTY3MQ_a17914fb-258b-418b-a9ca-4563cd5cfc48"
      unitRef="usd">974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb622ed9f6534687aa3bf61cf0d3f889_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTEwLTEtMS00Mjk2NzE_79069066-5ead-4735-9ca9-a0c728f6a653"
      unitRef="usd">1348000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a658246e2b34fd6a44cebc005385303_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTQtMS0xLTQyOTY3MQ_aa74b27b-e029-43be-91c4-6fb72d18cea4"
      unitRef="usd">1689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53a9464430b1419fba05017b8bd79cf5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTYtMS0xLTQyOTY3MQ_fc2bc24b-83b8-432b-b22f-3642aadca53b"
      unitRef="usd">2068000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifde011cdb7ec481f92dc1a4d3d485ee1_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTgtMS0xLTQyOTY3MQ_6f4867db-9cd0-4a81-b155-dce5f254dc89"
      unitRef="usd">6320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica70d473e5c64734bc680a816c324426_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU5LTEwLTEtMS00Mjk2NzE_5635311a-555b-422b-8098-c661e7c6770e"
      unitRef="usd">5718000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7336380d9d6f4a4495fae7cd4004e307_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU1Njc_f2b0c3ef-8a69-4aed-bb0c-4790df02f01e"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ef9df7820e54c5ebe5b2bbcfce634fb_D20220101-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU1NzQ_9179279d-daba-436f-a071-8611cfcdeb00"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i111ea6956a0241f7b44852b8f11b8f68_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc0NTEzOTQ_f61e56ef-771a-4b71-ac7d-a6324f8d92dc"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f1dfd6335a24eddb48dd65039a27f6d_D20210101-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzU2MTc_1d99a33d-b25a-4941-8958-b2ae498b727e"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0729378a52374c80919b47eeb89d45c8_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzY5Mjc_ab3fb277-1d9b-427f-ad70-63b76588b547"
      unitRef="usd">22000000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i22e6b4b0386445c2b216f9309b164440_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzcxNjc_e6f95e6d-34a9-405a-ba05-04173b206f79"
      unitRef="usd">9000000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id8bf1cff4bcf46a8a95e2b2f3561e4d8_I20221002"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzcxNzk_88733067-7c93-4016-b36a-61bd8b7c5e58"
      unitRef="usd">13000000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i26e1cf1555744ef5a90bad26608bf34f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzcxOTQ_6b1c4730-beac-4cb6-a44e-131c8fa4c054"
      unitRef="usd">200000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5156002b7783431eaae2362428a7dad3_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2MTI_6a998a2c-408d-4e74-8870-95ac221abf77"
      unitRef="usd">6200000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5156002b7783431eaae2362428a7dad3_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2MzA_4dd003b3-1878-4e38-ad20-f9bc55e6d5c1"
      unitRef="usd">6100000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5156002b7783431eaae2362428a7dad3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2Mzc_36f2b42e-829e-4fd5-a10a-5cb2810614eb"
      unitRef="usd">126000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia747d02316fd4b71a97be55a1aeac96c_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc3NTE_bad2e8c8-fc71-4257-af02-be06d4a29795"
      unitRef="usd">3300000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia747d02316fd4b71a97be55a1aeac96c_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc3ODQ_c56e9b60-3b10-469a-8fe7-7ec086fc4f41"
      unitRef="usd">3000000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia747d02316fd4b71a97be55a1aeac96c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc3OTE_d22feb7f-dd14-49a3-a7d1-280eb5676aa4"
      unitRef="usd">249000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2ec84b4e39aa4cbfa3468dab7b9c69a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc4Nzk_0443e8a0-2424-47c0-93e8-09dbf7afb399"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i134056e8daf84277a6603491cf1250cf_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzE2NDkyNjc0NTEyMjE_d74cbde5-6a71-492b-b3a0-df0e013e761e"
      unitRef="usd">68000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0f817b3f9c904714845e29d3b0c9c8f6_D20220101-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzgzNTQ_10e60b03-493b-4545-ad83-98d506981fcd"
      unitRef="usd">2500000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts reclassified from OCI were reclassified into OID.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#x2014;net, included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtNi0xLTEtNDI5Njcx_10766cc4-497b-4d71-90e2-70dce9afa69a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma&#x2019;s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $1.3 billion recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $701 million ($344 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the remaining amounts primarily recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $1.6 billion recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and (ii) actuarial valuation and other pension and postretirement plan gains of $932 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $1.1 billion ($310 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $899 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $823 million ($150 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expense</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the remaining amount primarily recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). For additional information, see </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTYtMS0xLTQyOTY3MQ_17d20585-f67b-440d-aae6-0dbe632ed11b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reflects an intangible asset written down to fair value in 2022. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1F </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2021 Form 10-K</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0yLTEtMS00NTU0Nzg_8deb7d1e-0d62-4226-9fe7-02493ed585af"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTAtMS0xLTQyOTY3MQ_b8932a67-cd9c-4629-9454-31595739845b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtOC0xLTEtNDI5Njcx_72c4959c-08cf-4acb-834d-eb500cf3a2ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtNi0xLTEtNDI5Njcx_a95bd646-0ed5-4189-84b1-11620096a21b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related short-term borrowings&#x2019; carrying value as of December 31, 2021 was $1.1&#160;billion. The related long-term debt carrying values as of October&#160;2, 2022 and December 31, 2021 were $726 million and $844 million, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTAtMS0xLTQyOTY3MQ_92287eda-434e-424c-bb52-13beb8abf537"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtNi0xLTEtNDI5Njcx_1ebefa14-d3aa-4b09-aeab-4d198b38405a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMi0xLTEtNDI5Njcx_3a22c6d2-ec34-41b0-95ce-b52fff4ed2ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7&#160;million and $108&#160;million for the third quarter and the first nine months of 2022, respectively, and $187&#160;million and $274&#160;million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtOC0xLTEtNDI5Njcx_6ba1594c-9441-42e1-9461-793146fc9708"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtMTAtMS0xLTQyOTY3MQ_4ba4b32f-8d30-4c99-b6f1-86bbaab487d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for IPR&amp;D, is partially offset by an impairment (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNi0xLTEtNDI5Njcx_6d25629d-b307-47cb-b2b1-bdb83213914d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi02LTEtMS00Mjk2NzE_a758acb1-473e-4cac-b302-eb02a754872f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtNi0xLTEtNDI5Njcx_cd3ca38a-94bb-40db-b46f-7312f87e9122"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTItMS0xLTQyOTY3MQ_bdec1b69-2238-4a45-98e5-b057ebef86c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts reclassified from OCI into COS were:<xhtml:div style="padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $125 million in the third quarter of 2022; </xhtml:span></xhtml:div><xhtml:div style="padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $227 million in the first nine months of 2022;</xhtml:span></xhtml:div><xhtml:div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $18 million in the third quarter of 2021; and</xhtml:span></xhtml:div><xhtml:div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $94 million in the first nine months of 2021. </xhtml:span></xhtml:div><xhtml:div style="padding-left:9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $1 billion within the next 12 months into income</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMC0xLTEtNDI5Njcx_f6638020-da32-4676-a582-d743de61ccf4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy04LTEtMS00NTU0ODY_53a1d44f-2b18-4a97-bd50-666d91afbd90"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTAtMS0xLTQyOTY3MQ_6dd0bc86-6ad4-44e9-bf8f-4a9757642099"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMTItMS0xLTQyOTY3MQ_abc37ceb-9397-4496-8038-aa1d9098b470"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTAtMS0xLTQyOTY3MQ_484ca012-21fd-4f20-8215-7b744bd0c6c8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtMTItMS0xLTQyOTY3MQ_1da28a72-eb43-42e7-b483-331df4bdb26b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTAtMS0xLTQyOTY3MQ_0d1e1fed-8399-4a65-8576-2a83bc26adb7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtOC0xLTEtNDI5Njcx_bc65651f-b1b3-427d-b5a6-1f0f806f4288"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtOC0xLTEtNDI5Njcx_be47a90e-dc04-45e9-ad68-ce3137190a7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtOC0xLTEtNDI5Njcx_5deb8f05-26ae-45a3-b746-aa868cb0cc84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS0xMi0xLTEtNDI5Njcx_e1164f70-8318-4e1a-a897-75f4e55f38ec"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtOC0xLTEtNDI5Njcx_2134aa0c-08a9-4733-8f00-f88ae0669b6c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTAtMS0xLTQyOTY3MQ_9b7e84c6-8b63-49c2-983f-0516e492700b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktOC0xLTEtNDI5Njcx_357f9dc4-e44e-4a12-8cc6-9c2c55f71b78"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtNi0xLTEtNDI5Njcx_c98a8a45-4e97-4458-8b05-4a09cf17d3e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtMi0xLTEtNDI5Njcx_c8bf4c07-9c08-4ba0-a14e-633c1ce32a16"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;D</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $426 million of acquired IPR&amp;D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of approximately $400 million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $516 million. In the third quarter and first nine months of 2021, earnings include $706 million of acquired IPR&amp;D expenses associated with our collaboration with Arvinas.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTYtMS0xLTQyOTY3MQ_e57209a7-32a0-409f-8ded-bee8436aa631"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTItMS0xLTQyOTY3MQ_5781ed10-150a-459c-8aae-4f7fd5e82603"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi04LTEtMS00Mjk2NzE_9497dd27-677d-4adb-8a82-08f10c9108d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzgtMTAtMS0xLTQyOTY3MQ_ecf9480f-b3a7-48af-94e8-f6eda3b96dac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtOC0xLTEtNDI5Njcx_9a2727cd-22f6-43dd-97f9-d20bcad45c78"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtMTItMS0xLTQyOTY3MQ_5bd4a229-b36e-4798-997c-3d7c25ec2ea0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTItMS0xLTQyOTY3MQ_a2d67434-1504-4850-a669-436e98127552"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTAtMS0xLTQyOTY3MQ_3630bdc8-d90d-47d1-909f-64ef6c328876"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNC0xLTEtNDI5Njcx_5df8c177-a631-41fe-b3ba-93767a4577aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzMtNi0xLTEtNDI5Njcx_f4c01c9f-d885-4082-834f-266a6254f92d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtMTAtMS0xLTQyOTY3MQ_8dedba3d-e313-4a99-9289-1e2908e177b8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTAtMS0xLTQyOTY3MQ_e1d2e04c-36d4-4b1d-9156-26abdac13f66"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtOC0xLTEtNDI5Njcx_200c6356-5fc1-44ac-818e-fca6301705fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTQtMTAtMS0xLTQyOTY3MQ_f5b000e4-f67a-4645-aee8-20ea844ae5ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTEw_9923cd38-7dbe-4b3b-b819-55589f178430" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTEw_9923cd38-7dbe-4b3b-b819-55589f178430" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Additions relate to our acquisition of Arena. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTEw_9923cd38-7dbe-4b3b-b819-55589f178430"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMy0xMC0xLTEtNDI5Njcx_f3b2e404-cf96-439a-a2c1-de8cf82c9957"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS02LTEtMS00Mjk2NzE_96e55bc6-01c3-4402-81e1-00b7cd8ccbd0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy00LTEtMS00NTU0ODA_bd405618-a258-4624-9d02-f57eee5c768e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctNi0xLTEtNDI5Njcx_49177805-4b5f-4f3e-b93f-3add4d47407c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNi0xMC0xLTEtNDI5Njcx_f797ce5c-7617-4b82-baf7-db8f94826362"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNS04LTEtMS00Mjk2NzE_9618a62d-2862-462c-bd8f-6cb6f511eb85"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA4_88447592-90a8-41ca-a4c9-329debacc876"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTQtNC0xLTEtNDI5Njcx_eb84945e-52b0-4615-b8a5-3694fefcee40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtOC0xLTEtNDI5Njcx_fce33337-df7e-4066-992c-f6ce42739cc0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTQtMS0xLTQyOTY3MQ_a32cdefc-e04d-40dd-a345-e55339a7cc5f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjAtOC0xLTEtNDI5Njcx_fff98f6c-316f-4c6d-91fa-9f19923aab99"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtNi0xLTEtNDI5Njcx_d37a383b-bd31-4324-bbdd-cce7d2012e6b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA0_6ca71259-76f1-49da-935c-89714090a072" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA0_6ca71259-76f1-49da-935c-89714090a072" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other represents the impact of foreign exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTA0_6ca71259-76f1-49da-935c-89714090a072"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNC0xMC0xLTEtNDI5Njcx_3cfb3c69-7349-4c55-8481-b98a43d0b959"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtOC0xLTEtNDI5Njcx_ff8e9dc4-ca3d-4017-ba9e-40ba3254d60b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctOC0xLTEtNDI5Njcx_a2f0f377-5518-499a-af26-551e26ba34e4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDAtNi0xLTEtNDI5Njcx_ffe5d2dd-94f4-41dc-a442-22dcd3a0fb72"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktMTItMS0xLTQyOTY3MQ_090c4023-eb14-4cca-b16a-e70737a4401f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDQtNi0xLTEtNDI5Njcx_bb3ec4e0-5e57-4753-ba40-30eff0c8b3c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDEtMTItMS0xLTQyOTY3MQ_ede301f0-4cb6-4063-a6fd-62331dafc61d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0OQ_1fddf87d-d523-4bfa-ac81-3f05e398c1c0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy02LTEtMS00NTU0ODI_ab898217-4818-4c19-9393-5b8a36165082"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzAtMTItMS0xLTQyOTY3MQ_ba330290-d952-4b20-afa6-ff27d1da5af8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5Ng_badb3790-a5d0-4bc3-b229-cdb6ae197c8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE0LTEtMS00Mjk2NzE_b743906b-f7a5-4e1c-85b0-649b12992cfc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTctMTItMS0xLTQyOTY3MQ_ff32da27-5284-4edf-b7cb-46af7a1a8dfe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTYtMTItMS0xLTQyOTY3MQ_9d285ef5-ed1c-4221-9c73-ee4d4a8382f1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAyMg_8f5f638c-9e57-48f7-be9b-361c196e6491"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTE2LTEtMS00Mjk2NzE_5e715d68-c763-4829-9649-88f5b8e8bfa3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNi0xLTEtNDI5Njcx_f3159688-42a9-4a15-ba7a-8175631012b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTgtMS0xLTQyOTY3MQ_d45e9f13-7677-4173-965f-b52916cb3ead"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5NA_912560c3-6721-4270-bbba-56596ec6d5c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjktNi0xLTEtNDI5Njcx_cf0cc69a-d7ba-4334-b0f9-a2b1447649d1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEyLTEtMS00Mjk2NzE_82f8212f-cbfd-4463-bb16-46a3bf600668"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEyLTEtMS00Mjk2NzE_82f8212f-cbfd-4463-bb16-46a3bf600668"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTItMS0xLTQyOTY3MQ_4963ea75-ee90-4f56-94c3-f8145aae7c59"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTItMS0xLTQyOTY3MQ_4963ea75-ee90-4f56-94c3-f8145aae7c59"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEwLTEtMS00Mjk2NzE_5b3efcd4-f969-46c7-80c1-a92dec07a833"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEwLTEtMS00Mjk2NzE_5b3efcd4-f969-46c7-80c1-a92dec07a833"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTQtMS0xLTQyOTY3MQ_eefa11be-3c33-414f-aa24-e637b9e13a2d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTQtMS0xLTQyOTY3MQ_eefa11be-3c33-414f-aa24-e637b9e13a2d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEyLTEtMS00Mjk2NzE_82f8212f-cbfd-4463-bb16-46a3bf600668"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTItMS0xLTQyOTY3MQ_4963ea75-ee90-4f56-94c3-f8145aae7c59"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTEwLTEtMS00Mjk2NzE_5b3efcd4-f969-46c7-80c1-a92dec07a833"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzEwLTQtMS0xLTQyOTY3MQ_eefa11be-3c33-414f-aa24-e637b9e13a2d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNTg_7b93e293-e435-4762-827b-5506499e3aa6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC0yLTEtMS00Mjk2NzE_7ec794a7-64fc-462c-ba71-8d64150189b3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC0yLTEtMS00Mjk2NzE_7ec794a7-64fc-462c-ba71-8d64150189b3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC00LTEtMS00Mjk2NzE_a263b85b-e520-4043-a264-bac7e134fa07"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC00LTEtMS00Mjk2NzE_a263b85b-e520-4043-a264-bac7e134fa07"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjIy_3f8ba6ba-a903-4756-95e1-240772a5e732" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjIy_3f8ba6ba-a903-4756-95e1-240772a5e732" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 7F</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC0yLTEtMS00Mjk2NzE_7ec794a7-64fc-462c-ba71-8d64150189b3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjIy_3f8ba6ba-a903-4756-95e1-240772a5e732"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RhYmxlOjYzMjZlNDI4YWE2MTQ0NWRiODc1MDI1M2VjMThmYTAyL3RhYmxlcmFuZ2U6NjMyNmU0MjhhYTYxNDQ1ZGI4NzUwMjUzZWMxOGZhMDJfNC00LTEtMS00Mjk2NzE_a263b85b-e520-4043-a264-bac7e134fa07"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83MC9mcmFnOmU1YjE0NTQ1MzUzYTRmYmJiM2YwMGJkN2JiYWU4ZGVmL3RleHRyZWdpb246ZTViMTQ1NDUzNTNhNGZiYmIzZjAwYmQ3YmJhZThkZWZfMjIy_3f8ba6ba-a903-4756-95e1-240772a5e732"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNi0xLTEtNDI5Njcx_0a9e4766-78e0-4f4d-a516-d8ff1d77c48e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNi0xLTEtNDI5Njcx_0a9e4766-78e0-4f4d-a516-d8ff1d77c48e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktMi0xLTEtNDI5Njcx_4ec007b4-6ac4-497a-8dec-4da658597588"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktMi0xLTEtNDI5Njcx_4ec007b4-6ac4-497a-8dec-4da658597588"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNC0xLTEtNDI5Njcx_65a1690b-56f3-43a3-ba0b-a7b1b251e5f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNC0xLTEtNDI5Njcx_65a1690b-56f3-43a3-ba0b-a7b1b251e5f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktOC0xLTEtNDI5Njcx_d3fed0bf-d915-4612-8a1c-f7389bce1827"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktOC0xLTEtNDI5Njcx_d3fed0bf-d915-4612-8a1c-f7389bce1827"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNi0xLTEtNDI5Njcx_0a9e4766-78e0-4f4d-a516-d8ff1d77c48e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktMi0xLTEtNDI5Njcx_4ec007b4-6ac4-497a-8dec-4da658597588"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktNC0xLTEtNDI5Njcx_65a1690b-56f3-43a3-ba0b-a7b1b251e5f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RhYmxlOmEzMzZiY2QxY2JlNTQ4YTViODZmMDc0ZDg0NGE5ZTI3L3RhYmxlcmFuZ2U6YTMzNmJjZDFjYmU1NDhhNWI4NmYwNzRkODQ0YTllMjdfMTktOC0xLTEtNDI5Njcx_d3fed0bf-d915-4612-8a1c-f7389bce1827"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85NC9mcmFnOmNiYWY5MzEyNzA0ZDRkOTM5NTExNzM1MWM1YTBlODQ2L3RleHRyZWdpb246Y2JhZjkzMTI3MDRkNGQ5Mzk1MTE3MzUxYzVhMGU4NDZfMjQ0_ad8f2bcf-105e-4aa9-b004-7a2b146a8535"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS02LTEtMS00Mjk2NzE_8544ae2b-5f21-437e-b021-ac522c5a2d24"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS02LTEtMS00Mjk2NzE_8544ae2b-5f21-437e-b021-ac522c5a2d24"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS04LTEtMS00Mjk2NzE_94b6c3d5-e3c3-45f7-bb93-09c0ebe86c83"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS04LTEtMS00Mjk2NzE_94b6c3d5-e3c3-45f7-bb93-09c0ebe86c83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS00LTEtMS00Mjk2NzE_29b75c68-773e-4ad8-bbb3-abd94eb1b2cb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS00LTEtMS00Mjk2NzE_29b75c68-773e-4ad8-bbb3-abd94eb1b2cb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS0yLTEtMS00Mjk2NzE_0f02e791-2a53-4174-8273-fb3671668c74"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS0yLTEtMS00Mjk2NzE_0f02e791-2a53-4174-8273-fb3671668c74"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($758 million) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($110 million).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS02LTEtMS00Mjk2NzE_8544ae2b-5f21-437e-b021-ac522c5a2d24"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS04LTEtMS00Mjk2NzE_94b6c3d5-e3c3-45f7-bb93-09c0ebe86c83"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS00LTEtMS00Mjk2NzE_29b75c68-773e-4ad8-bbb3-abd94eb1b2cb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNS0yLTEtMS00Mjk2NzE_0f02e791-2a53-4174-8273-fb3671668c74"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc2Nw_bfb6d8e6-c739-47e6-99bf-60f0d96c81e4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItOC0xLTEtNDI5Njcx_00d1ae0d-5416-453b-a4cc-e1d982d37e99"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItOC0xLTEtNDI5Njcx_00d1ae0d-5416-453b-a4cc-e1d982d37e99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNC0xLTEtNDI5Njcx_97d270b7-b1ce-45e6-b737-833c464ba639"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNC0xLTEtNDI5Njcx_97d270b7-b1ce-45e6-b737-833c464ba639"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNi0xLTEtNDI5Njcx_626fee7e-657f-4788-a035-b8cd2f31808f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNi0xLTEtNDI5Njcx_626fee7e-657f-4788-a035-b8cd2f31808f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItMi0xLTEtNDI5Njcx_57e6f583-7137-404d-adb6-5515aacc01aa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItMi0xLTEtNDI5Njcx_57e6f583-7137-404d-adb6-5515aacc01aa"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amount in the </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">third quarter and first nine months of 2022 represents an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&amp;D asset for the unapproved indication of symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), acquired in our Array BioPharma Inc. acquisition. The intangible asset impairment charge was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItOC0xLTEtNDI5Njcx_00d1ae0d-5416-453b-a4cc-e1d982d37e99"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNC0xLTEtNDI5Njcx_97d270b7-b1ce-45e6-b737-833c464ba639"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItNi0xLTEtNDI5Njcx_626fee7e-657f-4788-a035-b8cd2f31808f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTItMi0xLTEtNDI5Njcx_57e6f583-7137-404d-adb6-5515aacc01aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk0Nw_c30a46bb-161c-4b73-9a8d-a660d9f5f036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS0yLTEtMS00Mjk2NzE_5eb218ae-d9ad-49f3-b2f8-d149de85dbf7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS0yLTEtMS00Mjk2NzE_5eb218ae-d9ad-49f3-b2f8-d149de85dbf7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC0yLTEtMS00Mjk2NzE_4f224122-0a35-4e3f-9dd0-11041329633b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC0yLTEtMS00Mjk2NzE_4f224122-0a35-4e3f-9dd0-11041329633b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi04LTEtMS00Mjk2NzE_e873dbff-e914-4e5b-8326-561e7d2cf216"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi04LTEtMS00Mjk2NzE_e873dbff-e914-4e5b-8326-561e7d2cf216"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi02LTEtMS00Mjk2NzE_5437d538-f3b1-46a7-bced-fe9257f5f05a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi02LTEtMS00Mjk2NzE_5437d538-f3b1-46a7-bced-fe9257f5f05a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS04LTEtMS00Mjk2NzE_7624d374-59ee-4834-9165-8897722eb1be"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS04LTEtMS00Mjk2NzE_7624d374-59ee-4834-9165-8897722eb1be"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC02LTEtMS00Mjk2NzE_4e16e5b6-403b-4338-ba8d-a34667b802d1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC02LTEtMS00Mjk2NzE_4e16e5b6-403b-4338-ba8d-a34667b802d1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi0yLTEtMS00Mjk2NzE_44117283-5b09-4994-af4d-2d8dda2ed9cf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi0yLTEtMS00Mjk2NzE_44117283-5b09-4994-af4d-2d8dda2ed9cf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC00LTEtMS00Mjk2NzE_2fa4bb9e-0957-4c96-9091-0393874e4de4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC00LTEtMS00Mjk2NzE_2fa4bb9e-0957-4c96-9091-0393874e4de4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS02LTEtMS00Mjk2NzE_5f1649a3-e04e-4ee8-a021-870ef2ee4d98"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS02LTEtMS00Mjk2NzE_5f1649a3-e04e-4ee8-a021-870ef2ee4d98"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC04LTEtMS00Mjk2NzE_3b2e2844-68e7-410e-8433-e1a05ba0a696"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC04LTEtMS00Mjk2NzE_3b2e2844-68e7-410e-8433-e1a05ba0a696"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi00LTEtMS00Mjk2NzE_53845acb-2cf8-4668-b312-61c0ac2a9c31"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi00LTEtMS00Mjk2NzE_53845acb-2cf8-4668-b312-61c0ac2a9c31"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS00LTEtMS00Mjk2NzE_ed942a2c-7590-489c-aabc-dfef446d4052"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS00LTEtMS00Mjk2NzE_ed942a2c-7590-489c-aabc-dfef446d4052"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Exclusive of amortization of intangible assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS0yLTEtMS00Mjk2NzE_5eb218ae-d9ad-49f3-b2f8-d149de85dbf7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC0yLTEtMS00Mjk2NzE_4f224122-0a35-4e3f-9dd0-11041329633b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi04LTEtMS00Mjk2NzE_e873dbff-e914-4e5b-8326-561e7d2cf216"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi02LTEtMS00Mjk2NzE_5437d538-f3b1-46a7-bced-fe9257f5f05a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS04LTEtMS00Mjk2NzE_7624d374-59ee-4834-9165-8897722eb1be"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC02LTEtMS00Mjk2NzE_4e16e5b6-403b-4338-ba8d-a34667b802d1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi0yLTEtMS00Mjk2NzE_44117283-5b09-4994-af4d-2d8dda2ed9cf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC00LTEtMS00Mjk2NzE_2fa4bb9e-0957-4c96-9091-0393874e4de4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS02LTEtMS00Mjk2NzE_5f1649a3-e04e-4ee8-a021-870ef2ee4d98"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNC04LTEtMS00Mjk2NzE_3b2e2844-68e7-410e-8433-e1a05ba0a696"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNi00LTEtMS00Mjk2NzE_53845acb-2cf8-4668-b312-61c0ac2a9c31"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNS00LTEtMS00Mjk2NzE_ed942a2c-7590-489c-aabc-dfef446d4052"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTk1_ed28ad59-bd66-44e1-bd8e-543a85ecf08d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTYtMS0xLTQyOTY3MQ_945cea22-a4ed-4fcc-a514-2cd8d824094b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTYtMS0xLTQyOTY3MQ_945cea22-a4ed-4fcc-a514-2cd8d824094b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTEwLTEtMS00Mjk2NzE_1b1bd2f4-3d49-406d-a698-4ea9fc91acac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTEwLTEtMS00Mjk2NzE_1b1bd2f4-3d49-406d-a698-4ea9fc91acac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTgtMS0xLTQyOTY3MQ_f6b12f8a-bcea-47d3-9125-6393606efd3c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTgtMS0xLTQyOTY3MQ_f6b12f8a-bcea-47d3-9125-6393606efd3c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTQtMS0xLTQyOTY3MQ_0c8722b8-2872-4bf9-b21e-e3d503546382"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTQtMS0xLTQyOTY3MQ_0c8722b8-2872-4bf9-b21e-e3d503546382"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Erbitux</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#xae;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTYtMS0xLTQyOTY3MQ_945cea22-a4ed-4fcc-a514-2cd8d824094b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTEwLTEtMS00Mjk2NzE_1b1bd2f4-3d49-406d-a698-4ea9fc91acac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTgtMS0xLTQyOTY3MQ_f6b12f8a-bcea-47d3-9125-6393606efd3c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzM1LTQtMS0xLTQyOTY3MQ_0c8722b8-2872-4bf9-b21e-e3d503546382"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjE_965542cf-a5b3-4bd9-ace9-320e6893b132"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMC0xLTEtNDI5Njcx_493e4ba9-7b8f-408d-ac44-f4a29de69d63"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMC0xLTEtNDI5Njcx_493e4ba9-7b8f-408d-ac44-f4a29de69d63"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0yLTEtMS00Mjk2NzE_4ca766d1-f980-4cf2-8135-ebd81ac499b7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0yLTEtMS00Mjk2NzE_4ca766d1-f980-4cf2-8135-ebd81ac499b7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC00LTEtMS00Mjk2NzE_de3ad6c3-47cb-4953-bb35-35061c8d9092"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC00LTEtMS00Mjk2NzE_de3ad6c3-47cb-4953-bb35-35061c8d9092"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMi0xLTEtNDI5Njcx_3ccb185c-d21e-497d-9541-82146f5868b4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMi0xLTEtNDI5Njcx_3ccb185c-d21e-497d-9541-82146f5868b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC02LTEtMS00Mjk2NzE_4bd91447-2eeb-4b1d-84e8-75f3886b7b62"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC02LTEtMS00Mjk2NzE_4bd91447-2eeb-4b1d-84e8-75f3886b7b62"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in Haleon/the Consumer Healthcare JV (see</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMC0xLTEtNDI5Njcx_493e4ba9-7b8f-408d-ac44-f4a29de69d63"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0yLTEtMS00Mjk2NzE_4ca766d1-f980-4cf2-8135-ebd81ac499b7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC00LTEtMS00Mjk2NzE_de3ad6c3-47cb-4953-bb35-35061c8d9092"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC0xMi0xLTEtNDI5Njcx_3ccb185c-d21e-497d-9541-82146f5868b4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RhYmxlOjBhMDMwODkzNDdlMjQ3ZDg4NDZhYzFlYjU0YWU0NTllL3RhYmxlcmFuZ2U6MGEwMzA4OTM0N2UyNDdkODg0NmFjMWViNTRhZTQ1OWVfNC02LTEtMS00Mjk2NzE_4bd91447-2eeb-4b1d-84e8-75f3886b7b62"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82MS9mcmFnOjUzYzMwMzE2OTMzMDQ5Y2Q4NTQyY2FlYjUwZjhiZTcyL3RleHRyZWdpb246NTNjMzAzMTY5MzMwNDljZDg1NDJjYWViNTBmOGJlNzJfMzI4_458437eb-e1ec-4dd8-a6cc-ade6a431a4a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS00LTEtMS00Mjk2NzE_e4668477-5c06-4db4-abbd-1dbe4b47532b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS00LTEtMS00Mjk2NzE_e4668477-5c06-4db4-abbd-1dbe4b47532b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS0yLTEtMS00Mjk2NzE_024cc055-6b5e-4f81-9da0-c6acda341735"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS0yLTEtMS00Mjk2NzE_024cc055-6b5e-4f81-9da0-c6acda341735"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTA5_e27b3df5-fe48-465d-9f76-7923a63796dc" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTA5_e27b3df5-fe48-465d-9f76-7923a63796dc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS00LTEtMS00Mjk2NzE_e4668477-5c06-4db4-abbd-1dbe4b47532b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTA5_e27b3df5-fe48-465d-9f76-7923a63796dc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNS0yLTEtMS00Mjk2NzE_024cc055-6b5e-4f81-9da0-c6acda341735"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTA5_e27b3df5-fe48-465d-9f76-7923a63796dc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTgtMS0xLTQyOTY3MQ_bea1bcfd-0ccb-44e5-9196-b6600e3f9f50"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTgtMS0xLTQyOTY3MQ_bea1bcfd-0ccb-44e5-9196-b6600e3f9f50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktOC0xLTEtNDI5Njcx_013b7d41-ff1d-4bc4-9652-bab9578b9d88"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktOC0xLTEtNDI5Njcx_013b7d41-ff1d-4bc4-9652-bab9578b9d88"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTYtMS0xLTQyOTY3MQ_2c73d3fe-554a-48ee-a459-c86ae5e5b0d6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTYtMS0xLTQyOTY3MQ_2c73d3fe-554a-48ee-a459-c86ae5e5b0d6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtOC0xLTEtNDI5Njcx_3970ef26-7ab4-4db5-9b5c-26484f676cc9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtOC0xLTEtNDI5Njcx_3970ef26-7ab4-4db5-9b5c-26484f676cc9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNi0xLTEtNDI5Njcx_070c8ab3-8d87-4f6e-aab6-87c2cfbc7637"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNi0xLTEtNDI5Njcx_070c8ab3-8d87-4f6e-aab6-87c2cfbc7637"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNi0xLTEtNDI5Njcx_ce73b70f-34ce-448f-807d-04c0483f9a88"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNi0xLTEtNDI5Njcx_ce73b70f-34ce-448f-807d-04c0483f9a88"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTQtMS0xLTQyOTY3MQ_074836b2-faee-4d14-b5d9-ab6657e72802"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTQtMS0xLTQyOTY3MQ_074836b2-faee-4d14-b5d9-ab6657e72802"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTYtMS0xLTQyOTY3MQ_bab49336-8663-4d3a-b54b-642ee3f94a67"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTYtMS0xLTQyOTY3MQ_bab49336-8663-4d3a-b54b-642ee3f94a67"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTQtMS0xLTQyOTY3MQ_226e5b3b-54b5-4194-b403-f87f87f87f9c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTQtMS0xLTQyOTY3MQ_226e5b3b-54b5-4194-b403-f87f87f87f9c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtOC0xLTEtNDI5Njcx_4cdfb2b0-ed3d-4b43-8cda-eab2c971db6e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtOC0xLTEtNDI5Njcx_4cdfb2b0-ed3d-4b43-8cda-eab2c971db6e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTYtMS0xLTQyOTY3MQ_1b6cb69e-152f-4b80-b384-2bb98a4369c5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTYtMS0xLTQyOTY3MQ_1b6cb69e-152f-4b80-b384-2bb98a4369c5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTQtMS0xLTQyOTY3MQ_ddcf4ce1-5e2a-490e-b1be-26e2a0de3ab1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTQtMS0xLTQyOTY3MQ_ddcf4ce1-5e2a-490e-b1be-26e2a0de3ab1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTYtMS0xLTQyOTY3MQ_6962e718-3d63-4e6f-9c5e-93659d844f06"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTYtMS0xLTQyOTY3MQ_6962e718-3d63-4e6f-9c5e-93659d844f06"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNi0xLTEtNDI5Njcx_9efc31e5-89bc-4e23-ab26-ff76bde76ab9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNi0xLTEtNDI5Njcx_9efc31e5-89bc-4e23-ab26-ff76bde76ab9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE0LTEtMS00Mjk2NzE_c87a90a1-97f6-4519-9d12-26b54b67d3b6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE0LTEtMS00Mjk2NzE_c87a90a1-97f6-4519-9d12-26b54b67d3b6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE2LTEtMS00Mjk2NzE_eee3e1e2-82fe-4633-bb68-b14a0ba0abc1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE2LTEtMS00Mjk2NzE_eee3e1e2-82fe-4633-bb68-b14a0ba0abc1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTgtMS0xLTQyOTY3MQ_bea1bcfd-0ccb-44e5-9196-b6600e3f9f50"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktOC0xLTEtNDI5Njcx_013b7d41-ff1d-4bc4-9652-bab9578b9d88"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTYtMS0xLTQyOTY3MQ_2c73d3fe-554a-48ee-a459-c86ae5e5b0d6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtOC0xLTEtNDI5Njcx_3970ef26-7ab4-4db5-9b5c-26484f676cc9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtNi0xLTEtNDI5Njcx_070c8ab3-8d87-4f6e-aab6-87c2cfbc7637"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtNi0xLTEtNDI5Njcx_ce73b70f-34ce-448f-807d-04c0483f9a88"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTQtMS0xLTQyOTY3MQ_074836b2-faee-4d14-b5d9-ab6657e72802"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTYtMS0xLTQyOTY3MQ_bab49336-8663-4d3a-b54b-642ee3f94a67"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtMTQtMS0xLTQyOTY3MQ_226e5b3b-54b5-4194-b403-f87f87f87f9c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzgtOC0xLTEtNDI5Njcx_4cdfb2b0-ed3d-4b43-8cda-eab2c971db6e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzUtMTYtMS0xLTQyOTY3MQ_1b6cb69e-152f-4b80-b384-2bb98a4369c5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTQtMS0xLTQyOTY3MQ_ddcf4ce1-5e2a-490e-b1be-26e2a0de3ab1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktMTYtMS0xLTQyOTY3MQ_6962e718-3d63-4e6f-9c5e-93659d844f06"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzktNi0xLTEtNDI5Njcx_9efc31e5-89bc-4e23-ab26-ff76bde76ab9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE0LTEtMS00Mjk2NzE_c87a90a1-97f6-4519-9d12-26b54b67d3b6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzExLTE2LTEtMS00Mjk2NzE_eee3e1e2-82fe-4633-bb68-b14a0ba0abc1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDE_d2badc63-292d-47dd-86fc-0a89772ac6e5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtMi0xLTEtNDI5Njcx_982648aa-6469-48be-99c5-f6a8806bdbf1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtMi0xLTEtNDI5Njcx_982648aa-6469-48be-99c5-f6a8806bdbf1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtNC0xLTEtNDI5Njcx_9035346d-b158-4367-9a1d-296132bb041b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtNC0xLTEtNDI5Njcx_9035346d-b158-4367-9a1d-296132bb041b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgw_14ab4f6d-72db-4770-bbaf-3b5b5c0fc91d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgw_14ab4f6d-72db-4770-bbaf-3b5b5c0fc91d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represent investments in the life sciences sector</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtMi0xLTEtNDI5Njcx_982648aa-6469-48be-99c5-f6a8806bdbf1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgw_14ab4f6d-72db-4770-bbaf-3b5b5c0fc91d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMTMtNC0xLTEtNDI5Njcx_9035346d-b158-4367-9a1d-296132bb041b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzgw_14ab4f6d-72db-4770-bbaf-3b5b5c0fc91d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtMi0xLTEtNDI5Njcx_90ce7781-3290-4ad3-93af-3e5a8675bded"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtMi0xLTEtNDI5Njcx_90ce7781-3290-4ad3-93af-3e5a8675bded"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtOC0xLTEtNDI5Njcx_e0cfea43-1a3e-48c2-acee-7ea66cde29d7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtOC0xLTEtNDI5Njcx_e0cfea43-1a3e-48c2-acee-7ea66cde29d7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNi0xLTEtNDI5Njcx_b59868eb-033a-4a90-b591-19c42eeddd39"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNi0xLTEtNDI5Njcx_b59868eb-033a-4a90-b591-19c42eeddd39"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtMi0xLTEtNDI5Njcx_60d08d81-6843-466f-90a4-c0b3b770f412"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtMi0xLTEtNDI5Njcx_60d08d81-6843-466f-90a4-c0b3b770f412"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtOC0xLTEtNDI5Njcx_553fd7bb-a59b-4591-a381-13146ee4220f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtOC0xLTEtNDI5Njcx_553fd7bb-a59b-4591-a381-13146ee4220f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtOC0xLTEtNDI5Njcx_318869ec-9960-4b91-bdb4-182356a4bc99"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtOC0xLTEtNDI5Njcx_318869ec-9960-4b91-bdb4-182356a4bc99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNi0xLTEtNDI5Njcx_7ac490a0-73b9-452d-bf96-cfa38f3b8865"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNi0xLTEtNDI5Njcx_7ac490a0-73b9-452d-bf96-cfa38f3b8865"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNC0xLTEtNDI5Njcx_7dfd910b-3aeb-4666-97de-f5798800d3f7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNC0xLTEtNDI5Njcx_7dfd910b-3aeb-4666-97de-f5798800d3f7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtMi0xLTEtNDI5Njcx_9c51b6f7-67c7-432c-9e63-82529e0ef233"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtMi0xLTEtNDI5Njcx_9c51b6f7-67c7-432c-9e63-82529e0ef233"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNi0xLTEtNDI5Njcx_b6b5bcac-63bf-4b98-85bf-a5df968d5b98"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNi0xLTEtNDI5Njcx_b6b5bcac-63bf-4b98-85bf-a5df968d5b98"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNC0xLTEtNDI5Njcx_8a45feee-639e-4454-b3fc-f9624de079ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNC0xLTEtNDI5Njcx_8a45feee-639e-4454-b3fc-f9624de079ab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNC0xLTEtNDI5Njcx_82f5e9db-b6b1-4de1-aa74-6c64330ab4e1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNC0xLTEtNDI5Njcx_82f5e9db-b6b1-4de1-aa74-6c64330ab4e1"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtMi0xLTEtNDI5Njcx_90ce7781-3290-4ad3-93af-3e5a8675bded"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtOC0xLTEtNDI5Njcx_e0cfea43-1a3e-48c2-acee-7ea66cde29d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNi0xLTEtNDI5Njcx_b59868eb-033a-4a90-b591-19c42eeddd39"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtMi0xLTEtNDI5Njcx_60d08d81-6843-466f-90a4-c0b3b770f412"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtOC0xLTEtNDI5Njcx_553fd7bb-a59b-4591-a381-13146ee4220f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtOC0xLTEtNDI5Njcx_318869ec-9960-4b91-bdb4-182356a4bc99"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNi0xLTEtNDI5Njcx_7ac490a0-73b9-452d-bf96-cfa38f3b8865"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtNC0xLTEtNDI5Njcx_7dfd910b-3aeb-4666-97de-f5798800d3f7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTQtMi0xLTEtNDI5Njcx_9c51b6f7-67c7-432c-9e63-82529e0ef233"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNi0xLTEtNDI5Njcx_b6b5bcac-63bf-4b98-85bf-a5df968d5b98"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTYtNC0xLTEtNDI5Njcx_8a45feee-639e-4454-b3fc-f9624de079ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTMtNC0xLTEtNDI5Njcx_82f5e9db-b6b1-4de1-aa74-6c64330ab4e1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOQ_17796743-5a39-4c93-91ae-db644c990809"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTItMS0xLTQyOTY3MQ_47c50bf9-f17a-4da7-b80f-308b9a10ebb6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTItMS0xLTQyOTY3MQ_47c50bf9-f17a-4da7-b80f-308b9a10ebb6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS02LTEtMS00Mjk2NzE_911b960f-8d0b-4b2f-9c38-e805e112bc95"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS02LTEtMS00Mjk2NzE_911b960f-8d0b-4b2f-9c38-e805e112bc95"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTAtMS0xLTQyOTY3MQ_68ce4977-b848-4e99-96dd-167dd7408585"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTAtMS0xLTQyOTY3MQ_68ce4977-b848-4e99-96dd-167dd7408585"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNC0xLTEtNDI5Njcx_4142aa1c-bf9b-4904-9c6e-b7c56de66c64"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNC0xLTEtNDI5Njcx_4142aa1c-bf9b-4904-9c6e-b7c56de66c64"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS04LTEtMS00Mjk2NzE_d800e503-a11e-4212-9c70-e64fafc7d253"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS04LTEtMS00Mjk2NzE_d800e503-a11e-4212-9c70-e64fafc7d253"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMi0xLTEtNDI5Njcx_e4c0ad7d-28f7-4dad-9153-c0c4f47032a1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMi0xLTEtNDI5Njcx_e4c0ad7d-28f7-4dad-9153-c0c4f47032a1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNi0xLTEtNDI5Njcx_0afa9a43-daf4-408b-9916-d5dd42011727"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNi0xLTEtNDI5Njcx_0afa9a43-daf4-408b-9916-d5dd42011727"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMC0xLTEtNDI5Njcx_68f6d789-f455-46c8-a3ed-e2cdffa43f1b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMC0xLTEtNDI5Njcx_68f6d789-f455-46c8-a3ed-e2cdffa43f1b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0yLTEtMS00Mjk2NzE_09ed946a-8297-4206-96f6-5ac122523c37"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0yLTEtMS00Mjk2NzE_09ed946a-8297-4206-96f6-5ac122523c37"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMi0xLTEtNDI5Njcx_e6e616e8-ff43-412f-bc24-145f96133e33"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMi0xLTEtNDI5Njcx_e6e616e8-ff43-412f-bc24-145f96133e33"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS00LTEtMS00Mjk2NzE_1f004768-3046-4785-bc33-1afae8b0ea63"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS00LTEtMS00Mjk2NzE_1f004768-3046-4785-bc33-1afae8b0ea63"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtOC0xLTEtNDI5Njcx_7cece672-8cf3-429c-83fa-1158c7aa755c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtOC0xLTEtNDI5Njcx_7cece672-8cf3-429c-83fa-1158c7aa755c"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The third quarter of 2022 mainly reflects interim actuarial remeasurement gains, primarily driven by an increase in the discount rate, partially offset by unfavorable plan asset performance. The first nine months of 2022 mainly reflects interim actuarial remeasurement losses, primarily driven by unfavorable plan asset performance, partially offset by gains due to an increase in the discount rate. In the third quarter and first nine months of 2021, mainly reflects interim actuarial remeasurement gains, primarily due to favorable plan asset performance and an increase in the discount rate. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTItMS0xLTQyOTY3MQ_47c50bf9-f17a-4da7-b80f-308b9a10ebb6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS02LTEtMS00Mjk2NzE_911b960f-8d0b-4b2f-9c38-e805e112bc95"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMTAtMS0xLTQyOTY3MQ_68ce4977-b848-4e99-96dd-167dd7408585"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNC0xLTEtNDI5Njcx_4142aa1c-bf9b-4904-9c6e-b7c56de66c64"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS04LTEtMS00Mjk2NzE_d800e503-a11e-4212-9c70-e64fafc7d253"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtMi0xLTEtNDI5Njcx_e4c0ad7d-28f7-4dad-9153-c0c4f47032a1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtNi0xLTEtNDI5Njcx_0afa9a43-daf4-408b-9916-d5dd42011727"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMC0xLTEtNDI5Njcx_68f6d789-f455-46c8-a3ed-e2cdffa43f1b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0yLTEtMS00Mjk2NzE_09ed946a-8297-4206-96f6-5ac122523c37"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS0xMi0xLTEtNDI5Njcx_e6e616e8-ff43-412f-bc24-145f96133e33"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfOS00LTEtMS00Mjk2NzE_1f004768-3046-4785-bc33-1afae8b0ea63"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RhYmxlOjFjY2NmMzUyYmUyMjRjZDI5ODUxMzczNjBmYTViMDlmL3RhYmxlcmFuZ2U6MWNjY2YzNTJiZTIyNGNkMjk4NTEzNzM2MGZhNWIwOWZfMjMtOC0xLTEtNDI5Njcx_7cece672-8cf3-429c-83fa-1158c7aa755c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV85MS9mcmFnOjA4N2QzZDUyOTI5YzRlYTRiYzUwMjI5ZWRmMGMzZmI0L3RleHRyZWdpb246MDg3ZDNkNTI5MjljNGVhNGJjNTAyMjllZGYwYzNmYjRfNTkz_b73c72b6-9557-4eaa-9a07-e4810159b635"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtOC0xLTEtNDI5Njcx_e1a657ce-6f92-4b88-a040-01ced8e13634"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtOC0xLTEtNDI5Njcx_e1a657ce-6f92-4b88-a040-01ced8e13634"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtMTAtMS0xLTQyOTY3MQ_861ab00a-20e7-4f30-8db0-607aa59a0e6f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtMTAtMS0xLTQyOTY3MQ_861ab00a-20e7-4f30-8db0-607aa59a0e6f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNC0xLTEtNDI5Njcx_f54c2b3d-bcc0-4b2c-8ef0-3b3d36e9523a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNC0xLTEtNDI5Njcx_f54c2b3d-bcc0-4b2c-8ef0-3b3d36e9523a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNi0xLTEtNDI5Njcx_29ca35ef-f9cf-434c-8106-d7cfe2617f64"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNi0xLTEtNDI5Njcx_29ca35ef-f9cf-434c-8106-d7cfe2617f64"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtOC0xLTEtNDI5Njcx_e1a657ce-6f92-4b88-a040-01ced8e13634"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtMTAtMS0xLTQyOTY3MQ_861ab00a-20e7-4f30-8db0-607aa59a0e6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNC0xLTEtNDI5Njcx_f54c2b3d-bcc0-4b2c-8ef0-3b3d36e9523a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzUtNi0xLTEtNDI5Njcx_29ca35ef-f9cf-434c-8106-d7cfe2617f64"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzc2OTY1ODE0NzU3MzM_02853ff5-c677-4b4e-8611-796565c18aed"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNC0xLTEtNDI5Njcx_282468d2-ace2-4483-8f10-fd7dd8256097"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNC0xLTEtNDI5Njcx_282468d2-ace2-4483-8f10-fd7dd8256097"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtMi0xLTEtNDI5Njcx_cf9e841a-ac3f-456b-b46b-755690a8aad7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtMi0xLTEtNDI5Njcx_cf9e841a-ac3f-456b-b46b-755690a8aad7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtOC0xLTEtNDI5Njcx_8c5b20ac-1e31-43a7-9a2e-80389b83155b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtOC0xLTEtNDI5Njcx_8c5b20ac-1e31-43a7-9a2e-80389b83155b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNi0xLTEtNDI5Njcx_691a0ba8-5225-48b9-a6f4-1e75e20d734d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNi0xLTEtNDI5Njcx_691a0ba8-5225-48b9-a6f4-1e75e20d734d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNC0xLTEtNDI5Njcx_282468d2-ace2-4483-8f10-fd7dd8256097"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtMi0xLTEtNDI5Njcx_cf9e841a-ac3f-456b-b46b-755690a8aad7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtOC0xLTEtNDI5Njcx_8c5b20ac-1e31-43a7-9a2e-80389b83155b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfMTEtNi0xLTEtNDI5Njcx_691a0ba8-5225-48b9-a6f4-1e75e20d734d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjcw_b3b93648-a72e-4f3b-85ae-9aca0d5bee4f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy04LTEtMS00Mjk2NzE_86b449de-4569-4595-9b66-d97adb3d390c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy04LTEtMS00Mjk2NzE_86b449de-4569-4595-9b66-d97adb3d390c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy00LTEtMS00Mjk2NzE_824ff5fb-0912-42a1-801a-3a2c58508bc5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy00LTEtMS00Mjk2NzE_824ff5fb-0912-42a1-801a-3a2c58508bc5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy0yLTEtMS00Mjk2NzE_87621f1f-793f-4e86-9eb5-afa1e0e859ec"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy0yLTEtMS00Mjk2NzE_87621f1f-793f-4e86-9eb5-afa1e0e859ec"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy02LTEtMS00Mjk2NzE_a1c2893c-c20e-46fd-b88f-599e3e194b3b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy02LTEtMS00Mjk2NzE_a1c2893c-c20e-46fd-b88f-599e3e194b3b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy04LTEtMS00Mjk2NzE_86b449de-4569-4595-9b66-d97adb3d390c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy00LTEtMS00Mjk2NzE_824ff5fb-0912-42a1-801a-3a2c58508bc5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy0yLTEtMS00Mjk2NzE_87621f1f-793f-4e86-9eb5-afa1e0e859ec"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RhYmxlOmNlZWY4OWNjZjcyMDRkYzdhMmQ2YWY5Nzc4YzJhNDBmL3RhYmxlcmFuZ2U6Y2VlZjg5Y2NmNzIwNGRjN2EyZDZhZjk3NzhjMmE0MGZfMy02LTEtMS00Mjk2NzE_a1c2893c-c20e-46fd-b88f-599e3e194b3b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV81NS9mcmFnOmVhMWU5YWY5OTBhZTQyZDBhNzViYTM0MzA4MjExZTJiL3RleHRyZWdpb246ZWExZTlhZjk5MGFlNDJkMGE3NWJhMzQzMDgyMTFlMmJfMjQ5OQ_ced06755-7454-4204-8ff8-c1af0fc8dee4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMi0xLTEtNDI5Njcx_842617ea-9719-4eab-b73e-1115756af0c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMi0xLTEtNDI5Njcx_842617ea-9719-4eab-b73e-1115756af0c2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTAtMS0xLTQyOTY3MQ_ccb81272-5aac-4f1e-a246-4576be170c8b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTAtMS0xLTQyOTY3MQ_ccb81272-5aac-4f1e-a246-4576be170c8b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNi0xLTEtNDI5Njcx_0661d1b1-662e-4b85-97d1-02884e9bedf8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNi0xLTEtNDI5Njcx_0661d1b1-662e-4b85-97d1-02884e9bedf8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNC0xLTEtNDI5Njcx_6bfa4ccb-a89e-4014-b8a0-4f826bebfb8e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNC0xLTEtNDI5Njcx_6bfa4ccb-a89e-4014-b8a0-4f826bebfb8e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTQtMS0xLTQyOTY3MQ_0ef21eca-e6b7-48e6-88e1-69577f2efbaf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTQtMS0xLTQyOTY3MQ_0ef21eca-e6b7-48e6-88e1-69577f2efbaf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTItMS0xLTQyOTY3MQ_ceabc205-2d62-4e44-a517-a8483c87e5fc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTItMS0xLTQyOTY3MQ_ceabc205-2d62-4e44-a517-a8483c87e5fc"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Long-term equity securities of $139 million as of October&#160;2, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMi0xLTEtNDI5Njcx_842617ea-9719-4eab-b73e-1115756af0c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTAtMS0xLTQyOTY3MQ_ccb81272-5aac-4f1e-a246-4576be170c8b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNi0xLTEtNDI5Njcx_0661d1b1-662e-4b85-97d1-02884e9bedf8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktNC0xLTEtNDI5Njcx_6bfa4ccb-a89e-4014-b8a0-4f826bebfb8e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTQtMS0xLTQyOTY3MQ_0ef21eca-e6b7-48e6-88e1-69577f2efbaf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMTktMTItMS0xLTQyOTY3MQ_ceabc205-2d62-4e44-a517-a8483c87e5fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQyNQ_b834fc9e-983e-45ff-b206-3ce7287be5f6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS00LTEtMS00Mjk2NzE_50bb3f84-6761-493d-849a-d1eae1d8d3fc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS00LTEtMS00Mjk2NzE_50bb3f84-6761-493d-849a-d1eae1d8d3fc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS04LTEtMS00Mjk2NzE_80861cc7-b44f-4666-ac47-8bdbf158d915"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS04LTEtMS00Mjk2NzE_80861cc7-b44f-4666-ac47-8bdbf158d915"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMC0xLTEtNDI5Njcx_321577f7-e593-49a7-a7ac-2b0830e4ef5b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMC0xLTEtNDI5Njcx_321577f7-e593-49a7-a7ac-2b0830e4ef5b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMi0xLTEtNDI5Njcx_5af25e10-6100-474a-80a2-768f0c5ece86"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMi0xLTEtNDI5Njcx_5af25e10-6100-474a-80a2-768f0c5ece86"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS02LTEtMS00Mjk2NzE_99b7ca62-b866-4c59-9bc7-b23b4df8d23e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS02LTEtMS00Mjk2NzE_99b7ca62-b866-4c59-9bc7-b23b4df8d23e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0yLTEtMS00Mjk2NzE_98c53b55-1c37-4942-a131-1e3138a4fac2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0yLTEtMS00Mjk2NzE_98c53b55-1c37-4942-a131-1e3138a4fac2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.5&#160;billion as of October&#160;2, 2022 and $4.8&#160;billion as of December 31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS00LTEtMS00Mjk2NzE_50bb3f84-6761-493d-849a-d1eae1d8d3fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS04LTEtMS00Mjk2NzE_80861cc7-b44f-4666-ac47-8bdbf158d915"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMC0xLTEtNDI5Njcx_321577f7-e593-49a7-a7ac-2b0830e4ef5b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0xMi0xLTEtNDI5Njcx_5af25e10-6100-474a-80a2-768f0c5ece86"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS02LTEtMS00Mjk2NzE_99b7ca62-b866-4c59-9bc7-b23b4df8d23e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjZhNWFmZmJkZmQ2ZDQxMjQ4NTgxODE1ZTMzN2VkZmJlL3RhYmxlcmFuZ2U6NmE1YWZmYmRmZDZkNDEyNDg1ODE4MTVlMzM3ZWRmYmVfNS0yLTEtMS00Mjk2NzE_98c53b55-1c37-4942-a131-1e3138a4fac2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzA0Mg_bb92b191-0ea8-4276-a87d-a5ea466bd01a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTItMS0xLTQyOTY3MQ_f3c770c9-7c9d-4ac9-9927-009949ba22bc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTItMS0xLTQyOTY3MQ_f3c770c9-7c9d-4ac9-9927-009949ba22bc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNC0xLTEtNDI5Njcx_e9f4df3e-bde7-47ac-80c2-730480077951"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNC0xLTEtNDI5Njcx_e9f4df3e-bde7-47ac-80c2-730480077951"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMi0xLTEtNDI5Njcx_e9b9138e-fb58-4795-8f2c-a4d80e522093"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMi0xLTEtNDI5Njcx_e9b9138e-fb58-4795-8f2c-a4d80e522093"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTAtMS0xLTQyOTY3MQ_eafab965-bc26-4ea2-845d-e55fc001d4d0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTAtMS0xLTQyOTY3MQ_eafab965-bc26-4ea2-845d-e55fc001d4d0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTItMS0xLTQyOTY3MQ_f3c770c9-7c9d-4ac9-9927-009949ba22bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtNC0xLTEtNDI5Njcx_e9f4df3e-bde7-47ac-80c2-730480077951"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMi0xLTEtNDI5Njcx_e9b9138e-fb58-4795-8f2c-a4d80e522093"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTo2MjA2MDhlMjcwM2Q0NTk3ODY5NzRkM2Y5NmIzOTEwZi90YWJsZXJhbmdlOjYyMDYwOGUyNzAzZDQ1OTc4Njk3NGQzZjk2YjM5MTBmXzYtMTAtMS0xLTQyOTY3MQ_eafab965-bc26-4ea2-845d-e55fc001d4d0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDI_b56b708a-46fa-4c6c-af3e-8f3e6172a63c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC00LTEtMS00Mjk2NzE_45240349-7a57-4b66-8563-1735eb215c7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC00LTEtMS00Mjk2NzE_45240349-7a57-4b66-8563-1735eb215c7e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC04LTEtMS00Mjk2NzE_89cdec7c-14cd-4eb1-b43e-bd10aaa766ee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC04LTEtMS00Mjk2NzE_89cdec7c-14cd-4eb1-b43e-bd10aaa766ee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC02LTEtMS00Mjk2NzE_bd465f0a-3160-4eee-9aaa-b9f143521049"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC02LTEtMS00Mjk2NzE_bd465f0a-3160-4eee-9aaa-b9f143521049"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC0yLTEtMS00Mjk2NzE_312e8447-359d-4343-b5cc-758a50fea8f6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC0yLTEtMS00Mjk2NzE_312e8447-359d-4343-b5cc-758a50fea8f6"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes adjustments for foreign currency translation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC00LTEtMS00Mjk2NzE_45240349-7a57-4b66-8563-1735eb215c7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC04LTEtMS00Mjk2NzE_89cdec7c-14cd-4eb1-b43e-bd10aaa766ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC02LTEtMS00Mjk2NzE_bd465f0a-3160-4eee-9aaa-b9f143521049"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfNC0yLTEtMS00Mjk2NzE_312e8447-359d-4343-b5cc-758a50fea8f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgyOQ_66f4338a-a15f-4319-ae6d-b48e5bc1c0cd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy00LTEtMS00Mjk2NzE_86dd17bd-21d4-44d2-8df2-23e29c42b7bd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy00LTEtMS00Mjk2NzE_86dd17bd-21d4-44d2-8df2-23e29c42b7bd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy02LTEtMS00Mjk2NzE_2b68c9b4-d476-4c72-85b2-8e48b07f8779"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy02LTEtMS00Mjk2NzE_2b68c9b4-d476-4c72-85b2-8e48b07f8779"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy0yLTEtMS00Mjk2NzE_6b841c4b-f673-47a6-b336-32d761d15aeb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy0yLTEtMS00Mjk2NzE_6b841c4b-f673-47a6-b336-32d761d15aeb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy04LTEtMS00Mjk2NzE_2b96c6ba-c542-4577-a709-22e7b00662cd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy04LTEtMS00Mjk2NzE_2b96c6ba-c542-4577-a709-22e7b00662cd"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy00LTEtMS00Mjk2NzE_86dd17bd-21d4-44d2-8df2-23e29c42b7bd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy02LTEtMS00Mjk2NzE_2b68c9b4-d476-4c72-85b2-8e48b07f8779"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy0yLTEtMS00Mjk2NzE_6b841c4b-f673-47a6-b336-32d761d15aeb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RhYmxlOjhmYjZlMWM5NjQ3YjRlODA4MWRiZTA3YmNiZTg0YjNlL3RhYmxlcmFuZ2U6OGZiNmUxYzk2NDdiNGU4MDgxZGJlMDdiY2JlODRiM2VfNy04LTEtMS00Mjk2NzE_2b96c6ba-c542-4577-a709-22e7b00662cd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xOS9mcmFnOjc0ODQwNjMyNTc3YTRjYjlhZGZiOGI5NmYzNDZlOTdjL3RleHRyZWdpb246NzQ4NDA2MzI1NzdhNGNiOWFkZmI4Yjk2ZjM0NmU5N2NfMTg5_301d4f9d-f791-44c9-aab9-cb61785cbc06"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTQtMS0xLTQyOTY3MQ_fbd1b23a-4de5-4731-90bf-a49e2f6a8698"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTQtMS0xLTQyOTY3MQ_fbd1b23a-4de5-4731-90bf-a49e2f6a8698"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTEwLTEtMS00Mjk2NzE_79069066-5ead-4735-9ca9-a0c728f6a653"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTEwLTEtMS00Mjk2NzE_79069066-5ead-4735-9ca9-a0c728f6a653"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTYtMS0xLTQyOTY3MQ_668cc3dd-3341-4358-a350-cbf225cdbb2c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTYtMS0xLTQyOTY3MQ_668cc3dd-3341-4358-a350-cbf225cdbb2c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTgtMS0xLTQyOTY3MQ_a17914fb-258b-418b-a9ca-4563cd5cfc48"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTgtMS0xLTQyOTY3MQ_a17914fb-258b-418b-a9ca-4563cd5cfc48"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTQtMS0xLTQyOTY3MQ_fbd1b23a-4de5-4731-90bf-a49e2f6a8698"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTEwLTEtMS00Mjk2NzE_79069066-5ead-4735-9ca9-a0c728f6a653"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTYtMS0xLTQyOTY3MQ_668cc3dd-3341-4358-a350-cbf225cdbb2c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzU4LTgtMS0xLTQyOTY3MQ_a17914fb-258b-418b-a9ca-4563cd5cfc48"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNjA_571c7d51-32c4-4074-b473-e967289eb5ee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNC0xLTEtNDI5Njcx_7c89b3c6-eae2-4569-9415-e7d0b862ac03"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNC0xLTEtNDI5Njcx_7c89b3c6-eae2-4569-9415-e7d0b862ac03"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNi0xLTEtNDI5Njcx_bff3b0ab-ad48-49ee-979e-f9df13844b8c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNi0xLTEtNDI5Njcx_bff3b0ab-ad48-49ee-979e-f9df13844b8c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtMi0xLTEtNDI5Njcx_ca5fa3ae-21d5-4c48-93b1-a60c41f42be6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtMi0xLTEtNDI5Njcx_ca5fa3ae-21d5-4c48-93b1-a60c41f42be6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtOC0xLTEtNDI5Njcx_a5ab5888-7716-4238-ad86-b88c6ea5907f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtOC0xLTEtNDI5Njcx_a5ab5888-7716-4238-ad86-b88c6ea5907f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </xhtml:span><xhtml:span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNC0xLTEtNDI5Njcx_7c89b3c6-eae2-4569-9415-e7d0b862ac03"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtNi0xLTEtNDI5Njcx_bff3b0ab-ad48-49ee-979e-f9df13844b8c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtMi0xLTEtNDI5Njcx_ca5fa3ae-21d5-4c48-93b1-a60c41f42be6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfMTMtOC0xLTEtNDI5Njcx_a5ab5888-7716-4238-ad86-b88c6ea5907f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTQw_f4318c3b-525d-4459-a3a1-019a4dfc29cd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS04LTEtMS00Mjk2NzE_50323117-4703-41a1-9272-feb994edeef3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS04LTEtMS00Mjk2NzE_50323117-4703-41a1-9272-feb994edeef3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS0yLTEtMS00Mjk2NzE_38c92c39-bf18-49b7-a4a0-e25b66dbb213"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS0yLTEtMS00Mjk2NzE_38c92c39-bf18-49b7-a4a0-e25b66dbb213"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS02LTEtMS00Mjk2NzE_b00bcbae-500f-4f0f-9340-0122991a721f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS02LTEtMS00Mjk2NzE_b00bcbae-500f-4f0f-9340-0122991a721f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS00LTEtMS00Mjk2NzE_613077e8-5b40-4023-b819-a7c214d9ee06"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS00LTEtMS00Mjk2NzE_613077e8-5b40-4023-b819-a7c214d9ee06"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of October&#160;2, 2022, there were cumulative impairments and downward adjustments of $148 million and upward adjustments of $201 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2022 and 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS04LTEtMS00Mjk2NzE_50323117-4703-41a1-9272-feb994edeef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS0yLTEtMS00Mjk2NzE_38c92c39-bf18-49b7-a4a0-e25b66dbb213"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS02LTEtMS00Mjk2NzE_b00bcbae-500f-4f0f-9340-0122991a721f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfNS00LTEtMS00Mjk2NzE_613077e8-5b40-4023-b819-a7c214d9ee06"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzk1_693021e0-576b-4d20-b915-6e3e0933fcc2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy00LTEtMS00Mjk2NzE_bde52b2e-a777-41dc-b155-e237fd719780"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy00LTEtMS00Mjk2NzE_bde52b2e-a777-41dc-b155-e237fd719780"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy0yLTEtMS00Mjk2NzE_947423da-75c5-4888-8435-7ecabccea84f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy0yLTEtMS00Mjk2NzE_947423da-75c5-4888-8435-7ecabccea84f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcx_2a1b3533-c56a-4df2-8c6f-c6e181e09ceb" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcx_2a1b3533-c56a-4df2-8c6f-c6e181e09ceb" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes money market funds primarily invested in U.S. Treasury and government debt.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy00LTEtMS00Mjk2NzE_bde52b2e-a777-41dc-b155-e237fd719780"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcx_2a1b3533-c56a-4df2-8c6f-c6e181e09ceb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOmRlYmM1NTcyOGFjYjQ3MzQ4YTViOWI5ZDZlOTU3MmFhL3RhYmxlcmFuZ2U6ZGViYzU1NzI4YWNiNDczNDhhNWI5YjlkNmU5NTcyYWFfMy0yLTEtMS00Mjk2NzE_947423da-75c5-4888-8435-7ecabccea84f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzcx_2a1b3533-c56a-4df2-8c6f-c6e181e09ceb"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtMi0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtMi0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMi0xMC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMi0xMC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtNC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtNC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNS0xMC0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNS0xMC0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtMi0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfMi0xMC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yNS9mcmFnOjE3YjJhNDljZmVhNDRkNjliOWE2Mjg0MTY1NTIwZGI5L3RhYmxlOjI2YTFlZjZhNDIzZjQ3ZWQ5ZmMxMDQ5YWZmZmYxM2QxL3RhYmxlcmFuZ2U6MjZhMWVmNmE0MjNmNDdlZDlmYzEwNDlhZmZmZjEzZDFfMTQtNC0xLTEtNDI5Njcx_d8af22d9-b453-452e-b265-f57519f41633"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOmIzMzc1MTBlYWVlOTRiMGY4MjhkMmI4NTg5NjZhZWMwL3RhYmxlcmFuZ2U6YjMzNzUxMGVhZWU5NGIwZjgyOGQyYjg1ODk2NmFlYzBfNS0xMC0xLTEtNDI5Njcx_c03dc54d-9f67-463e-9ce4-e530d9e3a26e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNDc1_f7656e96-492f-4300-aebd-c069dd483b10"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi00LTEtMS00Mjk2NzE_5b63501f-3025-4448-9dae-f21d2b141cde"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi00LTEtMS00Mjk2NzE_5b63501f-3025-4448-9dae-f21d2b141cde"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi04LTEtMS00Mjk2NzE_14fa5f10-49f6-42ad-ba5c-7d5ca8c04911"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi04LTEtMS00Mjk2NzE_14fa5f10-49f6-42ad-ba5c-7d5ca8c04911"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi0yLTEtMS00Mjk2NzE_df7dc9d1-9615-488a-bbd0-c4f83be85ba2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi0yLTEtMS00Mjk2NzE_df7dc9d1-9615-488a-bbd0-c4f83be85ba2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi02LTEtMS00Mjk2NzE_59824e27-a17c-4205-aae0-a5a482b9df27"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi02LTEtMS00Mjk2NzE_59824e27-a17c-4205-aae0-a5a482b9df27"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($816 million) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($255 million).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi00LTEtMS00Mjk2NzE_5b63501f-3025-4448-9dae-f21d2b141cde"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi04LTEtMS00Mjk2NzE_14fa5f10-49f6-42ad-ba5c-7d5ca8c04911"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi0yLTEtMS00Mjk2NzE_df7dc9d1-9615-488a-bbd0-c4f83be85ba2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOjQzMjIyNmEwMjc1NzQwNDFhZDM3YmY3ZDBkNzkxZTFhL3RhYmxlcmFuZ2U6NDMyMjI2YTAyNzU3NDA0MWFkMzdiZjdkMGQ3OTFlMWFfMi02LTEtMS00Mjk2NzE_59824e27-a17c-4205-aae0-a5a482b9df27"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgxOA_38c7380d-f607-4024-bad8-f24b1546710a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0yLTEtMS00Mjk2NzE_9a8f71b8-8682-4d0b-8e7c-5991fa04886e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0yLTEtMS00Mjk2NzE_9a8f71b8-8682-4d0b-8e7c-5991fa04886e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC04LTEtMS00Mjk2NzE_e29d8cd7-34c4-4497-9fe5-877dba1f1d25"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC04LTEtMS00Mjk2NzE_e29d8cd7-34c4-4497-9fe5-877dba1f1d25"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi04LTEtMS00Mjk2NzE_339c5e19-4e13-4c0a-b6bc-eae3c491dace"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi04LTEtMS00Mjk2NzE_339c5e19-4e13-4c0a-b6bc-eae3c491dace"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0yLTEtMS00Mjk2NzE_7a699dba-090b-429c-97be-830060b328be"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0yLTEtMS00Mjk2NzE_7a699dba-090b-429c-97be-830060b328be"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC0yLTEtMS00Mjk2NzE_9a8f71b8-8682-4d0b-8e7c-5991fa04886e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfOC04LTEtMS00Mjk2NzE_e29d8cd7-34c4-4497-9fe5-877dba1f1d25"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi04LTEtMS00Mjk2NzE_339c5e19-4e13-4c0a-b6bc-eae3c491dace"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjdhNDk1ZTljNTRlMDRhNzhiYzI2OTU4Njk1ZDAxNmMwL3RhYmxlcmFuZ2U6N2E0OTVlOWM1NGUwNGE3OGJjMjY5NTg2OTVkMDE2YzBfNi0yLTEtMS00Mjk2NzE_7a699dba-090b-429c-97be-830060b328be"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMjk5OA_d032b866-7869-4a04-8a25-aeaa8a04cbad"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS02LTEtMS00Mjk2NzE_3bb528dd-20b9-49b4-a972-f922d43fbdbe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS02LTEtMS00Mjk2NzE_3bb528dd-20b9-49b4-a972-f922d43fbdbe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS0yLTEtMS00Mjk2NzE_35815b41-cffb-4b5c-9359-d379a907975e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS0yLTEtMS00Mjk2NzE_35815b41-cffb-4b5c-9359-d379a907975e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS04LTEtMS00Mjk2NzE_75e41cf7-4116-4583-ad8e-d640a5fc5cc1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS04LTEtMS00Mjk2NzE_75e41cf7-4116-4583-ad8e-d640a5fc5cc1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS00LTEtMS00Mjk2NzE_6c6b2ad1-9924-43b6-ab58-ece897ccfd1f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS00LTEtMS00Mjk2NzE_6c6b2ad1-9924-43b6-ab58-ece897ccfd1f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October&#160;2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138&#160;million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS02LTEtMS00Mjk2NzE_3bb528dd-20b9-49b4-a972-f922d43fbdbe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS0yLTEtMS00Mjk2NzE_35815b41-cffb-4b5c-9359-d379a907975e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS04LTEtMS00Mjk2NzE_75e41cf7-4116-4583-ad8e-d640a5fc5cc1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOS00LTEtMS00Mjk2NzE_6c6b2ad1-9924-43b6-ab58-ece897ccfd1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc1OA_d1c807cf-91cd-4a5e-98e8-22dc2c498ce5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMTItMS0xLTQyOTY3MQ_1bfb8b75-ee82-4190-b19d-033448001fcf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMTItMS0xLTQyOTY3MQ_1bfb8b75-ee82-4190-b19d-033448001fcf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtOC0xLTEtNDI5Njcx_5f924545-7cdf-419a-a41b-dab24a74c232"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtOC0xLTEtNDI5Njcx_5f924545-7cdf-419a-a41b-dab24a74c232"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItOC0xLTEtNDI5Njcx_77fa5bda-2010-4cea-bb57-14533aeb9398"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItOC0xLTEtNDI5Njcx_77fa5bda-2010-4cea-bb57-14533aeb9398"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMTItMS0xLTQyOTY3MQ_6b832ab6-88f2-4aab-a51a-d9475eb4d0ef"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMTItMS0xLTQyOTY3MQ_6b832ab6-88f2-4aab-a51a-d9475eb4d0ef"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMi0xLTEtNDI5Njcx_31a4bf64-afc9-420a-8aea-da78984567bc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMi0xLTEtNDI5Njcx_31a4bf64-afc9-420a-8aea-da78984567bc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItNi0xLTEtNDI5Njcx_a1142993-e425-47ab-a0d1-446a18afad15"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItNi0xLTEtNDI5Njcx_a1142993-e425-47ab-a0d1-446a18afad15"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtNi0xLTEtNDI5Njcx_9566c9fd-ec55-4d73-93d7-4a3c4e2174e6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtNi0xLTEtNDI5Njcx_9566c9fd-ec55-4d73-93d7-4a3c4e2174e6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMi0xLTEtNDI5Njcx_0ca3d8fc-7f0e-4e03-aace-8bacdd754f47"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMi0xLTEtNDI5Njcx_0ca3d8fc-7f0e-4e03-aace-8bacdd754f47"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMTItMS0xLTQyOTY3MQ_1bfb8b75-ee82-4190-b19d-033448001fcf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtOC0xLTEtNDI5Njcx_5f924545-7cdf-419a-a41b-dab24a74c232"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItOC0xLTEtNDI5Njcx_77fa5bda-2010-4cea-bb57-14533aeb9398"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMTItMS0xLTQyOTY3MQ_6b832ab6-88f2-4aab-a51a-d9475eb4d0ef"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItMi0xLTEtNDI5Njcx_31a4bf64-afc9-420a-8aea-da78984567bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTItNi0xLTEtNDI5Njcx_a1142993-e425-47ab-a0d1-446a18afad15"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtNi0xLTEtNDI5Njcx_9566c9fd-ec55-4d73-93d7-4a3c4e2174e6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RhYmxlOjRkYzczNWFjMjE2ZDRhZmQ5ZWMwODk3NjgxZjNkODlhL3RhYmxlcmFuZ2U6NGRjNzM1YWMyMTZkNGFmZDllYzA4OTc2ODFmM2Q4OWFfMTEtMi0xLTEtNDI5Njcx_0ca3d8fc-7f0e-4e03-aace-8bacdd754f47"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84OC9mcmFnOjQ0N2RlNWEyMzk1OTQzYzZhYzI4MmFhZGI5OGYxZmEzL3RleHRyZWdpb246NDQ3ZGU1YTIzOTU5NDNjNmFjMjgyYWFkYjk4ZjFmYTNfNTE1_9345fef8-bb41-435d-9556-db843e3364de"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDI5Njcx_8e5f7ad6-da14-4ab6-a1fb-eeb35bf1b71d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDI5Njcx_8e5f7ad6-da14-4ab6-a1fb-eeb35bf1b71d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDI5Njcx_8d93185f-f688-4c82-9b63-c777dc394dbb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDI5Njcx_8d93185f-f688-4c82-9b63-c777dc394dbb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQyOTY3MQ_29765147-b42d-4233-b960-9afb141a29f6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQyOTY3MQ_29765147-b42d-4233-b960-9afb141a29f6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDI5Njcx_937c2db7-ab03-49fc-b286-d87052678df6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDI5Njcx_937c2db7-ab03-49fc-b286-d87052678df6"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult). </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNC0xLTEtNDI5Njcx_8e5f7ad6-da14-4ab6-a1fb-eeb35bf1b71d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtOC0xLTEtNDI5Njcx_8d93185f-f688-4c82-9b63-c777dc394dbb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtMTAtMS0xLTQyOTY3MQ_29765147-b42d-4233-b960-9afb141a29f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzYtNi0xLTEtNDI5Njcx_937c2db7-ab03-49fc-b286-d87052678df6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwODc_abb2d6ed-0369-41ca-8af5-a42594b8b1fc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQyOTY3MQ_ecc725f6-bf13-469b-8990-b9f59b18f062"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQyOTY3MQ_ecc725f6-bf13-469b-8990-b9f59b18f062"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQyOTY3MQ_ffb545fb-dd46-48ab-b6ea-e15473bc3022"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQyOTY3MQ_ffb545fb-dd46-48ab-b6ea-e15473bc3022"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00Mjk2NzE_d37a0d72-b1c1-4bb5-9324-bd5157a70838"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00Mjk2NzE_d37a0d72-b1c1-4bb5-9324-bd5157a70838"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQyOTY3MQ_567f37c7-d373-4a0f-8f15-d40650e2874b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQyOTY3MQ_567f37c7-d373-4a0f-8f15-d40650e2874b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Immunoglobulin (Ig) portfolio includes the revenues from</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Panzyga, Octagam and Cutaquig.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTQtMS0xLTQyOTY3MQ_ecc725f6-bf13-469b-8990-b9f59b18f062"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTYtMS0xLTQyOTY3MQ_ffb545fb-dd46-48ab-b6ea-e15473bc3022"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTEwLTEtMS00Mjk2NzE_d37a0d72-b1c1-4bb5-9324-bd5157a70838"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzEzLTgtMS0xLTQyOTY3MQ_567f37c7-d373-4a0f-8f15-d40650e2874b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwNDU_283ec39c-bcda-4d53-9295-078b301db8cf"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy04LTEtMS00Mjk2NzE_9b9133fb-bec2-4fcc-9258-400dd16c8db6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy04LTEtMS00Mjk2NzE_9b9133fb-bec2-4fcc-9258-400dd16c8db6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy00LTEtMS00Mjk2NzE_14057630-317a-4fd9-baff-f0c8fddf43b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy00LTEtMS00Mjk2NzE_14057630-317a-4fd9-baff-f0c8fddf43b1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy0yLTEtMS00Mjk2NzE_5a0039dd-c615-4609-86b3-a10613f0009a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy0yLTEtMS00Mjk2NzE_5a0039dd-c615-4609-86b3-a10613f0009a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy02LTEtMS00Mjk2NzE_e6d2f62f-dc75-4d22-a788-915b8e020593"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy02LTEtMS00Mjk2NzE_e6d2f62f-dc75-4d22-a788-915b8e020593"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2013;&#x2013;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy04LTEtMS00Mjk2NzE_9b9133fb-bec2-4fcc-9258-400dd16c8db6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy00LTEtMS00Mjk2NzE_14057630-317a-4fd9-baff-f0c8fddf43b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy0yLTEtMS00Mjk2NzE_5a0039dd-c615-4609-86b3-a10613f0009a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RhYmxlOjE0MzcwNmEwZWVkNTQwYTNhOTQ2MzZjMTM0NTE4MTFkL3RhYmxlcmFuZ2U6MTQzNzA2YTBlZWQ1NDBhM2E5NDYzNmMxMzQ1MTgxMWRfMy02LTEtMS00Mjk2NzE_e6d2f62f-dc75-4d22-a788-915b8e020593"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82Ny9mcmFnOjA1ZTllZmU4OTJmOTQyZTU4MWJhYjU3MjI4MDhiOTE5L3RleHRyZWdpb246MDVlOWVmZTg5MmY5NDJlNTgxYmFiNTcyMjgwOGI5MTlfNzYw_6d7dd328-1e86-4b5e-b613-254f04d8d86c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy04LTEtMS00Mjk2NzE_238101c9-15cc-4c5a-9e7b-f64e349a2256"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy04LTEtMS00Mjk2NzE_238101c9-15cc-4c5a-9e7b-f64e349a2256"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy02LTEtMS00Mjk2NzE_de4ae461-5f30-4b05-adde-e986999b00d6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy02LTEtMS00Mjk2NzE_de4ae461-5f30-4b05-adde-e986999b00d6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy0yLTEtMS00Mjk2NzE_0ba4fb7e-a5d2-45f8-ba67-e60282dfe1d5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy0yLTEtMS00Mjk2NzE_0ba4fb7e-a5d2-45f8-ba67-e60282dfe1d5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy00LTEtMS00Mjk2NzE_342264cc-7d35-46b0-a05b-7b425eca7b6f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy00LTEtMS00Mjk2NzE_342264cc-7d35-46b0-a05b-7b425eca7b6f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62&#160;million and $108&#160;million for the three and nine months ended October&#160;2, 2022, respectively, and charges of $616&#160;million and $617&#160;million for the three and nine months ended October&#160;3, 2021, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy04LTEtMS00Mjk2NzE_238101c9-15cc-4c5a-9e7b-f64e349a2256"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy02LTEtMS00Mjk2NzE_de4ae461-5f30-4b05-adde-e986999b00d6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy0yLTEtMS00Mjk2NzE_0ba4fb7e-a5d2-45f8-ba67-e60282dfe1d5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfNy00LTEtMS00Mjk2NzE_342264cc-7d35-46b0-a05b-7b425eca7b6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzgwOQ_397962bd-3b85-45f2-91c6-fe0d06d66a83"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC0yLTEtMS00Mjk2NzE_7eb1ff7a-3406-4304-b88a-2092e3e02ae7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC0yLTEtMS00Mjk2NzE_7eb1ff7a-3406-4304-b88a-2092e3e02ae7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC02LTEtMS00Mjk2NzE_42e675e3-ca94-417e-8df2-65d6b5bc7731"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC02LTEtMS00Mjk2NzE_42e675e3-ca94-417e-8df2-65d6b5bc7731"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC00LTEtMS00Mjk2NzE_df798dc8-fee2-4fe7-884d-28e38adcae75"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC00LTEtMS00Mjk2NzE_df798dc8-fee2-4fe7-884d-28e38adcae75"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC04LTEtMS00Mjk2NzE_a02c4c71-59e8-4024-a3bc-f64111e01fcd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC04LTEtMS00Mjk2NzE_a02c4c71-59e8-4024-a3bc-f64111e01fcd"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC0yLTEtMS00Mjk2NzE_7eb1ff7a-3406-4304-b88a-2092e3e02ae7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC02LTEtMS00Mjk2NzE_42e675e3-ca94-417e-8df2-65d6b5bc7731"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC00LTEtMS00Mjk2NzE_df798dc8-fee2-4fe7-884d-28e38adcae75"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RhYmxlOmFkNGFmNjEzY2Y0MjQ5YWQ5N2NmZDI4YmZjMGFiMDYyL3RhYmxlcmFuZ2U6YWQ0YWY2MTNjZjQyNDlhZDk3Y2ZkMjhiZmMwYWIwNjJfOC04LTEtMS00Mjk2NzE_a02c4c71-59e8-4024-a3bc-f64111e01fcd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8yMi9mcmFnOjc3MWUyMjljNTczZjQ2M2I5Y2VhZjJkNGY4NjA2NzA3L3RleHRyZWdpb246NzcxZTIyOWM1NzNmNDYzYjljZWFmMmQ0Zjg2MDY3MDdfMjY5_aef96fab-0d76-46a9-b181-6a89a67a2d76"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItMTAtMS0xLTQyOTY3MQ_321a2ac2-0b2c-4ad4-a271-586a8acff56b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItMTAtMS0xLTQyOTY3MQ_321a2ac2-0b2c-4ad4-a271-586a8acff56b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItOC0xLTEtNDI5Njcx_9cd29b34-d049-4128-be6e-e3926374efee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItOC0xLTEtNDI5Njcx_9cd29b34-d049-4128-be6e-e3926374efee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNi0xLTEtNDI5Njcx_7f6beebf-da84-4f02-b2bf-af18544731d0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNi0xLTEtNDI5Njcx_7f6beebf-da84-4f02-b2bf-af18544731d0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNC0xLTEtNDI5Njcx_48b764de-0dc5-44cb-9b4e-5f3ce7a6c4ae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNC0xLTEtNDI5Njcx_48b764de-0dc5-44cb-9b4e-5f3ce7a6c4ae"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItMTAtMS0xLTQyOTY3MQ_321a2ac2-0b2c-4ad4-a271-586a8acff56b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItOC0xLTEtNDI5Njcx_9cd29b34-d049-4128-be6e-e3926374efee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNi0xLTEtNDI5Njcx_7f6beebf-da84-4f02-b2bf-af18544731d0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90YWJsZTplN2E5YWMxNTRhODM0NWJiYWQ1ZmU4NWYwNWRkZGYxMi90YWJsZXJhbmdlOmU3YTlhYzE1NGE4MzQ1YmJhZDVmZTg1ZjA1ZGRkZjEyXzItNC0xLTEtNDI5Njcx_48b764de-0dc5-44cb-9b4e-5f3ce7a6c4ae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV8xMDAvZnJhZzo2ZWE5ZTU1MDhhN2I0YzE5YTJhZTk1Mzc1YzRmMzEwZS90ZXh0cmVnaW9uOjZlYTllNTUwOGE3YjRjMTlhMmFlOTUzNzVjNGYzMTBlXzkwMzY_4f459b78-9bb8-444b-a1c3-6864df3e24f7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNi0xLTEtNDI5Njcx_ce90d9e5-ce46-4ede-9dd4-d3cea269650a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNi0xLTEtNDI5Njcx_ce90d9e5-ce46-4ede-9dd4-d3cea269650a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTItMS0xLTQyOTY3MQ_8fa38e40-5385-4021-9ea5-fd9e6bbd255e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTItMS0xLTQyOTY3MQ_8fa38e40-5385-4021-9ea5-fd9e6bbd255e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC00LTEtMS00Mjk2NzE_04673e43-36a2-45b3-b7ca-236158b88b87"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC00LTEtMS00Mjk2NzE_04673e43-36a2-45b3-b7ca-236158b88b87"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctNi0xLTEtNDI5Njcx_ce613522-b2e6-449d-9bda-6bbc50ef4241"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctNi0xLTEtNDI5Njcx_ce613522-b2e6-449d-9bda-6bbc50ef4241"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTItMS0xLTQyOTY3MQ_7434b05a-74c7-4239-a3ea-997576f4353d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTItMS0xLTQyOTY3MQ_7434b05a-74c7-4239-a3ea-997576f4353d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTItMS0xLTQyOTY3MQ_ab926219-d9a7-4b2b-bb7a-cd8b338b1a85"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTItMS0xLTQyOTY3MQ_ab926219-d9a7-4b2b-bb7a-cd8b338b1a85"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtNC0xLTEtNDI5Njcx_3bc803cd-e2a3-4377-b12f-8e60922a30b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtNC0xLTEtNDI5Njcx_3bc803cd-e2a3-4377-b12f-8e60922a30b1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtNC0xLTEtNDI5Njcx_3303e9d7-5cc1-4910-8497-2ac64d94653a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtNC0xLTEtNDI5Njcx_3303e9d7-5cc1-4910-8497-2ac64d94653a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtMi0xLTEtNDI5Njcx_f3cec9d4-f77d-4580-b599-484f01f1a5a7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtMi0xLTEtNDI5Njcx_f3cec9d4-f77d-4580-b599-484f01f1a5a7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtMi0xLTEtNDI5Njcx_72ec13bf-f3db-48f3-ae79-5c72c3f1d49f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtMi0xLTEtNDI5Njcx_72ec13bf-f3db-48f3-ae79-5c72c3f1d49f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctOC0xLTEtNDI5Njcx_6ed77661-b985-4278-9f00-9b1b503b67b7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctOC0xLTEtNDI5Njcx_6ed77661-b985-4278-9f00-9b1b503b67b7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNC0xLTEtNDI5Njcx_0bed8693-ae85-4b96-8618-be975923ee6b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNC0xLTEtNDI5Njcx_0bed8693-ae85-4b96-8618-be975923ee6b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC0yLTEtMS00Mjk2NzE_a28803af-4e40-48eb-b68f-7954fb1a17f1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC0yLTEtMS00Mjk2NzE_a28803af-4e40-48eb-b68f-7954fb1a17f1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTItMS0xLTQyOTY3MQ_9ae39430-7552-4461-b69f-37394ff1a54e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTItMS0xLTQyOTY3MQ_9ae39430-7552-4461-b69f-37394ff1a54e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNi0xLTEtNDI5Njcx_60eac3c4-32fd-43f6-8b03-4e76cadca988"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNi0xLTEtNDI5Njcx_60eac3c4-32fd-43f6-8b03-4e76cadca988"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtOC0xLTEtNDI5Njcx_07a36bed-d910-4d73-a6c6-5fd6bc7522b9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtOC0xLTEtNDI5Njcx_07a36bed-d910-4d73-a6c6-5fd6bc7522b9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItNC0xLTEtNDI5Njcx_d4c83559-1407-444f-99a6-6ba36c9f1d63"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItNC0xLTEtNDI5Njcx_d4c83559-1407-444f-99a6-6ba36c9f1d63"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktNC0xLTEtNDI5Njcx_b1341912-72e5-4de9-b371-e3fad6bff794"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktNC0xLTEtNDI5Njcx_b1341912-72e5-4de9-b371-e3fad6bff794"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMi0xLTEtNDI5Njcx_d76f42da-fb4e-446f-9ea5-f98760068047"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMi0xLTEtNDI5Njcx_d76f42da-fb4e-446f-9ea5-f98760068047"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktMi0xLTEtNDI5Njcx_d0a45c0d-3364-46a7-9fd4-57a6b63bf52e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktMi0xLTEtNDI5Njcx_d0a45c0d-3364-46a7-9fd4-57a6b63bf52e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTAtMS0xLTQyOTY3MQ_90670622-0649-4a76-bd2a-b31e91dfd5a3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTAtMS0xLTQyOTY3MQ_90670622-0649-4a76-bd2a-b31e91dfd5a3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtOC0xLTEtNDI5Njcx_9c90dcf1-6e88-4be7-b902-e170d48b4afa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtOC0xLTEtNDI5Njcx_9c90dcf1-6e88-4be7-b902-e170d48b4afa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItMi0xLTEtNDI5Njcx_e6218ca2-efe4-463d-9ce3-af6f1be6bb3d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItMi0xLTEtNDI5Njcx_e6218ca2-efe4-463d-9ce3-af6f1be6bb3d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTAtMS0xLTQyOTY3MQ_f4b64b37-90c3-402a-baac-3d920218e6fd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTAtMS0xLTQyOTY3MQ_f4b64b37-90c3-402a-baac-3d920218e6fd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTAtMS0xLTQyOTY3MQ_28197c73-6bbb-446f-a947-8e733c8ed5e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTAtMS0xLTQyOTY3MQ_28197c73-6bbb-446f-a947-8e733c8ed5e2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMi0xLTEtNDI5Njcx_96c0b094-7093-4d3c-91b6-849a99bc222f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMi0xLTEtNDI5Njcx_96c0b094-7093-4d3c-91b6-849a99bc222f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS0yLTEtMS00Mjk2NzE_0bf627f4-8dad-4eec-b99a-5aad854ec232"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS0yLTEtMS00Mjk2NzE_0bf627f4-8dad-4eec-b99a-5aad854ec232"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS00LTEtMS00Mjk2NzE_445e562c-2eb9-43d1-b0fc-b2019b0639a5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS00LTEtMS00Mjk2NzE_445e562c-2eb9-43d1-b0fc-b2019b0639a5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtOC0xLTEtNDI5Njcx_24e61d1d-f7c7-46f8-9779-ec9d74a71fe3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtOC0xLTEtNDI5Njcx_24e61d1d-f7c7-46f8-9779-ec9d74a71fe3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTAtMS0xLTQyOTY3MQ_1b6c0327-f807-478a-a8f0-0ac11991b5cb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTAtMS0xLTQyOTY3MQ_1b6c0327-f807-478a-a8f0-0ac11991b5cb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtNi0xLTEtNDI5Njcx_133301ad-6e91-4536-9645-63f6f0547007"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtNi0xLTEtNDI5Njcx_133301ad-6e91-4536-9645-63f6f0547007"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNC0xLTEtNDI5Njcx_211174d9-e259-4f54-9f87-7cc752aad16c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNC0xLTEtNDI5Njcx_211174d9-e259-4f54-9f87-7cc752aad16c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNi0xLTEtNDI5Njcx_ce90d9e5-ce46-4ede-9dd4-d3cea269650a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTItMS0xLTQyOTY3MQ_8fa38e40-5385-4021-9ea5-fd9e6bbd255e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC00LTEtMS00Mjk2NzE_04673e43-36a2-45b3-b7ca-236158b88b87"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctNi0xLTEtNDI5Njcx_ce613522-b2e6-449d-9bda-6bbc50ef4241"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTItMS0xLTQyOTY3MQ_7434b05a-74c7-4239-a3ea-997576f4353d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTItMS0xLTQyOTY3MQ_ab926219-d9a7-4b2b-bb7a-cd8b338b1a85"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtNC0xLTEtNDI5Njcx_3bc803cd-e2a3-4377-b12f-8e60922a30b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtNC0xLTEtNDI5Njcx_3303e9d7-5cc1-4910-8497-2ac64d94653a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzMtMi0xLTEtNDI5Njcx_f3cec9d4-f77d-4580-b599-484f01f1a5a7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDMtMi0xLTEtNDI5Njcx_72ec13bf-f3db-48f3-ae79-5c72c3f1d49f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctOC0xLTEtNDI5Njcx_6ed77661-b985-4278-9f00-9b1b503b67b7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtNC0xLTEtNDI5Njcx_0bed8693-ae85-4b96-8618-be975923ee6b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOC0yLTEtMS00Mjk2NzE_a28803af-4e40-48eb-b68f-7954fb1a17f1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTItMS0xLTQyOTY3MQ_9ae39430-7552-4461-b69f-37394ff1a54e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNi0xLTEtNDI5Njcx_60eac3c4-32fd-43f6-8b03-4e76cadca988"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtOC0xLTEtNDI5Njcx_07a36bed-d910-4d73-a6c6-5fd6bc7522b9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItNC0xLTEtNDI5Njcx_d4c83559-1407-444f-99a6-6ba36c9f1d63"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktNC0xLTEtNDI5Njcx_b1341912-72e5-4de9-b371-e3fad6bff794"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMi0xLTEtNDI5Njcx_d76f42da-fb4e-446f-9ea5-f98760068047"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTktMi0xLTEtNDI5Njcx_d0a45c0d-3364-46a7-9fd4-57a6b63bf52e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzctMTAtMS0xLTQyOTY3MQ_90670622-0649-4a76-bd2a-b31e91dfd5a3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtOC0xLTEtNDI5Njcx_9c90dcf1-6e88-4be7-b902-e170d48b4afa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMzItMi0xLTEtNDI5Njcx_e6218ca2-efe4-463d-9ce3-af6f1be6bb3d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMTAtMS0xLTQyOTY3MQ_f4b64b37-90c3-402a-baac-3d920218e6fd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtMTAtMS0xLTQyOTY3MQ_28197c73-6bbb-446f-a947-8e733c8ed5e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtMi0xLTEtNDI5Njcx_96c0b094-7093-4d3c-91b6-849a99bc222f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS0yLTEtMS00Mjk2NzE_0bf627f4-8dad-4eec-b99a-5aad854ec232"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfOS00LTEtMS00Mjk2NzE_445e562c-2eb9-43d1-b0fc-b2019b0639a5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMjEtOC0xLTEtNDI5Njcx_24e61d1d-f7c7-46f8-9779-ec9d74a71fe3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtMTAtMS0xLTQyOTY3MQ_1b6c0327-f807-478a-a8f0-0ac11991b5cb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfMTMtNi0xLTEtNDI5Njcx_133301ad-6e91-4536-9645-63f6f0547007"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RhYmxlOjE4ZDAzM2YwNWIyMTRkODJiZjQwZDY2NDdlYWE2OTdmL3RhYmxlcmFuZ2U6MThkMDMzZjA1YjIxNGQ4MmJmNDBkNjY0N2VhYTY5N2ZfNDUtNC0xLTEtNDI5Njcx_211174d9-e259-4f54-9f87-7cc752aad16c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV83Ni9mcmFnOmYyYzEwNTgzNGVkOTQ0ODFiYjk0YmZkM2QzZGYwOTVlL3RleHRyZWdpb246ZjJjMTA1ODM0ZWQ5NDQ4MWJiOTRiZmQzZDNkZjA5NWVfMzAwNA_23390887-a020-4ce2-b851-c6375314732a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNi0xLTEtNDI5Njcx_e1f2d427-f765-49fa-839a-f5c432154997"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNi0xLTEtNDI5Njcx_e1f2d427-f765-49fa-839a-f5c432154997"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNi0xLTEtNDI5Njcx_7fca1ffd-896d-495a-a9d5-7b0cede00795"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNi0xLTEtNDI5Njcx_7fca1ffd-896d-495a-a9d5-7b0cede00795"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNC0xLTEtNDI5Njcx_8ece4338-3312-4216-a456-9e7e99d62f1b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNC0xLTEtNDI5Njcx_8ece4338-3312-4216-a456-9e7e99d62f1b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItMi0xLTEtNDI5Njcx_a86e56c8-94cb-4066-986c-23c2b8d97686"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItMi0xLTEtNDI5Njcx_a86e56c8-94cb-4066-986c-23c2b8d97686"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNC0xLTEtNDI5Njcx_afc4de30-418f-4e3e-b0ca-ef2323eda3f9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNC0xLTEtNDI5Njcx_afc4de30-418f-4e3e-b0ca-ef2323eda3f9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItOC0xLTEtNDI5Njcx_6cc8c14f-d7d8-4564-87d8-7758542b84a4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItOC0xLTEtNDI5Njcx_6cc8c14f-d7d8-4564-87d8-7758542b84a4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtOC0xLTEtNDI5Njcx_7ba0e3ea-e682-4737-996e-6547c9d8d1f8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtOC0xLTEtNDI5Njcx_7ba0e3ea-e682-4737-996e-6547c9d8d1f8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtOC0xLTEtNDI5Njcx_3fbd4518-51fe-483f-89a1-5cf9bf4a4751"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtOC0xLTEtNDI5Njcx_3fbd4518-51fe-483f-89a1-5cf9bf4a4751"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtMi0xLTEtNDI5Njcx_970aaef8-b5d6-42fb-a76a-f958b99c1684"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtMi0xLTEtNDI5Njcx_970aaef8-b5d6-42fb-a76a-f958b99c1684"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNi0xLTEtNDI5Njcx_42cb499f-f636-4adc-b8ac-a98d69c36b83"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNi0xLTEtNDI5Njcx_42cb499f-f636-4adc-b8ac-a98d69c36b83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktOC0xLTEtNDI5Njcx_0ac023e0-501c-45e6-8b76-9e5c1d60aa3c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktOC0xLTEtNDI5Njcx_0ac023e0-501c-45e6-8b76-9e5c1d60aa3c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNC0xLTEtNDI5Njcx_a4541278-e2cb-4393-a38b-ae8cad9d8c18"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNC0xLTEtNDI5Njcx_a4541278-e2cb-4393-a38b-ae8cad9d8c18"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktMi0xLTEtNDI5Njcx_a31d12ad-733d-454f-aacf-b9a02ebc2ddf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktMi0xLTEtNDI5Njcx_a31d12ad-733d-454f-aacf-b9a02ebc2ddf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNi0xLTEtNDI5Njcx_ad4f3559-591c-4f22-b2f9-04973e92ea32"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNi0xLTEtNDI5Njcx_ad4f3559-591c-4f22-b2f9-04973e92ea32"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtMi0xLTEtNDI5Njcx_b8d35731-3c3a-44a7-85f7-4d37b26a1ee7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtMi0xLTEtNDI5Njcx_b8d35731-3c3a-44a7-85f7-4d37b26a1ee7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNC0xLTEtNDI5Njcx_03da9fde-fd5e-4bb9-b48b-aefe07d232a3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNC0xLTEtNDI5Njcx_03da9fde-fd5e-4bb9-b48b-aefe07d232a3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNi0xLTEtNDI5Njcx_e1f2d427-f765-49fa-839a-f5c432154997"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNi0xLTEtNDI5Njcx_7fca1ffd-896d-495a-a9d5-7b0cede00795"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtNC0xLTEtNDI5Njcx_8ece4338-3312-4216-a456-9e7e99d62f1b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItMi0xLTEtNDI5Njcx_a86e56c8-94cb-4066-986c-23c2b8d97686"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNC0xLTEtNDI5Njcx_afc4de30-418f-4e3e-b0ca-ef2323eda3f9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItOC0xLTEtNDI5Njcx_6cc8c14f-d7d8-4564-87d8-7758542b84a4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtOC0xLTEtNDI5Njcx_7ba0e3ea-e682-4737-996e-6547c9d8d1f8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtOC0xLTEtNDI5Njcx_3fbd4518-51fe-483f-89a1-5cf9bf4a4751"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjAtMi0xLTEtNDI5Njcx_970aaef8-b5d6-42fb-a76a-f958b99c1684"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktNi0xLTEtNDI5Njcx_42cb499f-f636-4adc-b8ac-a98d69c36b83"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktOC0xLTEtNDI5Njcx_0ac023e0-501c-45e6-8b76-9e5c1d60aa3c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMjItNC0xLTEtNDI5Njcx_a4541278-e2cb-4393-a38b-ae8cad9d8c18"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTktMi0xLTEtNDI5Njcx_a31d12ad-733d-454f-aacf-b9a02ebc2ddf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNi0xLTEtNDI5Njcx_ad4f3559-591c-4f22-b2f9-04973e92ea32"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtMi0xLTEtNDI5Njcx_b8d35731-3c3a-44a7-85f7-4d37b26a1ee7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfMTgtNC0xLTEtNDI5Njcx_03da9fde-fd5e-4bb9-b48b-aefe07d232a3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzg0Mw_321bec03-e973-4b73-8e74-abf4280197c3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0xMC0xLTEtNDU1NDg4_e2b9857d-9a48-440e-b892-39f78f609815"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0xMC0xLTEtNDU1NDg4_e2b9857d-9a48-440e-b892-39f78f609815"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOmM1Zjc3MDIxY2VjZDQ4MzViNjEzOTVlNzFiOTJlMzM4L3RhYmxlcmFuZ2U6YzVmNzcwMjFjZWNkNDgzNWI2MTM5NWU3MWI5MmUzMzhfMy0xMC0xLTEtNDU1NDg4_e2b9857d-9a48-440e-b892-39f78f609815"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNzY5NjU4MTQwMTk1MA_78da5456-94da-41f4-a427-3b84f6a33fdb"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi00LTEtMS00Mjk2NzE_8bfa4640-17ef-44ef-ac97-dc7b2d8e9c11"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi00LTEtMS00Mjk2NzE_8bfa4640-17ef-44ef-ac97-dc7b2d8e9c11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi0yLTEtMS00Mjk2NzE_71e44f3a-392e-466e-875b-5da4ad8a675d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi0yLTEtMS00Mjk2NzE_71e44f3a-392e-466e-875b-5da4ad8a675d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTE5_795908f7-063c-467e-8921-7a9634d8d597" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTE5_795908f7-063c-467e-8921-7a9634d8d597" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi00LTEtMS00Mjk2NzE_8bfa4640-17ef-44ef-ac97-dc7b2d8e9c11"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTE5_795908f7-063c-467e-8921-7a9634d8d597"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RhYmxlOmI3YjFiNjg4MDNiZDRmZTE4YzRjYTg5ZmIzZjk1NDA5L3RhYmxlcmFuZ2U6YjdiMWI2ODgwM2JkNGZlMThjNGNhODlmYjNmOTU0MDlfNi0yLTEtMS00Mjk2NzE_71e44f3a-392e-466e-875b-5da4ad8a675d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV84NS9mcmFnOmE4YTgzODhiZjQ1MTQyOTQ5MWFhMzA4ZDNjMDBkYjdhL3RleHRyZWdpb246YThhODM4OGJmNDUxNDI5NDkxYWEzMDhkM2MwMGRiN2FfNTE5_795908f7-063c-467e-8921-7a9634d8d597"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC02LTEtMS00Mjk2NzE_ff34748e-e1cd-45ce-93ab-98ed5e2b47a4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC02LTEtMS00Mjk2NzE_ff34748e-e1cd-45ce-93ab-98ed5e2b47a4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC00LTEtMS00Mjk2NzE_f2ce4cd5-9bc0-46df-98a2-0a1357007693"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC00LTEtMS00Mjk2NzE_f2ce4cd5-9bc0-46df-98a2-0a1357007693"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC04LTEtMS00Mjk2NzE_8c1270d2-bc3a-444c-810e-7d0db83546a0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC04LTEtMS00Mjk2NzE_8c1270d2-bc3a-444c-810e-7d0db83546a0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC0yLTEtMS00Mjk2NzE_2baaca16-26a8-47d2-a221-754f24fd20cb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC0yLTEtMS00Mjk2NzE_2baaca16-26a8-47d2-a221-754f24fd20cb"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The losses in the first nine months of 2022 include, among other things, unrealized losses of $974&#160;million related to investments in BioNTech, Cerevel Therapeutics Holdings, Inc. (Cerevel) and Arvinas. The gains in the third quarter and first nine months of 2021 included, among other things, unrealized gains of $420&#160;million and $1.5&#160;billion, respectively, related to investments in BioNTech and Cerevel. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC02LTEtMS00Mjk2NzE_ff34748e-e1cd-45ce-93ab-98ed5e2b47a4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC00LTEtMS00Mjk2NzE_f2ce4cd5-9bc0-46df-98a2-0a1357007693"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC04LTEtMS00Mjk2NzE_8c1270d2-bc3a-444c-810e-7d0db83546a0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOC0yLTEtMS00Mjk2NzE_2baaca16-26a8-47d2-a221-754f24fd20cb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTI4_d642ba46-50e1-43e8-b0ad-f213610e8829"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNi0xLTEtNDI5Njcx_34e03b37-a1b3-477f-b8ea-6fc43d6d69b6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNi0xLTEtNDI5Njcx_34e03b37-a1b3-477f-b8ea-6fc43d6d69b6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTItMS0xLTQyOTY3MQ_a3b2da09-2fff-4dbe-9c94-5f0fbde322fa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTItMS0xLTQyOTY3MQ_a3b2da09-2fff-4dbe-9c94-5f0fbde322fa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMi0xLTEtNDI5Njcx_2721d866-8f12-475d-b329-5b2c2055214b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMi0xLTEtNDI5Njcx_2721d866-8f12-475d-b329-5b2c2055214b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTAtMS0xLTQyOTY3MQ_a4939c53-51b1-4072-8a3d-80ee90e928f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTAtMS0xLTQyOTY3MQ_a4939c53-51b1-4072-8a3d-80ee90e928f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTQtMS0xLTQyOTY3MQ_b6b9f342-3cf2-42b3-b1e1-5ae23c7067e7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTQtMS0xLTQyOTY3MQ_b6b9f342-3cf2-42b3-b1e1-5ae23c7067e7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNC0xLTEtNDI5Njcx_7701f7ed-5376-447f-a11e-2b480b14bb8f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNC0xLTEtNDI5Njcx_7701f7ed-5376-447f-a11e-2b480b14bb8f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNi0xLTEtNDI5Njcx_34e03b37-a1b3-477f-b8ea-6fc43d6d69b6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTItMS0xLTQyOTY3MQ_a3b2da09-2fff-4dbe-9c94-5f0fbde322fa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMi0xLTEtNDI5Njcx_2721d866-8f12-475d-b329-5b2c2055214b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTAtMS0xLTQyOTY3MQ_a4939c53-51b1-4072-8a3d-80ee90e928f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItMTQtMS0xLTQyOTY3MQ_b6b9f342-3cf2-42b3-b1e1-5ae23c7067e7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RhYmxlOmJmNmE1YjQwZGI3ZjQ1YTQ5MTMzYjFhODhjYWMzYTMxL3RhYmxlcmFuZ2U6YmY2YTViNDBkYjdmNDVhNDkxMzNiMWE4OGNhYzNhMzFfMzItNC0xLTEtNDI5Njcx_7701f7ed-5376-447f-a11e-2b480b14bb8f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV82NC9mcmFnOjUyMTNiYTgwNjFmNDRjZDE5NjRjODViN2NiY2FhOWNiL3RleHRyZWdpb246NTIxM2JhODA2MWY0NGNkMTk2NGM4NWI3Y2JjYWE5Y2JfMTQzMg_592d669d-c2e4-4b64-8f6e-960f302bf74a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS00LTEtMS00Mjk2NzE_78979520-f128-45f4-991e-aab26f802b5d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS00LTEtMS00Mjk2NzE_78979520-f128-45f4-991e-aab26f802b5d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS04LTEtMS00Mjk2NzE_ff367060-a416-42eb-ac91-4c9ed4241d0c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS04LTEtMS00Mjk2NzE_ff367060-a416-42eb-ac91-4c9ed4241d0c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS02LTEtMS00Mjk2NzE_64fe25dd-a57e-463f-adf8-62bd1b937c40"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS02LTEtMS00Mjk2NzE_64fe25dd-a57e-463f-adf8-62bd1b937c40"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS0yLTEtMS00Mjk2NzE_0e091c4d-563d-4a8d-8711-bd269d2da7a9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS0yLTEtMS00Mjk2NzE_0e091c4d-563d-4a8d-8711-bd269d2da7a9"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The first nine months of 2021 included, among other things, $188&#160;million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS00LTEtMS00Mjk2NzE_78979520-f128-45f4-991e-aab26f802b5d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS04LTEtMS00Mjk2NzE_ff367060-a416-42eb-ac91-4c9ed4241d0c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS02LTEtMS00Mjk2NzE_64fe25dd-a57e-463f-adf8-62bd1b937c40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RhYmxlOjdjNTgxMWZjNjRmZDQ5ODZiMmM2ZGZmZWE0NDRhNTYwL3RhYmxlcmFuZ2U6N2M1ODExZmM2NGZkNDk4NmIyYzZkZmZlYTQ0NGE1NjBfOS0yLTEtMS00Mjk2NzE_0e091c4d-563d-4a8d-8711-bd269d2da7a9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80OS9mcmFnOjE3MzRlMGZhMzliODQ0YTlhYWMzZTlhNzI1MDM1NzQ5L3RleHRyZWdpb246MTczNGUwZmEzOWI4NDRhOWFhYzNlOWE3MjUwMzU3NDlfNTIy_1b3ff844-6b68-41c7-8e55-c78f4c06fdf1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC00LTEtMS00Mjk2NzE_9fb5c4b0-0fed-4b82-a748-fa1f573f1bdd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC00LTEtMS00Mjk2NzE_9fb5c4b0-0fed-4b82-a748-fa1f573f1bdd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC0yLTEtMS00Mjk2NzE_488adaed-49b4-417c-9242-a756da55a909"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC0yLTEtMS00Mjk2NzE_488adaed-49b4-417c-9242-a756da55a909"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC02LTEtMS00Mjk2NzE_41178dd3-7bc7-461d-b007-624d30582aa9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC02LTEtMS00Mjk2NzE_41178dd3-7bc7-461d-b007-624d30582aa9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC04LTEtMS00Mjk2NzE_ee5555c1-19b6-4724-8563-ebcc82def2cf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC04LTEtMS00Mjk2NzE_ee5555c1-19b6-4724-8563-ebcc82def2cf"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents external costs for banking, legal, accounting and other similar services.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC00LTEtMS00Mjk2NzE_9fb5c4b0-0fed-4b82-a748-fa1f573f1bdd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC0yLTEtMS00Mjk2NzE_488adaed-49b4-417c-9242-a756da55a909"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC02LTEtMS00Mjk2NzE_41178dd3-7bc7-461d-b007-624d30582aa9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RhYmxlOmRmMTE3YmE1ZDU1MzQ1OGRiNmFkMmRjNTg1ZGNiNjBmL3RhYmxlcmFuZ2U6ZGYxMTdiYTVkNTUzNDU4ZGI2YWQyZGM1ODVkY2I2MGZfOC04LTEtMS00Mjk2NzE_ee5555c1-19b6-4724-8563-ebcc82def2cf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhjMjUzMGE5MWNlZDRjNDhiOTYyMDEyODIwNjgwOGYxL3NlYzo4YzI1MzBhOTFjZWQ0YzQ4Yjk2MjAxMjgyMDY4MDhmMV80Ni9mcmFnOjQ5ZWU4YmQzMjMyYTQ3MzQ5MDMwYjgzMjg2YjRkZjk5L3RleHRyZWdpb246NDllZThiZDMyMzJhNDczNDkwMzBiODMyODZiNGRmOTlfMzc4NA_6341faa6-0957-4603-b4c9-10f553be0433"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MQ5P5 H(5FD/1_\BJW#IG0D$+"TTB>)?DFIQCP5*H#N&9SL!.5K"]0F94&3M
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MKTB<DJLX22!LU)FC88IF(&=<3J=?3(?53,<C5S+5<T6B="(FB'W4;-]ML'>
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M**0YZ-"D#$KC*)HLW+;@[_[,QPJY4", 2HN@M!A*2Z"T%$IC4!I'T62YMT:
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M- :E<?-YEX77^AJ>V==X:F^P&=_[*@VU.3SBC0+*0P!B:,:$R&@[:MD&:EU
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MC\/[XWN$0S4^Z5#I515H0X38K(U3@5%N[G K RFZ=B$H_C(&Z@(O1K%$0A#
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M^/SE2HI4&A; ^X5&\]<W;&#[[]#E_P%02P,$%     @ HX!I52QVN@$."
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MP\DN(8C'%B@#Q^PVLLMG[)K8X1QNR>J+H4FE"3&'CS2A?-I@U] WX0(-+E6
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M2Y6O^?=,9GD%^\&/2PFS4] $?+[(83;T"QW0_L#-B_\#4$L#!!0    ( *.
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M3M3.@/8KI>Q^X@(<WN+%OU!+ P04    " "C@&E5#-'<;Y %  "P#   &0
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M%'@A^8)- #>)XQ-#D>@W7,>Q$J54 L\\=LEM-#F*\"5#$42?*=EM]S)B'83
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M=4-D0JBZ6;4=K"SB9=0OE0JT+\(&HCY)&YP>'02.W&CBA5(?RF-/TQ?:L,E
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M:P921#YH+L,E-'E=@9SD=-P,6-=.P=G5$$I8P&'@\(^?/WG*4O$<XO;L5].
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MQ" 22YX3>H^E]FQ@7"FUX!9;Y23Y+":LFU,-%F^MA'C4GQA*WX2@C;;Y9G\
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MT4J<AU.6Y(EBT0D*60Z %ZVQ@CTM7&Y$!BZL!)40 XAY'LK$(.7\&YH!QXS
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ME2+W7P ;CG[Y5PFQ-Q#P*N2,7+\CSJ]NVX4#8F."]2>Q[4<)*&H*Z4"LTQ=
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M"YDMUJ! 6W2(+TZORQ 1@ORJPM]E]$6,AXZX3?&_SR/'=B3S=&)KP,(/SY"
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MM_V1ZWF3/?U6(*#-)9HYI5'4,L0G)'2!DNA[N1R%5&+X]&E$EVN+,]3;VDW
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M$.%D K@2";>C*!4%V5#SAL=9?F6("7' ]UTC QMDD4 8FE7.>L\^V'$T; 3
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MS\8-3S$LX5J)'4J;.;*"K#\5OY;.F%AF/B.G?#LWIW)G74?\I7BRRUB(N>@
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MN+\5*SB4I$H_*!CM+&&&X>!X27W3B_N7UED -DMI[!IN*^./W:#&V[0T8>Q
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MCW71OT1TJAS6?99(_S(11M(_OC6!SZ5;(A.;PN"T43OMT#AB*'(HXL,AQV*
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MU\^I*C.IU_!@=&JTMT8I%F^U1XO..V@\B:5"UQS%GF@Q>)S6%*XJ"LDW*%S
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MF!G0QC,!6AS<,%6%TGV%_%&%Q%&%A/=6+DO/^0?/(*_VC=SOF[-#T;\+N>?
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M[:GM!(M(L$MVO\QE>58*N6))]BB*4OG%AS^KI-RP F51(C\EY9(A'";I!M
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MQ/KB"1Y@3SBMQ#R$15DY_([5=_>VAN7]/I^P+<.SPOJ*2>B.Q:3<Z@S<.MK
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MXX<5-9:HG0'METK9W<0%Z%O5^7=02P,$%     @ HX!I5<BOY_S/!0  E!$
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MZ/;2TDZL:OQ%8:4L73O\<$OW/-1N ZVOE;*'B0O0WQSG?P%02P,$%     @
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MA2%C=SPLM53IHZ8KK8H@]";%8C-10#>5/4Y#&.F*4- T=.R#LOL+-,%MP82
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M=B'(Y]63C<9?_]7,Z \93!99.LOML].+J5U;-Q5Q8/Q%$@OM^RA4"#G2_OZ
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MY?CBM52&OO-58#DB:T;^M-=#%SLB"5W- YBF8+^W!0@1IIT^S)CK_)_)1&;
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M-P*T9M0 W\G%U \T0?-[D/?_#5!+ P04    " "C@&E5=YG,CUD"  #_!
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ME*+[+RQ]8,+<H4 9"U"T)2B:!XKF@Z(%4&C=5&FY%3P#YT,Q*-D"BK8$1?-
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MJEA:1N7 ^Q*D3_TF,?2ACZ11#&N_R9.)VN+%?IGQR%3+V'D9:Z>,.9[6F&O
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M[SGM:!VRGY2BORF/@CCWL/G[6.T #VI*0=%L4#0'"DW5IS*P>'*< 1[2?BY
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MHJY/>5I WG]F3+R>I G*#6&S_P%02P,$%     @ HX!I5>OY+#RL!@  SQ<
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MCVU='"B,P\!6Q@$+AO8"[$P6AP<6*!QLM0E:M1E3 9Z_0!F=DPRV)@I6*YB
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M(#MC25:(I"\H=];!,:$+DZRR&Y9DA4CZLG(_'8SRTP;99+\KR0:1]&7C?CE
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M*<<XJ37&0<K<P -;3\4IX$W*X4TZ+WB3HL(;+&Y]Y7%XD_YCF1O#2)K,3:J
M3$,4HJ#Q-/&SE..E=(JL33KFK(R"2'M6)N6H*47-W*2*G$PL+5TR41AH JDI
MATPI#)D^525]<M99_86VSNVFO&FF ".P$-9V.$G],*& V+S"0"DJDL/B-JAK
M)A8V@P-!>,O8Q?-0_15)+BJIHM.7E22N4/K,A;$5;#X3;L0R"&9=$P>+W4"3
MGJ#)>=5U?98'38%3U'8EKE#_S?VGZKM>/ \%!39AFL%="&7B7#A5-L:@)GE?
M-@AF/Q^F (O$%6K8N>',# H$E?8*1&(W4*!04\^%42>J02D2D$I'I8"C@*,2
MZN^Y,"+]L7J@=;G>)LG9\\WN:+E\<EYWR7/G]]//IP;;0*V;B\9NH VAJI\[
MK^JYS_*@*7"2^G^N4 #0A0.7Q[V1/7/M9\-()-5R5-'%<:+9Z4#$LKJ&NKJC
M[0#3M< R63]]+'8#)8H%?\F\S >N'6ROP$G KEA9V%!:^$CS494.#I-$*HJK
MHHM]HJN(+!89-E09MC$?I "H023[AS]%")2(E9#)O(*@!"[-;*_ 29"M6)W9
M4)[Y6.M1A"85MJ/8M:8%8&*%9D.)9BO+F3!N (MI/QF0V WT*@#;?6'G^5@3
M+A;&8C=0H("%#26NC[4F\]E&F&8@L( ]X0+-7VM):&X)MRCU)%6IB5"6FGCS
MRK$3N$ZVM0*QV T4**!B0]'L(PUI1.ULF&8@L(!"#=6S[0UIFL@;+*;]1)@D
M$BN4^2;[<MGSL21<A#Q)-7 BE ,G<,GLHRU)/A^A?#U2T0&O1T(I;F*HQ?V5
M%H7EFF I[>?#))%8H7 XV5?QGH]!X8)D+'8#!0H@V5#/_%B#4FSE5)B38B^G
M]HU)*&M.#'7-=<9D#E?#C.T?WR315J%>.O'FM>. X%961V,W:(TE8%NX_OBQ
M\]]7]$M+Y>YC"K+ #746(%0U)X:RYJ,L !.)P?)8/W<L=@,%"@C7G]FF KCD
MN[T")X&ROMA4#H[W'FLX\MX I>'(9,QP=&\V0EEV I<N'VTX6( +MRX[&KN!
M_@0<Z\]L[P!<P-U>@9,@5J&X.YFDNCM15&Z78@$*&EW#0Z&X.S%4=Q]M,1.&
MIF$1[2?!))%5H0@]\6>VRP"W>CT:NX$"!=P+UW@_VHKDW0.R%4$T@QZG LXT
M%(W_"BO"<D6PA-9S (O=0*4"!@YFMM< KKEOK\!),+!0?)\8ZN8?:40CZNK#
M- .!!<QI**UO9T33A*1A$>TGP201U4#LOCRS/0=P6P)[!4Z"B(5.!<30JN!8
M*U(5RI%?A!1DP(N0T+> &!H7?(4MH3DDW%@J%KN!2@6D',QLPP'<[\%>@9/
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MM-4]FW8GSG75MM5Z^^>*9NR!= 3L]]N*W>'^0S? 8U5_V=[6^?\!4$L#!!0
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ME+; 7!\+H5<3>]167U;I'U!+ P04    " "C@&E5VM>[#%P$  #%#P  &0
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M29!& -^OA-"O"W- -;E/_P%02P,$%     @ HX!I50W8.3JO!P  *SL  !D
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M2(@.T/1I X.TN?-CEWAN"A00T=:=G]YPD.H<I$4_Q!,UJI"*VI&J>]^+ZIN
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MK,"2Z9&LL:(O6ZE*9FBJ=KZN%;+<@4KA1T&0^"7CE9?.W=J#2N>R,8)7^*!
M-V7)U+<[%/*P\$+O^\('OBN,7?#3><UVN$;SL7Y0-/-[EIR76&DN*U"X77BO
MP]GJUMH[@T\<#_IH#%;)1LHO=O(F7WB!=0@%9L8R,/K;XQ*%L$3DQC\=I]=O
M:8''X^_L]TX[:=DPC4LI_N2Y*1;>C0<Y;EDCS =Y^!T[/1/+ETFAW2\<.MO
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M0;%=:%';66LA-$YN]K' X1JD$<#]I1#Z:6'&MWY<3_\!4$L#!!0    ( *.
M:55EHVY8/@(  ' %   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;+64
MWV_3,!#'_Q4K2 @D6-*L'3#:2.O&1"4*U2;@8>+!3:Z--?\(Y^O:_?><G384
MJ>T;+XW/OOO>Y\X]#]<.'WT-0&)CM/6CI"9J+M/4ES48Z<]< Y9/%@Z-)#9Q
MF?H&058QR.@TS[*+U$AEDV(8]V98#-V*M+(P0^%7QDA\'H-VZU'22W8;=VI9
M4]A(BV$CEW /]+V9(5MIIU(I ]8K9P7"8I1<]2['@^ ?'7XH6/N]M0B5S)U[
M#,:D&B59  (-)04%R9\GN :M@Q!C_-YJ)EW*$+B_WJG?QMJYEKGT<.WT3U51
M/4K>)Z*"A5QING/KS["M)P*63OOX*]:M[V"0B'+ER9EM,!,89=NOW&S[L!?0
M.Q:0;P/RR-TFBI0WDF0Q1+<6&+Q9+2QBJ3&:X90-EW)/R*>*XZBX55;:4DDM
M)M83KKC?Y,5;<0.HGF3HF/@J$=O5JQL@J;1_/4R)<P>%M-SF&;=Y\B-Y/HBI
MLU1[\<E64/T;GS)S!Y[OP,?Y2<%O)9V)+'\C\BS/3^B==XTXCWK]8XUPR#=H
M!6S*6MHEB))YD?\T7CQ,P<P!?QVJ^J1HF*A+W\@21@F/C =\@J1X^:)WD7T\
M@=SOD/M1_?P(\MX=/7SA,S$A,/X@9O\_8 XZS,')SNYA$J 1;M'U]A#J:;%<
M/(-$?P@KW9L" [B,L^XYU\I2.Q#=;O><7+53]->]?8NF$I?*>J%AP:'9V3N&
MPG:^6X-<$V=J[H@G-"YK?A(!@P.?+YRCG1$2=(]L\0=02P,$%     @ HX!I
M58C:V;P3!0  /!H  !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULO5E1
M;Z,X$/XK%E>==J6[@ T)I)=&:A.MKM+VMFIO]QZJ>W"(DZ %.V<[22O=CS\;
M* 0PM,W1?6D SS?^9IBQOYK)@?'O8D.(!(])3,6%M9%R>V[;(MR0!(L!VQ*J
M1E:,)UBJ6[ZVQ983O$Q!26PCQQG9"8ZH-9VDSV[Y=,)V,HXHN>5 [)($\Z<K
M$K/#A06MYP=WT7HC]0-[.MGB-;DG\NOVEJL[N_"RC!)"1<0HX&1U85W"\SD*
M-""U^!:1@SBZ!CJ4!6/?]<WU\L)R-",2DU!J%UC][,F,Q+'VI'C\DSNUBCDU
M\/CZV?NG-'@5S (+,F/Q7]%2;BZLP )+LL*[6-ZQP^\D#VBH_84L%NE?<,AM
M'0N$.R%9DH,5@R2BV2]^S!-Q!(!N"P#E %0'>"T -P>XKP5X.<!+,Y.%DN9A
MCB6>3C@[ *ZME3=]D28S1:OP(ZK?^[WD:C12.#G]%%%,PPC'X)H*R7?JE4H!
M?@6?<,3!-QSO"& K,"<\VF/]AH 9@.D2W)$82[($?S#]1I7!9<)V>O##G$@<
MQ>*C\OOU?@X^G'T$9R"BX":*8V4J)K94H6A"=IC3GF6T40OM+Z$<  ?] I"#
MD $^[X;/23@ +DSAL JW50*++*(BBRCUY[;Z*_+S\%F-@6M)$O&W*:[,D6=V
MI+O\7&QQ2"XLU<:"\#VQIC__!$?.;Z8H>W)6B=DM8G:[O$\OA2#2%&$&&Z4P
MO>SLI\CW59;WQ\R;1N-14-A4"'D%(:^3T.<(+Z(XDD\F4AET>#0?]'V_1JII
M% 303&I8D!IVDBHK0ZCE2$1KFO8(%F!#ENN(KE4?E&WT<$.2!>'&PNF<YZV%
MTY.S2DI&14I&?37+J,^8>W)6B=DO8O9/:Q:_47+("X):73:- J>E68*"4'!Z
MLP3-9ADZPQJIII$/?3.I<4%J_ [- OX%2@*H#9X"\AAN,%T3$#(JN=(4W2W5
MR>:MY=63LTKBH%-NXTY?395[ZBGLOKQ5XSZ2+["S9)[%AH':U0O0!VA.#VP4
MMNLBWZN5O\$,C8?^R-P!L%02L'/3;ETIKE[ M46## N,/ZX'T[3R@Y9FAJ5
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MD?R</O])BX2\#"],(Y'_!<^%K=,#X4K(-"Z<500Q2];_R<^"B T'B%L<4.&
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MRJ%V"V@^5:2X&;@ [>-P^1]02P,$%     @ HX!I5::] [_^!@  52D  !D
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M$]1C_.>6$[D-A$\^0W. =:$:HSJ&0=2YK?"K.EZECDFED!^X&T3JL%311A1
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MN5 "N+])$OGT10U0GJ1<_ ]02P,$%     @ HX!I51S+TTO. @  =@D  !D
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M+8H62")1LF4Y=0PDOF#[T&[0;+</BWV@)=HF*HDN2=GI?OT.)476A5:SK;I
M$$O4F>'P<.;P,CUR\47N*%7H,8X2>3/8*;6_MBP9[&A,Y!7?TP2^;+B(B8)7
ML;7D7E 29D9Q9#FV[5DQ8<E@-LW:[L5LRE,5L83>"R33.";BVQV-^/%F@ =/
M#1_9=J=T@S6;[LF6/E#U:7\OX,TJO80LIHED/$&";FX&M_AZA<?:($/\R>A1
M5IZ1'LJ:\R_ZY5UX,[!U1#2B@=(N"/P<Z)Q&D?8$<7PMG [*/K5A]?G)^RH;
M/ QF322=\^@S"]7N9N /4$@W)(W41W[\C18#&FE_ 8]D]A\="ZP]0$$J%8\+
M8X@@9DG^2QX+(BH&V#UCX!0&3M-@=,; +0S<IL'PC,&P,!@^MX=183!Z;@]>
M8>!EW.=D94POB"*SJ>!')#0:O.F';+HR:R"8)3JS'I2 KPSLU&Q)1,*2K43W
M5* YCV.8[8<=$13=*B78.E5D'5&D.+K?L'\ \RX)KFK '8]"*B1ZO:"*L$B^
M09?HT\,"O7[Y!DD-D(@EZ#V+(L@D>8%>5E^GEH)!Z%"LH AXG@?LG G81>]Y
MHG82+9.0A@;[9;?]I,/> O)*!ITG!N=.I\/? W6%;.<".;;C&.)9/,?<S<RQ
M:3@_U_OJAWNOD>&6Z>1F_MQSZ73_@#ZD,15$<?'JA>]@_+;XN2.2!:;YSCT.
MS1ZULE[+/0GHS0"D4U)QH(/9JQ?8L]^:R.[3V;)/9ZN>G-6F95A.R[#+^PR*
MEL<4;02/40#ISY(4BA[!^@03I>L0D8YJ#_)JEY5J-\UC'H*7A: 7M,/,]UQ[
M:AVJ\V, X=&D#EJV08[GCMTZ:M5&8=]WAR6JQM2H9&K4R=2"R8(@&E;XJ:=R
M BL^WR!%'DT\Y!V,*G%=ZMJJT6# X,;XEFW,L,& J:>A;R; *PGP.@GX &-C
M>;KTD!->*T+?L_T&&080'GH--MH@G1,-5ZLV"OLCWS-3,BXI&?^HJ"U8E"KC
M,C0?]REK?3I;]NELU9.SVL3XY<3X_Z^L(9*$B$C89D/U@\<#M)W;IOB&U&[)
MG0'4EKLVR"1W;52'W$U*!B=]RMW%KR1T\@S=-&!:NMG&-'73U-,YW<3V:2=M
M_R+E_"\L%4%XW9)J0K4UU8 RB:H!UJ&JN'+TP-_5U05-.!QKM+(:1XO[5-%>
MO2U[];;JRUM]+IS37#B=R?LY.X+3\)) \I$M14D:KR%EH>ZK"2L13Y54D*\@
MM,_<WQ<]5\MMY-GC9L8:44VI-*.\9L(:4*/)^$R^GLXVN'.//LM/O9<9$8A^
M3=F!1#11\AK!,3WX OI9+#I0S7D+@YK.-""%PZ9 --Y'_!NEFM(]360FMF@?
M$3!ZS9XH?F,DT6W+/VZJHQ'4*GH#R&DJI $TP6?X.QU"</<IY.=SK&.[5?1=
MF_,Q;NFB">6,FA0949,F1P:4YY];1DX'$-Q] KF%Y?@RU -E!UH2DZ53)>>^
MDR]WW^GD+_RWD<3VB<)M,MB&V$WZVA#<Y*ZKHSIQ^N!2;SGMVW'G[E./\H\=
MB.5Y%H\42KF2;FC#!5([BF KQ'@H42:V">3<!8+U/,<G/%OHHS2$Y1JF0>-U
M1<-ZGQ4TY'.8)RK22USNDLN3TS4-2 KO8,A$[BJ[J3WR- K1#LH#_L&.((&_
M:C+0S88&ZLHD^%;E"A!.*MOLLE9"6&FB\M-OV5I>"-]EUZ"-]CF^7F!#^U)?
M(!O:;[%WO<2>\<L8OF1WSM8II/S&^CT16P:J%]$-A&=?C2$31'X)G+\HOL\N
M+==<*1YGCSM*0$0U +YO.%=/+[J#\BI^]B]02P,$%     @ HX!I597(&>X@
M!@  _#$  !D   !X;"]W;W)K<VAE971S+W-H965T-S(N>&ULU9MK;]LV%(;_
M"N$50PNDL27'SF6)@<:2>D&=!DW;#2CZ@9&.;:(2Z9*4W0S[\2,E6;("A8V'
MLPW]DNAV'E)ZCWBDU]3Y1LBO:@F@R?<LY>JBM]1Z==;OJW@)&56'8@7<[)D+
MF5%M5N6BKU82:%($96G?'PS&_8PRWIN<%]NNY>1<Y#IE'*XE47F647EW":G8
M7/2\WG;#>[98:KNA/SE?T07<@/ZXNI9FK5]3$I8!5TQP(F%^T7OAG47^D0TH
MCOC$8*-VEHD]E5LAOMJ5U\E%;V![!"G$VB*H^;>&*:2I)9E^?*N@O;I-&[B[
MO*5'Q<F;D[FE"J8B_9TE>GG1.^F1!.8T3_5[L7D%U0F-+"\6J2K^DDUU[*!'
MXEQID57!I@<9X^5_^KVZ$#L!OO= @%\%^(\-&%8!P\<&'%4!1_<"A@\%C*J
MT?T6_ <"QE7 N+CVY<4JKG1 -9V<2[$ATAYM:':AD*N(-A>8<9M9-UJ:O<S$
MZ<E4<,WX GC,0!'*$S(%J4U&DJG(,J9-$FE%GI-KJLT2><LT6] B)YX&8(Y+
MU3/RA)C#9RQ-S69UWM>F6Q;>CZLN7)9=\!_H@D=FIA-+14*>0-(1'_X@WG<
M^N9ZU!?%WUZ42]])O('5(1D.#H@_\'VR*DZ]HU]3-^5%OC 4[T>4P$UYDZ>/
MH81N2@#QEN(=5Q1[ P)/:"<O<O/>Q?J0#/RJ5Q]O O+TR3/'E1_6Z3@LN,,'
MN"_+S-O-R<]OS3'DM89,?>E*KA)XU VT _.96M$8+GIFY%4@U]";_/J+-Q[\
MUJ4H)BS A(68L @)UI+XJ);XR$6??%@:YE*D"3%UD21,Q:E0N00BYF0E10R0
M&/$5R<W-+ GP-9."VV&(IB2E&T7^(D^Z\L#9ZKYY@ D+,&$A)BPJ8>,"9I]!
MUA/OO+_N$'=4BSMRBCN#KUJL&?D\@^P6Y!<CUO6<_6F$M*7E$TB5*W(#:Y!&
MS9? 0;*8S"C/Y^81PR2!5*W0<IQZS>?2C@<V"5J[S>AEMN\6I>W>K@1Q]GS?
M!,&$!9BP$!,6(<%:N32N<VF,70O&F!)CP@),6(@)BY!@+8F/:XF/G<-%(7%<
M2WQW0'AN[]^B%A0WOWDF35-80)+>F:?,<AQ(2+X2O$M_9VO[ZE_"1CN#X[@>
M'$M1,9L+,6$1$JPEZDDMZLE/40/,WO#[BMDP\Y@Z'#B+@_.4]LT<3%B "0LQ
M81$2K)5DIW62G6(7AU-,B3%A 28LQ(1%2+"6Q-Z@\28&_VEY<#>W;PI4M-T"
MX=\K$*@-AJBT"(O6UG;'=_)^QBHQ=%8)]SGMG4"8M "5%J+2(BQ:.]?\)M=\
M[&)1$;&4QJ0%J+00E19AT=I*-_:AY[2N\"L&JKM8T9P5 ]4T1*5%6+2VMHUO
MZ+F-PZG(F.14WY&$28@U432M?K,PDC+*8R#2% R>0ZLVS$0")N[#'YU58DH5
MN,=\5&,1E1:@TD)46H1%:V=+8T1Z(_0Q']4A1*4%J+00E19AT=I*-S:AY[2H
M)F^%4JAC_OA'H_34W:.]M44U!U%I$1:MK6WC#WIN@_"?COGEJ\0!N63BZ@/$
MRR*B7FE>(^Q3_\OL]M7VA6-JWBP^T?B O,F315$?WLW)E>#/.]\L.K,'U8-$
MI06HM!"5%F'1VHG6>);>"7JY0/4,46D!*BU$I458M+;2C7'H.4VK1Y6+N<C-
M>,&%;LI%9P:@6HJHM*"B[5:Q8;N*A:@-1EBT]HR=QBOTW5YAF+)O.5,=9<$.
M_:WJT6TY7<YN_N<?J-UGN&\ZH=("5%J(2HNP:.W,:YQ,W\,N'3ZJCXA*"U!I
M(2HMPJ*UE6Y\1-_I7J&[2^[F]DX#5),1E196-$<UBK :;&O;.(>^VSF\JI6L
MIT7:J6:N.9*7;N3>^J%./D2EA7Z'<SFZ+^"_80_ZC3WHN^W!JT??B@<$["\^
M9BV N"C'=EKL::?"J.8?*BU I845;5=A[[[ J(Y>?V?2>@9R47Q>8)_,<Z[+
MJ=KUUOH3AA?%Q/U[VR^]LZ#\$*'!E-]%S*A<,*Y("G.#'!P>F[.3Y:<&Y8H6
MJV)J_*W06F3%XA)H M(>8/;/A=#;%=M _<''Y&]02P,$%     @ HX!I5;%L
M:9:Z @  , 8  !D   !X;"]W;W)K<VAE971S+W-H965T-S,N>&ULM55M:]LP
M$/XKAP=C@ZY.G*8M76+(R[86DBVTK/M0]D&QS[&8+7G2.6G'?OQ.<N*FT.3;
M(-B2[NZYYQ[Y+H.--K]LCDCP6!;*#H.<J+H*0YOD6 I[JBM4;,FT*07QUJQ"
M6QD4J0\JBS#J=,[#4D@5Q -_MC#Q0-=42(4+ [8N2V&>QECHS3#H!KN#6[G*
MR1V$\: 2*[Q#^EXM#._"%B65)2HKM0*#V3 8=:_&?>?O'>XE;NS>&EPE2ZU_
MN<U-.@PZCA 6F)!#$/Q:XP2+P@$QC=];S*!-Z0+WUSOTS[YVKF4I+$YT\4.F
ME ^#RP!2S$1=T*W>7..V'D\PT87U3]AL?3L!)+4E76Z#F4$I5?,6CUL=]@*B
MBP,!T38@\KR;1)[E5)"(!T9OP#AO1G,+7ZJ/9G)2N4NY(\-6R7$43[0BJ5:H
M$HD6A$IA@H;X,F&BRU(2ZT\6/L#"Z+1."&:2Y$HX04^\!YI$BL('?J,<#<P%
M$1I[ C-<L8'C$L244UAX-T5&+NS[04A,W1$(DRW-<4,S.D"S&\&<F>86/JD4
MTY< (=?<%A[M"A]'1Q&GF)Q"KWL"4:=[R8JJ.N,OI#9HCH#W6E5['OSL /@B
MDW]8BQ&K<JUM)8WPZWMAI*YMJ]1S3@OW_&#37%KK?E4E842DC<(G^((*#8OY
M,,=RB>8G_(4IRTKB$5\<+E YI?<NJ;6^)OG1&MPTN+*52' 8<+M;-&L,XK=O
MNN>=CT<4.FL5.O/HO0,*S;2U\/+C>YBQ#]P0EO95NF?_@6Z_I=L_>J%?:Z<B
MZ,QU/*LL7%=H?XV4"P5N_#V;7F/?X/<]OIN4Z_AR$*[W*85[7<Q]M?*SRD*B
M:T5-0[>G[3@<-5/@V;V9I7-A5E)9*##CT,[I!><US7QJ-J0K/Q.6FK^QTB]S
M'NEHG /;,ZUIMW$)VC^)^!]02P,$%     @ HX!I5>=5C]VG!@  AS(  !D
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MKAE=,*$%U/TEY_+EAVZ@>/=D^C]02P,$%     @ HX!I539,U\73$0  $H@
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M!W17QA@,#HSGT<ZN(VV'_PQ[O@7LV[+^>91D8+,+,&N8+&+Y!QA[MDEQ=$.
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M4\$YH& 7"G93H7] H5\H]'_5@E,H.+]JP2T4W"SV>;"R2$\#&4S&G&T15]*
MI@ZR=&7:$. H597U(#E<C4!/3A[H$NI$GJ%WE"UYL%Y%<Q2D(;J5*\K1/7VB
MZ8:B#VE>PZH6WCZ/"G3U8U?M$BH;G4RI#*+X%,0^/4S1R9M3] 9%*;J)XABT
MQ;@GP6MENS<O/+S./20'/+31#4OE2B O#6G8HN_I]4<:_1Y$JPP9>0[9-=$"
MWLYE%UGD#!&+D!9_IK^B;F?JN&TZ_\^Z_V+KM6#89?W8&9Y] *^LA05G"?*^
M2\K3($;76>52+K)B^LC2Y=N/P" ANA2"2H$>/P(.^B!I(KZTE41NM-]N5+'M
MN5@'<WK1 3H5E#_1SN2O/[!K_=V6#Y-@GDDPWQ!8+7/],G-]'7J9N1:_KO2:
MC[@U9[F2FRFI!]K3A!#7'HY[3[O):)'J6[93E_+VI0:NU;?J4OZ^E#/H.Y54
M+2Y.&1='.[L[RN? B/!81?-5D,)?I)ZA6;#:IJU'.W&[EO7G:5M9:A6/+<L<
M#..=6%A=FS0"9LAD+:YN&5=7&XE/W8<N>KRAR8SRUOK1JA][SYL$\TR"^8;
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MZ[0^:;\D15K5JVQ3=Y-]Q0<5_RHX>;;.'OKE [Q*BCK;CZL?WH(_LJ2I,GY
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M7O[9W88UAT E:<PM#P'G+3 LYJ"6H#(-5UR+4#"),__"T).^/\9I2R@-5H'
MB8NDVP]R:V9P,)1LA63XF#)MB8MX:7A#S:^5287%$T&S'4MY9FG8TYS!H>$D
ME<]O<+@X@@7=.1P=PP5?"2F%7-'XEG-EVD;P.4-^Y$0-N3-N3T@F X$:L')P
MM#>T71J(FN@N@NX4<A-#80(<R@260P@J19MHP#3'<(/6O"5+O)=0?4-/T)"'
M890M5&9=O#3&5^*C7C$IOKI=M".(F%QQI*3N+&009R'.IWHSP+I&06BR0[/
M4@2S)3YD&GUN%Q!R/^ :9UH)4Y4(;"OV_H7F,2-/*I#\JD18@>SHD8L\.B<Q
MH!&+EQ20\L?C\&"$([V;B-W,?8!%6BZ0IQ13&PD=EN$FL3S2VEB0U,^2?*[-
M$X$3(88^Y>Z^)KYO%[SC'458Z#^IR*LJ.LHU/0YL?G,$:<0P98$K.4P+!DKS
M4%#"J(K-0_;;5!AK'L?TOZ3;A!HKGTAW(HZ*39:F\3TPI.5TGX$< JNT*/R8
MKUAP#]=+\17?%IE!=XSAID.'1')M(I&:[60OL*CP*$ L$I'KQ0+73!I1U-6S
M+?@HF-4" Z)B/% D[ YZ*N0+M5QN#NB']%\52;@H+-LZZ/N.'-7T]JDGA5BA
M%*'=$Y_FUS20*FW1%*&.ZYIY9^L>">$K=^-G\'!DTN8C5;E:WBI>N+NTG?6I
M=WKIU:S/Z!:R9OVEYYW.O/H='W><CLZ#2?FUYQ73V)P,IG>)YG6/1_B1I_.;
MQ/S%JM3=?"V4Q2\ ]QAQ%G)- KA/'6_S0@K*^]S)_U!+ P04    " "C@&E5
MW>ATQ5D#  #*%   #0   'AL+W-T>6QE<RYX;6S=6-%NVC 4_94HW:96FAH@
M;2 K(&U(E29M4Z7V86^5(0Y8<NS,,1WTL;^RUWW%/F5?,M\X)$!]4=>'%1;4
MQO>>W'//M:^)VWZAEYQ>SRC5WB+CHACX,ZWS=T%03&8T(\6IS*DP2"I51K0Q
MU30H<D5)4D!0QH-.JQ4%&6'"'_;%/+O,=.%-Y%SH@=^M79Z]?4P&?CLZ\SU+
M-Y()'?BWQV^^S:6^>.79^]';HZ/6[<G%MO^X!$[\P$EZ_@32TQ;.:S",.G)3
M__J!"*Z!W8J[F[0K%:W7ANJXL;#PGB.\"47#8G<QOQ]^(M4TR,YRNBUW.1O5
M6%5!U2;#?BI%TRVA;QV&G634NR-\X(\(9V/%("HE&>-+Z^Z 8R*Y5)XV;6K2
MM<%3W%NX;2WHX(HG8T*J,K?-8'^/J\>W@)4% AGGM<".;QW#?DZTIDI<&J-\
MN'0^@KQJ?+/,C<*I(LMVY]QO LJ;23*6*J&J3M/V5ZYAG],4Y"@VG<%=RSP
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M>N?OU'L8/X]EN/5\K?'YWTGU>+FWW!Y_77Z=1 E75YSK^XKA^2]02P,$%
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MU:+(:E%DM2BR6A19[?^4]:?W^T^.GY_UX+KQ)9_-?WJ^_@U02P$"% ,4
M" "C@&E5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( *. :54HHYX<[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *. :5697)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ HX!I5<>D:HM0!@  ="4  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *. :56<E[7F
MK0D  $@K   8              " @9,.  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " "C@&E5XP$$JJH&   "'   &
M@(%V&   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ HX!I
M55I/@34)"@  @"8  !@              ("!5A\  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( *. :56=B667R (  )\&   8
M      " @94I  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" "C@&E5S69";YX0   (N   &               @(&3+   >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ HX!I51]YD);5 @  #0@  !@
M             ("!9ST  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( *. :56U(LFN,@D  *LJ   8              " @7)   !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "C@&E530V]WNH.  #=
M)P  &               @(':20  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ HX!I50E5D)AA$@  #C4  !D              ("!^E@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "C@&E5:1N'
M;*@*   @'0  &0              @(&2:P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( *. :54B;=D4T@<  "D2   9
M  " @7%V  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MHX!I52QVN@$."   A!,  !D              ("!>GX  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " "C@&E59BA[D]0#  "-"   &0
M            @(&_A@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( *. :575 2[PCQ0  .Q&   9              " @<J*  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ HX!I5;9+FHUI P
MEP<  !D              ("!D)\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " "C@&E5#-'<;Y %  "P#   &0              @($P
MHP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *. :54&
M#;4G#P4  'P.   9              " @?>H  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ HX!I5?^*+S\#!   #@L  !D
M     ("!/:X  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *. :55L#_Q4C ,  -D'   9              "
M@:H& 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ HX!I
M5<-E91#B!@  *A(  !D              ("!;0H! 'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " "C@&E5X>2#)?T'  "T$@  &0
M        @(&&$0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( *. :56N0(T,[0,  #@)   9              " @;H9 0!X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ HX!I51#B5"[C P  0 @
M !D              ("!WAT! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " "C@&E5/$KMQI\1  "D3P  &0              @('X(0$
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *. :57)O+<^
MBP,  +8*   9              " @<XS 0!X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ HX!I5<BOY_S/!0  E!$  !D
M ("!D#<! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "C
M@&E5PW#,O]<#  !%"@  &0              @(&6/0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( *. :56Z0!:8%P0  +,*   9
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M970S-RYX;6Q02P$"% ,4    " "C@&E5W><;B[L$  #)&P  &0
M    @(';:0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M *. :5608&(8W@P  #ZO   9              " @<UN 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ HX!I5<^E]E99!0  5",  !D
M             ("!XGL! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " "C@&E5GXI EO\#  "D$   &0              @(%R@0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( *. :55;$<V%L@,
M #H.   9              " @:B% 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ HX!I50ZZKD<%"@  )4<  !D              ("!
MD8D! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "C@&E5
M6);57-T&   <-@  &0              @('-DP$ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( *. :57K^2P\K 8  ,\7   9
M      " @>&: 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ HX!I51_-M"GZ!   <Q@  !D              ("!Q*$! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "C@&E5KA$MC*D#  "A#0
M&0              @('UI@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( *. :54LV8,@Z (  #T)   9              " @=6J 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ HX!I504(F<IV
M!0  KA0  !D              ("!]*T! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " "C@&E5TP/F] \'   Y,0  &0
M@(&ALP$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( *.
M:5427]Y/AQ   /JD   9              " @>>Z 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ HX!I5=25W^'< @  90D  !D
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M=#4V+GAM;%!+ 0(4 Q0    ( *. :56?V)Q:>P,  -8)   9
M  " @=#A 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
MHX!I5;S\\W9N P  N@L  !D              ("!@N4! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " "C@&E59:-N6#X"  !P!0  &0
M            @($GZ0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( *. :56(VMF\$P4  #P:   9              " @9SK 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ HX!I59SLK:"\"0
M?C\  !D              ("!YO ! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    " "C@&E52;LVE9\%  "P(P  &0              @('9
M^@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( *. :57"
M-0=UM@,  -,.   9              " @:\  @!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ HX!I54_(U*)7 @  OP4  !D
M     ("!G 0" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *. :56FO0.__@8  %4I   9              "
M@109 @!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ HX!I
M51S+TTO. @  =@D  !D              ("!22 " 'AL+W=O<FMS:&5E=',O
M<VAE970W,"YX;6Q02P$"% ,4    " "C@&E5$G?49&H%  "6%P  &0
M        @(%.(P( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0
M   ( *. :565R!GN( 8  /PQ   9              " @>\H @!X;"]W;W)K
M<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ HX!I5;%L:9:Z @  , 8
M !D              ("!1B\" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q0
M2P$"% ,4    " "C@&E5YU6/W:<&  "',@  &0              @($W,@(
M>&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( *. :54V3-?%
MTQ$  !*(   9              " @14Y @!X;"]W;W)K<VAE971S+W-H965T
M-S4N>&UL4$L! A0#%     @ HX!I5>A2N^0+!@  ]2$  !D
M ("!'TL" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "C
M@&E5R;OI\_@6  ":[@  &0              @(%A40( >&PO=V]R:W-H965T
M<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( *. :54&/>5[R04  -L5   9
M          " @9!H @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#
M%     @ HX!I5=WH=,59 P  RA0   T              ( !D&X" 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "C@&E5EXJ[',     3 @  "P
M    @ $4<@( 7W)E;',O+G)E;'-02P$"% ,4    " "C@&E5Q3'298$%   C
M-   #P              @ ']<@( >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ HX!I57H$ UU< @  (2X  !H              ( !JW@" 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ HX!I52XH"M@5 @  _"P
M !,              ( !/WL" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ %8 5@"1%P  A7T"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>618</ContextCount>
  <ElementCount>408</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>175</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement</Role>
      <ShortName>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Other (Income)/Deductions - Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNet</Role>
      <ShortName>Other (Income)/Deductions - Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Tax Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMatters</Role>
      <ShortName>Tax Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Identifiable Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssets</Role>
      <ShortName>Identifiable Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Pension and Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlans</Role>
      <ShortName>Pension and Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Contingencies and Certain Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitments</Role>
      <ShortName>Contingencies and Certain Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Segment, Geographic and Other Revenue Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation</Role>
      <ShortName>Segment, Geographic and Other Revenue Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables</Role>
      <ShortName>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Other (Income)/Deductions - Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</Role>
      <ShortName>Other (Income)/Deductions - Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Tax Matters (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTables</Role>
      <ShortName>Tax Matters (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMatters</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/FinancialInstruments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherFinancialInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Identifiable Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables</Role>
      <ShortName>Identifiable Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/IdentifiableIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionandPostretirementBenefitPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Discontinued Operations Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Discontinued Operations Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Equity Method Investment Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails</Role>
      <ShortName>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Equity Method Investment Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Schedule of Equity-Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails</Role>
      <ShortName>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Schedule of Equity-Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Collaborative Arrangements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail</Role>
      <ShortName>Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Collaborative Arrangements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail</Role>
      <ShortName>Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Other (Income)/Deductions - Net - Schedule of Impaired Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Schedule of Impaired Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Tax Matters - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersNarrativeDetail</Role>
      <ShortName>Tax Matters - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Financial Instruments - Investments by Classification Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails</Role>
      <ShortName>Financial Instruments - Investments by Classification Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Investment Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Financial Instruments - Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments - Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Financial Instruments - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Financial Instruments - Derivative Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails</Role>
      <ShortName>Financial Instruments - Derivative Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails</Role>
      <ShortName>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Financial Instruments - Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails</Role>
      <ShortName>Financial Instruments - Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Other Financial Information - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails</Role>
      <ShortName>Other Financial Information - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail</Role>
      <ShortName>Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Identifiable Intangible Assets - Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail</Role>
      <ShortName>Identifiable Intangible Assets - Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Pension and Postretirement Benefit Plans - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Contingencies and Certain Commitments - Patent Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails</Role>
      <ShortName>Contingencies and Certain Commitments - Patent Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Contingencies and Certain Commitments - Product Litigation, Commercial and Other Matters, Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails</Role>
      <ShortName>Contingencies and Certain Commitments - Product Litigation, Commercial and Other Matters, Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="pfe-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 -  pfe-20221002.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="pfe-20221002.htm">pfe-20221002.htm</File>
    <File>pfe-20221002.xsd</File>
    <File>pfe-20221002_cal.xml</File>
    <File>pfe-20221002_def.xml</File>
    <File>pfe-20221002_lab.xml</File>
    <File>pfe-20221002_pre.xml</File>
    <File>pfe-exh311x1002202210q.htm</File>
    <File>pfe-exh312x1002202210q.htm</File>
    <File>pfe-exh321x1002202210q.htm</File>
    <File>pfe-exh322x1002202210q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1651">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pfe-20221002.htm": {
   "axisCustom": 2,
   "axisStandard": 44,
   "contextCount": 618,
   "dts": {
    "calculationLink": {
     "local": [
      "pfe-20221002_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20221002_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pfe-20221002.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20221002_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20221002_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pfe-20221002.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 755,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 8
   },
   "keyCustom": 70,
   "keyStandard": 338,
   "memberCustom": 98,
   "memberStandard": 66,
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20221002",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.pfizer.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement",
     "role": "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement",
     "shortName": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Other (Income)/Deductions - Net",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNet",
     "shortName": "Other (Income)/Deductions - Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Tax Matters",
     "role": "http://www.pfizer.com/role/TaxMatters",
     "shortName": "Tax Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Financial Instruments",
     "role": "http://www.pfizer.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Other Financial Information",
     "role": "http://www.pfizer.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Identifiable Intangible Assets",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssets",
     "shortName": "Identifiable Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Pension and Postretirement Benefit Plans",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlans",
     "shortName": "Pension and Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Contingencies and Certain Commitments",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitments",
     "shortName": "Contingencies and Certain Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Segment, Geographic and Other Revenue Information",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation",
     "shortName": "Segment, Geographic and Other Revenue Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement (Tables)",
     "role": "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables",
     "shortName": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Other (Income)/Deductions - Net (Tables)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables",
     "shortName": "Other (Income)/Deductions - Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Tax Matters (Tables)",
     "role": "http://www.pfizer.com/role/TaxMattersTables",
     "shortName": "Tax Matters (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Other Financial Information (Tables)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Identifiable Intangible Assets (Tables)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables",
     "shortName": "Identifiable Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Pension and Postretirement Benefit Plans (Tables)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables",
     "shortName": "Pension and Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables",
     "shortName": "Segment, Geographic and Other Revenue Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "operatingsegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
     "shortName": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "if02ecae4c145465fbebfc17542366c8c_I20220311",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Discontinued Operations Narrative (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
     "shortName": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Discontinued Operations Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Equity Method Investment Narrative (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
     "shortName": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Equity Method Investment Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i28e0ab0e158f46899e45c2d773856f14_I20220703",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbp",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Schedule of Equity-Method Investment (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails",
     "shortName": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Schedule of Equity-Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "id859aeb95872427ca6e14971df36fe79_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i158261a31a1c413799e169c8d84fe9ba_I20221031",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Collaborative Arrangements (Detail)",
     "role": "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
     "shortName": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Collaborative Arrangements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i158261a31a1c413799e169c8d84fe9ba_I20221031",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "iadd388f3beca428899e121e6042d61eb_I20221002",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "iadd388f3beca428899e121e6042d61eb_I20221002",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "iecf59b86323f44bc955f877e15b9942e_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "iecf59b86323f44bc955f877e15b9942e_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail",
     "shortName": "Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
     "shortName": "Other (Income)/Deductions - Net - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i5120c338e7784bc0a405cf860830dc96_D20220101-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Other (Income)/Deductions - Net - Schedule of Impaired Intangible Assets (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails",
     "shortName": "Other (Income)/Deductions - Net - Schedule of Impaired Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "ic05981cd1fe44b799fb2bd2a7043b2f5_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Tax Matters - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersNarrativeDetail",
     "shortName": "Tax Matters - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail",
     "shortName": "Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i291c881a539a4386ace0953f2e533606_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "ia28d11de768f4acfa1899aa6f92f42fe_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i752fb6da23f74a17911b22b40176bdc2_I20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i49a36bebd932477abb647b4c3f1f7229_I20221002",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i49a36bebd932477abb647b4c3f1f7229_I20221002",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Financial Instruments - Investments by Classification Type (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails",
     "shortName": "Financial Instruments - Investments by Classification Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails",
     "shortName": "Financial Instruments - Schedule of Investment Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Financial Instruments - Short-term Borrowings (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails",
     "shortName": "Financial Instruments - Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Financial Instruments - Long-Term Debt (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
     "shortName": "Financial Instruments - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i8bdb0dbdb3524c57926943b1fac9dcef_I20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i8472588c67134a13847983bdf694f4dc_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Financial Instruments - Derivative Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
     "shortName": "Financial Instruments - Derivative Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i8472588c67134a13847983bdf694f4dc_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i342523194f354c36af8db3ac1d92928a_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i342523194f354c36af8db3ac1d92928a_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i9f47fc0e281c43afac185ec01923d406_I20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
     "shortName": "Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "ia27ee9bbb7f54cd8be9aff24de29fdbd_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Financial Instruments - Credit Risk (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails",
     "shortName": "Financial Instruments - Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Other Financial Information - Inventories (Details)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails",
     "shortName": "Other Financial Information - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Other Financial Information - Other Current Liabilities (Details)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
     "shortName": "Other Financial Information - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i8308f5a4b0dc4a5e84bd59beff89e949_I20221002",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
     "shortName": "Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "iecf59b86323f44bc955f877e15b9942e_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Identifiable Intangible Assets - Goodwill (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail",
     "shortName": "Identifiable Intangible Assets - Goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
     "shortName": "Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i3a8d97b6e8224ee89549e43cd0db2830_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Pension and Postretirement Benefit Plans - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
     "shortName": "Pension and Postretirement Benefit Plans - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i1ed9c4010e8b4aa1996067a2e4e28e89_D20220101-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Contingencies and Certain Commitments - Patent Litigation (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
     "shortName": "Contingencies and Certain Commitments - Patent Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i0729378a52374c80919b47eeb89d45c8_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i498fe9705333412a85d84b8175400688_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Contingencies and Certain Commitments - Product Litigation, Commercial and Other Matters, Legal Proceedings (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails",
     "shortName": "Contingencies and Certain Commitments - Product Litigation, Commercial and Other Matters, Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i498fe9705333412a85d84b8175400688_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "operatingsegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "ia747d02316fd4b71a97be55a1aeac96c_I20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "shortName": "Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "ief168de902d9492590aa5220b5b73f29_D20210705-20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "2",
      "lang": "en-US",
      "name": "pfe:PercentageChangeInRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i3a658246e2b34fd6a44cebc005385303_D20220704-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i716250fdc59e4c239f0c68b1cf8343e2_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i7336380d9d6f4a4495fae7cd4004e307_D20220704-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20221002.htm",
      "contextRef": "i6e3a3c2c80374d7aa48830bdd0893af1_D20220101-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 175,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pfe_A1365ConsumerHealthcareJVLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.365% Consumer Healthcare JV Loan",
        "label": "1.365% Consumer Healthcare JV Loan [Member]",
        "terseLabel": "1.365% Consumer Healthcare JV Loan [Member]"
       }
      }
     },
     "localname": "A1365ConsumerHealthcareJVLoanMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AccruedRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.",
        "label": "Amortization Of Intangible Assets Not Associated With Single Function",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ArenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arena",
        "label": "Arena [Member]",
        "terseLabel": "Arena [Member]"
       }
      }
     },
     "localname": "ArenaMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AromasinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aromasin",
        "label": "Aromasin [Member]",
        "terseLabel": "Aromasin [Member]"
       }
      }
     },
     "localname": "AromasinMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ArvinasIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arvinas Inc",
        "label": "Arvinas Inc [Member]",
        "terseLabel": "Arvinas Inc [Member]"
       }
      }
     },
     "localname": "ArvinasIncMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetImpairmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset impairments [Member]",
        "label": "Asset Impairments [Member]",
        "terseLabel": "Asset Impairment Charges [Member]"
       }
      }
     },
     "localname": "AssetImpairmentsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetWriteOffsAndAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-Offs And Asset Impairment Charges",
        "label": "Asset Write-Offs And Asset Impairment Charges",
        "verboseLabel": "Asset write-offs and impairments"
       }
      }
     },
     "localname": "AssetWriteOffsAndAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Available-for-sale securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BMP2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMP2 [Member]",
        "label": "BMP2 [Member]",
        "terseLabel": "BMP2 [Member]"
       }
      }
     },
     "localname": "BMP2Member",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BavencioAllianceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bavencio Alliance Revenues",
        "label": "Bavencio Alliance Revenues [Member]",
        "terseLabel": "Bavencio Alliance Revenues [Member]"
       }
      }
     },
     "localname": "BavencioAllianceRevenuesMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BeneFIXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bene F I X [Member]",
        "label": "Bene F I X [Member]",
        "terseLabel": "BeneFIX [Member]"
       }
      }
     },
     "localname": "BeneFIXMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BesponsaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Besponsa [Member]",
        "label": "Besponsa [Member]",
        "terseLabel": "Besponsa [Member]"
       }
      }
     },
     "localname": "BesponsaMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechAndCerevelTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioNTech and Cerevel Therapeutics, LLC",
        "label": "BioNTech and Cerevel Therapeutics, LLC [Member]",
        "terseLabel": "BioNTech and Cerevel [Member]"
       }
      }
     },
     "localname": "BioNTechAndCerevelTherapeuticsLLCMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechCerevelTherapeuticsLLCAndArvinasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioNTech, Cerevel Therapeutics, LLC and Arvinas",
        "label": "BioNTech, Cerevel Therapeutics, LLC and Arvinas [Member]",
        "terseLabel": "BioNTech, Cerevel Therapeutics, LLC and Arvinas [Member]"
       }
      }
     },
     "localname": "BioNTechCerevelTherapeuticsLLCAndArvinasMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BionTech [Member]",
        "label": "BioNTech [Member]",
        "terseLabel": "BioNTech [Member]"
       }
      }
     },
     "localname": "BioNTechMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiohavenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biohaven",
        "label": "Biohaven [Member]",
        "terseLabel": "Biohaven [Member]"
       }
      }
     },
     "localname": "BiohavenMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiopharmaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biopharma Segment [Member]",
        "label": "Biopharma Segment [Member]",
        "terseLabel": "Biopharma [Member]"
       }
      }
     },
     "localname": "BiopharmaSegmentMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BosulifMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bosulif [Member]",
        "label": "Bosulif [Member]",
        "terseLabel": "Bosulif [Member]"
       }
      }
     },
     "localname": "BosulifMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BraftoviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Braftovi [Member]",
        "label": "Braftovi [Member]",
        "terseLabel": "Braftovi [Member]"
       }
      }
     },
     "localname": "BraftoviMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.",
        "label": "Business Combination, Acquisition Related Costs, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCostsTransactionCosts",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "label": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "terseLabel": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract",
     "nsuri": "http://www.pfizer.com/20221002",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]",
        "terseLabel": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract",
     "nsuri": "http://www.pfizer.com/20221002",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]",
        "terseLabel": "Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ChantixChampixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chantix / Champix [Member]",
        "label": "Chantix Champix [Member]",
        "terseLabel": "Chantix / Champix [Member]"
       }
      }
     },
     "localname": "ChantixChampixMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Investment From Collaborator, Amount",
        "label": "Collaborative Arrangement, Committed Investment From Collaborator, Amount",
        "terseLabel": "Committed investment from collaborator"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ComirnatyAndPaxlovidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comirnaty and Paxlovid",
        "label": "Comirnaty and Paxlovid [Member]",
        "terseLabel": "Paxlovid and Comirnaty [Member]"
       }
      }
     },
     "localname": "ComirnatyAndPaxlovidMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ComirnatyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comirnaty",
        "label": "Comirnaty [Member]",
        "terseLabel": "Comirnaty direct sales and alliance revenues [Member]",
        "verboseLabel": "Comirnaty [Member]"
       }
      }
     },
     "localname": "ComirnatyMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsumerHealthcareJVHaleonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Healthcare JV / Haleon",
        "label": "Consumer Healthcare JV / Haleon [Member]",
        "terseLabel": "Consumer Healthcare JV / Haleon [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareJVHaleonMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsumerHealthcareJVSeniorNotesEURDenominatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Healthcare JV Senior Notes, EUR Denominated",
        "label": "Consumer Healthcare JV Senior Notes, EUR Denominated [Member]",
        "terseLabel": "Senior Notes, EUR Denominated [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareJVSeniorNotesEURDenominatedMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsumerHealthcareJVSeniorNotesGBPDenominatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Healthcare JV Senior Notes, GBP Denominated",
        "label": "Consumer Healthcare JV Senior Notes, GBP Denominated [Member]",
        "terseLabel": "Senior Notes, GBP Denominated [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareJVSeniorNotesGBPDenominatedMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsumerHealthcareJVSeniorNotesUSDDenominatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Healthcare JV Senior Notes, USD Denominated",
        "label": "Consumer Healthcare JV Senior Notes, USD Denominated [Member]",
        "terseLabel": "Senior Notes, USD Denominated [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareJVSeniorNotesUSDDenominatedMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CorporateEnablingFunctionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Enabling Functions",
        "label": "Corporate Enabling Functions [Member]",
        "terseLabel": "Corporate Enabling Functions [Member]"
       }
      }
     },
     "localname": "CorporateEnablingFunctionsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "label": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "terseLabel": "Net fair value adjustments related to hedging and purchase accounting"
       }
      }
     },
     "localname": "DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Gain",
        "label": "Debt Securities, Accumulated Gross Unrealized Gain",
        "totalLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Loss",
        "label": "Debt Securities, Accumulated Gross Unrealized Loss",
        "negatedTotalLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Amortized Cost Basis",
        "label": "Debt Securities, Amortized Cost Basis",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, After Year Five, Fair Value",
        "label": "Debt Securities Maturities, After Year Five, Fair Value",
        "totalLabel": "Debt securities maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "label": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "totalLabel": "Debt securities maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "label": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "totalLabel": "Debt securities maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "label": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "terseLabel": "Schedule of Gains and Losses on Investment Securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "label": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.",
        "label": "Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DerivativeNetReceivablePositionAggregateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Net Receivable Position, Aggregate Fair Value",
        "label": "Derivative, Net Receivable Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net receivable position"
       }
      }
     },
     "localname": "DerivativeNetReceivablePositionAggregateFairValue",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DevelopedEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed Europe [Member]",
        "label": "Developed Europe [Member]",
        "terseLabel": "Developed Europe [Member]"
       }
      }
     },
     "localname": "DevelopedEuropeMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DevelopedRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed Rest Of World [Member]",
        "label": "Developed Rest Of World [Member]",
        "terseLabel": "Developed Rest Of World [Member]"
       }
      }
     },
     "localname": "DevelopedRestOfWorldMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal",
        "label": "Disposal Group, Including Discontinued Operation, Proposed Ownership Percentage Disposal",
        "terseLabel": "Proposed percent of ownership disposal"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProposedOwnershipPercentageDisposal",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DocetaxelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Docetaxel [Member]",
        "label": "Docetaxel [Member]",
        "terseLabel": "Docetaxel [Member]"
       }
      }
     },
     "localname": "DocetaxelMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliquisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliquis [Member]",
        "label": "Eliquis [Member]",
        "terseLabel": "Eliquis alliance revenues and direct sales [Member]"
       }
      }
     },
     "localname": "EliquisMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Markets [Member]",
        "label": "Emerging Markets [Member]",
        "terseLabel": "Emerging Markets [Member]"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enbrel [Member]",
        "label": "Enbrel [Member]",
        "terseLabel": "Enbrel (Outside the U.S. and Canada) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EpiPenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EpiPen [Member]",
        "label": "Epi Pen [Member]",
        "terseLabel": "Epi Pen [Member]"
       }
      }
     },
     "localname": "EpiPenMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EquityMethodInvestmentAdjustmentOfBasisDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Adjustment of Basis Differences",
        "label": "Equity Method Investment, Adjustment of Basis Differences",
        "terseLabel": "Equity method investment, adjustment of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdjustmentOfBasisDifferences",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "label": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "negatedTerseLabel": "Decrease due to foreign currency translation"
       }
      }
     },
     "localname": "EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesFVNIRestrictedNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "label": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "terseLabel": "Long-term equity securities held in trust"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictedNoncurrent",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "label": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative impairment losses and downward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ExpirationPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Period",
        "label": "Expiration Period [Axis]",
        "terseLabel": "Expiration Period [Axis]"
       }
      }
     },
     "localname": "ExpirationPeriodAxis",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ExpirationPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Period [Domain]",
        "label": "Expiration Period [Domain]",
        "terseLabel": "Expiration Period [Domain]"
       }
      }
     },
     "localname": "ExpirationPeriodDomain",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_Expiring2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring 2030",
        "label": "Expiring 2030 [Member]",
        "terseLabel": "Expiring 2030 [Member]"
       }
      }
     },
     "localname": "Expiring2030Member",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_Expiring2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiring 2033",
        "label": "Expiring 2033 [Member]",
        "terseLabel": "Expiring 2033 [Member]"
       }
      }
     },
     "localname": "Expiring2033Member",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FSMEIMMUNTicoVacMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FSME/IMMUN-TicoVac",
        "label": "FSME/IMMUN-TicoVac [Member]",
        "terseLabel": "FSME/IMMUN-TicoVac [Member]"
       }
      }
     },
     "localname": "FSMEIMMUNTicoVacMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "terseLabel": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://www.pfizer.com/20221002",
     "xbrltype": "stringItemType"
    },
    "pfe_FocusedCompanyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Focused Company Plan [Member]",
        "label": "Focused Company Plan [Member]",
        "terseLabel": "Focused Company Plan [Member]"
       }
      }
     },
     "localname": "FocusedCompanyPlanMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency long - term debt [Member]",
        "label": "Foreign Currency Debt [Member]",
        "terseLabel": "Foreign currency long-term debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyDebtMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyShortTermBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency short - term borrowings [Member]",
        "label": "Foreign Currency Short Term Borrowings [Member]",
        "terseLabel": "Foreign currency short-term borrowings [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyShortTermBorrowingsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FragminMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fragmin [Member]",
        "label": "Fragmin [Member]",
        "terseLabel": "Fragmin [Member]"
       }
      }
     },
     "localname": "FragminMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK [Member]",
        "label": "GSK [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GainContingencyNumberofDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Defendants",
        "label": "Gain Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberofDefendants",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "label": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "terseLabel": "Number of patents allegedly infringed upon, expired December 2019"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GenotropinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genotropin [Member]",
        "label": "Genotropin [Member]",
        "terseLabel": "Genotropin [Member]"
       }
      }
     },
     "localname": "GenotropinMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GoToMarketModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Go-to Market Model",
        "label": "Go-to Market Model [Member]",
        "terseLabel": "Go-to Market Model [Member]"
       }
      }
     },
     "localname": "GoToMarketModelMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GovernmentAndGovernmentSponsoredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Government Sponsored",
        "label": "Government and Government Sponsored [Member]",
        "terseLabel": "U.S. Government [Member]"
       }
      }
     },
     "localname": "GovernmentAndGovernmentSponsoredMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HedgedItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Item [Axis]",
        "label": "Hedged Item [Axis]",
        "terseLabel": "Hedged Item [Axis]"
       }
      }
     },
     "localname": "HedgedItemAxis",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_HedgedItemDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Hedged Item [Axis]",
        "label": "Hedged Item [Domain]",
        "terseLabel": "Hedged Item [Domain]"
       }
      }
     },
     "localname": "HedgedItemDomain",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HeldToMaturityCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held-To-Maturity Cash Equivalents",
        "label": "Held-To-Maturity Cash Equivalents",
        "terseLabel": "Held-to-maturity cash equivalents"
       }
      }
     },
     "localname": "HeldToMaturityCashEquivalents",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IbranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ibrance [Member]",
        "label": "Ibrance [Member]",
        "terseLabel": "Ibrance [Member]"
       }
      }
     },
     "localname": "IbranceMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IgPortfolioProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ig Portfolio Products",
        "label": "Ig Portfolio Products [Member]",
        "terseLabel": "Ig Portfolio Products [Member]"
       }
      }
     },
     "localname": "IgPortfolioProductsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 4.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.",
        "label": "Implementation Costs",
        "terseLabel": "Implementation costs"
       }
      }
     },
     "localname": "ImplementationCosts",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "label": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "negatedTerseLabel": "Income from collaborations, out-licensing arrangements and sales of compound/product rights"
       }
      }
     },
     "localname": "IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders Basic",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders diluted",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "label": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "negatedTerseLabel": "Haleon/Consumer Healthcare JV equity method (income)/loss"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InflectraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inflectra [Member]",
        "label": "Inflectra [Member]",
        "terseLabel": "Inflectra [Member]"
       }
      }
     },
     "localname": "InflectraMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InlytaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inlyta [Member]",
        "label": "Inlyta [Member]",
        "terseLabel": "Inlyta [Member]"
       }
      }
     },
     "localname": "InlytaMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InterestPaidReceivedInterestRateHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Paid (Received), Interest Rate Hedges",
        "label": "Interest Paid (Received), Interest Rate Hedges",
        "terseLabel": "Interest rate hedges"
       }
      }
     },
     "localname": "InterestPaidReceivedInterestRateHedges",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LicensingAgreementsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements And Other [Member]",
        "label": "Licensing Agreements And Other [Member]",
        "terseLabel": "License Agreements and Other [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsAndOtherMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "label": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "terseLabel": "Current portion of long-term debt, principal amount"
       }
      }
     },
     "localname": "LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "label": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "totalLabel": "Total long-term investments"
       }
      }
     },
     "localname": "LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Investments [Member]",
        "label": "Long-term Investments [Member]",
        "terseLabel": "Long-term Investments [Member]"
       }
      }
     },
     "localname": "LongtermInvestmentsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LorbrenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lorbrena",
        "label": "Lorbrena [Member]",
        "terseLabel": "Lorbrena [Member]"
       }
      }
     },
     "localname": "LorbrenaMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "label": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "terseLabel": "Number of defendants other than main defendant"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendantsOtherThanMainDefendant",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_ManufacturingOptimizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Optimization [Member]",
        "label": "Manufacturing Optimization [Member]",
        "terseLabel": "Manufacturing Optimization [Member]"
       }
      }
     },
     "localname": "ManufacturingOptimizationMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MedrolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medrol [Member]",
        "label": "Medrol [Member]",
        "terseLabel": "Medrol [Member]"
       }
      }
     },
     "localname": "MedrolMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MektoviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mektovi [Member]",
        "label": "Mektovi [Member]",
        "terseLabel": "Mektovi [Member]"
       }
      }
     },
     "localname": "MektoviMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MeridianMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Meridian",
        "label": "Meridian [Member]",
        "terseLabel": "Meridian [Member]"
       }
      }
     },
     "localname": "MeridianMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ModernaTXPatentInfringementCaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ModernaTX Patent Infringement Case",
        "label": "ModernaTX Patent Infringement Case [Member]",
        "terseLabel": "ModernaTX Patent Infringement Case [Member]"
       }
      }
     },
     "localname": "ModernaTXPatentInfringementCaseMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NimenrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nimenrix [Member]",
        "label": "Nimenrix [Member]",
        "terseLabel": "Nimenrix [Member]"
       }
      }
     },
     "localname": "NimenrixMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20271.000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "terseLabel": "1.000% Notes due 2027 [Member]"
       }
      }
     },
     "localname": "NotesDue20271.000Member",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology [Member]"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accruals",
        "label": "Other Accruals",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "OtherAccruals",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherAntiinfectivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Anti-infectives [Member]",
        "label": "Other Anti-infectives [Member]",
        "terseLabel": "All other Anti-infectives [Member]"
       }
      }
     },
     "localname": "OtherAntiinfectivesMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax",
        "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Non-Derivative, Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "All other net, Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "All other net, Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.pfizer.com/20221002",
     "xbrltype": "stringItemType"
    },
    "pfe_OtherNonoperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Net",
        "label": "Other Nonoperating Income (Expense), Net",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseNet",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology Products [Member]",
        "label": "Other Oncology Products [Member]",
        "terseLabel": "All other Oncology [Member]"
       }
      }
     },
     "localname": "OtherOncologyProductsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherPrimaryCareProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Primary Care Products",
        "label": "Other Primary Care Products [Member]",
        "terseLabel": "All other Primary Care [Member]"
       }
      }
     },
     "localname": "OtherPrimaryCareProductsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherSpecialtyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Specialty Care",
        "label": "Other Specialty Care [Member]",
        "terseLabel": "All other Specialty Care [Member]"
       }
      }
     },
     "localname": "OtherSpecialtyCareMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherTaxAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Tax Assets, Current",
        "label": "Other Tax Assets, Current",
        "terseLabel": "Current tax assets"
       }
      }
     },
     "localname": "OtherTaxAssetsCurrent",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement [Member]",
        "label": "Patent Infringement [Member]",
        "terseLabel": "Patent Infringement [Member]"
       }
      }
     },
     "localname": "PatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaxlovidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paxlovid",
        "label": "Paxlovid [Member]",
        "terseLabel": "Paxlovid [Member]"
       }
      }
     },
     "localname": "PaxlovidMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Pursuant to Terms of Separation Agreement, Financing Activities",
        "label": "Payment Pursuant to Terms of Separation Agreement, Financing Activities",
        "terseLabel": "Payment pursuant to terms of the separation agreement"
       }
      }
     },
     "localname": "PaymentPursuantToTermsOfSeparationAgreementFinancingActivities",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Asset Acquisitions, Before Working Capital Adjustments",
        "label": "Payments for Asset Acquisitions, Before Working Capital Adjustments",
        "terseLabel": "Payment for asset acquisition, base payment"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitionsBeforeWorkingCapitalAdjustments",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "label": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "negatedLabel": "Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsToCollaboratorsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Collaborators, Upfront Payment",
        "label": "Payments to Collaborators, Upfront Payment",
        "terseLabel": "Upfront payment to collaborators"
       }
      }
     },
     "localname": "PaymentsToCollaboratorsUpfrontPayment",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment",
        "label": "Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment",
        "terseLabel": "Upfront payment and premium paid in equity investment"
       }
      }
     },
     "localname": "PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "label": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "negatedTerseLabel": "Utilization and other"
       }
      }
     },
     "localname": "PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).",
        "label": "Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)",
        "negatedTerseLabel": "Benefit plan contributions in excess of expense/income"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PercentageChangeInRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage change in revenue.",
        "label": "Percentage Change In Revenue",
        "terseLabel": "Percentage change in revenue"
       }
      }
     },
     "localname": "PercentageChangeInRevenue",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "label": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "terseLabel": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]"
       }
      }
     },
     "localname": "PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerAndVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer and Versus Several Generic Manufacturers",
        "label": "Pfizer and Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer and Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerAndVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement",
        "label": "Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member]",
        "terseLabel": "Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member]"
       }
      }
     },
     "localname": "PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerCentreOneSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer CentreOne Segment",
        "label": "Pfizer CentreOne Segment [Member]",
        "terseLabel": "PC1 [Member]"
       }
      }
     },
     "localname": "PfizerCentreOneSegmentMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerandBMSVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "label": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer and BMS Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerandBMSVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PremarinFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premarin family [Member]",
        "label": "Premarin Family [Member]",
        "terseLabel": "Premarin family [Member]"
       }
      }
     },
     "localname": "PremarinFamilyMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrepaymentsAndPaymentsToCollaboratorsCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments and Payments to Collaborators, Cash",
        "label": "Prepayments and Payments to Collaborators, Cash",
        "verboseLabel": "Payment to collaborators"
       }
      }
     },
     "localname": "PrepaymentsAndPaymentsToCollaboratorsCash",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PrevnarPrevenarFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevnar/Prevenar Family 13 [Member]",
        "label": "Prevnar Prevenar Family [Member]",
        "terseLabel": "Prevnar Family [Member]"
       }
      }
     },
     "localname": "PrevnarPrevenarFamilyMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrimaryCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Care",
        "label": "Primary Care [Member]",
        "terseLabel": "Primary Care [Member]"
       }
      }
     },
     "localname": "PrimaryCareMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Equity Investments",
        "label": "Private Equity Investments",
        "terseLabel": "Private equity securities at cost"
       }
      }
     },
     "localname": "PrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ProceedsFromEquityMethodInvestmentDistributionTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Equity Method Investment, Distribution, Total",
        "label": "Proceeds from Equity Method Investment, Distribution, Total",
        "terseLabel": "Dividends received, total"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDistributionTotal",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ReFactoAfXynthaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Re Facto AF Xyntha [Member]",
        "label": "Re Facto AF Xyntha [Member]",
        "terseLabel": "ReFacto AF/Xyntha [Member]"
       }
      }
     },
     "localname": "ReFactoAfXynthaMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReViralAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ReViral Asset Acquisition",
        "label": "ReViral Asset Acquisition [Member]",
        "terseLabel": "ReViral [Member]"
       }
      }
     },
     "localname": "ReViralAssetAcquisitionMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RebatesAndDiscountsAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts",
        "label": "Rebates And Discounts Accrual",
        "terseLabel": "Total accrued rebates and other sales-related accruals"
       }
      }
     },
     "localname": "RebatesAndDiscountsAccrual",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ReconcilingItemsAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciling Items, Acquisition Related Costs",
        "label": "Reconciling Items, Acquisition Related Costs [Member]",
        "terseLabel": "Acquisition-Related Items [Member]"
       }
      }
     },
     "localname": "ReconcilingItemsAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReconcilingItemsAmortizationOfIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciling Items, Amortization of Intangible Assets",
        "label": "Reconciling Items, Amortization of Intangible Assets [Member]",
        "terseLabel": "Amortization of Intangible Assets [Member]"
       }
      }
     },
     "localname": "ReconcilingItemsAmortizationOfIntangibleAssetsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReconcilingItemsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciling Items, Other",
        "label": "Reconciling Items, Other [Member]",
        "terseLabel": "Certain Significant Items [Member]"
       }
      }
     },
     "localname": "ReconcilingItemsOtherMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ResearchAndDevelopmentInProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development in Process",
        "label": "Research and Development in Process [Member]",
        "terseLabel": "Acquired In-Process Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RestructuringAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring, Asset Impairment Charges",
        "label": "Restructuring, Asset Impairment Charges",
        "netLabel": "Asset impairments"
       }
      }
     },
     "localname": "RestructuringAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "label": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "totalLabel": "Total costs associated with acquisitions and cost-reduction/productivity initiatives"
       }
      }
     },
     "localname": "RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.",
        "label": "Restructuring Charges And Acquisition Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs",
        "totalLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Acquisition-Related Costs [Member]",
        "label": "Restructuring Charges And Acquisition-Related Costs [Member]",
        "terseLabel": "Restructuring Charges And Acquisition-Related Costs [Member]"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RestructuringChargesChargesIncurredToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges, Charges Incurred to Date",
        "label": "Restructuring Charges, Charges Incurred to Date",
        "terseLabel": "Restructuring charges incurred to date"
       }
      }
     },
     "localname": "RestructuringChargesChargesIncurredToDate",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring",
        "label": "Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring",
        "terseLabel": "Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring"
       }
      }
     },
     "localname": "RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringandRelatedCostNoncashChargesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "label": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "terseLabel": "Percentage of expected costs to be non-cash"
       }
      }
     },
     "localname": "RestructuringandRelatedCostNoncashChargesPercentage",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RetacritMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retacrit [Member]",
        "label": "Retacrit [Member]",
        "terseLabel": "Retacrit [Member]"
       }
      }
     },
     "localname": "RetacritMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RuxienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ruxience",
        "label": "Ruxience [Member]",
        "terseLabel": "Ruxience [Member]"
       }
      }
     },
     "localname": "RuxienceMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Line Items]",
        "terseLabel": "Schedule Of Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesLineItems",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Table]",
        "terseLabel": "Schedule Of Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTable",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Table]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]",
        "label": "Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification of Accruals"
       }
      }
     },
     "localname": "ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ShorttermDebtGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term Debt, Gross",
        "label": "Short-term Debt, Gross",
        "totalLabel": "Total short-term borrowings, principal amount"
       }
      }
     },
     "localname": "ShorttermDebtGross",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term Investments Excluding Held-To-Maturity Securities",
        "label": "Short-term Investments Excluding Held-To-Maturity Securities",
        "totalLabel": "Total short-term investments"
       }
      }
     },
     "localname": "ShorttermInvestmentsExcludingHeldToMaturitySecurities",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Site Contingency, Regulatory Proceedings, Disclosure Threshold",
        "label": "Site Contingency, Regulatory Proceedings, Disclosure Threshold",
        "terseLabel": "Threshold for disclosure of proceedings under environmental laws"
       }
      }
     },
     "localname": "SiteContingencyRegulatoryProceedingsDisclosureThreshold",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SomavertMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Somavert [Member]",
        "label": "Somavert [Member]",
        "terseLabel": "Somavert [Member]"
       }
      }
     },
     "localname": "SomavertMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SpecialtyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty Care",
        "label": "Specialty Care [Member]",
        "terseLabel": "Specialty Care [Member]"
       }
      }
     },
     "localname": "SpecialtyCareMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SulperazonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sulperazon [Member]",
        "label": "Sulperazon [Member]",
        "terseLabel": "Sulperazon [Member]"
       }
      }
     },
     "localname": "SulperazonMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SutentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sutent [Member]",
        "label": "Sutent [Member]",
        "terseLabel": "Sutent [Member]"
       }
      }
     },
     "localname": "SutentMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalAllianceBiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Alliance Biopharmaceuticals [Member]",
        "label": "Total Alliance Biopharmaceuticals [Member]",
        "terseLabel": "Total Alliance revenues [Member]"
       }
      }
     },
     "localname": "TotalAllianceBiopharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ToviazMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Toviaz [Member]",
        "label": "Toviaz [Member]",
        "terseLabel": "Toviaz [Member]"
       }
      }
     },
     "localname": "ToviazMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TrazimeraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trazimera",
        "label": "Trazimera [Member]",
        "terseLabel": "Trazimera [Member]"
       }
      }
     },
     "localname": "TrazimeraMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TrumenbaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trumenba",
        "label": "Trumenba [Member]",
        "terseLabel": "Trumenba [Member]"
       }
      }
     },
     "localname": "TrumenbaMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VfendMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vfend [Member]",
        "label": "Vfend [Member]",
        "terseLabel": "Vfend [Member]"
       }
      }
     },
     "localname": "VfendMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViatrisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viatris",
        "label": "Viatris [Member]",
        "terseLabel": "Viatris [Member]"
       }
      }
     },
     "localname": "ViatrisMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViivHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Limited [Member]",
        "label": "ViiV Healthcare Limited [Member]",
        "terseLabel": "ViiV [Member]"
       }
      }
     },
     "localname": "ViivHealthcareLimitedMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VyndaqelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vyndaqel [Member]",
        "label": "Vyndaqel [Member]",
        "terseLabel": "Vyndaqel/Vyndamax [Member]"
       }
      }
     },
     "localname": "VyndaqelMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalkoriMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xalkori [Member]",
        "label": "Xalkori [Member]",
        "terseLabel": "Xalkori [Member]"
       }
      }
     },
     "localname": "XalkoriMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XeljanzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xeljanz [Member]",
        "label": "Xeljanz [Member]",
        "terseLabel": "Xeljanz [Member]"
       }
      }
     },
     "localname": "XeljanzMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XtandiAllianceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xtandi Alliance Revenues [Member]",
        "label": "Xtandi Alliance Revenues [Member]",
        "terseLabel": "Xtandi alliance revenues [Member]"
       }
      }
     },
     "localname": "XtandiAllianceRevenuesMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZaviceftaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zavicefta",
        "label": "Zavicefta [Member]",
        "terseLabel": "Zavicefta [Member]"
       }
      }
     },
     "localname": "ZaviceftaMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZirabevMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zirabev",
        "label": "Zirabev [Member]",
        "terseLabel": "Zirabev [Member]"
       }
      }
     },
     "localname": "ZirabevMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZithromaxZmaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zithromax / Zmax [Member]",
        "label": "Zithromax Zmax [Member]",
        "terseLabel": "Zithromax [Member]"
       }
      }
     },
     "localname": "ZithromaxZmaxMember",
     "nsuri": "http://www.pfizer.com/20221002",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r164",
      "r215",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r235",
      "r239",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r383",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r164",
      "r215",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r235",
      "r239",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r383",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r80",
      "r82",
      "r162",
      "r163",
      "r392",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r247",
      "r440",
      "r445",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r247",
      "r440",
      "r445",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r242",
      "r366",
      "r367",
      "r440",
      "r443",
      "r727",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r242",
      "r366",
      "r367",
      "r440",
      "r443",
      "r727",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r81",
      "r82",
      "r162",
      "r163",
      "r392",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r200",
      "r292",
      "r293",
      "r555",
      "r646",
      "r647",
      "r648",
      "r649",
      "r687",
      "r690",
      "r691",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r200",
      "r292",
      "r293",
      "r555",
      "r646",
      "r647",
      "r648",
      "r649",
      "r687",
      "r690",
      "r691",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "terseLabel": "Reclassification Adjustment [Member]"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r440",
      "r444",
      "r785",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r440",
      "r444",
      "r785",
      "r803",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r65",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts [Member]",
        "verboseLabel": "Trade Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r249",
      "r250"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts: 2022\u2014$474; 2021\u2014$492"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": {
     "auth_ref": [
      "r90",
      "r95",
      "r104",
      "r105",
      "r106",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]",
        "terseLabel": "Prior Service (Costs)/Credits and Other [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r95",
      "r104",
      "r105",
      "r106",
      "r107",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r95",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Available-For-Sale Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r51",
      "r92",
      "r94",
      "r95",
      "r763",
      "r792",
      "r796"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r91",
      "r95",
      "r104",
      "r105",
      "r106",
      "r166",
      "r167",
      "r168",
      "r595",
      "r691",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "verboseLabel": "Accum. Other Comp. Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r84",
      "r95",
      "r104",
      "r105",
      "r106",
      "r595",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r49",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r540",
      "r541",
      "r542",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Add'l Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r55",
      "r251",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive common stock equivalents (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition, consideration transferred (up to)"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r579",
      "r580",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Asset acquisition, contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r148",
      "r334"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Certain asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r38",
      "r157",
      "r223",
      "r230",
      "r237",
      "r288",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r589",
      "r596",
      "r666",
      "r692",
      "r694",
      "r732",
      "r761"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r28",
      "r63",
      "r157",
      "r288",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r589",
      "r596",
      "r666",
      "r692",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r257",
      "r300"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Available-for-sale debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r261",
      "r263",
      "r757"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r261",
      "r262",
      "r756"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r254",
      "r258",
      "r300",
      "r737"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale debt securities",
        "totalLabel": "Available-for-sale debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r256",
      "r300"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r33",
      "r256",
      "r300"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r611",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits and other [Member]"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r530",
      "r534",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r530",
      "r534",
      "r570",
      "r571",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, per share in cash (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "verboseLabel": "Integration costs and other"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Post closing compensation expense"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Exit costs/(credits)"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value [Member]"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r25",
      "r31",
      "r150"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r143",
      "r150",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r143",
      "r670"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r18",
      "r143"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by/(used in) investing activities from discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r18",
      "r143"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by/(used in) operating activities from discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Derivative, Amount of Gains/(Losses) on interest rate contract Recognized in OID"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Derivative, Amount of Gains/(Losses) on hedged item Recognized in OID"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r155",
      "r157",
      "r185",
      "r186",
      "r191",
      "r194",
      "r196",
      "r204",
      "r205",
      "r206",
      "r288",
      "r373",
      "r378",
      "r379",
      "r380",
      "r386",
      "r387",
      "r413",
      "r414",
      "r416",
      "r417",
      "r419",
      "r666",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral posted"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r74",
      "r738",
      "r768"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r369",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Certain Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r166",
      "r167",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock, $.05 par value [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED",
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "terseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r47",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r100",
      "r102",
      "r103",
      "r118",
      "r748",
      "r778"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income/(loss) attributable to Pfizer Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r100",
      "r102",
      "r117",
      "r587",
      "r588",
      "r600",
      "r747",
      "r777"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income/(loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r100",
      "r102",
      "r116",
      "r586",
      "r600",
      "r746",
      "r776"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income/(loss) before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r115",
      "r129",
      "r745",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r247",
      "r663",
      "r664",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r247",
      "r663",
      "r664",
      "r798",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r247",
      "r663",
      "r664",
      "r798",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r208",
      "r209",
      "r247",
      "r663",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r247",
      "r663",
      "r664",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r427",
      "r428",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r427",
      "r428",
      "r441"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues",
        "verboseLabel": "Deferred revenues, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r427",
      "r428",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r476",
      "r524",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate and other [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other Business Activities [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostDirectMaterial": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of material used for good produced and service rendered.",
        "label": "Cost, Direct Material",
        "terseLabel": "Cost, excess raw materials"
       }
      }
     },
     "localname": "CostDirectMaterial",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r122",
      "r727"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r123",
      "r157",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r666"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk [Member]"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r207",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings",
        "totalLabel": "Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted",
        "verboseLabel": "Short-term borrowings, including current portion of long-term debt: 2022\u2014$2,566; 2021\u2014$1,636"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r43",
      "r156",
      "r164",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409",
      "r410",
      "r411",
      "r412",
      "r685",
      "r733",
      "r734",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r43",
      "r406",
      "r734",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total long-term debt, principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r388",
      "r409",
      "r410",
      "r683",
      "r685",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r71",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r72",
      "r156",
      "r164",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409",
      "r410",
      "r411",
      "r412",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchase amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r72",
      "r156",
      "r164",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r409",
      "r410",
      "r411",
      "r412",
      "r420",
      "r421",
      "r422",
      "r423",
      "r682",
      "r683",
      "r685",
      "r686",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r395",
      "r407",
      "r409",
      "r410",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Net unamortized discounts, premiums and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity": {
     "auth_ref": [
      "r737"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1": {
       "order": 3.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss",
        "totalLabel": "Debt securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r148",
      "r158",
      "r553",
      "r558",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred taxes from continuing operations"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Noncurrent deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44",
      "r450",
      "r451",
      "r474"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Pension benefit obligations"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit": {
     "auth_ref": [
      "r452",
      "r491",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of 10 percent of greater of fair value of plan assets or benefit obligation.",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit",
        "terseLabel": "Net periodic benefit, actuarial valuation and other pension and postretirement plan gains"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r452",
      "r491",
      "r518",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gains)/losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r452",
      "r492",
      "r519",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r90",
      "r92",
      "r495"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax",
        "negatedTotalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r468",
      "r476",
      "r478",
      "r522",
      "r524",
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contributions by employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r505"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "verboseLabel": "Special termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r452",
      "r490",
      "r517",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r452",
      "r457",
      "r489",
      "r516",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r487",
      "r514",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit costs/(credits) recorded in Other (income)/deductions\u2013\u2013net",
        "totalLabel": "Net periodic benefit cost/(credit) reported in income"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r453",
      "r494",
      "r521"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedTerseLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r455",
      "r488",
      "r515",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r78",
      "r79",
      "r82",
      "r660"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Current derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Noncurrent derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r82",
      "r612",
      "r615",
      "r624",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r609",
      "r612",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r623",
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82",
      "r660"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Liability",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Current derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Noncurrent derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": {
     "auth_ref": [
      "r637"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.",
        "label": "Derivative, Net Liability Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net payable position"
       }
      }
     },
     "localname": "DerivativeNetLiabilityPositionAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "terseLabel": "Remaining period of hedging exposure"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r602",
      "r604",
      "r605",
      "r609",
      "r610",
      "r617",
      "r624",
      "r639",
      "r640",
      "r643",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "EPS Numerator\u2013\u2013Diluted"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r17",
      "r113",
      "r773"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations, pre-tax income (loss)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r335",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r530",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Cash [Abstract]",
        "terseLabel": "Cash dividends declared, per share"
       }
      }
     },
     "localname": "DividendsCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r529",
      "r533",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r119",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r182",
      "r185",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r648",
      "r649",
      "r749",
      "r779"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013basic:",
        "verboseLabel": "EPS Numerator\u2013\u2013Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r119",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r185",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r648",
      "r649",
      "r749",
      "r779"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013diluted:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r670"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate for income from continuing operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related items"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "verboseLabel": "Employee Termination Costs [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r104",
      "r105",
      "r106",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r180",
      "r203",
      "r291",
      "r419",
      "r424",
      "r540",
      "r541",
      "r542",
      "r554",
      "r555",
      "r647",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r691",
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r112",
      "r142",
      "r148",
      "r771"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Dividend received, distribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r24",
      "r157",
      "r288",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r24",
      "r157",
      "r288",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Equity-method investment, quoted market value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r224",
      "r283"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity-method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r658"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r27",
      "r40",
      "r658"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Net (gains)/losses recognized during the period on equity securities",
        "negatedTotalLabel": "Net (gains)/losses recognized during the period on equity securities",
        "terseLabel": "Net gains/(losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r282",
      "r780"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Less: Net (gains)/losses recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r282",
      "r780"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date",
        "verboseLabel": "Unrealized gain (loss) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative upward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r397",
      "r409",
      "r410",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r650",
      "r651",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r397",
      "r409",
      "r410",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r524",
      "r651",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r397",
      "r409",
      "r410",
      "r650",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r650",
      "r651",
      "r652",
      "r653",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r397",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging [Member]"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r397",
      "r476",
      "r478",
      "r483",
      "r524",
      "r651",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r397",
      "r409",
      "r410",
      "r476",
      "r478",
      "r483",
      "r524",
      "r651",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r397",
      "r409",
      "r410",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r524",
      "r651",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r397",
      "r409",
      "r410",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r524",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r654",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r270",
      "r274",
      "r279",
      "r280",
      "r281",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r405",
      "r418",
      "r645",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r36",
      "r327"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-lived intangible assets, accumulated amortization",
        "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r321",
      "r324",
      "r327",
      "r329",
      "r728",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r327",
      "r729"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r321",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r327",
      "r728"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Pre-tax gain expected to be reclassified within the next 12 months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r82",
      "r476",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r476",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Government and agency - non U.S. [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r529",
      "r533",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Gain contingency, number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Net (gains)/losses on asset disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Loss on litigation settlement",
        "negatedTerseLabel": "Certain legal matters, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r35",
      "r307",
      "r308",
      "r315",
      "r319",
      "r694",
      "r731"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r309",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r121",
      "r157",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r666"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Actively Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r635"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r609",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r252",
      "r264",
      "r294",
      "r297"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Held-to-maturity securities, amortized cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r266",
      "r272"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity securities, gross unrealized gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r267",
      "r273"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity securities, gross unrealized losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r256",
      "r264",
      "r294"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r269",
      "r276",
      "r755",
      "r757"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r268",
      "r275",
      "r754",
      "r756"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Held-to-maturity securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r265",
      "r271",
      "r737"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Held-to-maturity securities, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r256",
      "r264",
      "r294"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r270",
      "r274",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity [Table Text Block]",
        "terseLabel": "Schedule of Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r148",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development Expenses"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r111",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r730",
      "r742",
      "r752",
      "r781"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income from continuing operations before provision/(benefit) for taxes on income",
        "totalLabel": "Income from continuing operations before provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r157",
      "r169",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r586",
      "r649",
      "r666"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income from continuing operations before allocation to noncontrolling interests",
        "totalLabel": "Income from continuing operations",
        "verboseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r108",
      "r119",
      "r169",
      "r171",
      "r172",
      "r174",
      "r175",
      "r185",
      "r194",
      "r195",
      "r649",
      "r740",
      "r743",
      "r749",
      "r772"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r108",
      "r119",
      "r169",
      "r171",
      "r172",
      "r174",
      "r175",
      "r185",
      "r194",
      "r195",
      "r196",
      "r649",
      "r749",
      "r772",
      "r775",
      "r779"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r21",
      "r24",
      "r565",
      "r773"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r17",
      "r21",
      "r586"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "verboseLabel": "Discontinued operations\u2013\u2013net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r113",
      "r119",
      "r186",
      "r194",
      "r195",
      "r749",
      "r773",
      "r775",
      "r779"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r186",
      "r194",
      "r195",
      "r601"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r112",
      "r148",
      "r220",
      "r283",
      "r741",
      "r771"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity method investment earnings"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r530",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r3",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r19",
      "r22",
      "r23",
      "r24",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r338",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r550",
      "r551",
      "r552",
      "r556",
      "r561",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Tax Matters"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r160",
      "r179",
      "r180",
      "r221",
      "r548",
      "r557",
      "r563",
      "r782"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r322",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "verboseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": {
     "auth_ref": [
      "r650"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure",
        "terseLabel": "Intangible assets-IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r322",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r320",
      "r325"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable Intangible Assets, less Accumulated Amortization",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r109",
      "r217",
      "r681",
      "r684",
      "r750"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r140",
      "r145",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r82",
      "r476",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate contracts [Member]"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).",
        "label": "Interest Revenue (Expense), Net",
        "negatedTotalLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestRevenueExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r56",
      "r306"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r26",
      "r61",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Noncurrent inventories not included above"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r61",
      "r306"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r57",
      "r306"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-off"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r126",
      "r216"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r68",
      "r157",
      "r231",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r590",
      "r596",
      "r597",
      "r666",
      "r692",
      "r693"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r54",
      "r157",
      "r288",
      "r666",
      "r694",
      "r736",
      "r766"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r70",
      "r157",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r590",
      "r596",
      "r597",
      "r666",
      "r692",
      "r693",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements and Other [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method.",
        "label": "Life Settlement Contracts, Fair Value",
        "terseLabel": "Insurance contracts"
       }
      }
     },
     "localname": "LifeSettlementContractsFairValueMethodCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r43",
      "r396",
      "r408",
      "r409",
      "r410",
      "r734",
      "r762"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt, carried at historical proceeds, as adjusted"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "totalLabel": "Total long-term investments and equity-method investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments [Abstract]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r72",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Loss contingency, number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPatentsFoundNotInfringedNumber": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity was found not to have infringed.",
        "label": "Loss Contingency, Patents Found Not Infringed, Number",
        "terseLabel": "Loss contingency, number of patents found not infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsFoundNotInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Investments by Classification Type"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Reconciling Items [Member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r77",
      "r157",
      "r288",
      "r373",
      "r378",
      "r379",
      "r380",
      "r386",
      "r387",
      "r666",
      "r735",
      "r765"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Equity attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by/(used in) investing activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r143",
      "r146",
      "r149"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r143",
      "r146",
      "r149"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r98",
      "r101",
      "r106",
      "r114",
      "r149",
      "r157",
      "r169",
      "r171",
      "r172",
      "r174",
      "r175",
      "r179",
      "r180",
      "r192",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r649",
      "r666",
      "r744",
      "r774"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Income attributable to shareholders",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r101",
      "r106",
      "r179",
      "r180",
      "r592",
      "r599"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r171",
      "r172",
      "r174",
      "r175",
      "r182",
      "r183",
      "r193",
      "r196",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r193",
      "r196"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "verboseLabel": "Net periodic benefit costs/(credits) other than service costs"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standard Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash transaction:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r424",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivative Financial Instruments Not Designated as Hedges [Member]",
        "verboseLabel": "Derivatives not designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Nontrade receivables"
       }
      }
     },
     "localname": "NontradeReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating costs"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r62",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other noncurrent assets",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r83",
      "r92",
      "r667",
      "r668",
      "r671"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r92",
      "r96",
      "r97",
      "r495"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "verboseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax",
        "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r92"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "totalLabel": "Available-for-sale securities, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r104",
      "r105",
      "r115",
      "r284",
      "r672",
      "r677",
      "r679",
      "r745",
      "r775"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income/(loss), before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r85",
      "r92"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "totalLabel": "Derivatives qualifying as hedges, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r85",
      "r92",
      "r614",
      "r619",
      "r641"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net",
        "verboseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r92",
      "r96",
      "r621"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income",
        "terseLabel": "Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": {
     "auth_ref": [
      "r86",
      "r92",
      "r96",
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax",
        "terseLabel": "Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r86",
      "r92",
      "r620",
      "r628",
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r83",
      "r93",
      "r669",
      "r678"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Derivative, Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r99",
      "r102",
      "r104",
      "r105",
      "r107",
      "r115",
      "r419",
      "r672",
      "r677",
      "r679",
      "r745",
      "r775"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other\u00a0comprehensive income/(loss), net of tax",
        "totalLabel": "Other comprehensive income/(loss) before allocation to noncontrolling interests",
        "verboseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": {
     "auth_ref": [
      "r93",
      "r586"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax",
        "negatedTotalLabel": "Pension and other postretirement benefit plans, net prior service cost (credit), tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "auth_ref": [
      "r92",
      "r96",
      "r97",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r93",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r93",
      "r104",
      "r115",
      "r548",
      "r562",
      "r564",
      "r672",
      "r675",
      "r679",
      "r745",
      "r775"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision/(benefit) on other comprehensive income/(loss)",
        "totalLabel": "Tax provision/(benefit) on other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r87",
      "r92",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r88",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities [Member]",
        "verboseLabel": "Other current liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r447",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r69",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r43",
      "r734",
      "r762"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-Term Debt",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r33",
      "r769"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-Term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Total Long-term investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities [Member]",
        "verboseLabel": "Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/deductions\u2013\u2013net",
        "negatedTotalLabel": "Other (income)/deductions\u2013\u2013net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income)/deductions\u2013\u2013net [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r449",
      "r450",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r502",
      "r505",
      "r509",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Plans [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44",
      "r450",
      "r451",
      "r474"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent",
        "terseLabel": "Postretirement benefit obligations"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r344",
      "r345",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Exit Costs [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-Term Borrowings",
        "terseLabel": "Other short-term borrowings, principal amount"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r62",
      "r739",
      "r770"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-term investments"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "verboseLabel": "Shareholders' Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r131",
      "r134"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r132",
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments for acquisition, cash portion",
        "verboseLabel": "Payments to acquire businesses, gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of business, net of cash acquired",
        "terseLabel": "Payments to acquire businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r133",
      "r579",
      "r580",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire asset"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersLegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r475",
      "r477",
      "r483",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r524",
      "r526",
      "r527",
      "r528",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r448",
      "r450",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r502",
      "r505",
      "r509",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r529",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "verboseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r130",
      "r142"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Dividends received from Haleon/GSK Consumer Healthcare JV (Note 2C)",
        "verboseLabel": "Dividends received, return of capital"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r136",
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "auth_ref": [
      "r135",
      "r138",
      "r151"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.",
        "label": "Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less",
        "terseLabel": "Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale, Maturity and Collection of Long-Term Investments",
        "terseLabel": "Proceeds from redemptions/sales of long-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Proceeds from redemptions/sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r24",
      "r98",
      "r101",
      "r106",
      "r141",
      "r157",
      "r169",
      "r179",
      "r180",
      "r223",
      "r229",
      "r233",
      "r236",
      "r239",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r586",
      "r591",
      "r593",
      "r599",
      "r600",
      "r649",
      "r666",
      "r752"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income before allocation to noncontrolling interests",
        "totalLabel": "Net income before allocation to noncontrolling interests",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r337",
      "r694",
      "r758",
      "r767"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, less accumulated depreciation: 2022\u2014$14,931; 2021\u2014$15,074"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedTerseLabel": "Payments on short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r343",
      "r345",
      "r348",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r344",
      "r347",
      "r354",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring cost incurred to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r344",
      "r347",
      "r354",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r148",
      "r342",
      "r351",
      "r354"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Provision",
        "totalLabel": "Restructuring charges/(credits)"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring charges/(credits):"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r344",
      "r345",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r345",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Additional depreciation\u2013\u2013asset restructuring"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r50",
      "r424",
      "r694",
      "r764",
      "r791",
      "r796"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r180",
      "r291",
      "r540",
      "r541",
      "r542",
      "r554",
      "r555",
      "r647",
      "r787",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r505",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r529",
      "r533",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r505",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r529",
      "r533",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r502",
      "r505",
      "r509",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r502",
      "r505",
      "r509",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r214",
      "r215",
      "r228",
      "r234",
      "r235",
      "r242",
      "r243",
      "r247",
      "r439",
      "r440",
      "r727"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues and Trade Accounts Receivable"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, period of recognition"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r110",
      "r157",
      "r214",
      "r215",
      "r228",
      "r234",
      "r235",
      "r242",
      "r243",
      "r247",
      "r288",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r382",
      "r384",
      "r386",
      "r387",
      "r666",
      "r752"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r688",
      "r689"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "negatedTerseLabel": "Royalty-related income"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Inventory sales [Member]"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r208",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r95",
      "r677",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r570",
      "r571",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementAcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r72",
      "r164",
      "r409",
      "r411",
      "r420",
      "r421",
      "r422",
      "r423",
      "r682",
      "r683",
      "r686",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r508",
      "r509",
      "r512",
      "r513",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative assets at fair value.",
        "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Assets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r612",
      "r624",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r602",
      "r604",
      "r605",
      "r609",
      "r610",
      "r617",
      "r624",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Significant Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r24",
      "r157",
      "r286",
      "r288",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r321",
      "r326",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofImpairedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r321",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.",
        "label": "Schedule of Impaired Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Impaired Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r328",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r328",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r30",
      "r58",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Noncurrent"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r349",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r345",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Components and Changes in Restructuring Accruals"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r110",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r223",
      "r226",
      "r232",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r223",
      "r226",
      "r232",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Borrowings"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesReceivedAsCollateral": {
     "auth_ref": [
      "r710"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.",
        "label": "Securities Received as Collateral",
        "terseLabel": "Collateral received"
       }
      }
     },
     "localname": "SecuritiesReceivedAsCollateral",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r247",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r347",
      "r356",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r223",
      "r227",
      "r233",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r246",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, Geographic and Other Revenue Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, informational and administrative expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee terminations"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt [Member]",
        "terseLabel": "Short-term Debt [Member]"
       }
      }
     },
     "localname": "ShortTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r10",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r247",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r339",
      "r347",
      "r356",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r155",
      "r157",
      "r185",
      "r186",
      "r191",
      "r194",
      "r196",
      "r204",
      "r205",
      "r206",
      "r288",
      "r373",
      "r378",
      "r379",
      "r380",
      "r386",
      "r387",
      "r413",
      "r414",
      "r416",
      "r417",
      "r419",
      "r666",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r76",
      "r104",
      "r105",
      "r106",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r180",
      "r203",
      "r291",
      "r419",
      "r424",
      "r540",
      "r541",
      "r542",
      "r554",
      "r555",
      "r647",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r691",
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r203",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r46",
      "r47",
      "r419",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r46",
      "r47",
      "r424",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r47",
      "r52",
      "r53",
      "r157",
      "r253",
      "r288",
      "r666",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Pfizer Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r105",
      "r157",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r288",
      "r291",
      "r424",
      "r540",
      "r541",
      "r542",
      "r554",
      "r555",
      "r584",
      "r585",
      "r598",
      "r647",
      "r666",
      "r672",
      "r673",
      "r679",
      "r691",
      "r788",
      "r789"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Axis]",
        "terseLabel": "Subsegments Consolidation Items [Axis]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Domain]",
        "terseLabel": "Subsegments Consolidation Items [Domain]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r680",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r680",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r680",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid/(received) during the period for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Repatriation tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Brands [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r270",
      "r274",
      "r279",
      "r280",
      "r281",
      "r405",
      "r418",
      "r645",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r75",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r75",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Ending balance (in shares)",
        "negatedPeriodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r47",
      "r419",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of common stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r75",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r419",
      "r424",
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionDiscontinuedOperationsEquityMethodInvestmentandCollaborativeArrangementCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r344",
      "r345",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r161",
      "r476",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government and agency - U.S. [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Common-share equivalents: stock options and stock issuable under employee compensation plans (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r184",
      "r196"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares\u2013\u2013diluted",
        "totalLabel": "Weighted-average number of common shares outstanding\u2013\u2013Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "EPS Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r182",
      "r196"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares outstanding\u2013\u2013Basic",
        "verboseLabel": "Weighted-average shares\u2013\u2013basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "325",
   "URI": "https://asc.fasb.org/extlink&oid=73718008&loc=d3e42732-111610"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r815": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r816": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r817": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r818": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r819": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r820": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r821": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r822": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r823": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r824": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r825": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r826": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r827": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0000078003-22-000101-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-22-000101-xbrl.zip
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M:Y\Z:9-?9/Z7,CM>/0YKS/D%;AW1],7?OI;IP8]/OU:J"]5O_WHL2_JJ?_A
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MZI_A^;\/C9[GS:-?7KCG_?5CO9_O\.R"#\J+?]I']YZ'1[?_!S4##J;E@]*
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M#/IG[A[18J&>9#DK/]U^,UE\_>WE(7=GQ\>SZ>J-\_/\]9L/GO[JT5W=Q2#
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M^16>LY/>SKYK_?-;OL+JLDG]29-;5P<]/3_H\J0?:F3_X9E6 \774HBC!<K
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M>QE7K4/GG754:P#6")M[20R!X@J+X[9O<74WH-Y*S(VQNA!#*UXEE/KF'$D
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M%2!1!F-=:!6+M4U\&D :LK,]6,<E>NO>MR0F<G)LK=+5U4BMA&0$@[?)FCJ
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MF,0F@1B!%EMVQ6)QK2;CV0W*;8V<VA$_92%J$(R);(Q @!B;B[VT6_#(&<J
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MS#Q4NNT.U'AX ,/N1*VV_%Z+M]OU\IUJ7%D?\G,W!_<_[(;]<SL72=G F74
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ML%8A!_W6 ZUJU[XMVC$OH$#G1,^O.R<Z)WJ<>!&<:#.]]L<_UF*SSED$J"!
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M/:0=AE66CRAU[LKJ2QY@#ZL%O6'U5$4);=0G&UB@T9PD.U5\9A&K5=< 7_(
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MBTE"698$3Y3 9N4R 9^&L4# S$BI9=+:='E!V]4AZ^WHHI"!"DS%-<P*T(M
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M(G_O[O/6H[?Y9],M"N'JP ,YYLG@;>N]W W!CWB[N2'_A!_JC_6H;3Z'J#\
M;PJ<#]R)&8*3@1Y0!,P,[@C\VUX4M]VN;&Y$UZ_1!M]D[FOKX'Z-BT/3CR?C
M]F!8^%7@X7S]UC>N&DT ,$-XPFCK<'.].!6/?"GG _K ,GE$<V_@,;0:OKQT
M#O?Q16]5?,53D-!HDKH(G,0<P_O1*\:C"V"&@L[F.!3G#;IXRV(5T:D#9ZL;
MS&@<21J='$?_-TVCKAW]OS^F/M5T1 70:?BEBZO/L;E[=+"Y?T#>#3X2'GTN
M]NS'881%_.O%7<[:@PC-%KA\&^X$ FET4KP?D.L8+E:TD 5?;01Z9OCEG6ZZ
MFVV<KHN2]7(ZAQ*^[($N[8UH:R&(/D\Q,)HN[.UE^ ;1\1E.ASAK</P588&3
M<UCL"0Y5 LKY*+Z2(%]HF-T3E<57U&PE'O[U+Z#>B!IP_BT60BH/^N#+W\(<
M7MI/AC/:34GD@^N:V4>%G^WRH9OTL-$,-MT*YSD H3.!=<PNBGX,\)VKRUY?
MZ&LPSZ[<F_5;A>7%::%XYZL+7+_/*08M@!%G"W 0IE-%52Q?V3]>L3^NKK6]
M77F'J]3%D;>W'QM<KG$8]H"SQU-F_?KY8"D')T4T8] /0^!:!'< F(7B2KCB
MVP;1VPY%*>PX^M7R\OXF0B&_S\[.-K VPS.-L9CA.?S5^^4/>4>YL7]F1(H*
M*GWV,Y8GDQ%2::E$VOC:J+B>8/-H#W+/$3V--G#(]F#8BQ@E>U=!P!%V6KGJ
MW ULYL"4,R#F'%R@X-O1&(1NP G3W5DKE@$(U&$^F(S@&@3O<\7;A0S[<RK*
M"UYW\'>.QM:H$%#(;K.KC2].\>HHG$!*G9IAH=%,!-R,S7+MP%\43W/U%' 1
M\]4CC"8@$*_ON_">4WU3B(DOK]@&I0*O-VH/)EV0_;@;V1^!AX/#R/)^<39\
M@C;;E="Y]4CX)#B--D*+!B7+^I>G!"5[]:SX6J.)[:!"A,?U.0X\PV?'KC9#
M4"SC:;_SXB'7(]0SH!KQ!^BK'+- BJN,X")9EF/SP_'TM4\Q9%L\V,AD87QQ
M1?, -W"HD3'2.R7F'$D*J5CDF* 6FV:7%"K!]&^OY3I0^W@"]!X,KQ5(D1G5
M,Q>%D3-J%_IE,BP>=ZJ^\-@P_&>2HWZ?D>>*(' 7/ QF\,7,-D(+K#L>' =X
MF>$\ERSNT+:D^58'@QZ\4@_;=XRF./F*F:Z( B\-"B[@2@WA7+16-J+-+FB_
M,,0)5& PW+1" #,.:0S8PQ#],:BVXFL8FI_>:_KM\=" ?C3#$R _7 6HBF<,
MIYH+2 E7'U_,\)H/H\$9:#CXZO,F*5HL>1_#_%,<(MN9(FB/DFB"EJ@%&Q.L
M'/P#='.P@\$)]N@!J^1X:'KK47,P:4SLU(QZG_=!O0-?GA9$!KCAUQIG6*X(
M '=%ZQ5@MP+M:/+E0T]0\%Q\N5$^M=]!-,ZJ>*?FX3#@L$*LAP3F'=Q:^V\#
M]P6.@9/?'@.'3YO[_UG+4\>5H$8S%[QT,K4ZYI3QE-,XI6G&/C&Z]N;G9\=)
M79#])Z;'?>W;BZ_C'DN:)R>3#<[YC\R3T^F&?M3!;[/'9D44:HRL\@]J.-?Z
M9BQIP='O!).F1+U-A>F-OH%H)77R0V%DQFXA.ED8F/NPN=^(=C?^^Q\LIG]%
MV[NUS=J[W<WWT6YMN[Y?W6SLUFOWF0QY3^3':_>*,=V0WP5C?AU?4[>#3O(I
MA/P<^0J!L-O8JD9LXP;A#AJ;\-E6K7$P+SCO227]'2HA3=)OL.HR).*'[=W6
MUC[ Y1VH\EHE.CA\>[!;V=W<;X+[6_VP6=O=6D"(9R;6W]5KE:W:P58%GKEV
M4'^_6X$UK-Q8RJB^C:]8KV[=97/<0/%S>;M7A[7-PPH@M?+' E?M:>4[")T-
M.A73#Q7P4FU0G?[0P-#O'P-N?/0QI(QMQ$R7#UL^;,S5(QHE5S;'E\VK']B_
M^J[!\0NE4<'W4TOC_IN!WW]CBN^[J*&0_FG*_8"Q]JMIUR@Z.52GX?BMN4X.
M)1WO2<<:!H*^2<8[./%9,%MZK_=\5=U]_QXL^(/U:.O_O-OZT(@^@*T&9DRU
M7HL._K6YOQ6!I;/YQSU0="=0%@*N" W<'RK%YOVS0DK=C0>8?<G7"X^:4\X?
MQG+?H\ +I:6XIN5]VHH^#K%6DU*/AKI'@MQJ4O%;>+N_Q?5 UGMV-M<^;K],
MPGTRG;\%E(<3A4:K0)K_=9LF/_"BSYL-_IF?8S/-[:&99AU,^OEX/V3_LS89
M^;6KS<#B@SQAX*W0S#NE@W1<Z(RZ.+7,9:F0(O!/%11%-*&2X#_@^GP-<Q3R
MGNF._F>-Q&M1W_0"7IH<&W/Z>@:\[>&@]PYNA(]PE(_;[R8CH$<8;IW/4EZF
M+1B#;YCSM6BZ90*/<SY^W9_TB!^,R>PF %.@*MP [E0$T[SX>&$K@\_O^?[G
MIJA.?&?K<VM'=^J==J?:.;RL[FRIZE&MVZKL=VJ5=EYO-"^JE:V+>F7WK-8Y
M/JOO-,_?BUJW>3F0S<M=5KU\VZXWMCNMHSW:O-R3S<X)KW8VSZN=8_A>4U8K
M[5[U8WI>/] ]U]ONUSN.UBM[<*WJ1:WA1+.QWVEVNNW63BNO[^RJ6J]Y6:NT
MNO6&[[P7^^UF[[P+S]9K=EK=ZE%5U3I[HMG9[]8KF[)ZM)^W&INBV:O![V/:
M[-2Z5]^!>TU:_#"NPW5KO</SYN4)KU5\7MLYA&<Z/F_M_-VMPM]-_C=<:S^O
M\H]9-:<7[QM;X^H!I55XC]KEUB?J>29X$"1S4A+)M"7&24J"3SBSS,."R[4W
MG*_'(OWGGU\CYQNNVP^)R^B!C%-*K%)B+9)8(6-QZH.FW&NIN=+4& 4BRBJ;
MB(SK0F(QD%@*)1:#ZXM28CUGB45O2RPE%$T53PCH)$6D!=UCA=#$&.&HT3&L
MM &))=>I4+^]Q'H9XNHWE55Q$(!9[E(J$ND38V2:"FJ]IZD6)F,SZXI15EI7
M*R&K^&U999,D9%F6$BMU2J2).;'&.Q+'F4N#BE,1DK4W2;Q.)7TT6?4L!=6+
MD56_K[C*:&*%E6!2T4PZX0TS,A&Q#%XJ^*5FIM5,7)6FU;,75_*VN$IT', ;
M=,2S!$PK81-B6.))QIBW#I8],6SMC4K6I7H\<?58$FL5=FGNR93O!J-9*5,X
M/\7ZJ]'KQPV,EZ<N//470>A)"T,? #%,H!Z!P!S]DG*1^.YR$8J%DG-IPB@D
MB-A8D#Z$75/P FMO7IE;J4L_@PJ^<(476B@KK< ?/9J+(*IG.X.!'VWV_<&T
MK^+H8-#UI9Y^+#U=>S<?M)49YY)Q3J@1H*>#R(@&KY& S269X#H6PJZ] :\B
M%@]3TT_O.;PX)GST &7)A$_"A'-Q2)X9::T.A&J5$.ET3#35C%"A19K(('V0
M:V_TNA:\9,)GQH2/'GDKF?!)F' NP"8#BX.R,9%46/!814JL23TQ0L9Q8E.0
MLJS8#(AU7'+A,^/"1P\HE5SX)%PX%S<2E@>>2DGB-( J9#20%'B1!&:HLH8:
MX#[@0K9.TP=NR3WCP-!S].H/0K=;-)ZY46<\Z_MC?"_OYZ/QK"?Y56"I=/U?
MA*A]=-=_AK0=[&!KNB!M-[_"U]847J78?32Q>S ?!E#!<I::0+PVGDB="6)Y
MEA+/I/8A5=YFR=H;L2XT*VV?9\:0CQX&*!GRR1ER+B008"VYX8XDL)Y$IMH1
M8ZPC/@N9E+&75'&P@]93K4N&?&8,^>@A@9(AGYPAY\(#"J2LU 8\$2H#D2&D
MQ( T)6E"0\9#D%ZG&*.C98SNV3'DHT<'2H9\<H:<SS")N?0@8#%Y%Q@2G ^B
M6:Q(FNHDX3Q89L'%2]?5,C3D"PH4[']CF'$9%WA90O87%'A-@07B]4;C_)EL
M_9+1YXJ>B7ZW_V$X<&$TPLAM*7D?3?(N*/22DK&$IX(H2S616DMB,ND)]ZGW
MAH/KXC+T3<J-DN?'I;^@J*GDTN? I0N*FU*IC+.$@P0F,HY38@7C)&:.&L>-
M=H(57)J6(;WGQJ6_H)RGY-+GP*7S804I$@^L2C)A&7"I28AUP9,L@'!.,I51
M9=;>).LI*_/OGAN7_H(JEI)+GP.7SL4:0IH(;[.,!,TDD4%9D@H>$Q6SD'A0
ML!S;S\;K</2WCS7,S65:9O#ABA>P!?_IE!MPJLYO%Y"P94#BN08DL*1P?(7#
M.LYC:+1-O]$>#B;'[:OIS>^*H;I%$LW1$-OJ]^M95HKEAXCEB_E 1&Q3R9RT
M)(L3061B8NS?$!/!?1(SSY0)=NV-XDL0RB5O/H<P1,F;3\6;<^&'-/:>)=83
MSCR83-)SDOJ,$PZ25SO)+1S#?@7E;NESX\TG"CZ4O/E4O#D7=. V3IVVDGB9
MQ$2Z!'A36?@19&IIDJ5)HM?>I.D#*_-+WOQ=0@X_PYME'.+1&'<N#L&MCEUL
M#7%*<B)5DA"34$TX#XFE-(ZY Z7*U@&OSST.<?\1[DOES<W> ![FRYS6O#\V
M_>,<YYH89)*?Z7O[XJ37HWGDIUEX?7-EZMGN];H4LFM4&Z 0&[@<!]%A*Z #
M(&LW;$_ZQ5.6DN@!DJB^H&^ BS-FP"PDAL:.2!,"L9(QXJW+?$:]%3H!$X*7
MYOUS8\)'<[U+)GQB)ISSL1E7L?2,$\]\ "9DGEBF,Q+B%"2M33C8B&MO=/S
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MAE?!&%06Q:B04>O):+D^M$)&39)1S7E&F;72( -<$P$L$1!H3"RHJ)DQWH;
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M28CVGH$FRH 0+&$\6:'>\JU=LLU9W2=?,+T^3#?@\RF">&-@6_,<">N\L2%
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MVBPS%$^O0L!Y@6V45=+]W*I#ZW+M'P2X-RIXH4"Z24C7C'1M%77(4D#:)'.
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M=]M.T^NQ^[MA<AS+B42C1#ZC"2]W3%0U^QP6$9B,$6S2>R%(PYUV)OI@JM
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MF,_/3E^FL51S0KO[3],GI,_ZZ^C#&?FMU]WO]L[>'*1GR,F4?_S-E$5)P4/
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M76(BAY7T&CN/?!5OIGCI]-0R"#;6R;% <)40K*D D1*!790@(D+ @G5@HB#
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MOS6&C=%NKI6#K.H4S:WMS#TM-WERWOOO2IYMF^__?'N'-S,1]T5Z+*&@YM[
M%P?T,N7"P:P2VT$X2B.@) F *21 !2G 2ZV(#8R)R+=VL>;;E*-;"89&8-.L
M@EB8L3!C^_7JPHRK9,::QHR]$L0G4G0B(F#,))N8)NL8>^(8DC1)OMSL1.'M
MA0O]M($9*YWZ4662I7]][]_=_Z8?5R,\-Z-7O4$U )&UY,MOA$Q,C]G.]3^-
MIJC9N:%,NY -N^E?>@.??LM(:QJ\&'T/O22C]R2$SI[+\<9F\"$?Y76'DS#>
M^;0\-Q__\F96/>=EFZ''H] WD]Z_X:=W/3]Y?<4+U^ZZ7$_T^19CT\)=3+Y^
M2VW"UC1!\LNIN/XSC[9B$.4(I\AH[()GCBFK!4&8*(*$0BKBOS,>+F]Z/?KL
MC'D5P(Z"^0=,3 _XV/3?F0_CK4=?[K>TV:[J%8HTXIOS-9V5W?_:4;IOQE!;
M.*7/GQZ^/'C1.>P^V>GL=?<[)W_\?'*X?[CWXJSSY/CH^5[W\.#DJQNP+0_Q
MY+B[?] ].=A/8^Z>'#\[W-\[3;^<G*9_C@ZZIR>=XZ>=@]__.#P]^^JS7'+)
M)3IFTL2:GNZ'/[I[?^P?IB?Z<<[13]7!:8# EV2>QMPW;\?A\=6+GZYJ,?0&
MU3=7-_U4GXP;+%W-S?3M2Q1HL8,XR4"X=(%<?O$E1G8JC-R0,-/WB-C!C'_U
M;;2#;_D>%W/?N1$E,A:95+9#I5[OG,X]5K[#M=R0L;(=K=3&C'63]@!C;&/&
MNCG[=9/F5>P0M&8YL,!8$:<;--;Y>&"^(XR[=GYHZ&-:*: _7<GX0L\[P[UV
M:9NNQ+TDYW(O73<63G[=>W'PZ_&S_8,7)_,?\[1DZZSK8^:,;VJV)'US>UK?
M)B)AC;M:5.Z>N4N_G\Q9KVW.A[_;!EKQ)]W7I?U4C.\A+^Y#^:1V7GJ+H%9^
MTT]=';5=]U+#U)7=%JQ-'55'A\^>'1YW3[8[!__WR<'ST\[SI"T\.3XZ.NY.
M]87._M[I7BW#N"WB;;E7WIY75WC,."^MGN0,YWDRC%9.$YLQ?\_-J%.525Q.
M"[?-F(0][R^SX_N=ZLPD%[J&PT'G27/E_N_I_BGXNZO&/YX\9.A]*FUYT&!I
MRTV=C*IXS4ZG*ES3R95K=J9T]*RA6E^;.B\5R4 U%3>*F1PTELNTJ7/3'0Y@
M:5G7FSHITU#P&9OC]G[E[XB6;X8@7CL?GQ$95+>FUF4W_6SZ9N#"=N>WB_Z'
M:4@6W>[DP.0;020/P%[:R*2G>?'QU?#,JF#4^$:$IE9(46,CMQ@QH922!B/#
M*<%,<(/D-'8=243G;@,W51L/Q^.+X#<C,//XR55@YMF[[E^_L^/3HX]GIP?D
MZ..+_LLWKWM'?_UVWOWXNO?RK[/T]_X_W5-W+3 S_>U-MW=&SM!1^L[C_1?]
MLS<'[.S4O7_Y2P[H=+C[\?=W+T__(#<#,[OIOB/RVYN7;W[_F)Z/=7_YLW=T
M^OIU]^/3?\[2LW4__D&[^S_WNZ<OX]$'1')0YM$)0D?I.;H?#_[6*%BCK08J
M"0<6%0>M \Y%CRB/SFOO<\+B-M.WB\IL3[YB0W!=73#YO&C]3CAYFZ/%[TQ(
M]7CQIMBHJ3S,PD^+\!.[R4^(NX!<(! <%<"P3?PDB 6.8A!.N"!-O$5SV,).
MA9W6P4Z>&J^L%U19S81 1F&-$24(,V10C*MFIZ):-49=[X]NYKQ$XA0G0H&F
M#@$308)1CD(0R&&E(_,YQE_C;:P6;,3;.OIZ&';1UTM7SS2,0DA(#I8+$BSC
MDFF/ M+6*Q.(]%K/"_8OFE:=7'Y306Z#R+V9QZN-$<Y$FM4,!DS3"&GQ)'@;
M&?4Q,(O=UB[=UJ@.W*\5IFX=9HO*L;DJQT)%]&]-0U\IHE^4C_916+UZGB6"
MDQ@@1IN4#VD8&$0\("=CP$0;ETO45*TN:;TH92&Q=2/\ 9#8(O51G">.:&&E
MU,P'K)S76/"0/LA2P7BQFS:8NFK:%R$1">[ <1Z!*:<AV<P1.%8\Y-(/Q.8J
M*EAL"Z0VW' J_+6Y_+6($F:<IEQ@90R.S"&B)75:)%ICGB.L55'"[@&3'=]4
MPI@)F'J>^,OHQ&182$@JN */>=!)EC$>U-:NW,:XJ&"%PMJM@F$??626><TD
M8Y081X3 CD4D;=0F%!5L8XGK0\UUK00C"B$!1H=$7-K9]$HK"$EJD<@CBYIN
M[:K<2:5H8(6^-H"^/(Z&6QVYB80%)(WRBEJ':,SM!#PI<0'M9JA:I7645BD&
M#T1F%[TT.C$4-3EP"1F,5>!6Y>X0FUYFO=#3@Z GHK%3"AM.M6%4">,"TIQ&
M$CBE HFB76TN=]5\\]9A)7W X%"PP&CN*LEQ@, 1"4:3$!6OM"LF%NP7M?[R
M\:WH4S=O1'LW3#J]JNOSP\SU;6<B>KET=D3-)H;,+" "*<G$ASG&DC,OJ?6(
M<4LY-X8(:M'?^Y<BD,%\Q?"?CX:Q-\G9<46>-27/LBRK'=@$K941G@ G-FG@
M7 :P 2&P/M?M)H$RFXA(+7Y<L\9 M@+F.Q[82N]R[PHO!,,46\L4CCQ*CQTG
M(A8PMP/,==>?HXS'1,) K1733J8JBO0J,D2BH)H@NFE@?CBPH]J3R)$+FC(E
MI-6!!XID@IUV0=U-AA9D+8:LFV*2"NQR PL@BFM@,OW0E%,@SDFB@Z%8BZU=
MS NLV@8KB07A*'K'=6".4!V1$\IB%Q5E-) BS5J"N7K?$:NXP%)!0 EIS"0E
M55,?P<MHF29<*,HK:4863,%HL2ME ^H)5 "L"IE,)SDW$QF%UV$P[OT;+ETR
MCW[H)WS\N-T9A$EG&#L3\_[AU1E8N\52+EW[I9LM9A>)DJ,&(:<UDB$ZQBU7
M'.E()2(:!XFHGT/.?B5<KN*:)]=9YK BF2R"NV%R'$_-^R**&Q/%)S."X:26
M.FCN09" @"D=P#!KTZ^*4(*3/%:) O$V1O5D[J\%PQ7E=P6H;,"74U#9#E36
MW3U:QJ0#8P,$"Y=0J1C8H"EX$Y1%6"-G=4%E&U%Y=U?/G5!9@+<8\&J]@GDT
M3',.FB@/C# *VN78<)Y4'6.(HHYL[=:=005T:P1= XZ@(@I;@LB:KRBI,R+@
MP$ JJX#Y0,%J[T&Q2+Q"-'I#*U&(ZT&%RT3EPW433;MFFO'K3AIL+XW%CS.:
M^F84_';G;1AUJL(;CSO_^1:&GX=1536C62R3;]0OW+\:[=57[U\.^A-(40'I
M]T':0^]NU /[U__R)_.__M9_2?K_VC=O_^G^=?3NY?E9>LZC]]U]A_)<I6=.
M8WEZ?GSZYYNC\VZO>]I]\_*I2M_W#^N>'J'C_5<?CSXFP'-,DUTC)%#,;-)]
M>=)]N0M C!(H2*MH8%N[:(>A&MZ+)[+-'K-R:;ETLWOHM$5#)M?ZCHWG;$U5
M**]<6HY)EGE,TG2D["=]]9H.F]7N8G VILO.*G2"+#8R&1S)PB04&(D$%/4.
MO#8ZN]>I,(F7R#9A&^$&*K!>^SE+@?7*85T_4N$^1,LE3K!&#IA4"=8.64",
M2$:1P2[[D0JL'PBL&P\>++!>!:SK[F&$O.$B@(@N  O6@4TK"3EU5Q@C,'5L
M';#^CLVY*296N;)<6:Y<SI7WTRWU9>V"9;6V:]]JMDJ/*Y?>TTN7J:#'ZG_+
M5-"K#J#DIY(YM6[KI_&,Q*/>8#BJZMI,Z7X_N-P?(SP=#<_W>^-I<9LTJ/'7
MBMO\.JV.4PRB!0RBXYD1;,A%)GR$Z)P'YFDRB' D8(U%DF@A(Z9;NW(3?!P/
M!X^->R,*'M>$QYJ#@AA*D,$,.&41F'08=$ :B.%IG:DC7(E5X[$QRZ,>C]8:
M#)+/3<AMVOB^\]9\.$_C[$Q&Z1.GD_R@C)+-9M/%FGRE>Y1',3&GLRSF+":!
M260:6ZTP]WIA/JW<N=/6Q_L7HS1YS]-S#/VT[U?U\^>\R7*H<$B[*P^Q4.<B
M%?E.]R;UEA-,<"NYR*I, &;2*Q4P FVDE-@:1*MJHO4XP&)@%.MMPR9WD6;*
M+GV$=!('C9F+027KS46#C+#:$+7XB?17R.U/T[\(A=L:X;;J_R>9WW[_D)Z=
M'OW^-Q;18L,8(&)RCA_F8*5/>J+6@1I,J)=N:Q=+4NBMT-NF3^XBQG!D@3-A
M/=?6,AFM\I@I8TW 7$AJY.W3N0K1K8#H?K])=%%&PKU'("-.:ERT$A03'@3"
MC#-/"<_)S"61N54@;"":M8!P?2 \NPE"17V.:F6@K:/ L+2@),&@M28T$6XD
M2F](8O/FG:RURGQH/*"U 'KY@'Y3,Q^,XA++W%L%94 SI4%'&8#CZ)17@0:F
MDOFP:*N5@NM-Q77C9T@%URO =4U;QEK29/5$\!PG<..@01&#(%JAB>1.Z:K>
MP3IP_6".C9Y?C-SKM+G'N<*E*WF6K0^+*J*C^+/*Y&[FI64C;-Q&V.PE6Z=.
M?9JCL"Y&'RK=NM*D]]S_7O1&68\>3X["Y/70?YDQ%GOO@X>/830LVO5"VO7!
M+.V:24<\10J8CCPG=T?02B"@7$CO<5IC[3Z!NG4:]J8HC.7*<F6YL@U98^W.
M%:O*:Q:;NNCEFQY/]:VCSB_Z/E<[OBAR"RER1[.BIX(,7AM%(>C<0B@ZDQ0Y
M(L$K2Y1$AAIFMG;9QAQ^E,2^,KEE<LOD%M'>LEB'(MJ7*]KKD0W6&1L(5V $
MRFD?(HEVZS78@"GREB*B?!'M;0P:;#RMO*"L*90=WD0995Y(EZ.&--:0'9]@
M<4*98%XY'R-W"LU"60L# C<;8&L/\9F%KW("T1#N:B<06@;,;+94(^:0P$;!
M"BH@,&22Y4HBUJ2])Q"W=2]N2EN3GTW?#%S8[AR[R=!>-<(EVYV,I[G;2]CA
M*"$*ID__F*:E\,,+VP^=JR>X-PY-,O\S7UXP&;Y]C/)J=,;#?L_7IN1>4/?,
MI'3#L%0!^Z0@"49BLD0H(U3)('6B;T[_/IR/M*\5&)WFGT]C-$NAT>:8^_=Z
M,CIG$B7F]L"-3U:)X *L3D:*EM)HS87'2&SMZFV.ZTD4WV3M)H'3K.)U:QI;
M%26TZD2K8H3_K&"1%UC<=K%B7:%MBA+K>NSAP/4O\I0]'X[R*/8FTYI')DWZ
MUVH>%9)<D"1KW:1-=$@E0@3D?&Z?20287)>9!!LL#4%&E(U*64_V+!19*+)0
MY R*)(I2IBTU 6M&-%9(!BX51P1Q@U!8-446);,Y_IQUKFV2)*1$@T&YYE$4
M$A0V'&(4F@G&(Q,FJ9EXFW+]X$FTF*'?<='/M$.U\X(&)*60FAF,3=I:6@>9
MBS1H&_6\C/)%+//)Y3<5>FB2'FI>^VB=YX)K\%%28$DL@$XJ-"A-.?-I#6.T
M6[MT6R,ZM^?^'A)#T:X>LG:UR)'E[<EP[L" HF>MGTCK18F<D4A@ 1+'"$PH
M#H8Z#H)31UQP%/.XM8MQHM(%.@<5*BU4>J^H=)&*42I:) 27FM,<9:4ID8YY
M:2)/!.I7[LLK!-HD@=8*2F%+*<*<@#$\&:HZUS6G$0-)&\D:B9'P(1$H(=M:
MU*N;/S1+M;#H0V;1A0KO81$]8=XC;Y@(7$GB4=)(M+?(,%T4TOO!IZ]N\BGW
M$6FK#5#-#3!O(RA.+7 J#$*<<R^29:^V"2GJ:"'2!TJD"_ HHSJ08$DP0C(N
MO5;:2H^TL(1+94511S>8/NM) QA%:6CD@(G2P*AS8+DSH*1VS&D=;$!;NYIL
M"[I@Y;1"HH5$'RJ):D6L%P)I%00C#BL4I##*$NJB"XB7^)R6\V3M ,EJ+[$+
M$F(R*Q)/&@T&>P>8>N>TM%&IW"^]'"X7DBPD.6?6FR2:2I7[^4GF%-)86R9#
ML"IGGCI5-,U-9M#ZR9$Q2:5D%H0C&)BA#K1F")*5;JU@B4$%J31-I3=0T[S,
M_[D:TB4F:,6,UPE6U!@VCVI>>OU.EM$WGG.1U)F&/J;=&3B,+_2\,P20"YDZ
M5D._<B[R??[T\.7!B\YA]\E.Y^37O1<'OQX_VS]X<3)'J:AV;9UU?<R<67S-
MEIUH;D_K>9Z\1;MZ7J5BFKG5.9FSE/B<#W^W#;3B3[JO2WL5#/F@%_>A?%([
M+WTP[1E^.#I\]NSPN'NRW3GXOT\.GI]VGB=MX<GQT=%Q=ZHO=/;W3O=JIV)M
M$6_+O?+VO-I",WP:5MY&.MV,^7MN1IVJS'BS6-BL2=CSOJJG(7_J=_YK1X_2
MK/0\' XZ3\S;WL3TFYV;>[5_"O[NJO&/)P\9>B_"Q*0_^LZ!&0W2L.?92O=V
M,O:<NSC?Z50EECJY;]K.E(Z>#<</>EXJDH%J*B[=WY=TW9FZP1_RW'2' [CF
MY>_T+MW\#WK#G Z3U)ZU.6[O5_Z.:/E><:MUEZOZ[:+_87JVP*I:57CN6E7W
MQ@*JY0#?IQ3?Q3)\ PDQ\O_'WK<VM75LV_X5%7?7K>PJIM./V2_G%%7$D(2<
M (Z-=Z[])=5/(P<06Q))\*^_W4M@8R_A2%A(2]#[G!""EI:6NGN,'G/V?,@@
MG:'(K;:2<>FYEE9JY&QR(DE+G<!::6K%1XQ_M"M-1::-58R#9JI4YO0(3@H'
M%J7FCG N22J5IE"0.YTO+C\&8[80B\<30?'( B0614<UBFPE!-6J\B2B<WG>
M'&#2!#!$#DYQA"@$,L4-QN!+E2=6Z:G24_?IR5@MB<7D% E(57 TBN@C!HI6
M&&:634]57"V.NZ946"(D)!0JLU>>4T!M/&B;(EAC'5622!'4QI8VFUEHK3F!
M/0[;:,[R1Y1(K5%2:@UBUM-%E"CJ.67*EA4P*]QK^:-[QVXK>IU([Y@6&J2,
M-,L/8\$R88&4G%EON26.E_)'6K1#+_\A2;([J*VR8WUEQSR9WG<GHIKIO48D
MU@H@YREJ3BD'$;/V0"\,&"L36)UEB6"*$&U*Z:%2X[&M0"J-K1KCCX#&YK&>
M0J#96E+$.X-,*L/R5FQ4B%12*_G2G3N5O!9)7JVR/T91$:G18((5@,(B:",D
M2)MHB#HQ1O3&EI&;'-?=>JH$MKX$-H\.TXJB89[:1#QZI(90&Y"99+Q1QE0=
M]C"HK%5Q)QC"@N2F'*R%4FJ;@^&&@I66"\\98X)M;.&F$KJJL$IBG59AC@9M
MA4R<1X)6:YMM2D,))3HDZ6RJ*FR-J6M*M1OMB97,0E!.9A6F'1CE'3#C P\H
MB%)D8TN138+U$*X2V!H06/#<AQ@S8PF&J&Q>X$1;7CQD";-]66,$.LY1[0;#
M21DE8BFI71J=,NVSLDH<*/J4E/;>L\Q13+4;%52"Z@1Z*T'=)*@DA N!:.YU
MQ(#.D43R"B=4)(Y.8%58Z\Q>+2>]LH8@B0FH\0I0FFPFYDTI6X@Z!4,C=RXU
M"HO?L=_G$HJXW"'8OU,LU(2X'\1QKY\A<+K@%,9N![-W/=>\7CH]O&8=XV?F
M*76&AB0C?6*"HW#:<!F]D8PGXUQT_O>=JTU00/DEWY]_>3=\/ARD_K@DP-4=
M;6$[6O$73#FYD3*$8!D@X1P0K0;' @4E'0G.N$BL+@7&Z;P'-RN,:ZMP_KJS
MVR2EL,D9'CAJ%8U(0KE(5?12.H85SEV!<]L%Z(5TDDM:3B\D8&(NF]?1@2>4
M,:9*,RN_;G!^-,"C1@0EE(W"E P8M":;E4E;&Q1BB.:K@%>Q-2>VVF&F@BA)
MG0&TQ&9LT92W2I= *I:<\M:S26^C"JRN 2LF*G4&$&'!H&'"$&L%8\0)IWAB
M7P>LNJ,M$G4MEXN+43I,$62* 9 B R?R1+F@4V346F5LLZ/-6YQ\^2Z5-2ZN
MUE0GF0RG'YR>#^-Q/!OU_XQ73IAOOSG)6/CW9N\LCGN#U!O;OZM?IIM>B7II
M-0^_+C*N''<0JZ1.3B-2;3VWECJ)6?\@M;/8A[>$R#4L\^PFO^PU]%(VVH,X
M/DQ']N^ZI\ZUI^Y.BW&CSGKKD@--E0!T(>^I(3&P-"6&WADO34EVG#U=JJK8
M970E_WK'3 7>$H'7=L]8)J5DW$!RA&43,B(XXC3DN<PVB?8R>5J!USG@+< Q
M4X&W3."U?#<8>3FE(H#*^_PC&G">*8B.4NFCH#[AQE8[Z*C";H6P6X#;IL)N
MF;!K.6^$08_!.\BZ4@*2D"6G3@(2385/N9:EKYPVN%3@W5,@3.C_^=DMH%S_
M%#]Z?#[Q\*S*E_/,CHY[^6'[^5G"J #FQ YCV.R=QV&O*8[QM/>O+\'T>1PV
ME2T6"U?VA3J#.]=/>_W1.U</_0&DI()T!I#F??&SLEWY?B?QIQ>7;WX+Y]F$
MD >G_SD]./KUK\.C_+YWN^\/?MR[/'CW1_Z>>_EOW[_+]R3Y]WS/GU-^5G&X
M\^K]P<Y;W'^_WUB6 9NL7V#46,A:28!UAH')J&?)>D+SI&^1)[SMK'U\M4E7
M[K.JE]9+NW[IPHY8NB*#V8V>7Z.RN?7J44EWEEN]]'':F@N/8?T@66_(V**\
M:\# XN3L_K2(5F8))X$&4+K$ZC!DD,U,!I$29,;Z@.5P@VU2TX[4Z:"[IP)[
MY8<F%=@K ';[\,2E$)E!!]Y:!!3$@0F: $\. Z),C.H*[$<#[(4']55@+P?8
M+2\QM<I+9P7$S,Z UB$XC004=RF*R%FP*P'V/YB>ZV)HU2OKE?7*^[GR87JG
M/JTN<%_=Y;HWFYU2<O72!WKI?4KTU/SO/B5ZTX23?5=SFE9M_RP\6W"_?S88
M-I5G)G2_$WUI9A%_& Y.=_JC2?F9_%"CV\K/_#2I7U--HKE,HE?3XM4L]9J4
M0%'.-0/TP8/E@H%Q3F?CU@=#^<;6[!5(*R+7T2-1$;DR1+:<%-II$K6DX'3)
MF? T(]*+XJ0P/ 5CE YAV8A\-.F'DU[@+B_]T#NWEZ?Y.7OC8;[C9) ?E6&R
MWGPZ7U<N96T,G ;.)45FN=9&)(Q">V:(\V1N1FV<NI-^Q3L7PSQXS_/W&(1)
MHZ[FY_=ED970X)A75WG$2IYSD>?K=NMBID**2#00YRB@I1)*PPBP1D<B-?>V
M^'?IG"4_JZ2Y_\()R\+??^S)1:SP6PC\6HUYJ7$^T&P\9$TJ 9W6H'DP$"V)
M2NM@;"FYVTXYJ^A;=5T]GYS-,..4(%J;',&HE>'9$C0I\(J^#J)O6FM91@/Q
MRH)V/)82>Q*<T@:$L )1>A$9V]B27%4$+@6!U8/9$7^)2LXE)R1)0:/@PGE%
MDC!&,I24$W7W_+Y*=$L@NK:+Q*K@G4T0?2*EA[8!+00%(P4O4ZJ%YC7)MF,@
M7$#@<P7AZD#8"G^VJ+6T2H,74@,R@Z!ER!9W(,)PP8D1<9K:[R (U^_XM5/F
MP\(CGRN@[Q_0[;!GIF+>/86%Q*@"%#Z!)HZ#2D$&D]'NB"OF0SN'OJL*M^*Z
M6]5,*ZZ7@.N66HXD$)J\AN P GI&P)6,)<*DD(':9%5:$:X?S;GB\XNA/\Z+
M>U2*EOH;.;F/Z4!QY<R]\DO7>^NH_JS'.[CK=&E="&NW$-9[RE:IJ8]*H-[%
M\++1UHV2WO;_O>@/BXX>C??C^'@0/DTL3/V_8X#W<3BHZGHN=>VGANL%)6Q@
M)8#6D7+RC>""Y4"(0JD\,;K$G%R!NG,*>UT$8[VR7EFO[$)J8;<3"IMZJ]6F
M?GRZO.:CU<&M@UL']Z&'0$PY4#F>Y%[M9JMO?-EL@-6NF\NN^V-:>(/37$DO
M/%B,"=#Q  5%$%5@25IE.,J-+6S'4M;XA@>'V_L)<*BX_7K<MJ,84"CJG/=
M?.G"$50$ZRQ"IEU.><0D8U@7W*XWPCK1]Z8B;5%(:Y4.B)0AB4%#Y,8 &F?
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MNW%*A7YKM 1,H83]HP8M P7GHQ,F6$4\??34\7A OG G3@7Y\D'>T@<R:_%
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M;5LO5' OG15 58R 4BJP/E#PT2GD@G$T*:N=3<9KO%FG(+GX7J\5DBN!9,L
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M@JD0<AC ]FY1T*JP0:@GE#(;10>+QX&'6 \# ^F44-0A?L=,,.3=?-B+TFD
MHFR"&]S+^UF+,D09 .>SYI\!>HM-T_-QXR]@>_GNL"(!;-0X0/,#95^:9N'6
MAW<;C@8!9%VG9P$T I#(F&,\'U?68.,X1N=B=WR6\7#^ZH(PG0M,A)PU5IQQ
MP#+WU/@Z.Y'QXV;]L8\/P2? WX<].\D;DFH\"V_F1X/Q.-/>%0*'/0+(A<_/
MM\R/J,$O:%9<[,(2FK7N+JRP6]^TW[NL#:7*:UXM=[>#@;/M0KN5-U3M;9*J
M5UL%^?"V;[/&'?/C1C<+MF6[=J5#^=Y&I:(#!7:Q77NR[5"YQ@97M?]L%"O*
MY&$O3BJ#/;,E,F,V#KI@VONK]G]C3];J?(4K8A\,JL:IN*B4;OI&)R<'1!3(
M^>^C^+X[F(Y!JL).@@Z!*P[@.V#V].<&T&4E[@?C"?&]P?BZQR7-G%.K;M>@
M)51=VRFEQQVZ62F]??*8;582KU1;.UNX3UG)LQ\W+Z0?*!:=]>].P;CN!U(O
M-^7__/ 9%E_4+OWLN\[V2(,R1]'W['B<@X:5?;3HWQTT;GP0-]W!B-2-WNPY
M1J7&C61#US#*WN%B.!(E55@M,8&Z?';,A\ZKU[_]MST?_K _\Q1FRFN@\<Q/
M?VW/O[L63UE?.6U3./'')P\GPDLMA!)'@S[\Z"M_:!M8S(%%>K!W8I-(I0V&
M2.,+(DIEB8NN)+X03%E/RZCC4DC;:1.#MRY)+C1UMBQ4,HPY3X-1(5T/+")Y
M+43FWTZ W.TH=/;"8#B'*NS.4.-6(;'5X<T[M^;Y4;_SBX7O .JA.W.'2;0C
M0#6VWI'*P+;S/1LW>X8B9N8"6H@OS#Y;##3,1 YZ V9("4&B PR(J][M_#Z+
M'N(CF^<LB*O[/VT4F^ACJ+P6*&D'IY6S-KNHHD4C/7O,\(GU,T8X%'WV>Y4R
MVL%855XW;,(H &"M? NK"&G<>3$(<VE>%B5Z,6K#_W3:K;Y]&OOHC<H&_A78
M.UM%L]KLD;CW6T_R3<8@>^8Z F.$%W%4;< H++UQW,4@>XUE=^H(3O/MV1?K
MG;N^67#O'%Y\;WO36(<-5NW>;@>T7T-1,T?(C))0[Z'[)P>?T?7G<OP_QY8P
M[-2Y@%OW![7=@ =:>=#OB"3NKE!4G\3(VZ2U7CRYUJK#B#^-!N<O:G+[$\C^
M!>"3 3RQU5D';TY@0P65+!+I2D6$+$OB3!&)3=Z#J"TLTTOY9DGQ%&)A$S-4
M>.&,,YQ3^%H(U+I27-=933@W\\/Q".%C+7G&G:KT'!V$MZNLE1KB[H5<7;CT
M2BO-J;%.",Z$L_#%6%#-N-<<.]-O0C6N:<?4NXD[AU(-=R/';.D/]3^;-'#^
M;,0T_%,?>@+VF[G&Q[8''UV<Q7XM&%%*UO[Z*NR1%<.@UPCBYHOY+M,%DZ'B
MX2R7)Y=##+"@)R-.,)6G'U?>L@H282Y'_?S9W6$5X[/N<%BEXH38 QD^JA7M
MI#OIP96HNU8\_B?$$+4MU.BT<95A !*].SZ#NS1/P<P!D.Q@DM@1;#TJ=;A-
M?LZDBE2,\C\Y%$2&=C2Y1,=.<]O!:%P'YSL@KVKG496P!("DV^L16"XY&_3@
M?J,1AAPJ?WM#,/"2"YH0MN'&[\PT\7#0K9*L)D D\VUK7K^NTA[?=&@Y5M:;
M?9P&/3!_,R(8=7/"UD(RU'F<?%^IWODZ\KE,':K97"1S_<RZ6 ($8"6BQ0?[
M!7H3@=^X@W9V_S2W%[]Z8$NWP%2?*M5H>'8YSG&Z&>DL?1??!_!E&.0$D+SV
MO.*J# ZOQPKVQ2=D(Q9V'9Z5U;[M5]ZW.0&]ZL^H%M>[[AYGP-ND3\THL=L/
MB." 8G;JJ%-][_SPB]J0MXW%W<D55[B^H;W,&Y_9;7$9.[-O5_P 6_$=9H,L
M) R/NN-WS=BSBPPE8:F#"T"*R%OU=M5[6\/:*R^:=[=^R/Q#[^-PDD'G63[8
MF'T.N5W)YOW+:XKN!GF,MT=@'TVS*W@,'#G,BO5:T+HF,Z"C60)<_(!'4@="
M7]L/O<'[+AHY(,W'*$B&(R"Y[C +9#CC"Y N$>4^$J.;(I@'H3 > ,N":*BX
MH[IR%(%XJ^O. $KCML*/'A;=]?##Z0"$<A6/M&" ^&Z-*.H5=]%KG=-.YX_/
MCVB6B(^XRPUTJV/HJZO@H\7-)7QM-5Y;C==6XVV^;.ZKK<9;[3.\NT)HY?>V
MTS*\53BO4(<93389N!D9@C(\KXR-K K1NG@/D HMI$:S7U'!&:;'D%/-Y@_8
MZ;S8?[%S59,CQ 2E.JTPPOL,/P<)H" F:U>:?$$SUWE4DW@ZRMZNVL2Z[/3C
MY&(P>@=+/[J607S'^K,MMK@'F-H[Z).%CP U UB=9D/I7ECQ"7J0/Q@K[D<\
MG6SC93#>.%&V!SH^D?<.FQ.^]6 W3WOQ*!U$M&1&\;?H@'#&U:_=D$<\8G9$
M>(O>TM>C 1#6>7W1ZSC*B;M@-/R()G_C_*O__ *H\C1B.'7\%MT1>VB5XL5C
MK$W%3WZ+D^FHC[_BY*J<MX'.JF,40E^QOY ?[9THREC ^E0:!"=PJHG8R"4!
M1:3@+[947%UWNUDEK4HF1EM(D8+5A312"!9\$25\<MU?B#8),/D(9$N5L=(0
MP4ZG.?_:S,P44#G,40HA#50FP9P"ZM3@6;QA5!'!#F9E-F2P4_NE[(P2JBAR
M_G!4$<-\=G=HZ"&;/'9<^S7&W]^COF^E\KES?[X@J*/HKI8/PR2W_TWRFQ_Z
M4*1# >D4]T,Z6[!8NDOU_7;V?DTD4>/1U0ALL_W [M=!]^#5K[^^ CMFJ4_J
M@]YXO:FB]]^VS]AE[)YI/'514X?M9'NZRA9H=W"-'=R//F+)4(=760=TG8&%
MZPTR?LA@G:L"GV_"0*G:ND;X(KJ93]%_/=E8.N"2:R&OKHI#VB8..9K%(7<Z
M/4SLF&&!*A-M,'63-.W-OO!8XQGO8P]O08_&>Q[Y P;>;T6#QGN^WEK]&;$K
MH_?6E518(QPSA08KR 0EP !*>=C]';,1:GL%S)"9";)7P>(OH^/B TV4NN.B
MIW\=OV2'[,V'PS_QN[]U#_YY(P^.?Y=___FJ./KYY8>_C_<^_OW/3^?7.RX>
M?OSC[.#X+_[W_DOZ-Y@WAS^_NCS<?_<!3)K>7__ >H]_ZAWL'YX?_/EW.GA;
M7&*W1?BW.(#W./SX\D0RJLJBL$1*7A+!F"?.R$3*A!T8"YX<IWD@$G]8']D[
MV>"SCGIL)="_4P+Y5#K+DB\-2T(X 13,HDI2"UL4+E82B%(&M-Q*H,U*H&)9
M OE04!N(Y-X0074DVAA&X"!U2CP6S!<H@0JEMDL"/?W8R,^(;M=$E$=UYD)5
MS+!B0L$F!,;WGPQ4MWH>QBJ:5;MJ8R,O[GDJ68CF"K\L7_^]X\>>0*TYZXOD
M@W?>XYA<%U*PW*LH.6@W)^X#K.OMK[5;J\H>395=+H/I) I$T)( %'%$1%!J
M+GE/;"ILP6R27*5GS_F.,>UTT6WC-24+[1PM4Q!"2, >+!:E4\(F6HI8W M"
MMKSV9+RV!!M3<#Z4A2;<<4N$2(Z86"BB:!&Y<DQIQI#7--T K_T[-7D%^IIH
M9:O(/Z\BS[M?6Z3;,ZOP2Q ?AR^65754+ K+"Y*H$D0H*XFQ-( ,*9/CFOJ8
MIR?1=DCHMO'28RCJEI<^@9>65+&+,1A5"D(-PEY9.N+*F(@QQ@:C>;3HP9&;
M&+C;^FA@NV]QTWRZI^1K$3NAT"7U-%+)@^""NC)1:YDJM=7.1/ZI0:Y6!MU?
M!JV(8U%I9"F*2(R6A@A>@#XW7A"E0>[P6%#/#>ASLZ8/N=7G3\Y8K'!*JN!<
M*)-(S-G F4])1F^-X9%]:NRF9:QU&&M)N1LPK^%D(E&) V,9'8E512"!6\^3
M$CAS%!AKW?#P9U#NMX[\VYH,P'LRU/%@8GN5[3WWI><\W:K(-N?ODB9+> T;
M_=Z[])#1J_C]-9+ _A5A]\?9B7^->"\4,UQI*QE7PNO"4..$BM%I$X3TNDT.
MVA+9WUT&5991Q9C1!.0))2)Y2TPRDK "#DX66&@6GSTO=PJ^IFGWF*SR&<=0
MM^*P%8>?* ZC3]+@R"K&,5/)&RF35@K,2F>,8+'-5-H:<;@$A8./#HS)1#P7
M@@ I4&)"%(0E,#(C+652^MESN0.B\<L3AU=KCY>;1=Q22KH9I]<-X[IN:KFU
M/;6D-V;C5VU%)A6"STV)NB,L&JXF'GS,E^3F?=6HKZM9^Q[G;4PZO4'NW32*
MJ9=GPV$5L8OC"0YBZ.+H.&QD@OUC<TOOJU^JN^W,%S3N8$O9!+0VF+>;"DW7
M1=?,_3OK8FNGW$(E3Y?(8TIV9MEA"R/)9J.,P+@?3_*7ZYD2$<AM<%Z5UE93
M/\9UOZ#<KSRW-SJ+\[? 5U[]&CO8>&?U!E=5C'7#W-S>$ML #0 %Y!%*5<?&
M$(>QGWL(P7L"E;^# _@F3UX"_AE/Q]7$K'X]DN/;G5S?W?^_*;ST93Z]:3V!
M9=;79W(YC)UOSH $<M^@YCYP>M7O>/%"*7?]YZL%WM_66]?]D,V_JMH$]AJ[
MAMC3^LUFPS9BU? S3YK!]\M'>^.N['8V7C!^*\-<:QM53S1;VH$UWOA*)ZEZ
M(M1**JXZ <V:GC4]C9;/-S<".)WVL!%5U9>^%T_Q5OWWW=&@7X_^R2N9]:U'
M5SP^#HE@9\&6!RL^OL<N4PT'Y9.O^*3AG8B#>_QH,..;5'5-F\UAJ5@BT]>\
M0U:FDO,!P)/<BBVW\JS'\&"/MLS0DP5>GS?"R@WLYAW,;/]R8=1+Q9K-2A9>
MN>YHFF<-UJN(#1_/*'756<[G$U8]MF.H-NC: ,7\ K#OU72<V?IKZ0=O.L+^
MK5@K/3SK>I*G%B58XGF<P$G#9NW-1@QA/]4+;-5&!BDUK;T\\E^W$HVSX[XN
M3[#6^AV*[+KV"TN48]W.8*T=7KD3HWB>)_0,AZ/!<-2M^K-BX[1J8E3>90<+
M17ZS%[@>7.LU@IV_>4TFU<'4+5H7:&6G,[MRH4"\'BP'9/6N/[B XQYE>!+F
MO&47>M;N=F[7<+C+DX@=M4#F8A.EW#</)Q -^OFB\VC[=4/UO)/S^8)5J]O.
M-_,^;\A#I[5NN<A$NK!3WRY0;/QP9C,A/; ]^N;$WWXUF>M1)_OMS(9KS?H\
MW@(G'L(9N1LQM@Z<S:N==P*^[VS<JN7D? S8E>FF@VH8PXU"'DAY*\=Z=.C_
M;-\0BT<9VOE9.RY3>6O'Y?TG[[C\JO]Z-,#YO5C[:T?^#.WQ^72=JN/REVEI
M?TKCE.+P](1J(*[ -)$Z4B(<C<0DZX@-5%E?)DI3>;UQBI""QR)Q7[)2<,V=
ME0[,ZM(:[Y(/]'KCE+W96(P^J0^BTYQ$EE$+9]%Y60_,^(2IY#>W-+E[Y5??
MM##1)5<:QQT7PBK#A&*) _'IPFM3?'XU0UF%LJM.OB/ ,*MF,U:#46=C1FX9
M3(*-8NRL36T'G]4!_7'>R)XK@G]AW# \#30[J)(G'\F\AIQA_UD@-@ #PYK8
M1HO$MCA6*\Z(;2-2/B^XF;^(K73'U:CRZ:B>Z "[WX\+@[Z_L=]F!#8=)H#M
M]5#0+NCPR0!;IU5=<C.4S<UW7"UMZS9G!':P.O-3P":UG3/'9T/ K]WI>?XZ
MSGC -L\X'[T>@@"W^,9]6YG>BX,(*H-\B<!FUDU^J0PQ%F9[S88FP$MN%_W\
MMLVT4ML3%[-1$=GG5'M#LIU0-X%&MLU-YN+"5!"<5@ZOE+)G"#8^>TI^WMM[
MO8-#($X'@W#1!>*ZVI"[FAJ_)#[@HGI#ZFGV"_,J@![F%RX.*+E.SJL'EC0+
MR/0Q<V#U,MX%*S2_\)81S:NZXW>VB;I@#O9/N]F&RB<STTY+]LLF:&BU9KQ;
MTZV8^K%=T_CRV]73^%YN5*)OU92YO"1:;&K 7'Y\!2:V:TLVNB%73;KMVIA[
M>5VRT-">25Y80WT,P@OM3 F&&-.L*'6AP303B) W-A/H]O;3>>[B[N<A@M5+
MN)4"G_K]G[!-:C/!]L5<IX_WN^/A8&Q[/X\&T^'X50,Z%X?/'LTF*;[,Z/,@
M3LX&X54?I\!FL)J[JZXRX/?FLSGPAKT!CB#;DHZHQ<&+QK!_(_[>?WEQL+\'
M!OKO8)2_88?LL'OTYQ_=OSYZ_O<Y&/W[A[W#XS_.KAOV?^^?O3LXWH/O>G%X
M?-8[W/^+_\5>R;___.6?PX_A_.]C7QRPW^GAGS^EH^,]=G!QPA,<&<,BC^ Y
M$:#=B>$Z$*68BT4$ZUZGZ^9NL(Q9*;Q6I1&N],Y%.'YM//5:"U.N-.QK*V#G
MZB#AHX6QF-5QDNH\._,#S7KRQ=Q0>1\["R?Y@,%+=Z__VI1##H9_"H8&9N'"
MTB1;AE+3Q(V,WM ;VVO?[&'>IE%F>[N=Q1/:>.1P;4OLC^[(]C:IIJ]F(N!<
MQRG8V68VU/&L"X9BPA;@M;OD2L"YFIBTTD$SLXKJE]S)4V^Z[ZM106>Q%YH)
M([8'^V9/P03J#JX-0<%)X!C=2P,_K4=(Y2; Z.[OG^XL!N2KV8;GP$GHMZ_F
M'_;APEXGSS#")>3 (3 WWKPV)B?8BAAS&L9#N"*'2\>7?7\Y0=\_? G#YQB!
ML)U)SGENPGVV&<,R'6(HX;_62+HJ%:.A$,SYJ 4%WG7 3R5E3,#622-JU5,6
MAC0_K,Z^:GR_>VB"+;#!B\4U'L_G_GP1^5B?79D<_..+HWW/0:F(@\ICS(62
MAFI-7*""".\,T2PEPK6,R8FD@PO/GDM>+B56H:NJE\-_<Z=3X\F:^Z[29NGE
M=;V0XT'M27Q=#20 [91)Z<OH%;%I0N$XP]&+(E%-B=<B @*))=%&,:)BB<TF
M39 NEZ/<3"A '>C*!#R'I+(02K9Y:-YL+-BF: ;!;D,O8,Q=%S7C'R/F@/PY
M&+V#1;^P>734WGP0>4M)*RGI^*_BZ/@5._SXAL/ZBX.]DU)K:Y--1'(,4FGF
MB0EE(B57@-5B9 F;]0@F;Z:D86\Z[EQ4)]'QU5$L#H7_MG)T]A=#V%^$WGJ1
M$>TIO,.5*UK:NH>4D@>G)Z6TI;5@'14T&: M98A12A(P":(HN(NN$.@_6\X3
MGM&6GQU!);#J_*_%X,$L2+,%$U]N1;Q_SA(TZL3$G,N"Y%;S ,8+^\M1H Z(
M:%\EC/6B#=4%._#I> IP> !@$;/NZL&.&$ILYF?F@7B+TSBOQ!'PD]/1 !M?
MUT.Z:^ ,ILUDY4CL#*]GX0.[62:^P5TQ8VUXD5SZ?WQF^\=GH\'T]&R%\^3/
M*@OK**66JU=S]4L)''UY\/$5/SS^_2. 5.]=E,I+3&901*2B($8'#B!5%PK4
M!1PM]HQAMV"/:A#+G&@K,VI5+*QBAAS1Z@^ EFL3\'W,<U>W+L+YQ47(&T.[
M.^[,!4C.6\B#;P;32<($[3R/:E#YG7+. QJVDSQ_K&Z'=56$5*F_\T8;^/?I
M>0SS?+B%,;+KI")^?0,YZ;7=:0=RM@,Y/^?2VX&<[4#.]09RWN7YOQ8IX($R
M[XPM59D 'SJ;A'8Q40RI^%(7#X@4;$#QCV+?;D5Q75[.4;]SD#$'I3LK/.-Y
MM>@7;_S@G<H/7GN]*\_SK>C^=1R]!1 7EV:@L.C!N/-42%'*!"9>\E1)P7A9
M>NVK-@<%IU?J>HOKV+X!Z@LV>G[:ZU'7QQD6+[XR+'YX_$8>?OR=PKHYO%=Q
MHIAAUA:>% 9 N* I$2N$)<$(ZDLERG2C?3W$9BFXI3EW#*!>E6E6Q1J6[<2K
MT8?)W$72N0"PN(X=6%"I!"]U<$@5RAK&.-@-NBP3TZY@M1T(%$)6D0K1=SJ5
M&^*)XY_1NKV?76>^9EKZ>$!Q DZ4G!D2P!@G GB86*<T4444P;J".XM-+G:7
MK;JJHL;5IMTWVTH,AW%RE'"X:V.CM81Q-V&\N3BAH)-C*AT)-&HB0E!$6\-)
ML%X[YKCFPB%AL&4AXYJ8%&;28H44FI2-$OHV%S8W+N&=M82(5EHS4ZIHC18F
M1&VY,-08QW20L2COHILE9](*S]#;.F^_=_G;+&/W>.ZL&S?%%'O]\&LN#YM?
MUKJ2[J:LTP\GH3#.:RJ)-J##!),E<3J"^G)&Y8:%@/Y ?:WHJC-S)('RFD4W
M)X,*UW3B^; WN(SSBLUK"FTA5WZ:$V9 C?4&_5."Q:@8/T6/%$XQO+"C,,X:
M;C%I&]L!C">D"9TA9@)"J#3CK/*CK@[<VCS\R6CJ)U5%9>6,JXNYZXK9!<_O
MK)M:56VP253[S5:5,LYRHCM\DYOR[99'/>:6D?IAL9/&K#1GP25:I^,L9,N
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MI95ED(7[FFS9.FA?3Q?AL/ PF.*LDB^Q96D=_[8+'B,<+92G39X->O"B]XF
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MWA*+1CD&=#&+R,V _)J4(;5-!@A2%,H(%TH+@,P+&M'43(HV.0FW$L05N+"
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M0J'!FHI>!!7Q:*RCCJ9H.3<BI]HXSAF7G,C )9L?%3VW7BN/QT+X)@L))YG
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MWO%-:P!/\]/:JI>GS2'FNH"YCF 9(T#^&/TUG2T[]5S=Y*YIOS^Z()] XWP
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MZ]"QF5UCM4S?0Z8/OY$],,5]L"(BV(-)+H\ID;/&PIZF18B@B5(F0$VAM]4
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MAR&G6EZY>XY*SR'EPUX9;>YR ]+5(B>>@=K5?>"4WKMDGY'WB\PS'N7*EE4
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ML!9\;1T"F"XA:17 ))65,$9)3!O;5L\Y$V@4ZN5.PVY1H?GKP:Y[' N!XW"
MM1.R.GZ<1CL+B*Y"E)* ^=2+Q%A,OO:BF9%"<E%A]VX);P-Z@_-*S;M/VC'@
MDF9+R-!+O)AM, 7J8HL-R:Z7)>R5W2L/J7<HWX:HO:21!P8=LM%@6M%*ZR
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MD%XXP$(1$@H$KW4MD8IR(C'Y;'H<7Z^8SCV=>Y:2*NS<LPSN&>0&0W:HO!-
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M;<Y0BTZ ,E1(0@F@UB1%DV.C%;MGW;FP<^$X4NJ=\^;FO&$B7=OJHXF@#65
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M8Y?U<-Z :>@/CO,<#3Y$A[&WWPY5L_5O[/9J&^]-M1_!)H1'Y2_NQ/JKX88
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M@!5@N#?57Q9>*Z_]:6SU4Q'?@QB&)KQK?Z;[?QQ4+H#5O8&Q//?>9F?,W<L
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M5I\RKR[6WKH%D]T<C \Y6.2LVUQ=D$P,5YJZ6]C^NL?N>UYE6/#S6^O]L=[
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M_,&X&@Z7Y,H9V)A@>\IIQAP[I 7\L ;,=6<BYX$!KM3"XZKHML^"#;1SEO"
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M+#P-9]:]!2R*+#V=++W?*+)49.D!LG1M 19QO"#H![;;;:8FB'KJM \7?\B
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M=H<[0Y_K#:!1%$U@(DW@1V_SILLL8,N%QP$Q)GG>_14R*7 DE)5.,I<$!3V
MT^'BH*5-]#S;M;/@'+8L4!%YB,$01;U5Q 6AHB3DX>W:"R:?&I.-H2@NPC@Q
MA")%HT"PO 8YI@B*+-D@74K*\*45-=RYLT"R'..5R2V36R;W94SN[*RV>15V
M/#BHVMEC6+5B;R:9XG*9J$>DBK-E1DN%QH4"09G<,KES.RM11%*!4_#"1.XI
M,PE[J1WQ23/.(IW->6<NXG;E7_5])0ONJ4RR[ZO#D476"!<DEPC' "89T09I
M[@@B(!\8&VDI<>7(<V%A'!.1&NQH3(/AA@J#K16 6R><8HF:V1QY%AC/&<9#
M@4<I):.3](@1F5#.N4*&)(M,(L909JTSIL!X86&\>+MQB5V8-89'Q!\Y;1BU
M4B$?C$=<4H,,%QQ +8Q0S&@NRF:\N"A>O,VXH'CV*!Z*0"+!4FT51=%QACB-
M"CFN&6*,A,1=<%3.$\4S\KTM2DFKT6_EVIT0.Z@_VG<,IBZTC]U!K/(@?[N-
MPL:Z>?!I]K+A/.RJVSYHANL/OI7P%F]*_W.+Z$UI$A:<[2<YJIZ"TG;O4?4Y
MD6]=#S@M-#T13:\/AX<8Z;'#AB.%#9!T8!X,)B>1YL8:XSRE-$T6'C(=@$Q7
M-RNT5VAOVK0W!2VWT-X3T=Y0! YV,6@)C&=C;A#H##">)!JY:)0PE,68==,)
M(G *ZQ76>ZZL]]P<=).[V%O'ARBT>V@PDL*?D_+G4)\SV/>"B0+YR&7.+HK(
MA)!K2/IHJ3128+NT0MXP,V&OA\*CA4=? 8\NA(NTU$*8 54.]YGC49)  DK*
M*\1ETL@H95#T)BAN%4F1@84M6"'*0I2%*!=9X;SC&*FPY&1^R!%=_KB3W#&%
M#/8,<4PM<M9ZQ(+)6Z".,H6E%<E5X<G"DZ^#)^?KCBR,N5B,.=QMT1DJ*3$H
M& N:I:,..:<L\D$[QF"3M%HLK5#R3)R8@P/Y\\$,D,!J#KS&H^8FD>8AC<6B
M]YSYAV;WZ,">YKF*UVYYV[/PX)7SB6P<'X*H^XL4$?AKQF*S=5P+^;6R"8/7
MX!GQPSDI)\W0VS_7BJ[<-5@"?'F+=3#=Q[W;;[DRV3X",72FS5H$WT=:-(\I
MR]NU!)HK/_<O5O?(?HO(=:+]@6R"P;ZS!R?VM+OT]MH['39;YP^7JB;-2=]^
MY;^N \^\-J+IIT<-38T:.35__[&QM_ZIVFB\7ZY6&VO5]N??MS?6-E8_[5;O
MMS;_7FULK&\OR% ;6SOKV]7.%@RLL;;>V%Y?R[]M;WW86%O=@7_\L=%8;;S?
M6/U0;>_ 'S;7&SN+,O1?/C=6/Z]MP"A_'3&B&LDW^ -&=F"/NO'=^2^_G3-!
MLU4_O[[IMT/;^08".<"F&$XCJX6P__&EH"[COK .:&?PS8./E^N/;M!P_S-&
MERECMWZ,E\FMG\WKL7RLQX[+\R-I_M:=9YCG+TC["@'=8.J^Z@&J$+,.1YH"
MV)26Z: L4=12&DTDDO<U+;@GAM5\H)!,D(X8SX-C/$5K);%)@]Y%LVF:RVF,
M_AZ&HQ<X*.JQ OM&:2J3U-;JZ)V.(2X].Q&5RY*8!\G2W9\Q/9XH33)8O2R-
M*&,M8RUCG<%8%:93)?]A)?]<)1Y_ [A=T9]X0YG!8\9^P0GLKH?4=9NYW3"N
MMR/[#+IO?\EN@]C]M=;;/T7?_M:"AX3<G'YK8^U9EA2PXY<4*!+UM!+U?J-(
M5)&H!TO43?-RX<9[Z7\%@4^=]N'B#QDP"=#LM3/=5[85JO=;VR\'I&-F'4VE
M8NQD)# "GGU!>*(SD;&$HP%_J3;ALOUNM=X*,5SS9#^'E"X]WLG/YL:'#QM;
MC>TA5_WCA.:!@K" 9V-;OM=VL5/1-_6^G@__Q\]_>PK%_WE-([N81E*FL4AC
MD<:7,(U%&F<JC5-P,ET]+Q>7/2JN*"7#/2L6:Y+N[60!9O9[V]VO_CAHG_2;
M6%2?:D6ZW>KN-X^N=+1XM1K.T#GF9$G]+WQV'EGRX(7/3I&=(CM%=N8J.Z7W
MSO7>.\_*2^<>7^]YQ#H_\_#JYQ0DO9B5E(M,%)DH,K%([S!!+H4F@E/%!>.>
M<&&]M9I8%VUTB1,6["#IC&!R3]+9>467N](HLG&<;>-K+5-_'YF2NUI*&TPY
MK^+'B-(&"7LOC45!.8LX8QPYG RRU!'.E>0FD+JT 5OX]N6%<)X)X?"DG M&
M,F\T#R['! <?L5/ .)0Q/$C>&A#.'>4 9D0XA5,FXI2A&@!,J&2"YRAR'A&W
MA"(-)(.,IUZ(I(A3&CAETMS6PBB%4196A2FIG].BDQ')\DPR[(+7*!@<$%>!
M((--0I+')#VC6BNYM*(5+812"&4Z">93T%%NJ7=9J&6.U#*458X-]AQ3AB+8
M.XA[;Y$CTJ*HL&+*<HY)6EIAY&F[TSZUCUTLJXO3^&NG[_."ZNIA^[C5RU[W
M@^,P".:M8DK19V=W*W:[52]V>_ &=="L/6S#&_?#W'OM*MI."SYZGB[ZTI)Q
ML?V:97++Y#Y7T^4R?&E]P*SYPG8+"!\NZD1@H;78_V]?RU@-WX^[O3JTJ7A'
M)M<YSD;T7O2!><NT188[AS@.#CDN$U*,T*15-(32I16"Q:(;,Z\/JT_JN"Q8
M?7*LCFBPJ&/MR03$!L J4<A9$^$W9QD5/$CLLG50H+IH4%W4;?4*2(L=_U"<
MCG 11A)HQ-PC)@/8\8[D5JA"(BJM"]83EJ3,N^IP9Y\"U;*K%JC.#JI#+C?8
M.AFF!J-@!,V%'#&RR4J4$E6!!"MLTDLK5"]ZD\07GL;RAVUVJG_LP7%\@CR6
M<NFSO_1UQ85OY%H!L=NK.K8W(BC\M;MN)SIJ$UHS:T@0V'+8](WT/#&;0"<P
M-,0XAJI^RU';^SID?Z/UN04;^D$^'[AL,9?IK6:W3&XPO5?8CY1=?J)=?F.X
MT6:4E&AO*8HI@CHNP7HV/C+8Z&4B+DKG6 ##F0_W2YKEL5J!XGUEU1D1.&CF
M"18\<F:]Y)(;)KA+@2O[\%/O L4G@N)0\\? O69"&$0X5HASGI QH&Y+T,.E
M-XD$R996"A#+B5N9W#*Y97)?ZN2^+ONL=EF$JMF+A\4FF]PE^WB3;'SUK[]4
M&[!2&]=5P5BTO\FTO\UA0RPQGULO<I24"@C6%2,GC$%<\X1)(E98-=H0*VP_
M[ZZICS?&"@CG <(A$XPQS*()"@GO">*&8*2Y48CF)0V&2\'L*!.L0/ Y*UQE
M<LODELDMDSN9'3:J*U^Y\G5>642E7#D=49FV=X<O+U:^V#@!+8W8@S_]&_LQ
M77<'M3S:550N?4&7OB[7Z?TE#U^[)[7HX65RG^?D3N!^Q)%88QS3G J>A#*<
M"Z=XXE(:PHB8:@8%[,V76W.I#3<'MZ4?D:D8)6&"4N1HE(AS$Y!QP2+IG!<X
M)DYY71L.KBJNRT6#K[8.R\@8C2)R[IC%G#*1(I,BT&#I5+,J'@K?@M")$#J4
MGRAC4$I*@IS1 G&J-#()8X I<0(S)Y7+IWMLX0LCO3Y\+LCV>D=QH:M[:VK^
MC &=Q4Z[@'9"T(Y(5C18*BQA8\62&\2MDL@%:I%C)!H24A"672C"!;J+!MT%
MV5H+=&</W:'D1<49=UA8I+A7L.,R@RR+%AFCA)*),Y$3&^8&W5(X;'$+AXEE
M^HBZ8719E[)AQ8%4)O<%3^ZBF@^E%-$3JQ[?AIUQ!(.A[SU'W"B'>%"Y!G*D
M2.'@H\D%%$R.(2R>N(6#ZI.:"P6J3P[5(:^<"-'IA$4N/A01!V,> 35+9*V6
MVCOLO>9+*V*XI'"!:ME52RFB6>%T5-4PGPS7."%@9;#FM4W(\*A1DC%8YHP,
MUB^MF%**<^&0NJB;:D'J5) ZY'<32I,8"$9$8 M[JO%(V[R[)I6"B)I*6. 5
M/8>#KE<>>=EHM]"4HR^G^AZS+M<?INAW*Y>^H$L?4$R0T#KP<[$[ 9V'A_KC
M3B>V_&G5W6]W>J@7.X>5:W<Z[9.K'O37J\P43VF9W.<YN9,8S-+8*(R..&&N
M%-4T2:R8B(8(!^;4V ;S48IW'X.W6Y=:QNUGXFYDN)DMCJU)U?#&VHC6%2G%
M;%T%,)(31YP$CRSG%%$:?  3+#E%EU9H261?.)Q*EP)5CE&B'=?*&DUPT@%'
M;ZG7T8UM+A><+AY.AQS0SDLA!4G($<=R6&A 3EB)2()%QS)QJO72BBA1H0N'
MTT7;3TN,V:S!.\(KK4,,+C><B8P ?*TQR%!M$(G48!V)4DZ7\-"%Q?"B[;4%
MP[/'\'"3"UA0XJ0!W9AIP# 7"%A=((>%BJ#]:.GILXD3?<;.J8-VZUO?-Q6B
MZQ6O5'&<E,E]GI,[P0[L? [?8)H3@;E@V@4J LEZ=5(Q>5>\4L]VLUT?]DH%
MIBS3S"$7&$&<48Z<"P%Y'U6 5:91NJ450DQ1E1<-J&#;Q(!SXSZK>0K<*D6(
M#-[YX$B8H,1I >KB 77(+64L553Y #IQD@#4[$A6R2  J?,V<.$5V+6RN(\7
M#J>+MJ$6DW;6X!WAEN*:>PO;*:(D!<03Q0C478&44YR[@+WTQ2VUN!A>M+VV
M8'CV&!YR2\40&28)(^X=;,%8,F0EH%E2QDBPR4OR?-*77W(#UD:[5ZW%W$S-
M]F*H;+<?,5GZKI9+2W'*4ISRCAF:I-^CP"Y1PQG16G"-J</>"AU<%$19:O3#
M6Z]>$MP55@-2N^2TU>YPN\=SW0"TAK+;3[3;CVC]HVCTA+F$$@L.<9U@KX_*
M(#"SJ6>)!&[2THH>41RLM'Z<9P]6DAB1"1 9 P^,&B4H#(^ Z@Z*NAPGLZE@
M<D$P.=P)R'F-F0\H4LL09THA1VA".DIL*/P-.[*T8E2!9#FK*Y-;)K=,[@N=
MW%>>-;IZ<%"ULP^Q:L7>L\S[+/76"A^5R7W>DSM)4&]DEGF:M7?%@[*6:PW*
M>@A8&V83F<T):"[)=.5?]7WCQ2J4(Y0I&' ?AX.-G&/1\XB1B$(AK@1#SG*,
M&(XI8:\=FVM<;X'QW3!.6#GFN# 8)^Y9L,1RQ22/@0OXCYC-(>C#85S@.A%<
MAT*.%/7<Y&(Q6/N$N/4.:<8#BDY@[!.SU(:E%5* NFA 7;S]ML0KS!J]HSHE
M.!4U]Q)I)QGBQE-D-$L("R(C-U1A[,IVN[ H7KSM]@X4%[1.B-;A(FTN<$NI
M08[)",JQT;DO@D<L*$]%]#1:/)?=]AYOFVMW0NR@_CWO&'Q):!^[@UAE-/TV
M08#&PQXTULV#3[-S"F>@5MWV03-<?_"M++)XB7K_N66UIS0)"TZADYP'3T$3
MNO<\^)P=MZY';A9.G(@3/P_'8(3<$X8&BY+CP(A<)F2B%2@9K23&4F.N)HO!
MF Y IJOP%-HKM#=MVIN"ZEAH[XEH;RC,!=:#P&9E4*3"()X$1R9IA93W2E!K
M Y%^HC"7PGJ%]9XKZSTWK]?D!TRE\_8C^?.FVBAQM)YYCAC-J78L90<89HA'
M);T-WII<P(V]H7+")B*%1PN/O@(>70B_8SGAFP%5#A<5\ 8'GPB246O$753(
M&4Q1) H'KAVW*?=%TQ,V1BM$68CR%1#E0BF<8YZP%FWSD4[*X6-6XJ3'C"J4
M-,Y13=HBJQ-&V'I"C"%.^%Q"Z0V6NM!HH='70:/S]5;.F% +9T[(F4.'W<9&
M9CC#2 E!\]$.04Z:A)B"/Z=$K.!Q:87B80M],9V<]1GYVYZ%+SS/:;@MF\3<
MS"4QT\\D$<OT/I32V],WZ+*^,WO#7JP!K$UJMWNM=B\^2R@<Q/]].MW[$HX<
MY7+O^U_?87LG6VN;&+Y/--9 K+_\!6/\U-P[A/O6&C] Y$7CRS]I\VSUI+'Z
ME3)FL-8*64QS69A(D=."("^9$HP BU&;]:_^%'UJY\7=[_6.WKU]>W)RLOS3
M=0Z6VYUO;RE0VML.?/SV_-II2X0>2QZNRBE;ICQ+YM;&6O7_536;5K\T:PK]
M]6V(X;C&8W<0/M:*O3<5?%HW>,PMZV:2EW3Q%O4#WS5[()O^WO>"=[A_]+,=
M[YVCR],% \R;(C!"-V;%JU435%V^IMN#__0+V[13U7^'A9K=Y7G.W?NM;1#/
M]^UN+\_.-FS,W046Q/-Q=O,XGY?(+5=;[S<NF,!?5:P&5[S]Y0#TIE^O3__8
MWS+JB1=[_96-9D%6<OEZ!N/+W>W=KW.3T^L;$ETV]8;TBK6.[S\$:!V&4"&Q
M9T@J2G*'(HR<<Q8)*8R,7@;A6=_$:K:.8UCMU3:6]1:G&+027'EODA0AAX>+
M:*GFX:%:R@[ VQZVCS.(.Q<6$X [==J'-6,T6[UVS=(GL1/?W8#R-0S!)X-!
MUP97?VWO'?@=U;;T$X!O/+[->@:5ORT(DF0FC*45F_/'JV]@[V;^_<\$%KLE
MW!&&%8L\@NW&'-88OB!(24FBR0P\GPKS>SR?XS00?V^[^W\<M$\>4@#SA;D[
M'\$<JW1K]6O"5 9-)*($^()3HY&-AB.-'>?8.,)-=E52,61V5R"1!S4H^UMZ
M;[_9"=7_'=M.#[0!$)^\SK]5XVV*!9BS J83SFAJ:#"><**LH=(JXZ3D6%(M
M[=A'$@683P7,]9/-CU\IHS$)85%(1"%NL4(N)8%D4 0HU6M#U-(*I<-!?S>!
MF9H=,#%:(&;5(4C&?O<"G+=B\]!VOC5;YZZS[%@O:)T8K=GTF12M+$F;-'4R
M8,H=CC8%G1B)3#C0M=2YXUMA,6F8;H'MS&%[MKGZ%6,G$ZP7"MI0Q(TVR.%<
MD8[*1"-+#(><(3U\[C?.=DI^JVPK%-0N&FH35_ MV)/H!9<<MEI%F%0VB!A-
M8H\(KB^HG3EJ:>/;5TH899I&Y!W/!_;9:Y^40\1C$;0FU F^M&*&SY[&W6O)
M\IB*\-P@F<WV3CP$,8*Q7!CPV4*_RXK?VEA;KGZWV9$'DS!@*Q1;(4O;]<K2
M'=N#P?;V;:^R\-#NL?L>?:^"A_0O> -?!E<?#?YX\:6GE:U _%'/_GR0 FPP
M!3-&X("QX#9X(Q))SC"@9B&B-5\W1NJ]YB84!Z6RWP]:(8Y$WT[[]RN1B3&L
M'7=@-ALP%D(W:WD8#X;FM<'P;$-LK7T^:ZQ]XXWO'PELI)QP0)X(B'O&$,<L
MH1S#C:CP3%+&B1!N5/)SY0:(/&G"%MI'90L6H"+T')*UY"[BJ<F,3R;NQ?^A
M_=D\/#ZL#F+K6V\_ ZT'WU"U_P4-Y&2_Z?<S1#-X]_MEC:OV<2=#MMT]AC_"
MI.;)_M=VFA86H=D[S:R8CGOYPR$Z\("?*@& 8#VZE3TZZK3ARX$C#DZK ;H;
MQX?P*OZ&ALPIIU1S9[C)IZD.,^Q,5" N3A(G1]JSMV6L?3HGO$T+HX01DVOX
MA*GT[\)QYS3:SFM#)+Q+X^0K6*"@UGB/@HD8<08 -$X+9%1(SN(D;))@A5[
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MODNGE]O'/D?5GU8#OYTW[_X_>W3\Y_;Y!"]T#&)#BUD\?,?]8:=R[0UBUXX
ME']FQPAB&R1_?7J&[3".O7]_V%^G(S#=A41G(%&/A='$!Y(BYTX9DQQU :Q1
MS)FC2=R? 5).*A;%L"_K;@;L+0LZ>:02CL"OF"%K?43:61^"$CQE?E7KFC:^
MG5)1E@K."\['.*]Y(8R0TIL44/0"]*B@&#(L*,0M\SQ2HGB4#PWG3P21";1<
MXBGP<2(\$>\TIS;09)P@3N-[-%\*(A>'R)J30B23?1$"*5A8Q(D!RX83AX)U
ME%O%?=7YE*UC\W"JM!;)6W#^Q'%^A0]#.LVH=1)IG2A(7.N0%<2B8+@2T?&
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MTYP*MOL>8[B&ML]>?E*::,N50YY%AWB4!)D8*")8$T&XIY:0[&S5E- _FU5
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MK40T:9-<<#RQNQ9$+<14B&GYQ!0DT83 'C8!<\:(421$%EGR*B@9^:(UID)
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M''4FVN_DDT$<'H.V#.I]]W2]E0;]H^H)GV&=!W"?2OF%R[X?=OSAN:(&FNX
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M%7\T/IV;'!!D9TW_.(XEP[!E;SB&\.-CB.&E8X@[BX<KIO9A)Y8\H,20.0(
M%)%4X!2\,)%[RDS"7FI'?-*,LT@GYSX*\UL" (Y3?#[>?[D;U2O8@B]^[L"]
MGQMPZYOM=*OCG_[XU.O]J.^_3G9;I9$\C+B .YX:C7-(CEZ>[9Y][!S0MS\.
MZ+^[[7UXSOY_.GO;'X]VMSW<XS-NP[@_[N^PZ1R2@_W=L_;1O[]\W'[UY>#H
M X%WRCDCO'UT\+U]!L_>AG'O=[N[7T)J=_!I3C'>?8_Q+KQ'^^SEIV!<2!(K
MY*C/,=7)(9>T090J[I.@AHJPMJG7):NGD#2LPFPAF =!,#$1J4,TF ;#87L9
M;*T 1G'"*9:HF22>*2QNJ8M;"*:!!(.G"48QXJG0"1;3&L1=9+E]LT328.,E
MDS8JF@F&"%,(IA#, @CF3I$KA6 >",'0:8(AUF*7F$:8>H$X 8(Q@E/DG>+1
M1*$ESW6CY#I3K#!,89A%=*[#RC''077!B7L6++%<,<ECX +^3\Q<VK\P3 ,9
MAD\S3+3!NJ@%\CQWS*$LY0:3"6&6%-C$'JN8&]?I=;"0E\\P3\25M9V3)">A
MN!<<6/5\NGYJC>R/)]\P=YY:( OP^5Q3"^0RN5U<PU_TUHZCO;1O?Q2>FH>G
M3NN^'$=EB,('A)6@B'/'D//)(,](BCQ%X:(%3:C>@&3YS<D+]A;H#BG86SKV
M:FZ.)*W56F(4L0J(XRB0=DDBPBSQVG.F:*Y-5K= "O8>OJ.@(.[^$5>S^[60
MD1-J<B,\@GB@&!GK/-+!)J\\YT3(M<T5*.1/$75S-;?X?>NY2+REXZ]F%5M.
MF(M"(64T!_Q9BC1G^1]-G0HXB$K;Y'JI(J_$UJS\RK($*[_R#CXA47E\FNQC
MSMT-QP65EA^U=$.DY>,KE7O[6S9;&5E%M-.Y"@*;])<64ASWRU-1JGKATSUE
MDL9!2X&12,D@KH-'UBJ-,"9*:&Y"M./H)ES74FZT$V9%RE*/#0M)/4Z26EC$
M5"&I!I!4K1<@9L8%$QG2,=?PSET!#0X$12^P,$IY9FP5(<7K!9X*2162:@9)
M+=R96DAJE215Z\XGH[32Y<;.5B(N*-!5(!3)P @7D<#2^DF455&E"DLUE:46
M%KE56*H!+%7KF9>2<EYICA@E%J@J1.2<LTCQI%W4AF@2JD@MH1NF2SV:>B-W
M3#Z?5 *\M_3S&SIH/8@#MIDK)I7I*=-3IN>WI^>)1-4N/$%\W.-D. 26SQ/7
M@Y?-]:1+XOBC3XIH4N)X&&L31=M>G+:]4S]=(4D8X6Q GE;]6 -&!A/X57&K
MC O8$E)RQPO'-/ DI'!,,SFF?CBBDH"M3%%P$3C&"8YLX (1)@21UEN;8DD?
M+QS3P(.,PC$-Y9B:'L-$,E0%)#7)S;9R\P5&-(I6@A;#H\0RE0SR0C)-/(<H
M)--,DJD?30CO=4@"!1HMXBQ(Y*QRB!+CK4_68%V2R.\;H7,FD:\WP/OU]/*#
MFI&-?K$_UW[_73SNPVSV/K^$+XQ."QW.18>[==\1:--4\YB0U[GY&C,!&2P(
MBB0)D'I E%R77/6&(;,9N>H%F8M$9LWC(H,($6Q>%)S*X:@^(J.(1S(HQG2P
MT3%:,MF;94ZL-).]X'&A>)R6E)0Q$JP'F\%0@GCB%FEC0/>),C$E+&&&E#SW
M!DK+9N2Y%W0N$IUULYYSK!*(1Q52/@-U@$Z%$[(B)L,M9=0W+PO^L9CS=\\(
MOK\PE3FZ"#ULQ^P\+]IL4G\8^<+;Q4V[:#Y_>T5,BY88:VR0#L(#GW.*#&8$
M^>2]L["D(NE%9PPW-=.E\-6#YZL5I@X7OKH'OJIY:T 0)0T""4GG,.+1"F2=
M)DA&+Y2VU&"N%YT\7/BJ\-5#<605OEHM7TWK5Y('ERA-R&DI$:>@7UE)%')&
M$.XUT2JPA><1%\(JA-7T0)Y"6(T@K+J#SUCK HTH4,80+*I'P%(.*1R<L\$3
M4+,6GE*\*,)Z,EG%V['7/^KT<EYQR7(L2:!E>LKTK'QZGL@AS#_5+S$@"Z.R
MGV,+5! 7!SF$\N+!R[#5/QD-1[:77_IRP&55&>7)ATA>JW2.I^^^#R+.EW%K
MO(KM:A'WTOOJX7N_EJZ4L5FPSGE0/X2(S( A'"W"UEG$.0$CF5D"$ZQ2H,H[
M+L/:IEB76)6PC^9A<^%.]X+-E6&SYG /5G(2J42&2X(XPPQ9)3%RV)M$D\"2
MN3$V&Y^0^A2QN7 '<\'FZK!9DYLT81-<0BJY@'@D'&GA<U\@ Z*2$JO3!)MS
MNFH*-I>!S87[4@LV5X;-FA]5 M%:*1+"1)LQ-FUP%!%#@O;<8LQ5QJ8P*]!I
MGXBI/CY#0!7X6O&_)YUOL*=[H^%S&$C??VWUCR<UOWIA\I?.<'A2A516_M96
M/#KN]D]CS);]<>P-*U]LZ[AK2XIC(^WWR1%1C?"VPI>3X>@(UKX0VUS$YJ^(
M&#364D\U"CYQQ(4 6X &A3#3RF$9O',YL9O44QF+RK%R&"['5"\P7#@,:W9Y
M<M@8IB,RQ.<B+DR ?@'L:3V@4/E$A!$9AD7S;R ,EV.5%Q@N'H8U$UQ(G:C"
M( U=1+","AD ($J819*M.);[1!!:\A4;",/E&. %A@N'8<W:]I9QXC5!'(P*
ML+950$82AL"TX"0FH0R/:YMF!3KI$S&U?_]4?($=$>A5$1=W"D9]Z RWK&/S
MZSBN.!D71WN?Z[:XQ=$9QL$(D$PC'D % ;W2(Q,(8 J+&'+M$K&NR$,/+B_8
M7MFQ>\'V,K!=,_"9C=:Q9!!CN0.=-0PY1@#@V 2AA O"FPK;5!1L/S9L+^O8
MOF![*=BN^="Q $;F"CD.L.:2":2MLDB8@(D#6\4G.\;VG$$U!=O-Q_:RCOT+
MMI>![?K!O]6$6A.1(X[D"DD!&4\$<BHFC<$2BXI403FZ>3KY+<Z*R0C&WYDS
MA>'&!*O0^39%)"A?_]P<7^7X6!'*MWJC#JJ*AW>^Q9]>C2ILX$)LP?GB+72$
M8H/.DC1VW!]VJFRQ0>S:/,H_\V9!=$-?X2VRPSC.)_O#_BK-!0LQ2P;+[3M@
M=CEP_;UF3Y=YE')BX;Z;O('/]^_[Z$\&L%GB\.4/WST),8QKZ1\=GXRJ*)>]
M]-(.>C#!PS=Q4,F0K:/^2?%5SRD@OM:=-J#=85 !.)+6<\0-Z'U@QGO$@Y5"
M"Z.$UFN;<W;>6""8%JL8%L9XP!ZA!3'&17TS=7[$@,[BH%^89$XFJ9>N%I9(
M@QT2,N6S+LN0L_"K5:![4D&B2#2G:FI*Z)^%3PJ?K-H+5320E?#&M :"P3SE
M2DJD=,2YQ'9 5A")@DZ)!*4\UV 7S'E87ABC,,;B?5N%,5;!&#6G5F I!NP2
M"H8(Q"6A2%OB45),&^<CT50]1)NE<G@]JZIHGWL_9O9%F<5[HF;P\]!%^'D6
M.F@]TY O3B7;H+R:/-@MJ=\?]?JC^""!V8W_]^[TXS_AV%$N 92''[]\/=L%
M .["]]JOW\)]OI+=_9=L]^S#CX.S_QSNOO[ V]L?T^Z7M_B3!7E+G4\H1VH@
M;JU!#F..E*6.<&FU8"(;3^,)>M?/JW4X&AT_?_;L^_?O&S_<H+O1'WQ^1H%%
MGPW@XV?GUZYM[A_&X?5.RM;W.(@70[&RB=8:'<;6,2QN/PQ;Q\#M<&4,ZRUW
M,AI?#W?.Y><KYH4?JNO]+_;-L5Z3WHJM7*-J?,O^\-=-7?3V!'Z'+W8&XUOE
M*O2M[_V3;F@=VF\1_@DMV)OVDJ\UIA3]:*-BE_-7W)SR68Z)IWUR!,_RX]\G
M72*JP5W"]61C\AQ$5\?2]TX8'9Y+OPO?FO 4_O45ZX;]_+[7?N4"&?D\FX/E
M"W&:QY1#!"[-UH5_\W K[&E/!0/5D'B0UJ ".B-!MZ>:8JFQ!FW?J+7S+QT.
M?G'DYXC<(-JOR"9XP^>V^]V>#M>>79J(HT[O?$125<&+\T[9YO^ZP;.I1:_^
MN=_Y5%?.YYM7.Q]?OFOMM%]LM+;:VZWW'_YZO[.]L_7NH/5B;_?-5GOGY?N&
M#+6]M__R?6M_#P;6WG[9?O]R.__T?N_OG>VM??CEU4Y[J_UB9^OOUOM]^,/N
MR_9^4X;^QX?VUH?M'1CEOZX8T;CUQ655 D;6M<?#^/S\AS]#9WC<M:?/.[WJ
M_M67_CRR@\^P(2> OB*4MMJ$XX]_;=2-_Y^]-V]NVUCVAK\*RL^M^]I5A()E
ML,7OXRI9<ASE6+)CRTF<?UPS@X$$F2)X %*+/_W3/0LVDA(IRQ:5X-Q[CB41
M! 8SO?>ONQU%K#H_II^L/]Z1'_4,'/69[^UXOK_R8V?'7?G90]V6K'5;G2WL
M255?:O:V^Y2LD_I?[H4ML<\6K#1]FGC3>*5)%I DXM^3S="$<;T=Z__O**)[
MB*=T_2$L:<YET4"U.TG5[.,3,>'@%.%<I'%1S4MQ#$]\.0:=_]#NSK6VJLX^
M@<O!KSZ=?;R$[P=@'8T/O5].C_9W??AO</0U_?+I_/?+0^_O<=^J.CK[Z!Q]
M_24_.GX):_UR>?3ZX]=/?[YRT.4YW/_B'WGO\[_W=[_^??Y'=K1_Z!R>'7X&
ME>7Q+''LA#O<)MB^-/8$%LB)*!1NXKD\5(ZK'"*UBZ'I-(L(Y9%P4Y*1F)(D
M"QT2N6','"Y\X3RQ!#B14]10Y5Q@;7EKZV4%^1[($ IF4>N(%LV2MACKF2CZ
MK&Y=1V_=;ABRA*5Q'#O$\],D8SQ)P$L+&*=1P)XLXQ4M^=!R7XM[OK=]\J>0
M.\CU#H(A6<Q!KLQ9!<X_+>4.@P$*?S@#0Q#G'4UP1XMYI7>C/H<RK]"<U=8I
MB)M\0LMKN&I>@N$)-V9@<DY$58VT*8M7S^B5?/Y8G-!Q]XX[%EC28,J.Q\4E
M7@HV,RZ_D@M<>OTO8/92,(0K/J\J;1;CQ?B0SJ4CJQ+"^BXN6;/M\HX_YS/0
M:WR-@Y!B+'BYLZ!OEQ/0#6 ,D+?9#USZ30US=W>L-_*DWI4%%P*/O%KS!?T'
M8XFWR^G+.&#*+:/:*QOG('' [9H5(TGW-;W^O/Y[/O_AT8XU=P+S5U[X_#LS
MRMK!BT!!D-[1&>P+[/PL/Y$4-[(N3W-^:LVNIVA)CJ_AJ"Z*\06L@I_"[P*.
ML$+1I=QF728%8N<G$!C@EX.DFUVCL)C*.X.$F<"?P7&>HS=>I',^ Y$Q11*N
M*A1 I946%=X#TZL@>';!;4YQL)OT[.64."X=:W#EYV-TW2TP#ZKF$7BSF5!A
MW4Q*+?V<$?R(HQCS#-X$7U)_K107 A1/965E<=Y<CDO)SZ<T+U'IR5GR\(KP
M2G,I<6E5%3RG2)_PHYC!4E'>ET(%',8@\6=YEAF9?4[/BE)OQ4Q&,50L$;XV
M$//W(F9]D..<LGR,FX_JL(#M+\TAVS(^ F?84+QE_@1$S>=E*0^_E.38?*\R
M? &49(07!H2J8@*R+9^<S<OK$<HXG$U8CN#4,WM,F1CC#<X+Q5E5'?D?R= 0
MF&#53*X1(P]P<UEF.)EAV-GB0%'G>.%Y@0H;7T)^#5XH [)OV/(4-F5\+4-8
M8W$E>__ 7U4<"*V"PCH'9<%1!--YI9E<K>U2YQGD;>$;.9UP@1RK E[F8U@Y
M"&TD;W %Q$4.U,>5J9/E,NZ&"^.S.1U+SKZ0+JW:D]8)G-/9#-YA7:4\D/^F
MY(\6NRA!1HU;NXZRJD3J!I*>3^K?]&$LHVK*_SO/56C0!D+)N9B@,6JCJ3D3
MH 'D2>-! _W/KFTD^S'0DS99;'P2+^R:[FN6PT49-IR"'X'4J:A<?B0F%WE9
M3%#X(JTV'TP;>T<Q@%JM)']#]I*K@&SIS+K,QV-4.==*OJLWE6P@?]K *!SH
M;R/Z>XW6@#P_/!U1&0%;4YD27*@R6R(7E27L*A+9!7YP,A_7<?CI*2W/*1?S
MF9)?<-9T@@?-KJV)O I%3C6#>RG/I\#+3IIUT,;>E _ZN/-A1UZ)[IGD#Q!2
M>07B4>GF;W<8OO/)[S6^Y4SG1MIF==]2 IX&S5+!3HLK[/RF?'PTU= 8$AWW
M,:7GL%WPI[*XIF-0GE-Z+=W_$8KYYIL\O\B!_07LO5)E6H3(1S/IWF(^9I;C
MV9COE#G.^1BC#5F>B/6-H(?;:3#N0$7F8"LJL8+.;TLHI2)3^PF[K(4I_JCV
MXE(9AE1=E:+QJ1W_9F?0\6D9(3E^'0@2-AR4^7PR+5%IJ^BPE(Y7:# CBP!Q
MXR<5V,U6P<&BD(8H_((N5&?)=-(R/\TBI7B422J*?X/-07VA+6Z5HD(+ %\7
MCAT, OS<Y(IVK%^+2[@_6#B7QBX'"IHC'Z4GFEIDO@.510$6SVPV%N?*$2C1
M\LZE75]*>N0JXX;&R@DM50SCM#'[8>E]-=5DV&Y=O&(":? 7]7AU0X_R,&EU
M:F7@8-;2027XFF/$OU$)O5"!&\IY.5>J%-R$]'$0L=HMO?*LYGQ-(?!6L,A3
MU+&LIC44&2!:&1 B2O%S_&#'^M!0+WP _V-"0OW852?"U7; YA,=&IOI8*-T
M\TL!JQ(CX!4X3Y 2A@S&^1<@YM.B2*7[I=PW?7[2PX)5SDMAG#4D=GD)6@>L
M-@QVK#TX=_'?N62LD6'-^<2,'%=O.%-N7$GA/92/6&\!T'Z5X\7R[D <BA7E
M,PUQJ.W=L3#<@39656E>4(2D!;+V-XVECF<JY'UJYK' C *YD,UG<^SU>:'^
M!D?2V;J1.C<IUX':S1NTQJ/KCJ#RC"4!, &:-Q4"!Z?7[R90CP*-@=C'IRN9
M)+]S3J^E)2]WB DUKAT6/1/22YY0E#OPR)%>')(%SZ=2I[=6S?.2S\^1:F#'
MY$VEP-+/0#JU5"I]+D,*H!QP^Y7SL?*MME])[VJR*#&.EQJVDU&P)89N5X'3
MR7U32VTR@]%U;9T*"NK[^D:Z4='?EMEM^LAV%CZFE_+4%(G3EMF%[SF'4Y3Q
M#U!L%,0E> J2^90X2HNI] AD@%EE>^#8X<5Q2!Z^X_]L,,S/B;S$CV(:>'Y$
M>.PD;L)() 2+DY0$//Y\<#.L=YJ)GS_D,]'D0J[?*S.T**];P=969LHL]9$4
MH?[@!-;AUP/G[>^?8R=R! M<FV'6BD0IMRE+,EMD/$MH%F>9'R[#YX)D&(^E
M330!X8LA/M3R&-E3GF>'T,Z+B9BALP<,NYD1_W!Y(LS%@ ,\08DI+6EI^A@#
MK6:IVHJ4W"-_UOD8@88V6"X[UL&DHS<O3X7R^GMWU5Q8/U/]51MQX'DA=TL[
MX+]S&9B2$"(I%N /8_-[!@=0J!4J)5?;8#ER=S5'.; 0LFJL* FM4EZ&O#=^
M FX<,C^:$G+E&(42F545<]@O<$_@1S 4P8(0Z7-I;5SD< @Z.(OI2&7BR6AT
M8YWKOU0SL*=/9J?&4C%&^_-ZH^3BE(29SLMI4<XJI?)&4M'AR^!]T?)05TFK
M!5:%QC8*6;FRT<+*6L:+,K3T7:3UC=:)^2JJ8!5*GY>SY_+'MDO:-48;D8P'
MJH^X>9DZT*(8H:7Y9V#85)DH2^5SGX-^R8&69F7.VU[(<VE%H6D.N@9C?"J@
M@DI_A-_#M_PR*2['(CW!'9)/;;SR&OH&BZ[ X1O3CA9I%MJ2^GJ_].Y>&B<R
M/\>S0*,1B0U-EE2U8>OZ)=+UUZ96X\DN>8PV-I2!8>XG2XJBYU6M4;5"7?4,
MF7N0-T+;3QG N/A\HK1 +B.GL&/(;68&K(EQJ$>J$VZD&B8<>)UL:)UO[<48
M7.+SFF5DM$1^9SIGXYS+N!PHI%F3>Y"!+A0.&*;1:9U\)@W1J3;,=?)DE>_:
M26IT!$6'O^$Z%9>3^;IFSVJKGXO6R\GHO$[7-*2O5O*T>F;)K:OFZ&QH![!Y
MG:HO_.J I0Y6R]4WUJQQA;45O.A1K&_7XWF"HP'+WB1XV(4DM!'=V# SSZZ_
M'\;G_G+.[I*D<[?AH<X@OJF%R-:;YSIMIR/(2EK-\UDW9X+,IU.8;=&"'M)B
MJAKI;T$U'Q:2(W686NDFH'BP+R6D*BWGJ)TG<]2J(*)*3:@F;RISJPJKT62A
MK*<U&KEVOENQ]Y_J:+VT&29]<V(1;#R BVMP<;@:7#S@A ><\( 3?GA [[\6
M)[P<8WD;9K*'L80G>L)WTRA..7CC&0N2("%I&+"4TO!FC.7#:6OI5"B]IN!"
M[=RR)8OCM#?94G0RU%C*?U16Q'C1SV[ 'AFK $%,)M"LTRI2&7>L6&V;KM3F
M("G'58&Y\3F*]1K-@45+X#G OP85A>ED=.6D_\%UPK1QW;)\C"[=>"Q.5&1<
MYZ)4*E_Z>44FO54TD\^GRH$5Z))P\-&TF:_WJ>\$&*AJ;5^@D0_^/RAL:S[)
M:*[<.S'+C?,K85YY,:;FT2TD"T8$.UY'C1-;0([)1*PQ=>I41,^&ZJ^^M6!M
M_=3KWM@LDA%T(2$(9G'2$C2GLBP[7'LE"T_ YR]Y"!##LI=OP^14$5GW/6$9
MDV)BRSWJK0 #L^**8D@8S5)K=UKF8POCFR.]K__9L7Z%VUA[&%!0[A0&6FL7
M5T-V&D*W7AY^J!?0Y.5?C7/$@5CI7*5)KJ:Y9 ]\6"A/^0B80G9'5X_'VY2"
MBQQMZBF&I!1P&!WXZ52 #X$+;-96>]\8+JUD<G%7TXU*%)M= ]=+TJ@P"U]^
M.(K?LMX&_38?7^L%[@%?_D&YM?O:>JI_?F:Q4D::I'R8*>A"AF:W\B%-T.<$
M%@ $_C(OCHX%1KFZ,&]T'CHP;^V(OX9= (GY'EA7OI0ZDRXO[Q7G>3FA&"G7
M3Z[J6^OOSV<*S79>I @HTUS37H,ZG50'_\UOK^:(T8$;Z*^LVF#EI."*FL68
MIZ (9<)((;T/\SH15^_(\E,Q&Z%2%+V(!'SVEL^*AH)V.>9+K%^!5F:G'#GT
MS2S=J8\(G;0&R %T;I:#?X ]5EEF)9<_3G),"FLFVP-*!\*8Y+1^;9-E[/&B
MNK$FA=H%,Q&J"V2 $\S,*TJQ_I*%IR;-I_:]TDP2XW:KS+2A<+,?K73\-Z>T
M=VY! 67?B%^_43E_;]S_.GX\!;[7(?(FK&7"S,JQ;\GU+GE.YV4UUU%&=8:K
MW7/41M?RWR8!(16/!IC""NK\MQ!?6I :E<J#ATMX,G*_2!&Q2>=270!34TE_
MYMEPX_+Z<: +Y.93&<=M@5);^*H.>$]G"%3 4NZ8%.\8.!]A/&YFGY14JB'U
MIU+8*,OS2:UDBZF)+'3OS"2(H#$M=%0*Y>%Q25/0(.47ZVV6Y6@3X56U;-17
MFL_J\\3[@7-D##A<[&*$:"DBTM( A>4?:AUO$AZUXLKA#Y/:NC#B-T>BF2OK
MEC76*;M6>]G9 T,^1<MHNQ!MV\X$UX&^\&_RG+1-@ALD9EK$M&J/1%F8\I^*
MCE4"6N%W\DI>9V[?LTTJ1 G1.D1>OX^29-.)F)\7O."(U[N@G -M61CQS\!#
M*EK6;]<X6T(W"B':)YU.\KJ-_;N!+GK:B4X,7\MO7-*JMYA,I/(-N3*T)M8^
M$,<E\(*)U%-$-T@8=:6!4/)['\1T5MM-KD1;"_0^T,^H%4!=8(&Y%9 %;U6J
MI6-*+M]$O=$]HTE'P/7K'Y<&)+RK++.7!2V5]8#=%/*TQ4G'IS79U;C,!EAV
MX\$V!ZI(KTY[*/Q0<5EOMP9W(LG*,A+Y+I5D"K =$8B2CI1;,]-^F*+7Z1@M
M;$'+<2[_KGLN:"B*/%%)Q B-Z&/B&D.J%)K):M>OML72D89@J*75-JM>8F^%
M*LO$),^=YDQ&B*7LE^LVEH1F-5FJTGKK^LLEMKC0F3I0.=+:,J#,[4]NM[5R
M"P<V[1<:+=&]4O[!1BA)G@-%&J6*"K6=.OY)HI#.YA-EE.FD,?J'9L*Q:"O;
MKE&O#79S_"!+E3]7H^=K'2!M/@DM[TDW_,*O107F'EVL[VPKP6DC;]2/-1H>
M0W5SE&,FM)!W/7@FZ<7(]!X2NI;I$M:.Y 2TWE$@ZJ\B;2YMJQ*S'YKBN^ZG
M1-LU^V\R^ZV_&*\ Q1WBF]H@/W-*"/=< !+#'W5T1C*)Y$O#(QF(4=ST6LVH
M=(A:/L(/80WFYOH.8G**&48$+UGGVK9 &)&P,\01 6_*W'5[7[IN6FM+I,[!
M]'PV5U5O6@"LM46+;/DP,>1=;=>"W/M3LA1PXRZ0) KQ=R:;>YL(P7CECS J
ME[_"7V)\1B=?K:>S DQO8+Y)SA8#XMMF"K]$CWZB[2;/<2.9,C>>JV;]):&%
MJG9BC<%D.'Y):E YX94 DD,!MWNTOZM#>JA6?MG?K1T/I9*4':'5C9(PYN[2
M.=8!O-9&6S+VK-6YDL82%@17!=;YB91CKH,_Z<"I0=CHRASXFKP^/\>:,U.6
M(0$+J42>CK$:P91Z'A? T @B-;A 8R69O9'O9C:FNR$KS::Y+G97!I#<#'TW
M$PWO&(3[!@6C8C.F@53]9WAS8]>A=$E%Q<N<U5G>K2?,@TZ0Q>V0)6UH:36%
MU@3Z(5<6,9U*+81"AN]83_M_?F8BT]K:Z=[2&%DZXM*X.DVP92FUS%L!YPZ]
M2H!2US8'A;ZP5G0>@*R196YB$MIGD/[S7!>)?V&)FFT>!3G\-@?&5@&WFVCA
MQD#HX8<CZXV*?A=2D[XK\PO\K@S8/86/-R8#M-RD+KXA^$9/2J'NL.+<<5VM
MHZYN.NO;1&$CPWJG;#U%63A2@O"9\II00$F@ ^X2TLA/YV^D^[$[/\'42+W?
M1L3)%,[BIMXDUK;$QCB8C*]GU'I*KU8IYP<C;5"\R<AZ#?0@_?IW':.YTL1I
M/GZ&>ZPPF'.M8/.9A"_J8/=$B8MU%>Q2V:$V:Z=9D^**2O-$S01(1)CSZ3LJ
M,@A07E<SH')T[U$6&@Y!7:4/0ZZ^$W[V'4E^:D<N30!?AM -O=5KNJ,^'/58
MO/,R=WN1G0&A= -"*1H02@-":4 H#0BEQX)0NA5QU$,H<?B8B8ASZOK$)3[S
M(L?U.7$"&@?$"Y<BE!XV7'' 2@ER?SJE8U;PG(\?7;CB-W"LL8)*^8?].$13
MWK%@+H%.OVX93)O%(Y:9WV8SC3LE'?G%A: OWL[C5Q*64[9+,II6=SK,^[/U
M-']6YU1,#K$N,3>FB+2AZC".%SV'K]WA>[[\GO[BN9B=JI(#+'6]X0L7SVXT
MD[I?\8G*,SV%;U&]8VU7><6W0MDMH!N86N;J-8$ITYFH#7?# R\[>75I/'92
M8M7&]F$-?>_X=+-E-"#?HA,SDG2G [T*8K%(.#=X5RI^=2DQ:(A<$FEK2<LW
MJ)T,7GIN=8NRT>8$-%I).J.Z$&CUH;>1,8O;H,O"T_9&JRVK@4+'FS**CK=5
MIIIB"7SA803TJSDO\XH^+I'<S1$_K%#6&]C0A!;"DK?7]6/I1M04 O5?%DNI
MOUJ@/-T4#3E?YH_6$+?:.>[O\D+$_F;!N%P@_A!/>A-)N25\^+($=[2XR*VG
M8H*E9IEX%(F=?@B/]G;X^D=$D<S>M7GP>L-0TD(GP;48Q5]DE'[<>(UP\2)A
M7O\P5EGO+1^>25P/J.U0?%$\PO()W'>CY.?#03XZJJO#+0^IM_1>?IO>6MF&
M1!%2KQ,)RRB)O"R)><()]QD-N9_XOA>3) Q\P71G_%AWQG=BWVVW)#DX^J7?
M*/\U,%"K+XG";U6[!D-Z8% *'Z>R/3NP:*<E"9PHQ[8DE^#G5V)2=R1Q_FT=
M28YW@[?''Z\.C_GEX?[OY&CW,XW\.!998+LXJ(#0.+)I**CM!$D2!S')XL!]
M\@+,D"7]2=:P2WQG71$+AL=F5!8)'M'((2EQ&'&\-$[3**19R-TH]ES?'ZAL
M.Z@L./K]L^]2-V4)M5,G)38A@MMQQAV;)[%'A9?Y@6#?0F6^LGZ;)M;LVA2X
MK=;HJUT-[[$8P1CJV8QK:.IY$>@O$86$D)BQB N'TX +."#?<P:NV0JN^7@)
M7,-B)V99Z-I!X$4V]O"RF>\$=LS#U N\,.8Q<$V57RURC8E@;)'1=#-4+V]!
M]4SCE7W3-O3AS5+5==:4A3T&=^V0EK";NJ)L/+D>T_,^$F"DL4OZXV?&5U/-
M]A F>7>,F):+[S)8=2EEEWYX3JW_I>?3Y];'Z5EQB@-V=JPW;_84F/CRM$#4
M:7$YD5EZC5&]'JU1+-BN:SB">[KN"#APE*!NT 716'*C"D'AM7X1K#3Q?D^I
M#V-9SR=ULZVFL9K&W$I'L%5-:;;6;!U(LP(K$N]Y!T>W;E^G*+/^Y;!&"^*+
MO3YGO]YQ+_W8&R51LGPO6_NQ]CX^!A[J.'&'12I@HX[_,FQ3_T&!G_2OUL</
MO0N>67*?S$&:LQG==$K=4_SX0=UQ0UHZ!$N"\M,YY@:J=<Y=@L8[1>F2W'-9
M-:4)NMX(U1$LK8,]>;58\+>R]@#[GZJV/A.L@D&$AI98T4CN]R.FCUH6W! 2
MJJN:KY>)2E//W$C QG/O-$]86HF]XENWG_YEL:16>DG<J_^F-QG(3:&R04;C
MKT>R,]T8_E+UWU\2^O?:A$(]O@(#=D.[.7&#)&8AS\!0)I%(XR"+'1ZX 0W
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M+VFP+!.MZHNJ<'[:,23;8?#.ZRNS4F)N02#)-+$9>2_GAJM9,;IP4PG1;H+
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M-'0V3U$2M C;*+5^?$@RLQFIB4\Y L(US_VFQ\EHOY1LJRFW85,5!6VKRS5
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M@-!SX4T81(9%L)T/;-#Y-+_ZU_4/]6_M'[I7CSJ0>_E6X>K5@*GM%F2'0!E
M]H7]7GL26[;JE5:\FR01#HQ5R\=>OG((P=-?%"#6?/!,AN;*G,UGK;HW?BK.
M>Z@RB=X!M4AG-;B^U0]-6O83<8D&2B'[C_.F(>8(S/;Q? 9J4 TDU[\]TP8<
M&&H@:90O68$\4M:LOLAXE>"(]%8.+%Z>&+S"RK'TZJWA:EQ6<]E.ZQOPW$G'
MF5&-#T&^@0R<RZ!J\]ZM%S7ZN>E".9).>KIDUZ7=9[:\[@ V:UY>UDC-+@NL
M93U1-7NUGRR-&[2,A38'8#^\]AO<V#S3WZ1YYM:3==_LE!C)*:Q,4="JW1I9
M[1/0^+54.TE+.I\V>RNA;'B&*\(*]96U9C>0\S8%F<#'3G<=Z!TIR[$)T^3F
M3])HJ->QQ.0VNK!5CM'"U'4A=R-5NFR6K3N$+5NBVI1ZB$V])]WE7"+3F"VY
M;EU^KN9$8+RI08S7'Y?8LPX#:35:7$(!E[[!(R?&W,A@(_PV);H5!-<3@S79
MU3+;'*0$._5;M^6R+V%1GM!)_I7JE WZ]6"\3#&TX;KM7NW@@TZ^E//IC*-G
MBA7W^FWJQYKEFX%S!1OK\^OV+=A@V:I';)G#,>>R@US=D;O*,=8AV=SL*I)6
MW8U3"6JQ6..[)7*C>:F['6C+VATMZ5BN'JC!M<U3._NE7V%GX2!E]63K99L/
M\!M3';MNO;KD[)O>7H5(.S#@Z70LM;%IU5K[U7A36+N:A=)M?+'Q+C7PO9;X
MK+1NEOY-[:UW-M349L@-U99+O< ZK"<F%WE9R'PQNGD+7<V6=9&=%N-K?HIA
M2N7ULWP*\O,:*Q[K<S' ]C:YU?WKOZ\NV(@"E78PKM+6J(<!3]?!T[D#GF[
MTPUXN@%/]UCP=+?BX_K]WIR(4-<7+N.<Q"%C2>2'(6=9XE&2,'\IGFYYY.T!
M:[H[ML2JT-(#XLR<1+9_;E>/R4"#TH=U+V@U4$]9EA*^@UVWM.[/9+^A]GNJ
MV*VV3!3<3'64_K48JTS(FS=[LF^R:JW_90(&/MQ^U+^L/70%C8-Z2L7>-<7\
M86H",,_D%!]#/VBTS"N5GJY-'!W,DKVM7N*L'>ME*;M0MPOI/DAHA(JGYU@
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MM?58BZ9.':P>O'MK&?"R9FKM4(0"MQ;+US'J]C.N'>H!,W8#9LP;,&,#9FS
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MH>>%JI$H*GVN)G6JV8-U-5N-QFX _)CH*6IL/UIV)<X5FECSJ80=U( F#!_
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MT.F)" )!(B88=W\,B&B0FAM(S4]+<$()2UP_%G;& O 2(^R/EWG<IB2-'1'
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MSDWH<ZC\/9^DV,C*)CO+$!</R+2[MXU)OP\>?LR6QP:&1^*EX"L$'J@209*
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MA+H!N\/,Y8$V'H8V&/$Y<5-J1UZ0V@@. -KPF!TX-$DBCMA<D$V1<X\>93^
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MW^Y^_>AA(4,2%@95,$B\DI)76&M5/H?F34@I&'/>".28N?H6=0 &;BZ'X@L
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M]69]?-I@R<&2@R4]1F 7$I"O@![)1=<D'D^:J>IHAT2];2RY)E&'3,8C%(4
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M-221B-.&H 37LZ0SU.0B8HX 5Z,$C*'M'Q*?K\D$S^1X?GL88K1@K%%EU=M
MUE41DGR73+!:5V]JVMDSN\Z.2J+)&4GG W@$+BUG*!QSK95U:14\U&RN*"5A
M(/1#(O1U'6'?'SSX\:&M53L-5;$CTVL<G$(2L(9(;$NLF )VB ).;W!B7BPK
M+Y7$P5_H?O_/3A>'\SKK,/IRT\?'S<D,UQ%6QXWHO'\B=S8=GEU87+C(%;B
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MERE9KUQLND+,H40G7&EVK5X?;OOY<N4'UI"GGZGVSZ?'E?X?'_Y]]<T17:0
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MD\4IAY(U$5+M#0!22)9J&$V=)PG!-3TD9Z\SZ*!2YJR@5*MR,4DY9YC!4X#
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M!-/HLCXY")9L/55 TW23:!)22&0DQ'2U&9"5&[K )"'XZ#P$(]M U24E@:5
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M,$$V-AOR!*BDB$8WY2Q4!3602@&R:N+F9EGC J'L[,7A#TT.@3JCJ=I6ZR"
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M?*'!#05@:@A<4P!"!0%<<TJ"1J- LU:R?*2")V^"<S$90:!)PPA.#H(IIFH
M(D$A2,;E8$TMKI0D7F@C.Q2 24)PPVQ!N14*:U0LR]4QZ%5JO7E.\,54(][-
MJFO'=93E?)(*P#\;'W^0*OAMC/K_\>3XT6@6^*Z<VX*VS9KHH$5 +Y%',H$H
MY%(#8!JA__0X]XT) J\J(4,3[P:=8C:@@&M69%L5\@5=@^%2V$CH/YH%3@Z!
MG#@$\6Y(O%00S!&&W"IFRPXSZM$.8)H(7,OY%_-#5E=22>A201 O-25;5,]T
MI-90)ZP#@9-$H$TUYYX$IQE,]11;[SA?FY7(/_D1^D\3@6LY_[)NU6O(*F+U
MO1*Y*LHI*-(QE6 MV=!#_]$Q=WH0=(*SN!JT @#94/+:BPDT3MP69W49H?\D
M(;AAIB U[XO$^C9F\4,EHE!(&151'U>.;#FM-O^W9(+ Y$/_FX>'L\798U[.
M7G;)ZU'PK_Q!HN!ME /^2<OYXLD0 2[5KYQ=EK@#/!0-Q1+VR0$M]#WCI(MQ
M0P28'OOZ32* 1C"8JQ)#BCW[42ORE!08AS7Y4,4/VMESH^YX>A"LP;FL3920
MT0'$AJE!D_ _>$N08<P1G"8$UU2 JG6K%+-RT0GP@BLJ.Q.59VM[$DXQLG![
MX$='LLE!, =9+@\1 E7P$OG;U R4%HT$D7A5-0!ML3RB,SF<W\^^.'YRI.KB
M3+WXD('/=R\0>#72@UU@<%EQ3A*?E! 5<>X5.Q;)@O:NE^B877,=5<D#H7^1
M(*!-9>;&EC*4B)1:T;820 HIZG U*L% Z,>I'W@I(3 D76N56,,+.L%85*B-
M[\D$.7,O#M&]K^ZNVY8QA%LD(MP_D1N9#L^>SF[1DH>&,#2$"^=/!LN1<G,,
M%1+KI'-#;0.WG(VA,5=@>O3[1@W!2P<I>HE3@G!N[\"CP%52) 97^9B,33EU
MF:C7$(RA9U?#S9>1\314UY.8M2=H7-%#T,P%C$0UFH>&,$T(KF<2(!*9E!5B
MR J28T41K,(BS&I-39I<;R,PBI@G9P6-X0R>L32 KJ03%RLQ)G23QZU>T=S!
M$:%\E!*#E_C$F$TQR"JUWM?,9@E0$%"E:"@Y-#DD[ %*,L-(3LY(0K8^&Z^;
MK&%'*FF7=$/C@W4"T"LJ,A@(_3@5""\U!!\@4:#>>:"5/IN'5$H452*NUB'5
MQKWUX*YQT],0\F)9>:DD_OU"]_M_=KHXG-=9A]&7FSX^;AYH>!WA=-R(SKO'
M_:,>7:0KWT7._0)2PP=ZF[<]]9(+M9%%-ZW159'HVC*MW)Q_?\LM?^'3G(R1
MV'Q^E]D*2CH[9R#8; %-Q9H!>@]V3KFBA:L1,X:1^&!&XO<-2H>O5&PL355;
MG +V3>5<DZ+6$OD8V?F\L^=V]8:&;2^A<BWQR)\:J,M:CX_K7PZF_,29LH:
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M]+/:_O>>.EF<SGMUX-__]_8]JX[Y$?6?9D=\1J=G\GV9Y27+M[/2+_#RPR;
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M-5^(H&V8+C4=.^!^R/2@KQ3KI C.5XHYH>?I1 M4UZ8&'H.F2HG'L>O-TL/
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M;*8'6C^XN)L2.!>QH89K\I &JD-U,%B9ZZN^Q\!]#%T-A=-T" 4)[&.FG9-
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MSM#-S.Y[LL;S,\ OOY]>_.LO7>.VYFLF<(+IJ\0BX/@'KJEZ;F!IMN?J(0O
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M#E)^EFB2-._^T\]>OUNTW-U4#"P# !5T/;DX_J@80^7CP>G!K\<?CT\O1&6
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MJ-PQ-I'EJ+\Z9'LT:\Y+J&P<$M6*Q("6O48UVT8E&N,[U:>K1$X94<1&0J,
MH1%Y(8#71G!\3DKHG@HO7Q2AM:JE9\-#8JQ1+N$7);TS+H&A$0+Z,LKC4ASX
M:!RGM_@%_!@V+(L6/HEE:#<P')(#&SH-'(/[! ]DDZP\Y,8B5L,F>"&0.I!<
MD'$?IPD,X!"B,?89<G:5P'ZA#XEALUP04" _X5$=IZQ!H!&J&)84U.>>M$[*
M VN@X$X8VENT[K"G2QX+634SH:*"^);(<0_Y<% 6A&.?EQS91>L7A!T71V@D
MQCP*1L;^,(3.PYRY>,%<EI.DLM=5!@'E]4#"5P,LSL)A;156.JSCMAH7@.^
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M<6W6ANP2-Z<%Q9;A\15"Z%V)MNTEZQ3KP/L;VL_UY4B>MV5%R13-$WZ9"H%
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M ^&$NB9+"W'-27(5^5$-R-/6,I_JE7\J5_[J59DGP217M;QH-)HD*0:V06/
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M.#DZN(!?SB_@GX_'IQ?BBR>GAV<?C^__WDYGX](+"Y;6MQ EHDN=9\21OZH
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M":K 2NM<"-6#J@U/5$*ND7Z[XDH( IO>8%?].$NOHP!N#RNA"8UO\RA'-5#
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MU5; (^<$-NAV[+EMW[A-Y!B,MUWBM^WDH/;!^O^/K2"0;24UM[/6YL?>&-U
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MN#<NX,6ZWD60L[S!4(1V"%<, !)!$/FRB/FZ;[M\)4AT#>P6D?L\^[ZJ!Z[
MS#6LFH=U%.895A=&^5 EJ+D&4_U4ZDI/)$ZN3=:\F:SDS3VV::31)G]H4ZD<
M'6U.0H89JY-.-*A2H-K_>!4]UE+79>XK<%H!4;OSNDR5 Z>-S2LU==Q4&6ZK
M2R[/3*<K%TIK<M75*L'2&)8W##,+QIHB&[4P[.2CHI6M,]YUR>79!V[.);^Y
M4&T>UD8_&\ VUO ?#=@MHT<5W<!TMQ!M*@)07;ZY35A*&Q4G;%206RU':JS&
ML+QA6+G0K.<)PTY"Y*I55G@R4%5J$(,NUHS-[;:/HV94B*FI!QQ=I;E=E:;9
M*)]FH]0;[]5EY2/&%JM9=CG#9]4$I0Z Z@"HUO/'Y7MUI3I0ZE+14\:U1BZG
MA)YJ('3YA"I%+T)7@QZM&I3*'B?C31>5A<+?//]R)+C/\%MX,":'K\:EEE11
M.%4@66!#!Z>K4E6F)7!]7] 7PS['69ZH)L)+7K%X$Y[UF.AVA84_3R\%3[X(
M!Q2[9/YH4* *S<DL6=N52R=UJD/?&WH^56UZW:1$-6#<LD1 1:&Q?0I?]KVH
MUY\4MS[&Y:PM^%X0TG<>?:_G\X%"]9[CFWH5OEA8\MF')X3/7CPG&LA:SS6#
M:G6"@$X02"71Z!3^S+!J*N6 /!6P7AA[K80\1XC63J6T="N'[^F'\<_%)LZ7
M64QN:P5:XVK\R2O^E!LYZ^)]&N)2ZQ\[!NA>&X#H,E==YKJOR',9T[I/./)L
MZOFC.A:L8\$G'I\S"Y5FGB)T&L/RAV'5LE*MJ<\^!FR>;0QX5TFZ.LQUNA:I
M42BO:?FE!$_*(V"K):5F1)X*8"^,DO9*'2A-2N'*$1U TP&TLPF E-<V55 N
M *)1+9^H5BF4MC=@E;%A<RB$JXH(X9,!Z%+#7V&MYI3K8?\8N1W^IW ^, J<
MT*\#_D.%8)QZP-+UL=M$*6LE\S3#>+\/F=G4(4H=HM0!I!,/()5-I<)'NESU
MA''-5&M^YKF'*BNK)V$H>AN'B5<>IT[UL$B0'DOJ<+\GIJI/)Y6>\=31:!CR
M[P*+.[%RL_7MV]/E]=?4W,I"JHC5=E,%I+>1#_^E\M&DYG/QN%&^I'I5%J\N
MJEG])T>(Q16H@8 ]=]B?$2PM?-RH63+-:75&QZ%U')I$47UU7I8NMSP>K+82
M!BOH4#F $A6:<^ \-QHTJBJAE0X&'ST8K.TUM0BT5CIZ*RN--'E#FFJN^FB?
MA" U=>+?/J"ZVC&JL'IROF',K8LMZ;)6F/<;]CX[:G!4U6F>/QF%>JVF>'00
M(Y];C!P]Z<CGYCY9'235AM )Z;2-9IX&3FK\RAM^U:HZ,*K0=917.R85O0UE
M"SEWIC[D(ZRJ8VUS'?'U%*8]@+7>U&#=1U1*.]/VDOJE$E2/*<1RX&O3,4%M
MJBSO,U"OK98[:JG'&L/RAV&5:BXS4W,MGP\[?>!<H*K4G(+=%(;&8:4YPLN!
M7I,MAOC?PODW=_]2H1Q2/>!DK1.=0YM3"K"J$<W[J7JJU:?4(=>H_,Q.\W@Z
M#'N8,*RN)3QA*Z%<42I(HW'MA'&MLL8GK+P]>EKAV0MCZ5@M16]"X3FK.S;G
M<C:&]2:9ZAG7O4XJ6-NC<?DIEJ.*P/+M(4TW309\]FB$*WP5/HR<$ #"NKXW
M8)[;\_"7H&]W0YH#&C_>QK\.>8AC5@-XRN$AK!UZ[)^MWYCE\"!@#F\+AUE]
M[O9$4)S7?X\"I#N7X87+&E^<A?K*X5B#(;=P_Q)0$HIP5E>$2?5N)/!PD=OE
M+Y[/VXY(#H;?PQ]=..O _D&5P>FOO?8]1P3<$3Y\$ZXE]'RXD&@T!;^XZ'=*
M"7S36-5CI2DH7Q*<9P^<43ULM^D\P\I<4[FCA"J3/[!>F*IT!CP9B!I[[2"M
M:'; 5KYB)8N&U^O"YV($Y\L.KFY?#[Q# TQC3SZQI[:]%T491TH>965#:Q\[
MAFA%%>UC>6!TC5OGU,/46]<!'Q1N.8LW&X5RJ7*:(5DYD]74$6?U(\['3'G6
MA;]G%OEK'+\#DL:O$\8OHV"4\X1AIQ];-IMG&UO>5>ZPCJ?ILM\,WD(EN%?^
MP+JN*:,&ZY9>G;KVD^T6HDLEJ<)U+UO+KIT[CK;RN2D9[MO:@MDB-^T4;9Q=
M@$%I3D&.Q2Q6T X@<0Q+7./QN>!QO7Q:>+S<WE]VA!SJ*>;24;@;G%7?QP'R
MY=2Z#](K/X28LKP@\A.?J8+]=X=>0.G3'RGIVWX15Z GA?WXP.FGDJ--'N%M
M.&$4+G]D[R$FHY0I3;PR$QM,_]OW)Y#LB<NV+_CW2]Z%S7[DSBL?!>\^3)<'
MV&ZR>,4LUA&&L\=?'GZ;NXJYALBH]U.F^31> :0</@S$Q^2'JXX=#!T^^FB[
M=%YZZ&J^O_(,1M&-R(\GVRZ6Y-;)&!EC=/QQD3Z:P7;Y6;W8-*I+/RT5C2T_
M*U<K6SVY:J^58K51R\E>F\5*9?FG:NVU6FS6RSG9:PV,W+S -4][+0,;W&Y5
MO=>5>ZT7ZY5L3"MV)&6(OQBYC6!<?+W[\N7NX?YY3@?;ZL2;A:WT(HHLTGP;
M4A_2.9DM(?!)O @WRN*:U%";0.UG=DT5FXJR@NS\^.W9K,>\AD??ZT16N(N
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MI,D%Q3FE\RBGQ'ZGT^? [J=>MQN(<'SL]BAKF].N$UEAQ*E;K'!]SW'05\%
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MP4&-HWTR]CRIH7@Q,:,)TFQP%>?2KJ-]W\@,$V\-AL[H!WOL<W_ +1%1Q7Z
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M=6Z"C(L@;NX4<]DQH!$=L:73"[82G?2NZT[Z><2*-+:799XU*=NFWAT<V]H
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MLNOY63E3LMFV$"X(+%AB "_M(%;3W]?B+2TV7F;I06E?&4Y[/E2PKW9/V_/
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MHW%FM&5SG"3-0ZY5A1,J <M)B^^#=@_*OS*A44]9U#OOL)!&3!6*O^*1GV7
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M2> 4&#6(3  V848#/D+ (K29G8 2X8\OYB_<=M"J+-+1C"LVS?_,[/P/M%M
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M 3-:1?:$L/\L=4D2ZN;5(Z#O92N^=SK!AU;"8&[0];/GHZS<.%RZ6I \*C2
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MH3RX!+G<YJ!;#60G2W+V-ROU<J.N&<G&217I*N94+&M2R?^K#R!W18]4<H:
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M4F#HA:8_<)^8^4AP_Q(MUTO\B0$_M(.,+O;R+-WHBUQSD<"TP=S'H I64U*
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MJ8L$T'E '6F4!NB$D0^? (;T*?4!ZR5E;8W,?"!H)N8PG1*TZ#:0&,()NZ>
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MF.H;:23*G<WFUJ:'ZIRD$H$?,_+;8,8.5<!WVM;'5%F^&=*;I'!7-O*1P+R
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M\@0'I46@.'TX,$Q+*'6N4CP >?<;CNI]6L$OH%["(FTJD[)@CU.;_-L0Q.#
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M9Z6-M%GSUAKA4:*&Y (W1D9;@;2M$;B'&(8^N42**L@8R8>Q@516R("(R<?
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MCY,)IOJ4U5GI\M9];X,J8A$6T E-O.(.0D(-5G'"HP^VY-:#6':G]@ED0OO
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M^:__\>#W?Y?3W^;>^Y^F?WO]J^/^LE^DC^4__>]?WWQ,YW@9H#\83\(@W3R
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ME*:U2:6KW4A^A)."Z;03O[>?]LTSNK7HEG"X4PBLWBA?O#\?#A:.O10\<?(
MP46LX3@R_5W2$8)-(=.W6OO=8IOWG_C-<[F3")?PN5.LZR.FJQ&MD*SX3_W)
M!?:*B:1=Q4*25H+R%4>,@JR\)+"0I:_%;GS>?^(WS^=.(ES"YT[!KD^C4!-P
M/GZ]C,.+'MGEH63:'X2W=4G2@X^T)%&R,P;1\"AV(O/.X[YY)K<7WA(:=PIL
M+73JY1_I/ S.<!IHLQH=(IGD4D='QKGG$+2C4QRE16[0%Z&;O)JWG_K-D[JS
M*)=PVR!8]?QJ-,+!9';;496.S/*K<<_*XH)."$4P4^TS3:<"(Y-<2$^(0W'8
MPNQ=_O1OGNMFHEW">8-0U>O!!$<A3?I?\$68A#G.GF,90T@&-&:RXK H",P%
MR%FPK#!J#*9)A'K9TT^$\P:B7<)Y@Z!5O0,;/2>7^VPX^MI+,H08!!EXTI,.
M)JLA1B]!RN0D]P79CA?%2QYZ(@QO+\@EQ#:(5'V\#!<7/U^-:7GC<:]HKWQ6
M'H(A;UK9BD=*#MQYE\D<S#RWN"*^\] 3(79[02Y)[V@0CGIYB:,S.C9^&0U_
MGYP_'UY^#H.O/1F=3LH6R$&1DT:K J>"ABS)C) RI!!M X*7/OQ$B-Y=L$L(
MWRDB-5? <[RX6,#120N.AOPVK0KIGZZ+I15''FND-$4C6EP7WW[FB="[M1B7
ML+I3C&IN!0XO+^LM]3#]]O$\C'#\[FI2BRFJA]<C#X[9;"NHFETD/%:[( 'Y
M>\BU3XR7)F;V(QA.A/5F8EZB!0VRN)Z3%3@*%Z\'&?_X7_BU9P.ZF*PA=X^\
M/Z6U@,A, )E2L"4S%4*+7(![CST5KG<0YA)Z=PITS2W\5_UQ"A?_!\-HD1_*
MK+61:09<>@7*,0'.R@S:.,=8X,G9L-O%PHHG?_,D-Q'I$IYWBH0M$D1O4+VB
MGY"=R(,-I3"01EI0.9$K( 1Y=C+086-ELM@FY?;>@[]YEEL(= G).X7$[F*:
MY7O/4'$FHU#<@A<UVSL0JHA(BT9OZ7]H,>[V-J]\](D1O:U0EU"]4R3L&4'*
M4U@7X:QGC41I:6=1+#M"8AQ$8Q@(4:)F"AW7NZ7AWGG<-T_I]L);0N/NP:T^
MCC^%>($]*Z-1-99*)[\!)1TAR2(!;2DH1'*,<[>[5;5X7$,:;U4?[\>&VDID
MRXJ4?IB5DOXU70S'F/_VXV1TA3<_' XF^,?DY0569?G;CV,\NWP0ZUV?\*LQ
MG(7PN3=-':H?]/PBC,?ORM3J?_9'?]Q3UKL20@*LQ73*>%H-_0E.6\L+60A"
M/*8 )8SCE)_YDV9:@!>3\>(G-^KP))B&ZO%((?@2==F.VV$7,FY8UK8 =AO/
MB^GNMQ:BWKUR]$;L/T33<G-?54M_0WICNH:=R'I?6F"RYLE""46"(N,"0K4K
M6'+*1Q439X]E<ATS^W<Z$QR4_/5%W 7I-S&>7Z<&3X]Y581Q!02ON>#(,X1(
M^ )#DX/4SJ;'HJ1;<7X?Q/ZLN5;,W"=Z)[$VK$[_7+#W=CC!\8LK)+E;_A?&
MV!P2LIR2HV.,*8.U<$^ ERQ!Y*((4NZ0\[T4H@<])A[Y^&^6PU8B6_FV_MM/
M]T1"!NAO6_8'>??VQ<NW'U^^H"\^OGOS^L6S3R]??/Q$?_[Z\NVGC^]>O?R/
M?[S^]'_^\?;9/UZ\IK^ZBVV]-B*;/F+W;B,[+>I>4Q+IA'><"XS1*\U$S-PJ
MJW+.9.Q[GGH;/ZV1H7WC=1@O"_T?KV7OTWM14E*7."3TP?E *E@>2_[:R<*^
M1K'K0?)ZD$88QO@"9_]]/=O]SH<7I/KCE_]U5:M+AQ<7KX:CW\,H][*W3@DG
MP68=Z$VBE;O &2 ZC<X3.8_F+VZSZ TA[G\#VU$W[A]"75+2\(A:<F;.KIM>
MC\=7F'N&D>?M!9(K7F^::(\%EY(&])H<L>!J#[CN#)+;4/:O$9U2N-IFV5K^
M'5BH#Q=,0KFXJI>0[VL2((E_,AGUX]6D.NB?AF^'@QHC(2G3)YY-D\=P/.GI
MXHI,3D#B@AQW8S)XICG$6)3'(H7!QS+QMMMD6R _;:4[ +L-.\<L5O&IRNEJ
M]/76R]-#;DM*7$%BTUR)3"^0I^U;:BN5=R*11=I8X9; .&WMV57N#;O++""]
M'PU+?_)F.![W')K(2HK@)*U'!<\@,EW35#&DD%"%1S-1MM& FZ>?-O%;2KEA
M^YD%DG>3<QS5U*@1GM?8TA>LK30NL6)[BY-WY5/X@]Q0ZZ).&0P/$934=(0&
M+<'1T1F8M#8EU5@3UL%UVCK2G)F&'6X6&%_TO_0SN:OCYV%\_BS6UCMIT@LF
MVVIT 89:GH12@Q<.04JMF R!8#[6^V ;=5D*Y+3U8W?9-VQU\Q#4C35>\?6T
M$<[)HL PDT"YXL%GXP M=U:C+8JU#A*LPK)_M6A U4KR=Y!S!][.K_W!<+0H
M>B'+=O$BO"*9O*BMN:HI3+(>KS*%_SY[57K1HO:<%W#HZ%@L2&80PP@L,*5$
MR0S58TGMV^A+*^RGH%\'X;$#SV;Z8LP" 2^N1M4KFR8;S6SMZ9\_TZIR/6;I
MC)VF4_1,"4YXH4'94IL8" ^N) ..Y514"='[UG;O%C!/^W#KFK>&_;Z>@/S/
M<'&%*Q!'+9W2WH"5G#9K$ZK';P5(IE-M549O3NL@\N8HOTM%:\5:PVYCCP0-
MGB62R0A)$L8+U-F 3IK> R\32:)P",:$R$N4>1]!FP6<T]:<5CPT;%:V%-I4
ME1?(G@_'DU]Q<C[,/6?H;$XV@K4J@XHU$40'2^9!29ZKX,E@[%)75N#ZCI2F
M!3,M^YZM#FI/8Q$])S73&!AHGLF@#,Y#M%)5GDV.C@7YZ#B -G<04RBGK20M
MY-^R0]I3-VQ>V>R\D)"2)UR\./"26^"R:#HC2W2FM5ZL=<-YL,NZH%'3FB59
MHL',6XK+2&^Q-$99GA%EZ[S#+B[KVEPD25*#4&HPHN1IX\X(484,-GEGA#*&
MI=8WET]>).V0]S++HRXZ&AEM H&U-67V#)P5$73425H7 X;.<E[V4FG044['
M#F(\NE*#V6M678/A@+X=3]-K.9)O8 1)H_:J54$8\$E8L,4G+H0U 5M;58\"
MVG?)00NB5^G,S@+O(.!Y#],\;W,=4!V5'RP%=. *A-V)&W8E];VIA"N>V=JP
MNECKZ"QT#D)& \5+'8PD^\"V-I+VJ KKEB/L21,V$78'&O ^U&KU><YUE%8Z
MDPKDK,DZ9K% I,T01"BL&D!"L=;VS^WG[]]5:D#)_72);>79;9KG'!"M0K&<
MR0HRBE:FE 7/ H+515F5")%^K!#\&ZTXV9Z3)VM--A%H!V_OLYRGL@L7[T,_
MOQX\#Y_[DW Q!\>U"(;S .3"B^KL9H@Z,@@Q%^FU%BP]UDYM&[8?!?0-,]].
MT%WG1,XA:6&"E\*!MUR!BK1]!:<M<&9ES2XFO7RLL\?.KNPWS_BN0NT@X?$#
M3D@$F%^&T: _.!O/47FN$;/*4'N"U<O$#+4^BK[5RH5BF ZMK^:6(_F&V6X@
MV@XR'I^E='5Y=4$&:5Z58K=8NXE)VQ3!<X*GLM3@6" =M0DS%[0%E<<:SF^U
MU:\+[AM6BVX(Z""[<7F,=(Z-S) 0:G\:XPRCXXGL65^K3,B323S6N9'-ZXP?
MPW,*9GXS>>^C=/7G,.Z/A^4]0:353S,#PB!_[)\-IG/H!A-2\SJ"<!J O^BG
M/HX_IG/,5Q<X+#^'BS!(^/$<<5:A?SV[;ECHWXVNPL7X1=T]+\9WU[16R>O>
MH.U<*GL8(=XKL<V<:24*"R8J);4,V<6<LK'&&,<P]O:&<OL:^<7SWLT^$_.;
M?HC]BVGGEYO(O1>F*/09LJ.M6V6F(%A)F[AV5@8KM+H_E&YIQ?Q:#]NEXO\#
M1CH=QL\&^45_/!7M>"ZJGG9,V,S)&2R)O (F)!T.*8&5MJA8G+<^K;&$U4_8
MWT;:#6^WVP TDF/C?@[SE<[!]8*V:'7R$+.K1[OSX.H8,.]85D$04!W78/3N
MIYX2BSO(JV%TI"*9FFN+3:N7Z-$ZH844"JW'DS'OLHI [CFA"+I$J=<@[LZ'
MGA)OVTNK83CCJ67.KN<84](DQX"IVBZWM@=R.7%@T0=G6<C>J!T/AKW<6G=/
M:EM9'LN=]FTCY<UP9IY,KV:883$XTMIHJI^7C &G2'6++^2K<^NT:AWM7(5E
MWS?9'; ][$#J'03 E^&:NW?K(.OH8GLUJL/<;K=A;PV5V$'T^U4.(XN4"15(
MI0(H9PFKX ED#L&1;Y4D;QT2V;=2/''/O6^=V$3B7=R4S?S>\0=,V/]2]\-Y
ML,99%Y(U$5 7VA5]*&2>Y@0\:4EGK8XYM*Y#6(5E_X&Q5GP]#)ON+NP.+L1G
M,=Q9@_Y;Q^.B;Z#ER18;(>@ZYHS18J.(&I)F0BF&:)MW/WH4T,FH0SNQ=[ Q
M3,'5<.Y*?*8D'<E_S;&FQZ/B9'Z3#>YS$"%QGG7SGG%/83HMS6@E_)6N:,-0
M^K0$9CS]D&F<JD92R=9^1T;Z5";SA/99=<SKP1<<3ZK3$P;Y^?""M&]8?^T+
M/AN-ZA35^E>W/G'\-HQF?[]]0'W/ '<.JQ]2H/?[5RJ92O)>R6(41N<QH%?.
MH)!:\\!Z>\:ZH_$[GP5XZQ$W(07D3!:-#&((=<^-@LYA3R]N,D*7&)-\=(+F
M5N;O(WAV-N[&8[PMR^<DSGZ>L_*)I#TN.*K%CC%+&0P:L#FFFL#A(+#D(')6
M>$K"W9HZT,K86Q/; ?;T5AKRP/SK@HX.S,'WX6M]"<>?AO/*QO>C8;Z:CK^=
M+F'<LZX$R>I($%N+8YDF7\@Z"[SPC+0K,)Y;5T<]">J$%*4M 8UO$!;@7@U'
M]Q5Z_#.6X0C_<SCZK3\XF^<"/LO_NIIM^..>+*@,)V/%\3JX40<&KAJVG'%I
MLO')WB^M61JDW@'""6C)/DGH("MSW5WP^=2..*L#$&[_1L^F9%(564!+IF_2
MB39',JZ#<([@*ZM#Z[UG1\@GH'.'(*^33-$QT@>>U^MT_((7P\]3:_-Z4:-Y
M/MNG\S#X=#X:7IV=+T3Y?'@9^X/I*OYSU)^0A?RNE)YC%M';#+FF2:DZ##[*
M0#Y?R9PIK8CLUFT56Z_AA+3SH/1VD.>Z1%#34NCWHW["GHK">,,":"9)4J44
M<(%V="."DB&0I^9:C\5Z%- )*5([P7>0T_K .ER@Q?$OH]J/E@?M4V0"D%E.
M[H,2$(L)]&VF'5=F'DWSKK]/8#HAW6@J_@[Z=SZ";]IS=MI@<-'EB'8QH[3F
M= IS"PK)T_2,1<B>9<,2R4FU=OPWP?=]J,UNM'30!V_)H?@1/P>RX?#BZP=,
MP[-!_[\Q3^V]D&8AOC]J=[5IHF+M;HSCFU_KA6CD=#*[T+4?>JB-=%CA@#89
M9TJ(L;1NJ-!V!2>DA@>DMH-&>DM6<P/N=:;WK5_Z]9YU%C99O%]U)3=7*O1W
M5Y?TZS4B?=:__N5K2_&7X3#_WK^XZ$6E3*Y3JXV85CVY"%X(5PL;/9?:(6O>
M)&FO"SQM-3\2Q>B@5^ UCE#;-&E?VQ62^:%<G9/CM*L]5).-(G!]/[-^9P4]
M0=W92IQ=-/%KJ<0O<!:8^13^N/67I+F9J5 OJ;4@0X-;5Z."#I(O*?#DR,,]
MYBUM^:I.2!>/3 6Z:$EXDZ"[1(KCG[_>^FZ6K\NCUBBSK:U8,^VV6,??2G*_
MG>#(?);*-V_<MB'&?;5VZTSO.B7E6%+F[P>SIVF>@K%4XWK I375HC40>2+1
M&5=3'F+AH;6SL@S'P9J^=4K\$[<)&Q/014+L/4SS;*YU4'64-;\<T6$RYG=G
M[ D5V$'<^U,&YY0KA4= Y<G*]_1J>6<S,)F$-"';9%N?0/M4@B<RY/>E YM(
MN7&.PP?\9W\4+NX#FR=?JDA[GB$XG+L 2M"9&KCU4)2,)CB9=+Y74;6B@/F1
MA^S?AFW!PK +$7:0X;3D;)MJ,9U>RFC!R)'/>3:++:(P@,@U2\%9VUF$YWL\
M_UO0T$&&RC)8,\<*YR_%.@"[JJ%["MR!2NE:4+F&>NS.0Q<%=4\"I1TM,&$\
M,"9E[8?((41RLJVRL=XBIXRMKV0/I"A/E=<=1$\V$7]C4^+9" =A?NI))F@=
MV4 NK! ,KR$R%T&@XEY(@3*NT_GDUD<>1:AK%V$/=Y=4!_;!Z\%<E/BF_^7A
M#<#/7W\-_QJ.IKV IMI+1A*&4DVC7"< HQ4$5PC0V1#>Z'EI/MI]0XC?A3W1
M)6T=9",^ ?<&[-MPB3?F^).0.[(\MH![&%ND4S783.6:<=B!U;(-=!]=3(9K
M*+XV<10LUA8X#(1BKEB!J6#K?II'HW9/6#;'KG6;4->)MKT?#1/M_\N3=!>%
M\(C&)H;@HJV3AK(#SZ4!+KP*7C'/FO=K70O8(::5=4SQ Y5JS4\'=MF;?JIO
MX^#LV1G9F]-\NCFPDHO*UEAZ?:K!Z&O2I2\6R%QP-@IM/6N=^K 2S.DK2QL>
M.MEE:N_AFXE7MQNX""9K_7(!IEFN$ST5^26E0+$Q>6MS)D5NOK>LA/.=&.1M
MZ.B@MF(%M.O[IZ?!=69F/P+L4 9U(QK74X\=.-C?EC('F5%;CK40UYM:T!9#
M[6].7UD97'9)HVI= '8 !7G2]#V$?FPB^N;W@^/)Z"I-IN/&GY^'T=DT/?K6
MWOD!I]WQZTC@Q=$H/68O1(*$M:J_U(8P5BEP10FK>.:*W>NMMN+:</-G'V38
M;BOJAGN4^TJ;]:A[Y2S_F*/LFK,FU"/LG[.-D.]UTG'*:60BANRSXMJX9$7M
M/IIR\()IU4$GG351-STB;S?%JF_G]8RH"N9B.+X:(1F:],WGX3A<_#(:7GT>
M7X\Z7@[XS<WH6N&S3DQ!*8(VC)@2.,<M)!-"$%9(T[SB>H_+:S#O9#(*&6\Z
M#([G#>9ZDJL< VVW06D&M.=EB-,B5NDS2F%XQM8>\FHT!S^0CD9'ETQ0:<%@
MXX;_\^K%]U>C\5483#X-/^'H<ORNS&O'*G.+2,"K_H D6V,#M6'-+,<<,6=C
M,=+!R^N\Z2(A6%? (H],>%J47:<Y^6XH_M2Y92;5'IGMP#E;*I69V&NMXBNB
M9.FOS'KDS'[Q4_BC%W)VY)!8$$Y)4"0MB(D)$%(K+TR4Q;3>'!M!_U.K5^VD
MA]"-#K+1?B%.*MZY9_-I^(;D>S:OW)U,9C41/:4#9FDRI*())$/RJ)0S@(9A
M25@"ZM:-N]<"]J=ZKBPS;,YK)RD*70MS/H.!'*+$;03'702EHH!(ZX2BK<]>
M2B-XZR$5>UK:ODK!OA6U/T:-.G1!VG@TZ3VOG>%Q1$;7Y&N]I9O-'! A."DU
M)%\M?D[GCXM)0+:^8'3,\+"6LTL/N/5*T'<WK\.J9Q_J?NHH]6/8D*>&5G#%
M\P$_7XW2>1CCM9U^'^)B^L@:(#>YTWI"J=8&MM\[K38<#O=%P,&TQ4BTREL!
MMK:95X%>$OHB@.8L^>0Q%K]6*<QQ:\F*BZT#*LDF<F]\J_7/?IB,^HMK$W)V
M! ^F0&;&UAF]!7Q0#)CW6CD=C+#W%&!IS.;.A^[/&^A0Z,,6$FL8GZM+G3>(
M?C?ZB*,O_3135@S62N<\&)<%J&01/,OD1= Y%[U/R9BU1O@\\0HO>_:?UL-R
MZV%GGAH&&&[AJ9>H<T3C^2NQ#JB&UL)*(/NW#G;GZ"'AC03<V!IX!!S+/O/,
MP/B0")RT$'**(*3E!%O9@N';8_V1TWY?I&\@U\:G^\O/_?>XJ+_F0<94C*>S
MKI;K:Y?!U\0(+@QJQ3 *[=8XW&]_YG[/]D8B'C:03P=YSG=.I+LCYV>*B4$F
MK7A=(\%36@ !9F!YM)A#$<ZU3I-_ M*?!_[# [\+-CN(\3X";_%*K0&PHVS8
M)\$=)B.V*:7KJ\L.?'1S^?H$T)(<8P02(B9;DS\UN<O*@G=H@XE9^=2ZO?2!
M%.:)#-G#ZLLF-.SKDGX\@TT_*3]__1BN1Z%JI7W*W('/B8[O+!,$E!D4_<'1
M9Q99Z_RN3?#M_SZS,;WK7)*WX*:3JORNS_KINZBY8HE>.;+Z0ZP=CTB<6G*0
MB1F=K4G&M;Y*W\_*_K315MMH1ZA;'10];03X5GQT'=C[, #7AWP4A5)'H46/
M60L=JT#7-N<&\#%')PD=L&(X*,,-T&(\2*VS]Y8Q)EHW8#HJS=VL@NN4%'<3
MYAN'W'[%43_WPR*H)"(K.60#Z%6-3"D/,4KZPQK%;2A2JG6F7][]U ,;I%T1
M,6PBQ6^SG&OY/SC*<JXUH1YA.=<V0KY7SI52(,650DL3%/<ZJN($<A0I)!]=
MZ*"<:TW4K3KR+W_<K4Q 853FN;9[",9!G0X/7C'R"E(06)QU*%KG;:Z/;E=;
M8_GGO_M]@*/Q>?_S>_* *EMGV,O9Y<),A)"RHG.-TU?!:1 )O;,^^&Q;BV%M
M</L_(#K2G_L&03?T=!"W6"&%GK4%4PX%$JL#&HHE:ZA$!1BCESKJ:)O?XJR
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M]U++6)#;1$=$\TN5=OAW.13>C_!S^+IX\OOYEY^&-_B&H_'S,#[OD81DEKH
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M T](+;H3= <Y-S<AO4>T>!ZKRU%ZKDAQ\[3A="!AN%3C]8%);C)ME,U[/&\
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M:'WS]P2D;^&Z8"--V' ,X":,['7*VSK _AP#N#&%:X][VT;^>U40I(,Y1%:
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MKP[HZ: (\AK:KQAJD&1ZD?$0[_R=6@=L1P;71D /8VIUP?@JI>J,K@Y.N\U
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M%$*#=M)%\F=0V>9I=X\!.M1]6W=JL*IF;F<ZNAC$>Q?38D;E&J ZNE!;"NC
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MC^_*+HZ3.B!GM?N/KOEUNJQE),JTENLX$J-:"P-9G)AV3]UB8RA*!>N %2-
M:1[ "0J:I=!9<&V$:UX:=_J6^A _VZD;:A^ECF"@K\/\GQ](FC_AE\5J=K&Z
M)@E341>F8X$0E065A0#GF(?"@S>&,YYB:^K2W4BFOQ$]GG87S54SWJR^7Q=?
M<3FO2]V*C:Y!AJQ4-!&T30F4=:J&SQ(8ZNC)_RBV>2MC)V#/V)S:*VZ$[>@?
M[V_PO?J()(;M'JUKG,FBHVB+TX8=ZHCN7$-LP2$S],YY)PAH8P/KBNT9V]@H
MZANA/^'-8OEEL0P7N!.<#,6&S!58$D&=AEIS?YX!<U$5)DMAI;5MW0OH&1M4
M.T7MK0<:F<KT]@B^ML2ENYX\"DWI@TO8(B5E2I62Z*AP.BL3M,NA$M9B#DH*
M'O5.4M)=+QE^DWSS@ILDG3>:K*-H\$R3Z\^L!R^* VL*LXHL2JO6G_<>*"WN
MRF\>NQG+<36.XXS;Q%F,%EA4$I1!!S['"#9S:3TC$>"XR_P1SS&F)@_7_ZZ+
M[282;^B9;RXH;G#=E&OF_[Z\XO==_1OFCP0US/.?E\OT*:SP54H5-OWP3$E.
MFW!BX&(2E3L@@I.*@\E,T8^XEZP\L$,-1_&X+61B+8S@>_^(_A_SL*E$K.-7
M*L8_E_AY=OF9?(+U7UVM+FD7QUJGN'J+%V<Y,&.EC<!8RO6<QUH2[.E#B-ZB
M(O3-7?*!D!^WQ1U#;R/XXN\N/N'R]NE_9LA/=)@U"))));5+$+E20++(F3X1
MJ6/K01-W0#P-TQ@FVQ%*Z&]C>;N8DS^_I,6>&9E],"Z E8(<>4G08B$39(F;
M'+.I8YT::WPWDJ>A]@92'J'#]L>57EU21E]XD-Q#7#>T,:-HO=%!-(Y,L^CD
M=.M1HCM@3#6+>_S=O[]43Z42H-KLQ;7-UIS"^I8F)^EU3I7>E)%'1&L"%[@&
MY-EEDS@*V=H\=N$XUKRTP;K=L2\,DO$(7N<VINND41=4(]W.[T9TG'OVX1I[
MP 0&B'LZ8W"A9&[JE1>Y+J"R(J<%F:LCM$+AJ-&EUI1Q4QK! U?84]E 'RF/
M<?4S7]7\+JZ#E,UM%">/I;@"-M6#L7!:)3<"$NUUGGQ5I7WK2& 'C.F=PA8:
MVKZ:&2C>8XT"^PF7LZ_A8O85WX;E<OV+MFGT>UXP2C:]ZX*VDNK!2N42IB2<
M4S(FEP0%YTQR@PYESCN3ZO>\:Z@OOWGPC1>K;6+.>@DBE "*; I"=!9RKG8I
ML["\]9W_#AC#HY3-(VL$]:Z\(7?WBOVHH"E6T1;+4JVGM BT+/+#>!;1VJ+;
ME\3LPW*,*'68ON]&+0VD/$)URRU<:V^[>!^Y%87B,4,A,Y<U)1M5G3:=>'!"
M"]LZ,;$%8;K8=#0-]Y;DJ<2D-VNXV5/_FJW^N?; ,# I(K-@?!WI2KLQ1&8B
M,(?,<YY4:#X.]SX\QXM1!^AYK\T,E/<HMR,;;)N]ZI9CU@7;2-'J?;B.$[.V
MT^)>\VBD@JG-I&B1&0H-.B3:3SVWX#%QT,Z+$CPKS(WG0DQE'@]$L\>QCCZ2
M'\$JKFLO?_X[?0KSC]\!7H=A7'##G,Y@@Z]#G#R"3\J D.0(H1(.>?/!ZO<!
M.J9[.51WNXM>&PC^6/'O]RJ"1;F1TJZ_&.;Y+URS>KQ=5!CA_*HLI?&X['9X
M1HFN1Q+75C#NR#$NC$7O4E'>F^B,E(8QXW,(6/S.8+P=M#%B=]IY?3! 7KVD
M;RQ$",G1E\"M]$(QR<)X)],(L?N/@CNK=:(.<Z$O._K*H"5J0!F )R&\C-))
MT[J==!^64XG=N^M[_T$[0,JCQNZO5BN\6)V1U\!%8 :2J1P.*0:(3B0@G,B9
M,;7P932M7V%X2MH^0*JC.MB_ST*<G5\Q,"9EK<'DP#"L=!V<3$_2/U I+Y@U
M/)@Q<X_?@3PE?1\JWQ%JQ+:3##)$50)Z<&@UJ.S)!HUF4)1V%HUG:-J3?IU0
M6JZ%>OM+\MAIN2O^V/P1<Y7#U35H=)REJ,%:VH>4B 5B80*$%M'EQ%WF_@$G
M]^Y33R65UDLWBR8R:KAA_XAD4V?0 <ON1-D#>CM&PFNHK'>J;("@QE8>#UZF
MF".44NL'@U,0/&9@!3'KA.08="&^FT9I>])08^JLCWQ&\(PJ/\RF,X[E4)QQ
M"(DS<L5UC."BJ?-:M$7T:%E4C0_(6Z^?EAULF!X6;80X0CQSW2OR$ZYF'^=A
M+;^UN9:@#/<<?/"58TI[.OU+(3_ 1UY$H3]L/[IH%Y+'?$PVE/$([NY=5)M3
MH0.ND>Z9]F$ZSAU3"[T]: H#A#[*&)8]^$HL-NMLP6N3R/XEA0/"8^VOCE$'
M%WCS&H5IC>&!&Z4I;:&/K$=)?EP!POQJTTIXDS?>%/4II,@\)>!!4:AN,TF@
MT'88)3HO+$KO6@\DZP#K&)--6NCP3OC<5@$CN UO%_/\'>4U),LS@:&%<I--
M=7$MA"(8T%=@E>)6)=DZ7[(#QA.Q@:$"'C4INN-2G3/I#=<)D M+VQ_YQ+$.
M92I68DS248PS7F[T= N5AKB-S>0]0HOEO7?I7;"]%"KUUF*?4I1#5#!UH9+0
M*GC'Z/3"@A1!D]OD9!'@.07 G&O'%3YZ\QA2J#2:=?21_.2%2EEI(;0UX',B
M1SJ' L%F"3)YE5D2(;'69O&8"I5ZZ:Y7H5(?P8_@4OXVO\ EKB[^(H]G"UE)
MR:T=*=21'"FI#:W9D>\;E=(L\>AEZ\J*_6B>D#TT$OG>+6*RKJT]!4[7GOFK
M1'_G>@#D.$U=?=\_<L_7('%L5:'%XGW2DOOLO3(Z.X7(C DL<)>EBP^TA/6%
MTCY$N2*QWW[=;%4ODR^7MP<K<#1H&;GH*+0 E4P&9Y.$&),04HC,I9\@AND,
M>#!!Y?H4^&W^XTB_.I_MW?Q['>&=!,2*GR5M*X6U!RM,N.*UCBP:X)YGIQ79
M2&S-F' HUF/NUF/;X!T>RRGT.<+)?Q_NFWNWWWY< _(S<DMXX)J#--K6?(B#
MX$AJQ5A??6?A8^OO]4"H+U;85IL39;=6;Q<7]R9C5YNE58HS*0+&.E50.%EO
MA'TEV,$(LN1HE#:%87N:H8&@GY-A3JOA40L4;[ZH6W72!)"%XFTV!;RNP8#'
M!$%21! P%U'+]HH:KV1Q#ZCG:6(M-#1"WG;-U?=F\?G+$C_5%%45$0456*&^
M":M/OYPO_G>]'V_PO\:R6%*4EL[#:C4KLW1U]SG/'\+?9P6C\Z96ABI.BU$1
M(7HG@4N3D+O$;6P]DK[I IZ3:1Y/\R.P_-VWF!L1__QW.K_,=<C]YR^+.4F:
M_A+Y)"O\":_^?;7$6\RYUZO3TAJ9:9_'Y$7E,*35&2$A>2ZL+$Z1M">TZ^$K
M>C'TH]C&7<L_>.!]E]71^?+;_"M>X>W^+?,<F3'6@"F9T;?,:$7*.3JAK!8^
M(->B3&CMAZWBQ<(GLX&[5FV&5(#?NYK%C^[3GJ7%G4L+UTM3R@=-KKJTO X;
M"AIBR9S.*\]LE#[)[:[3G07E(\-\#O9[:MJ^:\AV$D->K4G2O_]N_;_KM+B:
M=L\Y)<!L:YZN"MUQ#5PPBD65<%;+EJ9\*- 78SZ&QN^:LSN&.7=:%V,^\5Q'
M*3E#YXT3'(+Q"6SQD9;*HK)V1$M^,>(3U/-=^_63ISNVEW'E--65J%)\H5,$
MK'8D7LXMA$ 1+S.TBDC?)#>M"^#;H7\.MGQDG>^XDAA\,=8HE+T5Q-ZLS=H8
M(YH$1NA(7Z:6X%4@$:-WG"3LO6Q=9C7B<EX,?'JKV&'Q@V_A#@MM[_F"R8&*
M3#'P6=82*59O;+B#8+WWT5?*K]/(;;QLW4?6_@YK/OC"KE&@NW]A@07'HO.0
MF:O-9D9#T#F "?3%.Z,8*C--3N-9V^U)Z7F' 1]\7=@LN-V_-):-Y,I+P&1C
M'<YL(69O0)0B60@YJZ"FRF6\&/'IZ'J'&1]\7=@BO-V_*FM3T$(:2#([B@Y"
M[0*F4)?$KHN+TI7T4%7QJ !?C'=*#>^PV\&7?8?(\ZKO$'-47+($16I-!T<=
MYQ*BAD(_SZAD,7Z26K0N8*=G.3N)RK/F>CPV<]J]J_U^"_GM>M%K\EG2\NK3
M[,NZVRVQ5)!%<FX2TE)C3N!<\, ->3P8A#=)3V&R#R(]?F_QJ%;4Q7;;:G,\
M'I/;L*[[I;H &Y?=YBZHT^E,;JW9W90GC=0RJ=TXJ51!P8#S2/N_(%?.:\LK
M,Z93FA61?.OM:6)[.:!5^6CFTD<;(YC)[7L$ GC=,^G1,2.T@QQ2'7U,WH$O
MHM"7B%%GPXS4K9.-.X$<C0)EJ**V.TD&2WF$9J7M1JIK5!*5%RF56@Q((6ZI
MB7//$'11')GCAF'S\1H[D3P5Y3>0\P@?_ITDWBV[Y)8Q)RLG3Z 0T195@T6*
M%Z(R3&!"%ULSX.Q'\U2LH)&\)Z%/7!]W$JV+63DHP==$@384(:*%7+R.5BO-
M?>L.G%,ESIPR2FF@C2DI-KO@>LX4F[WTUI56\1"A3TFQR:V(6B<-GM&NIC"K
M6BM%_\@NV)"E*;$UI^)CH-@<Q1;ZR/I(%)O:Y\B1CK;"? '%788HM*J-)I;;
MXI/9OEYX9A2;O71X ,5F'P5,1+$I;98195K[3I5T7$(,2"=F#,J)9$O.K2=H
MG3;%YA ;&"K@J2DV== HO2[ <KV!"+01AL@R9.531(Z8MFNFGSC%YK'3X =I
M9FHRSB[87L@X>VNQ#]WB(2J8FHPS!JF#4!;0)P:521B"-1JP&..L3$ZYUJW\
MCXN,<S3KZ"/YR<DXB\Q>>Z[!Z))IRW0< G(!+-2R8"S,A=;IC,=$QME+=[W(
M./L(?EHR3I=325P8<(%'<KG6(P\" L/"BZ0#U>C6I26/AHQSB#TT$OD86\1=
M#L?UEJ@B;8-)>G#<UU&L6D(0.8/AY$\9+G*0K1W2/5">ER_:0A\CD+)\6(;Y
MJN"R"N ]+K_.$HG@7=G% %H_F=7N/[K^DKJL922WM>4ZCN/F-C&0Q8EI=X2-
MK>V:N"\83(1@A -5R9%<JE7[2C*7E:;/NK4'??J6^H#'??J&VD.IC2=C7ON'
M;RZ72YRG;^\_+987'W#Y^?5BN5S\+ZUI,T$P,)84LQ2/%%YGC!02ED-;60F9
M-H[<$=6EE[[K^Z9WN8ZGT<7(ZFCHN>_ ^!/&C0=)+J/G0@80N4Z9]*R6340/
MGL?$K8T.69<1QGM?\&(4 P3^>/CS?UDL+N:+B^,3Z=\!<B*,^O<+:(M:GR<K
M/"M88J1=@0M7*"90(;(4G, @&E'KW\'4*HWX^_?F""=X-IFVNV)HIU/1,@@L
M6:CW9]$E32H9[VKB]U9\^ V9(T+0+FM;PSLZ"51B&NH^ J)>(,4DN-@^DU_8
M0@;8U(@<('TT.4:YZ8\GS$[P'Q:O;_'O8/[I<DD;P%O:;;CX8S&_^+0Z2UY&
M&VR$[!FO]YH"0M("O(M,>_*OBQAIJ-) Y(_?%H^@P5$OC_["*L9:AQDN".;%
M-W[F@V&\("=$+%"XY@SXBLW5$:5<"6^WZ0@:;O]W\3Q^FVDF[5%8Z./%E3%?
MG"D6C$840'AHC5IQ("=&@LDI,QX-V65[OOGOKW\*>CY,EB,4$?R^F'^L\6R%
M=":%\C%X 1C-.CM=B:^RA"RE%3%%'55K NS;[W_\BCU8FB/DY6_6=G7U4$0P
MM(,8$,+4DX0[6A)S(#&KY#7]P,31=NLC=7RWWI;[2_)4NK/W5-G2.IS0*0)S
MU48CCQ"+ER#JI#^3I0VF=>_:J?8M'*#;;MT(?60\9>%Y%US/N1NAE]ZZ5J ?
M(O0IC<)BPB+HT$H,:R)420B*[#^[Y'Q2R:D\?B/3Z74CC&(+?61]K&X$FTNR
MQD)MV@:5)0/G?:J#[+E7*?'4? 3OX^I&Z*7#0[H1>BA@E(*PFC][?T$@*ZC?
M%^GFF_ AIQ05'9!(L:@218.CSP$R9\9)G9-HGERZ!\Y3<"!:27N$\'\/M.NO
MH NXD5R)>X$=QY]HIL9NYC% !R.<*O>#S+4:LGCZLIC&ZU&*67E0/%.H'+QA
MI76\<00#><#'.(Y]]!']&-PIB]7%N_(^G..F8@+1>V:L PQ.D4^%!ARS&ECQ
MMI2(UKO6Z>,[(*;W)!HJ:9LW99"$1W >[FVL\#R85,BR;0@6E P1/&<>BE::
MD<_C/&OO69YR6]MP]Z&9O*=N5NN"[:59K;<6^[0C':*"J9O5F,,B40<(K&Z)
MSM!V)HH C4'+('P2<KP,]F-H5AO-.OI(?O)F-6LC'90\ HI*]U_[MAWG#$R2
MPCDAN,3GW*S62W>]FM7Z"'[<DM=[RG)E+J$$ 5X$5CG(*V= -F 3X66\%GIV
M&0-YNE72S74_FGC'+92_580;DD]&!G*=-7E.*I,['2W+8(1%C)B***&_SH]9
M]3R%D@\4X-Y<T\A5S&\N/U^>KT7R.JQFJUMCC<IB^0.+8.NRY4/>/$J=\F 1
M;!4F2^=EH.@S.^.5U^A"*@:CBDQ8'9/=69A\"(CVE<BLV)"TXW045;I9E!GJ
MY"I@1AEF0N;"M&;(&:$2>2VE_/LLQ-GY[.+;C]([R[J._O09F&25BMY&")I%
MD-DQG81*0;3N-+L7T&F4Z_31_*Z;N3;R'B%[<B^XFZ]N>[[;F1<I*Y4S<%YG
MQVH7*N]F O+)K,M1YK3M\8QK)ONA/G$#:J2CD6[_;\&N7>KD5LSFEY@[+X%9
M3,P&"4G2)Z)"J.0$28"-"2D.#=FEUH-1&\!^<B8WNNY&*27^,>?)BHR)T=>0
M2B%Q.&\HG&#TC\B-2<)RTYQ _80J$X<8PQ!)GDIEXNMP3DXEOO^$^.-5F TZ
M1HIL@ MKZ_D;P'$K@%-4(I40Y)RV;J;:A^54;@=ZZ7<Q@IQ'.(QVX=H4UW1
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MAF)/GQP%)B+UMXHAD)ZB_4RFHA%XUG8?J[\L+N?Y[>)B^U1%*77P.0'S4I/
M'!)8YT '1U&I9]S%UA6:O0 ^>NL:7RTC<*?=D<'5_5F63J%,"!@E[:&*).&\
ME<#)I^<I*$-V/W84.6G!Y22NRD'B/78YY=ZY\Y&%G#7+$%D*=7016:ZK;>.)
M6U$4!7O=V!KI!;?L@WYW8QO[WGVL2^@6ZEPT%&O#Z.?^0?5=0/6Y3NZF\[M
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MSLQTH6GI]=(G;A_-Y#WR-K(NUKZ&E70N7*<"/I7U*/4$3J,!CY%V5<MDSO8
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M6+= '#^E>S2[N+.Q#M'/"'=8/P#:S&_L &FDSHD=<([3'3%04?>I?8"4)S(
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M\-#'KJO#)=2XEN'/)7Z=AV7]%]*_?PF?9^>;[UUIIC09"CEVA3SV*#+0/A_
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M>* @<OOG\B.0;_/K+_\#4$L#!!0    ( *. :57@M7H#^G !  7\#@ 4
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M5FG"?I)XR(=)&"@#4%$;)'&40HY2%M.(A8%G=&;\?."YT54M&WCUZ7&M<UZ
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M?ETV)*5$9OGM*OO'KB+;(TG FWKLN_._JJ_(V.%1LZHSFJC&DOER624[Z7.
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M[;W^[:<O/X&MM /:8AA"W?_RCP/@R'30@4T[6IT?-S*/AZ=Y7+A[7"<*[C;
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M._%"2+$,H R"-/9(%,3<,ZT)^6SLN7%J)1YH:AO:='T[A%O_NWXF&B._W39
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MRV\OPMSX<B.J24\@5\M@YHN/"^[(%'NB%=,AV$>IRC0<Q'&[,_4),(<N308
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M0!3)"!+IQS!09"*8SP,46:4U.)5N;L2S;5X&[NIBN.!6J5&^?E57K/X1Y"O
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MMI&NB1<3SB6'01PHNU'9D!!C?49'O3@6?IABWZKFUVB2SHT;C?J!DW[CTUF
M]/G/P7E6Z:2K.QNKM?,(-&H?;"7="5:>K(FTLP49V=@]7\Y9&,/.X#8UEMU-
M./#H]7E%ZJ>/V2(A/":8<,B$+AWK>^I;0B(,4YDFC%+.8V94?:1ODKE]!M[M
M%?;7-:" 6AVN(S>YT.7_LU45G+#M_&P9\G$0;<.#V#,Q'/L0]FBA^2M7E>5-
MD'!U"'MHBFD/8'N4W#M\[;MV&"UTJUKH;V0;^W&YXE?Y<BF8-HL_2=T70[\7
MVV(7Y2)%0<)I0F"8" )1H&Q0&OH^]!B/8JR+3R.C?B'GBS(WBMFM\E((KKSP
MRKUXK0W*JF/F<M-H)-OJ8<<Q9RR=&1--LR C\]7N6M1FX"8&K0Z);E71ZU(U
M@/FJU^7:8%VL*>U\2!T1WQF"3$J/YP/VG$0=C#B,:G];53:'X%5/^:: MR^2
ME.( $O4OB,+4AUB0%*9)BF0<^R%'5G%O!^:8&SEN1*Q=MF'%NP]A:49J9R(T
M,EO9@F--0#WJ.V*60S-,2AD]*C[G@KY+A[WD=5[FE99TM2ZJ4^;/6?EG\XAZ
M'.OP-0:)1+I5!PUARD0,<1Q&2<JBF$7<YG7OG6UN+WXM+-B1%FAQ!W) /]1F
M;. ,P)%YX0SLK"G""!-'9-$_UZ2T8:3V<P(QN^G<\G]5Y[!'MJZVA92=\KDN
M\*'SP.N:5@O&/.EA[,'0Y[J1K4P@15X()28H(1+S*!E8ZN_DW'.CF6X*SX[P
ME;7?B%_5JRB;'!3;QB$6ZV+&0B.A/3(GN03ZC&I\QI YK[QW>N87JK)G#,GQ
MBGKF0PPC-^U>:3=;&U[-QN$"5T%OL80)IHK$E#D$::K^$PLF:.+%89H8Y6?W
MS#$WLFK$ @^Z5$B] ['=&>)*;CMJ.H2J&06=B=7(5+/=E='R;;::VXV<OHQ,
M:V;I0<(1@QR:85*FZ%'Q.2/T73KLS?\HUKHT_TVA\YH%?_/]MU+PZ]7[;$56
M3),-6V=/U9HN*/=3PK&$GI !1$&:P%0$#"8!BQGG@?Z[38BL^=16/#%!3*R2
M'##=%..AD1W0[Z]?/2KQ0;;Z$<A6 T V*M@QA\6JF!'*.%B/S#,:YJKWR,T6
M9O#JMQ;FC?#@\C3,UL1CCY@C/K*8>%*:L@?D.7L-&,$^?[%J,,)UE]>F6[!D
M 65>%$#?\R5$(4HA35(*110+'L4!(<*XI\?SP>=FP-3R5=V$+1LN'X2NGUO.
M!61D]G",A7DBXSF83)3)V.(!9%Z ': <)43UX="3X+AWRV09CL>$[:8X'KWF
M/*>K>Q2,XDB0B'-(8BX@XIA"3+@'A<\EY5)23S ;&^O '',SINHJW0=/X*NM
M"U&%6<#[NBW+X//Y0VC;.6/S/%$?^8B\1WG'_M>+'6KWJ'C,_W)W#-WUZ-Z3
MK/A=A[<M)$W4_T4A3#E!$"&/PA1[(10>QI&B!L1\-G3O93/+W(R7#SM;+1>=
M<+_AVRY;2.TW7@8!-?'6BY81_-Z+T5E;+GL8C+#ILIWCQ;9=]M3LVWC9OWA@
M#'"=VR*:S=P/&:'9LG)_-ENPP@NXIVP 5I7(]'P.*94^C%.:8DR\0*16!]0G
M9YP;)5PR5CPJVY3E]P]B53;%]951T!;5SY0Q9AL,?!)V,ZIP"N;(M-'*"EO<
M.M*.$2IL"HVKN.&3\TT;1&RJ_EY$L?&-YU15T6D..MQ.I]IEJ\=L=?OI0=2G
MY66=WU!?]Y5\$^6[;^N"J#FR%2F^:]>G_*A T$EZ^5+-='N]4CR@;*%%(A*$
M41S#T/<BB(($0Y)R#"5F<< XHTGHV7@N(\HZ-P^HJ4]2A<2RC:(@WVC:9D)5
MV\VZ3OWK5[1.F?RQ\N#76GN=+Y=5(PVI C/.0\$C7\0L1E!@CT!$&(,T4E^Q
M1,1>PE&:ALCJ#'$N#\5TI7[^?_A0F'U>9[+4(W^8=QLF5HN]515\VEOLYOI*
MW0NPJQYH]7-=SVC417!:#VD<25^@GM*HD!^NQS3NE&YK9"\\083 4029QY2U
MD2($*4XYY'[BB9C(()%69]'')IJ;J;!7!;N;#M^T%ZO\I1X6L$/:C*U=X#<R
MU9ZL@7T!+C< ZLBJ;0+Z<IG_1=3;6WU7F^#?WL;#SDID.V;)H]/,HB#V,7XZ
M>?W B%YQ6_4)K\_W@M /PU Q2IAR"5&D/)E4]T4-?"(H#3A.[ IY[(P^-^.R
M$:ZT/!@]C)P90PS&8V1:,(?"/BKVD,JNXEYWQIXVLO606GNQJP<O.C?T?K/U
MJH]B*S-#Q\56Z[<I)UFJR^J($K*\$86B['O-W9<KOOUU7F;:KFDK3S[K\!ZE
MB1<0G\"$1!RB))20>C*&5##)6<A"$<IAX?N3R#\[LNE$IM>'O>H[^[A:ZY_?
M$7;7.C5Z7_?=-[W/*\"';"64XPK^NLO4!9]%^:C>!GW#]L"CCELH@2X\_UDP
M_4 =[W SB^?*D"CG^[2,3<6=!^79.M?N[4;]BVTQW_JI:'4%'0RJ!ZKSEP:&
MBT[YWQ&;GKS0,CI/JYA&^A=*S9AT:8ZG=TPKQH">$-GZ3J%(OOV'^O\FHS-
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M_60=>?#0Z*2HNE7*?/?^S'4\?=@QW>J,OAM(UYUZU=T^K9WDGZH'R79M6HW
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M=92W\=KVKK[>V=Q'?Q1KO3U_MRS_;"IPMP?HG6&!B"1"Q!SFG$::'3.8,QE
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M'_#W./W>9&X?@V+WO3^&'W1)ROA=+,M'P=\^5>J/[GL+PBA(@SB%F!)%;&F
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M6;)0$A-&$8,BHFK-2G$ B: (YCB,HCA/F<"1S9IUOJNYK3<;24&U$]5N,1B
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MTC B:1K"1*2LC8M1'Y(N;1)Q%L52JN7"*2YFV\7<F'\K(?A#RP@:(5U#879
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M=::322EG6-%#ZKCPM*,#R7G3]==*5YA%#"GCD!.(&6,0A314M)!)J#@B5SQ
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M.C*'=8/91 QHE<!.IU[,_"Z<2-]TM7J!OF*@TVSR(3._OYQ^Z":ZNOSZ4-1
M+-O$!)5X5&VW!_@/HG-+4QS:1.0-SMGM"*L)NYFD_1'^\Z%@#^ ;>09D69>
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MR"!*,$SR.(6(YQ1BG*4P0UA9F32429*9)J@=ZFAN?/+Y+G1(TCH(Y>6[+5\
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M2P3JA]W\'VYUDJEOI-AFUIL][&8=O"65+B52JQ:;H@*O25VP[84"XB+*DT3
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M;CYY3N4##2C/WN)&-M5B>?>A7);WM5M[32MY]:.L[@C*\SS3;J8@N78X,Y%
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MV2YJ?C9EM0'7&M1.4/V#W.A2?[A8:WK\0L=:C#U\,^R8]I7MW??NX-K4*_W
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M4*X@12J#B%,*F3!-NP1*TR+B@F6)#6<<>?[8:*(1$=0RKNO-V%'#,01/LT$
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MT 2"2*\O(),9A2K/\TP5*,[<ZB<>&VAL5/C!?^%P%E-..2)17$ LXDC/+**
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MBD)5&+>#% K%L4VTELU@3G0P0-36NQ!5X:Q0/N^R_%M7>]NJ[%8?KUFN8ZW
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M181V4)NX@E ]]RS+!^W ,K1VT.X@;@=3E8&J-9_?O]R'DB/"HA0BF5*(0Y%
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M[?TW+1B6=-&6="O?OGXJ5N*9K\OKI6A2XLLZ*CY-1<ST!PQ%)!.(%4<PBW$
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M%/KORQ?].^.X<<S;<%Y".X5IU(496229-:F);XNJ;Q@PZU*S +H\;.HJ>,P
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M*]K,*0T;%[: N&3U[&3=1&LRL@3<70[#QQ5H.:F.F2TO9FDJ;@Y:3O@3CAY
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MNJ'3*:[U#*IV>M#E6(TL(X? Y*P4]:/@234Z,<FD"E(_H_MJTIFGAWHJ7O2
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MZWO@\>">Z(KX[C$O@:SO!;=7PR5XD_]0>R'V=\ 5^.,Q-Q<DA02TJ3]1_TD
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MY;D"W=5PK-1SP6HXA-M-LBK?N8)/6P[E;&F5*KEKA.HP;648*E[R<E6\'BD
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M(98DA!E)$BAI%-! Q0PS)^G@,/?<1,:65O!6+J7*[9R-%R^!G2 9"=B1I<M
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M\=E=NX_Z7__K?[2_T?]C6O+\K__Q_P%02P,$%     @ HX!I584\-_8CY@
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MR^CZ9^=3R/_V\Y=<WLDYHY27-_[?-W_[R\W+OTQAAGA9,/L.?[!Z1'G9/H3
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M%A=MT![@,"AAI7*:&,%PB]&^)'H,)X*JZ%3,N%AKGU_L3F6_$XT: &DM#3:
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M#LO2$1$TC4%'!G>[P6[$]Y:OZ]<A;PJI72BHB3N&KU8O7@H5@XW7WTH=*+R
M,6!,/. Z2W :V3#E2,[[2"R-0)@H-R8C-R+5]C&>(*E?[[D95':AP"80^4!-
M,G<V6*\Y":SPD;DO39X3 :9HILI8JFM?/CR@<KPS=[4Y_%505\^;[\=R:W?A
M=RPJ^#Y.4"KHB4P7&>S5,BIQZ_6%I$5>9IN_6BW%@8[)>9XLR;PT[-1<DN#
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M:@PUT5>7)@&Q3E*2<Q;>04 E5,]5U2*^W\:T/1K>XZF\(3M\QYU?%.IL$/9
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MW?.T*@,-=T;=!7</&[MC*[F!5,OO?OH/6/1X^5RX6G"ZUHTQ" K>"F*4M.6
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M$]"?<3I<I_<!<J" >]Z*7G\9?H2K=F?,BQ Q3$%C7#KK*9N(*W>D&->@)(7
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MLFQ%L_S@J?\V\"E9$Z(AW$I1!N!I$B+EA LE'==!9%W;*%<B_4<_-*ECP?O
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M%(>M,[0_HFG<:V](5+521 ? .NAAT!4=5. ,C$QDTYWSX&NC1L+@A5'<Y3S
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M]U,S[CW91ML'0.@$T7< HO>?9O/E!YQ_OFMGN@VP,3%3)Q@9[\FL2\7 66G
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MK'RRS=?@[*>F%RB=J_'9(.+O $C;;?#_3I_"].-C9DS*%()S#8&O4BL.P;-
ML7I"^C73/I;FKXA/$31N%F,P.+530@^(:N [O+J=0!&<2($5"=G7TB5C/?@D
MZ+<\<8TAN=1\LE=3!L;=5]>''S<>(CHX#NO^YKN2O%^_OIY<9>9D$KE 874A
MI5]MR18%G,T9C<"HF@^IV45')R'LY6&Q<V3Q&3KJ &?[]^L]+ F]4HX%<J(C
M$!?$ET@)'"H!J(W!Z*T.N?FLQ -IZZ228W0\#J++D9^^5@]XCQYL;M=W_!.O
M\X?9[V%9&;MW$*^$9\(YCR"T)-^GWCC1JP2812JH&?'^:,;<SF>QDS[^_ M
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MC[-&"'L]H^!_R]>&"<LSD4^BX2:;ZN99"$4PH#-GE>)6)=DZGMU!QM@;8 =
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M!UDA"INC-LTGO?<B;"K%7D-;S^VE-$GH;9L<UUNS,\_(VC-T6"M7%U-,K&5
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MN/XW;^?IQD]\Z2Y(S-N6[\L#[K$;O;C!U?80+&ATVWV#M U1NTO(6HJC=?'
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MC>KG;B;VW.)!R2X[:<@DBIF!\E*1V>7)[.(QQ\*9#G=#)(],/-I[EP_26'H
M:1_!L G$QFKIQ'HNT^O+Y6R.R^764-IX9DD;FXVQ8)+D-7790K"< _HH0M R
M.]L\Z_,I@L;MU?72ET3M9#,%H&UHWWESSM,Y&"VX7'>)-IK<+:]J [+,DQ(L
M^-87D+<(&#G'L)U@[T+F8"Z/;&:\GG7?O@3:0]L5[&X:,K-&" M1.C+$M4Q
MFR:2=+41D9AD<I\Y[ \_?1+ITH>(JFO*M^D<#@^=I^^NZFBTS<QX4M Z(H(J
MUD"(D79(]!BE)?WL>[5<.*($X2&Z>J'(_C0ZJ;6D)H"^7675AV]8;\#FY[OC
MF#A5E"U10V"BYCUZ0[NRSA]1.DE;)U\FWQARCQ(SB=.JH=R[(80P 32]6BZ1
MJ':<):2]!$67.N"TNA.*)1!:FR!"-AI;F\Z;-X^<J#XT3@Y@[P1 <>^"_2,N
MZC?".?(SK[DKM3Y*H"4FH/3@->,0N# YB>2-';S0X08](V?B#0V@9J*8 *QZ
M%0^=88HN2-HAA9NZ*'(M2.=G^A Q9)^X+Z-4A(V<QC TT-H+YU00]U2YVF:@
M&S]SR2<GZL2U.LY(Y3K!(WAR4Z(LK 212L0Q0-F#]I$O/">!V]8BG@"T:Z^%
M6J_\]]GJRR[YX-TLQ-G%;/7CS'K:E3$)6DPACB8CP7,KP?FL;#0R^'X9._LI
MZ<<)&CD4^@):NI$PIHZL-Y>+RO$SEZU64B!8M EH&1J\J!<'1K/@3 A&MAX-
MWX>ND<,;H^+L$-&,>H'7:U7OR0#>+LRZ6+*/Q"\K,AD?RH)'X2"7VI!124M+
M?4G,79/6"W;NYX3=@0*:^D%W95>D[GP^^Q?FLQ*C*;;49NE(?*L%QO6B%40P
M1GOOF<ON)>%WC\)>*/0_)PJ/$]?/UECJ[$X=^L"MI<[XN,VE[B[WJKW4?PS.
M^-V-1O?4C4;<W6@</IQI<))>5H -V#9T#S$>F63>.9#:6% U228HZ8!)CBHZ
M*91M76XUI1YB3!45 GDI*=>A"$7QVE/2@8A&95T2U[&UMOMY>HCM@YT6/<3V
M$=8$#*^G,TJ*+](%P\A&, $4)]?%6R:JC6"393Q$UKK/]/%I7)/J\+47'/9*
MX]I'-E, VJVL%6XYTTA\8+Y:A#%[\*PHL(&C2SX+IUO'+$XFC6LOP3Z9QK4/
MEZ>9QE64,$5;#CYI6?M'U<EZQD/,W$:+$9/NDT4\_32NO43U?!K7/GP;N;;H
M3:VGNYCE->/7KNEZ%XC,.;<IU DA!E2( 6)P&G)@7FOAO(F][AZ?*2QZ^.VG
MU[/O$#W3B/N3P\]V2R476"J"@>6BT#G* P1'7Y;,9,DA:IY;E*8]]O[Q*I):
MR/1)B!S X E8(/<2Q+9GI73*6>,E&%Z[27@40(=N NM=D%ZR@J[U!=TCI$P)
M,H?(N&O/\ G@YDVWH..7++;WW?RVEO7>*L.+!:9=KI8:*6W#!42;H_/)IBA:
MI^H]2LPX*FLP[+1A^@30\SNM83$+%S4</D^SBZK%*X]V)7ZLI%I !H6L^UHC
M&B'6##*#S@MI10K-)SD]3=$X27R#X:@A^R< ID^7<;D]2Q]1\L9(S)(A&%T-
M_^04.%8_LSY)YR+9_:W;Y3U+U.EU:#PJ:M-41E,'W7:+&E]8M%R"MI&!JBU.
M'98$PM 6BJ3OBVA=[]"#K)$=_+9 V =F!TAEY/C/W?/YU=>Z1_^U7M*'\I;$
M-C^?T=;<9/'OHAQ&:5VR!O2UTV4H$5R-[1?I.6K%>+AK?ST8'3KDW1.&UB'"
M[UY0$E-#6OKOR]ERMD[JQPLR%_*;;GFU,!%X$M(@8+$(M) ,GIP44$($J97.
MS/3I6K'72T>./KTDMIKQ?F*@6M^U;Y>1="Y<IP(^E75I2 *GT8#'2*>_93)G
M>P"$;KQB9 /K!0%S*%]'CE%>VZ"_$N!K?Y?5ERZ_G7_'Y:HR[OYW$6M'NTU9
MO^=!\J A.N/K%"P%GA$7DXJ\R)2T5KVR'YZ)8QY#X^GU%3TT7OYBDAP9L8^M
M8[N?5699*]+RTFQ:32"X.N; H2[DC:-(=YLY'83)IZD8+USZ<BCH!A')R-KR
M;[/9]__$<+'ZDHC5[V9?9ZNK?IK!9&,3!LC"&5+Z+D) HR!DXZ5A4H04>FC+
M)UXQ'FQ:2K!KS\Z1CYP_B!_;O(CU/HE")#+S(EC4-4'9T!%MG01#OH1*M(%8
MD_N[.Z\]O::DAZJR8_@]':AL]PX+V9(QJ( [5P>M!R(^<D*\I&59'Z-MTA?[
MWHO'.TR.$M_#,#B EZ,#X3OYCS4P\7$QZQ:; E)R&B["<CDKL[211/['Y48O
M;P_%G$L,AHY7A74JDW$%@LL!9 Y.E^ SJA8]CP\B;A* .@0(W4M*91K]D&_W
M_N4&=:41HK>U$U?1X#CCH+4.49GD$'NUF1JJD_:DVAL>JK2.YOPTD/- MV!$
M$3$:3=9?817^#EPI$K1D0OJ4:V?I=O"9?"?MO63:JY/V/@P>V4&ZTQI6A2)J
M%UER%D,MYC0(GCL-OG@1E4\ZJ#[W'-/OF+V7B!YOI;L/OR9PP?IVGKJO>)44
M_J[;*LBZ#30K-@4"?TB\9KL(A!AYA%B4L=&RJ&7K;B=/D'-Z+0N/N<EO)9?I
M0FPW_[0$F9,@KK! UIVO0[H\,<F$4K)BQDO6NL#L28+&O5QM)O9^<#I !A,
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MX%3(RF3'@FD]:?<6 2//26LGV+N0.9C+8SNLNQ-WNX+M>2MX1$EF&5GFH:Z
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M/@(?>9CCF^YR3D\B$:Q^O ]?-X,+17128[90?."@D@X0,FD:+#:HS%!D3'T
M^\P<QX?>_3..G]\+#EU#V8R,+=JJEXOT)2SQU?D"U^&JNTO:>:U>1N8<!^:$
M):\U\AI\CV!##$4)I4P0#0#7FZ#QQDH>+_-N: &,'^=[_QG3EUWVE H"9>T.
M5I0!13\+WFL$Q=![J00&TR?I]/93QY/_0"+KFO!O L[OTX'O7#3/T2>0DGPP
M%8* (#T#F1*WI9!9H'J=(R]Z'W5B8Z\/T6;MI3<%*-X*O):D9<+@H$070>5B
M:T=B X&<\:2-MN+N.?3O<Q^UEV"?O(_:A\M3OI7@6*_Z+>V?(EF=,*$@1NT
M9<K99*V]ZI-B=_2MQ O=3>TEMKZW$OOP< +'Q>'A15F*M99XYJ04=8"DA. B
M^;OT90JY;J#6\8-A;R5.+ /C&(WW,E*? +P/B6,;I@.CC0I,9EJB\ 5\=K).
M0K;)ZE PR\; _C>ZE=@+0 UN)?:1YO"W$MN_J!\B>5/____W?P%02P,$%
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M:\R/U"(DZN2[[R!DD=4LL2;^I?ILL;;@]TJBRGXU585_JVIW7W,!?8H[:JI
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MEW13V/I\8T7#GE&[JRX\MEI5;KO+5[[XJ*_AXQ/_&<S)_P!02P,$%     @
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M_9HK9H>=M@G<5GZ?/ #,X.;%\#Y]<-,7+%DK'-GHZ?0ZR4BQ8DUSA./^ +=
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M,#(R,3 P,BYX<V102P$"% ,4    " "C@&E5MUW_-;8\  !#<@( %
M        @ %&J@0 <&9E+3(P,C(Q,# R7V-A;"YX;6Q02P$"% ,4    " "C
M@&E5;2/12+.E  !M=P< %               @ $NYP0 <&9E+3(P,C(Q,# R
M7V1E9BYX;6Q02P$"% ,4    " "C@&E5X+5Z _IP 0 %_ X %
M    @ $3C04 <&9E+3(P,C(Q,# R7VQA8BYX;6Q02P$"% ,4    " "C@&E5
MA3PW]B/F  !E4PH %               @ $__@8 <&9E+3(P,C(Q,# R7W!R
M92YX;6Q02P$"% ,4    " "C@&E5-"HKFML'  !A(P  &@
M@ &4Y < <&9E+65X:#,Q,7@Q,# R,C R,C$P<2YH=&U02P$"% ,4    " "C
M@&E5]@,M%-D'  !9(P  &@              @ &G[ < <&9E+65X:#,Q,G@Q
M,# R,C R,C$P<2YH=&U02P$"% ,4    " "C@&E5+HGF8>T$  ".$0  &@
M            @ &X] < <&9E+65X:#,R,7@Q,# R,C R,C$P<2YH=&U02P$"
M% ,4    " "C@&E5.SE+O_H$  ![$0  &@              @ '=^0< <&9E
M+65X:#,R,G@Q,# R,C R,C$P<2YH=&U02P4&      H "@"D @  #_\'

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
